<SEC-DOCUMENT>0001193125-26-130490.txt : 20260330
<SEC-HEADER>0001193125-26-130490.hdr.sgml : 20260330
<ACCEPTANCE-DATETIME>20260330083541
ACCESSION NUMBER:		0001193125-26-130490
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260330
DATE AS OF CHANGE:		20260330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tempest Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001544227
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				451472564
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35890
		FILM NUMBER:		26810105

	BUSINESS ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY
		STREET 2:		SUITE 400
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		415-798-8589

	MAIL ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY
		STREET 2:		SUITE 400
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Millendo Therapeutics, Inc.
		DATE OF NAME CHANGE:	20181207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OvaScience, Inc.
		DATE OF NAME CHANGE:	20120308
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tpst-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-30T08:19:14.2553+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:tpst="http://www.tempesttx.com/20251231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_52dc9e07-b38c-418d-9941-12a551955bee" name="dei:AmendmentFlag" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_8edeec8e-b1c2-40e4-aca9-6d622747d550" name="dei:EntityCentralIndexKey" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8">0001544227</ix:nonNumeric><ix:nonNumeric id="F_0743b076-071e-4274-9c3a-052099742eaa" name="dei:DocumentFiscalPeriodFocus" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8">FY</ix:nonNumeric><ix:nonNumeric id="F_e4806dbc-e3c2-42da-9512-4b39ded09472" name="dei:NoTradingSymbolFlag" contextRef="C_9ac57279-acec-4da3-9e70-2e34cfbd934d">true</ix:nonNumeric><ix:nonFraction id="F_a61cf309-8cf1-44dd-9cf6-1e067a7c3d48" name="us-gaap:CommitmentsAndContingencies" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_eafdf1b5-430a-4ed1-b977-b8a69e22fd10" name="us-gaap:CommitmentsAndContingencies" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_6e1cc23c-49a3-467c-968a-b436b08a6a1b" name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="C_4fefbbfc-8096-46ef-bd2f-5065850f98d4">one-for-thirteen</ix:nonNumeric><ix:nonNumeric id="F_9df2eff9-6afb-4328-8d1e-a0eef5583eb8" name="us-gaap:RestructuringAndRelatedActivitiesInitiationDate" contextRef="C_92c5db01-9c2d-4afd-bde1-9f72beed84e5" format="ixt:date-monthname-day-year-en">April 17, 2025</ix:nonNumeric><ix:nonNumeric id="F_05603c4a-63ad-49f7-8c55-20c2929846cf" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_73e1d41b-207d-4eef-a0f5-e1ba66b3ef90" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76">http://fasb.org/us-gaap/2025#LeaseholdImprovementsMember</ix:nonNumeric><ix:nonFraction id="F_cc2526f0-0ec8-49fd-83a9-ebb177d174dd" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_b2e0866a-1fa4-4872-b525-bcf7fc4bf8cf" unitRef="U_shares" decimals="INF">0.000001</ix:nonFraction><ix:nonNumeric id="F_98cdff81-3c83-4c66-ba34-8998155d3a60" name="us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8">http://xbrl.sec.gov/country/2025#US</ix:nonNumeric><ix:nonNumeric id="F_14cb7b7c-9f29-479f-8c41-fb9c6a5ca935" name="us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622">http://xbrl.sec.gov/country/2025#US</ix:nonNumeric><ix:nonNumeric id="F_73408227-2688-4970-8a0c-a936196fb1ad" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tpst-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="C_83ad0427-46c9-40f3-8ea3-599adc8b0338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-08</xbrli:startDate><xbrli:endDate>2025-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83e9d5ae-1ac2-4dfe-901d-1fb708223a37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_872c6937-1351-451b-abf9-2a2a83e2dc84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8748646b-ce49-4cf2-b51c-cd12c0ce32e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8889779c-cd1a-4a88-8d46-c213f770f4d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:A2019EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89243837-7c70-4e55-8184-5818a993b299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpst:SeriesAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a8915cd-0e0b-49eb-b2b3-419b16f12b37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpst:NovemberTwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bd98920-97ac-43e9-83d8-1afbd38624a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:Pre-FundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c81e754-6ec2-4618-b538-4c6094074920"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-24</xbrli:startDate><xbrli:endDate>2025-11-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e605970-763d-474d-b0cb-5de22ba59e68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-15</xbrli:startDate><xbrli:endDate>2023-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ef892e0-d716-4056-9b12-9c9a7aa12c94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-23</xbrli:startDate><xbrli:endDate>2022-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ff57b73-22de-44f4-b372-68161891a853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9031d7bf-fa77-4e96-815d-3e2cf8c46a92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_916c82b9-f557-4ed2-9797-e0d652612305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">tpst:NotSubjectToExpirationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92c5db01-9c2d-4afd-bde1-9f72beed84e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-17</xbrli:startDate><xbrli:endDate>2025-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98b385cd-564a-43ce-b857-c685a4784e21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-15</xbrli:startDate><xbrli:endDate>2021-01-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ac57279-acec-4da3-9e70-2e34cfbd934d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:SeriesAJuniorParticipatingPreferredPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b1b80e6-f451-436f-91eb-8955ad7e6679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b1ec7d9-4f7f-4128-b459-36816f64018b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-24</xbrli:startDate><xbrli:endDate>2025-11-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b27f837-5200-4262-b142-35394e148530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b755a49-74f8-491a-8e35-1ea2c98f61f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d204fd8-22c5-49c0-9f16-eaa7fe7bc752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f019654-8ffe-45bb-a4e5-13052063f719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f9f175a-2500-4de7-add4-0941b73b5ed4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">tpst:NotSubjectToExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3400db3-e1b2-4661-adf2-7b1ef948c2b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a379ad4f-c5be-41b5-b49e-a2850e59bc53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a46cd5e9-4d74-498e-9bdd-3fe5cb08caf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:EmploymentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-03</xbrli:startDate><xbrli:endDate>2026-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5315be7-426f-4a35-bc3e-9d8bdffaf36b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6cb3954-c17c-46fe-8f17-edc83f6fb2e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a94b87ad-49e1-4a01-a0e5-9ac323ad9f6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a962bb72-7e5c-4f7e-9290-db4536a5d91c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab6430cb-a886-405c-91eb-7aff47df90b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad6d3810-e138-47f4-b494-587bf0b0da1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adde1910-6137-46eb-9b4b-8af558580c47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b06ce1d5-43af-4875-915d-0b69099c48e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0987cd9-5a24-4759-9d16-ae81baf465af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:Pre-FundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b166bd00-a5b2-46eb-bcf0-8a5010ef48da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tpst:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:ErigenAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-03</xbrli:startDate><xbrli:endDate>2026-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2e0866a-1fa4-4872-b525-bcf7fc4bf8cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-10</xbrli:startDate><xbrli:endDate>2023-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3405bb2-c492-46ef-ba86-83755523024a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5528348-f1b5-4a4d-8927-ae662ee9eccf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tpst:LegacyMillendoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b90d1f82-feeb-4b7e-b350-61e27474eff0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf3af50f-3aed-4972-822b-f4464ec34192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tpst:OrphanDrugCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0d8ea89-cc8c-45be-bc99-628196dc6c0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3d09bfa-c82c-410e-8c05-013d4096ded0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6e78168-a2c5-460b-b80d-8a8b0415a3a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7a9e8d9-54e8-4bd7-bfcf-2da3a970b22f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7f4e70e-297e-4e0f-9e4c-cf579d45fbdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbae41ba-0f21-46c1-8226-08889ddc8bc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tpst:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:ErigenAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-19</xbrli:startDate><xbrli:endDate>2025-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc23a656-ad79-4d18-bc37-248f3df07c4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:A2019EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-17</xbrli:startDate><xbrli:endDate>2022-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d07960dd-fe9c-4566-abd3-ddc3571ebd35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DividendsAxis">tpst:O2026Q4DividendsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-20</xbrli:startDate><xbrli:endDate>2026-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d48d584b-746c-47de-a737-fa3d182f9772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6236c64-7c86-4bbd-a146-18c57a7267cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbd9479a-dda8-49f7-909e-f327ddced2a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TrancheBTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcb60290-a2fa-4e02-8588-a3425a10e251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e001f4eb-5e39-4fc6-86f8-e7d36c542298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TrancheATermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1a70b55-a6e2-4450-8567-d8933403aa20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e36e743c-bf65-4bdb-bbe8-1719a8f75e7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tpst:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4e85a24-a7ee-432a-b926-c4bcdd8d3d4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7009405-d7f0-4b5c-971c-06a829c4d118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e84c96bf-09c7-4644-ac47-8073761fa16a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:A2019EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8e8425e-8552-48b9-b19d-732d38689041"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpst:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9697112-510d-4538-addd-de1c50b2db0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eae918eb-3de4-4147-a020-481aebcd8e1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tpst:IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec6026bd-9c80-4233-9bc5-2e05dc22c3d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec632eae-fdb8-4bbe-ae31-e0618a3ad9ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee3c2c67-1de7-4901-bc90-59a0afc42477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee9ba139-9295-4f17-8cd1-d43d46ee649d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f01f9f21-5e95-48cc-83bd-51259e351e7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1d00723-6493-47bb-9c20-796c424cdfab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tpst:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-20</xbrli:startDate><xbrli:endDate>2024-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4bab170-e7d7-4e1f-9859-dfd7e52308cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f546958e-8be6-48f3-adf2-b8d67c893d64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-20</xbrli:startDate><xbrli:endDate>2026-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f721aedf-b106-461a-903b-46e34a9f1d0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8276a73-58b9-40f0-8e8c-d2c73f397848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8ce6377-25b1-417f-a67b-27dd94b6927b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f941fd95-2c63-4333-b1fe-fd70c5cce07d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9dcc510-706f-4f08-bade-b100bcff92b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb5c878c-f0d7-482c-814a-fe0164e7e33e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01635993-0ae0-46f3-a1ac-7f468a6e22a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02b78ddf-da38-4509-a735-32afb066d3b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03c240c2-1a9c-4f7e-818d-a75b93b79bc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06328e98-1580-41cc-a910-5db61b65b8fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_066bf70d-7a44-4797-b1fa-45ce89b04609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_072f2ea3-60bc-461a-af30-65a53c97af2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:PreFundedWarrantAndCommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_090576ed-b8aa-4a6c-bd24-ad4fc236805a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0914ade8-ff10-4219-ba68-53e47ff2c071"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b479aa9-6c7e-49ea-a261-63a2a337465f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c195dac-9159-4433-aab9-8a61697eeb1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d904433-7564-4710-8699-0c23e7ee67c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ec6ba97-3919-4714-a934-2525e2f12f8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tpst:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-20</xbrli:startDate><xbrli:endDate>2024-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_112906e9-cd45-450d-8e9f-7f8daac97dbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_151f94be-33aa-4e72-91ab-8bdd1b7a21c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-27</xbrli:startDate><xbrli:endDate>2026-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15eeec6d-ae98-4bbc-b091-1fe5a22f07be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TrancheBTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-15</xbrli:startDate><xbrli:endDate>2021-01-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1637137e-aed7-4f2d-9427-075a1f55122b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_172aae3a-09ec-40f0-8e3c-93da515273fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1da28e56-a036-4c1c-9957-b3069151a0bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1eb9e2a4-c74a-4bb4-9c41-89af539af6a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_217bd4e1-fa9f-48ab-92f5-c15124d00b07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23067402-fab4-4583-a8ba-7a645e0e1ef8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27158267-e15b-4d03-925a-581587ce58e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2996b18a-b543-4592-ab8d-b832965d6add"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f5116a4-019d-49e2-b693-5a9344db56a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3665f268-732d-4aa6-b123-f1529af2e05d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DividendsAxis">tpst:O2023Q4DividendsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-10</xbrli:startDate><xbrli:endDate>2023-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ac82a9a-bb9c-42a2-a8f7-52fd9198caf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3baddcb5-d5e9-4033-a4a1-870013c37ef9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-11</xbrli:startDate><xbrli:endDate>2025-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3dd1d89e-976b-47de-b4a0-39ee50aa0671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40c12f7b-2097-4b34-b237-498396a49865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_472dac54-6d43-4ba3-b05b-f300ae5059c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tpst:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-23</xbrli:startDate><xbrli:endDate>2021-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49c54967-da26-4ce8-b371-c1af8c5252ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b4a9e1c-7ea2-4fd6-9990-5b75e3c05009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bcca309-5038-498e-a62b-782042e16268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ecf269e-0f88-4788-aa4d-c460ebc3cf9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tpst:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:ErigenAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-19</xbrli:startDate><xbrli:endDate>2025-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fefbbfc-8096-46ef-bd2f-5065850f98d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-04</xbrli:startDate><xbrli:endDate>2025-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5044accb-f46c-4dbe-954f-4ba8e4e9b034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5380a6a2-f90a-47a7-8a71-4bbe6510990f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5637d434-2834-4e0a-be2f-fed606708f35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5674d468-6c98-412c-9336-57931dcfe277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_593fb7f1-b481-4017-9df8-af3cd7cf78c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ac6b064-5ae9-4c1e-a875-a49f5a60bd9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpst:JuneTwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cc9aad1-44ab-4aae-ac30-ebf9766e2451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:A2019EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fd11135-0c20-48b6-804e-5fe44ae3180d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tpst:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62d04cb4-5a63-46ed-a664-419caec2a7a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65c167d4-fb8b-486d-a124-daec790a028c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69c4f05e-7e57-48e6-b6d6-083e708f8908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TrancheCTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c5a716f-97f5-415f-b72f-9c157e671bc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cdf488d-d731-4f05-b3e5-69a6c55aa717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-20</xbrli:startDate><xbrli:endDate>2026-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70845e48-f71f-4ea8-8d6e-8b92f4df5950"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tpst:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-03</xbrli:startDate><xbrli:endDate>2026-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_717feb2e-7a7f-45b4-b13f-aa87773d18bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tpst:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:ErigenAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-03</xbrli:startDate><xbrli:endDate>2026-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71ec2d54-80b0-474c-b65c-486a56573a94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73aeb815-2afa-4516-9756-8b7f3643ad5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79115bce-54bc-47dc-8643-ab28b5ab2326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tpst:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b1d730e-ab40-4eba-8cbf-0692f0eabf49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bc99182-65b5-47d2-9586-940c0ab19557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c4289a6-f95b-49ac-b1e3-b9d55e86a9a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:EmploymentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-03</xbrli:startDate><xbrli:endDate>2026-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ca8d315-3fdd-4df9-a57f-592e58b29648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001544227</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-11</xbrli:startDate><xbrli:endDate>2025-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Employees"><xbrli:measure>tpst:Employees</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Tranche"><xbrli:measure>tpst:Tranche</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>tpst:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_74241657-edda-4a4a-85ad-6d4a0c4dfaad" fromRefs="F_9095b77b-8616-4328-bf62-7772ddb0da59 F_d279497e-f43f-4de1-9102-97489a93c8f2 F_7a823370-0688-4ec5-a3c3-9cc56cb1fa4d F_9cee43fb-5ccc-4e36-909b-199a1d954e50"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_b817ca04-9246-4cb1-a879-d662ded3e863" fromRefs="F_97f8f9d8-ccc1-41b2-99d2-edaf2bb90a5a F_6448a7f3-d0ae-4461-bf4e-c13a95ec4ec0 F_c6e60cb1-7625-45d8-890d-f502ccb2045a F_b454cb84-8963-4090-ad49-9160d559a804 F_06d8a560-9214-464d-ad7f-d5ceb179abd3 F_5b799a36-beb6-4e4c-98b2-34a6c04e7709 F_a4deed85-14a1-438a-b3cd-6a644a58efa7 F_a0c20a1c-3071-4a19-adb9-c780da554e35"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section1">&#160;</p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:3pt double #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, DC </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8edeec8e-b1c2-40e4-aca9-6d622747d550;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20549</span></span></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_______________________________________________________________________________________________________________________________</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_754e9ab2-330d-46e4-8daf-f757175550ad" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_______________________________________________________________________________________________________________________________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:2.92%;box-sizing:content-box;"/>
     <td style="width:97.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span><ix:nonNumeric id="F_277100bf-b0bf-4472-b9bb-3deec85320cd" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0743b076-071e-4274-9c3a-052099742eaa;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fiscal year</span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eec4eee0-19bb-4d41-9277-c35a8d5a2a27" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db98e06d-7497-47c7-9bf9-64772e245ed8" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62aa3888-4a51-4818-9451-b4335c2777fb" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:2.92%;box-sizing:content-box;"/>
     <td style="width:97.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="font-family:'Wingdings',serif;"><ix:nonNumeric id="F_494bc836-c6d8-44d4-8008-acbe690aafac" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4888d952-8ac9-4f3c-931d-4064d422f820" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-35890</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">________________________________________________________________________________________________________________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89a6fbbe-7aeb-44eb-8c6d-16ad937cb9c6" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">___________________________________________________________________________________________________________________</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_9811e36d-6304-47ba-9828-8453af4aa67e" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_ca96e718-c123-4dea-9052-13104d971854" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">45-1472564</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:21.6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
    <tr style="height:21.6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_38249a19-ff61-4461-9cd8-dc60b452cd75" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2000 Sierra Point Parkway</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_cbc150ae-1c59-438c-bdd7-37c0aff35633" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 400</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_49238708-cae9-43c8-b998-db6aeb584a38" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Brisbane</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">,  </span><span style="font-size:8pt;"><ix:nonNumeric id="F_80a5d3c8-c2f8-4322-9fee-caf0bb3f76be" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_0b206e27-a1de-45eb-87b7-d9ca4bcbb45c" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94005</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0bb2bd59-9d0a-437d-a532-6c7bb4957dd0" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(415)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_223309eb-34d7-4e68-a585-f8619492ef95" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">798-8589</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:33.106%;box-sizing:content-box;"/>
     <td style="width:33.447%;box-sizing:content-box;"/>
     <td style="width:33.447%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of Each Class</span></p></td>
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Each Exchange on which Registered</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_e2397b0c-9023-4212-88b9-9821140202e3" contextRef="C_2f5116a4-019d-49e2-b693-5a9344db56a5" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_1a70b696-7aa1-42ab-b082-2b38c3ff7c2a" contextRef="C_2f5116a4-019d-49e2-b693-5a9344db56a5" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TPST</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_59a5461f-a7af-40d2-996d-ba1899996dde" contextRef="C_2f5116a4-019d-49e2-b693-5a9344db56a5" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td rowspan="2" style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_83a716b5-2e47-4b43-bb23-07ad21dc2d56" contextRef="C_9ac57279-acec-4da3-9e70-2e34cfbd934d" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A Junior Participating Preferred Purchase Rights</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_e4806dbc-e3c2-42da-9512-4b39ded09472;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">N/A</span></span></span></p></td>
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_27b55552-1ac3-4515-8bbf-937c6b50d5e4" contextRef="C_9ac57279-acec-4da3-9e70-2e34cfbd934d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.06in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:8pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:8pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_________________________________________________________________________________________________________________</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#168;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55c9e220-aa03-4561-bb26-1e4774bed59b" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   &#9746;</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.   Yes  &#9744;   </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2cefa73-3c96-4f5e-b466-5b45fc0c1b34" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_360ed4c8-ce85-4ecc-b136-f90e87ec7eb8" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;   No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#168;</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f284b4d-8159-4e4b-838f-4fccff68e911" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;<br/>No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#168;</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:24.155%;box-sizing:content-box;"/>
     <td style="width:3.959%;box-sizing:content-box;"/>
     <td style="width:43.771%;box-sizing:content-box;"/>
     <td style="width:24.155%;box-sizing:content-box;"/>
     <td style="width:3.959%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:11.5pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:11.5pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_2822a9ed-d3f0-4a35-ae97-af0997eac297" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:right;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;text-align:right;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:justify;"><span style="font-size:8pt;"><ix:nonNumeric id="F_50495445-e512-4d7f-bc1d-609a1a7ff2de" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:11.5pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="font-size:8pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_25b248ce-84e4-44c2-96d1-4b9dcaf9f140" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#168;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center; margin-left:0; margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicated by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.    </span><span style="font-size:8pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_8f70e38f-3c5f-453f-9020-d825910aa836" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#168;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_14810ef1-2dc0-44b0-91e0-4e1ca6682872" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#168;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#168;</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#168;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2859d60-a46d-48e6-9969-9ddbd53b3ca6" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity of the registrant held by non-affiliates as of June 30, 2025 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), based on a closing price of $6.80 per share of the registrant&#8217;s common stock as reported on The Nasdaq Stock Market LLC on June 30, 2025, was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_410133f8-45b7-41eb-83e0-5988a049c569" contextRef="C_adde1910-6137-46eb-9b4b-8af558580c47" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. For purposes of this computation, all officers, directors, and stockholders that the registrant has concluded are affiliates of the registrant are deemed to be affiliates. This calculation does not reflect a determination that certain holders are affiliates of the Registrant for any other purpose.</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 25, 2026, the registrant had </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58fcc11b-9f22-4267-81f6-e734e19522a3" contextRef="C_217bd4e1-fa9f-48ab-92f5-c15124d00b07" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,344,034</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, $0.001 par value per share, outstanding.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9726c0c-f483-401e-a1c1-6bfc8925b40d" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></ix:nonNumeric></div>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:3pt double #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center; margin-left:0; margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:12%;box-sizing:content-box;"/>
     <td style="width:80.8%;box-sizing:content-box;"/>
     <td style="width:7.2%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#special_note_regarding_forward"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section4"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section6"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1A.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section6"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section7"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1B.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section7"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1C.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section8"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 2.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section8"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section9"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 3.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section9"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section10"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 4.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section10"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section11"><span style="color:#0e32e1;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 5.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 6.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section14"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 7.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section14"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section20"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 7A.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section20"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section21"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 8.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section21"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section40"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section40"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section41"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9A.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section41"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section42"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9B.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section42"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9C.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 10.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 11.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 12.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 13.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 14.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section50"><span style="color:#0e32e1;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section51"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 15.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section51"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibit and Financial Statement Schedules</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section52"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 16</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section52"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#section53"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center; margin-left:0; margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="special_note_regarding_forward"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K (this &#8220;Annual Report&#8221;), contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;), that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 1. &#8220;Business,&#8221; Part I, Item 1A. &#8220;Risk Factors,&#8221; and Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; but are also contained elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by the words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and &#8220;ongoing,&#8221; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Asset Acquisition (as defined below), including, but not limited to, our expectations regarding the benefits and expected synergies of the Asset Acquisition;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our new strategy and the potential benefits thereof;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expected future growth and our ability to manage such growth;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our, or our partner's, ability to develop, obtain regulatory approval for and commercialize our current and any future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the development, regulatory approval, efficacy and commercialization of competing products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to retain regulatory approval for our product candidates or future product candidates in the United States and in any foreign countries in which we make seek to do business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to retain and hire our board of directors, senior management, or operational personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop and maintain our corporate infrastructure, including our ability to design and maintain an effective system of internal controls;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad, including as a result of bank failures, public health crises or geopolitical tensions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectation regarding the period during which we will qualify as a smaller reporting company under the federal securities laws; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding our ability to obtain, maintain and enforce intellectual property protection for our products and technology, as well as our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should refer to Item 1A. &#8220;Risk Factors&#8221; in this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Annual Report represent our views as of the date of this Annual Report. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As used herein, the words &#8220;Tempest,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and "Company" refer to Tempest Therapeutics, Inc. and its direct and indirect subsidiaries, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="section5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1. BUSINESS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. In February 2026, we expanded our pipeline through a strategic transaction under which we acquired rights to a portfolio of dual-targeting chimeric antigen receptor T-cells (&#8220;CAR-T&#8221;) product candidates with the potential to treat certain blood cancers, solid tumors and immunology indications, including TPST-2003, an autologous CD19/B-cell maturation antigen (&#8220;BCMA&#8221;) CAR-T therapy currently in clinical development for relapsed or refractory multiple myeloma (&#8220;rrMM&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our portfolio also includes two clinical-stage small molecule product candidates with the potential to treat certain cancer indications. One of our small-molecule product candidates, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma (&#8220;HCC&#8221;). Amezalpat remains Phase 3-ready in HCC and we plan to pursue business development discussions to advance pivotal development. Our second small-molecule product candidate is TPST-1495, which we plan to initiate a Phase 2 study for in familial adenomatous polyposis (&#8220;FAP&#8221;), with first patient enrollment expected in 2026. The study is expected to be funded by the National Cancer Institute (&#8220;NCI&#8221;) and conducted through the Cancer Prevention Clinical Trials Network (&#8220;CP-CTNet&#8221;), enabling advancement with limited internal capital deployment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients&#8217; lives.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Developments</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Strategic Acquisition of Dual-Targeting CAR-T Programs</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 19, 2025, we executed an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Erigen LLC, a Delaware limited liability company (&#8220;Erigen&#8221;), and Factor Bioscience Inc., a Delaware corporation (together with Erigen, &#8220;Sellers&#8221;), pursuant to which Sellers agreed to sell and transfer to the Company all right, title and interest of Sellers, worldwide outside of China, Russia, India, and Turkey, in and to all of the assets primarily related to (a) the autologous BCMA/CD19 dual-targeting CAR T-cell therapy known as TPST-2003 currently being evaluated in a Phase 1/2a clinical study in patients with rrMM, a Phase 1/2 investigator-initiated trial (&#8220;IIT&#8221;) in patients with rrMM, and a Phase 1 clinical study in patients with POEMS Syndrome (&#8220;POEMS&#8221;), a rare blood disorder caused by abnormal plasma cells, (b) the autologous CD70/CD70 dual-targeting CAR T-cell therapy known as TPST-2206, (c) the allogeneic BCMA/CD19 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as TPST-3003, and (d) the allogeneic CD70/CD70 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as TPST-3206 (collectively referred to herein as the &#8220;Assets&#8221;), in exchange for an aggregate purchase price of 8,268,495 shares of our common stock issued to Erigen on behalf of both Sellers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Asset Purchase Agreement, at Closing we assumed Erigen&#8217;s rights and obligations under each of the Novatim License Agreement and the Restated Factor License Agreement (each as defined below under &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;). Under the Novatim License Agreement, we obtained an exclusive license to specified patents and know-how in all fields worldwide, but excluding Greater China, India, Turkey, and Russia, to exploit the TPST-2003 and TPST-2206 programs and allogeneic CAR-T therapies based on the TPST-2003 and TPST-2206 programs. We also received a right of first negotiation to negotiate a license to exploit allogeneic CAR-T therapies and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAR-T therapies in Greater China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Restated Factor License Agreement, we obtained an exclusive license to specified patents in all fields worldwide, but excluding Greater China, India, Turkey, and Russia, to exploit the TPST-3003 and TPST-3206 programs. The Restated Factor License Agreement also establishes a Joint Steering Committee for the purposes of discussing and coordinating collaboration opportunities and serving as a forum for information sharing.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 3, 2026, we completed the acquisition of the Assets (the &#8220;Closing&#8221;) under the Asset Purchase Agreement (the &#8220;Asset Acquisition&#8221;) and issued to Erigen 8,268,495 shares of our common stock (the &#8220;Share Issuance&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the transaction, we are prioritizing a capital-efficient development strategy across our portfolio. This approach includes seeking partner support, external funding sources, and staged investment decisions based on clinical data generation and regulatory feedback. We expect this strategy to allow us to pursue parallel development of multiple programs while managing internal cash resources and extending our operational runway.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Pipeline</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development pipeline consists of the following product candidates:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img81402019_0.jpg" alt="img81402019_0.jpg" style="width:683px;height:301px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. &#8220;RCC&#8221; renal cancer; &#8220;CCA&#8221; cholangiocarcinoma; &#8220;FPI&#8221; First Patient In; &#8220;SLE&#8221; lupus.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAR-T Cell Therapy Programs</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cell therapy programs expand our oncology pipeline with a portfolio of next-generation CAR-T product candidates designed to potentially address the limitations of currently available cell therapies and broaden the applicability of CAR-T therapy across hematologic malignancies and solid tumors. Our programs include autologous, allogeneic and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> approaches utilizing dual-targeting strategies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead cell therapy product candidate, TPST-2003, is an autologous dual-targeting CAR-T therapy directed against CD19 and BCMA for the treatment of rrMM. In addition, our pipeline includes TPST-2206, a dual-targeting CAR-T therapy directed against CD70 for solid tumors, as well as allogeneic dual-targeting CAR-T programs, including TPST-3003 and TPST-3206, and an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dual-targeting CAR-T program, TPST-4003.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our cell therapy portfolio has the potential to address tumor heterogeneity and antigen escape and to improve access through scalable manufacturing approaches. We are evaluating these programs across hematologic malignancies, solid tumors, and immunology indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Small-Molecule Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our small-molecule programs consist of two clinical-stage product candidates with the potential to be first-in-class to treat a wide range of cancers. Our programs include: amezalpat (previously known as TPST-1120), that is poised to begin a pivotal study in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">first-line HCC, subject to business development discussions, and TPST-1495, which we expect will enter Phase 2 development in 2026. We believe both amezalpat and TPST-1495 are the first clinical-stage molecules designed to inhibit their respective targets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amezalpat (TPST-1120)</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha (&#8220;PPAR&#945;&#8221;) being developed for the treatment of first-line unresectable or metastatic HCC. Amezalpat remains Phase 3-ready in first-line HCC, supported by global regulatory alignment and positive randomized Phase 2 data. We plan to pursue business development discussions to advance pivotal development.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we unveiled positive survival data from the global randomized Phase 1b/2 clinical study demonstrating that amezalpat delivered a six-month improvement in median overall survival (&#8220;OS&#8221;) with a hazard ratio (&#8220;HR&#8221;) of 0.65 when combined with atezolizumab and bevacizumab in comparison to atezolizumab and bevacizumab alone, the standard of care, in the first-line treatment of patients with unresectable or metastatic HCC. Additionally, the survival benefit was preserved across key subpopulations, including patients with PD-L1 negative disease and &#946;-catenin mutated disease, consistent with amezalpat&#8217;s proposed mechanism of action targeting both tumor cells directly and the patient&#8217;s immune system.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, we announced the successful completion of our end-of-Phase 2 meeting with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) regarding the development of amezalpat for the treatment of first-line unresectable or metastatic HCC. The FDA provided positive feedback on the pivotal Phase 3 clinical trial design, which closely mirrors the positive randomized Phase 2 study. The planned Phase 3 trial is designed to use the current Phase 2 amezalpat dose and schedule in combination with atezolizumab and bevacizumab and will be compared to atezolizumab and bevacizumab alone, the standard of care. The primary endpoint of the trial will be OS. Additionally, the FDA agreed to a pre-specified early efficacy analysis, which, if met, would potentially reduce the time to primary read-out by up to eight months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we received a &#8220;Study May Proceed&#8221; letter from the FDA, authorizing the initiation of our pivotal Phase 3 trial. In January 2025, the FDA granted Orphan Drug Designation (&#8220;ODD&#8221;) for amezalpat for the treatment of patients with HCC. In February 2025, the FDA granted Fast Track Designation (&#8220;FTD&#8221;), underscoring the agency&#8217;s recognition of the urgent need for new treatment options for HCC. In addition to receiving ODD from the FDA, in June 2025, the European Medical Agency (&#8220;EMA&#8221;) also granted ODD for the treatment of patients with HCC.  These designations provide potential regulatory benefits, including increased engagement with the FDA, eligibility for accelerated approval and priority review, and, for ODD, potential market exclusivity upon approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TPST-1495</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our second clinical-stage small-molecule program, TPST-1495, is a novel, dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (&#8220;PGE2&#8221;), a pathway implicated in multiple cancers. Our development strategy for TPST-1495 includes evaluation in FAP, a rare genetic disorder that significantly increases the risk of gastrointestinal cancers and for which there are no approved systemic therapies. Given that prostaglandin signaling is also implicated in FAP and based on positive preclinical data in a relevant mouse model, we believe there is strong mechanistic support for this approach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, the CP-CTNet received a &#8220;Study May Proceed&#8221; letter from the FDA, authorizing the initiation of a NCI-funded Phase 2 clinical trial evaluating TPST-1495 in patients with FAP. This trial, run by CP-CTNet and financially supported by the NCI&#8217;s Division of Cancer Prevention, underscores the urgent need for innovative cancer prevention strategies in high-risk patient populations. The Phase 2 study is expected to begin in 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Strategy</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our objective is to build a capital-efficient oncology company by advancing a pipeline of advanced CAR-T cell therapy and small-molecule product candidates through clinical development while maintaining disciplined capital allocation. Our strategy includes the following components:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advance TPST-2003 through upcoming clinical milestones</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>We plan to continue development of TPST-2003 with near-term clinical data expected from an ongoing Phase 1/2a clinical trial in China. We anticipate initiation of a registrational Phase 2b in China by the end of 2026, with interim data expected in 2027. Development activities in China are funded by our strategic partner, Novatim Immune Therapeutics (&#8220;Novatim&#8221;), providing access to pivotal data while preserving internal capital.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expand the portfolio with allogeneic and </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAR-T development </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>TPST-3003 and TPST-4003 represent our first allogeneic and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAR-T programs, respectively, and are each designed to extend the TPST-2003 biology into potentially more scalable and patient-friendly modalities. We expect to advance these programs through preclinical development and evaluate potential clinical entry through strategic partner-funded IIT clinical studies in the near term.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Position amezalpat for pivotal development through business development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>Amezalpat remains Phase 3-ready in first-line HCC, supported by global regulatory alignment and positive randomized Phase 2 data. We plan to pursue business development discussions to advance pivotal development.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advance TPST-1495 through externally funded clinical development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>We plan to initiate a Phase 2 study of TPST-1495 in FAP, with first patient enrollment expected in 2026. The study is expected to be funded by the NCI and conducted through the Cancer Prevention Clinical Trials Network, enabling advancement with limited internal capital deployment.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advance a diversified next-generation CAR-T pipeline<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to progress additional dual-targeting CAR-T programs that broaden the platform across modalities and indications, including:</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-2206: a dual-targeting CD70/CD70 CAR-T</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-3206: an allogeneic dual-targeting CD70/CD70 CAR-T</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAR-T Cell Therapy</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Background on Cancer and CAR-T Cell Therapy</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cancer remains a leading cause of death worldwide and continues to represent a significant unmet medical need despite advances in surgery, radiation, targeted therapies and immunotherapies. Hematologic malignancies, including multiple myeloma and certain lymphomas and leukemias, often have limited treatment options in relapsed or refractory settings, where outcomes remain poor. Similarly, many solid tumors, including renal cell carcinoma, remain difficult to treat in advanced stages, particularly following progression on standard therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adoptive cell therapy, including CAR-T, has emerged as an important treatment modality in oncology. CAR-T therapy typically involves collecting a patient&#8217;s T cells, genetically modifying them to express engineered receptors that recognize tumor-associated antigens, expanding the modified cells ex vivo, and infusing them back into the patient to target cancer cells. CAR-T therapies have demonstrated meaningful clinical responses in certain hematologic malignancies and have led to multiple regulatory approvals. However, currently available CAR-T therapies face limitations, including antigen escape, limited durability of response, manufacturing complexity, safety risks and reduced efficacy in certain patient populations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Next-generation CAR-T approaches are being developed to address these limitations. These include dual-targeting CAR-T therapies designed to recognize multiple tumor antigens, which may help mitigate antigen escape and improve durability, as well as allogeneic and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAR-T therapies designed to improve manufacturing scalability and patient access.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CD19/BCMA Dual-Targeting CAR-T Therapy in rrMM</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead cell therapy product candidate, TPST-2003, is an autologous dual-targeting CAR-T therapy directed against CD19 and BCMA for the treatment of rrMM. Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">malignant plasma cells in the bone marrow. Despite advances in treatment, including proteasome inhibitors, immunomodulatory agents and monoclonal antibodies, patients with relapsed or refractory disease often experience progressive disease and poor outcomes. While currently approved CAR-T therapies targeting BCMA have demonstrated clinical benefit in rrMM, disease relapse remains common, and treatment options following relapse are limited.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BCMA is a cell surface receptor that is preferentially expressed on mature B cells and plasma cells, including malignant plasma cells in multiple myeloma, and plays an important role in plasma cell survival and proliferation. As a result, BCMA has emerged as a clinically validated target for CAR-T therapy in multiple myeloma. However, resistance to BCMA-targeted therapies has been observed, including through antigen loss or downregulation, which may contribute to disease relapse. CD19 is a B-cell lineage antigen that is expressed earlier in B-cell development and has been implicated in certain subsets of multiple myeloma, including progenitor or disease-propagating cell populations. Targeting both CD19 and BCMA simultaneously may help address tumor heterogeneity and reduce the risk of antigen escape.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical and clinical studies reported in the scientific literature have suggested that dual-targeting approaches may improve depth and durability of response compared to single-target therapies. This body of literature provides the scientific rationale for the development of dual-targeting CAR-T therapies such as TPST-2003 for the treatment of patients with rrMM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TPST-2003: Dual-Targeting BCMA/CD19 Autologous CAR-T Therapy</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-2003 is an autologous, dual-targeting CAR-T therapy designed to target both BMCA and CD19. TPST-2003 is being developed for the treatment of rrMM.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mechanism of Action</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-2003 incorporates a proprietary parallel dual-targeting CAR architecture designed to recognize both BCMA and CD19.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img81402019_1.jpg" alt="img81402019_1.jpg" style="width:364px;height:469px;"/></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Figure: TPST-2003 parallel dual-targeting CAR construct targeting BCMA and CD19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Scientific Rationale for Dual-Targeting CAR Architecture</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAR-T therapies function by engineering a patient&#8217;s T cells to express receptors that recognize tumor-associated antigens. Most currently available CAR-T therapies in multiple myeloma target a single antigen, typically BCMA. While these therapies can produce deep responses, relapse may occur when tumor cells reduce or lose expression of that antigen or when heterogeneous tumor populations express different surface markers.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By enabling recognition of two distinct targets, TPST-2003&#8217;s dual-targeting approach is intended to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reduce the likelihood of tumor escape through antigen loss;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improve targeting of heterogeneous tumor populations; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potentially enhance persistence of anti-tumor activity.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical responses have been observed across multiple dose levels and study settings to date; however, additional follow-up and larger studies will be required to determine the reproducibility and durability of these findings.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The same dual-targeting CAR architecture forms the basis of additional programs in our pipeline, including TPST-3003, an allogeneic CAR-T program, and TPST-4003, an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAR-T approach.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical studies described below were designed to evaluate the safety and clinical activity of this dual-targeting approach, including in heavily pretreated patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Study Design</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-2003 is currently being evaluated in a Phase 1/2 IIT clinical study and a REDEEM-1 Phase 1/2a trial, in each case in patients with rrMM, including patients who have received multiple prior lines of therapy. The IIT and REDEEM-1 Phase 1/2a trial are being conducted by investigators affiliated with Novatim and are being funded by Novatim.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To be eligible for the Phase 1/2 IIT clinical study and the REDEEM-1 Phase 1/2a trial, patients must have rrMM and must have received at least one prior line of therapy. The Phase 1/2 IIT clinical study 	and the REDEEM-1 Phase 1/2a trial are primarily focused on evaluating the safety and tolerability of TPST-2003, as well as determining the clinical recommended dose of TPST-2003. Accordingly, the primary endpoints of the Phase 1/2 IIT clinical study and the REDEEM-1 Phase 1/2a trial are the assessment of adverse events (&#8220;AEs&#8221;) and serious adverse events (&#8220;SAEs&#8221;). The secondary endpoints cover both PK and PD assessments, examining how the therapy behaves and acts within the body, as well as a set of efficacy measures including: progression-free survival (&#8220;PFS&#8221;); overall response rate (&#8220;ORR&#8221;); complete response (&#8220;CR&#8221;); strict complete response (&#8220;sCR&#8221;); duration of response; disease control rate (&#8220;DCR&#8221;), minimal residual disease (&#8220;MRD&#8221;); and OS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development Program</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical experience with TPST-2003 to date consists of early-phase studies, including the ongoing Phase 1/2 IIT and the ongoing REDEEM-1 Phase 1/2a trial. As of the January 31, 2026 data cutoff, a total of 36 patients with rrMM had received one infusion of TPST-2003 across these two studies:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24 patients treated in the Phase 1/2 IIT; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 patients treated in the REDEEM-1 Phase 1/2a trial.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients enrolled in REDEEM-1 had received a median of four prior lines of therapy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among the six patients evaluable for efficacy as of the January 31, 2026 data cutoff in REDEEM-1, including three treated at dose level 1 (1 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cells/kg) and three treated at dose level 2 (2 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg), the CR rate was 100% (6/6) based on International Myeloma Working Group criteria.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Across both studies, among 25 evaluable patients with measurable disease at baseline, the ORR was 100% (25/25). These findings are based on a limited number of patients to date, and additional follow-up will be required to determine clinical benefit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Safety Profile Observations to Date</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The safety profile observed in REDEEM-1 has included:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Grade 3 or higher cytokine release syndrome (&#8220;CRS&#8221;);</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One patient treated at the highest dose level experiencing low-grade immune effector cell-associated neurotoxicity syndrome (&#8220;ICANS&#8221;); and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Grade 3 or higher ICANS.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that the observed safety profile together with the consistency of responses observed in the REDEEM-1 trial support our plan to accelerate our development timeline and meet with the FDA to discuss initiating a U.S. registrational study later this year.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Durability of Response Observed in Earlier Study</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe clinical findings from the REDEEM-1 study appear generally consistent with the earlier IIT. In the IIT, among 19 evaluable patients with measurable disease at baseline:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ORR was 100% (19/19);</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CR rate was 89.5% (17/19); and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the highest evaluated dose level, CR was observed in 100% (5/5).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IIT also reported durable disease control, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Median PFS of 23.1 months across all patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Median PFS of 23.1 months in patients with extramedullary disease (&#8220;EMD&#8221;); and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MRD negativity at month 12 in all evaluable patients (5/5).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients with EMD are often associated with poorer outcomes and shorter disease control in rrMM. We are continuing to evaluate the durability of response observed in these studies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-2003 is also currently being evaluated in an ongoing Phase 1 clinical trial in patients with POEMS, a rare blood disorder caused by abnormal plasma cells. The POEMS trial is being conducted by investigators affiliated with Novatim and is being sponsored by Novatim.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Development Plans</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to present additional results from the REDEEM-1 study and updated IIT data at a scientific meeting in 2026. Based on data generated to date, we plan to submit an Investigational New Drug (&#8220;IND&#8221;) application to the FDA and, subject to regulatory clearance, may initiate a U.S. registrational study in 2026.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Clinical Programs</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TPST-3003: Allogeneic Dual-Targeting CD19/BCMA CAR-T</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Allogeneic CAR-T cell therapies are manufactured from donor cells, unlike autologous CAR-T cell therapies, which are manufactured from the patient&#8217;s own cells. Allogeneic CAR-T cell therapies thus have the potential to offer an off-the-shelf alternative to autologous products, that may reduce manufacturing complexity, potentially increasing availability to patients.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To manufacture an allogeneic CAR-T cell therapy, the T-cell receptor of the donor cells is typically eliminated (&#8220;knocked out&#8221;), to reduce the chance that the donor cells may nonspecifically attack the patient&#8217;s healthy cells (&#8220;graft-vs-host activity&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-3003 is an allogeneic dual-targeting CD19/BCMA CAR-T product that we are developing for the treatment of rrMM. Because TPST-3003 uses the same dual-targeting architecture as TPST-2003, we believe that TPST-3003 has the potential to maintain the same positive safety and efficacy profile that we have observed in early-stage clinical studies of TPST-2003, while reducing manufacturing complexity and potentially increasing availability to patients. We are planning to evaluate TPST-3003 in patients with rrMM in an strategic partner-sponsored IIT, with enrollment potentially beginning in the third quarter of 2026.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TPST-4003: In-vivo Dual-Targeting CD19/BCMA CAR-T</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAR-T therapies typically comprise nucleic acid molecules that encode a CAR sequence and which are formulated for delivery to a patient&#8217;s T cells in the patient&#8217;s body. Most typically, an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAR-T therapy consists of one or more mRNA molecules encoding a CAR sequence, formulated as a lipid nanoparticle, which is designed to target delivery to a specific type of cell in a patient&#8217;s body (e.g., a T cell that expresses the CD8 protein). Because </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAR-T therapies generally do not require manipulating either the patient&#8217;s or a donor&#8217;s cells as part of the manufacturing process, they have the potential to reduce manufacturing complexity as compared to both autologous and allogeneic CAR-T approaches. Because of the potential advantages of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAR-T therapies, these approaches are being explored for potential treatment of immunology indications, including lupus, in addition to cancer.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-4003 is an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dual-targeting CD19/BCMA CAR-T product that we are developing for the treatment of lupus. Because TPST-4003 uses the same dual-targeting architecture as TPST-2003, we believe that TPST-4003 has the potential to achieve a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">favorable safety and efficacy profile as compared with single-targeting approaches. We are planning to evaluate TPST-4003 in patients with lupus in a strategic partner-sponsored IIT, with enrollment potentially beginning in the second quarter of 2026.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TPST-2206: Autologous Dual-Targeting CD70/CD70 CAR-T</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CD70 is a protein that is often expressed on the surface of cells that make up a solid tumor, including in patients with renal cell carcinoma (&#8220;RCC&#8221;). While therapeutic approaches targeting CD70 have shown promise across various experimental settings, some cancer cells within a solid tumor may only express low levels of CD70, while other cancer cells may downregulate expression of CD70 during treatment with a CD70-targeting therapy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-2206 is an autologous dual-targeting CD70/CD70 CAR-T product that we are developing for the treatment of RCC. TPST-2206 uses the same dual-targeting architecture as TPST-2003, but replaces the CD19 and BCMA-targeting CARs with two CD70-targeting CARs. We believe that this dual-targeting structure may allow TPST-2206 to more effectively target and treat CD70-expressing solid tumors than single-targeting approaches. TPST-2206 is being evaluated in pre-clinical studies with a Phase 1 clinical trial of TPST-2206 in patients with RCC planned to begin in the second quarter of 2026. These pre-clinical activities and the planned Phase 1 clinical trial are being conducted and sponsored by our strategic partner, Novatim. We are planning to review the results of these studies, and, depending on those data, evaluate the potential to develop TPST-2206 in countries other than China, India, Turkey, and Russia.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TPST-3206: Allogeneic Dual-Targeting CD70/CD70 CAR-T</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-3206 is an allogeneic dual-targeting CD70/CD70 CAR-T product that we are developing for the treatment of RCC. TPST-3206 uses the same dual-targeting structure as TPST-2206 and the same manufacturing approach as our other allogeneic CAR-T program, TPST-3003. We are planning to review the results of the ongoing pre-clinical and planned clinical evaluation of TPST-2206, which is being conducted and sponsored by Novatim, and, depending on those data, evaluate the potential to develop TPST-3206 in countries other than China, India, Turkey, and Russia.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Small Molecule Programs</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amezalpat: PPAR&#945;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transcription Factor Antagonist</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amezalpat, a potentially first-in-class oral small molecule antagonist of PPAR&#945;, has completed a Phase 1a/b trial, and a global randomized Phase 1b/2 trial. The Phase 1a/b trial was a multicenter, open-label, dose-escalation, that evaluated amezalpat as both a monotherapy and combination therapy with nivolumab in patients with advanced solid tumors. Results from both the monotherapy and combination arms were presented in an oral presentation at the ASCO conference in 2022. The  Phase 1b/2 trial was a randomized, multicenter, global study in collaboration with Roche that was evaluating amezalpat in combination with atezolizumab (TECENTRIQ&#174;) and bevacizumab (Avastin&#174;) in previously untreated patients with advanced HCC, compared to atezolizumab and bevacizumab alone, which is a standard of care for that indication and patient population. As of an updated February 14, 2024 data cutoff date, the global randomized Phase 1b/2 trial continued to show positive outcomes in patients with advanced or metastatic HCC who received the amezalpat combination therapy as compared to the control arm, including a survival benefit in both the overall population and key subpopulations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tumors evolve to promote their own survival by alternating energy sources, promoting angiogenesis and evading immune recognition. PPAR&#945; is a transcription factor that is activated through binding of long-chain fatty acid ligands, which in turn regulates the expression of genes that control glucose and lipid homeostasis, inflammation, proliferation, differentiation and cell death. Included among these regulated genes are those that enable fatty acid oxidation (&#8220;FAO&#8221;), and &#946;-oxidation metabolic pathways in cellular peroxisomes and in mitochondria. An FAO metabolic profile is associated with tumor proliferation, induction of angiogenesis and immune suppression. Published studies and internal Tempest analyses of over 9,000 primary or metastatic tumor samples in the Human Cancer Genome public database reveal a metabolic gene expression profile characterized by increased PPAR&#945;, FAO genes and lipogenesis associated with increased metastatic potential and reduced survival enrichment among multiple cancers, including HCC, CCA, breast carcinoma, colorectal adenocarcinoma, RCC, lung adenocarcinoma and prostate adenocarcinoma. Amezalpat is designed to block the pathways that support tumor cell proliferation, angiogenesis and immune suppression, resulting in reduced disease and patient benefit.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img81402019_2.jpg" alt="img81402019_2.jpg" style="width:683px;height:284px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Amezalpat Preclinical Results</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have conducted pre-clinical pharmacology studies along with pharmacokinetics (&#8220;PK&#8221;), and toxicology studies with amezalpat to support its ongoing evaluation for the treatment of patients with advanced solid tumors. The combined results of the preclinical studies that we have performed indicate that amezalpat has a dual anti-tumor mechanism of action that involves both directly inhibiting tumor proliferation and targeting suppressive immune response pathways to promote effective tumor-specific immunity. Our preclinical results support the large body of published literature that the PPAR&#945; target genes play an integral role in tumor growth, angiogenesis and evasion of immune recognition, and provide the scientific rationale for targeting this pathway with amezalpat.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immune checkpoint blockade enhances anti-tumor immunity by restoring the activity of cytotoxic T (Teff) cells. Emerging experimental results suggest that inhibiting FAO with a PPAR&#945; antagonist may target resistance mechanisms to both anti-PD-L1/PD-1 and anti-VEGF therapies, supporting the combination of amezalpat with either or both therapies. We have conducted preclinical studies showing that while both amezalpat or anti-PD-1 monotherapy inhibited outgrowth of established flank MC38 tumors, the combination of these two agents resulted in synergistic anti-tumor activity. In addition, MC38 tumor-bearing mice cured by the combination therapy, unlike age-matched na&#239;ve control mice, were completely resistant to tumor growth when rechallenged with autologous MC38 tumor cells, demonstrating that amezalpat in combination with anti-PD-1 induced lasting tumor-specific immune memory. In addition, activating mutations in the Wnt/B-catenin pathway represent the most frequently dysregulated pathway in HCC. Such mutations render a tumor cell dependent upon FAO for its energy source, and in preclinical studies, Tempest has shown reduction and long-term durable cures in mice bearing Wnt/B-catenin activated HCC tumors treated with amezalpat and an immune checkpoint inhibitor. The promise of these pre-clinical results have been observed in the clinic, where we observed increased clinical benefit in our Phase 1b/2 study in HCC patients who had a mutation in this pathway.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Efficacy in Syngeneic &#946;-Catenin-driven Hepatocellular Carcinoma Model</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img81402019_3.jpg" alt="img81402019_3.jpg" style="width:683px;height:408px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tumor resistance to anti-angiogenic drugs is also associated with elevated lipogenesis and FAO, primarily through the vascular regression and hypoxic environment that this class of therapies engenders. In response, tumor cells can switch to FAO as a mechanism of resistance against anti-angiogenic therapy. In a preclinical study, we confirmed that combination of amezalpat with tyrosine kinase inhibitor-(&#8220;TKI-&#8221;), based anti-angiogenesis therapy confers potent anti-tumor activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preclinical data for amezalpat are consistent with the data observed from our Phase 1 trial presented at ASCO in 2022. Taken together, we believe the hypothesis behind the amezalpat program, the preclinical data, and the Phase 1 data support the design of, and data observed from, the ongoing study of amezalpat in first-line HCC in combination with standard of care as well as the potential evaluation of amezalpat in combination with other therapeutic agents, such as a tyrosine kinase inhibitor (&#8220;TKI&#8221;), in FAO-reliant malignancies such as HCC and RCC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of amezalpat Clinical Trials</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We completed a Phase 1a/b study and a global randomized Phase 1b/2 clinical study of amezalpat. We have released positive data from both studies, and we believe the continued positive data announced in 2024 supports the advancement of amezalpat to a pivotal Phase 3 trial in first-line HCC.  The Phase 1a/b trial evaluated both monotherapy and combination therapy with the anti-PD-1 agent nivolumab in patients with advanced solid tumors that our PPAR&#945;-dependent transcriptome analysis of diverse human cancers revealed favor the usage of FAO. Results from both the monotherapy and the combination arms were presented in an oral presentation at the ASCO conference in 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amezalpat demonstrated monotherapy clinical benefit in patients with late-line, treatment-refractory cancers where objective responses (RECIST v1.1) would not be expected, including pancreatic, CCA, and colorectal cancers (&#8220;CRC&#8221;). Results showed that 53% (10/19) of patients experienced clinical benefit in the form of disease control, including tumor shrinkage in 21% of the patients. One subject with late line CCA had a 15% tumor shrinkage and was on study for over nine months of treatment, while also demonstrating on-target inhibition of expression of PPAR&#945; target genes on pharmacodynamic (&#8220;PD&#8221;) assessment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the combination therapy portion of the trial, 15 evaluable patients with heavily pretreated RCC, HCC and CCA were treated with oral twice-daily amezalpat and the anti-PD-1 therapy, nivolumab. All the HCC and RCC patients had received an approved anti-PD-1 therapy in at least one prior line of therapy and discontinued that treatment due to disease progression. We observed objective responses (RECIST v1.1) in two patients with late-line RCC who had previously progressed on anti-PD-1 therapy without having achieved an objective response (ORR 50%, n=2/4, in evaluable RCC patients), and we observed mixed response in a third RCC IO-refractory patient with significant reduction (&gt;30%) in the target lesion, but the appearance of new disease precluded designation as a RECIST PR. A third RECIST response was observed in a patient with late-line, heavily pre-treated CCA, a tumor type generally not responsive to anti-PD-1 therapy alone. All the RECIST responses were observed at the two highest doses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><img src="img81402019_4.jpg" alt="img81402019_4.jpg" style="width:583px;height:233px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notably, one RCC patient who achieved a response after treatment with amezalpat and nivolumab had previously been treated with nivolumab in combination with ipilimumab without experiencing an objective response and progressed on treatment, followed by further progression of cancer on both cabozantinib and everolimus. The initial RECIST PR was seen at the first on-study assessment at eight weeks and included a response in all target lesions as well as complete radiographic resolution of multiple sites of metastatic disease (see CT scan below) and has been confirmed at subsequent assessments beyond 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Partial Response in Late-Line RCC Patient Treated with amezalpat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Nivolumab Combination Therapy</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img81402019_5.jpg" alt="img81402019_5.jpg" style="width:683px;height:271px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Randomized Data in HCC</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of an updated February 14, 2024 data cutoff date, the global randomized Phase 1b/2 trial of amezalpat, combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab continued to show positive results in patients with advanced or metastatic HCC. The study is comparing the amezalpat arm to standard of care alone, and enrolled 40 patients randomized to the amezalpat arm and 30 patients randomized to the control arm. With 10 additional months of follow-up since the April 2023 primary analysis, the median OS in the amezalpat arm reached 21 months, representing a 6-month improvement over the 15-month OS in the control arm. Importantly, the HR remained stable, demonstrating a sustained reduction in the relative risk of death compared to the control arm.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the data cutoff date, 50% (20/40) of patients in the amezalpat arm remained in survival follow-up versus 30% (9/30) in the control arm. We believe this reinforces the meaningful clinical benefit observed in this population, with OS serving as the primary endpoint for regulatory approval globally for first-line HCC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The confirmed ORR for the amezalpat arm remained consistent at 30%, compared to 13.3% in the control arm. Notably, one patient in the amezalpat arm who had previously achieved a PR as of April 2023 converted to a CR by February 2024, with at least an 80% reduction in tumor burden. This patient, despite having a PD-L1 score &lt;1% and an immune desert phenotype, achieved a CR with the addition of amezalpat, highlighting its potential efficacy in hard-to-treat tumors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img81402019_6.jpg" alt="img81402019_6.jpg" style="width:683px;height:228px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Data not provided by Roche</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally in biomarker subpopulation analyses, patients with b-catenin activating mutations (21% of the study population) showed an increased confirmed ORR of 43% and a DCR of 100% in the amezalpat arm. The triplet regimen with amezalpat remained active across PD-L1 negative tumors, with a confirmed ORR of 27% in the amezalpat arm, compared to a reduced ORR of 7% for the control arm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img81402019_7.jpg" alt="img81402019_7.jpg" style="width:683px;height:354px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img81402019_8.jpg" alt="img81402019_8.jpg" style="width:683px;height:354px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early in the development of amezalpat, given the expression profile and attributes of PPAR&#945;, we selected HCC, RCC and CCA as cancers of interest and checkpoint inhibitors and anti-angiogenic therapeutics as potential companion therapies with the goal to maximize the opportunity to bring meaningful benefit to patients with these cancers. Based on the pre-clinical and clinical data released to date, we believe that the emerging clinical benefit profile of amezalpat for patients shows alignment with these predictions, and we look forward to the potential benefit amezalpat could bring to patients with these cancers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own worldwide rights to amezalpat, and have filed and been issued patents, including composition of matter, pharmaceutical compositions, and related methods of use, which are expected to expire between December 2033 and November 2043, without giving effect to any patent term extensions.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TPST-1495: Dual EP2/EP4 Prostaglandin Receptor Antagonist</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our second small-molecule product candidate is TPST-1495, a potentially first-in-class, oral, small molecule dual antagonist of the prostaglandin E2 (&#8220;PGE2&#8221;), receptors, EP2 and EP4. TPST-1495 is engineered to inhibit only these receptors while sparing the homologous - but differentially active - EP1 and EP3 receptors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is extensive literature demonstrating that PGE2 both enhances tumor proliferation and inhibits anti-cancer immune function; it is known from the scientific literature that many tumors express elevated levels of the cyclooxygenase enzymes that produce PGE2. Elevated expression of COX-2 and overproduction of PGE2 is correlated with progression of diverse malignancies by stimulating tumor cell proliferation, survival, evasion and metastasis as well as host angiogenesis. In addition, PGE2 suppresses anti-tumor immunity by inhibiting the function of critical anti-tumor immune effector cell populations such as dendritic cells, natural killer (&#8220;NK cells&#8221;), T cells, and M1 macrophages, while promoting the activity of suppressive immune cell populations including myeloid-derived suppressor cells (&#8220;MDSCs&#8221;), M2 macrophages, and regulatory T cells. Recent studies have also shown that increased expression of COX-2 and production of PGE2 can play a role in the effectiveness of immune checkpoint inhibitor therapy and in the development of adaptive resistance to therapy. This body of literature provides the scientific rationale for developing therapeutics that maximally inhibit the prostaglandin pathway, as well as for combining TPST-1495 with immune checkpoint inhibitor monoclonal antibodies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted preclinical studies to evaluate TPST-1495, including its ability to reverse PGE2-mediated suppression of primary human monocyte to dendritic cell differentiation and activation in vitro, as well as comparisons to other agents designed to operate in the same pathway such as a single EP4 antagonist and, as described, COX2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also conducted preclinical studies to evaluate TPST-1495 in a spontaneous APCMin/+ mouse model of FAP that demonstrated a significant survival advantage in comparison to other inhibitors in the prostaglandin pathway.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img81402019_9.jpg" alt="img81402019_9.jpg" style="width:683px;height:323px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Source: Francica et al., Cancer Res Commun; 3(8) August 2023 https://doi.org/10.1158/2767-9764.CRC-23-0249</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of Ongoing TPST-1495 Clinical Trials</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-1495 was evaluated in a first-in-human, Phase 1, multicenter, open-label, schedule and dose optimization trial in subjects with late-stage solid tumor cancers that are deemed incurable. Study objectives include evaluation of safety, tolerability, PK, PD, and preliminary anti-tumor activity of TPST-1495 as monotherapy and in combination with the checkpoint inhibitor,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pembrolizumab. TPST-1495 has been evaluated on a once daily (&#8220;QD&#8221;) or twice daily (&#8220;BID&#8221;) schedule and with continuous or intermittent administration as monotherapy and in combination with pembrolizumab. Results from the Phase 1 study were presented at ASCO 2023. The data showed that in a diverse and treatment-refractory patient population, treatment with TPST-1495 as a monotherapy and in combination with pembrolizumab resulted in tumor shrinkage and prolonged stable disease in certain patients with a monotherapy safety profile on the recommended QD schedule that was tolerable, with predominantly Grade 1-2 treatment related adverse events (&#8220;TRAEs&#8221;). For the combination with pembrolizumab, Grade 1-3 TRAEs were reported.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our preclinical results in the APC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Min/+ </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lead us to consider the application of TPST-1495 in familial adenomatous polyposis syndrome (&#8220;FAP&#8221;). FAP is a hereditary condition characterized by the development of numerous polyps in the colon and rectum. These polyps have the potential to become cancerous if left untreated. FAP is caused by mutations in the APC gene, which normally helps regulate cell growth and division in the intestinal lining. Individuals with FAP have a significantly increased risk of developing colorectal cancer at a young age, often before the age of 40. Additionally, FAP can lead to the development of polyps in other parts of the gastrointestinal tract, as well as other non-gastrointestinal tumors. Management of FAP typically involves regular surveillance with colonoscopies and surgical intervention to remove the polyps and reduce the risk of cancer. Currently, there are no systemic therapies approved to treat FAP. We are working with CP-CTNet on an NCI-funded Phase 2 study, which we expect will begin this year.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we own worldwide rights to TPST-1495, and our issued United States patents covering TPST-1495 as compositions of matter, pharmaceutical compositions and related methods of use, are expected to expire between April 2038 and April 2039, without giving effect to any patent term adjustments or patent term extensions for regulatory delay.</span></p><p style="font-size:10pt;margin-top:8.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and Collaboration Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Novatim License and Collaboration Agreement</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 18, 2025, Erigen entered into an Exclusive License and Collaboration Agreement (the &#8220;Novatim License Agreement&#8221;) with Novatim. On February 3, 2026, the Novatim License Agreement was assigned to us in connection with the Closing pursuant to the Asset Purchase Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Novatim License Agreement, we obtained an exclusive license to specified patents and know-how in all fields worldwide, but excluding Greater China, India, Turkey, and Russia, to exploit the TPST-2003 and TPST-2206 programs and allogeneic CAR-T therapies based on the TPST-2003 and TPST-2206 programs. We also received a right of first negotiation to negotiate a license to exploit allogeneic CAR-T therapies and in vivo CAR-T therapies in Greater China. We are obligated to meet certain diligence milestones by specified dates and to use commercially reasonable efforts to develop and make commercially available at least one licensed product in the licensed territory. No upfront payment was paid pursuant to the Novatim License Agreement. We are obligated to pay Novatim up to $80 million in total upon achievement of certain development milestones for the programs and up to $1.24 billion in total upon achievement of certain commercial milestones for the programs. In addition, we are required to pay Novatim mid-to-high single digit royalties on net sales of licensed products, subject to certain customary reductions, up to a lifetime maximum of $800 million, following which our license shall become fully paid and royalty-free.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Novatim License Agreement is subject to termination (i) by either party, subject to specified cure periods, for the material breach by the other party or the bankruptcy or insolvency of the other party, or (ii) by mutual agreement of the parties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Factor Amended and Restated License and Collaboration Agreement</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 19, 2025, Erigen entered into an Amended and Restated License and Collaboration Agreement (the &#8220;Restated Factor License Agreement&#8221;) with Factor Bioscience Limited. On February 3, 2026, the Restated Factor License Agreement was assigned to us in connection with the Closing pursuant to the Asset Purchase Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Restated Factor License Agreement, we obtained an exclusive license to specified patents in all fields worldwide, but excluding Greater China, India, Turkey, and Russia (the &#8220;Licensed Territory&#8221;), to exploit the TPST-3003 and TPST-3206</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">programs. The Restated Factor License Agreement also established a Joint Steering Committee for the purposes of discussing and coordinating collaboration opportunities and serving as a forum for information sharing. We are obligated to meet certain diligence milestones by specified dates and to use commercially reasonable efforts to develop and make commercially available at least one licensed product in the licensed territory. No upfront payment was paid pursuant to the Restated Factor License Agreement. We are obligated to pay Factor Bioscience Limited up to $40 million in total upon achievement of certain development milestones for the programs and up to $620 million in total upon achievement of certain commercial milestones for the programs. In addition, we are required to pay Factor Bioscience Limited mid-single digit to high-teens royalties on net sales of licensed products on a country-by-country and licensed product-by-licensed product basis until expiration of the last to expire valid claim of certain licensed patents covering such licensed product in such country, subject to certain customary reductions, and low-to-mid double digit sublicense fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Restated Factor License Agreement will continue until expiration of the last-to-expire Royalty Term. &#8220;Royalty Term&#8221; is defined as, on a product-by-product and country-by-country basis, the period commencing on the first arms-length sale of a product in a country of the Licensed Territory, and ending on the date of expiration of the last to expire valid patent covering the exploitation of the applicable product in the applicable country of the Licensed Territory. The Restated Factor License Agreement is subject to termination (i) by either party, subject to specified cure periods, for the material breach by the other party or the bankruptcy or insolvency of the other party, (iii) by us for any reason upon 60 days notice, or (iii) by mutual agreement of the parties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Factor Amended and Restated Master Services Agreement</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 19, 2025, Erigen entered into an Amended and Restated Master Services Agreement (the &#8220;Restated Factor Services Agreement&#8221;) with Factor. On February 3, 2026, the Restated Factor Services Agreement was assigned to us in connection with the Closing pursuant to the Asset Purchase Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Restated Factor Services Agreement, Factor will perform services requested by us on a fee-for-services basis and provide us access to Factor&#8217;s facilities as mutually agreed upon in one or more written work orders. All deliverables developed as a result of Factor&#8217;s performance of the services or as set forth in a work order, other than specified improvements, will be our property and confidential information. Furthermore, Factor granted us a freedom-to-operate license to its background intellectual property, excluding certain technology and improvements licensed under the Restated Factor License Agreement, solely to the extent necessary or reasonably useful to use, practice or otherwise exploit the deliverables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Either party may terminate the Restated Factor Services Agreement at any time without cause upon 30 days&#8217; notice, provided that termination of the Restated Factor Services Agreement will not terminate any ongoing work orders. Either party may terminate individual work orders in accordance with the terms of the applicable work order.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Roche Collaboration Agreement</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2021, we entered into a collaboration agreement with F. Hoffmann-La Roche Ltd. (&#8220;Roche&#8221;) to accelerate the development of amezalpat into a global, first-line, randomized study. The companies are evaluating amezalpat in a Phase 1b/2 clinical study in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic HCC, not previously treated with systemic therapy. Pursuant to the terms of the agreement, Roche is managing the study operations for the trial, and we retain global development and commercialization rights to amezalpat. Pursuant to the agreement, Roche provides us with notice of the amount of amezalpat required and the delivery timeline, and we supply the amezalpat. All rights to invention and discoveries relating solely to amezalpat or biomarkers solely related to amezalpat made during any study will be our exclusive property. All data generated in the performance of any study under the collaboration agreement will be the property of Roche, but we are entitled to use the data for any lawful purpose.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreement applies on a study-by-study basis until the last treatment of the last patient in a study receiving amezalpat in accordance with the protocol for such study or until the termination of this collaboration agreement by either party. Each party has the right to terminate the collaboration agreement upon 60 days prior written notice to the other party. Upon any termination</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the agreement, neither we nor Roche will be entitled to any compensation, damages or other payment. If any individual study supplement is terminated, Roche must return all unused amezalpat to us free of charge or destroy such product at our request.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Roche Master Clinical Supply Agreement</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we entered into a master clinical supply agreement (&#8220;Roche Supply Agreement&#8221;) with Roche, pursuant to which Roche will supply Roche&#8217;s atezolizumab (TECENTRIQ) for use in one or more clinical studies conducted by us involving amezalpat in combination with atezolizumab, in each case, in accordance with the applicable study protocol prepared by us and reviewed by Roche. Under the Roche Supply Agreement, the parties may execute one or more clinical supply agreement supplements (each, a &#8220;CSA Supplement&#8221;) that will set forth the study to be conducted by us, the quantities of atezolizumab to be supplied by Roche for such study, and the delivery timeline for such quantities of atezolizumab. In October 2024, we entered into a CSA Supplement for Roche to supply atezolizumab to us, free of charge, for use in a potential Phase 3 trial.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales and Marketing</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to retain significant development and commercial rights to our product candidates and, if marketing approval is obtained, to commercialize our product candidates with a partner, in the United States and other regions. We currently have no sales, marketing or commercial product distribution capabilities. Clinical data, the size of the addressable patient population, the size of the commercial infrastructure and manufacturing needs may all influence or alter our commercialization plans.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely and expect to continue to rely on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates obtain marketing approval. We also rely, and expect to continue to rely, on third parties to package, label, store and distribute our investigational product candidates, as well as for our commercial products if marketing approval is obtained. We have internal personnel and utilize consultants with extensive technical, manufacturing, analytical and quality experience to oversee contract manufacturing and testing activities. We will continue to expand and strengthen our network of third-party providers but may also consider investing in internal manufacturing capabilities in the future if there is a technical need, or a strategic or financial benefit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing is subject to extensive regulations that impose procedural and documentation requirements. At a minimum these regulations govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance. Our systems, procedures and contractors are required to comply with these regulations and are assessed through regular monitoring and formal audits.</span></p><p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biopharmaceutical and immuno-oncology industries are characterized by intense competition and rapid innovation. Any product candidates that we successfully develop and commercialize will have to compete with existing and future new therapies. While we believe that our technology, development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our current or any future product candidates are approved for the treatment of cancer, they may compete with existing therapies as well as product candidates currently in development. There are a variety of treatments used for cancerous tumors that include chemotherapy drugs, small molecules, monoclonal antibodies, antibody-drug conjugates, bi-specific antibodies, cell therapies, oncolytic viruses and vaccines, as well as other approaches. In addition, there are several competitors in clinical development for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the treatment of HCC, RCC, cholangiocarcinoma, and other indications that we may target with TPST-1495, and amezalpat, including companies such as Ono, Adlai Nortye, Merck, Roche, Exelixis, and AstraZeneca.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the field of cell therapies, there are several competitors developing CAR-T and other cellular therapies for the treatment of system lupus erythematosus (SLE), multiple myeloma, and other hematologic malignancies that we may target with TPST-2003, TPST-3003 and TPST-4003, including companies such as Johnson &amp; Johnson, Bristol Meyers Squibb, Gilead Sciences, Arcellx, Legend Biotech, Allogene, Cellectis, AstraZeneca and other biotechnology and pharmaceutical companies developing BCMA-targeting and dual-targeting cell therapies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TPST-2003, our dual-targeting CD19/BCMA CAR-T cell therapy is, to our knowledge, the first parallel structure CD19/BCMA dual-targeting CAR-T under development for the treatment of rrMM specifically targeting patients with EMD. We are aware of other clinical-stage CD19/BCMA dual-targeting CAR-T product candidates, including a product under development by AstraZeneca. We are also aware of several approved therapies and products under development that utilize either a CD19 or BCMA single-targeting CAR structure. Amezalpat, our small molecule designed to be a selective antagonist of PPAR&#945;, is, to our knowledge, the first PPAR&#945; antagonist to enter the clinic. We are not aware of other companies developing such an antagonist. For TPST-1495, our small molecule designed to be a dual antagonist of the EP2 and EP4 receptor, we are aware of other clinical-stage EP-4-only antagonists being developed by Adlai Nortye and Ono.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunity could be substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products. The key competitive factors affecting the success of all our programs are likely to be their efficacy, safety, convenience and availability of reimbursement. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic drugs.</span></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to our business, including obtaining, maintaining, and defending our patent rights. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications and obtaining issued patents in the United States and in markets outside of the United States directed to our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position in the field of oncology. We also plan to rely on data exclusivity, market exclusivity and patent term extensions when available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, improvements, and product candidates; to preserve the confidentiality of our trade secrets; to defend and enforce our proprietary rights, including any patents that we may own or license in the future; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to TPST-2003, as of February 28, 2026, our in-licensed patent portfolio included one pending U.S. patent application, and nine pending patent applications in various markets outside of the United States, including Europe and Japan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pending patent applications cover TPST-2003 as compositions of matter, pharmaceutical compositions, and related methods of use. Any patents that may issue from the pending patent applications are expected to expire in March 2044, absent any patent term adjustments or patent term extensions for regulatory delay.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to TPST-2206, as of February 28, 2026, our in-licensed patent portfolio included two pending PCT applications. The pending PCT applications cover TPST-2206 as compositions of matter, pharmaceutical compositions and related methods of use. Any patents that may issue from the pending PCT applications are expected to expire in July 2045, absent any patent term adjustments or patent term extensions for regulatory delay.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to our TPST-3003, TPST-3206, and TPST-4003 programs, as of February 28, 2026, our in-licensed patent portfolio included ten issued U.S. patents, four pending U.S. patent applications, one pending PCT application, and five issued patents and eight pending patent applications in various markets outside of the United States, including Europe and Japan. The issued U.S. patents are expected to expire in May 2032, absent any patent term adjustments or patent term extensions for regulatory delay. Any additional patents that may issue from these pending patent applications are expected to expire between May 2032 and April 2045, absent any patent term adjustments or patent term extensions for regulatory delay.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, our patent portfolio consisted of issued patents and pending patent applications that we own related to amezalpat and TPST-1495. In total, as of the same date, we owned ten issued United States patents, four pending United States patent applications, one pending Patent Cooperation Treaty (&#8220;PCT&#8221;) application, and in various markets outside of the United States, including Europe, China and Japan: 68 issued patents and 8 pending patent applications.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to amezalpat, as of December 31, 2025, we owned issued patents and pending patent applications in the United States, Europe, China, Japan, and other markets outside of the United States as well as one pending PCT application. The issued United States patents covering amezalpat as compositions of matter, pharmaceutical compositions, and related methods of use are expected to expire in December 2033, absent any patent term adjustments or patent term extensions for regulatory delay. Any additional patents that may issue from these pending patent applications are expected to expire between December 2033 and March 2046, absent any patent term adjustments or patent term extensions for regulatory delay.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to TPST-1495, as of December 31, 2025, we owned issued patents and pending patent applications in the United States, Europe, China, Japan, and other markets outside of the United States. The issued United State patents covering TPST-1495 as compositions of matter, pharmaceutical compositions, and related methods of use are expected to expire between April 2038 and April 2039, absent any patent term adjustments or patent term extensions for regulatory delay. Any additional patents that may issue from these pending patent applications are expected to expire between April 2038 and April 2039, absent any patent term adjustments or patent term extensions for regulatory delay.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also possess substantial know-how and trade secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to our product candidates and processes that we intend to develop and commercialize in the normal course of business, we intend to pursue patent protection covering, when possible, compositions, methods of use, dosing, and formulations. We may also pursue patent protection with respect to manufacturing and drug development processes and technologies.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for patent applications filed in the United States can provide exclusionary rights for 20 years from the earliest effective filing date. The term of United States patents may be extended by delays encountered during prosecution that are caused by the USPTO, also known as patent term adjustment. In addition, in certain instances, the term of an issued United States patent that covers or claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of patents outside of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United States varies in accordance with the laws of the foreign jurisdiction but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of oncology has emerged in the United States. The relevant patent laws and their interpretation outside of the United States are also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions, and improvements. We cannot guarantee that patents will be granted with respect to any of its pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting its products, the methods of use or manufacture of those products.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, even its issued patents may not guarantee us the right to practice our technology in relation to the commercialization of its products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our issued patents may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for its product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing, and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.</span></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States at the federal, state and local level and in other countries and jurisdictions extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of pharmaceutical products, such as our investigational medicines and any future investigational medicines. Generally, before a new pharmaceutical product can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span></p><p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Approval Process</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, biopharmaceutical products are subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (&#8220;FFDCA&#8221;), the Public Health Service Act, and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and import and export of biopharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending New Drug Applications (&#8220;NDAs&#8221;) or Biologic License Applications (&#8220;BLAs&#8221;), warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investigational medicines and any future investigational medicines must be approved by the FDA before they may be legally marketed in the United States. The process generally involves the following:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations, including studies conducted in accordance with Good Laboratory Practice (&#8220;GLP&#8221;) requirements;</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval by an Institutional Review Board (&#8220;IRB&#8221;) or independent ethics committee at each clinical trial site before each clinical trial may be commenced;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance of adequate and well-controlled human clinical trials in accordance with applicable Investigational New Drug (&#8220;IND&#8221;) regulations, Good Clinical Practice (&#8220;GCP&#8221;) requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Submission to the FDA of an NDA for small molecule candidates and BLA for biologic candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment of any user fees for FDA review of applications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A determination by the FDA within 60 days of its receipt of an application to accept the filing for review;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug, or components thereof, will be produced to assess compliance with Good Manufacturing Practices (&#8220;cGMP&#8221;) requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity, and in the case of cell therapies, compliance with Good Tissue Practices;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in support of the application to assure compliance with GCPs and integrity of the clinical data;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of an NDA or BLA, including consideration of the views of any FDA advisory committee; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with any post-approval requirements, including risk evaluation and mitigation strategy (&#8220;REMS&#8221;), where applicable, and post-approval studies required by the FDA as a condition of approval.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all.</span></p><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Studies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before testing any product candidates in humans, the product candidate must undergo rigorous preclinical testing. Preclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLP. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some long-term preclinical testing may continue after an IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></p><p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational new drug or biologic to healthy volunteers or patients under the supervision of a qualified investigator, generally a physician not employed by or under the trial sponsor&#8217;s control. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of an IND.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, clinical trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Disclosure of the results of these clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the trial.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the clinical trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacokinetics, pharmacologic action, side effect tolerability, safety of the product candidate, and, if possible, early evidence of effectiveness.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2 clinical trials generally involve studies in disease-affected patients to evaluate proof of concept and/or determine the dosing regimen(s) for subsequent investigations. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These Phases may overlap or be combined. For example, a Phase 1/2 clinical trial may contain both a dose-escalation stage and a dose expansion stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials (as in traditional Phase 1 clinical trials) and provide insight into the anti-tumor effects of the investigational therapy in selected subpopulation(s).</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Typically, during the development of oncology therapies, all subjects enrolled in Phase 1 clinical trials are disease-affected patients and, as a result, considerably more information on clinical activity may be collected during such trials than during Phase 1 clinical trials for non-oncology therapies. A single Phase 3 or Phase 2 trial with other confirmatory evidence may be sufficient in rare instances to provide substantial evidence of effectiveness (generally subject to the requirement of additional post-approval studies). The manufacturer of an investigational drug in a phase 2 or 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including non-compliance with regulatory requirements or a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must develop additional information about the chemistry and physical characteristics of the product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the investigational medicines do not undergo unacceptable deterioration over their shelf life.</span></p><p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Review Process</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After completion of the required clinical testing, an NDA or BLA is prepared and submitted to the FDA. FDA approval of an NDA or BLA is required before marketing of the product may begin in the U.S. An NDA or BLA must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture and controls. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be marketed in the United States. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), each NDA or BLA must be accompanied by a substantial user fee. The FDA adjusts the user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on applications for products designated as orphan drugs, unless the product also includes a non-orphan indication. The sponsor under an approved application is also subject to an annual program fee.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA reviews each submitted NDA or BLA before it determines whether to file it and may request additional information. The FDA must make a decision on whether to file an application within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is filed, the FDA begins an in-depth review of the application. The FDA has agreed to certain performance goals in the review process. Most applications for standard review products are reviewed within ten months of filing; most applications for priority review are reviewed in six months from filing. Priority review can be applied to products that the FDA determines may offer significant improvement in safety or effectiveness compared to marketed products or where no adequate therapy exists. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA does not always meet its goal dates for standard and priority timeframes, and the review process can be extended by FDA requests for additional information or clarification.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may also refer applications for novel products, or products that present difficult questions of safety or efficacy, to an outside advisory committee&#8212;typically a panel that includes clinicians and other experts&#8212;for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving an NDA or BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also typically inspects clinical trial sites to ensure compliance with GCP requirements and the integrity of the data supporting safety and efficacy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the FDA evaluates the application and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter (&#8220;CRL&#8221;), generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application, such as additional clinical data, additional pivotal clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant may resubmit the NDA or BLA addressing all of the deficiencies identified in the letter, withdraw the application, engage in formal dispute resolution or request an opportunity for a hearing. The FDA has committed to reviewing resubmissions in two or six months depending on the type of information included. Even if such data and information are submitted, the FDA may decide that an application does not satisfy the criteria for approval.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a potential condition of approval, the FDA may require a REMS to help ensure that the benefits of the product outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals and elements to assure a product&#8217;s safe use (&#8220;ETASU&#8221;). An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#8217;s safety or efficacy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of an NDA or BLA supplement or, in some case, a new application, before the change can be implemented. A supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing supplements as it does in reviewing NDAs and BLAs.</span></p><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Other benefits of orphan drug designation include tax credits for certain research and an exemption from the NDA user fee.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Development and Review Programs</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition.</span></p><p style="font-size:10pt;margin-top:6.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast Track Designation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor of an investigational drug product may request that the FDA designate the drug candidate for a specific indication as a fast track drug concurrent with, or after, the submission of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#8217;s request. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#8217;s NDA or BLA before the application is complete. This rolling review is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. At the time of an NDA or BLA filing, the FDA will determine whether to grant priority review designation. Additionally, fast track designation may be withdrawn if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span></p><p style="font-size:10pt;margin-top:6.85pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Breakthrough Therapy Designation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Breakthrough therapy designation may be granted for products that are intended, alone or in combination with one or more other products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new drug candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of an IND for the drug candidate. The FDA must determine if the drug product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#8217;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical studies in an efficient manner.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Priority Review</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6.55pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated Approval</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accelerated approval may be granted for products that are intended to treat a serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a sponsor&#8217;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Information</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Pediatric Research Equity Act (&#8220;PREA&#8221;), an NDA or BLA or supplements thereto must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any product for an indication for which orphan designation has been granted, with certain exceptions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Best Pharmaceuticals for Children Act (&#8220;BPCA&#8221;) provides NDA or BLA holders a six-month extension of any exclusivity&#8212;patent or nonpatent&#8212;for a product if certain conditions are met. Conditions for exclusivity include the FDA&#8217;s determination that information relating to the use of a new product in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</span></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Requirements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an NDA or BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biopharmaceutical products, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Products may be marketed only for the approved indications and in a manner consistent with the approved labeling.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse event reporting and submission of periodic reports are required following FDA approval of an NDA or BLA. The FDA also may require post-marketing testing, known as phase 4 testing, REMS, and surveillance to monitor the effects of an approved</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging and labeling procedures must continue to conform to cGMP after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the Agency inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or a product recall;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fines, warning or other enforcement-related letters or holds on post-approval clinical studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product seizure or detention, or refusal to permit the import or export of products; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Injunctions or the imposition of civil or criminal penalties.</span></div></div><p style="font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Term Extension</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Hatch Waxman Amendments permit a patent term extension as compensation for patent term lost during the FDA regulatory review process. Patent term extension, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. After approval, owners of relevant  patents may apply for the extension. The allowable patent term extension is calculated as half of the product&#8217;s testing phase (the time between an IND application and an NDA or BLA submission) and all of the review phase (the time between NDA or BLA submission and approval) up to a maximum of five years. The time can be reduced for any time the FDA determines that the applicant did not pursue approval with due diligence.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The United States Patent and Trademark Office (&#8220;USPTO&#8221;), in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. However, the USPTO may not grant an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than requested.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total patent term after the extension may not exceed 14 years, and only one patent can be extended. The application for the extension must be submitted prior to the expiration of the patent, and for patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage, Pricing, and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and in foreign markets, sales of pharmaceutical products depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and commercial payors are critical to new product acceptance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the U.S. Department of Health and Human Services (&#8220;HHS&#8221;). CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Decisions regarding the extent of coverage and amount of reimbursement to be provided for each of our product candidates will be made on a plan-by-plan basis. One payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product. Additionally, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. Further, HHS imposes rebates on many Medicare Part B and Medicare Part D products to penalize price increases that outpace inflation on an annual basis. HHS has also been empowered to negotiate the price of certain single-source drugs that have been on the market for at least seven (7) years and biologics that have been on the market for at least eleven (11) years covered under Medicare as part of the Medicare Drug Price Negotiation Program. Each year up to twenty (20) products will be selected by HHS for the Medicare Drug Price Negotiation Program. Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from the Medicare program on a per unit basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has, and will continue to, put pressure on the pricing and usage of therapeutics such as our product candidates.</span></p><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Healthcare Laws</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain general business and marketing practices in the pharmaceutical industry. These laws include anti-kickback statutes, false claims statutes and other healthcare laws and regulations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to commit a violation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal civil and criminal false claims laws, including the federal civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs where the federal government reimburses, such as Medicare and Medicaid, as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply Schedule. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Additionally, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Most states also have statutes or regulations similar to the federal Anti-Kickback Statute and civil False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payor knows or should know is likely to influence the beneficiary to order a receive a reimbursable item or service from a particular supplier, and the additional federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which prohibits, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to commit a violation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, pursuant to the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation (the &#8220;Affordable Care Act&#8221; or the &#8220;ACA&#8221;), CMS has issued a final rule that requires manufacturers of prescription drugs to collect and report information on certain payments or transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, as well as investment interests held by physicians and their immediate family members. The reports must be submitted on an annual basis. The reported data is made available in searchable form on a public website on an annual basis. Failure to submit required information may result in civil monetary penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, imposes obligations, including mandatory contractual terms, on covered entities, business associates and their covered subcontractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, several states now require prescription drug companies to report certain expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual healthcare practitioners in these states. Other states prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals. Still other states require the posting of information relating to clinical studies and their outcomes. Some states require the reporting of certain drug pricing information, including information pertaining to and justifying price increases. In addition, certain states require pharmaceutical companies to implement compliance programs and/or marketing codes. Certain states and local jurisdictions also require certain regulatory licenses to manufacture or distribute products commercially and/or the registration of pharmaceutical sales and medical representatives. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws may face significant penalties.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that business arrangements with third parties comply with applicable healthcare laws and regulations involve substantial costs. If a drug company&#8217;s operations are found to be in violation of any such requirements, it may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of its operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other federal or state government healthcare programs, including Medicare and Medicaid, integrity oversight and reporting obligations, imprisonment, and reputational harm. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action for an alleged or suspected violation can cause a drug company to incur significant legal expenses and divert management&#8217;s attention from the operation of the business, even if such action is successfully defended.</span></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Healthcare Reform</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of health care and, more generally, to reform the U.S. healthcare system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the ACA was enacted, substantially changed the way healthcare is financed by both governmental and private insurers.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been judicial, executive brand, and Congressional challenges and amendments to certain aspects of the ACA. For example, on July 4, 2025, the One Big Beautiful Bill Act the (&#8220;OBBBA&#8221;) was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance.  The OBBBA also is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expired ACA subsidies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year, which began in 2013 and will remain in effect until 2032 unless additional Congressional action is taken.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current administration is pursuing policies to reduce regulations and expenditures across government agencies including at HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. For example, the current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer, through a direct to consumer platform (&#8220;TrumpRx&#8221;) U.S. patients and Medicaid programs prescription drug Most-Favored Nation pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient discounts and repatriation of foreign revenues. Other recent actions, for example, include (1) directing agencies to reduce agency workforce and cut programs; (2) directing HHS and other agencies to lower prescription drug costs through a variety of initiatives; (3) imposing tariffs on imported pharmaceutical products; and (4) as part of the Make America Healthy Again Commission&#8217;s Strategy Report released in September 2025, working across government agencies to increase enforcement on direct-to-consumer pharmaceutical advertising. Additionally, the current administration recently called on Congress to enact "The Great Healthcare Plan," to codify and expand Most-Favored Nation pricing, lower government subsidies to private insurance companies, increase healthcare price transparency, expand pharmaceutical drugs available for over-the-counter purchase, and enact restrictions on pharmacy benefit manager (&#8220;PBM&#8221;) payment methodologies, among other things. These actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and compliance risks.  In June 2024, the U.S. Supreme Court&#8217;s Loper Bright decision greatly reduced judicial deference to regulatory agencies, which could increase successful legal challenges to federal regulations affecting our operations. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees and Human Capital Resources</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 1, 2026, we had four employees, including four full-time employees and three holding Ph.D., MBA and/or M.S. degrees. Our employees have established internal expertise in cellular biology, pre-clinical development, and early-to-late-stage clinical development, as well as finance, business development and strategic transactions. None of our employees are represented by a labor union or covered by collective bargaining agreements. We will continue to add experienced and talented scientists in areas, such as medicinal chemistry, that we believe are critical for the discovery of highly differentiated small-molecule compounds.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consider a number of measures and objectives in managing our human capital assets, including, among others, employee engagement, development and training, talent acquisition and retention, employee safety and wellness, diversity and inclusion, and compensation and pay equity. We provide our employees with salaries and bonuses intended to be competitive for our industry, opportunities for equity ownership, development programs that enable continued learning and growth and a benefits package to promote well-being across all aspects of their lives, including health care, retirement planning and paid time off.  The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of equity-based compensation awards and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that a diverse workforce is important to our success and we are fundamentally committed to creating and maintaining a work environment in which employees are treated fairly, with dignity, decency, respect and in accordance with all applicable laws.  We understand that varied perspectives lead to the best ideas and outcomes. We believe that by creating a workplace where every individual can feel welcome and valued, we will be better able to achieve our corporate objectives. All employees must adhere to a code of business conduct and ethics and our employee handbook, which combined, define standards for appropriate behavior. Our recruitment, hiring, development, training, compensation, and advancement is based on qualifications, performance, skills, and experience without regard to gender, gender identity, sexual orientation, race, or ethnicity. People of color and those who are part of underrepresented groups in the biotech industry are encouraged to apply for open positions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in Delaware in April 2011.  Our corporate headquarters are located at 2000 Sierra Point Parkway, Suite 400, Brisbane, California 94005, and our telephone number is (415) 798-8589.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our internet website address is www.tempesttx.com. In addition to the information about us and our subsidiaries contained in this Annual Report, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through our website as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission (&#8220;SEC&#8221;). Additionally, the SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC&#8217;s website is www.sec.gov.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="section6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1A. RISK FACTORS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business involves significant risks, some of which are described below. You should carefully consider the risks described below, together with all of the other information contained in this Annual Report, including the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the financial statements and the related notes. Any of these events could cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made or may make from time to time.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Selected Risks Associated with Our Business</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, any one of which could materially adversely affect our business, financial condition, operating results, and prospects. You should read this summary together with the more detailed description of each risk factor contained below.</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is substantial doubt regarding our ability to continue as a going concern. We will require significant additional funding to finance our operations, which may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or our operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future. If we fail to obtain additional funding to conduct our planned research and development efforts, we could be forced to delay, reduce or eliminate our product development programs or commercial development efforts.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Integrating the Assets with our business may be more difficult, costly or time consuming than expected and we may fail to realize the anticipated benefits of the Asset Acquisition.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are in the early stages of integrating the Assets into our business, and unknown or unanticipated risks associated with the Assets could adversely affect us. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to expand our organization in the future, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to develop, obtain regulatory approval for and commercialize our product candidates, including TPST-2003, TPST-1495 and amezalpat, or any of our future product candidates, or if we experience significant delays in doing so, our business will be materially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Success in preclinical studies and earlier clinical trials for our product candidates may not be indicative of the results that may be obtained in later clinical trials, which may delay or prevent obtaining regulatory approval.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interim and preliminary data from our or our licensors&#8217; clinical trials that we may announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may derive results and data for TPST-2003 and TPST-2206 from clinical trials led by Novatim in China&#894; our role in any such trials and our access to the clinical results and data, will be limited and there is no assurance that the clinical data from any such trials will be accepted or considered by the FDA, or other comparable regulatory authorities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to work with our collaborator, Novatim, to conduct clinical trials for TPST-2003 and TPST-2206 outside the United States, including China, and the FDA and similar foreign regulatory authorities may not accept data from such trials conducted in locations outside of their jurisdiction.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to expand our pipeline of product candidates and develop marketable products.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial success of our product candidates, including TPST-2003, TPST-1495 and amezalpat, will depend upon their degree of market acceptance by providers, patients, patient advocacy groups, third-party payors and the general medical community.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in an environment of rapid technological change, and it is possible that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may harm our business, financial condition and ability to successfully market or commercialize our current and any future product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biologics are complex and difficult to manufacture. We intend to rely on third party manufacturers, potentially including Factor, Novatim, and/or contract development manufacturing organizations (&#8220;CDMOs&#8221;) to manufacture clinical supplies of our cell-therapy and in vivo CAR-T products, including TPST-2003, and to produce preclinical and clinical supply of other product candidates and to produce commercial supplies of any approved product. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or any approved products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenues.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be successful in finding strategic collaborators for continuing development of certain of our future product candidates or successfully commercializing or competing in the market for certain indications.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in part on our ability to obtain, maintain and protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have collaboration and license agreements with third parties, including our existing license and collaboration agreements with Novatim and Factor. If we are unable to maintain these agreements, our business could be adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our owned and in-licensed patents and patent applications may not provide sufficient protection of our product candidates or result in any competitive advantage.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of the shares of our common stock has been and is likely to continue to be volatile, and purchasers of our common stock could incur substantial losses.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We completed a reverse stock split of our shares of common stock, which may reduce and may limit the market trading liquidity of the shares due to the reduced number of shares outstanding and may potentially have an anti-takeover effect.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is thinly traded and our stockholders may be unable to sell their shares quickly or at market price.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to maintain listing of our common stock on Nasdaq or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our stockholders to sell their securities.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Position and Capital Needs</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There is substantial doubt regarding our ability to continue as a going concern. We will require significant additional funding to finance our operations, which may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or our operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our existing cash and cash equivalents of $7.7 million as of December 31, 2025 is expected to fund our operations through less than 12 months from the date our consolidated financial statements are available to be issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have finite cash resources available to fund our operations. On February 3, 2026, we closed the Asset Acquisition. For more information regarding the Asset Acquisition see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Developments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Strategic Acquisition of Dual-Targeting CAR-T Programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; Pursuant to the Asset Purchase Agreement, we entered into a funding commitment letter (the &#8220;Funding Commitment&#8221;) with Factor, which will provide us with financial support for at least 18 months following the closing of the Asset Acquisition, up to a maximum amount of $20.0 million that is inclusive of any amounts raised and received by us after the date of the Asset Purchase Agreement, on the terms and subject to the conditions and other provisions set forth in the funding commitment letter. As of the date of this report, we have $13.75 million available under the Funding Commitment. There is significant uncertainty as to whether we will be able to satisfy the terms and conditions and other provisions set forth in the funding commitment letter, and, if we are unable to do so, we may be limited in the amount of funding that we are able to access under the Funding Commitment or we may not be able to access any funds under the Funding Commitment. The timing of any additional funding from Factor is uncertain.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated product revenues from our activities and have incurred substantial operating losses. We expect that we will continue to generate substantial operating losses for the foreseeable future until we complete development and approval of one of our product candidates. As such, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. Our ability to raise additional capital has been adversely impacted by potential worsening global economic conditions, inflation expectations, and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from geopolitical tensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These conditions raise substantial doubt about our ability to continue as a going concern. We have evaluated the significance of the uncertainty regarding our financial condition in relation to our ability to meet our obligations, which has raised substantial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">doubt about our ability to continue as a going concern. There can be no assurances that we will be able to secure additional financing. In the event we do not, we may be required to wind down our operations and our stockholders will lose their investment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. Other than the Funding Commitment, we do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, including through the Funding Commitment, your ownership interest may be further diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. In addition, we may issue equity or debt securities as consideration for obtaining rights to additional compounds.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could negatively impact our ability to conduct our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we raise additional capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to raise capital may be limited by applicable laws and regulations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Using a shelf registration statement on Form S-3 to raise additional capital generally takes less time and is less expensive than other means, such as conducting an offering under a Form S-1 registration statement. However, our ability to raise capital using a shelf registration statement may be limited by, among other things, SEC rules and regulations. Under SEC rules and regulations, if our public float (the market value of our common stock held by non-affiliates) is less than $75.0 million, then the aggregate market value of securities sold by us or on our behalf under our Form S-3 in any 12-month period is limited to an aggregate of one-third of our public float. As our public float is currently less than $75.0 million, we are currently subject to this limitation. If our ability to utilize a Form S-3 registration statement for a primary offering of our securities continues to be limited to one-third of our public float, we may need to conduct such an offering pursuant to an exemption from registration under the Securities Act or under a Form S-1 registration statement, which would increase the cost of raising additional capital relative to utilizing a Form S-3 registration statement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future. If we fail to obtain additional funding to conduct our planned research and development efforts, we could be forced to delay, reduce or eliminate our product development programs or commercial development efforts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company with a limited operating history. Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. Our operations to date have been limited primarily to organizing and staffing, business planning, raising capital, acquiring and developing product and technology rights, manufacturing, and conducting research and development activities for our product candidates. We have never generated any revenue from product sales, and we have not obtained regulatory approvals for any of our product candidates. We incurred net losses of $26.3 million and $41.8 million for the year ended December 31, 2025 and 2024, respectively. As of December 31, 2025, we had an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accumulated deficit of $233.4 million. Substantially all of our operating losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future as we continue to conduct research and development, clinical testing, regulatory compliance activities, manufacturing activities, and, if any of our product candidates is approved, sales and marketing activities. Our prior losses, combined with our expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations to date have been limited to organizing and staffing, business planning, raising capital, acquiring our technology, identifying potential product candidates, undertaking research and preclinical studies of our product candidates, manufacturing, and establishing licensing arrangements. We have not yet demonstrated the ability to complete clinical trials of our product candidates, obtain marketing approvals, manufacture a commercial scale product or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a licensing and research focus to a company that is also capable of supporting clinical development and commercial activities. We may not be successful in such a transition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business and Strategy</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Integrating the Assets with our business may be more difficult, costly or time consuming than expected and we may fail to realize the anticipated benefits of the Asset Acquisition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 3, 2026, we completed the Asset Acquisition. The success of the Asset Acquisition will depend, in part, on our ability to realize the anticipated benefits from incorporating the Assets into our business and pipeline of product candidates. To realize the anticipated benefits from the Asset Acquisition, we must successfully integrate the Assets into our businesses in a manner that permits those benefits to be realized. If we are not able to successfully achieve these objectives, the anticipated benefits of the Asset Acquisition may not be realized fully or at all or may take longer to realize than expected. In addition, the anticipated benefits of the Asset Acquisition could be less than anticipated and integration may result in additional unforeseen expenses, which could have material adverse effects on our reputation, business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are in the early stages of integrating the Assets into our business, and unknown or unanticipated risks associated with the Assets could adversely affect us.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we conducted due diligence on the Assets prior to consummation of the Asset Acquisition, we are still relatively new to the development and operation of the Assets. As a result, we may not yet be aware of all material risks, liabilities, or challenges associated with the Assets, including risks that were not identified or fully appreciated during our due diligence process. There can be no assurance that our due diligence identified all risks, liabilities, or other material matters, that all material issues that could be uncovered through a customary level of due diligence were identified, or that factors outside of our control will not later arise. Even where due diligence successfully identifies certain risks, unexpected risks may arise, and previously known risks may materialize in a manner that is inconsistent with our preliminary risk assessments or assumptions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We must attract and retain highly skilled employees to succeed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan, harm our results of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations and increase our capabilities to successfully commercialize our product candidates. In particular, we believe that our future success is highly dependent upon the contributions of our senior management, particularly our Chief Executive Officer and President, Matthew Angel. The loss of services of Dr. Angel, or any of our other senior management, could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates, if approved. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates and our business will be limited.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to expand our organization in the future, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 1, 2026, we had four full-time employees. As the clinical development of our product candidates progresses, we will need to hire additional employees and expand the scope of our operations, particularly in the areas of research, drug development, manufacturing, clinical operations, regulatory affairs, business and development, finance and accounting and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage any future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such potential growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. Any expansion of our operations may lead to significant expenses, additional dilution and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may acquire additional businesses, product candidates or drugs form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses or product candidates with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. For example, in February 2026, we completed the Asset Acquisition. We may encounter numerous difficulties in developing, manufacturing and marketing any new drugs resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. The risks we face in connection with acquisitions, include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of management time and focus from operating our business to addressing acquisition integration challenges;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coordination of research and development efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retention of key employees from the acquired company;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in relationships with strategic partners as a result of product acquisitions or strategic positioning resulting from the acquisition;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cultural challenges associated with integrating employees from the acquired company into our organization;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the need to implement or improve controls, procedures and policies at a business that prior to the acquisition may have lacked sufficiently effective controls, procedures and policies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">liability for activities of the acquired company before the acquisition, including intellectual property infringement claims, violation of laws, commercial disputes, tax liabilities and other known liabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated write-offs or charges; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure to address these risks or other problems encountered in connection with our past or future acquisitions or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, cause us to incur unanticipated liabilities and harm the business generally. There is also a risk that future acquisitions will result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and tax credit carryforwards may be subject to limitations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to use our federal and state net operating losses (&#8220;NOLs&#8221;) to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our NOLs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal NOLs generated in tax years beginning on or before December 31, 2017, are permitted to be carried forward for only 20 years, and federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the utilization of such federal NOLs is limited to 80% of taxable income. In addition, under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; its ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. An &#8220;ownership change&#8221; under Section 382 of the Code is generally defined as a greater than 50 percentage point change (by value) in the corporation&#8217;s equity ownership by certain stockholders over a three-year period. We may have experienced ownership changes in the past, including as a result of our merger with Millendo Therapeutics, Inc. (&#8220;Millendo&#8221;), and may experience ownership changes in the future due to subsequent shifts in our stock ownership (some of which are outside of our control). Furthermore, the merger with Millendo constituted an ownership change of Millendo which may have eliminated or otherwise substantially limited our ability to use Millendo&#8217;s federal and state NOLs to offset our future taxable income. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our NOL carryforwards and other tax attributes, which could have a material adverse effect on cash flow and results of operations. Similar provisions of state tax law may also apply to limit our ability to use our accumulated state tax attributes. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Product Development and Regulatory Approval</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to develop, obtain regulatory approval for and commercialize our product candidates, including TPST-2003, TPST-1495 and amezalpat, or any of our future product candidates, or if we experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to invest a substantial amount of our efforts and financial resources in our product candidates, including TPST-2003, a dual-targeting CD19/BCMA CAR-T product under development for the treatment of multiple myeloma. Our ability to generate product revenue will depend heavily on the successful development and eventual commercialization of our product candidates and any future product candidates, which may never occur. We currently generate no revenue from sales of any product and we may never be able to develop or commercialize a marketable product.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our product candidates will require further clinical and/or preclinical development, regulatory approval in multiple jurisdictions, obtaining preclinical, clinical and commercial manufacturing supply, capacity and expertise, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. TPST-2003, TPST-1495 and amezalpat, and any future product candidates, must be authorized for marketing by the FDA, the Health Products and Food Branch of Health Canada (&#8220;HPFB&#8221;), the European Medicines Agency (&#8220;EMA&#8221;), and certain other foreign regulatory agencies before we may commercialize any of our product candidates in the United States, Canada, European Union, or other jurisdictions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of TPST-2003, TPST-1495 and amezalpat and any future product candidates depends on multiple factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful completion of preclinical studies, including those compliant with Good Laboratory Practice (&#8220;GLP&#8221;), or GLP toxicology studies, biodistribution studies and minimum effective dose studies in animals, and successful enrollment and completion of clinical trials compliant with current Good Clinical Practices (&#8220;GCPs&#8221;);</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effective Investigational New Drug applications or other regulatory applications, that allow commencement of our planned clinical trials or future clinical trials for our product candidates in relevant territories;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing and maintaining relationships with contract research organizations (&#8220;CROs&#8221;) and clinical sites for the clinical development of our product candidates, both in the United States and internationally;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful technology transfer and scale-up of cell therapy manufacturing processes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance of arrangements with third-party contract manufacturing organizations (&#8220;CMOs&#8221;) for key materials used in our manufacturing processes and to establish backup sources for clinical and large-scale commercial supply;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful collaboration with development partners, including those conducting clinical trials outside the United States;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">positive results from our clinical programs that are supportive of safety and efficacy and provide an acceptable risk-benefit profile for our product candidates in the intended patient populations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of regulatory approvals from applicable regulatory authorities, including those necessary for pricing and reimbursement of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory acceptance of clinical data generated outside the United States;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment and maintenance of patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercial launch of our product candidates, if and when approved, whether alone or in collaboration with others;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of our product candidates, if and when approved, by patients, patient advocacy groups, third-party payors and the general medical community;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to effectively compete with developers of other therapies available in the market;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment and maintenance of adequate reimbursement from third-party payors for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to acquire or in-license additional product candidates;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prosecution, maintenance, enforcement and defense of intellectual property rights and claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance of a continued acceptable safety profile of our product candidates following approval, including meeting any post-marketing commitments or requirements imposed by or agreed to with applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">political factors surrounding the approval process, such as government shutdowns; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, natural disasters including earthquakes, typhoons, floods and fires, and public health crises.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Success in preclinical studies and earlier clinical trials for our product candidates may not be indicative of the results that may be obtained in later clinical trials, which may delay or prevent obtaining regulatory approval.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical development is expensive and can take many years to complete, and our outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical studies and early clinical trials may not be predictive of results in later-stage clinical trials, and successful results from early or small clinical trials may not be replicated or show as favorable an outcome in later-stage or larger clinical trials, even if successful. We will be required to demonstrate through adequate and well-controlled clinical trials that our product candidates are safe and effective for their intended uses before we can seek regulatory approvals for their commercial sale. The conduct of Phase 3 trials and the submission of a New Drug Application (&#8220;NDA&#8221;) or Biologic License Application (&#8220;BLA&#8221;) is a complicated process. We have not previously completed any pivotal clinical trials, have limited experience in preparing, submitting and supporting regulatory filings, and have not previously submitted an NDA or BLA. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials and other requirements in a way that leads to NDA or BLA submission and approval of any product candidate we are developing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our clinical trials demonstrate acceptable safety and efficacy of current or any future product candidates and such product candidates receive regulatory approval, the labeling we obtain through negotiations with the FDA or foreign regulatory authorities may not include data on secondary endpoints and may not provide us with a competitive advantage over other products approved for the same or similar indications.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies in the biotechnology industry have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and there is a high failure rate for product candidates proceeding through clinical trials. In addition, different methodologies, assumptions and applications we utilize to assess particular safety or efficacy parameters may yield different statistical results. Even if we believe the data collected from clinical trials of our product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Preclinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our partners, which could delay, limit or prevent regulatory approval. If our study data does not consistently or sufficiently demonstrate the safety or efficacy of any of our product candidates to the satisfaction of the FDA or foreign regulatory authorities, then the regulatory approvals for such product candidates could be significantly delayed as we work to meet approval requirements, or, if we are not able to meet these requirements, such approvals could be withheld or withdrawn.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with our protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until our conclusion. The enrollment of patients depends on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient eligibility criteria defined in the protocol;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to study sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in our clinical trials will drop out of the trials before the infusion of our product candidates or trial completion.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates or could render further development impossible. For example, the impact of public health crises or geopolitical tensions, such as war or terrorism, may delay or prevent patients from enrolling or from receiving treatment in accordance with the protocol and the required timelines, which could delay our clinical trials, or prevent us from completing our clinical trials at all.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites are also being used by some of our competitors, which may reduce the number of patients who are available for our clinical trials in that clinical trial site.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because our product candidates represent unproven methods for cancer treatment, potential patients and their doctors may be inclined to use existing therapies rather than enroll patients in our clinical trials.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may derive results and data for TPST-2003 and TPST-2206 from clinical trials led by Novatim in China&#894; our role in any such trials and our access to the clinical results and data, will be limited and there is no assurance that the clinical data from any such trials will be accepted or considered by the FDA, or other comparable regulatory authorities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Novatim License Agreement, we expect Novatim to fund and lead clinical trial(s) of TPST-2003 and TPST-2206 in China. While these trials may provide us with clinical data that can inform our future development strategy, we do not have control over the protocols, administration, or conduct of the trials or their compliance with regulatory requirements. There is also no assurance that the clinical data from any such clinical trials will be accepted or considered by the FDA or other comparable regulatory authorities. Additional risks include procedural delays, timing issues and difficulties or differences in interpreting data. As a result, our minimal control over the conduct and timing of, and communications with the FDA, the National Medical Products Administration (&#8220;NMPA&#8221;) with respect to the trials that Novatim is conducting expose us to additional risks and uncertainties, many of which are outside our control, and the occurrence of which could adversely affect the prospects for our product candidates. Furthermore, any data integrity issues or patient safety issues arising out of any of these trials would be beyond our control, yet could adversely affect our reputation and damage the clinical and commercial prospects for our product candidates. Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates and our business will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We plan to work with our collaborator, Novatim, to conduct clinical trials for TPST-2003 and TPST-2206 outside the United States, including China, and the FDA and similar foreign regulatory authorities may not accept data from such trials conducted in locations outside of their jurisdiction.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Asset Purchase Agreement, at Closing we assumed Erigen&#8217;s rights and obligations under each of the Novatim License Agreement pursuant to which Novatim is pursuing clinical trials of TPST-2003 and TPST-2206 in China to generate clinical data from patients with rrMM and RCC, respectively. In addition, we may choose to conduct other clinical trials outside the United States, including in the Australia, Canada, Europe, the United Kingdom or other foreign jurisdictions. The acceptance by the FDA of data from clinical trials conducted in China or any other clinical trial outside the United States may be subject to certain conditions or may not be accepted at all. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice&#894; (ii) the trials were performed by clinical investigators of recognized competence and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. For example, in February 2022, the FDA publicly rebuked an oncology product sponsor for submitting a marketing application with Phase 3 clinical data solely from China and since that time, it has declined to approve other applications that contained primarily China-generated clinical data. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States, including China, or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim and preliminary data from our or our licensors' clinical trials that we may announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publish interim or preliminary data from our or our licensors' clinical studies. Interim data from clinical trials that we or our licensors' may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preliminary or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data is available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently are investigating amezalpat and TPST-1495 in combination with other approved therapies, and we may in the future investigate product candidates in combination with other approved and unapproved therapies, which exposes us to additional risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently investigating and may continue to investigate one or more of our product candidates in combination with one or more other approved or unapproved therapies to treat cancers. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies, including shortages of those products for use in our intended clinical trials. If the therapies we use in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. We also may choose to evaluate our current product candidates or any other future product candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell our current product candidates or any product candidate we develop in combination with an unapproved cancer therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved cancer therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval. If the FDA or comparable foreign regulatory authorities do not approve these other products or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the products we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain approval of or market such combination therapy.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to commercialization, TPST-2003, TPST-1495, amezalpat and any future product candidates must be approved by the FDA pursuant to an NDA or BLA in the United States and pursuant to similar marketing applications by the HPFB, EMA and similar regulatory authorities outside the United States. The process of obtaining marketing approvals, both in the United States and abroad, is expensive and takes many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have no experience in submitting and supporting the applications necessary to gain marketing approvals, and, in the event regulatory authorities indicate that we may submit such applications, we may be unable to do so as quickly and efficiently as desired. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining marketing approval or prevent or limit commercial use. Regulatory authorities have substantial discretion in the approval process and may refuse to accept or file any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval of our current and future product candidates may be delayed or refused for many reasons, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate, to the satisfaction of the FDA or comparable foreign regulatory authorities, that our product candidates are safe and effective for any of their proposed indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the populations studied in clinical trials may not be sufficiently broad or representative to assure efficacy and safety in the populations for which we seek approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA, BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the facilities of third-party manufacturers with which we contract or procure certain service or raw materials, may not be adequate to support approval of our product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our product candidates meet their pre-specified safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner and may not consider such clinical trial results sufficient to grant, or we may not be able to obtain, regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings, contraindications or Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;). These regulatory authorities may also grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and adversely affect our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current and any future product candidates may cause undesirable and/or unforeseen side effects or be perceived by the public as unsafe, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product candidates&#8217; use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. As we continue developing our product candidates and initiate clinical trials of our additional product candidates, serious adverse events (&#8220;SAEs&#8221;), undesirable side effects, relapse of disease or unexpected characteristics may emerge causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective or in which efficacy is more pronounced or durable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any such adverse events occur, our clinical trials could be suspended or terminated and the FDA, the HPFB, the European Commission, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Even if we can demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may adversely affect our business, financial condition, results of operations and prospects significantly, including our ability to successfully sign collaboration or license agreements with external partners. Other treatments for cancers that utilize prostaglandin E2 antagonist or a PPAR&#945; antagonist or similar mechanism of action could also generate data that could adversely affect the clinical, regulatory or commercial perception of our current and any future product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if any of our product candidates receives marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of the product outweigh our risks, which may include, for example, a Medication Guide outlining the risks of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product for distribution to patients and a communication plan to health care practitioners, or other elements to assure safe use of the product.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, if we or others later identify undesirable side effects caused by our product candidates, several potentially significant negative consequences could result, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings in the product labeling;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the way a product candidate is administered or conduct additional clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these occurrences may harm our business, financial condition, results of operations and prospects significantly.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to expand our pipeline of product candidates and develop marketable products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. Our business depends on our successful development and commercialization of the limited number of internal product candidates we are researching or have in preclinical development. Even if we are successful in continuing to build our pipeline, including through the Asset Acquisition, development of the potential product candidates that we identify will require substantial investment in additional clinical development, management of clinical, preclinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply capability, building a commercial organization, and significant marketing efforts before we generate any revenue from product sales. Furthermore, such product candidates may not be suitable for clinical development, including as a result of their harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we cannot develop further product candidates, we may not be able to obtain product revenue in future periods, which would adversely affect our business, prospects, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although our pipeline includes multiple programs, we are primarily focused on TPST-2003, TPST-1495 and amezalpat, and we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. Our understanding and evaluation of biological targets for the discovery and development of new product candidates may fail to identify challenges encountered in subsequent preclinical and clinical development. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and the activities associated with their development and potential commercialization, including their testing, manufacturing, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other U.S. and international regulatory authorities. These requirements include</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, including current Good Manufacturing Practices (&#8220;cGMP&#8221;), quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA and other regulatory authorities and requirements regarding the distribution of samples to providers and recordkeeping. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of any approved product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed in a manner consistent with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products. If we promote our product candidates in a manner inconsistent with FDA-approved labeling or otherwise not in compliance with FDA regulations, we may be subject to enforcement action. Violations of the FFDCA relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws and similar laws in international jurisdictions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on such product candidates, manufacturers or manufacturing processes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the labeling or marketing of a product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning or untitled letters;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of any approved product from the market;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recall of product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, it may lose any marketing approval that we have obtained, and we may not achieve or sustain profitability.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-compliance with Canadian and European requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To market and sell any of our current or future product candidates in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time and data required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Failure to obtain foreign regulatory approvals or non-compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business prospects could decline.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Commercialization and Manufacturing</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The commercial success of our product candidates will depend upon their degree of market acceptance by providers, patients, patient advocacy groups, third-party payors and the general medical community.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the requisite approvals from the FDA, the HPFB, the EMA and other regulatory authorities internationally are obtained, the commercial success of our product candidates will depend, in part, on the acceptance of providers, patients and third-party payors, as medically necessary, cost-effective and safe. In addition, we may face challenges in seeking to establish and grow sales of any current or future product candidates. Any product that we commercialize may not gain acceptance by providers, patients, patient advocacy groups, third-party payors and the general medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that coverage and reimbursement by third-party payors will be essential for most patients to be able to afford these treatments. Accordingly, sales of our product candidates will depend substantially, both domestically and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government payors, private health coverage insurers and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other third-party payors. Even if coverage is provided, the established reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered and reimbursed. The Medicare program covers certain individuals aged 65 or older, disabled or suffering from end-stage renal disease. The Medicaid program, which varies from state-to-state, covers certain individuals and families who have limited financial means. The Medicare and Medicaid programs increasingly are used as models for how private payors and other government payors develop their coverage and reimbursement policies for drugs. One payor&#8217;s determination to provide coverage for a drug product, however, does not assure that other payors will also provide coverage for the drug product. Further, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to government and private payors, professional organizations such as the American Medical Association, can influence decisions about coverage and reimbursement for new products by determining standards for care. In addition, many private payors contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit compared to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our product candidates, if approved. Even if favorable coverage and reimbursement status is attained for one or more product candidates for which our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the EU, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by government and other third-party payors, in the United States and internationally, to cap or reduce healthcare costs may cause such payors to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. For example, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;), imposes rebates on many Medicare Part B and Medicare Part D products to penalize price increases that outpace inflation on an annual basis. HHS has also been empowered to negotiate the price of certain single-source drugs that have been on the market for at least seven years and biologics that have been on the market for at least eleven years covered under Medicare as part of the Medicare Drug Price Negotiation Program. Each year up to 20 products will be selected by HHS for the Medicare Drug Price Negotiation Program. Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from the Medicare program on a per unit basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of certain third-party payors, such as health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the healthcare market. Recently there have been instances in which third-party payors have refused to reimburse treatments for patients for whom the treatment is indicated in the FDA-approved product labeling. Even if we are successful in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining FDA approval to commercialize our product candidates, we cannot guarantee that we will be able to secure reimbursement for all patients for whom treatment with our product candidates is indicated. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our product candidates that we develop, which could have an adverse effect on our operating results and our overall financial condition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If third parties on which we depend to conduct our planned preclinical studies or clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with adverse effects on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party CROs, CMOs, consultants and others to design, conduct, supervise and monitor key activities relating to, testing, discovery, manufacturing, preclinical studies and clinical trials of our product candidates, and we intend to do the same for future activities relating to existing and future programs. Because we rely on third parties and does not have the ability to conduct all required testing, discovery, manufacturing, preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of discovery, manufacturing, preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs, CMOs and consultants are not our employees, and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties we contract with might not be diligent, careful or timely in conducting our discovery, manufacturing, preclinical studies or clinical trials, resulting in testing, discovery, manufacturing, preclinical studies or clinical trials being delayed or unsuccessful, in whole or in part.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial, as well as in accordance with GLP, GCP and other applicable laws, regulations and standards. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. The FDA and other regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fails to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials have complied with GCP. In addition, our clinical trials must be conducted with product produced in accordance with cGMP. Our failure to comply with these regulations may require us to repeat clinical trials, which could delay or prevent the receipt of regulatory approvals. Any such event could have an adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition in an environment of rapid technological change, and it is possible that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than our therapies, which may harm our business, financial condition and our ability to successfully market or commercialize our current or future product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biopharmaceutical industry, and the immuno-oncology industry specifically, is characterized by intense competition and rapid innovation. We are aware of other companies focused on developing cancer therapies in various indications. We may also face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our potential competitors, alone or with their strategic partners, may have substantially greater financial, technical and other resources than we do, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market, if ever. Additionally, new or advanced technologies developed by our competitors may render our current or future product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To become and remain profitable, we must develop and eventually commercialize product candidates with significant market potential, which will require us to be successful in a range of challenging activities. These activities include, among other things, completing preclinical studies and initiating and completing clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products that are approved and satisfying any post marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our common stock and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue operations. A decline in the value of our common stock also could cause you to lose all or part of your investment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We must currently rely on outside vendors to manufacture supplies and process our product candidates. We have not yet manufactured or processed our product candidates on a commercial scale and may not be able to achieve manufacturing and processing and may be unable to create an inventory of mass-produced, off-the-shelf product to satisfy demands for any of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product. In addition, we anticipate reliance on a limited number of third-party manufacturers exposes us to the following risks:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited, and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third-party manufacturers could breach or terminate their agreement(s) with us.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Each of these risks could delay our clinical trials, the approval, if any, of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our product candidates for patients, if approved, could be delayed or stopped.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to establish manufacturing relationships with a limited number of suppliers to manufacture raw materials, the drug substance and finished product of any product candidate for which we are responsible for preclinical or clinical development. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain. As part of any marketing approval, a manufacturer and its processes are required to be qualified by the FDA prior to regulatory approval. If supply from the approved vendor is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through an application supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of manufacturing drugs is complex, highly regulated and subject to multiple risks. Manufacturing drugs is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at the facilities of our manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover, if the FDA determines that our CMOs are not in compliance with FDA laws and regulations, including those governing cGMP, the FDA may deny an NDA or BLA approval until the deficiencies are corrected or we replace the manufacturer in our application with a manufacturer that is in compliance. In addition, approved products and the facilities at which they are manufactured are required to maintain ongoing compliance with extensive FDA requirements and the requirements of other similar agencies, including ensuring that quality control and manufacturing procedures conform to cGMP requirements. As such, our CMOs are subject to continual review and periodic inspections to assess compliance with cGMP. Furthermore, although we do not have day-to-day control over the operations of our CMOs, we are responsible for ensuring compliance with applicable laws and regulations, including cGMP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if our collaborators obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that we will rely upon a limited number of manufacturers for our product candidates, which may include single-source suppliers for the various steps of manufacture. This reliance on a limited number of manufacturers and the complexity of drug manufacturing and the difficulty of scaling up a manufacturing process could cause the delay of clinical trials, regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our product candidates successfully. Furthermore, if our suppliers fail to deliver the required commercial quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement suppliers capable of production in a timely manner at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biologics are complex and difficult to manufacture. We intend to rely on third party manufacturers, potentially including Factor, Novatim and/or contract development manufacturing organizations (&#8220;CDMOs&#8221;) to manufacture clinical supplies of our cell-therapy and in vivo CAR-T products, including TPST-2003, and to produce preclinical and clinical supply of other product candidates and to produce commercial supplies of any approved product. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or any approved products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely, and expect to continue to rely, on third party manufacturers, which may include Factor, Novatim and CDMOs, to manufacture and to perform quality testing for our cell-therapy and in vivo CAR-T products, including TPST-2003. Reliance on third parties exposes us to risks associated with having reduced control over manufacturing activities, and any disruptions to the operations of our third-party manufacturers, including those caused by conditions unrelated to our business or operations such as bankruptcy of the manufacturer, could materially and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not operate manufacturing facilities for the production of clinical or commercial supplies of our product candidates and currently have no supply agreements for the production of any of our product candidates. We have no personnel with experience in manufacturing bispecific antibodies and lack the resources and the capabilities to manufacture any of our product candidates on any scale, including clinical or commercial scale. We currently plan to rely on third parties for supply of our product candidates and for commercial supply if any of our product candidates are approved for sale.r</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to enter into supply agreements with Factor, Novatim and/or one or more CDMOs for supply of our cell-therapy and in vivo CAR-T products, including TPST-2003, for use in clinical trials. Other than the Restated Factor Services Agreement, we currently have no agreements with third-party manufacturers for development, validation and manufacturing of our cell therapy or in vivo CAR-T products to secure the long-term clinical or commercial supply of our cell therapy or in vivo CAR-T products or for any of our other products candidates. We may be unable to secure agreements for commercial supply with third-party manufacturers, or may be unable to do so on acceptable terms. Any third-party manufacturers may not successfully carry out their contractual duties or obligations, the occurrence of which could substantially increase our costs and limit our supply of such product candidates. The demand for third-party manufacturer&#8217;s services is very high, and such manufacturers could be subject to market transactions including mergers, acquisitions and other market consolidation transactions that limit their ability to provide products and services to us thereby increasing the time and cost it could take us to manufacture our product candidates or any approved products.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers, which may include Factor, Novatim and CDMOs, entails additional risks, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on the third party for regulatory compliance and quality assurance&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible diversion of manufacturing capacity to other customers by the third party&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how&#894; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party manufacturers, which may include Factor, Novatim and CDMOs, may not be able to comply with current cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, which may include Factor, Novatim and CDMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. In addition, in order to conduct late-stage clinical trials of our product candidates, we will need to have them manufactured in large quantities. Our third-party manufacturers, which may include Factor, Novatim and CDMOs, may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, if our third-party manufacturers, which may include Factor, Novatim and CDMOs, are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained, which could significantly harm our business.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the third parties, which may include Factor, Novatim and CDMOs, that we engage to manufacture product for our preclinical tests and clinical trials should cease to continue to do so for any reason, we likely would experience delays in advancing these clinical trials while we identify and qualify replacement suppliers, and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the drug substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenues.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently do not have an organization for the sales, marketing and distribution of any current or future product candidates, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. To market any products that may be approved, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. With respect to certain of our current programs as well as future programs, we may rely completely on an alliance partner for sales and marketing. In addition, although we intend to establish a sales organization if we are able to obtain approval to market any product candidates, we may enter into strategic alliances with third parties to develop and commercialize our current and any future product candidates, including in markets outside of the United States or for other large markets that are beyond our resources. This will reduce the revenue generated from the sales of these products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any future strategic alliance partners may not dedicate sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective alliances to enable the sale of our product candidates to healthcare professionals and in geographical regions, including the United States, that will not be covered by our marketing and sales force, or if our potential future strategic alliance partners do not successfully commercialize the product candidates, our ability to generate revenues from product sales will be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in finding strategic collaborators for continuing development of certain of our future product candidates or successfully commercializing or competing in the market for certain indications.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, we may decide to collaborate with non-profit organizations, universities and pharmaceutical and biotechnology companies for the development and potential commercialization of existing and new product candidates. We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one for our product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay our development program or one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our expense. If we elect to increase our expenditures to fund development or commercialization activities on our product candidates, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of any potential collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of such collaboration arrangements. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration, or any failure by our partners to perform their obligations under collaboration agreements, would adversely affect us financially and could harm our business reputation or negatively impact our ability to successfully develop, obtain regulatory approvals for and commercialize our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA regulatory approval process is lengthy and time consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining FDA approval is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval for our product candidates, the FDA may approve our product candidates for a more limited indication or a narrower patient population than originally requested or may impose other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prescribing limitations or warnings that limit the product&#8217;s commercial potential. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our product candidates will ever obtain regulatory approval. Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also experience delays in obtaining regulatory approvals, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining regulatory authorization to begin a trial, if applicable;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">redesigning our study protocols and need to conduct additional studies as may be required by a regulator;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">governmental or regulatory delays and changes in regulation or policy relating to the development and commercialization of our product candidate by the FDA or other comparable foreign regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, and other comparable foreign regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of financial resources to commence and complete the planned trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negotiating the terms of any collaboration agreements we may choose to initiate or conclude;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of third-party contractors, such as CROs, or investigators to comply with regulatory requirements, including GCPs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay or failure in obtaining the necessary approvals from regulators or institutional review boards (&#8220;IRBs&#8221;), in order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to recruit and enroll suitable patients to participate in a trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty in having patients complete a trial or return for post-treatment follow-up;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing any patient safety concerns that arise during the course of a trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to add new clinical trial sites; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">varying interpretations of the data generated from our preclinical or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of establishing, expanding and scaling manufacturing capabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to manufacture, or obtain from third parties, sufficient quantities of qualified materials under cGMP, for the completion in pre-clinical and clinical studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">problems with biopharmaceutical product candidate storage, stability and distribution resulting in global supply chain disruptions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of establishing sales, marketing and distribution capabilities for any product candidate for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential unforeseen business disruptions or market fluctuations that delay our product development or clinical trials and increase our costs or expenses, such as business or operational disruptions, delays, or system failures due to malware, unauthorized access, terrorism, war, natural disasters, strikes, geopolitical conflicts, restrictions on trade, import or export restrictions, or public health crises.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data Safety Monitoring Committee. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek Breakthrough Therapy designation or Fast Track designation by the FDA for one or more of our product candidates but may not receive such designation. Even if we secure such designation, it may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek Breakthrough Therapy or Fast Track designation for some of our product candidates. For example, in February 2025, we announced that the FDA had granted Fast Track Designation to amezalpat for the treatment of HCC. If a product candidate is intended for the treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address unmet medical needs for this condition, the product candidate may be eligible for Fast Track designation. The benefits of Fast Track designation include more frequent meetings with FDA to discuss the drug&#8217;s development plan and ensure collection of appropriate data needed to support drug approval, more frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers, eligibility for Accelerated Approval and Priority Review, if relevant criteria are met, and rolling review, which means that completed sections of our application can be submitted for review by FDA, rather than waiting until every section of our NDA or BLA is completed before the entire application can be reviewed. NDA or BLA review usually does not begin until the entire application has been submitted to the FDA.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effects observed early in clinical development. Drugs designated as breakthrough therapies by the FDA may be eligible for all features of Fast Track designation, intensive guidance on an efficient drug development program, beginning as early as Phase 1, and organizational commitment involving senior managers at FDA.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible, we cannot assure that the FDA would decide to grant the designation. Even if we obtain Fast Track designation and/or Breakthrough Therapy designation for one or more of our product candidates, it may not experience a faster development process, review or approval compared to non-expedited FDA review procedures. In addition, the FDA may withdraw Fast Track designation or Breakthrough Therapy designation if it believes that the designation is no longer supported. These designations do not guarantee qualification for the FDA&#8217;s priority review procedures or a faster review or approval process, including for amezalpat for the treatment of HCC.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may attempt to secure FDA approval of our product candidates through the accelerated approval pathway. If we are unable to obtain accelerated approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we currently contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing certain product candidates for the treatment of serious conditions, and therefore may decide to seek approval of such product candidates under the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition and provides a meaningful therapeutic benefit over existing treatments based upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability of or lack of alternative treatments. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verity and describe the drug&#8217;s anticipated effect on irreversible morbidity or mortality or other clinical benefit. In some cases, the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. If the sponsor fails to conduct such studies in a timely manner, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit, or if other evidence demonstrates that our product candidate is not shown to be safe and effective under the conditions of use, the FDA may withdraw its approval of the drug on an expedited basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we decide to submit an application seeking accelerated approval or receive an expedited regulatory designation for any of our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. If any of our competitors were to receive full approval on the basis of a confirmatory trial for an indication for which we are seeking accelerated approval before we receive accelerated approval, the indication we are seeking may no longer qualify as a condition for which there is an unmet medical need and accelerated approval of our product candidate would be more difficult or may not occur.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates would result in a longer time period to commercialization of such product candidate, if any, and could increase the cost of development of such product candidate harm our competitive position in the marketplace.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Although we have received orphan drug designation for amezalpat and may continue to seek orphan drug designation for some or all of our current or future product candidates, we may be unsuccessful in obtaining Orphan Drug Designation for our product candidates or transfer of designations obtained by others for future product candidates, and, even if we obtain</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">such designation, we may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, we received Orphan Drug Designation for amezalpat for the treatment of patients with HCC. We may seek orphan drug designation for one or more of our current or future product candidates. The FDA may designate drugs intended to treat relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA or BLA. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for tax credits for qualified clinical research costs and exemption from prescription drug user fees. Generally, if a drug with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes FDA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. If a competitor is able to obtain orphan drug exclusivity prior to us for a product that constitutes the same active moiety and treats the same indications as our product candidates, we may not be able to obtain approval of our drug by the applicable regulatory authority for a significant period of time unless we are able to show that our drug is clinically superior to the approved drug. The applicable period is seven years in the United States.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek Orphan Drug Designation for one or more of our product candidates in the United States as part of our business strategy. However, Orphan Drug Designation does not guarantee future orphan drug marketing exclusivity. Even after an orphan drug is approved, the FDA can also subsequently approve a later application for the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer in a substantial portion of the target populations, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enacted and future legislation may increase the difficulty and cost for us to commercialize and obtain marketing approval of our product candidates and may affect the prices we may set.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the Affordable Care Act (&#8220;ACA&#8221;), was enacted to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Since its enactment, there have been amendments and judicial, Congressional and executive branch challenges to certain aspects of the ACA. For example, on July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance.  The OBBBA also is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expired ACA subsidies. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the current administration is pursuing policies to reduce regulations and expenditures across government agencies including at HHS, the FDA, the Centers for Medicare &amp; Medicaid and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. For example, the current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer, through a direct-to-consumer platform (&#8220;TrumpRx&#8221;), U.S. patients and Medicaid programs prescription drug Most-Favored Nation pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient discounts and repatriation of foreign revenues. Other recent actions, for example, include (1) directing agencies to reduce agency workforce and cut programs; (2) directing HHS and other agencies to lower prescription drug costs through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing Most-Favored-Nation pricing for pharmaceutical products; (3) imposing tariffs on imported pharmaceutical products; and (4) as part of the Make America Healthy Again Commission&#8217;s Strategy Report released in September 2025, working across government agencies to increase enforcement on direct-to-consumer pharmaceutical advertising. Additionally, the current administration recently called on Congress to enact &#8220;The Great Healthcare Plan,&#8221; to codify and expand Most-Favored Nation pricing, lower government subsidies to private insurance companies, increase healthcare price transparency, expand pharmaceutical drugs available for over-the-counter purchase, and enact restrictions on pharmacy benefit manager payment methodologies, among other things. These actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and compliance risks.  In June 2024, in Loper Bright Enterprises v. Raimondo, the U.S. Supreme Court greatly reduced judicial deference to regulatory agencies, which could increase successful legal challenges to federal regulations affecting our operations. Congress may introduce and ultimately pass health care related legislation that could impact, among other things, the drug approval process and make changes to the Medicare Drug Price Negotiation Program. At the state level, legislatures and agencies are increasingly passing legislation and implementing regulations designed to control spending, on and patient out-of-pocket costs for, drug products. These measures include constraints on pricing, discounting and reimbursement, restrictions on certain product access and marketing, cost disclosure and transparency measures that require detailed reporting of drug pricing and marketing information both at product launch and in the event of a price increase, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that these, as well as other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA&#8217;s ability to review and approve new products may be hindered by a variety of factors, including budget and funding levels, ability to hire and retain key personnel, statutory, regulatory and policy changes and global health concerns.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. In addition,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including in October 2025, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA and other government agencies to properly administer their functions is highly dependent on the levels of government funding and the ability to fill key leadership appointments, among various factors. Delays in filling or replacing key positions could significantly impact the ability of the FDA and other agencies to fulfill their functions, and could greatly impact healthcare and the pharmaceutical industry. In addition, the current administration has implemented substantial reductions in force at various government agencies including the FDA, which could significantly reduce the FDA&#8217;s capacity to perform its functions in a manner consistent with its past practices and could delay reviews and negatively impact our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security, and our (or the third parties with whom we work) actual or perceived failure to comply with them could harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, &#8220;process&#8221;) a large quantity of personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, and patient health information in connection with our preclinical and clinical studies. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there are numerous federal, state, and local privacy and data security laws and regulations governing the processing of personal data, including health information privacy laws, security breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). Each of these laws is subject to varying interpretations and constantly evolving. In addition, we obtain health information from third parties (including research institutions from which it obtains clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended (&#8220;HIPAA&#8221;), which imposes specific requirements relating to the privacy, security, and transmission of protected health information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain states have also adopted comprehensive privacy laws and regulations that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. For example, the  California Consumer Privacy Act, as amended by the California Privacy Rights Act (collectively, the &#8220;CCPA&#8221;) gives California residents expanded rights to access and delete their personal data, opt out of certain personal data sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation.  Although the CCPA and other comprehensive U.S. state privacy laws exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts if we become subject to those laws, potentially increasing our legal risk and compliance costs for us, and the third parties with whom we work. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and security.  For example, in Canada, the Personal Information Protection and Electronic Documents Act (&#8220;PIPEDA&#8221;) and similar provincial laws may impose obligations with respect to processing personal data, including health-related information. PIPEDA requires companies to obtain an individual&#8217;s consent when collecting, using or disclosing that individual&#8217;s personal data. Individuals have the right to access and challenge the accuracy of their personal data held by an organization, and personal data may only be used</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the purposes for which it was collected. If an organization intends to use personal data for another purpose, it must again obtain that individual&#8217;s consent. Failure to comply with PIPEDA could result in significant fines and penalties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As another example, the European Union&#8217;s General Data Protection Regulation (the &#8220;EU GDPR&#8221;) and the United Kingdom&#8217;s GDPR (the &#8220;UK GDPR,&#8221; and together with the EU GDPR, the &#8220;GDPR&#8221;) also impose strict requirements for processing personal data and substantial fines for breaches and violations (for example, under the EU GDPR, up to the greater of &#8364;20 million or 4% of our annual worldwide gross revenue). Additionally, under the GDPR, companies may face temporary or definitive bans on data processing and other corrective action or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we may receive personal data collected and processed by our business partners in China. China enacted the Personal Information Protection Law (the &#8220;PIPL&#8221;) in 2021. The PIPL establishes a comprehensive data privacy and protection framework that applies to the processing of personal information both within China and outside of China where such processing is conducted for the purpose of providing products or services to, or analyzing or evaluating the behavior of, individuals in China. The PIPL imposes significant fines for serious violations of up to RMB 50 million or 5% of annual revenue from the prior year. Certain industry&#8209;specific Chinese laws and regulations also impose requirements for processing of certain specific types of data. China&#8217;s Regulations on the Administration of Human Genetic Resources (the &#8220;HGR Regulation&#8221;), promulgated by the State Council in 2019 and revised in 2024, prohibit foreign organizations, individuals, and entities established or controlled by them from collecting, preserving, or exporting China&#8217;s human genetic resources. Foreign parties may access or use China&#8217;s human genetic resources upon satisfying applicable regulatory requirements, including through approved international collaboration with qualified Chinese institutions and completing required governmental approval, filing, and information backup procedures. We may need to provide necessary assistance for our Chinese business partners to comply with their obligations under Chinese privacy and data security laws and regulations, and our data processing activities may be subject to obligations applicable to the recipient of personal data collected or generated in China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (&#8220;EEA&#8221;) and the United Kingdom (&#8220;UK&#8221;) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt or have already adopted similarly stringent data localization and cross-border data transfer laws. For example, under the PIPL, entities conducting cross&#8209;border transfers of personal information are required to meet certain conditions, including satisfaction of the security assessments conducted by competent government authority, signing and filing of standard contracts or obtaining certifications from qualified institutions, and fulfillment of notice and consent requirements. In the EEA and UK, although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Department of Justice issued a rule entitled Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons which places additional restriction on certain data transactions involving countries of concern (e.g., China, Russia, Iran) and covered persons (i.e., individuals and entities who are designated as such by the U.S. Attorney General or considered &#8220;foreign persons&#8221; and are majority owned by, organized under the laws of, a primary resident in, or a contractor of, a covered person or country of concern, as applicable) that may impact certain business activities such as vendor engagements, sale or sharing of data, employment of certain individuals, and investor agreements. Violations of the rule could lead to significant civil and criminal fines and penalties. The rule applies regardless of whether data is anonymized, key-coded, pseudonymized, de-identified or encrypted, which presents particular challenges for companies like ours and may impact our ability to engage in certain transactions or agreements with certain third parties in the future.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If there is no lawful manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to data privacy and security laws, we are contractually subject to industry standards adopted by industry groups and, we may become subject to such obligations in the future. We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We publish privacy policies, marketing materials and other statements concerning data privacy and security.  Regulators in the United States are increasingly scrutinizing these statements, and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty.  Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions.  Preparing for and complying with these obligations requires us to devote significant resources, which may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.  In addition, these obligations may require us to change our business model.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with these obligations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms designed to ensure compliance with these obligations. If we fail (or are perceived to have failed) to comply with any such obligations, we may face significant consequences, including without limitation government enforcement actions (e.g., investigations, fines and penalties, audits, inspections); litigation (including class-action claims) and mass arbitration demands); additional reporting requirements and/or oversight; bans or restrictions on processing personal data; orders to destroy or not use personal data; imprisonment of company officials; or other consequences that could adversely affect our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems or those of third parties with whom we work, or our data, are or were compromised, we could experience adverse consequences, including disclosure of sensitive information, damage to our reputation, and significant financial and legal exposure.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we and the third parties with whom we work, process proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, trade secrets (collectively, sensitive information).  Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties with whom we work.  These threats are increasing in their frequency, sophistication and intensity, have become increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyberattacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.  During times of war and other major conflicts, we and the third parties with whom we work are vulnerable to a heightened risk of these attacks, including retaliatory cyberattacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, social engineering attacks (including through deep-fakes, which are increasingly more difficult to identify as fake,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and phishing attacks), malicious code (such as viruses and worms),  denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data, attacks enhanced or facilitated by AI or other information technology assets, fraud or other means to threaten confidentiality, integrity and availability of our sensitive information. We and the third parties with whom we work may also experience telecommunications failures, natural disasters, terrorism, war and other similar threats.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive information and income, reputational harm, and diversion of funds.  Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As more of our employees work remotely, the risk of a cybersecurity incident potentially occurring, and our investment in risk mitigations against such an incident, is increasing. For example, there has been an increase in phishing and spam emails as well as social engineering attempts from &#8220;hackers.&#8221; Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.  Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we rely on third parties and their technology to operate critical business systems to process sensitive information, including our CROs, CMOs and other contractors, consultants and law and accounting firms. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If these third parties experience a security incident or other interruption, we could experience adverse consequences.  While we may be entitled to damages if our third-party partners fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.  In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches. We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our and the third parties&#8217; with whom we work hardware and software). We have not, and may not in the future, however, detect and remediate all such vulnerabilities including on a timely basis.  Further, we have, and may in the future, experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities.  Vulnerabilities could be exploited and result in a security incident.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the previously identified or similar threats have in the past and may in the future cause a security incident or other interruption that have in the past and may in the future result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties with whom we work. For example, we have been the target of unsuccessful phishing attempts in the past, and expect such attempts will continue in the future. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to provide our services.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expend significant resources or may have to modify our business activities (including our clinical trial activities) to try to protect against security incidents.  Certain data privacy and security obligations require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive information. Applicable data privacy and security obligations require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services.  Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.  We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A successful or perceived security incident experienced by us or the third parties with whom we work could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of sensitive information, disclosure of corporate strategic plans, material disruption of our development programs and our business operations, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections), additional reporting requirements and/or oversight, restrictions on processing sensitive information, litigation, indemnification obligations, reputational harm, negative publicity, and other harms. For example, the loss of data from preclinical studies or clinical trials could result in significant delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security incident were to result in a loss of, or damage to, our sensitive information or applications, or inappropriate disclosure of such information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be significantly delayed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, principal investigators, CROs, CMOs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of FDA and non-U.S. regulators, to provide accurate information to the FDA and non-U.S. regulators, to comply with healthcare fraud and abuse laws and regulations in the United States and abroad, to report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and could cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operations and relationships with future customers, providers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to penalties including criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with providers, third-party payors and customers will subject us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we obtain marketing approval.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictions under applicable U.S. federal and state healthcare laws and regulations include the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti-Kickback Statute, a criminal law that prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal civil False Claims Act, imposes significant civil penalties and treble damages, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Criminal Statute on False Statements Relating to Health Care Matters makes it a crime to knowingly and willfully falsify, conceal, or cover up a material fact, make any materially false, fictitious, or fraudulent statements or representations, or make or use any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items, or services;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Federal Civil Monetary Penalties Law authorizes the imposition of substantial civil monetary penalties against an entity that engages in activities including, among others (1) knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity that is excluded from participation in federal health care programs to provide items or services reimbursable by a federal health care program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to report and return a known overpayment;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA imposes criminal and civil liability for, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on health plans, healthcare clearinghouses and certain healthcare providers, known as &#8220;covered entities&#8221;, and their respective HIPAA &#8220;business associates&#8221;, which are independent contractors that perform certain services for or on behalf of covered entities involving the use or disclosure of individually identifiable health information, as well as their covered subcontractors. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Physician Payment Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, among others, to track and report payments and other transfers of value provided during the previous year to U.S. licensed physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and, teaching hospitals, as well as certain ownership and investment interests held by physicians and their immediate family;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">certain state and local laws require certain regulatory licenses to manufacture or distribute products commercially and/or the registration of pharmaceutical sales representatives in the jurisdiction; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, it may be costly to us in terms of money, time and resources, and we may be subject to criminal, civil or administrative sanctions, including exclusion from government-funded healthcare programs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. our operations also may produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws or regulations could materially adversely affect us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us, which could adversely affect our business and financial condition. For example, the U.S. government recently enacted the OBBBA that (along with other recent U.S. federal tax reform legislation) has resulted in significant changes to the taxation of business entities, including, among other changes, the imposition of minimum taxes and excise taxes, changes to the taxation of income derived from international operations, changes in the deduction and amortization of research and development expenditures, and limitations on the deductibility of business interest. The IRA enacted in 2022 includes, among other changes, a minimum tax equal to 15% of the adjusted financial statement income of certain large corporations, as well as a 1% excise tax on certain share buybacks by public corporations that is imposed on such corporations. Future guidance from the Internal Revenue Service and other tax authorities with respect to any legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation or sunset in future years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our collaboration with Novatim subjects us to risks and uncertainties relating to challenged and changing relations between the United States and China.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Political relations between the United States and China are strained. Each country has been enacting sanctions and threatening additional sanctions against the other. The United States Congress has been pursuing potential legislation targeting certain China-based biopharmaceutical companies, and other China-based companies. Additionally, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations affecting biopharmaceutical companies, and U.S. laws and regulations affecting biopharmaceutical companies based in or operating in China are also unpredictable. Any regulatory changes and changes in United States and China relations may have a material adverse effect on our collaboration with Novatim, which could harm our business and financial condition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S.-China trade relations may adversely impact our supply chain operations and business.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. and Chinese governments have taken certain actions that change trade policies, including tariffs that affect certain products which are manufactured in China and mutual exchange of certain types of data. Due to our collaboration with Novatim, we are reliant on collaborating with a company with significant operations in China. It is unknown whether and to what extent new tariffs, laws or regulations will be adopted that increase the cost or feasibility of importing and/or exporting products, components and information from China to the United States and vice versa. Further, the effect of any such new tariffs or actions on our industry and customers is unknown and difficult to predict. As additional new tariffs, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or if China or other affected countries take retaliatory trade actions, such changes could have a material adverse effect on our clinical development plans, business, financial condition, results of operations or cash flows.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our success depends in part on our ability to obtain, maintain and protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success will depend in large part on obtaining and maintaining patent, trademark, trade secret and other intellectual property protection of our proprietary technologies and product candidates and any future product candidates we have in development, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending our patents and other intellectual property rights against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to our, and our ability to commercialize any product candidates we may develop may be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. If we are unable to adequately fund our patent prosecution and maintenance, or if the costs of defending our patents against third-party challenges become prohibitive, our competitive position could be weakened. Additionally, recent reforms and changes at government agencies of the United States and those of non-U.S. jurisdictions could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications, and the maintenance, enforcement, or defense of our issued patents. For example, the ability of the USPTO and other applicable patent authorities to properly administer their functions is highly dependent on the levels of funding available to the agency and their ability to retain key personnel and fill key leadership appointments, among various factors. Termination of employees or delays in replacing or hiring for key positions could significantly impact the ability of the USPTO and other applicable patent authorities to fulfill their functions and could greatly impact our ability to timely and adequately prosecute or maintain our patent applications, and our ability to timely and adequately maintain, enforce, or defend our issued patents. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development activities before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and may be reliant on our licensors or licensees to do so. Our pending and future patent applications may not result in issued patents. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we hold or in-license may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether any of our platform advances and product candidates will be protectable or remain protected by valid and enforceable patents. In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, such as our license agreement with Novatim, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. In addition, our current or future licensors may not always act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated, or if disputes regarding these licenses arise, we could lose significant rights that may be important to our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a party to license agreements under which we are granted intellectual property rights that are important to our business and our product candidates. If we fail to comply with our obligations under the license agreement or we are subject to a bankruptcy, the license agreements may be terminated, in which event we would not be able to develop, commercialize or market our product candidates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, pursuant to the Novatim License Agreement, we obtained an exclusive license to specified patents and know-how in all fields worldwide, but excluding Greater China, India, Turkey, and Russia, to exploit the TPST-2003 and TPST-2206 programs and allogeneic CAR-T therapies based on the TPST-2003 and TPST-2206 programs. We also have a right of first negotiation to negotiate a license to exploit allogeneic CAR-T therapies and in vivo CAR-T therapies in Greater China. We are obligated to meet certain diligence milestones by specified dates and to use commercially reasonable efforts to develop and make commercially available at least one licensed product in the licensed territory. In addition, pursuant to the Restated Factor License Agreement, we have an exclusive license to specified patents in all fields worldwide, but excluding Greater China, India, Turkey, and Russia, to exploit the TPST-3003 and TPST-3206 programs. Under the Restated Factor License Agreement, we are obligated to meet certain diligence milestones by specified dates and to use commercially reasonable efforts to develop and make commercially available at least one licensed product in the licensed territory.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our licenses to patents, know-how and proprietary technology licensed from third parties may not provide exclusive rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our products in the future. The agreements under which we license patents, know-how and proprietary technology from others may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future we may also need to obtain additional licenses from third parties to advance our research or allow commercialization of product candidates Tempest may develop. It is possible that we may be unable to obtain any licenses at a reasonable cost or on reasonable terms, if at all. In either event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology or product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our current or future licensors fail to adequately protect our licensed intellectual property, our ability to commercialize product candidates could suffer. We may not have complete control over the maintenance, prosecution and litigation of our current or future in-licensed patents and patent applications. For example, we cannot be certain that activities such as the maintenance and prosecution by our current or future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. It is possible that our current or future licensors&#8217; infringement proceedings or defense activities may be less vigorous than had we conducted them ourselves or may not be conducted in accordance with our best interests.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the resolution of any contract interpretation disagreement that may arise could narrow what we might believe to be the scope of our rights to the relevant patents, know-how and proprietary technology, or increase what we believe to be our financial or other obligations under the relevant agreement. Disputes that may arise between us and our current or future licensors regarding intellectual property subject to a license agreement could include disputes regarding:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates and what activities satisfy those diligence obligations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">royalty, milestone or other payment obligations that may result from the advancement or commercial sale of any of our product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If disputes over intellectual property that we currently license or may license in the future prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected technology or product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our owned and in-licensed patents and patent applications may not provide sufficient protection of our product candidates or result in any competitive advantage.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications and those of our licensors may not result in patents being issued which protect our product candidates or which effectively prevent others from commercializing competitive product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. For example, while our patent applications are pending, we may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;), or become involved in interference or derivation proceedings, or equivalent proceedings in foreign jurisdictions. Even if patents do successfully issue, third parties may challenge their inventorship, validity, enforceability or scope, including through opposition, revocation, reexamination, post-grant and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review proceedings. An adverse determination in any such submission, proceeding or litigation may result in loss of patent rights, loss of exclusivity, patent term adjustment being jeopardized, patent term being reduced, or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. Moreover, some of our owned and in-licensed patents and patent applications may be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in development, testing, and regulatory review of new product candidates, the period of time during which we could market our product candidates under patent protection would be reduced or eliminated.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since patent applications in the United States and other countries are confidential for a period of time after filing or until issuance, at any moment in time, we cannot be certain that it was in the past or will be in the future the first to file any patent application related to our product candidates. In addition, some patent applications in the United States may be maintained in secrecy until the patents are issued. As a result, there may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim, and we may be subject to priority disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that, if challenged, our patents would be declared by a court, patent office or other governmental authority to be valid or enforceable or that even if found valid and enforceable, a competitor&#8217;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, that block our efforts or potentially result in our product candidates or our activities infringing such claims. It is possible that our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to our products and technology. Those patent applications may have priority over our owned and in-licensed patent applications or patents, which could require us to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain rights to issued patents covering such technologies. The possibility also exists that others will develop products that have the same effect as our product candidates on an independent basis that do not infringe our patents or other intellectual property rights, or will design around the claims of patents that we have had issued that cover our product candidates or their use. Likewise, our currently owned patents and patent applications, if issued as patents, directed to our proprietary technologies and our product candidates are expected to expire from 2033 through 2046, without taking into account any possible patent term adjustments or extensions. Our earliest patents may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Additionally, we cannot be assured that the USPTO or relevant foreign patent offices will grant any of the pending patent applications we own or in-license currently or in the future. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make or use compounds that are similar to the active compositions of our product candidates but that are not covered by the claims of our patents; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the APIs in our current product candidates will eventually become commercially available in generic drug products, and no patent protection may be available with regard to formulation or method of use;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current or future licensors, as the case may be, may fail to meet our or our obligations to the U.S. government regarding any patents and patent applications funded by U.S. government grants, leading to the loss or unenforceability of patent rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current or future licensors, as the case may be, might not have been the first to file patent applications for certain inventions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications will not result in issued patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our owned or in-licensed patents, as the case may be, or parts of our owned or in-licensed patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that others may circumvent our owned or in-licensed patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our product candidates or technology similar to ours;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the laws of foreign countries may not protect our, or our current or future licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the United States;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not adequately cover our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes that design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our owned or in-licensed patents or patent applications may omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable or such omitted individuals may grant licenses to third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have engaged in scientific collaborations in the past and will continue to do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies for which we can obtain patent protection;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#8217; patents or other exclusive rights; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our strategy of obtaining rights to key technologies through in-licenses may not be successful.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The future growth of our business may depend in part on our ability to in-license or otherwise acquire the rights to additional product candidates and technologies. We cannot assure you that we will be able to in-license or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, our agreements with certain of our third-party research partners provide that improvements developed in the course of our relationship may be owned solely by either we or our third-party research partner, or jointly between us and the third party. If we determine that exclusive rights to such improvements owned solely by a research partner or other third party with whom we collaborate are necessary to commercialize our drug candidates or maintain our competitive advantage, we may need to obtain an exclusive license from such third party in order to use the improvements and continue developing, manufacturing or marketing our drug candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our drug candidates or allow our competitors or others the opportunity to access technology that is important to our business. We also may need the cooperation of any co-owners of our intellectual property in order to enforce such intellectual property against third parties, and such cooperation may not be provided to us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the in-licensing and acquisition of these technologies is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire product candidates or technologies that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to license rights to us. Furthermore, we may be unable to identify suitable product candidates or technologies within our area of focus. If we are unable to successfully obtain rights to suitable product candidates or technologies, our business and prospects could be materially and adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to patent protection, we rely upon know-how and trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third-parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">individual or entity during the course of the party&#8217;s relationship with us are to be kept confidential and not disclosed to third parties, except in certain specified circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and that are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information (or as otherwise permitted by applicable law), are our exclusive property. In the case of consultants and other third parties, the agreements provide that all inventions conceived in connection with the services provided are our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We have also adopted policies and conducts training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information through other precautions, such as physical and technological security measures. However, trade secrets and know-how can be difficult to protect. These measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and any recourse we might take against this type of misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent us from receiving legal recourse. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, such as through a security incident, or if any of that information was independently developed by a competitor, our competitive position could be harmed. Additionally, certain trade secret and proprietary information may be required to be disclosed in submissions to regulatory authorities. If such authorities do not maintain the confidential basis of such information or disclose it as part of the basis of regulatory approval, our competitive position could be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. Even if we are successful, these types of lawsuits may result in substantial cost and require significant time from our scientists and management. Although we take steps to protect our proprietary information and trade secrets, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology, through legal or illegal means. As a result, we may not be able to meaningfully protect our trade secrets. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent, delay or otherwise interfere with our product discovery and development efforts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property or other proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates. We are aware of certain issued patents and pending patent applications in the United States and elsewhere that contain claims that may cover certain cell therapy programs of ours. While we believe we would have valid defenses to claims of patent infringement or noninfringement positions, we cannot be certain that we would prevail in any dispute, and we cannot be certain how an adverse determination would affect our business. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our field, third parties may allege they have patent rights encompassing our product candidates, technologies or methods.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a third party claims that we infringe, misappropriate or otherwise violate their intellectual property rights, we may face a number of issues, including, but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">infringement and other intellectual property claims that, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages plus the patent owner&#8217;s attorneys&#8217; fees;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third-party licenses our product rights or proprietary technology to us, which it is not required to do, on commercially reasonable terms or at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement that we redesign our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization, including by enforcing our patents against us by filing a patent infringement lawsuit against us. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There may be third-party patents of which we are currently unaware of with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringe upon these patents.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, or materials used in or formed during the manufacturing process, or any final product itself, the holders of those patents may be able to block our ability to commercialize our product candidate unless we obtain a license under the applicable patents, or until those patents were to expire or those patents are finally determined to be invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of that patent may be able to block our ability to develop and commercialize the product candidate unless we obtain a license or until such patent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expires or is finally determined to be invalid or unenforceable. In either case, a license may not be available on commercially reasonable terms, or at all, particularly if such patent is owned or controlled by one of our primary competitors. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee time and resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any license of this nature would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates and we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In that event, we would be unable to further develop and commercialize our product candidates, which could significantly harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these legal proceedings may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of these third parties may be able to sustain the costs of such proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent proceedings could compromise our ability to compete in the marketplace. If we do not prevail in the patent proceedings, the third parties may assert a claim of patent infringement directed at our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful and could result in a finding that such patents are unenforceable or invalid.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our patents or the patents of our current or future licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, non-enablement, or obviousness-type double patenting. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. These types of mechanisms include re-examination, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). These types of proceedings could result in revocation or amendment to our patents such that they no longer cover our product candidates. The outcome for any particular patent following legal assertions of invalidity and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Defense of these types of claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conversely, we may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings), or we may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the Canadian Intellectual Property Office (&#8220;CIPO&#8221;), the European Patent Office (&#8220;EPO&#8221;), or another foreign patent office. The outcome following legal assertions of invalidity is unpredictable. Additionally, we may be subject to claims of patent infringement during those proceedings, and delays caused by the federal agencies may increase the time period that we are subject to such claims.  For example, administrative changes, including reduced staff and budgets experienced by the Patent and Trial Appeal Board, could further delay our ability to timely challenge any such patents. Even if successful, the costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, CIPO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. Any of the foregoing could have a material adverse effect on our business financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. For example, patents covering methods-of-use are not available in certain foreign countries. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we do not have or have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our product candidates in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert management&#8217;s efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert management&#8217;s efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geopolitical actions in the United States and in foreign countries (such as, ongoing wars or similar conflicts; retaliatory measures by foreign countries in response to actions by the United States, in particular; and tariffs) could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, the United States and foreign government actions related to the Russia-Ukraine war may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have a predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Also, many foreign countries could threaten to impose retaliatory measures that may adversely impact our intellectual property rights in those countries. For example, on March 14, 2025, Brazil enacted Law No. 15.122/2025 (known as the &#8220;Economic Reciprocity Law&#8221;), which provides a framework that allows for the suspension of obligations related to foreign entities&#8217; intellectual property rights. Consequently, we would not be able to prevent third parties from practicing our inventions in such jurisdictions or from selling or importing products made using our inventions in and into such jurisdictions. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. We may then have to pursue litigation to defend against these claims. If we fail in defending any claims of this nature, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these types of claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities, and we may not have sufficient financial or other resources to adequately conduct this type of litigation or proceedings. For example, some of our competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than we can because of their substantially greater financial resources. In any case, uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign patent agencies also require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable laws and rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Were a noncompliance event to occur, our competitors might be able to enter the market, which would have a material adverse effect on our business financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Past or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. For example, in March 2013, under the Leahy-Smith America Invents Act (&#8220;America Invents Act&#8221;), the United States moved from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; patent system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes continue to evolve as the USPTO continues to promulgate new regulations and procedures in connection with the America Invents Act. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on the specific patents discussed in this filing have not been determined and would need to be reviewed. Moreover, the America Invents Act and our implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. We cannot predict how decisions by the federal courts, the U.S. Congress or the USPTO may impact the value of our patent rights. For example, the Federal Circuit recently issued a decision involving the interaction of patent term adjustment (&#8220;PTA&#8221;), terminal disclaimers, and obviousness-type double patenting. This decision creates uncertainty to the patent terms of certain U.S. patents that share the same priority claim where on expires later than another due to accrued PTA. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain or license in the future. For example, in the case, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Assoc. for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Molecular Pathology v. Myriad Genetics, Inc</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the U.S. Supreme Court held that certain claims to DNA molecules are not patent-eligible. In another example, the U.S. Supreme Court held in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amgen v. Sanofi (2023)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that a functionally claimed genus was invalid for failing to comply with the enablement requirement of the Patent Act.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, other cases by the U.S. Supreme Court have held that certain methods of treatment or diagnosis are not patent-eligible. U.S. law regarding patent-eligibility continues to evolve. While we do not believe that any of our patents will be found invalid based on these changes to U.S. patent law, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents and patent applications. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a further example, as of June 1, 2023, European patent applications and patents may be subjected to the jurisdiction of the Unified Patent Court (&#8220;UPC&#8221;). In 2012, the European Union Patent Package (The &#8220;EU Patent Package&#8221;) regulations were passed with the goal of providing a single pan-European Unitary Patent and a new European UPC for litigation involving European patents. The EU Patent Package was implemented on June 1, 2023. As a result, all European patents, including those issued prior to ratification of the EU Patent Package, now by default automatically fall under the jurisdiction of the UPC. European patent applications will have the option, upon grant of a patent, of becoming a Unitary Patent, which will be subject to the jurisdiction of the UPC. The UPC and Unitary Patent are significant changes in European patent practice. It is uncertain how the UPC will impact granted European patents in the biotechnology and pharmaceutical industries. Our European patent applications, if issued, could be challenged in the UPC. During the first seven years of the UPC&#8217;s existence, the UPC legislation allows a patent owner to opt its European patents out of the jurisdiction of the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation in the UPC. As a single court system can invalidate a European patent, we, where applicable, may opt out of the UPC and as such, each European patent would need to be challenged in each individual country. We may decide to opt out future European patents from the UPC, but doing so may preclude us from realizing the benefits of the UPC. Moreover, if we do not meet all of the opt-out formalities and requirements under the UPC, our future European patents could remain under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain pan-European injunctions. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates due to increased competition and, resultantly, on our financial condition, prospects and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we or our partners commercialize those candidates. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during clinical trials and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent per product may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. U.S. and ex-U.S. law concerning patent term extensions and foreign equivalents continue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to evolve. Even if we were to seek a patent term extension, it may not be granted because of, for example, the failure to exercise due diligence during the testing phase or regulatory review process, the failure to apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable requirements. Additionally, administrative changes at the USPTO or other applicable patent authorities, such as reduced hiring and/or funding, may result in delays in issuance of a patent or in accrual of patent term extension, thereby reducing the amount of patent term extension that could otherwise be received. Administrative changes (e.g., at the FDA or USPTO) may also lead to delays in review and analysis of requests for patent term extension, which could result in a patent term extension not being timely granted (e.g., before the expiration of the patent). Moreover, the applicable time period of extension or the scope of patent protection afforded could be less than we project or request. If we are unable to obtain patent term extension or term of any such extension is less than we project or request, our competitors may obtain approval of competing products following our patent expiration sooner than expected, and our business, financial condition, results of operations and prospects could be materially harmed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property discovered through government funded programs may be subject to federal regulations such as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">march-in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we do not currently license or own issued patents or pending patent applications that have been generated through the use of U.S. government funding, we may in-license or acquire in the future intellectual property rights that have been generated through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as march-in rights). Recently, the government released a draft framework that may be used by an agency when deciding to exercise its march-in rights for public comments, and as such, the framework for deciding when march-in rights are exercised may change. If the U.S. government exercised its march-in rights in our current or future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership of Our Common Stock and Other General Matters</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the benefits of the Asset Acquisition do not meet the expectations of investors or securities analysts, the market price of our common stock may decline.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock may decline as a result of the Asset Acquisition if we do not achieve the perceived benefits of the Asset Acquisition as rapidly or to the extent anticipated by financial analysts or the effect of the Asset Acquisition on our financial results is not consistent with the expectations of financial analysts. Accordingly, holders of our common stock following the consummation of the Asset Acquisition may experience a loss as a result of a decline in the market price of such common</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock. In addition, a decline in the market price of our common stock following the consummation of the Asset Acquisition could adversely affect our ability to issue additional securities if needed and to obtain additional financing in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The trading price of the shares of our common stock has been and is likely to continue to be volatile, and purchasers of our common stock could incur substantial losses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock has been and is likely to continue to be volatile. For example, during 2025, the closing price of our common stock on The Nasdaq Capital Market ranged from $2.84 per share to $12.81 per share. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of clinical trials and preclinical studies of our product candidates, or those of our competitors or our existing or future collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to meet or exceed financial and development projections we may provide to the public;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to meet or exceed the financial and development projections of the investment community;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions or departures of key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of securities by us or our securityholders in the future;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if we fail to raise an adequate amount of capital to fund our operations and continued development of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the introduction of technological innovations or new therapies that compete with our products and services;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad, including as a result of bank failures, public health crises or geopolitical tensions, such as wars or terrorism; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">period-to-period fluctuations in our financial results.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty about economic stability. For example, the macroeconomic uncertainty and volatile business environment have resulted in ongoing inflation, volatility in the capital markets, significantly reduced liquidity and credit availability, decreases in consumer demand and confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. Our general business strategy may be materially or adversely impacted by if these unpredictable and unstable market conditions continue. Additionally, geopolitical tensions, wars and terrorism, and the imposition of tariffs in the U.S. and abroad, has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences for us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of future bank closures or political unrest, war or a global or domestic recession or the fear thereof,, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade disputes, trade restrictions, tariffs and other political tensions between the U.S. and other countries may also exacerbate unfavorable macroeconomic conditions, including inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns, which may also negatively impact customer demand for our services, delay renewals or limit expansion opportunities with existing customers, limit our access to capital, or otherwise negatively impact our business and operations.  In addition, retaliatory trade policies or anti-U.S. sentiment in certain regions whether driven by trade tensions, political disagreements, or regulatory concerns may make customers and governments more hesitant to purchase U.S. products. This may lead to increased preference for local competitors, changes to government procurement policies, heightened regulatory scrutiny, decreased intellectual property protections, delays in regulatory approvals or other retaliatory regulatory non-tariff policies, the introduction of trade barriers applicable to pharmaceutical products, which may result in heightened international legal and operational risks and difficulties in attracting and retaining non-U.S. customers, suppliers, employees, partners and investors. Ongoing tariff and macroeconomic uncertainty may also contribute to volatility in the price of our common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, inflation can adversely affect us by increasing our costs, including salary costs. Any significant increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations and financial condition. A weak or declining economy could also strain our suppliers and manufacturers, possibly resulting in supply and clinical trial disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our common stock is thinly traded and our stockholders may be unable to sell their shares quickly or at market price.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we have had periods of high-volume daily trading in our common stock, generally our stock is thinly traded. As a consequence of this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influence the price of those shares in either direction. Our common stock price could, for example, decline significantly as a result of sales of a large number of shares of our common stock on the market without commensurate demand, as compared to a seasoned issuer that could better absorb those sales without adverse impact on its share price, or from the perception that these sales could occur.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a smaller reporting company, and the reduced reporting requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company&#8221; as defined in Section 12 of the Exchange Act. For as long as we continue to be a smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including not being required to comply with the auditor attestation requirements of Section 404 of Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Chief Executive Officer and principal stockholder collectively own a substantial portion of our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collectively, our Chief Executive Officer and Lotus Capital BVI Limited (&#8220;Lotus&#8221;) beneficially own approximately 59.3% of our outstanding common stock as of March 25, 2026. Specifically, Dr. Angel, our President and Chief Executive Officer, beneficially owns approximately 35.3% of our common stock and Lotus beneficially owns approximately 23.9% of our outstanding common stock as of March 25, 2026, respectively. As a result, stockholders may face challenges in affecting matters involving our Company, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the composition of our Board and, through it, any determination with respect to our business direction and policies, including the appointment and removal of officers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any determination with respect to mergers or other business combinations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our acquisition or disposition of assets; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our corporate financing activities.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although there are no voting or similar agreements in place, our Chief Executive Officer and Lotus may act in concert to significantly influence these and other matters requiring shareholder approval. Furthermore, this concentration of voting power could have the effect of delaying, deterring, or preventing a change of control or other business combination that might otherwise be beneficial to our shareholders. This significant concentration of share ownership may also adversely affect the trading price for our common stock because investors may perceive disadvantages in owning stock in a company that is controlled by a small number of shareholders.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Status as a Public Company and Other General Matters</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance with our public company responsibilities and corporate governance practices.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Stock Market (Nasdaq) and other applicable securities rules and regulations impose various requirements on public companies. Our management and other personnel need to devote a substantial amount of time to compliance with these requirements. Moreover, these rules and regulations increase our legal and financial compliance costs and will make some activities more time-consuming and costly. We cannot predict or estimate the amount of additional costs we will continue to incur as a public company or the timing of such costs. Once we are no longer a smaller reporting company or otherwise no longer qualifies for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, and the rules and regulations of the stock market on which our common stock is listed. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting and a report by management on, among other things, the effectiveness of our internal control over financial reporting. We will not be required to have our auditors formally attest to the effectiveness of our internal control over financial reporting until we cease to be a smaller reporting company.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may identify weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. We cannot assure you that there will not be material weaknesses or significant deficiencies in the internal control over financial reporting in the future.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to accurately report our financial condition, results of operations or cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begins its reporting on internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq Stock Market, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to maintain listing of our common stock on Nasdaq or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our stockholders to sell their securities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although our common stock is currently listed on Nasdaq, we may not be able to continue to meet the exchange&#8217;s minimum listing requirements or those of any other national exchange. The Listing Rules of Nasdaq require listing issuers to comply with certain standards in order to remain listed on its exchange. If, for any reason, we should fail to maintain compliance with these</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">listing standards and Nasdaq should delist our securities from trading on its exchange and we are unable to obtain listing on another national securities exchange, we anticipate that our securities would begin trading on the over-the-counter market. Delisting from Nasdaq and trading on the over-the-counter market could adversely affect the liquidity of our securities. Securities traded on the over-the-counter market generally have limited trading volume and exhibit a wider spread between the bid/ask quotation, as compared to securities listed on a national securities exchange. Consequently, you may not be able to liquidate your investment in the event of an emergency or for any other reason.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If Nasdaq delists our securities from trading on its exchange for failure to meet the listing standards, we and our stockholders could face significant negative consequences including limited availability of market quotations for our securities, a determination that the common stock is a &#8220;penny stock&#8221; which will require brokers trading in the common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of the common stock, a limited amount of analyst coverage, and a decreased ability to issue additional securities or obtain additional financing in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by natural disasters and other calamities, including public health crises, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, fire, hurricane, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our suppliers&#8217; manufacturing facilities, or that otherwise disrupted operations, such as data storage, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Occurrences of epidemics or pandemics, depending on their scale, may cause different degrees of damage to the national and local economies within our geographic focus. Global economic conditions may be disrupted by widespread outbreaks of infectious or contagious diseases, and such disruption may adversely affect clinical development plans. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even greater risk if we commercialize any of our product candidates. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in a product, negligence, strict liability or breach of warranty. Claims could also be asserted under U.S. state consumer protection acts. If we cannot successfully defend against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for any product candidates that we may develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation and significant negative media attention;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant time and costs to defend the related litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination of our collaboration relationships or disputes with our collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">voluntary product recalls, withdrawals or labeling restrictions; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any product candidates that we may develop.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we currently have insurance that we believe is appropriate for our stage of development, we may need to obtain higher levels prior to clinical development or marketing any of our future product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation and by-laws and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation and by-laws may discourage, delay or prevent a merger, acquisition or other change in control of the company that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a classified board of directors such that not all members of the board are elected at one time;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit the manner in which stockholders can remove directors from the board;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and for nominations to our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit who may call stockholder meetings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit actions by our stockholders by written consent;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require that stockholder actions be effected at a duly called stockholders meeting;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our certificate of incorporation or by-laws.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in October 2023, we implemented a stockholder rights plan (the &#8220;Rights Plan&#8221;), also called a &#8220;poison pill,&#8221; that may have the effect of discouraging or preventing a change of control by, among other things, making it uneconomical for a third party to acquire us without the consent of our board of directors. We amended the Rights Plan on October 9, 2024 and on December 5, 2024, and on January 27, 2026, our stockholders approved the Rights Plan at our 2026 annual meeting of stockholders. As a result of the amendments and the stockholder approval of the Right Plan, the rights will expire on October 10, 2026, unless the rights are earlier redeemed or exchanged by us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or combination is approved in a manner prescribed by the statute.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against it arising pursuant to any provisions of the DGCL, our certificate of incorporation or our bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. The provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in the bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current expectation is that we will retain our future earnings, if any, to fund our growth as opposed to paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. We have no control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section7">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><div><ix:nonNumeric id="F_642cee8b-6acc-4f69-942c-a39dac411cf0" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_642cee8b-6acc-4f69-942c-a39dac411cf0_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1C. CYBERSECURITY</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_642cee8b-6acc-4f69-942c-a39dac411cf0_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to our clinical trials and employees (&#8220;Information Systems and Data&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security function is led by our Chief Financial Officer &amp; Head of Corporate Strategy (&#8220;IT Lead&#8221;), who reports to our CEO and is supported by our third-party security provider, and it helps identify, assess and manage the Company&#8217;s cybersecurity threats and risks. The information security function identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example analyzing report of threats and threat actors and conducting periodic vulnerability assessments for certain systems.  Our assessment and management of material risks from cybersecurity threats are considered as part of our risk management processes. For example, our IT Lead and certain management, including our CEO, evaluate identified material risks from cybersecurity threats against our overall business objectives and our IT Lead periodically reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, systems, and data, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: risk assessments for certain systems, systems monitoring for certain systems, access controls, asset management, and employee training. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d5b82f0-34d9-4fe2-8f5a-8ee2adc339f8" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9bfb13a-7700-4a5c-b6a5-7ac945ea40b4" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example our managed security provider and professional services firms, including legal counsel.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_594c2328-5673-4f32-b133-3cf55612d3ec" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including that if our information technology systems or those of third parties upon which we rely, or our data, are or were compromised, we could experience adverse consequences, including disclosure of sensitive information, damage to our reputation, and significant financial and legal exposure.</span></p><div><ix:nonNumeric id="F_8deab51d-f14b-4ef3-b7d1-6ae2a49c18f8" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><ix:nonNumeric id="F_664ef5bc-9198-4fc3-9272-1adde526897b" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_093a338f-9494-4915-a53b-e811738a2705" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true" continuedAt="F_093a338f-9494-4915-a53b-e811738a2705_1"><div><ix:nonNumeric id="F_dca79e32-2f40-47db-a66d-19b4c00e508c" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c679215f-02e2-4bb2-9404-8dadb91cb34a" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including the IT Lead.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The IT Lead has 5 years of experience in roles that include oversight of cybersecurity risk management programs.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_e6c6c55c-8835-4621-b9fe-9ef09b90f93b" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><ix:nonNumeric id="F_8d470aeb-3e09-4d5e-9c37-1c2c3731f426" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Lead is responsible for hiring appropriate personnel, helping to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_853d8e72-3c82-47de-8be2-b0f479dfa2d2" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrate</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p></ix:nonNumeric></ix:nonNumeric></div><div><ix:nonNumeric id="F_470e733c-5a43-4155-8d21-e5139e1c7754" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#8217;s incident response processes include reporting to the audit committee for certain cybersecurity incidents.</span></p></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_093a338f-9494-4915-a53b-e811738a2705_1"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c75b0bed-b782-4ce5-b1ce-e53b4277c88a" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives periodic reports from our IT Lead concerning cybersecurity issues, including certain threats and risks and the processes the Company has implemented to address them, as applicable.  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7ebaf81-7639-418c-acde-c718aa2846bc" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" continuedAt="F_b7ebaf81-7639-418c-acde-c718aa2846bc_1" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></ix:nonNumeric></span></ix:nonNumeric></span></ix:continuation></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b7ebaf81-7639-418c-acde-c718aa2846bc_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:continuation></span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="section8"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 2. PROPERTIES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2022, we entered into an agreement to lease approximately 20,116 square feet of laboratory and office space at 2000 Sierra Point Parkway, Brisbane, California 94005, which we occupied and began operating as our new headquarters beginning in December 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our existing facilities are sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternative space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section9"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 3. LEGAL PROCEEDINGS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are not currently a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section10"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 4. MINE SAFETY DISCLOSURES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section11"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="section12"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is listed on the Nasdaq Stock Market under the ticker symbol &#8220;TPST.&#8221;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 25, 2026, we had 14,344,034 shares of common stock outstanding held by 60 holders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 3, 2026, we issued a dividend to each holder of record of our common stock as of January 30, 2026 in the form of a warrant to purchase a share of common stock for each share of common stock outstanding on January 30, 2026. We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Parties</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section13"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 6. RESERVED</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="section14"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the related notes to those statements included later in this Annual Report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs and expectations that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report, particularly in Item 1A. &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. In February 2026, we expanded our pipeline through a strategic transaction under which we acquired rights to a portfolio of dual-targeting chimeric antigen receptor T-cells (&#8220;CAR-T&#8221;) product candidates with the potential to treat certain blood cancers, solid tumors and immunology indications, including TPST-2003, an autologous CD19/B-cell maturation antigen (&#8220;BCMA&#8221;) CAR-T therapy currently in clinical development for relapsed or refractory multiple myeloma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our portfolio also includes two clinical-stage small molecule product candidates with the potential to treat certain cancer indications. One of our small-molecule product candidates, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma (&#8220;HCC&#8221;). Amezalpat remains Phase 3-ready in HCC and we plan to pursue business development discussions to advance pivotal development. Our second small-molecule product candidate is TPST-1495, which we plan to initiate a Phase 2 study for in familial adenomatous polyposis, with first patient enrollment expected in 2026. The study is expected to be funded by the National Cancer Institute and conducted through the Cancer Prevention Clinical Trials Network, enabling advancement with limited internal capital deployment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients&#8217; lives.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Events</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset Acquisition</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 19, 2025, we executed an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Erigen LLC, a Delaware limited liability company (&#8220;Erigen&#8221;), and Factor Bioscience Inc., a Delaware corporation (together with Erigen, &#8220;Sellers&#8221;), pursuant to which Sellers agreed to sell and transfer to the Company all right, title and interest of Sellers in and to all of the assets primarily related to (a) the autologous BCMA/CD19 dual-targeting CAR T-cell therapy known as ERI-2003, (b) the autologous CD70/CD70 dual-targeting CAR T-cell therapy known as ERI-2206, (c) the allogeneic BCMA/CD19 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as ERI-3003, and (d) the allogeneic CD70/CD70 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as ERI-3206 (collectively referred to herein as the &#8220;Assets&#8221;), in exchange for an aggregate purchase price of 8,268,495 shares of our common stock issued to Erigen on behalf of both Sellers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 3, 2026, we completed the acquisition of the Assets (the &#8220;Closing&#8221;) under the Asset Purchase Agreement (the &#8220;Asset Acquisition&#8221;) and issued to Erigen 8,268,495 shares of our common stock (the &#8220;Share Issuance&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Dividend</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 20, 2026, our Board declared a record date of January 30, 2026 (the &#8220;Record Date&#8221;), for the distribution of a dividend (the &#8220;Warrant Dividend&#8221;) in the form of a warrant to purchase a share of our common stock (collectively, the &#8220;Warrants&#8221;) for each share of common stock outstanding on the Record Date. The Warrants were issued on the terms and conditions described</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Warrant Agreement, dated February 3, 2026, between the Company, Computershare Inc., and its affiliate, Computershare Trust Company, N.A., as Warrant Agent (the &#8220;Warrant Agreement&#8221;), on February 3, 2026. In addition, on February 3, 2026, certain warrants that were outstanding on the Record Date also received Warrants on a one-for-one basis, pursuant to the terms of such warrants (together with the Warrant Dividend, the &#8220;Warrant Distribution&#8221;). In the aggregate, 6,784,989 Warrants were issued pursuant to the Warrant Distribution.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Private Placement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 20, 2026, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with (a) two institutional investors (the &#8220;Institutional Investors&#8221;) and (b) Factor (together with the Institutional Investors, each, an &#8220;Investor&#8221; and, together, the &#8220;Investors&#8221;), pursuant to which we agreed to issue and sell in a private placement (the &#8220;Private Placement&#8221;) an aggregate of 462,964 shares (the &#8220;Shares&#8221;) of our common stock, and, in lieu of common stock, pre-funded warrants to purchase up to 462,963 shares of our common stock (the &#8220;2026 Pre-Funded Warrants&#8221;), in each case accompanied by (i) Series A warrants to purchase up to 925,927 shares of our common stock (the &#8220;Series A Warrants&#8221;) and (ii) Series B warrants to purchase up to 925,927 shares of our common stock (the &#8220;Series B Warrants&#8221; and, together with the Series A Warrants, the &#8220;Common Warrants&#8221;). The Shares and the Common Warrants were immediately separable and were issued separately. The combined purchase price per Share and accompanying Common Warrants was $2.16 and the combined purchase price per Pre-Funded Warrant and accompanying Common Warrants was $2.159. The gross proceeds to us from the Private Placement were approximately $2.0 million (excluding up to approximately $4.0 million of aggregate gross proceeds that may be received in the future upon the cash exercise of the Common Warrants), before deducting placement agent fees and other offering expenses payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Purchase Agreement, we agreed to seek approval from our stockholders for the issuance of the shares issuable upon exercise of the Common Warrants within 90 days following the date of the Purchase Agreement (the &#8220;Stockholder Approval&#8221;). The Series A Warrants will become exercisable on the effective date of the Stockholder Approval (the &#8220;Stockholder Approval Date&#8221;) and have a term of five years from the later of the Stockholder Approval Date and the Effectiveness Date (as defined below). The Series B Warrants will become exercisable on the Stockholder Approval Date and have a term of twenty-four months from the later of the Stockholder Approval Date and the Effectiveness Date. The Common Warrants have an exercise price of $2.16 per share. The Pre-Funded Warrants are exercisable immediately following the closing date of the Private Placement have an exercise price of $0.001 per share and may be exercised at any time until exercised in full. In addition, pursuant to the Purchase Agreement, we agreed not to sell any shares of our common stock or any securities convertible into or exercisable or exchangeable into shares of our common stock, subject to certain customary exceptions, for a period of thirty (30) days after the Effectiveness Date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Private Placement, we entered into a registration rights agreement with the Investors (the &#8220;Registration Rights Agreement&#8221;), pursuant to which we agreed to file registration statements under the Securities Act with the SEC covering the resale of the Shares to be issued in the Private Placement and the shares of our common stock underlying the Common Warrants and Pre-Funded Warrants no later than 15 calendar days following the date of the Purchase Agreement, and to use reasonable best efforts to have the registration statement declared effective by 45 calendar days following the date of the Purchase Agreement, and in any event no later than 75 calendar days following the date of the Purchase Agreement in the event of a &#8220;full review&#8221; by the SEC (the &#8220;Effectiveness Date&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Going Concern</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no products approved for commercial sale and have not generated any revenue from product sales. From inception to December 31, 2025, we have raised $242.5 million, through sales of our capital securities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had cash and cash equivalents totaling $7.7 million compared to $30.3 million as of December 31, 2024. We have incurred operating losses since inception and our accumulated deficit as of December 31, 2025 is $233.4 million. We expect that our existing cash and cash equivalents will fund our projected operating expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued. Accordingly, there is substantial doubt regarding our ability to continue as a going concern for a period of 12 months from the date of the issuance of the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we implemented cost reductions in 2025, we have finite cash resources available to fund our operations. To date, we have not generated product revenues from our activities and have incurred substantial operating losses. We expect that we will continue to generate substantial operating losses for the foreseeable future until we complete development and approval of one of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to continue to rely on additional financing to achieve our business objectives, including pursuant to the Funding Commitment (as defined below under &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Commitment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) with Factor. As of the date of this report, we have $13.75 million available under the Funding Commitment, however, there is significant uncertainty as to whether we will be able to satisfy the terms and conditions and other provisions set forth in the Funding Commitment, and, if we are unable to do so, we may be limited in the amount of funding that we are able to access under the Funding Commitment or we may not be able to access any funds under the Funding Commitment. Adequate additional financing may not be available to us on acceptable terms, or at all. Our ability to raise additional capital has been adversely impacted by potential worsening global economic conditions, inflation expectations, and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from geopolitical tensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 8, 2025, we effected a one-for-thirteen (1:13) reverse stock split (the &#8220;Reverse Stock Split&#8221;). Pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company&#8217;s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company&#8217;s equity incentive plans have been reduced proportionately. The Reverse Stock Split did not reduce the number of authorized shares of common stock and did not alter the par value.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All share and per share amounts of common stock presented in this Annual Report on Form 10-K have been retroactively adjusted to reflect the Reverse Stock Split. Refer to Note 1 of our Consolidated Financial Statements and the notes thereto included elsewhere in this Annual Report on Form 10-K for further information.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="section16"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Results of Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expense</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses represent costs incurred to conduct research and development, such as the development of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize all research and development costs as they are incurred. Research and development expenses consist primarily of the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">salaries, benefits and stock-based compensation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">licensing costs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allocated occupancy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materials and supplies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contracted research and manufacturing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consulting arrangements; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other expenses incurred to advance our research and development activities.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The largest component of our operating expenses has historically been the investment in research and development activities. Despite reductions in 2025 as we pursued our evaluation of strategic alternatives, we expect research and development expenses will increase in the future as we advance our product candidates into and through clinical trials and pursues regulatory approvals, which will require a significant investment in costs of clinical trials, regulatory support and contract manufacturing and inventory build-up. In addition, we continue to evaluate opportunities to acquire or in-license other product candidates and technologies, which may result in higher research and development expenses due to license fee and/or milestone payments, as well as added clinical development costs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely developing and achieving regulatory approval for our product candidates. The probability of success of our product candidates may be affected by numerous factors, including clinical data, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation, for our personnel in executive, finance and accounting, and other administrative functions, as well as fees paid for legal, accounting and tax services, consulting fees and facilities costs not otherwise included in research and development expenses. Legal costs include general corporate legal fees and patent costs. In addition, we expect to continue to incur expenses as a result of being a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other (Expense) Income , Net</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other (expense) income, net consists primarily of interest expense, interest income, and various income or expense items of a non-recurring nature.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our operating results for the years ended December 31, 2025 and 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:47.83%;box-sizing:content-box;"/>
     <td style="width:1.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.602%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.602%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.582%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.062000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/ (Decrease)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage Increase/ (Decrease)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025 vs. 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025 vs. 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,606</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,476</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,870</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(56</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,969</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,550</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">419</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(26,575</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(42,026</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,451</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(37</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(207</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,316</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,109</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(84</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income and other income (expense), net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">520</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,499</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(979</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(65</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(26,262</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(41,843</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,581</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(37</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We typically have various early-stage research and drug discovery projects, as well as various potential product candidates undergoing clinical trials. Our research and development expenses for the years ended December 31, 2025 and 2024 were primarily incurred in connection with amezalpat and TPST-1495. Our internal resources, employees and infrastructure are not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">directly tied to any one research and drug discovery project and our resources are typically deployed across multiple projects. The following table shows our research and development expenses by program for the years ended December 31, 2025 and 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:47.83%;box-sizing:content-box;"/>
     <td style="width:1.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.602%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.602%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.582%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.062000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/ (Decrease)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage Increase/ (Decrease)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025 vs. 2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025 vs. 2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amezalpat</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,428</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,206</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,778</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(62</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TPST-1495</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,307</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,307</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(100</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical and other</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,108</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,279</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,171</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(51</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total candidate-specific research costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,536</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,792</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,256</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(65</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel and other costs</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,677</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,108</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,431</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(34</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation and depreciation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,393</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,576</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,183</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(46</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,606</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,476</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,870</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(56</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses for the years ended December 31, 2025 and 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:47.83%;box-sizing:content-box;"/>
     <td style="width:1.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.602%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.602%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.582%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.062000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/ (Decrease)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage Increase/ (Decrease)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025 vs. 2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025 vs. 2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development outside services</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,937</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,501</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,564</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(64</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,526</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,923</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,397</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(28</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,179</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,222</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,043</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(47</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consulting and professional services</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">598</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,223</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,625</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(73</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expenses</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,366</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,607</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,241</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(48</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,606</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,476</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,870</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(56</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expense decreased by $15.9 million to $12.6 million for the year ended December 31, 2025, which was primarily attributable to a decrease in costs incurred as a result of re-prioritizing efforts towards exploring strategic alternatives.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses increased by $0.4 million to $14.0 million for the year ended December 31, 2025. The increase was primarily related to employee compensation costs, inclusive of one-time separation costs for employees terminated during the year ended December 31, 2025 as a result of our reduction-in-force in April 2025, as well as consulting and professional services.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income (Expense), Net</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2025 and 2024, interest income and other income (expense), net consisted of total interest expense of $0.2 million and $1.3 million, respectively, related to the Oxford Loan (as defined below), and interest income of $0.5 million and $1.5 million, respectively. The Oxford Loan was repaid in full and terminated in accordance with its terms in April 2025.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;" id="section17"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception through December 31, 2025, our operations have been financed primarily by net cash proceeds from the sale of our common stock, convertible preferred stock and issuance of debt. As of December 31, 2025, we had $7.7 million in cash and cash equivalents and an accumulated deficit of $233.4 million. Following the Closing of the Asset Acquisition, we expect that our research and development and general and administrative expenses will increase, and, as a result, we anticipate that we will continue to incur losses for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lack of operating revenue or cash inflows and our cash resources at December 31, 2025 raise substantial doubt as to our</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ability to continue as a going concern.  See &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; below for additional information on our future capital needs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Commitment</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Closing, we entered into a funding commitment letter (the &#8220;Funding Commitment&#8221;) with Factor, which will provide us with financial support for at least 18 months following the Closing, up to a maximum amount of $20.0 million that is inclusive of any amounts raised and received by us after the date of the Asset Purchase Agreement, on the terms and subject to the conditions and other provisions set forth in the funding commitment letter. As of the date of this report, we have $13.75 million available under the Funding Commitment, however, there is significant uncertainty as to whether we will be able to satisfy the terms and conditions and other provisions set forth in the funding commitment letter, and, if we are unable to do so, we may be limited in the amount of funding that we are able to access under the Funding Commitment or we may not be able to access any funds. The timing of any funding pursuant to the Funding Commitment is uncertain.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Loan Agreement with Oxford Finance</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 15, 2021, we entered into a loan and security agreement (the &#8220;Oxford Loan&#8221;), as amended from time to time, with Oxford to borrow a term loan amount of $35.0 million to be funded in three tranches. On April 8, 2025, we repaid $3.5 million in full satisfaction of the aggregate outstanding amount, including accrued interest and exit fees as of such date. As a result of the repayment, all liens and security interests were terminated.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-the-Market Offering</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which we may sell, from time to time at our sole discretion through Jefferies, as our sales agent, shares of our common stock (the &#8220;ATM Program&#8221;). Any shares of our common stock sold will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-280918). On June 11, 2025, in connection with the June RDO (as defined below) we delivered written notice to Jefferies that we were suspending and terminating the prospectus supplement, dated February 6, 2025, related to the ATM Program (the &#8220;ATM Prospectus&#8221;). We will not make any sales of our securities pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect. As of the year ended December 31, 2025, we have sold an aggregate of 312,830 shares of our common stock for proceeds of $2.8 million pursuant to the ATM Program.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date of this Form 10-K, our public float was less than $75.0 million. As a result, we are subject to the limitations of General Instruction I.B.6 to Form S-3 until such time as our public float exceeds $75 million, which means we only have the capacity to sell shares up to one-third of our public float under the S-3 Registration Statement, including the ATM program, in any 12-month period.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Registered Direct Offerings</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 11, 2025, we sold an aggregate of 405,000 shares of our common stock pre-funded warrants to purchase 334,000 shares of our common stock in a registered direct offering (the &#8220;June RDO&#8221;). The offering price was $6.25 per share of common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and $6.249 per pre-funded warrant, which is the price of each share of common stock sold in the offering, minus the $0.001 exercise price per pre-funded warrant. The net proceeds from the RDO were approximately $4.1 million, after deducting placement agent fees and estimated offering expenses payable by us. As of December 31, 2025, all pre-funded warrants related to the June RDO had been exercised.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 24, 2025, we sold an aggregate of 487,000 shares of our common stock, pre-funded warrants to purchase 685,414 shares of our common stock and warrants to purchase an aggregate of 1,172,414 shares of common stock (the &#8220;Common Warrants&#8221;) in a registered direct offering (the &#8220;November RDO&#8221;). The combined purchase price of each share of common stock and accompanying Common Warrant was $3.625. The combined purchase price of each pre-funded warrant and accompanying Common Warrant was $3.624 (equal to the combined purchase price per share of common stock and accompanying Common Warrant, minus $0.001). The exercise price of each Common Warrant is $3.50 per share. The net proceeds from the November RDO were approximately $3.8 million, after deducting placement agent fees and estimated offering expenses payable by us. As of December 31, 2025, all pre-funded warrants and Common Warrants related to the November RDO remained outstanding.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Private Placement</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 20, 2026, we completed the Private Placement pursuant to which we sold an aggregate of 462,964 Shares, and, in lieu of common stock, Pre-Funded Warrants to purchase up to 462,963 shares of our common stock, in each case accompanied by (i) Series A Warrants to purchase up to 925,927 shares of our common stock and (ii) Series B Warrants to purchase up to 925,927 shares of our common stock. The gross proceeds to us from the Private Placement were approximately $2.0 million (excluding up to approximately $4.0 million of aggregate gross proceeds that may be received in the future upon the cash exercise of the Common Warrants), before deducting placement agent fees and other offering expenses payable by the Company. See &#8220;&#8212;Re</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">cent Events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Private Placement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for more information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for the years ended December 31, 2025 and 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash used in operating activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(26,820</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(33,027</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash used in investing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(435</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash provided by financing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,259</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,500</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(22,561</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,962</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows from operating activities</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities for the year ended December 31, 2025 was $26.8 million, consisting of a net loss of $26.3 million, add back of non-cash adjustments for depreciation, stock-based compensation, non-cash operating lease expense and other non-cash items totaling $4.6 million, plus changes in operating assets and liabilities of $5.1 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities for the year ended December 31, 2024 was $33.0 million, consisting of a net loss of $41.8 million, add back of non-cash adjustments for depreciation, stock-based compensation, non-cash operating lease expense and other non-cash items totaling $7.2 million, plus changes in operating assets and liabilities of $1.6 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows from investing activities</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in investing activities for the years ended December 31, 2025 and 2024 was related to purchases of property and equipment, primarily related to office, laboratory and computer equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows from financing activities</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2025 was related to proceeds from the issuance of common stock, pre-funded warrants and common stock warrants of $10.6 million, offset by Oxford Loan principal payments of $6.4 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2024 was related to proceeds from the issuance of common stock of $28.9 million, offset by Oxford Loan principal payments of $4.4 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Requirements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary use of cash is to fund operating expenses, which has historically consisted primarily of research and development expenditures related to our therapeutic discovery and preclinical development efforts and clinical activities, and to a lesser extent, general and administrative expenditures. We have based our estimates on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we currently expect.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future funding requirements will depend on many factors, including the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with the scope, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with the manufacturing of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs related to the extent to which we enter into partnerships or other arrangements with third parties to further develop our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and fees associated with the discovery, acquisition or in-license of product candidates or technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish collaborations on favorable terms, if at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of future commercialization activities, if any, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until we can generate a sufficient amount of product revenue to finance our cash requirements, if ever, we expect to finance our future cash needs, including those set forth above, primarily through the issuance of additional equity, borrowings and strategic alliances with partner companies. To the extent that we raise additional capital through the issuance of additional equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">favorable to us. If additional capital is not available to us on a timely basis, or at all, we will be required to take additional actions, including exploring potential merger opportunities and other strategic options, such as partnerships or collaborations for our programs, or we may need to reduce operating expenses or delay, reduce the scope of, discontinue or alter our research and development activities, or we may be forced to wind down our operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Cash Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our material cash requirements primarily relate to our operating leases for office space, trade payables, and accrued expenses. As of December 31, 2025, we have $3.3 million payable within 12 months, including $1.2 million related to the Brisbane Lease. Refer to Notes 5 and 6 to our Consolidated Financial Statements for additional information.  We cannot estimate whether we will receive or the timing of any potential contingent payments upon the achievement by us of clinical, regulatory and commercial events, as applicable, or royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property as contractual obligations or commitments, including agreements with Factor and Novatim. Pursuant to these license agreements, we have agreed to make milestone payments up to an aggregate of approximately $1.98 billion upon the achievement of certain development, regulatory and sales milestones. We excluded these contingent payments from the consolidated financial statements given that the timing, probability, and amount, if any, of such payments cannot be reasonably estimated at this time.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 2025, Erigen entered into an Amended and Restated Master Services Agreement with Factor (the &#8220;Factor MSA&#8221;), which was assigned to us in connection with the Closing pursuant to the Asset Purchase Agreement. Under the Factor MSA, we are obligated to pay Factor a service fee and all non-cancellable obligations in the amount specified in each work order associated with the agreement for the provision of services. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. We can terminate the Factor MSA or any work order at any time upon 30 days&#8217; prior written notice and immediately upon written notice if Factor breaches the Factor MSA or any work order, as the case may be, and does not fully cure the breach to our satisfaction within 30 days. Upon termination any work order, unless the applicable work order expressly provides otherwise, we will pay Factor fees for all services performed and reimburse Factor for all authorized, non-cancellable expenses reasonably incurred in connection with such services prior to termination.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as disclosed above, we have no long-term debt and no material non-cancelable purchase commitments with service providers, as we have generally contracted on a cancelable, purchase-order basis. We enter into contracts in the normal course of business with equipment and reagent vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manufacturing services. These contracts are cancelable by us upon prior notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;US GAAP&#8221;). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We define our critical accounting policies as those accounting principles that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. Our significant accounting policies are more fully described in Note 2 to our Consolidated Financial Statements located elsewhere in this Annual Report. We have listed below our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">critical accounting policies and estimates that we believe to have the greatest potential impact on our Consolidated Financial Statements. Historically, our assumptions, judgments and estimates relative to our critical accounting estimates have not differed materially from actual results and no significant assumptions used have a high degree of subjectivity.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record accrued expenses for estimated costs of our research and development activities conducted by third-party service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and we include these costs in accrued liabilities in the consolidated balance sheets and within research and development expense in the consolidated statements of operations. These costs are a significant component of our research and development expenses. We record accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these third parties.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period, which includes gathering information from multiple sources. In certain circumstances, the determination of the nature and level of services that have been received during the reporting period requires judgment because the timing and pattern of vendor invoicing did not correspond to the level of services provided and invoicing from clinical study sites and other vendors may not yet be available to us. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment may vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from clinical research organizations and other third-party service providers.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize noncash stock-based compensation expense related to stock-based awards to employees, non-employees and directors, including stock options, based on the fair value on the grant date using the Black-Scholes option pricing model. The related stock-based compensation is recognized as expense on a straight line-basis over the employee&#8217;s, non-employee&#8217;s or director&#8217;s requisite service period (generally the vesting period). Noncash stock compensation expense is based on awards ultimately expected to vest and is reduced by any forfeitures as they occur.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the fair value of stock options, we use the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, risk-free rate of return, and the fair value of the underlying common stock on the date of grant, and generally requires significant judgment to determine.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="section19"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 2 to our Consolidated Financial Statements for a description of recent accounting pronouncements applicable to our Consolidated Financial Statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Smaller Reporting Company Status and a Non-Accelerated Filer</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 of the Securities Exchange Act of 1934, or the Exchange Act, meaning that the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year for which audited financial statements are available as of the determination date and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced disclosure obligations regarding executive compensation. If investors consider our common stock less attractive as a result of our election to use the scaled-back disclosure permitted for smaller reporting companies, there may be a less active trading market for our common stock and our share price may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, as a non-accelerated filer, we may continue to take advantage of the exception from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="section20"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not required for smaller reporting companies.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section21"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TEMPEST THERAPEUTICS, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:94%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section22"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;(PCAOB ID </span><span><ix:nonNumeric id="F_ec5d9cf2-decc-48ef-a4da-b3ab4cd517fe" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#notes_to_consolidated"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section22"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of Tempest Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0242edf-327b-4fd2-992f-0ab3f2a7f0ae" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Tempest Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, stockholders' equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's Ability to Continue as a Going Concern</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred operating losses since inception and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:13.88%;box-sizing:content-box;"/>
     <td style="width:86.12%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:23.05pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Valuation of modified stock-based compensation awards</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Matter</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">As described in Note 8 to the financial statements under the caption &#8220;Stock-based compensation,&#8221; in the fourth quarter of 2025, the Company modified 416,005 stock options to extend the post-termination exercise period. The modifications of current and former employees' stock option grants resulted in modification accounting under ASC 718, Compensation &#8211; Stock Compensation. During the year ended December 31, 2025, the Company recognized $0.8 million in stock-based compensation expense due to modifications, a portion of which related to the modification of stock options in the fourth quarter.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditing the Company&#8217;s valuation of certain stock options modified in the fourth quarter, including the derived service period, was complex and required significant auditor judgment due to the subjectivity in estimating the fair value of the modified awards and the fair value of the original awards immediately before they were modified, including the adjustment to the stock price on the modification date for the fair value of the warrant dividend and the expected stock price volatility.</span></p></td>
    </tr>
    <tr style="height:119.5pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To test the valuation of certain stock options modified in the fourth quarter, our audit procedures included, among others, assessing the completeness of the awards modified, evaluating the key terms and conditions of the awards modified to assess the accounting treatment, and testing the clerical accuracy of the calculation related to the expense recorded. Also, our procedures included evaluating the methodologies used to estimate the fair value of the modified awards and the original awards immediately before they were modified. Additionally, we involved our internal valuation specialists to (i) calculate the adjustments to the stock price by assessing the fair value of the warrant dividend on the modification date, (ii) develop an independent estimate of the volatility by utilizing third party historical data of closing stock prices, and (iii) perform a Monte Carlo simulation to assess the fair value of the awards after modification and the derived service period over which the compensation expense will be attributed.</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5621ff4b-9b6e-4497-8c48-6d906501b3fc" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company's auditor since 2021.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab496330-6ceb-4a13-9af3-30364b9d1048" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chicago, Illinois</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section23"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c069e2e8-a13b-45ca-9f81-3dd0472ec6f2" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,707</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c67d744b-8a31-4477-a031-d47c5854bf52" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,268</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30cd859f-ad28-400c-8114-4cfabf05ec8b" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">562</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4fc84fe-226b-4d09-aa1c-36bbcea58694" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,206</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffd73efd-673c-4d74-90a5-136afd288661" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,269</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fc8f61b-5bc7-4bf8-a65d-cc2e03e245af" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,474</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment &#8212; net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b520529-d2e3-4fe7-a14c-01baf3d6c428" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">605</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d74ce3d8-f55f-4b54-b00f-6ac321dc7f4b" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">886</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4c2695f-6618-4a5b-8d28-30c503945e0e" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,540</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34ff7f4c-7e80-4731-b194-871e3d1bafdb" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,643</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other noncurrent assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8fb8fb8-5f58-4050-937f-2a3c56d7332d" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f3a7b5f-7de0-4564-b8af-7899af798aa6" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">485</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e6cc10e-4125-4398-9ac3-f5d38a617b3e" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,931</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2293a8f5-1213-43ac-92b1-cafd434067a6" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,488</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb01508e-c8f1-479f-9829-95d4592b3049" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,038</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab2e428c-e25a-4a55-b356-4a5e7dbc189f" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,450</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c2bbbcd-354a-4b94-834b-40bb7d5a9d74" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">937</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d004455a-3db3-4899-8e03-160aba7500c5" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,726</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current loan payable (net of discount and issuance costs of </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aea821b9-9dde-421f-be68-c3b2a946e800" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredFinanceCostsCurrentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd93a1c7-de31-426f-8731-c88a660e9e41" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredFinanceCostsCurrentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, respectively)</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba10a5ec-dcdd-426e-88d9-a04929e8b675" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f0056a5-0123-422d-99dc-c065e6aa95ca" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,354</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34f5f3b6-d3e8-441f-95be-91bcd3dc8654" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8348152-a5d1-4c9f-ba99-ea127b7af8bf" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">869</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7d49d84-e295-4e7c-b350-b11a470d02e8" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a936472-33e7-4070-8ae7-2e340ad2ed9e" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,762</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest payable</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7847be7b-6dc5-4283-9a3e-fa462a0bfb70" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:InterestAndDividendsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd3e7e6d-18ca-4cf7-b872-3e39582b0a2f" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:InterestAndDividendsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32dc3532-5f95-47a0-9f5a-a2cb430840b9" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,314</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dc13bd4-a545-4e5a-91a7-7ff6a589115b" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,220</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, less current portion</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99776cdf-ad61-4b58-8201-9e938ac4bc70" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,949</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fadae0cf-d08a-466d-b736-a873510fa9bd" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,142</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c167e0cf-897e-4860-a0b2-5d0e9ef45513" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,263</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05b71ed8-3171-451a-8851-95c0083bb5da" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,362</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_a61cf309-8cf1-44dd-9cf6-1e067a7c3d48;"><span style="-sec-ix-hidden:F_eafdf1b5-430a-4ed1-b977-b8a69e22fd10;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Note 5)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4013ee34-8236-408b-82f9-a727a80e1cc7" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bc06d075-b296-4568-9617-96e61a67bbba" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6de793cc-8edd-4b6e-a6c2-583538e4e388" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d1e2e04b-6071-4c33-b913-e4fcdc85257c" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef02e0d9-4617-46db-8a78-ab8ec21df597" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7ad5425e-c6af-420c-a289-ade0ad3f78d4" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,927,161</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a825041d-7b1a-4e40-93a7-71735bfc1683" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c49487f4-c674-42b2-8689-808d4378f62d" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,382,432</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cee43fb-5ccc-4e36-909b-199a1d954e50" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9095b77b-8616-4328-bf62-7772ddb0da59" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a823370-0688-4ec5-a3c3-9cc56cb1fa4d" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,031</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d279497e-f43f-4de1-9102-97489a93c8f2" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226,229</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07f4055f-0878-44ce-8210-0f1a31ec7665" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">233,368</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd61f735-4de0-45ca-ba9e-78292d2d7859" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,106</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84885503-d27a-47ef-9f5c-5fa0c61f0fd8" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,668</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b5dde92-d256-44bd-9581-1ac29b0d66b2" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,126</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e300e6ea-5f36-4366-97d1-1a385c11e18d" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,931</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a56b0e22-87f7-4cce-b86c-d6ad631f5c85" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,488</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><ix:footnote id="FNT_74241657-edda-4a4a-85ad-6d4a0c4dfaad" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results, including shares issued and outstanding have been adjusted to reflect the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6adafa2d-ee1b-4d9d-9637-e18cd2281e36" contextRef="C_83ad0427-46c9-40f3-8ea3-599adc8b0338" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-thirteen</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.</span></ix:footnote></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying Notes to Consolidated Financial Statements</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section24"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="statements_of_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:66.593%;box-sizing:content-box;"/>
     <td style="width:1.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.063%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.063%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfa800ab-ff4e-47fb-9626-44e375380d21" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,606</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d5559be-483b-45de-970a-6e3024c9dfd9" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,476</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02c49138-adae-4482-b5f8-854c31c08ce5" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,969</ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8df0ec52-8d4b-4261-9c91-9a9374d7f555" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,550</ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0a6c4d8-601d-4314-8add-530629bd10f0" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,575</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44520852-5123-43f1-82d6-76c75a507385" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,026</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other income (expense), net:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45f94701-b18c-4f79-9876-028ece12f11d" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_458530c6-814d-45ea-97ae-0a4a7f3e1233" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,316</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income and other income (expense), net</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_795a930c-43ac-4f3c-8977-23ccfe2fb346" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">520</ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c413fba0-5cc0-4ecc-ae75-d084956d6a83" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,499</ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense), net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b6f9539-98eb-4f6d-aec9-7a1d6f805516" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">313</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_151f2354-08b7-410f-a4ac-905f33fa4685" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04a3c696-619c-42f5-b4c1-e65bd1598a70" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c63df706-1748-4ce1-8031-7115476c52fb" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e518c21-3dd8-45cf-9d2d-1a75dcb0b632" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,262</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfc3ea47-86ce-4d47-b630-44e0e8076fbf" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,843</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share of common stock and pre-funded warrants, basic and diluted</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6e60cb1-7625-45d8-890d-f502ccb2045a" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_06d8a560-9214-464d-ad7f-d5ceb179abd3" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">6.33</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6448a7f3-d0ae-4461-bf4e-c13a95ec4ec0" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b454cb84-8963-4090-ad49-9160d559a804" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">19.50</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares of common stock and pre-funded warrants outstanding, basic and diluted</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97f8f9d8-ccc1-41b2-99d2-edaf2bb90a5a" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a4deed85-14a1-438a-b3cd-6a644a58efa7" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,149,733</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b799a36-beb6-4e4c-98b2-34a6c04e7709" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a0c20a1c-3071-4a19-adb9-c780da554e35" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,146,276</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><ix:footnote id="FNT_b817ca04-9246-4cb1-a879-d662ded3e863" xml:lang="en-US"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Results, including shares of common stock, have been adjusted to reflect the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_746f33fe-fb05-4adc-b8a4-cd6a7ebf54fa" contextRef="C_83ad0427-46c9-40f3-8ea3-599adc8b0338" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-thirteen</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.</span></p></ix:footnote><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying Notes to Consolidated Financial Statements</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section25"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="stockholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:34.761%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.288%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.121%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.867999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.121%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.867999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.121%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.867999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.121%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.867999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional <br/>Paid-In</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders'</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity (Deficit)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BALANCE &#8212; December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deb034ee-1ce5-4660-b1ff-6565a703b6c0" contextRef="C_06328e98-1580-41cc-a910-5db61b65b8fe" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,695,788</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b42365a0-32ef-4d2a-afb4-37ca6f666a0f" contextRef="C_06328e98-1580-41cc-a910-5db61b65b8fe" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_752287a4-7e99-4e43-aea7-2cf109f6388f" contextRef="C_62d04cb4-5a63-46ed-a664-419caec2a7a0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,029</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b21e6b15-3d12-4408-a953-a3ef68d63943" contextRef="C_ee9ba139-9295-4f17-8cd1-d43d46ee649d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">165,263</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_122135c1-c10f-49b7-b270-7e4ac2dd08b1" contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,768</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock for cash (net of issuance cost of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12c14a01-5590-4e1a-a6d0-0a6b97deb82b" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="tpst:StockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,105</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27531bba-54fa-42b6-b8ad-71688d4e0f82" contextRef="C_9031d7bf-fa77-4e96-815d-3e2cf8c46a92" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,663,554</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b5e468a-7a63-4681-8e1c-57b1a4eb3585" contextRef="C_9031d7bf-fa77-4e96-815d-3e2cf8c46a92" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fbea954-085e-4929-9b7e-60ac1ebb49b3" contextRef="C_27158267-e15b-4d03-925a-581587ce58e0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,590</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34efdc33-3757-478d-bf1a-4224af8b2900" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,591</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d913b6c3-f5ce-41af-8deb-9a945e46952e" contextRef="C_27158267-e15b-4d03-925a-581587ce58e0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,303</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6b0afdd-a781-44f5-bb4a-f95a9be6bef0" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,303</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under equity plan awards</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3788bf6c-3a4f-44f2-9bf9-3b4dcdb41289" contextRef="C_9031d7bf-fa77-4e96-815d-3e2cf8c46a92" name="tpst:IssuanceOfCommonStockSharesUnderEquityPlanAwards" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,090</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_487a9565-f187-4f49-8711-72c292e1b871" contextRef="C_27158267-e15b-4d03-925a-581587ce58e0" name="tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">307</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4520479d-bfae-43d9-bdbc-f1ef04e92f46" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">307</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0855fa8e-edb1-4b1c-923e-7a2ef09e7bff" contextRef="C_8ff57b73-22de-44f4-b372-68161891a853" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,843</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5dc921b-f6c9-406a-8ba8-75c7a1cda353" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,843</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BALANCE &#8212; December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b4f5945-1a0f-4c72-8a16-e7bfba68263d" contextRef="C_5637d434-2834-4e0a-be2f-fed606708f35" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,382,432</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_185932d9-88b6-4e9c-b712-af4da160f375" contextRef="C_5637d434-2834-4e0a-be2f-fed606708f35" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d0697dd-a1d0-44c6-9ca8-8c80df509bc3" contextRef="C_3ac82a9a-bb9c-42a2-a8f7-52fd9198caf3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226,229</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_017e31eb-d163-4eb2-ad37-b42aa72aff16" contextRef="C_65c167d4-fb8b-486d-a124-daec790a028c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,106</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4689e5e5-9c8a-4547-8713-cf6f78c8a0b5" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,126</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock for cash (net of issuance cost of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8197f69-05d1-4da8-9e7b-627dabdbf922" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:StockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">535</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfb43dd2-f338-4fc0-8213-45aa0d6716d4" contextRef="C_5380a6a2-f90a-47a7-8a71-4bbe6510990f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,204,774</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95c135e1-af53-434e-ba3d-7cf382b0b536" contextRef="C_5380a6a2-f90a-47a7-8a71-4bbe6510990f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a5d85ac-912f-4efb-948b-07e2d13ec4ec" contextRef="C_7bc99182-65b5-47d2-9586-940c0ab19557" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,045</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7b366de-50c3-4f01-b2f3-7a24e5abfb77" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,047</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_778e11f4-be7e-4cab-a85d-b7901716a2be" contextRef="C_7bc99182-65b5-47d2-9586-940c0ab19557" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,118</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38d7a618-9c61-4697-a06f-eb03db3aabf2" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,118</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of pre-funded warrants (net of issuance cost of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a68e08c-c7ce-4024-bb5f-fc28438d01a5" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:Pre-FundedWarrantsIssuanceCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">416</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a462288b-bed1-42c8-aa73-735832d06c53" contextRef="C_5380a6a2-f90a-47a7-8a71-4bbe6510990f" name="tpst:IssuanceOfPre-FundedWarrantShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">334,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_491435e4-3c7a-420e-bb0d-7fc0fc485461" contextRef="C_7bc99182-65b5-47d2-9586-940c0ab19557" name="tpst:IssuanceOfPre-FundedWarrantValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,309</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55372564-7cc1-4c94-8ca2-aca835e26309" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:IssuanceOfPre-FundedWarrantValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,309</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock warrants (net of issuance cost of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a9941dd-1471-45ca-baf1-2badd4c50b57" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:WarrantsIssuanceCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b50220b-9e2f-4e3d-86b7-100b86a06f33" contextRef="C_7bc99182-65b5-47d2-9586-940c0ab19557" name="tpst:IssuanceOfCommonStockWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,283</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_277cc70b-62a9-4c68-8725-b5de169089ea" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:IssuanceOfCommonStockWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,283</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under equity plan awards</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0682ce31-7e6b-4a2c-b4ff-617aabfe1ce9" contextRef="C_5380a6a2-f90a-47a7-8a71-4bbe6510990f" name="tpst:IssuanceOfCommonStockSharesUnderEquityPlanAwards" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,955</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abb286dd-bd06-40d2-a7cd-5a87d166e339" contextRef="C_7bc99182-65b5-47d2-9586-940c0ab19557" name="tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f83e5338-9a5e-4d60-aed1-bee2d2719629" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d226580f-a494-40a7-93c9-4db01f623ba6" contextRef="C_9f019654-8ffe-45bb-a4e5-13052063f719" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,262</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_440e188d-ad84-4c07-8623-db11d901eae3" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,262</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BALANCE &#8212; December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ab235ab-b734-4cbd-9281-bb73d72e9afb" contextRef="C_ad6d3810-e138-47f4-b494-587bf0b0da1a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,927,161</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61dae98f-89b0-4eab-b520-94706c44c865" contextRef="C_ad6d3810-e138-47f4-b494-587bf0b0da1a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_870058e3-ac45-40b7-b81b-13c6c0eff3f3" contextRef="C_a94b87ad-49e1-4a01-a0e5-9ac323ad9f6b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,031</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02b6a170-e6fa-416d-ac93-80af0d18d338" contextRef="C_71ec2d54-80b0-474c-b65c-486a56573a94" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">233,368</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72b55801-b7d4-4dec-b6f4-636f283877f3" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,668</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Results, including shares of common stock, have been adjusted to reflect the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c36b434a-023d-4c79-a3a8-17f6089a4103" contextRef="C_83ad0427-46c9-40f3-8ea3-599adc8b0338" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-thirteen</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying Notes to Consolidated Financial Statements</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.24%;box-sizing:content-box;"/>
     <td style="width:1.56%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.56%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a129d77-bfc3-495c-8c7f-fd466c41bf44" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,262</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7025527-f95c-40dd-ab03-fb28483d46d6" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,843</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb60e182-eaa3-48b0-8c9a-46bfbf4a0155" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">266</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fecfecfd-eecb-4d35-9e76-e2660c7e4837" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_376febd6-7c30-4bf7-8e75-6440df9aa9d6" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,118</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa5c2fb0-d937-4ad8-9c1c-21b752ab8263" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,303</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncash lease expense</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_299bd61c-d6de-4ccd-ab0b-1f36820582cf" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcca4ded-52f0-4184-b93e-26ed4f8bde6c" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="tpst:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,309</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncash interest and other expense, net</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79b7db5e-6939-4939-ab7a-6e9375161b8e" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:NoncashInterestAndOtherExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a81f6dc-c5c8-4998-88e4-673b79d9c3d7" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="tpst:NoncashInterestAndOtherExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e97cc797-8f85-475d-9564-8578d97adc17" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">615</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a843a280-da38-44d2-9025-f4112f415645" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed7bb6d1-a7f7-4de5-958b-70aedb16f62d" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18ce6673-4e67-482b-822d-5be12a8eadf1" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,605</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9da7c75-e439-4d79-af89-1f5160a4692f" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,404</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_858a1327-fb14-49d6-965a-ab52aaaf3eb3" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,273</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest payable</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f033ea76-e6c8-4f8f-adb8-7371de04629b" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f1027d4-4efa-410f-86d3-462ce400f3b2" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_242d3544-25c3-489f-8354-ee05bd67473f" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">870</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ac93702-059e-4f1a-961a-d0ad2dfc92b0" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,101</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d167881d-990b-4201-b75c-0879b06bdab0" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,820</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e6e10ed-541a-4b75-b3b5-9e5f087f165e" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,027</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_385d1c77-2f93-4f4c-b18d-57855dcc99c4" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83593086-0c9b-4a52-9f65-8b86a2b28ecf" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2cc059a-8491-43ab-ac54-9269e83b8ab8" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73aaf04d-9152-43c6-87ac-63b95bea72b3" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">435</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the issuance of common stock, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0de3ced2-5a67-498d-8111-3040ba924319" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,045</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3769e5fe-6dc0-495b-b092-01c0659ffb87" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,591</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the issuance of pre-funded warrants, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb114eb9-a7e0-4086-aa0a-fca55f2102ed" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,309</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9050282d-5f01-4920-b112-4ff3d3559fbd" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the issuance of common stock warrants, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27567631-3598-429d-9a5d-85868c37c003" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:ProceedsFromIssuanceOfCommonStockWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,284</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8de2c2c7-6e34-4c00-977c-a430ca431c8f" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="tpst:ProceedsFromIssuanceOfCommonStockWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repayment of loan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8443224-3061-4418-9c48-6fbc985d4057" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,426</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f19fe438-4430-479e-9ffc-782c087e608b" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,398</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the issuance of common stock under equity plan awards</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbf369fa-d18d-4a05-8e57-915c51a1b388" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff30d48b-ce2f-4340-9e92-d3769c215d81" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">307</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_493342a6-b70e-4f54-a46b-b739629293a8" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,259</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31e98d6c-b425-48c9-a671-8a33a8f9d499" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in cash and cash equivalents</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5a3ae2e-7c03-4f96-8163-626e70f798bd" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,561</ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e23d547-278f-4ccf-b7cc-6b326279a42c" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,962</ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_870b727f-9100-40a9-b33b-b573c9075b5a" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,711</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a1bef66-dc06-4fa9-910a-2b6ca561431c" contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,673</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fc2ed94-cf31-47a5-b968-4933cd44c777" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,150</ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb3c75d4-8c8e-4215-a9ed-f14b081a6285" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,711</ix:nonFraction></span></p></td>
     <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77dc302a-529c-4452-b150-598877e77240" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b132dd22-96ba-4123-8149-aba9f52cb6f5" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,177</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for business taxes</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2595f321-e6eb-403c-bfb5-219fc8e866af" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:Corporatetaxespaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b95920b3-2d74-486b-a274-85b3dd6af6a7" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="tpst:Corporatetaxespaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-cash investing activities: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment in accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72e695b3-abb4-4fea-8974-13a0607d889d" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1af23daa-0e42-4f6c-a6bd-da935d37ddb3" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying Notes to Consolidated Financial Statements</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section27"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Financial Statements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of and For the Years Ended December 31, 2025 and 2024</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In Thousands, Except Share and Per Share Amount)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_40ddd2dc-7ef3-4b75-9e81-f305adbec75d" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_40ddd2dc-7ef3-4b75-9e81-f305adbec75d_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section28"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. ORGANIZATION AND DESCRIPTION OF BUSINESS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc. (&#8220;Tempest&#8221; or the &#8220;Company&#8221;) is a clinical-stage biotechnology company advancing a diverse portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a wide range of cancers. Tempest&#8217;s portfolio includes both cell therapy and small molecule product candidates spanning discovery through late-stage development. The Company is headquartered in Brisbane, California.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 3, 2024, the Company&#8217;s stockholders approved a proposal to effect an amendment to the Company&#8217;s Restated Certificate of Incorporation to implement a reverse stock split. On April 4, 2025, the Company filed a certificate of amendment to the Company&#8217;s Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the one-for-thirteen (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6e1cc23c-49a3-467c-968a-b436b08a6a1b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:13) reverse stock split of its outstanding common stock (the "Reverse Stock Split").</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 8, 2025, the Company effected the Reverse Stock Split. Pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company&#8217;s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company&#8217;s equity incentive plans have been reduced proportionately. The Reverse Stock Split did not reduce the number of authorized shares of common stock and did not alter the par value.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would have otherwise been entitled to receive a fractional share received a cash payment in lieu thereof. The Reverse Stock Split affected all stockholders proportionately and did not affect any stockholder&#8217;s percentage ownership of the Company&#8217;s common stock (except to the extent that the Reverse Stock Split resulted in any stockholder owning only a fractional share).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred operating losses since inception. As of December 31, 2025, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_682f356d-a0e1-4558-90c5-1552b6a069aa" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash and cash equivalents. While the Company implemented cost reductions in 2025, the Company has finite cash resources available to fund its operations. In </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9df2eff9-6afb-4328-8d1e-a0eef5583eb8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2025</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company announced plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. The Company retained MTS Health Partners, L.P., an internationally recognized financial advisor with substantial experience in the biotechnology industry, to support it with the strategic evaluation process. As part of the cost reductions, the Company reduced its workforce by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d478ddc-9c9c-4b27-9b21-ee5bad88c4eb" contextRef="C_ec632eae-fdb8-4bbe-ae31-e0618a3ad9ad" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" unitRef="U_Employees" decimals="INF" format="ixt:num-dot-decimal">21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b41a7aa3-6663-4d32-9512-e5345f3fbb19" contextRef="C_ec632eae-fdb8-4bbe-ae31-e0618a3ad9ad" name="tpst:RestructuringAndRelatedCostNumberOfFullTimeEmployees" unitRef="U_Employees" decimals="INF" format="ixt:num-dot-decimal">26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> full-time employees, which became effective </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40e40a43-850d-4237-8628-4e4a465d4dd0" contextRef="C_ec632eae-fdb8-4bbe-ae31-e0618a3ad9ad" name="us-gaap:RestructuringAndRelatedActivitiesCompletionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 30, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Further, in support of such efforts, on June 5, 2025, each of Stephen Brady, the Company&#8217;s Chief Executive Officer and President, Samuel Whiting, the Company&#8217;s Executive Vice President and Chief Medical Officer, and Nicholas Maestas, the Company&#8217;s Chief Financial Officer and Head of Corporate Strategy, transitioned to consulting arrangements with the Company, pursuant to which they continued to serve the Company in their respective executive roles. The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c75da55c-28d3-4952-b39f-06321d3812a8" contextRef="C_a379ad4f-c5be-41b5-b49e-a2850e59bc53" name="us-gaap:SeveranceCosts1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of one-time cash severance payments, benefits and other related costs (excluding non-cash charges associated with stock-based compensation), with the majority of such costs incurred in the second quarter of 2025.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 3, 2026, the Company closed the Asset Acquisition (as defined below). See Note 13, Subsequent Events. Pursuant to the Asset Purchase Agreement (as defined below), Factor (as defined below) has made the Funding Commitment (as defined below) to provide the Company with financial support for at least 18 months following the closing of the Asset Acquisition, up to a maximum amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87e694a0-4821-4f55-816e-4d4d0bb75bc4" contextRef="C_70845e48-f71f-4ea8-8d6e-8b92f4df5950" name="tpst:AssetAcquisitionMaximumFundingCommitment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that is inclusive of any amounts raised and received by the Company after the date of the Asset Purchase Agreement, on the terms and subject to the conditions and other provisions of a funding commitment letter contemplated by and entered into concurrently with the Asset Purchase Agreement. However, there is significant uncertainty as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_40ddd2dc-7ef3-4b75-9e81-f305adbec75d_1" continuedAt="F_40ddd2dc-7ef3-4b75-9e81-f305adbec75d_2"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we will be able to satisfy the terms and conditions and other provisions set forth in the funding commitment letter, and, if we are unable to do so, we may be limited in the amount of funding that we are able to access under the Funding Commitment or we may not be able to access any funds under the Funding Commitment. The timing of any additional funding from Factor is uncertain.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects that its existing cash and cash equivalents will fund the Company&#8217;s projected operating expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued. Accordingly, there is substantial doubt about the Company&#8217;s ability to continue to operate as a going concern for a period of 12 months from the date of issuance of these consolidated financial statements. The accompanying financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any separate adjustments relating to the recovery of recorded assets or the classification of liabilities; however, such adjustments may be necessary in the future when the Company is unable to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ATM Program</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 23, 2021, the Company entered into a sales agreement with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which the Company may sell, from time to time at its sole discretion through Jefferies, as its sales agent, shares of its common stock having, up to an aggregate sales price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cd8a4ce-7ff9-4dd6-8a71-ec0c447881c4" contextRef="C_472dac54-6d43-4ba3-b05b-f300ae5059c5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of its common stock through Jefferies (the &#8220;Prior ATM Program&#8221;). As of June 20, 2024, the Company had sold an aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7b9f1f3-34e3-4a07-9930-14d1ccce4137" contextRef="C_79115bce-54bc-47dc-8643-ab28b5ab2326" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,017,110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8067a6ad-1034-4b66-a1c3-5c3b951ddaf4" contextRef="C_f1d00723-6493-47bb-9c20-796c424cdfab" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">42.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba5126a8-2289-4a9e-ae31-755eff75c533" contextRef="C_f1d00723-6493-47bb-9c20-796c424cdfab" name="tpst:NetProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million net of commissions and estimated expenses) under the Prior ATM Program. On June 20, 2024, the Company and Jefferies terminated the Prior ATM Program and entered a new Open Market Sale Agreement (the &#8220;Sales Agreement&#8221;) to sell shares of common stock from time to time through Jefferies acting as sales agent (the &#8220;ATM Program&#8221;). The Company will pay Jefferies a commission up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_393c9d9b-5917-47da-888f-103a0fdc4a75" contextRef="C_472dac54-6d43-4ba3-b05b-f300ae5059c5" name="tpst:PercentageOfCommissionOnSaleOfStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross sales proceeds of any shares of its common stock sold through Jefferies under the ATM Program and also has provided Jefferies with indemnification and contribution rights.  Pursuant to the prospectus supplement dated June 20, 2024 filed by the Company with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), the Company was able to offer and sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88f5c195-79f6-41c4-8ecd-caebf2d421e9" contextRef="C_0ec6ba97-3919-4714-a934-2525e2f12f8c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">205.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of its shares of common stock pursuant to the Sales Agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> On February 6, 2025, the Company filed a prospectus supplement with the SEC limiting the availability under the ATM Program to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da3dc099-7d6b-4e33-8014-5354899c5630" contextRef="C_40c12f7b-2097-4b34-b237-498396a49865" name="tpst:RemainedAvailableForIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> On June 11, 2025, in connection with the RDO (as defined below), the Company delivered written notice to Jefferies that it was suspending and terminating the prospectus supplement, dated February 6, 2025, related to the ATM Program (the &#8220;ATM Prospectus&#8221;). The Company will not make any sales of its securities pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under current SEC regulations, if at any time the Company's public float is less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b0b1abe-f28f-4e2b-a84e-552881514dee" contextRef="C_f4bab170-e7d7-4e1f-9859-dfd7e52308cc" name="tpst:PublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and for so long as the Company&#8217;s public float remains less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b279fe4-5b17-4753-86b2-2754c37fe555" contextRef="C_f4bab170-e7d7-4e1f-9859-dfd7e52308cc" name="tpst:PublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, the amount the Company can raise through primary public offerings of securities in any 12-month period using shelf registration statements is limited to an aggregate of one-third of the Company's public float, which is referred to as the baby shelf rules. As of the year ended December 31, 2025, the Company has sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afb163ed-aed7-4e5d-b149-b89d8df4d8fa" contextRef="C_73aeb815-2afa-4516-9756-8b7f3643ad5d" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">312,830</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock for proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98e5db4e-c04e-4314-9632-41ecac17a658" contextRef="C_6c5a716f-97f5-415f-b72f-9c157e671bc9" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, pursuant to the ATM Program.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Registered Direct Offerings</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 11, 2025, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20ffc007-b3ea-49b8-beb2-4371743b9620" contextRef="C_3baddcb5-d5e9-4033-a4a1-870013c37ef9" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">405,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26b5aed3-40e2-45e0-a7ae-63b1e871766e" contextRef="C_5ac6b064-5ae9-4c1e-a875-a49f5a60bd9e" name="tpst:SaleOfStockWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">334,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the &#8220;June 2025 Pre-Funded Warrants&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a registered direct offering (&#8220;June RDO&#8221;). The offering price was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64b1da2c-320b-4747-86b4-14a4c9ced044" contextRef="C_a5315be7-426f-4a35-bc3e-9d8bdffaf36b" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">6.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95669863-450b-47e9-9384-3e31d84b3931" contextRef="C_5ac6b064-5ae9-4c1e-a875-a49f5a60bd9e" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">6.249</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 2025 Pre-Funded Warrant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which is the price of each share of common stock sold in the RDO, minus the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d918bd2-cb01-4584-a2b8-403ec447c37e" contextRef="C_5ac6b064-5ae9-4c1e-a875-a49f5a60bd9e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 2025 Pre-Funded Warrant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The net proceeds from the RDO were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d369927-eda2-48e9-befa-7d4e86152375" contextRef="C_7ca8d315-3fdd-4df9-a57f-592e58b29648" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting placement agent fees and offering expenses payable by the Company. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, all June 2025 Pre-Funded Warrants had been exercised.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 24, 2025, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ada7b591-eed8-4fb7-bb0a-9e3ff7ca7901" contextRef="C_8c81e754-6ec2-4618-b538-4c6094074920" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">487,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90380e16-6861-4bce-b1af-2f85f393662b" contextRef="C_8a8915cd-0e0b-49eb-b2b3-419b16f12b37" name="tpst:SaleOfStockWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">685,414</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock (the &#8220;November 2025 Pre-Funded Warrants&#8221;) and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f937c59f-7e2c-4b6f-9018-676511a35b79" contextRef="C_f8276a73-58b9-40f0-8e8c-d2c73f397848" name="tpst:SaleOfStockWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,172,414</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the &#8220;Common Warrants&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a registered direct offering (the &#8220;November RDO&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_40ddd2dc-7ef3-4b75-9e81-f305adbec75d_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">combined purchase price of each share of common stock and accompanying Common Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_375e6e7b-2cfa-4a71-836b-829d31432854" contextRef="C_a6cb3954-c17c-46fe-8f17-edc83f6fb2e0" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">3.625</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The combined purchase price of each November 2025 Pre-Funded Warrants and accompanying Common Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41f57811-d729-45f6-88ac-2022296585af" contextRef="C_8a8915cd-0e0b-49eb-b2b3-419b16f12b37" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">3.624</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (equal to the combined purchase price per share of common stock and accompanying Common Warrant, minus $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0105305d-c54b-41d9-bb1b-cecce089cef3" contextRef="C_8a8915cd-0e0b-49eb-b2b3-419b16f12b37" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) The exercise price of the Common Warrants is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_721f765c-20c1-4fa6-8d0e-9bd549f3110a" contextRef="C_f8276a73-58b9-40f0-8e8c-d2c73f397848" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">3.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The net proceeds from the RDO were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc5b9d5f-422c-48bd-abba-f9dd0e4b2f16" contextRef="C_9b1ec7d9-4f7f-4128-b459-36816f64018b" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting placement agent fees and estimated offering expenses payable by the Company. As of December 31, 2025, all November 2025 Pre-Funded Warrants and Common Warrants remained outstanding. All November 2025 Pre-Funded Warrants were subsequently exercised in January and February 2026.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_0d7e37a0-bab5-4d6c-931f-b040800c466f" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_0d7e37a0-bab5-4d6c-931f-b040800c466f_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38e3599a-7792-4061-98ba-fb1e07f0f4a1" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The accompanying Consolidated Financial Statements have been prepared in accordance with US generally accepted accounting principles ("GAAP") and necessarily include amounts based on estimates and assumptions by management.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06f0f3de-c69b-4b5e-a053-ee5443e7ac5d" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e44fd417-881e-4fb6-ba12-96bdd91d4583" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d914ab86-53d5-42af-be73-0174df85a58e" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ae69006e-93a3-4b03-aa3b-f1a5e9530ccf" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable and operating segment, which is the business of discovery and development of small molecule drugs to treat cancers. All assets and operations are in the U.S. The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_05603c4a-63ad-49f7-8c55-20c2929846cf;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who is the chief operating decision maker (&#8220;CODM&#8221;), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. For additional segment information, see Note 12, Segment Reporting.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e98e3528-a3ec-4782-a301-e81e4c88e592" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company&#8217;s product candidates are still in development and, to date, none of the Company&#8217;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_3a03beaf-f080-4c1c-b68f-a1803de939e8" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_3a03beaf-f080-4c1c-b68f-a1803de939e8_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">instruments, which potentially subject the Company to concentration of risk, consist principally of cash and money market fund. All of the Company&#8217;s cash and money market fund are deposited in accounts with a major financial institution in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents to the extent recorded in the balance sheets. The Company has no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_0d7e37a0-bab5-4d6c-931f-b040800c466f_1" continuedAt="F_0d7e37a0-bab5-4d6c-931f-b040800c466f_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3a03beaf-f080-4c1c-b68f-a1803de939e8_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">off-balance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e2d67d8-ddb2-4d4c-aa0d-658dc3c0decd" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisitions to be cash equivalents. As of  December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s cash and cash equivalents consisted of bank deposits and money market funds.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_ec5de951-8f9e-4e68-892c-d894b75a7ca8" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company determines if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the customer has the right to control the use of the identified asset.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. When readily determinable, the Company uses the implicit rate in determining the present value of lease payments. When leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date, including the lease term.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The right-of-use (&#8220;ROU&#8221;) asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8edf8a65-0cb4-496f-a588-d8aead18a11f" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Property and equipment is recorded at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Upon disposal of an asset, the related cost and accumulated depreciation are removed from the asset accounts and any resulting gain or loss is included in the consolidated statements of operations. Repair and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_103b4d4e-fc30-48f6-ac51-8ec8160bbd7a" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_103b4d4e-fc30-48f6-ac51-8ec8160bbd7a_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated useful lives of the Company&#8217;s respective assets are as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_103b4d4e-fc30-48f6-ac51-8ec8160bbd7a_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:40.5%;box-sizing:content-box;"/>
         <td style="width:59.5%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><ix:nonNumeric id="F_ad5d93d1-03e5-452c-8b94-3bde40e2c28c" contextRef="C_f01f9f21-5e95-48cc-83bd-51259e351e7a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><ix:nonNumeric id="F_37f4e70b-6f83-4b85-9e5b-4a449454b48f" contextRef="C_0914ade8-ff10-4219-ba68-53e47ff2c071" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><ix:nonNumeric id="F_40b22d30-45d7-4668-bdb9-e3a7f01f21ad" contextRef="C_172aae3a-09ec-40f0-8e3c-93da515273fc" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><span style="-sec-ix-hidden:F_73e1d41b-207d-4eef-a0f5-e1ba66b3ef90;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of the useful life of the asset or the life of the lease</span></span></span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c6425c9-d8e7-4d14-8d02-2a3bdf0abe73" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Long-lived assets are reviewed for impairment if events or circumstances indicate the carrying amount of these assets may not be recoverable. If this review indicates that these assets will not be recoverable, based on the forecasted undiscounted future operating cash flows expected to result from the use of long-lived assets and their eventual disposition, the Company&#8217;s carrying value of the long-lived assets is reduced to fair value based on a discounted future cash flow approach or quoted market values.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_35463e5a-bbb7-4b1b-bab5-3d38dd9847a3" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_35463e5a-bbb7-4b1b-bab5-3d38dd9847a3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses and Accrued Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include certain payroll and personnel expenses including stock-based compensation, laboratory supplies, consulting costs, external contract research and development expenses and facility or lease expenses. In-licensing fees and other costs to acquire technologies that are utilized in research and development, and that are not expected to have alternative future use, are expensed when incurred. Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_0d7e37a0-bab5-4d6c-931f-b040800c466f_2" continuedAt="F_0d7e37a0-bab5-4d6c-931f-b040800c466f_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_35463e5a-bbb7-4b1b-bab5-3d38dd9847a3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers, the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e768b6f-5e32-4756-995e-c4d6ba4d2def" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:PatentCostsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These patent-related legal costs are reported as a component of general and administrative expenses.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de4e138d-ec44-407f-a6e0-570a652a01b1" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;General and administrative costs are expensed as incurred and include employee-related expenses including salaries, benefits, travel and stock-based compensation for the Company&#8217;s personnel in executive, finance and accounting, and other administrative functions, as well as fees paid for legal, accounting and tax services, consulting fees and facilities costs not otherwise included in research and development expenses. Legal costs include general corporate legal fees and patent costs.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c28da51f-7e3f-43c2-af01-5cf0e9a3e991" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments approximate fair value due to their short-term maturities.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa1b8769-54e6-47c5-bfc2-7f9c6b4d0ac9" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all share-based payments made to employees, directors and non-employees based on estimated grant-date fair values. The Company uses the straight-line method to allocate compensation cost to reporting periods over each optionee&#8217;s requisite service period, which is generally the vesting period.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates the fair value of stock options to employees, directors and non-employees using the Black-Scholes option-valuation model. The Black-Scholes model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, risk-free rate of return, and the fair value of the underlying common stock on the date of grant. Due to the lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The group of representative companies have characteristics similar to the Company, including stage of product development and focus on the life science industry. The Company uses the simplified method to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company accounts for forfeitures as they occur.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_454d2a26-b480-4c06-b5b9-88cbc6faf9c9" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_454d2a26-b480-4c06-b5b9-88cbc6faf9c9_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company follows the two-class method when computing net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0d7e37a0-bab5-4d6c-931f-b040800c466f_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_454d2a26-b480-4c06-b5b9-88cbc6faf9c9_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding stock options, convertible preferred stock and warrants to purchase shares of convertible preferred stock are considered potential dilutive common shares.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c35e2e2-7c59-4399-bfb7-677cd9c7b653" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2025 and 2024, the Company has recorded a full valuation allowance on its deferred tax assets.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cc6342e-9846-4ec9-8855-58093638d797" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; which requires public entities to disclose specific tax rate reconciliation categories, as well as income taxes paid disaggregated by jurisdiction, amongst other disclosure enhancements. The ASU is effective for financial statements issued for annual periods beginning after December 15, 2024, with early adoption permitted. We adopted the ASU retrospectively for the period ending December 31, 2025, and it affects only our disclosures and does not impact our results of operations or financial condition.</span></p></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8370cd4b-0603-4872-92e2-412b1d2f81bf" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;" id="section31"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. FAIR VALUE MEASUREMENTS</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6803e81e-6f03-4f2a-843b-d7b426e18c7e" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present the Company&#8217;s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f8e0a1b-3917-48e2-818c-d0d372f62557" contextRef="C_593fb7f1-b481-4017-9df8-af3cd7cf78c1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,707</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6993a35-6ef9-49a2-b9b0-d83832bc67e6" contextRef="C_83e9d5ae-1ac2-4dfe-901d-1fb708223a37" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a85b7df1-30b5-4274-942e-2338e44009f1" contextRef="C_4bcca309-5038-498e-a62b-782042e16268" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abc80f9f-115b-435c-a4fb-30ec2c7c5066" contextRef="C_9b755a49-74f8-491a-8e35-1ea2c98f61f7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,707</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6137ef6e-1838-419e-99fa-4ddb8486e653" contextRef="C_593fb7f1-b481-4017-9df8-af3cd7cf78c1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,707</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_106567d5-017f-4626-83f5-9b091263fb8f" contextRef="C_83e9d5ae-1ac2-4dfe-901d-1fb708223a37" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_718888f1-5852-4172-af73-4e9e408dd1f1" contextRef="C_4bcca309-5038-498e-a62b-782042e16268" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6bcaec7-120b-4510-8578-db305952010e" contextRef="C_9b755a49-74f8-491a-8e35-1ea2c98f61f7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,707</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fea32db1-b4a8-478f-b84a-a56caebeacfc" contextRef="C_e9697112-510d-4538-addd-de1c50b2db0d" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,268</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2db810b-f970-4f21-b5e3-1dfeab9ebc74" contextRef="C_1da28e56-a036-4c1c-9957-b3069151a0bc" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b32e8cff-3aa2-4a9c-b000-87fc89ed101e" contextRef="C_b90d1f82-feeb-4b7e-b350-61e27474eff0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65be45a7-c715-4d29-9aa8-6028ae64336c" contextRef="C_0b479aa9-6c7e-49ea-a261-63a2a337465f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,268</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d0b19fa-54f9-4226-88e3-c7a07675cbbd" contextRef="C_e9697112-510d-4538-addd-de1c50b2db0d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,268</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ef8d228-03ea-4011-b5f0-891fa111ac66" contextRef="C_1da28e56-a036-4c1c-9957-b3069151a0bc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4f71df9-1e3d-4d67-92a4-055492395466" contextRef="C_b90d1f82-feeb-4b7e-b350-61e27474eff0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8a4aa85-fbe4-4b32-9b31-b9654fe3badb" contextRef="C_0b479aa9-6c7e-49ea-a261-63a2a337465f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,268</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa67e4d2-5d57-4d99-bea3-405fd57cf23c" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;" id="section32"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. BALANCE SHEET ITEMS</span></p><p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c065dcb-0c1f-4e5a-91e2-7eaacb449b5d" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current asset consist of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.207%;box-sizing:content-box;"/>
         <td style="width:1.841%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.785%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.841%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.325000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f70deb4-4ef9-4298-a8b4-460c02154125" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed70d322-a2fe-44ce-8942-bc5a413d28db" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">642</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1b4b775-c0e1-4551-85d0-f9f0834b47e2" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="tpst:PrepaidResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22a4f1e4-45f2-42d8-91b6-81a2bb068c12" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="tpst:PrepaidResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0e176af-ce50-4ed2-ae3b-11a4f67d08dc" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9de7024f-1c58-44c1-a132-e9ed682e22d3" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">535</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67c1de5c-b5d5-497b-91ca-1ef59b1372be" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">562</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_877ffc44-a886-4bb6-9b48-833a766f56de" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,206</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fec32ed9-fc80-4bc1-9d6e-d2550ea6abe4" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net, consists of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.207%;box-sizing:content-box;"/>
         <td style="width:1.841%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.785%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.841%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.325000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47777dfa-af42-40ce-a6f7-8c197455ab6a" contextRef="C_f01f9f21-5e95-48cc-83bd-51259e351e7a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0580909f-72dd-489b-a2e3-7220bbf3d26e" contextRef="C_a3400db3-e1b2-4661-adf2-7b1ef948c2b3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d94c7ccc-0157-43b4-8dae-465a91f3c2e0" contextRef="C_0914ade8-ff10-4219-ba68-53e47ff2c071" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acf3c103-2dae-4622-9b2b-7d6507eab66d" contextRef="C_1637137e-aed7-4f2d-9427-075a1f55122b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">328</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccf0f35a-eb8b-440d-bac4-6249bce3682d" contextRef="C_9d204fd8-22c5-49c0-9f16-eaa7fe7bc752" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,446</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae2988fe-05d4-4e47-84e0-8abde093d9de" contextRef="C_5044accb-f46c-4dbe-954f-4ba8e4e9b034" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,485</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3a7d79b-483d-452f-b477-fb48c6555e7f" contextRef="C_0d904433-7564-4710-8699-0c23e7ee67c2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecf2ee0f-5e37-475e-82a1-ca05f3b48775" contextRef="C_fb5c878c-f0d7-482c-814a-fe0164e7e33e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">201</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf21c18f-0e83-429b-9d99-82444d5a6c6e" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,058</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68e86532-a552-48d1-b421-532372fa3221" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,206</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47346723-22e0-48b3-80cf-0e5e950b889a" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,453</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6957b62b-4d01-4c57-be64-d75f27b6895c" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,320</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment&#8212;net</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a86fc56-7cb6-48cd-a60f-34505b762e62" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">605</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba3defbc-f6f3-44fd-a811-b5903800bb94" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">886</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense for the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4f92c0e-6f60-4466-89a6-ee127ed39667" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">266</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b7a64bd-b25f-40c9-b456-362326c0fd6d" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16224a33-98a7-4327-a48f-f6864d23a488" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.207%;box-sizing:content-box;"/>
         <td style="width:1.841%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.785%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.841%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.325000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other liabilities</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06972d93-d370-4634-8c84-9aaacbba3dfb" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">627</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa7d52d6-2524-4e82-97aa-806a1878ffbf" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,335</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a567d05e-965e-41b6-aa2e-6aa6eb9a42de" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="tpst:AccruedClinicalTrialLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8233e25-51c0-4353-a5b6-87a4be6116ba" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="tpst:AccruedClinicalTrialLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,391</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_824b70a9-47fc-4d6e-8461-6887ce026106" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">937</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e01bf9ad-6ea4-414f-a97e-929ab87318f4" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,726</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_2071214c-81bd-4ba5-a4f0-4c1a2419b43f" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_2071214c-81bd-4ba5-a4f0-4c1a2419b43f_1"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;" id="section33"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities Lease Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In January 2022, the Company entered into an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21d22392-588b-4283-95ac-569238ecfa60" contextRef="C_ec6026bd-9c80-4233-9bc5-2e05dc22c3d2" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> office lease agreement for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2044bf8-05e3-46aa-bbd9-52bfac80f518" contextRef="C_ec6026bd-9c80-4233-9bc5-2e05dc22c3d2" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">20,116</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet facility in Brisbane, California (&#8220;Brisbane Lease&#8221;). The lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d48222fe-a5e9-4cc3-af08-2e8e55d8aa49" contextRef="C_066bf70d-7a44-4797-b1fa-45ce89b04609" name="tpst:OperatingLeaseCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the balance of the operating lease right of use assets were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c45ee610-3419-4257-a9de-bbd067437045" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,540</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b525723d-0705-4b09-aba3-b99623c00d77" contextRef="C_4b4a9e1c-7ea2-4fd6-9990-5b75e3c05009" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,643</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and the related operating lease liability were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e55478cc-925f-4e93-80a8-cb871e4edca4" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,141</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_435e75a5-fc71-4cc6-a7f4-4fc7852078b2" contextRef="C_4b4a9e1c-7ea2-4fd6-9990-5b75e3c05009" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,011</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, as shown in the accompanying consolidated balance sheets.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rent expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff6b5770-b7f4-437a-84fa-108c67259d95" contextRef="C_f8ce6377-25b1-417f-a67b-27dd94b6927b" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,946</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a79a8df8-637d-4d87-96e9-dd0a92e9a831" contextRef="C_3dd1d89e-976b-47de-b4a0-39ee50aa0671" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,244</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2071214c-81bd-4ba5-a4f0-4c1a2419b43f_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82b05689-940b-45e8-a76e-df9f778727c4" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, future minimum annual lease payments under the Company&#8217;s operating lease liabilities were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.823%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Commitment</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4a25d73-29a3-4cc1-a398-f759ec0baec9" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,926</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d82e79ae-66fc-4c56-a22e-d10902452227" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,994</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31ba7be7-d069-4493-941d-1d6fd216e6ec" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,064</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72b50670-1430-45e9-a6e5-878cb258089c" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,136</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fccf8b29-f900-408e-9667-8bcf67ea74fd" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,210</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total minimum lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83283d63-032d-4aa3-96c3-43c2238aca34" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,330</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d3e526e-b4a8-4816-b487-a9c0329365bd" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,189</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of operating lease obligations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_925fc019-54e4-45e0-a4a7-3f5942529bbb" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,141</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: current portion</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5b6bff4-b8f9-45fe-b8cd-63e966d5d53c" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent operating lease obligations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d443ffa7-566e-41e9-ac4c-a9af2758e3a4" contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,949</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related to this Brisbane Lease agreement, the Company entered into a letter of credit with a bank to deposit $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_422c78ea-89c7-4bf8-ae6c-85acbb374b7c" contextRef="C_090576ed-b8aa-4a6c-bd24-ad4fc236805a" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">388</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a separate account that is restricted cash to serve as security rent deposit. This amount is included in other noncurrent assets in the accompanying Consolidated Balance Sheets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_387058d6-0554-4084-b6c8-ed2ccfa73a56" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;" id="section34"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. LOAN PAYABLE</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 15, 2021, the Company entered into a loan agreement with Oxford Finance LLC (the &#8220;Lender&#8221;) to borrow a term loan amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_980d885a-32f1-4a2f-987c-7b9666d3b61a" contextRef="C_c0d8ea89-cc8c-45be-bc99-628196dc6c0b" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be funded in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_662fed36-d0cc-42fb-a5ad-bc523aa5bce3" contextRef="C_c0d8ea89-cc8c-45be-bc99-628196dc6c0b" name="tpst:DebtInstrumentNumberOfTranches" unitRef="U_Tranche" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> tranches (as amended, the &#8220;Loan Agreement&#8221;). Tranche A of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdf4b670-5a8e-4340-adf5-46579bb5653b" contextRef="C_e001f4eb-5e39-4fc6-86f8-e7d36c542298" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was wired to the Company on January 15, 2021. Tranche B of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_058bba6b-d763-4136-98f7-64b04d201e6c" contextRef="C_dbd9479a-dda8-49f7-909e-f327ddced2a0" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expired on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8acdf799-3258-4fef-9ed5-720e062e2d0a" contextRef="C_15eeec6d-ae98-4bbc-b091-1fe5a22f07be" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Tranche C of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b728de1-608c-48c5-94f8-8cf46288eca1" contextRef="C_69c4f05e-7e57-48e6-b6d6-083e708f8908" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was available at the Lender&#8217;s option.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 23, 2022, the Company entered into a First Amendment to the Loan Agreement. The amendment modified the Loan Agreement as follows: (i) each of the Company and Millendo Therapeutics US, Inc., a Delaware corporation and wholly owned subsidiary of the Company (&#8220;Millendo&#8221;), were joined as co-borrowers under the Loan Agreement; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b73a5389-2bf1-41c8-a0c8-4aa4acf21b17" contextRef="C_c6e78168-a2c5-460b-b80d-8a8b0415a3a5" name="us-gaap:DebtInstrumentInterestRateTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the interest-only repayment period was extended through December 31, 2023 (which interest-only period may be further extended through June 30, 2024 under certain circumstances)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; and (iii) a security interest in all of the assets of the Company, TempestTx and Millendo, including any intellectual property, was granted to the Lender. In addition, the Lender permitted a one-time prepayment in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a1521c1-2662-4cb3-81da-38df38486b93" contextRef="C_8ef892e0-d716-4056-9b12-9c9a7aa12c94" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which the Company paid on December 23, 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the amendment to the Loan Agreement, the term loan had a maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cabdc669-5523-4c44-85c7-ad6518a4b4ed" contextRef="C_8ef892e0-d716-4056-9b12-9c9a7aa12c94" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 1, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and an annual floating interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da3661c8-e2dc-46c4-bf58-f9e8089e0b2e" contextRef="C_23067402-fab4-4583-a8ba-7a645e0e1ef8" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, which is an Index Rate plus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b6d157f-fffb-4449-b028-14a7e4761c21" contextRef="C_8ef892e0-d716-4056-9b12-9c9a7aa12c94" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. Index Rate is the greater of (i) 1-Month CME Term SOFR or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79e40e68-02cc-42f5-84d7-b5659e5ec26b" contextRef="C_23067402-fab4-4583-a8ba-7a645e0e1ef8" name="tpst:ThersholdIndexRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. In the fourth quarter of 2023, the Company achieved the circumstances necessary to extend the interest-only repayment period through June 30, 2024. Monthly principal payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38d34cef-7bbe-49b2-9396-6d33e28ea12d" contextRef="C_8ef892e0-d716-4056-9b12-9c9a7aa12c94" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">733</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were required to begin on July 1, 2024. Related to this borrowing, the Company recorded loan discounts totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a82f6427-d26a-4f21-91d7-d68f0c4dd816" contextRef="C_c0d8ea89-cc8c-45be-bc99-628196dc6c0b" name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">898</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69f16f0e-a6e9-4b26-b594-8add6792e986" contextRef="C_98b385cd-564a-43ce-b857-c685a4784e21" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of debt issuance costs. These amounts would be amortized as additional interest expense over the life of the loan.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 8, 2025, using cash on hand, the Company made a repayment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc7a16ce-5f41-4086-aadf-0e41d86bbdf4" contextRef="C_83ad0427-46c9-40f3-8ea3-599adc8b0338" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in full satisfaction of the aggregate outstanding amount, including accrued interest and exit fees as of such date, under the Loan Agreement with the Lender. The payoff amount paid by the Company in connection with the termination of the Loan Agreement was pursuant to a payoff letter with the Lender and included payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfc320c1-f83b-45e4-b86a-3b5cc0d53c2c" contextRef="C_83ad0427-46c9-40f3-8ea3-599adc8b0338" name="tpst:DebtInstrumentExitFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as an exit fee. Upon making the repayment, the Loan Agreement was terminated in accordance with its terms and all liens and security interests granted thereunder to secure the obligations were released.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total interest expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2002640-f89a-4e4c-b8ae-050875c4ece0" contextRef="C_c6e78168-a2c5-460b-b80d-8a8b0415a3a5" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_209b4a74-163f-4134-98f7-b6f5e6af1e9f" contextRef="C_e4e85a24-a7ee-432a-b926-c4bcdd8d3d4a" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,316</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64ef9e28-b259-4a79-9981-74c3bb6d6dd4" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;" id="section35"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. STOCKHOLDERS' EQUITY</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorized Stock</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcc634ef-69ca-4973-b380-52c1af8bd4fb" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fceefa88-7474-4b97-8fff-dfef1e9c6f75" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_774c2427-e78a-4364-b45d-4d850acefee5" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a337341-e519-470f-a76e-99e3feb1e0d1" contextRef="C_9b1b80e6-f451-436f-91eb-8955ad7e6679" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of which have been designated as Series A Participating Preferred Stock (the &#8220;Series A Preferred Stock&#8221;), par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d0695ac-47ed-4a29-8127-2bb51e7519e7" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share pursuant to the Company&#8217;s adoption the Rights Plan (as defined below). </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a277550-673f-4d60-b7c3-71c80890cdef" contextRef="C_9b1b80e6-f451-436f-91eb-8955ad7e6679" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b7189df3-0b76-4b63-8479-dd6624e31ee7" contextRef="C_d6236c64-7c86-4bbd-a146-18c57a7267cc" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Series A Participating Preferred Stock were outstanding as of December 31, 2025 and 2024. Stockholders are entitled to dividends as declared by the Board of Directors, subject to rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9db4e6f-b969-4ede-95a1-841b18a9bcc2" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:DividendsCommonStockCash" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash dividends declared to date. The holders of each share of common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0aa33c5-0c6b-48ff-93ad-5d0d4667fa73" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote and the holders of each share of Series A Preferred Stock, if issued, are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_daf961b4-c868-410a-9470-2d01eb86c4a9" contextRef="C_b3405bb2-c492-46ef-ba86-83755523024a" name="us-gaap:PreferredStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1,000</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> votes. Except for effecting or validating certain specific actions intended to protect the preferred stockholders, the holders of common stock vote together with preferred stockholders.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights Plan</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 10, 2023, the Company&#8217;s Board of Directors adopted a limited duration stockholder rights plan (the &#8220;Rights Plan&#8221;), effective immediately, and declared a dividend of one preferred share purchase right (a &#8220;Right&#8221;) for each outstanding share of the Company&#8217;s common stock. The dividend was effective as of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2acb0d63-6a05-4c5b-9997-30d2be8215c7" contextRef="C_3665f268-732d-4aa6-b123-f1529af2e05d" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 23, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Record Date&#8221;) with respect to stockholders of record on that date. The Rights will also attach to new common stock issued after the Record Date. Each Right entitles the registered holder to purchase from the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cc2526f0-0ec8-49fd-83a9-ebb177d174dd;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one one-thousandth</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of a share of the Series A Preferred Stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_661d1adf-56a1-4523-a60f-cf69f7fd3f16" contextRef="C_0c195dac-9159-4433-aab9-8a61697eeb1c" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">25.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per one one-thousandth of a preferred share, subject to adjustment. The descriptions and terms of the Rights are set forth in a Rights Agreement, dated as of October 10, 2023 (the &#8220;Rights Agreement"), between the Company and Computershare Trust Company, NA.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 9, 2024, the Company entered into Amendment No. 1 (the &#8220;Amendment&#8221;) to the Rights Agreement. The Amendment extends the Final Expiration Date of the Rights Agreement until immediately following the Company&#8217;s 2025 Annual Meeting of Stockholders or, if the Company&#8217;s stockholders approve the Rights Plan at or prior to such meeting, to October 10, 2026, unless the Rights are earlier redeemed or exchanged by the Company. The Company does not have any obligation under the Rights Agreement to seek stockholder approval for the Rights Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 5, 2024, the Company entered into Amendment No. 2 (the &#8220;Second Amendment&#8221;) to the Rights Agreement. The Second Amendment makes certain technical amendments to the rights and obligations of the Company&#8217;s Board of Directors to administer and make determinations with respect to the Rights Agreement and the rights issued thereunder. The Rights Agreement otherwise remains unmodified and in full force and effect in accordance with its terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_1495140c-8fe8-40ce-8465-55edac490660" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true" continuedAt="F_1495140c-8fe8-40ce-8465-55edac490660_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;" id="section36"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. STOCK-BASED COMPENSATION</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Plans</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2011, Private Tempest adopted the 2011 Equity Incentive Plan (the &#8220;2011 Plan), and in 2017, Private Tempest adopted the 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;), and together with the 2011 Plan, the &#8220;Tempest Prior Plans.&#8221; The Tempest Prior Plans have been terminated and no additional grants may be made under either plan. All stock awards granted under the Tempest Prior Plans will remain subject to the terms of the applicable prior plan. As a result of the merger with Millendo, the Tempest Prior Plans were assumed by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 29, 2019, the Board of Millendo adopted the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;), subject to approval by the Company&#8217;s stockholders, and became effective with such stockholder approval on June 11, 2019. On June 17, 2022, the Company&#8217;s stockholders approved the Amended and Restated 2019 Equity Incentive Plan (the &#8220;A&amp;R 2019 Plan&#8221;), which amended and restated the 2019 Plan and was the successor to, and replacement of, the 2019 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_1495140c-8fe8-40ce-8465-55edac490660_1" continuedAt="F_1495140c-8fe8-40ce-8465-55edac490660_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Tempest adopted the Amended and Restated 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;) on April 30, 2023, subject to approval by the Company&#8217;s stockholders. On June 15, 2023, the Company&#8217;s stockholders approved the 2023 Plan, which amended and restated the A&amp;R 2019 Plan and will be a successor to, and replacement of, the A&amp;R 2019 Plan.  The number of shares of the Company's common stock reserved for issuance under the 2023 Plan will automatically increase on January 1st of each year, for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2680257-81e8-4b0c-84c2-b7871888fc75" contextRef="C_8e605970-763d-474d-b0cb-5de22ba59e68" name="tpst:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, from January 1, 2024 continuing through January 1, 2033, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7620b672-3bd5-4bc4-a801-642482727c07" contextRef="C_8e605970-763d-474d-b0cb-5de22ba59e68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of the Company's common stock outstanding on December 31</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the preceding calendar year, or a lesser number of shares as may be determined by the Board of Directors. Accordingly, on January 1, 2026, the common stock reserved for issuance was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a9e7d5e-837c-4b78-948f-8ca779fa904f" contextRef="C_03c240c2-1a9c-4f7e-818d-a75b93b79bc7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">197,086</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a255b65-656f-4ccf-9bc6-0d9837506e18" contextRef="C_f721aedf-b106-461a-903b-46e34a9f1d0d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">47,745</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future grant under the 2023 Plan. In addition, on January 27, 2026, the Company's stockholders approved the amendment to increase the number of shares issuable under the 2023 Plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dec7cc4-b1b5-4c72-a872-a1c807dc9781" contextRef="C_151f94be-33aa-4e72-91ab-8bdd1b7a21c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,410,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2023 Plan allows the Company to grant stock awards to employees, directors and consultants of the Company, including incentive stock options (&#8220;ISOs&#8221;), non-qualified stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Tempest adopted the 2023 Inducement Plan (&#8220;2023 Inducement Plan&#8221;) on June 21, 2023, pursuant to which the Company reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d107dff-28a7-4fed-812e-6d2d7d9b8a63" contextRef="C_eae918eb-3de4-4147-a020-481aebcd8e1d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,150,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual&#8217;s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2023 Inducement Plan was approved by the Company&#8217;s Board of Directors without stockholder approval in accordance with such rule. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efb29447-5eb6-4ffb-94f0-5fee3e236cd1" contextRef="C_c7f4e70e-297e-4e0f-9e4c-cf579d45fbdc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">67,615</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future grant under the 2023 Inducement Plan.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures employee and non-employee stock-based awards at grant date fair value and records compensation expense on a straight-line basis over the vesting period of the award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Stock Ownership Plan</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Millendo adopted the 2019 Employee Stock Purchase Plan on April 29, 2019, which became effective upon stockholder approval on June 11, 2019. On June 17, 2022, the Company&#8217;s stockholders approved the Amended and Restated 2019 Employee Stock Purchase Plan (the &#8220;2019 ESPP&#8221;). The 2019 ESPP enables employees to purchase shares of the Company's common stock through offerings of rights to purchase the Company's common stock to all eligible employees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 ESPP provides that the number of shares of common stock reserved for issuance under the 2019 ESPP will automatically increase on January 1, 2023 and continuing through (and including) January 1, 2029, by the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af7b8001-f90b-4cd1-86b8-701dccfb87fd" contextRef="C_cc23a656-ad79-4d18-bc37-248f3df07c4e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of Common Stock outstanding on December 31</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the preceding calendar year, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83376484-8a3d-43d0-aac2-d828d5381590" contextRef="C_cc23a656-ad79-4d18-bc37-248f3df07c4e" name="tpst:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock, or (iii) such lesser number of shares of Common Stock as determined by the Board of Directors (which may be zero). On January 1, 2026, the common stock reserved for issuance was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a25ff35-32c1-4184-82ae-ba0f8dbf27cd" contextRef="C_5cc9aad1-44ab-4aae-ac30-ebf9766e2451" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">38,461</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c14cfc2-ac6f-4f19-ade1-4ab3793227b9" contextRef="C_e84c96bf-09c7-4644-ac47-8073761fa16a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">68,608</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock remained available for future issuance under the 2019 ESPP. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b04075db-0afe-4ab3-b9ef-5f954040fb04" contextRef="C_8889779c-cd1a-4a88-8d46-c213f770f4d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,955</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock had been issued under the 2019 ESPP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Options</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options to purchase the Company&#8217;s common stock may be granted at a price not less than the fair market value in the case of both NSOs and ISOs, except for an options holder who owns more than 10% of the voting power of all classes of stock of the Company, in which case the exercise price shall be no less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7aa1cba-87da-4e2d-b326-e4d22219b5a9" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value per share on the grant date. Stock options granted under the Plans generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5b77a05-871f-4dc4-88bf-93885c428fb4" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and expire no later than ten (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04d2a762-47a8-4e76-b2d1-350bb8078de7" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) years from the date of grant. Vested options can be exercised at any time.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the merger with Millendo, the grant date fair market value of the shares of common stock underlying stock options was determined by the Company&#8217;s Board of Directors. Up until the merger, there had been no public market for the Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_1495140c-8fe8-40ce-8465-55edac490660_2" continuedAt="F_1495140c-8fe8-40ce-8465-55edac490660_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">common stock, and therefore the Board of Directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which included valuations performed by an independent third-party, important developments in the Company&#8217;s operations, sales of convertible preferred stock, actual operating results, financial performance, the conditions in the life sciences industry, the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company&#8217;s common stock.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f648362-ebae-4ee6-aea1-dbbecdcc65ba" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following shows the stock option activities for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:57.489%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:12.697%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.238%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.778%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Options Outstanding</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_170c9803-68a6-49f7-bcbd-87857e3a4b97" contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">273,393</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46787330-aaa0-421b-87a8-0f5fd9ab61d9" contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">94.64</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab84e1a1-cd95-4e3e-b93d-07d8f5d32a04" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">69,009</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_becd5a6c-e322-4d87-baca-bbc41abc8c09" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">51.48</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9158b34-a389-4595-8c23-fdab4cd2c19a" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,284</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28a64d87-60cd-4adb-9b1a-8d5fbd0b95c9" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">24.83</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled and forfeited</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1377f10-c5f0-4aab-85fb-804fbb05f015" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,028</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eb736d6-942d-4fb7-b938-185ca08e7d21" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">106.99</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f56ef6db-b756-4103-8f66-fb0f4e6af23f" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">320,090</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8a52eb8-8452-427c-9cb1-b76b97aa23f8" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">86.06</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93084b63-d474-4777-ba56-5ee0a76ee00a" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">130,014</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a703ea2a-9bb8-470f-a862-61c3e85c946d" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.20</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a18f243-fc36-4704-92a2-4fcaadba0c22" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0779ca61-2631-46a9-8e4b-1f7a12273732" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled and forfeited</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd66a802-a56f-4ea0-9c80-787d379942bb" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecec0db6-7b19-4883-8785-1e2bf69864c5" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a0bf6c8-9d98-448b-b0f6-c32ffcab9e5e" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">450,104</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80a74f16-3a71-4fa3-9e2a-b5bfef1f4a58" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">64.44</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09f23c56-296a-4328-887c-43234652bce7" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes information about stock options outstanding at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:50.11%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.422%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.662%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.182%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.182%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Life (In Years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options outstanding</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83281dc7-6c10-4e3c-a64e-b491bb298ce9" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">450,104</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_0ccb1725-ff4e-46ed-bc08-46dfefbe46c9" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.71</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_305962c4-af2b-411c-b28f-453753033026" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">64.44</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f39fd556-cf0e-4913-9cf6-2b730bc0865a" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bae21b5-81b3-4d7e-bc78-371dde1133ef" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">450,104</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_699000cb-3d32-41f7-ace6-3cdcf218993f" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.71</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfee0614-8e03-4464-9013-458e59837752" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">64.44</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14a5a242-f00f-4d0f-a288-171d17397681" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_861857b5-ce27-48ed-9b8e-80b7c1a3109a" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">441,792</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8e4fb0c4-391b-4c79-8643-306696f90222" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.70</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_248f7790-d1f6-40b7-9910-42915195158f" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">64.51</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70618d25-0066-4af8-b4ba-aca7f8e5454e" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company granted employees and non-employees stock options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29a76ca1-bd88-4cc3-a006-8150c464c037" contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">130,014</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8da764e1-8a27-418e-896e-90e8baaec9b5" contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">69,009</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock with a weighted-average grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_984f988e-7771-41f3-9a87-59d256619e52" contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad1bf0ed-2875-4399-97ba-b2c158ac8a37" contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">51.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized compensation costs related to unvested employee stock options were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ac44bf9-fc1d-44eb-a46f-5154cb9c08cf" contextRef="C_dcb60290-a2fa-4e02-8588-a3425a10e251" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d8d387b-fbff-43c6-a30e-d41b3038fd9f" contextRef="C_b06ce1d5-43af-4875-915d-0b69099c48e3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,352</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. These costs are expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05bb933d-604a-4aee-97dc-896c93aa3e54" contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_828b461f-be53-4bf2-a992-a6de9f3d45e9" contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. The fair market value of stock options vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59b13f20-cc85-45eb-be6b-bcedc279ea93" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,576</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f006e19-a93d-4bef-b341-10b175d458ae" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,303</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of stock options using the Black-Scholes option pricing valuation model. The fair value of employee stock options is being amortized on the straight-line basis over the requisite service period of the awards. </span><span><ix:nonNumeric id="F_8d393c9e-76ac-40da-ac87-38152e383cbc" contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_8d393c9e-76ac-40da-ac87-38152e383cbc_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of employee stock options was estimated using the following assumptions for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_8d393c9e-76ac-40da-ac87-38152e383cbc_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.358%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.358%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6a3073e7-1145-4513-af3f-67bd755124a9" contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_fa2a42bc-9157-4981-a828-301908cd8bb5" contextRef="C_f941fd95-2c63-4333-b1fe-fd70c5cce07d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_56c3a4a8-d110-4f99-9ba7-7fe72e849226" contextRef="C_1eb9e2a4-c74a-4bb4-9c41-89af539af6a5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55c99471-a4b1-4906-adba-298d7a34fe42" contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">115</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcd942d2-6ad5-40dc-b2c8-72e7424c3f6b" contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">116</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87d8f4b1-55e2-442b-95cf-63e453b16670" contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">109</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40baa22e-a591-427e-a545-3e44836ca27b" contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">124</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22fe92de-4fff-478f-95b3-dbf7dcdb0701" contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a49b3639-d8f0-4e44-af95-78e813417363" contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f91b725-392d-437c-b818-c5c2bba8081c" contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividends</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e60d739-ae95-450b-ac7f-5ea75456e252" contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">&#160;%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dcad65d-7813-46cb-bbc3-899d2b579e60" contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">&#160;%</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected term of options granted represents the period of time that the options are expected to be outstanding. Due to the</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of historical exercise history, the expected term of the Company&#8217;s employee stock options has been determined utilizing the simplified method for awards that qualify as plain-vanilla options.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_1495140c-8fe8-40ce-8465-55edac490660_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company did not have any trading history for the Company&#8217;s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the Company&#8217;s common stock becomes available.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#8217;s stock options.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company has not paid any cash dividends on common stock since inception and does not anticipate paying any dividends in the</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreseeable future. Consequently, an expected dividend yield of zero was used.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Company accelerated the vesting of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f393956e-a0a4-4533-bcd7-c0164bba7be4" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">266,108</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> time-based vesting stock options grants previously awarded to the Company's employees, pursuant to the separation agreements entered into with such employees. The Company also extended the post-termination exercise period from 90 days to 180 days immediately following the separation date for any options that were vested, including the options that were accelerated in vesting, as described above. Further, in the fourth quarter of 2025, approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_617b818b-9739-4ef8-816d-ff10a7f265c5" contextRef="C_5674d468-6c98-412c-9336-57931dcfe277" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">416,005</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of modified stock options were further modified to extend the post-termination exercise period from either (i) 180 days to December 31, 2026 or (ii) to the earlier of (a) the date that is 90 days following termination of continuous service, and (b) the expiration of the term of the options as set forth in the award agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The above modifications to current and former employees stock options grants resulted in modification accounting under ASC 718, Compensation &#8211; Stock Compensation. As a result, the Company recognized approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_319ea4a1-bac8-4873-a43e-73f100c5687b" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of stock compensation expense during the year ended December 31, 2025. For vested awards with no future service period required to be provided, the expense was measured on the modification date by calculating the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified with immediate expense recognition. For unvested awards with no future service period required to be provided, the Company reversed any stock compensation expense previously recognized, remeasured the fair value of the modified award and immediately recognized stock compensation expense on the modification date. For stock options that were further modified to extend the post-termination exercise period upon termination of continuous service, the Company measured the expense by calculating the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified. The fair value of those awards included a reduction to the share price for the fair value of the warrant dividend as the holders of the modified stock options were not participants in the warrant dividend. A portion of this modification was recorded as stock compensation expense in the fourth quarter and the remainder to be attributed over the derived service period.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the components of stock-based compensation expense recognized in the </span><span><ix:nonNumeric id="F_7d3784da-6642-4101-b9bf-b46a57b94f9c" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true" continuedAt="F_7d3784da-6642-4101-b9bf-b46a57b94f9c_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s consolidated statements of operations for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7d3784da-6642-4101-b9bf-b46a57b94f9c_1" continuedAt="F_7d3784da-6642-4101-b9bf-b46a57b94f9c_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.403%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.403%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd2f3691-df46-4712-89c7-d0e4000e1956" contextRef="C_c3d09bfa-c82c-410e-8c05-013d4096ded0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,179</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae012e03-8645-40b2-a056-e71971359d4d" contextRef="C_f9dcc510-706f-4f08-bade-b100bcff92b0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,222</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d170b7bd-7de3-4580-b2fd-f08d046af9d1" contextRef="C_ee3c2c67-1de7-4901-bc90-59a0afc42477" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,939</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_190475a7-e72c-4f0d-ac15-beb8c73f3ff5" contextRef="C_c7a9e8d9-54e8-4bd7-bfcf-2da3a970b22f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,081</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c52b02f4-71cd-430c-a9db-4c79e5849074" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,118</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1132e4c8-4a83-481a-b12d-d26e4b671c04" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,303</ix:nonFraction></span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div></ix:continuation></div><div><ix:continuation id="F_7d3784da-6642-4101-b9bf-b46a57b94f9c_2"></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_0dedbd16-ba36-46d0-9446-cfd6ee76fccd" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_0dedbd16-ba36-46d0-9446-cfd6ee76fccd_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section37"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. INCOME TAXES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e1fff73-116b-4995-b0a9-d78b2ba53a99" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_34f21e69-6a09-4d68-8500-c9a484c7684a" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provision for income taxes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, because the Company has incurred losses since inception.  At December 31, 2025 and 2024 the Company concluded it was not more likely than not that it would realize its deferred tax assets, and therefore has recorded a full valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_0dedbd16-ba36-46d0-9446-cfd6ee76fccd_1" continuedAt="F_0dedbd16-ba36-46d0-9446-cfd6ee76fccd_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27e0667e-6a43-4e0d-a303-8553c843124b" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9d7a8860-dc7a-4a28-9d06-2470405ccba6" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> income taxes for the years ended December 31, 2025 and 2024, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d54386c-2bfa-475e-8701-518958abb586" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ec13452-d978-4f42-b369-0df16946bcf1" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_61d520ad-638d-43fb-8370-9f36964f3933" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to pre-tax loss as follows (in thousands):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:34.454%;box-sizing:content-box;"/>
         <td style="width:1.981%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.925%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.866%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.981%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.925%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.866%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">U.S. federal provision (benefit)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_98cdff81-3c83-4c66-ba34-8998155d3a60;"><span style="-sec-ix-hidden:F_14cb7b7c-9f29-479f-8c41-fb9c6a5ca935;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">At statutory rate</span></span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb9a7f0f-fe0b-4f6b-8f95-8529941b766c" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,514</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecfce884-69db-4948-b1fb-e57f840b6775" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b468568-1d3d-41ec-971d-f1e3642d1be7" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,786</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3baa14b-9e18-4ffc-8c5b-481b5d8c2d39" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb94cf8f-39d2-4c32-99cb-83621440eb21" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,105</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78c195f2-b1eb-4a6a-a352-3695413b064f" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">19.4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51ffac50-803f-4855-ad2d-7e8a1e0f7cdc" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,199</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eceb92b-57d9-465b-84f0-18b91b4f896b" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">22.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or Nondeductible Items</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f9ea619-107b-4b64-a755-1db38a905919" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">343</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ba26399-6a6e-4d90-8443-ffac57a2addd" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d2920d3-ea30-4d28-84b6-7a49d6acb540" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">709</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93d80805-9905-4c97-a8d4-eecc20060c65" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transaction costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89e90af0-9219-4035-a1d6-a5077843f50b" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">454</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ca12b9c-901c-4cbc-bb18-7cd68195afcc" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fcba0e5-5f22-4262-8aef-04998526b5ad" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cdffa17-7256-4e9f-9880-34912539362e" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8aacb2a2-0533-410b-9373-507c6bf094e4" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_541ed3e8-0f71-4842-a65d-e15971ec6a77" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdad1c71-c712-45df-a71b-4fb1b40d636b" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_987d8135-a002-49b1-ab18-3783946d0379" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8683d97e-91b4-4cf4-b24c-dbea3f1da3f6" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">478</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_253ba773-db45-4692-9369-db4712f70aae" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65126cce-8bc9-43d2-8553-0ea3b7a3209b" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,136</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6628d36f-b2d9-47f9-8436-6ab5eeec6463" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8ffd299-52da-4dad-8823-fd294574118a" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1a9d2f7-a9d3-43ac-962c-3875a5e74565" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0938c358-8b0c-4792-b19a-22c47550c722" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c80573e-a795-4778-98b0-90536189b5d5" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">State income taxes in California comprise the majority of the state income taxes, net of federal effect category for the years ended December 31, 2025 and 2024, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24e9e969-d6d8-4f76-8f29-ddd4ff4fca54" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 are shown below.</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:62.84%;box-sizing:content-box;"/>
         <td style="width:2.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.46%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.46%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_610de1f1-9ec8-4bb5-a901-8406cee14ce9" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,074</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c7ba049-3bde-4b81-bc99-de84e55cade6" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,896</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab73a5da-8352-4e99-89ad-6c2042b29c92" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,198</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5f41589-63f6-4e61-97f5-aae08eea799b" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,513</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efcd9b0c-cbfe-4cbe-a367-2d1c90521b3d" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="tpst:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">489</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dce36c93-24b3-4e7e-8374-357a5afd28a5" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="tpst:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">603</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3eef81d-f78f-41e3-8ce4-5c11625176e8" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="tpst:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,354</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61383256-3457-4b0d-be29-d2a6e342fe9d" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="tpst:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,625</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86218abd-6660-43bc-991b-174478d551ff" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,583</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5201d6a-4c85-490a-9921-a36a6ca9e4d6" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,167</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7e21ef5-adde-49d6-9fdc-a66f43ae5338" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9726f43b-8042-46d2-a6ec-c5517639f74d" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_069d4749-dd26-4d17-abc9-b905b67485a7" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="tpst:DeferredTaxAssetsCapitalResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,901</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_716e450f-7965-4bc6-9fda-569ad5d78e6c" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="tpst:DeferredTaxAssetsCapitalResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,041</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad71cc4b-2c7d-48b3-90af-a3f42b1fb560" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,697</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bf8a5c5-5056-4275-a6b5-9ba953d47680" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,336</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e37e53bd-21f7-4ef5-98f7-dc2540adc5d8" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,498</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3f78759-97ca-4e9f-8e4b-02736124b320" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,799</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15f1f5bf-186f-4b83-ad67-28eca0a81c16" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,199</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92163a29-0d58-4832-87b4-792b565ac747" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,537</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred tax liability:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6aa6a17-c063-4043-8754-64a3cf4a163b" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="tpst:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,180</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0663100a-7616-4c2e-b9b1-6fd6612057a6" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="tpst:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,518</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_018f6f89-9d2e-4c0f-a534-fb9ca88ae32b" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_208f49b3-6ad4-4243-ab0e-b2f182f27d21" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05db6c44-0dc6-4309-bb18-bcf7ca587f0c" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,199</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_933fa6f5-b13f-4e58-ba20-1b975b416bb2" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,537</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf8e4783-4ac6-4e70-9603-16a2c6fc580b" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_400b99f6-37a6-4054-a4bb-b489d547b884" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6878619c-88b8-40dd-9a08-bb737431e43d" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 to December 31, 2025 due primarily to the generation of net operating losses and research and development credits.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required under ASU 2023-09, the Company has included only the portion of the valuation allowance related to federal deferred tax assets in the "change in valuation allowance" line of the rate reconciliation. </span><span><ix:nonNumeric id="F_6a9a11bb-781c-43e6-9847-22201329f3d0" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SummaryOfValuationAllowanceTextBlock" escape="true" continuedAt="F_6a9a11bb-781c-43e6-9847-22201329f3d0_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a reconciliation of the total change in the valuation allowance (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_6a9a11bb-781c-43e6-9847-22201329f3d0_1">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:62.84%;box-sizing:content-box;"/>
         <td style="width:2.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.46%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.46%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning Balance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73eda927-ebed-4dfb-988d-2e66db6bff30" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,799</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e7f85fe-7bd0-42ff-b4d3-dd333c85dc62" contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,643</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change related to continuing operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_521bc147-2656-4226-a592-a8288ceabe5a" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,699</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d4ce301-dbb5-4318-a7a0-ac3a03286caf" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,156</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending Balance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59e97c9a-b316-4e6e-ac2c-8aaab6d13eb0" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,498</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af9ab513-cdcd-438e-954d-e52137deb96d" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,799</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0dedbd16-ba36-46d0-9446-cfd6ee76fccd_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2dacf9d-2737-451f-b44d-6972e29012cc" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">534.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92f62300-f770-46e6-b7d9-7f48b7257b6a" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">501.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f02096-8fb4-48d7-8869-4ef491d37e8e" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">502.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9438165-91b7-49ce-a594-66294ae7142d" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">487.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal and state net operating loss carryforwards begin to expire in 2031 and 2025, respectively, if not utilized. Federal net operating losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94cb502a-9a98-4050-b84d-446ef026461a" contextRef="C_9f9f175a-2500-4de7-add4-0941b73b5ed4" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">313.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million are not subject to expiration.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal and state research and development carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bde609b-aace-41ea-b091-54ecad4ef1bd" contextRef="C_9b27f837-5200-4262-b142-35394e148530" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_716fd5d2-82bf-4807-9bf2-3f78dc547e4c" contextRef="C_01635993-0ae0-46f3-a1ac-7f468a6e22a4" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The Company also had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0569662-5aac-46c8-95c0-7f5b713a7c80" contextRef="C_bf3af50f-3aed-4972-822b-f4464ec34192" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of Orphan Drug Credit. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal and state research and development carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c126ff20-602c-4378-9466-36cb840395e3" contextRef="C_49c54967-da26-4ce8-b371-c1af8c5252ca" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b02debce-6439-475a-8f3d-d8e491cf9761" contextRef="C_112906e9-cd45-450d-8e9f-7f8daac97dbd" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal and state credits begin to expire in 2031 and 2029, respectively, if not utilized; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a9b6f0f-b512-4380-9a21-958833ea6293" contextRef="C_916c82b9-f557-4ed2-9797-e0d652612305" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the state credits can be carried forward indefinitely.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of some of the federal and state net operating loss and credit carryforwards may be subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization.  The Company has not performed a Section 382 study as of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fe1d538-8ad4-4bea-af3c-8a885a5830e6" contextRef="C_b5528348-f1b5-4a4d-8927-ae662ee9eccf" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">455.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand of legacy Millendo federal net operating losses are expected to expire unused due to prior ownership changes.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2483af98-53c2-4914-b578-046de1f3cf8f" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the following activity relating to unrecognized tax benefits as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:62.84%;box-sizing:content-box;"/>
         <td style="width:2.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.46%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.46%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf24ad9b-664c-4e70-9b98-a63010fd4dff" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,239</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9aa4fe87-6898-46b0-afe0-523e0be8289e" contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,923</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross increase - tax position in current period</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa629fd0-035d-4e9e-a702-480a8632e20a" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8232c55-d9b4-4452-a5fc-c3baa9744141" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f96c1937-784c-41ea-8f2d-7ae27590368e" contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,406</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2b016b4-e878-4765-8386-f61e11727d7f" contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,239</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, none of the unrecognized tax benefits would impact the Company's effective tax rate due to the valuation allowance.  The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest and penalties on the accompanying balance sheet as of December 31, 2025 and 2024, respectively, and has not recognized penalties and/or interest in the accompanying statements of operations for the years ended December 31, 2025 and 2024, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to taxation in the United States, California, Massachusetts, and Michigan. The Company's tax years from inception are subject to examination by the IRS and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_784a21ed-0bc5-4e6c-9b79-ef189bcff86f" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;" id="section38"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. RETIREMENT PLAN</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company participates in a qualified 401(k) Plan sponsored by its professional service organization. The retirement plan is a defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. During the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_433b9df6-529b-46ed-a992-bed531dbd105" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the 401(k) Plan. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e6cfaae-45ba-4afd-b0d8-afc230df4a35" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the 401(k) Plan.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_ce2fe71c-2c16-45f3-910b-33c7a2d0c54e" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_ce2fe71c-2c16-45f3-910b-33c7a2d0c54e_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;" id="section39"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. NET LOSS PER SHARE</span></p><div><ix:nonNumeric id="F_89202f75-acda-41ff-9c8a-8c22c6bf0d2c" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true" continuedAt="F_89202f75-acda-41ff-9c8a-8c22c6bf0d2c_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the Company&#8217;s basic and  diluted net loss per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands, except share and per share amounts):</span></p><p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_ce2fe71c-2c16-45f3-910b-33c7a2d0c54e_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_89202f75-acda-41ff-9c8a-8c22c6bf0d2c_1">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.2%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.780000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.780000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_334f28fb-6633-4cbe-9a5e-aa0ef609f0c8" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,262</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03c4086e-e1c2-4e11-82bc-3fed697cc084" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,843</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ee9d0cc-a7ad-439a-806e-404cb8fd6a13" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,149,733</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cfdbe2f-9c5d-4a33-b1a0-20d6cd2d2291" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,146,276</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing basic and diluted net loss per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26965830-e5d8-436d-a5d7-9db86d0a97fc" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_65ef2f88-a8b4-46b2-81b9-daa5550d0294" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,149,733</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa760a87-cfc4-4cb4-87d6-ccb110f3dbc8" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9cc12566-b4ee-44bd-9340-48efdcb4d27d" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,146,276</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4264d6a5-a711-4a0c-8db3-a69900da9261" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5a9f4e5e-888b-49e3-9188-964cb272e48e" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">6.33</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecbd2e47-769c-4b97-a1f1-5629d9f41ce8" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fa9fbfea-65d8-47cd-803e-5cb5478b6fcb" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">19.50</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s potentially dilutive securities included unvested stock warrants and stock options, which have been excluded from the computation of diluted net loss per share attributable to common stockholders as the effect would be anti-dilutive. The issuance of pre-funded warrants and vested RSUs have been included in the computation of basic and diluted net loss per share attributable to common stockholders. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be79b2c7-e08d-40f6-9d0f-fd9c42765614" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_be79b2c7-e08d-40f6-9d0f-fd9c42765614_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the amounts outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_be79b2c7-e08d-40f6-9d0f-fd9c42765614_1">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.2%;box-sizing:content-box;"/>
         <td style="width:1.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab1ebd36-91f9-49ea-a988-dd9a45f83d6a" contextRef="C_a962bb72-7e5c-4f7e-9290-db4536a5d91c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">450,104</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bd6c827-6a63-43bc-b45d-8878b3eee981" contextRef="C_8748646b-ce49-4cf2-b51c-cd12c0ce32e9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">320,090</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5110a425-10fc-4a95-8dbe-138b6c6d581b" contextRef="C_ab6430cb-a886-405c-91eb-7aff47df90b0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d777908-552e-470e-a6b3-52403d83b99b" contextRef="C_d48d584b-746c-47de-a737-fa3d182f9772" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96838ba6-6db3-4f80-bc3c-6b36b47f6b5b" contextRef="C_5fd11135-0c20-48b6-804e-5fe44ae3180d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,172,878</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af33111b-757d-4f48-ac45-46edc191567f" contextRef="C_e36e743c-bf65-4bdb-bbe8-1719a8f75e7c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">464</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aeda049f-d86f-429d-aab6-79826d1626af" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,622,982</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbb605fa-eafd-47c4-9a0e-77bce7ba138e" contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">320,554</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f232d177-ca5d-457c-bfa8-e367fc326cae" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. SEGMENT REPORTING</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_064ed277-98fa-4a05-a76c-cd428eee68dc" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_130b0e9a-432a-46e5-97d3-0a449d9b2337" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable and operating segment, which is the business of discovery and development of small molecule drugs to treat cancers. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_73408227-2688-4970-8a0c-a936196fb1ad;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the Company has not generated revenue, the CODM assesses Company performance through the achievement of research goals towards advancing the Company&#8217;s product candidates through stages of development. As such, the CODM is regularly provided with budgeted and forecasted expense information as well as the Company&#8217;s Consolidated Financial Statements which is used to determine the Company&#8217;s liquidity needs and pipeline resource allocation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5642c8b6-ed1c-426c-a206-b84dba0473ff" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><ix:nonNumeric id="F_1aaee9f0-beaa-40b9-aab8-3b4c4b99fce8" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM regularly reviews and evaluates research and development expenses and uses consolidated net loss, as reported on the Company&#8217;s Consolidated Statements of Operations, to assess the performance of the segment and to allocate resources.</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The consolidated net loss and significant segment expenses reviewed by the CODM are reported on the Company&#8217;s Consolidated Statements of Operations for the years ended December 31, 2025 and 2024. The measure of segment assets is reported on the Consolidated Balance Sheet as total assets. The CODM monitors the Company's cash and cash equivalents as reported on the Consolidated Balance Sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All financial information required for segment reporting that is provided to the chief operating decision maker is contained within the financial statements and notes to financial statements.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_96f0508e-a2ed-44b9-bf46-4dac5132fbee" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="us-gaap:SubsequentEventsTextBlock" escape="true" continuedAt="F_96f0508e-a2ed-44b9-bf46-4dac5132fbee_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUBSEQUENT EVENTS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acquisition of Erigen Assets</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d37a15e-0a5a-4869-a2c9-bd35f16145b9" contextRef="C_cbae41ba-0f21-46c1-8226-08889ddc8bc8" name="us-gaap:AssetAcquisitionDateOfAcquisitionAgreement" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 19, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company executed an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Erigen LLC, a Delaware limited liability company (&#8220;Erigen&#8221;), and Factor Bioscience Inc., a Delaware corporation (together with Erigen, &#8220;Sellers&#8221;), pursuant to which Sellers agreed to sell and transfer to the Company all right, title and interest of Sellers in and to all</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_96f0508e-a2ed-44b9-bf46-4dac5132fbee_1" continuedAt="F_96f0508e-a2ed-44b9-bf46-4dac5132fbee_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the assets primarily related to (a) the autologous BCMA/CD19 dual-targeting CAR T-cell therapy known as ERI-2003, (b) the autologous CD70/CD70 dual-targeting CAR T-cell therapy known as ERI-2206, (c) the allogeneic BCMA/CD19 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as ERI-3003, and (d) the allogeneic CD70/CD70 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as ERI-3206 (collectively referred to herein as the &#8220;Erigen Assets&#8221;), in exchange for an aggregate purchase price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14926b0a-7392-434e-9229-07e929bd81f8" contextRef="C_4ecf269e-0f88-4788-aa4d-c460ebc3cf9b" name="tpst:AssetAcquisitionSharesEquityInterestYetToBeIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,268,495</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock to be issued to Erigen on behalf of both Sellers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_920acc23-f21b-4018-af99-21487ac998e7" contextRef="C_b166bd00-a5b2-46eb-bcf0-8a5010ef48da" name="us-gaap:AssetAcquisitionEffectiveDateOfAcquisition" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 3, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company completed the acquisition of the Erigen Assets (the &#8220;Erigen Closing&#8221;) under the Asset Purchase Agreement (the &#8220;Asset Acquisition&#8221;) and issued to Erigen </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c07d6cf-f853-4fc2-b704-72600f6cc185" contextRef="C_717feb2e-7a7f-45b4-b13f-aa87773d18bb" name="tpst:AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,268,495</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock. Based on an assumed common stock price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_906b1af6-c6dd-48fa-94ac-0c36cdd77813" contextRef="C_717feb2e-7a7f-45b4-b13f-aa87773d18bb" name="tpst:AssetAcquisitionSharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.41</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, the aggregate consideration related to the Asset Acquisition  is approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3405374a-8abd-4e1b-b7e7-d2ad6ee34524" contextRef="C_b166bd00-a5b2-46eb-bcf0-8a5010ef48da" name="us-gaap:AssetAcquisitionConsiderationTransferred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company incurred approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6d973be-73f4-4f56-8813-617b62dbdb1d" contextRef="C_b166bd00-a5b2-46eb-bcf0-8a5010ef48da" name="tpst:AssetAcquisitionTransactionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of transaction costs in connection with the Asset Acquisition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects to account for the Asset Acquisition as an asset acquisition. Transaction costs are expected to be capitalized as part of the total cost of the Asset Acquisition. The Company is in the process of evaluating the assets acquired and any liabilities assumed and has not finalized the allocation of the consideration. Accordingly, the Company cannot reasonably estimate the financial statement impact of the transaction as of the date these consolidated financial statements were issued.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Asset Purchase Agreement, Factor has made a funding commitment (the &#8220;Funding Commitment&#8221;) to provide the Company with financial support for at least 18 months following the Erigen Closing, up to a maximum amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_372fd4a9-34a6-4fd1-b147-d2d07d264e28" contextRef="C_b166bd00-a5b2-46eb-bcf0-8a5010ef48da" name="tpst:AssetAcquisitionMaximumFundingCommitment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that is inclusive of any amounts raised and received by us after the date of the Asset Purchase Agreement, on the terms and subject to the conditions and other provisions of a funding commitment letter contemplated by and entered into concurrently with the Asset Purchase Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Dividend</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 20, 2026, the Company&#8217;s Board of Directors declared a record date of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ee73a95-eb61-4f03-8936-3c888363a8e2" contextRef="C_d07960dd-fe9c-4566-abd3-ddc3571ebd35" name="us-gaap:DividendsPayableDateOfRecordDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 30, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Record Date&#8221;), for the distribution of a dividend (the &#8220;Warrant Dividend&#8221;) in the form of a warrant to purchase a share of the Company&#8217;s common stock (collectively, the &#8220;Warrants&#8221;) for each share of common stock outstanding on the Record Date at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22a1c669-6186-4533-a174-72b2041ee67c" contextRef="C_e7009405-d7f0-4b5c-971c-06a829c4d118" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Warrants were issued on the terms and conditions described in the Warrant Agreement, dated February 3, 2026, between the Company, Computershare Inc., and its affiliate, Computershare Trust Company, N.A., as Warrant Agent, on February 3, 2026. In addition, on February 3, 2026, certain warrants that were outstanding on the Record Date also received Warrants on a one-for-one basis, pursuant to the terms of such warrants (together with the Warrant Dividend, the &#8220;Warrant Distribution&#8221;). In the aggregate, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74bfd87d-de30-4536-9531-1d9be8db74c0" contextRef="C_7b1d730e-ab40-4eba-8cbf-0692f0eabf49" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,784,989</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Warrants were issued pursuant to the Warrant Distribution.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Plan Amendment</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 27, 2026, the Company&#8217;s stockholders approved Amendment No. 1 to the 2023 Plan to increase the number of shares of the Company&#8217;s common stock issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcf9b1c7-bc72-49d2-95a7-cc7e8c5721d0" contextRef="C_151f94be-33aa-4e72-91ab-8bdd1b7a21c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,410,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights Plan Approval</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 27, 2026, the Company&#8217;s stockholders approved the Company&#8217;s Rights Agreement. Such stockholder approval extended the final expiration date of the Rights Agreement until October 10, 2026, unless the rights thereunder are earlier redeemed or exchanged by the Company. The Rights Agreement otherwise remains unmodified and in full force and effect in accordance with its terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">connection with his appointment as President and Chief Executive Officer of the Company, effective February 3, 2026, the Company entered into an employment agreement with Matthew Angel (the &#8220;Angel Employment Agreement&#8221;). Pursuant to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_96f0508e-a2ed-44b9-bf46-4dac5132fbee_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Angel </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreement, Dr. Angel is entitled to receive an annual base salary of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62a97c94-ace0-49ed-bd74-14377a3a686b" contextRef="C_a46cd5e9-4d74-498e-9bdd-3fe5cb08caf8" name="tpst:AnnualBaseSalary" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">650,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and will be eligible to receive an annual bonus equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1bbff44-c48b-470f-9ffa-4392e1ae56cc" contextRef="C_a46cd5e9-4d74-498e-9bdd-3fe5cb08caf8" name="tpst:PercentageOfAnnualBonus" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of his base salary, as determined by the Board in its sole discretion. In addition, on February 3, 2026, Dr. Angel received an option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbe36441-8c5f-4e1c-a988-e629acbcb240" contextRef="C_7c4289a6-f95b-49ac-b1e3-b9d55e86a9a6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">269,621</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, with an exercise price per share equal to the fair market value on the grant date (the &#8220;Option&#8221;). The Option vests over a four-year period, with one quarter (1/4) of the shares subject to the Option vesting on the first anniversary of the grant date, and the remaining shares vesting equally over the following 36 months of continuous service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 3, 2026, the Company entered into an employment agreement with Nicholas Maestas (the &#8220;Maestas Employment Agreement&#8221;), pursuant to which Mr. Maestas is entitled to receive compensation consistent with his previously filed employment agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Private Placement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 20, 2026, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with (a) two institutional investors (the &#8220;Institutional Investors&#8221;) and (b) Factor Bioscience Inc. (together with the Institutional Investors, each, an &#8220;Investor&#8221; and, together, the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and sell in a private placement (the &#8220;Private Placement&#8221;) an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_830e3121-0c8c-4541-9f69-e8534ea935c2" contextRef="C_6cdf488d-d731-4f05-b3e5-69a6c55aa717" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">462,964</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, and, in lieu of common stock, pre-funded warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_846358f0-2ec3-445c-9a7f-98ec1a83d6d9" contextRef="C_8bd98920-97ac-43e9-83d8-1afbd38624a3" name="tpst:SaleOfStockWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">462,963</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;2026 Pre-Funded Warrants&#8221;), in each case accompanied by (i) Series A warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3979989c-6e05-42f7-a531-1615a740f981" contextRef="C_89243837-7c70-4e55-8184-5818a993b299" name="tpst:SaleOfStockWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">925,927</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;Series A Warrants&#8221;) and (ii) Series B warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93167e24-0525-47f1-9a6b-03f6ede7554b" contextRef="C_e8e8425e-8552-48b9-b19d-732d38689041" name="tpst:SaleOfStockWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">925,927</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;Series B Warrants&#8221; and, together with the Series A Warrants, the &#8220;Common Warrants&#8221;). The Shares and the Common Warrants are immediately separable and were issued separately. The combined purchase price per Share and accompanying Common Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f25fa92d-1736-4bc1-a922-8b5ad0e8c38b" contextRef="C_8bd98920-97ac-43e9-83d8-1afbd38624a3" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the combined purchase price per Pre-Funded Warrant and accompanying Common Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a8d04a5-7253-4e54-aac1-a80336432f68" contextRef="C_072f2ea3-60bc-461a-af30-65a53c97af2b" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.159</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The gross proceeds to us from the Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8a680c6-95c7-4ff4-b306-85588b6f9dd3" contextRef="C_6cdf488d-d731-4f05-b3e5-69a6c55aa717" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (excluding up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b89750e0-5ee5-4967-b7a5-a8e708a791aa" contextRef="C_f546958e-8be6-48f3-adf2-b8d67c893d64" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of aggregate gross proceeds that may be received in the future upon the cash exercise of the Common Warrants), before deducting placement agent fees and other offering expenses payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Purchase Agreement, the Company agreed to seek approval from our stockholders for the issuance of the shares issuable upon exercise of the Common Warrants within 90 days following the date of the Purchase Agreement (the &#8220;Stockholder Approval&#8221;). The Series A Warrants will become exercisable on the effective date of the Stockholder Approval (the &#8220;Stockholder Approval Date&#8221;) and have a term of five years from the later of the Stockholder Approval Date and the Effectiveness Date (as defined below). The Series B Warrants will become exercisable on the Stockholder Approval Date and have a term of twenty-four months from the later of the Stockholder Approval Date and the Effectiveness Date. The Common Warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8620451a-6392-4b52-825a-c46ac608cf0d" contextRef="C_e1a70b55-a6e2-4450-8567-d8933403aa20" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Pre-Funded Warrants are exercisable immediately following the closing date of the Private Placement have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3131b590-3c26-4d8a-9249-121cd39a8a67" contextRef="C_b0987cd9-5a24-4759-9d16-ae81baf465af" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and may be exercised at any time until exercised in full. In addition, pursuant to the Purchase Agreement, the Company agreed not to sell any shares of the Company&#8217;s common stock or any securities convertible into or exercisable or exchangeable into shares of common stock, subject to certain customary exceptions, for a period of thirty (30) days after the Effectiveness Date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Private Placement, the Company entered into a registration rights agreement with the Investors (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company agreed to file registration statements under the Securities Act with the SEC covering the resale of the Shares to be issued in the Private Placement and the shares of the Company&#8217;s common stock underlying the Common Warrants and Pre-Funded Warrants no later than 15 calendar days following the date of the Purchase Agreement, and to use reasonable best efforts to have the registration statement declared effective by 45 calendar days following the date of the Purchase Agreement, and in any event no later than 75 calendar days following the date of the Purchase Agreement in the event of a &#8220;full review&#8221; by the SEC (the &#8220;Effectiveness Date&#8221;).</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section40"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section41"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9A. CONTROLS AND PROCEDURES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer (principal executive officer) and Chief Financial Officer &amp; Head of Corporate Strategy  (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) or 15d-15(e)) as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15, as of December 31, 2025. Based on the evaluation of our disclosure controls and procedures as of December 31, 2025, our Chief Executive Officer and Chief Financial Officer &amp; Head of Corporate Strategy concluded that, as of such date, our disclosure controls and procedures were effective.</span></p><p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal Control Over Financial Reporting</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d (f) under the Exchange Act). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2025. In making this assessment, management used the criteria set forth by the Committee of Sponsoring organizations of the Treadway Commission (COSO) in Internal Control &#8211; Integrated Framework (2013). Based on that assessment, our management concluded that, as of December 31, 2025, our internal control over financial reporting was effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company, and therefore our independent registered public accounting firm has not issued a report on the effectiveness of internal control over financial reporting.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in internal control over financial reporting during the quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section42"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9B. OTHER INFORMATION</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, no director or officer of the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5dad0284-6673-489a-83db-b8ee4a5eb4bf" contextRef="C_5674d468-6c98-412c-9336-57931dcfe277" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_a6112b65-f8e1-4fae-97b4-c49a79027c61" contextRef="C_5674d468-6c98-412c-9336-57931dcfe277" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd98e336-329d-4192-8799-e0316af25d53" contextRef="C_5674d468-6c98-412c-9336-57931dcfe277" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_c923ac0a-75a6-4560-adaf-18534016dd87" contextRef="C_5674d468-6c98-412c-9336-57931dcfe277" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section43"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9C. </span><span id="disclosure_regarding_foreign"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="part_iii"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_10"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Officers and Corporate Governance.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information regarding each member of our board of directors (the &#8220;Board&#8221;), including their ages as of March 1, 2026. There are no family relationships among any of our directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:39.828%;box-sizing:content-box;"/>
     <td style="width:6.661%;box-sizing:content-box;"/>
     <td style="width:41.128%;box-sizing:content-box;"/>
     <td style="width:12.382%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Director Since</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Matthew Angel</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer, President and Director</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephen Brady</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chair of the Board</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Christine Pellizzari</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Raab</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ronit Simantov</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></p></td>
    </tr>
   </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Angel was appointed as the Company&#8217;s Chief Executive Officer, President and director, effective immediately following the Closing of the Asset Acquisition.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Raab, Chair of the Board since 2021, in light of his other professional commitments and in consideration of our current strategic objectives, determined that it would be appropriate to transition the role of Chair of the Board to a successor. Accordingly, Mr. Raab proposed that Mr. Brady succeed him, which the Board approved, effective immediately following the Closing of the Asset Acquisition. </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Matthew Angel</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Matthew Angel has served as our Chief Executive Officer, President and as a member of our Board since February 2026. Dr. Angel is the Co-Founder and Chairman of the Board of Directors of Factor Bioscience Inc. (&#8220;Factor&#8221;) and previously served as Factor&#8217;s President and Chief Executive Officer from 2011 to February 2026. From January 2023 to December 2023, Dr. Angel served as President and Chief Executive Officer and as a director of Ernexa Therapeutics Inc. (f/k/a Eterna Therapeutics Inc.). From May 2022 to December 2022, Dr. Angel served as Interim President, Chief Executive Officer and as a director of Ernexa Therapeutics Inc. In 2020, Dr. Angel co-founded Exacis Biotherapeutics Inc. (&#8220;Exacis&#8221;) and served as the Chief Science Officer, Secretary, Treasurer and as a director of Exacis from 2020 until the sale of Exacis in May 2023. Dr. Angel also co-founded and served as the Chief Science Officer, Secretary and as a director of Novellus, Inc., from 2014 until the sale of Novellus in July 2021. Dr. Angel received a Ph.D. from the Massachusetts Institute of Technology in 2012 and a B.S. in Engineering from Princeton University in 2003. Mr. Angel&#8217;s role as our Chief Executive Officer, his business expertise and his prior leadership roles in biotechnology companies provides him with the qualifications and skills to serve as a member of our Board.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stephen Brady</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stephen Brady has served as a member of our Board since June 2021. Mr. Brady served as our Chief Executive Officer from June 2021 until February 2026 and as our President from September 2023 to February 2026. Mr. Brady also served as President and Chief Operating Officer of our legacy company from September 2019 until June 2021. Previously, from September 2013 until April 2019, Mr. Brady served in various leadership positions, most recently as Executive Vice President, Strategy and Finance, at Immune Design, Inc., a biopharmaceutical company that was acquired by Merck &amp; Co., Inc. (&#8220;Merck&#8221;) in 2019. At Immune Design, Mr. Brady led the general and administrative functions at the company, including strategy, corporate development, finance and investor and public relations. Prior to Immune Design, he held roles of increasing responsibility in multiple biopharmaceutical companies, including as Vice President of Corporate Development at Proteolix, where he had primary responsibility for the company&#8217;s business development activities and sale to Onyx Pharmaceuticals. Mr. Brady served as a member of the board of directors of Atreca, Inc. from July 2021 to May 2024, and has served as a member of the board of the Biotechnology Innovation Organization (BIO), Emerging Companies Section Governing Board, since 2022. Mr. Brady received a B.A. in English from the University of Oregon, a J.D. from the University of the Pacific and an LL.M. from New York University School of Law. Mr. Brady&#8217;s prior role as our Chief Executive Officer, his business expertise and his prior leadership roles in biotechnology companies provides him with the qualifications and skills to serve as a member of our Board.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Christine Pellizzari</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Christine Pellizzari has served as a member of our Board since July 2021. Ms. Pellizzari has served as the Chief Legal Officer of Cleerly, Inc. since September 2025 and as the Principal of CAP Strategic Advisory Services since May 2024. Ms. Pellizzari</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">previously served as the Chief Legal and Human Resources Officer of Science 37 Holdings, Inc. (Science 37) from July 2021 to May 2024. Ms. Pellizzari has served as a director and member of audit and compensation committees of Imunon, Inc. (formerly Celsion Corporation) since June 2021 and a director and member of the audit and compensation committees of Neurosense Therapeutics Ltd. since December 2021. Ms. Pellizzari served as Chief Legal Officer of Insmed, Inc. from 2018 to 2021 and prior to that as the General Counsel and Corporate Secretary from 2013 to 2018. Prior to joining Insmed, Ms. Pellizzari held various legal positions of increasing responsibility at Aegerion Pharmaceuticals, Inc., most recently as Executive Vice President, General Counsel and Secretary. Prior to Aegerion, Ms. Pellizzari served as Senior Vice President, General Counsel and Secretary of Dendrite International, Inc. Ms. Pellizzari joined Dendrite from the law firm of Wilentz, Goldman &amp; Spitzer where she specialized in health care transactions and related regulatory matters. She previously served as law clerk to the Honorable Reginald Stanton, Assignment Judge for the Superior Court of New Jersey. Ms. Pellizzari received her B.A. from the University of Massachusetts, Amherst and her J.D. from the University of Colorado, Boulder. Ms. Pellizzari&#8217;s legal, financial and business expertise in the biotechnology industry, including her experience in the capital markets and financial and legal compliance, qualifies her to serve as a member of our Board.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Michael Raab</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Michael Raab has served as a member of our Board since June 2021, and served as Chairman of our Board from June 2021 until February 2026 and as a member and Chairman of the board of directors of our legacy company from December 2018 until June 2021. Mr. Raab has served as Ardelyx Inc.&#8217;s President and Chief Executive Officer since March 2009 and as a member of the board of directors since 2008. Before Ardelyx, Mr. Raab was a partner at New Enterprise Associates (&#8220;NEA&#8221;), where he focused on the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries, including serving as Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation, or Genzyme, a biotechnology company. Mr. Raab also spent two years with Genzyme&#8217;s diagnostic products and services division. Before Genzyme, Mr. Raab held business development and sales and marketing positions at Repligen Corporation, a life sciences company, and Bristol-Myers Corporation. Mr. Raab has been the lead independent director of Amicus Therapeutics, Inc. since 2004. Mr. Raab received his B.A. from DePauw University. Mr. Raab&#8217;s industry and investment experience qualifies him to serve as a member of our Board.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ronit Simantov, M.D.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Ronit Simantov, M.D. has served as member of our Board since August 2021. Dr. Simantov has served as Chief Medical Officer of Gamida Cell Ltd. since July 2017 and as the Chief Scientific Officer since July 2021. From July 2021 to July 2023, Dr. Simantov served as a member of the board of directors of Clovis Oncology, Inc. Prior to joining Gamida Cell, Dr. Simantov served as Vice President, Oncology Global Medical Affairs at Pfizer Inc., where she was responsible for multiple oncology programs in various roles. Prior to Pfizer, Dr. Simantov served as Vice President of Clinical Research at OSI Pharmaceuticals, as Chief Medical Officer at CuraGen Corporation (acquired by Celldex) where she led development of small molecules and antibody-drug conjugates, and at Bayer HealthCare Pharmaceuticals, where she led the Phase 3 study of Nexavar&#174; (sorafenib) resulting in the first approval of a tyrosine kinase inhibitor in renal cell carcinoma. Prior to joining industry, Dr. Simantov spent seven years on the academic faculty at Weill Medical College of Cornell University, where she directed the fellowship program and conducted angiogenesis and vascular biology research. She has authored over 40 peer-reviewed manuscripts. Dr. Simantov holds an M.D. from New York University School of Medicine and a B.A. from Johns Hopkins University. She completed a residency in internal medicine at New York Hospital Cornell Medical Center, and a fellowship in hematology and oncology at Weill Cornell Medicine. Dr. Simantov&#8217;s extensive clinical and scientific experience provides her with the qualifications and skills to serve as a member of our Board.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Officers</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information regarding our executive officers who are not listed above as a member of our board of directors, including their ages as of March 1, 2026. There are no family relationships among any of our executive officers.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:34.6%;box-sizing:content-box;"/>
     <td style="width:9.62%;box-sizing:content-box;"/>
     <td style="width:55.78%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Matthew Angel</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer, President and Director</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nicholas Maestas</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Corporate Secretary</span></p></td>
    </tr>
   </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Angel was appointed as the Company&#8217;s Chief Executive Officer, President and director, effective immediately following the Closing.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biographical information for Dr. Angel is included above with the director biographies under the caption &#8220;Board of Directors.&#8221;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nicholas Maestas</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Maestas has served as our Chief Financial Officer and Head of Corporate Strategy since January 2025, having previously served as Vice President, Finance and Strategy from July 2021 through December 2024, and has served as our Corporate Secretary since September 2022. Prior to joining us, Mr. Maestas served as the head of FP&amp;A and strategic finance at Alector, a biopharmaceutical company that develops therapies for the treatment of neurodegeneration diseases, from July 2019 to July 2021. Prior to joining Alector, from November 2014 to July 2019, Mr. Maestas served in a variety of roles at Immune Design, an oncology immunotherapy company that was acquired by Merck in 2019, including as Senior Director, Corporate Development &amp; Operations from January to July 2019 and Director, Corporate Development &amp; Operations from January 2017 to December 2018. Mr. Maestas received a B.A. in Molecular and Cell Biology from the University of California, Berkeley and an M.B.A. from The Wharton School, University of Pennsylvania.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Governance</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board has a separately designated Audit Committee (the &#8220;Audit Committee&#8221;) established in accordance with Section 3(a)(58)(A) of the Exchange Act to oversee the Company&#8217;s corporate accounting and financial reporting processes and audits of its financial statements. Geoff Nichol, Christine Pellizzari and Michael Raab, served as members of the Audit Committee during 2025 with Ms. Pellizzari serving as Chair. On February 3, 2026, Dr. Nichol resigned from the Board and all committees thereof and Ronit Simantov was appointed to the Audit Committee to fill the vacancy created by Dr. Nichol&#8217;s resignation. The Board determined that each current member of the Audit Committee satisfies the independence requirements under Nasdaq listing standards and Rule 10A-3(b)(1) of the Exchange Act. Our Board has determined that Ms. Pellizzari is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. Each member of the Audit Committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, our Board has examined each Audit Committee member&#8217;s scope of experience and the nature of their employment.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary purpose of the Audit Committee is to discharge the responsibilities of the Board with respect to the corporate accounting and financial reporting processes, systems of internal control and financial statement audits, and to oversee the independent registered public accounting firm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code of Business Conduct and Ethics</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a Code of Business Conduct that applies to all officers, directors and employees. If we ever were to amend or waive any provision of our Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or any person performing similar functions, we intend to promptly disclose on our website (i) the date and nature of any amendment (other than technical, administrative or other non-substantive amendments) to the Code of Conduct that relates to any element of the code of ethics definition enumerated in Item 406(b) of Regulation S-K and (ii) the nature of any waiver, including an implicit waiver, from a provision of the Code of Conduct that is granted to one of these specified individuals that relates to one or more of the elements of the code of ethics definition enumerated in Item 406(b) of Regulation S-K, the name of such person who is granted the waiver and the date of the waiver. The full text of our Code of Conduct is available at the investors section of our website at www.tempesttx.com. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this Amendment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_826435bc-b587-4b1f-977c-de87f0948c7b" contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insider trading policy governing the purchase, sale, and/or other dispositions of the Company&#8217;s securities by directors, officers, employees and designated consultants that is designed to promote compliance with insider trading laws, rules and regulations, as well as procedures designed to further the foregoing purposes. A copy of our insider trading policy was</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">filed </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as an exhibit to our Annual Report on Form 10-K for our fiscal year ended December 31, 2024, originally filed with the SEC on March 27, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="item_11"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. EXECUTIVE COMPENSATION</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share numbers included in the following tables and footnotes included in this Executive and Director Compensation section have been adjusted for the 1-for-13 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of our common stock, on April 8, 2025, as applicable.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary Compensation Table</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information for each of the last two completed fiscal years regarding compensation awarded to or earned by our Former Chief Executive Officer and the two other most highly compensated executive officers (the &#8220;Named Executive Officers&#8221;) during the fiscal years indicated:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:31.24%;box-sizing:content-box;"/>
     <td style="width:7.3%;box-sizing:content-box;"/>
     <td style="width:9.38%;box-sizing:content-box;"/>
     <td style="width:10.42%;box-sizing:content-box;"/>
     <td style="width:14.58%;box-sizing:content-box;"/>
     <td style="width:15.62%;box-sizing:content-box;"/>
     <td style="width:11.46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Principal Position</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Salary</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>$</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option<br/>Awards<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)(3)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Equity<br/>Incentive Plan<br/>Compensation<br/>($)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Other<br/>Compensation<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>($)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephen Brady</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">906,400</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">556,981</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">836,094</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,299,475</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Former Chief Executive Officer and President</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">600,000</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">977,999</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">280,500</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,800</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,872,299</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Samuel Whiting</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,708</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,246</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453,459</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">976,413</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Former Chief Medical Officer</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481,749</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">391,200</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175,838</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,800</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,062,587</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nicholas Maestas</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">487,850</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196,092</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">426,362</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,110,304</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">365,547</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,480</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,068</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">622,095</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;border-bottom:1pt solid;margin-right:66.667%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For 2025, such amounts reflect (i) salary paid to our Named Executive Officers, (ii) consulting payments following the Transition (as defined below) of $576,400, $13,950 and $254,100 for Mr. Brady, Dr. Whiting and Mr. Maestas, respectively, and (iii) salary paid to each of Mr. Brady and Mr. Maestas following the Rehire Transition (as defined below). See &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Narrative Disclosure to the Summary Compensation Table</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Annual Base</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Salary</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; below.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts reflect (i) the aggregate grant date fair value of the option awards granted to our Named Executive Officers during the relevant fiscal years under our equity incentive plans and (ii) the incremental value of awards accelerated pursuant to the terms of the separation agreements entered into with each of the Named Executive Officers in connection with the Transition during 2025, and related extension, each as computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (&#8220;ASC 718&#8221;). The assumptions used in calculating the grant date fair value of the options are set forth in the notes to our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. These amounts do not reflect the actual economic value that may be realized by the Named Executive Officers.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Narrative Disclosure to Summary Compensation Table&#8212;Equity-Based Incentive Awards</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; below for a description of the material terms of the program pursuant to which this compensation was awarded.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amounts reported represent (i) severance benefits of $825,802, $444,662 and $424,946 paid to Mr. Brady, Dr. Whiting and Mr. Maestas, respectively, pursuant to separation agreements we entered into with each of Named Executive Officers in connection with the Transition, and (ii) matching contributions made by us to the Named Executive Officer&#8217;s 401(k) plan account in amounts of $10,292, $8,797 and $1,417 for Mr. Brady, Dr. Whiting and Mr. Maestas, respectively. For Mr. Brady such severance payments include $600,000, representing 12 months of base salary, a prorated 2025 bonus of $142,738, and COBRA upfront payments of $83,064. For Dr. Whiting such severance payments include $361,312, representing nine months of base salary, and a prorated 2025 bonus of $83,350. For Mr. Maestas such severance payments include $318,750, representing nine months of base salary, a prorated 2025 bonus of $73,532, and COBRA upfront payments of $32,664.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 3, 2026, immediately following the Closing, Mr. Brady resigned from his positions as the Company&#8217;s President and Chief Executive Officer. Dr. Angel was appointed to serve as our President and Chief Executive Officer, succeeding Mr. Brady in such capacities.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 5, 2025, Dr. Whiting transitioned to a consulting agreement with us, pursuant to which he continued to serve the Company as a consultant.</span></div></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Narrative Disclosure to the Summary Compensation Table</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Annual Base Salary</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	On June 5, 2025, each of our Named Executive Officers transitioned (collectively, the &#8220;Transition&#8221;) to consulting agreements with us, pursuant to which they received hourly compensation. In connection with the Asset Acquisition, on November 19, 2025, we rehired each of Mr. Brady and Mr. Maestas on a full-time basis. During the time period where each of our Named Executive Officers were not employed on a full-time basis, they received compensation pursuant to consulting arrangements. See &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consulting and Employment Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for additional information.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Our Named Executive Officers received a base salary to compensate them for services rendered to us while employed on a full-time basis. For 2025, such annual base salaries were $600,000, $481,749 and $425,000 for Mr. Brady, Dr. Whiting and Mr.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maestas, respectively. The annual base salary payable to each Named Executive Officer was intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	None of our Named Executive Officers is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base salary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity-Based Incentive Awards</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, our equity award program was the primary vehicle for offering long-term incentives to our executives. We believe that equity awards provided our executives with a strong link to our long-term performance, created an ownership culture and helped to align the interests of our executives and our stockholders. The use of options also can provide tax and other advantages relative to other forms of equity compensation.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We historically have awarded equity grants broadly to our employees, including our non-executive employees. Historically, grants to our executives, including the Named Executive Officers, and other employees were made at the discretion of the Board and were generally made upon commencement of employment, promotion or annually during the first quarter of each year. Moving forward we believe that our equity awards are an important retention tool for our Named Executive Officers, as well as for our other employees.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our annual grant process, on January 2, 2025, our Compensation Committee approved the grant to each of Mr. Brady, Dr. Whiting and Mr. Maestas of an option to purchase 42,307, 20,768 and 15,383 shares of our common stock, respectively, at an exercise price of $11.18 per share, under our Amended and Restated 2023 Equity Incentive Plan, as amended (the &#8220;2023 EIP&#8221;). Each option originally vested in equal monthly installments over a four-year period, subject to the executive&#8217;s continuous service to us through each vesting date. In addition, as described below under &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consulting and Employment Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#8221; on June 5, 2025, we entered into separation agreements with each of Mr. Brady, Dr. Whiting and Mr. Maestas pursuant to which they became entitled to full acceleration of all outstanding unvested equity awards, which became fully vested and exercisable as of June 5, 2025. See &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Outstanding Equity Awards at Fiscal Year End</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for further information.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Annual Performance-Based Cash Compensation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically we have developed a performance-based bonus program annually. Under the 2025 annual performance-based bonus program, each Named Executive Officer was eligible for an annual performance bonus based on (1) the individual&#8217;s target bonus, as a percentage of annual base salary, and (2) the percentage attainment of our 2025 corporate goals established by our Board in its sole discretion and communicated to each officer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Named Executive Officer was assigned a target performance bonus expressed as a percentage of their annual base salary, which for 2025 was 55% for Mr. Brady, 40% for Dr. Whiting and 40% for Mr. Maestas. As described more fully below under &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consulting and Employment Arrangements,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; in connection with the Transition, we entered into separation agreements with each of Mr. Brady, Dr. Whiting and Mr. Maestas. Each separation agreement provided for severance benefits resulting from a termination by us without &#8220;cause&#8221; under each of Mr. Brady&#8217;s, Dr. Whiting&#8217;s and Mr. Maestas&#8217;s respective employment agreements, each as described below in &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control and Severance Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221; As a result, none of Mr. Brady, Dr. Whiting and Mr. Maestas were eligible to receive annual incentive compensation for 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding Equity Awards at Fiscal Year End</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows for the fiscal year ended December 31, 2025, certain information regarding outstanding equity awards for the Named Executive Officers.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:17.884%;box-sizing:content-box;"/>
     <td style="width:16.103%;box-sizing:content-box;"/>
     <td style="width:14.163%;box-sizing:content-box;"/>
     <td style="width:4.101%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:12.563%;box-sizing:content-box;"/>
     <td style="width:13.763%;box-sizing:content-box;"/>
     <td style="width:10.642%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vesting<br/>Commencement<br/>Date</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="margin-left:0.133%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:5.36pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Expiration Date</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>(#)<br/>Exercisable</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>(#)<br/>Unexercisable</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option<br/>Exercise Price<br/>($)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephen Brady</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/2025</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/1/2035</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,307</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.18</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/2024</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/2034</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,230</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.58</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/11/23</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/11/23</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/10/33</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,768</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127.01</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/23</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/23</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/33</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,637</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.99</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/21/22</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/21/22</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/20/32</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,347</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.55</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/4/22</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/4/22</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/32</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,269</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.85</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:17.884%;box-sizing:content-box;"/>
     <td style="width:16.103%;box-sizing:content-box;"/>
     <td style="width:14.163%;box-sizing:content-box;"/>
     <td style="width:4.101%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:12.563%;box-sizing:content-box;"/>
     <td style="width:13.763%;box-sizing:content-box;"/>
     <td style="width:10.642%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/29/21</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/25/21</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/28/31</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,909</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">343.20</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/10/21</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/5/21</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/9/31</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">619</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133.25</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/30/20</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/20/20</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/29/30</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,404</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.70</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/16/19</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/9/19</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/15/29</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,494</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.61</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Samuel Whiting</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/2025</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/1/2035</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,768</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.18</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/2024</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/2034</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,691</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.58</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/11/23</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/11/23</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/10/33</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127.01</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/23</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/23</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/33</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,361</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.99</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/21/22</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/21/22</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/20/32</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,282</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.55</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/4/22</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/4/22</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/32</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,229</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.85</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/29/21</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/25/21</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/28/31</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,338</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">343.20</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/10/21</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/5/21</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/9/31</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">232</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133.25</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/16/20</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/16/20</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/15/30</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,765</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.70</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nicholas Maestas</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/2025</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/1/2035</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,383</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.18</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/2024</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/2034</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,076</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.58</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/11/23</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/11/23</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/10/33</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,691</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127.01</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/23</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/23</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/33</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,955</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.99</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/21/22</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/21/22</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/20/32</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,943</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.55</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/4/22</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/4/22</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/32</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,499</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.85</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/12/21</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/12/21</span></p></td>
     <td style="padding-top:0in;text-indent:0.7pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/11/31</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,786</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">314.47</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:1pt solid;margin-right:66.667%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described below under &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consulting Agreement and Employment Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#8221; on June 5, 2025, we entered into separation agreements with each of Mr. Brady, Dr. Whiting and Mr. Maestas pursuant to which they became entitled to full acceleration of all outstanding unvested equity awards, which became fully vested and exercisable as of June 5, 2025. </span></div></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consulting and Employment Arrangements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 5, 2025, each of Mr. Brady, Dr. Whiting and Mr. Maestas transitioned to consulting agreements with us, pursuant to which they continued to serve the Company in their respective executive roles. Each consulting agreement had a term of one year, unless earlier terminated by either party thereto. On November 19, 2025, we rehired each of Mr. Brady and Mr. Maestas on a full-time basis, terminating the consulting agreements (collectively, the &#8220;Rehire Transition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).  Dr. Whiting&#8217;s consulting agreement remains in effect in a non-executive role.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Transition, we entered into a separation agreement with each of Mr. Brady, Dr. Whiting and Mr. Maestas. Each separation agreement provided for severance benefits resulting from a termination by us without &#8220;cause&#8221; under each of Mr. Brady&#8217;s, Dr. Whiting&#8217;s and Mr. Maestas&#8217;s respective employment agreements, as described below under &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control and Severance Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221; In addition, each of Mr. Brady, Dr. Whiting and Mr. Maestas became entitled to full acceleration of all outstanding unvested equity awards, which became fully vested and exercisable as of June 5, 2025. The foregoing severance benefits were contingent upon a general release of claims set forth in the separation agreement.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our Named Executive Officers&#8217; employment was &#8220;at will&#8221; and could have been terminated at any time. Below is a description of our employment arrangements with each of our Named Executive Officers prior to the Transition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stephen Brady</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We previously entered into an employment agreement, dated January 12, 2022, with Mr. Brady that superseded, amended and restated all prior agreements. Under the terms of the agreement, we agreed to an initial annual base salary, which was increased to $600,000, effective January 1, 2024. Mr. Brady was eligible to receive an annual bonus equal to 55% of his base salary, as determined by the Board in its sole discretion, and certain change in control and severance benefits as discussed below in &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control and Severance Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221; Mr. Brady&#8217;s employment agreement was terminated in connection with the Transition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sam Whiting</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We previously entered into an employment agreement, dated January 12, 2022, with Dr. Whiting that superseded, amended and restated all prior agreements. Under the terms of the agreement, we agreed to an initial annual base salary, which was increased to $481,749, effective January 1, 2024. Dr. Whiting was eligible to receive an annual bonus equal to 40% of his base salary, as determined by the Board in its sole discretion, and to certain change in control and severance benefits as discussed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below in &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control and Severance Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221; Dr. Whiting&#8217;s employment agreement was terminated in connection with the Transition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nicholas Maestas</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We previously entered into an employment agreement, dated January 1, 2025, with Mr. Maestas that superseded, amended and restated all prior agreements. Under the terms of the agreement, we agreed to an initial annual base salary of $425,000. Mr. Maestas was eligible for an annual bonus equal to 40% of his base salary beginning in 2025, as determined by the Board in its sole discretion, and to certain change in control and severance benefits as discussed below in &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control and Severance Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;  Mr. Maestas&#8217; employment agreement was terminated in connection with the Transition.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 3, 2026 entered into an employment agreement with Mr. Maestas that superseded, amended and restated all prior agreements. Under the terms of the agreement, we agreed to an initial annual base salary of $425,000. Mr. Maestas is eligible for an annual bonus equal to 40% of his base salary beginning in 2026, as determined by the Board in its sole discretion, and to certain change in control and severance benefits as discussed below in &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control and Severance Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control and Severance Arrangements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the prior employment agreements with our Named Executive Officers (collectively, the &#8220;Former Employment Agreements&#8221;), if a Named Executive Officer&#8217;s employment was terminated by us without Cause or if a Named Executive Officer resigned for Good Reason (each as defined below), they would have been entitled to receive (i) semi-monthly payments equal to the sum of 12 months of the executive&#8217;s base salary for Mr. Brady, 9 months for Dr. Whiting and 9 months for Mr. Maestas, plus a prorated portion of the executive&#8217;s target annual bonus for the calendar year in which termination occurred and (ii) if the executive elected to continue health insurance coverage under COBRA, the payment of the monthly premium under COBRA until the earlier of 12 months for Mr. Brady, 9 months for Dr. Whiting and 9 months for Mr. Maestas following termination date or the date on which the executive commenced full-time employment or employment that provided eligibility for healthcare benefits substantially comparable to those provided by us.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, if a Named Executive Officer&#8217;s employment was terminated by us without Cause or a Named Executive Officer resigned for Good Reason within three months prior to or 12 months following a Change in Control, then in lieu of the severance benefits described above the Named Executive Officer would have been entitled to receive (i) a lump-sum amount equal to the sum of 18 months for Mr. Brady, 12 months for Dr. Whiting and 12 months for Mr. Maestas of the executive&#8217;s then base salary plus the executive&#8217;s then annual target bonus at 150% for Mr. Brady, 100% for Dr. Whiting and 100% for Mr. Maestas and (ii) payment of COBRA premiums as described above for up to 18 months for Mr. Brady, 12 months for Dr. Whiting and 12 months for Mr. Maestas.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Named Executive Officers&#8217; receipt of any severance benefits under the Former Employment Agreements was subject to the execution and non-revocation of a separation agreement containing, among other things, a general release of claims in favor of us and our related persons and entities, confidentiality, return of property and non-solicitation and non-disparagement covenants.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if we were subject to a Change in Control prior to the termination of a Named Executive Officer&#8217;s service, then 100% of any unvested shares subject to any stock options then held by the Named Executive Officer would have vested and become exercisable in full.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to his employment agreement with us, dated February 3, 2026, Mr. Maestas is entitled to severance payments consistent with those provided for under his respective Former Employment Agreement as described above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Health and Welfare Benefits; Perquisites</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the Transition, our Named Executive Officers were, and following the Rehire Transition, Mr. Brady was and Mr. Maestas is, eligible to participate in our employee benefit plans, including medical, dental, vision, disability and life insurance plans, in each case on the same basis as all of our other full-time employees. Any part-time employees we hire would not be eligible to participate in our employee benefit plans. We generally do not provide perquisites or personal benefits to our Named Executive Officers, except in limited circumstances, and we did not provide any perquisites or personal benefits to our Named Executive Officers in 2025.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">401(k) Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We participate in a multiple employer tax-qualified 401(k) savings plan which allows participants to defer eligible compensation up to the maximum amount allowed under Internal Revenue Service guidelines. Under our 401(k) plan, we currently make matching contributions of 100% on up to 4% of an employee&#8217;s eligible contributions to the plan, up to a maximum of $14,000 per year.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clawback Policy</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Incentive Compensation Recoupment Policy (the &#8220;Clawback Policy&#8221;), designed to comply with Rule 10D-1 of the Exchange Act and Nasdaq Listing Rule 5608, provides for recoupment of incentive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under the relevant securities laws. The Clawback Policy applies to our current and former executive officers. Compensation that is granted, earned or vested based wholly or in part upon attainmentof a Financial Reporting Measure (as defined in the Clawback Policy) is subject to recoupment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we grant stock options to our employees, including our named executive officers. Historically, we have granted new-hire option awards on or soon after a new hire&#8217;s employment start date and annual refresh employee option grants in the first quarter of each fiscal year, which refresh grants are typically approved at the regularly scheduled meeting of the Compensation Committee occurring in such quarter. Also, non-employee directors receive automatic grants of initial and annual stock option awards, on the date of each annual meeting of stockholders, pursuant to the non-employee director compensation policy, as further described under the heading, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director Compensation&#8212; Non-Employee Director Compensation Program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; below. We do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. The Compensation Committee considers whether there is any material nonpublic information (&#8220;MNPI&#8221;) about the Company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to our public disclosure of MNPI. We have not timed the release of MNPI for the purpose of affecting the value of executive compensation.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Compensation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation Program</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a description of the standard compensation arrangements under which our non-employee directors were compensated for their service as directors for the fiscal year ended December 31, 2025, including as members of the various committees of our Board.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Compensation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each non-employee director received an annual base retainer of $40,000 with the non-executive Board Chair receiving an additional annual base retainer of $35,000. In addition, our non-employee directors received the following cash compensation for committee services, as applicable:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each chair of our Audit, Compensation, Nominating and Corporate Governance, and Science &amp; Technology committees received an additional annual retainer of $15,000, $10,000, $8,000 and $8,000, respectively; and</span></div></div><p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each other non-chair member of our Audit, Compensation, Nominating and Corporate Governance, and Science &amp; Technology committees received an additional annual retainer of $7,500, $5,000, $4,000 and $4,000, respectively.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following reflects the retainers to be paid to non-employee directors for service on the Board and for service on each committee of the Board on which the director is a member, effective as of January 20, 2026:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each chair of our Audit, Compensation, Nominating and Corporate Governance, and Science &amp; Technology committees received an additional annual retainer of $20,000, $15,000, $10,000 and $12,000, respectively; and</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each other non-chair member of our Audit, Compensation, Nominating and Corporate Governance, and Science &amp; Technology committees received an additional annual retainer of $10,000, $7,500, $5,000 and $6,000, respectively.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These retainers were payable in arrears in four equal quarterly installments on the last day of each quarter (each such date, a &#8220;Retainer Accrual Date&#8221;), provided that the amount of such payment will be prorated for any partial months of service. We also reimburse each of our directors for their travel expenses incurred in connection with their attendance at Board and committee meetings.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Compensation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2025, non-employee directors first appointed to the Board were eligible to receive an initial option to purchase 1,923 shares of our common stock (the &#8220;Initial Grant&#8221;). Further, on the date of each annual meeting of stockholders, each non-employee director that continued to serve as a non-employee member on our Board would receive an option to purchase 1,230 shares of our common stock (the &#8220;Annual Grant&#8221;). Effective as of January 20, 2026, the Initial Grant was increased to 25,000 shares of common stock and the Annual Grant increased to 12,500 shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The shares subject to each Initial Grant will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the non-employee director&#8217;s Continuous Service (as defined in the 2023 Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the 2023 Plan). The shares subject to the Annual Grant will vest in full on the first anniversary of the date of grant; provided, that the Annual Grant will in any case be fully vested on the date of Company&#8217;s next annual stockholder meeting, subject to the non-employee director&#8217;s Continuous Service (as defined in the 2023 Plan) through such vesting date; provided, further, that the Annual Grant will vest in full upon a Change in Control (as defined in the 2023 Plan). With respect to a non-employee director who was first elected or appointed to the Board on a date other than the date of the Company&#8217;s annual stockholder meeting, upon our first annual meeting of our stockholders following such non-employee director&#8217;s first joining the Board, such non-employee director&#8217;s first Annual Grant will be pro-rated to reflect the time between such non-employee director&#8217;s election or appointment date and the date of such first annual meeting of our stockholders.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each non-employee director may elect to convert such director&#8217;s cash compensation under the Non-Employee Director Compensation Policy into a restricted stock unit (&#8220;RSU&#8221;) award (such election, a &#8220;Retainer Grant Election&#8221;). If a non-employee director timely makes this election, then on the first business day following the applicable Retainer Accrual Date to which the Retainer Grant Election applies, and without any further action by the Board or designated committee of the Board, such non-employee director automatically will be granted a fully vested RSU award under the 2023 Plan covering a number of shares of common stock equal to (a) the aggregate amount of cash compensation otherwise payable to such non-employee director on the Retainer Accrual Date to which the Retainer Grant Election applies divided by (b) the closing sales price per share of the common stock on the applicable Retainer Accrual Date (or, if such date is not a business day, on the first business day thereafter), rounded down to the nearest whole share. No cash will be paid in lieu of fractional shares.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, any member of our Board that is entitled to the above compensation may elect to forego all or a portion of such compensation from time to time by giving notice to the Company.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation Table</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information for the year ended December 31, 2025 regarding the compensation awarded to or earned by our non-employee directors. Mr. Brady is not included in the table below, as he was an employee and received no additional compensation for his service as a director. As a Named Executive Officer, the compensation received by Mr. Brady is shown above in &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Executive Compensation&#8212;Summary Compensation Table</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:57.7%;box-sizing:content-box;"/>
     <td style="width:14.44%;box-sizing:content-box;"/>
     <td style="width:14.44%;box-sizing:content-box;"/>
     <td style="width:13.42%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fees Earned or<br/>Paid in Cash<br/>($)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option<br/>Awards<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)(2)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>($)</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Geoff Nichol</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,500</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,500</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Christine Pellizzari</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,000</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,000</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Raab</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,500</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,500</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ronit Simantov</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,000</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,000</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;border-bottom:1pt solid;margin-right:66.667%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides information regarding the aggregate number of equity awards granted to our non-employee directors that were outstanding as of December 31, 2025:</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">138</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:3.333%;border-spacing:0;table-layout:auto;width:96.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:79.8%;box-sizing:content-box;"/>
     <td style="width:20.2%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards<br/>Outstanding at</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year End</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Geoff Nichol</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,823</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Christine Pellizzari</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,639</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Raab</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,044</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ronit Simantov</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,639</span></p></td>
    </tr>
   </table><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our 2025 Annual Meeting of Stockholders, held January 27, 2026, each of Mr. Nichol, Ms. Pellizzari, Mr. Raab and Ms. Simantov received an Annual Grant on January 27, 2026, which is not reflected in the table above.</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with Closing of the Asset Acquisition, Mr. Nichol resigned from our Board effective February 3, 2026.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="item_12"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information regarding beneficial ownership of our common stock as of March 25, 2026, the most recent practicable date for computing beneficial ownership, by:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each of our Named Executive Officers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each of our directors and director nominees;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all of our directors and executive officers as a group.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting or investment power with respect to those securities. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable percentage ownership is based on 14,344,034 shares of our common stock issued and outstanding as of March 25, 2026. The number of shares of common stock used to calculate the percentage ownership of each listed person includes the shares of common stock underlying options and warrants held by such persons that are currently exercisable or convertible or will be exercisable or convertible within 60 days of March 25, 2026. However, we did not deem these shares outstanding for the purpose of computing the percentage ownership of any other person.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:61.692%;box-sizing:content-box;"/>
     <td style="width:22.004%;box-sizing:content-box;"/>
     <td style="width:12.102%;box-sizing:content-box;"/>
     <td style="width:4.201%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Beneficial Owner </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:0.102%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent of<br/>Total</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="margin-left:0.107%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholders Owning Greater than 5%:</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.107%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities affiliated with Lotus Capital BVI Limited</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;3,431,425</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.9</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.107%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Directors and Named Executive Officers:</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.107%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Matthew Angel</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,068,552</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.3</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.107%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephen Brady</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,597</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.107%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Samuel Whiting</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,666</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.107%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nicholas Maestas</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,923</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.107%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Christine Pellizzari</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,869</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.107%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Raab</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(8)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,274</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.107%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ronit Simantov</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(9)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,869</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.107%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">All current directors and executive officers as a group (6 persons)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(10)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,294,084</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.102%;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.3</span></p></td>
     <td style="padding-top:0in;text-indent:0.55pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.107%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;border-bottom:1pt solid;margin-right:66.667%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Less than one percent.</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The address for each director and executive officer is c/o Tempest Therapeutics, Inc., 2000 Sierra Point Parkway, Suite 400, Brisbane, California, 94005.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares of common stock are held by Erigen LLC. Lotus Capital BVI Limited is the beneficial owner of such shares. The address of each of Lotus Capital BVI Limited is Mandar House, 3rd Floor Johnson's Ghut, Tortola VG1110 British Virgin Islands.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">139</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes 4,837,070 shares of common stock held by Dr. Angel and 231,482 shares of common stock held by Factor. Dr. Angel is the majority stockholder and Chairman of the Board of Directors of Factor. and exercises voting and investment power over the shares held by Factor Biosciences Inc. The address of Factor Biosciences Inc. is 1035 Cambridge St Ste 17B, Cambridge MA 02141. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents (i) 3,613 shares of common stock and (ii) 170,984 shares of common stock subject to options that are exercisable within 60 days of March 25, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents 71,666 shares of common stock subject to options that are exercisable within 60 days of March 25, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents (i) 590 shares of common stock and (ii) 36,333 shares of common stock subject to options that are exercisable within 60 days of March 25, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents 3,869 shares of common stock subject to options that are exercisable within 60 days of March 25, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents 6,274 shares of common stock subject to options that are exercisable within 60 days of March 25, 2026</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents 3,869 shares of common stock subject to options that are exercisable within 60 days of March 25, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents (i) 5,072,755 shares of common stock and (ii) 221,329 shares of common stock subject to options that are exercisable within 60 days of March 25, 2026</span></div></div><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Compensation Plan Information</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our equity compensation plan information as of December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
   <table style="border-spacing:0;table-layout:auto;width:92.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:41.52%;box-sizing:content-box;"/>
     <td style="width:19.02%;box-sizing:content-box;"/>
     <td style="width:16.16%;box-sizing:content-box;"/>
     <td style="width:18.86%;box-sizing:content-box;"/>
     <td style="width:3.44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:7.95pt;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:-1.695%;padding-left:1.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Category</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities to be issued upon exercise of outstanding options, warrants and rights<br/>(a)(#)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-average exercise price of outstanding options, warrants and rights<br/>(b)($) </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities remaining available for issuance under equity compensation plans (excluding securities reflected in column (a))<br/>(c)(#)</span></p></td>
     <td style="padding-top:0in;text-indent:0.65pt;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="margin-left:0.12%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5.36pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:7.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:-1.695%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans approved by security holders</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:0.65pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="margin-left:0.12%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:25.9pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:3.133%;text-indent:-1.751%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2017 EIP</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,859</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140.67</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;text-indent:0.65pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.12%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:25.9pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:3.133%;text-indent:-1.751%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019 EIP</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,867</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.53</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;text-indent:0.65pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.12%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:25.9pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:3.133%;text-indent:-1.751%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,608</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0in;text-indent:0.65pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.12%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:25.9pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:3.133%;text-indent:-1.751%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023 EIP</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">304,568</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.71</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,745</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
     <td colspan="2" style="padding-top:0in;text-indent:0.65pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.12%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:7.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="text-indent:-1.695%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans not approved by security holders</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;text-indent:0.65pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.12%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:25.9pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:3.133%;text-indent:-1.751%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023 Inducement Plan</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,841</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.74</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,615</span></p></td>
     <td style="padding-top:0in;text-indent:0.65pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:left;"><p style="margin-left:0.12%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:7.95pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="text-indent:-1.695%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">449,135</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,968</span></p></td>
     <td style="padding-top:0in;text-indent:0.65pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="margin-left:0.12%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average exercise price excludes any outstanding RSU awards, which have no exercise price.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our 2019 ESPP provides that the total number of shares reserved for issuance thereunder will automatically increase on January 1 of each year beginning on January 1, 2023, and continuing through (and including) January 1, 2029, by the lesser of (a) 1.5% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, (b) 38,461 shares of our common stock, or (c) a lesser number determined by our Board prior to the applicable January 1st. Accordingly, on January 1, 2026, the number of shares of common stock available for issuance under our 2019 ESPP increased by 38,461 shares. This increase is not reflected in the table above.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2023 EIP provides that the total number of shares of our common stock reserved for issuance thereunder will automatically increase on January 1st of each calendar year for a period of up to 10 years, beginning on January 1, 2024, and ending on (and including) January 1, 2033, in an amount equal to (i) 4% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, or (ii) a lesser number of shares determined by our Board prior to January 1st of a given fiscal year. Accordingly, on January 1, 2026, the number of shares of common stock available for issuance under our 2023 EIP increased by 197,086 shares (the &#8220;Annual Increase&#8221;). In addition, on January 27, 2026, our stockholders approved Amendment No. 1 to the 2023 EIP to increase the number of shares of our common stock issuable under such plan by 1,410,000 shares (&#8220;Amendment Increase&#8221;). Neither of the Annual Increase or the Amendment Increase is reflected in the table above.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consists of shares underlying options granted to employees as inducement awards material to the grantees entering into employment with us pursuant to Nasdaq Rule 5635(c)(4). Does not reflect 969 shares of common stock granted pursuant to inducement grants made outside of the 2023 Inducement Plan at a weighted average exercise-price of $28.34.</span></div></div><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="item_13"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and RELATED transactions, and director independence</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related Person Transactions Policy and Procedures</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a written Related Person Transactions Policy that sets forth our policies and procedures regarding the identification, review, consideration and approval or ratification of &#8220;related-persons transactions.&#8221; For purposes of our policy only, a &#8220;related-person transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any &#8220;related person&#8221; are participants involving an amount that exceeds or will exceed $120,000 or, during such time as we qualify as a &#8220;smaller reporting company,&#8221; the lesser of (1) $120,000 or (2) 1% of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">140</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">average of our total assets for the last two completed fiscal years. Transactions involving compensation for services provided to us as an employee, director, consultant or similar capacity by a related person are not covered by this policy. A related person is any executive officer, director, or a holder of more than 5% of our capital stock, including any of their immediate family members, and any entity owned or controlled by such persons.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Related Person Transactions</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than compensation arrangements for our directors and executive officers, which are described in the section titled &#8220;Executive and Director Compensation,&#8221; the following is a description of our related person transactions since January 1, 2024 to which we were a party or will be a party.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erigen Asset Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described under &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Developments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Strategic Acquisition of Dual-Targeting CAR-T Programs,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; on November 19, 2025, we executed the Asset Purchase Agreement with the Sellers, pursuant to which the Sellers agreed to sell and transfer to us all right, title and interest of the Sellers in and to the Assets, in exchange for an aggregate purchase price of 8,268,495 shares of our common stock, to be issued to Erigen on behalf of both Sellers. Erigen is a limited liability company and an affiliate of Factor with two members, Dr. Angel and Lotus Capital BVI Limited (&#8220;Lotus&#8221;), who own 58.5% and 41.5% of Erigen, respectively. At Closing, we issued 8,268,495 shares of our common to Erigen, resulting in Dr. Angel and Lotus beneficially holding approximately 37% and 26% of our common stock, respectively, immediately following the Closing. On February 3, 2026, Dr. Angel was appointed to serve as our President and Chief Executive Officer and as a member of the Board. Following the Closing, Erigen distributed 4,837,070 shares of common stock to Dr. Angel, and, as of the date of this Annual Report on Form 10-K, continued to hold 3,431,425 shares of common stock beneficially owned by Lotus.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Factor Amended and Restated License and Collaboration Agreement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described under &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Factor Amended and Restated License and Collaboration Agreement,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; on February 3, 2026, the Restated Factor License Agreement was assigned to us in connection with the Closing pursuant to the Asset Purchase Agreement. Pursuant to the Restated Factor License Agreement, we are obligated to meet certain diligence milestones by specified dates and to use commercially reasonable efforts to develop and make commercially available at least one licensed product in the licensed territory. No upfront payment was paid pursuant to the Restated Factor License Agreement. We are obligated to pay Factor Bioscience Limited up to $40 million in total upon achievement of certain development milestones for the programs and up to $620 million in total upon achievement of certain commercial milestones for the programs. In addition, we are required to pay Factor Bioscience Limited mid-single digit to high-teens royalties on net sales of licensed products on a country-by-country and licensed product-by-licensed product basis until expiration of the last to expire valid claim of certain licensed patents covering such licensed product in such country, subject to certain customary reductions, and low-to-mid double digit sublicense fees.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Factor Amended and Restated Master Services Agreement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described under &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Factor Amended and Restated Master Services Agreement,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; on February 3, 2026 the Restated Factor Services Agreement was assigned to us in connection with the Closing pursuant to the Asset Purchase Agreement. Pursuant to the Restated Factor Services Agreement, Factor will perform services requested by us on a fee-for-services basis and provide us access to Factor&#8217;s facilities as mutually agreed upon in one or more written work orders. All deliverables developed as a result of Factor&#8217;s performance of the services or as set forth in a work order, other than specified improvements, will be our property and confidential information. Furthermore, Factor granted us a freedom-to-operate license to its background intellectual property solely to the extent necessary or reasonably useful to use, practice or otherwise exploit the deliverables.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Private Placement and Registration Rights Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described under &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Private Placement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#8221; on March 20, 2026, we entered into the Purchase Agreement with (a) the Institutional Investors and (b) Factor Bioscience Inc., pursuant to which we agreed to issue and sell in a Private Placement an aggregate of 462,964 Shares of our common stock, and, in lieu of common stock, pre-funded warrants to purchase up to 462,963 shares of our common stock, in each case accompanied by (i) Series A Warrants to purchase up to 925,927 shares of our common stock and (ii) Series B Warrants to purchase up to 925,927 shares of our common stock. Dr. Angel is the majority stockholder and Chairman of the Board of Directors of Factor Biosciences Inc. Pursuant to the Purchase Agreement, we sold an aggregate of 231,482 Shares, 231,482 Series</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">141</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Warrants and 231,482 Series B Warrants to Factor in exchange for $462,964, before deducting placement agent fees and other offering expenses payable by us.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Private Placement, we entered into the Registration Rights Agreement with the Investors, pursuant to which we agreed to file registration statements under the Securities Act with the SEC covering the resale of the Shares to be issued in the Private Placement and the shares of our common stock underlying the Common Warrants and Pre-Funded Warrants no later than 15 calendar days following the date of the Purchase Agreement, and to use reasonable best efforts to have the registration statement declared effective by 45 calendar days following the date of the Purchase Agreement, and in any event no later than 75 calendar days following the date of the Purchase Agreement in the event of a &#8220;full review&#8221; by the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Professional Services Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 24, 2026, we entered into a Professional Services Agreement, effective April 1, 2026, with YQ Advisors Limited (&#8220;YQ&#8221;) pursuant to which YQ will provide various business development and corporate development activities to us at an hourly rate of (i) $1,250 for services provided by Andrew Fang and (ii) $250 for services provided by other YQ service providers, up to a maximum aggregate amount of $720,000 per year. The agreement has a term of 12 months unless extended by mutual written agreement of the parties. Mr. Fang is the son of Bangxia Yang, the beneficial owner of Lotus, a greater than 5% holder of our common stock.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into indemnification agreements with each of our current directors and officers. These agreements provide for the indemnification of such persons for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were serving in such capacity. We believe that these indemnification agreements are necessary to attract and retain qualified persons as directors and officers. Furthermore, we have obtained director and officer liability insurance to cover liabilities our directors and officers may incur in connection with their services to us.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Independence of the Board of Directors; Executive Sessions</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required under the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) listing standards, &#8220;independent&#8221; directors must comprise a majority of a listed company&#8217;s board of directors. In addition, applicable Nasdaq rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit committee, compensation committee and nominating and corporate governance committee be independent within the meaning of applicable Nasdaq rules. Audit Committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board undertook a review of the independence of each director and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. As a result of this review, our Board determined that all of our directors, other than Mr. Brady, our former Chief Executive Officer and President, qualify as &#8220;independent&#8221; directors within the meaning of the Nasdaq rules. Accordingly, a majority of our directors are independent, as required under applicable Nasdaq rules. The Board also determined that each member of our Audit, Compensation and Nominating and Corporate Governance Committees satisfies the independence standards for such committees established by the SEC and the Nasdaq listing standards, as applicable.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our non-employee directors have been meeting, and we anticipate that they will continue to meet, in regularly scheduled executive sessions at which only non-employee directors are present.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_14"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accounting Fees and Services</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The following table represents aggregate fees billed to the Company for the fiscal years ended December 31, 2025 and 2024 by Ernst &amp; Young, the Company&#8217;s independent registered public accountant. All fees described below were pre-approved by the Audit Committee.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:66.887%;box-sizing:content-box;"/>
     <td style="width:16.497%;box-sizing:content-box;"/>
     <td style="width:16.617%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal Year Ended</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit Fees</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	930,000</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	755,000</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit-related Fees</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#8212;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">142</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:66.887%;box-sizing:content-box;"/>
     <td style="width:16.497%;box-sizing:content-box;"/>
     <td style="width:16.617%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Fees</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#8212;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Other Fees</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#8212;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Fees</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	930,000</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	755,000</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:1pt solid;margin-right:66.667%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit fees relate to the audit of our annual financial statements, review of interim financial statements and assistance with registration statements filed with the SEC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Approval Policies and Procedures</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee has adopted a pre-approval policy under which the Audit Committee approves in advance all audit and permissible non-audit services to be performed by the independent accountants (subject to a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">de minimis </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exception). These services may include audit services, audit-related services, tax services, and other non-audit services. As part of its pre-approval policy, the Audit Committee considers whether the provision of any proposed non-audit services is consistent with the SEC&#8217;s rules on auditor independence. In accordance with its pre-approval policy, the Audit Committee has pre-approved certain specified audit and non-audit services to be provided by our independent auditor. If there are any additional services to be provided, a request for pre-approval must be submitted to the Audit Committee for its consideration under the policy. The Audit Committee generally pre-approves particular services or categories of services on a case-by-case basis. Finally, in accordance with the pre-approval policy, the Audit Committee has delegated pre-approval authority to the Chair of the Audit Committee. The Chair must report any pre-approval decisions to the Audit Committee at its next meeting. The Audit Committee has determined that the rendering of services other than audit services by Ernst &amp; Young is compatible with maintaining the principal accountant&#8217;s independence.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">143</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section50"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART IV</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section51"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have filed the following documents as part of this Annual Report:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)(1)     Financial Statements</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements are included in Item 8. &#8220;Financial Statements and Supplementary Data.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)(2)     Financial Statement Schedules</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All schedules are omitted as information required is inapplicable or the information is presented in the financial statements and the related notes.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)(3)     Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:8.56%;box-sizing:content-box;"/>
     <td style="width:52%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:9.44%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="5" style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporation by Reference</span></p></td>
    </tr>
    <tr style="height:23.75pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Number</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File Number</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed or Furnished Herewith</span></p></td>
    </tr>
    <tr style="height:20.15pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000110465921042768/tm2111026d1_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Agreement and Plan of Merger, dated as of March 29, 2021, by and among Tempest Therapeutics, Inc., Mars Merger Corp. and Tempest Therapeutics, Inc.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/29/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000155837019005038/mlnd-20190331ex31b53fa83.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Restated Certificate of Incorporation of the Registrant, as amended</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/15/2019</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:28.1pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312521201157/d196630dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment to the Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware on June 24, 2021</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/28/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:28.1pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312521201157/d196630dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment to the Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware on June 25, 2021</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/28/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312523253882/d547808dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Designation of Series A Junior Participating Preferred Stock filed with the Secretary of State of the State of Delaware on October 10, 2023</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/11/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312525073987/d905141dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment to the Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware on April 4, 2025.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/7/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312521281694/d222030dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/24/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:20.15pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="tpst-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000095017024033555/tpst-20231231.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Tempest Therapeutics, Inc. Warrant to Purchase Stock</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/19/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312523253882/d547808dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Rights Agreement, dated as of October 10, 2023, between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., which includes the form of Certificate of Designation as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/11/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000119312524235598/d877681d8k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1, dated as of October 9, 2024, to Rights Agreement, dated as of October 10, 2023, by and between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., as rights agent</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/10/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000119312524272464/d899818d8k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2, dated as of December 5, 2024, to Rights Agreement, dated as of October 10, 2023, as amended, by and between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., as rights agent.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/06/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312525298604/d37881dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Tempest Therapeutics, Inc. Prefunded Warrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/26/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312525298604/d37881dex43.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Tempest Therapeutics, Inc. Common Stock Warrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/26/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312526041190/d159400dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Warrant Agreement (including Form of Warrant), dated February 3, 2026, between the Company, Computershare Inc., a Delaware corporation, and Computershare Trust Company, N.A., as Warrant Agent</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/6/2026</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312521208968/d184348dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2011 Equity Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257727</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/7/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">144</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:8.56%;box-sizing:content-box;"/>
     <td style="width:52%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:9.44%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312521208968/d184348dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2017 Equity Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257727</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/7/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000162828022007717/tempest-2017eipxformofst.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Agreement under the 2017 Equity Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/29/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312522177053/d370249dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated 2019 Equity Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/21/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000155837019007932/mlnd-20190630ex107cfce16.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Option Grant Package under 2019 Equity Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/12/2019</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:21.6pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000154422720000004/mlnd-20191231xex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Agreement under the Sub Plan for French Residents under 2019 Equity Incentive Plan</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/11/2020</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:21.6pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000154422720000004/mlnd-201912x31xex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Inducement Nonqualified Stock Option Agreement subject to the terms of the 2019 Equity Incentive Plan</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/11/2020</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312522177053/d370249dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated 2019 Employee Stock Purchase Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/21/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312521209988/d69289dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/07/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:20.15pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017023009237/tpst-ex10_24.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement, dated January 24, 2022, by and between HCP Life Science REIT, Inc. and Tempest Therapeutics, Inc.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/22/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017023041429/tpst-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/10/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tpst-ex10_12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017023041429/tpst-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Option Grant Package under the Amended and Restated 2023 Equity Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/10/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017023041429/tpst-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc. 2023 Inducement Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/10/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017023041429/tpst-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Option Grant Package under the 2023 Inducement Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/10/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16#</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017025046144/tpst-ex10_32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Roche Supply Agreement, dated October 7, 2024, by and between the Registrant and F. Hoffmann-La Roche Ltd.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/27/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017025106558/tpst-ex10_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Offer Letter, dated August 11, 2025, by and between Tempest Therapeutics, Inc. and Justin Trojanowski.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/11/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017025106558/tpst-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Separation Agreement, dated June 13, 2025, by and between Tempest Therapeutics, Inc. and Stephen Brady</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/11/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017025106558/tpst-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Separation Agreement, dated June 13, 2025, by and between Tempest Therapeutics, Inc. and Samuel Whiting</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/11/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017025106558/tpst-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Separation Agreement, dated June 13, 2025, by and between Tempest Therapeutics, Inc. and Nicholas Maestas</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/11/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017025106558/tpst-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Consulting Agreement</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/11/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017025106558/tpst-ex10_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Success Bonus Agreement</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/11/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23*</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312525287163/d97617dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Asset Purchase Agreement, dated November 19, 2025, by and among Erigen LLC, Factor Bioscience Inc., and Tempest Therapeutics, Inc.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/19/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312525287163/d97617dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lock-Up Agreement, dated November 19, 2025, by and between Erigen LLC and Tempest Therapeutics, Inc.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/19/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25#</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tpst-ex10_25.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive License and Collaboration Agreement, dated July 18, 2025, by and between Erigen LLC and Novatim Immune Therapeutics Co., Ltd.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26#</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tpst-ex10_26.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated License and Collaboration Agreement, dated November 19, 2025, by and between Factor Bioscience Limited and Erigen LLC</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27#</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tpst-ex10_27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Master Services Agreement, dated November 19, 2025, by and between Factor Bioscience Limited and Erigen LLC</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tpst-ex10_28.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Employment Agreement, dated November 19, 2025, by and between the Registrant and Matthew Angel</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tpst-ex10_29.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Employment Agreement, dated February 3, 2026 by and between the Registrant and Nicholas Maestas</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000095017025046144/tpst-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc. Insider Trading Policy</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/27/25</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1544227/000119312522092417/d328059dex211.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K/A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/1/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;text-align:left;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="tpst-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="#section53"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (included on signature page)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:30.95pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="tpst-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:30.95pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="tpst-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:39.6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">&#x5E;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="tpst-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(b) and 15d-14(b) promulgated under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to section 906 of The Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1+</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000095017024033555/tpst-20231231.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Incentive Compensation Recoupment Policy</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-35890</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/19/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">145</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:8.56%;box-sizing:content-box;"/>
     <td style="width:52%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:9.44%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page formatted as Inline XBRL and contained in Exhibit 101</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:8pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_______________________________________</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*  Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+     Indicates management contract or compensatory plan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x5E;     These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">#     Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain portions of this exhibit (indicated by ***) have been omitted because the identified information is not material and is the type that the Registrant treats as private or confidential.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="section52">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 16. FORM 10-K SUMMARY</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">146</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="section53"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:92%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TEMPEST THERAPEUTICS, INC.</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Matthew Angel</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Matthew Angel</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer &amp; President (Principal Executive Officer)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Nicholas Maestas</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nicholas Maestas</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer &amp; Head of Corporate Strategy (Principal Financial Officer)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: March 30, 2026</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">147</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.59in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Matthew Angel </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Nicolas Maestas</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Tempest Therapeutics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:29%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:56.84%;box-sizing:content-box;"/>
     <td style="width:13.16%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:2pt solid #000000;padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:1.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
     <td style="border-top:2pt solid #000000;padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:2pt solid #000000;padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:9pt;margin-top:1.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
     <td style="border-top:2pt solid #000000;padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:10pt;margin-top:1.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">/s/ Matthew Angel</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer, President and Director </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Matthew Angel</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">/s/ Nicholas Maestas</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer &amp; Head of Corporate Strategy</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nicholas Maestas</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:2.9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">/s/ Justin Trojanowski</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate Controller, Treasurer</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Justin Trojanowski</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:2.9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">/s/ Stephen Brady</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman of the Board of Directors</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephen Brady</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:2.9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">/s/ Michael Raab</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Raab</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">/s/ Christine Pellizzari</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Christine Pellizzari</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">/s/ Ronit Simantov</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2026</span></p></td>
    </tr>
    <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:9pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ronit Simantov, M.D.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.59in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">148</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tpst-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T08:19:11.7081+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-4.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES<br>REGISTERED PURSUANT TO SECTION 12 OF THE<br>SECURITIES EXCHANGE ACT OF 1934</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc. (the &#x201c;Company,&#x201d; or &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d;) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (a) our common stock and (b) Series A junior participating preferred purchase rights (&#x201c;Series A Preferred Shares&#x201d;).</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following descriptions of our capital stock, provisions of our restated certificate of incorporation, as amended (the &#x201c;Restated Certificate&#x201d;), amended and restated bylaws (the &#x201c;Bylaws&#x201d;), certificate of designation of rights, preferences and privileges of Series A Preferred Shares (the &#x201c;Certificate of Designations&#x201d;), the Rights Agreement (as defined below), and certain provisions of Delaware law are summaries and do not purport to be complete. You should also refer to the Restated Certificate, the Bylaws, the Certificate of Designations, and the Rights Agreement which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part. We encourage you to read these documents for additional information.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Restated Certificate authorizes us to issue up to 100,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share, of which 100,000 shares are designated as Series A Preferred Shares. All other shares of preferred stock are undesignated. For a description of the rights of our Series A Preferred Shares, see below under the heading &#x201c;Preferred Stock Purchase Rights.&#x201d;</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of common stock have no preemptive, subscription, redemption or conversion rights. There are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of Preferred Shares, upon issuance of any such shares, and of any other series of preferred stock that we may designate and issue in the future.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Stock</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our Restated Certificate, our board of directors has the authority to determine the number, rights, preferences, privileges and restrictions of each series of preferred stock that it may, from time to time, issue, including voting rights, dividend rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of outstanding shares of preferred stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of shares of preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of our company before any payment is made to the holders of shares of our common stock. In some circumstances, the issuance of shares of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a large block of our securities or the removal of incumbent management.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The General Corporation Law of the State of Delaware (&#x201c;DGCL&#x201d;), the state of our incorporation, provides that the holders of preferred stock will have the right to vote separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of the class or change the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Stock Purchase Rights</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 10, 2023, our board of directors declared a dividend of one preferred share purchase right (&#x201c;Right&#x201d;) to purchase one-thousandth of one share of Series A Preferred Shares for each outstanding share of our common stock to the stockholders of record as of the close of business on October 23, 2023 (the &#x201c;Record Date&#x201d;), and adopted a limited duration stockholder rights plan (the &#x201c;Rights Plan&#x201d;), as set forth in the Rights Agreement, dated as of October 10, 2023, as amended by Amendment No. 1 to Rights Agreement, dated as of October 9, 2024, and as further amended by Amendment No. 2 to Rights Agreement, dated as of December 5, 2024 (collectively, the &#x201c;Rights Agreement&#x201d;), by and between the Company and Computershare Trust Company, N.A., as Rights Agent. The Rights Agent currently serves as our transfer agent with respect to our common stock and also has been appointed transfer agent with respect to the Series A Preferred Shares, if any, that may be issued pursuant to the exercise of rights under the Rights Agreement. The Rights will expire immediately following our 2025 Annual Meeting of Stockholders, or, if our stockholders approve the Rights Plan at or prior to such meeting, on October 10, 2026 (&#x201c;Final Expiration Date&#x201d;), unless the rights are earlier redeemed or exchanged by the Company. We do not have any obligation under the Rights Agreement to seek stockholder approval for the Rights Plan.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general terms, the Rights Agreement works by imposing a significant penalty upon any person or group that acquires beneficial ownership of 10% (15% in the case of a passive institutional investor) or more of the outstanding shares of our common stock without the approval of our board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Rights</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Rights will not be exercisable and will trade with shares of our common stock until the earlier to occur of (a) the tenth calendar day (or such later date as may be determined by our board of directors) after a person or group acquires beneficial ownership of 10% (15% in the case of a passive institutional investor) or more of our outstanding common stock (an &#x201c;Acquiring Person&#x201d;) or (b) the tenth business day (or such later date as may be determined by action of our board of directors prior to such time as any person or entity becomes an Acquiring Person) following the date of commencement of, or the first announcement of, an intention to commence, a tender offer or exchange offer, the consummation of which would result in any person or entity or group of persons or entities acting in concert becoming an Acquiring Person; provided, however, the term &#x201c;Acquiring Person&#x201d; is subject to certain customary exceptions whereby certain stockholders that would have otherwise been an Acquiring Person are excluded from the definition of &#x201c;Acquiring Person.&#x201d; Any Rights held by an Acquiring Person are null and void and may not be exercised. Any stockholders with beneficial ownership of our common stock above the applicable threshold as of the time of this announcement are grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the Rights. Prior to exercise, the Right does not give its holder any dividend, voting or liquidation rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exercise Price</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The date when the Rights separate from our common stock and become exercisable is referred to herein as the &#x201c;Distribution Date.&#x201d; After the Distribution Date, each Right will entitle the holder to purchase one-thousandth (1/1000</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of a Preferred Share for $25.00, subject to adjustment (the &#x201c;Exercise Price&#x201d;). Each one-thousandth (1/1000</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)&#x2003;of a Series A Preferred Share has economic terms similar to that of one share of our common stock. The Exercise Price payable, and the number of Series A Preferred Shares or other securities or other property issuable upon exercise of the Rights will be subject to adjustment from time to time to prevent dilution in the event of a stock dividend on, or a subdivision, combination or reclassification of, the Series A Preferred Shares. The exercise of Rights to purchase Series A Preferred Shares will at all times be subject to the availability of a sufficient number of authorized but unissued Series A Preferred Shares. Notwithstanding the foregoing, with certain exceptions, no adjustment in the Exercise Price will be required until cumulative adjustments require an adjustment of at least 1% in such Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Price. No fractional shares will be issued (other than fractions which are integral multiples of the number of one one-hundredth (1/100</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of a Series A Preferred Share issuable upon the exercise of one Right, which may, at our election, be evidenced by depositary receipts), and in lieu thereof, an adjustment in cash will be made based on the market price of the Series A Preferred Shares on the last trading day prior to the date of exercise.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consequences of a Person or Group Becoming an Acquiring Person</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Flip-In</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If a person or group becomes an Acquiring Person, all holders of Rights except the Acquiring Person or its affiliates may, for the Exercise Price, purchase shares of our common stock with a market value of twice the Exercise Price.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In lieu of &#x201c;flip-in&#x201d; feature described above, our board of directors may, at its option at any time after a person or group becomes an Acquiring Person, exchange the Rights (other than Rights owned by the Acquiring Person or its affiliates), in whole or in part, for shares of our common stock at an exchange ratio of one share of our common stock per Right (subject to adjustment).</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Flip-Over</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If we are later acquired in a merger or similar transaction after the Distribution Date, all holders of Rights except the Acquiring Person or its affiliates may purchase, for the Exercise Price, a number of shares of our common stock of the person engaging in the transaction having a market value of twice the Exercise Price.</font></div></div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions of the Series A Preferred Shares</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Series A Preferred Share, if issued:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will not be redeemable;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">when and if any dividend is declared on our common stock, entitle the holder to a preferential quarterly dividend payment equal to 1,000 times the aggregate per share price of all cash and non-cash dividends declared per share of our common stock;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will entitle the holder upon liquidation either to receive $1,000 plus an amount equal to accrued and unpaid dividends and distributions thereon or an aggregate amount per share equal to 1,000 times the aggregate amount to be distributed per share to holders of our common stock;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will have 1,000 votes, voting together with our common stock;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if shares of our common stock are exchanged via merger, consolidation, or a similar transaction, will entitle the holder to a per share payment equal to 1,000 times the amount of consideration received per share of our common stock; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Series A Preferred Shares would rank junior to any other series of the Company&#x2019;s preferred stock.</font></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The value of one-thousandth interest in a Preferred Share is intended to approximate the value of one share of our common stock.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expiration; Amendments</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Rights will expire on the Final Expiration Date. The terms of the Rights Agreement may be amended by our board of directors without the consent of the holders of the Rights. After a person or group becomes an Acquiring Person, our board of directors may not amend the Rights Agreement in a way that adversely affects holders of the Rights.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Redemption</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors may redeem the Rights for $0.001 per Right at any time prior to the earlier of (A) such time as any person or group becomes an Acquiring Person or (B) the close of business on the Final Expiration Date. Following the expiration of the above periods, the Rights become nonredeemable. If our board of directors redeems any Rights, it must redeem all of the Rights. Once the Rights are redeemed, the only right of the holders of Rights will be to receive the redemption price of $0.001 per Right. The redemption price will be adjusted if the Company effects a stock split or stock dividend of our common stock.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Miscellaneous</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights will have the benefit of certain customary anti-dilution provisions.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Rights Agreement does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of a future board of directors to redeem the Rights. Until a Right is exercised, the holder thereof, as such, will have no rights as a stockholder of the Company, including, without limitation, the right to vote or to receive dividends.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Extraordinary Warrants</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Common Stock Warrants</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 15, 2021, TempestTx, Inc. (formerly Tempest Therapeutics, Inc., &#x201c;Legacy Tempest&#x201d;) issued warrants for the purchase of shares of preferred stock of TempestTx, Inc. to Oxford Finance LLC (the &#x201c;2021 Warrants&#x201d;). Upon the closing of Legacy Tempest&#x2019;s business combination with the Company, in accordance with the terms of the Agreement and Plan of Merger, dated as of March 29, 2021, by and among the Company, Legacy Tempest and Mars Merger Corp., a Delaware corporation and a wholly owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;), pursuant to which, among other matters, Merger Sub merged with and into Legacy Tempest, with Legacy Tempest continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the &#x201d;Merger&#x201d;), the Company assumed all of the outstanding 2021 Warrants. Following the Merger, the 2021 Warrants were restated and become exercisable for shares of the Company&#x2019;s common stock. As of December 31, 2025, 2021 Warrants exercisable into 464 shares of common stock remained outstanding. The 2021 Warrants are exercisable at any time and from time to time, in whole or in part, until their expiration on January 15, 2031, at an exercise price of $322.92 per share (subject to customary adjustments), and may also be exercised on a cashless basis. The issuance of common stock upon exercise of the warrants is not covered by an effective registration statement.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2026 Dividend Warrants</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 3, 2026, pursuant to the terms and conditions described in the Warrant Agreement, dated February 3, 2026, between the Company, Computershare Inc., and its affiliate, Computershare Trust Company, N.A., as Warrant Agent, the Company issued, as a dividend, warrants to purchase an aggregate of 6,784,989 shares of common stock (the &#x201c;Dividend Warrants&#x201d;). As of February 28, 2026, Dividend Warrants exercisable into 6,784,989 shares of common stock remained outstanding. The Dividend Warrants cannot be exercised until there is an effective registration statement covering the sale of shares of common stock upon exercise of the Dividend Warrants. The Company intends to file a registration statement registering up to 6,784,989 shares of common stock issuable upon exercise of the Dividend Warrants under the Securities Act of 1933, as amended, following the effectiveness of which the Dividend Warrants will be exercisable at any time and from time to time, in whole or in part, until their expiration on February 3, 2031, at an exercise price of $18.48 per share. The Dividend Warrants are not eligible to be exercised on a cashless basis. The exercise price and the number of shares issuable upon exercise of the Dividend Warrants are subject to customary adjustments in the case of stock dividends, stock splits, pro rata distributions, and similar events in respect of our common stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Issuable Upon Exercise of Warrants</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have Series A warrants to purchase shares of common stock (the &#x201c;Series A Warrants&#x201d;), Series B warrants to purchase shares of common stock (the &#x201c;Series B Warrants&#x201d;) and pre-funded warrants (&#x201c;Pre-Funded</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants&#x201d;) to purchase shares of common stock issued and outstanding. The Series A Warrants and the Series B warrants are collectively referred to as the &#x201c;Common Warrants,&#x201d; and together with the Pre-Funded Warrants, the &#x201c;Warrants.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fractional Shares</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No fractional shares shall be issued upon the exercise of any Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of shares of common stock to be issued shall be rounded down to the next whole number and we shall pay the holder in cash the fair market value (based on the closing sale price) for any such fractional shares.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exercise Limitations</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Warrants, we may not give effect to the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of any such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder&#x2019;s affiliates, and any other persons whose beneficial ownership of common stock would or could be aggregated with the holder&#x2019;s for purposes of Section 13(d) or Section 16 of the Exchange Act) would exceed a percentage set at the discretion of each Holder between 4.99% and 9.99%, of the number of shares of common stock outstanding immediately after giving effect to such exercise, which percentage may be increased or decreased at the holder&#x2019;s election upon notice to us, up to 9.99% upon at least 61 days&#x2019; prior notice from the holder to us.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transferability</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to applicable laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Listing</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no established trading market for the Warrants, and we do not expect a market to develop. We do not intend to apply for the listing of Warrants on the Nasdaq Stock Market, any other national securities exchange or any other nationally recognized trading system.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Rights as a Stockholder</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except by virtue of such holder&#x2019;s ownership of shares of our common stock, the holder of a Warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until such holder exercises the Warrant.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Warrants</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exercise Price</font></p><p style="text-indent:2.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Common Warrants have an exercise price of $2.16 per share.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Series A Warrants will become exercisable on the effective date of approval from our stockholders for the issuance of the shares issuable upon exercise of the Common Warrants (the &#x201c;Stockholder Approval Date&#x201d;) and have a term of five years from the later of the Stockholder Approval Date and the effectiveness date of a registration statements covering the resale of the shares of common stock underlying the Common Warrants (the &#x201c;Effectiveness Date&#x201d;). The Series B Warrants will become exercisable on the Stockholder Approval Date and have a term of twenty-four months from the later of the Stockholder Approval Date and the Effectiveness Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fundamental Transactions</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, at any time while the Common Warrants are outstanding (i) we effect any merger or consolidation of the Company with or into another person, in which we are not the surviving entity or in which our stockholders immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii) we, directly or indirectly, effect any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of our assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by us or another person) is completed pursuant to which holders of our common stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding our common stock or greater than 50% of the voting power of the common equity of the Company, (iv) we, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of our common stock or any compulsory share exchange pursuant to which our common stock is effectively converted into or exchanged for other securities, cash or property (except for any such transaction in which our stockholders immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such person immediately after the transaction), or (v) we, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another person or group of persons whereby such other person or group acquires greater than 50% of our outstanding shares of common stock or greater than 50% of the voting power of our common equity (in any such case, a &#x201c;Fundamental Transaction&#x201d;), then following such Fundamental Transaction the holder shall have the right to receive, upon exercise of the Common Warrants, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of warrant shares then issuable upon exercise in full of the Common Warrants (including any Distributions or Purchase Rights then held in abeyance without regard to any limitations on exercise contained herein (the &#x201c;Alternate Consideration&#x201d;)). We shall not effect any Fundamental Transaction in which we are not the surviving entity or the Alternate Consideration includes securities of another person unless prior to or simultaneously with the consummation thereof, any successor to us, surviving entity or other person (including any purchaser of assets of us) shall assume the obligation to deliver to the holder such Alternate Consideration as, in accordance with the foregoing provisions, the holder may be entitled to receive, and the other obligations under the Common Warrants.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Funded Warrants</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exercise Price</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Pre-Funded Warrant will have an exercise price of $0.001 per share. In lieu of making the cash payment otherwise contemplated to be made to us upon exercise of a Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the Pre-Funded Warrants.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Pre-Funded Warrant will be exercisable immediately upon the Original Issue Date (as defined in the Pre-Funded Warrant) until the Pre-Funded Warrant is exercised in full.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fundamental Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, at any time while the Pre-Funded Warrants are outstanding (i) we effect any merger or consolidation of the Company with or into another person, in which we are not the surviving entity or in which our stockholders immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii) we, directly or indirectly, effect any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of our assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by us or another person) is completed pursuant to which holders of our common stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding our common stock or greater than 50% of the voting power of the common equity of the Company,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) we, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of our common stock or any compulsory share exchange pursuant to which our common stock is effectively converted into or exchanged for other securities, cash or property (except for any such transaction in which our stockholders immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such person immediately after the transaction), or (v) we, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another person or group of persons whereby such other person or group acquires greater than 50% of our outstanding shares of common stock or greater than 50% of the voting power of our common equity (in any such case, a &#x201c;Fundamental Transaction&#x201d;), then following such Fundamental Transaction the holder shall have the right to receive, upon exercise of the Pre-Funded Warrants, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of warrant shares then issuable upon exercise in full of the Pre-Funded Warrants (including any Distributions or Purchase Rights then held in abeyance without regard to any limitations on exercise contained herein (the &#x201c;Alternate Consideration&#x201d;)). We shall not effect any Fundamental Transaction in which we are not the surviving entity or the Alternate Consideration includes securities of another person unless prior to or simultaneously with the consummation thereof, any successor to us, surviving entity or other person (including any purchaser of assets of us) shall assume the obligation to deliver to the holder such Alternate Consideration as, in accordance with the foregoing provisions, the holder may be entitled to receive, and the other obligations under the Pre-Funded Warrants.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Takeover Provisions</font></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 203 of the Delaware General Corporation Law</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, Section 203 defines a &#x201c;business combination&#x201d; to include the following:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.</font></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, Section 203 defines an &#x201c;interested stockholder&#x201d; as an entity or person who, together with the person&#x2019;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Staggered Board</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Restated Certificate and Bylaws divide our board of directors into three classes with staggered three year terms. In addition, our Restated Certificate and Bylaws provide that directors may be removed only for cause and only by the affirmative vote of the holders of 75% of our shares of capital stock present in person or by proxy and entitled to vote. Under our Restated Certificate and Bylaws, any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. Furthermore, our Restated Certificate provides that the authorized number of directors may be changed only by the resolution of our board of directors, subject to the rights of any holders of preferred stock to elect directors. The classification of our board of directors and the limitations on the ability of our stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of us.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Authorized but Unissued Shares</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of any exchange on which our shares are listed. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Special Meeting of Stockholders; Advance Notice Requirements for Stockholder Proposals and Director Nominations; Stockholder Action</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Restated Certificate and Bylaws provide that only our board of directors, the chairman of the board or our chief executive officer may call special meetings of stockholders, and the business transacted at a special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of meeting. Our Bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary of the preceding year&#x2019;s annual meeting. Our Bylaws specify the requirements as to form and content of all stockholders&#x2019; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. Our Restated Certificate and Bylaws provide that our stockholders may not take any action by written consent in lieu of a meeting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Super Majority Voting</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#x2019;s certificate of incorporation or bylaws, unless a corporation&#x2019;s certificate of incorporation or bylaws, as the case may be, require a greater percentage. Our bylaws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt any provisions inconsistent with certain of the provisions of our Restated Certificate.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exclusive Forum</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by applicable law, be the sole and exclusive forum for (A) any derivative action or proceeding brought on behalf of the Company; (B) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&#x2019;s stockholders; (C) any action asserting a claim against the Company or any director or officer or other employee of the Company arising pursuant to any provision of the DGCL, our Restated Certificate or our Bylaws; or (D) any action asserting a claim against the Company or any director or officer or other employee of the Company governed by the internal affairs doctrine.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Restated Certificate provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, other than an action by or in the right of us, by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#x201c;Indemnitee&#x201d;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses, including attorneys&#x2019; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>3
<FILENAME>tpst-ex10_12.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T08:19:11.6091+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.12</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDMENT NO. 1 TO TEMPEST THERAPEUTICS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></h1><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN</font></h1><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Section 2(b)(vii) of Tempest Therapeutics, Inc.&#x2019;s (the &#x201c;Company&#x201d;) Amended and Restated 2023 Equity Incentive Plan (the &#x201c;Plan&#x201d;), the Plan is hereby amended as follows, subject to approval of the Company&#x2019;s shareholders:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3(a) of the Plan is hereby deleted and replaced as follows:</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to Section 9(a) relating to Capitalization Adjustments, and the following sentence regarding the annual increase, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed 1,907,849 shares (the &#x201c;Share Reserve&#x201d;), which number includes (1) the Prior Available Reserve, plus (2) an additional 176,923 shares of Common Stock that were approved by the Company&#x2019;s stockholders at the 2023 Annual Meeting of Stockholders, plus (3) an additional 1,410,000 shares of Common Stock that were approved by the Company&#x2019;s stockholders at the 2025 Annual Meeting of Stockholders, plus (4) Returning Shares, if any, as such shares become available from time to time.</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Share Reserve will automatically increase on January 1st of each year, for a period commencing on January 1st of the year following the Effective Date and ending on (and including) January 1, 2033, in an amount equal to 4% of the total number of shares of Capital Stock outstanding on December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence.</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a). Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3(c) of the Plan is hereby deleted and replaced as follows:</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incentive Stock Option Limit. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the provisions of Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 7,000,000 shares of Common Stock.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Amendment to the Plan (this &#x201c;Amendment&#x201d;) constitutes an integral part of the Plan. For all purposes of this Amendment, capitalized terms used herein without definition shall have the meanings specified in the Plan, as the Plan shall be in effect on the date hereof after giving effect to the Amendment.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth herein, all of the terms and conditions of the Plan, as in effect prior to the effectiveness of this Amendment, shall continue to remain in full force and effect as originally stated therein.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adopted by Board of Directors: November 30, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approved by the Stockholders: January 27, 2026</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>4
<FILENAME>tpst-ex10_25.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T08:19:11.7479+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.25</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT TEMPEST THERAPEUTICS, INC. TREATS AS PRIVATE AND CONFIDENTIAL</font></h1><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT</font></h1><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into as of this 18</font><font style="color:#231f20;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day of July 2025 (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between NOVATIM IMMUNE THERAPEUTICS (ZHEJIANG) CO., LTD., a company organized and existing under the laws of the People&#x2019;s Republic of China (&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensor</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and ERIGEN LLC, a limited liability company organized and existing under the laws of the State of Delaware (&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensee</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Licensor and Licensee may each be referred to in this Agreement individually as a &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Licensor owns or controls certain Licensed Technology (as defined herein);</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Licensee desires to receive from Licensor certain rights to the Licensed Technology in order that Licensee may develop and commercialize Licensed Products in the Licensed Territory (as such terms are defined herein); and</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, in furtherance of the foregoing, Licensor agrees to grant such rights to Licensee, and Licensee agrees to use its Commercially Reasonable Efforts (as defined herein) to develop and make commercially available one or more Licensed Products in accordance with this Agreement for commercial exploitation in the Field and in the Licensed Territory (as such terms are defined herein).</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></p><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1<br></font><font style="color:#231f20;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Definitions</font></h1><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise specifically provided herein, the following terms, when used with a capital letter at the beginning, will have the following meanings:</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Party, a person, corporation, partnership, or other entity that controls, is controlled by or is under common control with such Party. For the purposes of this definition, the word &#x201c;control&#x201d; (including, with correlative meaning, the terms &#x201c;controlled by&#x201d; or &#x201c;under common control with&#x201d;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Preamble.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Law</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all statutes, ordinances, regulations, rules or orders of any kind whatsoever of any agency, bureau, branch, office, court, commission, authority, department, ministry, official or other instrumentality of, or being vested with public authority under any law of, any country, state or local authority or any political subdivision thereof, or any association of countries that may be in effect from time to time and applicable to a Party&#x2019;s obligations or exercise of its rights under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Allogeneic Products</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means allogeneic CAR-T therapies derived from Licensor&#x2019;s proprietary platforms, including technologies based on KQ-2003 and KQ-2206.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.38in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.5.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Autologous Products</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Licensed Products comprising autologous CAR-T cells, including, without limitation, KQ-2003 (autologous BCMA/CD19 dual-targeting CAR-T) and KQ-2206 (autologous CD70/CD70 dual-targeting CAR-T).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.6.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BLA</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Biologic License Application (as more fully described in U.S. 21 C.F.R. Part 601.20 or its successor regulation), as may be amended from time to time, or any analogous application or submission with any Regulatory Authority outside of the United States.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.7.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Calendar Quarter</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each of the following three (3) month periods during each year: January 1 through March 31; April 1 through June 30; July 1 through September 30; and October 1 through December 31.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.8.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Combination Product</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any product comprising a combination of (a) a Licensed Product and (b) any active ingredient(s) (other than a Licensed Product) for which rights are not included in the licenses granted under this Agreement but, with respect to the item(s) in (b) of this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.8</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which may each or collectively  [***] (an &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Product</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.9.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commercially Reasonable Efforts</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the performance of activities hereunder by or on behalf of a Party, the carrying out of such activities using commercial and business efforts and resources [***] in the development, manufacture and commercialization of products similar to the Licensed Products would typically devote to such activities, [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.10.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Competitive Infringement</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, on a Licensed Product-by-Licensed Product and country-by-country basis, where the making, using, selling, offering for sale, or importing, by any third party (other than any Sublicensee or authorized purchaser or other authorized transferee of a Party with respect to such Licensed Product), of such Licensed Product is Covered by at least one Valid Claim.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.11.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Information disclosed by or on behalf of one Party to the other during the negotiation of or under this Agreement in any manner, whether orally, visually, electronically, in writing or in other tangible or intangible form, that relates to Licensed Technology, Licensed Products, or this Agreement. Notwithstanding the foregoing, the following information shall not constitute &#x201c;Confidential Information&#x201d;: (a) information lawfully in the receiving Party&#x2019;s possession or control prior to the time it received the information from the disclosing Party; (b) information developed by the receiving Party independently of, and without reference to, the Confidential Information of the disclosing Party; (c) information that was, at the time it was disclosed to or obtained by the receiving Party, or thereafter became, available to the public through no act or omission of the receiving Party; and (d) information lawfully obtained by the receiving Party from a third party with the right to disclose such information free of any obligations of confidentiality.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.12.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Control</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Controlled by</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, in the context of a license to or ownership of Intellectual Property, the ability on the part of a Party to grant access to or a license or sublicense of such Intellectual Property as provided for herein without violating the terms of any agreement or other arrangement between such Party and any Third Party existing at the time such Party would be required hereunder to grant such access or license or sublicense.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.13.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cover</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Covered</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that the use, manufacture, sale, offer for sale, research, development, commercialization, or importation of the subject matter in question (including a chemical or biologic agent, or a process) by an unlicensed entity would infringe a granted Valid Claim (or, in the case<br></font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.38in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of a pending Valid Claim that has not yet been granted, would infringe such Valid Claim if it were to be granted in its then-current form) of a Licensed Patent.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.14.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Preamble.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.15.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exploit</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exploitation</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; mean to make, have made, research, develop, manufacture, use, sell, have sold, offer for sale, commercialize, distribute, import and/or export.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.16.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Food and Drug Administration or any successor agency thereto.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.17.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Field</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all fields.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.18.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">First Commercial Sale</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, following Regulatory Approval in a particular jurisdiction, the first arm&#x2019;s-length sale or other transfer for value of a Licensed Product by or on behalf of Licensee, or an Affiliate or Sublicensee, to an unrelated third party in such jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.19.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IND</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an Investigational New Drug Application (or the foreign equivalent thereof) filed with the FDA required for the initiation of clinical trials in humans for the applicable Licensed Product in the United States.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.20.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Information</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all information, know-how, data, results, technology, materials, scientific, business or financial information of any type whatsoever, in any tangible or intangible form, provided by or on behalf of one Party to the other Party, either in connection with the discussions and negotiations pertaining to this Agreement or in the course of performing this Agreement, or that otherwise relates to the Licensed Technology or the Licensed Products, whether disclosed orally, visually, electronically, in writing or in other tangible or intangible form, and which may include data, knowledge, practices, processes, ideas, research plans, antibodies, small molecules, compounds, targets, biological and chemical formulations, structures and designs, laboratory notebooks, proof of concept and pre-clinical studies, formulation or manufacturing processes and techniques, scientific, manufacturing, marketing and business plans, and financial and personnel matters relating to the disclosing Party or to its present or future products, sales, suppliers, customers, employees, investors or business.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.21.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvement(s)</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any invention, discovery, advancement, development, or creation which is invented, developed, authored, created, or reduced to practice by or on behalf of Licensor or its Affiliates (or any of their respective personnel or agents, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise having an obligation to assign inventions to) them) that is an improvement, modification or enhancement to the Licensed Technology or Licensed Products.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.22.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvement Patents</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Patents claiming any of the Improvements, and any reissue, divisional, continuation, continuation-in-part or reexamination certificate thereof. During the Term, all Improvement Patents shall be set forth in </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.23.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all (A) patents, patent applications, patent disclosures and all related continuation, continuation-in-part, divisional, reissue, reexamination, post-grant proceeding, utility model, certificate of invention and design patents, applications, registrations and applications for registration, and any equivalent in any jurisdiction; (B) trademarks, service marks, trade dress, Internet domain names, logos, trade names and corporate names and registrations and applications for registration thereof; (C) copyrights and registrations and applications for registration thereof, including all moral rights; (D) Information, inventions, trade secrets and confidential information, whether patentable or non-<br></font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patentable and whether or not reduced to practice, Know-How, show-how, manufacturing and product processes and techniques, batch records, bills of materials, material and process risk assessments and other quality documentation, research and development information, notebooks, formulae, diagrams, technical and engineering specifications, business and marketing plans and customer and supplier lists and other information; (E) other proprietary rights relating to any of the foregoing (including remedies against infringement thereof and rights of protection of interest therein under the laws of all jurisdictions); and (F) copies and tangible embodiments thereof.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.24.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Know-How</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all unpatented inventions, technology, methods, materials (including biological and pharmaceutical materials), know-how, studies, pre-clinical and clinical data (including toxicology and safety data), tests and assays, reports, manufacturing processes (including quality documentation), regulatory filings (including drafts) and regulatory approvals.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.25.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensed Know-How</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Know-How and other Information Controlled by Licensor or its Affiliates as of the Effective Date and/or that may become Controlled by Licensor or its Affiliates during the Term, in each case that are necessary or useful to Exploit Licensed Products in the Field in the Licensed Territory.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.26.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensed Patents</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Patents Controlled by Licensor and/or its Affiliates as of the Effective Date and during the Term, and that are necessary or useful for Exploiting Licensed Products in the Field and in the Licensed Territory, including those Patents set forth on </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and any Improvement Patents.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.27.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensed Product</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201d; </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means any product incorporating, derived from or made using the Licensed Technology.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.28.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensed Technology</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Licensed Patents and Licensed Know-How, collectively.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.29.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensed Territory</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the entire world, excluding Greater China, India, Turkey, and Russia.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.30.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensee</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Erigen LLC.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.31.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensor</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Novatim Immune Therapeutics (Zhejiang) Co., Ltd.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.32.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensor Territory</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Greater China.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.33.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">MAA</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any new drug application or other marketing authorization application, in each case, filed with the applicable Regulatory Authority in a country or other regulatory jurisdiction, which application is required to commercially market or sell a pharmaceutical product (including a biopharmaceutical product) in such country or jurisdiction (and any amendments thereto), including all New Drug Applications (NDA) or equivalent submitted to the FDA in the United States in accordance with the PHSA, BLA submitted to the FDA in the United States in accordance with the United States Food Drug and Cosmetics Act, or any analogous application or submission with any Regulatory Authority outside of the United States.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.34.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Sales</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means gross amounts invoiced or otherwise received for Licensee&#x2019;s, its Affiliates&#x2019;, or Sublicensees&#x2019; sales of Licensed Products, less the sum of the following: [***].</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The sale of a Licensed Product by a selling party to another selling party for resale by such selling party to a third party shall not be deemed a sale for the purposes of this definition of &#x201c;Net Sales,&#x201d; </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that the final resale in any such chain is included in the computation of &#x201c;Net Sales&#x201d; by the last selling party that resells such Licensed Product. Failure by the last selling party to report final resale for Licensor to</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">calculate the royalties, within [***] shall entitle Licensor to [***]. [***].The gross amounts invoiced and all permitted deductions shall be determined in accordance with the selling party&#x2019;s usual and customary accounting methods, which are in accordance with U.S. generally accepted accounting principles (GAAP) or international financial reporting standards, in either case, consistently applied, provided that Licensor shall have the right to audit and verify such records upon reasonable prior notice in accordance with </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.4</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On a country-by-country basis, if a Licensed Product is sold in a country as part of a Combination Product, Net Sales of such Licensed Product for the purpose of determining royalties due hereunder shall be calculated as follows:</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that both (x) the Licensed Product is sold separately in finished form in such country during a Calendar Quarter and (y) the Other Product(s) in such Combination Product are sold separately in finished form in such country during such Calendar Quarter, then Net Sales of such Licensed Product shall be determined by [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the Licensed Product in such Combination Product is sold separately in finished form in such country during a Calendar Quarter, but the Other Product(s) in such Combination Product are not sold separately in finished form in such country during such Calendar Quarter, then Net Sales of such Licensed Product shall be calculated by [***]. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the Licensed Product in such Combination Product is not sold separately in finished form in such country during a Calendar Quarter, but the Other Product(s) in such Combination Product are sold separately in finished form in such country during such Calendar Quarter, Net Sales of such Licensed Product shall be calculated by [***]. </font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that neither the Licensed Product in such Combination Product is sold separately in finished form in such country during a Calendar Quarter, nor the Other Product(s) in such Combination Product are sold separately in finished form in such country during such Calendar Quarter, then the fair market value of the Licensed Product and such Other Product(s) shall be [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.35.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Product</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.6</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.36.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Preamble.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.37.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all patents and patent applications and all substitutions, divisions, continuations, continuations-in-part, any patent issued with respect to any such patent applications, any reissue, reexamination, utility models or designs, renewal or extension (including any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all counterparts and equivalents of any of the foregoing in any country or jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.38.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 Clinical Trial</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a clinical trial of a pharmaceutical product (including a biopharmaceutical product) with the primary endpoint of determining initial tolerance, safety, metabolism, pharmacokinetic, or pharmacodynamic information in single dose, single ascending dose, multiple dose, or multiple ascending dose regimens, that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167; 312.21(a) and its successor regulation or equivalents in other jurisdictions.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.39.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 Clinical Trial</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2b Clinical Trial</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a clinical trial of a pharmaceutical product (including a biopharmaceutical product) the principal purpose of which is to evaluate the effectiveness of such product in a human population and that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167; 312.21(b) and its successor regulation or equivalents in other jurisdictions.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.40.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 Clinical Trial</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a clinical trial (or any arm thereof) of a pharmaceutical product (including a biopharmaceutical product) on a sufficient number of patients, which trial the FDA or equivalent Regulatory Authority in other jurisdictions permits to be conducted under an open IND and is designed to: (a) establish that such pharmaceutical product is safe and efficacious for its intended use; (b) define warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed; and (c) support the filing of an MAA with a Regulatory Authority for such pharmaceutical product, and that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167; 312.21(c) and its successor regulation or equivalents in other jurisdictions.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.41.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Approval</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all technical, medical and scientific licenses, registrations, authorizations and approvals (including approvals of new drug applications, supplements and amendments, pre- and post- approvals, pricing and third-party reimbursement approvals, and labeling approvals) of any Regulatory Authority that are necessary for the use, development, manufacture, and commercialization of a pharmaceutical product in a regulatory jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.42.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Authority</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a given country, any national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental authority involved in the granting of a Regulatory Approval.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.43.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty Term</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, on a Licensed Product-by-Licensed Product and country-by-country basis, the period commencing on the First Commercial Sale of a Licensed Product in a country of the Licensed Territory, and ending on the date that the cumulative Royalty on Net Sales payable hereunder equals Eight Hundred Million USD ($800,000,000). Notwithstanding the foregoing, if at any time after the First Commercial Sale in a particular country, sales of the Licensed Product in such country are permanently prohibited due to the Licensed Product&#x2019;s infringement of a third party&#x2019;s patent, then the Royalty Term with respect to such Licensed Product in that country shall terminate immediately and no further Royalty on Net Sales shall be payable with respect to Net Sales in such country from the date of such prohibition or restriction. However, Licensor shall be entitled to all Royalties on Net Sales accrued prior to that date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.44.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sublicensee</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a third party granted a sublicense to any of the rights granted to Licensee under </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.1</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.45.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.1</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.46.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Valid Claim</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) a claim of a granted and unexpired Licensed Patent that (i) has not been rejected, revoked, or held to be invalid or unenforceable by a court or other authority of competent jurisdiction, from which decision no appeal is or can be taken or (ii) has not been finally abandoned, disclaimed or admitted to be invalid or unenforceable through reissue or disclaimer; or (b) a claim included in a pending patent application which is a Licensed Patent that (i) has not been pending for more than [***]  (provided, however that for purposes of clarity, in the event such pending claim is subsequently granted, then such claim shall again be a Valid Claim as of the date of grant of such claim) or (ii) has not been finally determined to be unallowable by the applicable governmental authority (from which no appeal is or can be taken).</font></div></div><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2<br></font><font style="color:#231f20;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses</font></h1><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Grant</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to the terms and conditions of this Agreement, Licensor, on behalf of itself and any successors and/or assigns, hereby grants to Licensee an exclusive (even as to Licensor and its Affiliates), royalty-bearing (subject to </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), non-transferrable (except in accordance with </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) license, with the right to grant sublicenses pursuant to </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, under the Licensed Technology to Exploit Licensed Products in the Field and in the Licensed Territory.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sublicensing</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee may sublicense the rights granted to it under </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.1</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through multiple tiers [***]. Each such sublicense shall be in writing and contain terms not inconsistent with the terms and conditions of this Agreement applicable to the licenses granted to Licensee hereunder. In each case, Licensee will be responsible for the performance of its Sublicensees relevant to this Agreement, including, without limitation, making full amount of any payments due hereunder in a timely manner in accordance with the terms and conditions provided for hereunder. For the avoidance of doubt, contract research organizations, contract manufacturing organizations, distribution partners and similar third parties to which Licensee or Sublicensees delegate development, manufacturing or commercialization activities relating to Licensed Products may perform such development, manufacturing or commercialization activities on behalf of Licensee or such Sublicensees without a sublicense of the rights granted to Licensee hereunder. Licensor shall have the right to [***] and following which [***] Licensee shall [***]. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Additional Rights</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.3.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Grant of Other Technology or Patent Rights</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party understands and acknowledges that the other Party owns its own Intellectual Property and all rights therein. Except as otherwise expressly provided in this Agreement, under no circumstances shall a Party hereto, as a result of this Agreement, obtain any ownership interest or license, or be deemed to obtain any ownership interest or license, in or to any Intellectual Property of the other Party, including, but not limited to, items Controlled or developed by the other Party, at any time pursuant to this Agreement. This Agreement does not create, and shall under no circumstances be construed or interpreted as creating, an obligation on the part of either Party to grant any license to the other Party other than as expressly set forth herein. Any further contract or license agreement between the Parties shall be in writing. No licenses are implied by Licensor to Licensee, except as specifically stated in this Agreement. Except as explicitly set forth in this Agreement, Licensor shall not be deemed by estoppel or implication to have granted Licensee any license or other right to any Intellectual Property of Licensor or its Affiliates.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Right of First Negotiation</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensor is willing to explore potential collaboration with Licensee to Exploit Allogeneic Products and </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAR-T Licensed Products in the Field and in the Licensor Territory, particularly in connection with [***]. In furtherance of the foregoing, Licensor, on behalf of itself and any successors and/or assigns, hereby grants to Licensee a right of first negotiation to negotiate with Licensor for a license to Exploit such Allogeneic Products and </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAR-T Licensed Products in the Field and in the Licensor Territory (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ROFN</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). If Licensor intends to license the right to Exploit Allogeneic Products and/or </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAR-T Licensed Products in the Field and in the Licensor Territory to a third party, Licensor will first provide Licensee with prompt written notice of such intent and information necessary or useful to evaluate such an opportunity (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ROFN Notice</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Licensee will have [***] after receiving the ROFN Notice to review such information and provide Licensor written notice that it wishes to exercise the ROFN. If Licensee timely exercises the ROFN, then Licensor and Licensee will negotiate in good faith, for a period [***], commercially reasonable terms and conditions of a license to Exploit such Allogeneic Products and </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAR-T Licensed Products in the Field and in the Licensor Territory.</font></p><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3<br></font><font style="color:#231f20;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</font></h1><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Joint Steering Committee</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Within [***], the Parties shall establish a joint steering committee (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Joint Steering Committee</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">JSC</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) for the purposes of (a) overseeing and effectuating the Technology Transfer to Licensee; (b) discussing and coordinating potential collaboration opportunities between the Parties, including the provision of potential support by Licensor to Licensee for the clinical and commercial development of the Licensed Products, including, without limitation, [***]; and (c) serving as a forum for information sharing and to facilitate communications between the Parties with respect to </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">research, development and other Exploitation of Licensed Products. The JSC shall be composed of [***] representatives from each Party. Each representative shall have the requisite technical experience and seniority to enable such person to make decisions on behalf of the applicable Party with respect to the issues falling within the decision-making authority of the JSC. From time to time, each Party may substitute [***] representatives to the JSC on written notice to the other Party.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Responsibilities of the JSC</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The JSC shall perform the following functions: (a) review and serve as a forum for discussing and coordinating activities related to the development of Licensed Products; (b) review and discuss regulatory filings, applications and submissions related to Licensed Products to any Regulatory Authority, including any material regulatory correspondence; and (c) perform such other functions as are set forth herein or as the Parties may mutually agree in writing, except where in conflict with any provision of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JSC Meetings and Minutes</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The JSC shall meet at least [***], or at such frequency as otherwise agreed to by the Parties, either in person or by teleconference or videoconference, with the venue of the in-person meetings alternating between locations designated by Licensor and locations designated by Licensee. Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to such proposed items [***].Licensee shall prepare and circulate to Licensor draft minutes of each meeting within [***] for the Parties&#x2019; review and approval. The Parties shall agree on the minutes of each JSC meeting promptly, but in no event later than [***]. Each Party will [***]. Each Party may, with the consent of the other Party, which consent shall not be unreasonably withheld, invite a reasonable number of non-voting employees, consultants or scientific advisors to attend the meetings of the JSC, provided such invitees are bound by appropriate confidentiality obligations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JSC Decision-Making</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All JSC decisions shall be made by [***]. The presence of [***] constitutes a quorum for the conduct of business at any JSC meeting, and no vote of the JSC may be taken without a quorum present. If, after reasonable discussion and good faith consideration of each Party&#x2019;s view on a particular matter, the JSC representatives of the Parties cannot reach an agreement as to such matter within [***], then either Party may, by written notice to the other Party, have such issue referred to the executive officers for resolution. The Parties&#x2019; respective Executive Officers shall discuss within [***] after such matter is referred to them, and shall negotiate in good faith to resolve the matter. If the Executive Officers are unable to resolve the matter within [***], [***] on research, manufacturing, development (including conduct of clinical studies and regulatory activities), commercialization and Exploitation of Licensed Products in the Licensed Territory. Without limiting the foregoing, neither Party shall exercise its final decision-making authority to (A) determine any matter or make any decision that is outside of the authority expressly granted to the JSC under this Agreement; or (B) amend the terms and conditions of this Agreement. The Parties intend and agree that all matters within the scope of the JSC&#x2019;s decision-making authority shall be resolved in accordance with this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and no matter within the scope of the JSC&#x2019;s authority shall be subject to the dispute resolution mechanisms set forth in </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4<br></font><font style="color:#231f20;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Due Diligence</font></h1><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Approval</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensee will be solely responsible, at Licensee&#x2019;s expense, for securing any federal, state, or local Regulatory Approval from Regulatory Authorities necessary for commercial sale of Licensed Products in the Field in the Licensed Territory.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensor Responsibilities</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensor shall [***] and Licensor will [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensor shall [***] on [***].</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensor shall, [***]. It shall [***]</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***], Licensor agrees to effectuate the transfer to Licensee of all Licensed Know-How, including all tangible embodiments or manifestations thereof, and provide such technical assistance and support as reasonably requested by Licensee, [***], to enable Licensee to completely and independently practice the Licensed Technology within the Field (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Technology Transfer</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensee Responsibilities</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee shall be solely responsible, at its expense, for the commercialization of Licensed Products in the Licensed Territory and Licensee will use Commercially Reasonable Efforts to make commercially available at least one Licensed Product in the Licensed Territory during the Term.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee shall provide periodic updates on Licensee&#x2019;s Licensed Product development and commercialization activities in the Licensed Territory to Licensor through the JSC.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee shall achieve the following milestones specifically for [***]: (a) within [***], Licensee [***]; (b) within [***], Licensee shall [***]; and (c) within [***], Licensee shall [***]. It shall be deemed a material breach of this Agreement and Licensor may elect to terminate this Agreement, but solely with respect to [***], in the event that Licensee&#x2019;s achievement of the foregoing milestones is delayed by [***], unless the delay is caused by Licensor&#x2019;s material breach of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee shall achieve the following milestones specifically for [***]: (a) within [***], Licensee shall [***] for [***]; and (b) within [***], Licensee shall [***]. It shall be deemed a material breach of this Agreement and Licensor may elect to terminate this Agreement, but solely with respect to [***], in the event that Licensee&#x2019;s achievement of the foregoing milestones is delayed by [***], unless the delay is caused by Licensor&#x2019;s material breach of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Data Sharing</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Parties agree that all data generated during a Phase 1 Clinical Trial, a Phase 2 Clinical Trial and/or a Phase 3 Clinical Trial of the Licensed Products, including raw clinical data, lab data, and reports (collectively, &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Data</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall, subject to the obligations of confidentiality set forth herein, be shared upon reasonable written request by the other Party, as follows: (i) the Licensor shall, upon reasonable written request by the Licensee, provide the Licensee with Clinical Data from clinical trials conducted in Greater China or by its affiliates or collaborators outside the Licensed Territory, provided that such Clinical Data is reasonably available and accessible to Licensor, and subject to any third-party confidentiality or cooperation limitations; and (ii) the Licensee shall, upon reasonable written request by the Licensor, provide the Licensor with Clinical Data Controlled by Licensee and resulting from clinical trials conducted or sponsored by Licensee or its Affiliates or collaborators in the Licensed Territory . In each case, the shared Clinical Data shall include, where available, raw datasets (anonymized patient-level data), statistical analysis reports, clinical study protocols, and adverse event reports. Such shared Clinical Data may only be used by Licensor in the Licensor Territory, and by Licensee in the Licensed Territory for the following purposes: (a) regulatory submissions to Regulatory Authorities (e.g., NMPA, FDA, EMA); (b) Licensed Product safety monitoring and pharmacovigilance activities; (c) Licensed Product efficacy assessment and related internal analysis; or (d) joint publications, subject to the mutual written agreement of the Parties.</font></div></div><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5<br></font><font style="color:#231f20;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consideration; Records &amp; Reports</font></h1><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Continuing Payments</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1.1</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payments</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] development or commercial milestones set forth in </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.1</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> [***], Licensee</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall pay to Licensor the corresponding [***] payment set forth in </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.1</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (each, a &#x201c;[***] </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), such [***] Payment to be made within [***]. For the avoidance of doubt, in the event that the achievement of [***], then Licensee shall [***]. No [***] Payment [***].</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1.2</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties on Net Sales</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the applicable Royalty Term, on a [***] basis, Licensee shall pay to Licensor a royalty equal to the percentage of Net Sales set forth in </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 02</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty on</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Sales</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), until such time as Licensee has paid a total Royalty on Net Sales of Eight Hundred Million Dollars ($800,000,000), following which no further Royalty on Net Sales shall be payable hereunder and Licensee shall have a fully paid, royalty-free, [***] license under the Licensed Technology to Exploit Licensed Products in the Field and in the Licensed Territory. Payments under this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be due within [***] of the end of [***].</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1.3</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Offset for Third Party [***].</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On a Licensed Product-by-Licensed Product and country-by-country basis, in the event that Licensee is required to pay royalties to a third party for licenses to intellectual property rights entered into by Licensee to avoid infringement of such rights by the Exploitation of a Licensed Product in a country, then Licensee may deduct the amount of any such third party [***]  from any Royalty on Net Sales due to Licensor under </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in such country, provided that notwithstanding anything set forth in this Agreement to the contrary, in no event shall the Royalty on Net Sales under </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> otherwise due to Licensor for such Licensed Product in such country be less than [***] of the percentage set forth in </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1.4</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Multiple Royalties. </font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, no multiple Royalties on Net Sales will be required to be paid because a Licensed Product or its manufacture, use, sale or importation is covered by more than one (1) Valid Claim.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Late Payments</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any payments by Licensee that are not paid on or before the due date under this Agreement shall bear interest, to the extent permitted by law, at [***]. If any such late payment is not remedied within [***], such failure shall be deemed a material breach of this Agreement. In such case, Licensor shall have the right to pursue available remedies, including the right to terminate this Agreement. This </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not limit any other remedies available to either Party under this Agreement or at law or in equity.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Records and Reports</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Within [***] commencing with the [***] in which the First Commercial Sale of any Licensed Product is made anywhere in the Licensed Territory, Licensee shall provide Licensor with a report containing the following information for the applicable [***], on a Licensed Product basis: (a) the amount of Net Sales in the Territory; (b) calculation of Net Sales in the Licensed Territory showing deductions provided for in the definition of &#x201c;Net Sales&#x201d;; (c) a calculation of the royalty payment due on such Net Sales; and (iv) the exchange rate for such country. For the purpose of converting any local currency into U.S. dollars to determine any amounts payable under this Agreement, the rate of exchange to be applied shall be [***]. Concurrent with the delivery of the applicable quarterly report, Licensee shall pay in U.S. dollars all amounts due to Licensor pursuant to this Agreement with respect to Net Sales by Licensee and its Affiliates and Sublicensees for such [***]. All payments due to Licensor hereunder shall be made in U.S. dollars by wire transfer of immediately available funds into an account designated by Licensor.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Audit and Inspection Rights</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee and its Affiliates and Sublicensees will maintain records in sufficient detail to permit Licensor to confirm the accuracy of the calculation of royalty payments made by Licensee under this Agreement. Upon reasonable prior notice, the records of Licensee and its </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliates shall be available during regular business hours (without undue disruption of Licensee&#x2019;s or its Affiliate&#x2019;s business) for a period of [***] from the end of the calendar year to which they pertain for examination by a nationally recognized independent accountant selected by Licensor and reasonably acceptable to Licensee or its Affiliate, for the sole purpose of verifying the accuracy of the reports and payments furnished by Licensee pursuant to this Agreement. Any such auditor shall not disclose Licensee&#x2019;s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the reports furnished by Licensee or the amount of payments due by Licensee to Licensor under this Agreement. Licensor shall provide Licensee with a copy of the accountant&#x2019;s report. Licensor shall have the right, [***] per [***], to request that Licensee exercise its audit rights with respect to any Sublicensee. If Licensee has already exercised its audit rights with respect to the subject Sublicensee for the relevant calendar year, then Licensor shall have the right to request that Licensee share the results of such audit with Licensor. Licensor shall bear the full cost of any such audit.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.5.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding or similar obligations in respect of payments made by a Party to the other Party under this Agreement. To the extent either Party is required to deduct and withhold taxes on any payment to the other Party, such Party shall pay the amounts of such taxes to the proper governmental authority in a timely manner and promptly transmit to the other Party an official tax certificate or other evidence of such withholding sufficient to enable the other Party to claim such payment of taxes. Each Party shall use reasonable efforts to provide the other Party with any tax forms that may be reasonably necessary in order for the other Party to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax.</font></div></div><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6<br></font><font style="color:#231f20;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Representations, Warranties and Covenants</font></h1><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Representations and Warranties of Licensor</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensor hereby represents and warrants to Licensee that, as of the Effective Date:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensor is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization, with full power and authority to operate its properties and to carry on its business as presently conducted.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensor is the sole and exclusive owner of the Licensed Technology.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The execution of this Agreement and performance of Licensor&#x2019;s obligations under this Agreement do not conflict with, cause a default under, or violate any existing contractual obligation that may be owed by Licensor or any Affiliate of Licensor to any third party.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no action, suit, proceeding or investigation pending or, to Licensor&#x2019;s and its Affiliates&#x2019; knowledge, currently threatened orally or in writing against or affecting Licensor or any Affiliate thereof that questions the validity of this Agreement or the right of Licensor to enter into this Agreement or consummate the transactions contemplated hereby and, to Licensor&#x2019;s and its Affiliates&#x2019; knowledge, there is no basis for the foregoing.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.5.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any governmental authority, or any third party, on the part of Licensor or any Affiliate thereof is required in connection with its execution, delivery and performance of </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.6.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensor has the right to grant the licenses and rights that it purports to grant under this Agreement and has not granted to any third party any license or other right that conflicts with the licenses and rights granted under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.7.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the best of Licensor&#x2019;s and its Affiliates&#x2019; knowledge, the issued and unexpired claims included in the Licensed Patents existing as of the Effective Date are valid and enforceable.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.8.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No reexamination, interference, invalidity, opposition, nullity or similar claim or proceeding is pending or, to the best of Licensor&#x2019;s and its Affiliates&#x2019; knowledge, threatened with respect to any Licensed Patent as of the Effective Date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.9.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the Licensed Patents set forth on </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, neither Licensor nor any of its Affiliates owns or controls any Patents necessary or useful for or that would be infringed by, the manufacture, use, sale, offering for sale or import of Licensed Products in the Licensed Territory.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.10.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of Licensor or any of its Affiliates has received written notice from any third party claiming that the manufacture, use, sale, offer for sale or import of any Licensed Product infringes, misappropriates or violates, or would infringe, misappropriate or violate the patent or other intellectual property rights of any third party as of the Effective Date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.11.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no claims, judgments, liens, encumbrances, or settlements against Licensor or any of its Affiliates with respect to the Licensed Technology, and none of Licensor or any of its Affiliates is a party to any legal action, suit or proceeding relating to the Licensed Technology as of the Effective Date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.12.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of Licensor or its Affiliates has received any communication from any third party, including any Regulatory Authority or other governmental authority, threatening any action, suit or proceeding which would be reasonably expected to adversely affect or restrict the ability of Licensor to consummate the transactions or perform its obligations contemplated under this Agreement as of the Effective Date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.13.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of Licensor or its Affiliates has employed, or otherwise used in any capacity, the services of any individual or entity debarred or disqualified under Applicable Laws.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.14.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of Licensor&#x2019;s or its Affiliates&#x2019; research or development of the Licensed Technology, manufacture of Licensed Products, or research leading to the inventions Covered by a Valid Claim of the Licensed Patents was supported in whole or part by funding or grants by any governmental agency or philanthropic or charitable organization.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Representations and Warranties of Licensee</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensee hereby represents and warrants to Licensor that, as of the Effective Date:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization, with full power and authority to operate its properties and to carry on its business as presently conducted.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The execution and performance of Licensee&#x2019;s obligations under this Agreement do not conflict with, cause a default under, or violate any existing contractual obligation that may be owed by Licensee to any third party.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of Licensee or its Affiliates have employed, or otherwise used in any capacity, the services of any individual or entity debarred or disqualified under Applicable Laws.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any governmental authority, or any third party, on the part of Licensee or any Affiliate thereof is required in connection with its execution and delivery of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclaimer</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as expressly provided in </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, nothing in this Agreement will be construed as:</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.3.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a warranty or representation by Licensor as to the validity or scope of any of the Licensed Technology;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.3.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a warranty or representation by Licensor that anything made, used, sold or otherwise disposed of under the licenses granted in this Agreement, or the practice of the Licensed Technology, will or will not infringe patents of third parties; or</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.3.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an obligation of Licensor to bring or prosecute actions or suits against third parties for infringement of Licensed Patents or misappropriation of Licensed Know-How.</font></div></div><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7<br></font><font style="color:#231f20;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term and Termination</font></h1><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The term of this Agreement will commence on the Effective Date, and will continue until the date that this Agreement is terminated in its entirety under the provisions of this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or by the mutual written agreement of the Parties (the period from the Effective Date until such termination, the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination by Either Party</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Either Party may terminate this Agreement at any time upon written notice to the other Party if the other Party is in material default or breach of this Agreement and such material default or breach is not cured within [***] after written notice thereof is delivered to the defaulting or breaching Party, or in the case of a breach (other than a breach of a Party&#x2019;s payment obligation) that cannot be cured within [***], within a reasonable period not exceeding [***] after written notice thereof is delivered to the defaulting or breaching Party, so long as the breaching Party is making a good faith effort to cure such default or breach of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination by Licensor</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensor may, at its option, terminate this Agreement effective upon [***] written notice to Licensee if Licensee (i) files for protection under bankruptcy laws; (ii) makes an assignment for the benefit of creditors; (iii) appoints or suffers appointment of a receiver or trustee over its property; (iv) files a petition under any bankruptcy or insolvency act or has any such petition filed against it, which is not discharged within [***] of the filing thereof; or (v) is unable to pay its debts as they become due in the ordinary course of business. Nothing in this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall prohibit Licensor from pursuing any other remedies at law which it may have in connection with Licensee&#x2019;s uncured material breach.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination by Licensee</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensee may, at its option, terminate this Agreement, effective upon [***] written notice to Licensor if Licensor (i) files for protection under bankruptcy laws; (ii) makes an assignment for the benefit of creditors; (iii) appoints or suffers appointment of a receiver or trustee over its property; (iv) files a petition under any bankruptcy or insolvency act or has any such petition filed against it, which is not discharged within [***] of the filing thereof; or (v) is unable to pay its debts as they become due in the ordinary course of business. Nothing in the foregoing subsections of this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall prohibit Licensee from pursuing any other remedies at law which it may have in connection with Licensor&#x2019;s uncured material breach.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.5.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effects of Termination</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.5.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination of License</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon a termination (but not upon an expiration) of this Agreement for any reason, Licensee&#x2019;s rights to the Licensed Technology which have been granted hereunder will terminate, and all rights in the Licensed Technology will revert back to Licensor, and (a) each Party, in its capacity as a receiving Party of the other Party&#x2019;s Confidential Information, shall promptly return to such other Party or, if requested by such other Party, destroy all Confidential Information, including information and materials related to the Licensed Products, supplied by such other Party, and certify to the destruction in writing within [***] of the termination, and (b) Licensee hereby grants to Licensor an option, exercisable by Licensor upon written notice to Licensee delivered within [***] of such termination, to negotiate in good faith the right and license (with the right to grant sublicense) to use, in and outside of the Licensed Territory, [***]. In addition, any amounts properly owed to Licensor hereunder that Licensee has paid will not be refunded. Subject at all times to Licensee&#x2019;s continuing compliance with the terms of this Agreement, for a period of [***] following the termination of this Agreement (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sell-Off Period</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), Licensee shall have the right to sell off its inventory of finished Licensed Product then in Licensee&#x2019;s, its Affiliates&#x2019; or Sublicensees&#x2019; possession. Following the Sell-Off Period, upon Licensor&#x2019;s request, Licensee shall promptly destroy all unsold Licensed Products.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.5.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effect on Sublicenses</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that this Agreement is terminated for any reason by Licensor in accordance with </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 7.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.3</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> [***], provided that the Licensor is provided a copy of such sublicense agreement and all amendments thereto within a reasonable amount of time following such termination and the Sublicensee agrees in a writing delivered to Licensor within [***] of such termination that (i) Licensor is entitled to enforce all relevant provisions of this Agreement directly against such Sublicensee, and (ii) Licensor shall not assume any obligations to such Sublicensee in excess of those obligations corresponding to, and consistent with, those of Licensor set forth in this Agreement with respect to the applicable rights of such Sublicensee to Licensed Technology. Subject to this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.5.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an expiration of this Agreement shall have no effect on sublicenses.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.5.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Obligations</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expiration or termination of this Agreement will not release either Party from any obligation that matured prior to the effective date of such expiration or termination. Upon expiration or termination of this Agreement for any reason, any unpaid amounts payable to Licensor shall become immediately due, and payment thereof shall remain an ongoing obligation of Licensee until such amount is paid in full.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.5.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Survival</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon expiration or termination of this Agreement, </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 2.3</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.3</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.5</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.5</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through and including </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will, with related definitions, survive and remain in full force and effect.</font></p><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8<br></font><font style="color:#231f20;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Protection of Intellectual Property Rights</font></h1><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Prosecution</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the Term, Licensee will be responsible for preparing, filing, prosecuting and maintaining all patent applications and patents included in the Licensed Patents in the Licensed Territory. For the sake of clarity, as used herein the term &#x201c;prosecution&#x201d; shall include interference, opposition, derivation, re-examination, ex partes review, inter partes review, or any other administrative proceedings in connection with the Licensed Patents. Licensee shall (a) select patent counsel to conduct such activities regarding the Licensed Patents and (b) provide Licensor with a reasonable opportunity to comment thereon and will reasonably consider in good faith such comments. Should Licensee decide that it is not interested in maintaining a particular Licensed Patent in the Licensed Territory, it will promptly advise Licensor in writing, and Licensor will have the right, but not the obligation, to assume such maintenance responsibilities in the Licensed Territory [***].  If Licensor desires to assume such </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance responsibilities of any such Licensed Patent in the Licensed Territory pursuant to the immediately preceding sentence, then Licensee will not so fail to maintain such Licensed Patents if Licensor advises Licensee, within [***] of Licensor&#x2019;s receipt of notice of Licensee&#x2019;s intention not to maintain the applicable Licensed Patents in the Licensed Territory, that Licensor desires to assume maintenance of the applicable Licensed Patents. [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enforcement of Licensed Patents</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notice</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will promptly report in writing to the other Party of any Competitive Infringement of which such Party (or any of its Affiliates or Sublicensees) becomes aware.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Competitive Infringement of Licensed Patents by Third Parties</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.2.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the case of any Competitive Infringement in the Licensed Territory by any third party, Licensee will have the first right, but not the obligation, to cause such third party to cease infringement and to otherwise enforce such Licensed Patent, or to defend the Licensed Patent in any declaratory judgment action brought by third party(ies) which alleges the invalidity, unenforceability or non-infringement of the Licensed Patent in the Licensed Territory.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.2.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If Licensee does not, within a reasonable period after becoming aware of Competitive Infringement of the Licensed Patents in the Licensed Territory, but in any event no less than [***], (i) initiate legal proceedings against such threatened or actual Competitive Infringement, or defend legal proceedings brought by a third party, as provided in </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2.2.1</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, or (ii) take other reasonable steps to cause such Competitive Infringement to terminate (for example, by initiating licensing discussions), Licensor may deliver written notice to Licensee that it intends to take action to cause such Competitive Infringement to terminate, and Licensor may take such action as it deems reasonably necessary to enforce its rights in the Licensed Patents in the Licensed Territory, including, without limitation, to bring, [***], an infringement action or file any other appropriate action or claim related to such Competitive Infringement against such third party.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.2.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For any action or proceeding brought by a Party under this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Initiating Party</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), regardless of which Party brings such action or proceeding, the other Party (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Initiating Party</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall cooperate reasonably in any such effort, [***], and the Parties shall reasonably cooperate to address new facts or circumstances that come to light during the course of any such action or proceeding that may affect the need for one Party or the other to participate in such action. The Non-Initiating Party agrees to be joined as a party plaintiff, [***], in any such action if needed for the Initiating Party to bring or continue an infringement action hereunder. The Non-Initiating Party shall, [***] with its own counsel, have the right to observe and provide comments with respect to any action brought by the Initiating Party under this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (which comments the Initiating Party shall consider in good faith but be under no obligation to incorporate). Neither Party may settle an action or proceeding brought under this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a manner that, or knowingly take any other action in the course thereof that, (i) imposes any monetary restriction or obligation on or admits fault of the other Party or (ii) adversely affects the value, scope or validity of, or otherwise adversely affects the other Party&#x2019;s rights under this Agreement to as applicable, any Patents within the Licensed Patents, without the written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.2.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any recovery realized as a result of any litigation under this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (including, for greater certainty, [***], as applicable, will [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvement Patents</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensor will promptly disclose to Licensee during the Term any material Improvements and related Improvement Patents that are reasonably necessary or useful for the development, manufacture of commercialization of the Licensed Products(s) in the Field and in the Licensed Territory, and Licensee and the Licensor agree to promptly to update </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon written </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">request by either Party from time to time, to reflect the inclusion of any Improvement Patents.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Infringement of Third-Party Rights</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will promptly notify the other Party in writing of any notice or claim of any allegation of infringement or commencement against it of any suit or action for infringement of a third-party patent based upon or arising from actions taken under the licenses granted in this Agreement (&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third-Party Infringement Claim</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). If such Third-Party Infringement Claim is alleged or commenced against Licensee, Licensee will have the sole right to defend and settle such Third-Party Infringement Claim, and Licensee will not be obligated to enter into negotiations with such third party to obtain rights for either Licensee or Licensor under the third-party patent. If such Third-Party Infringement Claim is alleged or commenced against Licensor, Licensee will have the first right, but not the obligation, to defend and settle such Third-Party Infringement Claim, </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that Licensee will not be obligated to enter into negotiations with such third party to obtain rights for Licensor under the third-party patent. With respect to any such defense by Licensee of a Third-Party Infringement Claim alleged or commenced against Licensor, Licensee will not make any settlements of such Third-Party Infringement Claim that would materially adversely affect Licensor&#x2019;s rights or interests in the Licensed Technology without first obtaining Licensor&#x2019;s prior written consent. If Licensee opts not to defend or settle such Third-Party Infringement Claim alleged or commenced against Licensor, Licensee will notify Licensor of such decision and, [***], Licensor will have the right to undertake the defense or settlement of such Third-Party Infringement Claim. In all cases, the Parties shall cooperate in good faith and provide reasonable assistance in connection with the defense of any such Third-Party Infringement Claim.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party will maintain the Confidential Information of the other Party in strict confidence, and will not disclose, divulge or otherwise communicate such Confidential Information to others, or use it for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement, or with the express written consent of the Party who provided such Confidential Information. Each Party will maintain the confidentiality of the other Party&#x2019;s confidential information using methods and practices that are substantially similar to those that the receiving Party uses to maintain the<br></font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">confidentiality of its own confidential information, but in no event less than a reasonable degree of care. Except as may be authorized in advance in writing by the disclosing Party, the receiving Party will disclose or grant access to the Confidential Information to only those of its employees and agents as reasonably necessary or useful to exercise its rights or perform its obligations under this Agreement and such employees and agents will have entered into non-disclosure agreements, or be bound by professional obligations of confidentiality, no less protective of the disclosing party&#x2019;s Confidential Information than those set forth in this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.5</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the receiving Party shall be liable to the disclosing Party for any breach of such employees and agents</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">' </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">confidentiality obligations.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, a receiving Party may disclose Confidential Information of the disclosing Party to:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its Affiliates, and to its and their directors, employees, consultants, contractors, attorneys, advisors and agents, in each case who have a specific need to know such Confidential Information in connection with an activity under or relating to this Agreement and who are bound in writing by obligations of confidentiality and restrictions on use at least as stringent as those herein, and the receiving Party shall be liable to the disclosing Party for any breach of such employees and agents</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">' </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">confidentiality obligations;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any bona fide actual or prospective collaborators who are under written obligations of confidentiality and non-use at least as stringent as those herein, to the extent reasonably necessary to enable such actual or prospective collaborators to (i) determine their interest in collaborating with the receiving Party on the development and/or commercialization of Licensed Products and (ii) engage in such a collaboration, and the receiving Party shall be liable to the disclosing Party for any breach of such employees and agents</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">' </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">confidentiality obligations;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">governmental authorities in connection with filing, prosecuting, or maintaining patent rights as permitted by this Agreement;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Authorities in connection with regulatory filings for Products that the receiving Party has a license or right to develop hereunder in a given country or jurisdiction;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.5.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent required to do so by Applicable Law or a proper legal, governmental or other competent authority, or by the rules of any securities exchange on which any security issued by either Party is traded, or included in any filing or action taken by the receiving Party to obtain or maintain government clearance or approval to market a subject Licensed Product; </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that, (i) to the extent permissible and practicable, the receiving Party required to make such disclosure shall give the disclosing Party reasonable advance notice of such disclosure requirement and shall afford the disclosing Party a reasonable opportunity to oppose, limit or secure confidential treatment for such required disclosure, or, where it is impracticable or illegal to give an advance notice, the Party required to make such disclosure shall give the disclosing Party reasonable notice promptly after such required disclosure; (ii) the Party required to make such disclosure shall disclose only that portion of the Confidential Information legally required to be disclosed; (iii) the Party required to make such disclosure shall use reasonable efforts to secure confidential treatment of such Confidential Information; and</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.6.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to any [***]; </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided,</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in any such case said Party shall first obtain a written obligation of confidentiality no less stringent than that imposed in this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.5</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any information disclosed pursuant to </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.5.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.5.2.3</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.6.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Names</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither Party may identify the other Party in any promotional advertising or other promotional materials to be disseminated to the public or any portion thereof, or use the name of any staff member or employee of the other Party or any trademark, service mark, trade name, symbol or logo that is associated with the other Party, without the other Party&#x2019;s prior written consent. Notwithstanding the foregoing, and for the avoidance of doubt, without the consent of the other Party either Party may comply with disclosure requirements of all Applicable Laws relating to its business, including, without limitation, United States and state securities laws. During the Term, and with the prior written consent of the other Party, each Party may include the other Party&#x2019;s name, logo, and a brief description of such other Party on said Party&#x2019;s website and such other Party hereby consents to such inclusion of its name, logo, and a brief description on said Party&#x2019;s website; </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that either Party shall have the right to revoke such consent at any time and for any reason, and promptly following written notice of such revocation, and in any event within [***], the posting Party shall remove the other Party&#x2019;s name, logo, and description from the posting Party&#x2019;s website.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.7.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Press Releases</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties shall mutually agree upon the timing and content of any press releases or other public announcement relating to this Agreement and the transactions and/or activities contemplated herein.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.8.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliates and Sublicensees</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For the avoidance of doubt, and notwithstanding anything to the contrary in this Agreement, each Party&#x2019;s Affiliates and Licensee&#x2019;s Sublicensees may exercise such Party&#x2019;s rights under this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9<br></font><font style="color:#231f20;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification; Insurance</font></h1><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification by Licensee</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensee will indemnify, defend and hold harmless Licensor, its Affiliates and their respective directors, officers, employees, consultants, licensors and agents, and their respective successors, heirs, and assigns (each a &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensor Indemnitee</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), against all suits, actions, claims, proceedings, in each case brought by a third party (each, a &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claim</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the resulting liabilities, demands, damages, losses, or expenses (including legal expenses, investigative expenses, and attorneys&#x2019; fees) (&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Losses</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to the extent arising out of Licensee&#x2019;s or, as applicable Licensee&#x2019;s Affiliate&#x2019;s or Sublicensee&#x2019;s:</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) gross negligence or intentional misconduct, (b) failure to comply with Applicable Laws, or (c) Licensee&#x2019;s, its Affiliates&#x2019; or Sublicensee&#x2019;s Exploitation of Licensed Product in the Licensed Territory or the exercise of the licenses granted under this Agreement, including the production, manufacture, sale, use, lease, consumption, administration, shipping, storage, transfer, advertisement, analysis, measurement, description, or characterization of the Licensed Technology, or Licensed Products, or any activity arising from or in connection with any right or obligation of Licensee hereunder, except in each case (a) through</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) to the extent resulting from a Licensor Indemnitee&#x2019;s (i) gross negligence or intentional misconduct; (ii) failure to comply with Applicable Law; (iii) Exploitation of the Licensed Technology; or (iv) breach of this Agreement.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification by Licensor</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensor will indemnify, defend and hold harmless Licensee, its Affiliates, Sublicensees, any contractors of the foregoing, and their respective directors, officers, employees, consultants, licensors and agents, and their respective successors, heirs, and assigns (each a</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensee Indemnitee</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) against any Claims and Losses to the extent arising out of Licensor&#x2019;s or its Affiliate&#x2019;s: (a) gross negligence or intentional misconduct; (b) failure to comply with Applicable Laws; or (c) Exploitation of the Licensed Technology; except in each case (a) through (c) to the extent resulting from a Licensee Indemnitee&#x2019;s (i) gross negligence or intentional misconduct; (ii) failure to comply with Applicable Law; (iii) Exploitation of the Licensed Technology; or (iv) breach of this Agreement.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Procedure</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party&#x2019;s agreement to indemnify, defend, and hold harmless under </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.1</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as applicable, is conditioned upon the indemnified Party (a) providing written notice to the indemnifying Party of any Claim as soon as reasonably possible, and in any event no later than within [***], (b) permitting the indemnifying Party to assume control over the investigation of, preparation and defense against, and settlement or voluntary disposition of any such Claim, (c) assisting the indemnifying Party, at the indemnifying Party&#x2019;s reasonable expense, in the investigation, preparation, defense, and settlement or voluntary disposition of any such Claim, and (d) not compromising, settling, or entering into any voluntary disposition of any such Claim without the indemnifying Party&#x2019;s prior written consent, which consent shall not be unreasonably withheld; </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, if the Party entitled to indemnification fails to promptly notify the indemnifying Party pursuant to the foregoing clause (a), the indemnifying Party will only be relieved of its indemnification obligation to the extent materially prejudiced by such failure. In no event may the indemnifying Party compromise, settle, or enter into any voluntary disposition of any Claim in any manner that admits material fault or wrongdoing on the part of the indemnified Party or incurs non-indemnified liability on the part of the indemnified Party without the prior written consent of the indemnified Party, and in no event may the indemnifying Party settle, compromise, or agree to any voluntary disposition of any matter subject to indemnification hereunder in any manner which (i) imposes any monetary restriction or obligation on or admits fault of the other Party or (ii) adversely affects the other Party&#x2019;s rights under this Agreement, without such other Party&#x2019;s prior written consent.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insurance</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensee shall maintain in full force and effect during the Term, worker&#x2019;s compensation, general liability and professional liability, clinical trial liability, and product liability insurance coverage, all in such amounts as are customary in the life sciences and pharmaceutical industries.</font></div></div><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10<br></font><font style="color:#231f20;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Alternative Dispute Resolution</font></h1><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Negotiation</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event of any dispute or disagreement between the Parties as to the interpretation of any provision of this Agreement (or the performance of any obligations hereunder), the matter, upon written request of either Party, shall be referred to representatives of the Parties for decision, each Party being represented by an executive officer (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Representatives</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Representatives shall promptly meet in a good faith effort to resolve the dispute. If the Representatives do not mutually agree upon a decision within [***], each of the Parties shall be free to exercise the remedies available to it under </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party may extend the period of time for negotiation among the Representatives for an additional period of [***] on [***]. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Submission to Arbitration</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Parties are unable to resolve such dispute pursuant to </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, either Party may submit the dispute to binding arbitration (without any recourse to the federal or state courts except to enforce any arbitral award or, within [***], to appeal such final decision based solely on a claim that the Arbitrator engaged in gross misconduct or made a material error or miscalculation in his or her decision) under the International Chamber of Commerce Rules (with the option to use ICC Expedited Procedures by mutual agreement of the Parties) then in force (except as expressly modified below). The number of arbitrators (&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Arbitrator</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall be three (3). Each Party shall name one (1) Arbitrator, and the two (2) Arbitrators so named shall name the third Arbitrator, who shall act as chairman. The seat or legal place of arbitration shall be [***], and the language to be used in the arbitration shall be English. The arbitral result is final and binding to both Parties. The provisions of this paragraph may be enforced by any court of competent jurisdiction, and the Party seeking enforcement of the arbitral result shall be entitled </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to an award of all costs, fees, and expenses, including reasonable attorney&#x2019;s fees, to be paid by the Party against whom enforcement is ordered, including reasonable attorney&#x2019;s fees.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conduct of Arbitration</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Arbitrator shall be required to (a) follow the substantive rules of New York State or Federal law, as applicable, (b) require all testimony to be transcribed, and (c) accompany his or her award with findings of fact and a statement of reasons for the decision. The Arbitrator shall have the authority to permit discovery for no more than [***], which may be extended once by mutual agreement of the Parties, to the extent deemed appropriate by the Arbitrator, upon reasonable request of a Party. The Arbitrator shall have no power or authority to (i) add to or detract from the written agreement of the Parties set forth herein, (ii) materially alter the express terms of this Agreement, or (iii) address or resolve any issue not submitted by the Parties. The Arbitrator shall hold proceedings during a period of no longer than [***], and the Arbitrator shall render a final decision within [***]. The Arbitrator shall have the power to reasonably interpret any ambiguous provisions of the Agreement in good faith, and to grant injunctive relief (without the necessity of a Party posting a bond) in the event a Party has violated the confidentiality provisions set forth in this Agreement, but shall have no power to award punitive and/or exemplary damages in the event of a breach, </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that nothing in this Agreement will operate to prevent a Party from seeking injunctive relief in a court of competent jurisdiction. In the event of any conflict between the commercial arbitration rules then in effect and the provisions of this Agreement, the provisions of this Agreement shall prevail and be controlling.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim Relief</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Either Party may, without waiving any remedy under this Agreement, apply to the Arbitrator for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights regarding the Intellectual Property of that Party pending the arbitration award. The Arbitrator shall have no authority to award punitive or any other type of damages not measured by a Party&#x2019;s compensatory damages.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.5.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Arbitration</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party shall share in the actual and direct costs of the engagement of the Arbitrator, but the prevailing Party in the arbitration shall be reimbursed by the non-prevailing Party for the prevailing Party&#x2019;s fees and costs of arbitration (e.g., the costs, fees and expenses of outside experts and counsel retained by the prevailing Party). If one Party is not deemed by the Arbitrator to be the primary prevailing Party, then each Party will pay its own costs, fees and expenses (including attorneys&#x2019; fees) and an equal share of the Arbitrator&#x2019;s fees and any administrative fees of arbitration.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.6.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excluded Claims</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything to the contrary herein, nothing in this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall preclude a Party from seeking injunctive relief or specific performance in a court of competent jurisdiction. Unless otherwise mutually agreed upon by the Parties in writing, any Excluded Claims shall be brought in the federal court for the Southern District of New York, if federal jurisdiction is available, or, alternatively, in the state courts in New York, or, if mutually agreed by the Parties, another mutually acceptable jurisdiction. Each of the Parties hereby submits to the exclusive jurisdiction of such courts for the purpose of any such litigation; </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that either Party may raise a good faith objection based on forum non conveniens to request a transfer of venue to a more convenient court. A final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Each Party irrevocably and unconditionally agrees not to assert any claim that such court lacks jurisdiction over such litigation, except as provided above. As used in this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.66</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the term &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excluded Claim</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a dispute, controversy or claim that concerns: (w) the</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">scope, construction, validity or infringement of a patent, trademark or copyright; or (x) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.7.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidentiality</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor an Arbitrator may disclose the existence, content, or results of the arbitration without the prior written consent of both Parties, except to its directors, officers and investors. In no event shall arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations.</font></div></div><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11<br></font><font style="color:#231f20;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Miscellaneous</font></h1><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance with Law</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with its Exploitation of Licensed Products, Licensee agrees to comply with all Applicable Laws. Without limiting the foregoing, by entering into this Agreement, the Parties specifically intend to comply with all Applicable Laws pertaining to Licensed Products, including, without limitation (i) the federal anti-kickback statute (42 U.S.C. &#167;1320a-7b) and the related safe harbor regulations; and (ii) the Limitation on Certain Physician Referrals, also referred to as the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stark Law</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; (42 U.S.C. &#167;1395nn); (iii) foreign trade law, regulations on the administration of technology import and export, export control law; (iv) cybersecurity law, data security law, personal information protection law; (v) GCP, GMP, GSP, their relative rules and regulations, and the revisions thereof. Accordingly, no part of any consideration paid hereunder is a prohibited payment for the recommending or arranging for the referral of business or the ordering of items or services; nor are the payments intended to induce illegal referrals of business.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Assignment</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement will be binding upon and will inure to the benefit of each Party and each Party&#x2019;s respective transferees, successors and assigns, pursuant to the provisions set forth below. Licensee may not transfer or assign this Agreement without the prior written consent of Licensor, except that Licensee may transfer or assign this Agreement without the prior written consent of Licensor in the event that a third party (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquiring Party</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) acquires all or substantially all of Licensee&#x2019;s business, capital stock or assets, whether by sale, merger, change of control, operation of law or otherwise (an &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisition</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Upon an Acquisition, the rights granted to Licensee under this Agreement pertaining to any and all Licensed Products shall inure to the benefit of the Acquiring Party. For the avoidance of doubt, in the event of an Acquisition, the Acquiring Party will be responsible for all payments and other obligations set forth in this Agreement, including, but not limited to, all payments set forth herein, and any obligations that matured prior to the Acquisition date. Upon an Acquisition, any unpaid portion of any deferred payments payable to Licensor hereunder shall remain an ongoing obligation of the Acquiring Party until such amount is paid in full. For the avoidance of doubt, an Acquisition shall not include any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by Licensee or any successor, indebtedness of Licensor is cancelled or converted or any combination thereof. Any attempted assignment in contravention of this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be null and void.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.3.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement constitutes the entire agreement between the Parties hereto with respect to the subject matter thereof and supersedes all previous agreements, negotiations, commitments, and writings with respect to such subject matter. Neither Party shall be obligated by any undertaking or representation regarding that subject matter other than those expressly stated herein or as may be subsequently agreed to by the Parties hereto in writing. In the event of any conflict or inconsistency between any provision of any Exhibit hereto and any provision of this Agreement, the provisions of this Agreement shall prevail.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.4.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amendment</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No amendment, modification or supplement of any provision of this Agreement and Exhibit(s) will be valid or effective unless made in writing and signed by a duly authorized officer of each Party.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.5.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any notice required to be given pursuant to the provisions of this Agreement will be in writing and will be deemed to have been given at the time when actually received as a consequence of any effective method of delivery, including but not limited to hand delivery, transmission by electronic transmission, including PDF (portable document format), delivery by a professional courier service or delivery by first class, certified or registered mail (postage prepaid) addressed to the Party for whom intended at the address below, or at such changed address as the Party will have specified by written notice in accordance with this </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.5</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that any notice of change of address will be effective only upon actual receipt.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Licensor:</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novatim Immune Therapeutics (Zhejiang) Co., Ltd. <br>Building 5, Lane 908, Ziping Road, Pudong New Area, <br>Shanghai 201321, PRC<br>Attn: [***]</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Licensee:</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Erigen LLC<br>1035 Cambridge Street, Suite 17B <br>Cambridge, MA 02141<br>Attn: [***]</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with copy (which shall not constitute notice) to:</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]<br>[***]<br>[***]<br>[***]</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.6.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.6.1.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The substantive law governing this Agreement (which shall be applied in the arbitration) shall be, with respect to disputes involving general contract or trade secret matters, the internal laws of the State of New York, and with respect to matters involving patents, the United States Patent Act, as to copyright matters, the United States Copyright Act, and as to trademark matters, the United States Trademark Act, each as amended from time to time. The Parties agree that the arbitration shall be seated in [***] under ICC rules. Any award rendered by the Arbitrators shall be final, conclusive and binding upon the Parties to this Agreement. The Parties agree that the arbitration judgement and award may be entered and enforced in all relevant jurisdictions.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.6.2.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any provisions of this Agreement are or will come into conflict with the laws or regulations of any jurisdiction or any governmental entity having jurisdiction over the Parties or this Agreement, those provisions will be deemed automatically deleted, if such deletion is allowed by relevant</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">law, and the remaining terms and conditions of this Agreement will remain in full force and effect. If such a deletion is not so allowed or if such a deletion leaves terms thereby made clearly illogical or inappropriate in effect, the Parties agree to substitute new terms as similar in effect to the present terms of this Agreement as may be allowed under Applicable Law.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.7.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Descriptive Headings</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement has been prepared jointly by the Parties and shall not be strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of each Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Section. Except where the context otherwise requires, the use of any gender shall be applicable to all genders, and the word &#x201c;or&#x201d; is used in the inclusive sense (and/or). The term &#x201c;including&#x201d; as used herein means including, without limiting the generality of any description preceding such term.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.8.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Independent Contractors</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Both Parties are independent contractors under this Agreement. Nothing contained in this Agreement will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. Notwithstanding anything contained herein to the contrary, and for the avoidance of doubt, Licensor shall not be deemed an Affiliate of Licensee, and Licensee shall not be deemed an Affiliate of Licensor.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.9.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The illegality or partial illegality of any provision of this Agreement will not affect the validity of the remainder of the Agreement, or any provision thereof, and the illegality or partial illegality of any provision of this Agreement will not affect the validity of the Agreement in any jurisdiction in which such determination of illegality or partial illegality has not been made, except in either case to the extent such illegality or partial illegality causes the Agreement to no longer contain all of the material provisions reasonably expected by the Parties to be contained therein. Moreover, in the event that a court of competent jurisdiction determines that any provision of this Agreement is illegal or partially illegal, then it is the intention of the Parties that such provision be modified to the minimum extent deemed necessary by such court to make such provision enforceable and to give effect to the original intention of the Parties.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.10.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Waiver of Compliance</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The failure of either Party to comply with any obligation, covenant, agreement or condition under this Agreement may be waived by the Party entitled to the benefit thereof only by a written instrument signed by the Party on granting such waiver, but such waiver or failure to insist upon strict compliance with such obligation, covenant, agreement or condition will not operate as a waiver of, or estoppel with respect to, any subsequent or other failure. The failure of any Party to enforce at any time any of the provisions of this Agreement will in no way be construed to be a waiver of any such provision, nor in any way to affect the validity of the Agreement or any part thereof or the right of any Party thereafter to enforce each and every such provision. No waiver of any breach of such provisions will be held to be waiver of any other or subsequent breach.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.11.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed by original or facsimile signature in any number of counterparts, each of which need not contain the signature of more than one Party but all such counterparts taken together will constitute one and the same agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.12.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Authority</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The persons signing on behalf of Licensor and Licensee hereby warrant and represent that they have authority to execute this Agreement on behalf of the Party for whom they have signed.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.13.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Solicitation</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. [***], neither Party shall, without the prior written consent of the other </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party, directly or indirectly solicit for employment any employee of the other Party or any of its Affiliates or subsidiaries, or any person who has terminated his or her employment with the other Party or any of its Affiliates or subsidiaries within the previous [***] prior to any purported solicitation; </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the foregoing will not [***]. [***].</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.14.</font><div style="display:inline;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Force Majeure</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither Party hereto shall be liable for failures and delays in performance due to strikes, lockouts, fires, acts of God or the public enemy, riots, incendiaries, interference by civil or military authorities, acts of terrorism, endemic, pandemic, and the results related to such acts, compliance with the laws of various states/countries, or with the orders of any governmental authorities, delays in transit or delivery on the part of transportation companies, failures of communication facilities, or any failure of sources of material (&#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Force Majeure Event</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Notwithstanding the above, should the event of Force Majeure last for more than [***], the other Party shall be entitled to terminate this Agreement effective upon giving written notice to the Party affected by the Force Majeure Event.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Remainder of page intentionally left blank.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the Parties hereto have duly executed this Exclusive License and Collaboration Agreement as of the Effective Date.</font></p><p style="font-size:10pt;margin-top:0.5500000000000007pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOVATIM IMMUNE THERAPEUTICS (ZHEJIANG) CO., LTD. (LICENSOR)</font></h1><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-7.117%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:49.833%;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/  Guoxiang Wu</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> <br>Name: Guoxiang Wu</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: CEO &amp; Chairman</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:12.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><h1 style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERIGEN LLC (LICENSEE)</font></h1><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-7.117%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:49.833%;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/  Matthew Angel, Ph.D.</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> <br>Name: Matthew Angel, Ph.D.</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: Manager</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.8in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.278%;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.537%;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Terms</font></p><p style="margin-left:0.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.537%;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-15.986%;padding-left:13.333%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.259%;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:1.01in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensed Patents</font></p><p style="margin-left:0.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="font-size:10pt;margin-top:1.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:1.01in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvement Patents</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:12.6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#231f20;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[To be added during the Term]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4926-6413-5580, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>5
<FILENAME>tpst-ex10_26.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T08:19:11.8388+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.26</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.26</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT TEMPEST THERAPEUTICS, INC. TREATS AS PRIVATE AND CONFIDENTIAL</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into as of this 19</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day of November, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Execution Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and completely supersedes, as of the Effective Date, the License and Collaboration Agreement dated as of the 6</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day of August 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between FACTOR BIOSCIENCE LIMITED, a company organized and existing under the laws of Ireland (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensor</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and ERIGEN LLC, a limited liability company organized and existing under the laws of the State of Delaware corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Licensor and Licensee may each be referred to in this Agreement individually as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pa</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">rty</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.&#x201d;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Licensor owns or controls certain Licensed Technology (as defined herein); and</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Licensee desires to receive from Licensor certain rights to the Licensed Technology in order that Licensee may develop and commercialize Licensed Products in the Licensed Territory (as such terms are defined herein); and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, in furtherance of the foregoing, Licensor agrees to grant such rights to Licensee, and Licensee agrees to use its Commercially Reasonable Efforts (as defined herein) to develop and make commercially available one or more Licensed Products in accordance with this Agreement for commercial exploitation in the Field and in the Licensed Territory (as such terms are defined herein).</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Definitions</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise specifically provided herein, the following terms, when used with a capital letter at the beginning, will have the following meanings:</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Party, a person, corporation, partnership, or other entity that controls, is controlled by or is under common control with such Party. For the purposes of this definition, the word &#x201c;control&#x201d; (including, with correlative meaning, the terms &#x201c;controlled by&#x201d; or &#x201c;under common control with&#x201d;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. For the purposes of this definition and this Agreement, and notwithstanding anything set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1.11</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the contrary, for the avoidance of doubt, (a) Licensor, Factor Bioscience Pty Ltd, Factor Bioscience LLC, and Factor Bioscience Inc. (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Factor Bio Entities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) are each deemed not to be Affiliates of Licensee, and (b) Licensee is deemed not to be an Affiliate of any of the Factor Bio Entities.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Preamble.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all statutes, ordinances, regulations, rules or orders of any kind whatsoever of any agency, bureau, branch, office, court, commission, authority, department, ministry, </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">official or other instrumentality of, or being vested with public authority under any law of, any country, state or local authority or any political subdivision thereof, or any association of countries that may be in effect from time to time and applicable to a Party&#x2019;s obligations or exercise of its rights under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BL</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Biologic License Application (as more fully described in U.S. 21 C.F.R. Part 601.20 or its successor regulation), as may be amended from time to time, or any analogous application or submission with any Regulatory Authority outside of the United States.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Calendar Quarter</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each of the following three- (3)-month periods during each year: January 1 through March 31; April 1 through June 30; July 1 through September 30; and October 1 through December 31.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Combination Product</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any product comprising a combination of (a) a Licensed Product and (b) any active ingredient(s) (other than a Licensed Product) for which rights are not included in the licenses granted under this Agreement but, with respect to the item(s) in (b) of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which may each or collectively [***] (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Product</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commercially Reasonable Efforts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the performance of activities hereunder by or on behalf of Licensee, the carrying out of such activities using commercial and business efforts and resources [***] in the development, manufacture and commercialization of products similar to the Licensed Products would typically devote to such activities, [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Competitive Infringement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the infringement of a Foundational Patent, an Improvement Patent or a Licensed Patent by the making, using, selling, offering for sale, or importing, by any third party (other than any Sublicensee or authorized purchaser or other authorized transferee of a Party with respect to such Licensed Product), of a Licensed Product, where such Licensed Product is Covered by at least one Valid Claim.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Information disclosed by or on behalf of one Party to the other under this Agreement in any manner, whether orally, visually, electronically, in writing or in other tangible or intangible form, that relates to Licensed Technology, Licensed Products, or this Agreement. Notwithstanding the foregoing, the following information shall not constitute &#x201c;Confidential Information&#x201d;: (a) information lawfully in the receiving Party&#x2019;s possession or control prior to the time it received the information from the disclosing Party; (b) information developed by the receiving Party independently of, and without reference to, the Confidential Information of the disclosing Party; (c) information that was, at the time it was disclosed to or obtained by the receiving Party, or thereafter became, available to the public through no act or omission of the receiving Party; and (d) information lawfully obtained by the receiving Party from a third party with the right to disclose such information free of any obligations of confidentiality.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Controlled by</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, in the context of a license to or ownership of Intellectual Property, the ability on the part of a Party to grant access to or a license or sublicense of such Intellectual Property as provided for herein without violating the terms of any agreement or other arrangement between such Party and any Third Party existing at the time such Party would be required hereunder to grant such access or license or sublicense.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.11</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Co</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cov</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ered</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that the use, manufacture, sale, offer for sale, research, development, commercialization, or importation of the subject matter in question (including a chemical or biologic agent, or a process) by an unlicensed entity would infringe a granted Valid Claim (or, in the case of a pending Valid Claim that has not yet been granted, would infringe such Valid Claim if it were to be </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">granted in its then-current form) of a Foundational Patent or Licensed Patent included in the Licensed Technology.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.12</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Preamble.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.13</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ERI-3003 Product</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an allogeneic cell therapy product consisting of human T-cells comprising a CD19/BCMA bicistronic dual chimeric antigen receptor and a gene edit in the TRAC locus that inactivates the T-cell receptor. For the avoidance of doubt, the ERI-3003 Product may comprise additional [***], but does not comprise additional [***], such as, by way of non&shy;limiting example, additional [***]</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.14</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ERI-3206 Product</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an allogeneic cell therapy product consisting of human T-cells comprising a CD70/CD70 bicistronic dual chimeric antigen receptor and a gene edit in the TRAC locus that inactivates the T-cell receptor.. For the avoidance of doubt, the ERI-3206 Product may comprise additional [***], but does not comprise additional [***], such as, by way of non&shy;limiting example, additional [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.15</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exp</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">loit</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exploitation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; mean to make, have made, research, develop, manufacture, use, sell, have sold, offer for sale, commercialize, distribute, import and/or export.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.16</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FD</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Food and Drug Administration or any successor agency thereto.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.17</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fi</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">eld</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Exploitation of Licensed Products in all fields.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.18</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">First Commercial Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, following Regulatory Approval in a particular jurisdiction, the first arm&#x2019;s-length sale or other transfer for value of a Licensed Product by or on behalf of Licensee, or an Affiliate or Sublicensee, to an unrelated third party in such jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.19</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foundational Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the Patents set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and any Patent that claims priority to any of Patents set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.20</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IN</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">D</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an Investigational New Drug Application (or the foreign equivalent thereof) filed with the FDA required for the initiation of clinical trials in humans for the applicable Licensed Product in the United States.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.21</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all information, know-how, data, results, technology, materials, scientific, business or financial information of any type whatsoever, in any tangible or intangible form, provided by or on behalf of one Party to the other Party, either in connection with the discussions and negotiations pertaining to this Agreement or in the course of performing this Agreement, or that otherwise relates to the Licensed Technology or the Licensed Products, whether disclosed orally, visually, electronically, in writing or in other tangible or intangible form, and which may include data, knowledge, practices, processes, ideas, research plans, antibodies, small molecules, compounds, targets, biological and chemical formulations, structures and designs, laboratory notebooks, proof of concept and pre-clinical studies, formulation or manufacturing processes and techniques, scientific, manufacturing, marketing and business plans, and financial and personnel matters relating to the disclosing Party or to its present or future products, sales, suppliers, customers, employees, investors or business.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.22</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvement(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any invention, discovery, advancement, development, or creation which: (a) is invented, developed, authored, created, or reduced to practice by or on behalf of Licensee, or Sublicensee(s), or any of their respective Affiliates (or any of their respective personnel or agents, including </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise having an obligation to assign inventions to) them); and (b) is an improvement, modification or enhancement to one or more of the inventions claimed in the Foundational Patents or Licensed Patents that does not specifically relate to or require the use of any Licensed Products.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.23</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvement Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Patents claiming any of the Improvements, and any reissue, divisional, continuation, continuation-in-part or reexamination certificate thereof. During the Term, all Improvement Patents shall be set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.24</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all (A) patents, patent applications, patent disclosures and all related continuation, continuation-in-part, divisional, reissue, reexamination, post-grant proceeding, utility model, certificate of invention and design patents, applications, registrations and applications for registration, and any equivalent in any jurisdiction; (B) trademarks, service marks, trade dress, Internet domain names, logos, trade names and corporate names and registrations and applications for registration thereof; (C) copyrights and registrations and applications for registration thereof, including all moral rights; (D) Information, inventions, trade secrets and confidential information, whether patentable or non&shy;patentable and whether or not reduced to practice, know-how, show-how, manufacturing and product processes and techniques, batch records, bills of materials, material and process risk assessments and other quality documentation, research and development information, notebooks, formulae, diagrams, technical and engineering specifications, business and marketing plans and customer and supplier lists and other information; (E) other proprietary rights relating to any of the foregoing (including remedies against infringement thereof and rights of protection of interest therein under the laws of all jurisdictions); and (F) copies and tangible embodiments thereof.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.25</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensed Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Patents set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and any Patents that claim priority to any of the Patents set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For the avoidance of doubt, the term &#x201c;Licensed Patents&#x201d; does not include any of the Foundational Patents or Improvement Patents. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.26</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensed Products</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means the ERI-3003 Product and the ERI-3206 Product.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.27</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensed Technolog</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">y</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Foundational Patents, the Licensed Patents and the Improvement Patents, collectively.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.28</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensed Territory</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the entire world, excluding Greater China, India, Turkey, and Russia.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.29</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Erigen LLC.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.30</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensor</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Factor Bioscience Limited.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.31</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensor Territory</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Greater China.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.32</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">M</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">AA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any new drug application or other marketing authorization application, in each case, filed with the applicable Regulatory Authority in a country or other regulatory jurisdiction, which application is required to commercially market or sell a pharmaceutical product (including a biopharmaceutical product) in such country or jurisdiction (and any amendments thereto), including all New Drug Applications (NDA) or equivalent submitted to the FDA in the United States in accordance with the PHSA, BLA submitted to the FDA in the United States in accordance with the United States Food Drug and Cosmetics Act, or any analogous application or submission with any Regulatory Authority outside of the United States. </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.33</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.34</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means gross amounts invoiced or otherwise received for Licensee&#x2019;s, its Affiliates&#x2019;, or Sublicensees&#x2019; sales of Licensed Products, less the sum of the following: [***]. The sale of a Licensed Product by a selling party to another selling party for resale by such selling party to a third party shall not be deemed a sale for the purposes of this definition of &#x201c;Net Sales,&#x201d; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that the final resale in any such chain is included in the computation of &#x201c;Net Sales&#x201d; by the last selling party that resells such Licensed Product. Failure by the last selling party to report final resale for Licensor to calculate the royalties, within [***] shall entitle Licensor to [***]. [***]. The gross amounts invoiced and all permitted deductions shall be determined in accordance with the selling party&#x2019;s usual and customary accounting methods, which are in accordance with U.S. generally accepted accounting principles (GAAP) or international financial reporting standards, in either case, consistently applied, provided that Licensor shall have the right to audit and verify such records upon reasonable prior notice in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On a country-by-country basis, if a Licensed Product is sold in a country as part of a Combination Product, Net Sales of such Licensed Product for the purpose of determining royalties due hereunder shall be calculated as follows:</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	In the event that both (x) the Licensed Product is sold separately in finished form in such country during a Calendar Quarter and (y) the Other Product(s) in such Combination Product are sold separately in finished form in such country during such Calendar Quarter, then Net Sales of such Licensed Product shall be determined by [***].</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	In the event that the Licensed Product in such Combination Product is sold separately in finished form in such country during a Calendar Quarter, but the Other Product(s) in such Combination Product are not sold separately in finished form in such country during such Calendar Quarter, then Net Sales of such Licensed Product shall be calculated by [***].</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	In the event that the Licensed Product in such Combination Product is not sold separately in finished form in such country during a Calendar Quarter, but the Other Product(s) in such Combination Product are sold separately in finished form in such country during such Calendar Quarter, Net Sales of such Licensed Product shall be calculated by [***].</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	In the event that neither the Licensed Product in such Combination Product is sold separately in finished form in such country during a Calendar Quarter, nor the Other Product(s) in such Combination Product are sold separately in finished form in such country during such Calendar Quarter, then the fair market value of the Licensed Product and such Other Product(s) shall be [***].</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.35</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Product</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.36</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the Preamble.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.37</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all patents and patent applications and all substitutions, divisions, continuations, continuations-in-part, any patent issued with respect to any such patent applications, any reissue, reexamination, utility models or designs, renewal or extension (including any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all counterparts and equivalents of any of the foregoing in any country or jurisdiction.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.38</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all reasonable fees, costs, and expenses (including attorneys&#x2019; fees) paid or incurred in the preparation, filing, prosecution, issuance, and/or maintenance of the Improvement Patents.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.39</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 Clinical Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a clinical trial of a pharmaceutical product (including a biopharmaceutical product) with the primary endpoint of determining initial tolerance, safety, metabolism, pharmacokinetic, or pharmacodynamic information in single dose, single ascending dose, multiple dose, or multiple ascending dose regimens, that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167; 312.21(a) and its successor regulation or equivalents in other jurisdictions.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.40</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 Clinical Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2b Clinical Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a clinical trial of a pharmaceutical product (including a biopharmaceutical product) the principal purpose of which is to evaluate the effectiveness of such product in a human population and that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167;312.21(b) and its successor regulation or equivalents in other jurisdictions.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.41</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 Clinical Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a clinical trial (or any arm thereof) of a pharmaceutical product (including a biopharmaceutical product) on a sufficient number of patients, which trial the FDA or equivalent Regulatory Authority in other jurisdictions permits to be conducted under an open IND and is designed to: (a) establish that such pharmaceutical product is safe and efficacious for its intended use; (b) define warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed; and (c) support the filing of an MAA with a Regulatory Authority for such pharmaceutical product, and that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167;312.21(c) and its successor regulation or equivalents in other jurisdictions.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.42</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all technical, medical and scientific licenses, registrations, authorizations and approvals (including approvals of new drug applications, supplements and amendments, pre- and post- approvals, pricing and third-party reimbursement approvals, and labeling approvals) of any Regulatory Authority that are necessary for the use, development, manufacture, and commercialization of a pharmaceutical product in a regulatory jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.43</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a given country, any national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental authority involved in the granting of a Regulatory Approval. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.44</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty on Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.45</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, on a Licensed Product-by-Licensed Product and country-by-country basis, the period commencing on the First Commercial Sale of such Licensed Product in such country of the Licensed Territory, and ending on the date of expiration of the last to expire Valid Claim Covering the Exploitation of such Licensed Product in such country of the Licensed Territory. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.46</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sublicensee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a third party granted a sublicense to any of the rights granted to Licensee under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.47</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sublicense Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that portion of any cash payment (or the fair market value of any other consideration) received by Licensee or any of its Affiliates attributable to the grant of a sublicense of, or other right with respect to the Licensed Technology granted to Licensee hereunder, including, without limitation, [***], but specifically excluding [***]. Sublicense Fees shall be net of all withholding taxes or other amounts withheld or deducted from the amounts received by Licensee, provided that if Licensee later recovers withholding taxes or other such amounts withheld or deducted from the amounts received by </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee, the amount of any such benefit shall be included in Sublicense Fees. Notwithstanding the foregoing, if [***]. In allocating any such payment or consideration attributable to the grant of a sublicense of the Licensed Technology granted to Licensee hereunder, Licensee shall allocate such payment or consideration in good faith and in such a manner as to not disproportionately disadvantage Licensor.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.48</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0f0f0f;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.49</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Valid Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) a claim of a granted and unexpired Foundational Patent or Licensed Patent included in the Licensed Technology that (i) has not been rejected, revoked, or held to be invalid or unenforceable by a court or other authority of competent jurisdiction, from which decision no appeal is or can be taken or (ii) has not been finally abandoned, disclaimed or admitted to be invalid or unenforceable through reissue or disclaimer; or (b) a claim included in a pending patent application which is a Foundational Patent or Licensed Patent included in the Licensed Technology that (i) has not been pending for more than [***] (provided, however that for purposes of clarity, in the event such pending claim is subsequently granted, then such claim shall again be a Valid Claim as of the date of grant of such claim) or (ii) has not been finally determined to be unallowable by the applicable governmental authority (from which no appeal is or can be taken).</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to the terms and conditions of this Agreement, Licensor, on behalf of itself and any successors and/or assigns, hereby grants to Licensee an exclusive, royalty-bearing, non-transferrable (except in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) license, with the right to grant sublicenses (through multiple tiers) pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, under the Licensed Technology to Exploit Licensed Products in the Field and in the Licensed Territory.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sublicensing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Licensee may sublicense the rights granted to it under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, provided, however, that Licensee shall provide Licensor with written notice and a confidential copy of any such sublicense agreement within [***]. Each such sublicense shall be in writing and contain terms not inconsistent with the terms and conditions of this Agreement applicable to the licenses granted to Licensee hereunder. In each case, Licensee will be responsible for the performance of its Sublicensees relevant to this Agreement, including, without limitation, making full amount of any payments due hereunder in a timely manner in accordance with the terms and conditions provided for hereunder. For the avoidance of doubt, contract research organizations, contract manufacturing organizations, distribution partners and similar third parties to which Licensee or Sublicensees delegate development, manufacturing or commercialization activities relating to Licensed Products may perform such development, manufacturing or commercialization activities on behalf of Licensee or such Sublicensees without a sublicense of the rights granted to Licensee hereunder.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Additional Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party understands and acknowledges that the other Party owns its own Intellectual Property and all rights therein. Except as otherwise expressly provided in this Agreement, under no circumstances shall a Party hereto, as a result of this Agreement, obtain any ownership interest or license, or be deemed to obtain any ownership interest or license, in or to any Intellectual Property of the other Party, including, but not limited to, items Controlled or developed by the other Party, at any time pursuant to this Agreement. This Agreement does not create and shall under no circumstances be construed or interpreted as creating, an obligation on the part of either Party to grant any license to the other Party other than as expressly set forth herein. Any further contract or license agreement between the Parties shall be in writing. No licenses are implied by Licensor to Licensee, except as specifically stated in this Agreement. Except as explicitly set forth in this Agreement, Licensor shall not be deemed by estoppel or </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implication to have granted Licensee any license or other right to any Intellectual Property of Licensor or its Affiliates.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Joint Steering Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Within [***], the Parties shall establish a joint steering committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Joint Steering Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">JSC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) for the purposes of (a) discussing and coordinating potential collaboration opportunities between the Parties, including the provision of potential support by Licensor to Licensee for the clinical and commercial development of the Licensed Products; and (b) serving as a forum for information sharing and to facilitate communications between the Parties with respect to research, development and other Exploitation of Licensed Products. The JSC shall be composed of [***] representatives from each Party. Each representative shall have the requisite technical experience and seniority to enable such person to make decisions on behalf of the applicable Party with respect to the issues falling within the decision-making authority of the JSC. From time to time, each Party may substitute [***] representatives to the JSC on written notice to the other Party.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Responsibilities of the JSC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The JSC shall perform the following functions: (a) review and serve as a forum for discussing and coordinating activities related to the development of Licensed Products; (b) review and discuss regulatory filings, applications and submissions related to Licensed Products to any Regulatory Authority, including any material regulatory correspondence; and (c) perform such other functions as are set forth herein or as the Parties may mutually agree in writing, except where in conflict with any provision of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JSC Meetings and Minutes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The JSC shall meet at least [***], or at such frequency as otherwise agreed to by the Parties, either in person or by teleconference or videoconference, with the venue of the in-person meetings alternating between locations designated by Licensor and locations designated by Licensee. Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to such proposed items [***]. Licensee shall prepare and circulate to Licensor draft minutes of each meeting within [***] for the Parties&#x2019; review and approval. The Parties shall agree on the minutes of each JSC meeting promptly, but in no event later than [***]. Each Party will [***]. Each Party may, with the consent of the other Party, which consent shall not be unreasonably withheld, invite a reasonable number of non-voting employees, consultants or scientific advisors to attend the meetings of the JSC, provided such invitees are bound by appropriate confidentiality obligations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JSC Decision-Making</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All JSC decisions shall be made by [***]. The presence of [***]constitutes a quorum for the conduct of business at any JSC meeting, and no vote of the JSC may be taken without a quorum present. If, after reasonable discussion and good faith consideration of each Party&#x2019;s view on a particular matter, the JSC representatives of the Parties cannot reach an agreement as to such matter within [***], then either Party may, by written notice to the other Party, have such issue referred to the executive officers for resolution. The Parties&#x2019; respective Executive Officers shall discuss within [***] after such matter is referred to them and shall negotiate in good faith to resolve the matter. If the Executive Officers are unable to resolve the matter within [***], then Licensee shall have the final decision-making authority on research, manufacturing, development (including conduct of clinical studies and regulatory activities), commercialization and Exploitation of Licensed Products in the Licensed Territory. Without limiting the foregoing, neither Party shall exercise its final decision-making authority to (A) determine any matter or make any decision that is outside of the authority expressly granted to the JSC under this Agreement; or (B) amend the terms and conditions of this Agreement. The Parties intend and agree that all matters within the scope of the JSC&#x2019;s decision-making authority shall be resolved in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and no matter within the scope of the JSC&#x2019;s authority shall be subject to the dispute resolution mechanisms set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Due Diligence</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensee Responsibilities</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee shall be solely responsible, at its expense, for the commercialization of Licensed Products in the Licensed Territory and Licensee will use Commercially Reasonable Efforts to make commercially available at least one Licensed Product in the Licensed Territory during the Term.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee shall provide periodic updates on Licensee&#x2019;s Licensed Product development and commercialization activities in the Licensed Territory to Licensor through the JSC.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee shall [***]for [***] within [***]. It shall be deemed a material breach of this Agreement and Licensor may elect to terminate this Agreement, but solely with respect to [***], in the event that Licensee&#x2019;s achievement of the foregoing milestone is delayed by [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee shall [***] for [***] within [***]. It shall be deemed a material breach of this Agreement and Licensor may elect to terminate this Agreement, but solely with respect to [***], in the event that Licensee&#x2019;s achievement of the foregoing milestone is delayed by [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Data Sharing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Parties agree that all data generated during a Phase 1 Clinical Trial, a Phase 2 Clinical Trial and/or a Phase 3 Clinical Trial of the Licensed Products, including raw clinical data, lab data, and reports (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Data</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall, subject to the obligations of confidentiality set forth herein, be shared upon reasonable written request by Licensor. The Licensee shall, upon reasonable written request by the Licensor, provide the Licensor with Clinical Data Controlled by Licensee and resulting from clinical trials conducted or sponsored by Licensee or its Affiliates or collaborators in the Licensed Territory. In each case, the shared Clinical Data shall include, where available, raw datasets (anonymized patient-level data), statistical analysis reports, clinical study protocols, and adverse event reports.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consideration; Records &amp; Reports</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Continuing Payments</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone Payments</font></div></div><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The first time one of the development or commercial milestones set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is achieved by Licensee or a Sublicensee, Licensee shall pay to Licensor the corresponding one-time milestone payment set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), such Milestone Payment to be made within [***]. For the avoidance of doubt, in the event that the achievement of one or more development milestones set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Development </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is [***], then Licensee shall [***]. No Milestone Payment will be payable more than one time.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalties on Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the applicable Royalty Term, on a [***] basis, Licensee shall pay to Licensor a royalty equal to the applicable percentage of Net Sales set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty on</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Payments under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be due within [***] of the end of [***].</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Multiple Royalties; Offset for Third Party Royalties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, no multiple Royalties on Net Sales will be required to be paid because a Licensed Product or its manufacture, use, sale or importation is covered by more than one (1) Valid Claim. On a Licensed Product-by-Licensed Product and country-by-country basis, in the event that Licensee is required to pay royalties to a third party for licenses to intellectual property rights entered into by Licensee to avoid infringement of such rights by the Exploitation of a Licensed Product in a country, then upon expiration of the last-to-expire Valid Claim of the Foundational Patents in such country, Licensee may deduct up to [***] of the amount of any such third party [***] actually paid to such third party in a given [***] from any Royalty on Net Sales due to Licensor under Section 5.1.2 in such country during the same [***], provided that notwithstanding anything set forth in this Agreement to the contrary, in no event shall the Royalty on Net Sales under Section 5.1.2 otherwise due to Licensor for such Licensed Product in such country be less than [***] of the applicable Royalty on Net Sales due to Licensor during such [***].  No other offsets or deductions from the Royalty on Net Sales are otherwise permitted hereunder.</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.1.4	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sublicense Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee shall pay to Licensor the percentage of Sublicense Fees set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such payments to be made within [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Late Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any payments by Licensee that are not paid on or before the due date under this Agreement shall bear interest, to the extent permitted by law, at [***]. If any such late payment is not remedied within [***], such failure shall be deemed a material breach of this Agreement. In such case, Licensor shall have the right to pursue available remedies, including the right to terminate this Agreement. This </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not limit any other remedies available to either Party under this Agreement or at law or in equity.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Records and Reports</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within [***], commencing with the [***] in which the First Commercial Sale of any Licensed Product is made anywhere in the Licensed Territory, Licensee shall provide Licensor with a report containing the following information for the applicable [***], on a Licensed Product basis: (a) the amount of Net Sales in the Territory; (b) calculation of Net Sales in the Licensed Territory showing deductions provided for in the definition of &#x201c;Net Sales&#x201d;; (c) a calculation of the royalty payment due on such Net Sales; and (iv) the exchange rate for such country. For the purpose of converting any local currency into U.S. dollars to determine any amounts payable under this Agreement, the rate of exchange to be applied shall be [***]. Concurrent with the delivery of the applicable quarterly report, Licensee shall pay in U.S. dollars all amounts due to Licensor pursuant to this Agreement with respect to Net Sales by Licensee and its Affiliates and Sublicensees for such [***]. All payments due to Licensor hereunder shall be made in U.S. dollars by wire transfer of immediately available funds into an account designated by Licensor.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Audit and Inspection Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee and its Affiliates and Sublicensees will maintain records in sufficient detail to permit Licensor to confirm the accuracy of the calculation of royalty payments made by Licensee under this Agreement. Upon reasonable prior notice, the records of Licensee and its Affiliates shall be available during regular business hours (without undue disruption of Licensee&#x2019;s or its Affiliate&#x2019;s business) for a period of [***] from the end of the calendar year to which they pertain for examination by a nationally recognized independent accountant selected by Licensor and reasonably acceptable to Licensee or its Affiliate, for the sole purpose of verifying the accuracy of the reports and payments furnished by Licensee pursuant to this Agreement. Any such auditor shall not disclose Licensee&#x2019;s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the reports furnished by Licensee or the amount of payments due by Licensee to Licensor under this Agreement. Licensor shall provide Licensee with a copy of the accountant&#x2019;s report. Licensor shall have the right, [***] </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">per [***], to request that Licensee exercise its audit rights with respect to any Sublicensee. If Licensee has already exercised its audit rights with respect to the subject Sublicensee for the relevant calendar year, then Licensor shall have the right to request that Licensee share the results of such audit with Licensor. Licensor shall bear the full cost of any such audit.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ta</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">xes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding or similar obligations in respect of payments made by a Party to the other Party under this Agreement. To the extent either Party is required to deduct and withhold taxes on any payment to the other Party, such Party shall pay the amounts of such taxes to the proper governmental authority in a timely manner and promptly transmit to the other Party an official tax certificate or other evidence of such withholding sufficient to enable the other Party to claim such payment of taxes. Each Party shall use reasonable efforts to provide the other Party with any tax forms that may be reasonably necessary in order for the other Party to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Representations and Warranties; Disclaimers; Limitation of Liability</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Representations and Warranties of Licensor</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensor hereby represents and warrants to Licensee that, as of the Execution Date:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensor is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization, with full power and authority to operate its properties and to carry on its business as presently conducted.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensor is the owner or licensee of the Licensed Technology and/or has the right to grant the licenses and rights that it purports to grant under this Agreement and has not granted to any third party any license or other right that conflicts with the licenses and rights granted under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The execution of this Agreement and performance of Licensor&#x2019;s obligations under this Agreement do not conflict with, cause a default under, or violate any existing contractual obligation that may be owed by Licensor or any Affiliate of Licensor to any third party.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no action, suit, proceeding or investigation pending or, to Licensor&#x2019;s and its Affiliates&#x2019; knowledge, currently threatened orally or in writing against or affecting Licensor or any Affiliate thereof that questions the validity of this Agreement or the right of Licensor to enter into this Agreement or consummate the transactions contemplated hereby and, to Licensor&#x2019;s and its Affiliates&#x2019; knowledge, there is no basis for the foregoing.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any governmental authority, or any third party, on the part of Licensor or any Affiliate thereof is required in connection with its execution, delivery and performance of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the best of Licensor&#x2019;s and its Affiliates&#x2019; knowledge, the issued and unexpired Patent included in the Licensed Technology existing as of the Execution Date are valid and enforceable.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No reexamination, interference, invalidity, opposition, nullity or similar claim or proceeding is pending or, to the best of Licensor&#x2019;s and its Affiliates&#x2019; knowledge, threatened with respect to any Patent included in the Licensed Technology as of the Execution Date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of Licensor or its Affiliates has employed, or otherwise used in any capacity, the services of any individual or entity debarred or disqualified under Applicable Laws.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of Licensor&#x2019;s or its Affiliates&#x2019; research or development of the Licensed Technology, manufacture of Licensed Products, or research leading to the inventions Covered by a Valid Claim of the Licensed Technology was supported in whole or part by funding or grants by any governmental agency or philanthropic or charitable organization. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the Foundational Patents set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the Licensed Patents set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, neither Licensor nor any of its Affiliates owns or controls any Patents necessary or useful for, or that would be infringed by, the Exploitation of any Licensed Product in any country in the Licensed Territory. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1.11</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factor Bioscience Pty Ltd, Factor Bioscience LLC, and Factor Bioscience Inc. are affiliates of Licensor and affiliates of each other.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Representations and Warranties of Licensee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensee hereby represents and warrants to Licensor that, as of the Execution Date:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization, with full power and authority to operate its properties and to carry on its business as presently conducted.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The execution and performance of Licensee&#x2019;s obligations under this Agreement do not conflict with, cause a default under, or violate any existing contractual obligation that may be owed by Licensee to any third party.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of Licensee or its Affiliates have employed, or otherwise used in any capacity, the services of any individual or entity debarred or disqualified under Applicable Laws.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any governmental authority, or any third party, on the part of Licensee or any Affiliate thereof is required in connection with its execution and delivery of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee further covenants to Licensor not to use or otherwise Exploit the Licensed Technology outside of the Field or outside the Licensed Territory, and Licensee acknowledges that any such use or Exploitation of the Licensed Technology outside the Field or outside the Licensed Territory shall be a material breach of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclaimer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. EXCEPT AS EXPRESSLY PROVIDED IN </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 6.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, LICENSOR IS PROVIDING THE LICENSED TECHNOLOGY &#x201c;AS IS,&#x201d; AND LICENSOR MAKES NO REPRESENTATIONS, AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR AS TO THE VALIDITY OR SCOPE OF ANY PATENTS, AND LICENSOR DOES NOT ASSUME ANY RESPONSIBILITY WHATSOEVER WITH RESPECT TO USE, SALE, OR OTHER DISPOSITION OF PRODUCTS INCORPORATING OR MADE BY USE OF THE LICENSED TECHNOLOGY IN </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONNECTION WITH THIS AGREEMENT, OR WITH RESPECT TO ANY OBLIGATION OF LICENSOR TO BRING OR PROSECUTE ACTIONS OR SUITS AGAINST THIRD PARTIES FOR INFRINGEMENT OF ANY PATENT INCLUDED IN THE LICENSED TECHNOLOGY.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LIMITATION OF LIABILITY</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. TO THE FULLEST EXTENT PERMITTED BY LAW, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ANY OTHER PERSON FOR ANY INJURY TO OR LOSS OF GOODWILL, REPUTATION, BUSINESS PRODUCTION, REVENUES, PROFITS, ANTICIPATED PROFITS, CONTRACTS, OR OPPORTUNITIES (REGARDLESS OF HOW THESE ARE CLASSIFIED AS DAMAGES), OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, PUNITIVE, OR ENHANCED DAMAGES, WHETHER ARISING OUT OF BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, PRODUCT LIABILITY, OR OTHERWISE (INCLUDING THE ENTRY INTO, PERFORMANCE, OR BREACH OF THIS AGREEMENT), REGARDLESS OF WHETHER SUCH LOSS OR DAMAGE WAS FORESEEABLE AND THE PARTY AGAINST WHOM LIABILITY IS CLAIMED HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS OR DAMAGE, AND NOTWITHSTANDING THE FAILURE OF ANY AGREED REMEDY OF ITS ESSENTIAL PURPOSE. THE FOREGOING LIMITATIONS WILL NOT: (A) APPLY TO INFRINGEMENT BY A PARTY OF THE OTHER PARTY&#x2019;S INTELLECTUAL PROPERTY RIGHTS, A PARTY&#x2019;S BREACH OF [***], OR LICENSEE&#x2019;S BREACH OF [***], OR (B) LIMIT A PARTY&#x2019;S INDEMNIFICATION OBLIGATIONS UNDER </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 9</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term and Termination</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Te</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">rm</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The term of this Agreement will commence on the Effective Date, and will continue until the date of expiration of the last-to-expire Royalty Term, unless earlier terminated under the provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or by the mutual written agreement of the Parties (the period from the Effective Date until such expiration or termination, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Subject to the terms and conditions of this Agreement, Licensor hereby, effective upon the expiration of the last-to-expire Royalty Term, grants to Licensee an exclusive, fully paid, non-transferrable (except in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), perpetual license, with the right to grant sublicenses, under the Improvement Patents, to Exploit Licensed Products in the Field and in the Licensed Territory.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination by Either Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Either Party may terminate this Agreement at any time upon written notice to the other Party if the other Party is in material default or breach of this Agreement and such material default or breach is not cured within [***] after written notice thereof is delivered to the defaulting or breaching Party, or in the case of a breach (other than a breach of a Party&#x2019;s payment obligation) that cannot be cured within [***], within a reasonable period not exceeding [***]after written notice thereof is delivered to the defaulting or breaching Party, so long as the breaching Party is making a good faith effort to cure such default or breach of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination by Licensor</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensor may, at its option, terminate this Agreement effective upon [***] written notice to Licensee if Licensee (i) files for protection under bankruptcy laws; (ii) makes an assignment for the benefit of creditors; (iii) appoints or suffers appointment of a receiver or trustee over its property; (iv) files a petition under any bankruptcy or insolvency act or has any such petition filed against it, which is not discharged within [***] of the filing thereof; or (v) is unable to pay its debts as they become due in the ordinary course of business. Nothing in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall prohibit Licensor from pursuing any other remedies at law which it may have in</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">connection with Licensee&#x2019;s uncured material breach.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination by Licensee</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee may, at its option, terminate this Agreement, in its entirety, upon written notice to Licensor of any of the following events or otherwise as provided in this Agreement:</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.4.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at any time without cause, by giving at least sixty (60) days prior written notice of such termination to Licensor; or</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.4.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effective upon [***] written notice to Licensor if Licensor (i) files for protection under bankruptcy laws; (ii) makes an assignment for the benefit of creditors; (iii) appoints or suffers appointment of a receiver or trustee over its property; (iv) files a petition under any bankruptcy or insolvency act or has any such petition filed against it, which is not discharged within [***] of the filing thereof; or (v) is unable to pay its debts as they become due in the ordinary course of business.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nothing in the foregoing subsections of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall prohibit Licensee from pursuing any other remedies at law which it may have in connection with Licensor&#x2019;s uncured material breach.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Challenging Validity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensor has the right to terminate this Agreement upon written notice to Licensee in the event that Licensee or any of its Affiliates or permitted Sublicensees directly or indirectly challenges in a legal or administrative proceeding the patentability, enforceability or validity of any Patent included in the Licensed Technology or the scope or construction of any Valid Claim (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Challenge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); provided that with respect to any Sublicensee, Licensor will not have the right to terminate this Agreement under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if Licensee (A) causes such Patent Challenge to be terminated or dismissed (or in the case of ex-parte proceedings, multi-party proceedings, or other Patent Challenges in which the challenging party does not have the power to unilaterally cause the Patent Challenge to be withdrawn, causes such Sublicensee to withdraw as a party from such Patent Challenge and to cease actively assisting any other party to such Patent Challenge), or (B) terminates such Sublicensee&#x2019;s sublicense to the Licensed Technology being challenged by the Sublicensee, in each case, within [***] of the Licensor&#x2019;s notice to Licensee under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effects of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.6.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination of License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon a termination (but not upon an expiration) of this Agreement for any reason, Licensee&#x2019;s rights to the Licensed Technology which have been granted hereunder will terminate, and all rights in the Licensed Technology will revert back to Licensor , and (a) each Party, in its capacity as a receiving Party of the other Party&#x2019;s Confidential Information, shall promptly return to such other Party or, if requested by such other Party, destroy all Confidential Information, including information and materials related to the Licensed Products, supplied to such Party by such other Party, and certify to the destruction in writing within [***] of the termination, and (b) Licensee hereby grants to Licensor an option, exercisable by Licensor upon written notice to Licensee delivered within [***] of such termination, to negotiate in good faith the right and license (with the right to grant sublicense) to use, in and outside of the Licensed Territory, [***]. In addition, any amounts properly owed to Licensor hereunder that Licensee has paid will not be refunded. Subject at all times to Licensee&#x2019;s continuing compliance with the terms of this Agreement, for a period of [***] following the termination of this Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sell-Off Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), Licensee shall have the right to sell off its inventory of finished Licensed Product then in Licensee&#x2019;s, its Affiliates&#x2019; or Sublicensees&#x2019; possession. Following the Sell-Off Period, upon Licensor&#x2019;s request, Licensee shall promptly destroy all unsold Licensed Products.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.6.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effect on Sublicenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that this Agreement is terminated for any reason by Licensor in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 7.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any sublicense agreement shall be considered a direct license from Licensor to such surviving Sublicensee, provided that the Licensor is provided a copy of such sublicense agreement and all amendments thereto within a reasonable amount of time following such termination and the Sublicensee agrees in a writing delivered to Licensor within [***] of such termination that (i) Licensor is entitled to enforce all relevant provisions of this Agreement directly against such Sublicensee, and (ii) Licensor shall not assume any obligations to such Sublicensee in excess of those obligations corresponding to, and consistent with, those of Licensor set forth in this Agreement with respect to the applicable rights of such Sublicensee to Licensed Technology. Subject to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.6.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an expiration of this Agreement shall have no effect on sublicenses.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.6.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expiration or termination of this Agreement will not release either Party from any obligation that matured prior to the effective date of such expiration or termination. Upon expiration or termination of this Agreement for any reason, any unpaid amounts payable to Licensor shall become immediately due, and payment thereof shall remain an ongoing obligation of Licensee until such amount is paid in full.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.6.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon expiration or termination of this Agreement, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0f0f0f;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 2.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0f0f0f;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0f0f0f;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0f0f0f;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through and including </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will, with related definitions, survive and remain in full force and effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Protection of Intellectual Property Rights</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Prosecution</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the Term, Licensor will be responsible for preparing, filing, prosecuting and maintaining all Patents included in the Licensed Technology in the Licensed Territory. For the sake of clarity, as used herein the term &#x201c;prosecution&#x201d; shall include interference, opposition, derivation, re-examination, ex partes review, inter partes review, or any other administrative proceedings in connection with the Licensed Technology. Licensor shall (a) select patent counsel to conduct such activities regarding the Licensed Technology, and (b) provide Licensee with a reasonable opportunity to comment thereon and will reasonably consider in good faith such comments. Should Licensor decide that it is not interested in maintaining a particular Patents included in the Licensed Technology in the Licensed Territory, it will promptly advise Licensee in writing, and Licensee will have the right, but not the obligation, to assume such maintenance responsibilities in the Licensed Territory [***]. If Licensee desires to assume such maintenance responsibilities of any such Patents included in the Licensed Technology in the Licensed Territory pursuant to the immediately preceding sentence, then Licensor will not so fail to maintain such Patents if Licensee advises Licensor, within [***] of Licensee&#x2019;s receipt of notice of Licensor&#x2019;s intention not to maintain the applicable Patents in the Licensed Territory, that Licensee desires to assume maintenance of the applicable Patents. Licensee shall [***] within [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enforcement of Licensed Technology</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will promptly report in writing to the other Party of any Competitive Infringement of which such Party (or any of its Affiliates or Sublicensees) becomes aware.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Competitive Infringement of Licensed Technology by Third Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.2.1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the case of any Competitive Infringement in the Licensed Territory by any third party, Licensor will have the first right, but not the obligation, to cause such third party to cease infringement and to otherwise enforce such Licensed Technology, or to defend the Licensed Technology in</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any declaratory judgment action brought by third party(ies) which alleges the invalidity, unenforceability or non-infringement of any Patents included in the Licensed Technology in the Licensed Territory. In the event Licensor elects not to initiate any action to abate any Competitive Infringement or to defend any such declaratory judgment, then Licensee will have the right, but not the obligation, to cause such third party to cease infringement and to otherwise enforce such Licensed Technology or defend such declaratory judgment, and Licensee shall consider in good faith the views of Licensor and the potential effects of such enforcement action or defense activities on Licensor, its Affiliates and their third-party licensees.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.2.2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For any action or proceeding brought by a Party under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the other Party shall cooperate reasonably in any such effort, and the Parties shall reasonably cooperate to address new facts or circumstances that come to light during the course of any such action or proceeding that may affect the need for one Party or the other to participate in such action. The other Party agrees to be joined as a party plaintiff, [***], in any such action if needed for the enforcing Party to bring or continue an infringement action hereunder.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2.2.3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any recovery realized as a result of any litigation brought under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to abate a Competitive Infringement (including, for greater certainty, awards, damages, and other amounts received in resolution or settlement of a claim of Competitive Infringement, but excluding all other awards, damages, and other amounts, including, without limitation, amounts received in resolution or settlement of any other claims within such litigation) will be allocated first to [***] and any remaining amounts [***] shall be [***]. For clarity, Licensor shall have no right to resolve or settle a claim of Competitive Infringement in contravention of the rights granted to Licensee in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements; Improvement Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.3.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee will promptly disclose to Licensor during the Term any Improvements and related Improvement Patents, and the Parties agree promptly to update </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon written request by either Party from time to time, to reflect the inclusion of any Improvement Patents.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.3.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the rights granted to Licensee in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Licensor shall own, and Licensee shall assign and hereby does assign to Licensor all right, title and interest in and to all Improvements and Improvement Patents, including all related certificates of correction, reissue certificates, and supplementary protection certificates, and all other rights granted under 35 U.S.C. &#167; 307, 35 U.S.C. &#167;318, 35 U.S.C. &#167;328, and 35 U.S.C. &#167; 254-257. Licensee shall execute and assist with any and all applications, assignments, or other instruments which Licensor deems necessary to perfect the foregoing assignment and/or to evidence, apply for, obtain, maintain, defend or enforce patent or other intellectual property protection in any and all countries worldwide with respect to Improvements assigned to Licensor as set forth above or to protect otherwise Licensor&#x2019;s interest therein.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Infringement of Third-Party Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will promptly notify the other Party in writing of any notice or claim of any allegation of infringement or commencement against it of any suit or action for infringement of a third-party patent based upon or arising from actions taken under the licenses granted in this Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third-Party Infringement Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). If such Third-Party Infringement Claim is alleged or commenced against Licensee, Licensee will have the sole right to defend and settle such Third&shy; Party Infringement Claim, and Licensee will not be obligated to enter into negotiations with such third party to obtain rights for either Licensee or Licensor under the third-party patent. If such Third-Party Infringement Claim is alleged or commenced against Licensor, then subject to, and without limiting Licensee&#x2019;s indemnification obligations under this Agreement, Licensee will have the first right, but not the </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obligation, to defend and settle such Third-Party Infringement Claim; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that Licensee will not be obligated to enter into negotiations with such third party to obtain rights for Licensor under the third-party patent. With respect to any such defense by Licensee of a Third-Party Infringement Claim alleged or commenced against Licensor, Licensee will not make any settlements of such Third-Party Infringement Claim that would materially adversely affect Licensor&#x2019;s rights or interests in the Licensed Technology without first obtaining Licensor&#x2019;s prior written consent. If Licensee opts not to defend or settle such Third-&shy;Party Infringement Claim alleged or commenced against Licensor, Licensee will notify Licensor of such decision and, [***], Licensor will have the right to undertake the defense or settlement of such Third-Party Infringement Claim. In all cases, the Parties shall cooperate in good faith and provide reasonable assistance in connection with the defense of any such Third-Party Infringement Claim.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidential Information</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party will maintain the Confidential Information of the other Party in strict confidence, and will not disclose, divulge or otherwise communicate such Confidential Information to others, or use it for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement, or with the express written consent of the Party who provided such Confidential Information. Each Party will maintain the confidentiality of the other Party&#x2019;s confidential information using methods and practices that are substantially similar to those that the receiving Party uses to maintain the confidentiality of its own confidential information, but in no event less than a reasonable degree of care. Except as may be authorized in advance in writing by the disclosing Party, the receiving Party will disclose or grant access to the Confidential Information to only those of its employees and agents as reasonably necessary or useful to exercise its rights or perform its obligations under this Agreement and such employees and agents will have entered into non-disclosure agreements, or be bound by professional obligations of confidentiality, no less protective of the disclosing party&#x2019;s Confidential Information than those set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the receiving Party shall be liable to the disclosing Party for any breach of such employees and agents&#x2019; confidentiality obligations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, a receiving Party may disclose Confidential Information of the disclosing Party to:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its Affiliates, and to its and their directors, employees, consultants, contractors, attorneys, advisors and agents, in each case who have a specific need to know such Confidential Information in connection with an activity under or relating to this Agreement and who are bound in writing by obligations of confidentiality and restrictions on use at least as stringent as those herein, and the receiving Party shall be liable to the disclosing Party for any breach of such employees and agents&#x2019; confidentiality obligations;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any bona fide actual or prospective collaborators who are under written obligations of confidentiality and non-use at least as stringent as those herein, to the extent reasonably necessary to enable such actual or prospective collaborators to (i) determine their interest in collaborating with the receiving Party on the development and/or commercialization of Licensed Products and (ii) engage in such a collaboration, and the receiving Party shall be liable to the disclosing Party for any breach of such employees and agents&#x2019; confidentiality obligations;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">governmental authorities in connection with filing, prosecuting, or maintaining patent rights as permitted by this Agreement;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Authorities in connection with regulatory filings for products that the receiving Party has a license or right to develop hereunder in a given country or jurisdiction;</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent required to do so by Applicable Law or a proper legal, governmental or other competent authority, or by the rules of any securities exchange on which any security issued by either Party is traded, or included in any filing or action taken by the receiving Party to obtain or maintain government clearance or approval to market a subject Licensed Product; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that, (i) to the extent permissible and practicable, the receiving Party required to make such disclosure shall give the disclosing Party reasonable advance notice of such disclosure requirement and shall afford the disclosing Party a reasonable opportunity to oppose, limit or secure confidential treatment for such required disclosure, or, where it is impracticable or illegal to give an advance notice, the Party required to make such disclosure shall give the disclosing Party reasonable notice promptly after such required disclosure; (ii) the Party required to make such disclosure shall disclose only that portion of the Confidential Information legally required to be disclosed; (iii) the Party required to make such disclosure shall use reasonable efforts to secure confidential treatment of such Confidential Information; and</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.2.6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to any [***]; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in any such case said Party shall first obtain a written obligation of confidentiality no less stringent than that imposed in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any information disclosed pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.5.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Names</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither Party may identify the other Party in any promotional advertising or other promotional materials to be disseminated to the public or any portion thereof, or use the name of any staff member or employee of the other Party or any trademark, service mark, trade name, symbol or logo that is associated with the other Party, without the other Party&#x2019;s prior written consent. Notwithstanding the foregoing, and for the avoidance of doubt, without the consent of the other Party either Party may comply with disclosure requirements of all Applicable Laws relating to its business, including, without limitation, United States and state securities laws. During the Term, and with the prior written consent of the other Party, each Party may include the other Party&#x2019;s name, logo, and a brief description of such other Party on said Party&#x2019;s website and such other Party hereby consents to such inclusion of its name, logo, and a brief description on said Party&#x2019;s website; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that either Party shall have the right to revoke such consent at any time and for any reason, and promptly following written notice of such revocation, and in any event within [***], the posting Party shall remove the other Party&#x2019;s name, logo, and description from the posting Party&#x2019;s website.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Press Releases</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties shall mutually agree upon the timing and content of any press releases or other public announcement relating to this Agreement and the transactions and/or activities contemplated herein.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliates and Sublicensees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For the avoidance of doubt, and notwithstanding anything to the contrary in this Agreement, each Party&#x2019;s Affiliates and Licensee&#x2019;s Sublicensees may exercise such Party&#x2019;s rights under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification; Insurance</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification by Licensee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensee will indemnify, defend and hold harmless Licensor, its Affiliates and their respective directors, officers, employees, consultants, licensors and agents, and their respective successors, heirs, and assigns (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensor Indemnitee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), against all suits, actions, claims, proceedings, in each case brought by a third party (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the resulting liabilities, demands, damages, losses, or expenses (including legal expenses, investigative expenses, and attorneys&#x2019; fees) </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Losses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to the extent arising out of Licensee&#x2019;s or, as applicable Licensee&#x2019;s Affiliate&#x2019;s or Sublicensee&#x2019;s: (a) gross negligence or intentional misconduct, (b) failure to comply with Applicable Laws, or (c) Licensee&#x2019;s, its Affiliates&#x2019; or Sublicensee&#x2019;s Exploitation of Licensed Product in the Licensed Territory or the exercise of the licenses granted under this Agreement, including the production, manufacture, sale, use, lease, consumption, administration, shipping, storage, transfer, advertisement, analysis, measurement, description, or characterization of the Licensed Technology, or Licensed Products, or any activity arising from or in connection with any right or obligation of Licensee hereunder, except in each case (a) through (c) to the extent resulting from a Licensor Indemnitee&#x2019;s (i) gross negligence or intentional misconduct; (ii) failure to comply with Applicable Law; (iii) Exploitation of the Licensed Technology; or (iv) breach of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification by Licensor</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensor will indemnify, defend and hold harmless Licensee, its Affiliates, Sublicensees, any contractors of the foregoing, and their respective directors, officers, employees, consultants, licensors and agents, and their respective successors, heirs, and assigns (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensee Indemnitee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) against any Claims and Losses to the extent arising out of Licensor&#x2019;s or its Affiliate&#x2019;s: (a) gross negligence or intentional misconduct; (b) failure to comply with Applicable Laws; or (c) Exploitation of the Licensed Technology; except in each case (a) through (c) to the extent resulting from a Licensee Indemnitee&#x2019;s (i) gross negligence or intentional misconduct; (ii) failure to comply with Applicable Law; (iii) Exploitation of the Licensed Technology; or (iv) breach of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Procedure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party&#x2019;s agreement to indemnify, defend, and hold harmless under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as applicable, is conditioned upon the indemnified Party (a) providing written notice to the indemnifying Party of any Claim as soon as reasonably possible, and in any event no later than within [***], (b) permitting the indemnifying Party to assume control over the investigation of, preparation and defense against, and settlement or voluntary disposition of any such Claim, (c) assisting the indemnifying Party, at the indemnifying Party&#x2019;s reasonable expense, in the investigation, preparation, defense, and settlement or voluntary disposition of any such Claim, and (d) not compromising, settling, or entering into any voluntary disposition of any such Claim without the indemnifying Party&#x2019;s prior written consent, which consent shall not be unreasonably withheld; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, if the Party entitled to indemnification fails to promptly notify the indemnifying Party pursuant to the foregoing clause (a), the indemnifying Party will only be relieved of its indemnification obligation to the extent materially prejudiced by such failure. In no event may the indemnifying Party compromise, settle, or enter into any voluntary disposition of any Claim in any manner that admits material fault or wrongdoing on the part of the indemnified Party or incurs non&shy; indemnified liability on the part of the indemnified Party without the prior written consent of the indemnified Party, and in no event may the indemnifying Party settle, compromise, or agree to any voluntary disposition of any matter subject to indemnification hereunder in any manner which (i) imposes any monetary restriction or obligation on or admits fault of the other Party or (ii) adversely affects the other Party&#x2019;s rights under this Agreement, without such other Party&#x2019;s prior written consent.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Licensee shall maintain in full force and effect during the Term, worker&#x2019;s compensation, general liability and professional liability, clinical trial liability, and product liability insurance coverage, all in such amounts as are customary in the life sciences and pharmaceutical industries. Upon written request of Licensor, Licensee shall provide evidence of such insurance to Licensor. Licensee shall ensure that Licensor will receive no less than [***] prior notice of any cancelation, non&shy; renewal or material change in such insurance coverage.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Alternative Dispute Resolution</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Negotiation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event of any dispute or disagreement between the Parties as to the interpretation of any provision of this Agreement (or the performance of any obligations hereunder), the matter, upon written request of either Party, shall be referred to representatives of the Parties for decision, each Party being represented by an executive officer (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Representatives</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Representatives shall promptly meet in a good faith effort to resolve the dispute. If the Representatives do not mutually agree upon a decision within [***], each of the Parties shall be free to exercise the remedies available to it under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party may extend the period of time for negotiation among the Representatives for an additional period of [***] on [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Submission to Arbitration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Parties are unable to resolve such dispute pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, either Party may submit the dispute to binding arbitration (without any recourse to the federal or state courts except to enforce any arbitral award or, within [***], to appeal such final decision based solely on a claim that the Arbitrator engaged in gross misconduct or made a material error or miscalculation in his or her decision) in accordance with the rules of JAMS/End Dispute (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #0e0e0e;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">JA</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">MS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) then in force (except as expressly modified below), and the arbitration hearings shall be held before a single arbitrator (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Arbitrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in [***]. The Parties agree to appoint an Arbitrator who is knowledgeable in the patenting prosecution, patent licensing, biotechnology and/or life sciences industries. If the Parties cannot agree upon an Arbitrator within [***], either or both Parties may request the JAMS to name a panel of [***] candidates to serve as Arbitrator. The Parties shall each, in successive rounds (with the Party demanding the arbitration having the first chance to strike a name), strike one name off this list until only one name remains, and such last-named person shall be the Arbitrator.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conduct of Arbitration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Arbitrator shall be required to (a) follow the substantive rules of Massachusetts State or Federal law, as applicable, (b) require all testimony to be transcribed, and (c) accompany his or her award with findings of fact and a statement of reasons for the decision. The Arbitrator shall have the authority to permit discovery for no more than [***], to the extent deemed appropriate by the Arbitrator, upon reasonable request of a Party. The Arbitrator shall have no power or authority to (i) add to or detract from the written agreement of the Parties set forth herein, (ii) modify or disregard any provision of this Agreement or any of the other related documents, or (iii) address or resolve any issue not submitted by the Parties. The Arbitrator shall hold proceedings during a period of no longer than [***], and the Arbitrator shall render a final decision within [***]. The Arbitrator shall have the power to grant injunctive relief (without the necessity of a Party posting a bond) in the event a Party has violated the confidentiality provisions set forth in this Agreement, but shall have no power to award punitive and/or exemplary damages in the event of a breach, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that nothing in this Agreement will operate to prevent a Party from seeking injunctive relief in a court of competent jurisdiction. In the event of any conflict between the commercial arbitration rules then in effect and the provisions of this Agreement, the provisions of this Agreement shall prevail and be controlling.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim Relief</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Either Party may, without waiving any remedy under this Agreement, apply to the Arbitrator for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights regarding the Intellectual Property of that Party pending the arbitration award. The Arbitrator shall have no authority to award punitive or any other type of damages not measured by a Party&#x2019;s compensatory damages.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Arbitration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party shall share in the actual and direct costs of the engagement of the Arbitrator, but the prevailing Party in the arbitration shall be reimbursed by the non-prevailing Party for the prevailing Party&#x2019;s fees and costs of arbitration (e.g., the costs, fees and expenses of outside experts </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and counsel retained by the prevailing Party). If one Party is not deemed by the Arbitrator to be the primary prevailing Party, then each Party will pay its own costs, fees and expenses (including attorneys&#x2019; fees) and an equal share of the Arbitrator&#x2019;s fees and any administrative fees of arbitration.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excluded Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything to the contrary herein, nothing in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall preclude a Party from seeking injunctive relief or specific performance in a court of competent jurisdiction. Unless otherwise mutually agreed upon by the Parties in writing, any Excluded Claims shall be brought in the federal court for the District of Massachusetts, if federal jurisdiction is available, or, alternatively, in the state courts in Suffolk County, Massachusetts. Each of the Parties hereby submits to the exclusive jurisdiction of such courts for the purpose of any such litigation; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Each Party irrevocably and unconditionally agrees not to assert (a) any objection which it may ever have to the laying of venue of any such litigation in such courts, (b) any claim that any such litigation brought in any such court has been brought in an inconvenient forum, and (c) any claim that such court does not have jurisdiction with respect to such litigation. As used in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excluded Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a dispute, controversy or claim that concerns: (w) the scope, construction, validity or infringement of a patent, trademark or copyright; or (x) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor an Arbitrator may disclose the existence, content, or results of the arbitration without the prior written consent of both Parties, except to its directors, officers and investors. In no event shall arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable Massachusetts statute of limitations.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 11</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Miscellaneous</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance with Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with its Exploitation of Licensed Products, Licensee agrees to comply with all Applicable Laws. Without limiting the foregoing, by entering into this Agreement, the Parties specifically intend to comply with all Applicable Laws pertaining to Licensed Products, including, without limitation (i) the federal anti-kickback statute (42 U.S.C. &#167;1320a-7b) and the related safe harbor regulations; and (ii) the Limitation on Certain Physician Referrals, also referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stark Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; (42 U.S.C. &#167;1395nn); (iii) foreign trade law, regulations on the administration of technology import and export, export control law; (iv) cybersecurity law, data security law, personal information protection law; (v) GCP, GMP, GSP, their relative rules and regulations, and the revisions thereof. Accordingly, no part of any consideration paid hereunder is a prohibited payment for the recommending or arranging for the referral of business or the ordering of items or services; nor are the payments intended to induce illegal referrals of business.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement will be binding upon and will inure to the benefit of each Party and each Party&#x2019;s respective transferees, successors and assigns, pursuant to the provisions set forth below. Licensee may not transfer or assign this Agreement without the prior written consent of Licensor, except that Licensee may transfer or assign this Agreement without the prior written consent of Licensor in the event that a third party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquiring Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) acquires all or substantially all of Licensee&#x2019;s business, capital stock or assets, whether by sale, merger, change of control, operation of law or otherwise (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Upon an Acquisition, the rights granted to Licensee under this Agreement pertaining to any and all Licensed Products shall inure to the benefit of the Acquiring Party. For the avoidance of doubt, in the event of an Acquisition, the Acquiring Party will be responsible for all payments and other obligations set forth in this Agreement, including, but not limited to, all payments set forth herein, and any obligations that matured prior to the Acquisition date. Upon an Acquisition, any unpaid portion of any deferred </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments payable to Licensor hereunder shall remain an ongoing obligation of the Acquiring Party until such amount is paid in full. For the avoidance of doubt, an Acquisition shall not include any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by Licensee or any successor, indebtedness of Licensor is cancelled or converted or any combination thereof. Any attempted assignment in contravention of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be null and void.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement constitutes the entire agreement between the Parties hereto with respect to the subject matter thereof (with the exception of the contemporaneous Amended and Restated Master Services Agreement and Amended and Restated Trademark Agreement by and between the Parties) and supersedes all previous agreements, negotiations, commitments, and writings with respect to such subject matter. Neither Party shall be obligated by any undertaking or representation regarding that subject matter other than those expressly stated herein or as may be subsequently agreed to by the Parties hereto in writing. In the event of any conflict or inconsistency between any provision of any Exhibit hereto and any provision of this Agreement, the provisions of this Agreement shall prevail.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No amendment, modification or supplement of any provision of this Agreement and Exhibit(s) will be valid or effective unless made in writing and signed by a duly authorized officer of each Party.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any notice required to be given pursuant to the provisions of this Agreement will be in writing and will be deemed to have been given at the time when actually received as a consequence of any effective method of delivery, including but not limited to hand delivery, transmission by electronic transmission, including PDF (portable document format), delivery by a professional courier service or delivery by first class, certified or registered mail (postage prepaid) addressed to the Party for whom intended at the address below, or at such changed address as the Party will have specified by written notice in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that any notice of change of address will be effective only upon actual receipt.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Licensor:</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factor Bioscience Limited</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c/o Factor Bioscience Inc.</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1035 Cambridge Street, Suite 17B</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cambridge, MA 02141</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: [***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email: [***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with copy (which shall not constitute notice) to:</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Licensee:</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Erigen LLC</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1035 Cambridge Street, Suite 17B</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cambridge, MA 02141</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attn: [***]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.6.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The substantive law governing this Agreement (which shall be applied in the arbitration) shall be, with respect to disputes involving general contract or trade secret matters, the internal laws of the Commonwealth of Massachusetts, and with respect to matters involving patents, the United States Patent Act, as to copyright matters, the United States Copyright Act, and as to trademark matters, the United States Trademark Act, each as amended from time to time. The Parties agree that the arbitration shall be seated in [***] under JAMS rules. Any award rendered by the Arbitrators shall be final, conclusive and binding upon the Parties to this Agreement. The Parties undertake to recognize and enforce the arbitration award in all relevant jurisdictions.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.6.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any provisions of this Agreement are or will come into conflict with the laws or regulations of any jurisdiction or any governmental entity having jurisdiction over the Parties or this Agreement, those provisions will be deemed automatically deleted, if such deletion is allowed by relevant law, and the remaining terms and conditions of this Agreement will remain in full force and effect. If such a deletion is not so allowed or if such a deletion leaves terms thereby made clearly illogical or inappropriate in effect, the Parties agree to substitute new terms as similar in effect to the present terms of this Agreement as may be allowed under Applicable Law.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Descriptive Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement has been prepared jointly by the Parties and shall not be strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of each Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Section. Except where the context otherwise requires, the use of any gender shall be applicable to all genders, and the word &#x201c;or&#x201d; is used in the inclusive sense (and/or). The term &#x201c;including&#x201d; as used herein means including, without limiting the generality of any description preceding such term.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Independent Contractors</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Both Parties are independent contractors under this Agreement. Nothing contained in this Agreement will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. Notwithstanding anything contained herein to the contrary, and for the avoidance of doubt, Licensor shall not be deemed an Affiliate of Licensee, and Licensee shall not be deemed an Affiliate of Licensor.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The illegality or partial illegality of any provision of this Agreement will not affect the validity of the remainder of the Agreement, or any provision thereof, and the illegality or partial illegality of any provision of this Agreement will not affect the validity of the Agreement in any jurisdiction in which such determination of illegality or partial illegality has not been made, except in either case to the extent such illegality or partial illegality causes the Agreement to no longer contain all of the material provisions reasonably expected by the Parties to be contained therein. Moreover, in the event that a court of competent jurisdiction determines that any provision of this Agreement is illegal or partially illegal, then it is the intention of the Parties that such provision be modified to the minimum extent deemed necessary by such court to make such provision enforceable and to give effect to the original intention of the Parties.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Waiver of Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The failure of either Party to comply with any obligation, covenant, agreement or condition under this Agreement may be waived by the Party entitled to the benefit thereof only by a written instrument signed by the Party on granting such waiver, but such waiver or failure to insist upon strict compliance with such obligation, covenant, agreement or condition will not operate as a waiver of, or estoppel with respect to, any subsequent or other failure. The failure of any Party to enforce at any time any of the provisions of this Agreement will in no way be construed to be a waiver of any such provision, nor in any way to affect the validity of the Agreement or any part thereof or the right of any Party thereafter to enforce each and every such provision. No waiver of any breach of such provisions will be held to be waiver of any other or subsequent breach.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.11</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed by original or facsimile signature in any number of counterparts, each of which need not contain the signature of more than one Party, but all such counterparts taken together will constitute one and the same agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.12</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The persons signing on behalf of Licensor and Licensee hereby warrant and represent that they have authority to execute this Agreement on behalf of the Party for whom they have signed.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.13</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Solicitation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. [***], neither Party shall, without the prior written consent of the other Party, directly or indirectly solicit for employment any employee of the other Party or any of its Affiliates or subsidiaries, or any person who has terminated his or her employment with the other Party or any of its Affiliates or subsidiaries within the previous [***] prior to any purported solicitation; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the foregoing will not [***] . [***].</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.14</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither Party hereto shall be liable for failures and delays in performance due to strikes, lockouts, fires, acts of God or the public enemy, riots, incendiaries, interference by civil or military authorities, acts of terrorism, endemic, pandemic, and the results related to such acts, compliance with the laws of various states/countries, or with the orders of any governmental authorities, delays in transit or delivery on the part of transportation companies, failures of communication facilities, or any failure of sources of material (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Force Majeure Event</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Notwithstanding the above, should the event of Force Majeure last for more than [***], the other Party shall be entitled to terminate this Agreement effective upon giving written notice to the Party affected by the Force Majeure Event.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Remainder of page intentionally left blank; signature page follows.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the Parties hereto have duly executed this Amended and Restated License and Collaboration Agreement as of the Execution Date.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FACTOR BIOSCIENCE LIMITED (LICENSOR)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.341%;padding-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/: Christopher Rohde	</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name: Christopher Rohde, Ph.D.</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: Director</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERIGEN LLC (LICENSEE)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.341%;padding-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/: Matt Angel	</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name: Matthew Angel, Ph.D.</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: Manager</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.51in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Terms</font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sec: 5.1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development Milestones</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: The development Milestones set forth below shall apply only to the Licensed Products set forth below. Each time a Milestone set forth below is achieved by Licensee or a Sublicensee, Licensee shall pay to Licensor the corresponding development Milestone Payment set forth below:</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:42.1%;box-sizing:content-box;"></td>
     <td style="width:28.92%;box-sizing:content-box;"></td>
     <td style="width:28.98%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Development Milestone Payment (USD)</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Development Milestone</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">ERI-3003 Product</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">ERI-3206 Product</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">TOTAL</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Milestones</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For each Licensed Product set forth below, the first time each commercial Milestone set forth below is achieved by Licensee or a Sublicense, Licensee shall pay to Licensor the corresponding commercial Milestone Payment set forth below. For clarity, for each Licensed Product set forth below, commercial Milestone Payments shall be [***].</font></p>
   <table style="margin-left:17.454%;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:34.96%;box-sizing:content-box;"></td>
     <td style="width:32.56%;box-sizing:content-box;"></td>
     <td style="width:32.48%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Commercial Milestone Payment (USD)</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Commercial Milestone</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">ERI-3003 Product</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">ERI-3206 Product</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">TOTAL</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sec. 5.1.2	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Agreement,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commencing upon the First Commercial Sale of a Licensed Product by Licensee in any country in the Licensed Territory and continuing until the expiration of the Royalty Term for such Licensed Product in such country, on a [***] basis, Licensee shall pay to Licensor a Royalty on Net Sales in such country equal to [***] of Net Sales of such Licensed Products; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that upon [***], the Royalty on Net Sales in such country shall be equal to [***] of Net Sales of such Licensed Product for the remainder of the Royalty Term.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sec. 5.1.4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Licensee shall pay to Licensor an amount equal to the percentage of Sublicense Fees received by Licensee or any of its Affiliates in accordance with the table set forth below as follows:</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:60.28%;box-sizing:content-box;"></td>
     <td style="width:39.72%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;background-color:#d9d9d9;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;border-left:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Sublicense Fee Event</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">% of Sublicense Fee</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    </tr>
   </table><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foundational Patents</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensed Patents</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvement Patents</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[To be added during the Term]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>6
<FILENAME>tpst-ex10_27.htm
<DESCRIPTION>EX-10.27
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T08:19:11.6090+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.27</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT TEMPEST THERAPEUTICS, INC. TREATS AS PRIVATE AND CONFIDENTIAL</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDED AND RESTATED MASTER SERVICES AGREEMENT</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS AMENDED AND RESTATED MASTER SERVICE AGREEMENT (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into as of this 19</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day of November, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Execution Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and completely supersedes the Master Services Agreement dated as of 6</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day of August 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between FACTOR BIOSCIENCE INC., a corporation organized and existing under the laws of the State of Delaware (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Factor</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and ERIGEN LLC, a limited liability company organized and existing under the laws of the State of Delaware (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erigen</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Factor and Erigen may each be referred to in this Agreement individually as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and collectively as the &#x201c;Parties.&#x201d;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Erigen and Factor&#x2019;s subsidiary, Factor Bioscience Limited, a company organized and existing under the laws of Ireland, are parties to that certain Amended and Restated License and Collaboration Agreement, dated as of the Execution Date and effective as of August 6, 2025 (hereinafter, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), pursuant to which Factor Bioscience Limited licensed certain Licensed Technology to Erigen in the Field (as such terms are defined in the License); and</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, in support of Erigen&#x2019;s obligations set forth in the License to develop Licensed Products (as such term is defined in the License), Erigen desires to engage Factor to perform certain services; and WHEREAS, Factor agrees to perform such services in accordance with this Agreement.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Factor shall perform the services requested by Erigen on a fee-for-service basis and provide Erigen access to Factor&#x2019;s facilities, all as mutually agreed upon by the Parties and more particularly set forth in one or more written work orders (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Work Order</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) entered into by the Parties hereunder (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). As soon as is practicable after the Effective Date, Factor and Erigen shall negotiate in good faith and enter into one or more Work Orders pursuant to which Factor shall use its laboratory facilities and personnel to perform agreed upon research and development services for Erigen. Factor may contract with third parties to conduct any part or all of the Services, provided that Factor obtains from such third parties written obligations at least as restrictive as those set forth in Section 5. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Work Orders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Work Order shall be substantially in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and shall set forth specific activities to be performed, specific Deliverables (as defined herein), headcount on an FTE basis, relevant facilities, and a payment schedule, on a fee-for-service basis, associated with the performance of such activities. The Parties will attach sequentially numbered Work Orders to this Agreement, and each such Work Order shall be a complete statement of the relevant project terms and shall supplement the terms and conditions of this Agreement solely for the purposes of such Work Order. The terms and conditions of this Agreement shall be deemed incorporated by reference in each such Work Order, except that in the event of any contrary or inconsistent terms or conditions appearing in or referred to in any such Work Order, the terms of the Work Order shall control with respect to the applicable Work Order to the extent such Work Order specifically identifies the applicable terms of this Agreement it is intending to supersede. The Parties acknowledge that purchase orders or other similar related documents </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.13in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may be issued or executed by Erigen in connection with the Services, but this Agreement and any applicable Work Order shall take precedence over any additional, contrary or inconsistent terms and conditions appearing or referred to in any such purchase orders or other similar related documents.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Services and/or Deliverables</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties acknowledge and agree that in the event that Erigen desires Factor to provide any additional Services or Deliverables that are not expressly identified in a valid, unexpired Work Order, including, without limitation, any research or development services, creation of any Deliverables or creation of any Intellectual Property (as defined in the License), it shall be subject to the Parties first agreeing to mutually acceptable additional terms to be set forth in a new Work Order or an amendment to this Agreement, including, without limitation, representations and warranties, indemnification, ownership and/or licensing of Intellectual Property related thereto, which the Parties shall determine through reasonable negotiations conducted in good faith.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Exclusivity and Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. It is understood and agreed by and between Factor and Erigen that Factor maintains the right to perform similar services on behalf of itself or third parties during the term of this Agreement, so long as the confidentiality of information proprietary to Erigen is at all times protected by Factor in accordance with Section 5.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Factor Workplace Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event that Factor makes its premises available to Erigen or its personnel in connection with the Services performed hereunder, Erigen shall, and shall cause its personnel to, comply with and to perform its obligations in accordance with Factor&#x2019;s applicable instructions, rules, regulations and policies governing conduct in the workplace, as may be updated by Factor from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Workplace Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Factor may [***] remove any Erigen personnel from Factor&#x2019;s premises or suspend their access to such premises for noncompliance with the Workplace Rules. Factor will promptly notify Erigen after the removal or suspension of such personnel, as reasonably appropriate under the circumstances. The Parties will mutually determine in good faith how to resolve the non-compliance in the time frame needed by the Parties to avoid any material interruption to the Services. Erigen agrees that [***].</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance of Services; Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General Performance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Factor shall perform the Services in material compliance with all applicable laws and regulations, including, without limitation, laws and regulations relating to health, safety and the environment, fair labor practices and unlawful discrimination. In the event that any noncompliance with applicable laws or regulations occurs, Factor shall take such actions as necessary to eliminate such noncompliance to the extent and as soon as practicable.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Animal Welfare</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. With respect to Services involving the use of animals: (a) all such Services will be conducted under Factor&#x2019;s supervision and control (whether directly by Factor or by one or more third parties hired by Factor pursuant to Section 1.1); (b) all such animals will be cared for, used, and disposed of in conformity with the applicable legal and ethical standards of animal testing; (c) the relevant environment, housing, management, veterinary care, and physical plant used in connection with such animals in the Services are appropriate for the nature of the Services; (d) in no circumstances will any such animals be used as food for humans or animals; and (e) if specific instructions for animal use, care, handling, or disposal are mutually agreed upon by the Parties in the applicable Work Order, Factor will comply with such instructions in connection with the applicable Services.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Debarment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party represents and warrants that neither it nor any of its employees or consultants performing hereunder have been debarred under Section 306(a) or (b) of the U.S. Federal Food, Drug and Cosmetic Act. If at any time after the Effective Date a Party becomes aware that it or any of its </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.13in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4928-7326-4540, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employees or consultants have been debarred or is in the process of being debarred, such Party shall promptly notify the other Party thereof in writing and, in any event, within [***].</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement shall be effective as of the Effective Date and shall continue in effect until terminated by either Party in accordance with Section 7. Notwithstanding the foregoing, should any Work Order(s) entered into during the term of this Agreement require Services to be performed beyond the termination date of this Agreement, then the terms of this Agreement shall remain in effect with respect to such Work Order(s) until the expiration or termination of that Work Order(s).</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In consideration of the Services performed hereunder, Erigen will make payments to Factor in accordance with the applicable Work Order. Unless otherwise specified in any Work Order, Erigen shall make all such payments within [***]. If a portion of any invoice submitted by Factor hereunder is disputed in good faith by Erigen, then Erigen shall provide Factor with prompt notice thereof, pay the undisputed amounts as set forth in the immediately preceding sentence, and the Parties shall use their good faith efforts to reconcile any disputed amount within [***], following which Erigen shall promptly remit such reconciled amount, if any, to Factor. Late payments are subject to an interest charge of [***]. In addition to all other remedies available under this Agreement or at law (which Factor does not waive by the exercise of any rights hereunder), Factor shall be entitled to [***].</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. It is expressly understood and agreed that Erigen will pay any and all applicable taxes levied or based upon the Services performed under each Work Order (other than Factor&#x2019;s income taxes and employment related taxes applicable to Factor employees). Any such taxes will appear as a separate item on Factor&#x2019;s invoices.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As used herein, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all information furnished by one Party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosing Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to the other Party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Receiving Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that is confidential or proprietary to the Disclosing Party (whether or not reduced to writing or other tangible medium of expression, and whether or not patented, patentable, capable of trade secret protection or protected as an unpublished or published work under the United States Copyright Act of 1976, as amended), including without limitation, (a) information relating to the intellectual property and business practices of the Disclosing Party; (b) information observed or otherwise made available to Erigen or its personnel while on Factor&#x2019;s premises; and (c) any third party confidential or proprietary information in the possession of the Disclosing Party that is provided to the Receiving Party. Each Party, in its capacity as a Receiving Party, agrees to treat as the confidential and exclusive property of the Disclosing Party all Confidential Information that is disclosed or otherwise made available by the Disclosing Party in connection with this Agreement or the Parties&#x2019; business relationship. The Receiving Party agrees to use any Confidential Information of the other Party solely for purposes of its performance under this Agreement unless otherwise mutually agreed in writing. The Receiving Party shall maintain at least the same degree of care and diligence in the protection of the Confidential Information as it uses with regard to its own confidential or proprietary information, which in any event shall be no less than a reasonable standard of care and diligence for the industry.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.13in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4928-7326-4540, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Receiving Party agrees not to disclose any Confidential Information of the Disclosing Party to any third party for any purpose without obtaining the prior written consent of the Disclosing Party, except to its employees and personnel who have a need to know in order to perform its obligations under this Agreement; provided that such employees and personnel are obligated in writing to maintain the confidential nature of such Confidential Information on terms at least as restrictive as those set forth herein, and the Receiving Party will be responsible for any damages resulting from any breach of this Agreement by its employees and personnel.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Confidential Information does not include information that the Receiving Party is able to demonstrate (a) was rightfully in its possession prior to receipt from the Disclosing Party, as evidenced by the Receiving Party&#x2019;s written records, (b) is now, or hereafter becomes, part of the public domain through no act or failure to act on the part of the Receiving Party or its agents or collaborators, (c) becomes known to the Receiving Party at any time through disclosure by a third party having no known obligation of confidentiality with respect to such information, or (d) was independently developed by or on behalf of the Receiving Party without the aid, application, use or benefit of the Disclosing Party&#x2019;s Confidential Information, as evidenced by the Receiving Party&#x2019;s written records. In addition, a Receiving Party may disclose such Confidential Information to the limited extent required to do so by applicable law or a proper legal, governmental or other competent authority, or by the rules of any securities exchange on which any security issued by either Party is traded. Except where impracticable, such Receiving Party shall give the Disclosing Party reasonable advance notice of such disclosure requirement and shall afford the Disclosing Party a reasonable opportunity to oppose, limit or secure confidential treatment for such required disclosure, or, where it is impracticable to give an advance notice, such Receiving Party shall give the Disclosing Party reasonable notice promptly after such required disclosure. In the event of any such required disclosure, the Receiving Party shall disclose only that portion of the Confidential Information legally required to be disclosed.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Return of Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party agrees that, upon the earlier to occur of (a) the other Party&#x2019;s written request, or (b) termination of this Agreement, the Receiving Party shall (i) return to the Disclosing Party any or all parts of the Confidential Information of such party provided to the Receiving Party in documentary or other tangible form, including all copies and other tangible embodiments thereof, and (ii) destroy any or all Confidential Information in the Receiving Party&#x2019;s possession and stored in then&shy; accessible electronic or other media, in accordance with the Receiving Party&#x2019;s own policies and timing for the destruction of its own Confidential Information.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term of Confidentiality Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The provisions of this Section 5 shall remain in effect for [***]  following the termination of this Agreement, except that with respect to any Confidential Information constituting a trade secret as defined under applicable law, the provisions of this Section 5 shall remain in effect for as long as such Confidential Information continues to constitute a trade secret.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deliverables</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Unless otherwise specified in the applicable Work Order, all deliverables developed as a result of Factor&#x2019;s performance of the Services or as set forth in one or more Work Orders (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deliverables</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) are and shall be the sole property and Confidential Information of Erigen except to the extent that they qualify as Improvements (as such term is defined in the License). Factor, on behalf of itself and its Affiliates, shall and hereby does assign to Erigen all right, title, and interest in and to all such Deliverables. Notwithstanding the foregoing, Deliverables shall expressly exclude any discovery, advancement, development, or creation which is invented, developed, authored, created, or reduced to practice by Factor prior to the Effective Date or independently of the Services performed hereunder.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.13in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4928-7326-4540, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Solely to the extent necessary or reasonably useful to use, practice or otherwise exploit the Deliverables, Factor, on behalf of itself and its Affiliates, hereby grants to Erigen a non-exclusive, royalty-free, fully paid-up, transferrable, perpetual, irrevocable license, with the right to grant sublicenses, under any and all of Factor&#x2019;s and its Affiliates&#x2019; patents, technology, information, know-how, copyrights, trade secrets, or other intellectual property or proprietary rights (but excluding the Licensed Technology (as such term is defined in the License) and Improvements) [***] and solely for the purpose of, using, practicing and otherwise exploiting the Deliverables.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be terminated by either Party for any reason upon [***] prior written notice to the other Party, provided, however, that any Work Order issued hereunder that has not terminated or expired as of the date of the termination of this Agreement shall survive the termination of this Agreement, and the terms of this Agreement shall remain in full force an effect with respect to any such Work Order. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination of Work Order</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Erigen may terminate any Work Order at any time with or without cause for its convenience, effective upon [***] notice to Factor. In addition, either Party may terminate any Work Order [***] written notice to the other Party if such other Party materially breaches this Agreement or the Work Order, as the case may be, and does not fully cure the breach to such Party&#x2019;s satisfaction within [***]. Upon termination a Work Order, unless the applicable Work Order expressly provides otherwise, Erigen will pay Factor fees for all Services performed [***].</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The provisions of Sections 5 (Confidentiality), 6 (Intellectual Property), 7.2 (Survival), 8 (Indemnification), 9 (Warranties; Disclaimer; Liability Limitation), 10 (Notices), and 11 (Miscellaneous) shall survive the termination of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mutual Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnifying Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) will indemnify, defend and hold harmless the other Party, its Affiliates and their respective directors, officers, employees, consultants, licensors and agents, and their respective successors, and assigns (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), against all third party suits, actions, claims, proceedings, liabilities, demands, damages, losses, or expenses (including legal expenses, investigative expenses, and reasonable attorneys&#x2019; fees) resulting from, arising out of, or otherwise attributable to the Indemnifying Party&#x2019;s breach of its express representations and warranties set forth herein, except to the extent resulting from, arising out of, or otherwise attributable to the Indemnified Party&#x2019;s breach of any of its express representations, warranties or covenants set forth herein, or any act of gross negligence or intentional misconduct by the Indemnified Party. As used in this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any person or entity directly or indirectly controlling or having the power to control, or controlled by or being under common control with another person or entity. For this purpose, &#x201c;control&#x201d; means the direct or indirect possession of power to direct or cause the direction of the management or policies of such party, whether through ownership or stock or other securities, by contract or otherwise. Ownership of more than fifty percent (50%) of the beneficial interest of an entity shall be conclusive evidence that control exists.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Indemnified Party will promptly give notice to the Indemnifying Party of any suits, actions, claims, proceedings, liabilities, demands, damages, losses, or expenses which might be covered by this Section and the Indemnifying Party will have the right to defend the same, including selection of counsel and control of the proceedings; provided that the Indemnifying Party will not, without the written consent </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.13in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4928-7326-4540, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Indemnified Party, settle or consent to the entry of any judgment with respect to any such third party claim (x) that does not release the Indemnified Party from all liability with respect to such third party claim, or (y) which may materially adversely affect the Indemnified Party&#x2019;s or under which the Indemnified Party would incur any obligation or liability, other than one as to which the Indemnifying Party has an indemnity obligation hereunder. The Indemnified Party agrees to reasonably cooperate and aid such defense. The Indemnified Party at all times reserves the right to select and retain counsel of its own at its own expense to defend the Indemnified Party&#x2019;s interests.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 9.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warranties; Disclaimers; Limitation of Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Representations, Warranties and Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party hereto hereby represents, warrants and covenants to the other that (a) it is a corporation duly incorporated, validly existing and in good standing; (b) it has taken all necessary actions on its part to authorize the execution, delivery and performance of the obligations undertaken in this Agreement, and no other corporate or regulatory actions (e.g., obtaining permits, licenses or authorizations) are necessary with respect thereto; (c) it is not a party to any agreement or understanding, and there is no applicable law or regulation or third party rights, that would prohibit it from entering into and performing this Agreement or that would be violated through entering into this Agreement or any Work Order or the provision or use of the Services or Deliverables (provided that, [***]); and (d) when executed and delivered by it, this Agreement will constitute a legal, valid and binding obligation of it, enforceable against it in accordance with this Agreement&#x2019;s terms. Factor further represents and warrants that the Services shall be performed in a professional manner by competent and properly trained personnel in accordance with Factor&#x2019;s training standards and practices, which are reasonably consistent with standards that are generally accepted in the industry.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">DISCLAIMER</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, FACTOR IS PROVIDING THE SERVICES AND THE DELIVERABLES &#x201c;AS IS,&#x201d; AND MAKES NO REPRESENTATIONS, AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, OR NON&shy; INFRINGEMENT, AND FACTOR DOES NOT ASSUME ANY RESPONSIBILITY WHATSOEVER WITH RESPECT TO USE, SALE, OR OTHER DISPOSITION OF PRODUCTS OR SERVICES INCORPORATING OR MADE BY USE OF THE SERVICES OR THE DELIVERABLES.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LIMITATION OF LIABILITY</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. TO THE FULLEST EXTENT PERMITTED BY LAW, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ANY OTHER PERSON FOR ANY INJURY TO OR LOSS OF GOODWILL, REPUTATION, BUSINESS PRODUCTION, REVENUES, PROFITS, ANTICIPATED PROFITS, CONTRACTS, OR OPPORTUNITIES (REGARDLESS OF HOW THESE ARE CLASSIFIED AS DAMAGES), OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, PUNITIVE, OR ENHANCED DAMAGES, WHETHER ARISING OUT OF BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, PRODUCT LIABILITY, OR OTHERWISE (INCLUDING THE ENTRY INTO, PERFORMANCE, OR BREACH OF THIS AGREEMENT), REGARDLESS OF WHETHER SUCH LOSS OR DAMAGE WAS FORESEEABLE AND THE PARTY AGAINST WHOM LIABILITY IS CLAIMED HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS OR DAMAGE, AND NOTWITHSTANDING THE FAILURE OF ANY AGREED REMEDY OF ITS ESSENTIAL PURPOSE. THE FOREGOING LIMITATIONS WILL NOT: (A) APPLY TO A PARTY&#x2019;S BREACH OF [***], OR (B) LIMIT A PARTY&#x2019;S INDEMNIFICATION OBLIGATIONS UNDER SECTION 8.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.13in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4928-7326-4540, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any notice required to be given pursuant to the provisions of this Agreement will be in writing and will be deemed to have been given at the time when actually received as a consequence of any effective method of delivery, including but not limited to hand delivery, transmission by telecopier, facsimile or electronic transmission, including PDF (portable document format), delivery by a professional courier service or delivery by first class, certified or registered mail (postage prepaid) addressed to the Party for whom intended at the address below, or at such changed address as the Party will have specified by written notice in accordance with this Section 10; provided, however, that any notice of change of address will be effective only upon actual receipt.</font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Factor:</font></p><p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factor Bioscience Inc.</font></p><p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attn: [***]</font></p><p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1035 Cambridge Street, Suite 17B</font></p><p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cambridge, MA 02141</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	[***]</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Erigen:</font></p><p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Erigen LLC</font></p><p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1035 Cambridge Street, Suite 17B</font></p><p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cambridge, MA 02141</font></p><p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attn: [***]</font></p><p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">Section 11.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Entire Agreement; Amendments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement and any Work Orders issued hereunder, together with the License, represents the entire understanding of the parties with respect to the Services that are subject matter hereof and (with the exception of the License and the contemporaneous Amended and Restated Trademark Agreement by and between Erigen and Factor&#x2019;s Affiliate FACTOR BIOSCIENCE LLC) shall merge and supersede all prior and contemporaneous agreements or understandings, oral or written, with respect thereto. This Agreement shall not be modified except by a written agreement signed by the Parties hereto specifying that it is a modification to the Agreement.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Independent Contractor</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any Services performed by Factor under this Agreement are to be performed by Factor in Factor&#x2019;s capacity as an independent contractor. Neither Factor nor its employees, agents or representatives are employees of Erigen. Factor retains the sole right to hire, discipline, evaluate and terminate its own employees and to set their hours, wages and terms and conditions of employment in accordance with law and Factor&#x2019;s obligations herein. All income, employment and other similar taxes required to be withheld and/or paid with respect to all Services provided hereunder will be timely paid by Factor directly to the appropriate governmental agency. The employees, representatives or agents of Factor are not entitled to and will not receive from Erigen in connection with the Services, any benefits normally provided by Erigen to its employees.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The failure of a Party to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver or deprive that Party of the right to insist upon strict adherence to that term or any other term of this Agreement. Any waiver must be in writing and signed by the Party making the waiver.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The invalidity or unenforceability of any term or provision of this Agreement shall not affect the validity or enforceability of any other term or provision hereof.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.13in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4928-7326-4540, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governing Law and Venue</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement shall be construed under and governed by the laws of the Commonwealth of Massachusetts, without regard to the conflict of laws principles thereof. The Parties hereby submit to the exclusive jurisdiction of the federal and/or state courts sitting in [***].</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Failure of either Party to perform its obligations under this Agreement shall not subject such Party to any liability or place such Party in breach of any term or condition of this Agreement to the other Party to the extent that such failure is due to causes beyond the reasonable control of the affected Party including, but not limited to, fire, explosion, flood, drought, hurricane, war, terrorism, riot, civil unrest, sabotage, vandalism, embargo, epidemic, pandemic or other declared national, state or local health emergency, compliance with any order or regulation of any government entity acting with color of right, or any other cause beyond the reasonable control of such non-performing Party and not caused by the negligence, intentional conduct or misconduct of the non-performing Party (such event or cause referred to as &#x201c;force majeure&#x201d;). The Party unable to perform hereunder due to force majeure shall, as promptly as reasonably practicable, notify the other Party and shall use reasonable efforts to eliminate, cure or overcome the force majeure, keeping the other Party informed of its progress, and resume performance of its obligations as soon as reasonably practicable. If a condition constituting force majeure exists for more than [***], the Parties shall meet and discuss in good faith modifications to the Services, timetable for provision and completion of the Services and/or other affected aspects of the Agreement or Work Order.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Injunctive Relief</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party agrees that it would be impossible or inadequate to measure and calculate the other Party&#x2019;s damages from any breach of the covenants set forth in Section 5 of this Agreement, and that a breach of such covenants could cause serious and irreparable injury to such other Party. Accordingly, each Party shall have available, in addition to any other right or remedy available to it, the right to seek an injunction from a court of competent jurisdiction restraining such a breach (or threatened breach) and to specific performance of any such covenant. Each Party further agrees that no bond or other security shall be required in seeking such equitable relief.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement will be binding upon and will inure to the benefit of each Party and each Party&#x2019;s respective transferees, successors and assigns, pursuant to the provisions set forth below. Neither Party may transfer or assign this Agreement to any entity other than an Affiliate without the prior written consent of the other Party, except as provided in this Section 11.8. In the event that a third party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquiring Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) acquires all or substantially all of a Party&#x2019;s business, capital stock or assets, or the portion of such Party&#x2019;s assets pertaining to this Agreement, whether by sale, merger, change of control, operation of law or otherwise (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), such Party may assign this Agreement and the Work Orders hereunder to the Acquiring Party without the prior written consent of the other Party, provided that the Acquiring Party agrees in writing to assume the assigning Party&#x2019;s obligations under this Agreement and the Work Orders hereunder. In such event, the rights granted to the Party being acquired under this Agreement shall inure to the benefit of the Acquiring Party. For the avoidance of doubt, in the event of an Acquisition of Erigen by an Acquiring Party, the Acquiring Party will be responsible for all payments and other obligations set forth in this Agreement, including, but not limited to, all payments set forth herein, and any obligations that matured prior to the Acquisition date. Upon an Acquisition of Erigen by an Acquiring Party, payment thereof shall remain an ongoing obligation of the Acquiring Party until such amount is paid in full. Any attempted assignment in contravention of this Section 11.8 will be null and void.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Announcement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As soon as reasonably practicable after entering into this Agreement, the Parties may issue a joint press release announcing their entering into this Agreement, provided that the content of such press release shall be determined by mutual agreement of the Parties acting in good faith. As applicable, each Party shall also be entitled to disclose this Agreement in its filings with the Securities and Exchange Commission and as otherwise required in order to comply with applicable legal requirements and the rules or regulations of any securities exchange on which such Party&#x2019;s securities are listed.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.13in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4928-7326-4540, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed by original or facsimile signature in any number of counterparts, each of which need not contain the signature of more than one Party but all such counterparts taken together will constitute one and the same agreement.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Remainder of page intentionally left blank; signature page follows.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.13in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4928-7326-4540, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the Parties hereto have duly executed this Amended and Restated Master Services Agreement as of the Execution Date.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FACTOR BIOSCIENCE INC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.341%;padding-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/: Christopher Rohde	</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Christopher Rohde, Ph.D.</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Technology Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERIGEN LLC</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.341%;padding-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/: Matt Angel	</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Matthew Angel, Ph.D.</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manager</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Form Work Order</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Work Order No. [  ] is incorporated into the Amended and Restated Master Services Agreement dated September [&#149;], 2025 by and between Factor and Erigen (for the purposes of this Work Order, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  This Work Order describes Services and Deliverables to be performed and provided by Factor pursuant to the Agreement.  In the event of any conflict between the Agreement and any provision of this Work Order, the Agreement will control unless the Parties&#x2019; intent to alter the terms of the Agreement is expressly set forth in such provision, and such alteration shall only apply to this Work Order and shall not be construed as an amendment to the terms of the Agreement.  All capitalized terms used and not expressly defined in this Work Order will have the meanings given to them in the Agreement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approach &amp; Activities</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[DESCRIBE METHODS/PROCESSES/TASK SUMMARY of the Services]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deliverables</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[DESCRIBE EXACTLY WHAT IT IS THAT ERIGEN IS RECEIVING AS A RESULT OF THE SERVICES]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">optional</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Obligations of Erigen</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[DESCRIBE EXACTLY WHAT, IF ANYTHING, ERIGEN MUST PROVIDE SO THAT FACTOR CAN SUCCESSFULLY PROVIDE SERVICES]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">optional</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Specifications</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[DESCRIBE ANY TECHNICAL SPECIFICATIONS THAT THE DELIVERABLES MUST MEET]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Points of Contact</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Erigen</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Erigen LLC</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1035 Cambridge Street, Suite 17B</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cambridge, MA 02141</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attn: [***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	If to Factor</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factor Bioscience Inc.</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attn: [***]</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1035 Cambridge Street, Suite 17B</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cambridge, MA 02141</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		[***]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Budget</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[IDENTIFY THE MAXIMUM AMOUNT THAT ERIGEN IS AGREEING TO PAY FOR THE SERVICES, EITHER IN THEIR ENTIREY OR FOR PARTICULAR SERVICES]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment Schedule</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factor will invoice Erigen only for the Services actually rendered and the expenses actually incurred.  In full consideration for Factor&#x2019;s timely and satisfactory performance of the Services and provision of the Deliverables, Factor will be compensated as follows:</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.25in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PICK ONE OF THE THREE LISTED BELOW</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Time &amp; Materials Basis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: as invoiced by Factor at the rates set forth below; provided, however, that Factor will obtain Erigen&#x2019;s prior written approval before providing more than [_____ dollars ($__.__)] worth of Services.</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Rates:</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fixed Fee Basis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:  Total fee of [_____ dollars ($__.__)] payable in [_____ (__)] installments of [_____ dollars ($__.__)] each.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Milestone Fee Basis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:  Fees payable in accordance with the table immediately below and the development schedule of this Work Order.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:81.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:49.82%;box-sizing:content-box;"></td>
     <td style="width:50.18%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Milestone</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fee (US$)</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of this Work Order will begin on __________ and shall terminate on ____________.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Remainder of page intentionally left blank; signature page follows.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.25in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4928-7326-4540, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the Parties hereto have duly executed this Work Order No. [  ] as of the date first written above.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FACTOR BIOSCIENCE INC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.341%;padding-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Christopher Rohde, Ph.D.</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Technology Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERIGEN LLC</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.341%;padding-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Matthew Angel, Ph.D.</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manager</font></p><p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.25in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> DOCVARIABLE ndGeneratedStamp \* MERGEFORMAT 4928-7326-4540, v. 1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>7
<FILENAME>tpst-ex10_28.htm
<DESCRIPTION>EX-10.28
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T08:19:11.6428+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.28</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.28</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="letter"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc.</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2000 Shoreline Court, Suite 400</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Brisbane, CA 94005</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 19, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Matthew Angel, Ph.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VIA EMAIL</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-8.333%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Re:	Executive Employment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-8.333%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dear Matthew:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tempest</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is pleased to offer you employment on the terms set forth in this letter agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  This offer of employment is conditioned upon the closing of the transactions contemplated by the asset purchase agreement, entered into as of November 19, 2025, by and among the Company, Factor Bioscience Inc., and Erigen LLC (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  If the Transaction does not close, then this Agreement will have no effect, will not be binding on the Company, and neither you nor the Company shall have any rights or obligations hereunder.  Your employment with the Company will start upon the closing of the Transaction (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Position; Duties.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You will serve as President and Chief Executive Officer of the Company, reporting to the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  You agree to devote substantially all of your professional efforts to the performance of your duties.  You are also required to adhere to the general employment policies and practices of the Company that may be in effect from time to time, except that when the terms of this Agreement conflict with the Company&#x2019;s general employment policies or practices, this Agreement will control.  The Company may change your position, duties, work location and compensation from time to time in its discretion, subject to the terms and conditions set forth herein.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Salary.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Your annualized base salary will be $650,000, less applicable deductions and withholdings, payable in accordance with the Company&#x2019;s payroll practices, as may be in effect from time to time.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You will be eligible to participate in the benefits to be offered by Tempest on the same terms and conditions as it makes such benefits available to employees in positions similar to your position.  As is the case of all employee benefits, such benefits will be governed by the terms and conditions of applicable Tempest plans or policies, which are subject to change or discontinuation at any time.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest shall reimburse you for all reasonable expenses of the type authorized by Tempest and incurred by you in the performance of your duties under this Agreement, all in accordance with the Company&#x2019;s reimbursement policies.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Award.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Subject to approval by the Board, the Company anticipates granting you an option to purchase a number of shares of the Company&#x2019;s common stock equal to 2% of Company&#x2019;s outstanding shares on Start Date at a price per share equal to the fair market value on the grant date, as determined by the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The Option shall vest over a four-year period, with one quarter (1/4) of the shares subject to the Option vesting on the first anniversary of the grant date, and the remaining shares vesting equally over the following 36 months of continuous service.  The Option shall be issued </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant to the terms and conditions of the Company&#x2019;s Amended and Restated 2023 Equity Incentive Plan, as may be amended from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Beginning in calendar year 2027, and in the Company&#x2019;s sole discretion, you will be considered for future equity incentive award grants under the Plan (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The Option and any Future Award shall be governed in all respects by the terms of the Plan, the grant notices and the option agreements, and the Company&#x2019;s policies in effect from time to time.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Discretionary Bonus.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Each year, you will be eligible to earn a discretionary bonus, with a target equal to 50% of your annual base salary.  Whether you receive a bonus, and the amount of any such bonus, will be determined by the Board in its sole discretion, and will be based upon achievement of performance objectives, as well as such other criteria, each as determined by the Board.  If you are awarded any bonus for 2025, such bonus will be pro-rated based upon your Start Date. In order to earn and receive the Annual Discretionary Bonus, you must remain employed by the Company through and including the bonus payout date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At Will Employment; Severance.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At-Will Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Your employment with the Company will be &#x201c;at-will.&#x201d;  This means that either you or Company may terminate your employment at any time, with or without Cause (as defined below), and with or without advance notice.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination For Cause; Resignation Without Good Reason.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  If, at any time, the Company terminates your employment for Cause, or if you resign without Good Reason (as defined below), or if your employment terminates as a result of your death or disability, you will receive your base salary accrued through your last day of employment, as well as any unused vacation (if applicable) accrued through your last day of employment.  Under these circumstances, you will not be entitled to any other form of compensation from the Company, including severance benefits.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination without Cause or Resignation for Good Reason Unrelated to Change in Control.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  If, outside of a Change in Control Period (as defined below), the Company terminates your employment without Cause or you resign for Good Reason, and other than as a result of your death or disability, and provided such termination constitutes a &#x201c;Separation from Service&#x201d; (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then subject to the preconditions set forth in Section 9 below, you will be entitled to receive the following severance benefits:</font></div></div><p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will pay you an amount equal to 12 months of your then-current base salary plus your annual bonus at 100% of target in the calendar year in which your employment is terminated, prorated based on the number of days you are employed in that calendar year, less all applicable withholdings and deductions (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-CIC Severance Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Non-CIC Severance Payment will be paid in installments in the form of continuation of your base salary payments, paid on the Company&#x2019;s ordinary payroll dates, commencing on the Company&#x2019;s first regular payroll date that is more than 60 days following your Separation from Service date, and shall be for any accrued base salary for the 60-day period plus the period from the 60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day until the regular payroll date, if applicable, and all salary continuation payments thereafter, if any, shall be made on the Company&#x2019;s regular payroll dates (and in no event less frequently than once per calendar month).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you timely elect continued coverage under COBRA for yourself and your covered dependents under the Company&#x2019;s group health plans following such termination or resignation of employment, then the Company will pay the entire COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest of (A) the close of the 12-month period following the termination of your employment, (B) the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expiration of your eligibility for the continuation coverage under COBRA, and (C) the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">COBRA Payment Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums hereunder would result in a violation of applicable law, then in lieu of paying COBRA premiums pursuant to this paragraph, the Company shall pay you, on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, less applicable deductions and withholdings, for the remainder of the COBRA Payment Period.  If you become eligible for such coverage under another employer's group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause will cease.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination without Cause or Resignation for Good Reason Related to Change in Control.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  If, during a Change in Control Period (as defined below), the Company terminates your employment without Cause, or you resign for Good Reason, and other than as a result of your death or disability, and provided such termination constitutes a Separation from Service, then subject to the preconditions set forth in Section 9 below, you will be entitled to receive the following severance benefits:</font></div></div><p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will pay you an amount equal to 18 months of your then-current base salary plus your annual bonus at 150% of target in the calendar year in which your employment is terminated, prorated based on the number of days you are employed in that calendar year, less all applicable withholdings and deductions (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CIC Severance Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The CIC Severance Payment will be paid in installments in the form of continuation of your base salary payments, paid on the Company&#x2019;s ordinary payroll dates, commencing on the Company&#x2019;s first regular payroll date that is more than 60 days following your Separation from Service date, and shall be for any accrued base salary for the 60-day period plus the period from the 60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day until the regular payroll date, if applicable, and all salary continuation payments thereafter, if any, shall be made on the Company&#x2019;s regular payroll dates (and in no event less frequently than once per calendar month).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you timely elect continued coverage under COBRA for yourself and your covered dependents under the Company&#x2019;s group health plans following such termination or resignation of employment, then the Company will pay the entire COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest of (A) the close of the 18-month period following the termination of your employment, (B) the expiration of your eligibility for the continuation coverage under COBRA, and (C) the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CIC COBRA Payment Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums hereunder would result in a violation of applicable law, then in lieu of paying COBRA premiums pursuant to this paragraph, the Company shall pay you, on the last day of each remaining month of the CIC COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, less applicable deductions and withholdings, for the remainder of the CIC COBRA Payment Period.  If you become eligible for such coverage under another employer's group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause will cease.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The Company will fully accelerate the vesting of your equity awards such that you will be deemed fully vested in all such awards.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Conditions.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Your</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of the severance benefits set forth in Sections 7(b) or 7(c) is conditional upon (a) your continuing to comply with your contractual obligations to the Company; (b) your resignation from the Board; and (c) your delivering to the Company an effective and irrevocable </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general release of claims in favor of the Company within the timeframe specified therein.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means conduct involving one or more of the following by you: (i) your willful and continued failure or refusal to perform material, lawful duties required of you as an employee of the Company, which failure continues for, or is not permanently cured within, a period of 30 days after written notice given to you by Tempest, except in the case of your physical or mental illness; (ii) your gross negligence, willful misconduct or intentional misrepresentation in connection with the performance of your duties; (iii) the conviction of (x) a felony or (y) a misdemeanor involving moral turpitude, or fraud;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) the commission of an act of embezzlement or fraud; or (v) the material breach of any agreement between Tempest and you, which breach is not cured (if deemed curable by the Company in its reasonable discretion) within 30 days after written notice given to you by Tempest.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, without your express prior written consent, any of the following actions taken by the Company: (i)<br>any reduction in your base salary unless pursuant to a salary reduction program applicable generally to the Company&#x2019;s senior executive employees; (ii) a material reduction in your duties (including responsibilities and/or authorities); (iii) a material change in the geographic location at which you provide services to the Company; (iv) the material breach of this Agreement by the Company; (v) the appointment of an officer of the Company whose responsibilities, function, title, reports and reporting would indicate that you are subordinate to such officer; or (vi) you no longer serve as an officer with a similar title or responsibilities at the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">top-level</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; corporate entity following a Change in Control of the Company.  In order to resign for Good Reason, you must provide written notice to the Company within 30 days of the initial existence of the condition constituting Good Reason, allow the Company at least 30 days from receipt of such written notice to cure such event, and if such event is not reasonably cured within such period, you must resign from all positions, including the designation as the Company&#x2019;s principal executive officer, you then hold with the Company not later than 30 days after the expiration of the cure period.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  For purposes of this Agreement, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Plan.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control Period.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  For purposes of this Agreement, a Change in Control Period means the 3 month period prior to and 12 month period following, a Change in Control.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The payments and benefits under this Agreement are intended to qualify for exemptions from the application of Section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and the final regulations and any guidance promulgated thereunder (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A to the extent necessary to avoid adverse taxation under Section 409A.  To the extent any payment under this Agreement may be classified as a &#x201c;short-term deferral&#x201d; within the meaning of Section 409A, such payment will be deemed a short-term deferral, even if it may also qualify for an exemption from Section 409A under another provision of Section 409A.  Notwithstanding anything to the contrary herein, to the extent required to comply with Section 409A, a termination of employment will not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of amounts or benefits upon or following a termination of employment unless such termination is also a Separation from Service.  Your right to receive any installment payments will be treated as a right to receive a series of separate payments and, accordingly, each installment payment will at all times be considered a separate and distinct payment.  Notwithstanding any provision to the contrary in this Agreement, if you are deemed by the Company at the time of your Separation from Service to be a &#x201c;specified employee&#x201d; for </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purposes of Section 409A, and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be &#x201c;deferred compensation,&#x201d; then, to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Section 409A and the related adverse taxation under Section 409A, such payments will not be provided to you prior to the earliest of (a) the expiration of the six-month period measured from the date of Separation from Service, (b) the date of your death or (c) such earlier date as permitted under Section 409A without the imposition of adverse taxation.  With respect to payments to be made upon execution of an effective release, if the release revocation period spans two calendar years, payments will be made in the second of the two calendar years to the extent necessary to avoid adverse taxation under Section 409A.  With respect to reimbursements or in-kind benefits provided hereunder (or otherwise) that are not exempt from Section 409A, the following rules will apply: (x) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during any one taxable year will not affect the expenses eligible for reimbursement, or in-kind benefit to be provided in any other taxable year, (y) in the case of any reimbursements of eligible expenses, reimbursement will be made on or before the last day of the taxable year following the taxable year in which the expense was incurred and (z) the right to reimbursement or in-kind benefits will not be subject to liquidation or exchange for another benefit.  Notwithstanding anything to the contrary in this Agreement, the Company reserves the right to amend this Agreement as it deems necessary or advisable, in its sole discretion and without your consent, to comply with Section 409A or to avoid income recognition under Section 409A prior to the actual payment of severance benefits hereunder or imposition of any additional tax.  In no event will the Company reimburse you for any taxes or other costs that may be imposed on you as result of Section 409A.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">280G. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any payment or benefit you will or may receive from the Company or from another source</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">280G Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then any such 280G Payment pursuant to this Agreement (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) will equal the Reduced Amount.  The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduced Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; will be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that results in the greatest economic benefit for you.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pro Rata Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).   </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding any provision of paragraph (a) to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows:  (A) as a first priority, the modification will preserve to the greatest extent possible, the greatest  economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), will be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#x201c;deferred compensation&#x201d; within the meaning of Section 409A of the Code will be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.    </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of Section 10(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you agree to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 10(a)) so that no portion of the remaining Payment is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of Section 10(a), you will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">12.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside Activities.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  During your employment with Tempest, you will devote substantially all, but in no case less than 40 hours per week, of your professional efforts to the business of Tempest, except that you may engage in the business activities described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement, and other activities that may be approved in advance by the Nominating and Governance Committee of the Company&#x2019;s Board of Directors, in each case, so long as these activities do not interfere or conflict with your obligations to the Company.  You will not be in violation of any obligation to the Company simply by virtue of your participation in the activities listed in Appendix A, but you remain subject to any obligations you have to the Company under any employee confidentiality and inventions assignment agreement between you and the Company and Company policies.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">13.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidentiality Obligations.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  As condition of your employment, you must sign and abide by an employee confidentiality and inventions assignment agreement between you and the Company.  By signing this Agreement, you are also representing that you have full authority to accept this position and perform the duties of the position without conflict with any other obligations and that you are not involved in any situation that might create, or appear to create, a conflict of interest with respect to your loyalty to or duties for the Company.  You specifically warrant that you are not subject to an employment agreement or restrictive covenant preventing full performance of your duties to the Company.  In addition, you agree not to bring to the Company or use in the performance of your responsibilities at the Company any materials or documents of a former employer that are not generally available to the public, unless you have obtained express written authorization from the former employer for their possession and use.  You also agree to honor all obligations to former employers during your employment with the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">14.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arbitration.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  To aid the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, and in exchange for the mutual promises contained in this Agreement, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims (including but not limited to, the Massachusetts Antidiscrimination Act, Mass. Gen. Laws ch.151B and the Massachusetts Wage Act,Mass. Gen. Laws ch. 149), arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">JAMS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or its successor, under JAMS&#x2019; then applicable rules and procedures appropriate to the relief being sought (available upon request and also currently available at the following web address: (i) https://www.jamsadr.com/rules-employment-arbitration/) and (ii) https://www.jamsadr.com/rules-comprehensive-arbitration/) at a location closest to where you last worked for the Company or another mutually agreeable location. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Federal Arbitration Act, 9 U.S.C. &#167; 1 et seq., will, to the fullest extent permitted by law, govern the interpretation and enforcement of this arbitration agreement and any arbitration proceedings. This provision shall not be mandatory for any claim or cause of action to the extent applicable law prohibits subjecting such claim or cause of action to mandatory arbitration and such applicable law is not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excluded Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), such as non-individual claims that cannot be waived under applicable law, claims or causes of action alleging sexual harassment or a nonconsensual sexual act or sexual contact, or unemployment or workers&#x2019; compensation claims brought </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">before the applicable state governmental agency. In the event you or the Company intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration. You acknowledge and agree that proceedings of any non-individual claim(s) under the California Private Attorneys General Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PAGA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that may be brought in court shall be stayed for the duration and pending a final resolution of the arbitration of any individual or individual PAGA claim. Nothing herein prevents you from filing and pursuing proceedings before a federal or state governmental agency, although if you choose to pursue a claim following the exhaustion of any applicable administrative remedies, that claim would be subject to this provision. In addition, with the exception of Excluded Claims arising out of 9 U.S.C. &#167; 401 et seq., all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class, representative, or collective proceeding, nor joined or consolidated with the claims of any other person or entity. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive all rights to have any dispute be brought, heard, administered, resolved, or arbitrated on a class, representative, or collective action basis.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. If a court finds, by means of a final decision, not subject to any further appeal or recourse, that the preceding sentences regarding class, representative, or collective claims or proceedings violate applicable law or are otherwise unenforceable, as to a particular claim or request for relief, the parties agree that any such claim(s) or request(s) for relief be severed from the arbitration and may proceed in a court of law rather than by arbitration. All other claims or requests for relief shall be arbitrated. You will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration and procedural questions which grow out of the dispute and bear on the final disposition are matters for the arbitrator to decide, provided however, that if required by applicable law, a court and not the arbitrator may determine the enforceability of this paragraph with respect to Excluded Claims. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as you or the Company would otherwise be entitled to seek in a court of law; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#x2019;s essential findings and conclusions on which the award is based. The Company shall pay all JAMS arbitration administrative fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law. Each party is responsible for its own attorneys&#x2019; fees, except as may be expressly set forth in your Employee Confidential Information and Inventions Assignment Agreement or as otherwise provided under applicable law.  Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">15.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  This Agreement (including the agreements referenced herein) is the complete and exclusive statement of your agreement with the Company on the subject matters herein, and supersedes and replaces any and all prior agreements or representations with regard to the subject matter hereof, whether written or oral.  It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified, amended or extended except in a writing signed by you and the Chief Executive Officer.  This Agreement is intended to bind and inure to the benefit of and be enforceable by you and the Company, and our respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties or rights hereunder without the express written consent of the Company.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced as if such invalid, illegal or </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unenforceable provisions had never been contained herein.  This Agreement and the terms of your employment with the Company will be governed in all aspects by the laws of the Commonwealth of Massachusetts.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This offer is subject to satisfactory proof of your right to work in the United States and satisfactory completion of a Company-required background check.  If you agree to the terms and conditions set forth herein, please sign below.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We look forward to having you join us.  If you have any questions about this Agreement, please do not hesitate to call me.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Best regards,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Stephen R. Brady			</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stephen R. Brady</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accepted and agreed:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Matthew Angel			</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Matthew Angel, Ph.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 19, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">APPROVED ACTIVITIES</font></p><p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>8
<FILENAME>tpst-ex10_29.htm
<DESCRIPTION>EX-10.29
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T08:19:11.6960+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.29</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.29</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2000 Sierra Point Parkway, Suite 400</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Brisbane, California 94005</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 3, 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nicholas Maestas</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[address on file]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RE:	Executive Employment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dear Nic:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This employment agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) sets forth the terms and conditions of your employment as the Chief Financial Officer and Head of Corporate Strategy of Tempest Therapeutics, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tempest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), reporting to the Company&#x2019;s Chief Executive Officer (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CEO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The effective date of this Agreement shall be the closing of the Transaction (as defined herein).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During your employment with Tempest, you will devote substantially all of your professional efforts to the business of Tempest, except that you may engage in the business activities described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement, and other activities that may be approved in advance by the Company&#x2019;s Chief Executive Officer, with advice from the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (which together with the activities set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may include one for-profit board membership), in each case, so long as these activities do not interfere or conflict with your obligations to the Company.  Your employment under the terms of this Agreement shall continue until it terminates in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement supersedes, amends and restates in all respects all prior agreements and understandings between you and the Company regarding the subject matter herein, including any employment agreements that you may have previously entered into with the Company in connection with your prior employment with the Company; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, nothing in this Agreement changes any benefits payable pursuant to the terms of the separation agreement that you entered into with the Company on June 13, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Separation Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or the success bonus agreement that you entered into with the Company on August 11, 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement is intended to summarize some of the terms and conditions of your employment.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Location</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Your place of employment will be at Tempest&#x2019;s principal offices, currently located in Brisbane, California.  You will be required to work from this location as reasonably determined by the Company in accordance with its &#x201c;work from home&#x201d; and &#x201c;work from office&#x201d; policies, taking into account relevant factors of your responsibilities.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Your annualized base salary rate is $425,000, less standard deductions and withholding and payable bi-weekly in accordance with Tempest&#x2019;s regular payroll practices.  Your salary shall be reviewed annually and may be adjusted in connection with any such review.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bonus Program</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  You will be eligible for an annual target bonus of forty percent (40%) of your annual base salary, as determined by the Board in its sole discretion based upon, among other things, the achievement of pre-determined performance milestones.  Any annual bonus, if earned, shall be paid no later than March 15</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the year immediately following the year to which the applicable annual bonus relates.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">c.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Withholding.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest shall withhold from any compensation or benefits payable to you by Tempest any federal, state and/or local income, employment and/or other similar taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  You will be eligible to participate in the benefits to be offered by Tempest on the same terms and conditions as it will make such benefits available to employees in positions similar to your position.  The benefits are currently expected to include health insurance and such other benefits provided by similar companies of a similar stage, as approved by the Board.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest shall reimburse you for all reasonable expenses of the type authorized by Tempest and incurred by you in the performance of your duties under this Agreement, all in accordance with the Company&#x2019;s reimbursement policies.  </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case of all employee benefits, such benefits will be governed by the terms and conditions of applicable Tempest plans or policies, which are subject to change or discontinuation at any time.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Definitions.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  For purposes of this Agreement:  </font></div></div><div class="item-list-element-wrapper" style="text-indent:21.733%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:21.731%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:0.935%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">i.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means: (i) any unpaid base salary for services rendered prior to the date of termination of employment; (ii) any earned but unpaid annual bonus for any completed fiscal year prior to the year in which termination of employment occurs; (iii) reimbursement of any unreimbursed business expenses incurred as of the date of termination of employment in accordance with Tempest&#x2019;s reimbursement policy; (iv) accrued but unused vacation (if applicable), earned through the date of termination of employment; and (v) all other payments, benefits or fringe benefits to which you shall be entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant with or by Tempest or this Agreement. </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">ii.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means conduct involving one or more of the following by you: (i) failure to perform a substantial portion of your duties and responsibilities in accordance with the terms or requirements of this Agreement and your position, which failure continues for, </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or is not permanently cured within, a period of 30 days after written notice given to you by Tempest, except in the case of your physical or mental illness; (ii) disloyalty, gross negligence, willful misconduct, or dishonesty that materially injures Tempest or a breach of fiduciary duty to Tempest; (iii) the conviction of (x) a felony or (y) a misdemeanor involving moral turpitude, or fraud;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) the commission of an act of embezzlement or fraud; or (v) the material breach of any agreement between Tempest and you.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">iii.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Company&#x2019;s 2017 Equity Incentive Plan; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Transaction shall not constitute a Change in Control for purposes of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">iv.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the three (3) month period prior to, and twelve (12) month period following, a Change in Control.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">v.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, without your express written consent, (i) any reduction in your annual base salary other than a reduction which is proportional to general reductions affecting other senior executive officers of Tempest generally, or (ii) any material reduction in your title or scope of responsibilities without your consent (other than your removal from the Board).</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">vi.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall refer to the transactions contemplated by the asset purchase agreement, entered into as of November 19, 2025, by and among the Company, Factor Bioscience Inc., and Erigen LLC.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:7.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:8.292222222222223%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Severance Benefits and Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">i.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Generally</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If your employment with Tempest is terminated (x) by Tempest for any reason other than Cause, or (y) by you for Good Reason, Tempest will pay you (1) the Accrued Benefits; (2) subject to your compliance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below, after the execution and delivery of the Separation Agreement and General Release in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Separation Agreement and General Release</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (as such form may be modified to take into account changes in the law) and the expiration of any revocation period without the release being revoked, nine (9) months&#x2019; base salary, plus a prorated portion of your bonus at target for the year of your termination, less standard deductions, payable in bi-weekly installments in accordance with the Company&#x2019;s regular payroll policies; and (3) if you elect to continue your health insurance coverage pursuant to your rights under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">COBRA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), following the termination of your employment, your monthly premium under COBRA on a monthly basis until the earlier of (x) nine (9) months following the effective termination date, or (y) the date upon which you commence full-time employment (or employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by Tempest).  A termination of your employment by Tempest due to physical or mental illness which is not a Disability (as defined herein) shall be treated as an involuntary termination other than for Cause.  The term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean that you have not been able to materially engage in your duties and responsibilities by reason of any medically determinable physical or mental impairment for a period of not less than 120 consecutive days or not less than 180 days during any one-year period.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:17.467%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:17.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:0.67%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">ii.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In connection with the Change in Control Period.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  If your employment with Tempest is terminated (x) by Tempest for any reason other than Cause, or (y) by you for Good Reason, in either case during the Change in Control Period, except as otherwise set forth below in subsection 4(b)(iii) below, Tempest will (1) pay you the Accrued Benefits; (2) subject to your compliance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below, after the execution and delivery of the Separation Agreement and General Release and the expiration of any revocation period without the release being revoked, pay you twelve (12) months&#x2019; base salary plus your annual bonus at one hundred percent (100%) of target, less standard deductions, payable in a single lump sum on the 60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day following the termination of your employment; (3) if you elect to continue your health insurance coverage pursuant to your rights under COBRA following the termination of your employment, pay your monthly premium under COBRA on a monthly basis until the earlier of (x) twelve (12) months following the effective termination date, or (y) the date upon which you commence full-time employment (or employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by Tempest); and (4) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fully accelerate the vesting of any outstanding equity awards such that you will be deemed fully vested in all such awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  A termination of your employment by Tempest due to physical or mental illness which is not a Disability shall be treated as an involuntary termination other than for Cause.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:18.4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:18.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.269%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">iii.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Further Severance in Connection with Transaction.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge and agree that pursuant to the Separation Agreement, you are already eligible for certain severance benefits as a result of and in connection with the Transaction. You and the Company have therefore agreed that the Transaction shall not constitute a Change in Control for purposes of this Agreement.  By way of example, if your employment is terminated without Cause or as a result of Good Reason during the three (3) month period prior to, and twelve (12) month period following, the Transaction, you would not be eligible to receive the Change in Control-related severance benefits contemplated by Section 4(b)(ii), but would remain eligible to receive the non-Change in Control related severance benefits contemplated in Section 4(b)(i). Additionally, for the avoidance of doubt, any changes to your employment title or scope of responsibilities as a result of the Transaction shall not in and of itself give rise to Good Reason or any right to any further severance benefits under this section 4(b).  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">c.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Eligibility for Severance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Eligibility for receipt of the items in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  above shall be conditioned on your (i) returning to Tempest promptly upon termination of your employment all of its property, including confidential information and all electronically stored information, and (ii) signing and not revoking the Separation Agreement and General Release within the applicable deadline set forth therein, but in no event later than forty-five (45) calendar days following your employment termination date.  No benefits set forth in Section 4(b) above will be paid or provided hereunder prior to the effective date of the Separation Agreement and General Release (other than any Accrued Benefits required to be paid).</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">d.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Accrued Benefits shall be paid to you (or your estate in the event of your death) upon termination of employment regardless of the circumstances giving rise to such termination.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At-Will Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Your employment with Tempest is at will, meaning it may be terminated by you or Tempest at any time, subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, for any reason with or </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">without Cause.  You understand that this Agreement is not a contract for employment for a definite term.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Information and Inventions Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This offer of employment is subject to the Proprietary Information and Inventions Agreement attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix C</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which shall be effective as of the date set forth therein.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Inconsistent Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  By accepting this offer of employment, you represent and warrant to Tempest that you are under no obligations or commitments, whether contractual or otherwise, that are inconsistent with your obligations set forth in this Agreement or that would be violated by your employment by Tempest.  You agree that you will not take any action on behalf of Tempest or cause Tempest to take any action that will violate any agreement that you have with a prior employer.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delayed Commencement Date for Payments and Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The intent of the parties hereto is that payments and benefits under this Agreement comply with, or be exempt from, Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Code Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith or exempt therefrom.  If you notify Tempest (with specificity as to the reason therefor) that you believe that any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause you to incur any additional tax or interest under Code Section 409A and Tempest concurs with such belief or Tempest independently makes such determination, Tempest shall, after consulting with you, reform such provision to try to comply with Code Section 409A through good faith modifications to the minimum extent reasonably appropriate to conform with Code Section 409A. To the extent that any provision hereof is modified in order to comply with Code Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to you and Tempest of the applicable provision without violating the provisions of Code Section 409A.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A unless such termination is also a &#x201c;separation from service&#x201d; within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a &#x201c;termination,&#x201d; &#x201c;termination of employment&#x201d; or like terms shall mean &#x201c;separation from service.&#x201d; Notwithstanding any provision to the contrary in this Agreement, no payments or benefits that are considered &#x201c;nonqualified deferred compensation&#x201d; under Code Section 409A to which you otherwise become entitled under this Agreement in connection with your termination of employment, shall be made or provided to you prior to the earlier of (i) the expiration of the 6 month period measured from the date of your &#x201c;separation from service&#x201d; with Tempest (as such term is defined in Code Section 409A) or (ii) the date of your death, if you are deemed at the time of such separation from service to be a &#x201c;specified employee&#x201d; under Code Section 409A and if, in the absence of such delay, the payments would be subject to additional tax under Code Section 409A. Upon the expiration of the applicable Code Section 409A(a)(2) deferral </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">period, all payments and benefits deferred pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such deferral) shall be paid or reimbursed to you in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.    In addition to the above, to the extent required to comply with Code Section 409A and the applicable regulations and guidance issued thereunder, if the applicable deadline for you to execute (and not revoke) the applicable Separation Agreement and General Release spans two calendar years, your severance benefits set forth in Section 4(b) above shall commence to be paid on the first regularly scheduled payroll date that occurs in the second calendar year.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">c.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of Code Section 409A, your right to receive any installment<br>payment pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.  Whenever a payment under this Agreement specifies a payment period with reference to a number of days (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, &#x201c;payment shall be made within 30 days following the date of termination&#x201d;), the actual date of payment within the specified period shall be within the sole discretion of Tempest.  Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes &#x201c;nonqualified deferred compensation&#x201d; for purposes of Code Section 409A be subject to offset, counterclaim or recoupment by any other amount payable to you unless otherwise permitted by Code Section 409A.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">d.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by Tempest or incurred by you during the time periods set forth in this Agreement.  All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year.  Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">e.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If under this Agreement an amount is to be paid in installments, each installment shall be treated as a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii).  </font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">280G</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the amount of any compensation, payment or distribution by Tempest or its affiliates to or for your benefit, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aggregate Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which you become subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in you receiving a higher After Tax Amount (as defined below) than you would receive if the Aggregate Payments were not subject to such reduction.  In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (i) cash payments not subject to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A of the Code; (ii) cash payments subject to Section 409A of the Code; (iii) equity-based payments and acceleration; and (iv) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167; 1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treasury Regulation &#167;1.280G-1, Q&amp;A- 24(b) or (c).  For purposes of this Section 9, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">After Tax Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on you as a result of your receipt of the Aggregate Payments.  For purposes of determining the After Tax Amount, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.  The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to this Section 9 shall be made by a nationally recognized accounting firm or a firm specializing in Section 280G calculations selected by Tempest, which shall provide detailed supporting calculations both to Tempest and you.  The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by Tempest.  Notwithstanding the foregoing, if (i) Tempest is not publicly traded prior to the occurrence of a change in control such that the private company exception pursuant to Q &amp; A #7 of the regulations promulgated under Section 280G of the Code is applicable and (ii) you request that Tempest seek shareholder approval of the portion of any payments to be made to you which are parachute payments under Section 280G and exceed 2.99 times your &#x201c;base amount&#x201d; (as such term is defined in Section 280G) in order that, upon obtaining such approval, all of the payments will be exempt from the excise taxes imposed under Sections 280G and 4999 of the Code, Tempest shall use its reasonable best efforts to obtain such approval.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This offer of employment is made subject to you having the legal right to work in the United States.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Your employment with Tempest is subject to all Company policies and procedures, and Tempest retains the right to change its policies or procedures at any time.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">c.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. Facsimile and electronic image copies of signatures shall be equivalent to original signatures.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">d.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither this Agreement nor any of your rights or obligations hereunder shall be assignable by you.  Tempest may assign this Agreement or any of its obligations hereunder to any subsidiary of Tempest, or to any successor (whether by merger, purchase or otherwise) to all or substantially all of the equity, assets or businesses of Tempest.  This Agreement is intended to bind and inure to the benefit of and be enforceable to you and Tempest and Tempest&#x2019;s permitted successors and assigns.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">e.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by you and such officer or director as may be designated by the Board.  No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">f.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California without regard to the choice of law principles thereof.</font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sincerely,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TEMPEST THERAPEUTICS, INC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Stephen R. Brady				</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Stephen R. Brady</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACCEPTED AND AGREED</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Nicholas Maestas					</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nicholas Maestas</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 3, 2026				</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendices:	Appendix A &#x2014; Approved Activities</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Appendix B &#x2014; Separation Agreement and General Release</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Appendix C &#x2014; Proprietary Information and Inventions Agreement</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>tpst-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T08:19:11.6105+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font><font style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">           </font></p><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.112029584511638%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-1 No. 333-292026) of Tempest Therapeutics, Inc.,</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.112029584511638%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-286186) pertaining to the Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan, Tempest Therapeutics, Inc. Amended and Restated 2019 Employee Stock Purchase Plan,</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.112029584511638%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-3 No. 333-280918) of Tempest Therapeutics, Inc.,</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.112029584511638%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-278071) pertaining to the Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan, Tempest Therapeutics, Inc. Amended and Restated 2019 Employee Stock Purchase Plan,</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.112029584511638%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-275637) pertaining to the Tempest Therapeutics, Inc. Amended and Restated 2019 Equity Incentive Plan, Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan, Tempest Therapeutics, Inc. 2023 Inducement Plan, and Inducement Stock Options,</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.112029584511638%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-265718) pertaining to the Tempest Therapeutics, Inc. Amended and Restated 2019 Equity Incentive Plan and Tempest Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended by Post-Effective Amendment No. 1 filed on November 17, 2023,</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.112029584511638%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-264943) pertaining to the Millendo Therapeutics, Inc. 2019 Equity Incentive Plan and Millendo Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended by Post-Effective Amendment No. 1 filed on November 17, 2023,</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.112029584511638%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-257727) pertaining to the Tempest Therapeutics, Inc. 2017 Equity Incentive Plan and Inception 2, Inc. 2011 Equity Incentive Plan,</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.112029584511638%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-255261) pertaining to the Millendo Therapeutics, Inc. 2019 Equity Incentive Plan and Millendo Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended by Post-Effective Amendment No. 1 filed on November 17, 2023,</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.112029584511638%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-235515) pertaining to the Millendo Therapeutics, Inc. 2019 Equity Incentive Plan, Millendo Therapeutics, Inc. 2019 Employee Stock Purchase Plan, and New Hire Inducement Stock Options Grants of Millendo Therapeutics, Inc., as amended by Post-Effective Amendment No. 1 filed on November 17, 2023, and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.112029584511638%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(11)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-249993) pertaining to the Millendo Therapeutics, Inc. 2019 Equity Incentive Plan, Millendo Therapeutics, Inc. 2019 Employee Stock Purchase Plan, and New Hire Inducement Stock Options Grant of Millendo Therapeutics, Inc., as amended by Post-Effective Amendment No. 1 filed on November 17, 2023;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our report dated March 30, 2026, with respect to the consolidated financial statements of Tempest Therapeutics, Inc. included in this Annual Report (Form 10-K) of Tempest Therapeutics, Inc. for the year ended December 31, 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chicago, Illinois</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 30, 2026</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>tpst-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T08:19:11.5238+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="section1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATIONS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Matthew Angel, certify that:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Tempest Therapeutics, Inc.;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:62%;box-sizing:content-box;"></td>
     <td style="width:4%;box-sizing:content-box;"></td>
     <td style="width:34%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 30, 2026</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Matthew Angel</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Matthew Angel</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer &amp; President</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>tpst-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T08:19:11.6272+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="section1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATIONS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Nicholas Maestas, certify that:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Tempest Therapeutics, Inc.;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:62%;box-sizing:content-box;"></td>
     <td style="width:4%;box-sizing:content-box;"></td>
     <td style="width:34%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 30, 2026</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Nicholas Maestas</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nicholas Maestas</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer &amp; Head of Corporate Strategy</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>tpst-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-30T08:19:11.6214+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="section1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#x201c;Exchange Act&#x201d;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Matthew Angel, Chief Executive Officer of Tempest Therapeutics, Inc. (the &#x201c;Company&#x201d;), and Nicholas Maestas, Vice President, Strategy and Finance, of the Company, each hereby certifies that, to the best of his or her knowledge:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, to which this Certification is attached as Exhibit 32.1 (the &#x201c;Annual Report&#x201d;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dated: March 30, 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:36.687%;box-sizing:content-box;"></td>
     <td style="width:28.846%;box-sizing:content-box;"></td>
     <td style="width:34.467%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Matthew Angel</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:1pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Nicholas Maestas</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Matthew Angel</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:1pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nicholas Maestas</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer &amp; President</font></p><p style="font-size:10pt;margin-top:1.15pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:1pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:2.65pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer &amp; Head of Corporate Strategy</font></p><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:1.15pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Tempest Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img81402019_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img81402019_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $M JL# 2(  A$! Q$!_\0
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MS]5/%^N:E:_LK7VKPW]S%JR^%!<K?)*1,)?LP;S-_7=GG/7-?G,/CI\2,?\
M(_\ B7_P:3?_ !5?H9XV_P"3/-0_[$T?^D@K\NQTKS\'%-2NNIUXAM.-GT.X
M_P"%Z?$C_H?O$O\ X-)O_BJ/^%Z?$C_H?O$O_@TF_P#BJYZZ\'Z[91Z.\VD7
MBC6(C/IP6$L;N,'!:,#)(_\ U]*-1\(:[I.KSZ5=Z-?PZE _ER6OV=F=6SC'
MR@YYR..X(ZUW<L.R.6\NYT/_  O3XD?]#]XE_P#!I-_\51_PO3XD?]#]XE_\
M&DW_ ,57*2:'J<4+S/IEZD*2>2TC6T@59,XV$XP&SQCKGBFSZ/J%MYWG:=>0
M^0ZQ2^9;NOENWW5;(^5CV!Y/:GRP[(.:7<ZW_A>GQ(_Z'[Q+_P"#2;_XJC_A
M>GQ(_P"A^\2_^#2;_P"*K)M?AWXGO-:LM'BT*\&JWEL;V"SE012/ -Q,F'(V
MJ C_ 'L?=-5M9\&:]X>U)]/U'1KVUO%4.8C"7RI"D,&7(8893D$CYAZTN6&U
MD%Y^9MW'QU^)*P2$>/\ Q*"%."-4F]/]ZOUF\+327'AG2)97:662SA9W<Y+$
MH"23ZU^,=[&\,=Q'(C1R(&5D<$,I'!!!Z$>E?LSX0_Y%/1?^O*#_ -%K7FXZ
M*2C9=SMPK;;N:]%%%>0>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7C?[87_)MOC;_ *]X?_2B*O9*\;_;
M"_Y-M\;?]>\/_I1%6U'^)'U1G4^!^A^6M:GA?P[=>+O$>FZ)8M$MY?S"")IV
MVH&/]XX.!^%9=:'A[7KSPOKMCJ^GND=]92B:%I$#J&'3*GK7TSO;0\1>9T6C
M_!_QCK.M:9ID>@W=M+J!4PS7,92((S(!(S=E_>Q^_P Z\<BJ^H_"_P 2Z>\8
M72Y[R*182L]O&QC+2A2B@L!D_.N<9'S#GD5LV7Q[\86$T4B7-E((G218Y;-&
M0NGV?8Q'<K]EA(]P?[QJ)OCAXIF?2GN&TV[DTHJ;%[G3XY#;81$(3/3<L:9[
MG&01FL_WE^A?N%9O@UXQATYKN?1+BWY9([9T)GE=98XF4(H)!W3)RV 1G!/&
M:]C\)O&-_<0Q1^';]%EN8[0321$1K([(%RWI^]C^;IAP>];DO[0WC:6[:Z^V
MV<=P2?WB6:Y"DPDH,_PDV\>1_O<_,:=H_P"T)XOT>ZTUXY;,VM@R+%:+:JBI
M"K0'R5/55Q;1 =2.?4TOWMN@>YYG/2?#+Q!#!>SRV1BMK>TFOHYY 52[@B=5
M=X21\P 8-SC*@D5RM>@GXSZLVCW>DM#&VG?8[NRL$.-]JEP5#9?&7Q&I4 ;1
MD[L9KSZM(\WVB7;H=7\*463XCZ KJ'4W!RK#(/R-VKD[53(D*#[S;5&?4\5U
MWPF_Y*3X?_Z^#_Z+:N0M6*1PN/O*%8?44+XG_7<70](U3X"^*-/GO8;=;;5Y
M;.>6TECTWS96^T1O$C0@; =W[^,@_=()P<C%<U_PKSQ1YC1_V!?EUG^RE1"2
M?-X^7WQD9/09&3713?'KQ?+?75TL]C!)=2//.D%HJ)+*\D4CR$9^^3!$,@C
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MUL6^0YJ[\)W-IX1L?$8NK2>QN[EK3RXI&\V*4+NVLI4#[N#E20,@'!-8,_\
MJ)/]T_RK:F\4WLWAB#0 EM!IL<XN6$$"I)-*JLJM(W5BJNP'L><\5BW'^HD_
MW3_*M5?J0[=#]2O'H _9#U0 8'_"']!_UZBORWP&&#G!ZXK]2/'W_)HFJ?\
M8H?^VHK\N!TKSL%M+U.O$[Q]#VV3]J"[N);19/"NGP6MDDMM:+87,MM/!:R6
MZP-&)ADAL1Q$2  _*1CYC3+[]I[4M3O&DN]!MIK:369=5DA%W(CE&5BEN)%
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M?_@*_P#D@YZG9??_ , ]MHKQ+_AG3X9?]"7I_P#WW-_\71_PSI\,O^A+T_\
M[[F_^+H]G1_F?_@*_P#D@YZG9??_ , ]MHKQ+_AG3X9?]"7I_P#WW-_\71_P
MSI\,O^A+T_\ [[F_^+H]G1_F?_@*_P#D@YZG9??_ , ]MHKQ+_AG3X9?]"7I
M_P#WW-_\71_PSI\,O^A,T_\ [^3?_%T>SH_S/_P%?_)#YZG\J^__ (![;17B
M7_#.GPR_Z$S3_P#OY-_\71_PSI\,O^A+T_\ [[F_^+I>SH_S/_P%?_)"YZG9
M??\ \ ]MHKQ+_AG3X9?]"7I__?<W_P 71_PSI\,O^A+T_P#[[F_^+I^SH_S/
M_P !7_R0<]3LOO\ ^ >VT5XE_P ,Z?#+_H3-/_[^3?\ Q='_  SI\,O^A+T_
M_ON;_P"+I>SH_P S_P# 5_\ )!SU.R^__@'MM%>)#]G/X9GIX+L#W^_-_P#%
MT?\ #.GPR_Z$O3_^^YO_ (NCV='^9_\ @*_^2#GJ=E]__ /;:*\2_P"&=/AE
M_P!"7I__ 'W-_P#%T?\ #.GPR_Z$O3_^^YO_ (NG[.C_ #/_ ,!7_P D'/4[
M+[_^ >VT5XE_PSI\,O\ H2]/_P"^YO\ XNC_ (9T^&7_ $)>G_\ ?<W_ ,71
M[.C_ #/_ ,!7_P D'/4[+[_^ >VT5XE_PSI\,O\ H2]/_P"^YO\ XNC_ (9T
M^&7_ $)>G_\ ?<W_ ,71[.C_ #/_ ,!7_P D'/4[+[_^ >VT5XE_PSI\,O\
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MF_\ !E<__'*/^&)/@_\ ]"U-_P"#*Y_^.5\6?\+.\9?]#;KO_@RF_P#BJ/\
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MG_XY7S<L!6A5J4G5=XNWK^)[<<73E3A45/XE<ZC_ (8D^#__ $+4W_@RN?\
MXY1_PQ)\'_\ H6IO_!E<_P#QRN5_L6V_YZ7W_@RN?_CE']BVW_/2^_\ !E<_
M_'*/J57_ )^O^OF'UNG_ ,^_Z^XZK_AB3X/_ /0M3?\ @RN?_CE'_#$GP?\
M^A:F_P#!E<__ !RN5_L6V_YZ7W_@RN?_ (Y1_8MM_P ]+[_P97/_ ,<H^I5?
M^?K_ *^8?6Z?_/O^ON.I/[$?P?((/AJ;'_82N?\ XY5O5?V/OA/XBU*YU.ZT
M"6XN;I_,DE74;@!CZ@!\=NU<7_8MM_STOO\ P97/_P <ID'AVQM84A@%W#$@
MPL<>H7*JH] !)1]1J_\ /U_U\P^MT_\ GW_7W'6_\,2?!_\ Z%J;_P &5S_\
M<H_X8D^#_P#T+4W_ (,KG_XY7*_V+;?\]+[_ ,&5S_\ '*/[%MO^>E]_X,KG
M_P".4?4JO_/U_P!?,/K=/_GW_7W'5?\ #$GP?_Z%J;_P97/_ ,<H_P"&)/@_
M_P!"U-_X,KG_ ..5RO\ 8MM_STOO_!E<_P#QRC^Q;;_GI??^#*Y_^.4?4JO_
M #]?]?,/K=/_ )]_U]QU7_#$GP?_ .A:F_\ !E<__'*LWG['OPGU."SMYO#\
MLB:?#]FB4:C< QJ6:3:</US(3SZBN,_L6V_YZ7W_ (,KG_XY3(_#UC"TC1_;
M$:1M[E=0N07; &3^\Y. !] */J-7_GZ_Z^8?6Z?_ #[_ *^XZW_AB3X/_P#0
MM3?^#*Y_^.4?\,2?!_\ Z%J;_P &5S_\<KE?[%MO^>E]_P"#*Y_^.4?V+;?\
M]+[_ ,&5S_\ '*/J57_GZ_Z^8?6Z?_/O^ON.J_X8D^#_ /T+4W_@RN?_ (Y1
M_P ,2?!__H6IO_!E<_\ QRN5_L6V_P">E]_X,KG_ ..4?V+;?\]+[_P97/\
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M_P ,2?!__H6IO_!E<_\ QRN5_L6V_P">E]_X,KG_ ..4?V+;?\]+[_P97/\
M\<H^I5?^?K_KYA];I_\ /O\ K[CJO^&)/@__ -"U-_X,KG_XY5FQ_8\^$^E)
M=QP>'Y8A?0-:2@ZC<'?&2K%1E^N4!XYXKC/[%MO^>E]_X,KG_P".4R7P[8SF
M,R?:Y#&V]"^H7)VM@C(_><'!//O1]1J_\_7_ %\P^MT_^??]?<=;_P ,2?!_
M_H6IO_!E<_\ QRC_ (8D^#__ $+4W_@RN?\ XY7*_P!BVW_/2^_\&5S_ /'*
M/[%MO^>E]_X,KG_XY1]2J_\ /U_U\P^MT_\ GW_7W'5?\,2?!_\ Z%J;_P &
M5S_\<H_X8D^#_P#T+4W_ (,KG_XY7*_V+;?\]+[_ ,&5S_\ '*1M$MBI GU&
M,GHZ:G<AE]P?,X-'U*K_ ,_7_7S#ZW3_ .??]?<=7_PQ)\'_ /H6IO\ P97/
M_P <JSIG['GPF\/:C:ZI;>'Y(+BSD6>.5]1N"$93D$@OC\ZU_AE\3)WNH/#7
MB6</J3 K8:FP"K?J!G:V.%G '*]& W+W"]K\0.? ^O?]>4O_ *":\FK[>E/V
M<Y/[ST:?LJD>>*1Y4?V)?A 23_PC4W)S_P A*Y_^.4?\,2?!_P#Z%J;_ ,&5
MS_\ '*]T'04M8>VJ_P S^\T]G#^5'A7_  Q)\'_^A:F_\&5S_P#'*/\ AB3X
M/_\ 0M3?^#*Y_P#CE>ZT4>VJ_P S^\?LX?RH\*_X8D^#_P#T+4W_ (,KG_XY
M2-^Q'\'W4J?#4V",'_B97/\ \<KW:BCVU7^9_>'LX?RHPAX<T+6O!O\ 8!AA
MU#P]):?8#!YGF(\(7RRA8')X&#SFN!_X9-^$7_0B:9_Y$_\ BJ\UOT#_ +$H
MARRQS7B0R"-RA9'U@*ZY!!P5)!]B:Z"?]G[X<+/(!X0L0 Q 'F3>O^_7=1HW
M@Y.;6K6B[6\UW.:I5M)+E3T_KHSJO^&3?A%_T(FF?^1/_BJ/^&3?A%_T(FF?
M^1/_ (JN2_X9_P#AS_T*-E_W\F_^+H_X9_\ AS_T*-E_W\F_^+K;V*_Y^R^[
M_P"V,O:?W%]__ .M_P"&3?A%_P!")IG_ )$_^*H_X9-^$7_0B:9_Y$_^*KDO
M^&?_ (<_]"C9?]_)O_BZ/^&?_AS_ -"C9?\ ?R;_ .+H]BO^?LON_P#M@]I_
M<7W_ / .M_X9-^$7_0B:9_Y$_P#BJ/\ ADWX1?\ 0B:9_P"1/_BJY+_AG_X<
M_P#0HV7_ '\F_P#BZ/\ AG_X<_\ 0HV7_?R;_P"+H]BO^?LON_\ M@]I_<7W
M_P# .L;]DOX0NI4^!-,((P1^\_\ BJ]7M;:*RMH;>!!'#$@C1!T50, ?E7SK
MJ'P!^'2:?=LOA*R#+!(P(EFX(4X_CKU/X!SR7/P,^'DLTCS2OX>T]GDD8LS$
MV\>22>2?>N;$4N6"GSMZ]5_P6;T:G-+EY4O3_AD9/QO_ .0S\*_^QOB_](;V
MNJKE?C?_ ,AGX5_]C?%_Z0WM=56<OX</1_FRU\<OZZ!1116184444 %%%% !
M1110 5\^_MG^+'L_A_HG@NTM]2OK[QEJL-A+::-"9KU[",B:\,2 @D^6H7J/
MO=:^@J\FUOXP>$[769M2OM!:XU#1GO;6UOO]&DGC:)Q',%^?? C?WGVJ0!D\
MC/9A+QJJ:C>VOSZ?B<]>S@XMVO\ TSYP\!_&+Q;X>^'_ (:^'/AV_NO"NOZ=
MX^A\+K_PD>G![N/2KH22VC2P2'(8+QUYV#G!KH?!7QR^*<&N>&;C6/$MAKVF
MMXQU3P;<:;#I$=O)>_98I)%N3(I)61B@78H"X]2:]OO?&7@2?4;77-1\,6TF
ML/J\5@]\+2WN9()(D5DN3<(6!CB$J#>K$H7VX!S3K#QKX#BUV2UET#3])CL-
M1U"[&H2QVH2WNK??]ING56+PDA7_ 'K*-W )RP!]6=>,E)^QWNWMN[WL]]]4
M<4:;5OWFWK^1\\_"K]ICQ[XKTN^U?Q/XXT+1-"OM N]5GNHH["2ZT"2.0!#%
M:K*TLJ<^6RSJ&WLM6?!/Q[\>W'P[TZ_UGX@0WNJ>*-<2VT2QTS3-/DU2.R$<
MCXE7>MO;RR!0^9BP55(P2>/H?3KCX5:YX/\ $_B31M+\.ZSHUPK_ -KRV.G1
M'[:Z8?RI04'F/DIA6_B*]ZSM*L_@VNC647_"+^&M)&L1QWQTJ;1H4D+HS(/-
M14*B1)/,C&3][*@DGDEB*,N:U"VJZ+2W3:_KW2Z78U2FK?O.G=GSCI7QG\3^
M+4^'GCN\O83XEM_ _C"1;B")!&\MM*JQR&,90GY 3CY2<XX-7- _:J\6:%I,
M-YK'Q%T3Q-;:KX*_MZ6ZT_1DD;P[>^9%$D3Q1./,W-)MVR%?G&>%KWW4#\*_
M&7@2XT^T?3/#D>KZ)=?9[B+3E@N+6WND!F:,%  QWHS(#DDKD&IO =A\*/!_
M@ZRT&SGT"[AGTV.QO+N6QC1]22W1HBUU\F"W[F3Y7YRC8!Q52Q%%Q]ZB]]K=
M+M[VTM?\-="53J)JU3IWZV2VN?+_ ([^+?CWQAX2UO3]1\:7'A^+P]XYT2R^
MW75M9+<"*X3?FY,#>3B-UW[0<$?*_2OOBV)-K 3<K>,8US<J !,<#]X . &Z
M\<<\5Y?#<?!]=&FM(=.\+C1-01%F@33HA%<>64$:-#LW.1YJ%?E/#@C@UW/A
MGQ-I7B ZC:Z2Q,>DSK8R@1&-%;RDD4)D#*['7!'':N#%U%5BE"GRI7Z6[+\U
M^)TT(.#?-*[?GZ_H;=%%%>6=H4444 %%%% !1110 5XA^T%_R&1_V)7B+_T.
MPKV^O$/V@O\ D,C_ +$KQ%_Z'85Z67?[W3]3BQG^[S]#XHHHHK]V/R0Z?1OA
MIXDU[1K75K337.FW=_%IEO<RL(UFN)#A57/49&"W0=S65:>'KZ^\21:##$K:
MG)=_85B+@ S;]FW=TQNXSTKK? GQ0'A+1X[&Z@NKY8M:T_5(@)1LCCMGD9HU
M!Z%C)GCC.<T_4?&'A"U\>Z-XDT'2M;A,&J?VC?PZC=0R>;^]$FV+8HV_Q#YL
M]17F^UQ*J3BX76O*UZ:7U^1W>SH.$9*6NEU\^FAE:7\*O$VM2;+'3UN6_M*7
M2FV3IA+B)=\FXDX5%4$ES\OO5]?@=XQ;6Y-,_LZW62.U2]:[:]A%IY+MM1_/
MW;""P*CG)(-=O/\ M-2ZO;SVVMZ;+J-M<7MZ)%B\JW86%Q$8_*4HH_>KG.]@
M<XP:YVU^(7@>VM-3\/+X8U=?"%_;VRR@:BIOS/ [.LNXJ8P#O*E  ,8(YKD5
M;,->:FEZ:]==>:.RZ6U[G1[+!:6FWZZ=/1]>M].QY]X@T#4/"VM7FD:K;-9Z
MC9R>5- Y!*MUZC@@@@@CJ#6?6IXGU"PU7Q!?W>EV#Z7ITLF8+22=IVC7  !=
MN6/&3]:RZ]JFY."<][:_U=_F_4\N:2DU';^O3\D?6'P0_P"30/'?_7Q>?^BH
MJ["7_6O]37'_  0_Y- \=_\ 7Q>?^BHJ["7_ %K_ %-?F%?_ 'S$?XW^2/O*
M7^[4?\*&T445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 5[^P@U.T>VN4+Q,0?E8JRL#E65ARK @$,.017
M2V'Q*N)O">K^&?$<XDU)K&86&IL JZ@H0G8W99P!RHX8#<O<+A5CZKX;N?B'
MHFN6EJ/+T:PB=[_4BN<2I\P@@_Z:@@;G'^K_ -[IRXBG3J0_>:6Z]OZ[=3HH
M3G"?N:W/J<=!2TV-0D:J"2  ,L<G\Z=7QQ]*%%%% !1110!\MWG_ "99#_V$
M(?\ T]+7L%Q_Q\2_[Q_G7C]Y_P F60_]A"'_ -/2U[!<?\?$O^\?YU[=+^%_
MV]+\HGF5/C^2_4\>\8^,/B&GQE@T#PM96MWH%I8V=_J GAC^Y)-*LO[QI X;
M9'\@C1_FQNP#FN#E_:M\0R6-CJ5OX8T^2R$\JW,4%Q/(\A^Q/<):(QC7;=(R
M;)%P0#@ U],UY7\:?'GCGPWKOA?1_ VFVVJZEJL=Y,T-Q ),^2L949::((I+
M_,^6('(5NE>E1G";4'!;=[=-6SCJ1E%.2D_S.+T#]IKQ+XBBT22#P;9117T$
M1DD>]=L232W,4+1!4(:,M I.6# ,1U%9FA?M7ZP-(T.?4M,TN]O;^YL89(K6
M2:-&26&W:8PGR\%XWGY1S_ V,A21TL'[3%[JOC2\\+Z1X>T[4M2CU.WTV*1=
M6=82S_:!)YA,.Y&1K9AMVG(92#@@G$\.?M;ZK<Z3;W>I^$[6ZC%FTMS)HVHF
M5OM'V:YN%A6(Q]EMF5B6RK'H>:Z_8[_N?_)C#VFW[S\!?B#\=_%OA[X8> -<
MMKG3[#4=;DO4O9KBVB$2F)9#& )I45,E5!RV3V!-6OA]\<_$GBCQ[IFGW-_I
M\GVN\@MIO#::8\-W;6SZ='<->F0MD(LK%-K+C! SFNJ^$/QTU#XL:E80Q^&8
M]+M)-+;4KJXDO_,*_P"D2P1B%0G[Q6,1.XE2.F,BO7=Q.>>O6N:I.-*].=-)
MZ]5U?IT-HQ<[2C/30JZE_P @R]_Z]Y/_ $ UI?L^_P#)!_AS_P!BYI__ *31
MUFZE_P @R]_Z]Y/_ $ UI?L^_P#)!_AS_P!BYI__ *31UX^)_@_-?DST*/\
M$^7^1F?&_P#Y#/PK_P"QOB_](;VNJKE/VA?^$<_X1O0#KY\0K.-9B_LH^%A(
M;_[9Y,V-FSG'E^=G/&,UY3OLO^>GQ^_[XN?\*BG2]K2B]K7Z>9<Y\DV?0-%?
M/V^R_P">GQ^_[XN?\*-]E_ST^/W_ 'Q<_P"%5]5\_P "?;>1] T5\_;[+_GI
M\?O^^+G_  HWV7_/3X_?]\7/^%'U7S_ /;>1] T5\_;[+_GI\?O^^+G_  HW
MV7_/3X_?]\7/^%'U7S_ /;>1] T5\_;[+_GI\?O^^+G_  HWV7_/3X_?]\7/
M^%'U7S_ /;>1] UR\WPXT2?P_J^CM _V75;F6ZNI 5\UVDF$S#=M^[N'0YXX
MKR;?9?\ /3X_?]\7/^%&^R_YZ?'[_OBY_P *I8>4=I/[A.JGNCU7Q9\+?#?C
M>5FUBP^TQ_89;"*!&\N*!)6W2/&JXPY(7YN?NCBLJ[^!?A:_TV2SN8KJ43Q7
MEO=7'G!9KN*Z):6.5PH+#?MD7NK*I!Z@^?[[+_GI\?O^^+G_  HWV7_/3X_?
M]\7/^%:*G4BDE-Z?UW)<H/5Q1Z+I/P:T33?#%YH-Q>ZMK-E?:FNKWKZI="66
MZG!0D2,JKE"8T)4 =.PI;7X+^&[&2Z^SK>0P3S)-]F2X_=Q%;D76U 1D*9<L
M1D_>;IFO.=]E_P ]/C]_WQ<_X4;[+_GI\?O^^+G_  I\E3^=_<+FA_*CJKW]
MGC1?+AGLK^_?4K.W6&QDOIP\<)58U0G:@;"B)" #M# MM.YLV-(^!.G)I;1:
MQJ=]J%Y=.\^H/#((X[N8R3R([#;G*&X?&"H.%RIP!7&[[+_GI\?O^^+G_"C?
M9?\ /3X_?]\7/^%4U6:MSO[A7IWORGH-[\$O#UZ]T[27JO<P+;R$O'(I0) F
M-KHR]+:/J.N2,$C'2>%?"%EX/AO(;&:[ECNI(Y7%W-YK!DA2+.XC<<K$A.2<
MG)XS7C6^R_YZ?'[_ +XN?\*-]E_ST^/W_?%S_A6;I3DN5R=O0I3BG=(^@:*^
M?M]E_P ]/C]_WQ<_X4;[+_GI\?O^^+G_  K+ZKY_@7[;R/H&BOG[?9?\]/C]
M_P!\7/\ A1OLO^>GQ^_[XN?\*/JOG^ >V\CZ!HKY^WV7_/3X_?\ ?%S_ (4;
M[+_GI\?O^^+G_"CZKY_@'MO(^@:*^?M]E_ST^/W_ 'Q<_P"%&^R_YZ?'[_OB
MY_PH^J^?X![;R/H&O$/V@O\ D,C_ +$KQ%_Z'85F[[+_ )Z?'[_OBY_PJUX>
M_P"%?MX@O_\ A*7^(ID_X1^_S_PG(N1#]AWP?:_*X^]GR,XYQC%=6&I^PK1J
MZNW1+4PKR]K2E#17[L^,**^O/+_9:_OVWYW]'E_LM?W[;\[^OTO^V_\ J%J_
M^ ?\$^$_LK_I_3_\"_X!\AT5]>>7^RU_?MOSOZ/+_9:_OVWYW]']M_\ 4+5_
M\ _X(?V5_P!/Z?\ X%_P#Y#HKZ\\O]EK^_;?G?T>7^RU_?MOSOZ/[;_ZA:O_
M (!_P0_LK_I_3_\  O\ @'R'17UYY?[+7]^V_._H\O\ 9:_OVWYW]']M_P#4
M+5_\ _X(?V5_T_I_^!?\ I_!#_DT#QW_ -?%Y_Z*BKL)?]:_U-:6FZC\+KKX
M+>-M*\#7B1Z%;PO+J'E&<&$R+@ONE&<[4/3.-O2JQM_AH22?'FNY[Y=O_C%?
M#5<3S8FM-TY*\KV<=5=+?L?64Z%J%**G%V5KWT^14HJU]F^&?_0^:Y_W\;_X
MS1]F^&?_ $/FN?\ ?QO_ (S2^L+^67_@+#V#_F7WE6BK7V;X9_\ 0^:Y_P!_
M&_\ C-'V;X9_]#YKG_?QO_C-'UA?RR_\!8>P?\R^\JT5:^S?#/\ Z'S7/^_C
M?_&:S_#Z_#^YT6SEU'QQKL5\T8,R%F7#=^/(XH^L+^67_@+#V#_F7WDU%6OL
MWPS_ .A\US_OXW_QFC[-\,_^A\US_OXW_P 9H^L+^67_ ("P]@_YE]Y5HJU]
MF^&?_0^:Y_W\;_XS1]F^&?\ T/FN?]_&_P#C-'UA?RR_\!8>P?\ ,OO*M%6O
MLWPS_P"A\US_ +^-_P#&:HZ<GP^EN]36Y\<ZZD,=P%MCN8;H_*C)/^HY^<N,
M^WM1]87\LO\ P%A[!_S+[R2BK7V;X9_]#YKG_?QO_C-'V;X9_P#0^:Y_W\;_
M .,T?6%_++_P%A[!_P R^\JT5:^S?#/_ *'S7/\ OXW_ ,9H^S?#/_H?-<_[
M^-_\9H^L+^67_@+#V#_F7WE6BK7V;X9_]#YKG_?QO_C-9S+X _X2%(1XXUW^
MSC:L[2;F_P!;O  SY']W/%'UA?RR_P# 6'L'_,OO)Z*M?9OAG_T/FN?]_&_^
M,T?9OAG_ -#YKG_?QO\ XS1]87\LO_ 6'L'_ #+[RK15K[-\,_\ H?-<_P"_
MC?\ QFE6U^&3, ?'VM)D@;I)BJCW),. /<\4?6(_RR_\!8_82_F7WE2BO0T^
M!.D2(K+X@U]E89#"\C((_P"_=9.O_!JPTVXT9(M?U_;=WRV\F;J,_*8Y&X_=
M^JBL%F%!]7]QI]3J^1R5%>B?\*&TK_H/>(/_  +3_P"-T?\ "AM*_P"@]X@_
M\"T_^-TO[0P_=_</ZE6\CSNBO1/^%#:5_P!![Q!_X%I_\;I&^ FDNI5M>\0E
M2,$"]521]0@(^H.:/[0P_=_<'U*MY' >&_#=]\1=5FL+"62ST>V?R]1U6(X8
M,.MO ?\ GI_>?H@/][I[!XFT:Q\._#/5--TVUCL[&VT^2.&"(85%"G_]9/4G
MDUOZ+HMCX=TJUTW3;6.SL;9!'#!$,*BC_.23R3R:S/B!_P B/KW_ %Y2_P#H
M)KQ<1BI8B:Z16R/4HT(T8^9OCH*6D'04M<!UA1110 4444 ?+=Y_R99#_P!A
M"'_T]+7L%Q_Q\2_[Q_G7GOA:W\+W/[)"1^,[RXL/#F^9KFYLS()HV&HN8C'Y
M8+[O,"8"@G..*YIK[X=%CN^(7Q;W9YS;ZO\ _(M>YAUS4VDGI)[)OM_D>95T
MDG=;+=V[GL=(54L&*@L.AQR*\<^V_#C_ **%\6_^_&K_ /R+1]M^''_10OBW
M_P!^-7_^1:Z/9O\ EE_X"S'F\U]Z/81!$'WB*,/G=N"#.?7/K2)!%&<I#$AS
MGY4 Y]>GN?S->/\ VWX<?]%"^+?_ 'XU?_Y%H^V_#C_HH7Q;_P"_&K__ "+1
M[-_RR_\  6',NZ^]'L,<,<( CB2, ;0$4+@>G';VI]>-_;?AQ_T4+XM_]^-7
M_P#D6C[;\./^BA?%O_OQJ_\ \BT>S?\ ++_P%AS+NOO1ZWJ7_(,O?^O>3_T
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M687-BBL?_A,-"_Z"]E_W_7_&C_A,-"_Z"]E_W_7_ !HLPN;%%8__  F&A?\
M07LO^_Z_XT?\)AH7_07LO^_Z_P"-%F%S8HK'_P"$PT+_ *"]E_W_ %_QI/\
MA,M!W;?[9L=V,[?M"YQ],T687-FBL?\ X3#0O^@O9?\ ?]?\:/\ A,-"_P"@
MO9?]_P!?\:+,+FQ16/\ \)AH7_07LO\ O^O^-'_"8:)_#JMK(W9(Y [,?0*,
MDD]@.319@:5W=PV%L\\[^7$G4X).2<  #DDG  ')) %=-X>\!7=MJ7AG7]<C
M:"Y?4E%IIC'BV0PR_/(.C2GTY"=!SDUN_#;X;3&Y@\0^(;<QW2?/8:9)@BT!
M_P"6DG8S$?@@.!SDUV'B_P#X_/#7_853_P!$RUX.+QG,W2I/3J_T_K_A_8PV
M%Y5[2>_0Z.BBBO!/6"BBB@ KG_B!_P B/KW_ %Y2_P#H)KH*Y_X@?\B/KW_7
ME+_Z":J/Q(3V-\=!2T@Z"EJ1A1110 4444 ?+=Y_R99#_P!A"'_T]+7L%Q_Q
M\2_[Q_G7CVH.(OV)?.8-Y<-XDTA52VU$U@,[8 )P%!)]@:Z"?]H+X;-/(1XS
MTT@L2#^\]?\ <KWJ$)SI>ZF_>E^43RJLE&>KZ+]3O:Q[_P &Z#JEZUY>:-8W
M=VT\%T9YH%9S+""(7R?XD#, >P)]:Y?_ (:!^&W_ $.>F_\ D3_XBC_AH'X;
M?]#GIO\ Y$_^(K94JRVB_N9DYTWNT;NE_#?PGH=M!;Z?X:TNRM[>^&IPQP6J
MJ([H @3KQPX!(![ X%44^#7@**W>W3P=HJ0/,;AHUM%"M(5="Q'KMD=?HQ%4
M/^&@?AM_T.>F_P#D3_XBC_AH'X;?]#GIO_D3_P"(J^7$=I?B3>EW7X'00?#[
MPQ;7$4\/A_3XIXI!+'(L #(XD:4,#ZB1W?ZL3705Y_\ \- _#;_H<]-_\B?_
M !%'_#0/PV_Z'/3?_(G_ ,14NE6EO%_<RE.FMFCM]2_Y!E[_ ->\G_H!K2_9
M]_Y(/\.?^Q<T_P#])HZ\OU#X_P#PX?3KM5\9:<S-!(H $G)*G ^Y7J7P"ADM
M_@7\.XI8WBE3P]IZM'(I5E(MX\@@\@^U<>+A*%'WE;7]&=&'DI5-'T_R(/C-
MXH\0>'[?PE9>&[RRTZ_US78]+:\OK1KI(8S;SREA&)$R<P@?>[FL/^S?BO\
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MHXYE!;><XQQ7H+!UVHR7*T_[J\_[NNST5WY'-[>FFT[Z>?IY^9]'?V;\5_\
MHH'A_P#\)5__ )-H_LWXK_\ 10/#_P#X2K__ ";7B7COXS?$F+]F_3_BCX=\
M6^#V:T@"7\.GZ:][;7TK7*PJ\4DC(T. V6C920V1FO8='\4ZQX8T>^T36O$>
MA>/?B/"DEQ;Z-I9ATN>Z7 ,<8A:1RG&29#QCGM7/.E5A'F?+NU;E6ZW^S:VJ
MUOU-(SA)VUV3W?7YES^S?BO_ -% \/\ _A*O_P#)M']F_%?_ **!X?\ _"5?
M_P"3:\R\ ?M$ZZ?@QK_B;Q;86EUXL@\27OA[3=#T<'%U=)($@MHSU?G.Z0X^
M568XQ7F<_P"UAX__ .%5_#?5KW5?#OA6^U^TU:ZO=?U+37FLFN+6=XX;&)%8
M!7D"_>)).. 3Q6T<)B)-I*.CMLM[-Z::Z(S=>DDG=[7W?>W?S/IG^S?BO_T4
M#P__ .$J_P#\FT?V;\5_^B@>'_\ PE7_ /DVOF_Q/^U?X[U+1O!/B/2X)_"7
MA.^\-0ZOK6M#PQ)K%K:7#SF)E+^8FR-0I).6(R,CO7V);2K/:P2I(LR21JZR
MI]UP0"&'L<Y'UKGKTZV'2<U'6_V5T^5OQ-:<H56U%O3S?^9Q?]F_%?\ Z*!X
M?_\ "5?_ .3:/[-^*_\ T4#P_P#^$J__ ,FUW%%<GM9=E_X#'_(WY%W?WO\
MS.'_ +-^*_\ T4#P_P#^$J__ ,FT?V;\5_\ HH'A_P#\)5__ )-KN**/:R[+
M_P !C_D'(N[^]_YG#_V;\5_^B@>'_P#PE7_^3:/[-^*__10/#_\ X2K_ /R;
M7<44>UEV7_@,?\@Y%W?WO_,X?^S?BO\ ]% \/_\ A*O_ /)M']F_%?\ Z*!X
M?_\ "5?_ .3:[BBCVLNR_P# 8_Y!R+N_O?\ F</_ &;\5_\ HH'A_P#\)5__
M )-KD?%'Q=\??"N_UV#6-1T7Q0+?P\-8MC#I<ECLD%Y';E&_?R;@5<GC&"*]
MFKYT_:6_Y#?B'_L1C_Z=H*]'+U'$8F%*K%.+:Z)=5V5SCQ;=&A.<&TTGU?8Y
MK_ANWQ9_T+6C?]_)?\:/^&[?%G_0M:-_W\E_QKYIHK]4_L++?^?*_'_,_/?[
M6QW_ #]?X?Y'TM_PW;XL_P"A:T;_ +^2_P"-'_#=OBS_ *%K1O\ OY+_ (U\
MTTFY<XR,^F:/["RW_GROQ_S#^UL=_P _7^'^1]+_ /#=OBS_ *%K1O\ OY+_
M (T?\-V^+/\ H6M&_P"_DO\ C7S1N7&<C'KFE!##(.1[4?V%EO\ SY7X_P"8
M?VMCO^?K_#_(^EO^&[?%G_0M:-_W\E_QH_X;M\6?]"UHW_?R7_&OFFBC^PLM
M_P"?*_'_ ##^UL=_S]?X?Y'VIX,_:$UCXK?"SXBW^H:58V<FBVL;PQVSOME+
M!SAB<XY0=/4UV3?%[Q:K$?V5H1P<?\?<_P#\:KYZ_9Y_Y(Q\9?\ KR@_] EK
MU^7_ %K_ %-?"XS X:GC*M.,/=35EK_+%]SZS#8NO/#4YREJT[[=V=+_ ,+@
M\6_] G0O_ N?_P"-4?\ "X/%O_0)T+_P+G_^-5S%%<OU/#_R?G_F;_6JW\WY
M'3_\+@\6_P#0)T+_ ,"Y_P#XU1_PN#Q;_P! G0O_  +G_P#C5<Q11]3P_P#)
M^?\ F'UJM_-^1T__  N#Q;_T"="_\"Y__C59^@?$GQ9H.BV>GKIVA3"WC""3
M[5.-WOCRS6111]4P_P#)^?\ F'UFM_-^1T__  N#Q;_T"="_\"Y__C5'_"X/
M%O\ T"="_P# N?\ ^-5S%%'U/#_R?G_F'UJM_-^1T_\ PN#Q;_T"="_\"Y__
M (U1_P +@\6_] G0O_ N?_XU7,44?4\/_)^?^8?6JW\WY'3_ /"X/%O_ $"=
M"_\  N?_ .-51T[XF>+-/NM3F&FZ$YO;@7!'VJ<;,11QX_U?/^KS^-8U%'U/
M#_R?G_F'UFM_-^1T_P#PN#Q;_P! G0O_  +G_P#C5'_"X/%O_0)T+_P+G_\
MC5<Q11]3P_\ )^?^8?6JW\WY'3_\+@\6_P#0)T+_ ,"Y_P#XU1_PN#Q;_P!
MG0O_  +G_P#C5<Q11]3P_P#)^?\ F'UJM_-^1T__  N#Q;_T"="_\"Y__C59
MS?$CQ8?$*:K_ &=H6Y;5K;R_M4_0N&SGR_;IBLFBCZIA_P"3\_\ ,/K-;^;\
MCI_^%P>+?^@3H7_@7/\ _&J/^%P>+?\ H$Z%_P"!<_\ \:KF**/J>'_D_/\
MS#ZU6_F_(Z?_ (7!XM_Z!.A?^!<__P :H'QB\6(0S:-HDJCDQI>S*S#T!,6
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MB%'DP)N [XC:,<-G(.=U85+U4E.JG;^OZ_I&L7R.\8'LP8,,J0P]0<TM<O\
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M '^OZK_TF)]OA/\ =*7H_P#TIC:***XSI"BBB@ HHHH **** "BBB@ HHHH
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ME^I'1115$GA?Q+MOBJGQ3>Y\+M>3>%99-&MI+97"I$//=[BXCYR0%4)*O=9
M1]VJ?@RU^(27^A?;(_&BW0U2Q.O/JUS"UBY'VC[2;55.X6_,7 PF-F!N!KZ
MHKL^L>[R\J.?V6M[L****XSH*VI?\@R]_P"O>3_T UI?L^_\D'^'/_8N:?\
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M_P"&>_A?_P!$]\-_^"Z/_"HI_@-\)[7;Y_@7PK;[NGG64*9^F>M'-0[?A_\
M;A:IW_'_ .U+OVCXL?\ 0M>"/_"DNO\ Y#H^T?%C_H6O!'_A277_ ,AUF_\
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M\_R.7%>[1DZJO&SNK^7HB+_A@W7_ /H;M-_\ Y/_ (JC_A@W7_\ H;M-_P#
M.3_XJOG;_A,/$'_0P:M_X'S?_%4?\)AX@_Z&#5O_  /F_P#BJ_2?JF;?]!2_
M\ 1\+]8R[_H'?_@3/HG_ (8-U_\ Z&[3?_ .3_XJC_A@W7_^ANTW_P  Y/\
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M+O\ ^.T?99?^@GK/_@XN_P#X[1RXC^9?=_P0YJ'\K^\Z/_A6WC7_ *!FC_\
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M9/\ Y'H_X5MXU_Z!FC_^#63_ .1Z]UHH_M&MY!]2I>9X5_PK;QK_ - S1_\
MP:R?_(]43X,\8#6UTO\ LK2O/:W-R&_M5]NT,%Q_J,YR:^@ZYI_^2CP_]@E_
M_1R52S&L^PG@J7F>7_\ "MO&O_0,T?\ \&LG_P CT?\ "MO&O_0,T?\ \&LG
M_P CU[K14_VC6\A_4J7F>%?\*V\:_P#0,T?_ ,&LG_R/1_PK3QN_RKI^C1$\
M!WU.1@ON5$ )QZ9&?45[K11_:-;R#ZE2\SF_ _@>S\$::\,+M=WUP1)>7\H
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MV2V[7_SZ'Q[X>3X1Z?\ ##QCXIUR]L],\#:CK.G76F_#;0-;BE:1HXV2"*\
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MF_-W&4,3.R*=GWL[D(QVZUT=>0XN.YW)I[!1114C"BBB@ HHHH *^=/VEO\
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M#%@#RU.]F!()! [9KA_%^J^'M2FL8_#>@2:%8VT/EL+B[-S-<,6)WNV .,X
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M%]/C7_Y7ZSIT_:TXZ/3ROU]324^2;V^\][Q1BO!,>!?3XU_^5^C'@7T^-?\
MY7ZKZMZ_^ _\$GVWI]__  #WO%&*\$QX%]/C7_Y7Z,>!?3XU_P#E?H^K>O\
MX#_P0]MZ??\ \ ][Q1BO!,>!?3XU_P#E?HQX%]/C7_Y7Z/JWK_X#_P $/;>G
MW_\  />\50UW0K3Q'I<VGWR.UO(5;,;E'1U8,CJPY5E900?45XGCP+Z?&O\
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M56K[.2NUHT[KW4M?ZV/I*&&=/#TZ?/%V3U3TW>Q7HJ?[/X _Z';Q7_X+F_\
MD.C[/X _Z';Q7_X+F_\ D.L?;K^67_@+-/8O^9?>B"BIC!\/U!)\;>*\ 9/_
M !+F_P#D.NRTKX.:+KFFVVH:?XOUN\LKE!)#/#+:LCJ>A!\BLYXNG3UFFO5,
MN.&G/X6G\SAZ*]"_X4/8_P#0S>(/^^[;_P",5D^$O@Y;ZYX;T^_N?$NNB>>(
M.^QK8+GV'D5G]?H;W_ OZG5[')T5Z%_PH>Q_Z&;Q!_WW;?\ QBC_ (4/8_\
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MPXF\:Z7J.H#5K+2K:RN;:T8W:2.9)9V98E4(IZE<$G &<U^V5*L*,>>;LO\
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MH/X8?]%!\.?^#&/_ !K%4YSI0<8M[]/-FKG&,Y*3M_PQZ!17G_\ PT'\,/\
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MI#&4Y3BTKK=>:.#'3C+#347=V?Y'RU6]H'C/4/#>G7-C:[&M[BYM[QU?_GK
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M4>'_ +!+_P#HY*J/4EG2T445)04444 %<YXO_P"/SPU_V%4_]$RUT=<YXO\
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MH]J^R^Y?Y!R+N_O9P_V?XL?]#/X)_P#";NO_ )-H^S_%C_H9_!/_ (3=U_\
M)M=Q7DW[2GBKQS\/_AOJOB[P;J.B6L6A6<U[?VNL6$ERUTJ[=JQ,LB!#][).
M<Y'I6M)RJS5-<J;[I?Y$32A%R=]/-_YG0_9_BQ_T,_@G_P )NZ_^3:/L_P 6
M/^AG\$_^$W=?_)M>!^+/C;\4O!'B;PEH?B'Q_P##GP\-=T6?6O[9U3298+5
MIB$=OAK@9<[V.<\@=.*S[C]K;Q]=_##P)XD-AI7AG3]7DOX=2\67&D7FHZ=&
M\$NR$I#$0Z), 6#L2  <5Z"P=>23CRM/R]?+79[79S.O35T[Z>?IY^9]&?9_
MBQ_T,_@G_P )NZ_^3:/L_P 6/^AG\$_^$W=?_)M>,^/?C;\3+']G?3OBAH&K
M^!V2WMP-0M[6"74;>[D:Y6%'MY0Z>6,,"R."RG([5ZY9:IXSTSPEJ6DW6M^$
MO$WQ/$<DEC8VK&P@?(!C$D3.\@ &6+#J,=.M<TZ52$>9\N[6RW6_2UM5U-8S
MC)V5]D]WU^?D6OL_Q8_Z&?P3_P"$W=?_ ";1]G^+'_0S^"?_  F[K_Y-KQWX
M?_&SXJ_$'PGXIM=)M_"U]XAT;7XM+EUR>*6RL[:T,6^>[EM)7$N(R"J\CS!\
MPX%8^@_M*_$KQWI'A;2/#UMX:B\3:H^M7']NW%O,^FWMC8$*L]O%N#@3,V 2
MQ "DC.:V^JU[M>[IOHM-+WV[+U\C/VU/3?\ 'O8]Z^S_ !8_Z&?P3_X3=U_\
MFT?9_BQ_T,_@G_PF[K_Y-KYCUK]NK6M1;PXVBCP[X>$FAV.KZBFO074T<\T\
MI1H$FB!%O&@4GSI 1EE%?:44@EBCD&W#J&^5MPY&>#W'OWK'$4:V&2=6*5_)
M=/D:4ITZU^1O3S9Q/V?XL?\ 0S^"?_";NO\ Y-H^S_%C_H9_!/\ X3=U_P#)
MM=Q17'[5]E]R_P C?D7=_>SA_L_Q8_Z&?P3_ .$W=?\ R;1]G^+'_0S^"?\
MPF[K_P"3:[BBCVK[+[E_D'(N[^]G#_9_BQ_T,_@G_P )NZ_^3:/L_P 6/^AG
M\$_^$W=?_)M=Q11[5]E]R_R#D7=_>SA_L_Q8_P"AG\$_^$W=?_)M'V?XL?\
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M (^)?]X_SKV:,8>SYG%-\S_3_,\VI*7,DG;1?J<I_P )/\7/^?'P!_W^OO\
MXU1_PD_Q<_Y\? '_ '^OO_C5=/16MJ?\B(O/^9G,?\)/\7/^?'P!_P!_K[_X
MU1_PD_Q<_P"?'P!_W^OO_C5=/11:G_(@O/\ F9S'_"3_ !<_Y\? '_?Z^_\
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M"$([7'GERP!RP&PXR6)[5,Z<([2OI^(XSD^AU]%%%<QL%?.G[2W_ "&_$/\
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M:***]8\\^@?V>?\ DC'QE_Z\H/\ T"6O7Y?]:_U->0?L\_\ )&/C+_UY0?\
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M5O\ HG_A[_PJG_\ D*JG_"AO"']W7O\ PI]3_P#DBC_A0WA#^[KW_A3ZG_\
M)%'/0[?@_P#Y,.6KW_%?_(EO^T?BM_T3_P /?^%4_P#\A4?VC\5O^B?^'O\
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MBM_T3_P]_P"%4_\ \A54_P"%#>$/[NO?^%/J?_R11_PH;PA_=U[_ ,*?4_\
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M;TRW5B,G   \CQ?G_F8-?_\ !Q<__%UZ#\-_B3-'<V_A_P 0W!EGD.RPU.3
M^T^D4AZ"4#H>C@<?-D5Q8N&)=)ZIKK:YU8:5!5-G?S/5*YSX=?\ (CZ-_P!<
M!_,UT=<Y\.O^1'T;_K@/YFOGOLL]GJ='1114C"BBB@ KG_#/_(6\4?\ 827_
M -);>N@KG_#/_(6\4?\ 827_ -);>J6S$]T=!1114C"BBB@ KFG_ .2CP_\
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M6[+KZ^3+_E_%?_H1/#O_ (5,G_R'1Y?Q7_Z$3P[_ .%3)_\ (=9O_"E?"_\
M>\0?^%/J?_R11_PI7PO_ 'O$'_A3ZG_\D5O>/])__)F5G_37_P B:7E_%?\
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MM2H0I-IN*?XML\ZHKT7_ (4-I/\ T'?$'_@:O_Q%'_"AM)_Z#OB#_P #5_\
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M_0[^//\ PHYJ/;4/YG]P>RJ]OQ-*BLW_ (9ST_\ Z'?QY_X4<U'_  SGI_\
MT._CS_PHYJ/;4/YG]P>RJ]OQ+.I?\@R]_P"O>3_T UI?L^_\D'^'/_8N:?\
M^DT=84G[.&FRQNC>-O'A1U*L#XCFY!&#7I/ACP[9>$/#>E:%IJ-%IVF6D5E;
A([EV6*- B L>2< <FN?$5J<J?)!WU[&U&G.,^:2Z'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img81402019_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img81402019_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '5 6P# 2(  A$! Q$!_\0
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M3M?\;^"W\)7=_I?]IW1$DJ;RN+M$(2::-U;$K+DJR\\8 !]Y45^;MM\9;/\
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M 3GFO??^&>/VG?\ H[G_ ,QKI?\ \<H_X9X_:=_Z.Y_\QKI?_P <H \T\?\
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M1_;J\$>(O%WQ#_9IN="T#5-:M])^(FGWVHS:=9R7"65NLT1::8HI$:  DLV
M,'FOKBOE7_AGC]IW_H[G_P QKI?_ ,<H_P"&>/VG?^CN?_,:Z7_\<H ]@_:,
MM/B/=?!SQ$?A-J$&G^/X8EFTTW,,4B3,K M%B4% 73<%+<!BN2!FO@WX_:7_
M ,-1>#IO#NE?LA^*_"WQEO&A'_"47>D1:;I]C.)%,DO]HJR^>@&_ 8<YXYKZ
M2_X9X_:=_P"CN?\ S&NE_P#QRC_AGC]IW_H[G_S&NE__ !R@#F/VM/"GC3P9
MJ7[-7B^V\->(?B6G@#4"=?'ANT-Y?S[K:*(S)#D,Y9D=CV'<C.:V-.TG7?%?
M_!0WPC\08O"OB#3O"][\)DC:\U+3)8%M;F2^DE%I.Q&V.X56&Z(G</2K_P#P
MSQ^T[_T=S_YC72__ (Y1_P ,\?M._P#1W/\ YC72_P#XY0!5_;9\(>-+'XD_
M _XN>$?"E[XXA^'VHZ@VJ:%I0#7LMO=Q11F2%.KE!$?E ))9>V2/,_BOXQ^)
M'[2'QF^ 6O:;\'/&7A+P)X=\8V\US<>)=.,.HL[#YI7MHR_D6\:H099& 8R)
MCH:]6_X9X_:=_P"CN?\ S&NE_P#QRC_AGC]IW_H[G_S&NE__ !R@#F?&VD>-
MOV6/VK_&7Q7T+P!KGQ'\ ?$"PM(]8L_"L(N=3TV]MDV(Z6Y(,B,N3P1RYY&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MLS5]8M]'MWGN[A;>)>A)Y/T'<_2L(>)]9U1"VEZ45@/"W%\VS/7G;UQG'YT[
M$\QV%%<<[>,&; N-,C)/"A';N._TS2O_ ,)@$^6[TS=CO$W7'U]:?*',=A17
M(JOC .Q:ZTS9G@>4V<9^OI2 >,.,W6F<CH(FZ\>_3K18.8Z^BN1(\7 _\?FF
MXY_Y8M[^_P!*0#Q?C'VK3=WO$WM[_7]*+!S'7T5R#+XQ R;O3 /^N3>A]_I2
M@>+\D?:M,Z\?NFZ9^OI1;S#F.NHKCW'C#HMWI>[U,38Z?7UIP'B[>1]KTW [
M>4V>IQW],46#F.NHKCR/&("_Z7I>X]1Y3>WO]:4CQ>3Q=Z9CWB;CK[_3]:+>
M8<QU]%<A_P 5>#_Q^:6>>GE-[>_UIK:QXIT[!N-/M=00'YOLCE6 ^C<?K18.
M8[&BL'0_%=GKDWE1N\-ROW[:==KCMG![>];U2-.X4444#"BD)Q6+KOB:#0RL
M;![F[E&8K2$;I']P/0<9- KFW17'(_BG5QEY+?1HCR$4>=*.G4]/7IZU W@_
M668LWB_4QD8 18P!U_V?<?E56\Q<WD=Q17#GP;J^<GQAJH]L1^HX^[[8_&D3
MP;K (SXQU4\8Y6/TZ_=HLNXN;R.YHKB#X/U;<2/%^J'G(4B/'7I]WI3/^$,U
M<8_XK+53]!%SP/\ 9]OUHLNX<WD=U17$?\(?JQ;/_"8:H"3G;B/'?C[ON/R%
M,/@[5P?^1QU4Y/818[?[/L?S-'+YAS>1W5%<.O@[5V/_ "-^JXQZ1>_^S[_I
M0/"&K G/B[53SG@1\#.?[OX4^7S#F\CN**X=/!VKHG/B_56&, D1YZ=?N]:#
MX0U;<3_PEVJD>@$?J?\ 9]\?A2Y?,.;R.XHKAAX-U=@5_P"$QU8' YQ%Z#_9
M]OUIP\'ZNG)\7:H<=B(_?_9]Q^5%O,.;R.WHKC18>)],SY&K1:@,9V7D6TGI
MT*_CV[U;TCQ?]IO18:C;R:7J&.(I>5D]=C=&H:'<Z>BH0YSU/TIZ$FI"X^BB
MB@H**** "L[7-2ATFPDNYV(CC'0#)8]A^=7I&('%<AJRGQ!XMM;(L3;:<HN9
M4!!S(>%![C Y]#0M=P$T309]5NQK.LC?=-S!:L?DME[<=VQ_%77H@*+GDBFQ
MK\OK4JC Q39*$\L9SC-($ Z+3Z*FQ0S:/[HHV@C[HI]%,!NP>@I-OM3Z* &;
M3Z"C;["GT4 -VC^Z*3:/[HI]% #-@/5011L7^Z*?10 S8/[HI?+7TIU% '/^
M(?"T.M()0QM+V([H;N+AT/\ G^=1^%M<EO7FL+_$>J6AQ*@& Z]G4=2#Z^M=
M$XRI&<>]<CXMB.EWNG:W"3NMY!#.%!)>)N.@ZX///2GN)*QUX((HZBH8"&4L
M&)!Y!I7) I,9D>*==_L.U5D4SW4S"*W@'\;GIGV'<]JK^&?#9TQ#=7K?:M4N
M/FGN'.2/]E?8=*JHG]L^-II' >'2X@D:GM(W).".N.X-=6@VJ >:;T%87;BD
M*ANHS3STI ,TAC,+W H^7VJ3;]*-OL/RH BVICH*-J>@J7;[#\J-OL/RH#4C
MPOM0 !4FT>@HP* (L*&SCVI>,5)@48% QG&:0@>E28%&!0!&"!VI>*?@48%
M$7E*>V:H:YH5KKMF8+E.AW)(IPT;=F!]16IMIA&010(YCPMJURMS/I&I'-];
M#Y)3_P MX^S#U/K[UU*G.:Y+QE;MI\MAK$.5DM)0DF,Y:-C@C@9//:NGM7WC
M(Z8XI]+D+<L4444BPHHHH AN.4ZX]ZYOPGBZU77KA\L_VKR@3NX"CH,CC\.*
MZ*=20,=ZY_P4I%WKY(./M[X)!&1^=4MF3U.F &*=114E!1110 4444 %%%%
M!1110 4444 %%%% !1110 5B>,H4D\,:D& P(&;G'89[\5MUE>*3CP[J7_7M
M)_Z"?8TUN)AX>E,NBV+Y^]"A['M[<?E6A)QBLOPQG^P-/R=W[A.0<]O6M.1@
M&3DT/<1S/@8F5M9E8,"UZXP5(Z?4FNIKEOA^H6#5L8YOY3QM]?;^M=93>X+8
M*3&*6BI*"BBB@ HHHH **** "BBB@ HHHH **** "DQBEI#TH PO&L8D\+:D
M" ?W1//MSZC^=7=$9I-/M7/&85XQCM]:I^-"!X5U0D _N&X.,?KQ^=6?#N/[
M)LR,8\E.F,=/;C\JKH3U-2BBBI*"BBB@"&1L[<"N;\$ "Z\0< '[>^<;?Z?U
MKI91C''Y5S?@DDW.O9)/^GOC+9Q^E4MF3U.IHHHJ2@I,TM-8#&>] #J*RM*\
M3:7K=S>6]AJ-O>3V;^7<1PR!C$WHP'2M-3GOFAZ"3N.HHHH&%%%% !1110 4
M444 %%%% !67XHS_ ,([J6!D_9Y. "?X3Z<UJ5E>*B!X;U,GD?9I../[I]::
MW$QGAL'^P]/S\O[A.#D=O?G\ZT9"<<5F^&2#H&G<8'D)Q@>E:3=JB6_S$<U\
M/7WVNJ9//VZ7C.>_T%=97)_#T$6VJ@Y_X_I>N[U]_P"E=96L_B81V"BBBH*$
M)Q0#FF2M@')P.N:P/"_CG1/%LE['H^I17SV<Q@N%CZHX[<_SH6JN!T=%(,TM
M !1110 4444 %%%% !1110 4AZ4M(>E &)XS)7PKJA#%3Y#<@D$?B,G\JL>'
M0?[)M,]?)3G.<\"JWC09\*ZH"-W[AN,$Y_ $?SJSX=!&D6><<0KV([>]5T)Z
MFI1114E!1110!%-V[US?@K(N=>SG/V]^H/\ 7^E=%<?,G7;[USG@IA]JUX #
M/VYN0 .WM_6JC\+)ZG54FX"FM)A2<=*JVMY'=0^:C!ADCCUK%RUY>I6I<W"J
MFJ3&WTZ[E7[T<3N/P4FB:Z2U7=(X520!GWJ'6>=$U#_KWD_]!-.$HR=DQ/0^
M=_ MN/!6F^"O&]O'Y,.I2/8:OMX$@D<F.1O4AN,^]?2D# CC&.",5X[X+\-#
MQA^SG;:7G$MQ9-Y+=UD5BR'\P*[;X4>)3XK\":5?R#%SY?DW"GJLJ?*P/XBN
MJMHW9[.QE#H=CD49IA(7KQ0K@\CD5S7Z&Q)12*<C-+3 ****8!1110 4444
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MT'O7GMO_ *Z/ZBOI[3%!T^U/_3)?Y5X?A'\>*_[=_P#;CMXH_P"77S_0^+O
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MP2<4HBP,9I@?)7P]\->)?"'B9?"-Q\-1J%ZFO76JR^+[D(UO]GDW$21N#O\
M-YV[2.U;_P"S7^S1H'AK0]/\2ZWX=N+'QE'?75PSRW,G!:1MIV!MN",'I7TL
M8N,9_2@1D ?,?K0!\J_$#X,^(]7^/B:3I]@3\._$EY!K^M7(8!8[FW&/*QW\
MPA6/TKZ5\2QA/#>IJH 'V5P <8^Z?7BM18<8Y[Y^M9WBIBOAW4B#@_9Y,'.,
M?*::W$QGA? \/Z;T_P"/=.F,=/;BM%E&_)K-\,KNT/3R3D^0F3G.>*TW.#GK
M]*B7Q?,1S'P_&+;5>"/].EZJ1GGW)KH+S_CUG_W3_*L#P 5-MJNT*/\ 3I<[
M0!W[X/\ .N@O1BVG_P!T_P JUE\?S,Y?!+T/S5\4O_Q4^J^UU)_Z%6M\)SGX
MC^'1_P!/J5D>*O\ D9]7_P"OJ3_T*M;X3<_$CPV?^GU/ZU_1%7_D7S_PO\C^
M+:'_ "-8_P#7Q?F?HRXS;M[J?Y5YS\!/^2;1#TN[D?\ D5J]&8_N#_N'^5><
M? 0Y^&\9];NY_P#1K5_.W1^J/[1^RCXD^()_XK[7_P#K[D_G4?@3CQKHN?\
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M<2XS=KHX6VVO<1A<D[NE?3NG$K86H _Y9J/TKY_\$^&IM>UFW"KB&-@TC@Y
M [5]#QJ$C5!_","O!\*\OKT*.(Q<HVC)I*_E>_YG;Q)7IU*D*<'>WZEA1Q2X
MI%'%+FOWU+0^+%HHHJ@"BBB@ HHHH *RO%.?^$=U(J"6^SO@+G/3VY_*M6LO
MQ/\ \B[J7 /^C2=>GW336XF0^%SG0=/ZAO)7.[.>GOS^=:CUF^& !H&GX &8
M$Z8QT]JTG SDFID(YOP)CR=4QVOI>X/?V KH9XS)&ZYZY%<[X 8M#JNX,/\
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M]<?_ !5+_P ,8^"?^@SXL_\ !]<?_%5[U1BCVU7^8-#P3_AC#P3C_D,>+/\
MP?7'_P 56;XC_8T\$PZ!J+G6/%A"V\A_Y#T_]WW;'YU]&UE^*/\ D7=2]?L\
MG?'\)]C35:K?XA/8\'\._L;^"9M"T]CK'BPY@7G^WI_3V;'Y5H']C+P2N/\
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MM!?Q'I[^)+S2X98+.6Y#33'RP=V!U%0_%G]G/P/\8++5/[;T"QFU6_MOLO\
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M)/3OFK[XS4RW0NAS7P]4+:ZI@ 9OY3P ._L3765R7P]*FWU7:0?].EZ$'O[
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MYPG^[4O1'MX1MTRQ:?M4Z-#H_B:?7/#VM>&M8T&R&H3Z+J,($\L!.%>-@2K
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MEP\>-@R,%9,\YKNOV2O&OAB_TC4K&758Y/B->WUQ>:[9W8,=V)=Y&,,,E5&
M,9&* /I.-MR TZHXON#-24 %%%% &)XR0_\ "+ZGM;8?(;YLD8_$#-6-!8G2
M[3.21$O)SSP._>H/&?\ R*VIX!;]PW !.?R(-6=#&-*L\]?)3/Y"JZ$]31HH
MHJ2@HHHH AN#A<@$^PKG/!*D76O$@@&^?!(/]3_*NCFX3KCWKF_!&/M>OX7'
M^G/G@#^1_G51^%D]3JJ***DH*:>AIU-(H ^?OV@;?R/'WA*\ P)K>XMV/;C!
M _G7*#J:]-_:2TIF\'66L1)F32;V.=B!G]VWRM^'.?PKS%75P&7D, 01Z5\Q
MF\7SQG;0\/%1:JMBU;^']N;_ .-'AI.OV2UN)V'IG"@U4]N_I74_L_::=7\>
M>)-<*_N+**/387[%OO/^IK'*HWK\RZ7,:,7*HCW/6="L/$6F7.G:I90:A87"
M[);:Y0/&X]"#7,>'?@OX'\):1J6F:1X6TW3[#4E*7D,-N )U(P5?U'M7;KTI
MU?6+8^B///!OP#^'OP_U3^T?#OA#2]*OPNU;BWMP'0>Q[?A6@?A)X-7QG_PE
M@\-:</$9_P"8C]G7SL],Y]??K79TA4'K3 \9;]GK2;3XX:;X\TI;70X[:&8W
M4%A"8WOYY.K3,#@J!T&.M>Q0?='M3P@'84!0 ,<?2@!U%%% !63XJ(7PYJ1.
M,"WDSD@=O?-:U97BKCP[J1SC%O)T)'\)].?RIK<3V&^%2#X>TXC 'D+T(]/:
MM*4X7(ZUF^&1C0-/)).8$ZY]/?FM&0<KWJ)/7Y@MCF?A\,6^JY YOY>@ [^Q
M-=97)_#[!MM5QM_X_P"7[I![^PKK*TENQ1V"BBBI*&O]VOG'XRVOV/XQV\Q4
MA+[2N&]T?&*^CV&17B?[2>EM;6?A[Q&@.W3KOR;@C_GE+\N3[ X_.L*U/GIR
MBNIRXF/-39YZN1P>II:7(/0CZT @. U? J_,X-:G@;:&G\)[,ZA\:K=\973]
M+D9_]EG? _E7TJ84F1D=%=&!!5AD&O#/V;]--_=^)_$Q&8KJX%I;-ZQQ\$CZ
MG->[+T%?>8>+A1IP?1'NX1<M)7*\.E65M;M!%:010,,-$D8"GZCI3;/1[#3V
M8VME;VQ;J8HE7/Y"KE%=)V%5M.M5N6NEMXEN6&&F"#>1Z9ZUQ,_PFTBZ^*=G
MXZF\QM5LK1[6VA4*L48<_._ RS' Y-=^1FDV^PH 2,82GTE+0 4444 8?C?'
M_")ZIG'^H;KC'Z\?G5G0&W:59=,>2G0 #I[<?E57QF3_ ,(OJ8/3R&Z'']#_
M "-6]!;?I-D>O[E.^>P]A3Z"ZFE1112&%%%% $4W./K7->""#>>(<$'_ $]^
MX./R Q72S_<'4?2N<\%9-UKQ.<&^?KN_K_2JC\+)ZG44445)04444 9?B+1+
M;Q'H=]I=ZN^UNXFAD'L1BOD_2;>Z\.ZC=^%M3)75-,8H"_6Y@_@D3UXQG'2O
ML,J#UKBOB)\*] ^(L4']IV\D=U!GR+RU<Q3Q^P8=O:N;$4(XBGR2.2O1]I'3
M<^=]>U<Z/9KY49N=0N&\FTMDY::4\* .O'4FOHCX2>"/^$"\$6&G2D-?.#<7
M<@_CF?EC^=9/@?X&>'?!&H_VE$+K4M3"[4O-2F,TB#T7/"_A7I$:!4Z8K+"X
M6.&@X[M[D8>BZ>LARC%.I%I:[CN"BBB@ HHHH **** "LKQ3_P B[J?&?]&D
MX_X":U:RO%/_ "+FI<@?Z/)UQC[OOQ36XF,\,,3H&G C;^X3C&,<>F36G)VK
M*\+$MH-@2<GR%YX]/;C\JU).HJ);_,70YKX?@K!JH.?^/Z7NWK[C^5=77)_#
M[/D:MD8_TZ7L?7ZFNLK67Q,([!1114%!6+XN\.6OBOP]?Z1>#-O>0M$WMGH1
M[@X-;5,;D<C-%[.XFN;0^/H7NO#&J3>&=?*VNK6GRPNYPEW%_#(C'KQC([&B
M\O+C6K]/#N@G[5K=Y\@\LY%JA^](Y' P.@-?4/BSP-H7C6T6VUK2X-0B7E?-
M3YE^AZC\*9X2\ :!X(MFAT32;?3U;[QB3YF^K'DUYGU"DJWMOF>:\)>?D2>"
M?"5GX)\+:?H]E_J;6()N/5V_B8^Y.370@8Q]* !MZ<>E+7IGI)**L@HHHH&%
M%%% !1110 4444 8?C+/_",ZGC.?(;&,Y_3G\JL: 3_9EH"N/W*=<YZ>_/YU
M#XS _P"$6U/(!_<-Q@'^9'\ZGT#']D66!C]RG0 =AZ570GJ:=%%%24%%%% $
M4^0F5ZUS?@G'VO7QC'^GOD[<9X^IKI)_N@"N:\#A1<Z_C!/V]\D$'^7]:J/P
MLGJ=51114E!1110 4A -+10 W;3J** "BBB@ HHHH **** "BBB@ K)\5 GP
M[J.#@_9Y#G./X3[&M:LKQ2-WAS4AC/\ H\G3/]T^E-;@1^&"S:'8,W4PJ3DD
M]O>M*3[R=?PJAX97;H&G]?\ 4)USZ>]:$C$8%1,A;',?#P 6VK8*G_B839V[
M?7V_KS76UR'P\NXKB'6/+G2<)J$JL58G:<]#D#%=<#FM9[CCL+1114%!1110
M A&: ,4M% !1110 4444 %%%% !1110 4444 8GC-@OA75"< "!NI 'Z@BI_
M#[;M*M#CCRDQCZ"J_C#</"^J%20P@8@C.?TY_*K/A]BVE6A;.[R4SU]!Z\U7
M0GJ:=%%%24%%%% $4WW :YGPNBV.M^((=H1FN!-P" VX=>?Z5U#J3T.*Y+7?
M^)!XFL]6)VV=TOV6Y/\ =;^!O7VIIV30K:W.O7H.<TM10N/*4\?A4@.0*D8M
M%%(>:8$*WMN\YA6>)IA_RS#C=^5.DNH8I4B>:-)'^ZC, 6^@[U\41V-W'XBU
MWQ"VC7-M#8^,W\SQ5!?$O!#O"E/)SRAR%(Z#.:]2^'G@+2/C'IVN>)O$<MU<
M:Q+JL\,5Q'</$UBD3X18@#A< 9SCG- 'T.)49BH=2PZ@'D4>:A8KO7<.2,\B
MOFK1M2E\!_M%^(=6N;^>30M2>+2KG[1(3'#+' 'CD&>!N (/J163X$\:7.A>
M+OB7X[U.XGVW^EI?VUL[%DCC#,D*JGJ< \=<T ?5:2I(#L=6P<'!SBG;AG&1
MFOF?]FKQ?8Z1KVM>'_[1OKT7MJ-=+WT,B.)6_P!>J[QR >PZ5V'Q.^+5KJ7P
MG\37_AB[N(+FV,5LUS);O$T(D=5+KN Z GF@#V2*ZAG9UCE21D.&"L"5^M/6
M1&8J&4L.H!Y%>7>&/A+X6^'SV?B+3Y+FQFMK,FYD-VQ6Z7;N9I 20QZG/6O(
M?@[\1[67XJ-JAO[UW\9K.TUO<PR)%;21Y\E4+#:,IZ=: /JJ*]MYY&CBGBDD
M7[RHX)'U%3 @U\5?"-&UCQ9X/L]*T6_T37HKVXO[W7+JYVQW]JLC!T5<_O"2
M1P1QBOM*+E<CCG.* )**** #I6%XUN$M_"^I,P#9A*!<CDG@#GCOWK:=AL.>
MF.]<EXDF&L:K8Z)"6^5A<W+1] B]%/7J>QH V] A:VTBRAQCRX%!& .WM5^3
M.!CK1 ".N/; [4]U)Y%)JXK'+^$F\C4==LSDM'=&09.?E89'85U,9RHZ'Z5R
M'B MX=\0V^KD?Z'<*+:Y8#[AS\CDYX';@=ZZN%U$8.[WS5-WU!*Q-12=:6D,
M0D#J<5SFJ_$/PUHFLQ:3?Z]I]GJ4F-EK-<*LASTX/3-=!)G/ !] ?6OG_P"$
M6F^%=;\#>)KGQ5%I\NH/K%S_ &O)J!42(ZRGRPQ;E<#;M_2@#U?4OBCX2T?6
M&TN^\2Z;::BK*K6TUPJNI/0$=LUL:IXFTK16M%U#4K6R-W((K?SIE4S.>BJ#
MU)]J\6\-:7X;O-8^+9UZ"QETD7@\R2Y"X$8@&,$^W2N4LM#AU#X)_#G6-4MA
M<:E!JMNEE<72YE2W,IV8ST.W'/6@#Z-U/QGH6BZK:Z;?ZQ9V=_<X\JWFF57?
M/3 ]ZV\CUKY?^..G7^AS?$:YCT6VUEM4MX'M=1>X0-8NNT!&4_,O/*XZYKU_
M0/%^L6]SH>D3^'=0N4DM(3-JX*^0KE!G(SGK0!OZW\0?#7A[5H=-U+7["POY
ML;+:>X57.>G!]:OW_B+3=+GLH;V_M[6:^D\FU264*9WQG:F>IQS@5XC\)]/\
M+:QX?\<7'BE+&XU$ZS<IJCZEMWQJK_N@2W*KMQMKCOB_J-SXO\87XT/P[?Z_
M:>$;.(Z?=:>R^7;W?$C'DY/R #CL: /HWQ#\1?#7A*^BL]9U^PTRZE4,D-U,
M$<J3C./3/>NB@F2XB66-UDC<;E=3D$=B#7R#\0/&E]J_BO4O$.B:-IFNVM[X
M4MC>M?Y;[+&[%7D"@'=LR21[5]*_";0(O"_PX\/Z7!?_ -J0V]HBI=YR)1C(
M(]N>* .MHHHH ***8S#!&<'WH P?'DPC\*WR)\TDRB)%'))8@=,BM/2H3!90
M1G&4C5<#V%<SJDH\1>*+72X@LMK9D7%VW4;OX%Z8///!R*Z^&,IG./PIWTL*
MVMR6BBBD,**** $(S534].AU2UEM;A!)!*I5U]15RB@#A[#6)_!MPFE:N2;(
MG;::@!\H'9)/[I[#UQ786]TDT2NC!U(X93D4R\LX[Q)(YD62)Q@HPR#7-#P.
M+%MVDW]SI@R#Y2-NCSD<;6Z<#'XT:=1._0ZWS >AI#*!GVKDCH?B<9_XJ!/8
M_9%]#[^N#3QH?B7YB=?CY.0!:CCGZ^E.R[D\S['%R_LY:%<:M>3RZMK,FEW>
MHG5+C1C=$6LDY.<E>N,C.,XJ_J_P'T75-8O;R'4=6TJTU"02WVFZ?=F*VN7&
M/F91T)P,XQFND&B>)M@7_A(4#=V^RKSQ]:)-$\2;2!KZ9S_S[#W]_I^5/E7<
M?,^QB^)_@EX;\5Z+K^EWJW"VNLO%).8IBK(T8 78?X>!@_4U)JOP4\-ZO=13
MS17""..VB\N.4JK) <Q@CN,\GUK5&B>)BF/[?3=[VJ^WO['\Z4:)XFRV?$$?
M/3_1%XZ^_N/RHY5W#F?8LZSX*L=9\0Z)K,IDCOM):0P-$VT%7&&5AW'3BK^L
MZ#8^(=(O=)U&VCN;"\B,4\+#AU/45D?V+XD5L_\ "0H1GI]E'M[_ %_.H_[#
M\3X('B&/=CAS:+Z>F:7*NX<S['*0?L]:.MK);7FNZ[J=N+9K.WBNKYF6VA;&
M50?08R<G%==K?P]T?7]%TS3)8WA@TR:*>U:%MK1M'PO/TX-)_8?B7S&(\0)M
M/0?91QS]:%T/Q. !_P )#'G'7[(O7 ]_K3Y5W#F?8SK7X.Z!86?AZ"!;A#HE
MT]U:2B4[P7)+JQ[J<\CV%=ZLF1TKE#H?B7!'_"0IR<_\>J^_O[C\J0:)XGX'
M_"0Q\=?]%7V]_8_G1RKN',^QUH<9YI#+S@$?C7*?V'XF.<>(4/\ VZK[^_T_
M*DE\*:I?974-=N)(L_<@01 CW(Y]12LNX7?8M:[XL6UE_L_3D%_JTGRK"G*Q
M_P"TY[ >G4U/X8T Z-"\D\OVF_N&WW$[=6/H/8=!5C1/#UCH47EVEN(MV"SG
MEGXQR3R:U@H'04%"*N.:=112 J:C81:C9RVTRB2*52K*?0UQ\&K77@AH['5R
M)=,/RV]^H)\L=DD';' W=Z[NJ\]I'<!E=%=&^\K#(/X4 ):WL5U$KQ2)*AZ,
MAR#]*F\U?6N3D\ V<,KR6$MQI;DG/V20JIXQG;TI_P#PBNIJ5"^([\@'^((>
M_P!*=EW)N^QT\A#+P>O<5Q6L?!WP=K^OMK5_H5I<ZBS*[S,"/,9?NEU!PQ'N
M*M?\(GJVTK_PDU^2>^U..GM['\Z<WA;4RW'B*_ [#:GO_L^_Z4:=PNS,UKX)
M>"M?U>?5+[0+>XO9W625V+!96  !90<'&!VJ]XH^%GA?QJ+5=:TN.\6U $*>
M8R+'CI@*0.*D7PKJORX\1WY(//RI[>WL?SH7PIJH5\^)+\EN00B<<'V]_P!*
M-.X7?8AO_A5X7U/6+34KK1X)[NU1$BE<L>%^[N&<-CL3FNO7&W&0*Y@>%]5P
MO_%1ZAP>?DCYY'M34\):JO/_  DNH%O=4/;']W\:?*NX7?8JZW\(/"'B36_[
M8U+0K6[U$LI:9@1OV_=W@'#8]P:WM'\-Z7H NET^RBM4NI&FG6-<"1SU)K-/
MA;5=X/\ PDE_P<XV)@\GC[M)_P (IJQ7_D9;_P#[Y3/0>WM^M'*NX7?8?I?P
M[\-Z&9OL&D6]OYL#6SA5^]$Q)*'VR3^=;6AZ39^'M*@T^P@6VLX%V10I]U%]
M!6"?"NK9R/$M^/\ @*<]?]GW'Y4O_")ZL<$^)K[Z%4]O;V_6ERKN%WV.J\X9
MZT>97*+X6U,$K_PD6H<\9VIQP?;_ #BE'A75<C/B6_P#DC:G//THLNX7EV.I
M,ZKDE@ .YZ5RNJ>*7U&X;3]"5;R\8#=< 9BMP>Y;N>N,=Q1_P@:W9SJ&HWNH
M*1ATDDVJWU"XKH--TJVTR!(;:!((U_A1<4]!J_4K>&]!C\/V(@5C+*Q,DT[?
M>E<]6-;%)BEJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img81402019_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img81402019_2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '4!&,# 2(  A$! Q$!_\0
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M)VF&PN&9UV@$ ZO_ (5#!_T.OC'_ +^Z!_\ *&C_ (5#!_T.OC'_ +^Z!_\
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M_#GQ3IGB.WTO4E#,=,UJWLYFOM#U(QJ95T_6+6QO'@*SK 875R ;W_"H8/\
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MU7]J?P?ITVK>)O@C:W=ZWC31M.M]#TGQ--=7ELUBMDL<>@Z[I&JL$O7<6E_
M^W)95 /4?^%0P?\ 0Z^,?^_N@?\ RAH_X5#!_P!#KXQ_[^Z!_P#*&O/OVI?V
MT_V5_P!B7PKX;\;_ +5WQN\%? WPGXO\0/X5\,Z[XVN;VVLM9\11Z=<ZL^DV
M;65E?2/=)IMG=7C!HT00P2,7XP</XT?M[_L=?L[>(?@AX3^-O[0/@'X<>(_V
MDI;:'X%Z3XBN[^*Z^)DMY?>'=-M4\-BVL+F.8SWWBWPW;(;E[8&35[3D*7*
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M;A-^6V@'M'_"H8/^AU\8_P#?W0/_ )0T?\*A@_Z'7QC_ -_= _\ E#7YO_\
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M'_"H8/\ H=?&/_?W0/\ Y0UZ_10!Y!_PJ&#_ *'7QC_W]T#_ .4-'_"H8/\
MH=?&/_?W0/\ Y0UZ_10!Y!_PJ&#_ *'7QC_W]T#_ .4-'_"H8/\ H=?&/_?W
M0/\ Y0UZ_10!Y!_PJ&#_ *'7QC_W]T#_ .4-?G'XX_:&UKP!\<]?^&5MJ=]?
MVFAZJMFMS>M#]HD5B)%\S[/'!"2J,BDI"BL0S!5'RK^O=?SJ_'__ )//^(?_
M &-$0_#[/;\?2@#]Z_ASKDNO>';&_E.7FA1V)Y)W*#D_GUY'.!7?UX_\%/\
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MS4GA[QYJ-SXYT?P[<:;HWB/3O$/P:\97\'B_0+JSE\.^)?$GAX:E=:1NF,"
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M^#_'7PU\9:5:Q%(;9O$?AG3_ !9I/Q&L]#CNQ?ZYI-[J)T=;B]M;N&W^&O\
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M@MC;DUK?\%/W3_B+0_X)'*63<OPJ\"$KE=P#^)OVB5C)'7#LK!"?O,"%R0:
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MT;P%XDB"+<+I+Z[%9M<SZ_\ P78_X* _M:?&+_@A-HWQF^%7[)7QQ^ VD_M
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MR]^)D=U/BS\07>C^"M)6[\12S6QUOV_O^#@SXN_L4?\ !4&+_@GMX6_8^?\
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M\0^,/#FKSI)?>$)_B1HWQ3^)$/A"_!^6UO/"NF>+K/1-4L2773M1L[NR,CK
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M86DTKZ&EC&3%I\H8 _<+_@T6_:B\6:;\)?VI/^"7/QKDGTSXP_L0_%KQ3?\
MA[P]J4DAO+3P+XB\5ZGHOCK0+)97)DM?!/Q;T_5[JX=$2-$^(.F+&6A,83\I
M_P#@H:G[!4G_  =:?&!?^"E)\%C]DX_"7P$?&)\?R>,X_#?_  D(_9.\%_\
M"%?:'\!,OB(7/_"1_8?L?D,+4S[1>9@W"O+;KX:_MF?\&^G_  6[_9-_:E_;
M@^.OA7XX:1^V/J7B33/CG\;O"UOJVGZ'XF\+>,-8TOP5\3SXI35M%\-H-?\
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MWL_B2WO/&/C*'PKH$]I?M;M;0C>;:".*5J_STOA5\(_VG/\ @GIX!_X)S_\
M!P+K&K>)=?O/C5^V)\4=8\?Z==VCK/>^&SKDPFO-1OBT5S/_ ,+]T&W^.]C(
M]T_V?['9Z3>V]SYFJHH_I*_X.EO'D7B*3_@GO_P0S_8X\->$_!NH_&KX@^#?
M$M_\,O FEZ7X:\*>%O#EQXBF^'OP1\+#PYX?MH;30_"UQXIU#QAXOO;.UT^W
M@M(?!>FZA%&R*0?(?C]_P;G?\%Q_%'[&UY^S7XM_X*1_"/XO?L^?";P38:AX
M#_9MM=)\76^F7K_"O2+B^\$>%_"Q?X=6;6.K%[5=+T>YN-2C62ZNPNI7$D,U
MPY /Z)/^"X__  4+UO\ 9A_X(Z_%+]K/]FCQ,/\ A(OB_P"$OAEX:^"7Q"TP
MQ.VD6/QZN-*BLO'VD,Y95U+3_ VIZIK/AVX7>UCK@TN^:.5;5XG_ "4_X(-_
M\&^O[ /Q-_X)_P#PB_:M_;%^$-K^T]\<OVJ_#]W\5=5U3XD:YXM?2?!_ASQ'
MJNK'P]I'A_3=+U_34N-7U#2/L^O^(O%NK&^UR^UK4I19W5G9VEN)/AS_ ()]
M/XT_X+.?\&VO[1W_  3DT:^&J?M8_L0Z[H#?#+PO?WMM::MXF\,>&_$$WQ"^
M$6C7"WDD1MCJ5GIWQ!^#FE2W0M[.PN-"T(WMU%&TK+[=_P $7O\ @Y%_9-_8
MV_8W\%?L-?\ !133?BE^SU\:_P!DNWU;X7VLTWPM\9^(K;Q/X;TC5]5N]%TO
M5=&T6QU#Q+X1\;^&+2>/PUK&E:[I%EIUX+&QU*QU!9;VZTZP /!M0^$<'_!O
M]_P<A?LQ?"_]EOQ#XG\/_L=_MY1?#G1/$?PGU?7=3UK1],T7XI>,=:^&5WH-
MQ-J$SS:NGPW^(=EI_CCP3K>H/>>(-)T74IO#,VI7T4VJ3ZI_H%>+O$ECX-\*
M>)_%^J!SIGA3P]K7B341&5$AL="TVYU2["%B%#FWM9 I8A0V,D#-?Y^OP=\:
M^/O^#BK_ (.!O@A^V!\)?A=XV\)?L)_L'W7@6]M?'OC/27T]-5L/A5XEUCX@
M^';359(9;K2HO&_Q6^).HPFU\&V&I7>H:+\/;#^T=6$=UI]\9/\ 05U[1-.\
M2Z%K7AS5X?M.D^(-)U'1-4MPQ0SZ=JMG-87L.X9*^;;3RIN )&[/:@#_ #TO
M^"(O[&_@#_@X'_;"_;=_X*2?\%(?[9^-7ASP=X_T;P?\-/@CJ.OZ[IO@K3AX
MDMM8U70=#NO[&OM-OT\&?##P7::)HWAWPOIMYI]GJFK:E>>(/$0U&^\\W_V!
M^V3_ ,$H/^"(\G[3OP0^,_[#O_!4']D#_@F'\9/V>_']W)\0],\'_'GX;^)9
M?^$D\'ZM VE3:;X/\2_&G0I_ WCGPSK=AJ>C>)K&6\32-<TZXFTK6]"2YM9Y
M;OXH_P"";O[5U]_P;"?MQ_M;_L4?M^_#WQ[I/[,'QR\7VOC/X0_'WPGX3U/Q
M%IUY8>%9]>L?!WC?3K2U6.7Q/X7\4>$=4L]+\7Z?X;CU+Q+X(\8:1'IEWI-T
MGVY[?\Q_^"R_C_\ X(W_ +6/B3PAX0_X(\_ #XW>/_VM/B]\?-9^(7Q/^(NG
M:'\6)]-\:6WBRW\67.L^"/"WP_\ &6K7_B'4?$/B'QUK^D^)$N-$\&:3I6D:
M?HTUG:WEU%J)M[0 _O7_ ."M'_!9OP'_ ,$S/A;\!K7P3X&F_:O_ &F?VJ+_
M $W0OV<OA+X'U:"QL/B +I=&M_\ A.;S4]*B\07,7A74M1U_0M/\.6GA^RUB
M_P#$^KZY9:?I4BV4&I:O8?&W[-__  7@_:I\#_ME?!3]B?\ X*U?L%_\,4>,
M_P!J(Z=9_L]?$GPCXZM_&W@+Q#XDU>^73=,\*^)%6\UBWT^YN=7O-+\,3ZAI
MWB>^NM(\27^G1:YX=TS2-6MM6@_%3_@XY^ /Q#^$OCC_ ((B_M2?%"[^.'PH
M^!?PF^$/P8^"'QI^)7P3F:P^+/[//C/PCJ7A+Q+JVL^%M2AAN+/PW\18]*NM
M6N/!%Y-.R7GB3P--:6[^=;0^;YYI_@;_ ()9?M6?\%"/V'O@;X'_ ."D/_!8
M_P#X*??$Y?&WAOQ[\.?&;^,/"_Q#\ _ W6+'Q3H/B"Z;Q:WQG\*^$?$7A_0H
M;7PU;^(OB3K'A!'_ + T'1[8W#76K_9;&$ _=?\ ;-_X.#_CC^S!_P %7/B'
M_P $U?AQ^Q--^TKKD/@'PA-\%-.^'GBF]L/B/\1?BMX[^&7AKQUHFA:\FJP#
MPQX5\#Z3-JVL7'BOQ03?2Z/X9T2756MW<S+#-^P5_P %[?VH/B#_ ,%([;_@
MF#_P4=_8FT?]DSX]>,=#U35_AS?>#O&5YXGTJ\N[/PSJ?CK3-,U:WN)M9L+_
M $SQ#X0TC5;C2?%WAWQ/=61UC39=)O=(LYII_P"S?BK2K:TNO^#U[Q0\ZQ22
M6'[-MK<VP<1N8KL_L=>'( RA@2DHM;N8@KMD".2#L)S0_;)*C_@\N_X)]\J"
M?V?-&!Z EC\+OVIB <8);;C&<G:!_"!0!][?M0_\%Y/VF_$_[</Q3_8*_P""
M37[#EM^VW\2/V<[34I/V@_'_ (G\<Q^#_A_X8UG1KJRL=:\+Z'.+K2+*6YT;
M6)KCPE=ZKK7B;3Y+WQC;WVE:'H&JV>D7>I3?1_\ P3Y_X+Q_"S]K#X!?MC^-
M?C[\(/&'[+GQ]_X)Z>'O&'B/]K;X#ZQ(_B#4?#FC>"].\47NJ:SX-NY[31[_
M %:-+GP=KVA:AHVJZ;INI:)K]M!9W,EW8:CIFK7O\;_PY^%OPR_9!_X+ _\
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M_@]_P7&_9"^*_P"R+_P5^_;8'[(OB&X_8Z^)GPX\!Z+J'[+4=_HNJ6_A*_\
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MNAZS9EA,MMJ<6BZ_>6LC1,MU92RW=NS1R1R*/4?^"+_AKP]<_P#!Q-_P7O\
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M"T$XG+0NR89OZWZ_%SX-?\$_?BU^S'_P6,_:+_;$^#T?A"Y_93_;F^"N@O\
MM"^&KG69=+\6^!_VE/AM>K'X9\9>&]$-K-;>(/#_ (VT2;6&UPI=VEY9^)?$
M>LZC,CVL=K'* ?CG_P %_F5?^"Y/_!NWN95_XR(T <D#E_VB/@>B#D]7?Y5'
M\3?*,GBOU>_X.5V5?^"(W[=A9@H/A+X6*"Q &YOCY\*E5<GNS$*HZEB ,D@5
M^QGBOX0?";QYXG\(>-?''PP^'GC+QE\/KQ=1\!>+?%7@OPYXA\3>"=02ZMKY
M+[PEKNK:;=ZIX<O$OK.TO%N='NK.9;JUMK@.)H(G7>\9^"/!GQ&\,ZKX+^(7
MA+PSX[\':[%##K?A/QCH.E^)O#6L0VUU!?6\6J:'K5K>Z9?QP7MK;7<*7=K*
ML5U;P7"!98HW4 _B7_X)4?\ !LA_P3G_ &K_ -@[]CW]I[XW^(_VFO%>O_%C
MX3^&_'_B[X?VOQ>L]#^&LFLWLUX+BSTW3-)\(V_B+3-+3RVB2&S\3Q7L:R3;
M;Y)'W+^CG_!9W]IWX=?\$L?A!^QI\ -?_P""?'P=^,?_  28\9:SH_P9^.UM
M?^&+_P 2V'P-T'1M2TI-(AT+P?Y<^E7/B&]\-W.N>)?"NMZ[=C5M:\5>'-4B
M.K+K^I0Z@_\ 2IX6\*>%_ WA[2/"/@KPWH/A#PIX?LH]-T'PSX7TC3] \/Z)
MI\.?)L-)T;2K>TT[3K.+<WEVUG;0PID[4&32>*_"7A7QWX>U;PCXW\,^'_&7
MA/7K5K'7/#'BK1M.\0^'M9LF97:TU71=6MKO3=0M6=$<P7=M-$716*94$ '^
M7_\ \%&-+_X)'>$_C3^QW\0O^#=WX@_%;_AO'Q5\>_#4NB^ /@Q<?%^X\&Z5
MI>H6<YL(!%\1]-AU[1?$LOB<:%I4GA;1M3U'PY?^%+WQ@OBS38K*WA>?^WG_
M (+YOJG_  Y'_;K;7Q;Q:XW[/^E?VRENRFV35W\6>"Q?I;LI*M"+TRI!M)#)
MLVDY%?HA\(OV+_V0/@!XAN_%WP,_9:_9Y^#OBN_:Y:\\3_#+X-_#WP/XAN/M
MB&*[$FM>&_#VG:D4NHR8[B,7(29#MD5EXKW7Q;X0\)^/O#FK>#O'7ACP]XT\
M):_:_8M=\+^*]%TWQ%X=UJS\R.;[)JNBZO;7FFZC;>=%%+Y%W;31>9'&^W<B
MD 'X=?\ !%;PSX[\;_\ !OW^RIX.^%7C5?AS\3/%?[*7Q!\-_#WXA&!KM? W
MCC6=;^(>F>&/%K6R)(UQ_P (WKMQ9:LT"QNTALS&$9CM+/\ @F=^P;_P5V_9
MI_:#U?X@?MT?\%.K?]L+X-7GPS\0>&=.^%47AO4]+>Q\=:AKGAB^T7QC]MO=
M*L4 TC2M,U_33"LK/.=;#E,0@C]Q_"/@_P )?#_PWI'@WP)X7\.^"O"'A^U^
MPZ%X6\)Z+IOAWPYHMEYDDWV32=$TBVL]-TZV\Z667R+2VAB\V623;O=B>CH
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MV_X1_1==TF_TW1C;Z:JZ= =.MK8PV(%I'MM_W=>>Z-^Q9^QUX=U?2_$'A_\
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M3(M2O(8I9(XKF\6::-)'1'"NP.3_ ,++US_H2F_\'%U_\SU'_"R]<_Z$IO\
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M"4W_ (.+K_YGJ /+O'G[!G[#_P 4_'7_  M#XE_L>_LP_$#XD&Y^VOX\\9_
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M*XPBCSXX5EPH&_ Q53_A9>N?]"4W_@XNO_F>H_X67KG_ $)3?^#BZ_\ F>H
MT?A/\$O@U\!O#*^"_@A\)_AO\'O""RK/_P (Q\,/!'AKP'H#7"1) MQ)I/A?
M3=+L9+A8(XX1/) TWE(D>_8J@2:;\%O@[HWQ#U;XNZ/\)_AKI7Q7UZUDL=<^
M)VF^!?"]C\0M9LIH[.&:TU7QG:Z7%XCU&VEAT[3XI(+O4IHGBL;.-E*6T(3*
M_P"%EZY_T)3?^#BZ_P#F>H_X67KG_0E-_P"#BZ_^9Z@#V"O,/!'P2^#'PSU[
MQ-XI^''PC^&7P_\ $WC6>2Z\8^(O!/@/PMX5UWQ9<S7MQJ4MQXEU;0M*L+_7
M9Y=1O+N_DEU2XNI'O;JXNF8SS2.V=_PLO7/^A*;_ ,'%U_\ ,]1_PLO7/^A*
M;_P<77_S/4 >P5YAH'P2^#/A3QWX@^*7A?X2?#+PW\3?%BW2^*?B+H/@/PMI
M'CKQ(M]-;W%ZNO>+=/TJWU_5UO+BTM9[I=0U"X%Q-;6\LP=X8V7._P"%EZY_
MT)3?^#BZ_P#F>H_X67KG_0E-_P"#BZ_^9Z@#OO%OA#PGX^\.:MX.\<^&/#_C
M/PEK]K]BUWPOXJT;3O$/AW6K+S(YC9ZMHNK6UWINHVIEBCD:WO+::%GC1BA*
M@BAX$^'?P_\ A;X<M?!WPR\#>#_AUX1L9KJYLO"W@7PSHOA'PY:7%].]U?7%
MMHF@66GZ;!/>7,CW%W+%;))<3N\LS/(Q8\A_PLO7/^A*;_P<77_S/4?\++US
M_H2F_P#!Q=?_ #/4 :/Q,^"7P9^--KI5E\8OA)\,OBQ9Z#/=76AVGQ*\!^%O
M'5MHUS?1Q0WMQI4'BC2M4BTZ:\A@@BNI;187N(X84F9UB0*VT^!WP5L/B#'\
M6K+X0_#"S^*D.FPZ/%\2[7P#X5@^($>D6VE1:%;Z6GC*+2E\1+I\&B00:/#9
M+J0MX]+ABT](UM(TA%#_ (67KG_0E-_X.+K_ .9ZC_A9>N?]"4W_ (.+K_YG
MJ .Q\=?#WP#\4/#=YX-^)G@CPA\1/"&H2VL]_P"%?'/AK1O%OAR]FL9TNK*:
M[T37[+4-,N9;.ZBCN;62:U=[>XC2:%DD16'*Q_ 3X&Q?#"_^"4/P:^%</P9U
M2WO[/4OA+%\/_"D7PTOK75+N34-2MKKP,FDKX8G@O[^62^O(I-,9+B]D>[E5
M[AFD,'_"R]<_Z$IO_!Q=?_,]1_PLO7/^A*;_ ,'%U_\ ,]0!Q?@W]C/]D/X=
M_#K7?A!X#_9;_9Y\'?"CQ3?6FI^)_AKX;^#7P[T?P)XCU*PN!=V&H:_X3L?#
ML.AZQ>V%TJW-C=:C8W,]G.JRVSQ2 ,/H32-(TK0-*TS0M"TS3]%T31=/LM)T
M?1])L[?3M+TG2M.MH[/3]-TW3[2.&TL;"QM(8;6SL[6**WMK>*.&&-(T51Y?
M_P ++US_ *$IO_!Q=?\ S/4?\++US_H2F_\ !Q=?_,]0!C_&;]EK]FC]HR;P
M[<_M ?L^?!3XW7/A&X%WX5N?BS\+_!7Q"N/#EP)1/YNB3^*]%U672RTRK,XL
MWA5Y561U9U4C;LOV?O@-IOB[PUX_T[X)_"33_'?@O1K;P[X/\:V/PX\'VGBS
MPIX?L[.\TZTT+PWXBM]&CU?0]&M=/U"_L;?2],O+6Q@L[V[MHX%@N9D=G_"R
M]<_Z$IO_  <77_S/4?\ "R]<_P"A*;_P<77_ ,SU &OX*^#/P@^&NN>*_$WP
MZ^%7PW\ ^)/'=X=1\;^(/!?@?PSX6UOQCJ!O+W4#?>*M5T/2[&^\07AO]2U&
M^-SJT]W,;R_O;DOYUU.[KX;^#?PA\'>-/%'Q(\(_"OX<^%OB'XW\X>,_'GAS
MP1X:T3QEXN%Q<Q7LX\3>)]-TRVUO7A/>007<PU2^NO,NH8KA]TL:.,?_ (67
MKG_0E-_X.+K_ .9ZC_A9>N?]"4W_ (.+K_YGJ .;\<_LD_LL?$[XE>'_ (S?
M$C]F[X$^/OB[X3DM)O#/Q/\ &7PF\">)O'^@RZ>BII\ND^+M9T*\UZQDT]$1
M;![>_1K((GV8Q;5QZ!X1^$/PG\ >(?%WB[P)\,/AYX*\5^/[S^T?'?B?PEX+
M\-^'/$/C74/M5W>_;O%FM:/IMGJ7B.\^VZA?W?VG6+F\F^TWMW/O\VXF=\/_
M (67KG_0E-_X.+K_ .9ZC_A9>N?]"4W_ (.+K_YGJ .[\8>"_!_Q#\-:KX,\
M?^%/#7CCP?KL,5OK?A3Q?H6E^)?#>L007,-Y!!JNAZS:WNF:A##>6UO=Q1W=
MK,D=S;PSHHEB1E9X,\#^"_AQX;TWP9\/?"'ACP)X0T9)H]'\*^#= TKPQX;T
MJ.YN9KRX33=#T2TL=,L4GN[B>ZF6UM8A+<3S3N&ED=FX?_A9>N?]"4W_ (.+
MK_YGJ/\ A9>N?]"4W_@XNO\ YGJ +NI_ SX)ZU\1=.^+^L?!_P"%^K?%G1TM
M8](^)^I^ ?"E_P#$+2H[*">ULX]-\:7>DR^([!+2VNKJ"V2UU*)8(KFXCB"+
M/*&]3KQ__A9>N?\ 0E-_X.+K_P"9ZC_A9>N?]"4W_@XNO_F>H M> /@1\$/A
M1K&O>(/A;\'/A9\-M>\5 #Q1K7@'X?>$_!^K>(PMU-?*->U#P]I.G7>K[;VY
MN+M?[0FN-MS<3SKB6:1F\W^,G[$O[&_[1&MV_B7X]_LI?LZ?&CQ):^6+?Q#\
M4?@O\._'6NQB*,0Q*-7\2^'=2U I%$JQQ(UP4B0;455XKOO^%EZY_P!"4W_@
MXNO_ )GJ/^%EZY_T)3?^#BZ_^9Z@#L/ GP]\ _"WPSI_@KX9^"/"/P[\':2A
M32_"G@?PYH_A3PWIRL%#"QT30K.PTVUW[5WF&V0N0"Q)&:["O'_^%EZY_P!"
M4W_@XNO_ )GJ/^%EZY_T)3?^#BZ_^9Z@#2^*WP3^#?QV\.?\(?\ &WX4?#?X
MO^%!,+E?#7Q-\$^&_'6A)<C;BYCTKQ/INIV45P-B8GCA67"@;\#%<'\%_P!D
M+]E']G":>Y_9]_9H^ OP1NKI9%N;SX4?"3P'X O;A)0XECGO/"V@Z7=2QR"2
M0/&\K(P=P5(8YZK_ (67KG_0E-_X.+K_ .9ZC_A9>N?]"4W_ (.+K_YGJ .X
M\:>!_!?Q(\,:QX)^(?A'PSX[\&^(;5K'7O"?C'0=+\3>&M:LV97-KJNAZU:W
MNF:A;ET1_)N[:6,.BN%W*I'CWP1_9#_93_9HGU.Z_9V_9K^!'P+N]:B$&L7G
MPC^$W@7X>7FJ0*XD%OJ%WX4T+2KF\MQ(JR""XEDB$BAPFX UU/\ PLO7/^A*
M;_P<77_S/4?\++US_H2F_P#!Q=?_ #/4 :Z_!KX0I\29/C*GPK^'"?%Z:P&E
MS?%1?!'AE?B/+I@L8]+&GR>-QI@\2O8C3(HM.%JVIF 6$4=GY?V=%C!J/P9^
M#^K_ !$TGXO:M\*?AOJGQ8T&S73]#^)VH^!_#%[\0M&L%AOK9;+2O&ESI<OB
M/3K1;?4]1@6WM-2AA6'4+V((([J=9,C_ (67KG_0E-_X.+K_ .9ZC_A9>N?]
M"4W_ (.+K_YGJ ,+XW_LI_LP_M,1:/#^T5^SO\$?CM'X>=I- 'Q>^%O@GXBM
MHC.7+_V3)XLT35I-.61I':1+1H4D9BSJS8(]*\ ?#GX??"CPKI?@7X7>!O"'
MPX\$Z)$8=&\(>!/#>C^$O#.E1-@LFGZ%H-G8:99AR-S^1:QF1OF<LQ)KDO\
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MD4?9+;_GA'_WR*L44 5_LEM_SPC_ .^11]DMO^>$?_?(JQ10!7^R6W_/"/\
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M 1E@LQP668K'XZ3Q>'AA,9DF!Q=)U,1CZU#&_6=W_P %"O ]Q9W\W@W]GO\
M;'\?7MO;SO96.A?LR_$?3EU*Y2*1K>VBO?$^G:':P+<RJD/VF=EBA$GFR#8C
M8_%KP_\ \$S[/XX_\%(?V?\ XJ_&_6[_ %WXQ3^"[_\ :Q_;+^'FHR07_AWP
MGJU_XG\CX ?#G2BNQ+:UT^&SC\+ZEHZ">"YL/A_?ZJDH740C?M@?V%KV^21?
M$'[9O[<>LF6)XI5MOC?8^&+=@X92RP>%?!NC^6RYRI20 , <'I7XX_MR_M1>
M,?\ @G;J/P^\1?%Q?''BO]J#X3:[;Z'^SW\=-,TLMX3_ &O?V9]3U&*;Q?\
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MA,7AL?A<-C<%7IXG"8NA2Q.&Q%&2G2KT*T(U*56G-:2A4A*,HM;IA1117,=
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MO)L][#8_#8K2$^6?_/NI:,_^W=6IK_"VUU2-FBBBO..T**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9FDD;+R.[DL8)99)Y&EE8N[8R3@<  *JJ %5%4!410$10%10H $=??X#+Z&
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M?FDL-@<+&4HTJ7-.<YRJ8C$5*V*KUZ]7*?J/I_4U4E_B_#^E>=?'/XT_"O\
M9K^&WB?XP_'?QOHWPP^&G@V*Q;Q'XL\3//;V-C-JM]#IFD6"0PPS7EYJFLZG
M=6VF:1IEG;3WNHW]S#;6T+N_%*]^+WARV^*?ACX0OX;^*<GB'Q?X&D^(6E^)
MK?X4>.KCX566AQ^:4T[Q'\68M&;P'X:\8720F>Q\%ZSK5IXCO;>:TGM[!XKN
MW9_=IUZ,9J#JTU.]-\G,G*U27+3;2=U&<HR46]).+2>C/AI4YM*2A)QM+WK/
ME]Q*4U?:\8RBY+=*2;W1Z(_WC^'\A567^+\/Z5I26MTL?VAK:X6W8@+.T,@A
M8D< 2E0A)P>C=JK-97DJAHK2YD612\;1P2NLB(0'9"J$,J'AF7(4\$BO2A*/
M*WS1MS-7NK72U5[[KL82V?H_R,M^@^O]#5!F9=K*Q5E8,K*2K*PR0RL"""",
M@@@@\@UH2 C@@@AL$$8((R""#R"#U%9S]!]?Z&NY;KU7YG-/X7\OS1],?!_X
MQ'3F@\,^)I\Z><1V-](?^/ D\+(2?^/#'+J!_H1S+&/L1D2S^P597571E='4
M,CJ0RLK#*LK D,K @@@D$'(.*_)UB5=64E67!5E)5E()(*D8((/((((/(KZ9
M^#?QF_LTP>&/%%Q_Q+B1'8ZA(V?[/)R=DA//V$\;T'_'EDRQC['YB6GYCQGP
M5[=5LWR>E^^5ZF,P5./\5;RKX>*_Y>Z-U*:7[WXH?O+JI]AP[Q%[+DP&85/W
M6D,/B)O^%TC2JR?_ "[V4)O^'I&7[NSI_9=%-5E=5=&5T=0R.I#*RL 596!(
M96!!!!((((.*=7XYMN?H04444 ?QN_\ !+V23_B*A_X+1C>V'^%%@C#<<,B:
MG\ MBL,\JFQ=H/ VKCH*]R_X+@_%OQ?X4_:E^&OA;XF_\%H[G_@GK^S>_P .
M#J.F_L_?LI^%/B!XG_;;^)WC6ZNY;1=>FM? &DZUK+^%;^X+V6C22W&FZ/;0
M:+=I;Z)K.K7=WJFE_:/[('_!*CXP_L[?\%D?V]_^"C_B?XB_#C7/A=^UCX,A
M\-^#O VAIXD'COP[=QWOPVN//\1M?:5;:"+=8_!5^A_LW4KV1WO+1@L:K,!\
MV_M9_P#!(S_@H)I/_!6K6_\ @J7_ ,$]/CM^S%I_BOXJ?"O2/A1X_P#!O[7'
MA#Q?XLT[X?VFGZ#X>\-W.M_#=O"VFZE=NLUKX1\/ZK9VEGJ7A&^LM4D\0V5S
M?ZKH6OWM@0#\>OV"_P#@I]^W'XN_X)H?\%[-"\2_M2_&7XF>(OV(?#UAJW[,
M?[0/Q*T&Y\#_ +0FC:5XFOOB)ID,_BBVU6"3Q#I.JM:>!M&UF+1_$MSJ>M^&
M-3U;7-+;4);9;2*T^I/^"9WB[_@I?I?["FF?\%ROVM_^"@_Q+^,GPY^''[)7
M[17BGPO^Q4;6ZTWP+XS3X;:-XD\%?#[Q+\3M:T_4H[3Q!XGUOQ+X8U?Q=KVK
M2>&9?$$,U[H4EMXA2VM;O1T]Q^"7_! +]L_X8_"S_@LS\-?'W[4OP;^-&O?\
M%/\ P-I,FE?%K4_#OBOP?K]K\65UCQ?KOB/7_'?A73=-U;2=&\/ZM?\ CO6S
M;V?A?4];ELULK 1VXBE>"W_73]E?]BS2/V/O^".6C_L4?M3W5C\4?"WPM_9C
M^,'@GXUS_"S2]=U9/%7@W5HO'VO^)X/ ^DW6FP^(M1UJ3PSK<UKH]M'I8U.Y
MUZ*(6%LTSVX8 _F9^ \O_!8_XP_\$EOC5_P6T;_@J]\5=*^)OB#P!\?_ (C^
M'_V91X5\/W7P LOA;X$UWQIX)U[2M)T>2X@M/ OCRS&A>(=?^'OB#PQI-O<:
M!?:7X6MM5O-7>YU&\M^7^./_  6G_;$^#O\ P1-_X)#V=E^TAKGA3]HO]OWQ
M7\9=(^+?[8/BS2)?'GCGX=?"KX:_'35O"/B/Q-I>EVNFWMUJ.OV>F>*O#,-O
M>:=IUUKT&@^&;RQT.(:[J%GJ5E\ Z5J/@[P3_P $N/VOO@I\!/\ @OE\)/$G
M_!//0M&^*.K?#_\ 95USX:P_#+]L_P"('BK6$O==\-?!1O#OQ!TO3_&6F^!/
M&7BZ\T>;QOKWP].M^%/$4DGB9[:Q\/Z?J&K)!^VO[,/_  1Z\9?M^_\ !!3_
M (),-X8^(<_[-?[7G[*UQXC_ &A?V;?B-X@T"36=$T]O&?QE\4>/M*L?%FB^
M4U\WA[Q9H\/@7QAINH6EO>S6=UINDS2:9JVF7=_87(!\_?L+_P#!27XH>!O^
M"D7PC_8G^#?_  5 _: _X*._LL_MC_#7Q;X U/XO?&CX1^-/#?Q0_9<_: N?
M#WBY?"?BCPUKGCW0]-O=6TXZG9:5?P:1_:DFA_8M62UO((=1T*TU/4.$_P"#
M=G]FG]I70_\ @HE_P5N\:^$_VOOB=XIU']E'XY:_HWQ'^&.H:%IEAH'[='C_
M %>T_:C\->"_$'Q?U-O$$LOA*\T3QOIG_"8VZ:6FLF34M<O;>34K:WB>:Y_H
M1_8J_8U_X+'O^UQI7[2G_!1/]N;X477PZ\">#[[PCX:_9:_9%\.:QX?^%'Q$
MU*2/4H;+QQ\3CXL\-:/<PZG!-JDNMRQ:3'>ZG>:K8:)81ZSI/AK2I-&U3YX_
M91_X(^?M^?L>_P#!2W]L_P"-'PG_ &F_@[I?[#7[=/Q$\8?$/XQ^'+;2O$%O
M^TEIK:UI_P 4[GP?8^ =:G\*WVA>$_$_P^\6?$^\U33O%=MXBGLM8M=.LY-1
MT 3JME$ ?S#>!O\ @I;^TMXJ\1^.]-_;A_X+$_\ !0/_ ()P?\%#=*^+6J16
M_P /O'WP7OYOV'?#&BP>([01>'M5^'/@N&_\0:>MO9IJ%L)];\#7'AJW6TL!
M=7/B*SO[W41_I"_LW^+M0\>_ #X,>--7^)GP^^,^K>)_AGX,UG5/BU\*+867
MPV^).I7N@V4U_P"-O!-@-1U<:?X<\27;2ZKING?VG>_V?!=+9_:'\C-?RE_'
M+_@BS_P6R^,/PN^)?['7Q&_;/_8K_:J_9R^(.N:PVC_M(_M8_"OQCXY_;(^&
M_A;5=6CU%-.\':O-H>LV&DZE8B+?I[V7BPKH]Q/>1^&[_0+.>W@L/Z<?V&OV
M4?"_[#7[(_P#_9+\'>(=6\6Z!\#/A_IW@V'Q3KD<<&I^)-06XNM5UW79[.%Y
M8=.CU;7M2U.^M-*AFGATJSGM]-BN)X[59G /XW?^"Q/Q"_::^%?_  <^_L7>
M._V._@OHG[0?[1.A_LFJ?A_\(O$?B"+PMHWBPZAH'[1^F>)%O==GU718K%-(
M\)WFN:Y&TFI6ZS3:;';D2^;Y,G]$'[ _[9'_  5,\=>(?C1K/_!3G]ASX7_L
M6_!#X9_"74?B#I7Q(\-?$ZQ\8MJ.JZ%?176OZ?JMK:^,/$OV'2],\(PZOKUQ
M?/;VBQ'3TC\Z7S]B<3\<?^"4?QE^*/\ P72_98_X*G:1\2/AMI_P?^ _P:U#
MX;^(OAWJ,7B4_$;6-4N_"GQFT!;W1I+;3)?#?V'[3\2=)N";S4[>=(--U%?)
MDDEMJ^U/^"J_[-?[1/[8G["GQR_9>_9B\>> _AE\1/CAH]AX"U7QM\0I?$46
MC:3\.]4U.V?X@VEH?#.F:MJ+:KXC\-P7GA:#-I]GBM-;OKEY$E@A# '^<1XY
M\??L7_\ !2;X6_\ !:G]N;]IS]HSX5?#O]KWXM_$?PYK?["OPQ\=:[-9^.M+
M\$?!V]37HO#^D6LEO<K&/'OPSMO#7P@T%#=6Z#6]&O[BY"1R1SM^Z_[7'_!2
M#QO^V+_P:.WGQ>\/^(K]OBA9S_!K]E?]IF^L+AVU2&]\)?$CPCX:\3WNKSH\
MD\=M\4?#47@_6-4,CJEW9>/;O2YFD66='_=W]D/_ (-\/^":OP*_9D^"7PD^
M,O[(/[-/QW^+?@?X?Z)I/Q-^,'BGX7Z1K6L?$#QX\)O/%?B ZAKEK+JSZ;<:
MW=7L6A6]ZPFL=#ATZR\N(6XC7Y0_8@_X-^-9_9MN/^"GO[+OQ1\;_#SQ]_P3
M2_;QN=3U/P%\(/#<WB73OB=\(=5A\0WEWX.OK.ZU#0U\/:?J7AGP]?V%G#JN
MGW^IROK7@'P+J36TD5I=0L ?I;_P19^$'P4^&W_!*']B7PQ\(_#_ (8'@KQG
M^S?\//&GB>;3M,L3!XU\8?$'PI8ZY\0M;\3?NW_MK5-7\0:CJEIJCZDURZP0
M1Z3B.QLK>TA_EZ_X)/?';X,_\$XO^"N?_!P7+#?WOA+]A[X%Z3XI^)OBG0/!
M&EWVNZ)X3U'PC\;-*T/1['P[X<TYY@]QH)\?>-O#.G:?8A'73[0VR!;734CA
M^L_AA_P1P_X."?V'_ VK_LI?L'?\%0_@</V1I]1UZ/P+=_%WP??V_P 4_A5H
M/B"_O;ZZA\)12_#3XD1Z%>_:+N6_EM_#OB^TT8:Q=7NKZ5I^CW5Y.A_7/_@D
M=_P14^#W_!-'X'_%7PMXZ\0VO[3WQS_:8U6U\0_M.?%;Q]X>M]0TSQ_=6TNH
M7MGX5M- \0RZY+/X3T[5=:US5YY?$-UJ.K^)M>U>_P!<UEXRVG:9I0!^=?[8
M/_!T#^R[XM_X)^?M@_&+_@G5XG\4^*/CM\&M%^&&C:1<_$3X8:SX8T?PGJ/Q
MG\=1>!-)\9):^)+2;3O$<_AJ)-8U:VT:XC>TN-3M--BU&*>PFN(7_$[_ (*U
M_LC_ /!1[X9?\$0O G[4'[1'_!2KXI_M2Z#^T5J'[//COX[_  "^*6D:?K/A
M'P5?_$-+3QG\.]0^#GBJYEFUOP[?>#M0GTOP_P"*-+TRVT?P[XE@U/4;VWL+
M6+3;*"?^TW]MS_@E?^RU^V+^R!\=_P!DZR^'?P^^!]K\:-!T>"/QU\+OASX4
M\-:QH'BSP=KMGXL\!^(KNV\/V6A'Q#9Z!XFT^VN;K0[Z]B@U'39]2T]+BS:^
M-S'_ #J?&O\ X(,?\%K_ -JS]B'0OV%_VBO^"AG[-&I_!WX MX/M/@#H/ASP
M%XOBU'XBP>!Y;+0?",_QQ\;MX;L=:M--\%>!)]:L_#&B:3IGB6>YUM-$N==U
M2Z;38[\@'@O_  4"_P""IWQ2^'?BC_@E#_P3>\+?M=^*_P!@#X#:[^P5^SE\
M8OVF_P!J+X:^#-<\:_%>/3M;^$K1>%_!O@RW\,:9JOB;2$D'@W[(;S0(K6>7
M5_%=C?ZQ>KHGA^XLM0]?_P""7W_!5'XY:I\6?^"CW[%$/[9'Q*_;G^#/@+]C
M_P"*O[0O[(7[9GQ ^'7B?X??%72M9\'> K*?Q%X/\1W?BG0]*U/6;W0]5\36
MKV&I:PEY*FK^$+[4-*G.E:X-,TG]%OVL/^")7[1.O>+?^"?O[8/[%/Q_^&7P
M?_;Y_8A_9V^'O[/&M:A\2/"^J^)?@=\:/!_A'X?W7A2^T[6;>UL;S7],AEGU
MCQ1I]O,^BWDE[X=\1?,=$UG1M-U!>_\ @M^R/_P4G^$WP+_X*)?'[_@HY^V9
MX=^-'B_XJ?LS_&#3O"/[._P2TJ\T?]G#X-VME\,=:2XU3PM'X@T31]>DUBZM
MM-M;"""VL]/LH8)]9U/6KCQ)KNLF_P!. /P3_8&\._\ !:#_ (*/?\$I/'?[
M<$G_  5T^-7PJ\0_L\2?&NZ^"_@7PU8P)=?%:_\ AA977C3Q+=_'KQ]::EI^
MIZY'JDEW)X)\&:/?Z9K&@>'=*T:RU"\TJ[^VW)FUOV@/^#B[]K#Q-_P1Q_X)
M\>,?#GC_ $CX'_M._M<_&WXG?L]_&G]I+3O"L>L_\(-X7^!&K^$M'\<_%+PI
MX-T_2;J*V\1^)-&^(_@77[Z'0M+N)M)FB\46?A*RMKZXT:73/#/^")W[$/\
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M_)YXBDMUH _G\_9$_P""Z'[;GPQ_X()_MV_'KXK>.X_C+^TW^RY^TE9?LO\
MPA^+WB^RM=3U2ZE^(3^$;72_$OC*.2R6W\67O@)M8\3:IH]SKEM+/KBVNAZ;
MXCEODCN9+CY7_P""K7[)?_!2#X>_\$-O!O[5G[0__!2OXI_M0Z%^T?)^SMX_
M^/'[/OQ1TC3M:\&>#G^)$^E^,_AOJ'P>\47$LNM>&M5\&ZG<Z'HOB?3=)M=&
M\-^)(-2U6XAL+>+3+&*Y_<S]D#_@W2U[P/\ \$Z_^"@W[!7[4_Q8\#^(;?\
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M2_:G_9X_X)+?\$\/C7\!/CY\0OAA\3_BC\2/V:-.\=>/_!^JPV&O^,-+\7?
M7Q+XDU^VU>[>TF2XM]9UNVM=8NT6&-9KN"-F'E;XFW_ G_!#G]NOXL_\$<OB
MC_P2U_;/_:2^ ]P?"\OPRC_8[\5_"'PUX@N]/^'5G\,-=O\ Q#%:?%*[U3PY
MX4U3Q99^);B:#2Y)+.TEU31-/GN[F.[U&X@@MI_F?]H?_@@I_P %EOVV_P!D
M_P" '[/?[5/[=?[+5S8?LG>*? =E\%O ?@?P'XLL/"GB'PMX.\.7/@^/Q[\6
M/'$?A73_ !%KGQ$TOPM!I^@>%]'TOPS9Z*EKJ?B74=8U>?5[X3R@'7_MR_'_
M /X**_$?_@X*^!O_  3[_9F_;3\:?LW?"SXT_L9>'-=\87%MH^E>,M-\)1/H
MWQ/\0^-_'/@SPCK*QZ6?BGJ.F^$K/1O#.OWLK1Z%?WD>KB)_L(C;Y;_8VL_^
M"LWQZ_X*)_M\?\$:Y?\ @K+\=M(^#7[--WJ'Q*UG]J"\\/V7B/\ :CU/2I&\
M*:7X;\!>#_'.JZJU_P"#M+UF_P#'FG:OXG%IJ\C6P\(W5IX5N-'L];O;6;]Z
M?%'_  2F^,6N_P#!<KX'?\%2+;XC?#B'X1?"[]F5?@CJ_P /ID\2'XAZCKR^
M%OB-H7]J:<4TH^'5THW7C*QN-]SJT=V(+2Z3[)YAB+:W[&?_  2V^+W[-G_!
M7;_@H;_P4,\4_$/X=Z[\,_VP?#6CZ+X*\$Z"OB,>-_#5QIU_X(NGE\3F_P!+
MM=#$)C\+WB+_ &7J-^[O<V[$1*LH !^"7[%/_!</]LGX _\ !'G_ (*>?$_X
M[^/_ /AH_P"//[#_ .T-I_[.GP,^)_CO3FO=4U_6/B/K:>#_  _JGQ$EBF@N
M/$VG^"]8@U?Q7;2:G.=5U>Q6U\,ZIJDR>3>11?%KX?\ _!;C]D?_ ()J^#?^
M"T$O_!6WXE?%#XGCP;\(?VA?B;^RIXW\+6&H?L_R?#3XOZEX973O"NC:0FJ1
MZ -2T73O&V@3:_;:/X1\*0S0KK=OX=U73+_3M+O]0_2W]D;_ (-X]3\(?LH?
M\%1OV2OVLOB;X,\4^$/V_/C4WQ4\&^)/A+#K<FN?#"ZTS5=4\1^#]>NH?%FD
MZ7;7'B#PYXFDT34FTVU>XT[4[2QO]*N=06VU!W7Y@OO^"&G_  6N^,?[/'@?
M_@FE^T7_ ,%(?@/<_P#!.?P-<^#=#NM;\ _#_7#^T1XV^%G@+5+;4O"7P_U5
M-6\,66GI8^'#I^CKHMKJGCC6+2QET713J=UXFL]$M;&Y /"_^"D'_!3#]O;]
MHG]I/_@AU9?L'?M"^)?V6E_X*0?L]:'>:WX<#PZ[X$\,^+?BQK\'A+5/$VNZ
M%?6,J>)[GX91:OJNH>'9IX0UQ=Z!I=U' )'*/T__  5<U3_@J+_P2H_98_8U
M^$^K_MM?MH?&WX%^+?C[\5O$'[:W[=OPI\+6WB']HGPCX,U'4_"Z_#CX;^%)
M_%&OZM_P@>E6_A;_ (275M.EU/QKIUCKWC&UNM.B\1:7I$=MH5U^KG[17_!%
M+Q)XN_;R_P""1_Q^_9_\6?#GX?\ [.O_  32\':!X"E^''B:3Q+=^-=9\,^%
MM1C;1K?P[=6.DW6E7E[_ &5!"EW>ZUJ&GRSZD)[N7S#,:^K?^"HG[&O[>7[1
MLWP9^)G[ ?[;VJ_LR?$WX.:S=7NN?"7QJNIZK^S=\?=$GEBNDT/XK^'M%M+Z
M]N_)DAETR:*]TOQ#H>KZ%JM[8WFE6EY;Z?JUJ ?DA_P0(_:VT[XR?M)?$OPK
M\,_^"R_C3]N7X(ZQ\.WUK0/V8?VQ_ /B'0OVRO 6O:2^B?;/%6F^.-7G31O%
MGAS2S=WFG^(+?P??^)-&GMM0T^^GL=#O=,>_U/\ KBK^8/\ X)__ /!%3]I_
MPA_P4BM_^"HG[=WC']DG0OB[X5^&^J> / OP<_8;^&VL?#WX8SZEK6E:QX>U
M#QUXZO\ 6=+T&]U[7WT+Q!K%M*TNG7U]JEU-I;WFL0Z=X>T_2I/Z?* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHKA/&WBR+0+-K:WE']I3Q_*$(WP1ON"N."%EE*N(BPQ&B23D.T<4,^
MV'P]7%5H4:,>:<W;RBNLI/I&*U;^23;2>5>M3P]*56H[1BK^<GTC%=92>B7S
M=DFUC>/O&:Z?#)I6GR9N90T=Q+&Y#* =KPHZX*J"&2YE1E<,#;0L)A<2V?S]
M)(\KM)(Q9W.68XY/3  P  ,!5 "J %4  "G3327$K2RL6=SR26. !A5!8LV%
M  &YF. ,DG),5?HN P-+ 4%2IZR?O5*C7O5)VLWY);1C?1>=V_C<5BJF+JNI
M4=EM""^&$>B7F]Y/>3[*R11117:<P4444 *#@@X5AW5U#(PZ%74@JR,,JRL"
M&4D$$$BOR"^"8_X85_;A\5_LRWI.G_LY?M?WNI_%;]G:>9F72O!?Q:B"#QM\
M,[:1V\FT@U7$:Z7:KY4>%\*Q0H]Q?735^OE?&W[=O[--Q^T[\ M8\-^&+@Z3
M\7? .HVGQ/\ @=XFMV$&H:'\2_"F;[2[>UO-I>UB\10Q2:),XRD-S<6%^REK
M".OBN-<KQM?!X+/LEHNMQ%PMB9YKEE"+Y99EAI4W2SC(92VY,YR_GH4>;W*6
M94LNQ<M<*C^@?H^\9</9;GF?^&GB#CHX#PK\:,JP_!7&.958NK2X0S:GC(X[
M@/Q.I4E[WUCP]XJ6%S/'^R_?XSA#%\6Y'3]W.JB?V317QU^QY^U?HG[1_P"S
MMX8^*'B&6#0/'FD2W7@;XO>%YD-OJ'A[XI>%UCL_$=D=+(^U6\>K.(M<T^W>
M/=#:Z@+60B6TGV^E:_\ %:^N2UOX?@^P0<J;ZZ5)+QQZQ0G=#;Y[%O-D _NG
MK]GP]./%&6X#-\G?M\MS+"T<9AL5-.G3=&O!3BIW3E&K"_)6HI2JT:L94ZD8
MRC)+\9X_X<SCPQXNXEX%XQPCRWB?A+.LPR'.<NC)5G2Q^6XF>&K2P]6-J>)P
M5=P6(P..IOZMCL%5H8O#3J4*U.<O:]2U;3-(A-QJ=];646"5,\@5G]HXQF20
MGL$1N:\OU?XMV,.Z+0]/EO7&0+J]+6UM[%(4S<2#_>,.?;@UX==75U>SM<WM
MS/=W#DEIKB5Y9#DYP&<G:N3PJX4=@*@K[C"\.86E:6)G+$3ZQ3=.DGZ1?/*W
M=S2?6'0_-\1GF(J7C0C&A#I)VG4?S?NQ]%%M?S/<ZW5/'/BC5BRS:I+:PMG_
M $?3Q]CBP1C:S1GSI!CN\ISUQFN28EV+NS2.>2\C,[D^I=RS'\2:**]VE0HT
M(\M&E3I172G",%\^5*[[MW;W9Y%2M5K2YJM2=27><G)_*[=EY+0****U,PHH
MHH **** "BBB@ I" >H!^H!I:* -K3?$>O:0P.G:K>0*"#Y+3--;M@YPT$_F
M1X]0%4XX!%>BZ3\7+Z';'K6G0WB< W%BWV:<>K&"3="_KA7C/;_:'D%%<6(R
M[!8J[K8>G*3WJ1CR5/\ P9#EF]MFVO(ZJ&-Q6'M[*M.*7V&^:'_@$KQ^Y)]F
MCZQT;QCX=UW:EEJ$:7+?\N=V/LMT#Z+'(=LGUB>3/;CFNGKXGQR#W!R#W!'0
M@]01V(Y%=MH7C_Q%H>R(W']IV2X'V34&>0HH[0763/#@=%)D3_8QD'Y[%\-R
M5YX.MS+5^QK64O2-6*47Y*48^<SV\-GR;4<52Y>GM:5VO65-W:75N,F^T#ZB
MHKBO#WCW0O$&R$2_V=J#  V-ZZH78]1;7'$5P,]%RDIX'EGK7:U\U6H5L/-T
MZ].=*:^S.+3:[Q>TH_WHMQ?1L]^E6I5X*=*I&I!]8N]O)K>+[II-=4%%%%9&
M@4444 %%%% !UZUZ]X$\<&(PZ'K4V83B/3[^5N83G"6ET['F$\+;S,<Q'$3G
M84*^0T5S8O"4<91E1JK1ZPFK<U.7247T?=;25T]&;X?$5,-452F[=)1Z3C=-
MQEY.V^Z>JU/K]A@,#Z'^55G^Z?P_F*\P\!>+S<)'H.J39N%79IMU(W,Z*#BT
ME8]9D Q Y.9$'ED[U7=Z>_W3^'\Q7Q5;"U<)7]C56J^&27NSC9VG%]GU6Z=X
MO5,^JHUZ>(I1J4WHW%2B]XR35XR\UT?56:T91E_B_#^E?B/_ ,'&,TJ_\$5?
MV\(UD<1MX&\ !D#,%(/QB^'9(*YP02JDC&"5!/(%?MQ+_%^']*\4^/GP%^$'
M[3_PE\:? ?X^>!M/^)/PB^(5II]CXS\$:K?:SINGZ]:Z5JVGZ]IT5Q?>'M2T
M?6;<6FL:7I]_&]CJ5K(9;5%=WB:2-Y<7.,XJUW'2_=--?\.)/E:?9IOT33:_
M _G/^(7Q.?P-_P %>O\ @W\T[Q)\1I_!G@#Q%_P3Y^)4.HZ?K/C"X\.>"M>\
M1+\'8DTF'4K.[U&ST#5-7\V2)=/2]BGNC<FT6W'GK:@?A=\4_C'XU\??L,?\
M%*?$_P /?CS\1;:TUS_@XU\(^'?AY\3?!/Q%U^34-%\$^(I]>&FS^ ]=BU6:
M&'0(X[N+5-#LK*1M D\JPN(;5[>&VV?W#?M(_P#!.[]B+]KGP7\+_AY^TI^S
M;\/OB]X1^"=O9V7PHT[Q,->@N_!&FV>G:;I,>DZ3KVB:UI/B%]&N-.TC2K;4
MM'O]5O-,U;^SK.;5+2\G@24>=6O_  2B_P""=&E_#/Q%\&M&_9-^'&@_"GQ7
M\:/#/[0VM_#[P]>^,] \+R_&7P;IZZ5X7\:V&FZ/XILDT231--C6SL]!T0Z=
MX6\D$3:'*6=FB.%JN+BFK2;:=VM^56TU6L=^[Z6NW[:%U)J5[I-65M))[WZ[
M;:?/3^3_ .,'[%,OA;]IW_@MY^R+HW[7/[<"_L\_L@?L3Z5^VA\+O!>H?M*>
M-=2U34_VD;OX2VNN6?CGQ[XLN)/[=\6V-GJT>M:A/X;GNK32M3O-7MKR_AGO
M=!T>ZMO0?"_Q4^(/[>OC?_@A9^Q[^V5^T]\6/AM^S3\</^"=.I?'_P"(/B/P
MQ\5KGX0>(/VH?V@O"]SXH\.:-X,\7_$V">SO-1OM#T7POH&MFT>]:\U'4-0O
MKK;_ &WK-G>P_P!;&O\ [%O[+7B7Q]^T-\5-=^#F@ZE\0OVK_A=!\%/VB?$\
MVK>*TN_BE\++?1E\.P^#=9M8/$$6F:;8IHBKIWVSPW8Z+J[0JK/J#3*LH\N^
M)?\ P3,_8&^,'[/_ ,+?V6_B?^RU\-O&_P "/@E8Q:;\(?!&N?\ "237/PWL
M(>#:^$O&L&OP?$'2HKI2(]3$7BLG5HDCBU0W<<<:KU1P5;EDHN&LI/6<DI)2
MC*,7:UE9-6V2;]#"6(A[MU+1+5*+::A9RC?K=;:7[G\:_P ?/C?\;M&_X)>?
M\%./V?\ X<?M-?%+XJ?"#]CS_@J?^SU\%/V0OVC[WQW?:UXVB\&:OXHU&?5O
M ,7Q1TNYM[GQC8_#Z]@T8PW<E]<VCIK"O:B'1Y]+M+7^SS]B_P#8X^&W[$_P
MCE^''P[\1_%?QE<^+];@^(GQ!\8_&3XG>)_BIXP\3_$+5?#NB:;X@UG^V/$M
MY<C1M/OY=,6\70-$ALM'@OKF^ODMVNKZXFD@U7_@G9^P]J?[-6C?L=2?LT_#
MFP_9C\.^(M%\8Z5\'] BUSPSX=3Q=X?U :OIGBB^OO#NLZ7XCUGQ"NIJM[?Z
MQK.MZA?ZQ,!_;$]^@"#[!90JQHHPL:+&@'14C1411_NJH&3DG&22>:]'!82=
M&JZE1J3<::A9M\KO)R5M%I=).VJ7S.3$5U4@HP3BN:;EI'WO<BDW97O>,I-.
M^KW>EOY(/C[X(\)?\% /^"KW_!3/X$?MJ_M=_&#]F+X6_L6_ 'X7ZY^RAX>\
M"_&^X^"V@Z!8^*?!UKXC\<_M)3:<EWI]GX_U'PQJ\]I=7<-W+,7L[VVTNXDC
MM(=.6V^=/VX/'7C/XR?M'_\ !,G]B?PY\>OC5^WA^R/JG[&_BWXJZ-XY^'W[
M7WPN_9(UW]LWXH^'_%'BOPH?$'B[XY>([O2/"FNZA\,-'T*T">$1?2^+)[NW
MN[B^DNM8N-:OKC^H+]J?_@FU^PA^VQXD\-^,_P!JG]E_X:_&7QCX/LTTW0?%
MFNQ:]HWB2#2()Y+FWT34-;\(ZWX=U'7]!MKB:>:UT/Q!<:II5J]Q<FWLX_M$
MH=_QR_X)T?L*_M(?"CX=?!#XT_LL_"3QG\*?@_;+9?"?P;%H=QX4L_AKI_DV
M]M-IO@>_\%7WAS6O#>F7L-K:C4M-TO4[>RU62WAGU*"ZGC62G++L1-5TIPO.
M;:GSS4JD74C-0FFG&*A'W%9--:6LDFHXJE%TFXR:@HQY>6#C"7*HN<'=-N4O
M>=^6VUWHU_)9\?[;]JG1_P#@DY^QQX2_:E\6:5X^/@W_ (+2_ 30O@%XTMOC
M]\-?VF/$6H_ %4\277A'0/'GQ9^%FN>(/#FN^,/!&ISZWX7O6GOEU VMA:M]
MFM]/-A#'^P?_  3O_P"4X_\ P7\_[&;]DO\ ]5NU?J!<_P#!.;]AL_!+X:?L
MX6_[-'P[TSX&_!WXD:)\8OAQ\.-!77_#NC>'OBIX>DOGTKQ_+=Z%K>G:UK_B
M:-]2OFO-1\3:IK+ZLUP3JRWPCB$?J_@;]FOX%_#'XQ?&_P#:#\!?#G2O#?QF
M_:0F\+W'QP\>VFH:_<ZG\0IO!=DVF^%WU.QU'5KS1=/_ +'L7>W@70=,TE)@
M[27:W$S&0]N&RW$1Q&%K2G!JC[*4[RE*3Y:52+2?(D[.<4KVNE<Y*V*IRI5H
MJ+3J>T4;))7G6HU%=<SMI2E>U]6K7U9_-W^W-\+?A]^TG_P<&_#?]FKX\_M%
M_%GX+? KQM_P3ECUW6/#/P^^.VI_!2Q^)GBCP]\1O&.I:5X4O-774K:PB98K
M:X\972V4"ZIJL?@JWL9YI--6YBK\9]2\:>/?'O[!/@S1KGXN^,O'6I?"O_@K
MWXP_9*^#/Q[F\77J^./B'^S3H'A>>?P[XEOO$0G=_&Z>%]9U."PT35Y9KJ&W
MM=1M=*^T2V>G:?!:_P!!_P#P4/\ V#?AO\2/^"E%I^UC^U!X"^"_QT_9IU;]
MAVX_9YTSX&^*=8UX?$?4/BY:?$*Z\6:/XTM;#2M-L6\,^%M%L[EH?^$WTGQG
MIOB*&YFNM+T^QE6[F8_,VJ? ?X)7_A3P+X#M_A7X0T+X?_"WQ!9^)_AIX%\-
MP:CHGAKP/K6GW-S=V5[HUM9:C'=7%S'<W=S=7=WK-WJEWK%Y--?:U/J%Y*\Y
M_,/$3-\%1HYADTZ&'QF,Q?-[E24VL$I2IRI8BJX2O3KTTG4PU.FXS]_GJVHR
MY,1_:/T2_"GC'->(,J\1J68YCPQPQE#Y(8K#QA"OQ3*#G3Q>48:G6A.E7R><
ME&EFV,KTJE%2I1P^7\V849XK*_SU^*?PT\-:!\?OV?OV0;CQY\0O!7[/NL>%
M/'?C^_FG^(^K67B'XC>/4OKQ4T'5?'=_.MZT-DMG9W5GID4T<$)NWCMH%N;F
M"4?-WQ'\1:T_[)7[9WPSB\9:Q\1?AO\ !_X^?#7PK\+O&.N:F-=OGT:X\6V%
MQ?\ AP^(1N.L0Z#/%;)'<-+*%^U%HBEO-!$G[A>*/V<_!W[4-QHGPY\6_#+2
MOBA=76HM-H>FWUO,EW87<@475[:ZO97%C?:-:B)0=2NH[ZUM/LZ#[66156N9
M\4_LN_"[PYX+U+]G/Q)\)='T'P/I&HVYU7X=I#?:3:#5--OHM0MK^YN=/O+;
M4M0N)+NWM[U=5EU"X?4T6*26XN86 /XG++L5.A4Q$:<HX6<ZN'CB'"JJ3K2P
M\4L*YJ'LKPB_;<BDY\MI.&KD_P#3&.:Y;',5E/UW!O-:6#HYC/+(XFA_:"R_
MZP\/''/!^T6)6#EB(RP\<0Z:H>VYJ49\Z<3Y8\)Z OCS]JG_ (**?#JZ\9>/
M;?P=9_\ !&)_'%G<>$=>UWP-J6B>-+31-&U+5[+2=7L+EGCMYSIZ>'_$367D
MQ^)/#.H:MI-ZOV'6+M)/DW1I?B;X4_8A_P""&/[-7AGQ+^T7XK^!?[:2_%KX
MA?&GP+I_[6MM\$AXU\6> -2&C^"?@7\/OC!\2K^V\&_ SX>7A#^))O ]I<V>
ME>(/$FHW=_8P2>)KJPN8?U[\->#O!GA/QWXG^(=AX4TVY\0^.OAO=?!OQ\;R
M[UDV7C;X2ZCIJZ1J?P^UVUM]3@C&BZAI:BTEN=/6SUB$I#=6VHQ74$<H_4+P
M)^S'_P $_P#]J3]DKP3^R[JW[.W@#6_@3\*5A70?@7XDGUW4I/AAJ7G:C.+_
M ,,>))M;_P"$ULA=S:KJOV?Q%I_B**\O+6]GL;R< -:I^_\ A]C\#FN!IY+0
M>&RS,\+0K1C1C*<(YC"6)I5YU:<YJ<I5)THU(8NG-U)Q3]I"-6A%PI?Y<?2M
M\+N,N&^*,?XBXK&YEQ7PKG6,HN68UHPJ8CA>?LZU'"Y1C*%%4J.'RZG4J4UE
M&*P]+#X:<_\ 9<3[#'U*=7'?S,_M#C]L?X+_ /!'_P#;9\(^)O'_ (CT#X>>
M#?VV/V?+?]D74(?VN_AK^TU\7OA%X7UGXA7%KXN^#WC7XM_!?Q'?!I? VL6F
MD/866O2V%RXU*_ABLDAMI(X/T6_:;_9X_9\_9A@_8A_85\-VO[;7[47Q7_:M
M^*?B'XQ7OP#M_P!K"Y^'^B_M+>-O#/@#0+3QGXA_:%^/'BFZM/$?A#X8^'KJ
M-_$>D?#OX9:QH0U?7IM1NYH+^Z$!D_8BR_X)G?L$Z3^SUJ/[*&C_ ++WPZT?
M]GO6/%FB^/-<^'&D2>)M,M_$/C/P[=6]YH?B;Q'XEL?$$'C3Q!J^F36MNEK<
MZSXCOMMK#'8,C6*BWKT']I']C7]E_P#:YT?P;HW[1OP=\/?$ZW^'6I/J_@'4
M+S4?$WAOQ+X,U":"WMKF;PWXP\%:[X:\6:3'>06EHM]:VFM1VE\UI:2W<$TU
MM#(GZY2R'$JC5]^C.M+"83#T76JU:JIQAB*M3%0NZ<8)2I3IT:<O93CRPM.D
MTG&7\8SS&E*4/=J0IJO6J3]G!0<G.C1IT9<JK.3<:D)5*B5:,KR<H58S=X_P
M[_%>'Q1\2/\ @BW_ ,%%O#'Q4\4>*M1TW]CG_@JCX:\(?!CPW:?&7Q9\2O"O
MPQ\-ZWXDT/PIK7@*Q\?>(%@UCXC^ ] A\0:L/#%YXGC1(]6-OXHM[:UU"3!_
M7;Q?'=?LE_\ !1_]ESP#^S+XB\<>-O!OPM_X(S_M-?$;X;>$M?\ B5X@^*-E
MXQ\=Z3-\6_&VAR:S>SZE=VOBZ]/B:Y_L^QEFBGGM-/@L-#M6CMM,LX8/W%T#
M_@F[^PIX1^%/QC^!7AG]F7X=Z+\&OV@-1TK6?B[\,K)O$:^#?%FM:'%##I&M
M0Z/)KTD'AC6-.^S6L]MJG@_^P+Y+VUMM0,YOH(KA=3X5?L$?L>_ CQ5\*O&_
MPB^!7AKP-XJ^!WPZ\1?"3X4:QIFK^,+J;P;\.?%_B#7?%?B?PQ9V^K>)-0LM
M0M]:\1^)_$&KWM_K=MJ>KM=:M=B/4(X66)-<-P]CH3A/VV'4W3P5.555*OM:
M?U7&5*KA"U*,90E1G"VL%&=&$%%0?,L:^:X>49PY*SC*>*G&FXP4)?6,+2I*
M4W[1N,E5IU&[<S<:LI\W/H_Y#='\07?PN_8._8M_X*G?"W]N'XU?$?\ X**?
M&W]ISP=H/C_P3JOQO?Q9X>^+$WC3Q_KV@>,O@+=? R2::WTW3/#VA6&F*J+I
M\<,4,\36,=G%>^&C8_07[1GP*N/VD/VYO^#@BX\6_&W]HCP9H_[+_P $OAS\
M7OA9X)^&GQ>\4>#_  C9?$_3O@1#K>B>(-=T:PNS;:K;Z!)H][:6VC1"SL;A
M]=U#4)V:]ALY8OZ./!?_  3+_P""?OPV^.TO[2W@3]DCX.>%_C<VJWFO6WC?
M3=#O ND^(-09I+SQ#X=\*W&HS^"O#/B":62:8:WX?\-Z;J<4]Q=3P744MU.\
MGI4O['_[-/\ PEW[2'CP_"71#XN_:[\+V/@O]I+6VU7Q0UQ\6/"VGZ!+X6L]
M&UN ZZ;/2[>#P_<3Z8)?#-MH=V\4C2R7#W($XZJ/#&,E2I4ZU7#<D*T)5*4:
MV*E"JZ>!Q>'EB9.47)U\37Q%*I7@^:*C17[RH[\T3S>@ISJ4X5E-PFHU)4Z*
MG3C/%8:LL/'EE9T:%*C4A2DWS.56RA3CMXG_ ,$N_B)XU^+/_!.;]C#XC?$?
MQ'J7B_QUXK^ O@V^\3>*=9G:ZUC7]0@AN-/&I:M>.3+>ZE<6UG ;V^F+7%[<
M"2YN'>>61V^XWZ#Z_P!#7(?"WX6?#[X'_#;P9\(?A1X8M/!?PV^'NBV_AOP7
MX4L+G4KVST'0[5Y9+?3[>[UB]U'5+B.)YI&$M_?W=PQ<[YFXQU[]!]?Z&ON\
M#2J4,+A*-::J5J-"A2JS3<E.I3A&,Y*4DI-2DF[R2;O=JY\WBIPJ5:]2G'EA
M4JU)PC9+EA*HY1C:-TK)I63:5K+0JOU'T_J:J8<L@BWF0NHC\O._?GY=FWYM
MV[&W;SG&.:NE6=U1%+.V%55!+,Q)   R22> !R37U+\&O@P+@6WBGQ5;!K8A
M9=-TR9<BZ[K/<(PQ]B(Y5?\ E^_Z\,G4(S;.L%D6"JXW&SLE[M&C%KVN(JM-
MQI4HMZM[MOW81O*32396 R_$YEB(X?#1NVXRJ3=^2E34ES5*C6R71;R=HQ3;
M/4/@7#XSA\+)_P )*T?]F,D3:%%,L@OTB)D,K9)V#374P_8D*@AQ.]OBP>T%
M>W4@         &  .  !P !P .E+7\TYGCGF6/Q6.="CAGB:LJOL:$>6G"]E
MY<TW;FJ3LG4J.4VDY6/V' X7ZEA*&%]K4K>QIJ'M*LN:<K?E%;0C=\D%&-W:
MX445\(_\%.?VN7_82_8(_:A_:KLK>TO/$?PH^%^JWG@2PO\ :UEJ'Q)\17%I
MX0^'%G>Q$,;FRE\;Z_H/V^U0>9<6*W$495W##@.H^TM%\3>&_$<FLQ>'O$&B
M:]+X<UFZ\.>(8]&U6PU1]"\0V,<$U[H.LI8W$[:7K-G#=6LMUI=Z(+ZWBN;>
M2:!$FC+;E?ASX7^*WP\_X(L_\$POV>Y/'^@>,/C;\>OBAK7@G1G\%^$/LUU\
M7/VM/VY_VE[Z7QCXU6'4=5D"W&M^+?'6J>)=5O\ 7]:FFBT#PCHT%I#%.FFZ
M1H\U[P/_ ,%1OVE_A=^T%\ /@9_P4=_87B_9$TG]K7Q6/AS^SY\7_ 7[0'A;
M]H/X>3_%VZL9-1T3X-_%*?1_#7A2^\#>-O$L$4EIX:O+.'7_  _KFKC[#I]]
M+;PZCJ&G '[<45_./\._^"T_[9O[3?@?XS^.?V,_^"5_B?XS:+^S7\6_C#\+
MOC-JWB_]HWP5\+M)U+5?A/XGU6RE\._!4:KX4U'6/B?XWU#P?9Z;XGU/35TK
M0]$T#4M<TSPHFN:SJL^5_8W]B#]KGX=?MX_LH_!/]K?X4V.LZ3X(^-7A-O$-
MAH?B)+5=>\.:IINK:GX9\4^&-7-E-<64U_X:\5Z'K>A7%U9S/:7KZ>;NV(@G
MC  /#?$G_!(+_@EQXN^)$OQ=\2_L#_LLZO\ $*YUJ3Q%>^(+OX0>$MNI:]/*
ML\FKZMI$>GQZ%J^H27(%RUSJ>F7<K79-SN^T,9#^B=C8V6F65GINFV=KI^G:
M?:V]C86%C;Q6EE8V5I$D%K9V=K D<%M:VT$<<-O;PQI%#$B1QHJ*JC^:/_@L
MU\>OVS/AU_P4:_X(_>#?@1\%9OB#X,U'XT_%+Q#H>@K^T/IWPNT3X\?$33_A
M+XABO?A]XRT:YTVYM=%L/ASH$H\:Z%XI\1Q:UI>I:IJ<ND:?IUK?Q&XE_6K]
MF7]N(?M#_M<_MY_LH3_#2?P;J?[#>J?LVZ/JWBQO$\&MVOCN^_: ^$#?%*>.
MTTR+2K%]%7P?+')H+R/>ZFFM83486LU9K5 #[\HK\%/BW_P7&T#X1?LV_P#!
M2G]H_6/V?M6O]&_X)T?MKZ3^R'K>@6?CNT^W?$FVO?'/PK\'7GQ#TZX;PX4T
M)K2#XE-JUOX7EBU.6\.CK8?VO!+?^;:\!X]_X+>_M&?L_P#B[X'ZI^U!_P $
MO_B[\,?@A^UWJ]QX*_9-U;PG\8OAW\2OCCXQ^*&J:*NL_#'X=?%+X.:9;Z9:
M?"OQ%\5HKBPAT^WNO&VL0^"[B:_@\77%N=$U1X #^BJBOQQ_9?\ ^"E'[1/B
M[]MIOV%/VUOV*T_9+^*GC?X+:[^T%\"M8\+_ !U\+_'KP?X]\!>%?$&G^'?%
M6@ZWK7A[P_X<3P]XZ\.W6I13W>G6\6J:?<6T,\\-VMK+IESJ7D4?_!6O]K3X
M^:S\9O&7_!/+_@G%J7[6/[,7P$\>>+OAQKOQJ\3?M$>#O@IJ_P ;/%GPZN9+
M/Q_IW[-O@+5_"WB6]\;V>AWUO<:;IFO>(-1\-:;XFU-!8:0'O5DMD /WKHK^
M=;XG_P#!P7X/?PA_P3]\0?LI?LL?$K]I_P 2?\%%-'^/^C?"CX:VOBKP]\/?
M&_@[XV_ FY\$Z/K/PG^(UMK-OJ6E:!_9FO>*=53QSXIEU5=-\)^'_"UYXC@B
MUK3[^R9OVH_9;^('QS^*/P+\"^./VD_@7;_LV?&K68-87QO\&;3X@Z-\4[7P
MA>:;K^J:59?9?'.@6=AI6MVNMZ7967B"T>VMU:UMM4AL[AFN8)C0!] T5\,?
MMW?MC>)/V0_!'PWD^&O[//Q&_:B^-?QO^*.B?![X0?"+P!+#H5EJ/BG6K6]O
MYM>^(7Q%U.RO?#?PS^'WA_3[":ZUWQ;KT;V\#R6MO' RRW%S9_'7P<_X*;_M
M,>'/VSOA7^Q9_P % OV+_#_[+7B?]HOP#\6?'_[/'Q1^&_[0.D?';X9>,H_@
M?H,/BWXG>%/$]X/!G@?5?!^O^&/"=Q%K=U=W=E/I,L4MI'#,RW\,L8!^UE'^
M?SZ5_.E;?\%I_P!K;XI?"WQU^V5^RQ_P3"\6_'+_ ()[_#W5_&2Q_&"?X\>&
M/!_QW^,7@/X<ZSJ>C^.?BM\#_P!GN?PEJEYXC\*:6^D:I<:/I^M>+='U_P 3
MPZ7>IIUG'>1S65MX#^U1^V/^UCXV_P""RO\ P2<U?]G7X&:WX^^!_P 1/V:?
MC?\ %#X8^$_$?QWC^$-K\4M$\?\ P_\  MUXZ\;>//ASKND2#P5XR^!&@ZU)
M#IN@>*].U#6_$5W=:EI^BW&D3I<$ ']3EEJNEZC+?V^GZE87\^EW1L=3ALKR
MWNI=.O0BR&SOXX))'M+H1NCFWN%CE",K%-K F_TZU_-);_\ !1[X$_L66W_!
M4/\ :!^&O[&E]HGA_P"#_P#P5!\!_"3]M7QIIOQ5U74+GQ'!\0-)\$^'/$/[
M53:/JNC:M!H]IX6N?$7AG3M0^'NAI:6,]I-+K#:M9,M\R?JS^V+^W-9?LW?$
M']BOX,>#/A[_ ,+I^*/[<'QTB^%7@?PUI_BNT\/6NB_#O0_"M_XW^+'QFOK_
M /L_6)-1\-?#GPC;VFHWEE8VR/J+ZO8HE_:QDRD ^\M,U;2]:LHM3T?4M/U;
M3IC,L.H:9>6U_93-;RR6\XBN[626"0PSQ2PS!)"8Y8Y(WVNC*(]<T31_$VBZ
MOX<\1:78:YX?\0:7J&B:[HNJVD%_I>L:/JMI-8:GI>I6-RDEM>V&H65Q/:7E
MI<1R07%O-)#*C1NRG^&OXS_M4^*_^'7O_!&W7_\ @G+^R!?? C]G+XA?\%+]
M%L[?X36'[4E[I;77CWPE^U3\8K'2O@/XCUC6[8ZOK_@KX\>,=$U[QYK?B35I
M[CPMX$FAT_1[_2K^VCLF7^GKP?\ M_>)8/V\OAQ^P9\<?@6_PB\;_%O]D"Q_
M:8\ ^+K;X@:?XS\.:YXST#5[71OC)\#K.2RT338[WQ!\,Y+DZLOB"SNI++Q#
MX>C&JPZ?8Q31J0#Z[^&?PN_9Q_9*\!:+\./A-X'^$'[.OPTO/%2V?AWP7X,T
M;PG\,?!]WXU\8WJK'9:/HFF0Z/I5SXF\3Z@JI#:6<$FIZO=@)%'<3 "O<Z_%
M[XX^/_#G_!4/Q/\ \%+?^"9^A> ;FS\,?LY_#7X::+_PTO#XF\C_ (1W]KSQ
MAHTWQ2^&5EX%L;72ENM-\3? G5M'\&>-M3\466NO>:3XB2TTA[&W9S))[U_P
M2'_:_P#$/[<O_!/+]G+]H'QV(D^*NH>&M5\ ?&:&*&.V ^,'PE\1ZO\ #3XB
M7WV2$F*RCU_Q%X7N_$UI:1?N;>QUJUCA_=!* /TGHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K%\2>)- \'Z!K'BKQ5K&G>'O#?A[3KK5
M]=UW5[N&PTK2-*L8FGO=1U*^N&2WL[*T@1Y[FZG=(8(4>65U168;5?-G[9.B
MR^(_V2?VFM!@M9;Z?5O@-\6+""R@@DNI[N:X\#ZW'%;0VT*22W$T[E8HH(XY
M))9&6-$9F"GCS#$5,)@,=BJ4(U*N&P>)Q%*G*ZC4J4:,ZD(2<?>492BHNVMF
M[:G!FN*JX'*\RQM"G&M7P> QF*HT9\RC5JX?#U*U.G)Q]Y1G."C+E]ZS=M3Z
M*LKVSU*SM-1TZ[MK_3[^V@O;&^LIXKJSO;.ZB6>VN[2Y@>2"XMKB%TF@GA=X
MIHG62-V1@39K^8?_ ((A6/[>'@'QWJWP;^*GB2#PA\'=&\!>'/B19_!3XR:?
MX@3XD?\ "&^,9]=T[P]XL^$MG/!:S^'_  ^NMZ3)8^)+74KU]+L;AH;63PS;
M:OJD.I1_T\5\]P3Q1+C#A_"YW4RG'9+5K2JT:^ QZBJE.O0ER5G2DN6I.A[1
M2C3G6HX:M)1;G0@K7^4\.>-)\?<+8+B.ID69\.UJ]2MA\1EF:*"K4L3A9*EB
M'1DG&K4POME.%&IB</@\1/DDYX6DN5R****^M/N@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***:S*BL[L%1%+,S$!5502S,3P
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M8M1C&HE9I.4_=BFVB+X/?!Q9_L_BCQ1;AK<J)-.TZ9<BZ!Y6:=&7_CS[J/\
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MX*V_\%+_ (H?M-?#[X]V?P9_X*)>&/V+?B]^RM\1_AQ\ OBS\5-)\;WGPO\
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MP-#$5/:4J<7F>;8I4*:Q<<I<ZV%?#XG\,?1K\,<#Q;PCPAQKGOT@>/*V88C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\67^BZWXAMM..E>#-&UO4X8WTGP]JURUY/:QVD?V81/,LLL2. ?;-%?SE?\
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M <29]4Q67Y+ALVJ8&>+RG*L#CED]7!U\35K'YB?'O_@E;\;OV*OA]K_[1O\
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M_9\_;+^('[/?[*?Q _:._9H_;9_9[TG0;'PI\1].\+>!++4=3T7Q3X:TD?\
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M5O %Q),4L]8U3PMHD=@]YX1G#Q07.N6VN(VEWI6/4[:UM+B"]/RK_P $W/\
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MA?$_X7V5Y\'?VL+;]E;XO^,+;X?^!?V[-9^#NI>%_P!G#Q%XL:6"UU5-!O\
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MG@FS\*:3K>IW(&CRW\^F:G;WD^@:AHR75OJ*2:5K2Q:;XDL]#N;FTCN/D/\
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MX :QX>\(:#=>';.W\1^$G\2RWFH7%W97$<MU=C4H98[G3]+:U,"6$"KX7?\
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M\6_'/2_V@-$LO%TOBRTUGX:^-(+^&X\2V7@#5?#NOZ5)I6@^.M,6ZT+Q/9W
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M1^R#^S[^UQ^SE\+?^"G'BKX;:MXZO?BS=:[^T9JWPT_:/^%V@>)+K9X(\-_
M#XX:^OAWP[XBU#PGI!L;?Q1K7CK6UT[5FT:VTZUT/5+:'2=2T[^F)_NG\/YB
MJ;_>/X?R%=JX?P4YUIN=9?6::ISC&.&5/E4J<TG3^KN%5KV:C'ZQ&LH1;C!1
M1Q3S/$0A2BE%JC4<XN4J[FY.#BWS^V4X7]HY25%TN:24I7:U_DY\5_\ !+K_
M (* ZQ_P2@_;2_9@BM_$>M:Y\9?C]\*/&O[*?[+_ ,3OVA?#/Q6\3_ 7X2>#
M?B-H>OZYX<\4?'75I=%\&:AK>H:=9G4+K2-"U&;0+>31XY-+EGU/5[N)OJ'Q
MC^S!_P %$OV/?VT/CO\ M9?L2_!7X/\ [3.A_ME? [X,^!_BAX$^(OQ9L/A=
MK_P9^+'PH\"Z1X0L?%MMJ&IF#3O%G@>+^SGN[C1])O)]0U5[J:U":?\ 8[;4
MKK^A>3M^/]*I-T/T/\J[:/#F#BJ3IXC'4JE&%!4JT*U-U*<L-+%\DX.=&4>:
M4,;B*<HRC*DJ<HPITX*,;<\LTKR<^>EAYPJ2JRJ4Y0J*$_:K#)J7+5C+W982
MC.,E)3<^:4YSYFC^9'1O^"2W[2GP>^!O_!)SX8^'V\-_%'QE^SS^WMXA_:R_
M:I\1Z+XBT?PYX9\,Q^/KO3M3U\>"[?Q'<:-?^(M+T!+6'2K6VT?3VU+4[JSN
M+^'2K:WO84C^^/V2?V7/C9\)_P#@I-_P5._:+\=>&+'2OA'^T]K'P%O?@QXB
M@\2:!J=YXF@\"^#9]&\2M>:!IU_<ZUX=^P7K1Q1+KUEI[W@9GM$EA02-^M+_
M 'C^'\A6?+W_ -T_UKT,)P]@,)/#5:+KQ>%K0KTH.I&4.>G@ZF 2ES4W.472
MJ2G*\^=U;2Y^6\'RXC,L16A7A45-^UA5ISDHM2<:F+AC)6M)13]K3BE:-E"\
M;7]Y4GZ#Z_T-:/A_PWJOBG5;?2-)MI+FZN90@5 ,*N=SN['"(B(&>21RL<:*
M7D95!-7?#_AS5/%&IVVDZ3;27%S<2!0$'"@ EW=B0B)&F9)'=E2.-6=V"J37
MZ ?#OX=:5X!TP0P+'<:M<HO]HZCM.9&R&-O;%@'CM48 \X>X=1-,!B**'/B;
MBK#<.X91CR5\RKT_]FPM[J*>GUC$6:<:,6K15U*M).,+)3G"\ER2MFU=-\U/
M"4FO;UK;N\9>RI-JSJ26[U5.+4I)MQC(^''P[TSX?Z2+: K<:I=1Q?VG?@,!
M*R%W6WMU;E+6!Y92A8"2:1WFD"[UBB]%HHK^>\9C,3F&)K8S&5IU\37GSU:L
MWK)V2225E&,8I1A"*4812C%**2/U?#X>CA*-/#X>G&G1I1480CLENVWNY2;<
MI2=W*3<FVVV%?@E_P<X)))_P1*_;02*.25VL/@^%2)'D<_\ %]OAH20J!FP
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M'CQ0?AEXST/P3\)_%MA\+[KP9:?#;Q#XKU;1K/P_?^._$.J2Z]J6E:3X<O\
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M"TS0-*2[OEQ<W@TW2;:SM/M$[!6GF$0EF*KYCD@$ '^=!_P;S_\ !8#]C?\
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M#1]+T/3D=Y4L-'T^TTRR224@R2+:V4,$"O(0"[B,,Y +$XH U*_@%_X)F_\
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M%K%SJ5GI7B_P=^R?:Z[X?U"ZT>\DT_5;>TU.PAFMIIM/OHI;2[1)"T,\;QN
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MY;XC$_\ E+R_Z=^2/AQ_A1XS.,:<QZ_\L-0]O^G&JC?"7QM@XTR0\'I!?_\
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MR[ 5\73I246I<DYTE&?*U)0;::=CRWP1^U1_P4T_:^T.+XM_LG? S]GWX0?
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M&4LHR6>?TL#G>'>5T:63XK,<KISQ-&6#Q.=TL.Z=6CB)1JPA&K_4*;ZR%V+
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M?'X:GE.42I99F$,WS65;*\=RQK/*\%R+"2JXRE+&1C2_K=)"@LQ"JH)9B0
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MXO-ZN=YW@\;F6&H1J5W1^M0PE*+HK$5*=-04(;'O=%%%?<GZ2%%%% !1110
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MVD?"[Q!877@'PY!/YL@DDMK2![J_:WGP3.EQ*S;BH).W>-P)"D]_K#Q[XO\
M D]I=>"]?U>1)]5M+BWN+J2$+$J[-LKF0JUNAC9^&4.5;@D;21\W0?#_ %3P
MNME;3:_I'BW1'BC_ +*U6YD6TUZ.P S:K)) LMGJ*1(P$<ZBV<JHWJ2":6 A
MB*:I>V]JZ3C>GA:KG"EB*<TE*2M>":<I>[)P3=[NQYR<:[JSG-O$59<]6HM'
M47,^:3L[0]I.7M&KMJZ3E*UWX?\ M,?&/6_%WP2\3MXKMI-/&GSF+3[>_A2&
M]DMA"&:9XE):-3(6$2.0^T9QC&/UR_X).Z9>Z9^P=\"?MK +J.F^(M8M(_,5
MS'I^J>*-6N[!7VLWEDVSQR")]C*KCY1D5_.7^V=XIG\9^._"OP!\"WZ7-_KE
M_"-<N8IO/%G',R^?/?2(2(H;&U,D\JMP<1J3\U?H/^P]8V?[./QO^#/@CX1^
M)O%>K:%XTU.?P)\0_#FI:IJ.IZ'J2'2KB_\ ^$DM=-GEEMM,NM)N;<7)FMHX
M%CM':"8E) *5;#K,J];ZJEAJ&4T<0HTX4_W-;$UW1JXF@JDI)4_JU+#J*M[1
M.I5FI.+49+U>-.'U@O"_+\ ZU.AF.?9L^+:&#J4VJJR7(,+FN7X6I4=VZ/\
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M]I0P%"-"-5)Q]O5<Y5L3BFI+FBL5BJM>O"$VY4:52%'F:IQMS@LU!&<_B?\
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MH$'[27@37]<ENGLH])\(0^(?%]_)=1R&)X8(/#VB:@;MA)A0UF;B-PRLCLK
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M[3OM\.D:=XINIUO#I-[J#C[):2RQS1/:O<R1+=HS>4S$ 5^PFL>(O#5S\7/
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MI7B*$Q:UJE_J<<L,_B:ZM)T62QL4@N;G^SHY(XI9YI_-1%AA1G_695P1\H
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MJDX7CC@#CBF445\2=H4444 %%%% !1110 5]!_".3=H&HQ_W-7=O^_EK;_\
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MU"\FFO-1U"XN;Z\FEN;B61@#^3+_ (+ Z!^Q#^TO_P %7O!7P5N_V4OVM?\
M@J;^V9\-/@(MX?V-?#?QLT/X0?L@_"7PQJ_V>^TSQK\0?$NI2:+J/A[Q'=CQ
M1I.M:Y<:;JT^DWD&K^$X_$37L\6BZ+!^1O\ P3<TWQI\,OV(?^#J3]G+6?"S
M_";PI\*?AOXD_LW]GS3_ (D2?%;PC\&?$UWIO[0>B>(O"WASQQGR/%+:79^'
M]$\,7_BN!5E\30>%]+O+R2XE@26OZU/VR_\ @A3\ _VL/VOM/_;G\&_M#?M6
M_L?_ +2-SX3@\"^/?'W[*WQ)T[P!J?Q$\+6NDP>'X+76;J]\/:S>Z??GP];6
MF@W=[I5U;V^H:78:6M[I\UYIMI>IROP._P"#>;]C;]G/PG^W;\//A3\1?VA]
M*^'?_!0'X2Q?"?XM>%M=\=:-XMET"W2TUFWD\8>$_$WB'PO?>*)O&-U-XE\2
MWUUJ/BO5O$EO/=ZW=,]H8HK6.$ _DQO?^"7?[+FK?\&MME_P44\9Z3XV\7_M
MBZ-X6T7Q#X%^+>L_$CQO=O\ #SPCX>_:;;X4^&_A9X/\+2:X?"&D_#_3_!\M
M]='2HM"^V)XJU?4=>M]1BF^SQQ>^_MR?$_Q[^V%\-?\ @UU_9!_:9^*/C*V_
M9I_:Z^'/P;\1_M):Q_PDTWAZ3XK^)4NOAAX/@B\4^*&E1KC4M.TO4YE@O+Z6
M1K75_&H\0L'U>"QN[?\ K5D_X(^?L\R_\$KH_P#@DDWCKXM?\*"C\-IX8'C@
M:KX7_P"%JFSC^*W_  MX3G4_^$6_X1C[0?$7^A$?\(QY']D?Z.(1/_I%?D)_
MP6Z_91^"G[.'_!/']B#]F'Q/^P;^T-^W'^S'^SU9V?P]7XY?!+Q_%H/[47[,
M \+:3X7T?PUXZL-/T/X:^(=+\56'CC2(=9M/%$5_I^@^#%U7P]H$&I_8+V\T
M'4M, /SR_;(_88_92_8&_P"#A?\ X(N_"S]D:QU#X>> _%_CS3O'_B'X#1?$
M#Q=XQ\)^ O%4OB0^'#XU\.Z1XQ\0>(M1\+7/Q)TO0;&#7(X;Q+?6;KP5!?K$
M)!(3W/[,OQ8\<_ ;_@K3_P '2WQK^&.GG4_B)\*?V>?'_C_P3:B!;H?\)-X6
MMSK.D73VKQRQW45A?6D.H36TD;1W$5J\4@V.QKY$_8>_9?\ @_\ M._\%@?^
M"=GCW_@G;\$OVY[[X.?LNW^I_%#]KG]K3]N+2/$8\6^+O$^BQ/)H/AB]\1ZI
M=WFC)/HEEIFB^#O"_A?0ETPK=:]?7<>D3V&EZGK\_P#9Q^SW_P $JOV?_P!G
M7]LS]LO]M?P[XB\?^+/'O[<%DFF_%CP1XVN?#&J_#FQT\WD-W=6/A[1[;PU9
M:D;.^$)M;NVUW5M:AELY9H"FV0T ?R%?L ?\$@/V&_VU_P#@A]\;O^"CW[3/
MB_QIX[_;3\>^'_VG?C)X@_:7U;XM>+8?$7PD^('PBU?QO_PC%E<V"ZXGAZ^:
M[7POH?B7Q)_PE6D:GK.IVGB6*'2;[3+8:+);_+?[0G[;G[3_ .U%_P $+O\
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M_P $%?V*?AG_ ,$[/C?_ ,$X_!%_\5-(\ _M(7FDZY\;OC'<>)-'U7XX^/\
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M5N=3OGT#PW)%^^_[8G_!$O\ 91_;(^'?[,?A[Q+XI^,WPH^+G['G@WPIX'^
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M&\BM/$6GS:I8?97N6C3^CWXH_P#!'K]GCXL?'?\ X)W_ +0.O>.OBW8^+/\
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MLF5;*TM[&V@M+.W@M+6VABM[:VMXDA@MX((UBAABB0*D<442)'%&H"HBJJ@
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M=Z)\/OAG\)[/PKX2TE)E6.YFT[3[[Q-=6Z:T\ ,,>N:O;:_>HCNB/% S0/\
M?W[,'[(GP,_9#\'7/A#X->&'L)=6>";Q3XPUN=-5\:>+[JW!$$NNZT882;6V
M+.;'2+"&STJQ+NT-KYSR3/\ 3-%7'$XI8*CESQ6)E@:$W4IX6=:I*C[9[XBI
M3YN2KB6M'B:JGB'&\74:;3F;4ZLZ[ITHU9Q493A2IPER+54TXQ3C23U5*+5-
M.S4;JYQGQ"^'?@CXK^#=;^'_ ,1?#>F^+?!_B*W%OJNB:I$7AD,;>9:WEK-&
MT=SI^IV$X6YTW5+&:WO["Y19K6>-P<_E3;?\$G]3^&GQ$M_B/^S3^U+XW^$N
MJZ:TO]C)KGA33_%U_86UTV;O2+O6[75]"B\0:#,BQI+IGB+0=36ZV*]W++,D
M4T7[$T4J=>O2IUZ5*M5ITL3!4\12A4DJ->*=XJM1NZ55P>M.52$I4Y>]3<7J
M.,N5QERPDX-N#E",G%O27*Y)N/,E::BTIK25UH>-?"_1/C]HA2V^+_Q&^&/Q
M!M(=/,2ZEX0^&NM^ ]>NM35HA'>7JS>-O$&A+;-$)3/;6.E6KM.Z/'+%&IB/
MLM%%<U.FJ4%",JDDMG5J3JS^<ZDI3?S;'4FZDG)J$6]U3A"G'Y0@HQ7R2"BB
MBM" HHHH ****  \ GTKZN\#VOV/PGH41&&>R6Y?W:Z=Y\\@'E74<^F>]?*D
M437$L5N@)>XEC@0 9.Z5UC&!W.6S7V=;6ZVEM;6J !+:"&W4#H!#&L8Q[?+Q
M7R_$]5*EA:/6=2I5]%3BH+[_ &K^X^@R"FW5Q%7I&G&'SG+F_*'X^9/1117Q
MY]0%!. 3Z#-%7M,LVU#4;&R7K=74$)]E9QO)]E0,3["E*2C&4I.T8IR;[)*[
M?R2&DY-12NY-)+NV[)?>>^Z':?8="TJV(PR64;N._F3#SGS[[I#G//'X5;?[
MI_#^8J[* JA5&%52JCT50%4?@ !5)_NG\/YBOA^=U)3F]YSE-^LG=]NK['U3
MBH4X06T5&*](QM^A2;J?J?YU0E[_ .Z?ZU?;J?J?YU0E[_[I_K7=2W^<?S9C
M/;Y/\XE)^@^O]#5*7^+\/Z5=?H/K_0U2E_B_#^E=T-WZ?JCCJ;OUC^:/R<_X
M*U_MZ_%G]AKX2_!>W_9M^%_A;XV_M1_M)?''1/@U\%?A9XP_MQ]#UGR](U+Q
M)XVUS4(/#>LZ!K#6V@:-96L*S0:I;P6][JUG-<K<11M!)H?LP?\ !3CX._%[
M_@F)X(_X*4_%Z_M/AQX#T_X:W/B+X_0>'M'\2^(K?X:^-O"GB!?!7Q$\/:;H
M%G!J_BW4;72?%X$>EV@@O]6DTB]L+FX,A,DM?F)^VU\*?V^_VRO^"V/PVN?V
M3;SP?\%/#?\ P3;_ &>[KQ/X+^-'[2?P?^(/BKX(>*?C-\</*T_Q?:^"EL=*
MAT?Q?XIT?PIK>C6=KJ&FZA=IX?N_#>K2LZ7")%7YZZ#\#/VU/V;?V*/^"^/_
M  33^+GPS\2_$S5]>\,V_P"U'\!/B!\$OA1\01\'?B1JGQC\1> [SXF^!O@W
MI_\ 8,Z1RZ3J,^BWUOX%TZYNM6TU['Q.5LFM+"6X7@^N8FG7JSA&HZ24Z=.]
M.4J3G%*TG9IJ2E[12UM*T=E\71&A3G1I)R@JEX3G[UI\DFHM6EH[1<))K9\U
M[['[FZ5^WC_P3!_X*=?$V3]F_P#9^_:3\.^*_P!H_2_#%UXF\"SV_A#QMH,&
MOZ9;6(U34]-T'Q#XA\.:3H7CVRTR!;B3Q#HVA:E?:EH,ECJMQ;QK-I>H(/QP
M\9?MT_LE>!O&'Q%\#:M\;?#.HZY\+/$6H^%/%4OA:TUOQ/HDOB#2-631-5TS
MPUKND:;<Z9XINM.U!]M]!HEQ=RVT"37,B>1!-(GTG=?L[^/+3]MC_@W7N/"_
MP>\5^%/#_@#_ ()_?&/P!\0O%6D_#;7=+T#X3>(-;_9]ATW1M-^(>K6&BPVO
M@S48/$>JZG-!IWB.XT[4#J]SJ(@A.H74_F?B;X[UC4OV>/\ @DMK_P#P37^-
MW['?Q/\ "G[4O[._[4^HZ]XC_:)U/P7HD7PCUSPSXI^)*:[I_COPI\4HM5>^
M\=ZSX\T74=.\)6-I;6]_ =%\G6%U,06$EA!^<^(6387$8'$YY4GA<OS#"^UC
M4KRI5(4<Q]G2H3H8:<(RE)XR:J5(4*T>:3C0<*R=-1GA_P"R?HH>+7%F4<29
M9X:QP&9<5<,9M5B\/@\/.G5QO"?/4JO&9MAZU9TZ=/(:<E&MFF"JSA3I3K/%
M9>UC*E7"YE^NOP]_:5UCP3^TKKV@>&/'_A'0[CP-\,M%^)"V*:-XLL_%&GZ3
MJJ6T]UJ7BG7]2*_#[4/!UY8S;I=&B U:W4K)?^7Y#.G)Z+^W7\#?VC_BIJ^C
M:3\8[;QE\2-:N;N=#J&G:WI5OXB>S,@EM?".H:MIUEI6LV]E#"XM+#1)Y4CM
M(2UM"R*S'X:^)WPC^(?Q%^/O[46A^&='UBQ?QS^Q%X(\)>&/$-S97MCX?U+Q
M)!!X?N)?#D7B&2*+2S>WB6LVF75N+PO ES(US&L*RXXOP_;^,_C2?V*OA)X=
M_9]^)'PI\0?LU>,_"?B#XH^,O%GA*/PWX8\-:;X.M;>TU?3O#&NF0/XD'C&[
MLFN?*MT:6>XE@>6*=C<7:_C"Q^-5'ZFJM5X18F5>.&<ZSH2K-PHNI"FIJE"L
MJ6CJN$I<GN_"F?Z51R?*?[3>>?V?@8YU/ K+)9M]5PRS%Y;"O+$QP,L;[/ZU
M+!QQ%ZZPOM/8JJ_:J/-%M?;OCW]N+]D[X7>)_$WA+XA_&G0?"^J>#+:>Y\53
M3Z5XBU/3='>TB>>[TD7^C:5?6^J>*(8(IWB\):2]YXAO9H9+&RL)[X?9Z_7O
M5_V]/^":7_!.GX7_  9\0?%OX_66BZC^TCX'T7XE^#]2M_ ?CKQ1X_\ &?@7
M6=-&JZ?XONO!/A;P[K/B;P3X"CA:2.VD\166F0K>07<5R9]0M;W[/_,K\0/B
MAJ?P'_X)H?\ !4S]C/X@?LC?$CXE?$GXI?$;Q3\:?#?Q_P!$\%^&[GX.:/\
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M[W4M-L+3Q7XKUWQ)H_AO4+'Q##)J-U8QP:P&O#/JC/%^K$W_  4-_P""K'[
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M>R;5I7'L'_!<3XL?\$"/@;::9_P3Z_;#_8\^)WA231_!?@'XI>#_ ![^Q_\
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M87K6-AX"\)7OA^Z7PWH4FOQZR+^[MH[KF/\ @O#^U1X[_:>^%?\ P;9_M?\
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M7LDLV@:G=6%O<7.ERVSS!Y-TK@'I]%%% !1110 4444 %%%% !1110 4444
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MD)4JDZ<U:5.4H27G%M/\M HHHK0@**** "BBB@ HHHH **** "BBB@ HHHH
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MVSK/<RXVS6E#D4U*I[++<MI3C*%%32O)MM1E4E",98C$5.6,8Q;?LZ,%&/\
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MK>:Y8)/>^(;6PM[;[S,Z9<?U/44 ?PD_L@_L,?\ !QW^P+_P3D\9_L(_"?\
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M ,I/RL_X45\4?^A4U'_OW_\ 7H_X45\4?^A4U'_OW_\ 7K]4Z*/^(EYM_P!
M&7?=B?\ YH#_ %%R[_H+QOWT/_E)^5G_  HKXH_]"IJ/_?O_ .O1_P **^*/
M_0J:C_W[_P#KU^J=%'_$2\V_Z ,N^[$__- ?ZBY=_P!!>-^^A_\ *3\K/^%$
M_%<_\R9J?_?S3A^AOP1GT(!'< \4?\*)^*__ $)FI_\ ?W3O_D^OU3HI?\1+
MSC_H!RW_ , Q7_S5Z_TM7_J+EO\ T%X[_P "P_\ \H/RO_X4-\5/^A3OOQ:#
M^DQ'Y$CT)%'_  H;XJ?]"G??]]0?_':_5"BC_B)><?\ 0#EO_@&*_P#FD/\
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M<_\ ?,G_ ,:K]3:*/^(EYQ_T Y;_ . 8K_YI#_47+?\ H+QW_@5#_P"4>O\
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M7COOH?\ RCU_I:_EH/@'\4#G/AV=/]Y;@Y^GEVTA_, >ASQ2_P#"@OB?_P!
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M?@OP7I46DZ%I46V*%"9+BZN' -SJ.HW3?O;W4;V0>;=W<Q+R/A5V1)%&G:8
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M7997K825>+G0I8B7+1HXG$033GA\+.I'$XB%X\U&E./-&_,M#PIXE_X+(_M
M>&K+XO\ A-OV4OV8_#'B*Q37/!'P;^(WA[QIX]\=7&A7D!N]%/CSQ%I\EO::
M'JFI6LMN]Q:Z=:0SV!=?M5A:3B>T3Z,_8:_;+\8?M!ZI\7_@E\>/AU;?"/\
M:C_9UURST/XI^$-(N[G4O!^O:9JR22^'_'?@/5+G?-<^'M;@C67[+-<7<UG'
M<Z=="\GMM4MA%^A$;1O&CQ,CQ.BM&\95HVC9049&4E61E(*E25*D$'%?#?[7
M_P"U7X0^"?P6_:QU7X9^)O!>J_M!?!3X*ZC\1-1\$0W=A=^*-$%[I:6WA+Q+
MXDT2,F^DTF"2[L;R&2[C:VEMHX8'=89T#>1/+JO#/L,YQ'%F;8FAA:&,J9QA
MLUJTL92SB%+ XC%2_L_"WPU/+<=2J4'B:,,NBJ,L-3KX>IA:D7"M0\&IE-;@
MY8;B#%\<9YB\-@\/CZN?83.Z]#,*.?PHY9B\;)93@^;"4LHS*E5PSQ>'I95%
M8>>#I8G"U,%5C*&(P_V+=>+_  G8ZU;>&[WQ1X=L_$5XJM::#=:WIMOK5TK
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MC"\8<1Y5F/%V*QN7T,PX9P'B!@\CGC:N;U89G@</FV'X;P5'^S\K_L^IAZN
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MMC>Z9J5K!>Z=J-I<V%_97,:RVUW97D+V]U:W$3@K)!<02212QL"KQNRD$$T
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MOVC/VX&_91F_:K^*7Q:^,6N:+I;:5X4\*_"3PSX3O?"WA[1=;MY%\3Z[K?\
M8&A6$4]_J>GV=SIO]F:1I&M ']F]%?@+_P &_?\ P4[^*'_!1OX$?'C2_C7K
M6@?$#XC_ +,7QFN?AG'\<_"?@;7OAEX>_: ^'&KV][J'PZ^*Z?#SQ'IND:CX
M+UK7[+2]536?#S:=IXM1;V,\NEZ7=W5S8P^8?MF?M=?MV?M-_P#!6&V_X))_
ML*_'[PO^QA8?#']FR']I+X_?M+ZI\)O#'QJ\>WHU75= MO#_ ()^'O@CQM/%
MX2%E'%XD\+_VM>WA@O[D:SK,D5]9IH%O::R ?TDT5_+7^VI^WI_P4_\ ^"0?
M_!+?QU\0OVR_B'^SA\=_VHO$?[0FA_ /]F[XT> _!>OZ3H(\*>*+;6;VV^*'
MQM^'MEHNDZ1+XJT?PSX0\1>([?PWX*M)--N-1O\ 1]%U%-3:PO;C6/C;_@F9
M_P %M/B]J?\ P46_9Y_9!\1_M_6?_!4+X,_M1>&_$VGZU\3+G]B_Q3^R%XO_
M &=/C3HN@WWB'2="T^UU'PCX5T_QW\//$D>CW6F6=[<P7>K127D=Y>G0)+!;
M+70#^GI?^"EW[!#_  6^(G[1B?M6?!]_@;\)?B*OPC^)7Q/3Q(K^%/!GQ+>?
M2+=/!>N7ZP$VNNO-K^BHMKY;[O[2M6#%9 U?:&BZSI7B/1M)\0Z%?V^J:)KV
MF6&LZ/J=FXEM-1TK5+6*^T^_M91@26]Y:3PW$#@ /%(K=Z_S*IO^5:W_ (*_
M_P#:8 ?^IY\ Z_T@_P!G/_DWOX$?]D:^&'_J$:'0![+1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XO^T-\!
M?A]^TY\&?'OP,^*%A+?^#/B!HS:7J+6CQPZEIEU#/#?Z3KFCW,L4R6NL:'JM
MK9ZKIMPT4B)=VL8FBE@:6)_:**PQ.&P^-PV(P>+HT\1A<51JX?$T*L5.E6H5
MH2IU:52#TE"I3E*$HO1Q;1S8S!X7,,)BL!CJ%+%8+&X>MA,7AJ\%.CB,-B*<
MJ5>A5@])TZM*<H3B]'&31^+?A#X/?\%CO@)X7L?@S\-/BY^R;\;?A_X>LHO#
M_@;XI_&;2_B!HGQ/\/\ AJR22UT>W\0Z5X>CN](\27^DV*6MO'<7%Y?2W"PQ
M"ZN[C$AKV[]FW_@G'H?@'P'^T.W[1WC>X_: ^-_[7NG7^E_M"_$J:R_L2WO=
M!O=+N=)L_!G@FQS(^A>'/#]M=R_V8ZI!))-!I\GV&RM=,TW3[/\ 3:BOEL'P
M1DV&K8>K7JYIFM/!4JU#+L'G&98G,L'EU+$8>>$JQPU#$2DISEA*E3"*OBWB
ML3##5*M&%:,*M12^+P'ASP_@\1A:V)KYUG=++J&(PV4X#/\ .,7F^7Y30Q>&
MJ8*O'!X;%2E&=2>!JU<"L3CI8S%T\'5JX>G7A3K5HS_%;P/^SG_P58^ ?PNM
M_P!EKX-_%S]F#Q5\)=#L+OPC\-OCS\1=-\?V'QH^'O@.5I(=*L[GPEHT=WX2
M\0:[X7TZ3['H5W)?-;H(+3[3YD,$4,6E\0_^"6M_IG[#?P9_9)^"_C+2[O6_
M 7Q^^'_QM\;^._B U]9R>-]8TKQ!J.O^.=8DBTJVU66#4M5N+V.'1[&1I8K>
MQM+6TN]1EEB>\E_9>BL8< Y$J%;#5IYIC*,LMJY-A(8W,L1B?[+RJM.A.K@L
MN=1MT85'A<-&=>JZ^+G3P]&E+$2I4XP7/#POX9^K5\'B*F<YAAY9/6X?P,,Q
MS?%8S^Q\EQ%3#5*V7Y5*JW*A"J\%@XU,16>(QM2EA</1J8J5&E&"^&/V]_V9
M/&W[4W@#X,^%? NL>'-%O_AU^TW\&OC3K$WB:74(;:[\-?#O4=3N]8T_3VTZ
MSO9&UBZCO8A81SQQ6CLDBSW,(*M5;]N?]EWQQ^TY'^S&G@G6O#6C'X*_M1_#
M#XW>)?\ A))-1C&H^&?!4U])J6FZ/_9]G>;]9N5ND%FEV+>T8JWG7,?&?O"B
MO7QW#>5YA_:WUF%9_P!M4\NIX[DK2AS1RNI*IA/9V_AN,I/G<?C6C/=S+A#)
M<U6>K&4\1+_6*EE5',_9XB=/GADU6=7 ^QM_!<9S?M''^(K*2WO^4W[7/[&G
M[2_Q2_;$^"W[5_[._P 5? 'PXUSX)_"#Q/X5TJT\:Z9K&N6'BKQ)J^O7EU)X
M9\4:5IT,>? OB+0-3O\ 3=5U.PU&/7M&OA9ZGI5I-<6L3+8^&7[*7[4/Q>_:
M8^'7[4G[<OB7X0PW'P'TGQ!9_ KX(_ S_A++_P %:#XH\56J:=K_ ,1?%/B'
MQ@MMJ.KZ\^GPQ0:380V?V6Q9;:<30R6!6^_5&BN*7!F3SS&OF$ZF8S6*S2AG
M6*RZ685WE6)S3"+#+!XRK@;^S<\++!X:I3A%QI3JT:-2O3K3H4'2\Z?A[D%3
M-L3FM2KFTXXW.<-Q#C<JEFF)>2XS.<$L(L!CZ^6W]E*I@IX'"5J-.+A0G7P^
M'JXFEB)X;#.C^9?PD_8O^)/@+4_^"EE[JWB'PA<Q_ME>+_%.O_#A;&;56?0+
M37/ VO>&;6/Q<)M/B$$\5[JL$LRZ6VH)]GBE='9RD9]L_8^_9Y\7_L^_L5_"
MW]G'Q;JN@:IXR\$?#C5_!^IZMH4M]+X?N-1U"[UNXAGLY;VTM+Y[1%U.%9&E
MLXI=R2;8R-N?LBBNS <,Y5EM:C7PL*RJ4,)FN"IN=:4U[#.,SCF^-332O*6,
MBI4Y;TZ?[M76IWY9P;DF48BAB<'3Q$:N&P.=9=2=3$3J)8;/\XCGN8IIK6<\
MPBITI[TJ7[I75FOQC\%?\$M_$%Y_P3<^&'['WQ ^(>E^&?C+\(/&6I_$_P"&
M_P 7? 45]J=AX,^(]E\0_$OC+PGK5G;:G#I%[J%I'8:X=*UBVD6T?,TUU9N+
MBTLY*M^,?@3_ ,%7_P!H7P[H_P %/C'\:?V>?@Q\-H]4T27XA?&/]G.X^)=C
M\:_B!HNBZA:WLMAX=MM1BTO1_ -WK;VJ'4KK3[M(D#/#'!)IKW&DW?[(T5Y/
M^H.10P^&PN&J9K@L-1RK 9)B:.!S/$X:&:99EE)T<%A\R=-J5:5*C*I2>)HR
MP^+G1J3H3KRH\M./B+POX:IX7"8'"5L[R_"8?(\KX<QE#+LYQ>#AG.39-1EA
M\OPF;^QE&5>=&A.K0EC*$L+CJN'JSPU3$RP_+2C0TO3X=(TS3M)MI+J:WTRP
ML]/@FOKJ>^O98;*WCMHI+R]N7DN;RZ=(E:XNKB1Y[B8O+*[2.S'\FOAM_P $
MX?$W@7_@I7X[_:[D\7>'[GX):C_PF?CWP)\-XS?MKGA_XU_%#PIX4\'_ !$\
M436[V":5%;ZKI^AZG,EU;WTMTYU"VA-O$8)I)?UTHKW<UR#+,YGE,\?0=262
M9EA\UR_DJ3IJGB\+&2H.:@U[6C&4HU'1G>G*K2HU&G*E!KZ3.^%\FX@J9%4S
M/#2JSX<SC"9YE;IU)T51QV"C-8?VB@TJV'A.4*SP\[TI5J&'JM<]&#7Y"? #
M_@FSXA^$7_!1'XT?M8:OXLT'4_A-KDWCSQ/\&? -G+J/]I>#/'WQB3PR?B?K
M=UI\UA%I&GK?)I.IZ?;S:9>SSWEG>6[7*1-'(E?0WP=_9:\=?#W]N_\ :X_:
MAU?6O#5UX'^/G@_X.^'_  IHUA+J+>)-,N_A[X<M='U>77(I[*+3XX+JX@>2
MP:SO;IWA9?.2%P0?O6BO/P7!N19?'#1PF'JTHX3B#&<344J\W_PJXW"XS U9
MRO?FH0PF-JX>AAW[E&E"A&.E&)Y>6^'_  SE,<'# 82M0C@>*<PXQH)8FI)+
M.LQP./RVO.?,VYX:G@<PK87#X9_NZ%*EAHPTHQ/Q^_9Q_8O_ &K_ (!)^U;\
M$'\9_!;Q+^S)\:)OV@/&OP]U);7Q5I_Q5T'Q]\8B8M-T[Q'$T,^A/X<TNTDD
MCU&6SFNKN2X1;FT^25K:+[ _8G_9]\6_LW?L;_"#]GGQEJFA:MXO^'_@C5/#
M6K:KX>DO9=!N;V^U?7-0BEL9;ZTL[U[=(M3@1VFM(9/,23;'MVD_8-%:93PI
ME635:%7"/&2>%P>.R_"QQ.+J8B.&P./Q6&QE7"TN?WO94ZV$I+#J<IRI4^:"
MDT]-<CX'R3A^MAJV ECYRP67YEE6"AB\;4Q4,)EN:8W!X^O@J'M$Y*A2KX&A
M]54YSE1I\]-2DI:?$/\ P3K_ &:?&O[(O[)?P[^ WQ!UCP[KWBOPCJ?CR]U#
M4_"DFH3:'/'XH\=^(O%%BMI)J=G87I>&QU>WAN1+:QA;F.41F2,)(WSW^W%^
MR/\ M5_%/]J+]FC]J#]EGQ;\&?#OBOX ^%/B)H4=K\7X/$M]IEY=^/+.?1IY
M5T[0+"<W,$6C:AJ 1GOK.6"^^S3H)%C*G]8J*5?A/*J_#V7\,WQE#+LKCE$<
M!/#XNI1QN'ED=7#5LMJPQ<?WGM:%7"4)\]KRE"[U9.)X%R/$\*95P;S9AALI
MR2GD4,LJ83'5:&8X67#=;"5\HK4\=%.I[?#5L#AJGM+7E.%WN?B/\2/V5/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\NFZC FI7T&G>(9H9M-_M2ST75]$E_9\_P"".OQJ@^)'[6W[9/[;'[2WA?\
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M/Z3]H+X.MXZ_:F_;>7]J;PSX\30O&L?A/PQX8&O?#;67\,:[:-:R:Q/KS?\
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M$VG?_(U '/\ _"Q-%_O2?]^9/\*/^%B:+_>D_P"_,G^%=!_PB?A7_H6?#_\
MX)M._P#D:C_A$_"O_0L^'_\ P3:=_P#(U '/_P#"Q-%_O2?]^9/\*/\ A8FB
M_P!Z3_OS)_A70?\ ")^%?^A9\/\ _@FT[_Y&H_X1/PK_ -"SX?\ _!-IW_R-
M0!S_ /PL31?[TG_?F3_"C_A8FB_WI/\ OS)_A70?\(GX5_Z%GP__ .";3O\
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M$VG?_(U '/\ _"Q-%_O2?]^9/\*/^%B:+_>D_P"_,G^%=!_PB?A7_H6?#_\
MX)M._P#D:C_A$_"O_0L^'_\ P3:=_P#(U '/_P#"Q-%_O2?]^9/\*/\ A8FB
M_P!Z3_OS)_A70?\ ")^%?^A9\/\ _@FT[_Y&H_X1/PK_ -"SX?\ _!-IW_R-
M0!S_ /PL31?[TG_?F3_"C_A8FB_WI/\ OS)_A70?\(GX5_Z%GP__ .";3O\
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M$VG?_(U '/\ _"Q-%_O2?]^9/\*/^%B:+_>D_P"_,G^%=!_PB?A7_H6?#_\
MX)M._P#D:C_A$_"O_0L^'_\ P3:=_P#(U '/_P#"Q-%_O2?]^9/\*/\ A8FB
M_P!Z3_OS)_A70?\ ")^%?^A9\/\ _@FT[_Y&H_X1/PK_ -"SX?\ _!-IW_R-
M0!S_ /PL31?[TG_?F3_"C_A8FB_WI/\ OS)_A70?\(GX5_Z%GP__ .";3O\
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MH **** "BBB@ HHHH **** "H+G_ (]Y?]PU/4%S_P >\O\ N&@#\,?V^?\
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M Z%X_NKC3/!.E^!/$VO);Z'I^M_9[^<O,JBQN+V006S+C\-M9C_;3_X."O\
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M1^%O$VFVVL:%K>FS[5,EGJ6FWEM=P%T201RA98XY R+_ "G?MI_\%/OVR/\
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M=_X.:]7TF\N-.U72O'WP6U+3-0M)/*NK#4+'X%_$FZL[RVE )CN+6YBCGAD
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MWPG\"-.T"ST[1/!6CWGB>0Z)<:C>ZCJ6IZ983&^^R:OJ%M?Z4 ?V'45^$_\
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M'_\ 3SJ] 'U?^Q)_R)]I_P!<X_\ T$5^@E?GW^Q)_P B?:?]<X__ $$5^@E
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M+_'7B^^D\!:[?)=:?K>N^)K+0/#EG?:B%TRS\*WJ6]A##<0/7]XU% '\%/\
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M#Q-XG\#:I!K-YX9AU'Q5=>%O!7Q"\-:5J.L6.GVFKVWC#P6H\Y]*NIO[,Z*
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M]T=-N-+\1!]/GUO2I[B72G#:GI[S2VT.[\+/V%/!W[2_[-7['OA#]CSX%_\
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M (*,?LE?L\_LH6GPD^)'[)O@Y/"7BWQ5\*OCK-H\$D?Q7@^$/C#5;3PO\3)
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M ,S]%% !_P )MX]_Z'75_P#P7^&/_F?H_P"$V\>_]#KJ_P#X+_#'_P S]%%
M!_PFWCW_ *'75_\ P7^&/_F?H_X3;Q[_ -#KJ_\ X+_#'_S/T44 '_";>/?^
MAUU?_P %_AC_ .9^C_A-O'O_ $.NK_\ @O\ #'_S/T44 '_";>/?^AUU?_P7
M^&/_ )GZ/^$V\>_]#KJ__@O\,?\ S/T44 '_  FWCW_H==7_ /!?X8_^9^C_
M (3;Q[_T.NK_ /@O\,?_ #/T44 '_";>/?\ H==7_P#!?X8_^9^C_A-O'O\
MT.NK_P#@O\,?_,_110 ?\)MX]_Z'75__  7^&/\ YGZ/^$V\>_\ 0ZZO_P""
M_P ,?_,_110 ?\)MX]_Z'75__!?X8_\ F?H_X3;Q[_T.NK_^"_PQ_P#,_110
M ?\ ";>/?^AUU?\ \%_AC_YGZ/\ A-O'O_0ZZO\ ^"_PQ_\ ,_110 ?\)MX]
M_P"AUU?_ ,%_AC_YGZ/^$V\>_P#0ZZO_ ."_PQ_\S]%% !_PFWCW_H==7_\
M!?X8_P#F?H_X3;Q[_P!#KJ__ (+_  Q_\S]%% !_PFWCW_H==7_\%_AC_P"9
M^C_A-O'O_0ZZO_X+_#'_ ,S]%% !_P )MX]_Z'75_P#P7^&/_F?H_P"$V\>_
M]#KJ_P#X+_#'_P S]%% !_PFWCW_ *'75_\ P7^&/_F?H_X3;Q[_ -#KJ_\
MX+_#'_S/T44 '_";>/?^AUU?_P %_AC_ .9^C_A-O'O_ $.NK_\ @O\ #'_S
M/T44 '_";>/?^AUU?_P7^&/_ )GZ/^$V\>_]#KJ__@O\,?\ S/T44 '_  FW
MCW_H==7_ /!?X8_^9^C_ (3;Q[_T.NK_ /@O\,?_ #/T44 '_";>/?\ H==7
M_P#!?X8_^9^C_A-O'O\ T.NK_P#@O\,?_,_110 ?\)MX]_Z'75__  7^&/\
MYGZ/^$V\>_\ 0ZZO_P""_P ,?_,_110 ?\)MX]_Z'75__!?X8_\ F?H_X3;Q
M[_T.NK_^"_PQ_P#,_110 ?\ ";>/?^AUU?\ \%_AC_YGZ/\ A-O'O_0ZZO\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img81402019_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img81402019_3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" , !00# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ5XV5KL,&1P5(8 @@@@$8I3\3?AR 3_PGO@\8!.3XCTC ]_^/OM7^4S\2O\
M@B)_P7FUGXE?$;5=&^$_[0DFCZCX]\87VE3P_$77H+>ZTV\\0:A<V-U;1)K:
MHEO<6TL4L*JJA8V4 #&!Y7XM_P""+7_!=OP-X4\4>-O$_P ,_P!H/2_#?@[P
M]K/BGQ!J,OQ*\1&.QT30-/GU35;QPNN$E+2PM;BX<#G9$V* /]=[2]9TW7+6
M.^T34=/U;3Y"Z+?:==P7EN70X($D$CQD@_>4-D<'H0:TD<,#@D[3@MC )]O7
M'Z=Z_P M'_@TN^,7Q=\7_P#!73P;X7\5?%?XE>)O# ^ _P <+X^'/$'CKQ/K
M.@R75OHVF"WN)-'U+4[G3VN(&D:2";[.)8G^9'!)S_J7J",YQC.5XP0#V(X&
M1[4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH B;Y7#*HR<!G)P%'N,CKV_KTKXN
M_P""@_[8W@W]@G]D?XR_M0^,U22U^'WANXDT6P=@/[7\4:B/L7AO3]I.7CN=
M5EMUE1 9'B5T0%W6OM%X4<@G/#!B <!B.FX?Q8]#7E_QA^!WPB_:!\#ZE\,_
MC;\//"_Q0^'^L/;R:IX/\9:7!K.@WSVLJS6S7-A< PR^1*HDC#@A7 8#- '^
M1A\!_P#@J#\ _BC^WAXL_;H_X*Q?"WXI?M>:S'>IJWPU^%OAC7-#L? _A^^@
MO9KG2M/U.QU^>W$F@>&E-K)H]A9NJSW< FODD 14_LX_8O\ ^#LO]D7]IS]H
M/X'?LI> /V1?C-\-[KXI^*M*^'_AC4+S7/  \,>&Y+I)1:M+I>B2"5;*".%@
M8[2%3M '7"U^X7_#G'_@EB>O[!7[,YZ#GX::*>!T',7;MZ5V?P\_X):_\$Z_
MA+XRT'XA_#/]C3X ^!_''A>^BU+P[XI\.> -)TW6M&OX?]5=Z?>P1K+;SI_#
M(A!% '\9'_!SM^S5\<_V2/\ @H?^S]_P5+^#/P\UCQ5X/M;G1;_Q;XBLK.6_
MT_1_'GAB:46NF:U#IZ/=6-A?>'8IC'J=RJVHD/EO("I4_%G_  5O_P"#@O4O
M^"QWP-^$G[&?[-_[-/Q$\,>)O$?B?0V\:QZK>:?XCN?$VMRKI^GV%EX:L?#G
MGSVNG+KLB2M<:H@$-O*IGD7;NK_37\:>!O!WQ&\,ZMX,\>^&=%\7^%->M9++
M6?#_ (AT^WU32M1M9D,<D-U9W2212*Z$J3M# $X85\K_  >_X)R_L)?L_>+X
M_'_P5_9/^!_PT\:Q(Z1>)_"G@72--UB-78NVR\2%I$)=BP92&5CN4@X- 'Y#
M^'/^"2'B*Q_X-_1^P!<Z'+#\9+GX/77BZ[\.>;;.Q^-']GG4UT:.XR8,2ZE#
M!8B8G*/(3GBOY1/^"1?_  7L\2_\$3OA3\8OV,_VIOV8?B/X@UC0_%>L7O@N
MPL'L/#&J^&_$BS:A::S9^(X?$?D'4=$EU14>WN]($BRPQ$PR.CK(?]0/:,YR
M<]CGIZX] <<U\??&W_@GS^Q%^TCXKB\=?'G]EOX+?%?QC#;K:Q^)/&O@?2-8
MU<0*P81M>30^8XW*&)<LQ8;B2>: /X>O^#:GX"?&_P#;A_X*;?'K_@J5\6_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:_VS?\ DT']
MJC_LW/XV?^JV\2U]*5\U_MF_\F@_M4?]FY_&S_U6WB6@#_,;_P"#0O\ Y3(^
M#O\ LWWX[?\ IFTBO]7BO\H?_@T+_P"4R/@[_LWWX[?^F;2*_P!7B@ HHHH
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M8R>.?$>A)=W$UM9WEQ%#;F222"UN945HX)67UWPOXM\*^.-%M/$G@OQ-X?\
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M_P#*9'P=_P!F^_';_P!,VD5_J\5_E#_\&A?_ "F1\'?]F^_';_TS:17^KQ0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%,4V?.P
M520I)ZDD\ ?[1/ /4=14M,>-),!QD#(QVYZY_P >H[4 ?F7_ ,%8/^";/A;_
M (*H_LIO^RWXM^*6O_"327^('A3Q]_PE?AS1=/\ $.H&7PHNHB+3)-.U*YM+
M9X+K^T TDWGB2)H$*!LD'_,B_P""\'_!'SP5_P $??B[\"OAEX*^-/B?XT6G
MQ@^&^O\ CR]U/Q/X9TOPS<Z)/HOB1]"BL;:#2KR\ANH+B,?:&GDD61'!38%
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M&@!C$:,T:Y!.T]1G)7G^]W)S[8H E0$(H( (4 @'(! Z GG [4ZD    X
M'L.!2T %%%% !1110 4444 %%%% !136;:">!]?_ *U1B0L <KSCD=/U[?K2
M;22;:5VTKM*]E?KY";:?PR:T]Y)N.]K-]UI?LFF3456>8HX4D $X'&0?\.?4
MY/:A)V).]0@R< G)('.Y<9XQUSCZXSAV?NV3:DFU)*ZTMNUMO;U').*BVFU+
M1-:KYVVMUO8LT5")1SD@$ XR#R1Z_P"1]/2 W+B4J5"IP%?@AF(R% &6 Z@D
M^G!HA[][:6ONTKVLGRZZZNVG4:5W))Q;BKM<ROTV6[>O0NT5!YC[P,#:3@'L
MQQG@]OQJ>HA-5%S)22NTN96O;2Z[KS%W\G8****L HHHH **** "O\YS_@ZP
M_P""'WQ"\*_%SQO_ ,%/OV7/!.H>*_A5\18O^$A_:N\%^$]&@EOOA5XXTVQM
M;74_C-%IFE1)=WG@7QY;6W]M_$35OL5U/X9\;1Z_XN\1:H^D^+0= _T8Z:Z)
M(C1R*KHZLCHZAD=&!5E96!#*P)#*0002",&@#_ )HK_9#^+G_!N3_P $5OC=
M\0/$'Q.\=_L)>"+?Q7XHN4O-9'P\^)'QU^#7A::[2&.%[JR^'_P>^*7@3P!I
M%Q=>7]HU";1_#-A)J5])<:CJ#7-_=7-S+YN/^#7+_@A0""/V&1D$$9_:8_;"
M(XYY!_:!((]000>A!% '^:9_P2<_X)2_M"?\%7?VE-!^$/PKT75M"^%.@:GI
M&H_M ?'>XTN:;P?\'O D]P\EU/-=RB*RUCX@>(K2TO[#X=> X+E=2\3:S')>
M79TGP?HGBWQ3X>_V8/@E\&OAW^SQ\(/AI\"OA)X=MO"GPR^$?@CPW\/O WAZ
MU>:9-,\->%=*MM(TN&:[NI)KS4+UK:U2;4-4OY[G4=4OY+C4-0N;F]N9YY,S
MX"_L]? []ESX8^'O@S^SO\*O _P;^%_A:W2'1O!G@'0+'0-)2;R8(+G5=0%I
M&MUKGB+5/L\=QKOB?7+C4?$7B"_\S4M<U34-0GFNI/8Z "BBB@ KS_XI?"7X
M5_'+P-K?PO\ C7\,_A]\8/AIXE.G'Q'\._BEX,\.?$#P-KYT?5;+7=(.M^$O
M%FFZOH&JG2];TS3=9TXWVGS_ &'5=/LM0MO*N[2":/T"B@#Y?^"O[$'[%O[-
MGBJ^\=_LZ_LA?LO? +QOJ>@7?A34O&7P5^ /PH^%GBK4/"]_J&EZM?>&[[Q#
MX&\)Z%J]WH%[JNAZ+J=WH]Q>2:=<:AI&EWDUL]SI]I)#]0444 > _&G]E']E
MO]I**Q@_:)_9K^ /Q[ATNXBN]-A^-/P<^'?Q3BTZ[@@N;:"ZL8_'/AS74M+B
M&VO+RWBFMQ')'!=W,2,(YY5?UWPMX1\)^!]&M?#G@KPQX>\'^'K$$66@^%M%
MTWP_HUH"%!%KI>DVUI8VX(501% F0J@\ 5T-% 'S!X<_8B_8O\'_ !EN/VC/
M"/[(G[,'A;]H.[\0>*?%EW\=O#GP"^%.B?&6Z\5>.8-7M?&WB:X^)^F>$[7Q
MM-X@\86WB#7K?Q3K,FN-J/B"#6]7AU:YNX]2O5FZ'XY_LH?LM?M0+X77]I?]
MFKX _M$+X(.M-X+7XY_!SX=_%M?"#>)!I0\1'PN/'WASQ - .O#0=#&M'2?L
MAU0:-I0OO/\ [.L_)]^HH \ \>?LG?LL_%3X5>#/@5\3_P!FGX ?$?X(?#C_
M (1W_A7GP<\>?!OX=>+_ (5> _\ A$- O/"?A+_A#/AYXA\.:CX1\+_\(OX6
MU#4/#7AW^P](L?[$T"^O-&TS[-IUS-;/WWPL^$OPJ^!G@71/A=\$_AG\/O@]
M\,_#1U-O#GPZ^%G@SPY\/O OA]M:U>_\0:RVB>$?"6FZ1X?THZMKVJZGK>IF
MPT^W-_J^HW^I77FWEY<32>@T4 ?/_P :OV3?V6/VDUT]?VBOV:/V?_CXNDS+
M<:4OQJ^#7PZ^*:Z9.D4UND^GCQSX<UT64R07$\*R6WENL4TT88)(ZM[)X<\,
M>&_!^D6GA_PEX>T/PMH-@I2QT3PYI-AHFD62$Y*6FFZ9;VME;J3R5AA0$\XK
M<HH ^8/#G[$7[%_@_P",MQ^T9X2_9$_9@\+?M!W?B#Q3XLN_CMX<^ 7PIT3X
MRW7BKQS!J]KXU\37'Q/TSPG:^-IO$'C"V\0:];^*=9DUQM1\00:WJ\.K7-W'
MJ5ZLWTCJ>EZ9K>GWFDZSIUCJ^E:A ]K?Z9J=I;W^GWUM*-LMO>65U'+;7,$@
MX>&:-XW'#*15ZB@#YN^&W[&W[(7P9\7:[\0/@_\ LJ_LW?"GQYXHOCJGB;QM
M\-O@;\,? OB[Q%J9N;V\.HZ[XD\+^%]+UG5[XW>I:C=&[U"]N+@W-_>S^9YM
MU.TGTC110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RE^
MV]\3OVD?@[^R[\4_B!^R%\"+;]I?]I+2X/">E?"?X,7WB:P\'Z9XGU_Q=X\\
M+^#KK5-8\1:K<V&FV.A^!M$U_5?B!KD=]JNB6U_I'A:]TV;Q!X?2\.M6'X >
M#_\ @WD^*G[;OC2T_:$_X+I_M<^-_P!K#Q[-YU]X<_9:^"WB+7?A=^S#\'(-
M0D:Z_P"$<T*XT0Z)XCU=M+BNKC23J_AJU\"ZK>Q11R>(/$7C:Y4:M-^M_P#P
M5E_X*9>#/^"6_P"S):_&;4_ 'B#XR?%/XB^/-#^#?[/GP2\*B]76?BG\7O%5
MKJ-YHVA27>G:9K5[IFCVMAI6H7^I7MKI&I7UW-%8>'M'L;O7M>TFVF_$SQ1_
MP<&?\% ?V!O!'C/6/^"QG_!-W2?V<]4\<?#KXC>+OV0/$OPF\=)XL^'_ ,4/
MB1X:MX[_ ,)_L_?$N[\(^)?CG)\-O%>N66HV#7?C#7M5T1X8=+US4Y/AS86@
M,6G@']$W[/W_  3M_81_95M'M?V=_P!D/]GKX33SQ64-]K?A3X5^$;?Q;JT>
MFF8Z<-<\:7.F77B[7C8-<W,EF^LZW?/;2W5U+"R27,[2?8<5K:P6ZV<-M;PV
MBQF);6*&..W6)@0T:P(HB$9!(*!0I!((Y-?R P^,/^#N7P=X/B_;B\6W/["O
MC#P!8>!+3XA>)O\ @G7I&@S:1\08?#=O;6_B/7M)TO4T^'LWB*U^)-MX?M[V
MTBT<?M/^+(X=0F:RM/#'B+78[;29?Z+O^"=W[</PU_X*,_L??!S]KOX66=YH
MVA?$_1;P:UX4U-VEU3P1XX\-ZI>>&_''@V_N&M[47S:!XETS4;2QU:*V@MM=
MTG^S]<LXUL]2MQ0!V?QU_8?_ &./VG=)71/VA?V6_@'\9+".4W%J?B#\*O!G
MB2_TZZ^SSV@O=(U?4-'EU?1[]+6YN+>.^TN^L[R**:5(YU5V!_ ;XL_\&RG@
MGX,_$6^_:3_X(\_M5?&'_@G)^T/:P-+I_A>T\0ZI\1OV>_$\WVW4;V31_%/A
MOQ*=8\4QZ'J"ZB;*73-9U'X@^"=-M;'3WL?AM)<1W,EU_4[10!^?O_!-WXC_
M +>?Q ^!7B73_P#@HW\$O!7P;_:,^&'Q6\1?"^75?AKXEL_$?P\^.W@O0?#7
M@W5M ^/W@J*TEG;PUH7CF_\ $&N:7%X6U"9=6TR[\,7<VJ:9X;O;R;PKH?Z!
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S7^V;_P F@_M4?]FY
M_&S_ -5MXEKZ4KYK_;-_Y-!_:H_[-S^-G_JMO$M '^8W_P &A?\ RF1\'?\
M9OOQV_\ 3-I%?ZO%?Y0__!H7_P ID?!W_9OOQV_],VD5_J\4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^;Y_P>[?\G8?
ML4?]F]>-_P#U8\]?Z0=?YOG_  >[?\G8?L4?]F]>-_\ U8\] ']@'_! /_E#
M9_P3Z_[()I7_ *?=>K]@Z_'S_@@'_P H;/\ @GU_V032O_3[KU?L'0 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0$^('P]UGQ==^!;6.Z\&KJ%SI>OQR3ZW-=K9 '^@S17^9]^P7_P3F_X.1_\
M@HE^R;\,?VQO@C_P6%^(GASX:_%@^.U\->'OB?\ \%!_V[M#\?6S_#[XA^+O
MAGK":QIOA?P5XS\-VK7FO^#-3N=*-IXKODFTFXT^XO6L+N6YL;3ZN_X)6_\
M!83_ (*B?L=_\%;M._X)2?\ !5/XH)\7M-\7>.-*^"#:UXZUKPMJ/B+X<_$;
MQ'X?BUSX.^+?!OQ*TK1['5_B#X<^,?\ :_@[1(O#_CF\FUFX3QEX;UBP;P[X
MCT_7O#'B8 _T$Z*_D9_X.>_^"X_QV_X)J6_P<_9B_9#U'PQX8^//QL\&:[\1
M_&?Q,UG2[+Q+KOPP^&::O=^$?"LO@SPSK-G>>')?$/C7Q'I/B](_$?B"VU6U
MT"T\&7<%GH-YJ.M6^K^'_P D/C-^Q%_P=>?L@_ KXC_\%"/$W_!2+5O$@\ _
M#JX^*/Q&^#&G_M-_$?Q_X@\*>#M-M[+7?%]\GP9^(GPRB_9DCN/ VB:;<:YX
MBM/"FL7%P=)T[6[3PT-=NK^;3-3 /]%6BOY[?^#=/_@KWXO_ ."L7[*'C;4O
MC='X3M?VFOV?O&5CX/\ BN/!]C%H>D^)_#?BFSO-4^&_Q$B\-#4M1ET&7Q';
M:5XCT'5((OLVD7GB/P=KU_H=KI^GW":/I?\ -]^T-_P1T_X.;_V=/@;\<OVB
M?&?_  67U_4O WP)^%'Q,^-/BO2?"G_!1#_@H%>>*+_PI\,/"&M^.==T[PW8
M:K\,-#TBZU^ZTC0[JVT>TU+6](TV?49+>&\U73[5I+N$ _T4Z*_R@?\ @E+\
M.O\ @OE_P6"E^.\/[-'_  5I_:!\#M^SU'\,I/&A^.?[>/[9WAE=37XK-\0%
M\.CPN? -C\33>FR/PXUS^VO[5&BBW%UI7V$ZCY]X+'^_O_@BG^R#^W[^Q;^R
M_P#$+X8?\%&/VH?^&LOC3X@^/?B3QYX4^(?_  NSXT_'?^Q/A?J7P]^&/A[2
M/!G_  EOQT\,^%?%>F_8/%?AGQGKG_".Z;I\_AZU_P"$@_M*UO)-2U;58+<
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M6$;FEMY4U-]"V1JAQLETZ8R8(W,ZG;TX^4?V9O\ @H]_P;2?VK\,O@Q\7?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBH9B54,&*@9W$'^$C!..Y Y4 'F@":O\WS_@]U_P"3L/V*/^S>O&__ *L>
M>O\ 1Q3S,H2X4%@(4!"L5;@M+G.2QY4#![=J_P X_P#X/<O^3L/V*OG4D?L\
M^.055@77_BX<Q^=>JALD@G@KG'W30!_7_P#\$ R/^'-G_!/KG_F@FE_^G[7J
M_8.OQB_X-_-;TG4O^".'[!MMIFI:5JUSI'P0TFQU>STN_M;NXTJ[.N:VYM-1
MA@EDDL;U$;S)+>Y6.4#+!-O-?L;*TJDA02 .900SLF"':,#^.-2"<@Y)X'&:
M -"BF1XV)AF8;1AFSN/'5L@')[\=:?0 4444 %%%% !1110 4444 %%%% !1
M110!_)I_P1-_Y3'_ /!;7_LH.E_^I=K=?UC#JW^Y_05_)S_P1-_Y3'_\%M?^
MR@Z7_P"I=K=?UC#JW^Y_05_2?TL?^3LTO^S;>$?_ *[+A<\;)/\ =%_V$YA_
MZF3)%Z#Z#^5+2+T'T'\J6OYJA\*^?YL]D****H HHHH *HZEJ>FZ-93ZEK&H
MV.E:=;>7]IO]2N[>QLK?SI4@B\^ZNI(H(O-GEBAC\R1=\LB1KEW4&]7P)_P5
M"_8]\2?M\_L+?'/]DKPAXQT/P!XB^+*?#=-.\7>)+"_U/1=(/@?XN^ ?B1=&
M]L=,9;Z?[=8^#[G3;?R"/+NKR":3]S'(*^FX+RK(<]XQX3R3BGB*/"'#&<\3
M9#E7$?%D\!6S6'"^0YAFF%PF;\12RO#U*6(S*.29?6Q&92P%"K3K8Q89X>E4
MA.I&2QQ$ZM+#UZE&E]8K4Z-6=*@IJ#K580E*G24VFH>TFE#G::CS7::1]A?\
M+/\ AI_T4/P-_P"%;H'_ ,L*^*_V]_\ @IG^S%^P!^SWXG^.7Q&\;^'/%.J6
M\,^F?#GX7^%O$^BW7C#XG^-Y8&;2_#6C06\U[+8:<LGEW7B;Q//9W%AX8T59
M]0F@OKUM.TC4_P"1/_B#K_:4_P"CQ_@=_P"$)X]_^/5_-Q^WE^PA\>O^"=_[
M0/B/]G[X]:&L&IZ>/[4\'>--)BO'\&?$SP;<RNFE^,O!FI74$!O--N]CVU_9
MRJFHZ#K%O?:'K%O;:E8W$*_Z\?1]_9]_0]\8?$/+LCX4^F=3\5991[//\]X#
MRKPXS'@G.,_R# XBBL=AL#F^=<0SJT:4W4I4<?B<KP&/QF#PM:56,<+.5/%4
MO@<UXKX@R_"3JU^'7@?:7I4L5/&0Q-.E5DO=E.G3HV;T;C&<X1E))7E9Q>+^
MVW^VK\<_V^_V@_%_[1/Q\\1-JWB?Q%+]AT#0+)IH?"OP\\&6<]P^@> _!6ER
M22+I?AW0XKB4J"TM_J^IW.I>(=>O-2\0ZQJNIWGR3117_2#P[P[D7".0Y/PO
MPQE. R'AW(,NPN4Y+DV68>GA,ORW+<#1C0PN#PF'I*,*5&C2A&,4E=V<I.4G
M*3_'ZU:KB*M2O7J3JUJLY5*E2<G*<YR=Y2DWJVVS^R+_ (-X?^"[J?!VX\)?
ML&?MF^,UB^$=Y+:Z#^SU\9_$]^_E_"^_N)!!I_PN\<ZO>2LL/PXO9'CM?!FO
M73QP^ ;MH]"U*9?!=S87'@W^[4?%#X:$9'Q$\#$'D$>+= P1Z_\ (0K_ !5_
M W@?7?B%XAM_#N@I:1RM!<ZAJ>JZI<KI^A>'=#TZ(W&K^(_$6J2*T6F:'I%H
MKW-]>.KOM"6UI!=7]Q:VD_[R_P#!._\ X-U/VH_^"@WPGUCX[Z/\1?!OP7^$
M5WX@N](^%'B?XB>&O$\E_P#%_2--NKRSU'QEX>\/6"QW^E>%$N;>*TT_4=5=
M'U:\^WQ6<!@TYKF?_&#Z=7T!/HOXWBW-O'+B3QPP/T;\%G=?"?ZWX'_5!\4Y
M/G?%6;XBNL-FF597@,XRG'8'-\YCA\;B\TP& P^81S"6"S#/_8814,XQ=7]%
MX8XJSN-"GEE'+)YQ*FI?5Y_6/85*="FH\U.I.=.I&5.G>,83FX<G/"E>5Z<5
M_ISZ1KNB>(+5[W0=8TK6[-)FMWN](U"TU*U2X1$D>![BRFFB69$EC=HBX=4D
M1BH#J3JU^1W_  1A_P""</C;_@E]^RKXK_9[\>?$CPM\4=8\0_&SQ5\5(/$/
MA'2M6T?3+?3_ !!X0\!>&X=*EM=99KIKRWG\'W-S+,A\AXKR!% >.2OUQK_G
MV\2<@X4X6X[XHX>X&XRAXA<(Y3FM;"9!QK3RG$Y%#B3+X1@Z69QR?%UJ^)R]
M592E'ZO6K5)QY+N3NC]6P=6O7PM"KB</]4Q%2FI5<,ZD:OL9O>'M(I1G;NDD
M%?!/_!57_E%[_P %(?\ LPG]L'_UGKXB5][5\$_\%5?^47O_  4A_P"S"?VP
M?_6>OB)7Q!TG\>'_  8R_P#'Y_P4^_Z]OV,?_1O[5=?HC_P>G_\ **WX'_\
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M07O[4?P)G\9? V2YTF"U^RW+>(?#>O>*KBS>PU#7;V6XOHM1O_JW_@YBOO\
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MFN['6(K7^P[_ (*J?\HO_P#@I!_V85^V#_ZSU\1* /X[O^#&7_C]_P""GO\
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M*&"&)#)+--+(52.*-%9Y)'941%+,0 34M?CS_P %_O&OQ>^'O_!'#]OGQ/\
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M$VE^(?#/B'XK>#])UO1=0MVVSV&J:=?:K!=65]">);:>))8SPRBOKNO\VO\
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M[I5D*;&_V!OV#/VR?AS^WO\ LN?##]IGX:&*'1_'FCQ/K&CP727D_A3Q5%!
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M"<P_]3)DB]!]!_*EI%Z#Z#^5+7\U0^%?/\V>R%%%%4 4444 %%%% !7YS_\
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MU9I_#VM7$8FF\)>*VM8I+W4_AUXJN(+>#7;*-+B[T:Y%OXDT6":_L9=/U/\
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M.?A(WB]?#9U4^'5\4'P#X;\/G7QH)U[7#HHU4W8TLZSJIL?(_M&\\[Z!HHH
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M **** "BBB@ HHHH **** "BBB@ P/04444 %  '0 ?2BB@ HP.N.?6BB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #71)%9'571U9'1U#*Z,"&5E((96!(92"""01BOYV/V[/^#<']E/]I#Q
MYJG[1O[(_C_X@_\ !.+]L&>34=1C^,_[,-]J'A/PYX@US4I[J_O]2\8^ /#&
ML^$634M6U*X^V:OK_@+Q)X&UK4[O_B8:[/K]PH1OZ*:* /XE]7T3_@\5_83U
M.ZTCPIXA^!7_  4K^&J2O!HFN:I;_#'4M6TC3=)N#%I\VMVFLWW[.GQGO=:\
M46$\,FK6RZY\2[+3+G39XX/$%O-+_:6N>'ZC_P %N_\ @ZVT+Q/_ ,(#??\
M!&WPW>Z\E]9:.VLZ=^P]^VCKOAA[S4A;_9KK_A/_  [\?;OX;M8P_:XC>ZO%
MK8T/2S'<#5+FU^QWHA_O8HH _B!M_&?_  >6?ML31>%K3P+\ ?\ @GSX7F@D
MNK_XA7%E\-/"<-P/+2U30I;?7/$'[3?Q@T^>Y6]?4X[[PWX+TXVTFE/%-K]E
M*\&GZC]V_LF?\&POP2TKXE0?M*?\%0/C[\2/^"GW[23$N'^,^H:[/\&]%B-Y
MJM_#I9\(^(=>\2Z]XXTZPO-8OKBSTSQ3KL/@6.6XFDM_AU9.VX?U(T4 9^DZ
M1I6@:7I^AZ%IFGZ+HND65MIVE:1I-E;:=I>F:?9Q)!:6&GZ?9Q0VEE96L$:0
MVUK;0Q001(D<4:HH4:%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\U_MF_\F@_M4?\ 9N?QL_\ 5;>):^E*^:_VS?\ DT']JC_LW/XV?^JV\2T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQZCTS]1S2]* "BHO.7+#!^4 @\?,",G&2"<9Y_.GJZOD \KC<.X)Y&>WY$T
M.KY>_;<_Y,V_:P_[-P^-/_JN?$E?4/2OEW]MD[_V-OVK\=_V<OC2BY_B_P"+
M=>(P"/8DXSZ@T ?YF7_!H1C_ (?%>'.2#_PSU\;^,9!7['H&<GM@[<>M?T??
M\'<O_!3.W^!7[.FD?L+_  WUYHOB1^T%:O?_ !$?3Y][Z1\,;69XKS2+TQL'
MMKK6KEK5X@Q#FV42* ,FOY>?^#6OXK>#O@5_P4Q\1?&CXA:G%I'@CX8?LG?M
M">,/$M]+)&C)IFDZ7H5Q/' )&7S;B15(AB4EG<  &OGS5]0^-/\ P7F_X*_0
M?)>7#_&OXK1:5!-9QW%SI7@CX3:)?-;V5_<AQLL+-=$MX3=.52,7MYCD8:@#
M^H+_ (,]/^":L'AGP5XT_P""A?Q/\+HNM^+VG\%? V75K)7>/P["$?6/%FCM
M,I-O)?3^=IB7$.&F@5L$@9/]VD88!BRA"6)P#G.>Y_VCU/4^O2O)/@7\%O!7
M[/OP>^''P5^'>C6.@^#?AIX5TGPUH6FV$?DVT*:?;+'/,J*!E[NY,]W,Q +2
MSN<#H/7%0*21U8DGDD9.,XSVXH ?7^;Y_P 'NW_)V'[%'_9O7C?_ -6//7^D
M'7^;Y_P>[?\ )V'[%'_9O7C?_P!6//0!_8!_P0#_ .4-G_!/K_L@FE?^GW7J
M_8.OQ\_X(!_\H;/^"?7_ &032O\ T^Z]7[!T %%%% !1110 444A.#T)]P,B
MIE.,+<SM?1:-];=$ M%0R3"/HK.VY5VKUY.,DG P.I]N1FI P.2,X7.3C@XZ
MX]:INR3?VMO/^KK4!U%-# ^WU--:15^@!)/0<>_3_(-*Z;:ZIV:ZW:O;UMK8
M3?+J[K6VSW?_  Z^\<Q(''?OZ5&1DCGG@GC&,XYX^O6E$BNH8#(.#C.#@YP?
M6FA223NX Y'/&!TY^G:H4KVG3C?5IR>WV;+JTXO66EFN^EE)II1:O>S>RT=K
M-W:]4EK]Y$SE6P&7:"-P(P0O'.1R2>H&/:OSH_X*1?\ !27X)_\ !.'X):K\
M2?B5J<.H>,M2M;BU^'/PZL72;Q#XLUYT9+*&*P5O.2Q%R8A/=  *I;D[3C]#
M-1^U"UN_L7EB^:UG^Q/*?W<=YY+_ &5YO6(2E"XY.,XK_+N_X*I>#_VUM4_X
M*#_$'Q%^WY+<M9>#1?>)O US92RGP-)X"M;R8>&&\'Q2N8RDEPMM!>,46X-Q
MYH(V!0/Z<^BCX+\*^+_'6/H<8\68#*<JR/!QS%\/8K$/#9SQGCXSG#!Y#D:5
M-I1Q%>$*>,JJ<:M.C6IPI1YZRJT?E...)H\*Y++,5!3=_8T5[J4\3))4J,;N
M/-5K3:ITH7O*35TU&Q]%_L3_ /!4+QM^QW^UK\8?VT/$.@V6J1_M->);;QA^
MTS\,[!4GU'1?">NZG-<://X>EXF_M7PXT\U[>6J*#*)#%)\I(/\ H4? ']H#
MX4_M0?"CPE\9_@GXLT[QC\/_ !AID&H:9J^GW$<LEK*\*2S:7J=NCL]GJ=BT
MGDWEI-AXI5(RP*L?\>3PY\6+S_A:][XJU;:VF>+)[K3=:L6!E@32]1 M;E4C
M8%1+!;?/;IC:'P0 37]5W_!N7H/[;GPK_:"UWPU\'M4'B7]E[Q5>QZIXR\&^
M));P>&O"FB3;C;:];W ?99>*)K5P^G65@!!>-O\ MN<XK^X?IB?1*PN59+C.
M+\XXCRW(^+,NX7P6>Y)A,SJ4LOPN><'95@\+A/["K5$H>SS[)(RPN695:\<7
M0P[P]>2E[*=/\E\,>*LXP.;U>'L\Q%3'2S;GS;+>>\GAJLI)XS"4]6I0P]6:
M5KOFIM23;34O[T4:/SMI!,A )/.W_!2>P'KD5HUE>2HGA*R$QJS (>AD))!+
M#DD#( ^[C' .!6K7^0D7!W]G":BG;FDE:=K+FB[N372\M;JVUC^AER*ZA3=-
MWO.+M9R:3<E;2S\K;;!1115#"BBB@ HHKBOB)\1?!'PF\':Q\0?B/XDT[PAX
M,\/BP.M>(M6>2/3].&J:G9:+IYN'BCED'VK5-1L;&+;&V9[F,' )88XC$8?"
M8>OB\77HX7"X6C5Q&)Q.(JPHX?#X>C"52M7KUJDHTZ5&C3C*I5JU)1A3A&4Y
MR44VL,5BL+@<+B<;C<30P>"P="MBL7B\56IX?"X7"X>G*MB,3B<16E"E0H4*
M4)U:U:K.-.E3C*<Y1C%M=K17Q3_P\:_8>_Z.3^'/_@9J/_RNH_X>-?L/?]')
M_#G_ ,"]2/\ +3:^5_XB'P!_T7/!_P#XDV2__-I\5_Q%/PQ_Z./P'_XE_#W_
M ,\3Y(_X+)?M4S?!?X$6/P=\(:Q+I_Q"^-TLUG=W&GW3V^HZ%\.=(EAD\0WJ
MRVTZ7%G+XDO6L_#-H98C!J&ER^*DBD6XL,KO?\$>_P!J+_A>'[.4?PQ\2:C]
MI^('P'^P>%9S<2[[O5? -S%+_P (/JIW'=(=/M;2[\+7 3S&C70K*YNI/-U)
M-W\V?[;_ .TE??M4_M'^/?BGYUP?"YO/^$:^'=C<"1/[-\ Z!+/;:"@MY<O:
M7&K;[KQ'JEMN9(M9UO4A&?+* =!_P3__ &F&_98_:9\#_$#4[ZXM? NK22>"
M_B5%$))(W\&>(988KG4);>(22S_\(UJD6F>)TBMHGNIQI$EI"&^U,C_P-A_I
M'U)_2,EQ++'R7 =>:X(C3E4:PD.'OK2A3SRS?)"7]J_\+E2LX>WCE\ZF"O:Q
M_F-AOI9U)_2O?%\\RDO#3$5%X=1ISJN."I\*/%J%+B1Q;]G"2SM+B.K7=-XF
M.5SJY>I6LC^YNBOBG_AXU^P]_P!')_#G_P #-1_^5M'_  \:_8>_Z.3^'/\
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M*U@;+3=(M[  ^N_^"&7P2_X4[-^T^?\ A^E_P^B_X2*+X,#RO^%N_P#"T_\
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M\0Z'<>#M>0ZKXD\-ZK8?\(C^'?Q/^,?_  5T_;-_X+K_ +5O[ /[+7_!2/\
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MKK6&C1'FU%/ 6A>"+**6=I)1I-GI<(<010QQ_AA_P0+_ .5IK_@M1_WD;_\
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MCBAABC"I'%&BJD<:*J(BA5   H EHHHH **** "BBB@ HHHH **** "BBB@
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M+>S=DVETCOLK6=U9%'5)X;&&:^N3&+:S@FN[C<&+;+>-I79<= J*V<YSBO\
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ML'3P&5Y;0CAL#@J+FZ6'H0;<:<'4G.;BFW\4Y/7<_P!$<@R#)^%LFR[A[A_
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MB?[,/[9W[.'[5?\ P;+?'OP1\"?B$WC7Q3^RQ_P1S\5? ;X[:3)X5\8^&I/
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MQA@M+2!,G;#;PQQKDX49H U**** "BBB@ HHHH **** "BBB@ HHHH ****
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M:K2*\N[7Y8_XC5O^"67_ $0/]O\ _P##6?LZ_P#T55<M_P &QG_!)C_@GO\
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M[,G_ &<M-_Z@&NUZ[_P9K?\ *+?QM_V<SX__ /3#X4H _K/,4GF'[GEL&."
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M'I7\Y7_!V-_RC[^%G_9TGPP_E?U_1U\%O^2-?";_ +)KX$_]1C3J_9.)K_\
M$$?"]\\DH\6<?J,4[17*^'7=+^]=*7=+74\N@W_:F,7-*T:.%:U>C_>/_P!N
M?WGI'DJBJ6)+8 ;&<''?;GMWQ]?JH96.W#8(R&QE0!V)Z9(Z8'4?A4T@)7AB
MO(R1U([CGCGOTJD\@<A'A9]TNS";1M Y\QB#PH'7GH:_&%K.<6M)M--):N/+
M*6FS=N]OF>FKR3EHY**]HW9MQ>D$DK62:^:WMI?\Z?\ @JW^V%I?[$'[$/QN
M^-37MG:^+D\+7_AOX:V-TVT:SXTUF%K73].3G=YKQR331%,L'B4C!Q7YG_\
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M_04^D7H/H/Y4M?S5!15Y**4IN\FDDY-+E3;6[LDM>A['ET6R[!1115@%%%%
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M6[@DMI?'WQS2.5=K-:W'P.L;@#(/[NZLO@7;W4).,%H9D8J2I)5F!_53X8^
M[;X7?#WP=\.K'Q!XE\4V'@GP_IOAK3M>\8W>FW_B?4-.TBW2ST]]9OM)TK1+
M&]O(;.*"V>[CTRVEN5A6:Z,UT\UQ+W5%?2\,^'G!?!N*Q6,X7X>P638G&T(8
M;%5<(\0G7H4ZGM:=.I&K6J0DJ=2\H/EYH.4U%I3FI?7<'^%?A[P!C,9F'!O"
MV7\/XS,,-#!XVO@98I2Q.&I5?;TJ56-;$5825.K>=-N/-3<ZBA)*I44BBBBO
MLS] "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KSGXPZ3\+M>^$GQ0T7XX6?A74/
M@OJWP\\9Z=\7+'QRMF_@J[^&=WX<U&#QU;^+EU BQ/AF7PP^J)KIO"MJ-,-T
MT[+&&(]&K\??^"_7A'XQ>.?^".7[?7ASX$RSIX_G^"R:G<PVMK)?7>I?#;P[
MXS\*>(_C9H=G:0Z5K,UQ>Z_\%M)^(&B6<4-DLS7.H1>5?Z1)MU:Q /X8_P!F
M+_@X0\'?\$</C?\ ';]GW_@G_:>)?VV?^"9FL>.]7\<_"#PK^T _B+X._$7X
M?>(/$,=@=<T_X9>-9H_&&HCX;RS6DDXM_&OPI\/:YK^ISR:_=^&O#/B"?Q)J
MWC/](O\ B.<_ZQ=?^;L__DCU^Q/_  :9?!KX$>%_^"0/P-^+7@7P=X0@^,/Q
M-\8_'.X^-?C>TTZQG\8ZAXB\.?&GQ]X1\,:-JVM-"VIVEEIOPRT;P1)8:&ER
MEA%#J$FJ1VZW.L7DLW].= '\ ?\ Q'.?]8NO_-V?_P D>O[??V3OCI_PU!^R
MQ^S3^TO_ ,(M_P (/_PT1^S_ /!OXZ?\(5_;?_"3?\(?_P +;^'7ASQ__P (
MM_PD?]D>'_\ A(/^$?\ ^$@_LG^V_P"P=$_M7[)]O_LC3?M'V.'W^B@ HHHH
M **** "HY7\M"V <8X+!>IQU/&?3U-25#<1&:)HP5!)4Y= XX(/W3W]#V/-
M#5;*B3>>"V$+8!)Z(V>"P/"GIT-"L3D,64DA@-P!P/O!5/.U/XO4XP,'%?S3
M_P#!<[_@O_\ "?\ X)R?"C5?AY^SOXX\$?$/]L?7+XZ9H?A:V^Q^+-%^'D=G
M-#'JVK>.8()FAM[J"*938Z5=,LEY*&C8(!N/TY_P0 _;K_:#_P""B/[ VB_M
M$?M+ZEX1U;XE7OCSQGH#WO@WPU;>%]*&DZ/J;6UE"=(M7DABNE@55G=7;S9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M: 37[7?\'6/[;'P#O/\ @F-IWPP\(_$_P#XP\1_'CQ-X:O?#^F>'/$6EZ[J
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MX/B:./4=/M-3:11,\^GV\QC(D)*;R!C!%?5\%*'AQX)\7\?U84Z7$'B1C9<
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M:1HG@"TU@ZC_ ,(3:7C8BL!?V;S:-H5NS!=L;*B[L$_ZZ/@GP9H'P[\'^%?
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MKX6$=OVI?A?V_P"PAG] >>Y-?T9_!@(?A!\*R[*%'PR\"N-QPJ@>&=,S(22
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M[2O_  D7_"*IX]\1^(%\/#71H6AKK TD6G]IKHVDB]\\:=9^3_1__P %)?\
M@L'^P[_P2U\(MJ'[2?Q0M'^*&K>'6\0^ /V??!7D^(OC-X^M+A]=M-(U"R\+
MP2J/#7A'5=7\-:WHT7Q \9W&@>"DU72[_2X]9N=9@73)?Y/?^#&7_C]_X*>_
M]>O[&7_H[]JJOZ__ (X_\$M?V'_VF/VMO ?[:O[07P4TCXQ?&OX7?#;PU\,/
MAX/'EW>:WX \*Z/X4\;>,?'^D:S;_#R61?"^K^*8?$/C;5IH]8\2V.MBQBM]
M-.DVNG7=M+=7 !_"U_P25_X*\?MU_M]_\'&?P7U/XH?&GXY?#[X,_%KQO^T
MUW^QWIOQD^*/_"AO!FA>#OV5OC OA'PC>?"R^UNR\&:EJOAR\\*:%KFMZM=>
M#],EUCXB65[XW?2=*UFZ$=M^_'_!SY_P6C^-W_!,SX<?!;X)?LGZGI7A;]H+
M]H2+Q5XAU3XDZKH&D^)YOAM\+_#(@T9KKPQI&M/<:0OC/Q3XEU)(-(UC6]$U
M_2M)TKPYXA"Z8=7OM*U+2OYM/^"<\4</_!Y!X]AAC2*&+]OW_@J%%%%$BQQQ
M1Q^!?VMU2.-% 5$10%1% 55     K_2M^)?P-^"GQHL+G2OC%\'OA;\6-+O-
M*N]"O--^)?P^\)>.["ZT/4$FBO\ 1KFS\4Z1JMO/I5['<W$=WITL;VERD\R3
M0NLKA@#_ #@/VJ-7_P"#EW_@C'\-_A+^WG\=O^"@.H?$3P?\=?B7X3TO4OAC
MX@^,'CSX]Z/X>\6:]H/B7XE6GP_\:_#'XJ>!-.\!^ M)UK1-%\5:7J%I\$-;
MM;>QBTXZ?H^KZ6-,\/7MG_<=^RU_P4^^%WQY_P""5'AC_@J-XGTY_"G@.#X
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M%-8^"&B_$SPE^T3\$- UYM2UU-2US4](L?B-K!@U;X4WT%UX8N;S1KB]T/\
M@!_;]_8._91^#?\ P<F^#/V"_AO\*O\ A'/V3]=_:N_8$^'>J_"G_A./B1J_
MVKP=\</#W[/.H_%'1_\ A.=>\8:I\28/^$GO?'?BN;^T+;QC#JFB_P!J^7X=
MOM)BL=-CL_Z1O^#J3]E?X#?L5?\ !#;]F3]FO]F7P)_PK3X*?#S]O3P;+X/\
M%_\ "4>,O&7]CR>,/AI^UIXX\1-_PD?Q \1>*O%FH?VCXI\2:UJF-4UZ]%I]
MM^Q6(M=.M[2T@ /Z:_\ @EEX'_X5Q^PO\%_!W_#=W_#RW^R;CXEM_P -I?\
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M>GZ9IMA%!96-E:PHD-O:VL,4$,2JD:*J@#_41H **** "BBB@ HHHH ****
M"BBB@ KG_%GA/PKX]\*^)O OCKPSX?\ &G@GQIX?UGPGXQ\'>+-&T[Q'X5\6
M>%?$>G7.C^(?#/B;P]K%M>:1KWA_7=(O+S2]9T;5+.ZT[5-.NKFQOK:>VGEB
M;X@_X*C_ +#'_#RC]A/XY_L4_P#"T?\ A2__  NC_A67_%R_^$)_X6-_PC7_
M  KKXQ?#[XL_\B;_ ,)=X$_MC^V/^$$_L#_D:]*_L_\ M7^U?].^P_V;>?R!
M?\0,?_647_S2;_\ *XH _K]_X=._\$LO^D:?[ '_ (AO^SK_ /.YH_X=._\
M!++_ *1I_L ?^(;_ +.O_P [FOY O^(&/_K*+_YI-_\ E<4?\0,?_647_P T
MF_\ RN* /[J_A7\#_@K\"]!A\+?!+X0?"[X.^&+>WAM+?PY\*_A_X3^'N@P6
MMMG[/;0Z1X2TG2-/BMX-S>3"ENL<6X[%7)KU&OX _P#B!C_ZRB_^:3?_ )7%
M?V^_LG? O_AE_P#98_9I_9H_X2G_ (3C_AG?]G_X-_ O_A-?[$_X1G_A,/\
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M 4444 %%%% !1110 4444 %%%% !7^/A^R?_ ,K&WP^_[24^)/\ U:_B"O\
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M1-_Y3'_\%M?^R@Z7_P"I=K=?UC#JW^Y_05_)S_P1-_Y3'_\ !;7_ +*#I?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[5'_ &;G\;/_ %6WB6OI2OFO]LW_ )-!_:H_[-S^-G_JMO$M '^8W_P:%_\
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M3J45_$@HG+Q);-\51X?BDW6BJN,E9-4L%&47.75.JYJ+@OA3C%2?[RQ\A_\
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M8^/X?C'\<?"Z^*-#T'P58:)I>A:LVE^!_#;27FEVMK.]]IZZ@9/M;M*?Z/\
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MO@VY_9X_9J\9?%2[NH;YBSZ+JG@OPS=^ =2ELK>XNX)?'EB8OLI?[=;?I_\
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M:UET/ZO8T0.608D<X=L9,@&0H.>F!P"<<<#DYIDI;D^8D6Q2S9PP0 Y,CDX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-?[9O\
MR:#^U1_V;G\;/_5;>):^E*^:_P!LW_DT']JC_LW/XV?^JV\2T ?YC?\ P:%_
M\ID?!W_9OOQV_P#3-I%?ZO%?Y0__  :%_P#*9'P=_P!F^_';_P!,VD5_J\4
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MS_\ J]Z_DY_X(,,?^'F7_!:UL9/_  N^#&,@_P#(V>+.F>AZ?C[8K^L93F0
M^A/MZ#C';'!K^3C_ ((,9'_!33_@M8!@_P#%[8?E/(##Q9XJV_/C:=Q+#;VV
MU_1G@S.I4\&?I2MRBG#@_@2,&FN2I%>(^1M7;OU;3>K]UZ,\G,W'^T,EBG:<
ML3BH.76+>"J\S^7NO>VW8_JMU?5K'0](U#6M7O(M.TK2K"YU#4+Z>18X;6UM
MHFFGFDD8@*L:(Q+=!7\/VH2ZU_P7B_X+-6GA^0W6H?L:_L:W\.H7T1>9]$\2
M/I&I#85EBS9-K-QK,*LL99I/L*$E&C.:_4C_ (.)?^"A^H?LT?L^1_L[_"Z_
MS\:/CP8?#5K9Z?(;G4M.T35'%E<!;. FY,MZ95\AD PH)[U]:?\ !#G_ ()_
MVW[!?[%WA;2]?M(G^+WQ?6T^(_Q.U1HPUU+K>L6BS6EMYT@-Q'%!831[X';"
MS%LKN!-=7AKR^%OAMQ%XO8R7U7BKB%XC@SPVP]2E3KTE/$4*F'XISN$9VY)Y
M3@J]%X'%Q@[8RO1BM):_'5JW^M/$,LMH2;RSA=P6/=Y*&8XY6M3@U>,U02<&
MGHISJOXZ<3]D].L+/2;"RTS3K>*TL=.M;>RL[>%%CB@M;6)(((DC0*B)'&BJ
M%50H[#'%7"<@<8_GGC.??_\ 53,.$ S\R\DYY/'/N>G/:I%.Y ,=CS[CKV[X
M&>?RZ5_--3GE5=7FYE4E.5:4KN<ZDK/F;DVVV[R;[W[GZ-"-H1FU;11C3V5)
M>[:*7E&R^_1'\O/_  =C?\H^_A9_V=)\,/Y7]?T=?!;_ )(U\)O^R:^!/_48
MTZOYQ?\ @[&_Y1]_"S_LZ3X8?ROZ_HZ^"W_)&OA-_P!DU\"?^HQIU?LO$W_)
MD/##_LK?$#_WW#SZ'_(TQW_7C"_E,]2HHHK\8CO/_$O_ $B)Z4=EZ+\@HHHJ
MAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVTN+.>%/OFOX!_\ @A]_P<"_LE_\$T?V?;?_ ()C?MTZO;>')OV9O%_Q2M?
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MO_3-I%?ZO%?Y0_\ P:%_\ID?!W_9OOQV_P#3-I%?ZO% !1110 4444 %%%%
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MW[.WP>DU+[?XH\4_\(YI,.B:']LFD87?]B:5;V=L-9UJ50H*_,6=GV?S0?\
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MVC_BEI5[\7=>M=;D74/C/=ZA>>-Y')EN=2N=2NI+B9A=,3.C1/,Y'S?,.&)
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MI],_0<4O6BB@"+RDRQY^8 =OEQQ\N0<9&,T]4522HP6QN/K@8!/;IZ?6G44
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MH)J6EG?JFMUYZI[IV"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%%
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MCX:_#_1X-&\.Z!IL4:)%%$/W]W>S(B->ZG?3[[G4+^8&>[N9'ED.2 /XK?\
M@V/_ ."K?_!.S]C3_@FLWPB_:=_:I^'?P?\ B:/CM\3/$[^#O%(UP:D= UB'
M0%TC4XCIVEW\#0WK6]T$&]'7R<L"'R/[C? GC/PI\1O!GA?X@>!=8M/$/@WQ
MMH.E^*O"^O6)D-EK.@Z[9PZCI>J6IE2.0V][97$-Q#OC1O+D7<JGB@#JF.%)
MQG SCZ51>9$"R L=^YHX\%Y)",CY%)PI4Y;WQBKKHKJ5894]1G'?/4?2F&)2
M".G.5( ROKM)'&>Y'- 'S'KO[%7['OC+6=3\5>+/V6_@!XC\2Z_>3:GK>NZ]
M\(O NI:UJVHW3>9<WVIW][HD]W=WD\A+S3W$TLKL<NY)K(/[ W[#B@D_L@_L
MTC'<_!3X>8'H?^1?'?W%?6X 48 P/\^M+0!X/\,OV;OV=O@SJU[X@^$/P)^$
MWPOUZ_L_[+OM8\!_#SPOX0U*^TUI4G:SN;_0],L[F>Q,T:2FWDD:(RHCE-R@
MCW2-U<,5# ;NI'#< 94]UZ8/'TIODKD$EC@Y'/?_  Q_#T[XZU*%"YQT)SCT
MX P/;B@!:*** "BBB@ HHHH **** "BBB@ I&Z'Z=Z6HY& (7^]G)/0 4I)R
M323;W23L]-=&-)MV6_\ 5_P&Y.W(P.<9P.0>2".G8#I7\L/_  =@%E_8X_9D
M4<*?VO\ X=$JHP"RPW(5MHX)7<Q!/3)Z9K^IKS%*;@> Q#$@XX../7OC'7\*
M_E@_X.P9X5_8[_9G\R:*)E_:W\!SKYLBJ%ABMYVEG=2<B*(<N^-J@C<1D5^P
M_1\H3Q7C#P)0I*;JU<UK*G&*=6K'GR[%M>ZO>:T;MV3?2Z\W-$E@*O/R\JAJ
MVDU=2I][K>UNSU/Z;?AZY/P\\!LSJ&;P?X7+2LH9AG1+$L3D8)8DC.>"2?05
MU#R,1)Y2[@SKADQR1C=N!PJJH(WR<8!R3FN)^&NJ::_PK\!:LNH6#Z2? ?A>
M[_M475N^F_9ET*R+7/VT2&V-N%#,TWF^6%!._C-?S'?\%,O^"S'Q#^)_Q"U[
M]A#_ ()?+!XT^* M=2LOC-^T78>8_@?X.:1"C1ZRD.MJJV#7EI'O%[(;@O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\/_ &E_V@? '[*7[/OQE_:3^*=S=6WP^^"/PZ\5?$CQ
M5_9\(N-3N]-\+Z5<:D=*TBV+(MSK.LW$,&D:/;/)''<:G>VD,DL2.TB^X5^7
M/_!:K]D[QC^V_P#\$M?VROV:?AU8ZAJ_Q$\:_#.P\2?#[P_I5UIUCJ'BKQW\
M(O&_A3XS>#O!UK=:LC:;"_C#Q'\/M,\,$WLME R:LR/JFD;AJEF ?R+>#?\
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M_=..G'/6J*'Y'/(XZ\]/KZ4M1[<X(.3P6(_BQD$'^0! Q_)2&R>&Z_W@/Z4
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MB:-04+IO\QO(9HB5DDC?.6#[?DP<-QQ5;"ELA<KP ,L <\99B21SC(! .1C
MH _W8/C!^US^S3\$/@SJ/[0'Q(^-GP_T/X0Z;:7E\OC:U\5:+JFD:NNG.8[N
MUT"YTZ\NHM?O(I5,,EGI374Z2 HZH02/\^7_ (*\_P#!UC\8?VC+S7_V??\
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M;^*,%U<;[M--CU />:"90[S-J&KPJ77_ %060;6\4_:G_P""MLG[,'_#1_\
MP3(\ _L0_L5:S^SA\+_BAX\^&VF3>)/AI=:IXUURY\&:]?Z%I'CKQ#XDBU:&
M2[\:1_8X[V:[C1(8;XS1)&8VE\W_ %AU6.W1401PP0HD<<2*D:6\:!5CBA1
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M_P#"MOB P)[D8O,8[8YP>_I_H[44 ?YPY_X,AOVH #_QG+\ \CD@_#CXA
MC))^VDC ]AVR0#7^@-^S)\)[_P" _P"SK\#O@IJNKV>OZE\)_A3X$^'E]KFG
M6\EI8:Q=>$?#>G:'/J5E:R_O;:UO)+)IX()/GBC=4;D&O<J* "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *^3OVZOVL_!G["O[(/[0/[6WCZ"._P##WP.^'>J^+(M%DU*ST@^*?$\T
MMMH?@;P9;ZC?R1VUK?>-O&^K>'?"6G.?.G:_UFVCM+6\NW@M)_K&O@W_ (*?
M?L;V_P#P4!_8%_:?_9">]M=-U3XP_#I[7P=J6H37\&FZ;\2?!NNZ-\1/A=J.
MJR:;=6EV=(L/B-X1\+7>JQ++)#/IT-S!=V>H6DD]A<@'^>7^R[^P%_P6^_X+
MA?%KXB?\%8/@=X^^"G[&NM_$_7=9\*6GQ:\&^+_'?[*-CXM7PY+;Z9X@L?!H
M^!'A'QS\3/%.G6.JZ7#HFN^,_'NI:UK.OZWHIT_5?%>MS^'-NF?I5_PX+_X.
MFO\ I-1_YT;_ ."BG_SFZ_5?_@V=_:O\!?!_]D'0O^"5'[2B7'[-?[;W['7C
M#XL:/XC^!WQG\CP+XI\=^$?B-\8?'?Q0T7QY\-3K-S#I_P 0/#\=_P"-M2\-
MW5SX1N]4\I-(TWQ J2>&?%?A77-;_JBCDCEC26)TEBE19(Y(V5XY(W4,CHZD
MJZ.I#*RDJRD$$@T ?P#?\."_^#IK_I-1_P"=&_\ @HI_\YNO[??V3O 'Q3^%
M'[+'[-/PM^.GC7_A97QM^&O[/_P;\ ?&+XB_\)'XC\8_\)]\4_!WPZ\.>'?B
M#XU_X2[QA9:=XM\5?\)5XMT[5]=_X2/Q3I]AXCUS[?\ VGK=E:ZG=74">_T4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\U_MF_\F@_M4?\
M9N?QK_\ 5;>)*^E*^:_VS?\ DT']JCV_9T^-9_+X;^)#0&G7;KZ=3_,<_P"#
M0O\ Y3'^#NO'[/GQUX]<Z/I(S] #^?Z_ZM<THB R"2QP6_A0=RW<#L3U!X]3
M7^4I_P &AG_*9#P;_P!F^?';_P!,^DU_JT3E%4%E!,GR#.>1G) QD YQR<#Z
MU2:2;?;;JWT7IW[Z+78F3IPO4J>]""ORONTK)+R:?S?F.,F"@X.\X)'0 ]"#
MWSZ?_JJ4D $M\HSW S^'^&1@=J^8OVE?VKO@9^R;H'AWQ7\>?'NG_#WP[X@U
M=]$T75M2MKRYAOM62$W#686SBE9-L W;I J].<U\B/\ \%I_^";<@&/VD_##
M\#A=,UGDXP2,6IR/SY//MY&*S;+,+5@L?C\-A*CO*G2JXFA"JX>[>7LIS4U%
M]&U9K79L^TR7PX\1.)<O_M;AW@[B'/\  5)N$,7E62YEC\'2G3ERU*<\5A<-
M6H\\9*TH\_-%W32=T?JJ2K<I)SD#!X&3@#&#[\YH68 @ ?,?E()Y!!Y '0_F
M>G:ORC/_  6H_P""<,>5/[2'AF!0"6=M+UA=JYY8EK; /< <GL,5]I?L]_M2
M_!#]J?P_J'BOX&^-+3QUX?T:\BL-2U&VL;^P^RW\T?G0QM%?0P2,LL.75U4J
MP.02"!5T,URW'24,+FF'J36JITJ]"K4<5:\G&G*4N5Z+IWWN7GGAOX@\+9=#
M,>*.#>),CP=248T\5F.29CE^&G*7*HQCB,9AJ-&<I2TC%3;D]DSZ4!R ?6HY
M>@&"QW [0<$@=<>I'7'>I 00.<_U/^>U<GXM\=>"_ EBVK>-O%WA?PCI4$,M
MQ-?>)M<T[1(!'"I9W2;4;FWC<* =P4LQ("J"Q /HIW2=[Z;]SXKRZ]NM^WJ?
MY@W_  =._&K]JOX/_P#!6;XD6_A#XR?'#X;?#W7?AQ\+;OPGIOA7XE^+O#/A
MJ\:W\*6D&LW.F:3H6N65I$QOBWVN5K9)IK@M(SN"NW^<3_AM#]L#_HZK]H__
M ,/=\2?_ )I*]]_X*H_M(?$+]J3]O7]IOXE>//B'JGQ*D@^+/C+POX+URZN(
MI]/M_A]X7UZ^TCPA8:/'"3:Q:=;:+:6BVS0 BX3$SL[N:_.PYSSG)Y]SFF!_
M3?\ \&V_[0_[47Q/_P""O'[,VA>,/CW\;_&W@JV;QS?^*=$\6?%?QAKOAR6Q
MB\$:]';/JNEZ]KMUI]U$M_):F!# \HN1"T?((/\ I]_&']JO]FCX!6TE_P#&
M7XZ?#3X;6T5O)>,?$_BC3K-HK=03)</ MP\ZQX!*[H@,<J#FO\.+X0>,OBAX
M&\?^']7^#GB7Q)X6^(=U?0:'X;O_  I>W%AK5QJ&N2+I=OIUK-!)&Q:_ENDM
M@C$@M*I W 5^_OPF_P"#<_\ X+5_M2:I#>?$WP'XS\!:;KXCO6\1_&GQM<WT
M5Q'?'SS<7%DFK:E<QQ,LGF>7(B$ E?*0 "E=)I-I-IM*ZNTK)M+=I-I/U7<3
ME%-1;2DTVHMI-I6NTMVE=7:[KN?W+_M"?\'/'_!)?X"1W L?C?<?&F:W4HD7
MP<TO_A)UN+A>!#'-//I\:C=PTK81!ECE1FOX_/\ @NY_P<<^$_\ @IO\#M,_
M9J^ _P .?%GP_P#A]%XZLO%6O>(_$.I-::OXFTO3K6YAMO#^H:5:2-:FWDNI
MH;R0%Y$WP(.QK[__ &>/^#*'Q!)+%+^U-^UAH]K;RNKR6WP:T:>6[A1E!-L)
MO%-FMK),C95I$7RR?N K@UY-_P %T/\ @CE^Q#_P1]_8-\+^(OA)\-Y?C+\2
MOC'\0XOA.?B9\5M4N/[<\"V\FA:GKA\3^&K31?L]@^MM=6$%F$N8FMDM99BJ
M9506VDKMV3V;T3N[+7UT]1MI;NVV^F^WW].Y_$7(@X\U6)3_ %BYVF-F&U%"
M#@*."2O4YS40C8JDC&.0DN#"&VL!%U+C@ ,#\IZG'%6#%?&((8RT:$X!QO&2
M?G)P"00< ') Z 'FD%O*S$F%5?8R_,<)MP KICDLO7!ZGKBIYX?SQ_\  E_G
MYHCVM/\ Y^0_\#C_ )G^B;_P9$(S_ ']N*5[6,)#\7?AK#9WC0+]H\J?PAJL
MMS:I<E=Q@\R*"5X@VWS=K$;@"/[DS$"""?O'+E0%+^F['IZ]<#'2OYK_ /@U
M&^'?@3PO_P $BOA)XW\-^%=-T/Q7\1O%7CZY\=ZW:*WVSQ1>^'?%6K:/I%[J
M#DX,EGIB):1*!\BJV6.0!_2ID>H_,512:>S3]&B/RER>!R0QR-W(Z=>P[#H*
M!$ X<,V?F)&3ABPQD\]NP[5)D>H_.DW*>A!YQ^-'Z;CW5UJN_0=4/DC<6)))
M)(ST .,KC."..A[DU-3=Z^O\_P#"@!HB4%3@9487 V@#T('4>F>E244=* "B
MD!!&<\?E_.@$'I1=:Z[;^7J%UM?5[+O;<6BD) X)Q2Y&2/3K^-']?U]Z#]-P
MHHHI76FJUVUW] "BDR!U('XT9!Z$'\:8KKNOO%HI,@#.>*,@=_0_GTH6JNM4
M]FMOO&+12;E)QG_/UZ4$@=2!]31=+=V 6BD#*>A!_$4N1ZTKK75:;ZK3U *8
M_'/4@<#W['/I]>*?43L,!A@X_3WQU]>O'YTFE*WE*,ON>WE?57$TVFH[O1/M
M?9_?Z>I4,C)DR*=K,%7Z=\#KT/XD5_,?^TE\)O\ @XUU3]H7XOWG[//[6/[+
M_A;X%ZIX[U2Z^$OA_P 3)HC>(-#\#R,O]E:?JPN-#NI_[0MTW)<+)/</(X\P
M.H=8D_IW)#8(4$J"PXX)YP" ,9'0XYK\/?VGO^"8OP0?6?C#^TC\6OVGOBQ\
M-/"5]?:GX[\4W,GC*72/"_A6".+S[E-.4WD8B@C2)A!:Q*7D?Y(HF=@I]/*.
M,L\X3QE'%<-<'Y'QQF./DL%'*,]P>%QE!.I."IU:-'$TY4W74K4X67.^;E5Y
M--?'\6XG/LOR["+A[+)YIB(XAU,7%8ZGE[A0I^]-JO5IU$TUS>ZHWVES)(_G
MW_91_:<_X.,/VQ/B-^TA\,?A?^U7\!M(\1_LN^.1\/?B'+XST3PSH^E:AK!N
MM0M5N?"URFC7!U:S9M-ED%RJI$(Y;<[P9XPW[X?\$V?AY_P6I\+?'/Q#J?\
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MQ+\0>#K#3?#GC2[AB;Q#>P1A;Z;1HG="UI!#"^\O%*K28V'()S_6[ X&$D#
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M3E[EY*$&N>=DGHFTKW>S:[^8L3$MDE<%B%P<Y &.?0^U?R>?\$&6_P"-FO\
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MABDF<2%(HWD811?\$?9Y2L:EF$<$"2332$ A(H8Y)9&PD:,Y"D D_P"(&/\
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M )$[_DNW_"NO#G_"W?\ DG?_ !;_ /Y*!_PD/_(C?\4=_P!"S_Q)?L- 'O\
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M,[+X+_$N^\5I-8V%CX9^'>J>$=0T;5[2+SKV'68=1F+L(H2-C%5 ?L.:Z_\
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MQ074\,UL ?/:54P2<5TY#@L%C,[RS"9I7S*. Q>+HT,1#+L)#,,TBJLXT_\
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MZ&5930IRJU<XQ5?/LPKT'2IQ4^7"R<JE/VU6*BG1<I.,9PE+^JS]JW_@H/\
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MQC^/NG:E\4?#VAZ;X7\<VFMWNG:'J6I2BWA\2V$=]XAU6W74-/1@4D$<<Y)
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M7915JX>C;&86C@X5*L7&GR\TL/"$^5Q;DU)/17:O:_MP.W;D$< GD'GZ\?\
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M3I%E#I^G6<"* $AM;.WA@C4 !410  * ->BBB@ HHHH **** "BBB@ HHHH
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M?^"5?PJU-]=^''[%WPB\':U) ]LVHZ;:ZU/<"&7[X1[_ %6\\MC@8DBV.O\
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M"F_X*X_\%W?B%(D7PR_X(]2Z+I%^4%GXOU[6-8061 )FBN()I_+4= 2 6.<
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M5,1EM2%-Y74CAZJA1E5G*;JR<FU%-/\ /_X<_M4_##X@^,O%TWCV]\)^%X/
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M7@#PY_Q3G@#P]X5\):=_9WA+PKH.D_\ $IT&P^V?8/M]_P#:M3NKV]N/G_\
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MP[D/&&189Y)3AC9T<-E/L)QR[#QJ82A"G2J-1A3E.-2<Y*K*45_2HSHQ42*
MB@*).BCGY]V?N[0.,XY'XU_F^?\ !4'QA8_&S]J3XYZ!\<? 7C=;OPY\0M<T
M;PO=ZW='3M:D\.V5T4TF\T_[1&KG0KN'+Z;( 8VB!V'&:_H^TW_@LO\ MBZ:
M@A\>_P#!-CXL:'JLBI)]AMH[^]MC;@Y,DTV?EWC*Y[]#7\S?[8NE^,?'GQ&\
M<?'#5=+^,<^J>-?$VH:MKMG\1/#5[:67@JTNYC)8^&-.U:?S'FL-)0M!9#Y8
MUCSC&:^9X_\ $;&\,K(L_P" ,^SO+.*\CS.GFN S+ 0Q>$AEZPMDJ>(YX4>9
MMM2A%\[BE*4DHM,_3_HD?0%X$\8_$-93])GAJGG?"6#PL<7PO/(.,Z-'$?ZQ
MSJQ6'<,1P[F=22I3HJ=/GQ#5&K.5*G1<JLI1?YZ?\*/_ &=0Q(\'>,W.$\Q)
M/$D!,NT=-WEXY/\ ]?BOM;]CSP5\,KWXO^!?AAX=^!#>.=*^)/B32_#>N:7X
M@0:Y#+IAN(6O8RD>WR(8;8R3*QP0Z[@0,U\ND;0BA68HZ+')GF1YB J-UQRP
MYZXY]J_I6_X(G?\ !./Q-XB^+?@G]JW6/'FM:#IOPEUBX=_!DFEQBQ\2:IJ&
MG,J64=SO^?3XK:19QJ"@MYP,6WH*Y,!]*/Z2OC)F>79#Q1XH<9YO@,-C*5?$
M8;"YQC<,_949QJSK5*M'%4Y*$%'F:3N_@:L]?[+^EY^S1_9T^!O@WQ%QGFOA
MYQ$LWH824>%\+B/$#BRHJ_$/+&664I4HXN24)8N-%3ERN,8+F:Y;L_1#XK_\
M&RG_  34^*EW#XD\/:#\3/A)KYM8IK-_AYXYO]$L+.XDB1V<Z:BE!\^-RJX=
M0"JMWKYNOO\ @W]_;0^%,T<O[(O_  51^,OPRL-+W/IOASQ1/K.MV<L<7S0V
M,LL5RB/"P A(N(YX0/O1C[P_JO1=B$(-ORJQW-D#/WMKGJ>HVCH<$=.7*4R8
M@'/)().%!/HW3!Z#W]<5_>/#_P!)[QGR&@L++C.GG=#$4J=.& XORC)>+L.Z
M$%"U.,>(\!F,H)+EBW3<&]4FI:G_ #\3R?!2G*5+#N@J4%22PTYTG*C&T5!U
M*4Z<G*$4KN5W-:2;3N_X#O\ @J=^S]_P7:^'G[/VB:/\<_BEIOQ?^"'AKXAZ
M7JMUXX\#1QP^-K">*)X%U'7FC1KBU\/+ 99)GE"QK+C<<CC^;+XS_M"?$VU\
M5P^'_"OQ(\01Z9X7TZVTXZA:WYCDUBY*)+<7MX=I\V<2M)"YXRJ#CFO]5'_@
MH#^QA/\ MR_!S2O@\?BIXK^%.F6OBNR\0ZY>^$Y&:7Q)IUK!/!-X:U6+S8EN
M-*OA,))X7W(9(U)7*\_Q"_\ !5__ ((F:9_P3E\,:%\6/!7PJ\1_M#_!S4Y_
MLWB[Q+'K5]I^O>"]?NIV\HZEI]DLN-#N0Z+#?L647#F)MH!(_M;Z*/TD/ GB
M/Q$R;+?'/P#X+SWB7+XYM2X;Q?#OASPQ/"\38KB",$\#F.%Q47&.,P]2DG@E
M3C[.=2JU3ITVWS?SAX@\#T9\54LZEPHLYRW#8.GAL)B9X+ X[$K$8J$57GB*
MF,G&I"AA805.G&:E2@ZLK5(R4+_@=\-?VEOBYI_C325UWX@^)=4TG4YQHVH1
MSWYG2VM]09;>6[M(PO\ KK5#YEN5R5<<9%?U(_\ !)S_ ((F_ /]NG2O&'Q,
M_:S\2?&+Q/>^#M>M_P"RM,LM6O-'\,>(-(U'?=:'+'K/DM::X8K-"NK6MOE[
M68K!/M9LU\A?\$S?^"-/AC_@H#/!K%Y\,->^$7@S1_M5SXL\7IXDO]2AM7=%
M;1=/\/"Y58[W6O.R-5MXV LDP^\]1_<9^P/^Q;JG[%'PXO?A9_PM75?B-X2A
MEMV\*6&I:/;Z6_AJVAC*3Q(UO+(;V6[;9)/<2X=G4$YR<>=]-OZ0'A%DW&KR
M'Z/7A%0\*.)9X!X/C/&X;@SAKA_,<!CXU\-6PZR[%X"G/$X*I/"TU1KO#NG4
MBJLIMPG[SY^!.#*.(XOPF=8'A#"8'*OJ6)P>.KXC 8+".>(ARK#8C#RH-SJP
M@Y5835->SJ)QYW+E2CXSX._X(O\ _!/7X?V=K;>#/@5H&@7=M&L2ZA#%%)J<
MZHNWS;B=HMTCN%Q(Y49)/0\U?U+_ ()&_LCZA<2:D?#VNVBX.ZPT[7+BRL(U
M;*L8K.+")P2?7=D^F/U/V,6! CWJN&8$%BO!V8., XR>_;UK"\2Q:G/H>JQ:
M"\4.NSZ;>+I+W'RV_P#:/V>3["LQY'E"X,9D)'W<DX%?Y?\ &=7$\=5Z^;<9
MSS#BS,:>&E&%3-\PQF;59I+^%2ABJ\U%-)I)63UCHF?MF:^'?!>.C5KXOAW#
M9CCZ>%K<LOJ\)5:[C!MTZ:T3<E:*3DKZZKFN?PE?M3_!Z3X&?'_XA_#CR]/M
M=#TS6+B;PJEIJ<6K.?"\[@::;^XC)\C5-@<75O*?.B^7=S@U\Q7'A_0XXK.V
MBL(9+>RO)-0@5LOY5]))O^TQ*&XD#'=GYAGM7[1_$G_@D3^WI\1_B)XR\=:]
M/\,KW5/%NOZAK4TY\3/&JK=REEB1/+(C5$"@(#A2.!Z\A#_P16_;;5P?)^&*
M[""2_BM@O'.0?(Z8P>^.F:_R1XF\'O%JIQ)Q'C.'>!N),#E./QV(EA\'AZ3A
M?"SJ*5.G>$TY02L^5:):-61_C'QI]'SQGQW%V?YKP]X:\6X3*\;FF,GE> HX
M->SH87WU0A5FJJ49QIU9J$FGR\TE&3O<Y+]@RU_:M^.GC'4OAQ\,/VB=;^&6
MF>$M &I:=%?21RVE_.)PBZ1;V:1+-)E"9-QD?:HQC( /ZG7/A/\ X+ _#E8X
M?#'B#X=_$FWC7S"VNF&WNM^[:83)(ZEE95WAL$#=@<U\J?LX?\$Q?V]/@!\9
MO!_Q*TF/X=;=$U6"YU")/&4K07=H[".Y1X1$$F MVD:-&R#)M Y-?T_6:.+:
MW-U&@O3;PFZP<QK<%%,_E-@YC$F[:1U&*_J[P'\,,U7"E6CQ.N..%\^P%7E4
M*F.Q%'"SIV3HSP^'G5G2O147>$815I1O=.T?[@^C1X.\0O@JCA>-<+XA<&<3
M9-BJE-5<5G&.PN#Q6#FU[)8'!2Q%;#)8:,'"<52BFI1ONE'\-[+]K/\ X*5_
M#,(WQ4_9CTKQ<-V&_P"$+O(GR%^\=T7F#)QD#Z5K:5_P5W\9V,A3XC?L=_&'
MP3#'<^1)JCZ==7UL\$)(GNOW5NNR*-P0,L0W# @8K]N"RLN(PN5))W(K@CN,
MGH/?FOBG]O/]H#PW^SM\ /%/C;6;73KW5KFVET/PE97<,,T5_P"(M1A>.SMI
MHV&%A)WLS8(!4 \GC]7X@R/B;A?+<UXACXI9M@<KRC 3K5:68Y3EV/I<B4:D
MI3KXANJFY6A[MO>:CI%NW[CQ+POQEP=D><<1T/&;,L'E6682OBJ]#,,BR?%T
MW3P\>=0GBJR]NYM)1BXVE.3BFTI7/YT?^"EO[?4/[6MUX2\#>!8]1TKX=^'T
M.IZ]9ZC;36NHW'B)6,:)<JS _98[=BOD2+R_SGIQ0_8G_:W_ &J]&\/1?LO_
M +/L&B7_ (AUJ_N+_1KOQ/>JRZ'ITJ WDML\S!=D40+V\"@!'[8)K\Q+S5[[
M7-1U76[[F\UB\NM6U' V^9)=W+RO L?2)("YCC49&Q5(YKK?AM\0=9^%OCWP
MSXZT.>6UOO#^LVFIVLMG.\%R\5K(DKZ=<RIAA:W07RI5/!1R":_S>I^*O$F.
M\2GQ3C,^S"5;'UJ>"QV,P4*>$JU,K=:%.KAZ$*3C"C#ZNG/EC&R=Y)-J[_R.
MP7CAQAF'BU6XYS[B+'T:F-KTLLS'&94X8:O4R3VU.A/#T:5.U'#Q=!.2<$^1
MOFMS'].'@+_@E;K?Q(UJQ\>?MD?&'Q9\8/$"3)J%GX>74;FP\.Z*)L2OIPMO
M]7=P(Q:)AP'7D'&*_6CX=?![X9_"C2;70OA[X-T/POI]I$JK;Z180VT;LH \
MQRJEFD?DNQ8EVR3@]>*_9M^-NB?M!?!OPA\2M$N+6XBU>P@_M:.TG$\=AK<4
M<:ZAIZ-U)MYB4Y&>_3!KZ A.%^4$1@Y4L?G)ZDMGH%)X'IV'-?ZH<'<*\'X3
M+<%FW#]+"X^IF%"GC*6=8N?U_'U54IQG&I#$U_:U4W=WIQG"$7S6BD['^U7A
MWP3P!@<IP&?\-X.EF%3-<%ALQH9UCYRS#,<11Q,(SI5OKV)E6JISO)N%.I&"
M;FN5)N(UT5HGW9"N#N4?>)QSN)&,$8!!P#SZUBIHFB7*LW]FVG<D&TM\D]WW
M&,[N.OIC/-;Y<;'+,,]-V,X!XR0WU].V/6OQ;^,O_!0+]LKP+\2O'W@?PA^P
MOXO\8^&O#'B.ZTOP]XQM+VXAM/%>CP%3%J]FJ(542[FQ&O&1R>:]OB+.,HR?
M O,<UHU,0XSIX:#I82IBJM.;2?+*C3A4E%3=W=*SM:[LD?2\39]D7#N#A7SK
M#8BLJKFZ;HX.KC)\T6G*"HT*=6<%.\4O=Y;I)7EH>>?\$F]+LKO]HC_@H+#>
MVMK/Y'Q@81?Z/"T<<37%T4CC#(RKL!(94"C)Y'I^YBZ'I"-'LL+1&5E*.EK
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M (AO^SK_ /.YH_X=._\ !++_ *1I_L ?^(;_ +.O_P [FOO^B@#X _X=._\
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M[-]^.W_IFTBO]7< #H*_RB/^#0O_ )3(^#O^S??CM_Z9M(K_ %>* "CI110
MA /6E  X%%% !1110 4444 %!Y!'K110!6*X)"\[L\^A[>X]B/S-<UXE\)^%
MO%EE;V7B_P +^'O%5E;3B>&S\1:/8:U;V\X7:+B"#4;>YBCG"_*)402;3C<
M>.E#X!&,DL%_GS]?S_#--=0<KN(*$'=T88P,CZGCH>IXYHNG*5*M&,J<E:TH
MIQFG9<K3TL]K-:]D5AJTJ5?#XVC6JT,1#F5*=*I.E4YMN:$X.,H2WLXM/SM<
M_"O_ (+.?L!>%/C?^RY?^)_A5X!T?0_'GPINIO%6FVG@SPWI.E3ZOIIB*ZX;
MQ=.M;>6Z%AIT4EU:0@2,TW 4\"JG_!'#]B+P=X!^ 5O\3OB+\+O#MUXJ^)]A
MIOV:#Q/X>L=3GE\-Z8I_LG6)K76+.=K&]U!2[WD:I&V57<.#G]V);5+E3'.J
M30L6S&ZATD##:8YD<%)$8?>4@JP)##!Q1#9Q6\2P1)';0Q!!'#:)'#%&B=(T
MC10D<?&-B!5 '0$FOCO]2LHCG[SVE0H_6)4HTI/V5*223BE-)05JBA>G:UG&
MS=VM?Z!I?2;\3(>!U7P(EFV/_P!6J_$DL^J8KZ[BGC(1:HU)9?[5U+_4WC*5
M/&J7,YJJYTU:,E;)T+0?#_AZS32_#>B:3X?T:V+>3IFBZ?:Z5IL,KMF1[:PL
M(H+6$N3F1HHEWL=QR>:WS#&=H"G)4<[W'KQP>GM21Q@CL2<_-C&%Z8 _7KU/
MI4P("GOCKZ<\<<>G7BOL*DDITZ4(VA&/PKX8I)**M;ELK.RLNR/P"IB)UJTZ
MWMJE3G2M4G4G.=2>\JDY2?-.3?Q2DVY7NV8L^FZ?<M(;O3K:X(78WGQ)*TL6
M"-H>0,_R]0H/3.:_F:_:1_X)W?\ !77XM^+OB]I.F?M(? >3X)>-_$'B!O#/
MA'5_"]M'J6G>"[^1C8Z-=WD5@)5O+2WQ$+J.0S!SN#YZ?T\RIN7;N(SA@5QN
M4@@XS@\>W)QGK42Q]5;+[OO;^F#W'<$\YYQG/'6O(S7)<+GF&Q6#Q$90PM6D
MX2]A6GAY3FX\LE*=%J3C9OF4FUTU5S]$\./%/BCPMSRGQ!PU1RJMF$'0JTWG
MN7X?.,+A*N%J0J4*^%H8SGAA\1"I!5*=6G&$DUI)637^9;<?L2_&[3_VC=0_
M97U6PL]/^)FC:M;Z+#%<_:?[,U6^ORS6 TV6/,K+<P*;J&24@+$I#%6P*_:;
MP;I'_!4__@DGJ7PSUOQUJMS\5?V4O"UVNI?$7PU\/-*_M:WATV[@6/[+J]W/
M%)JQNK%Y2X,*NH,>TL$&1_3YK7[%WP6UG]I71/VIYM%*_$G1M"GT0B,1#2]2
MEDE62WUS4874R2:SI\>ZVLKE"HCA8K@Y)'U!J^@Z;KUG<Z;K%E:ZEI5[%+%>
M:?>V\-S:W44L9CE@GAG21&C="5.5W9)(.<5^2\+^#]+AVKCL=@\QQ&!S"5:;
MR_$4ZLN6-!5%.%#%44E&O"HK*I!VNHIJW,[_ .@/C3^TDS3QARG@KAOB?@'A
M[B;A&GD%*GQSD6<X-N6*XE</J];,^'\RIUJF*RR>'H\U7 U^:4X5J[55N-)6
M^4OV4/VX/V>OVQ/"-IXC^#WCC3]2O&AB;5O#-U/%;>(=$NR@^T:??Z?,8I_.
MMW)5_*C<*,%B.<?7^",E<*S$#:Y!4@'[PP2<X''.>H/O^ W[6'_!'"6S\7S?
MM#_L#>-;[]GOXU:5,^J1Z#H]S/:^$/$%SN::YLY-.B<VZ/JQ407$LL>Q58E=
MO-<O^S5_P6!\7?"_QM8_LX?\%%_AW?\ P:^)MI=V^BZ5\2TM91X&\473MY=J
MD=VR+&TMSM/VBY67R(F/S$ YK[;#<2XG*ZM/!<89>L%6YE3PN<89>TRS%MZJ
MTM98.ILI4ZZ2OM)1M;^5\^\#^'>-LMQ?%_T>\ZQ7%.74*,L9G7AWF\J-'C_A
MJ"455<\-3Y</G^ 4[NCB<I=7$N"Y:M&=1.4_Z)T";#WYYP/0XX/H#P,GZ<\G
MDO&_@WPG\0O"7B#P5XYT+3O$?A/Q/IEWHVNZ)JUO'=6.H:?>PO;SPRQ2*P1B
MDC&*9 LD,FR6)U=588Q^+?PPM?#6G>+[WX@>#K#PKJIC&G^([[Q'I-IH=Y+.
M!(EO!JL]U'9R3E3GR5F+CTS7,-^T/\ Y$<K\<?A08FRN_P#X3WPP5SUP'&I%
M",=<?K7VU''TZ&*HXBCCZ.&DE3Q%&I'$1IUU)2C.E5I34XRA*-E.,X-234;2
M36G\Z1X<S^I&O&CDF:U/85*E&<(9;BZD%5IM1J8>IRT)*$HS]R=.;4XO26IK
M?![X._#'X!^ = ^%_P (?"6D^"_ _ANW%MINCZ:'81H6=BTMS,TES?7#,Y\R
MXNI9IB"!O(  ]5B5E4%F9GW,1N !VGD 8QP.@SR<=P*\3A_:$_9]7D?&[X3L
M8SL"GQ]X84(K'"@ ZF"6)(P<88]/?O/"WQ \!^,[:>Y\&^-?#/C"WMI1#//X
M:UW3-=CMY6X2&>73;FX2%@, )*RM[=JUK9BLQQ6)KXG'QQN*JU95*V)J8IXG
M$UYS?-.I7J3J3J3FY:RG.3E)W=[MG-5R//,!0IU,9D68X*%U>5?+\5AJ%)](
M<]6E&%Y)W6K6[['9A3@DCUX4 $G/4C'<=<Y]O=#_  @JN5Y&X<C@@D9[_P Z
M@291T8G+8!SG) R0.QQT]"<].E0W=Y;VL,EY=S1VUE;0O<7%W/(L<,,42EY9
M)G<JL<4:AG>1V5%4%F8 $UG&I&"DYQ=.FKVJ2YK-6M>VC6FCOIH<48RJU/9J
M3A4C92IPUDI2=XPT5VY7225W9]R\3SP<C!&<=..@';/0=@#30P)*L#C&#Z$=
M.0?KD=?I7CI_:*^ *N4;XV_"G?O,>!X^\,%MZDAD.-4X8$$$'D<@TQ?VB_@"
MS$?\+N^$[98H<_$#PN"&SC;C^T^3VY]#D5G]<P-->_B\,G%*-W7IQDMM7>2L
M[.^MMM5U/87#?$=D_P#5S/I1G:2G'*\:U!NVJ:H:W[JZMK<]G3C"K@*O0>V1
MQT_P_E37&,CKQTSSC\O3T]17D$/[0_P$GGMK2W^-/PKEN;N58+2WB\?^&&FN
MIG8(D4$:ZCNFD9R$1(PS,<  DXKUY)DF194(92 RNI!4JPW*0>C*PPP8'!!S
MS5TZM/$)3@Z=6FWHZ52,G)IJTG*,FFGKLWI;NCAQ>79CETHPQV"QF$G5=XPQ
M^&K8:56":YN2-6G!R6UVD]7KN-;<$;"X./D X.3T)[GJ#SC/-?G=^W+^P]X!
M_:ZL/"LGQ%^+7B/X;:5X5DE,5OI<^F1Z7J5Y.XDAENO[3FB@^UP_=A*YD"YV
MXY!_10#@DG=G.">G(XZ=<X/;'<U\H?M<?LM^#OVM_AG;_"[QGKGBK0M(MO$F
MF^)?MG@_59-(U)KW30PAMI+B)E=K242,9H@</CU%>!Q=D^%SW(,VRW'97A\X
MPM>@H2P%>=6C&NO<FZ<ZD)+E7,E+F[I7N?#\:Y)@>(.&<UR[,<FPV>TJ^#J1
MI\/XRO+#X+'55*/LZ=>K2:J4U*RO)3M%:N.[/P&_:H_X)<_ _P" ?[/WQ)^+
M_A;X_P"N>-->\&:.E[IWANXN/#9@U&9KF*(1E;*=KJ0A'+XB5LE>F,FM/]G7
M_@E1\ OC/\%/AG\3_%/[0.O>&M8\:^&+/6M4\.QW?AN&WL;FZ#%K<?:+E+A!
M&<?+( PZ,!7V@/\ @AK^S_*0;GXH?&VZ@!*FUN_&4US;("NWRC!,7C>,<X$J
ML0<&E;_@A5^SQ+"UO_PL_P".*6IB,,4$/C2X@B@C<$$6\4#)'$!GY550 <<
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MB>Z*);V[>(K.PBA\13Q1Q92. ZC'=2JJ@!%.T !10!]J5\U_MF_\F@_M4?\
M9N?QL_\ 5;>):RF_;>_9#MI9[6?]H_X2)<6EQ/:7,4GC'2DE@N;:5X;B"5&G
MW))#*C1NI *LI!Y%?/7[7'[:'[)FM?LI?M-Z5IG[0_PHO=0U']GWXQV-E:6W
MB[2YKBZO+SX>^(+6TMH(4F+RS7-S-#!%&H+-)(H YH _SM?^#0O_ )3(^#O^
MS??CM_Z9M(K_ %>*_P B'_@V&_:*^!?[+G_!4[PO\6/VB/BEX0^#WPXLO@A\
M8M$N/&7C?4ETG0H]8UK3=+@TK37O'1U2ZOG246Z$8D,3*#NP*_TD%_X+=?\
M!)0#G_@H%^S8>!S_ ,)W;^G7_4D<]>,4 ?J=17Y9?\/NO^"2?_20']FS_P +
MRW_^,4?\/NO^"2?_ $D!_9L_\+RW_P#C% 'ZFT5^67_#[K_@DG_TD!_9L_\
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M_(=>O85^7/\ P^X_X)(D8_X;_P#V:_\ PN[;_P",4?\ #[C_ ()(YS_PW_\
MLU^G_(]VW_QBDDY+][:4HR<H-75ET3OJ[:WUL^R)4>6SII1O937V7&VO*NDF
M];_)^7ZB-N/ V[3@-E0<KW4COGU_/I7RY^TU^R-\#?VM/!%YX(^,O@C3-9LY
M(KBWLM6CABAU_0S,"JW6DZHJ^=9N20X922",].OR]_P^Y_X))?\ 20#]FO\
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M_C'7 ?[/\I?*%G,UQ8;;=I$!,]O&VTS;F()R3]$VO_!7?]JGP;&]GJ__  5
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M >NS_"W3K7_A)].\4WOB;P#XOU'4I[RTL8Y%&AW]BL2QO:3&0/-O!4LJAMP
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M93RV-W^TG\&Q<6\LMO<H?&^DQO#/;2&&:&51*2DL,B-&ZG!5E((!R*^;[O\
MX+&_\$J;VVO;:7]N;X"O;WUK/:3H?$EPRM%<1/#*G%@%^:-W7L?F-?PV_M\>
M&/V7[+]J#QYJ_P"RU\4?AW\5_A/XVNI_%NC7O@6Z;4;#P[<7TSO>:7J4LUO
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M74IQ'!:6T<ADEDF; 1%!8GI7TW%(BQA@K $\AP258\LN>GRG@'L,=J_S]?\
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MH:%XGUWQ%8Z=<ZIIUEXPT>267Q=I'B06,3MH<&H:&ZBQU?4#'9F60AFW1A)
M#]DO^#Q,PC_@EOIJGR#+_P +N\ ;-R*9PHU%-WE.?G53C$@4X('.:^S_ /@W
M!MWNO^",7[-]E%+)++<Z+XTM+<S[P6EGU"\B2-=_/EK*Y"D?+@<&OXS/^"J'
M_!:+XM?\%^A\ OV._P!E_P#9A\:^#OMGC'2)-<T.XU&#Q?>:[XMU*]M++3+]
M[K1+)8="\-:9<L]Q-=:D3Y,(=I9685_HK_\ !/C]F6U_8]_8Z^ O[.ZP1Q:E
M\.? .AV7B"..6.2*'Q1=V,-WKT<,\>4F1=3EN8XYDRLB(K+D$&@#_.>^(/\
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MX _9&O[&=[>X@\6:W+#+$^V:-DL;H!PP^9>@Y]<'.<5^M'_!K+>WFI?\$I/
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MJ<(0A*//7<I.*C*/Z=O_ ,&SO_!0S7!#>_\ "Q_V/[2WN(DN$L]>T'Q3J-_
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M4Z4J5XN46S^"D?\ !L!_P4$!&_XA_L08/WE_X1#Q4 P]#_Q*,G./;/MS0/\
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MS*,NQ69< UJT:&'6(C/#4:$,HH0C&%.K5CC)3Q,=%)4Y/>,+K[6D_P"#9_\
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M7F<KQY?X+5_X-@/^"@C,3)\1/V(&+#.Z/PAXI4 GJ3G2">_;CIBG+_P;"?\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )M7
M&!@=.!Q7,>,_!'@[XB^&M5\&^/?"^@^,?">N6[6FL>'/$FEV>L:-J5LV=T-Y
MI]]%-;3QG)^62,]3ZFNHHH ^:_A-^QM^R?\  ?79?$_P6_9S^#7PM\1S0&VE
MUSP+\/?#7AO5'@;K$;W3-/M[C8?0.*^DMB$DE02<$G R<# S]!Q].*=10 44
M44 )M7(; W#(!QR >HS[T  #   ]!2TTM@XP3QG(QC/H,D<^W_U\ #J_(#_@
ML9_P2RC_ ."LO[/GASX%2?&&[^#*>'O&$?B<Z]#X8B\2_;3#Y(^Q264M[8%8
MV$0_>)<(Q)[C(/Z\F9!D'( X8GHI/&&QG'7MGJ.M1?.&P7)1N-P)(5AU1L]%
M.<!ASWXH _'K_@C)_P $G4_X)*? WQG\&8_C+-\9D\6>+7\4#69?#$/A<:?O
M6939QVD=]J#R*QE+EY+AB&!"X7 '[(5#$I&[.2V>K<<=@!Z#L>IJ:@ HIN\%
M=P!QMS_];ZGTJ,3H=H;,;,"0K\$ #))[#@_GD4 2L-RLO]Y2/S&*_C^L?^#5
M>'3_ /@H%:?MTK^V+?R7%K\9Y/B[_P (*_PQL^=]U-<_V&NKC7-@B"S>2;@Z
M<TA7<=OF,&7^OX2J1NP=N"<D<8&?QYQQQ0%.=V[J<D=00!@ 9Z#_ #U% $5K
M&\4*1N=WEQQQA^F_9&J;]G1-VW.T="3SC%6:!GOC/M10 5'(6"_*0OJY/W1Z
MX[^F*#+&#C<"<[<#UYX].V,],U"DR3J2$;=&3N1AC8P!X;G!R/F'7C'0T ?D
M)_P6/_X)8I_P5G^ /A;X$S?&*Y^#$7A;Q@OBU=>@\,0^)UU%FBAB^QR6LU[8
M%(_W():.X1^<=.E/_@C;_P $HQ_P24^ _BWX(P?&.Y^,R^+/%]WXH&N3>%XO
M"\>F"X0K]E2RCOM1,H!8NTLERQ9LA55,*O[$*>0JD;6&XD<\D\\$ *N>!C!Z
M>U.$1+M*<JY7:I#$C;GNIXSC&3C/6@!(7))5L[E 4$_+YF!RP7)P,_I5BF!2
M"I)SM7!X&2?7/;Z#BGT %(3CL3]/Z^@]Z8TJ)]XD#<%)[ DX7/?D\#BD>1=C
M-R0I()S@#'))((.T=3C/TH _D _9R_X-5+3X!?\ !0_P1^WG'^V%>>(IO!_[
M1&L_'<> &^&5O8B_DU;Q%K&NOX=?7!XAF$03^U6M7OET_+K&9$AB+KL_L$!S
MZCZ]:IEFVH@9G8LISM 5D(SG(P0BYQN&#].UL8  'IZY_7O0 M%%)D9([B@"
MNREG?#&,%E!)/W@!T4G[O;./Q&,5^*?_  6N_P""0</_  6"^$/P;^%%S\;9
MO@HOPC^)&K^._P"U8/"L7BLZZVJ>')=!_LY[634M,-IY E^TK.LSAF!1HSP1
M^U<J&1L-GR\98].ASY9],\'<.01CTI(\N<!]RL#)E5P-I&SRPY^;WW8SGO19
M/=?UO^:3^0'Y7?\ !(#_ ()IQ_\ !*3]DB7]F&'XJS_&-6^)GBWX@CQ4_AR/
MPTT3>*(-+@;2DTR.^U$M':'33*9WNG:5[AQM1551^K$(Q&!WYS]2><^A]NU5
M_LQVQC<Q,>_!W$85@!MX/S>FX\C)-6(D9$"LVXC/X9[>^/7OUH>JL]5IH_+;
M[A65[V5UHG;5)[JX\@'J,T  = *6F[O8\C/;K_=Z_>]J5DE:RMZ?UV0[+>VO
M<Q]=TUM4TK5=,CE^S_VII=_IQN0GF-;&\MI(%F$7_+787W!<@';C(!K^2+]E
MO_@U>M?V;O\ @H!X5_;C7]L'4/%+^'/B_KGQ6?P&_P -;33CJ#:SK%]JQT27
M61KDXCBA:],7VF*QCD/E(=HRX;^N]G#C<I^[PPY!4]P0.Q!//;J.II455(#,
M79B'')X  QQQA5! &>O7'6G=]]MOEM]P-)WNKW5G?6Z6R=^B[$^,?SHHIC/M
MX +'C(49(![GVH =@#/ YZT8&,8X]*0LHP"<$C(!ZTU959F7D%?O9'"CMD]L
MCD4"LNR[;=.Q^$?_  6Q_P""+"?\%?\ P_\ "+09/CU/\$T^%>IZEJ>^+P?#
MXICULZA;RVXCF#ZEILEL(/,WILE8%E&Y2",?5O\ P2K_ .">P_X)E_LF^'/V
M7X_B;=?%I-%\0:KK;>+)] B\/O.-2$6+--.BNKQ8(K<Q1[)&N)9' (=BS$G]
M+\EP=K%2.", X.<YS[CT.,4T(P;<."X D^8X4CNHXZGK1T:Z.S:Z-K9M=;=.
MPUIMIK?3OW]20JI.2!GUIV.,=NE%,,BJP0GYF!8 #G:.K?0'\>>E >?7:_EV
M%*K@C'4'Z_F>E<CXPT*3Q/X1\2>%TN/L,GB30=:\/K?I$MR=/75K">R^T&%B
M%F$/G>8$8X8J%) R:ZL2(Y*@YR#C'<8Y(].>/K46Q5 8Y1%V[06(.XGG)&=V
M> "3WH%9=E]Q_(]^Q7_P:W6W[(/[=?A[]M/_ (:^O_&TN@>-/$/B]_ X^&UI
MI1OSKE])?'3Y-636[D)' T@3?#IZ.P1,;1N#?UPY9@'VYW-D[QL\M!GAO[QQ
MV]>_:I-I*Y4;6)Y)P" ,^G0^O )SS08<D,QW.JE58YP02#\R=#R.M'?SW\_7
MN%EIHM'=>36S7F2@+V Q[ =*,#T'Y4HX ICN$&2#WZ>W;UY]@:++MMMY!9;6
M5NUAV!Z#CIQ7\\__  6U_P""%$7_  6$\3?!;Q!+^T1<_!1/A%H6LZ(;&/P7
M#XIAUO\ M;47OC>&1M4TV2W>W#F%(A(T;<LWS!<?T)-<1JP5B03@$8/#M]U.
MGWFYQVXYQ0Q&X$*P8YC!/0 C=G;T/."<]OKP!9=ENGMU6S]5T/A;_@FS^Q7%
M_P $^_V/_A1^RI%XZ?XDQ_#+2YM.'C&32$T-]8\ZYEN/..EQW-VMKL$@B51<
MS':BEI'8DU]W[5R#@9'2HHF+;@2<H2A& !D<Y&.V./ZU-3N^[_K_ (9?<#BG
MND[;70W8O/ YZU%*H5,AEC /+$9 R>_ISW[$YJ>FL,@ @,I/S C.1VXP<X.#
MTI/7?6VJOK9K9A9-W:5[6OY::?@O0X?QUX8/C+P3XR\&B].G?\)=X1\2>%3>
MB);A[ Z_I%YI?V](68"X%M]I$PA8A7\LID!J_E=_X)U?\&O,/[ _[<'AC]LB
M+]KF\^(TWAJ\\67C>"Y?AO;:)_:!\3B0-%-JZ:Y=K$MN9&9O)LX]Q5,>6F5/
M]:4:JLCA2F% W9)WJ[=>3RJD8QCBI2A+HW]T..O3<!P1T;IU/)[^YOOZ?+L%
MDE9))=K:#5#>8=QR& ;;M&%.!N^?^($]/3&*GIH!&0>@P%_ #.?QIU PP/2F
M/PC$#D D87<<^H'<_P"309 "PVL2N,X'8]QSTIKLI0\Y!R <D#/N1SC/4@?4
MB@#^>/\ X+:_\$)D_P""P_BSX&^);G]HNX^"$7P<\->)-"_LN/P1;^*TU^37
M]4@OTU!IGU;2IK(VJ1/;B)7EBD$I9EW*I'Z8?\$W/V+(_P#@GY^QM\(?V2H_
M'4OQ*3X6:;?V">,Y]+31)-8%_JMWJ1E&E1W%VMFD"W*VZ1"YG)6,.TKNQ-?<
MKL5;;&K%W4*SCYA$0."^?X,=QP>XZ5,!D>8A#.5"Y/ .&^;CMR/3C%";6J=G
MW6@FDTXM)Q>\6KIVVNGH[#PJK@!>&.3CH"!U_$<9^E+L49^4<]: &!Y(V[5
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MF)%*N3M)P1^W'[%O[-4?[(7[,?PG_9T_X2J7QP/A?X8M/#Y\3RV":9/JWV8
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M67K&HZ=H]A=ZSK-Y:Z;I&D6L^I7^HWDZV]M96]I&TL]S<2R,L<<$,2N[L[
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M#-;\=>']$CN+G4M2\(Z9K,=Q>SK%:@RRVEDBM<W\1!22#Y7!4$4 ?C/\?/\
M@\>\96WQ(UW4/V:/V1-3\7_L]>&]6ETZZ^(7BRUU@3ZG:65RT-QJUG>::JZ5
MIL=W&OF6MOJTD,D091*.<G^M#_@F_P#\%!OA1_P4M_9B\'?M)?">VO-#MM7=
MM/\ %O@G5+JTN=<\(>)+9WAN=,U22SD>'RI&C:YM67:9+5D< Y)'\'G[%O\
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M0H_9;S9O,V$$-@XV_.)%50<@#/ELV< -U/>@"_7XV_\ !=/]N_XO_P#!//\
M8,\;_'7X(>&[76_'K:E9>'-.U34$,NG^$UU$.9/$-U "/.%L$\N*,D*99%W%
M?O#]8;#QWX,U7Q/K'@K3?%OAS4/&OARUM+S7?"-EKNFS^(M'M;^,2V4^KZ+%
M</?V,-RA#6\UQ!'',IW(Q!%?EK_P76^#TOQS_P""4O[97A"SLX]1UVV^%UYK
M_AM$3S'M]7TB^L[C=M&22MJ+D$@;MK9X S0!^=7_  0+_P""_G@;_@HOX.TS
MX$_M"ZYI7@W]KSPO;2*T5Q/%I^F?%G3(P734]%\XK&-5A5@ESIZOYC[%:)2[
M?O?ZD*_Q[O@E_P $R/CQXE_8&\(_\%2OV%=;\77WCOX ^/M2\._&GP?H,MTW
MC#PIJ_A%;749_'?AE;0">^T0K=6GV[2HE8PV1EGE!12&_?3]DC_@[N_:#\=W
M_P"R/\ M5_9K;XC_ !5U/Q3IG@'XPZ]IMT#>^.8+ZZL](TK6/#UA&IETW5(%
MD>]UGSE83O#*0=S@N ?Z#M%8VD:E/J.D:9J4UE-87%_IME?3:;=-BXLY[R!)
MGLI6.!YMJ[-%(,?>4\#BKZ2M( T:N024<,=IC(&=P#8W8/&.I^AH X7XG_$O
MP3\'? ?BSXG?$KQ%8^$? G@G1M2\1^)O$FJW4-K9:7I6E6[7-Q(SRLH=I45D
M@A4F264K&BEF '\8'Q4_X/-?A;H7Q0OU^%G[)GQ'\<_ ?P_X@DT>^^(5Q<VM
MC-KUE;W#0R:EHSR-%9Z?]N4"2SM=4"2A"F\/NRW[=_\ !QC\*_B5\8?^"17[
M4/A+X86]W>^(K;3O#7B:_L;$R)<7OAOPOK]KK/B*W4Q')B?3K9VF0YC>%)$<
M%6(K\*O^#7SQ7_P3R_;-_8-\5?L&_&/X3_"S6_C5X6U7Q/JWB[PYXBT/31JO
MCKPGKDK+IGB31[NY'VV\U+2$CD^V-:.WV*4Q3E !(2 ?TJ_\$W?^"MG[('_!
M4+P+)XH^ /C+^S/&FC)#_P );\*?%%Q;V?COPV\R"6-)[0NL>J6ICP7O-.$\
M*,2KE,!F_49.5&00?1@ >#W XYZU_E^_\%6/^"57[3'_  04_:?\.?MS?L,^
M(O%"?L\R^*XKW2-2TVZNI;WP#<RSK=W'@7QK%;_+?^&=02.X2UO+B/[/!#LC
M;#(C+_>#_P $D?\ @I#X&_X*??L@>#/V@/#$/]C^,+*&'PK\5O"AD$H\->/;
M&WC;4+9)5.V6"^B*:A;2 +MBN0FT;* /U#HJHKN[%%8Y48=2,D$#D;^FXD\'
MMQUII68.P:1EB*H"S$90 $-M;NSL1SCY?RR ?SV?\%MO^"\/@_\ X):_\(E\
M(_AGX$3XV?M2?$C3WU+PSX%MIIKS3M!L4F:WAN?$UEI3G5FFOI?+^PV-H!=W
M$):2..0 [?(/^"$G_!87]O?_ (*7?$3XJ:!^TI^R-IGPD\!^ =.MF@^(NA:'
MXM\-6D>O7!++X9OK#QA(]U<731;+D269"*K,KHK1O7\]W_!23XC:;^Q;_P '
M1O@C]H_]JCP]!J?P4U7Q3\/-<T75M6TTW]AI?A"+0+'03K>E6=R&@FFT#4%?
M[5L4Q&6>XD89)S]??MD?\%#?^"J'_!4+]M;XR_LE?\$8-0T/P9\(_@9%8ZYX
MD^+G@O6-)\'S^.KK4=.LV&MZAXXF0VS0LUW!I]II3+/<+=0MYGE8'F ']Z5%
M?YYG[ '_  73_P""BG_!/3]M+1/V&/\ @KG#XC\1:%KOB#3O"<OBWQ5 ;WQ;
MH&J:U>KINB^(K3Q"@6W\1>&;N]GCCFN[=4A$0\S'R97_ $'[/4K75+*QU/2[
MN"\T_4[6"\L;F!Q+%=6MS$DL%S ZDAHGCD1P02""#0!HRJ&C=6!((.0.OMC'
MH>:\9^._QO\ AK^S1\(_&WQM^,'BBR\+?#SX?:%=:WX@UW4)%C'E6ZL\=K'R
MOF7EY($M+.,?,\\B#H":ZOXA?$GP'\*?"E_XZ^)WC#P_X"\&:,(6U7Q/XFU>
MUTC1[-IYE@MTGO;N2.(&:9E5(]VYB< '!K^97_@Z]M_B?\1_^"6&G:[\#+^?
MQ-\/[WQYH&K>.Y?"DC:K::_X2U!K4:%-"VGF5;VT?49(Y$:,NC$@8;(4@'Y.
M_M _\'C_ ,<I?'NI:]^RK^QY;:S^SWH&K/IU]XS^(5GXEN;S4K:WG\J2Z35-
M 4:-IDEQ&&FMH+^:*1"RI-'R6']6/_!)K_@JS\$O^"KW[/K_ !;^&=I=^#?&
M'A34(-#^)WPTU:YM[C6O"^NM$6CN5DMB8[C1M9*37.FS+O980J3,7^9OA?\
MX(??LD?!WXB?\$6/A[\&?BQ^S+%\/K+XC>$O$.G_ !$\/^,]"A_M_P 5ZI?6
M2Q/X]VW=M'?VDMX9UO-)C9D>U>$[0HE=6_G7_P"#6/7;KX+?\%>?VS_V7?"#
MW<?PW1/BK;PVLDK;5A^'?B^^TK0#<H3M>=+/;&&QN!#<[000#_1IHKSW_A9G
MP]F\?3_"J'QWX9?XEPZ*OB6?P#'KE@_BN#0FE$*:O+HZSF_ATXRD*)WA$3-C
M:Q!!KMHUE4N)'9G8*"X.$+=Q'&?NX!Z].,]* +3C*L!GD'[O!_ GC-?S9?\
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MDD?,#QP.HH _@ _X.&_^"$WQ3^$?Q?G_ ."F?_!.;0M9TZ_L-:@\;_%'P/\
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MX#\(>-) Z6NOWL=]XBN[*21S+OTUO$%UJ2V,Z,2L4ELL3VZ ) \:JH !T_\
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M.D_#^PU9['6_"GBZ[TZQU'48]"@ADAFU;P1J!?RYXYUD@D.]90-X# '[7?\
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M;PZ;;SM>R^ 9/$VM_P#",/J+W/VI9IHENUG^R))\HL$<6WD_N22F00#\;_\
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MS\.='C^U36[($=Y[KPY%'+=VD*JQE3=%L*LY(!\$?\&\O[%?[97B/XV^./\
M@LC^W9\=?%?PN\&^,X=6O4T[QGKL^D)\4+/4W$Z:SKMM?W,5MI?A+2$5%\,V
MX#@VK_N01O4?V+R_'+]F3]K/X>?%KX;?";XO?#/XMW>J^!?%&BZOH/@_Q5I>
MLWFZ_P!'O((HY;6UN)),F5U.0C;2NX_*"1_FX_ #]H/]O'_@X6\=?LI_\$V)
M/'<?P7\!? ?X>ZJWC[6_"EW?Z/#K_A/PHFEZ:FK:WIUL8+:YUC3-/6+3[#2Y
MXWMIYGDDD1WCVGL_^"D'_!&/]LO_ ((*ZK\/?VS?V6/VA?%_C7X?^'_$]C_:
M?BFQGN-)UWPYKL(>XCD\6:+IQ@TK4?#.H1J+-GNHG)ED*$;BK1@'PW\#_P!M
MO]OC]E+PG^TI_P $D/V9_"^M:?XX^.'QT\1^&]>&F6=W<>,5CNYY-$N])TJS
M6$MH\6I:5L?4M01E0:?*7E)B4;OTH\:_\&K_ /P4-_9@^&'[,?[1_P"SAX^3
MQ9^TW>>+?#EWX]\&Z/,NES_"?5=6N(9M*U/3M51)9-8T_29O^1BN9 HM@6)3
M;@'^OG_@DAX4_9'_ &XOA_\ "/\ X*UI\!/ _A[]K_XG_#'2_#'Q3\3Z399@
MM?$VF(MMJ]WIUM<1_9X]2O/+CN)M6ABCNW69H3*P16/[L%I"QV$%@K&$N2JN
MYYV.%ZHN._.>1T% '@G[.NB_%[P'^SY\--'_ &C?&NF^-/BWX:\$::?B9XLT
MRRAL].OM9T_3$?4YX5BPC)%Y,NZ[X:Z96F?F3)_A:_:S_P""I_\ P5F_X*W?
MM;_&G]GC_@E!'JWA?X$?!&]U.QFU[3HUT+5M=N_#MQ]FNM5U7Q&(KB>SEOKZ
M*>WTO2D#+/#AR4$BEO[_ #Q/H<?B7PQXA\,^;-:#Q!H.KZ/)?6I):SEU*QGL
MWDCWD9DC>8O"#D$@=!7^7I^Q7^W9\2/^#?'_ (*'_MQ_!3XW^$M8NM"\?OXQ
MTZ!I+5[=[+7+F\N]=\$^.+)RH6_M+J-K&SG\EI;8-YHR'B<4 ?VX_P#!+F[_
M &H?@Y^R%HGA#_@KO\?/AOJWQ5^) O[72/A]XLN]"L=3TKP9>V_V)=!\07-Q
M+%-KE]>Q/.+I9H=J+)LR)-ZC^0#_ (+'_P#!)3]I/_@DW^U)9_\ !2/_ ()Q
M3Z_%\$[OQ!-X[M-4\!(]^?A3JM_<'4-1TO5;'36>"]\ :BTFR!7WV<ML#'(J
MB/=%V7[)W_!$?]LW_@M7\"_B!_P4)^+_ .V;XR\._$SXH>(_$>J?"CPU+KM[
M>:%.MO(7L$U/R;I_^$>L7#P0P0:<MK+%&-\V7S(WM?\ P03_ &Y/VI?V3OVW
M_''_  1K_;_EN?B%\/\ 6I/$>@Z#9?$*63Q1'X=U^PD=$BTZXUI;B?6/"WB]
M!'Y$%_YJ0)%YD2JPC"@'L$W_  =,?L,_M>?\$Y?BC\%?VX/ASXJLOCKXI^&F
MK>$]8\*>'O"PU?P=XN\0OIQMM/\ $.E:QYJ#09I[]1?-"ENSV09HD,:,:]K_
M .#-3X,?%KPI\ ?VD_BSK.FZ[X;^#'Q*^(,/_"M--UB.>"UUL6-G C^(M,BF
M %W;P11'3FOD&V5X_D9D(8_L]XF_X-U_^"0/B/XBW_Q2U?\ 9(\.S>(=2U8Z
MU=V=IK_B.R\.2:H]RMVUZVA6FHPV,2^>,M;HOV1U)5K9E) _8_P9X,\'?#GP
MKHO@KP/X=T7PCX.\,Z?;:5HF@Z#86^F:;IMG;I'%#;V]G9QQ0IE8U+N$WRN6
MDE9G9B0#\*?^"_O_  5S\0_\$P_@'X0T7X+Z1#XA_:;^/VLS^$OA592VD>IV
M>@31FVCEUV]TUO\ C\GDDNH[72[1U(NKTK&.@9?QH_X)E_#+_@XXU?\ :M^%
M_P ;?VI/C8/AG^SKXOL$^(7Q+O?&\NG:EHH\+2+%>OX3C\-WL5M:>'M9UB&3
MRH)()I'TX LIQ\R=/_P>%?LS?%!_"?[,'[</PSTO5M;M/@7XVCA\:-;PR75E
MX52UO=.U3PGK4\$0=DMKC6(&CNYF18XT0-(X7.?S4^(O_!1W]I'_ (.&?B!^
MQ+_P3V_9^^(^M?L_Z4_@)-0_:%N+'6+O0IO$/B'P=9Z<FKZTEQ:S6\MU;V\*
M2/I&F1R&.\>[8SI(H>*4 _J,_P""SG_!,[X!?\%H?V=-2M_@UXX^'6K?M-?"
M>SO)_A7XNTO6]+O UP',MUX0\175K-+<6VCZC,"7E9"MO<K'NV@Y7^([_@E#
M_P %"_C7_P &]?[8WQ-^$'[6GP4\16O@OQ?+;^&OBCH364L'B71ET[4C+!XQ
M\)32QHFOVTJPX@A618[B!]PV2%E'T1_P4$_X)D?\%!/^#>WQU\.OVQOV:_VF
M/'GQ$^$MAXATZQO?%%QJ5ZUSINM7#>=<:1XU\,.[Z+>:3K2130Q7+6[':S@R
MB3=C^U#X"^!/V+?^"Y'["/P&^/G[1_[/?@3QS<_$KP58ZCXAMK^P2T\2:'KE
MF\NG7UG)XBTIK35D22>T:^MX4OS'!%<1>4J4 ?Q??\%8?V[_ (:?\%]_VZ/V
M/OA7^P=\'/&EYJ/A?Q!I5EJGQ'UGPN^B>,;_ $Z\U2SFOO[6M[>:[>QT#PY$
ML]Q!<W%T55@63YG"#_1:3Q3X!_8^_9?\/:Y\:_&^D^%O!_P4^&>AV7BSQ?K-
MY'#:+'X;T.WM;ITFF9&N9KI[5EAC7]Y.Y' !9E\M_9*_X)R?L4?L-PWT'[,7
MP"\&_#.XO(5@NM9M+:34M?DMU\PB&#7-5EO=35)'<M,4NE,G'FEN,?!__!=K
M_@E?\8?^"IO[.?A;X7?!OXXS_"GQ!X7\1VNJ7'AC5IKR'P+XSTR1S'>+XG?3
MR;R:XT^##Z;;E)+:29BTP 7) /XE?^"OG_!57]JK_@MW\4/'_P &_P!DKPCX
MP'[(OP,L=6\7:GI6BQW*1^(=$T"5HV\?>/)808[?3RX+:=82LT3 1S^6"-H_
MKR_X-E_BAI/[2_\ P23^'W@CXBM:_$:/X7^(-4^&FO:7XN2'Q''')H4\%]96
M5Y;ZDMPLB6BR0RV:S(VQ(T9#D''VG_P3]_X(_?LW?\$_?V-_$O[-GP_\/6.N
M>+_BCX#O]*^,WQ&U&UA?7?'GB74M FL+II+EAOMM!LKF9H=-TV%EMS%%%/,A
MD)"_RF?\&X/[1?B?_@GU_P %/?VI_P#@EI\<-173=.\<>//$5GX.L9)3#96O
MQ&TF=KV)XFF*1C^V/#"6T,>WF28E49]J"@#_ $(DM8+;3S9V-M#:6]O9M:V-
MO:Q1PP6\,<)CABMHHU5(D10JI&BJJJJJ  ,#_)-_94_X*8V'_!*S_@H__P %
M#OC6?!<WBSXA:]XE_:!\$?#NPFBS;:;XMU+QSJYL;_5RQYL8)D5IH&#K(%9"
MI!(/^MVK;7VL<E5))&<(,#"GMCTQSS7\?<O_  :V?#/X@?\ !6'XG_M9?%36
M=.U7]E;4]?LOB7H?PO!+:QXQ^(NK$:IXCM==4?NX?#=OK#RS 1E9;D. 5)&Y
M0#X-_P"#?_\ X)\_MU_MH?M@K_P6&_:^^)WQ"\%:/=ZI=:AX/TQ]0U#3-3^*
M]I=22!-%DT^1T^R?#BQ20BUM,"*>XMU?86+D?KI_P7T_X+\^"O\ @GIX,U7]
MG;]GC4]-\;_M?^,],GTM(+%DU&S^%%MJ*M9IJFJ+ TAD\1L6==.THKYT<K0S
MD"7:(_Z4X?"&AZ1X&;P+X7MH?!>A6OAJ?PSH=OH=K#:1^&[)K&73[.32[.%5
M@B>Q#I/;C:,RHI<G)8_R6_L6_P#!KGH7PW_;\^*O[67[8OQ0?]I/PC:>.K[Q
M9\$=#\127%_K.KWEW?/?V>L?$W[49H)+C26=$L;"UDDM<01K($!Q0!_.7_P0
M[\9?M1_LL_\ !;CX'^)?VM]2\<>%O%/[5?@75?$NO1>+=1O(IO'FG_$[39#X
M4O\ 6K:XD6*ZG6<--IL,RN]@XB$!125/^CI^TO\ L(?LC_M:26.K?'KX$?#[
MXE>(M#64Z/KNN:#8SZTC0V\L4%A-JC0?:9[16=2MI.[PHR(4"@$-_(M_P=P_
M!_Q9\#/B1^Q5_P %#OA'I0M=5^$OB;3]!UB]M87M;32I_#>HZ9J'@BSEDM$4
M6^G3SPRV"VZE8PID2-,$@_UP?L!?M7>%OVV/V1?@C^T;X/U*"_A\<^#M&N/$
M+P^65M_%EK86\'BFR,:<Q"UUI;N-$95?RPAQR"0#_/K_ ."-W[>?PS_X(J?\
M%,/VR/@C^V?X-D^%^A^-?%7B#PT=>TSP^MQ=>#+F/Q+_ &OX?L9F)@:'PI<:
M1);2QO"Y@BF\L98C:=+_ (*I_'GX*?\ !:C_ (*\?LF>$?\ @GCX2OO%_B'P
M_J_@R/QW\4K?1SI0U>'P[XFMM<U#4RT/G+<Z=X?TB%Y8]4GD5IKA$@4Y8A/[
M:_VY_P#@BU_P3Z_X*'>)H?B%\?O@Y9W7Q'M[5+$?$+P[=7.A:[>VB;,1ZDUC
M)%#JC*(UC26\C>9$0 .P  ]0_88_X)9?L1?\$[=+U"W_ &8_@SHWA/7M<1%U
MSQOJ?F:SXNU-HHA$Q_M?43-<V-M*H"O;6)MXG151Q( <@'TA\4OBIX"_9+_9
M[U_XL?%OQ'+#X1^"WP]DU+Q)KLV%NM3@T'2-TBQ0E@)]0OVMBEK!G+3S #J3
M7\ WQ9_X*^_\%WO^"G7B3XD?&;_@GK\+O%_@C]ESX3ZQ/=>'+'PCX;2^U/5(
MM(EN'BEU/6YHXYM:U*_LK9+N\T52MK:,981.WW(_[9_^"J?[*WB3]M#]@W]H
M/]GSP1>S67C3Q7X0OKKPM"C[4U3Q!86T]QINE3.Y7%MJ,X$+@D8++G Z?P#?
ML:?\%8?^"EO_  0Q^ WQC_8U\?\ [%YO[3PSJ6MZII'B?QM9:YI$'@74M72X
MM[F[DU/2H_[,UK3KJ=TU&V-S<S7&Z)(EBCC=UH _K&_X-U/^"NWQ0_X*5_!C
MXD>#/VD[*RM/VDO@%K:Z!XKOK'3XM(M?$FC[8(AJM[IB,$T_6+74#+8W]LBN
M2\3RL^ 2WXN_\'5S>,_V0OV^_P!AS_@H?X)TJ6[O]!BM-"#EIH;+4I?!=Z=6
M71;V\B1OL\=U;7,T:\ABL\I0-EA7Y??\$_O^"4W_  6H^+G[._Q!_;Z_93^*
M6A_!G0OC5/XE^*5IX8AUNYTCQ;\4;:2]U#4;FXT"WMM,NK=[22Z2>&PAO+JU
M\V55CC5GXK]9/^")W[:EY_P5>L?BU_P2?_X*[>![?XT>*? 5TGB3P?JOC2R@
MLO%D$_ARZD34O#&H7=I'!=6MUHXLPZ75JZ37%LWD7!=,D 'YM?L\?\$TOV]/
M^#EWXR_&+]N/]I#QA>?!CX87&F:CI/PLUB\TMY-,NKZQC<>&/"'A+2KE8DE\
M-Z7'Y=OK&M1JLCMM=<_(I_HG_P"#:K]@;_@I9^PC!\</AS^U'XMATS]FW2]?
MOM-^&'PVO9%U6>^UR*\E2;Q=X?NI5$NAZ+?0J9I=,@W175Q*L[L648_J&^&O
MPX\#?!_P!X9^&GPW\+:5X,\"^#](L]#T+P]I-M'9V6F:58P);PQK' JAYRD>
MZ69MTDLFZ21V=B3W))WKAPP)21%8L28\$$@MT)/T/7TH _F,_P""Z?\ P7D\
M2?\ !/7Q9X0_93_93^'<'Q;_ &M/BEH[WECF*35[3P(+NX:VTT?V+!#<-KFN
MW<L),&D3((OLS><^&"D?SW:7_P '(W_!</\ 8?\ B!X4UC_@H?\ L^?;/AYX
MS^RSZ5X?\4?"BW^$]U>:<9E>]FT75M-MV^U7"V;EH+6ZDCF#(&=BK%DUO^"]
MMK\7/^"</_!;WX*_\%'=9\ 7/Q'^$NH:WX?\3Z.^J6AF\._:;&"?3M:\*"<B
M2&+5[/399M1TZ.<1H]RL1W *2/O_ /X+7_\ !:3_ ()/?MQ_\$J]>T#PEXY\
M*_$WXX_$"S\-W_@CX33:9,?B=\-?$_VM9'EU.X?3E73)+!\K<Q:;?O%?QE5E
M  "  ]B_;=_9X_8[_P"#GS]AVU_:/_8ZU[1=*_:W^$>F*+72]3>WT_Q/I]X;
M4W5[\.?'MA$QN'M=2:$KX<UBX!1=@\K!98E_$3_@DS_P7B_:,_X(]_$;4OV'
M/^"D/A/XB7?P8\&7]WI,=KJ6D7=_\1/A9<0W#(LFBV]XT$_B'PU-Y9:SMTN!
M%]F*-;N"%9?@S]D_4OVUO^#??]KK]E/XX>/8;_1O@W^TUX/\&^*=:CA:[_X1
M3QK\-O$SV,VL:?>VDQ"Q>)?"MO?(Y:Y@2XM996,(VL=O^DE^TW_P3C_8#_X*
M?^!OA]XZ_:$^!7AWQ^FK^'M%\7>%?%UCYN@^*H[#7]-MM1M5FUW1VMKN]3[+
M<I&8KYKE$21D0)Q@ _@K_:Q^-OP=_P""L/\ P7@_9B^(O_!,KPWXOM[JYU;P
M+JGQ)\7/H$_AFZU77- UF35?$OB6]$,T_D6A\/11:5-=2SXN)5=1GE5_T?\
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M/]FFMF2+<%"L_P"UOCS_ (.V/V4_CQ_P3M^(GPJ^,_P;\73_ +3?CSX4^(_
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M 6"BDJQ4$K]T^GT[5#)( SJ"&95SY(.QGW8Y![@=">@S@U8JM)#YD@+*K#&
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M:8EO'%YD+;1)<>;+@L[.WZUB J<KCYCNE#8)E8],GMCKD#&>@[4_RSO1LMD
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MMP-N-N/;TSUQ^-.HH C=?E&W:&0?(6R0.QSCD\5_!S_P=)_\$XOB3\)OBO\
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MDC*J0TK.Q9=V2W)^@(+*&U@MK:TABM+>SC$5M;6L<<%K%"JA%ACMXE6..*-
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MI:5I%WX9USXHWTMAILOCSXD:E83:<UUXCT_5[>+6]=L+!KDV""TB6&_>(""
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M$%O#^K_8-&M=?ETRW\7:Q?>(+BW%K#HNFVEJ][8:4]T+N6X5A'"&>1U_TM_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.T')]N1GIC/3/M0'4G:",^F>O7./7&.<=.]?B-H'_!=?]CKXE_\ !0'X=_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTSX&N?'?PR3P'X]UB#0;?7M4T%TU/15D.F3R7VDSVU[(D!4;HA,@DZL3T/\
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MSQAIVN>-M9@^&6I7NL66B22^+[>[BO(1>Z9:S:J@L6NWFA=;8L70&10,FO\
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MX+\"ZYJMWH^G:SJUXLMQ)-<WU@DM]%;VMM$7F,,;L 1M5FXKQW_@DQ_P5O\
MB!^W/^Q/\2_VV/VG?A)X*_9M^'W@C4M9DTR70?$6L:W9ZQX8T'3A>WNMM/KL
M-M(OGS![2R2-0L\NU <MFOY:/^#N7]I/6?VAOVT/V<?V$OAW>7.K6WA.+2[C
MQ%X?T]A.UQXU\8ZC#'I,T4<6X-*FBWLGJP5%.,5_4M\9?^"<'B6/_@AIJ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPS]I_P#Y-J_:
M$_[(A\5O_4$UZO<ZYSQAX5T;QUX2\4>"/$4,ESX?\8^'=:\+:Y;PS-;S3Z/X
M@TVYTK4H8IT^>&26RNYD25/FC9@Z\@4 ?Y;W_!I-_P I>KS_ +)G\4/_ $":
MO]3/5_\ D%ZE_P!@Z^_])WK\?OV)_P#@@W_P3I_X)^?'!?VAOV:OAYXW\.?$
MU-&UG0(M1U_XC:_XGTZ'3->4)J,$.E:B3;1&10JHR >6%4*,*,?L;/#'<0RP
M2@F.>*2&0 X)CE4HX!'0E21GM0!_DR?\$T0&_P"#ECX:*>_[6GCG;CGD6^O'
M^AS^-?ZK7Q>\ 67Q5^%GQ(^&6H.8[+X@^!_%'A"XF4@-"OB#1;O2O.!.<-";
ME95)'!3Z5^2_PD_X-^?^":OP2_:OT3]M+P#\-_'=A\=_#WCK4OB-I>M7OQ+\
M0ZAH<'BK55O%O;T^'9S_ &>T4BW]T!!M")YI(.>3^UI /;_/3^5 '^/W^SUI
MGP*_X)*_\%5/'WPK_P""C_[+>G_&'X$Z5K7BWP?J&A^._#)UBXM/#VI:A+%X
M3^)?A^UNHO+U:VAM%%U)';Q2-=QR,D3I(BR#^@7X_P#_  5A_P"#7'X:1^#V
M^#7_  3Q^'7Q_EUG68;;Q.FF_!Y/A_\ \(?I) $FKRR>)-.E;6I(5+9T^P42
MN%"I(Y?"_P!@_P"VO_P3'_8K_P""@N@G1?VG?@OH7C&_6&&UM_&6G*N@^/;*
MS@SY=G9^+K"(:M#:KGY8/-9$P/+"#.?S_P#@I_P;+?\ !(/X%>-M*\>^&OV?
M-7\3ZOHUU%=VEE\1_'6M^.=!:6$?*MQH^L^9:SQ,0&DC<;78 MTH ^:?C'X\
M^"5__P $(?VG_CG_ ,$@O@>WP"LOB+X&E\0/HGA7P%=^!-6N@ZP:=XCU:UL&
MBBDU*6+1'N+:+5K55BEMO,=64 E?XYO^#>[]LS_@ES^RM\2_B]XF_P""D?PX
ML?$_B'4;71M5^%?Q+\0>![SXES>'=6M+NX.J65KIUO'=7FGWEXI6XEU&2*1I
MF*QY +FO]7_3/ _@W1O"5MX"TGPMH&F^";/26T&V\)66DV5OX=@T5XF@?2H]
M(CA6Q6P>)F1[40^4ZLP93DY_"?XL?\&QW_!(+XQ?%+7OBUXD^ 6OZ/X@\1ZR
M=<U+1O!GC_7?"O@TWK2K+(EOX6TW;IMO:3,N);6-/+="RD8- '^>%_P75_;O
M^'W_  4._;-F^/GP2^'>J>"?@!INCZ7\/_AWJ]YX;/AZ#Q6GA5([?5-8@A2T
MM8(Y)'V,]@0;BT.5F W M_IJ^*]/C^*7_!&272O#%J/$IU_]BSP_865BC";[
M;/9^ ]+$L(VY!:)[:5B.<"(9Z&L3]H?_ ((0?\$S/VF?A+\)_@GX]^ D.A>
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M]WX*T3PEH\,":?9Z.EI-IL5Y%$;F2/S]1GE%GNV6Z,&"M)_;?^W'_P $/_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img81402019_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img81402019_4.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (6!3D# 2(  A$! Q$!_\0
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M6K;9H[2X21HS_M 'BE9[H=T;M%96I>(-,TFZLK>^U"WM+B^E\FUBFD"M,_\
M=0'J?I6GW]*-1A@BE_"J.I:I9Z3:M<7MW#9VZD S7$@1 3TY/%9D?CWPW*P6
M/Q!ICL> %O(R?YTU&4M4B7)+<Z*BH8IDF0.C*RL,AE.0:K:EK-EHMJ]SJ%Y!
M96R_>FN)%C0?B32L]AW1>^M&T5@:#XZ\/>*-ZZ-K>GZHZ?>6SN4D(_ &KFJ>
M(-,T-8SJ&I6EAYGW/M4RQ[OIDC-/EE>UA<RM>YI?44ZN<3Q_X:D8*OB'2V8]
M +V,G_T*MV*9)HU='5T895E.01ZBDXN.Z!24MB:BBB@H**** "BBB@ HHHH
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MBP  X+#<<D>_0U[A\*/VEO!OQH^'NH>+/#ES)<1:;$\E[I\H"7-NRJ6VLON
M<'H:^;/^";7B#X?Z?^S[K4-_=:9:ZK'>3/JXO'16:':-A.[JFWCTR#7F'[$"
MI=>/OCY=^'D9/")TVZ$( (3!:0PCZ[<_A7D5L%0M.,8N+@UJWN=L,35]V4FF
MI7T['N,/_!3CP1J7A^2[TKPGXEU/58Y'#:3;PHTB1+UF=@Q55_'->Q?LZ_M4
M>$_VC/#>IZGI"7&D7&E$?;K+4-H> $$A]P)!4X//M7S=_P $IM#L;CP#X]OI
M;6*2[DU-;9I60%C&(@=N?3+'\Z\D_9SL[Q;']J:TT9&CN%L+Q((X1@@":48
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M!9[K:>2'SRW>O0/V =<OKZR^)G@U]2D\0^#_  _JYLM'O+H^8'@;<&BR>"H
M7C_:K<^/VB^%O@1X8.E_#3PMIND?$3QY<?V+ITEA %D7S#^]ES_"J*2>,#.#
MVK6I44*LJ5MW?3;5=?0S4'*G&=]O\^A+\.%B_:(_:3UKX@S?Z3X0\$%]$T!6
MYCFO?^7FY7MQD(#7U&HKXBM/A]K4/Q8T3X$>%_%^H^"_#GAGPLNJW5WI(5;C
M4+QY-ID9CSC<2<?A7M'['_Q(U[XC?#._7Q+=C4M9T+5[O19M2"!?M8A?:LI
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M_P#@H;\6_$^H^-_"'P:\)W\NG7&N&.2]E@<QO)YDFR*,L#D)D,3ZX%0^+/\
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M1 P/#'L#UKYWU^XTO1_^"G$D_CMH8]-8J;*6_P "%6-N!"?FXQNR >F<T_\
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MAG_D\;XR?]=+C_THJ<-./U>O3C%*RW[ZEU8R]K3FWN9?_!2#Q+I^O_'GX?\
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MIRDW%="?8PC)S2U/B+]A'P[<?$OXM_$[XXW]O)';ZQ?R66D>8#\T(;YG7/;
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M2T\ZMX8M;<01QW1S(,$D.&'(8$\$5X3I'_!,+X3Z;X@34)I]6U"R1]ZZ;<7
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M%% !1110 4444 %%%% !1110 4444 >%_MD?\D9;_L)V7_HT5[1IO_(.M/\
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M 9KXF7****@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\1_\ !5C_ )([X%_[&ZP_]"K[<KXC_P""K'_)
M'? O_8W6'_H5 'VGI_\ QXVO_7)?Y"K-5M/_ ./&U_ZY+_(59H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV^'GP#M+RW\#>&+703>D-=31L\LT^.FZ1R6('IG'M0!Z6O2EI%Z4M !1110
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MB@!:*3(HR* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXOO+)Y8-8D^(FGRBSTZR>,"62!Y -DF,@$=>G>@#Z9U+_@H5:1^%/!FJZ/\
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M?_ U?\*W/ O_  4+7QIXTT30/^$+EM3J5Y':>>;M6";V SC'.,U^?J]!7<?
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ME.W.[W]J3Q9\;/B=J'P/\;?&2#XOWNC:Q;^*WT:W\'PB'[-;VZ78A$81AO\
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M%%? 'T@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKF2W4F2<CIO=B6./K7HE% "+TI:** "BBB@ HHHH **** /"_P!LC_DC+?\
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MC3JO_7P_\ZR:UO%W_(TZK_U\/_.LF@#W[X:_\B7IO^ZW_H1KQ/XS?\C[>?\
M7./^5>V?#7_D2]-_W6_]"->)_&;_ )'V\_ZYQ_RKP<X_@+U.K#_$SAZ^@?@'
M_P BA-_U]/\ R%?/U?0/P#_Y%";_ *^G_D*\7*OXYT5_@.:^._\ R,.G_P#7
M _\ H5>9UZ9\=_\ D8=/_P"N!_\ 0J\SK^@\I_W.!^9X_P#WF9ZU\!?O:K]4
MK4^-_P#Q[Z5_UT?^0K+^ OWM5^J5J?&__CWTK_KH_P#(5\5FG^]S_KH?4X'_
M '>)Y/7??!C_ )&6Y_Z]_P"HK@:[[X,?\C+<_P#7O_45Y)Z)TGQT_P"1(?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>2OFS_@DQ_R9[HO_ &$;S_T90!W/B[_D:=5_Z^'_ )UDUK>+O^1IU7_KX?\
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M TOZO_Z :[+]LC_DW'QC_P!<(_\ T:M?0\.[Q_Q(X<=\+]#\FE^Z*[GX%_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*I_L:/ MHG'WG ]?3TR:PO\ AN/X!?\ 16?#'_@<M)_PW'\ <9_X6UX7_P#
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MKWW^*O O@E_R.,G_ %[-_,5[[_%7R.=_[V_1'TN5_P"[_-BT445X)ZX4444
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MT?\ [ZE_^+H_X=Z_L[_]$LT?_OJ7_P"+KZ)HH ^=O^'>W[.__1+-'_[ZF_\
MBZ7_ (=[_L[_ /1+-'_[ZF_^+KZ(HH ^=O\ AWK^SO\ ]$LT?_OJ7_XNC_AW
MO^SN/^:6:/\ ]]S?_%U]$;12T ?._P#P[W_9W_Z);H__ 'W-_P#%TG_#O?\
M9X_Z)9H^/]^;_P"+KZ)HHYI ?.H_X)Z_L[?]$LT?_OJ;_P"+IW_#O?\ 9W_Z
M)9H__?4W_P 77T/M%+3NP/G;_AWO^SOG_DENC_\ ?4W_ ,72?\.]?V=O^B6:
M/_WU+_\ %U]%4G;UI ?._P#P[U_9W_Z)9H__ 'U+_P#%T?\ #O7]G?\ Z)9H
M_P#WU+_\77T/^%+M%',!\[G_ ()Z_L[?]$LT?_OJ;_XND_X=Z_L[?]$LT?\
M[ZF_^+KZ*HH ^=?^'>O[.W_1+-'_ .^IO_BZ/^'>O[.W_1+-'_[ZF_\ BZ^B
MJ* /G7_AWK^SM_T2S1_^^IO_ (NC_AWK^SM_T2S1_P#OJ;_XNOHJB@#YU_X=
MZ_L[?]$LT?\ [ZF_^+KS7XJ?L._ C0KZQCL?AMI5NKQEF"M+R<^[U]J5X_\
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M"?\ ^SW#IEQ+'\+='5UA9E(:7J%./XZ_.;X=_P#)0_"W_83MO_1@K]G=6_Y
MMW_UP;_T$UAG5*%.M34%:_\ P#3 U)SIS<G<_/0_LA?!S)_XH33OSD_^*I5_
M9#^#FY?^*!TWJ,\R?_%5Z^WWC2C[Z_4?SKZ66%H>S?N+[CY]8FM[1+G9U.G_
M /!/O]GBXL;=W^%NCEFC4GYYNX_WZ^A-)TNUT/2[73;*%;:RM8EAAB7HB*,*
M!] !3M+_ .0=:_\ 7-?Y"KM?F$OB9]Q#X4%%)NHR*DL6BDR*,B@!:*3(HR*
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M;(R@VK^ P*UZP?!=K-8^#M!M;A&AN(;"".2-ARK"-00?<&MZ@ HHHH ****
M.'^-_P#R17Q__P!@#4/_ $GDKYL_X),?\F>Z+_V$;S_T97TG\;_^2*^/_P#L
M :A_Z3R5\V?\$F/^3/=%_P"PC>?^C* /LNBBB@ HHHH **** "BBB@ HHHH
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M:U22ZN_LZ) 2=L<?!W2$#//%8_[>T-N/V4]=9OE>%[.2 C@K()4VX]ZB\7?
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M@'5-7\(^&F\7>(+=5-MHZS"$W!+ $;STP"3^%?,[?M/_ +3;*5/[,,N",?\
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M\$]<^C_"/_(KZ7_UP7^5;-8WA'_D5]+_ .O=?Y5L9% "T444 %%%% !1110
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MB@ HHHH **** "D;I2TGK0!\:_\ !2K_ )$7PG_V$'_]%U^?5?H+_P %*O\
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M,9="HP46Y+J?'G@_X!?&'X(^*?&$'@&;PKJ6C>(M1DOTU76%<7=F7ZA@!^\
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M1?I7Z^?M0_\ )OOCO_L&2?TK\@QT7Z5X'#O\*?J>EF?\2/H=%\._^2A>%O\
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M+&OW2F-V2>>E '29%&17!377Q$_X1/Q!)#8^'SXE2ZE&CPR32_99+?>/+,[
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MYO\ T):^H?\ @H#_ ,F_W?\ U^V__H5>'CO^1K#Y'HX;_<Y?,_,6O9?V/O\
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MY5;W"OR67Q,_08?"B.1%D4HPW*P(*D<'VKC/"7P;\$> [O5KCP]X9TW1Y]5
M6_:T@"?: ,\,.X^9OS-:'Q$\9Q?#WP+KOB::WDNXM)LY;QX(B T@12=H)[\5
M%\,/'D/Q,\ Z'XHM[:2S@U6U6Y2"4@M&&&<$BFE.,.9;;"?*Y<KW$TCX5^$M
M!\)W/A?3O#]C:>';KS!/ID<($,@?[^5[YK5\.^%=(\)Z';:/HVGV^FZ5;H8X
M;.W0+&B\\ >G)_.M@MFC\:7-+JQJ*6R/*D_9?^%*>)?[<'@+0QJOF><)_LB\
M/G.X+TSGOBO4541J%4  < #I4FZC<,4.4I?$[A&,8[(P(?!.A0^*IO$J:5;+
MKTT"VLFI!/WS1 Y"%O0&HI/A]X<F\1:AKDNC6K:QJ%H+"[O#'^\FMQG$;'NO
M)XKHZ-U%Y=Q\J['S[\<OAOXGT7P+H>F_##P_HFH:!I\Q&H^#KR%%@O[8\E$+
M#"L#R.E>0>#?@)XC^('Q0\':B?A1I?P>\(>&KLZG-#%+%+=:A<%=JC,8^Z/?
MI[U]PTE=-/$U*<>5;ZZ^ISRHPE*[,/0_!6A>'-5U74]-TNVL=0U6037US"FU
M[AP,!G/<XINC>!_#_AW4M7U'3=(M;.^U>7S[^>&,!KF3&-S^IQ7)?#?XV67Q
M&\=^.?#$&G3V<WA2\2SFN)'!6=F7=N4#H/K7IE82YXZ2W-HN,E[IY4?V7?A/
M_P )"=</@#0_[3,GG>=]D7'F9SNV],Y]JZ7QU\*?"'Q+TV&P\4^'=/URT@.8
M8[N$-Y1Z?*>H_"NP)P.M%+VE1M-R=UYARPVL<=\/_A+X.^%MI/;>$_#FGZ#%
M/\THLX0AD(Z;CU/XTWPG\'_!?@?Q#J6NZ!X:T_2-6U(8N[NSA"-/R3\V/<D_
MC4?B?XL:'X4\>^&O"-X\QUGQ!YIM(HX\J%C&79F[#I7;<+S3E*>\F]?Q"*AL
MN@Y:=35IU9F@4444 %%%% 'S3^UU\-=9\?:A\/=<\'W.C:AXO\'ZJVKVOAC6
MIUCBU1#&4=1W# '*M@CK7@_['GPG\=>)/B%X'O\ Q5!X9\/VGPUCU.-;?1]4
MBO;^\FO)I'*3>63Y<:>8< ]2HXKR/XR>%= \>ZG^UI\0?$6KW$?COPAJ$5OX
M9GCU)H)+-(TX$2!AD'OQZ^M>B_"OX?\ @GX,_M(?LU3?#N2&TN?%'AVZB\1"
MUO#,;UQ:K+OF&X_/OR>WZ4 ?I)D5^>GQ"_:,^('B;XK:AI_@KX5?#^_TB7Q5
M-X3M=2\1'_2+F_CA\QC)A?E##A2>IP*^O?VCOC1%^S[\(-<\>3:5)K46EB,F
MQCF$)DWR*GWB#C&[/3M7EVO?L_\ P8^*OAGQ)>75Y#HEWXWFL=<O9K#5TBGM
MKR*/,<L39^1QN.2!SW% &]^Q5\1-:^)7P@O-2\1:;HFB:U;:Y?:?=:5H-OY,
M%G)"X0Q-R0SC&2PX((KZ"KS/]G_X2^$/@O\ #NW\,^"[AKS28YY9Y;R2Y%Q+
M<7#G,DDD@ZN>,_05Z90!\Q_$[_@GQ\*/BU\0=5\:^(%UY]?U(@S3VNK2P@*
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MB?MS_P#)RFO_ /7K:_\ H!K]._"/_(KZ9_U[I_*OS$_;G_Y.4U__ *];7_T
MU]'D'^]?)GE9E_!^9X)7V7_P31_Y';QK_P!@^#_T8:^-*^R_^":/_([>-?\
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M1110 4444 %%%% !1110 FT4M%% !2;12T4 %%%% !1110 4FT4M% !1110
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M'_P58_Y([X%_[&ZP_P#0J /K/QC_ ,DWUG_L%S?^BC7XK]V_WC_.OVH\8_\
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M-]T_2O!/7/H[PC_R*^F?]>Z?RK\Q/VY_^3E-?_Z];7_T U^G?A'_ )%?3/\
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M3?'_ %".:1/[+MR%8K]\]C7XSB,52PUN=[GZ+3A*:T/<\T9%>$_\-!:C_P!
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M_P#7W;?^AU^7G3->=P__  9>IUYI_%CZ$^G_ /(2L_\ KO'_ .ABOVV\/_\
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M.[^+X?\ AN.]CT6^G2X73(@ZR""1@X.W.<\Y]:\Q_P""3/\ R9WHG_80O/\
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MPK\#?!=IX5\':6NE:/;,SB,,7>1V.6=V/+,3W-?+?_!5C_DC_@;_ +&^P_\
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MDZ$\U^@?'>D^E33H4J3O"*0.4I:-GP3=0_M[7CJ7T_X?Y7^[,E5FTW]O-?\
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M[9'_ "1EO^PG9?\ HT5[1IO_ "#K3_KDO\A5OX#-?$RY1114&@4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=:%57@[DN+CN?&W[=WB3XG7T^D>"/ O@GQ!>:!JT./$GB3P_;1R7:V98AK6
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M'^*CZOTG_D&VO_7-?Y5=JEI/_(-M?^N:_P JNU^3R^)GZ##X4%%%%26%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5\1_\ !5C_ )([X%_[&ZP_]"K[<KXC_P""K'_)'? O_8W6'_H5
M 'VGI_\ QXVO_7)?Y"K-5M/_ ./&U_ZY+_(59H **** "BBB@ HHHH ****
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M 4444 %%%% !1110 5\1_P#!5C_DCO@7_L;K#_T*OMROB/\ X*L?\D=\"_\
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MOO"GP1\7+X>UC3]3N;MH%N/,M(U*;6S@9+#GBN$_X>/^ /\ H"Z[_P!^8_\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117CWQ_\
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M8(4X[G(/4FO7?B=X^L/A;\/?$7B[4U=K'1K*6^F2/[S!%SM'N3@?C0!\<_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP4'/>O*O^"GOB[6] ^"?A[2=,U>?P[IWB+Q!:Z7JNK6[%&M[5R=V6'0'J?\
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M!20/S%?#O_!-&1_&5MX\^*/B/QE=:OXV\0:G-9ZAH]Q=#;IR0N?+41DY!P<
MX QQ0!2_8*T?XU?L\^)A\(O&O@JVF\*7<]WJ47BS3[@30K.1N:-F7(R2.AP1
M7W]7Y[_"ZWN/@=_P4:NO _A?QI?^)O"WB_3+G6]5TF[N?M'V*ZR[@YZ*<CCH
M<-@]J_0B@#XP^,G_  3QT;Q-\3KWXD?#KQSJOP\^)%W,]W]JCD6:&20C#'8?
MF4=,XS]*\H_9S\)?M#_LI_'+6+;Q)X5L_'V@^.-7A?6/$NF3[VMY,%1,ZCE
M=Q)#*/K77_LUW,_Q._;G^+_BOQ;XONK;6/"ETVC:1X8>X$<(M64CS/+)^8<
M\#J<D]*ROVC8[GX$_MN_#;Q?X,\:7]WJ?CG4Q8:YX5^T^=&T 55#A!]U?0$<
M%<@]: /T,KY(_:(_X)_^%/B]\0O^%@Z+XFU7P-\1W='@U2SE#QF1%PI\H]\#
MD@U];"O@32;B[^*W_!3#Q';>+/%E]HMAX!LX9_#VAK<B&&\:1 KL5/WP=Q)'
M)/'84 <-X+\"?M-?LL_M#:CXQUC2K'XPVOB-+/2]5U:QEQ<1VZ,%29HAADP#
MR2I!Q7Z9QMO16QC(K\]_V^K>;X0_&;X<?%WPEXUO+/QA>ZK:Z+/X=2YWQ7EJ
M3AL1#H,'!SUW#O7Z!VLAEMXI&78S*"5/;CI0!\W_ +5'[$?@3]IZ^T[7=<U/
M4?#_ (FTV!;:QU:RG $8#EE#(W#'<WL:^5/%'P'_ &H?V>?C-H'Q'L[ZS^.*
MZ!82Z=:0S2".^-FQRR>5PS$?WEW8KTO]JV2Z^)7[;OPH^&^N^*[SPCX)AL3K
MJ"WG$"WUY'*2J%CP3\H&#Z'C)K6_X*:>%;6U^%MI\4M+\=7OA3Q;X/=)-(CM
M;P*EXSRJ&38#\S8YSSPI!&* /L3P7KEUXD\):/JM]8/I=W>VD4\UE)]Z!V4$
MH?<$X_"O OVVOV=M?^-7A?PWKW@K58=(\>^"]0_M;1YKQ@L#MP6C=CPN=B\G
MCCGK7L_P@\27_C#X5^$M<U6(P:EJ.EVUU<QE=N)'C5FX[<DU\G?\%,O$&JS0
M_"3P)'XAN/"OA7QAX@^Q:YJMO)Y96(>7M1G[ [V/)Q\O/ H X3Q#XU_;@^)F
MAWG@B[\#^'?"L6IQ-877B)ID1/+<;7*$R$9*DXV@GTK[._9M^"MK^SW\%_#7
M@6TNC?'3(,3W6,>=,S%Y' [ LQP/3%>7?M<?"/PYXP_99ETNX\<7GA^#PO9C
M4-/UB*_"M)-;PL(_,8$;]WMSD@CFMS]@[XB^(?BE^RSX'\0>)YY+O6)('@DO
M)A\]PL<C(LA]2549/<\T 6OVR_V=9OVDOA"VBZ;J2Z3XCTN\CU;2+R3_ %:7
M,6<!_12"1GL<&OF2;XF_MTW&FOX8_P"$"\.Q7$D/V;_A*5FC$ R-OG!_,VYY
MR#CKVKT[_@J%XY\0^#_@#IEEH>J3:';Z]KMMI6IZI;L5:WM7#%SN'0$@ ^W%
M=YXT^!_A'7?V28_AR_CF\LO#MCID:Q>)(]142XB&])'DSAER!D9Y'% &Q^QW
M^STW[-?P7L?"]YJ U76Y[B34=3O%SL>YE(+A<_PC  ]<9[UUO[0'P?M/CU\'
M_$W@6]N#:1ZQ:F%;H#/E2 AHWQW 8 XKQ'_@FA\1?$/Q(_9I@E\2:C-K4^E:
MG=:9:ZG-DM<6\17RV)/WL9(R?05W?[<7CKQ!\./V6O'VO^%Y9;;6;>RVQ7$'
MWX5=U1Y%]"JL3GMB@#Y9\->)OVVO@SX?L_ UAX)\/^,M/TJ,6=GXA6964Q)\
MJ,[>8.@ SD C'->__L2_LZ>)_@_I7BOQ;X_U6#5OB!XUO5U#4WLV#PP@ [8T
M8<-]X\CCICI4'[)?PS\/+^QY9>'AXWO-=M?$6GR75_K"WX\Z*2X3,H1R24VG
M(Y[@UP'_  37\1:KI^J_%KX<-XFNO&?A7PAK"VVC:O-)YG[MMV8PW.1E0>N!
MSC@T ?9?C#PKIWCKPOJOA[5H6GTS4[9[2YB5BI:-QA@".AP:^"_%G_!-GQ1\
M.=)\10? /XH7FAZ=JD4EOJ'AO6766"=64@H90,@X/<?C7V5^T+XJU?P/\#?'
M.OZ C/K.G:/<W-IM7<1(J'! ]1U_"OG[_@G-X<T^X_9C;5[KQI>^(M6\7&:_
MU>::]#26DT@*,BY)*,!SD]^: $_X)_WWQ8\$Z"WPE^(O@>/0]/\ "^GI_9?B
M&SF$MO?H9""H=258C.<@_45]A7%LEU#+#*H>*12CJ>A4C!%?!G["\]]\-OVG
M/B_\(-*\5WGB_P !Z-%%?V4UW-YYM)I&&^/S.Y^;!QU*Y]:^[M0DDM;"YFAC
M\Z:.)G2/^^P!('XF@#\[+7X9_M,_L9^(?$FB?"+1])^(?@#4[^34;2SN'7[5
M9&0Y*LNY2![\@XKN_P!G/X&_%WXC_M +\;_CA_9VE7^DV3:?HWAW39%<6^[A
MVDP3M(!;@G.6R<5E_P#!->>?QUKWQ-^)?B;QG<ZIXSU35)M/N=&N+D;;*&*0
MF,",GCK@8   QUS6?X.6Z^!__!1X^%/"WB^_\2>'?&EC<:KK&CW%S]H%A<9+
M!R>B\CCIPX![4 ?H11110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$W[.:V?BC]N
M#XX:_P"+M:F'C+0+E-)T+2;B<QQQ:4Z!O,CC)PP8J.1Z9[U]LUXA\</V/_AI
M\?M4MM8\3Z1<0Z[;1^5'K.E73V=WL[(SH1N4>C9H \)\76=A\._^"C7P_G\#
M:Y<S7_C>UO9/%^BQW9FA$447[F=DR0AR,#_=XZU]RUXS\"_V3/AQ^SS/>7GA
M+1Y!K%ZNRYUC4;A[J\D7CY?,<DA>.@Q7LU 'R#_P4GO[F/X4^"]&N=4N-#\&
MZ[XLL=-\2ZE;.4:&Q<L6!8?=4L!D^P'>NC_:K^'/P\U7]DW4-+OM<.DZ)X;T
ML7NBZE;:AM>&:WA/V=E<-^\.0..<YKWCQIX'T+XB>&K[P_XETRVUG1;Z/RKB
MRNHP\<B_3U!Y!'(KYTT?_@FC\#])URUOWTG6-2M+659H-(U'5YY[%&!R!Y1;
M!4>AR* /3/V1_$WB#QA^S1\.=:\4M))KMYH\,ES+,,/+QA9&]V4*Q^M>P-DJ
M0#@XZU7MK6&QMXX(8UAAB4)''& JHH&  !T %6&8*I)Z#DT ?G[^S#\;OAW^
MRGKGQ(\$?%2YC\%>-IO$E[J<FJ:E"PCU2VE??"\<V/F 4@;>QK5_9[U+1_C1
M^W1XD^)_PPM)+;X=VWAX:7JFJQVQM[?5K\R$@H,#>5&"6]JP_B)^U=J^I?"/
MXE_%+Q#X&\,:MX;L]8_X1OP7IVHVJ7%S/<I,8GFE+ _)D%MJXZ5W/[-_Q9^*
MG@GXU>'_ (4?$R/P_>P^)/#Q\0:3=>'[!;%;(J 9+=XE !P#C=CK0!]I5\3_
M +=YCU[XQ? 7P?XHU2?1OAIK.KRMJLR3&".>YC4-;PR29& 3GK7VQ7%?%+X2
M>$_C5X1N?#7C/1;?6]'G(8P3CE''1T8<JP[$&@#YS_X*,^'_  Q)\ #XN?7Y
M-%\4^$V2]\,W-E>%9'NRR*L00']YN&!C\:^G/AWJ6HZQX!\-WVL1&'5;G3;>
M:[C(P5F:-2XQ]2:\#\$?\$Z_@SX)\66>O)I>J:]<V$HFLK?7=4FO+>V<?=98
MW."01P3G%?4 4+TXH JW]Y#IMC<7=P_EP6\;2R/_ '549)_(5^>=[^TI\,_C
M-\3-*\8>)O@YK]IX0\3+<>!++QY+<*+>\CF?9Y<D*\@%Q\K'E3]./OOQEI\^
ML>$=;L+4*US=6,\$2L< NT;*H)[<D5^;5U^SQ^TW<?L\^$/A*/AYX76P\-ZO
M;ZK#J0UX>9,T,K2!2NW !+8)H ^V?V=_V5_!G[-::TWAF34[^^U=H_M5_K%V
M;F<QQ@B*(,>B*"<"O9VZ5XY\"?%/QA\0W>JQ_%'P1HGA*VABC^PR:3JAO&G8
MDAPPP-N %_.O9* /BOX\1VGBS]OKX4^'O&FJS:=X3T_19M:T6W-P8(+S58Y>
MC-D!F50"%[].]9O_  44T_3/"M_\._B5X:UJXL?BI8ZW9:9I-I9W9)OX))3Y
MD+0@_,O/7'?'>OISXT_L^>!OV@=#@TKQOHB:I#;2>;:W"NT5Q:N<9:*52&0\
M=J\^^$?[!_PE^#_BVW\4Z;I>H:OK]KG[)?:]?R7K6N>\0<X4XXSC- 'T) S-
M#&7&'*@L/?%8GCKQ?IGP^\'ZUXGUF5H=+TBTEO;ET7<PC12QP.YXX'K715Y?
M^TMX'U?XF? /QWX5T&*.?6=6TN:UM8YI!&C2,. 6[#WH ^.?#OQ)^''[0WQ"
MEL/&WP=\0^ XOC%8I!IOB26\&S5/LQ\R"0!?]5* %*OWPHZ5]B? ']G_ ,,?
ML[^$;G0?#;7UU]KNFO;R_P!3N#/<W4S #>[GK@  ?2OB_6/A/^U)K$/P6C;X
M;>%8?^%7R0R6FW7P?MOEPK$ _P ORY"@\5]K?!#Q!\2O$6@WTWQ.\*Z5X3U9
M+C;;6VDWYNTDAVCYF; P<Y&* /2VZ5\3^%VMO%/_  4I\8OXSU::VO\ POHU
ML?"6ERW)BADAFCQ/,J9P[99QCVSVK[9KQ_XY?LK_  Y_:&^Q3>,-&>34[$%;
M35K"=[6\@4]565"#M]CD4 > ?M!6ECX#_;>^"WB3P9K5P/%_BK4#I.OZ1!<F
M2*XTQ$YE>/.%V9X/^%?;]>&_ _\ 8[^&?P!U>YUKPUI5Q<>(+B/R7UC5KM[R
MZ5.Z([D[%/<+BO<J . ^.'Q=TCX%_"_7/&VM1RSV&EQ!_L]N,RS.6"I&ON6(
M%?%_@/1?AS^T1XP\1?#KQ=\+/$7P?\4^*'C\;65PNI?//(J[#<6[)_JGP?F7
MODU])_MM?"OQ/\9O@#JOAGPA:V][KLMY:7$,-U.(8V$4RN06/TKY[UCPW^U3
MK'QL\'_$AOA5X1BO?#6DW&E1V*^(?DF27&6+;<@C' % 'V)\&?@_X<^!/@&P
M\(>%8)H=+M&>3?-*9)9I';<\CL?O,Q.2:[MNE<+\'M7\=:YX+ANOB)X?T_PS
MXE\Z17L-,O/M4(C!^1@^!R1V[5W= 'Q)^R:UIXH_:M^._B3QCJ\G_"?Z7JQT
M:QTJXNMJVVE[%9#'$3R&(^\/3WIUKINF_#O_ (*,:;!X&UNXNAXRTB\O_%VC
M+=&>""1"/*G(R1&Q/&W_ !KV/XV_L9_"_P"/6MQZ[XATBXM/$4<?DC6='NWL
M[ID'179"-X'^UFM?X%_LM_#O]G>.^;P=H\D.HZAC[9JE_.]S>7 '16E<D[1Z
M#B@#U^O'OVF/CWI/[/?@&'5-1T>Z\27>KWL>CZ=HMF!YE[<R@A8\G@ @')/]
M:]AKYI_;4^%OCSXC:3\.[[P!I5CK6L>%_%%OKC6>H78MXY%B5L#=CN2!0!X1
M\*_A-\)?VE+35/A5JG@+Q)\'O%G@R[EU-](BU,B9(+X[I1'*O!A?@;.WRU]W
M>"?!ND_#WPCH_AK0[46>CZ5:QV=I #G9&BA5&>YP.M?#6C>%?VI]%_:'\1_%
MN/X5^$WU#6M(@TB33#XAQ'&L1!$@;;DDXK[B\!7WB'4O!^DW7BO3;;1_$4L"
MM?6-G/YT4$O=5?\ B'O0!T#KN4@]*_,G]M+]E[X%^$?#^EZYX=EMUU_4O%ME
M;ZCY>O%V\J:<^>"F_P"4<GG'RU^FS#<"*^;-4_X)U_ #6M6O=1O/ 5O->7DS
MW$TC7$OS.[%F/WNY)H N? /]FCX(?"'QA<ZS\.&MCK4ELT$@AUDW9\HD$_)O
M..0.:^A_>O&OA!^R+\*?@/XCFUWP/X5AT35)H#;/<1S2.3&2"5PS'N!7LS=*
M / _VJ_C]I7PATC1?#4GA.\\?:_XRFDTRP\,V953=J5_>;F;@* ?UKY^^$?P
M+^#/[77A>WTN;PMXE^'VL?#V4Z#JGAMM382"!G,RVTSCB6(D$KZ $5ZE^UI\
M,OB=KWQ@^$GCWX;:!I?B2X\)->O<6>J7XM48S*BK@X)Z!CQZ5Y3\,?"_[5/P
MQ^)OQ+\9VWPN\)WUQXXO;>]N+63Q#M6U,49C"J0OS9!SS0!]ZZ;I]OI-A:V-
MI$L%K;1+##$O1$4 *H]@ *YSXMZEJNC?"WQ=?Z&I?6;72;J:S"]?-6)BI'OD
M5O:)<7MQH]C-J5O'::B\"-<P1/O2.4J"ZANX!R,^U7V4,"",@\$&@#Y,_8%\
M/>$;S]DW3I1K+:Q>^*8);SQ+-<7V^4WDH*SJW.8R.F..F:P_^">\A\/^*/C3
MX%\/ZM<Z]\-_#.O)!H-[<7!G$6Z/=+ DG\2JW?\ QKL/&W_!.GX,>,_$][KG
M]EZKH,]_*9[RWT/59K.WG<_>)C0[03W(Q7N/PO\ A9X6^#?A&S\,>$-&@T31
MK7E+> ?>8]79CRS'N3S0!V#=*_/G]J&3X6ZG^W9HMC\9KG2U\'VO@F1K2'6I
M"ML+EYR,@?W]H./I[5^@S=*^4?CEX@\*>+?VH/!_PU/PKT?Q]KMS8_;M7U75
M(T(TO3@Q (+ Y8MR![T ?&W[(>@_!3QI<:/K_P 7_BO8:U)H-_)IOA/P;J%\
M5AL8(YB(&9?XRW!7MC;G-?KG%M**4QLQ\N.F*^+/C?;_  Y_9W^+'@N/5?@5
MX=?X?ZW=0V'_  EMM:Q>99:@[GRU>/;PO P?8^E?:<>WRQLQLP-N.F* /%_V
MS/$'B'PI^RW\2=5\*O+%KMMI+M!+ #YD:EE61U]"L9<Y[8S7)_L__#/X97G[
M'NE^%+36AJG@W6]*\W4KZ74/WDKSJ&G9I"V4.XGCM7T=>6<-Y:RV]Q$DT$JF
M.2*10RNI&"I!Z@CM7RWK7_!,[X'ZMK%Q>1Z1J^EV5Q(99M'TW5YX+%R>H\H-
M@#V&!0!#_P $XM<U*_\ A)XGTIM4N-=\,:!XGOM*\.:K<N7:YT^-AL.[^( E
ME!]J^M:YWP3X*T/X=^&M/\/>&],M](T6PB$-O9VJ;4C4?U]2>3714 %%%% !
M1110 4444 %%%% 'A?[9'_)&6_["=E_Z-%>T:;_R#K3_ *Y+_(5XO^V1_P D
M9;_L)V7_ *-%>T:;_P @ZT_ZY+_(5;^ S7Q,N4445!H%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %)_%2T4 ?F#^WAXX_9A\7?%V]L/&=
MUXP\+_$30=MK-KOAFR^8J "H8DX? /#=1TKSW]F7QM^REX)^+_AW63K_ ,0/
MB!XN>[CMM*NO$ECF*WED8(K !CR"W4].M?0W[8O[;7P9\)GXB_#G5/#]W-XR
M^PS67VM=)C=?.>+Y#YAYQ\PYKS[]CW]NKX(^%_AK\-/A]JGAR[D\71"WTY[H
M:1&R_:&DPK>9UZL.>M 'Z=5\:?\ !0"Q^ WB>Z\%>&OBC<:A:>+-2NA!H=UH
M:9OK?>X4NQ_YY;B.O<<5]EU^>W[86K-^S]^V=X%^.'B?PO=>)?A]'I#:5-<6
ML'G'3;C+XEVG@'#Y&<9YP<XH X7Q;^RU^S_^RU\6? L/Q?\ '/C'QD^IS&72
MXM7._3[=T=0#.5YP2PXZ<<\5^GEJ8F@B,)4QE1M*=-O;'M7YC?M:_ML?#7]K
M3X9CX9?#;PYJOC/QCK=U"EDT^FF/["P=290W)R.>G'//%?HY\-]#O/#'P_\
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MP5X^^!=G/\//#=SX9\&:==RZ=IUO>#$D\<>W]\?=V8GJ><\UZE\4M4\-:/\
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MM.6)^7+]2!MR:]C_ &2/^%$_!/\ :+F^''P^N-6^(?CZ\AE&L>,;UQ+';)&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <
M/\6OAM;?%;PJ-!NKV:QB^TQ7/G0J"V8VW8Y]:[*WMQ;P11 Y$:A0?H,444^@
MNI-1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img81402019_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img81402019_5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %3 U<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHIDLGEQN^TMM!.U>I]J $N)TM;>2:0[
M8XU+L?0 9->0^'?VKOA_XJU[3](T^YU"6[OKA;:#=82*A=FP,MC &>]9>J?&
MY_&WAWQ/I,WAO7?!,?\ 9EQ_Q.]?LVBM(LX0$L,G/SY 'I7F.AR>+?V?M-^'
M%W8^,[;Q3X4UBZ2T&EP6X2(+(V[=$Q&X_>)R<'/:N&I7=TX;=?ZNCX?'Y[.-
M6G+"/]TM9RY;M>\HK1RB[:N[2?H?4'Q ^(6A_#'P[)K>OW1M;)'6,;$+N[,>
M%51R3U/T!K#\3_'+PIX1TC1=0O[FY9-7@^TVD-O:O+,T04,SE%&0H!&2>E?)
M_P"T-\2M*^*]]XL:ZUE+.'P\19:'H^6\R\G\U5GG88P %# 9/05Z]8^![KXL
M>"?!'B+P5KVG+=Z=HTNB7(OHI&BVR1*DH&,$.I_"H^L2G*4:>MO\]3E_U@Q.
M,Q->A@%&2BDX]6_>Y9.UUM9V6FEGU1[+J7Q2\/:;I'A_4OM;75MKTT4&G?98
MVD>X:097"CG&.23T[UUM?)GAW7-.\&^(M%GEAO/$6F>$MOA?0+6R13)J&ILN
M;J902% 4?("3WKZ-^'?C[3OB5X7@UO34FAA=WBD@N%VR0R(Q5D8 D9!'8UT4
MJO.[/<][*\U^NSE3JM*72*\DE)W_ ,6W]VSZDGB+Q[H_A?7-"T>]F?\ M+6I
MC!9V\,9=F(&68X^ZH'4FN,\9_M.> / NO3Z/J.JS2W]N=L\=G;/,(6[JQ P"
M/3M7*:=*_B#]LS41=,6CT/0 +1.RF0KN;ZD2,/RKCM,\&^)(/%7B_6_@_P"(
M]#\0Z=?WK_VEI.I0_/'*22T99UY')[C^M8RK5/L=[?=Y71Y.*S?'/F>%BOXD
MH[<TK16K4>:+E[U[V>BMHSZ9\)>+M(\=:#;ZQH=['J&G3YV31^HZJ0>01W!K
M8KXW3XOOH/[/6N-X7T.U\$ZW'KJZ5?"P8F&*1P2TJ$DX.%V]\=CTKU#P+\+=
M9^&_CK2;L?$ZXU+3+BS9[S2]:N/-DN&QDO$"WRJ.#GDC'?-7#$.5DE?:_P#3
M.O!Y]+$NG"%/GTBYR3LES-I64K-ZIW73S/>**^%?B%XZN5T+5_$OA[Q+XRUW
M4X-3##Q$BO::3 FX 0+%O*MUP..>.W7T3Q]_PD'CKX]>#- M?$^I:!;:IX>$
M]VVGS,F1M9GVKG:&.,;L<5/UI/9=OQ.>/$\*CE&G1<I7@E:2UYVTM=MUK9M>
M9]351UK6K'P[I=SJ6IW45E8VR&26>9@JJHKPK]F6\UC2_&_Q*\(ZAKM]KMCH
M=W"EI-J$ADE ;S,Y8\\A5XZ9%>@?&;X9:-\0M#6YUG[1/%I,%Q<Q6B2E(99/
M+X,@'WMI7('N:WC4<Z?/%:GM4<PJXO /%4*=IZKED]$XR<7=J^BLWIN6]*^,
M7AS6OAS<^.+.2ZFT&W61G<6S>;A&PQ"=3C^0KJ]%UFS\1:19ZGI\ZW-C>1+/
M#,G1D89!KQ/]DJQBU3]G6VL[A=T%Q)>0R+ZJSL"/R-/_ &-=3N+KX0M8S.9$
MTW4;BTA9CSY8(8#\"QJ*=64N2_57.++\TK8AX3VR7[ZGS:=)+E;^34OP/=J*
MANXY9K69()1;SLC+'*4W!&(X;'?!YQ7FO_"#?$__ **A:?\ A-1?_':WE)K9
M7/>Q%>I1:Y*4IW[<NG_@4H_@>H5E>*/$EGX/T&\UC4!-]ALT\R9H(C(RIGEM
MHYP.I] ":X3_ (0;XG_]%0M/_":B_P#CM9?BC0?'GAOP[J.IZS\5+&/2[:!I
M+@R>&864ICD8\WG/3'?.*AU)6?NO\/\ ,\^MC\1&G*2PTXV3U;IV7F_WFR/6
M]-U*UUC3[>^L;B.[L[A!)%/"P9'4C(((JS7S9^RA\/?'7AVWDU74]4?3O"UX
M7FM=!F@ <AB2LFW/[@=#M!-?0VM:D='T>^OQ;37AM8'F%O;KNDEVJ3M4=V.,
M >IHIS<X*4E8URW'5,9@XXFO2=-M;/\ -=;/I?4-:UJQ\.Z5=:EJ5U'96%JA
MDFN)3A44=S7!_#_]H;P1\3-<?2-$U.1]0"&1(;B!XO-4=2A8?-BO$/VA?B]=
M_$3X,ZS /"?B'PS';W=HTK:Q:F%9T9S\JG/."%)_"IO"]]KW@_XJ_#F'QEI?
MAW4$UJR^SZ5=Z5!Y=QIRE,! W&1AP">?O$@URRQ#]HE';3\78^9Q'$4WCH4L
M-;V7N7;B_M2<=[KEU6FCN^RU/5]8_:G^'&A^))=%N=;8W$,OD2SQV[O!&^<$
M-(!C@]?I6UXP^.W@[P/JUMI^IZC(9IH4N6>V@>:."%V"I)(R@A%)/!->)?$#
MP[HUS8ZA\'/AAHBWUY>W8N-:U*8F6+3OF4DM*V3O^7IGC) Y-=-XZ_9OU2Y6
MYCT?7[*RT:_T:TTK56U")FE6*V8,)(B#C)"\AN/Z'M*SORI.W]6\R?[2SF2J
MJC&$W&VL4[)^]>-W)<UK1O)6M=Z:'LVI>/-(TSQ+HF@O+)-J>L))+;101EQY
M:#+2,1PJ\]3U-=%7RSX9^*5CH/B:Z\:W>DZEK5QJUM):Z%962*9(=(M.)+AM
MS #>P+>IQQ7TGX9\167B[P]IVM:=(9+&_@6XA9A@[6&1D=C732JJI?4^ARS,
MX8]S7,KWNEUY=+-][_%Y)JY0N/'VCV_C>W\)F=Y-:FM6O3#'&66*%3C<[=%R
M>!GK7G^J_M:?#72-8FT^369IFAD\J2XM[222%6S@_.!@X/<5RWPCGAU;XQ?&
MW6=7E.VUF&GF0Y/E6R!P<8Z<(.GI7!>'?!/C#POX(U.7P!J7ASX@?#FY:::2
MSOH0KN@SO5LA3D ?WO<8KFE6J6O'S\]M-KGSN(SK,)4XU<-%6;J=.:2C%\J]
MU23:;3<FKVT5CZ]TG5K/7M-MM1T^YCO+&YC$L,\+95U/0@U;KY$UWXJRZM\&
M?AQIG@Q/^$'M-?U-M,N#:L?]$"O\XC8\X8OG/7M7HGAKP5J7P>U;Q))<?$^2
M\T%=+:?[-K+_ &J[M' _U^-P^48/ Z].V:UC7YGHK[7?RN>KA\]]O**IT^:*
M47*2:23E'F5E*SM;TL>[T5\,MXVO]%UCP+JF@:UXTO3>ZLL-WKFM,\5EJ2NX
M!6.!F(  )' _6N_OO#FM_$S]I/QUX<7QCK6@Z/;VD$YBTZY926V1A0N3A1EB
M3CK^M2L3S;1UO^ESCI\3*LN6E1<I.48I*2M[T7).^W37IV;/J>J6M:U9^'=(
MO-4U&=;:QM(FFFF?HJJ,DUXQ^R+XEUC7O .JVVLZE-JLNF:I+9Q7%PQ:0HH&
M 6/)Y)ZUQ?[3'Q,TKQ%XP/P]U'64T/0K&W-]J<K[@]W-L+0VR8!XR58YX_*K
MEB$J2J=SOK9[3AED<P2LYZ13:7O/HWM96;;[(]DM?CUX1NO =OXR6YNE\/RW
M8LS<O;,/+<MMW..JKG^+WKT)'61%="&5AD,.A'K7R%\&[S2/$W[(?B[P_P#:
M8YK^RM[J>YMP#NAW%GB8_79D8]*]Y_9UUBYU[X(^#[R[D,MPUB(V=N20C%!^
MBBE1K.I9/JK_ .9ED^;5<<Z4:EGSTE/3H[VDMWU:]-3T:BBBNL^M"BBB@ HH
MHH **** "BBB@ HHKPO5_P!N+X&:#J]]I=_\0["VO[&XDM;B!K>X)CE1BKJ<
M1XX8$<>E2Y*.[*47+9'NE%> ?\-[_ +_ **3I_\ X#7/_P ;H_X;V^ 7_12-
M/_\  :Y_^-5/M(=T5[.?9GO]%> _\-[? +_HI&G_ /@-<_\ QJC_ (;U^ ?_
M $4C3_\ P&N/_C=/VD.X>SGV9[]17@/_  WK\ _^BD:?_P" UQ_\;H_X;V^
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M]._\!KG_ .-4O_#?W[/W_12]/_\  :Y_^-4N>/<.678^@J*^??\ AOW]G_\
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MH)K6L?!,?A_P)_PCF@7"Z2T=I]F@O%@4LC[=OFLJ[0S=STR:\8_X>(_L[_\
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ML?\ P!N__C-'_#QC]G+_ **?8_\ @#=__&:+H3CS*S1](T5\W?\ #QC]G/\
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M."<CYF4$%O<\5Y'_ ,/%/V=?^BFV7_@#>?\ QFC_ (>*?LZ_]%-LO_ &\_\
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MLT,G/[P.<Y8DG.<YS6'X6_9=\(^'6U>6[N-4\0WFIV;6$UWJUUYLJPL,%5(
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M^P;D'_ON.IA'WTPJ2]QGZV:I_P @V[_ZXO\ ^@FOYS%4)E1G )_G7]&>I_\
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M'C':CELB>:Y#_8-E_P \V_[[-'_"/V7_ #S;_OLUH45(&?\ \(_8_P#/-O\
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MP!O?U]*8SNS<GBM>4SN-^QA5.Y@*0V\2\F3-*?FX(YH\EG/ /Y57+V)N1,L
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M1U*6&QT\^&[;PQJ4$.B7=OY2G8D;)@H?F$F\^O(&*^%?C)+!-\7/&4EMH_\
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M<=F?!NH?#/Q+X1F=-1TJXB7IYBJ67\Q7/S0W,9*LS >]?HBZB>(I(JR)TVL
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MF\?\?\S%J/\ Z525^_U?@'\9!_Q>;Q_Z_P#"1:C_ .E4E95#HH]3E;>,R.%
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M06[XI1'+>RXP23[59L]-:XE/:,'[QK96..T4)$..[46)(+33H;.W7S1YDG7
MZ"GRREN@V+Z"C^(]Z8WWLCI18EB,>2<<8IK;"> <4K,2<4P\'J::1(DF.H[U
M&W&%P#Z&G-SSC!%1NQV\,/RJ@&-CZ&HCTY[U(QW=Q4#,6P>,=.M(3#E>G\Z:
MLA'RGYA3=Q&>/QI\4,\QQ&A8GT%22 ^9A2RQA[>3=]W&>:T[+PS=73X90OKD
M<BH-:AM[!?LD<ZSRG[VWG'M4B..NH-LGR%<'L.M1K9S/RHSVZ\U8US4+#PU;
MI=:K>06$3MM5I6QGVJG8>-_#MV0+75;>5B?X)!S46 E-A,!]UL&IX=)F*@.0
M!U%:":E;R<K(I'KG(J:&[1FXV_\  32L(S&LXHRN[.._%6HU@96"@K]:OR1Q
M31CO5<6D:CE,X/6E8=R.VNK:V8^:=Y]/2K;W6F3G&5([\8Q4$EO;2;E6/#X_
MB%4Q:Q19D=%P/;K4C1?N-$MYEW0L<]1Q5";3985!*MCZ=:[/PS<K:Z"MP(%D
ME,A#%OX14S>)HY6*S6,+ 'TYI#N<"MA.^-L9.[VJ9M#NUPWE<8KO#K&FA5)L
M57)_A-/MVTG4IA&(Y()&X&#D9HL%SA%T6:1LNI]J?_PCTNTD,H'N:T;VZDM[
MR18F$JHQ! ]C5=;BZO%;A4':E8I,HR:)<IG:F_Z52EMY(2=Z,OU%:WVBYM6Q
ML9N.O-1W%\\C8,1(Z_.*+#,K;QZ_6F;0O4'-;#7%I-#MD79+V('%5)K-UPRE
M60]Z5AE555A_$/:@89L"G21RQR ,#@]/2F\[L#K2&:-I#'%")G.!V7'6H6E#
M.61<DU9LK-[U=OF;84ZG^E:5O910L-IR!T-%F4C(^R74YW&-AZ<4O]DW)_Y9
M[16^6([\^M(6;'WLT[%&!_8\[9!3G/K43Z;=1MN$>2O:NA+'KU-'FOV./:IL
M.Y2TA9.6FR,=*NS7"R<9R.G2ECNF4;3AQ[BEC\J9RQ(3G@&G8LC8[8L'D8]*
MXN\1A<2XXYKK]6N)+:W(127(XKD)(Y6R2K$GK3+5R*20S "0DX'&*])_9O7;
M\1) !Q]BD_FM>;26[* ^"I[[C7I?[-[?\7$D'/\ QY2?S6L:GPLJ/Q(^F=2_
MY!]U_P!<F_D:_G^L[>3Q!JUM8VJ\22B- !ZGK7] .I?\@^Z_ZY-_(U^*_P
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MXUBRT^XM8]6:9]G[L8<BO4OVBE\+^.OAP=2T@0W$EHZ_O(1M8 ]C7RKX1O\
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M_#?V72XBKSM]WR]HC'7BO&]2LKN.]EMK])(;R([&BD!!7%1IHS7MO.WVN%1
MF\K(V"?85,6X72%)*5FS-L87>7<,8C^8EJ(]\TA?KELDT1W!V^4^51B!FKK0
MPV,TD(83Q#I-'S699W/POU2WT_Q/I0N(?-MC<*90O)%?;]GKBMXDL+.S4I9R
M1[LD8!.*^ ?"NLQ^'M2CO&M6N6;_ %.6VX/J175:E\7/%=WK5N\>HM;O"X\L
M1'@?6MH/E3.>I'F:/T&8^6IED. HY;IBF>'T63SI^SMD'VKYJF\=>-/$4V@:
M>;V-K.1HWG:%<%_7)KZCT6%5M%55  Q^'%;<UT<<H\I=$0\SY>?][BGLO8DK
M^-#(&5OE/7KVH7!!W?RI$B&,9^5P?<\4XJ?[JL?:D;KN& ,T%FY)^5O]FD!D
M>([$3V)D"KO _&KNFC-G"#R50<)46LR!+4@_Q&I]/B:2UCZ8QCCBGT'T+?(Q
MD>Y'K2;=R\ ^N*0(R<H>,XYI=S,>B*.AP:0(8R#/S>G ZUS'C:X$.DB(9W2-
M]T#M717EP+6%GDX&,GBO--:U9M2NW9W.P'"+[4TNI1EPRLLFP1GGCBMVPT*S
MO+*234%P,=.M9EA:^9<"0D+'GUKI(-+\V.6\OF:*U096/^]2+1\E?'[P'%IW
MFW]A!LBR6_"O"M+U*T9W%XTB.RE1(HSC\*^V/BAIT6N^'[\+G:$)5<5\+WT;
M:?JT\6WD.1@UE5BMT=5*=]"_:ZPEC;ZA;B63RYDP %X8@]ZZ7POI+^,?"+Z3
M9F-=0CNQ(H8[1L(Y)/M7$,0^YV7)!P8U'/UJPMTMJH;3IY8V:/\ >J3@@^U<
MIU&J]@VD_;X)959XW\LR(<JQ]C4NA6EMJVHP6T\AC#,!N6LR,2-I*D_,&D.,
M'DTV&Z?3_P#2%B<RI]P]@?6LVBTS]#_V?O'&S2;;PAJ-W_IULN=-N)F_UR 9
MV GJ17IOBC3_ #HQ=JFPN,.@[.*_+)/B)K\>H:;J'V^075A(LENRG&P@YK],
M_@W\2;/XS_#>TUF(JMW(GDWD/]R<#DX]^M=-.:ORF,XNW,9/S="OYTQF' QE
MNF*M:A;F&=@[<Y((QWJD"5(QE1BNDR'LS9.T<'U%0-E&Y'/J*=YFT<9#>]12
M28Y)!/>D.[$9L\DUZ)\ O^1ZDP/^71^_N*\X+%OSKT;X!$_\)TX/_/H_\Q6-
M7X&73^)'T3<?\>\O^Z?Y5\&?ZMBI& >?7-?>=Q_Q[R_[I_E7P6O0@C./TKBI
M=3O+$6WRF[/[#M6UIZJEIN!.X]^AK$C+2*1MSCD&NAMMOV.(X(7Z<ULQ$D:\
MC[V1R3WJ88X(8G-0KE6'S8 XZ=:G7;\C9RH'.*0R55QP,_532_(9 /F'IBHM
MP;.!CCCFI$W-SPN/4TR2:-FVDJ_.<8/I1NVE@R9!&>.U1<CY@>O' H'&0&P0
M: )EVCD#MSEL&GJQCA"J27D; YS35W%5+ X7EF%:.@VXN9VN7^54.0I'Y4A&
MC!:VVDVL@=<NL9D<GG  K\\OCU\2Y/''BJ\@6=SI]G(4B0="0>M?7W[2WQ+'
MPZ^&]Y)"V-7U3-O;KZ CYC^5?GYIY-Y<,)T!6;[S,.A/>HG+EC;N1%7E<MZ+
M8V>M6-Q:QR"VOU'F1>:<*^.P/K6EX-\9:CX)U!9DNMPW 21!\C&>16!K'AN]
MT)EF$EO/!(<+- X;'U]*H6]Y-I-TK&..4KSB1<Y^M<QL>B?&+QXGBJ2'['"T
M46T2':>,UYK9S&1I"Z-))U'/]:[K[?8>-8XUGMH='NXT_=M'\L<OM]:XZYM-
MUQ+'%N7:<;5]:&[B6@NK6GV:.WN8FVPW*[MG5E(ZUU'PV\?7_A?48K.6%M0T
MVX<;[?&6&?XE/8UR=JQ\WRB?-!! 5CTJ]X>U"ZT74[6YM'99EDP-HSBD,^E-
M*\-6WCK^U[^Y:;^S=&/F6S7"X>(XR5]Q7FFK6FFZY:SZSJ%Q/J$T<;*D<'!'
M.%SZBOH'X<W$NM?"+5KJ\2)KNXCD\U8QM8D#^(>M?/O@S4-,M=0/VQUC5"5$
M0Y&?0U:?NW,;:V(_A[JVD:+JUG<7=E&4\U2)&R9!7TT/%EEXHU"UCMRJ,%W+
MQD[:^?==TW0;6$W>G2AM0E;/D[< >M>T?#WPS%9Z?8ZH%)N+B!0^.0/:H>@G
MJ>GZ"WDOG+$[L;2<'OS72+YA[.!GD$C'UKG+"9HX59]H.>N#6U:WBW!RGROZ
MY^M&Q@T2M)N;YAT'3/TH#-O#J,*,9I74[1N&3U#=JC?]VC=0&&?E^E*X7)&C
M;=G!=1T[XI2V '8=NQ]J10Z-AG.W'&*BFF6*)T1@&Z_-S^5+KH-#H9%DU!G4
MXX'SGK5X2,7. &&/O-5+3X3PW4MR>.35Z.-MSK@#V_"F,5;AN<A<L1TYIK28
MR^"N/[W%2JBLI\MN!VQS4%U(L,>7&1C/KS2&8NOZF\-KG&\MT.>>]<I(&E;(
M)5F_A/.:U[R22^FE=,[1SG' YJO'EI4_=8&1AFXIC)=-ABTNW>2XP;AA\B@U
M8^UQ6ENTL[AKEONIG.!536;4V_EE7Y;[O'6LN%99BH9<LQX(YHL,I?99KR9W
M*JH?)XZG\*^8?BYX770_%TY5#%%*2VP@\U]=V(VJQE4)S@'&&(KQG]HC0C<6
M,5W#NRG4XSQ6BZH:W/GZ]NX9&C!4,B1A?+5<8/K6WX7\0,OAV^\,VUH)I]5E
M4J6 SD=LU@1P"ZM]JJTLH.YM@Y(JS)'';W$;V<,L<VW=N+<J:@V\B'5M-O/"
MNI36=Y']GNX^##'\P_.G0S#;#<1[HWC'8C(;UK'O+R>\FD>2X=YR<[LG/YFB
MXWQQ1GS8U4GDN?FH*/T(_9\\>+XP^&MI+++]HN[,_9YQG)QV)_"NBUJ$6MW-
M&2!&_*8^E?(G[*GQ*7P_\0X=)FRMAJJ_9W[*)/X3BOL_7+4R6*28&^$E2<<X
MJ8]AON<BI'RY0L<8P,#I3) R\< <CCFIKI49P5Y#9[8YJ!59AP#M]CBJ$)D1
M[>?G?KQ[5&K.V&QN4<Y/%+N95VL3\O ],CWI)%W2'#$D\8[4>I0R1OW8)"@J
M#G;U..E0MDJ%!P>1SUP>:E?(V8P>YR?P-12_,IV;?[HYZ$4%$98\LJL.A^O8
MU?T!"WBK0Y5!!-Y"ISQTD'-4&5> /F#?Q9]>U7_#LC?\))HI9N3>PG!'<2+5
M ?;=%%%29A7P_K5RTWB#5W!!']H70_*9Q7W!7P#I^H'4-0\02;L^7KFH1'_@
M-S)7HX%^^T85E[MS?C(DC ';DCTK1TVZ^RRJ_53UK(@8 Y_R:N+AN5;:<]J]
MMGFW.P7;(@=3D-T-+D#J./:L+3]4:U_=O\R>M:D>I0R,2K[?44A%C=\O'XT@
M8#J"<]:B:ZM\G=+@D9-1/J-LJ[E9G]<4"+3,.,#%#.%4F0B-/4C%9<FM;<B-
M-ONW6J5Q=27!/FR[E]*0%Z\U(S.(;=CMZ9QUJ0I]GM]K9+MQT_2JVEJK[WY(
M45TWAO2?[5U-6FYAA&YA[]J+VU R7LVMF@4*1NYP16N0(81@\8_B%5/CEXTL
MOAOX-_MN2(.5DV1+TW$]J^9_''[4VH:IH<5OI5D;&Z8AGESNR/:I<DMQ*+>Q
M]01R+(IP0:K:AB:W>+(*XP:^9_!W[1^IQJJ7ZQNI'#XP:U+WX^2?VH)9;R$V
M"?>P,$BI51/44J;.<\3:;IS>,);R&VBAN+>?YE;^+GK7T)X;\7Z7-HMJQNX8
MI60 HS <^F*^>_$7Q(\'ZYJ:?9/-DED7+.@^4GWKAO%%I-I:+*EV9%FF4Q;'
M^Z,YY]ZS;2=T7RMI)DG[2'DZY\3'M],A'V@1XDV <GW(KQ34;.73[F2VD785
M^]S]ZNV_X2J70/'EWJ-PC73,W*/UQBN=\7:U%X@U$W*V_D1G^%>M<U22DVS>
M$7%)&,T2+9QNDGF3,2)8RO"#MS3M.AEFN B)N'7"]Q4T:H8XXARS'G^E/(BT
M^/$CLEQ&^!M/!!]ZR+--K>"'=(K$E /+7&>>]>G>&_@E/<>$X?$YN8I[3_62
M"/EE [8]:X;PR]OKD9L[=?+F52VY!N)K6T'QQK_A?2;K0!=,--F;,D3#!Z]J
MTC;=[&,K[+<]G^$+?;=?2<AEA3 4?PC'2OJ#2;ORI5_>91ORKR#]G7PW#>>$
M[>]=,+*Y<''*@'I7M[Z7'(NZW7#+_#[>M:PU.6H];%X?=QN/)^\.<BD;*L,K
M@8YSTJM'=?9(V69 &7G<13%U2&7=B4,,=:JQD7#(C9&"3G^'@4TLL0R25'3D
M51DU:.)L(0[>@'%0,;G4,C'EQD] .M%A%:^<ZE=+&@R-W&*Z*!A';HC'(7CB
MJ-E8QV_S<[^]7&8G&2/H>#0,5L9QGC.!N. *20$ NV".QQTI/,]"K5DZQK*P
MQ^7'S*W\-!1C^)-:6;-M#(<=\]ZY*ZMW_NY/O73V^GLLGG20*SGGD\50U2.:
M.5B\ 16[@<"F7:V@W0=%4PB]F;$2C(5N]5M6U.\U:?RHV_T<=%S@ >M;^BR6
M_P#8MTDCL6P2,\BN;9H?+=4=E9C@8'&*GH,S;_09M2L+FSMY%2612H=AD5\1
M_%KP=>^"_&ES:7N&ESOW@<$'O7Z#:;:L(8QY.6]OZT_Q'\,_#_C2U>/6--AG
MD==HD*_./QI-*2LS2$N5W/S4TRWNAJ6VV;YY%.2V,$>];/ASPG]G\06,E[&\
MEM). <# 8=Z]4^*WPS_X4EXXMKB/R9M)O!B/S1D@#J*ROB!X^TN\L;6WTN &
MZ4@^;&, ''05S2AK9G4I=48GCZ^T#PKOL-!LS/<9.^>0Y\H$] /6O,VU2XCW
MXE)5LY4BK>H6][;S?:;C<CRMN^;J37L'[/OPP\/?$M]4M=423[=;R+)F,\%#
MVK.6KL:K17/#)%9K92H8AFR0*^E?V&_B5+X8\9W_ (?F<_8=0C\Q5;HLB]_R
MKN/C9^S;X9T[X<W]]I%D-/O[*(2JZL?GQU!^M?+?PEUQO#'Q)T.Y<[ LX1OH
MW%$H.%I%1DI*Q^E_B3RKJ\D>)E=77>-OKBN=].N?SIFFZH[R,LAR#RK-4MPK
M0RLJA<=<UVG,1LRCACQVJ)L<$J#3I&W'! 8@=:C;8O)!![BI'8&RPXX[GFO1
M?@"Q/CIN?^7.3/YK7FC..>.:])_9_8?\)XX[_8W_ )K653X&:07O(^C;C_CW
ME_W3_*O@R/B8GGDD$U]Y71VVTI]$/\J^!=+U*'5K-+J LT;YVLPP>#@UP4NI
MW&AY2!VPV<#)&<9K=LSYEE'P25/0'M6$O./GY/<UH:9??9F;<-R=, 5L(UHP
MO?IWYYIZLL8;;U/O0IBFPT)7!.?<'TJ15 R"%'.,8HN(>RDR(<*<C.*3:=H.
MT<'IFF;0RD@@8X^6I(T6)B&(*GC.?UI#!=BN "5YY!.33V4EB, ?0=:/*+ D
MML-1^<=Q2W^=VZL3Q^% A_WF\H L.KMG]*ZS3;=(K-%. 7^=\CM7*Q+Y,+!D
M_>9YYYI_B#Q0L6BNB-Y9AA+.V>< 4;B>Q\3_ +67Q&?QO\3IK6V<FQTI?LT2
M@\;OXC7B;-.2"'^HK;\17!O/$E_<@L5DG=LOWR:CL&L9+HQ7\4GE$?ZV$\J:
MYIN\F7%6B@T70?MMG-=_VK;VL\3?+;S$Y<_3I65>-)//([2AIN_ECK5FTL8+
MS51$976"1L(P'(]"14=C;PV>L.TLKX5CAE7@XJ!D%F9W(* 2)&?O8Z5M7>D7
M;6<NI6K!GA(\Q0,?*>]4M+U(6,EPZQ1L6)V_-[]Q7J/@7XH>&H;>73_$>@H$
MNEV&XMCR![BE<3/'X(S-Y:D+YI/3/-;%JK6++*DJK+&XP4ZY]J].USX,Z-XL
MT]]5\"ZLMTT()DT^XPDBX]/6O([J.[LY#;31/'+&2"K#'- CZQ_9?O4U'3=:
MBNIGF>]DVM'(W/3^M9WQG^#J>'9+>_TG35EM')$OE#E#ZD^E><_LYWUI9^,X
M(KB__LZ/B1VD8@'':ON._P!'MO$OAN[@AN8Y8KB)E#Q$$@D=<T1>MF9SNM4?
M!FM:I!:1V\<,BM<,,2QLO^KQTP>]?7?PKLEU;POIMPI_=M H91P,^U?&GC&Q
MGT?Q->V5];^7<0.5;G&X#HU?7_[-VI3S?#>Q$IS(H(4$?PYXHEHTB=U<]*%C
M#"%5$7:O'/>HIK.W;YU7:XX&VKDF9&8X)!/45&&98^1D=>1TZ4C S3>;=T<F
MY=IXSUIZSQ^6P+;1M)^;Z5G^(]S7$ C/S]?E_&EL]'EN5W7"LYQ\J_TH!%S[
M8F L7S.>AQ1%:>9(LDS8;'  ZU:6SCC= JK&GL*LB%5SP#CCBD%AI5F10<J%
MX!!IVUCE6;L.M*,JQR/?K45WJD-O@N%5@O'- RPVR!06?^G_ .NL'5+Z2;*0
M@J<X+<8 _K3MMSJTG[O A/<].M21:"%7,DC'/&.G:F4&E6[O#+$LJ E22549
M//0BL74M)NUDRHWKG^$X( %;RV0T^:1XEX*XW=AS6)<><NH;FN&V.<<\<8HO
M;4HJ74AD@CCDC8,G&YQGCZTU87C5$#-&PY&?IVK=N).9;65EGC904*CFLNY:
MW:]@6-3$RC&TM^M&X)$VU-@P59OXCW'X5P'Q6LC?^'[F-06;;P,<]/2O06^^
MVXAE]EYKE?'2AM'NGW*0J'[V1BM4!\?Z3IPAU8QF:2V>0E=[<8]:W]$_LS2M
M>OH-3B:XM7MGAB=3\P<]&J#2KJ&/4+^[ED8&/<JH5W#)[URVK"::8RA&VLW,
MG]TU)L=9=:+X0\,^&7%O<2ZQKL@W;I/EAC]AZFO.[BX@U*^C,=HL5SPN V0:
MDO;HW!\A)=Z ?>Z@&KUCX9N]#F75+N-98HQNCCCYWG\*114;43X?UZ&:*3%Q
M:3++F$=&!!Q7Z7^&=<C\8>";/58CM%W:K(^3RK;><_C7Y>W$L$US+*$*/(VY
MF9\XS7W%\ O$QE^%NF1QN7C*-$P/3(J=I(KH>A-)YC;E8;!U[<^M5Q&5)#'<
M_(.>_>K<!\VWV#;M.1C'-5)E\O*,Q&WD%>WUJP$^\H)V=B1[U#*=^",KZ<]<
M5))"(^"A.[/WCT]#415#@CA1ST-3J,8VT'/!!.,5#)(JAL*%SSS^M3%1\J@9
M(!Z>HJ-EV@[@OJ0HZ@U0_4BXVX5N!QE?TJUH4W_%5:(%)(2]M\ ]\R#-4I9A
MY)=CL"C=M]Q4.@:A#;^*-#EE9@/[1MQP-W+2*!^M V?>E%%%(S"OS9^'NHB[
MU[X@6Y.XV_B?41CZW,E?I-7Y2_"K6L?&;XJ:86QNUZ_E5<_]/,E=F$E:JC.H
MKP9[C&VT 8JU'(IR#^=9]NY"_P!#5M6([XKZ \RQ>CEVJ*G>:.1%P#NJA&PS
MUS4R\]\ #BI()-P/(XR:<ORG^51[B>/RIX^[][D=J8@\L.2<X(YZU-;0B\EV
M9"\<L:KM@?7O6EIMB9 L@<K_ 'EJ0-*RMDBM]@/![^M=KX1@$>ES28P9'QGZ
M5RFW9'C&%ZBNV\-VJMH5MD]<L?SI2V&?,W[=.JG[/X2T%)E1)Y6F<$\<< FO
M%_'WP@/@3P]I>N#4H;N";:'C4],^E=7^W%J#7/Q4TZT5ODM[%2/8D\U\^W.H
MW^I>7:W%U-/ G"1O(2JGV%<M224K/L;TX^[==ROJ&INTTD:.0N?EKK?!_@N'
MQ/I<MQ>W& AVJ%D[]LUQ]]IZQW3VLC!+H8QDY!K5\-L^CWD:7-Q):6LP(F(4
MD?4>]<ZEK=FK2MH:I\/'PPS;I8(T#'8P<%JU-'^RPPS1WNJ6\UI<L))(V8[U
M/JI[&N+U&U5;["3^? [925^XSU-9UPR17#))&9&7. G0T^:ST(4;G4>-O!][
M/XDM188U!=0(\AX6W=> #CH:]#N/V/?$,?AU+]K^)KO;O>W4'Y?;->9?"WQQ
M-X-\::;<W">;9QS R1.<A1ZU]5^.OVIO#EIX?D31':_OKA#&%48$)(QDUBZ]
M"$KU9J/J['=0RW,,8O\ 8J$ZG^&+E^29\B2:3#?7EQI2%8KJSW*K'_EJPZCZ
MUS,D+#=!*A1E;E6ZYK6O$F_M/[4EQF<R&1I1GEB<U]#?#WX>^ ?B!:6$NJ:]
M91>(+A-C0"14(/N#WK"&*PU27+"I%_-'?7R/-L+#VE?"5(KJW"27XH\3^&-Q
M:Z/X@L+B6$E/."LY;C!XZ5]5>-/V<;?QA-::GIC_ &9Y4#2#L<C@U2^(?[,.
ME>&?!<%QHC,TUO()992V?,3//->_^#Y+:Y\,Z9):RB2)8$4.O/0"O1C%QWZG
MR]2:EK'H8/PS\.OX!L;?2Y@[Q*NP2$<9]:]!7!X5M[YYVC%0,J21E!B3=SEJ
MR9M>&CW@@>$S*W K2W8YF[[G0R6Z-"0<,.Y/:O,Q)=/JUS';MO@9SMQVKKKR
M^N=5A:.&+[-&QP<=<4MCI<-BH"QC)'+=S1L@':+I@@423#>Y[]:VXQ]T$;E]
M%ZCWJA&X4;5//M5J%S_%P3_>Z5+8]RRL"LO'(/);%4[A1!\S%=G;-6VOH;6%
MG=L'K\W&?I7):M>RZH[I'A(L_C1$JQ7USQ8L;BWME5Y3P E9L.EZC>-YTVT;
MN=IZUK^'_#\-O<M,0)&/0GDUTT4<&X[!^#<57,.QRD<%U:E2S-A>W:I->URY
MFCC$:PL0,,A4<UU'V&.Y8@,P&.XKE/$FEK8W"A6W&49&#Q23'ON1K);1Z0DS
M0_O9>&"]!67I.FK*MS(>$7Y@I%.CFEBA*-PF:K6VK/&\R+]UO3FD6C2MUFFE
MRFY,>_&*VUF*E2S[I/I7RQ\1OVDM:\)^();&P$,D<389<?I7)#]K+Q==;EBC
MM8G)PNU#NHYE'1FJBY;'6?MJ>)+74)- TE)5^U1LTDWJ@/2OF&^N%@C9/(VW
M#$%)0W  KT#6[77O&7B!+74+<SZA?'S%FD!WL#_2NVU#]F^71? \NMW;%YM/
MB;;;@9\PG_"LI>^]#6*Y%J>,7>J#6;.TM7!\U !YF>37H7PM\7S_  *U&WU>
M]M&N$U0!3 6PPCS][ZUS7PT\)6E]J$^MZZS6^G67[P18QYK#M6KXN^)6F^*M
M4:;4- B,$2^7;M&Q#*HZ<5E:^YKMHCT3X@?&_4OC1 _AW0H7TO3';,TTC?,X
M':O!O%GA6^\*Z]"LGWE*RHV>2 >M+I^H_9;J6[TPO;,K?+&[]<U-J>H3:H7F
MNY/.N6&TL2> .PHDW):E1CRZH^[?"U\NJ>&='O2=WG6Z'<.><#-;4DWG+M&"
MW;(ZUY[\#;HWWPLT<[FS&A3YAZ&NX?>T> VUUY5@:V@_=1E+=CC([8&2.?3K
M1)(B]06)Z8J&.\-PQ20[+CN,<-[TC2!6.2R]OF%,$.D88X(->D_L^X_X3U^!
MQ9O_ #6O,=VY@ >OKWKTK]GK_DH$O.?]#?\ FM95/@9I#='TG<?\>\O^Z?Y5
M\&0 1J%@ABB0$X54 %?>=Q_Q[R_[I_E7P:H8MDME?2N*EU.TG7:^W=\O'.WC
M%(MNCRQAI)@#SN5B*3(VDL%.3QS4L*[<*#C'. :V$6[7_1=Q0LPSQORW\ZO1
MW\V["E!_M>6*H+_J\OG';UJ>-0RE=S%?KS4 :,>HRY&Z%6)P"1@4QKAI&P&=
M!G^!STJNDJPJ=RCV)%+'( V6_,#]*H"=97=E/F,ZJ>DOS5J:;@IDK&AS_P \
MP*RI+@<%2,_3%6;3YF(!9D8;L9SBI8KFA=98*I 7(^\IQ7 ?$M?L'@G6[A9)
M@WV=DR9"1STKNY(PP/[ML?WJX3XU74NG_#?5YX53>B<AN:J(GL?"D<,"I,MX
MTB.22O&:S7MY+=2X238YP&V_+6Y=7%QJRR33%9549("@8JCJ'B2_N+*WT\$+
M;1C B4#\_K7&S4FT;2F\11>1!*MO>)_JC(VW=[9]:J3>$]0LQ<F\LYHGA;#%
MFX/N#4'VNXLX_(*G#?, QQ@^M7]4UJ^U#38+>YF:95^[N;./;/>I Q)]-6WP
MPD5T;GY>?PS5K3[&WU*Y$3SK#(RG83P!CWJ.&QFDQ$O()XR<"I+I4L=0,(55
MV@ EVR WJ/:I&:F@Z]-HLSO"TL=T/]7+$QSD']:T_$UQ)XRO8[F[GCM[SRBQ
M8#EL#H1ZUS,;EKA&1A&2WRLIX/O3E22XF;>[!RV"1WH)9I^$;<SW^"[,6&"Y
M&.?3VKUKP#\1O%/PI\0-90P7=YI,A&Z+YF&3W4CI3/@+;^$]+U"YD\53().!
M$K D-D_SK[1TJRT4Z;#]AL(7C*C8_E\8[4KD29YQJ'P0T#XA7]KXDU2*9;F>
M)6:W_ASC/)KO-'\.VF@P)%8QQP+$ H15 &!6U&=L.QAL XVCH*:UP%^0*&'3
M*]:K?<Y_(@:ZB9BC$Q2]2!QQ]:C::-6(C\R7GGYCC%,DT^*2Y#NAQC^)JLB/
M[/AE V].OO29!5M;6&.1WD5))>V\9QQ5G]Y(Q*G<V[C:,"I JMN# *#R2>O:
MI88E6:/Y]PST-2P95$?F;<L3D<J"1VI_DB)2VXXZ?O#GC\:;>720+F,K(?0_
M>%9OF-J$B9D"C.=OKS0-$EUK07,<$*,>A.WFLI8_/N-[YW9Y7H*V?L<<8#<#
MG QS2SV:[QQ@8P30K#T+NFVL<<8$:[6[KDY(S5@L%  "].0R\_A52&;R5 /.
MTXY.*L6\T4K ].?KBA,?D385E<F-6!X^9<<Y%<5K21R74B.I21&R-N<&NX41
MG<&^<@< G&.1S7+ZSL6^9SR@&,+U_P#KTXLI'/*[_:!L?:R].2:EN;@S72-,
M$ 3JRH.U,?YY2Q0(N<JQX-1L 6=GDW$==W:@+$]WJD,,?F&4)'W+)MS^->(_
M&;XQ6^DV,^E6 2ZU&<;1L8G:/IZUA?'CXJ.X.C:9<A@AQ*R9R"*^?])^U^)/
M']M:@R3.[@B3/*XYS]*U^'4J.IVGAVXD\.:3+J&J+NENI/\ CWG')_"N9OKD
MIYF 6@N#O55'RK]:W/&]^;KQ#<VD=RMQ##]]V'"D#H#6C\+?A9JGQ,OD@AC>
M#3(V/F7C<(I'OWI&J.'NK&YM857 \N9-P,7'%;.G>.)M%\%W6C0P":ZN'.;J
M8DLBGJ *]+\>CPCX-W>%8+6>]EB.+C4E()SZ#VK@/$G@^Q$B76@:BNJVWE;G
MAV[9D]<BF%SBH)!#:[6C558_?V@G-?7W[,>;SX<P*5($5P_W>*^6]-CGDLVM
M4@C,>?,:248*>P-?4G[,*M'X%N0=Q4W+%14/H4CV.WA5%4NSC;\Q^8_E4C2%
M6+#RWC8'*[1^&:;YC#"[,;CRIZBIY&9H]@CP6_/BF!GW%T\:[F_>0J =I'(Q
MZ50:]AD3):9"V05#$?2K5XDL<>4&5)RY;G -8LT@;<[,1C&!GTI,9H_;H,DA
MB%X.2O-1/?1\@(-Y)&< ?2J2LV74!I#C QTYJ#<Q##@'NWO2391)J$QF^\7V
MYS\CX^M3>$1&/%6AQE<H-0@&V7YO^6BD&J$C!)&RH.#G'L:O^$RS>,-".XA3
M>P#GVD6J%?H??-%%%,@*_%_P_P"(/["_:G\6;FQ'<>(=1A;\;F3%?M!7X1_$
M747TOX[>,KN,E7A\2W[@_2ZDJX/EDF.UU8^Z8R58@I@YJ[&S'T/O6%X9UF/Q
M%X>L-3B;>EQ$K$^^.:VHB0/_ *U?3Q:DKGDO1V+B[2O/%*K;>.HIBY*Y8#'Z
M4O/I3,B<*&;BM33H88_GN"%R.*SK2(331J.YKII+1?LY!"?**0&#=6H63*XV
MGH?:M#05W3/D[E4=*@?3YY6RBG:O(/:M&SMXX%Q']X\&D!;N)AY;9_AZ>]=7
MH6MPVWA^.25@3&2NT5Q%]L7@ DXJM;S/Y;IDA6.<4-7 \X^*_P #)?C%\2EU
MN2\^SZ;'%Y<JJ/G..@%4M:_9)\,#2W_LV:>*[5?E9VW9/O7M&C3>2KJ7P<G/
M%6F:20D<!?6LW%-W:'S22LF?G3XJ\%?V+XDGT^\O1!-"<,V,MQ4EKK&D0V\=
ME.UQ>0CA&(&Y3[5ZU^U_X+M]+\1:=K4)"&^4I+GCYE[U\_1WD5M:R+" TQ;'
MG%>0/:O-Q-2&&O*6WY^2\SU\OP=?,JBHT%=ZMWT22WE)O112U;>QT-]I^EJJ
MD:@8>-Q@9,MSV%7-/^%_B+7H8Y],LOM,,QPJK(I=?=@.F:XF]DCFDBCMW>2?
MJ[L>":^POV4_"EJ?"TU_=$-?22?,@?)0#IQ7#&G5Q,OWKY8OHGK\VOR5O5GM
MU,7@LJ7+@8*K46]2<;QO_<IO2W]ZHI-[J,&?+.M_##QGI$[)=Z%>18.&,:9'
MYBM'P3HNHK=/H^H6US;?:ALCDE@/R,>ASBOI#]J3XC7?AG3[.RT2^%O>[]TI
M7!;'I7S[;_'KQ9' &>ZCF92/];$#G\:Z5A:&&?[N-GZ'D8C-<PS%7Q-:4UV<
MG9>BV2\EH=+;? 74KZ06-Q<^5>J<!C]QQVIGB;X6ZM\'X=/U?5+2TU:TW[9+
M68!E9?0BNZ\#_$[3OBI#!IUXDFD:NJ8^V1G"%@/6N'\8>"?&.H:\NFKK$FNK
M.^(8V?C&:WE3IU(OF5T<%'$XC#34J,W"2ZIM/[T:R_&3PL]G'#X<N-<\*W5Q
M^[FLEF-U9,3_ -,I"<#_ '2,5Z[\.?&6K_#6Q2/Q9I\EMHMPP:'6K52]JF[I
MYB_>C^I&*=\*_P!D_2/#\=MJ?B ?VEK'#B(<1Q'TQWKW^.SB6U:V,4<D&WRV
MB9 59?[I![5S1P?)K0?)Y?9_\!V^ZS\SV99Z\3[F:4U73^T]*B]*EKOR4^>/
MD5[&ZAOK6&YMYXYK>50\<T3!E=3W!'6II-/61MY"NW3..:\PU/PMJ7PJNIM8
M\&PM=Z(SF74/"N<K@_>DM?[CCKLZ&NW\-^--*\6:/;ZGIET)[.X'!^ZRL.J,
M#RK \$&NBE6<I>RJ+EFNG1KNGU7XKKTOYF.RR-&DL9A)^TH2=KVLXO?EFM>6
M5M5JXR5W%NS2V%C$>,9!_NMQ4C* NU_E'4"J<VH1,OWU]JQ=2\3?90=JDD?Q
M=JZ3PK&\TT5NW+@KZ+P:H3^(1$WEPC''WJX6XU^6_G"EMHS_  GFM[2(?-4E
MF)^HZ4NI:1ILLE^V96-*MNL(SOX]ZN1J% (4D56OI#MPJ'.?2J*)[&XCB;<9
M%7OUP15Y;^%Y"!*)#U-8,/AW[=^\G&WGC!Q6U:Z);V[ A</C/-3U M27BQ<J
M<9'.>:Y3Q9JPG"[T(V="*ZV:U3:=PVMZ 5E7&DPS+A@K^WI33&>:W&O32MY2
M1$CIFO,OB9\6KKP'.]G9W,(N)(\EE 8KD?I7H/Q,UO3?"IDM?.\JXN(F1>,[
M">,U\Y6'[.WB_P 8WTLUO=07BN=PDF8C(J9.QK%)[GDMU?/J5_-=7!:XD=S(
MS$]2:(87T_6;-MPWL0X"\X]*]DU7]FGQGHX<W5G;""%"Q: YW#TKSG2[/4M)
MUE72U6T&_89[Q-RQ_C6$DSIBUT/1/@WXB63XDP2^(9U5UB86_F_+CVKZ"^(?
MC#3)O"S0P7<*QL=K[&R:^?/!/@O2=2U9M7\0:JD)9MRS3#8A/^R.]=;X\U#P
M!:V<5I!JC7$T@.XQ#()Q5Q[DR5['C/Q UX+<'3]/B9+&([E;L_N:X>28W!_U
M.S']VNXO9KG5)8+*"!I$<^6BM'DA<\5N?\*?O=)TU[B_C<S_ /+.%1U'J:SE
M=[&JT/+HK-S(L@3<,@\<9J\JO)OW1C.>O3%:VK:1/IL>XKD.N0PZ UZU'^SU
M+_PJ[^WO-:;5)(?.$ /R8QG'UI1CK8IM)7/1_P!GO<_PUMANW!)6'ZUZ3'N9
M V1O'7Z5QW[*_A^:Z\"6RW&Z-3*^5QT]J[^XM5M[ZXB91B-RHYK6G\)E+<HR
M6\=ZG7:Z_P 0XK.FOY;)C'=+YR_PL!R*UYE2&X!+  ^E9VK7UOY)B*ERW\?H
M:T)$CNK>9?DDVX[-P:]/_9YS_P + D))_P"/.3 _%:\+DP.N?7BO7/V8I9&^
M(S[GW(;&3 ST^9:RJ? S6'Q(^K+C_CWE_P!T_P J^"T^5CAS[<8S7WI<?\>\
MO^Z?Y5\&;BVX&56P>XKAI=3M'^86_NGT%30ME@"H!'%554-RNTGH QQ5B$8'
MW0&SS\W-:L"Y!))P"N0.15H*RIGR\T[3;625E8G(!P,]ZVX[1]GER#Y,Y^45
M C&55V@D\CMCFI K*IXY4\D\"M&33XHYBY?&1Z9JK)-),V <Q_7% A%MX^^T
M%C@#T_&KNDVNWSMP&> ,-UJK;W%NH,<JXYZCG%:.F[&,H1LID8P.#3N YF1?
ME489<'K7 ?'E7D^%^NX;.8P>"*]/BLX;J[AB9<+(<?+7)?'KPF4^'>M26<>]
M6@(92>0133U%+8_/_P ->(H?#=U]HEL8M1A9=KPR\9'>FZY#HMU&-0T=I+4S
M2'-K(<^5^/I6IX<TBUU"17O9!#;IE7 7)K.F\*PQZQ)!;:A'=6^2PP=O'8'W
MKC-3,%C/<B%E/VC>VS&[I3]8LVM[,Q?9V6:$]<UT'AOPM=7EXA0K9K&VYI9&
MPN :]*F\1:!%9RV:V:ZWJ)4HUTR (/8>M(#QK0- N_%&B7S6@43V,?G-NZE.
M]<P6EFN' 7S&[G->P>"?".HW/B"Z>UA^RQ7<36Q9&X0-QDBJ_P 6OV>[OX;?
M8[FUU#^T()DRQ*X96_PJ?(+GF]NS3111(//V'B-.3[UV/AKPE<W]U+;M:M#-
M-"SPQ2MC)'8'UKE%L9M,AMW*^8TAW!(S@BNF\.>*+K3)EOYH997@D5564\@>
MU(+#([@:?J$<<R.M["0-K= 0:^N?@U^T%IFLVMCH6KM]FU)<1(ZK\DGXUY=:
M^%/#GCJ:?4+2YA>ZO+?,49QN28==U>D_!7X!MX1NO[4U01W=^0-KYRD8/I[T
MGW1GZGO37$4B860D8_@'%0R3,N5(W<_=;BG+:^5UZ>B]*9<;8U# X)XSGI3N
M8-#&97QO!![*.*%5BNU P&.0?2L+6/%FE:27%[>06P3DM-*!5#P_\6?"_B:Z
M-CI6N6MU?XP(=_WOIZTKBMV.U*JB;G"@=MO]:S+S6([?:(^&!_A7.?\ "AKM
MCM$B,,GHW(JA?1-)&QA)SR2,<=.E("H+QI;@;69B?4\CZ5M0GNY4D#LG-<M)
M*]JVX+LR>_:MW2;M;B-29=KGMBI8&NT@CC5E;EEZ8Z8K/FEDD<HBNSL<'T^N
M:U3;JP!(!/3YJ=% L?0X=N#ZGFDF%BFNG-)_KMY"C[JGWJ6'3UM_]7\JGU)J
MXV>/4>@Q36E!/4CV/THN,KM.\/F+G.> %Z]165-IYOFPW##NI_6M"XNHPS9.
M<<A@<=ZH17C&0J@WMC&2*=QHQ;C29,2&+-PX!^X,'I7BGQ>\7^(-*TRX@AL+
MJT@*X^T>6<_B1TKUKQM\8/#WPS:!=<G\B2X&Z,*I); ]>U8L7QW^'OBZUEMY
M]414D4AH;R,J"#[FM%H]0\SXZT^S?7-0MXG<QO+\KS3G]VI]36M=11^&YWM=
M-D@O+_:8WN+49;\*]&U/P/X<UOQ1/<Z1)]ITQO\ EG8$\#/.X]!79^&?%7PR
M^'[ )8F>^P-[>7O<>V:O8L\=^#WPIOO'>K7L.H65U;::Z?O;N0%"#^/6N\^*
MWQ*L? FA-X#\',+6.!0)[J/[SDCD<?SJ[\6OV@CJ=M#I7AFTFTZ&9<W%SY>&
M4'L,5\Y#4VM-4ED\M[IY,H[E2V<]\T_,K<N:AJ#:E&))5*3%=I?)(<^I-9%G
M>7.GWWRCRW( 9E.01_A70KH-U>+! ;:6VAP"\LPV)SWR:=-9Z;I,PC%Q_:04
M8<,-HX]#2+*%Y*TT>V.82IO/[O&!^%?5_P"SY9W6E?#RR\R(#SW:7&?FP>!7
MS-IL6E:I<1"$LKR2A!')T&??O7WI\/\ PG!IGA>V#QA4CM=L28QC Y-1?5(9
MFQS!E3.[>3_%P>*O[Q\K9PGJ3BJ=MB6-=O.TDDCWJ:.-XX6W;3@95FH&8VJ7
MDC-+'L4E3C[W856$'F8&43(Z,>N:NW%F+RX.2@7(8L@Q]::MBMK-R 5/ ?Z=
M :5P*C6++&0TWEM]WY3QQ5"Z3R9,N^1P>.0:Z-A ^ 0,D[NG2LK4HXEM\89F
M5NH/;M0F58QFD^7&TY)P3_*K_A#,GB[1,[@1?P8]/]8M9S*)#D?+D9XSG(K6
M\),K>+M"Y+#[? P'3_EHM: ??5%%%,S"OP2^,#8^,?CTX_YF'4/_ $IDK][:
M_!#XPM_Q>+Q[_P!C#J/_ *4R4T-'T;^RMXO.I^%[S196+36;>9&">JFO=8Y&
MP/2OA/X+>-)?!/C2RO,M]D=O+GQG&T]_PKZ\E^*_A>%L0:G]L8\A+*%YS]/E
M!P:].CC*%.%JLTFN[2-:>3YACGS83#SFO[L9/\D=U%ND&.H%3^;MC( P#UK@
ME^(U[=L/[+\):U>#'#SQK;1G\7/]*D75/'FI B+2='TE"?O75T\SC_@*  _G
M6_UZE+X%*7I%_G:WXFW^KV+A_O$J=/\ Q5()_P#@/,Y_^2GI.B!9+H=.!TKI
M)%WLH4#;GYCCBO']+\-^+KVY'VWQJ;%6."FDV")^&Y]Q'UK>_P"%-Z-?-NUC
M4]?U\]=M]J<FS_OE-O'M2]OB)?!1:_Q-+\N;\@_L[+:/\?')_P#7N$Y/_P G
M5)?B>BZWJV@^'=-6YOO$>EV#8RRW%W&O'TS7F]]\9O"2R'[#J-QK%SGA-+LY
M9PWT8+M_6N^\%_"_P7I5NS6'A32DOX?G$TENLDC#_>;)-=G;W5E-BSDLXX5D
M^7$483'Y5'^V2W<8_)R_6/Y"Y\CH[0JU?64*:^Y1J/\ \F/G+QKX\\1:]X-U
MC^QO"&OV,BVS.-2NGCM# %^;>%+;CTZ#DUS?[/\ XM^(GBVXBEU9K>70,<W=
MY#LFEQVCVXW?4C'O7T'K=JFDZE<6C+NMY.-K<@J>QK-O+1+1[>6T"QQ( HC1
M0%51V ["N:67UI8F&(EB)62U2LD_NZ?>_,]J/$V"I936RREEM+FG*ZG*\I1T
ML[.3>NBM:T5_*V&HZY8^&8C=:C=+:VA8+YLO"@GUK3B\2:3)9"X34K4VVW)D
M60=*X'XT>'1XD^&^L6@!DE\@S1@<C(YKX8T[4+]86MUNIHT'RE-YQ],5ZDZG
M)8^#A#GN>U?M5_$K2_&.I6.FZ;-]IBL<EY@?E)]J\;\#^&9_'/B*WT>T3+2G
MDMT45EW06$1LV2K-AB?YUZ%\']=MO /C^PEN6 CE S-CH#TKPH2^MU/K,MOL
M^G?U?Y6[L^TQ_P#PD8?^R:7QNSJOO+=4_2GU76I=N_+&WMNE_L<Z(;0&[O)3
M<D9RG&#7,+\#_$OA/QQ_8N@>)VL$NDWEM^#L[\=Z^B(/BEX<FL3<1:K"^ 6\
MM7&XX'I7S3=_%RY\>?%P:MI[-8VNGCRD+=67/)->M*,(QN?&Q<Y2L;OQ+_9P
M3P[H,^N_VG<ZW>PING%PQ)?Z5\RM"?.*G<(\Y ZU^A4WCJRU#PG-.D/]H;XF
M7;W8XZ5\-:K]IT?4;L-8IY$LK-Y;<E,GIFLZD59-%TY.[3/7/V>?@JWBS2Y=
M8O+V>RTP2 1QQCYI&'7GTKZ*T[X3Z+I>M6FKVOG?:K;A%DDW"LSX"W%M>?"W
M2/LJJHCW+)&IZ'->B&'<I5.GZU=.*Y=3*I)\S-2.X\S&3CCIFJ7B#7K/0](F
MN[B=8(H5W.['A17 ^._B]X;^'.H06FKWLL4\L7F*J)G\Z\V^,_Q>TOQ5\-I;
M/1C)<37^$Y7E1ZXK56OJS!Q;6AYQ\>_VH+BXU2*U\%ZS(L<7^ND5<9/L:\Q\
M#_'SQ/H.N75S]I647KB2YA9<),X_BQV8CN.O>DM_A'H_ATQW/C+63:B1=Z6%
MD-TY'JW]VNH\)_"OP!XNU #3-:N[ 0_.R7ZC#*/<5Y^)INNM':2V?9_UOW1[
MN68[^SZCYH\].:M./24>J\FMXO[,DGT/K'X?^*(O&_ABUU:,^69%RT+GE3[5
MIW@6;*$;F)^5,5Y5\&?%FB>"]<O?"<^IV]Q;Q.)=.NV;B2-^J'W5OT->\1W5
MF)?,Q&\@'\)&,5IAJSK4TY:2V:[-;_UVU.?-,"LOQ3I0?-!I2A+^:$E>+\G9
MZKH[KH>?W&GRVLQ+1[>X':MS0+YU=5D; )P.:TM4O;#5KA$^</G V]":>OA]
MX8?-:W(=3G*>E=!Y".GL;,21AMVVKZV,,?S<Y]ZQ;+5'MXD\R/.._>K?]M0>
M6"3A??N:6I1>V&,X4C']UL9I=Q*[3\C ?A]*P[GQ3:JI 4L1VK$U+Q)>2J/+
MVVL3<9/)Q0!U&J:E!8VI9W7(Y+5Y%XX_:%T+P;:S2M<I/=+G;#&<L375-8CQ
M%H]W;"YVM(C+EN.<5\6?%SX)^*O"4GVBXB&JQW#,8YK4ERF#T/I3V5T5%)O4
MY[Q=\4-7\9^)I]7N9"JRN?+BW?=&>E>G_#/]H+5].U:)+B)8[-$"A85].Y]Z
M\"M_#GB&:X2RBTVX$TIVX:,YKVCPA^RWX]C\C4;FZCTVURLFTG<Y YZ5SN3;
MN=5HI6Z'OGBW]H""3PS;W,1MP]RI ^T_(%Q]:^??$OBB#69"+!$N;IVW.S8,
M4;>JBN8^(4&L^)?'']E3(Q*,(D0+@8'&[%=SXV^"?AOPCX/CO;?Q-MU-55I(
MU;H<<K5W=^4E))7*'@%I]1\0Q1^(]-_MRS4$-Y9R5 _N@5RGCKQP-(UV6+3_
M  C#ID"R$0^<A+%<^]>G_LTZI:'Q@!-?*;!8BI:4#:&[<UZQ\</AOI_B[2UO
M--GLOM4.<988;-*.J:*<N5H^>O$'CP^+)-%7P_9OIUZD6R?R4 !XKU+P[XRN
MK'PJ=,\06DUU<SJ8;6;J[,1TKR.YT'6_ ,Y5+4*^"S/&=PQ_O5UW@'QC;IK6
MDZKJ;^=I]L=LL;G<86/1@*F]B]U8Y[Q=X%\2>&;47FH::[:.1B16;<1D]_2N
MI\$_'Q]'T";2-303VT:%;9HAG([ UW_QL^+_ (?D\#ZGI5C/%JMW>P%%2'Y@
M@(^\?2ODKP+H]UX@\3:3I%N[-)=74<6W/;<,_I3DU%*2"/O:,_2;X/Z>=)\!
MZ0#$(I[I?M+KC!&[G^58.JMOU[46+9!E.VO1(XXM)L!%@K%:0A1]%&*\M603
M3/+NSYC%N?<UI#;4S>K,#5KIVO&*MPO2DCCDOK<^J]@*O:AIIGFF$(&5^8FI
M-'C:-2D@\L@Y'J:;8&'<V+6\0D5@PQRIZBO3_P!EW_DIDA_Z<9.!_O+7&ZI;
M@PR%<;F!W>]=?^RY\OQ.E'3_ $&3C_@2UE4^!FL/B1]:W'_'O+_NG^5?!@4#
M.6(R?K7WG<?\>\O^Z?Y5\&<;C\N#DUQ4^IWB*$#$$+UQG-6$^9L;1QT;M1&R
M[3N1&7Z<U(K0[MH3;WQFM1'0::46'!=4R./:M/[1Y4'#?,>!MYS638MY<) 1
M0.H4UHVZE5!(&#R .U0(ECA,S+)*>^ #4\UC#,I/RXS]X<"GPX9CU'K4D<5P
MV5>V98V.<XX- F<[<0M'.P(0G.,BMC0I T>T#G_:Z5::TA9MS@ CBAHX[7:,
M8'>F,GA9H+R!GPH$@^;-='KFGQZS87>F3(&CNH67<1[5S,\;2'*L%7 PQ'>N
MMT]VU"TM)\C>IVL%Z<5+WN'0_.SQ9X2E\$Z]?Z9.&WQS,=RKG*YKF]7LTD*F
MR^R2#;O/F_+*I'\Z^DOVIO#:VOCBWO\ RQY<T?!V\9'KBOGK7--B>9F2VDCD
M&-LBL&0CN/6LYI7T'%Z'.:AJ3W4,22N1&JC_ %7RX(Z@CO5:QO9+=\6K,PZE
M@N./3FM.ZTGS+6)>$9'()Z9!KH_A?X*77-6FAU!UCB49C9C@-6++.1TWQ_JG
M@_5TO#<2"%FRT;#(;'2NEO\ XT7_ (PC=-9=8+>7Y5D"G&WZ5B_$[PG-!XJ>
MSL3#+9J 5?(Y;T%-\/\ POU?5-)N;EK:X98QE5:,X;'I4[,-&KB^(/#BV]I;
MW=OJ<-]:L"5:($&/V-8"3+M,;S23( 2175:+H<EY;W&D-+';SNN^'SB%^8?P
MUB-I=Q9:@T-S922.IVLH4EN/84@-+25GL]-2331+%-'\X6/AB3WS7T]^S;\8
M+S7=,DT/7)-VHPM^Z,@^9U_^M7'_  E\#1".'5;\);62Q_,TV!S^--\?>#-4
MT?QII&L>'D61;B02)M.WH<G..V*G?5$.U[,^L(V\^/.['\R*\G^/GQ4;X7^#
MI+^U@^T7\S>5%'C(3_::J^L_'B32FM=-N+>**_GB^5( 6W-3-*T.+Q=8M=^(
MRMV;MBL5C(.6P?3M5)VU9DXGPKKOBO5O&&H2WVI7<L\DC%MI)VCV K4^&]GJ
MMWXRTI=(AE-TEPK!HE/ SW]J^AO%/B?PMX#UJ?27^'MJMQ&<[F(*D>U=+\-_
MC9X>FU);2W\-P::\F-LEJH#=>A-5)Z%+NCWZQ67[#"UQ'MF*@MNYP<=JEDOH
M+566615;'/MZ5R]O\5-!U"Z:TAE;[<N08I%J6&&ZUN1_+B8(V6&U>>M8^IG;
MN;Z6,,WF/]FW!N3NXJK%IIL;@2V_3NA/;ZUJQV5^+<%HVP!_$G/Y5A1WCV-P
M\-\QVNV5DQ@?2EJ(WH[F*; 8-&RCCG]<TZ2\MU7<W7J#6:)(&7;&X=<_WJS[
MR&5KI42&%K?N6D.0<]A4ZC-2;Q#;1G;"S3,.0O-9=QJ]S/( (]F>, ^U6?[,
M7;D91E'I5.2UN;57\L9!XZ528K"+-Y.\7<L<8;[NYL9Y]ZN6S1LO[L[>/OJW
M!KX]_:@T[Q1I/BJ&:*^O;C3KA<PK Q(1O3BNG_9+U3Q3>SZE::M-=-I<2KY8
MNLY5SZ$U37*KEK5'N7CCX1>'OB5#'_;EFT_DG=&R.0V/K7AO[24.C^&?["TG
MPY:VPU*)-ALE@5R5P,;O4U]2M?"VM,;#NC7.U>2<"OA+X@>(=3UKXF:CK;1B
MVN()\*C?>4+TXK2.JN);V-GP_P"%_&NGVLES)X?NM+BE'[V>Q^3*^Z=ZUO!/
M@^+6?%"7>HR6\%M ^ZXD48,@'9E/0T_1_P!K3Q%8,MEJ.E6][M.T'[K8-:4G
MQ^TN.^>^O?#443<GRDP2Q]#1K:Q=CE/'WQ<C\/ZI>Z=H^G6_DER(99HL\9]:
M\XTGQC>VDD]U(L,ETTN\80!1CGI7I?QCU[3?B7X=T76])LXM/G+M%+:1H-RX
MZ9]<UY*UG:+A+JZCMF!Q(S=$-5=%(];L_C)'XSTXZ9X@L;6:ZVDV\@3"@@=&
MQ7G%_9W6I3-/;Z44@<$*5;Y#]#532KA_#-Y%?;H[RW+8C?9N##N.:-1^($6A
M?N8K)90S$A6<@H"<XQ36F@SV/X*^"M.\5:MH>CW%G']LCE\^3:<813DY-?:N
MJS)9:1<%/E55\J,#WXQ7A7['^FPZQX7NO%ILA9S7#&VB5AP0.I'UKV+Q1<!6
MM[0Y*J/,DVGOV%9;NXWV.;7,497.2!CY1S3+QS.ZQ\^4,$G'6K8F-Q/'%#$9
M7ZA1QBM(:;#IEOYMX/M,QZ1KT]A0!C6^GS/'M@C,@Z XXP:AN(Q;D^:/+D&.
MV>?I76+>8L?/E00A1Q&O R*Y*>1I)GE8[F+<DGIGTJ%J45Y2%5OE!P=OYUDZ
MQM\M0N%=AC:.O%7[S?!&&X7(VMZDBL.X<R,SN^Y< @&M%W IY8*>0#]X8_45
MJ^$MW_"7:$ N%%_ 1GT,BUE2;01M&%SQW//I6EX195\8:%][/VZ 8/\ UT6K
M&??E%%%49A7X-?&#5'A^,'CM8X((R/$&H#=LRQ_TF3GFOWEK\"_C$W_%X_'W
M_8PZC_Z525E4I0JZ35ST<'F&*P#E+"S<&^JW^3W7R,5=4NI"-T[8]%X'Z5]?
M?LX^/(_$GA3^S7$:7]CP=H +IZ\=:^,T;\:[OX3^-I?!'BVSOU8B'<$E4'@J
M>N:ZL*J>'DG"*7HK&6.QN+S!?[56E-_WI-_FV?>B-NYZY[U*K#:QZ?6J-G>1
M7EK#=0,)()T#HPZ8(JS'@L>V:^D3OJ?.EVWF"MGG-=)I]U]I@ \P;EX.*Y59
M-NW''.*NZ=<"WN%;=\IZT =EI]Z]G,)8WVN.]=/'J6FZDJ2O)]FN<\M[UQ D
M555P,J>]68Y <X/!J7&Y!O>,-/,RI<1LKQNFWS!ZBN,:Z:.VDC?Y67]?>NIT
MG5TM]]K<#?:2<-S]WW%4/%GAE[6,31-YT+#*R+Z4O(1:T?14\1^'I"&_?+D
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M4RJQ C8CD_A3M)U%+>1A>2D?W6 R0?I6SH\T+0W@O[6:>Z1N&8;55>Y^M7_
M?@,?$#Q,MK9L39KAYY'7D*#Z^]0U8U\CV_X3^%3KL%MX@U!%F*C%JC#V^]7L
M/]H26%K]F1]LLWWB.H7TJKINFVVAZ;;P0CRX84"(F. *B@AN-3O&,432X/\
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ME2YM9 &25#D8JWM.<X"GV_E749LGCDDVC#=\8K1MY2V#]UNF:S Z[N.#U_\
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MVQ[N/D'^-$MA)GTUX>99(9E4C.S&,8JZ@ARA;JI!&W(YK+\*W#74<TRA2S*
M$-:EYY%C"\\IVA1R,\&L[$/<>DZM,\/EA5YYS59HS]I1E93M(P>X]:S%UZ)5
MW-&S,&/S9Z@UK6LT-[#YL* D]>>AI/J3YF!XGM6FU1)C*8O+A^\.YK,T'5/+
MWV\IR-W!+8_&MOQ9(+=K>8\G859<]17%:D=TK3Q(#'_$5Y(XXHW'$[E9CS@
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M*??:@US)O9>!P!6?--YI/&!4MC$DD)KUW]D]L_%649Y_L^7_ -"6O&))FC.
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M/G;/'CCU KV'0/!&C:'86EO)";^2W8M$\B<J3Z4&;9PGPX^#$,5PFIZJT@3
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MLW&KW<_D'G?>/Y,0_#O6#.WAW1V*W6H/J,@_Y8V(VI^+FH^KJ/\ #G)?._\
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MV<@R$M$#]5KT?0]?\;V$7FZ%XBL/%-D!_JY)%9L?3K57,^6Q[^+AV D&%/;
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MOV-T?^><K^2_ZU^F7_#M/X"?]"UJ'_@ZN_\ XY2_\.T_@+G(\-:B#_V&KO\
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MBSXH$@W<D$4YIEQP#7VO_P ,Q_#[_H$SC_M\E_\ BJAN/V6_A_<+M-A>H/\
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M_2J#2,>,U^U'_#L']GW_ *%?4?\ P=W?_P <H_X=@_L^_P#0KZC_ .#N[_\
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M[XH_9.^&/C.'R]9\/F].,>8]S('_ .^@V:X)_P#@G#\"9&+'PU?9/IK%T/\
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M ?\ Z%K4/_!Q=?\ QRCD8<Z/QZ60\_KFI[:\GLI!+;W$D$HZ-$Y4_I7Z_?\
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MK(\3?\$\?@IXRU&2^UC1=6OKESDM)KEW@?0>9@4N6^X^<_)?XK_M!:KX_/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img81402019_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img81402019_6.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $8 T0# 2(  A$! Q$!_\0
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MRE3_ &S_ /LIVG_^H/X3K\L:_4[_ (+:?\I4_P!L_P#[*=I__J#^$Z_+&O\
M4K@K_DC>$O\ LF<A_P#55A#^+N(/^1]G?_8WS+_U-K!1117TQY 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_(^SO_L;YE_ZFU@HHHKZ8\@**** "BBB@ HHHH **** "BBB@ HHHH ****
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M2-4UJQ\2Z:VK:$T6C:C;W.G"6WFL>(_^"T_[5?B+XU_LV_%E/ O[.GA;P?\
MLEW>KZK\"_V9_ 7PTUGP-^S5X0U_6-#U709O$0\#^%_&NF>)KW5;&WU0W6BB
MX\<G3]$O+5?[+L+6SU3Q%9ZU]##@+B/!XN.*RC*,NR_$X3&4,PRC,Y9JJN89
M?D^"X9CE.&X)LL.W4PD\?2C.I6>*^HSHUZF.JPECX<DO*EQ-E&(H.AC\=B\5
M1KX>IA<=@XX+DPN*Q^(SCZ[6XB_BI0KQPLG&$%1^LQJ4XX:G)863:_HY_9V_
M:(G\7?MS_P#!P/\ %#POX7TGXEV'P?\ V?K;P%X)^'VKV47BSPKXFL_@!X0\
M>>"8O"EUH4GEV>K>&?$6N>$]3;4]!M4\C4+;5K^VB6\GNFFN?#?V.O$]S_P6
MJ_83\:3?\%!AX+\4>(_@C^VK^S5X5^'7Q9TOP?X>^&VO6/@SXC_$CX<^'?$G
MPHM[WP'IWARS32-7\/\ BK5_"-A:VD"7)NO$?A[6-1_M#7]!T/5(OYY?V-/^
M"J/[3W[#/C']H?XB?!^V^&FL^//VE;%X/&OBGXB>&-7\17NAZL^K>(-=7Q/X
M3L--\3Z!H46MIK'B.]U#RO$^D^*=!FDAM8;G0Y[07-O<]3^T?_P5Y_:;_:$^
M$?AKX%:#X-^ /[+?PK\/^/\ 3OBM=^$OV0_AK>?!*Q\5_$K1[R/5-*\;>*&M
M/%&MSW&MV.MP6GB&)M(DT:SE\1Z;HVO75G<:KH6BW>G\U?PPSVGF-6GE>$R[
M!N-3@J&5<6K&\N:9/AN'<GP>!S6%#"QP[K2_M+ZM/#N%/$4X8J-24L:G3I4;
MZT^,LMGA(3QE?%5[QXAEC<C>&3P685LVS"OB<'*K6=7V:^J>U5;FE2G*BX)8
M=\\ZC7]5W[1W[5O_  3Y^&/QM^/O[('[6G[<GPPL/V2=+\%GX0VW_!.[3_\
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MKC^>[]I+_@KM^TI^TG\:/@?^TA?>!?V??@_^T-\"=9MM>T7XV? WX;:EX/\
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MB+\#K[5/^$4NO"&J^ ?&/@9O%5E>+K>JZ%+.]W;3ZM<^(-3TO0GM?PV\7?\
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MT_Y2I_MG_P#93M/_ /4'\)U^6-?Z,\%?\D;PE_V3.0_^JK"'\F\0?\C[._\
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M)X4_Y)CAW_L297_ZA4#^)/\ X+:?\I4_VS_^RG:?_P"H/X3K\L:_TO/VD?\
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MRHK_ $3?^'&G_!$S_HG?B?\ \/%\</\ Y?4?\.-/^")G_1._$_\ X>+XX?\
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MB=^)_P#P\7QP_P#E]1_PXT_X(F?]$[\3_P#AXOCA_P#+ZC_B8_@7_H6<6_\
MAKP'_P ]O-?>'_$(^)O^@K)/_"S%?_,/FOO/\[*BO]$W_AQI_P $3/\ HG?B
M?_P\7QP_^7U'_#C3_@B9_P!$[\3_ /AXOCA_\OJ/^)C^!?\ H6<6_P#AKP'_
M ,]O-?>'_$(^)O\ H*R3_P +,5_\P^:^\_SLJ*_T3?\ AQI_P1,_Z)WXG_\
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MK)/_  LQ7_S#YK[S_.RHK_1-_P"'&G_!$S_HG?B?_P /%\</_E]1_P .-/\
M@B9_T3OQ/_X>+XX?_+ZC_B8_@7_H6<6_^&O ?_/;S7WA_P 0CXF_Z"LD_P#"
MS%?_ ##YK[S_ #LJ*_T3?^'&G_!$S_HG?B?_ ,/%\</_ )?4?\.-/^")G_1.
M_$__ (>+XX?_ "^H_P")C^!?^A9Q;_X:\!_\]O-?>'_$(^)O^@K)/_"S%?\
MS#YK[S_.RHK_ $3?^'&G_!$S_HG?B?\ \/%\</\ Y?4?\.-/^")G_1._$_\
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M'_#C3_@B9_T3OQ/_ .'B^.'_ ,OJ]#_B8_@7_H6<6_\ AKP'_P ]O-?><O\
MQ"/B;_H*R3_PLQ7_ ,P^:^\_SLJ*_P!$W_AQI_P1,_Z)WXG_ /#Q?'#_ .7U
M'_#C3_@B9_T3OQ/_ .'B^.'_ ,OJ/^)C^!?^A9Q;_P"&O ?_ #V\U]X?\0CX
MF_Z"LD_\+,5_\P^:^\_SLJ*_T3?^'&G_  1,_P"B=^)__#Q?'#_Y?4?\.-/^
M")G_ $3OQ/\ ^'B^.'_R^H_XF/X%_P"A9Q;_ .&O ?\ SV\U]X?\0CXF_P"@
MK)/_  LQ7_S#YK[S_.RHK_1-_P"'&G_!$S_HG?B?_P /%\</_E]1_P .-/\
M@B9_T3OQ/_X>+XX?_+ZC_B8_@7_H6<6_^&O ?_/;S7WA_P 0CXF_Z"LD_P#"
MS%?_ ##YK[S_ #LJ*_T3?^'&G_!$S_HG?B?_ ,/%\</_ )?4?\.-/^")G_1.
M_$__ (>+XX?_ "^H_P")C^!?^A9Q;_X:\!_\]O-?>'_$(^)O^@K)/_"S%?\
MS#YK[S_.RHK_ $3?^'&G_!$S_HG?B?\ \/%\</\ Y?4?\.-/^")G_1._$_\
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M !"/B;_H*R3_ ,+,5_\ ,/FOO/\ .RHK_1-_X<:?\$3/^B=^)_\ P\7QP_\
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M** "BBB@ HHHH **** .O\)_ZCQ=_P!BA?\ _IQTFN0KK_"?^H\7?]BA?_\
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M:S25FU9Z^6WS=OFW]CJ/]@74/VT= U[X3?LZ_'7_ ()N_M-V_P +_'WAV?\
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M+_/S7WA9]G]S./HKL/\ A7GC_P#Z$;QA_P"$SK7_ ,A4?\*\\?\ _0C>,/\
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M0_GA_P"!+_/S7WA9]G]S./HKL/\ A7GC_P#Z$;QA_P"$SK7_ ,A4?\*\\?\
M_0C>,/\ PF=:_P#D*CVD/YX?^!+_ #\U]X6?9_<SCZ*[#_A7GC__ *$;QA_X
M3.M?_(5'_"O/'_\ T(WC#_PF=:_^0J/:0_GA_P"!+_/S7WA9]G]S./HKL/\
MA7GC_P#Z$;QA_P"$SK7_ ,A4?\*\\?\ _0C>,/\ PF=:_P#D*CVD/YX?^!+_
M #\U]X6?9_<SCZ[#6O\ D4_!?_<Q_P#IRBH_X5YX_P#^A&\8?^$SK7_R%75:
MMX%\;R>&/"-O'X.\523VW]O?:8$\/:N\UOYVH1O#Y\:V9>+S4!>/S%7>H++D
M#-2YPO#WX_%_,OY9>?FOO7<:3M+1[=GW1Y+178?\*\\?_P#0C>,/_"9UK_Y"
MH_X5YX__ .A&\8?^$SK7_P A57M(?SP_\"7^?FOO%9]G]S./HKL/^%>>/_\
MH1O&'_A,ZU_\A4?\*\\?_P#0C>,/_"9UK_Y"H]I#^>'_ ($O\_-?>%GV?W,X
M^BNP_P"%>>/_ /H1O&'_ (3.M?\ R%1_PKSQ_P#]"-XP_P#"9UK_ .0J/:0_
MGA_X$O\ /S7WA9]G]S./HKL/^%>>/_\ H1O&'_A,ZU_\A4?\*\\?_P#0C>,/
M_"9UK_Y"H]I#^>'_ ($O\_-?>%GV?W,X^BNP_P"%>>/_ /H1O&'_ (3.M?\
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MIU&E_$P]6KAL32I8FESX>K5P]>G3JRG1J1C;HHHKVCZ **** "BBB@ HHHH
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M;A&C&IB-2BBBOU\_<0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>VU?]I+X7:WHE_#\<KKQGJ*3^*/%UEXEU'09[#2=2^P:9J5OIB:1:Z/\8?\
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MV<[W22:O>3FWS-RBT[=%:.J7HMD3==?R7E_D_P"FS^=GX2_%;]O#X-_M)?L
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MKVYD_B;=N1KI:VMGN[[ML=U\[+I;9Q:^ZS['S-_P2+^,OQ7^/?\ P3N_9O\
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M>%(_&%_JNC7'B6YM;?Q!J$W@JXT6ZT^23Q5J GBT[P_I5RR0V0CNXFCG:X_
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M+;\=_P#00TC_ ,)#P=_\H*/^%M^._P#H(:1_X2'@[_Y05I[&K_T[_P# I?\
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M_P#@4O\ Y#U_IZ'/'^]]R_S]?Z>GO]%> ?\ "V_'?_00TC_PD/!W_P H*/\
MA;?CO_H(:1_X2'@[_P"4%'L:O_3O_P "E_\ (>O]/0YX_P![[E_GZ_T]/?Z*
M\ _X6WX[_P"@AI'_ (2'@[_Y04?\+;\=_P#00TC_ ,)#P=_\H*/8U?\ IW_X
M%+_Y#U_IZ'/'^]]R_P _7^GI]+:3]S5O^P1<_P#H^UK(KR;PY\4/&EU#XF:>
M^TMC:>&;V[@V>%O"D6V=+[38U9Q#HD8F0)+(##,)(6)#-&61"O,_\+;\=_\
M00TC_P )#P=_\H*E4:EY?!HU?WI;\L7_ "=F/GC9/WON72W][S/?Z*\ _P"%
MM^._^@AI'_A(>#O_ )04?\+;\=_]!#2/_"0\'?\ R@JO8U?^G?\ X%+_ .0]
M?Z>BYX_WON7^?K_3T]_HKP#_ (6WX[_Z"&D?^$AX._\ E!1_PMOQW_T$-(_\
M)#P=_P#*"CV-7_IW_P"!2_\ D/7^GH<\?[WW+_/U_IZ>_P!%> ?\+;\=_P#0
M0TC_ ,)#P=_\H*/^%M^._P#H(:1_X2'@[_Y04>QJ_P#3O_P*7_R'K_3T.>/]
M[[E_GZ_T]/?Z*\ _X6WX[_Z"&D?^$AX._P#E!1_PMOQW_P!!#2/_  D/!W_R
M@H]C5_Z=_P#@4O\ Y#U_IZ'/'^]]R_S]?Z>GO]%> ?\ "V_'?_00TC_PD/!W
M_P H*/\ A;?CO_H(:1_X2'@[_P"4%'L:O_3O_P "E_\ (>O]/0YX_P![[E_G
MZ_T]/?Z*\ _X6WX[_P"@AI'_ (2'@[_Y04?\+;\=_P#00TC_ ,)#P=_\H*/8
MU?\ IW_X%+_Y#U_IZ'/'^]]R_P _7^GI[_17@'_"V_'?_00TC_PD/!W_ ,H*
M/^%M^._^@AI'_A(>#O\ Y04>QJ_]._\ P*7_ ,AZ_P!/0YX_WON7^?K_ $]/
M?Z*\ _X6WX[_ .@AI'_A(>#O_E!1_P +;\=_]!#2/_"0\'?_ "@H]C5_Z=_^
M!2_^0]?Z>ASQ_O?<O\_7^GI[_17@'_"V_'?_ $$-(_\ "0\'?_*"C_A;?CO_
M *"&D?\ A(>#O_E!1[&K_P!._P#P*7_R'K_3T.>/][[E_GZ_T]/?Z*\ _P"%
MM^._^@AI'_A(>#O_ )04?\+;\=_]!#2/_"0\'?\ R@H]C5_Z=_\ @4O_ )#U
M_IZ'/'^]]R_S]?Z>GO\ 17@'_"V_'?\ T$-(_P#"0\'?_*"C_A;?CO\ Z"&D
M?^$AX._^4%'L:O\ T[_\"E_\AZ_T]#GC_>^Y?Y^O]/3W^BO /^%M^._^@AI'
M_A(>#O\ Y04?\+;\=_\ 00TC_P )#P=_\H*/8U?^G?\ X%+_ .0]?Z>ASQ_O
M?<O\_7^GI[_17@'_  MOQW_T$-(_\)#P=_\ *"C_ (6WX[_Z"&D?^$AX._\
ME!1[&K_T[_\  I?_ "'K_3T.>/\ >^Y?Y^O]/3W^BO /^%M^._\ H(:1_P"$
MAX._^4%'_"V_'?\ T$-(_P#"0\'?_*"CV-7_ *=_^!2_^0]?Z>ASQ_O?<O\
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ML:O_ $[_ / I?_(>O]/0YX_WON7^?K_3T]_HKP#_ (6WX[_Z"&D?^$AX._\
ME!1_PMOQW_T$-(_\)#P=_P#*"CV-7_IW_P"!2_\ D/7^GH<\?[WW+_/U_IZ>
M_P!%> ?\+;\=_P#00TC_ ,)#P=_\H*/^%M^._P#H(:1_X2'@[_Y04>QJ_P#3
MO_P*7_R'K_3T.>/][[E_GZ_T]/?Z*\ _X6WX[_Z"&D?^$AX._P#E!1_PMOQW
M_P!!#2/_  D/!W_R@H]C5_Z=_P#@4O\ Y#U_IZ'/'^]]R_S]?Z>GO]%> ?\
M"V_'?_00TC_PD/!W_P H*/\ A;?CO_H(:1_X2'@[_P"4%'L:O_3O_P "E_\
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MWX+ZQJ&O?#K0]4U22&6]N)=6$LEO966GQ,(-8OH(]MKI]O:VD>(HT#&*!"[
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MO _[*W@K]K_]E?P;8V_BGQ'X9U/XP3?L_P#CGX,?%7X:ZSXRU/Q'X"@NC/\
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MGX8?&SX$_!WP!JW@3XDZ]\._V4?%R_M$^%=;\9^%O&?BSQS\5;Z[UWX?^&?
M?AKPGXJU;QC=^)[W29-6>PL]+TZ'1I;Y+U6Z\%>ZG&S:;<)))J/-R[;N.J77
MU:%R2Z6=]=UM>U]]D]&_T39_1#6)XF\3>&_!?A[7/%WC'Q!H?A/PGX9TJ^UW
MQ)XG\3:M8:%X>\/Z)I=M)>:GK&N:UJEQ:Z;I.E:=:0RW5]J%_<V]I:6T4D]Q
M-'$C,/Q2_8M_X*:_%#QM^T'H/[-W[3GQ-_X)U_%_7_B9X.\;^,/AI\1?^"=G
MQUU'XH>&=$O?AUIUMK7B+P'\5/!7BO7-:\::#J]_X<_M7Q)X<\66;GPUJ<>D
M76@10R:JK2)\I_M)_M=?\%)?VH/V%?VIOVB? W[./[.D?[ WQ&^"'QUT3PGX
M:OO&_CJW_;)N/AC_ &%XF\*#X[31+#/\(1HEI!:W?CB^^&\BVGBYO#UK<:5I
MFHZC?BPU+4TZ\.7F2DW:3LHMM<J3;=KZ)2CJK_$K7ULU!W2=DFUK?N^G?9_K
MT/Z8M&UG2/$6D:5X@\/ZKINNZ#KNFV.LZ)K>C7UKJ>D:SI&IVL5[INJZ5J5E
M+/9:AINH64\-W8WUI--:W=K-%<6\LD4B.?%OB7^U5^R_\&/$NG^#/C#^TA\!
M/A/XPU>&"XTKPI\2_C!\/? GB74X+J58+:?3]"\4>(M*U2]AN)G2&"2VM94E
ME=8XV9V /@W@?XCZK\'?^"87@WXMZ%IXU;6_A?\ L(>&OB%H^EFW>[&HZKX,
M_9_L?$6GV+6L4L$EREU=Z=#"]O'-"\RN8TEC9@X^8/V(_P#@FG^QSXH_9A^%
M_P 4_CO\$/A5^U!\</VA?AYX5^,?QE^-_P =/!GAWXL^-_&'C;XG^&[+Q1J]
MQI6O^,[#6;GPOHVDKK":)X:TWPJ^CP:=I.EZ=(?.U1)]1GISF^504>:4>=N3
M:26FFB;;=W;:UFWT322LVV][)+>^_72Q^M?B#QQX*\)^#]3^(?BGQ?X7\->
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M65A<7^A:F;6\CB%_IUG-=:?.OVJRMW>2!/RL\-_LJ_\ !6;]DK2HO@;^Q/\
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M #Q\8?\ A1Z+_P#,=7:44<TOYY_^!2_S\OS[L++LON1Q?_"LO '_ #Q\8?\
MA1Z+_P#,=1_PK+P!_P \?&'_ (4>B_\ S'5VE%'-+^>?_@4O\_+\^["R[+[D
M<7_PK+P!_P \?&'_ (4>B_\ S'4?\*R\ ?\ /'QA_P"%'HO_ ,QU=I11S2_G
MG_X%+_/R_/NPLNR^Y'%_\*R\ ?\ /'QA_P"%'HO_ ,QU'_"LO '_ #Q\8?\
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M (4>B_\ S'5VE%'-+^>?_@4O\_+\^["R[+[D<7_PK+P!_P \?&'_ (4>B_\
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M5EX _P">/C#_ ,*/1?\ YCJ[2BCFE_//_P "E_GY?GW8679?<CB_^%9> /\
MGCXP_P#"CT7_ .8ZC_A67@#_ )X^,/\ PH]%_P#F.KM**.:7\\__  *7^?E^
M?=A9=E]R.+_X5EX _P">/C#_ ,*/1?\ YCJ/^%9> /\ GCXP_P#"CT7_ .8Z
MNTHHYI?SS_\  I?Y^7Y]V%EV7W(XO_A67@#_ )X^,/\ PH]%_P#F.H_X5EX
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M79?<CB_^%9> /^>/C#_PH]%_^8ZC_A67@#_GCXP_\*/1?_F.KM**.:7\\_\
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M .T-IO[-VC?"O]K#X/\ BWQQX.UKXB? OQ3^T3^SYXF^#_@+]I/P%X>@AO\
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MK#2=9U;P)>:U:Z/!XMUR/TC]A+]F?Q=J'[;'[4GC'X0_L(_MY_LW?"/X^_\
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M/Q1XI^9OA)XFO/\ @G]\2_VG/AY\4OA1^T#XD^$GQP_:*^)_[4/P4^+?P,^
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MHHH **** "BBB@ HHHH **** "MB]_Y!.B_]Q+_TI2L>MB]_Y!.B_P#<2_\
M2E*F6\/\3_\ 2) 8]%%%4 4444 %%%% !1110 4444 %%%% 'S5^UAX,_:(^
M(7PAO_!W[,WQ!\,_"[X@:YJ^FV>H^-_$<FI0S:-X/<7/_"0-X:N-+T/7Y[7Q
M/<+]EM].O/LEN]I#)=W%GJ>F:C'97L/Y8Z;H_P 1?A=^W/H7[$G@[]KS]I;X
MP>!?B]\#O%L_QIOO&/Q*;Q5\5/@5K8\/Z[?^'_&?@KQ\-*,GP_UBY,?AXZ3I
M[6<WV:#Q#:7VJPZL^J>&[JS_ $#_ ."@/QG^.7P9^ 6I7?[.'PR\=_$GXO\
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M_P"$N\"?]#MI'_@J\8__ #+T?\)=X$_Z';2/_!5XQ_\ F7HM+^2I_P""Y_\
MR/G^?9A==X_^!+_/S_/LS;HK$_X2[P)_T.VD?^"KQC_\R]'_  EW@3_H=M(_
M\%7C'_YEZ+2_DJ?^"Y__ "/G^?9A==X_^!+_ #\_S[,VZ*Q/^$N\"?\ 0[:1
M_P""KQC_ /,O1_PEW@3_ *';2/\ P5>,?_F7HM+^2I_X+G_\CY_GV877>/\
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M_P#D?/\ /LPNN\?_  )?Y^?Y]F;=%8G_  EW@3_H=M(_\%7C'_YEZ/\ A+O
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M\?\ P)?Y^?Y]F;=%8G_"7>!/^AVTC_P5>,?_ )EZ/^$N\"?]#MI'_@J\8_\
MS+T6E_)4_P#!<_\ Y'S_ #[,+KO'_P "7^?G^?9FW16)_P )=X$_Z';2/_!5
MXQ_^9>C_ (2[P)_T.VD?^"KQC_\ ,O1:7\E3_P %S_\ D?/\^S"Z[Q_\"7^?
MG^?9FW16)_PEW@3_ *';2/\ P5>,?_F7H_X2[P)_T.VD?^"KQC_\R]%I?R5/
M_!<__D?/\^S"Z[Q_\"7^?G^?9FW16)_PEW@3_H=M(_\ !5XQ_P#F7H_X2[P)
M_P!#MI'_ (*O&/\ \R]%I?R5/_!<_P#Y'S_/LPNN\?\ P)?Y^?Y]F;=%8G_"
M7>!/^AVTC_P5>,?_ )EZ/^$N\"?]#MI'_@J\8_\ S+T6E_)4_P#!<_\ Y'S_
M #[,+KO'_P "7^?G^?9FW16)_P )=X$_Z';2/_!5XQ_^9>C_ (2[P)_T.VD?
M^"KQC_\ ,O1:7\E3_P %S_\ D?/\^S"Z[Q_\"7^?G^?9FW16)_PEW@3_ *';
M2/\ P5>,?_F7H_X2[P)_T.VD?^"KQC_\R]%I?R5/_!<__D?/\^S"Z[Q_\"7^
M?G^?9FW16)_PEW@3_H=M(_\ !5XQ_P#F7H_X2[P)_P!#MI'_ (*O&/\ \R]%
MI?R5/_!<_P#Y'S_/LPNN\?\ P)?Y^?Y]F;=%8G_"7>!/^AVTC_P5>,?_ )EZ
M/^$N\"?]#MI'_@J\8_\ S+T6E_)4_P#!<_\ Y'S_ #[,+KO'_P "7^?G^?9F
MW16)_P )=X$_Z';2/_!5XQ_^9>C_ (2[P)_T.VD?^"KQC_\ ,O1:7\E3_P %
MS_\ D?/\^S"Z[Q_\"7^?G^?9FW16)_PEW@3_ *';2/\ P5>,?_F7H_X2[P)_
MT.VD?^"KQC_\R]%I?R5/_!<__D?/\^S"Z[Q_\"7^?G^?9FW16)_PEW@3_H=M
M(_\ !5XQ_P#F7H_X2[P)_P!#MI'_ (*O&/\ \R]%I?R5/_!<_P#Y'S_/LPNN
M\?\ P)?Y^?Y]F;=%8G_"7>!/^AVTC_P5>,?_ )EZ/^$N\"?]#MI'_@J\8_\
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M*GSXG+\-E<WC'CXI8:M2A_LTZSK895_TRHK\U-6_;>\;?$Z/]GSP?^S!X/\
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MTW"VM[0C'5MV<4D^6[TC+>VEFNJ=DI2OY:MZ)*]^]NJZ?/Y]/1116I(4444
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ME3C%]>2_NI^:2BGW:N*3NV]KV=NE[:NWJ%%%%6(**** "BBB@ HHHH ****
M"BBB@ KL-:_Y%/P7_P!S'_Z<HJX^NPUK_D4_!?\ W,?_ *<HJF6\/\3_ /2)
M#6TO3]4<?1115""BBB@ KYE_:^M_CMJ/P&\8:%^SGHIUGXE^)5MO#MLT>N:)
MX>O-'T'57>#Q#K&F:GK^JZ-I\&J6^F^;;:?,+^.[L[F\CU&S22XLT6OIJBO/
MS;+UFV69AEDL7C,!',,'B,'+&9=5IT,?AH8FE*E.MA*U6E7IT<1",FZ565&I
M[.=IJ-TCS<YRU9SE.993+&8[+HYE@L3@9X[+*M.AF.%ABJ4Z,Z^"KUJ.(IT<
M33C-NC5E0J>SG::CS137\^OA"7XQ?"O]L#]ESPMH_P"Q^O@35/!'P=\1>&-!
M^&T7QP^'FN7GB3PY>3>(/^$H^(NH>,=.TVST--9AEN]5UG4M*NX4U'7K^WF%
MM+!]M@$?JO[7_P =?V5OCW\(/%'Q*M-<USP+^TI\"?$=WX8^&/AGQ)K,_ACX
MIZ-XTL_$VB&ZCL?A[INNZQ9:WI>H7%LB76K2Z7>FQ%C-;W=[I$UK/&G[(77@
MSP?>^*--\<7GA/PU=^--&L+C2M'\7W6A:7/XHTK2[SSOM>FZ;X@EM7U:QL+K
M[1<?:+.UNXK>?SYO-C;S7W8-W\(OA1?^,8?B'??##X>7GQ MY(9;?QS=^"O#
M=QXQ@EMX#;6\L/B:;3'UJ*2"V)MX72]5HH"8D*Q_+7Y$O"[.L)DV?9!@^(,!
MCLKSW,*U26&SW),OJQR_#_V5EF R[,,O6283(Z>'SG*:^74\1AHTZ<,%^XP,
ML-' 8JC6Q.(_%5X19]@\BXCX<P/$N79AE'$.9UZLL-Q#D.65HY;AO['RK+LL
MS/+HY#@L@I8;/,EQ&64\3A(4J<, _J^7RPT<NQ="OBL3X5J7PF^'GQ-^%?@+
MXH_M0^%[.'QMX?\ @_I\_P 2M4AUGQ-X-M;>PDT;3O$GCKP[XHM?#.M:1%KG
M@Y-6L;B]O_"/B6/5M 62"57TT[Y5?XY^'7Q$^(^A^(?"7C[PGI/A72/B'^VY
MJOCKQEX;U#X@:5JVL^'OAS\ ?@OX-DOOA=X-M_#OAS7O":S:EK.BWMEJ;S6_
MB33K+3#K%U=7ECJ$J0QC]3/B%\/_  G\4_!NO?#_ ,<Z=<:OX2\36J6.NZ7;
M:OK6A/J%DES!=&T?4_#VHZ5JT5M-);QI=PV]]#'>VIFLKM9[.XN()>:\?_ _
MX7?$[2O#6C^+_#!FMO!LDC^$[K0-;\1>"]:\-)/I4NAW5KH?B+P7J_A_Q!IF
MGWVCS/IFHZ;9ZG#I^HV0BM[ZVN(X(5C^ESK@W'XG%8?&914R_"XK!8?+ZGU^
M;EA<TSC,X8FAA,PQ.:YAAL#5K4ZL>&HYEE>7XZ'UO$4JN?X^M&CAY87#5:GU
M>>\#YCBL7AL;DM3+<)B\!ALMJ+,9N6#S;.\UABL/@\RQ>;YCA,OK5Z5:/"T,
MTRG+LPI_7,32K<19A6C0PTL'A:U3*_9Q^+K_ !W^"/PZ^+,VD#0;OQEH7VS4
M-)CDDFMK/4[*]N])U1+&>50\^G2:A87,VG3,7=[*2 N[R;F/Q;^P/;B[^*O[
M?MIKL!N=2N?VC-8M]6MK^(S1W&DS7/BB/3X)H95:SEM);=KN-(D5DDM6174V
MY@!_2#PMX7\/^"?#>A^$/"FDVFA>&O#>EV>C:'H]BA2UT_3;"!+>UMH@[/(^
MR)%WS3223SR%YIY99I))&^=_ GP)\0_#[]J'XP_%S1+_ $,_#CXT>#_"DWB+
M1)+[5U\1V/Q-\*32:=%J5GIQL)M%ET+4_#T\LEY=G5K;4(]6(BCTQ[9GN3T8
M[)\X>-\-\;BYK-,5D>(Q&&S^O1@H0JU,PX8QV7XC-8T;02I?VDJ490C!.G0Q
MM27*H4Y)=.8Y'G;Q_A;C\9-9OB^'\5B<+Q'B*%.,(5JF9\)YAEF)SB%'E@HT
MGFGL8RIQ@G3P^.J2Y(PIS2^7OBA8V.E_\%./V3=-TRSM=.TZP^"/CBSL+"QM
MX;2RLK.VT[QS#;6MI:VZ1P6UM;PHD4$$,:111JJ1HJJ /#?AQ\2O /[/FM?\
M%*? 'Q;\4Z7X)\2Z[XN\:^-?"FG:_<0Z;=^,M#\8Z+XC?03X3M+B5;GQ!?W*
MZAIY:PTR*YF1;V*0;HH[EX/V1O/!'@O4/%.E>.+_ ,(>%[[QKH5E<:;HGC"\
MT#2;GQ3HVG7:SK=6&E>()K1]6T^RN5NKI;BUM+N&"9;F<21L)I-V7XJ^%?PP
M\=:II.N>-OAQX"\8ZUH)C.AZQXJ\'^'O$.J:,8K@7<1TG4-6TZ[N].,=T!<Q
MFSFA*7 $RXD&ZO'QOA_FGUO&YIE>99=0S"?%&<9U@H8S"8BM@H8#.N%,%PSB
M,)7A0K8>JL10>$6.H5*4W3ER1PTHQC5E5I^'CO#7-OKN89ME.:Y9A\RJ<6YW
MGV IXW!XFM@(9?GW!^!X5Q."Q$,/7P]98C#O"+'X>K1FZ4O9PPTXQC5G5I?@
MQ^R_I8_9J^+'[$GCSXR747@7P=XV_9Y^(.AVOB;Q,8M#T+2-:UOQSX\\:Z=9
M:[JNI3066E"ZT'Q-H-Q%->30_-J=N)8XD\UX_KW]C[P7X.^.GQ(_;^\9:GIE
MEXV^"?QA^).C^%=*N+JWN!HGBZV\,)XAGU6[TN\5X)9K>WEUG2[BQU.PDAE@
MF:UO;"[2X1'A_3_Q9X)\&>/=';P[XY\(^&/&?A]YH;EM#\6:!I7B+1VN+?<+
M>=M,UBTO+(S0!W$,I@+Q;FV,NXYT-!\/Z#X5TBP\/^&-$TCPYH.E0+:Z9HF@
MZ;9:/I&G6R9V6]AINGPV]E9P+D[8;>&.-<G"C-<G#OA4\AQ>4X2>88/'\-9+
MB,1F.&PF(P-1X_%8[&<)T>$<3A\;.>(J8.IET\*L7C.3V$JDJF)AA9ITJ#J5
MN+ACP?EP[B\FP4\SP68\+9%B<1F>&P6)R^H\QQ>88W@S#\%XO"X^<\34P-3*
MYX..+QOLUAI59U<5#"SO1H.K7_+GXJ>'?AUX8^).I>#? ?AZ^O/A]^RYX?U#
M]K7X]6T_B;Q!XDUWQY\3-.\/W<GP8\'>)/%OBC4/$GBJ_O+6RT*\\2L=8O-3
ML;#1K30H(;>.WBCAC]]_9N_:.^(OQ$\?1?#KXG:=X*;5-?\ @/\ #_X_^'M4
M\!:7KND:?IFC>-+J6QN_".N6VN>(_$\][JFE7#VCVFOQ3Z+;ZO UTRZ#9&%-
M_P!,^'?A'\.O"K?$-](\,6Q;XL:[J'B/XB'5KO4_$7_"5:EJEA%I5W'J \0W
MNJ!-(_LR%=/M?#MH+;P]I]FTMMI^EVL,\Z28OPN^ ?PH^#$VIW/PZ\,3Z-=:
MMIVCZ+=7>H^)?%GBJ[AT'P\MTNA>'=+N_%VN:]<:'X;T@7ES_9WAW19=/T2S
M,I,%@A5"OKY=PGQ!EN>83,,%C,KP&75\?C,1F^6X'VE'#0P4%5PN4X#!X:&
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M1]:J?RP^Z7_R0*E'3673JNO+Y?WF'_"KOB+_ -"5XD_\%5U_\;H_X5=\1?\
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FE$D4B2)D?,CJPX(HHHKR:C<JE23WE.;=MKN3>AT1TC%>2_(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img81402019_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img81402019_7.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *7!0 # 2(  A$! Q$!_\0
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M3^)_+\D1/U'T_J:93WZCZ?U-,H7Q2_[=_(D*CD[?C_2I*CD[?C_2J CHHHH
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M:XG+J&88G+L!1A5JX*G4C&-25>5>MAZ=.,:_M*-.$JKKU94JBITYN$K?T1U
MW4_4_P Z_+O_ ()S_P#!0_4OVL?AO\<-'^.7@&#X0?M.?LC^*]4\!?M*_#'1
M9KG6;*QU/1X-5\GQ=X3C1KZXET'Q+=^&_%%GIVE1:EKL]O?Z!>0VVKZSIUUI
M&K:C^=?[-/[0W_!77_@I[X0\1?M/_LT?'O\ 9B_95^!\?Q!\4>$OAY\)]<\
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MTRUO=2L+K3-26WN3IFN:+J>IZ3=O;7=F;J'5+'4-/L_M>OYH/B/X;TS]C_\
MX."?@)K?PRMH_#/@[]M3X6:U!\5O#VFQI8:1J_BO5H_'%E>W<=M'_HJSWOB_
MP3\/O&6H2)"D]WKMQK,[-YVK3RR?TOUX/&&2Y?E>)RK&Y.\0LHXAR;"YU@*&
M+J1K8G!>UJXC"XO+ZU>,*<:[PF,PM>%.NJ<'4H2HRFG4YV_9R#,<7C:.-P^8
M*D\?E685LNQ52A&4*.)]G3I5J&*ITY2DZ2KT*].4J?/+DJ*HHM1Y4OS?_P""
MEG_!03_AWE\,_AG\0_\ A4G_  M__A8WQ1L_AM_8_P#PGO\ P@']C?:] UK7
M?[:_M#_A"_&W]H>7_8_V7^SOL5CO^T>?]O7R?)E_1BOYR/\ @Y5_Y-I_9F_[
M.AT?_P!0'QK7]&]&:Y3E^%X+X,S;#X?V>89MB^*:>88CVM:7UB&6XK+*>"C[
M*=25&E[&&(K1O0ITW4Y[U74<8N,9;C<56S[B#!5:O-A<%1R:>%I<E./LI8NC
MBY8A\\8*I/VDJ5-VJ3FH<MH**<DROSS_ ."B'_!1GX0?\$]/A4GC#Q?%:>./
MB9X@FM[;X<_!>Q\20:!XC\9DWB0ZEJMQ?C2_$$_ASPKHMHMW/?\ B6ZT*^LV
MOHK;1;6*XU._MX:_0ROY"?\ @IS_ ,$Q/!G[,G["OQ?_ &C/BM\4_'7[3O[6
M_B[QO\+;/Q%\;_B)>74::3::EXLL8=2T?P/X:;4-131M-FMUCTY9M2U'5[RW
MTNW33-$/A_1IKC1W[/#W)N'<[XAR_!\0XS$0HU\RRS!X?*\)0JRKYK4QN(E2
ME"IC(SI4\!@L/RPEC*JJ?7*D*L:>"INHYUL/CQ9F&:Y=E6)KY5AZ4JE/"8S$
M5<;7J05/!1P])33C0<9SQ.(K<TEAX.'U>,J;EB9*'+3J_P!:G@_7_P#A*_"7
MA;Q3]D^P?\)+X<T37_L/G_:OL7]LZ9:ZC]D^U>3;?:?LWVGR?/\ L\'G;/,\
MF+=L7;;J?J?YUP/P?_Y)+\+O^R=>"?\ U&M,K\7_ /@I-_P4E_8J\=?L5_M/
M_#;X:_M/> -9^*&L^ =5T'PYX=T'5-5AU^[U^+5;%7L;%UL;?9>)]GN 2+B/
M'EN _KXV4<.X_/LYAEN783&5*,\RP^#Q&)PV#Q&-IY?1Q6+^KPQ&)]DFHTZ<
M5.I>K5IJ<:4_WBM*2[<9FN%RS 3Q>+KX>%18*M7I4JV(I8>6*J4:*J.E1YW[
MTYR<8VA";BYQ]UW2?[NT5^,G[!'_  4B_8GTW]EC]D/X3^(_VF_A]%\6;;X+
M_!;P%J_A34-2U.;Q"OCT>%/#^A7.@W;/82"35CKI:QE+W#A[LG=*02]?LW7+
MG>1YCD..KX/'X3&8=0Q&)HX>MB\'7P<<93P]5TO;T(UHI3IS7+.\)U(Q4XKG
M=TWIEV8X7,\-3Q&&KT*KE2HU*M.C7IUWAYU::G[*JZ;]V<;M6E&+?*WRK5)&
MZ'Z'^505^9?[?_[47[4GPT\;? 3]G']C7X5:5XP^-?[06K:S#-\2/B#H?BF[
M^$?PA\+Z+ );K7/$^H:+;QV;ZE/:Q:UJUO!)?7L]AIOAB_D/AGQ!=ZIHVG77
MY_\ [4WQ!_X+0?L'?#G5?VI?&_[0?[.'[1/PH\&:MX:;XA_#.V^%EIX/DT?2
MO$'B#2?#-L^AWFE^'M"\1:A82:OK%G97-]+XLDU336N[?4O[*O\ 3X+]+;V\
MHX)QN;4LLDLVR#+\3G4I1R?+LQQ]:ECLQ:Q,\'35*G0PF)I8?ZQBJ=2AA7CZ
MV#6(G!NDY0<92\['<18? SQB>!S/%4<O2>/Q6$PU.>&PB]C'$3<YU:]&=7V5
M"<:M986G7=*+]])II?T:45^27_!03]NCQ]\)?^";'AW]LW]GEM.T37?'ND?
MOQAX7C\7:-;:_%9>&_BVFAZK]DU#3I)(K>2^BTG68X6D5PL5RK/&" !7S_/X
ML_X+7_M(?#2T_:9^!'B/]GCX#^"_$.B6GCKX3?LY>*/#\'B?XB^./ UWI":E
MH8\=^,-<\,ZGHNA^*O&%FT&I:7I.EZAX:L;)M3LM/UO5M ^SW=S2P/!.88O
M4\SQ68Y)DV"J9GC<G]MG&.J8;ES+!1PLZF&E3HX;$U??CBDXUH0EAZ2HUI8J
MKAX^R=5XGB'"T<3+!T,)F.88B.#P^/\ 9X##1K<V$Q#JQA64ZE6C#W72:=.4
ME5FYP5&%5\ZA^\M%?F+_ ,$]/^"A5I^U;^Q3XA_:<^+.CZ=\/-8^#E]X^\._
M'*/38K]/#^FZE\,_#.F>,_$&OZ1::@\^HVFFW'A'6M+UB;2[FYO9]+OI+[2O
MMUZ+-;J7XB^!/Q[_ ."M/_!0_3-:_:/_ &<O&OP$_99_9R_X2;7='^#_ (.^
M(G@QO''B3XG:?X<U&[TNZU#QCJPT?Q!=Z?9MJ4-QI>HZIX:N/#QAU+3;FPTO
M1KR"RFUK5"' ^;QQ&=4,QQ&69+2R#&0R_,,=FF*G3P:Q]9U?J^$PTL+0Q=;%
MUL13HU:]/ZO0G".'@Z]:=*FU)DN(L#*EE]3"4L7F$\SP\L7A<-@J,98AX:GR
M>UKU8UJM"G0ITIU(4Y^UJ1DZLE3IQG.Z7Z*> ?VZ_P#A./\ @HM\;OV _P#A
M5O\ 9?\ PISX-:3\7/\ A;'_  F_VW_A(_[4A^$4O_"/_P#""?\ "(6G]D>1
M_P +4V_VM_PF6J>;_8.?[-C_ +4QIWWXW4_4_P Z_EX_X)M_$#XP_$C_ (+A
M?M=:]^T!X"TCX;?&;3OV2Y/!_P 1/"_AZ^N=1\-_\)!X(\1?LO\ A.3Q#X9N
M;S==?\(SXQM=(M?%WAZ&>XOI+?1M;LH3J6I!!?3_ -0[=3]3_.M..LCPG#^9
M93@<+2I4Y5.&.'\9C94,5/&4*^8XO 0J8W$T:\JM:$Z6(K\U2G]7FL-R23H0
MC3:1/#>95LTPF-Q-:<YJ.<9G0PZJ450J4\+1Q,H8>C4I*%.49TJ=H3]K%U>9
M/VDG)-GYY?$;]O/_ (5__P %&O@'_P $_P#_ (55_:W_  O'X2ZS\4?^%M?\
M)S]@_P"$7_LG2_C3J7]A?\('_P (?>_VU]H_X5!Y/]I_\)GI/E?\)%YG]GR_
MV3Y>I_H97\NW_!1S]H3X<?LJ_P#!<W]CGX]?%JYU>S^'W@/]DS4/^$@N-"TJ
M76]5C_X2A_VMO!FE?9=,ADBEN=^M^(M-CGVNODVS37#96(@_9/\ Q$)?\$Y?
M^AD^+7_AK-3_ /D^O;S3P_S?%Y?PCF'#'#>:8W#YAPOA,9F>)P5#&8RE4S:6
M99I3KN4I2JPHU/JE+!7H4?9THQY9QI*52<I>;A.)\#1Q.>X7.,VP>'JX7.:]
M#!T<14H4)PP,<+@ITTDE"52/MIXBU2ISSD^:+FU!*/U?\//V\O\ A/\ _@HW
M\?/V ?\ A57]D_\ "C_A-HWQ1_X6S_PG/V__ (2?^UM*^"VI?V'_ ,('_P (
M?9?V+]G_ .%O^3_:?_"9ZMYO_"/>9_9\7]K>7IGZ$U_+W_P3F_:$^''[57_!
M<S]L7X]?"6YU>\^'WCS]DW3_ /A'[C7=*ET359/^$7;]DKP9JOVK3)I)9;;9
MK?AW4HX-SMYULL-PN%E 'V'\5/VT/VP/VH/VM?B=^Q__ ,$[U^&G@O1_V>O)
MM/C[^TG\4M)NO$&FZ'XQ-QJ&GS>!_"WA[[+?VLUU;:I8ZAHV^]T74;G5M:\/
M^(&@ET70=%_M77+XAX%JT\TPF78+#T<FC@^#N'LWXBQ&:XC$4,+EV,Q.#PT<
MPK8VI6^L5J56MF-94:>"PU*<W7G['"X6T7&)E7$D)8"OBL15J9@\1G^:8#*:
M6"I4JE;%8>CB*KPM/#QI^RISIT\)3=2>)K3C%4H^TK5KM-_N#7S3\>OVL?A!
M^SGXN^ W@#XA7^LGQI^TE\3=)^%OPLT#1-'N-1FU36=0UCP_HVHZKJ5\[6VD
MZ1H7AR7Q1HMQJ\]Y?IJ,T%XJZ+IFK7$<\,7Y60?MD?MR?L%_'SX,?"G_ (*'
M:M\*_C+\#?V@==3P7X-_:6^&VB'P7?>"_&/GQ6\=MX\\/VFDZ5HRVLLNI:3)
M?6\>DZ9#!HLM]X@TC7]9;P[KNAI\W?\ !87PS^U#-^WI_P $\KC1OB?\-[/P
M_P")OVAK"S_9?L+OP5>7%]\,?&5O<? >R\1:Q\2+I;@+XTTG4?&SVFM6&GVB
MV\EIH\4NG,S22!QED' 7M\^R_ YIF. GE.995G&:9?FN7XJM4P>9K+,%BIRH
MX6M]2E6IU<-BZ"EF&&Q6&PN)I86C7LHU:F%55YIQ-[/+<5B<'A<3''83&Y?@
M\5@L51A#$81XS$T(J=:G]85.4*U"K_LM:A6K49UJE*[<(UN3^G*OS?\ VT/V
MS/VF/V;/'?A7PK\$OV!?B=^UIH&N^$E\0:MXS\#^+-6\/Z?X;U@ZSJ>G'PQ=
MVVG_  K\>137@LK&UU4SOJ-G)Y&HQ1_8@J+/-]I_!O2OBMHGPS\*:7\</%7A
MCQO\5;2TNT\8>*?!NAS>&_#.KWKZG?2V<VDZ)<22S:?##I4EA:S1O(QDNH)Y
MQA90!Z;7QN!KX'+,RG+'9?@^(,+1E7HO#SQ68X7"8EIRA#$4Z^#JX'&J%TJM
M)2=)RBXJK26L%]%C*>(QF#BL/B<1EE:I[*I[6-'"UJ]%-*4J4Z=>&)P_-:\)
MM*:B[N$W9-_SC7?_  7'_:@L/BQIGP)O?^"4?Q3M?C+K6AR>)M)^&4WQGU>/
MQIJ/A^*'4+B36;306_9W%_-IR0:3J<K721&(1V-TQ;$+X^\/V2/VY_VK/V@_
MBT/A]\8O^"<GQ9_9>\'MX9UK6S\4/&7C+6=<T9=4TV2Q6Q\/&QOOA!X)@^U:
MNMU.\$W]MAXQ9R!;2XW$Q_&WQ%_Y6+O@+_V:;K'_ *C'QHK]6_V\OC%XT_9^
M_8^^/_QG^'4^G6WC?X>> KOQ#X;GU:PCU33HM1AOK"!&N]/E=([N'R[B0&)W
M4$D'/%?I/$&&X;7^K.5Y1P9E>%S#BS(<JQE'&SSGB2?]GYAF^-Q6"I^RIU\T
MKT)T:,J-.:^L4:Z?-)RA-)1?Q^5U<VOFV,QV?XROALDS/&4*F'CE^4Q^M8;!
M8>AB9<\J>#IU(SJ1J3C^[JT]HVE'5GU?17RS^Q%\6?&'QW_9(_9]^,7C^:PN
M/&GQ&^&?A_Q3XEGTNQ33-.EU;486>Y>SL(F>.T@+ ;(4=E0< FODG]@+]KOX
MR?M$?M3?\%)/A-\2;WP_=>#_ -F+XU:%X&^%<.D:%!I5_::#J'B[XVZ-<1ZW
M?12R/K-T;+P)H"I<S+&RR1W4@7-RP7\_?#N8*'$E3FP_+PM*G',_WDKR=3-*
M.41^JKV?[W_:ZT&^?V5J*E/XDH/Z>6:X5SRJ-JM\YBY8/W%HHX*>.?MO?]Q^
MPIR7N\_OVCL^8_5RHY.WX_TK^<+]G?\ ;:_X*9?MI^-OVB?@7\"IO@UX&U#X
M-_'#QWI_B3]H;Q[X7GN-#\*_#B/56\-_#WP#X5\'Z;9ZK;^)?B/>WNB>+?$&
MHZKKUN^D+HVGV]O<O87-Q:&\;X _;U_X*5>"?CY\1O\ @G/\0/"/PE^,_P"U
M[<RZ'??"/XW6\(\+?"/1_!6I>'Y/%'B+QW\3=+T+3M%N;W2]"\/-:2Z-IVA^
M'M$U*X\1F[T"[AU>8Z6FJ_2U/#7.Z53&X:68\/\ U_+L+2S''9?_ &IR8K"Y
M54]A*6:5W4H0PU+"4*6(I8BO">(CC(8><:RPLH3IN?DPXNRZ=*A46$S3ZMBZ
M\L+A\7]2O0K8V/.E@J?+5E6G7J3I3I4Y1I/#RJIP]NI*5OZ.Z*_ .+]I[_@H
MU^QE^V'^S-\(OVS?&WP=^.WP9_:W\9#X=^%O%/PZ\(P>$M4\%>,K[4-%T2SL
M($M]+\.SQQ6&O^*_#(F37H/$2ZWX;N;N?3=1MM;L+RW@]V_:[_;<_:'U;]JG
M0?V ?V#] \$:A\>'\+0^./C#\4_B3!>W7@SX)>$[J+2]1L9)-,MDD_M#5;C2
MM5T>^N[BXL=8M(8O$WAK2]-TC5=6U>XDT'AEP)FSQ>"HX?%Y3C,%CLKQ.<T\
MZP^,FLGHY;@JU3#X[$XK$8BA0KX=8/$4WAZU.IAE6=>=*C1IU:E6G&6ZXDP7
ML*]2K0QU#$8?&4L!++ZN'C]?GB\13C5PU&C2I5*E.JZ]*7M:<XUO9JG&<ZDX
M1A)K]@WZ#Z_T-15^ OQ4_::_X*6?\$WKWP1\3?VQ/$GPD_:J_9?\4>+].\(>
M._%GPT\)+X$\?_"N[UZ59+/4UTW3=#T>PU#3+6"#44TN.ZL-2BUVYMH-$U/7
M/#6K:OH]U<^T_P#!5+_@H!\1/V/?!'[*?Q2^"DNA>*O"/Q2^)UB/%-I_9<&L
MR^-?AS_9&F>(ELO"M[*P_LV_\0:9</%IFJ113,C7EO,L3[0ITH\"9OB,;E&#
MR_$Y7F=+/IXRGEF8X'%5)9?7Q& HNMBL+4G7P]#$X;$TH*#=+%86BVJU&<6Z
M4_:)3XEP%'#8_$8JEC,'/+5AYXS"8BC".*I4L5.-.A6C&G5J4:U&<G)>THUJ
MB3IU(NTX\K_9&BOQR^ ?C?\ X*C?"]OBO^T+^W;JOP:D_9^\/_ ;Q_\ &'_A
M57PTTFVE\>^"M>\,V,'B*S\!Q7%OH^GW/VFW\/6&NR7MS?>)/B! ]V+2Q&I"
MYGDDL?"/@!\0_P#@KO\ MQ?"S2?VJ/A/^T!^S!\#O /C*]\3S?#_ .#$G@%?
M&Z2:=X<UW5M @L/'7B^^T+7];T[4;O4-*E@U";2+Z.=+<1ZDNC:--.VAVTRX
M)Q%\76GQ!PS3R[!U<'A:N;_VABJV72Q^,I5ZU++Z53#9?7KU<5"GAJTZTH8=
MX6G"*D\2XS@V?ZQ4G["G'+,WEBL1"O6A@7A:-/%QPU"=*G/%5(5<53IPHRG6
MIQIJ57VTVVE1O&27[_OU'T_J:97PU^P%\>_VB?CS\'-5N_VI_@5XC^!7QF\!
M>,-1\#>(++5?#'B/PUX?\>VVF65A-;?$#P9#X@M4671=5N9[_3Y%TG4M=TDW
M>ER:AIVIG3=4L;6V^Y:^=S#+Z^58W$Y?B70E7PE1TJD\-7I8G#SLDXU*->C*
M5.K2J0<9PG&6L9+F497BO9PF*IXW#4<5152-.O!3C&M3G1JQOHX5*51*<)PD
MG&46M&G9M6;*CD[?C_2I*CD[?C_2N!_%'_M[\CH(Z***H J%_O'\/Y"IJA?[
MQ_#^0H ;1110 57JQ5>@ HHHH @;J?J?YTE*W4_4_P Z2@ I&Z'Z'^5+2-T/
MT/\ *@R?Q_./Z$%%%%!I+9^C_(*KU8JO6E/K\OU(I]?E^H44445.GS_0*G3Y
M_H-?[I_#^8J&IG^Z?P_F*AIPV?K^B$O@EZ_Y!1115D$<G;\?Z5'4DG;\?Z5'
M4P^%?/\ -@?:%%%%>">P%%%% !1110!_*C^VIX&^)O\ P5(_X*^:/^S;\&OC
M'<?!CPQ^P!\-XO'<_P 6[+PDGCZ#PG\9=0UKPEK]Y=Z3H<OB'PO97GB(ZI<^
M O#L,%QK,$FF77@3Q+J$<5V=.FM3[_\ &G_@C=^WI\;?A=XP^&/Q'_X*]^._
MBCX1\2Z=%]N\!>+_ -G/3K?PYXCOM'O;77M M-4O(OC3?3Z?%%X@TO2[R/4[
M>RO+C3)[>*_@M;B6W2%_U-_9"_8#^#W[&7BO]H#Q[X!\3_$WQWX[_:6\<IX_
M^*'C'XK:SX5UO7;S6$U#Q%JPL]+F\+>#/!EM9:2VJ^*]>U)[:>UO;B2ZO<O>
M-%!;11?<:]1]1_.OU',_$;'995R7+^$JN"IY1P]@,NP^ KX[A[(\7BZF/A".
M,S/,(5LRR[%XS"3Q.;5,15A&AB*:@H4ZL5"K*4CXO"<)X;&0S#%9Y#$2Q^:X
MO%U<53P^:9C0H1PLI.A@\)*GA,50P]>-+!0I0E*I2G=N<&Y044?S8?\ !)_]
MI76/BG_P2A_:@_9V^(3W%I\7OV-_AS\;?A#XCT74W']M6O@N7P5XRNO AOX=
MY\@:%)9>)?AW;P(H6"U\"6P=I))3(_IG_!OU\(?A-XP_X)L?#K6_%OPO^'?B
MG6I_B)\6H9M7\1^"O#6MZI-#;^,;V*WBEO\ 4],NKN2*",".&-Y2L2 (@50!
M7W+X2_X)<_ 'P)\?OVI_V@_!_C+XR>']:_;"\%^-O!GQ?\!6'B#P2/AHZ^/X
M[=]=\3^'=&F^'DVOZ?XL755U+7K#4]1\4:Q:VVJ^(?$"OI\VEZB=-B^"-,_X
M-J_V,=(MDL-(_:&_;CTJR1G=+/3?BU\*K&U1Y"7D=;>V^!$4*M(WS.P0%FY8
MD\U[..XCX*S6AQ5A:><YCPY3XBSO(N)82PV3U\;]5Q<,NQT,XR_V=+&8.U*.
M8XZK/#U(U73=%0BH.UUP8?*>(<#4R.M/+\)FT\JR[,<H<:N/IX;VU"6,PLL!
MBN:>'Q'OO"X:$:L'#F53F;EKKX/_ ,'$_P '/V7/@W\!_A!\8?AIX9\#?!G]
MK+3/C7X7?X7Z]\*M-TKP+\0->T:SLM:U#7KBYM_"O]E7>H6'AO4[7P_J^G^*
M;BTNM0\-^(H=(T[2M2T]?$5_;W_],'PDO/&&H?"WX:W_ ,0XHX/']]\/_!MY
MXXAAC6&*'QA<^'=-F\3111)% D4<>M/>HD:0PJB@*L48 0?E-^SK_P $)_V$
MOV>OB5X=^+LEG\6?CEX_\(7=CJGA36OCWX\L_%T&@:UI=^^H:7K=OHGAOPWX
M+T&_U#3)6C&G#6],U6QL9+:VO[6SBU6+^T#^S"=3]/ZBOCN+<^RK%Y)P[P[E
MF/S+/%D=;-<15SO-<*L'5J+,I85PR_ X:6+QM>C@<,L,ZC]M7O4Q%:<H4J4%
M[WOY)EF.H9EF>;8S"X3+7F4,%2AEN"KO$0A]3552Q6)K*AAJ=3$UG54%[.E:
M%&G",ISDW;XQ_P""A/[27Q'_ &0_V2_BE^T7\+OAMIOQ6\0?#&#0=8U#PGJM
M_J&GV8\,77B+3-*\2:]++I<,]Z\'AK3+^77+U(E18M.L;R[GECM[:5JU?V=_
MB_\  /\ X*&_LM_#GXHSZ!\-OB=X/^(/A30]1\8> =?L/#WC_2/!_C6;2K9_
M%7@7Q'I&LVE_;1:QX7U:>]TF>+4;&*:X@BBOH4>RO;>:7ZQU/2],US3=0T76
MM.L=8T;6+*[TO5M)U2TM]0TS5-,U""2TO].U&PNXYK6]L;VUFEMKNTN8I;>Y
MMY9(9HWC=E/X.>.O^#>/]E&7QQK?Q!_9Y^,G[2W[)^KZ[+/<3Z)\'OB#;P^$
M[&65FD2/2K;4M*D\5V=C'+-=,FF-XRFT^VCG%KIEOIMK$L)XLAEPEBLKG@<W
MQ>,X>SK#Y@\;@>(L)@Z^94J^%G1ITY9=C,+1Q="MAY4*U/ZSA,9A:=23=6O3
MK0LJ4CHS&.>4<;]9P&'P^:Y=5PSP^)RJOB*>$G3KQJRFL7AZU2A5IU55IS]C
M7H5I0BO9TYTY7<T?!?\ P5;_ &8/@!^P[^UK_P $_?BW^PCX?T[X-_M1^/OV
M@=%TF7X2?#"_N]/TCQEX;N-8T/3UOF\#65Y+:^'=%UB^U%_ >J:5HVF:=X;\
M7Z/X@U;3[K3KIM-O=_UBU_9_"+_@Y1U/5/B9?-INF?M#?L@V'AKX*7^L1O9Z
M9<^(+2S\)6]QX?TC4)$%I<7UU<_#7QLD=L9EEEU+6;?3XPUW?6$%S]K?L:_\
M$8_V2?V//B4GQRM+OXE_'7XZP"Z;2?BG\=?$]IXJU?PQ+?17-K>7?AC3--TG
M1-)LM4NK"Y-G)KNJ6VM:_;1M=)I>JZ;;ZA?6T_TU^VG^P)^SI^WGX.T#PQ\<
M=$UVUUSP5?S:M\./BAX"UE?"_P 3_AMJMU-837M]X0\1266J6<0OFTRP-YIN
MMZ/K>C3SV5AJ#:;_ &GINF7UG]K6XZR*4\OR;$9CG.=X"'"^>\+YGQ9BL)&.
M:U8YSBZ6.PM7#X+$8RK7K8#)JV&P]*E0Q..IXBMAJN-A35&+HTI?/TN&\R4,
M5F%+"8#+L5+.LLSG"9'0KMX*#R^A/#UX5<12H4Z4,3F$*M6<ZE'#2I0JPP\I
MNH^>:\:_X+-?$?P5\-O^"9_[6-WXVU&RLXO%_P -=0^''A>TNG7[1K/C7QQ+
M#HGAO3M,MLF6[O;>[F;6I4@1VM-,TC4=5G$=EI]U-%^,'[7W[)GQ,^(G_!N3
M^RA-;Z1JMUX]_9V\)_#']HFYTF*%DUM/A_>:/XN@U6+[.762!/#/@/XBV/BS
M4HFV7MK8^$YU,27$3VK?H_X4_P""%GP.O_B%X1\=?M._M)_M<?MK:?\ #N\^
MU^ ?A[^TM\6KGQKX"T4H\4D$=_I4EF+W5+>*2W@:?2X-2TKP[JL<7V36]"U.
MP=[1OV]:RLYK%].EM+:73Y;9[*6QD@B>SDLWC,#VDEJR&![9X"86@9#$T1,9
M0H2*\;"<695P=@^'<)PYBZN?8C+.*X\58_&UL'4RW"5'2P<,!2RG"T:TZF)E
M&KA98KZYBJD*24JU*-&%14W-]U?(\;G]?-<1FU"GEM+%Y*\DPN'IXB.+KQYZ
M[Q53&UITXPHIPKQH^PHPE-M4YRG*+FHGRC^PY^UQ\.OVU_V:_AI\=/ 'B'1]
M5N]>\-Z/#\0-"T^Z@;4? GQ'@TVU_P"$O\'Z]IJ32W6DWNF:LUPUC'=JBZGH
MLVF:WISW6E:E8W<_R5_P5>_X*<?\,!>"OAEX?^%.A>%?BS^T]\7O'WAOP]X#
M^"FI'6=0U'4_"US>-;ZYKLVF^&;RTU:U>]O6T[PKX4,DN_5/$FM1/8:;K=MH
MVM6T'CGQ+_X(%_LMZGX_\3?$W]F_XN?M'_L6^)?%ZW7_  D&E?LZ?$9O#?@B
M^DN;B2_.SP_<6,VJ:;IZ:A(+B+P[HWB73/#%C$HM=(T73(UA,7M_[(/_  1F
M_9+_ &2_BBWQ];4/BK^T)^T )GN].^+_ .T-XP@\;>(_#=W/82:;=77ANST_
M2-"TFWOY[.1H4UO6[3Q!XEL$:2'2]<L;::6!^6E#PRP68SSS^T,VS7 0G5Q6
M$X.KY3+"XB=:<7+#Y=F&<0QL\(L#0K2C&OBL+&IB*^'IM0P\*E3W=9RXPQ&$
MAEOU7 X+$RC3H5\_IXY5J4:<;*KB\+@)8:-=XFI!-TJ%=PI4ZLUS5I0C=_J7
MX3N/$EYX6\-7?C'3=.T;Q?=:!HUQXJTC1[Z34])TKQ)/IUM+KFFZ7J4L-O+J
M&G6.IM=6MC?2P027=M%%</#&TA1?Q)_X.*?V=/%'QX_X)UZ[XD\%:?>:GXC_
M &=_B+X9^.DUEIJ%]1G\(Z-H_B7PGXUE@ 92(-!T+Q?+XSU!T/G1V/A6=X=[
MKY4O[JTZYMK>\MY[2[@ANK2ZAEMKJUN8DGM[FWG1HIH)X95:.:&:-FCEBD5D
MD1F1U*D@_'<.Y[7X=XARKB#"TH2JY9F%'&QPUY1I5:<*EZN%YFYSA3K47.AS
M-SG&,^:\I+7W\URVGFV58W*ZTY*&,PM3#NK9.<)RC[E:RY8RE3J*-2UHQ;C;
M1,^2_P!AG]KKX<_MM?LV?#+XZ_#_ ,0Z/JUWKWAO18?B#H.G75N^H^ _B/#I
MMK_PE_@[7]-2:6ZTF]TS5FN&L8[M474]%FTS7-.>ZTK4[&[G^2/^"L?_  4Z
M_P"& /!?PS\/?"C0O"OQ:_:@^+_Q \-^'O 7P2U(ZSJ&HZIX6N;UK;7-=FTW
MPS>6FKVKWMZVG>%/"9DEWZIXEUJ)[#3=;MM&UJV@\;^)G_! 7]EK5/B!XE^)
MO[-WQ=_:1_8K\2^,!<_\)#I7[.?Q&;PWX(OY;FXDOCL\/W-C-JFFZ>FHR?:8
MO#NC>)=,\+V,2BUT?1=+C2$P^X?L@_\ !&+]DG]DGXIO\?FU'XK?M#?M!+.]
MWIWQ@_:(\8P>-_$?AN[GL)-,NKOPW9Z?I&@Z3;W]Q9R-"FMZY:>(/$M@C20Z
M7KEC;32P/]C2AX98+,JF>+,,VS7 0G6Q6$X.KY2\+B)UI)RP^79CG$,;/"1P
M-&K*,:^*PD:N(KX>FU##TZD]/!G+C#$82.6_5<#@L3*-.C7SZGCE7I1IQ<56
MQ6%P$L/&N\34IJ3I4:\H4J562<ZTX1U_/_\ ;_UC6/A?_P %BO\ @CG^T#\?
M(]/\)>"]9\!^(/AKXB>*ZN+OP'X/^,FLZ9XKTF_M(/%,]M!"]I'XE^)OA&.W
MO]06S632M%CU6Y6UM8[R6W_?C]JKXD^"/A!^S5\>/B7\1]1LM+\$^#_A/XZU
M77[C4'58)[8>'K^W@TJ*,G==W^N7L]MHNEZ?"'NM3U._M-/M(I;JYAB?#_:P
M_9#^ O[;/P@U+X*?M#>#(O%_@Z\NHM8TJXM[J;2_$?A'Q/:V=Y9:=XM\(ZY:
MG[3H_B#38-0O(H9MMQ8WMI=7>EZSI^IZ/?7VGW/Y41_\$ ?@SXDN_#'A[XW?
MMD?MX_M$? WP1J%A?^%?@!\6OCM+JWP^M4TQ/)M-/O8-/T73C;V,=K_HJGP=
M;^"[^* F*UOK>(LAF.:<*9]@.%GGN9X[),3POAIY=B<+@\KGCZ>9Y;#-<7FN
M&>6U8XFFL+CO]NKX.JL<U1]RAB?;S?M*12P>>99BLZ66X/#9C1SFM'%T:^(Q
MD<-+!8N6"P^"K/&0=&;KX;_9J5>'U:]3WJE+V45RS/R;^%?A3Q-X9_X-3OCI
M>^(H+JWM/&'C!_%?A2&ZC,3_ /",R_M2?"[08IXHV/F"UO-:T#6[VVD=$%Q#
M<I<PB2VFAFE_J,_X)N6T%K_P3T_81BMXDAC;]CO]FBY9(U"J9[SX->#+NZE(
M'\<]S/-/(W5I)'8\FN@_:+_8S^#7[2'[)WB7]C#6X-;^''P5\0^&_!?A&WL?
MA,_A_P -:KX6\.^ ?$7AKQ'X;TKPH=9\.^)M TRTM9_"FEZ<T-QX>OHAI1N(
M($@N'ANX/9?@I\*O#WP)^#OPD^"'A&\UG4?"GP;^&G@+X5>&-0\1W%C>>(;_
M ,/?#SPMI7A'1;S7KO3-.T?3;K6;K3='MI]4N-/TG2[&>^>>6TTZR@:.VBQX
MMXQP?$>2YA"-.IAL?F/B#GG$[PO+S4J.7YCEV PV&@ZZM&I7A/#U(5+1C=IU
M+)5++3(LAQ&4YCA9.<*N&PG"V79-[;FM.IBL+B\15K25-WE"E*-6$H7;M?DU
M<;GX0_\ !"C_ ).$_P""S/\ V?\ ^.?_ %-_BS67_P &]L,EKXL_X*H65PHC
MNK3]NGQE#<0%E9XI(]1\6Q,K!688$D4B!@2K%&VL<&OUS_9._84^$?['7C+]
MIGQO\,O$7Q&UW5OVJ_C!JOQK^(=OX[U?PSJ>G:-XJUC5?$6KW.G^#(O#_A#P
MQ<Z=X?CN?$M^D%KKEWXBU%8(K19-5EDCFEG^7/#W_!&;]G'P-^VU<?MO_"_X
MG?M"?##QAKWQ*OOBQXY^%?A'QSH4/P>\;>,-1EU"]U%M8\/W_A"^UQM&UC5-
M:\0:GJNC/XCN+6WGUJYA\+'PM:10P+Z>8\6<.YM6\0*%3&XK!X?B/*N%O[,Q
M3P$\0I8WAS#8!U,)B*,:U.K0CBZU"K1IXE*I"FDJLX\K2?'@\DS7!4^%:L,/
M1Q%3*<9G/URBL5&DUA\VK8A1KTIRIRA4="G4C4G1;A*>L(RO=KXE_P"#7*RM
M8_V(OVBM12!%O;K]MWXF65Q<@'S);6P^$?P+GLX'.<;+>;4KZ2,  AKF3).1
MA#J%G\'O^#F_5-4^*%^VEZ7^T;^QOI_ACX':AK,;V.EW7B*SL_!\%QX=T?49
M46SN;^ZNOAEXX2*V,ZS2ZGK5MIT2M>7^GV]S^O?[!?[!'P?_ ."=_P )_&/P
M=^"OB3XE>*/#/C?XK^(?C#JM]\4=8\+ZWKMOXF\2>&_!WA:^L=/NO"?@[P3I
M\6A1:?X)TJ:TMKG2[O4([RXU"2;4YX);:WM)_P!M[_@GO^S;_P % /!GA[PM
M\=]"U^UU[P/J$^K_  T^*GP^UM?"OQ3^&6K7<VGS7U]X.\226.JV42W[:7IY
MO=,US1M<T2>XL=/U!M,_M33-+OK+/%\9Y'BN/.,LSJSQO]@<79=F633QE+#Q
MGCL#A\=1PCH8V&#JU:7M?JV*P=!UL,J]*57"^VITY\THQE5+(,QH<-</8.$<
M/_:F1XK"8^-"=5QPV(JX:I5]KAI5X0GR>VHUZBIU?9SC"MR2G'E3:\/_ ."U
MOQ*\#_#+_@F#^UU>>.-1L;*+QE\,=1^&OA:TNW7[1K7CCQW+#H?AG3M+MN9;
MR^M[R=M<E2!':STO1]2U:?R[+3KJ>+^?[_@H-X3\3^"O^#=?_@F9H'C""ZM=
M<3XL?L[:N]K>QF&[M-+\3?#_ .-?B;P]:W$+'S();;P]K&E0-;RA)X#'Y,\4
M4R/$GZ]^$O\ @@O\"=0^(O@_Q[^U)^TU^V#^W!I_PXO?MGP_^'7[3OQ?N?&_
MP_T0H\4D$>H:3)9+?:K;Q26]NT^E6^IZ3X;U9(OLFN:#JFGN]FWWU^W7^P?\
M'_\ @H%\'O"_P1^,.O\ Q#\)^$?"7Q*\-?%'2[KX6:IX7T+6SKOA31O$>A:9
MI]Q/XH\'^,],.A/9>*+]KFTMM)MKQIH+(V^H6T44T-QUY!Q3PMPI4X5RW"YC
MB\WPF!XMEQ1G.:K+JN#I4E#+O[-PN"P&#K5)XJO*-.5:MBZU6-",ISHTJ4*D
M:<JASYKDN=9XLYQ=;"8? 5\3D?\ 8V7X)XN.(G-RQ2Q=?$8JO3A&C33G&G3H
M4X.HU&,YSE!S4%]I5_+#_P %M+#Q;_P4$_;B_8S_ ."2_P +_&2^$K:>+7OV
MA?C5XM71#XKTWP6+7P]XD@\(ZEK&@+JFAQ7UYX=\*:7XPN;71KS6-,@U>[^(
M?A6T-]:O>0NW]3U?!GPA_P"">'P7^#_[9OQY_;ML?%7Q3\:_'3]H#0U\+Z^_
MCW6_"6I^%O!OAB*;PV;?P_\ #[3=$\$>'M7TG3K:P\'>%]%@.MZ_XCO%TG1+
M:W:[:::]N+KXK@?/<%PSF>-SZLY/,\NRC'OAR"H1Q%/^WL536#PF)Q$:BE15
M' 4L1B,:E5C*,Z]"A!0?,VOHN)<NQ&;X*AEE-+ZGBL=A?[6E[5TI_P!F49_6
M*]*DX-5'4Q,Z5+#OD<7&G4J2<E;7\R/%G_!'[_@HSXZ\(>)/ 'C#_@MS\4_$
M7@KQAX<U?PAXH\,:I^RUHESHVN>&-?TVXT;6="U"R;X]"*;3=2TN[N;"ZMB
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M)8X3'X/+ZN8RIRRW,98RM&5&EB<))*I!1II^VBO?;M)1<7Z&>8+,:V8Y'F&
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M_P!DAT[_ -.NK5^@7B'_ ) &N?\ 8'U/_P!(IZ\M_9T^!/A']F3X(?#;X!^
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MQ;I3:IITZQ75JMUX>UO3K>WE>+R99].O[19#=Z??06_Z(_L5_L8_"_\ 8/\
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MK_\ .2K=YGPOQ%POD& SK/\ $Y+F>59AQ+C,3'#<//'X>N\]QF$Q,716'QF
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MW<6MS#/%;:GX>N[_ $76K*>2*1TBN=-U/3[RRO()&66VN+>6*=(Y$=5_.O\
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M6C3V#V,_+[SSRG)]X?C_ "->B?\ "(:;_P ][[_O[;__ "-2CPCIH.?/OO\
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MWV\K!R2\OO\ Z_I/ROS%3KT'T'\JZ'^Q+3_GI<?]]Q__ !JGC1[8 #S)^/\
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M<]C/R^\\L?H/K_0U%7JY\$:41@W&H?\ ?VV_^1*;_P (-I/_ #\:C_W^MO\
MY$H^LTN\ON_K^D_*Y[&?E]YY54#=3]3_ #KUS_A!M)_Y^-1_[_6W_P B4P^
M]())^TZES_TVM?\ Y#H^LTN\ON_K^D_*Y[&?E]YY+17K7_"!Z/\ \_.I?]_K
M7_Y#H_X0/1_^?G4O^_UK_P#(='UFEWE]W]?TGY7/8S\OO/'W^\?P_D*;7L!\
M :,3G[3J?_?ZU_\ D*D_X5_HW_/SJ?\ W^M?_D*CZS2[R^[^OZ3\KGL9^7WG
MD%1/U'T_J:]D_P"%?Z-_S\ZG_P!_K7_Y"II^'NBDY-UJG_?ZT_\ D*CZS2[R
M^[^OZ3\KGL9^7WGC5%>R?\*\T7_GZU3_ +_VG_R%1_PKS1?^?K5/^_\ :?\
MR%0L3233O+1KIZ?U\O2Y[&?E]YXO)V_'^E1U[6?AUHC8S=:KQ_TWM/\ Y!IO
M_"N=$_Y^M5_[_P!I_P#(-5+%47:SEI_=?6P>QGY?>>+4Q^@^O]#7MG_"N=$_
MY^M5_P"_]I_\@TA^&^AD8-UJO_?^S_\ D&I6)I73O+1I_#Z?U\B94*C<=M'=
MZ^AX?17MW_"M="_Y^]6_[_V?_P @4?\ "M="_P"?O5O^_P#9_P#R!6OURCWE
M_P" LKV,_+[SP]_NG\/YBH:]U/PTT(C'VO5O^_\ 9_\ R!3?^%9:#_S]ZO\
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MK?/_ $\V'_RMH^N4>\O_  %A]6J]H_?_ %_2?E?YXHKZ'_X5+X<_Y_=;_P#
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MN/\ I[TW_P"5-#S'#7B[STO]A]?F'U.MVC_X$CY3HKZJ_P"%&^$_^@CXB_\
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MW:/_ ($CY$;J?J?YTE?7)^ ?@\DG^TO$O/\ T^:7_P#*:C_A0?@__H)>)?\
MP,TO_P"4U']I87O/_P  ?^8?4ZW:/_@2/D:D;H?H?Y5]=?\ "@_!_P#T$O$O
M_@9I?_RFH/P#\'$$?VEXEY_Z?-+_ /E-1_:6%[S_ / '_F0\#7YKVC:Z^UVL
M?'U%?7W_  H#P;_T$_$W_@9I7_RFH_X4!X-_Z"?B;_P,TK_Y34?VEA>\_P#P
M!_YE/!UVFK1U3^T?(-5Z^QO^% >#?^@GXF_\#-*_^4U,_P"&?/!G_03\3_\
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M2DTHRBY2T5^.7Q'_ ."V'[/O@K4/'=SX,_9P_;M_: ^&'PQUSQ3X>\??M!_
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M,HM2C)-IIIH****Q- HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQB\BRTZTMK&S@WR2^3:VD*6]O%YDSR32>7#&B;Y9'D?&YW9B6-NBCB#BO/\
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M";%_^S?KWQC\(>!]?\?Z+\!?'UI\=-3^(4.L_$#3_#&GZQX@T+PWXXTB[M=
MM-5TC2[N[OM5L8;/[%>V]O=2Z=_7W17N4^.\/%YEAJF23GE68T\IP,L)'-90
MQ='*<HR'%Y#A\/#'O U%+'RI5Z&*ECI83ZM[?#SIO+)86O["EYLN&JK6#JQS
M&,<;A)X[$JN\$I4*F.Q^9X?-*M66&6)BUA8U*-2BL,J_MO9U8S6,5:E[6?\
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M?V4M5\%^!OV[?V:=*\9CX<WZ6WQ+\7VFI?L\_$+4_ASIOC3Q7?ZKI/B>RO\
MQ2_A"^\*>$+34[&X=X/&]W;RR:?%_:I17Z*_$[ 4Z-##8'AS%950AF$<=4AE
MF;Y5@N6/]GXW 5,%A84.%(8:6%E'%QDO[9PV>8BK"%2&.KXZI5A7H?)K@[%2
MJ5*V)S:CC:LL*\-"6,P.-Q'-+ZUAL5'$5Y5,[E6]NGAVG_9];+:4)2A+#4L-
M"G*G4_F<_9U^*OC;]I+]A']N[PY^UM_PT%_P4:_8MT6_\!Z+\$?C7X&_9X_X
M4]\>/COX#O=/T;5_%^N^"/AMJ^L>#M=\2V_P5\4Q:%X@T_QO<PR:[KMWI'B.
M\@_X2B6Q7PSI_P ^?LA?M)ZEH?[5G[/GPP_X)V?\%'_VL?V^_A9XB^*>A>'/
MC_\ LZ_M,?!/X@>)=1^#'P9.B:G'XE^(>M_M&?$?P9\/T\'1^"Y-.2U\/>%O
M#5KI=IJVO&PTE;368D.DZO\ US45YJX_P2AGE)\.P>&S6=2IA\M6)RK^Q\/6
MJY;ALOEB\5EDN')4?K\YX:&/GC.'I<,5'BY/V:IX>EAJ%#M?"^(Y\MJ?VJ_;
M8*,(5<6Z6->85:<,95Q4:%'&+-E4^K1C6EAHT,UCG,/8)<SG5G6J5?YT/A'^
MVS\$/^"7'QP_;M^%/[;UE\1?A#=_&?\ :^^)W[2'P4^*J_"?Q_XV\#?'CP5\
M4=.\.76A^&/!_B;P)X;\2RW'B_P.+#_A'=8TG7!8:;I+R65I%JD$@N["Q^:9
M?A=\:9OV.?$7[9UQ^S]\5M/\"W/_  6*TO\ X*0_\,W:IX3BMOBU#^S%I-W:
M:#J&J7'PZ17=/$ETT4OQ0N?#\AN;=].M$U^UN)+64>(;G^L6BLJ7'N'PU:..
MPV1RCF>+J92\[K5\TE6P>.H9715!TLOP<,#0K95+&QBIUZT\=F,J-16P2PM%
MNB[GPS5JP>'K9DG@Z$,:LNIT\%&GB,/4QM3VBJ8O$2Q%2GC8X=WC2IQPV$C4
MB[XAUJB51?BW\-_^"A?[+_[=WQOG3]E;X,#XXZ9\.OV?_BY<_$+]L?Q#\.O$
M/@"3X#2ZQI=K#I/P9\*ZG\0/AC8^)]?\1?$6\,MWXB\/Z+XB\-:1;:-H<FM+
M+XK6TN;;3_S3T?\ :N^,'[,G_!*C_@DI:^%_B[KW[+7P,^)?AC6]'_:#_:Z\
M-_ Q?V@M5^#>F:'!=ZCX+\.P^"+FRU>QL!\4-4N-5T8^*'T'7-1T-]*2ZTG3
M;F9)[>?^M"BN?"<79-@94L/0X:J5LJI8S!8J.#S'-Z69XB;PF S["<]6KB\G
MGELZZKYXL9AE_8T<MI3P%"&)RO&NMBJM;2OD688F,ZM7.(T\=.AB:+Q&$P,\
M%2BL1BLKK\L(4,?'&1I.EECP]9O,)8RI'%594<;AE3H0I_R _L0_%?P5\2_^
M"Q_[-GC'P3^TG^V%^U=X%\0? +]H3P[X;^/W[3?A>]\$_#KQKXN@TC3/$GB'
MPU^SKX5G\ > DT?1O#FE^1/XS273(IY]5GTZ&.VAT^UTBZU;T70_C)\/;?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=GW_ ,^Q?5,1_P!#3'_^"\L_^=W]7?E;XQ_X:B^.'_2.']L[_P +G_@GE_\
M1Y4?\-1?'#_I'#^V=_X7/_!/+_Z/*OLZBC^TL%_T3^4?^#L^_P#GV'U3$?\
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ML%_T3^4?^#L^_P#GV'U3$?\ 0TQ__@O+/_G=_5WY6^,?^&HOCA_TCA_;._\
M"Y_X)Y?_ $>5'_#47QP_Z1P_MG?^%S_P3R_^CRK[.HH_M+!?]$_E'_@[/O\
MY]A]4Q'_ $-,?_X+RS_YW?U=^5OC'_AJ+XX?](X?VSO_  N?^">7_P!'E1_P
MU%\</^D</[9W_A<_\$\O_H\J^SJ*/[2P7_1/Y1_X.S[_ .?8?5,1_P!#3'_^
M"\L_^=W]7?E;XQ_X:B^.'_2.']L[_P +G_@GE_\ 1Y4?\-1?'#_I'#^V=_X7
M/_!/+_Z/*OLZBC^TL%_T3^4?^#L^_P#GV'U3$?\ 0TQ__@O+/_G=_5WY6^,?
M^&HOCA_TCA_;._\ "Y_X)Y?_ $>5'_#47QP_Z1P_MG?^%S_P3R_^CRK[.HH_
MM+!?]$_E'_@[/O\ Y]A]4Q'_ $-,?_X+RS_YW?U=^5OC'_AJ+XX?](X?VSO_
M  N?^">7_P!'E1_PU%\</^D</[9W_A<_\$\O_H\J^SJ*/[2P7_1/Y1_X.S[_
M .?8?5,1_P!#3'_^"\L_^=W]7?E;XQ_X:B^.'_2.']L[_P +G_@GE_\ 1Y4?
M\-1?'#_I'#^V=_X7/_!/+_Z/*OLZBC^TL%_T3^4?^#L^_P#GV'U3$?\ 0TQ_
M_@O+/_G=_5WY6^,?^&HOCA_TCA_;._\ "Y_X)Y?_ $>5'_#47QP_Z1P_MG?^
M%S_P3R_^CRK[.HH_M+!?]$_E'_@[/O\ Y]A]4Q'_ $-,?_X+RS_YW?U=^5OC
M'_AJ+XX?](X?VSO_  N?^">7_P!'E1_PU%\</^D</[9W_A<_\$\O_H\J^SJ*
M/[2P7_1/Y1_X.S[_ .?8?5,1_P!#3'_^"\L_^=W]7?E;XQ_X:B^.'_2.']L[
M_P +G_@GE_\ 1Y4?\-1?'#_I'#^V=_X7/_!/+_Z/*OLZBC^TL%_T3^4?^#L^
M_P#GV'U3$?\ 0TQ__@O+/_G=_5WY6^,?^&HOCA_TCA_;._\ "Y_X)Y?_ $>5
M'_#47QP_Z1P_MG?^%S_P3R_^CRK[.HH_M+!?]$_E'_@[/O\ Y]A]4Q'_ $-,
M?_X+RS_YW?U=^5OC'_AJ+XX?](X?VSO_  N?^">7_P!'E1_PU%\</^D</[9W
M_A<_\$\O_H\J^SJ*/[2P7_1/Y1_X.S[_ .?8?5,1_P!#3'_^"\L_^=W]7?E;
MXQ_X:B^.'_2.']L[_P +G_@GE_\ 1Y4?\-1?'#_I'#^V=_X7/_!/+_Z/*OLZ
MBC^TL%_T3^4?^#L^_P#GV'U3$?\ 0TQ__@O+/_G=_5WY6^,?^&HOCA_TCA_;
M._\ "Y_X)Y?_ $>5'_#47QP_Z1P_MG?^%S_P3R_^CRK[.HH_M+!?]$_E'_@[
M/O\ Y]A]4Q'_ $-,?_X+RS_YW?U=^5OC'_AJ+XX?](X?VSO_  N?^">7_P!'
ME1_PU%\</^D</[9W_A<_\$\O_H\J^SJ*/[2P7_1/Y1_X.S[_ .?8?5,1_P!#
M3'_^"\L_^=W]7?E;XQ_X:B^.'_2.']L[_P +G_@GE_\ 1Y4?\-1?'#_I'#^V
M=_X7/_!/+_Z/*OLZBC^TL%_T3^4?^#L^_P#GV'U3$?\ 0TQ__@O+/_G=_5WY
M6^,?^&HOCA_TCA_;._\ "Y_X)Y?_ $>5'_#47QP_Z1P_MG?^%S_P3R_^CRK[
M.HH_M+!?]$_E'_@[/O\ Y]A]4Q'_ $-,?_X+RS_YW?U=^5OC'_AJ+XX?](X?
MVSO_  N?^">7_P!'E1_PU%\</^D</[9W_A<_\$\O_H\J^SJ*/[2P7_1/Y1_X
M.S[_ .?8?5,1_P!#3'_^"\L_^=W]7?E;XQ_X:B^.'_2.']L[_P +G_@GE_\
M1Y4?\-1?'#_I'#^V=_X7/_!/+_Z/*OLZBC^TL%_T3^4?^#L^_P#GV'U3$?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ^4?VK/VX_V4/V(M \,^)/VI?C5X7^$MCXTU*^TGP?9ZK!K6M^(O
M%5[I=G_:&L+X>\)>%-*U[Q3K%MHFGE;[7+^PT>>PT6T>*XU2YM(IHF?VGX2_
M%SX9?'GX;^#_ (P?!KQSX;^)7PP\?Z/!K_@WQQX2U*#5O#_B#29WDB6ZL+V
ME6,5Q#/:7=M*([JQOK>YL;V"WO+:>"/\COV[/A)^T_\ #;_@H/\ LT_\%"_@
M5^S1J'[:'A3X??LR?'+]F/QI\#/#'COX=^!OB%X+U?XD^+/!WC?PW\6/ \WQ
M5U70/!^I6^IOX8N? /CE(]=L=<T[PW?QWEE8ZY;FZL4_+S]M']B;_@H]\8?
M_P"SUK6K?L86IT^3]C3XY>!O#?[)_P"PM^TQI?[.'PR_8V_;U^('Q,O_ !1\
M)_VCM=GC\;_#33?'^D>&?!MSI-MXNO\ 0)_%T.A^.K+Q5?Z+X<US3]<AO;\
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MV-=,^ NNGQ-XMU70+GXA2QW6C1_&?Q/KBS>%KO23XRN6N;>*#0Y?#6FZ8EH
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M>6>:1(XT9F /Y<_\0_?[*/\ T5#XZ_\ @X\&_P#S&UVWPT_X(:_LR_"[XC^
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MO_\ !7;_ )1N?M:?]DYM?_4M\-U\0?MF?\K /_!&C_LW[_@H7_Z@?@JOM_\
MX*[?\HW/VM/^R<VO_J6^&Z^>XN_Y)3B?_LGLZ_\ 5;B3]F^CC_RD+X#_ /9Y
MO"__ -;?(S_/$7H/H/Y4-T/T/\J%Z#Z#^5#=#]#_ "K^ 8[KU7YG_;7'=>J_
M,_T8?^"6W_*/+]D3_LB_AC^5Q7WQ7P/_ ,$MO^4>7[(G_9%_#'\KBOOBO] ^
M&/\ DFN'O^Q'E/\ Z@8<_P"(;QZ_Y/GXT?\ 9V/$7_UL,X"BBBO</R<****
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M^$Z,YT%!K8B_X1K^TMYT@C4@/^/,BX\LU^D__$2'^QC_ -$Q_:!_\)WP;_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\&_#?P%\-_"?AW2/!NK>!+OPG9:78>%X!#)I-U(+N]AFBEK^>#PW_P $YO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 ?@%^V9_RL _\$:/^S?O^"A?_ *@?@JOM_P#X*[?\HW/VM/\
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M88'#U^$<+1KXN6'P]14*57$X>G.KRQG6IQ?.OZLJ***_6C_-D**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M &0?X:_^G7QE7]0>)?\ R:?AGTX;_P#516/^<S]G^E_Q4H\;'VJ^/'5]>/\
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M6L>G2:'XL\.Q0VS03.TR7$-S(TN&25%!0_D%_P 1%_[<W_0@?LU_^$9\0?\
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M,A^L** / I_@7J<_COQ5XW'Q[^/L%MXG^&;?#F'P+!XI\(KX$\+7;65O9_\
M"R_"NEOX$DU2Q^)BM ;Y=9O];U/1!>W%Q(?#AA=((\#2_P!F_5]-TWX):<_[
M3/[3FJ/\&M:U#6-0U+5/&?@>;4OC7'?7PO5T7XVS0?#>V@\2:+8*/L.GVWAF
MW\&W,5B3%->3RXG'*?M??MD^%/V3%^!&A7/A35_B1\3OVDOCCX-^!?PD^&GA
MW4++3=8U[6O$=TLGB#Q+=7M_'-;Z=X4\!>'TN?$/B?5)(9$MX5LK,!9M0@=?
M@3XP_P#!>?\ 98^#?[1OC3X*:O\ #+X^^(?AM\)OBMX7^!?QM_:H\,^#-.U#
MX!_"7XM^+I+B#3?"7B?7GUN'5&^P7=I=V6NWEMIA:QNK&_CLK/5%M2[_ *WP
M;X#^+WB#@L+F'!G >=<0X3'9=FV;8*I@?JG-B\NR7,\)D>,Q.'H5L52KUE5S
MS'4,DRNG3I2K9YG4<5E.2T\PS# XW#8?FJXS"T&U6K0I\LHPES-V4I0E4LVD
MTK4XNK.[_=TOWD^6#4G^CFI_LRZSJ7AWXN^'T_:C_:FTR7XK>+;+Q38^(M,\
M;> X?$7PD@L[]KYO"?PBNY_AE<V>@>$KQ2+&]L/$.G^*]0DL%6*/589<SGIQ
M\"=3'CR+QQ_POWX_FVC^& ^&I\"'Q3X0_P"$#EO/LAM?^%G2Z6/ 8U5OB>6/
MVPZT-<70OM8#CPT(OW->;>$_VS/!VN_MJ_$O]B#7?#.J^$?B%X5^#W@KX[_#
MGQ#J.I:==:!\:/AIXDOKS0?$NK^$$@\NZMKOP#XIMH=$U[3KG[1+/'>V^J6K
M_8Q+Y?U]?7UGIEE>:EJ-W;6&GZ?:W%]?WUY-';6EE9VD3SW5W=7$S)#;VUO!
M')-/-*ZQQ1(TCLJJ2/@L\X8S[AO$9;A<[RVO@:^<Y+D_$.51E*E7AF&39_@Z
M6.RK'86KAJE:C6IXFA54)TX5'7PF,IXG+\92P^883%8:CO"<)J3A)2Y92A*W
MV9P=I1:W337S5FKIIOYATW]F/6=.\,_"CPXW[4O[5&HS?"[QA=^+;SQ+J7C?
MP%-XF^*L%U?"]7PA\5[V'X8V]EKO@^T4&QM-/T'3?#&HQV+&*35I9<3"_JG[
M..KZG8_&^R3]I?\ ::TMOC/JFG:GI]]I?C+P/#??!)-/OOMK:7\$);CX;W47
MAK2]17_0=1@\3P^,YYK']W#<V\V9Z^!-2_X+4? ;0_V/[7]LO5/AC\5+OP/\
M1_V@_$O[/O[+W@CPO::7XB^)7[3VJ:3XDU+PKX?\4> ?#QNM-BTS1O%VHZ#X
M@N-.M]8O1>V^FZ6L[I/=:EIMC<R^&O\ @LM\*O&?['7[1G[5OAWX%_&FU\0?
ML@>-(O!_[3O[.'C*PTCPE\:/A3]BUG3K7Q7K-YITUWJ&EZI8>&_#UUJ7BHI!
M>6\]_9>'=>L"ECJ-A+"/U.7T:_'*-">)GX=9S3PU+C:AX=5L15KY52H4.,L1
MFN$R&.38BM4S"-/#^RS_ !V$X?QF85Y4\JP&?5Z>28['8?-&\(N;Z_@[I?6(
M7='ZPMU>CR.ISK3K3BYI?$X)S2<4V?HE;? O4[;QSX-\:M\>_C[<VWA#X9I\
M.9_ ]UXH\)/X&\8W:6-S9'XE>,M,C\"Q:KJ/Q,=K@7SZSINMZ1HAOK:VD'AQ
M84>"3B[+]EO6[/P1X(\&-^U=^UC>7'@SQ_+X[N/&U[XZ^'\GC?QM;27 N!X!
M\;ZE'\+(=+U+P!$ ;>+2M,T;1M66W)1M=9L./HOP7XQ\,_$/P?X5\?>"]8L_
M$/@_QMX=T7Q9X6U[3I1-8:UX>\0Z=;:MHVJ6<HX>VO\ 3[NWN86P"4E7(!R!
M\M_&O]LWPA\(OVG?V8?V3++POJOCKXK?M)R>.M>:STC4M/T^S^&'PJ^'&A7&
MK>*/BIXSFOE8KH?VZ.#P_HEC ([K6]7DNH+69383JWYADO"?$?$.;8W(\HRC
M%8K-LMR[/\VS'!25/"U<OR[A;*\=G7$.+QTL9/#T\)2RG+,MQV)Q?UB=.4?J
M\J,8RQ$Z=*?1.I"G%2G)*+E3@GJ[RJSC3II6O=RG*,5ZZZ:G;:K^SMJVIW'Q
MMG3]I+]I32Q\9;>QM]/M]*\8>"8+?X*&R96:X^"2S_#JZ?PW<7P79?/XFD\9
M)*K-Y4<+$,-32O@1J>F>,?A7XM?X_?M :I!\,? TG@J]\(:KXI\(3^#_ (IW
M,EC>67_"<?%33X/ =KJ.M^.8VNUOH]3T'5O#&EK?6=G*=$,22P3?E[\+/^"\
MW[+/Q6_:-\)?!73?AE\?= ^&7Q.^+_B3]G_X/_M6^)/!NFV'[/\ \4/C)X6D
M@@U'P?X=\0#6Y-307MW<V]GHNH7.FC[9<7=F;RTTVWN!.GW[^SM^V/X3^/GQ
MJ_:N_9ZG\+:O\/?BW^R;\2-)\)^*O"VOZCIU]/XJ\"^,= M?$OPW^+GAF2R\
MMG\*>-],ENUBMIXOMNBW]A-8:DPFEMS)]SQ;X#^+W M#&XGB[@/.LBHY=P]@
M^*\<\;]44\)D&-S[#<+0S"O1I8JK6IK"\28W!Y%FN&E36,R3-<7A<#G&'P.(
MQ%&G/&EC,+7M[&O"I>HZ2Y6VG-4_:V3M9\U+]Y"2]V</?@Y1U-&/]EC6X_AY
MIG@$_M8_M:276G?$H_$1_B%)X[^'Q^(>IVAV?\6WU/5E^%:Z/-\-1MXT:#0+
M;6?G?/B$Y&.KU;X :KJFO_&+7$_:'_:)TJ+XM^&[?P[8Z#I/BWP;!H'P?E@M
MX;<^(_@[:W'P_NKOP_XDN#$;BXO/$=]XMLGN)IG33HU9$3Z)K\C/&'_!8[]G
M3P%\//VU/C5XC\-^,Y/@I^QY\9-%_9WM/'?A\Z7KEU\?/CA=6=@OB3P!\)O#
MZW%H;JZ\*>(=4LO#MYJ>I:K;Z?=2KJ.J))!INFSS'YC@WP[XV\0J^*PO!7#>
M8\18G!XC(\'6H9?"G.J\;Q+G>"X=R' T(5*E.6*Q^:YOC\/AL)@<*JV+J4X8
MO&^Q6 R_'XG#:5:]&@N:M4C37+.5Y.R4:<'.I)O91A%-RD[):*]VD_N;2?V?
M-5TO7/@SK3_M%_M&ZK'\(-!O=#O]#U;Q=X,GT/XR27D$T"Z]\9K:W^'MK=>(
MM>LS,)[*Z\-WOA"TBGAA>2QE571^9?\ 99UM_A[J_@+_ (:P_:S2ZU7XE)\1
M4^(">.OA\/B%I-HF/^+;:1JQ^%9T>W^&KXR^C7&@W6M')QXB )%?*'[.'_!5
M[P9^TU\._P!JJZ\*_L]_&_P'^T;^R/X5N/%/Q"_9+^+VG:/X%^+&HVUUX8U'
MQ3X131)VO=3TMH/&-KILMAIMU>"W>TU&:T2^M8K2^T^[N_N3]EG]H_X=_M=?
ML]_";]I#X5W<ESX(^+7@_3?%.F6]TT3:EHEW.K6^M^%]:2!GBAU[PKKEOJ/A
M[6X(W:.+4]-NEB>2()(WH<8>$_B)P##,ZG%W"V.R6EDV<95D695:U7!8BEA<
MRS[(WQ-D$)5<%BL33J83/^'XU,WR',Z,JF69U@:&*KY7C,7#"XGV4TL30K<O
MLJD9\\9RBM4VJ<_9U?=DDU*E4:A5BTI4YM1FHMI!J/P+U/4/&/Q.\7)\?/C]
MIT'Q(\!+X&L_!^G>*?",/@[X97*V5O9_\)Y\,=.F\"7&HZ+X]9K<WK:IKFK>
M)-*-[<7$@T,1ND,>/I?[.FKZ;+\$)'_:4_:6U,?!A=274(M4\8^")HOC;_:,
MWFHWQO$'PYMF\2MIH_<Z:?##>#!##Q.+ER9*^EJ*_.S<^3[S]EO6KOP7X]\'
MK^U=^UC:7'CCQ_'X[MO&=GXZ^'\?C3P);1S^<? /@+49/A;+IFE^ )!B&32M
M5T?7-6: ;1KJL2Y[6X^!NIS^._%/C8?'GX]V]MXF^&I^'</@:W\4>$D\">%[
MLV,=E_PLCPMI;^!9-5L?B4'C-\-8OM;U/1?MTDDA\.F$K OO=% 'S%I?[-VL
M:;IGP0TU_P!IK]IW5'^#&N:CK6H:GJGC/P--J?QLCU"_AOET3XWSP?#:VA\2
MZ'IR1'3].MO#%MX,NH;"::*:]N)F6X2KJ/[,FLZAX<^+GAY/VI?VI].E^*WB
M^W\667B+3O&_@.'Q'\)8+>^>];PC\([R;X8W%EH'A"X5Q8W&G^(-/\5:BUC&
MD<>K1RAIV^IZ* / Q\#-3'CV/QQ_POOX^&VC^&G_  KH^ SXH\(_\(%)=_8C
M9_\ "RI-+_X07^U3\2]Q^V_VR-<71/MH$G_".>3^XKDM-_9BUK3O#7PF\.M^
MU/\ M4ZC-\+/&5QXNO?$FI>-_ ,WB7XKP3WR7H\'?%F\A^&%O8Z]X-MU0V-O
MI^@:=X6U)+&1XGU>24K.OU310!\R:G^S?J^I:?\ &^P3]IG]IS3&^,^L:?JV
MGZAIGC/P/#J'P2CL+^6];2/@A-/\-KF'PUH^H)*+#4+?Q/!XSN9;"**.&[@F
M5KANAMO@=J=MXZ\(>-C\>?CU<V_A/X;CX>3^!KGQ/X2?P+XNNQ8RV7_"Q_%^
MF)X%CU34/B07E%^=8T[6])T4WT44@\/"%6MW]ZHH ^3;3]EK6[7P3X&\&M^U
MA^UE=7'@KXA/X]N/&MWXZ^'TGC;QQ:O-YH^'_CG4H_A9%IFI_#U!^Z32=+T;
M1=7$)VMKS-AANZG^SKJVI3_&Z=/VD_VE=,'QFATZ+3X-,\8^"8(/@F=/D\QY
M?@BL_P .KE_#<VHC]WJ+>)Y/&:S1\0K;M\U?2M% '@.F_ K4].\8?"WQ8_Q\
M^/VI0?#/P-)X*O/"&I>*?",W@_XH7$EI<6G_  G'Q2T^'P);ZCK?CF-IQ=QZ
MGH6K>&=+6[M[>0Z*T:O%)Q2_LLZVOP\TWP#_ ,-8_M:-=:?\3&^([_$)O'7P
M^/Q#U&T92O\ PK74M6'PK&CS?#-2=ZZ-#H%OK8;&?$94!:^LZ* /G35?V?M5
MU/7_ (R:ZG[1/[1>EQ?%WP]9Z!8:!I7BWP;!H'P=EM+>&!O$'P;M+CX?75WX
M>\0W9A-Q>7?B2^\76DEQ/,\=A$ACCC-*_9^U72];^#>LO^T3^T7JL?PB\/W.
M@W^B:KXM\&SZ)\8I;F&6$:_\9+:#X?6MUXA\06QD$UM=^'+WPC:)-%$SV,@#
M*_T710!\E3?LL:W-\/=9\!#]K+]K6&ZU?XDCXB1_$&'QW\/E^(6CV@W'_A6^
MC:LWPK?2+?X;$MSHUSH-YK7RJ!XB !![?5/@5J>I^,_BCXO3X^?'[2X/B7X$
MB\$6?@W2_%/A*#P9\+[F.QLK(^.OA=IT_@2YU+1?'<C6;7TNJ:]J_B;2VOKV
M]D&B+%)%!#[]10!\U:7^SKJVF2_!&1_VDOVE=4'P9COX]0BU3QAX)GB^-AOI
M#(LGQN$'PZMF\226 /EV#>&&\&"*, 2K.^7.'??LM:U>^"O'O@Y?VK_VLK&X
M\<^/HO'-MXTL?'7P_B\:^ [:*Y-R? ?@+4I?A9/IFE^ 901;2Z5JVCZYJK6R
MA%UQ'S(?K&B@#P*X^!>IS^._%OC<?'OX^V]MXI^&C?#F#P+;^*/"2^!/"=VU
MC;V0^)7A+2W\"R:I8?$M6MS?+K.H:WJNB"^N+B0^'#"Z01X.E_LWZOIFG?!+
M3W_:9_:;U1_@UK&H:OJ&HZIXR\#SZC\:X[^^%ZNC_&V6#X;VT/B31]/4&QT^
MW\,6_@VYBL28YKR>7$X^FZ* /EC4_P!F36=1\.?%SP\G[4O[4^FR_%7Q;9^*
MK+Q'IGC;P%#XD^$L%G?M?-X2^$=Y/\,;FRT#PE>*187EAX@T[Q5J$E@JQ1ZK
M#-NG;J!\"=3'CT>./^%^_'\VP^&'_"M?^$$/BGPC_P (&;S[']D_X6<VE_\
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M_@RZAT^66*>\N)F%PM/4?V8]9U#PW\6O#R?M2_M4:=+\5/&%MXMLO$>G>-_
M</B3X306]Z]X?"'PEO)OAC<66@^#[E7%E<Z?X@T_Q5J+V2)&FK1RAIF^J**
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M&"P>+7&7$&(>%Q6*RG%XNAA\2L/5I5W0JSA55&K3J\O).,G_  UZY_R'M?\
M^P_KG_IUO*S*\*U;]K/]G*XUC6KB#XM>&9(+C6=6N() FL*)(+C4KJ6&10VE
M@XDC=' QN (+ =!GG]J[]G<8_P"+K^&N?1=7/YXTOC\:_FN7#'$MW_QCV>/5
M[93C_P#YG/\ ?3#?2*^CZL/AT_'3P=35&DFGXF<%IIJ$4TT\[NFGHT?WF?\
M!N#_ ,F<?%7_ +.'\1_^H1X%KS7_ (.6@#\#OV8<@'_B\'BOJ ?^9&N#W]P#
M]0/2OA?_ ((<_P#!9#_@F1^S'^R_\1?!?QW_ &O_ (;_  Y\4ZM\;M:\1:=H
MNKZ?XVNKFZT.[\)^#["VU*)M)\*ZA";>2\L+V DR*\;6[M(J(59N%_X+O?\
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MJ-><>UX2I#"X"C%^UE@YX123DHJK"E!4*DY7WY(REB(QO=U*<$G>Q^&7[/\
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M]G_#P'X.Y"A\_P!G?$/9@DKC?_PA6PMD<H&W@88J%()+I;M+Y@?LY17XQ?\
M$0Y_P1<V,_\ P\ ^#VU"X(_LSXB[SL)5ML?_  A/F."1\A16$@PT992":]U_
MP7O_ ."=/BY5L/V:_C1H'[47BVU/VW7_  =\-I=4TG5O#WAH 02>*+Z;QAH>
MBV,VFQ:K<:7I#Q6EQ-=B[U6U;R?*69T\C/L_RCAC)\?G^>XV&7Y1EE%5\=C9
MTZU:&'HRJ0HJ<J>&IUJ\DZE2$;4Z4W>2=K7:Y<;C<+EV%K8W&U50PN'BIUJL
MHSDH1<HP3<:<9S=Y2BK1BWKM8_:6BOQ.@_X+6?#BY#FV^ OQ'N!&Q20P>(O"
M4H1QR4<QSL%8#JK8/M4__#Z/P!_T;[\3O_![X6_^/5^/2^D[X$1;C+Q%RN,D
M[.,L!GB:>FC3RM-/5;]SYC_7_@__ *'5'_PGQOE_U#>:/VJHK\49?^"U'P\@
MC:6;X _$J&)!EY)?$'A2.-!D#+.\X51D@9)') [U1'_!;SX4D@#X(^/3G@8\
M5>##R<8'_'UG)ST]C50^DUX%U%>'B%ELTM&XY?GLDG9.S:RIJ]FG87_$0.#_
M /H=T?\ PGQO_P S>9^WE%?B?_P^K^'/_1!/B1_X4/A/_P"/T?\ #ZOX<_\
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MI)=WA<=;I_U"^:/VWHK\2(O^"VWPOG8I!\#/B#,X4L4B\3^#I&"C +%4N6(
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M_P"&=OV?A;QV@^!?P=%K"8FBMO\ A67@K[/$T,@EA:.'^Q/+0Q2@21%5!CD
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MGR'*\4+^S[\!$DEF3X(?"%)IQ&)I5^&O@Q9)A$I2(2N-%#2"-"5CWD[%)5<
MD5Z]10!XC>_LS_LX:E8II>H_L_?!&_TR*1)8].O?A3X$NK&.6,N8Y$M)]!DM
MTDC,CE'6,,I=RI!8YQO^&0_V3L@_\,P?L[Y'0_\ "E/AMD9ZX/\ PC7&:^AZ
M* /G?_AD+]DW!'_#+_[.^#G(_P"%*?#7!SUR/^$9YSWSUKIA^SO^S^(K: ?
MSX.B&S,)M(1\,O!0BM3;KL@-M'_8FR P)\L)B"^4ORIM'%>Q44 >0C]GWX""
M8W ^"/PA%PT2P-./AKX,$QA5S(L)E_L7>8E=F=8RVP.Q8 $DU'_PSO\ L_\
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M% 'D"_L]_ -3.5^!_P (%-RQ>Y*_#3P8#<.8Q$6G(T4>:QB58RTFXF-0A.T
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M.3.X0H9-7A34:5.G]5C",?=C"$<5022M9)):6VL?PA?V=I__ #XV?_@-!_\
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M^+B0V>FZ7I.GZ=I]I$/"7AIO+MK*SMX;:!"S,["*)0TCO(V7=F/Y;_V=I_\
MSXV?_@+!_P#$5^L7_!<+_E+-^W)_V6!?_41\,5^5-?Z\?1[R3):G@%X'5)Y1
ME<YS\'O#*<YSP&$E.<Y<%9'*4Y2=)N4I2]Z4FVV]6VSYW%3G];Q?O2_WO%?:
M?_014\S^JK_@TN^'O@#QI^UW^TY9^,? W@[Q9::?^SOI.H:?;>)O#&B:]!87
MZ_$KP_ +VRBU6QNTM+L032P_:(%CE,4CQERC$5_2/_P7]^#'P=\-_P#!)K]K
M;7O#WPF^&6AZ[#H/P\A@UK2/ /A33M7MXC\6/!0V6^I6FDPWMN-LLJ?N9T.R
M:9,[)I%;^>C_ (-"?^3P_P!JC_LVO2O_ %9_ANOZ8?\ @X7_ .40O[7?_8&^
M'?\ ZMGP-7^$GTN,%@Z7[5_PSPE+"8:GA)^(7T;HSPM.A2AAY1J8SA3VD948
MP5.2G=\Z<6I7?->Y]3EK;X=Q#;;?LLRU;=])U[:^70_RN/[.T_\ Y\;/_P !
MH/\ XBFOI^G[6_T&S^Z?^76#T/\ L5>IK_<;_=;^1K_H[60Y'=?\(V4[K_F7
M8/NO^G/DON/CI3G9^]+9_:?;U/\ 6#_X)2? _P""NJ_\$V_V(M9U/X/?"S4-
M7U7]F?X1W&J:I>?#WPC<ZCJ5P/"=@/M&H7LNCO<7EP<DM/<R22NS,[NS,Q/\
M-7_!R[X)\%^$?^"J?CW0O"?A#PMX7T2V^#WP7DMM'\.^'](T32X))_#$DLTD
M5AIEG:VL<DTC%Y76(-(V"Y) Q_?-_P $E/\ E&3^PG_V;#\)/_44L*_A _X.
M?O\ E+1\1/\ LCGP2_\ 45:O^=']G'@L%B?VAOCAAL1A,+7P]/*/&ETZ%;#T
MJM&#I^)7#\(.%*<)0CR1;C#EBN6+<59.Q]EGS:RK"M-I^VPVJ;3UHU+ZKN?S
MP?V=I_\ SXV?_@-!_P#$5_0'_P &S'@WP?XI_P""J7@S1O$_A/PSXDT>X^"W
MQG:?2M?T#2M9TZ5X] M#&\EEJ-I<VS.A)VN8]RAF4':S _@17]#?_!KW_P I
M9/ W_9%/C5_ZC]G7^S7TR,ER>C]%'Z1%6CE.64JM+P@XYG3JT\!A85*<XY%B
MG&<)QI*4)1:3C*+332:>A\WETI/'X-.4FOK-'1M_SQ\S^X'_ (*:_ KX(:3_
M ,$[OVT;[2_@U\)]/O=(_9D^,-WI-W9_#GP=;W&EW=KX$UH6EWITT6C+)8W=
MIG=:7-JT4]JX62WDC=58?Y*D>G:>8TS8V?*+G_18/0?[%?Z__P#P5%_Y1Q_M
MQ?\ 9KOQH_\ 4%UFO\@R/_5Q_P"XO_H(K_/#]BSEN78WPG\9YXS 8+%SAXAY
M)"$\3A:%>48?ZMPERQE5IS<8WUY4TKZVN>QQ,VL1@[-K]S7V;7VZ78K?V=I_
M_/C9_P#@-!_\17]O'[-'A7PMIO\ P08_8*\2Z;X8\-Z=XEU3XK_&2RU3Q'I^
M@Z39>(-2LX/'WQV,-IJ&M6MI%J=[;1&"WV075U+$HM;,!,6EL(OXDZ_N*_9U
M_P"5?W_@GW_V6#XT_P#J>_'JOC?](=RS+<'^SWQ=7!Y?@<+5?BQPK!U,-A,/
M0J.#X9XV;@YTJ<9.+<8MQO9N,6UHCXS-Y2>0Y^G)M?V4]&V_^8_ +KY:'YW?
M\'(=_?>!OB;^P'!X(O;SP;!K/["W@/5]8@\)W4_AN'5M6FUO41-JFIQ:-)91
MW^I2KA9;ZZ66ZD151Y2J*!_-U_PLGXC?]% \<?\ A6^(/_EC7]'?_!S9_P E
M2_X)X_\ 9@WP^_\ 3YJ-?S(5_;?[-W@/@?'?09^C5B\=P9PIC,77\.Z,Z^*Q
M7#N48C$5I_VSFRYZM:M@YU*DK)+FG*3LDKV1UXC#X?V\_P!Q1_A8+_EU#KEV
M$;^SU>OJ?K]_P1-\4>)O%?\ P55_8L\.>*?$>O\ B;P]JWQ.U6WU30?$.LZE
MK6BZE;KX \8S+!J&EZE<W5C>0K-''*L5S!(@ECCD"AT5A_I\^-?A/\+(/!OB
MV>'X9_#Z*:'PSKTL4B>#/#:O')'I5VZ.C#3<JR, RD<@@$5_EU?\$+O^4MW[
M#G_95-6_]5YXTK_54\=?\B1XR_[%7Q#_ .FB\K_)O]LQPIPOE?C_ .&5'+.&
M\@RZE/P<P56=+ 9/EV$ISJ_Z[\91]I.&'PU.,JG+"$>=IRY8Q5[15OHLEPV'
M_LG-W["C>,\19^RA=?[!0>GNZ:ZZ==3_ #<XM5U9HT)U75"2/^@C>^I':>I/
M[4U7_H*ZI_X,KW_X_69!_JD^A_F:EK_&S^S,M_Z%V!_\),/_ /*S_!=8[&V7
M^V8K9?\ ,16_^3/ZZ_\ @AKX+\'>+_V-->U3Q9X3\->*-3C^.?CRSCU+Q'H6
MEZWJ"6D.A>"WAM5O=3M;JY%M$\LKQ0>;Y4;2R,B@NQ/Y%?\ !V[I]C\-? /[
M#<_PYM+?X?S:MXU^.T.K2^"(4\)R:I%::!\,Y+2/4GT!=/:^2U>>=[5;HRK;
MM/.80AFDW?LU_P $$_\ DR;Q#_V7SX@?^H_X'K\</^#Q+_DGG[!?_8\_'[_U
M'?A=7]Y?LUN'>'\?]-'P+PV.R+)L;AJV+XT]MA\7E>"Q-"KR^&G&52/M:5:A
M.G4Y9PA./-%VG",E9Q37^T7A#2I5? 3@&M5ITZE6?#.3N=6I",ZDV\523<IR
M3E)M:-MMM:,_B2_X63\1O^B@>./_  K?$'_RQKZ$_9'\>>.=2_:O_9@T[4?&
MOB[4-/U#]H?X*V5_87WB76KNROK*[^)'AJ"ZL[RTN+Z2WNK6Y@D>&XMYXY(9
MX7>.5&1F4_(]?1O['7_)W?[*O_9R/P-_]6=X8K_JZXV\.O#Z'!G%LX<"\&QE
M'AC/I1E'AC)(RC*.58MJ46L"FFFDTTTTU='T5/#X?VM+]Q1_BTO^74/^?D?[
MI_L(?\*B^$__ $3#X>?^$5X;_P#E97^>U\:+Z^MOC+\8+:VOKZVMK;XK?$BW
MMK:VO+FWMK:W@\::W%!;V]O#*D,$$,2)%##$B1Q1JJ(JJH _T:*_SC?C=_R6
MOXS?]E<^)O\ ZF^NU_PNXG*<JCR<N69?&_-?EP6&5_A[4T?RU].UO"9/X<O"
MMX9SS/B-3>';H\ZCA<HY5+V?+S<MWRWO:[MNSS_^U-5_Z"NJ?^#*]_\ C]?T
MS_\ ! ?POX9\9_#S]I.;QAX>T/Q9-I_CSP)#83>)M)L-?FLH9_#6JR316LNJ
MV]W);Q2R*KR1Q,B.ZAF4D U_,57]27_!O%_R3C]I[_LH'P__ /47U:LZ&597
M*HE++< U9Z/!X=K1::.GT/YS^B5B*^(\=>%*6(K5:]*6"XE<J5:I.K3DX\.Y
MG*+E"<I1?+)*2NM))-:I'HW_  73\'>$?"'[)/@O4/"7A7PWX6U"?XY>%;6;
M4/#FA:7H=_):OX7\:.]J][IEK:W36TCI'));F7R9)(HG=&>*,K_)K_:FJ_\
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M ((T?]F_?\%"_P#U _!5?O[7X!?MF?\ *P#_ ,$:/^S?O^"A?_J!^"J_?V@
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MGW_V6#XT_P#J>_'JOXH?^$!\>_\ 0B^-/_"4U_\ ^5]?VT? *PO]-_X(#_L
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MN_Y+7\9O^RN?$W_U-]=K_1RK_.-^-W_):_C-_P!E<^)O_J;Z[7_!WB_^7?\
MV_\ ^VG\I_3U_P"1-X;?]C/B3_U%R<\QK^I+_@WB_P"2<?M/?]E ^'__ *B^
MK5_+;7]27_!O%_R3C]I[_LH'P_\ _47U:LL-_%7I+\C^;_HB?\GYX3_[ N)O
M_6;S0]I_X+Z_\F>^!O\ LO/A/_U%?&U?R"5_7W_P7U_Y,]\#?]EY\)_^HKXV
MK^02GB?XO_;J_4]?Z9O_ ">S&?\ 9-\/_P#IFN20?\?%I_U^6?\ Z515_I+^
M#/\ D3_"?_8M:%_Z:[6O\VB#_CXM/^ORS_\ 2J*O])?P9_R)_A/_ +%K0O\
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M$FEZAX;)@UBUGN[Z]@E\7>'Y8=0U&_CU"WUZS329-(\P_P""27AOXA_M1_\
M!2#XA?MP_MT?MU_L.?&[]L?X7?!'6?@1\+OV2_V,?B7X6\::%\ _AUJ?B?\
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MA^%/]GQD0E?#?]K"[ WRE')-8=_\(?VK;CP3\0=$L?VP[33_ !GXA\?0^(/
M/CD_LZ^!+R/X=>!$NC+-\/9?"TOB)-.\8RS6Q%K_ ,)?JMW9:I&P%PMD6)0@
M'UM17S]<?#SX]2>/?%>OP?M%06_@75OAB_A?PO\ #_\ X4]X4FE\)?$HV-O
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M7&IZC,9#=O:B552@#ZOHKY>U3X6?M,W6G?'*WTS]JRUTK4/'>L:?>_!/4F^
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MW)N\2ZD;2_NMGSVL>YJ_*?'S_DR/B#_V(Y_^IN%_X?\ X)_IG]'?_E%W#?\
M7[B7_P!:/%?IK_P3]:_V8O\ DV[X ?\ 9%_AA_ZA6BU[E7AO[,7_ ";=\ /^
MR+_##_U"M%KW*OT[A7_DF.'/^Q#D_P#ZK\.?USEO_(NP'_8%A?\ TQ3"BBBO
M>.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _G)_: _X-[/#_ ,=/VHOBO\75_:X\3^$/@%\?_P!H'P+^TM\:
M_P!GJ/\ 9\^"7B?QGK_Q*\$77@^^6/P1^U+KVFR?&7X8^%-6O?!.E33>'/#<
M[6MC'<:G;6<BP7SJO[Z:]\)?A=XH\>>"/BGXC^'?@K7/B9\-5UF/X>_$'5/#
M.CWOC7P5#XBTN^T37[;PQXGGM'UK1;36M)U._L-5L["]@M;^WNI4NH9<@CR_
MXQ_M@_LQ?L_>)?AMX.^,GQL\"^ O%'Q=^(NE_";X?:'J^J&34-<^(.M:?/JN
ME^'IX=/AO/[">[T^VDN5U'Q$=)TA$:W674(Y+JU29B?MA_LRS_M!^$/V5[+X
MQ^$=4^/?CSX?>)/BGX4^'^C3WFM76J^!?"6HV^EZ_K7]M:3:7GAJR>QO+A57
M2M1UFTUB\@BN[NQT^YM+*[GA /HC4K&RU/3M0TW4HDGT[4+*ZL;^&1BL<UE=
MP26]U$[*RE4D@DD1F#*0I)# C-?Y;/Q&A_8\^#_Q5\2_LV?#S_@X,\$^'/V.
M_"WP\^-G[)4&BZ?^QU\?/B-\3_"O[+?QJ^+%M\4OB_\ !'0O%_A7X.:K\/OB
M!_;WBVWG6'XA:?X]A@O8%D:PNM*T>[;01_J/ZXD$NB:Q'<Z?-J]M)I6H)<:5
M;@&XU.![299=/@!DB!FO8RUM$#+&"\J@R)]X?P,_\$H?!W_!8G4?V/-#F_8J
M_9$_X)<ZQ^S(?B7\;H_A7H_[4;6&L?M%>!=&'Q=\9FX\"?%_5]"33M1U7Q3X
M4U$W>CB\\9:=I_BV?2[33GOK2"Q;3HD /[E/V<M)^'.@_L]? ?0_@]=W>H?"
M31O@S\+])^%M_?I=Q7U[\.=.\$:'9^"+N]CO[6ROH[NY\,PZ9-<I>V=I=I,[
MK<VL$P>)/9JXCX9IXMB^&_P^B\?:;X<T?QW'X(\*)XUTCP>SOX2TKQ:F@V"^
M(]-\+-(J2-X<L=8%Y:Z(TB(YTR*U+*K$@=O0 4444 %%%% 'X!?MF?\ *P#_
M ,$:/^S?O^"A?_J!^"J_?VOP"_;,_P"5@'_@C1_V;]_P4+_]0/P57[^T %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?C3_P6L_Y('\*_^RN'_P!03Q?7[+5^-/\ P6L_Y('\*_\ LKA_
M]03Q?7XK](K_ ),IX@_]B>C_ .K/ GR7'?\ R26=_P#8-3_]2:!_))_P<V?\
ME2_X)X_]F#?#[_T^:C7\R%?W1?\ !8W_ ()%_ML_\%#=5_8@^)7[,7@SP7XD
M\)^!_P!C/X=>"?$%WXE^(GA[P==P>(9)9=<%O!8ZS)'/<V_]G7]I(+J'=$9'
MDA.UX_F_&7_B&*_X*W?]$J^$_P#X?+P-_P#)%?\ 7C^SZ^D]]'3@GZ%_T=^%
MN+_&_P +N&N),F\/\/ALVR+.^-,AR[-<MQ$\SS/$0HXW XK&T\1AZLJ%:E54
M*L(R=.I"5K23/"JX+&5*CJ4\)B:E.='!.$X4*LX22P&$@W&48--*491=GNGV
M9\L_\$+O^4MW[#G_ &535O\ U7GC2O\ 54\=?\B1XR_[%7Q#_P"FB\K^$O\
MX);_ /! G_@I+^RS_P % ?V8/V@_C#\._ASI/PS^%WCR_P!>\7ZCI'Q;\):]
MJ5IIMQX0\2:/')::183->7TAO=3M4,-NK.$=I#A$8C^[3QU_R)'C+_L5?$/_
M *:+RO\ ,G]K1XG^'/BKXX>'>=^&O''"_'>49?X483*L=F?"F=8#/,%A,RAQ
MAQ9BY8'$8G+Z]>E2Q4<+BL-B'0G)5%1KTJG+RSBW[V4T*]#*<V5>C5HN;Q$X
MQJTY4Y2C]1I1YE&:3MS1DKVM=-=&?YLD'^J3Z'^9J6HH/]4GT/\ ,U+7^2Q_
M@%'9>B_(_L0_X()_\F3>(?\ LOGQ _\ 4?\  ]?CA_P>)?\ )//V"_\ L>?C
M]_ZCOPNK]C_^""?_ "9-XA_[+Y\0/_4?\#U^.'_!XE_R3S]@O_L>?C]_ZCOP
MNK^_?V9?_*;'@/\ ]A?&O_KL>-#_ &P\'?\ DP'A_P#]DQDW_J53/X7J^C?V
M.O\ D[O]E7_LY'X&_P#JSO#%?.5?1O['7_)W?[*O_9R/P-_]6=X8K_K3XX_Y
M(OB__LE^(/\ U4XL^DI_Q:7_ %]I?^G(G^RG7^<;\;O^2U_&;_LKGQ-_]3?7
M:_T<J_SC?C=_R6OXS?\ 97/B;_ZF^NU_P=XO_EW_ -O_ /MI_*?T]?\ D3>&
MW_8SXD_]1<G/,:_J2_X-XO\ DG'[3W_90/A__P"HOJU?RVU_4E_P;Q?\DX_:
M>_[*!\/_ /U%]6K+#?Q5Z2_(_F_Z(G_)^>$_^P+B;_UF\T/:?^"^O_)GO@;_
M ++SX3_]17QM7\@E?U]_\%]?^3/? W_9>?"?_J*^-J_D$IXG^+_VZOU/7^F;
M_P GLQG_ &3?#_\ Z9KDD'_'Q:?]?EG_ .E45?Z2_@S_ )$_PG_V+6A?^FNU
MK_-H@_X^+3_K\L__ $JBK_27\&?\B?X3_P"Q:T+_ --=K6F%^U_78_7OH$?[
MWXH?]@_"'_ISB0_@P_X*)_\ )]7[5?\ V6+Q+_.WKXSK[,_X*)_\GU?M5_\
M98O$O\[>OC.N6?QR_P 4OS9_$7B#_P E]QO_ -E?Q+_ZNL:?T'_\&]?_ "6G
M]HK_ +)AX2_]2JYK],?^"T/_ ";?\/?^RS:5_P"H1XYK\SO^#>O_ )+3^T5_
MV3#PE_ZE5S7Z8_\ !:'_ )-O^'O_ &6;2O\ U"/'-?E/CY_R9'Q!_P"Q'/\
M]3<*?Z9_1W_Y1>PO_7[B7_UHL4?H=^S%_P FW? #_LB_PP_]0K1:]RKPW]F+
M_DV[X ?]D7^&'_J%:+7N5?IW"O\ R3'#G_8AR?\ ]5^'/ZYRW_D78#_L"PO_
M *8IA1117O':%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@G4/$-MKPN]7T?[)#%9SV=_+J)L](U;\YO\ @AL/^"?>H_M?_LN/\-(OVK_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME_$CP#X.\>Z;93.));/3_&'AW3O$-G:RR*D:O);V^HQPNZQH&9"P10=H[ZN
M^$_P^T[X2?"SX:_"K2+Z]U32?AEX \&_#[2]3U(0#4=1T[P9X=T[PY97VH"U
MCAMA>W=MIL5Q="WAB@$\D@AC2/:H[^@ HHHH **** /P"_;,_P"5@'_@C1_V
M;]_P4+_]0/P57[^U^ 7[9G_*P#_P1H_[-^_X*%_^H'X*K]_: "BBB@ HHHH
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M!_N."_[!,-_Z9@%%%%>R=84444 %%%% !1110 5_G&_&[_DM?QF_[*Y\3?\
MU-]=K_1RK_.-^-W_ "6OXS?]E<^)O_J;Z[7'B_\ EW_V_P#^VG^?WT]?^1-X
M;?\ 8SXD_P#47)SS&OZDO^#>+_DG'[3W_90/A_\ ^HOJU?RVU_4E_P &\7_)
M./VGO^R@?#__ -1?5JRPW\5>DOR/YO\ HB?\GYX3_P"P+B;_ -9O-#VG_@OK
M_P F>^!O^R\^$_\ U%?&U?R"5_7W_P %]?\ DSWP-_V7GPG_ .HKXVK^02GB
M?XO_ &ZOU/7^F;_R>S&?]DWP_P#^F:Y)!_Q\6G_7Y9_^E45?Z2_@S_D3_"?_
M &+6A?\ IKM:_P VB#_CXM/^ORS_ /2J*O\ 27\&?\B?X3_[%K0O_37:UIA?
MM?UV/U[Z!'^]^*'_ &#\(?\ ISB0_@P_X*)_\GU?M5_]EB\2_P [>OC.OLS_
M (*)_P#)]7[5?_98O$O\[>OC.N6?QR_Q2_-G\1>(/_)?<;_]E?Q+_P"KK&G]
M!_\ P;U_\EI_:*_[)AX2_P#4JN:_3'_@M#_R;?\ #W_LLVE?^H1XYK\SO^#>
MO_DM/[17_9,/"7_J57-?IC_P6A_Y-O\ A[_V6;2O_4(\<U^4^/G_ "9'Q!_[
M$<__ %-PI_IG]'?_ )1>PO\ U^XE_P#6BQ1^AW[,7_)MWP _[(O\,/\ U"M%
MKW*O#?V8O^3;O@!_V1?X8?\ J%:+7N5?IW"O_),<.?\ 8AR?_P!5^'/ZYRW_
M )%V _[ L+_Z8IA1117O':%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 8UQX<\/7<\ES=:#HUS<S-NEN+C2[&:
M>5L ;I)9(&D=L #+,3@ 9P!4EGH6AZ=-]IT_1M*L;C8T?GV>G6EM-Y;D%D\V
M&%'V,54LN[:2!D' K5HH **** "BBB@ HHHH **** /P"_;,_P"5@'_@C1_V
M;]_P4+_]0/P57[^U^ 7[9G_*P#_P1H_[-^_X*%_^H'X*K]_: "BBB@ HHHH
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MRQ+J2R=YO];_ +0I8.ER<BS/+?8>R^J<W-S5>?VEN6/+>7^:O]GNO^?.]_\
M *Z_^,U_4A_P;RQRQ_#C]IWS89HMWC_X?E1-#)$6 \,:N"5$B*3@]<9QQGJ*
M_H7_ +#T7_H#Z7_X+[3_ .,U;MK*SLPZV=I;6JR$,ZVT$4 =@, N(D0,0. 3
MD@<"IIX?V<U+GO:^G+:]U;>^FNO7MYGYMX0?1+GX5\>Y3QM+CR&>+*Z&9T?[
M-7#3RYU_[1RW%9?S?6WGV.]G['ZRZMOJT_:<G)>%^=?B'_P7U_Y,]\#?]EY\
M)_\ J*^-J_D$K_16^.O[._P;_:6\(V7@3XW>"K3QWX4T[7+7Q)9:3>:CK.F1
MP:W96M[96U\L^AZCIEVSQ6NHWD(B>=H&6=B\3,%*_)G_  Z1_P"">?\ T;AH
M7_A6?$/_ .:ZIK4)5)\R<4K):WOIZ+]3P?'[Z,''/BMXAXCBW(,YX4P.7U<I
MRS 1H9OB\VHXQ5<%3J1JS<,'DV.HJG)S7LVJ[DTGS1CHC^&"#_CXM/\ K\L_
M_2J*O])?P9_R)_A/_L6M"_\ 37:U\$+_ ,$D_P#@GHC(Z_LXZ$&1U="/%GQ"
MX=&#J?\ D;<'# '!R#C!!'%?HG9VEO86EK8VD8AM+*W@M+6%2S"*WMHDAAB#
M.S.P2-%4%F+$#+$G)-T:4J?-S-.]K6O\[W2^7?R/NOHS^!'%?@O6XQJ\2YGP
M_F,>(J610P:R/$9C7=)Y7/-I5WB?K^69>HJ:Q]'V7LG5;<:G.H6CS?P*?\%$
M_P#D^K]JO_LL7B7^=O7QG7[?_MH_\$QOVX_BK^UE^T%\2/ /P.FU[P5XU^)>
MN:]X9UH>//AMIPU/2;OR?L]V+'4_%UGJ-J)-K?N;VTMYUQ\\2\9^9/\ AT/_
M ,%$?^C>)O\ PY/PH_\ FWKCE3J.4K0G\3^S+N_(_P \>.O"OQ/Q?&W&.*PO
MASQYB<-B>*N(,1AL3A^$.(*U#$4*V;XNI1KT*U/+Y4ZM&K3G"I3J0E*$X2C*
M,G%IGW7_ ,&]?_):?VBO^R8>$O\ U*KFOTQ_X+0_\FW_  ]_[+-I7_J$>.:^
M<_\ @C7^Q5^TW^RW\4/C3X@^/'PRD\":1XK\!^'='T"\?Q3X-\0"_P!2L?$$
MU[=6PA\,Z_K$]N8K5UE\RZB@B8$*CL^5'T9_P6A_Y-O^'O\ V6;2O_4(\<U^
M3^/J<?!+Q!333_L.>C33_P!]PO1G^A7@=DN<</\ T;*669]E.99)F5&IQ!.M
ME^;8'%9;CJ4*V?XBK1G5PF,I4<13C5I2C4IN=-*=.49QO%IO]#OV8O\ DV[X
M ?\ 9%_AA_ZA6BU[E7AO[,7_ ";=\ /^R+_##_U"M%KW*OTWA7_DF.'/^Q#D
M_P#ZK\.?U-EO_(NP'_8%A?\ TQ3"BBBO>.T**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#\ OVS/^5@'_@C1_P!F_?\ !0O_ -0/P57[^U^ 7[9G_*P#_P $
M:/\ LW[_ (*%_P#J!^"J_?V@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\:?^"UG_) _A7_ -E</_J"
M>+Z_9:OQI_X+6?\ ) _A7_V5P_\ J">+Z_%?I%?\F4\0?^Q/1_\ 5G@3Y+CO
M_DDL[_[!J?\ ZDT#]-OV>O\ D@/P._[(_P##/_U"]$KV"O'_ -GK_D@/P._[
M(_\ #/\ ]0O1*]@K]1X<_P"2>R'_ +$V5_\ J#0/HL!_N."_[!,-_P"F8!11
M17LG6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^/_ /P6A_Y-
MO^'O_99M*_\ 4(\<U^P%?C__ ,%H?^3;_A[_ -EFTK_U"/'-?C7TA?\ DRWB
M'_V(G_ZF84^5XW_Y)///^P-_^G:9^AW[,7_)MWP _P"R+_##_P!0K1:]RKPW
M]F+_ )-N^ '_ &1?X8?^H5HM>Y5^C\*_\DQPY_V(<G_]5^'/=RW_ )%V _[
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M )R='U[!?]!F%_\ "BE_\F'^JO$__1.9]_X9\P_^9S]K:*_%+_B(F_X(X_\
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MQ?"_P))I5PNLV_@O5O/T;47O);E+G4K&2XOY_#^C7ECJ4@!_4K17\X/[=/\
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MW]F+_DV[X ?]D7^&'_J%:+7N5>&_LQ?\FW? #_LB_P ,/_4*T6O<J_1^%?\
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MPG\:S>(3X'GO[+_A,(A</8Z+K5E&VI^&KG7M0>WL)?U_H _!K_B&>_X(R_\
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MDB@B5?US_P"(9[_@C+_T:MK_ /XD9^TQ_P#/=KZ0_8X^*_A?0OC!\4? EO\
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M\-?!O@9]"\.R7'CA/#^N:BFN^.? \^I:*=!UPS:=HUQKUYY=S)^VM 'X-?\
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M7_HU;7__ !(S]IC_ .>[7[R*254E2I(!*G!*DC)4D$C(Z'!(]"12T ?@V/\
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M^C5M?_\ $C/VF/\ Y[M?H-^RWXK_ &4_#VO^// /P=^%TG[/7Q.^*'CKQ?\
M&WXJ_"W7_AEJGPT\7>*?B3XB&G_\)M\0];\RP'A[QEK6LI9Z;)J?BGP]KNO6
MNHP06LHOI%4;?M^@#\&O^(9[_@C+_P!&K:__ .)&?M,?_/=K\C/^"T?_  0_
M_P"":7[)/[*_PR^)/P"^!/B'P+XS\1?MA_LK_"O5]83XY_'G7&N_ GQ)^)MC
MX<\::&;3Q'\2=7L(EUG1;B6T-]#:QZC9$K<6%W:SH)*_M8K\V/VE?$ND?'OQ
M-XO^!6L_L^_L^?%_PE\%O%O@#QGJEI^T9\6-/\&1/X^T>PTWQYX1\1^$_!R^
M"O&%^MKX>.H64NE>.]4?3K!M=AU.RTZWNO[)O)Z /D(_\&S_ /P1D))'[*NO
M*/0?M&?M,8'L,_%XG ]R:3_B&>_X(R_]&K:__P")&?M,?_/=K]CO@A\5+3XU
M?"_PO\2K/29-"C\0)JL,^E-J5EK<%KJ&A:YJ7AW5!IFO:9_Q+?$6B2ZCI-U/
MH7B+3L6.O:/+8ZM:I'#=K&GJ] 'X-?\ $,]_P1E_Z-6U_P#\2,_:8_\ GNU^
M0G["7_!$3_@FI\:/^"B?_!8+X$_$;X$^(?$'PN_9:^*G[,7AOX%^%S\<_CQI
M\?@?1?B'\$9?&/C&R34M+^)%EK&M_P!K^(P+\3^(=0U6XLD M+.6&V C']E'
MQ+\=6GPQ\ ^+/B#?Z!XJ\46'@_1;O7K_ $'P/HW_  D/BS4+&P42WB:'H@N;
M1]4O(;82W/V.&=9YHH)5MTFG\N&3X_\ V=?&?P2U?XD>)_BG\)?V2/BG\._$
M/[4X\*>,?B+\<;KX8>%?#^E_$F/P]X3>W\"^(?''B?3/%^H:CJ:VGAJ5-*\/
MSSV-Q+!%>16FR%7D* 'PE_Q#/?\ !&7_ *-6U_\ \2,_:8_^>[1_Q#/?\$9?
M^C5M?_\ $C/VF/\ Y[M?O+10!_')_P %E?\ @A)_P3!_90_X)C?M??M#_ ;X
M ^(? _Q>^%GPZTW7_ OBQ?CM\?M<;1-6F\;^%=(DNAI/B+XFZMHE\'L-2O+<
MPZCIMW#B8L(Q(J.OWQ\*/^#;K_@CMXG^%OPT\2:S^R[K]WJ_B#X?^#-;U6[_
M .&B/VDXC=ZGJOAS3;Z_NFB@^+44$;7-U/+,R0110JSE8HHXPJ+^CG[4'Q,\
M#^+_ !/\1?V7OCA^S#J7Q^_9RU+X7>"O$'Q:ETG2(?B1':VWBKQ3XECTRR\5
M?!^&T?Q#X@\)VLW@0ZM=:YX977;[2KNW@:YT#R-M]#]<?"#X@_##XC^!]-U?
MX0ZM8:KX)TD_\(O8)I^GZAI$6CR:#;VUJ=!ETC5;+3M1TJ?2K8VL#:?>65M-
M;)Y<;1+C% 'XT_\ $,]_P1E_Z-6U_P#\2,_:8_\ GNT?\0SW_!&7_HU;7_\
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M#^%?_97#_P"H)XOK\5^D5_R93Q"_[$]'_P!6> /DN._^22SO_L&I_P#J30/
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MQ&8XFM5]C3J5:TZ=+GG+V<)UJLXPM&56I).;****^B/!"BBB@ HHHH ****
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M4- TGQ5\$GL[:2\^*GP2N$OQI^MR:C)KFLZKHCZ?XXTZ^OX$UG1+;]J6!*D
ME200&&,J2, C((R.HR",]017\\-U:?#6"_OO [/\ +WQRWC74-*7]N6?7_VB
M$\2Z=XJ?Q%);)XUN/%,'PYD\*0?$+3[QP\=A:_&*/X:KK5LFF2:A:Z$9-&C
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M86RH "G@ 8Q5VH;9'BMX(Y)VN9(X8D>Y=45[AT15:=UC"QJTK R,L:J@+$(
MN!4U>R=9\6_ME^&O'OCS3_A+\.= M9;?P#XX\?RZ3\3/%=I\*/"'QFG\)PQZ
M%?W'@V]U'PAXWTW6M"L?"MWXH2VM_$_BY](N;GP[9K"8;O1UO9=6L_/OV1K3
MXB>"_BOXT^%&L?!3PA\(?"/A#X9^'9KW5?A9\/\ 0O"WPA^*WCV?Q?XDM_\
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MV K\?_\ @M#_ ,FW_#W_ ++-I7_J$>.:_&OI"_\ )EO$/_L1/_U,PI\KQO\
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M /\ H>\U]Z$_%'PTL_\ C8?!&S_YJO(O_F_S_JS/W&_X(K_\F5:U_P!GB_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@JF)QV/X9SO!8/#TW*,%/$8K$X&E0HP<YP@I5*D8N4HQO=I'[RU\)_ME>)?
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M[30+30M-T;0M"31M&LM-BM-(^S*LUU!=7$OS;=?\%'?AC>W.GWEY^R'_ ,%
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MABP5\N*-%2./!Y&Q %P>1C!YJ6OS '_!5KX.L0H_9P_;\))  _X8H^. R2<
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M*9_;CR3@?\88_''D_P#A-US?AG_@N/\ L?>-+?6;OPC\.OVSO$=MX=\5>(O
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MI-Q;A4ISE"24DXMQ;M)-/5-'RN/\:?IA95C*^7YI]%?&Y9F&&E&.)P&8SS3
MXW#2G3A5A'$87%3I5Z,ITJE.K&-2G%RISA-)QE%O^O[X"?M4?L.^&/@_X$T3
MP=^TC\)-"\/6>DR/9Z?\1OC!X"TKQX;B]U"\O]5O_%VGZIXAMKZV\0:QJUU?
M:OJ:RVMJKW-])+!:VUN\4*>O?\-C?LB?]'4?LX?^'P^&7_S45_%'_P ,H?'_
M /Z(Q^T#_P"(F?M@_P#T/U-?]E/X]Q(\DOP;^/\ '''&\LDC_LF_M@*D<<:E
MY'=C^S^ JHH+$D] :T_MOBC_ *)S_P GG_\ )')_Q'GZ67_2,W_E]C?_ )>?
MU[_M#?M8_L,ZW\%_B!I_C;]H_P"%NO>&FT>*ZO\ 3OA;\5O!?B/XC";3=1L=
M2TS4/!6A^'=;U+6M2\1Z-JUI8ZQI=OIVG:A.;FP1_L-VB/;R?&_PB_;&_9%\
M9_%7X<R^/OVQOBEX^7POJ=]KW@.W^,MG\*/AK\/O#WB!?#.L:=!XE\6ZSH6@
M^$9+O7;;1=2U;3-)?7+R"RCO]6>-M).HR6[P?QU6G[1G[,^H6T-[8_'.SN[2
MX4O!<P? W]K1X955VC8HX_9YP0LB/&WHZ,IY!JS_ ,- _LX_]%KA_P##%_M:
M?_0\UYLN-,PA*4)X/*X3A)PG">9X:,X3B^6491EB%*,HRTE%I-/1I,^QH\:_
M3TQ-&CB,/]"GC7$8?$4J=>A7H9#Q76HUZ-:$:E*M1JT\-*G5I5:<X3IU(2E"
M<)1E&3BTS_0[_P"&QOV1/^CJ/V</_#X?#+_YJ*_*_P#X*V_M"? /XD? 'P+H
MWP[^.'P@\>ZQ9_%G3=2N]*\%_$OP9XIU*UTZ/P?XRM7O[BQT/6KZZ@LDN;JV
MMWNI8E@6>X@B,@DFC5OY%/\ AH']G'_HM</_ (8O]K3_ .AYKJ?#7Q!^&_CK
M[:/A]XVC\8G2OLW]KA/ OQ:\%'31??:/[/+?\+2^'G@+^TA>?8[[']A?VK]C
M^R'^T_L/VK3_ +9\?QYC:O&_!^?<)XOZG@L-GF"^I5L5@\;AL5B:$'6I5>>C
M0]M+VDDX133BTHMR=DKGPOB?XK?3%X-X$X@XC\0_HF\2<$\'8&C@J6<\3YYE
M/$^ RO*UF69X'*\!+%8O%8>%"D\7F>.P. P_M)+VF)Q=&E&\YQ1_H-?LD:]H
M?B3]E_X :KX=UG2=?TO_ (5)X%TW^TM%U&SU6P_M'0O#]CH>MV'VRQFGM_MN
MCZWIVH:/JMKYGGZ?JEA>:?=QPW=K/"GT/7YP_P#!)#_E'O\ L_?]U6_]7=\2
M:_1ZOV'A^DJ&0Y)03<E1RC+:2D]')4\%1@FTM$VE=V/[&\.<]J\4^'O ?$V(
MH4\+7XBX,X7SVMA:,I3I8:KF^28',*E"E.=ISIT9XB5.$I^]*,4Y:MA1117K
MGV84444 %%%% !1110 4444 %%%% '\97_!>3]F[X^?M-_\ !4;X6>$?V??A
MGXF^*'B/P]^P#I7B#7-)\-2:;%-IFC3?M&^.]/BU"[EU74=,M5AEO7CMT59W
MF=P6$92-W7\!/C9\ ?CQ^S?XHM_!GQX^&/C?X5>);VQ.IZ=IWB[3I;--6TX2
M>2]_HVI02W.DZS:13_N)[C2K^\CMY_W,[1RD(?[%OV\O!_B[X@_MY_M@^!_
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M/_@*_P B7SY_^>TO_?Q_\://G_Y[2_\ ?Q_\:BHHYY_S2_\  G_F')#^6/\
MX"O\B7SY_P#GM+_W\?\ QH\^?_GM+_W\?_&HJ*.>?\TO_ G_ )AR0_EC_P"
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M #UD_P"^V_QJ.BO[&/\ G9)/.E_YZR?]]M_C7PI^R/)(/V@O^"GV)'&?VS_
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MV_QJ.B@#@_V"&9OVQ/\ @I069F/]O?LD<L2?^:! =_8 ?@/2OUDK\F?V!_\
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MK_-G]J[_ ,HAYQ_V7W W_J7C3Z_@?_D?T_\ L$Q7Y4S]4****_Y=3]I/RO\
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M[-?P!_ZRF4A1117I'Z@%%%% !1110 4444 %%%% !1110!_#E_P<=Q?$6?\
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M@CHGAS2I=8UW4K'3H;W6]7TW3(9KF-KN]MX=TBG_ !-/QU_T(N#_ /PDSO\
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M]A-\'&L=*TVW\+:5%9:;9F\^$=W>&UL;9(K:W-W=7-R88D,\\\I>5OT/P_\
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MM&E.5Y)M<J<C^Q?(]1^8HR/4?F*]M_X<Y67_ $D?_P""EW_AU/V>/_H7J/\
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MXE5\6/\ GSPY_P"'OT_Z@_/\/6WX]_Q-'X5_\_>(?_#,O_FP_>O_ (*5D?\
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MMEN&C2H8'%5:LEF.&DXPA0E*;45K)I7=EJ[:'Z>^$R/^$1\(\C_D4O#'<?\
M0!T^M_(]1^8K^1S1?VB/VT4T31$A_;I_:;MX4T724AMXM0^%'E6\*:?;+%!%
MO^%4CB*&,+%&'=W"(H=V;+'3_P"&BOVU?^C[OVG_ /P8?";_ .=/7_<E_P 2
MK^*\O>5'ARTM5?.];.SU_P!CWU[]/6W^6K^E%X61;BZO$-TVG;)DU=.S_P"8
ML_K0W#U'YU\]V1!_X*7?L1X.?^+(?MD_^BO@G[_6OYL_^&BOVU?^C[OVG_\
MP8?";_YT]>@?LN:U^TG\=/VZO@EH'C;]MO\ :FCO=,^#?[0>H:%XNT76?A/9
M>*O#T8_X5W_:6F:5<7/PDOM(&FZ\8[(ZO'>:1>7$ATRQ-E=6)2<S_P J_3B^
MC?Q]P_\ 1$^D'FO$6*X>RK):'AKG=''YC''XG,/J5/'*C@(8B6#P> J8K$0I
MUL53<Z>'ISJN',XP;31^A>$_CCP/X@^(O"G!W#3SBMGF>9E[#+Z6,R^.$PTZ
MM##U\;.-7$RQ,XTDZ.&J<LG%ISY8Z<UU_=S17X1?\,]?&_\ Z2._M\_^%E\
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MBJU8J,+2YE=W5K']9>1ZC\Q1N'J/S%?R7_\ #17[:O\ T?=^T_\ ^##X3?\
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M1110 4444 %%%% '\P/_  =Y?\H;?&G_ &<!\"?_ $^:K7^<)_P2=_Y2F_\
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MO_JD\43Y[%?\E1DW_8FS_P#]2\A/N&BBBOS\^A/A+]N#_D8/V"/^TA_P+_\
M4%^,-?=M?"7[<'_(P?L$?]I#_@7_ .H+\8:^[:_0>)O^2(\-/^P+BG_UI<4?
M-97_ ,E%Q3ZY)_Z@3"BBBOSX^E/@G]G?_D^G_@I9_P!?W[%'_K/6IU][5\$_
ML[_\GT_\%+/^O[]BC_UGK4Z^]J_0_$__ )*7+/\ LW'@U_ZY[@0^6X0_Y%>,
M_P"RCXL_]:;-0KY _P""@W_)B7[8?_9N7Q6_]16_KZ_KY _X*#?\F)?MA_\
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M0,"%<QXW_P"1)\:?]BAXG_\ 3%?UT]<QXW_Y$GQI_P!BAXG_ /3%?U_9^/\
M]QQO_8)B?_3,S^=L!_OV"_["\-_Z>@87P?\ ^21?"K_LF_@C_P!1S3J]$KSO
MX/\ _)(OA5_V3?P1_P"HYIU>B5S9'_R),F_[%.6_^H5 Z,Z_Y'.;?]C/'_\
MJ55"OG/XF_\ )=O@1_V*?QJ_] ^']?1E?.?Q-_Y+M\"/^Q3^-7_H'P_K^>/I
ME?\ *,GBW_V),L_]:7)#^]_V4/\ RL7^B3_V=; _^JG-CTRBBBO^;H_]'8*_
M>G_@BU_R9GX@_P"SI?VF/_4\6OP6K]Z?^"+7_)F?B#_LZ7]IC_U/%K^7_IC?
M\F,Q'_9><)_^J[BD_P V/VC/_(H\'/\ LI^*?_6>IGZST445_DN?YC'Y[_\
M!5O_ )1X?M0_]BCX7_\ 5D^"J_G\G_UTO^^W\Z_H#_X*M_\ */#]J'_L4?"_
M_JR?!5?S^3_ZZ7_?;^=?]:G^CO\ _)@?I ?]GBR;_P!8G+C_  ]_:N?\G \)
M_P#LD<__ /5OA"*BBBO^A0_RA/WR_P"#:?\ Y/"_;B_[-]_9N_\ 4X^,=?T2
M_"S_ (*(_"OXF_M;_M)?L=R>$_&G@[Q_^S] M[HVO^)(=,C\*?&NQTKPWX6U
M_P ?_P#"L[ZVO99KK5/AJ_C;PE9^+=#U*&TU."W\1:1K-M#/I5Q+<0?SM?\
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MB&TTTZ7\)OAO<^)H[3X@A?L^K:CX_:'07N!8WTT/Y?\ [:WP%_:!_92^#/P
M_9F^-^JZ?XX\-_"3XM_M51? #XN:9:^&_#\/Q$^"OCF7X(?$/2K6Y\ >'[^\
M/P]N_AQXJ\3^*_AO;>')UCL5\/>&M N=#EN=,EC9/Q+C&G160<0QC**]GB:=
M3!MU(N,L'ALYP^7SIIPE4C5K5JLH8S#.4Z<ZN7QGB(0G27._R7Z9;J/Z,W'4
MFKS>'X(CC4HM26*Q7&O"V,C.TW#EI8>G%8:M&E&JX8VM*C5E"5)Q7UY^Q_\
M\FT_"O\ Z]?&7_JR?&E?25?-O['_ /R;3\*_^O7QE_ZLGQI7TE7_ "A>./\
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M^(7B7P1X-O[>\DO5\8^"/"/B#1/$&JZ-J=I;37^BW&H:KI9N+/1[]X_Y2?\
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M&D958$_3/_#F7_@K/_TC@_;/_P#$>?B7_P#,]0!^R'_!PG_P<3^!_P#@JO\
M#GX>_LQ?LS?"[QWX!_9\\)>.K3XJ>+_%?Q;CT/2_B)X\\;Z+I&M>'?#.F6GA
MCPEX@\3Z)X;\(:#:>(/$.I2-=^*=?U#Q3>:EH5W<:;X3N/#3VNI?$'_!MO\
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M#2;2UNHA+#X&DAE$<\4B"2*1XW"AE8J176_\*=_:3_Z,_P#VS/\ Q$_X\_\
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MLP?]"!^VU_XKV_;9_P#G$U^FE%?JA_G$?F7_ ,/9?V8/^A _;:_\5[?ML_\
MSB:_C%_;2TOXL_%[]OS]M_XY?#_]EK]L_6_AE\9OBU\/O%7P[\0/^Q[^T3ID
MFMZ)H?[/GPD\":K=2:3JWP\LM8TQK;Q3X6US3E@U2QL[B>*TCO8HFM+F&5O]
M&ZBOLN ^.,W\.^(J'$V24,OQ./P^%Q>$A2S2CB*^$=/&4O957*GA<7@JSG&.
MM-JO%*6LHR6A\?QUP3E/B#P]7X:SJOF&'P%?$X7%3JY96P]#%JI@ZJK4E&IB
M<+C*2@Y)*:=!MQTC*+U/\P__ (5E^T#_ -&D?MG?^(E?'K_YAJ/^%9?M _\
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ML'Q%@<%"A47 T:4</5H\39A+%0G1J5)U*.#=*K1C3K0Q'#4^D/QQ4S'"YG+
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MM1(@5KNUA6Y!\VV,L7SUX_\ \*R_:!_Z-(_;._\ $2OCU_\ ,-7^GA17^O\
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MQ")&:62-&_(27X:?']I'9?V2?VSB&8D?\8D_'H<$_P#8C5_IV45_H7]#;AS
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M_P ))_PE'@/4_!/]F_\ (.\-?V/]A_M'^T_MG_$U^U>3]B^RV_F?:X_Z_O\
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MR8FK6IX?"PH?P:?\*9/_ $,@_P#!,?\ Y;4?\*9/_0R#_P $Q_\ EM7]Y?\
MPZ0_X)[_ /1OW_F5OC=_\\FC_ATA_P $]_\ HW[_ ,RM\;O_ )Y-8_\ $%<+
M_P! ^6?^'#-__D/+\^[/4_XGZ_;O?])N^%__ (J#P0_^IC/Y"_\ @G!\73_P
M3[_:G\6?M+GP^/BY_P )1^S]K'P*_P"$*_M7_A ?L/\ :WQ&\%^/_P#A*?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'$\T:R,K.H/L&9\ZC_@J'_P3OYS^V7^SV/3'Q'T(^G_3<?ES_/#C_P %0O\
M@G?U_P"&R_V?3R!\OQ%T-N3_ +MP>/?H.YKWJ+X2?LRSZW>>&H/AC\"9_$>G
MVD-_?^'X?!?@"77+*QN"!;WMWI*:8U_;6LY($-Q-;I%*2 CL35RT^"7[.M_-
M>0V/PB^"UY<:7="TU"*T\ ^!KB;3KU8XK@6U['#I+O:70BEAG$$XCF$<D4H3
M:R,0#YX_X>A?\$[\'_C,K]GWCU^(NACGT.9^/RH_X>A?\$\,X_X;*_9\]O\
MBXVA\\9_Y[_3H3P<^@/T5>?#O]GC3]7T[P_J'@7X,6.O:PDLNDZ)>>&/ ]MJ
M^JI"3YTFG:;/8I>7R1$'S7MH91&0=Y&#6W_PI7X-_P#1)?AG_P"$'X6_^55
M'RT?^"H7_!._M^V7^SY^/Q&T,=.O_+<]*:?^"H?_  3R'3]LG]GK!QU^)&B#
MCO\ \M3^'//M7TEK7PR^ /AS3KC5_$7P^^#V@Z3:A3=:IK7A/P7I>G6P=@B&
MXO;ZP@MH0[$*OF2KN8@#).*P]*\,?LMZ]I6IZ[HGA[X!:SH>BAFUG6=*TGX=
MZCI6DA(O.=M3U&TMYK.P"P_O6-U-$%B_>'"<T >%?\/0O^">7_1Y/[/?X?$C
M1#^?[WCC_"E_X>A?\$\?^CROV>__  X^A_\ Q[TY_3WKZ.7X:_L^MIEGK2>
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M@O"O_P JJ /F;_AYM_P3V_Z/*_9W_P##G>&O_DVC_AYM_P $]O\ H\K]G?\
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M=J^I:S:/;6OA:><7UY=7.I2K--=%=D2*J G)K]4J /P;_P""GOP!_9]\7?\
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MQ;^ G[:VD>//AKH$OCC]E'7?@*GB5_V<?VC[S7/ OC32/BUX[\/:;H=WX/\
MC#X<T+0->TG4-$N96'B72)=*7[7!&]@9WL[V4U]2?%O_ ())^$OB=\/?&7A*
MV^-/B70=>UO]L;5_VS?#NM:CX*\)^,_"VE>--5LY-//@[Q9\-O$(E\*_$?P5
M#:SSE=/\2QEQ>?9[]2L]K'G@]-_X(PZ FB_M3V?B']I#QCKVL_M::#\#-/\
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MSPA\")_@/^TSX]^$_P =_P!G^W^+F@>&?C5!X*\'^*8O$_@'XR^-[[QWXD\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOC[JWP<M?CE^V;^T3H?_  49^)G[('[1VD?!3X,>+?$WP>US0O!'AW1=*M]
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MK;1=:27RVMH]5U2V@O;6YCMK^XB 8??5 !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPCH.NS>#=4@B2"&_\,2:G87+:'=10QQQQS::;9T6*(*1Y:;?1Z*T.(\D\=?
M+X&_%#Q'X<\8?$GX._#'Q]XL\(2++X6\2^,? OAGQ)KOA]XYA<1G2-5U?3;N
M]L!'<*)XUMYD6.<><@63+5+\3?@3\$_C3%HL'Q?^$?PV^*$/ARZ%[X?C\?\
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MV-BM#<QHS1L,@&OQ 3_@V+_X)LQQI"FJ?M/K'$JK&@^/.K;45%"J!_Q)\G:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img81402019_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img81402019_8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *8!0 # 2(  A$! Q$!_\0
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M3^)_+\D1/U'T_J:93WZCZ?U-,H7Q2_[=_(D*CD[?C_2I*CD[?C_2J CHHHH
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M7C4A*A.<*-3#+$1E2^L.46E^]J]1]1_.IZ_$']JS]NS]J7X@?MFI_P $[?\
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M1_\ X3[PAH_BO^P_[8_L_2?[6_LG^UOL']I?V7IOV_[/]J_L^S\W[-'^)O\
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MH_G4]?SG_"3QA_P7)_;Q\ ']H7X=_$[X ?L%?#GQ5KFJ2?"SX0>+_A5<^/\
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M3=1TQ-)M=5U;^SH-(U.36[#0KR"RUS1-9BM].USW7]M']MG]J?Q'^VU\)O\
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M8NI5P6)4\VRG"8;,<)6HRH^WI.G7QE"5'$TU[.JJD*^'A7HKDY<1GWUE9-/
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M:CN_LO\ PG__  GO_"/_ /"#?\3W^Q?,_P"$5_X0O6_^$F_Y^=O_  DGA_\
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M4?ASX,TA;ORH] \-_8K1-*U?Q#%'+HWVD(GB1;F]\5:3I1L]%6PUS6]-]O\
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M/#7[/_@KQK=W>G7OQ5U/PX5;3]172M4&DZ7:G7P?#<%[JUM_;.VWD$L?!_\
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M=1M-$BGOO#USK-U=:O)^NE?G?&^:95G57)<QR[%5ZE?_ %=R/+<RP5?"2H/
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MQQZU9R7?](]C_P $N/@!X<_;QO?^"AGP_P#&'QB^&/QE\06<]EX\\'>!=?\
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M^"MG[7WQ*^)/B7XU:%K_ .S;\/O&'A74?BE=7?CO0/$GAA;6>&Q\-67B:_\
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M&U\.W6KS7\-_;M-%<V5]I@WVDMH9_MBSPBT6=YHE?\<_^#=#_E&KX9_[*_\
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M_P!!M?#7[9'_  3^^ ?[;,'A*_\ B4/&7@[XB_#N\2\^'GQC^%/B%/"'Q/\
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M?_!1*^6%%N[G]M3QQ:3W !\R6VLI=0FM86.<;();^\=  "&N),DY&+/[2_\
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M3ZMMME0A"G&,*<8PA%)1A"*C&*6RC%)))=$DD?S[_P#!03_E,!_P2U_[CO\
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M'@W3 0?/O^/^FMO_ /(M3+$4W;XM&GL'L9^7WGGE.3[P_'^1KT3_ (1#3?\
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M<DO+[_Z_I/ROR50O]X_A_(5V?]@V?_/2Y_[[B_\ C--/AZR)SYMU_P!]Q?\
MQBE&I%.[OMV] Y)>7W_U_2?E?C*:_P!T_A_,5VG_  CME_SUNO\ ON+_ .,4
MA\.V1&/-NO\ ON'_ .,4Y58-Q:OH^WF@<)-/;5=_Z_I/ROPU%=O_ ,(U8_\
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M]_K;_P"1*8? >D$D_:=2Y_Z;6O\ \AT?6:7>7W?U_2?E<]C/R^\\EHKUK_A
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M_A]/Z^1,J%1N.VCN]?0\/HKV[_A6NA?\_>K?]_[/_P"0*/\ A6NA?\_>K?\
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M](_\*>\,_P#/]KO_ ($Z?_\ *RC_ (4]X9_Y_M=_\"=/_P#E95?7\/WG_P"
MO^O^&?E=RPM5JR4=_P"9=O\ @GS=37^Z?P_F*^D_^%/>&?\ G^UW_P "=/\
M_E92'X.^&2,?;M=_\"M/_P#E71]?P_>?_@+_ *_X9^5Y6#K)K2.Z^T?,]%?2
MW_"FO#'_ #_Z]_X%:?\ _*NC_A37AC_G_P!>_P# K3__ )5T?7\/WG_X"_Z_
MX9^5R6$K-MVC_P"!+L?--1R=OQ_I7TU_PIKPQ_S_ .O?^!6G_P#RKI#\&?"[
M8S?Z_P ?]/6G?_*NCZ_A^\__  %_U_PS\KM82MRM6C=N_P 2\CYBHKZ;_P"%
M+^%O^?\ U_\ \"M._P#E51_PI?PM_P _^O\ _@5IW_RJH^OX?O/_ ,!?]?\
M#/RO/U.MVC_X$CYA?H/K_0U%7U$?@MX6(P;_ %__ ,"M._\ E53?^%*>%?\
MH(>(/_ K3O\ Y55<<QPR6KGO?X'Y!]3K=H_^!(^7Z*^H/^%*>%?^@AX@_P#
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MLLL*FXU"&2Q7U/XZ_P#!4+]ECX!>&OV9O&_B/4?&WBOP-^UMH7B77_@SXL\
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M\/:A\#/VT_A5\-OC%XDT'PE\'OVF/B_^S9X@\%_LW_%'7O&-W;6?@*U\)?$
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M+90V^H:5)?\ I_[&?[</P9_;C\$^+O%GPJT_XA^$=;^&_C*_^'GQ3^%GQ?\
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M4JT\;B\/A94Z\Z$?:U5[_LZ.#K5)/3W/9QQM%U%)^Y2DJTFJ?,X_M=17YI_
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M!W[3LWQ=^$7@3X?Z[:3:YH%_%JEQK.C?%_4]3E\.^(FUSP[/!\-S<KHELO\
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M;^$YM+^('@_QCJ"2Z5XKT[QMI'BJQB75)?$46E76L:?:E_W;HKYS*N+<TR3
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M3QR52&5\/8"C5>%O"%?A[%8C&4,5.DL0G4IUZU:"J895*;C"G*,<0W44J?\
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MPTI5L+*O1=>E5G5A2JT*=:-5PJRY*D.5U(_C'^P%\ _ O[4?_#PV']E'QO\
MM.?LG?\ !//XR_$?X&:U^S;XG^!.K>)OV=_$C^/_  AH]Q=_'+QK\ !XHT2_
MOO"'PR\=ZM:^&M%UF&+PS86>LVT-WX<M=,T"/P^VF6'HG[97[%WC#]EG]F#X
M8>-/#7Q3_;._;DT+X ?MQ_L__M;_ !0T3]H/XF_\+_\ BI_PJSX:KJ6C>+M(
M^'D'_".>'Q/I6@1:I:^.IO#K65V#<Z7J.KM<6RPM<6G]!=%=E7Q S)YS''TJ
M4O[-6(P%6IEF*K4\37Q4,#@,)ECEC,V6%H8NMCL7A<)&>*QU.%#GQ=2IB8X>
M#?LSGAPOA%@'AIS7UMTL5".,HTY4:5"6)Q5;&<N'P+K5*%/#4*U9QH8:<JG+
M0C&BZLK<Q^17[.W_  4,_9A_;M_:M\'K^RI\%A\<]/\ AS\+_&]U\0/VQ/$/
MP[\0?#Z3X$3ZQ-I$.D?!?PKJGQ!^&-EXFUWQ%\1KTRW7B+0=&\1>&M'M=&T.
M36UD\5K:7-MI_P"#_C_]O3QM\=O!OQK\(_M*?MU_MQ> /VK[S6_B?X8T7_@F
M1^R%^S)<_#GQ?X<N;:_U?P]X7\"Q?&&#X:^,=0\:^']1TYK/7==\3:OXSLM9
M?1+Z]AL]#N[ZRTR*_P#[5:*VRKC#(<GQ5:KAN%JU2A&C@*> >*S?!8_,<+/!
MU\7B*WM,=F'#N,PT:..JXJ*Q$,FRW(\3"GA,.L/C*52IC:N,SQV09GCZ%.%;
M.J<*LJF*EBE0P&(PV$K+$4\/2I\F&PN;4*LJF&A0DZ4LPQ>94I3KU75H5(1P
MU/#_ ,D6F_$SP?\ "_\ X)-_\$.?CQXSO=3L?A/\#?VK/@[XL^+7B_3?#?B7
MQ);>!O#WA>/XS>'M<U/6]/\ #6D:OK$<%EKK1Z,%AT^:6ZU.>ULK..XN+JVC
ME/VV[#X1>!O^"@GQ&_:A_:0_:V_X*!_LG_LI?M7? ;X >)/@7^TQ^QAXN\9>
M#_AUK-[X8\+WFGWOPT^+/_"%_#+Q]XN;5KVUNK'QI\/+*]T* 6L'B'Q'->2(
MMZL>G?UNT5VT/$>G1QV(QBR?$P^N5.(:>*5#-<-&JL!GF<T<]I4L)5Q&28NE
M0QV!QM&,98VMAL7A\7AFZ3RZA)RJ2YZG"<YX:EA_K]&7U>&52HNI@:LH/%9;
M@)Y;.I7A2S&A.IAL3AZDFL/3JT*M"K::Q=1)17\=5[\-OV?KGX!6OQD^!WQ!
M_;U^/O@7XV_\%,_^"=VB:E\;_P!O*YT76K/X[0> _&5QI=EXI^$5QK'A/PA\
M4?$?@JQT?7HO!NJZU\1_#>GZ==3:):^'_#$$B>']<2']I_VG88?^'N7_  2Y
MN/*C^T'X6_MTPF?RU\XPK\/_  "ZQ&7&\QJ[,XC+;0S,P&237ZW45YV8<=U,
M?B8UYX&M)4\'Q+@:;Q&80K5G1S[(*.04'5J4L!AJ4IX"A0I59>RP]"EBG'V-
M*E@J:CR]>%X:AAJ,J4<333GB,GQ,O9865.FJF5YI+-*BA">*K34,54J3IQYZ
MU2='F=2<\3-RYOY6_P!J@ _!7_@Y+! (/Q ^!X(/((/P3^$.01W!K] O^"@.
MG:?9_P##G:"TL;.U@TW]O_\ 9JL].AM[:&"+3[1/A=X^@2ULHXD5+6V2&&*%
M8(%CB6**.,*$10/VBHJ)\;N4\LFLM:67.LW'Z[_']KPGDO"^_P!47L^590\;
MM4NL2\+I[+ZQ5<>'%&&,B\8G];5-7^K?P_9YYF&<[>W?-=X]8?>-G15;7G]E
M K\3_P#@G)\*;;XB?L%?M=_LC>,+B;3?$EA^T+^W?^SY\3[I74:G%J/Q"\;^
M+]5AU^7#2SEM4\&_$7P_KFG7,TD[WEA<VES%/-!)$U?MA7S;X4_9VMO ?[2_
MQ/\ V@?!WB<:1I/QP\&>%M+^+GPWDT"*YL_$7Q%^'^S2? WQ3T;Q#%JEG)H&
MKQ>"+G4?!GC/2[G1M=A\766G>!;ZTO\ PU<^%-13Q5X659I#"9;FV"E5>'K5
MJV59K@*ZC.7_  HY/7KJC0ER1DX0JX;,,9.,Y)P6)HX:-3DA.56GZ>-P<J^,
MP.(4/:TZ=/&X+$TG)1_V7'TZ3J5%S.*E*%;"X>,HIJ7L:E64.:45"?XZ_LO_
M /!5GX(_L+_ _P"'G['_ /P497XB_LW?M#_L[^%](^#]L-5^%'Q7\=^#OCIX
M:\"P/X7\&?$GX0^,? ?@SQ-:>(M!\4Z%I.E^=-K T66'7WO[%3<K:S7$?Z/_
M +!O[1'[0_[4^F?&+XS?%'X/7WP/^!NO^/K6Q_91\(^.O#.I^%_C7KGPQTG1
M;>UU;XA_$O3+W6KR#3K/QMX@$NI>"])&C:1?6>DI=7#7GB+0KWP[KU[]^T5V
M9OGN2YA3Q];"\.O!9MFU95\=C*V:/&X/#3E76*Q']B8#ZAA:N7+$UXI3>,Q^
M;3IX:53#4)TX5)R?/@,MS'"3PM.OFRQ&!P--TL-0IX+ZOB*L53]C2_M'%/%5
MH8MT:;;BL/A<#&=51K5(SE"*/R4_8\_Y2A?\%>_^O_\ 8=_]9XNZD^+H#?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZNFNZ:T&L)B$U_PJ8YVMHZ>66>VCMER>MM;-/5V:TL4445Y)W!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5^,7Q?_X+A_LC^ O^"B?[.G_!-+X;ZC;?'CX\?&+Q]XC\!_%"
M\^'WB;3IO"_[..IZ!8ZA,ND^/]6CL]1L=5\=W.I:1K.EZA\.]'OD\0>$9-)N
MG\:GP]<7>B66K_L[7\K_ /P55^&?PY^&?_!9C_@W<@^'/@+P=X#A\9?M.?\
M!0;XB>+X_!_AK1_#:^*?'WC?0/@!XB\8^-?$8TBSL_[;\5^*==O[W5]?\0:E
M]IU75M1NI[N^NIYI&<@'W1^W3_P6>LOV3?V@/'/[.'P=_8[^/'[9?CSX$_ F
M/]IO]J.Y^$>J>$?#VA? 7X*22N\>IZC?>*+GS?%?CJYT>&3Q)I_P]TFVM=4U
M30)(=0TZ]N4AU8:3;^.G_!:_X5^&O!?[$=S^R7\"?BK^VY\8O^"@O@C7/BA^
MSK\$OASJ/A;P)K,OPW\&^'+7Q/X\\3?$;Q3XSO3H?@&3PM;7%QH\VEWB7\]Y
MXGTC6]%CFA.F7%V/QS_:F_:J^$__  2Y_P""LW_!;/XB?MA3:I\/O!_[?G[$
M?P+\2_LD>*H_"_BO6].^+7B/X*?L_6WP4\5?"K0]5T;PYJ&F67C:Z\<3(US:
M:EJ=CI>C:0FB:SXAOK"TUK37KY@_9M>]_P""27Q,_P"" O[3O[=_A;Q/\'/@
M4?\ @G1\?/V>OB)\1]8\%>,]0L?@+\4?'_C+QG\>O!'A[XJ:9I7AC4O$/A'Q
M3XE\.^--'\)V_AB[TJW\00ZZ?&$,UJ=.\%>++G3P#^OC_@GI^WC\+/\ @HQ^
MS;HO[1/PNT+Q=X(:/Q/XH^''Q)^%OQ"L8M+^(/PB^+'@6\BL/&?PZ\::=#)(
MEKK.D27%CJ%ON\B>ZT35M(O[JQTRZNIM-M/N"OYI_P#@@A\&O%7Q;_X)[_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%? _CS_ (*4_LM?#OQQXJ\(:[K?
MCBZT+X=>++;P%\5OB]H/PZ\5:W\$OA+XXNKJUL1X6^(?Q+LK%]#T74[*\O[&
MUU^6W.H:;X4GNTB\5W^B20W2V_W@MW:/*L"75NTSVXNTA6:-I6M"P072QAB[
M6Y<A1, 8RQ"ALG% %BBN ^)7Q0\#?"/X>_$'XI^/M?M-#\$?"WP?KWCSQSJ[
M%KG^P_#'AO1[O7M5U":UM1+=2&/3+&YGM[>*)[B\*+%;1RR.BGB?@;^T%X1^
M/?A2[\8>'?#WQ!\'Z=9-I)EM?B?X.U#P+J4MOKGAO2O%>FWUI;:F[Q7MA-HV
MLV4LEW:W$T5O<_:+*X,5W:W$,8![K1562_L8C();RTC,,!NI1)<0H8K4,5-S
M(&<%( RLIF;$88$;L@BI'N;:.6"&2X@2:Z\S[+$\L:RW/E)YLOD1LP>;RX_W
MDGEAMB?.V%YH FHKRSXA_&?X??"W6?AQH'C+63I^J_%;QUIGPX\%VD-O+=R7
M_BK5[+4=0L+2X6 ,;*WGMM*O6%Y<!;</$(R^Y@*\$^//[=GP7_9Z^*%C\'/%
M6B?%SQ=\0+KX;K\7+O1/A5\+/%'Q(FT7X>/XDO\ PG'XCUH>'+:YEL[:77-,
MO[.&!(I[N8VLAB@?Y0P!]G45Y[\-/BM\._C#\// OQ6^&WBS2_%7P^^)>A:7
MXD\#^);*22&T\0Z1K-I]MT^>TAOH[6\2>6WWF6PN;:"_M98I[>ZMH9X)HT[&
M^U;3-,BO9[^_M+2/3M.N-6OC-/&KVNF6JR/<7\T>3(MI"L4F^?9Y8*,N=PQ0
M!HT5X_9?'[X-ZA\$4_:1@^(7AZ/X&/X&F^)7_"R[RXDL/#<?@:WT^35)O$<\
M][#;SP626$3SE9K=+DX$0@,S+&?!/@Y_P4 ^ 'QG\?\ A[X9Z=%\3OA_XL\=
MZ/J7B3X56GQA^%WB[X8VOQ>\.:/;B]U36/AQ>^)K"VM]:^P:>\6J76B7K:7X
MI@TJ4:E)H*V45Q/" ?;=%1O+%&K-)+'&JQO*S.ZJJQ1C+R,6( C0$%W.%4<D
M@5%]ML_(BN?M=M]FG2.2&X\^+R)DF"F)XI=_ER)*'4QLC$.&7:3D9 +-%>=_
M$[XJ>"/A#\/OB'\3_'&L1Z?X2^%?A'6O''C>ZM4;4+S1_#N@:5=:UJ-Y)IUJ
M7NW==.L[B>"!8Q)<A,0AB:XWPS^TC\)O%VD?&77-#UZ>XTWX"7*6GQ,GDTZ[
M@.BSR?##PM\8%6%)$#7X_P"$$\9:!JA:V#@2W3V?^OAD4 'NU%?G_P#"K_@I
M5^S?\5O$/P@\/6UK\6_ @_:!M+*Y^"'B'XG_  H\5^"_"'Q0EU30%\5:1IOA
M?Q3>6T^CR:OK/AHMK>CZ;J-SIUUJME%-]@2>XB: ??4=S;S//'#<0RR6KB*Y
M2.6-WMY"BRB.=58M"YC=) D@5BC*X&U@2 3453&H6!M/MXOK,V)C>47@N83:
M&*,D/)]H#^3Y:$$.^_:I!!((J:6YMX/)\Z>&'[1*D%OYLJ1^?/(&:.&'>P\V
M6159DC3<[!6*J0#@ FHJ!KFV2:*W>X@6XF\SR8&EC6:7R51YO*B+!Y/*22-Y
M-BGRU=&; 8$K'<VTTL\$5Q!+/:LBW,,<L;RV[2H)(UGC5B\+21D2() I="'4
M%2#0!-14-O<V]W$L]K/#<P.759K>5)HF:-VCD"R1LR$I(CQN 25=65L,I FH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L^[TG2K^ZL+Z^TS3[R]TMY9-,O+NR
MMKBZTZ2<1B:2PN)HWFLWF$40E>W>-I!%&')V+C0HH I7NFZ=J/V3^T+"RO\
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MSQO;V>@:/J?Q#^&GC>S\2:GHVMW.EW6JZ?\ \(E\5M;\.7 DUZ&:[M;S1/%
MU.X@"23VZ=1\6="^*O\ P4,^(_[,?@SQ-^RG\7_@)\.?@_X[U_XE_'?Q?\8Y
M/"&C31FY^&WBWP"WPB^%UWX3\5Z[?^.)_%<WBZ[36_&FA+:^$;+P[IZW<&KW
M>IW5KI:_LQ10!_+MXP_8S_;V\=_ ;QG>?$3P]XCOO%'P>\=_LZ?LQZ=X4T6[
MTKQ/J7QT_8P_9W\4:OXA\;^-].\'ZMKVF:+XEU#XJ^)O$.D^(+OPMKFJV&K>
M,/"'P^M_#-X]W=WEII\WH/P$_8#\:^(O'G[-;_%#X.^/->_9^\*?'G]J?XMZ
M+\+_ (IZ5X:\$>%/ L.K_##P79?"]A\*/#6L:Q8^!/#FH_%#1=;\9>#/".L2
MZIJGACQ-?W7BB2TTF>_@L+3^DBB@#^0F/]C_ /; \0ZYXU\167[+GBCP#KWC
MO]E#_@I1\,_BUI'A[PI;:+I&K?$KXLZ'9R?!?P[KOQ)\3?$OQIX^_:$U'6=5
MAU#5-)^(VHFU\%:3/J9L],AT*\:32;;]H?@K\#OBQX;^'?\ P4CTG6_!6HV&
MI?&'68+GX:6=P]JS>+84_8=^!?PT9[$).RHH\=>&->\.D7+0G[9ITS8\DI(W
MZJT4 ?SA>!/V!OVEO@YI'_!.?QA-XB^./QUTSPG\#_!OPW\5?"/XI^/+SQ'I
MO[&?[0E]\#H/#?@S]H_P3X6T^:PTKQ%IOPS\2S:IX'\3Z/K5KXFO?".@ZE#X
MC\$O%=6E^L_S7\"_V"_VD;'X>_$+P[XJ^%_[2>A>,F_9*^*?PQ_:#?P78_"7
MX:7/QL^)?B#QGX4U/3[O2/'FI^)O$UI^T%XN5-*\5^)?#/BO6[:P\-OHWB#5
M/"/B*_2Y\6SZ?IW]:-% '\CD'PI\1>!/$_[&W@+X^_LC>(?'OP>U']L;]HGQ
M+X7^%W@KX;?\*Q\4_%[P_!^Q7KJ:AX]\7?LQW/Q*UKPWI<GASQ+I02;PYH%]
MH]AXMNM/?QCI_P /;6:<3:GVP_8T_:$T;P%'I/[0/[*/Q6^/VG^(/V4?'WP_
M_9)\$>'_ !/H7B;4OV3/BAKWQ*^(&O\ @GP[XIUZY\86</@GQ)IGAG7/AV\'
MQJM+S4;;PE9>%!X776$/AVP@OOZE;[P]H&J:IH>MZGH>CZCK7AB>^N?#6KWV
MF65WJGAZYU2PFTK4[C0[^X@DN])GU'2[BXTV^EL);>2[L)YK.X:2WE>-MB@#
M^<*T_8&^.<&H^//C#XU^'>H>-OVJ='_;E_X)]>(_"_QF35[B76[CX4?#OX<_
MLF>&?CMKWA/4GU")M,\(W$^B_%^P\86MO;6S>)(8]8FN["^,MJ6^<)?V*_VT
M=-M?VNO!/[/WPE\?>%M9^)'PO^-VGZQ\3/B5IWAWPG\7(M0UGXY:5XZM/AQX
M<^-OA7QU8^"/VD]&^*7A'_A*K#P[K?B?P7H^O> M%U'2O#_B'QO:7$VH6D7]
M9E% 'Y!_\$M?@+XP^$&L_M#:_+X,^)7PN^&/C>[^&4?@[X=>-_ ?@_X1Z)!X
MC\.>&;JQ\8^)O"WPL\+Z[XBN/#TM^)M%T#Q#KFJ7UJGC#4O#BZUIEG/92+JM
M_P#KY110 5YSX+^*GA#Q]XK^+O@OP[<:C)K_ ,$/'.C?#SQ];7^D:CID%MXA
MU_X8?#WXO:8VC7=[;PVWB'2)_!WQ-\,LVM:1)=:;%KB:YX>DN%U?0-5M;;T:
ML'2/#>F:'J'BG4[ ZB;KQCKUOXDUO[;K.KZI;#4[7PQX<\(1#2++4KZ[LO#N
MG?V-X5T@RZ-X?@TS2)]6.J>()K&37M=UO4M0 -ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *_ '_@Z._Y04?MS?]VS?^MA_L^U^_U?@#_P='?\H*/VYO\
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MM])UV?Q7\4?&7@G69]3@T_2M=7Q?X?70M1M=2GUK^B*OB?\ ;3_X)R?L2_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OP/_ .#ASX_?&O\
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MF2Z-V9_GI_\ #TW_ (*-_P#1YWQV_P#"H@_^5]'_  ]-_P""C?\ T>=\=O\
MPJ(/_E?7]3/_ !"O_LF_]'&_M#_]^_A[_P#,M1_Q"O\ [)O_ $<;^T/_ -^_
MA[_\RU?[@_\ $Z_[.K_HF>&__%%8?_Z'_+\^[/Y=_P"(9^,O_0=B_P#Q)_\
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ML++PR=/NM,\1^5=W>G&;XITGXT_%KP+X$\'?M%Z?^U=\6OB#\3_B#^W=\?\
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MX?CO7UG_ ,&NW_-\G_=L_P#[\#7R9_P<L?\ )]7PH_[-,\"_^KA^.]>MF/\
MRC7D7_8UK?\ K3YR? <&_P#*[/Q9_P"S?Y;_ .N0\-#^>:O]#+_@AI_RBT_9
M>_[K9_ZT3\6Z_P \VO\ 0R_X(:?\HM/V7O\ NMG_ *T3\6Z\GZ-__)<9K_V2
MF._]6^1'W_[:G_E%G@'_ +/_ ,+?^NZ\53]9J***_M<_YA HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW5X[76=0CW1W>JVL4-_-&\D;W!22162U_9)_9ELO%?ACQO:? SX:6WBCP;H
M\+^&=5A\+Z=&VE: EO>V<.FQ6JQ"QFBM;/4;ZTLI+JUGGLK6ZFMK26&%RE '
MYC67_!5#XO7/A&^L=1^"'A3PK\5[V_\ "M]X'TKQ)J7C1-+\:^&O%/PN\<?%
M22V\,>$=*T/4OB/XBUSPSI/@2]MO$&LV^DZ=X(.G:E;>+].UV[T'3M3,.!<_
M\%E]3T+1-(^*'C#X*6/AWX0ZQ\&K3QQH,\OB.^O/$'Q \?S?"GQ/\2KSP!X)
M\0Z9I^H^ [77=/E\*:CIDOA7QEJ?AWQ/<Z.L_C&QAN]%TZ\Q^F</[#/[(%OX
M87P=!^SO\+X?#:>*XO&Z:='X<MT\OQ1!93Z9#JD=XI%_&8=,NKO2XK-+I=/C
MTR[N].2T%E<SP2;>E_L>?LLZ+XETKQ?I/P!^%FG^(-$\,-X-TN]M?"&E116G
MAEK&^TO^R$TY8/[,>!=*U/4=*BDELY+B'2K^\TV*9+&YF@< \N_8H_:H\=_M
M*:;\1;7XD?"V;X:^)O .H>#9(GB34[;2/$6@>/?"=IXKT>YL],\1I:>*=-OM
M+6:XTW4AJVFVMEJ8CL];T">]TC4H)5^XZ\J^$OP-^$/P'T/4/#?P>^'GACX>
M:+JVJ2ZWJECX;T]+-=2U66&*W-[?3$R7-W+';006ML)YGCM+2&*UM4AMXUC'
MJM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %?S!?\%J_^(;+_ (:G\ _\/B_^3FO^&?\ PK_P
M@W_)^G_)"?\ A8OQ5_X1G_DUS_BW_P#R4#_A9W_(8_XK'_H(?\27_A'J_I]K
M^3'PG_P6E_;M^+'[('@']I;X<^#/V>K?Q+_P4O\ V^-$_8[_ ."77@34-,\9
MWL'PQ^&VF>./B-X"\>?'O]IT#4;;5/$\FEW'P^U2^U#1O"$ME;:3+)HVH?V<
M^F7-_I$8!T'_  ;9?#_]CCPW\9/^"KWC'_@G7\.?%UO^PIXW^*_[,5O^SY\=
M_%T?Q>L7^)"^'/A1XLD^)?PK\/:?\7[J#Q'>>%O@9\2?$'B.]T;Q1K7AO2?&
MNJ1?%B30?%FK>)[;PEX=U"#^F_XK^!/^%I?"WXE?#+_A(-8\)?\ "Q? 'C+P
M)_PE7AZ7R-?\,_\ "7>'=1\/_P#"0:'/N3R=8T;^T/[2TR7>GEWMM ^Y<9'Y
M6_\ !+;]LO\ :B^,/QB_;X_8F_;7'PBU_P#:6_8!^)'P@TK7?BE\"=(UOP[\
M./BC\,/VB_ .I_$CX2:]_P ([K^IZK=Z#XVM=&T75+?QGH]K.FF:5<2Z?I=O
M]LNK&^U74?U"^-NB>//$OP8^+OASX6:X?#'Q/\0?##Q]HGPX\2B<6Q\/>/-5
M\*:M8>$-<%R4D%N=)\0SZ=?^>8Y!%]G\S8VW:0#^*>+_ ((6?\%,]6T.\_8_
M\2>#/^"8'A+X#^.?V5/@;^PWKG[0'AF3Q;/KM_X%_9X^.?Q,^+4'[1'AGX)W
MGA>UN[W]K_Q3I/CF6U\4:EJ'B Z.OC72K_Q"GBC3H]1%UI?]S.EV"Z7IFG:8
MES=WB:=8VE@MYJ$PN+^Z6SMX[=;F]N D8GNYQ&);F81H)9F=PBAMH_SF-)_X
M)2?M\?'KX(06VN?\$_\ ]IKP7\4/V:_@/^SW^R-^QQ9?$G]HF\\,7'@;]M3X
MA_&OQ;^TA^VI_P %'[7Q7:^.]0NM+\+:=\5(M=U:W\06CZE8>+]*\<^!/#GA
M6759O#ML/!7^C/I<-];:9IUOJ=ZNI:E;V-I#J&HK;QVJW]]%;QI=WJVL($5L
MMU.LDXMX@(X1)Y: *HH O4444 %%%% !7X _\'1W_*"C]N;_ +MF_P#6P_V?
M:_?ZOP!_X.CO^4%'[<W_ ';-_P"MA_L^T ?3'_!<O_E%I^U#_P!T3_\ 6B?A
M)7^>;7^AE_P7+_Y1:?M0_P#=$_\ UHGX25_GFU_%'TD/^2XRK_LE,#_ZM\]/
M^GO]BM_RBSQ]_P!G_P"*?_7=>%1_69_P:[?\WR?]VS_^_ U\F?\ !RQ_R?5\
M*/\ LTSP+_ZN'X[U]9_\&NW_ #?)_P!VS_\ OP-?)G_!RQ_R?5\*/^S3/ O_
M *N'X[UZV8_\HUY%_P!C6M_ZT^<GP'!O_*[/Q9_[-_EO_KD/#0_GFK_0R_X(
M:?\ *+3]E[_NMG_K1/Q;K_/-K_0R_P""&G_*+3]E[_NMG_K1/Q;KR?HW_P#)
M<9K_ -DICO\ U;Y$??\ [:G_ )19X!_[/_PM_P"NZ\53]9J*_,;Q]_P61_X)
MO?"_QWXU^&GCG]HW^P_&WP[\6^(_ WC'1?\ A4/QXU/^Q_%/A+6+S0/$.E_V
MEH_POU#2=0_L_5M/N[3[=I=_>Z==^3Y]C=W-M)%,YX!_X+(_\$WOBAX[\%?#
M3P-^T;_;GC;XB>+?#G@;P=HO_"H?CQIG]L>*?%NL6>@>'M+_ +2UCX7Z?I.G
M_P!H:MJ%I:?;M4O[+3K3SO/OKNVMHY9D_K'_ %TX.]O]5_ULX9^L^U^K_5_[
M>ROV_M^?V?L?8_6O:>U]I[GL^7GY_=Y>;0_Y\_\ B67Z2/\ 97]N_P#$OGC?
M_8G]G_VM_;'_ !"CCS^RO[*^K?7/[3_M#^P/JG]G_5/]J^N^V^K?5OW_ +3V
M7O'Z<T445],?B 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ ?M\?\ )]7[:?\ V=G^T;_ZN'QE1^P/_P GU?L6?]G9_LY?^KA\&T?M\?\
M)]7[:?\ V=G^T;_ZN'QE1^P/_P GU?L6?]G9_LY?^KA\&U^4Q_Y+A?\ 95K_
M -6Y_?T?^465_P!F 7_KNC^W_P#X+E_\HM/VH?\ NB?_ *T3\)*_SS:_T,O^
M"Y?_ "BT_:A_[HG_ .M$_"2O\\VOU;Z2'_)<95_V2F!_]6^>G\ _L5O^46>/
MO^S_ /%/_KNO"H_K,_X-=O\ F^3_ +MG_P#?@:_K,K^3/_@UV_YOD_[MG_\
M?@:_K,K^@?!'_DU_#'_=:_\ 6AS8_P @OVHW_*=?CE_WC/\ ]<]X?!1117ZL
M?P"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(>+_ (8P_L\7_AOP1X#E9[X3?$;1OBY\0?$$"VUHR?"RX-[,MA_,I_P:[?\
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M\5:CI6@Z2E_JM_8Z99O?W]NMUJ%[:64!>YN88G ,!]9^/ ^)D.E1_#?X1O\
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M:G>1WDUU8_0-% 'SM/XF_:T73_C/+:_!/]G:;5M"U:VA_9XLI_VHOB5;:?\
M%'0FU*ZBN]1^,^IQ_L@75S\!M6@TA+&^MM%\#Z1^T?9W6I7%UI4NO6=K9PZQ
M?=!;Z[^T4WB[X6V5W\+/@K#X"U?PB][\:_$EO\?/'-UXN^'_ (\&CSSQ^&_A
M;X)D_9MM-&^,'A%M?6VTQ_&WBSX@? [64T>6?7%^'\E[;Q^'KGVFB@#Y?D\6
M?MI#X<^*=3B^ /[+[_%RT\<MI_@GP1)^U[\5XOASX@^&H^Q[/%OBGXI+^Q!-
MXF\'^.6WZAN^'FD_![QSH"_9;/'Q/?[=/_9WH<^M?'E?B7?:5;?#;X12_!V/
MP%)J.F^.Y_C;XRM_B7=_$\3HL/@^^^$\?[/USX6T_P !26QDED^(]O\ &C4_
M$,4ZI;K\*YHW:YC]=HH ^9K/Q5^V2_@3P%J%_P# ;]F6V^)NH^.H]/\ B?X1
ML_VM?BG?>!/!_P ,S<W:2^+? 7Q%F_8JT_Q!\2/'26:6$\?P[\0_"WX5Z!+<
MW-W:-\4(8K*&]U#H[GQ#^TTGB#XOVUG\(_@3/X5T7PV+KX!:S<_M%?$"T\0?
M$OQ?_9*S-H?Q?\,Q?LN7NG? _P -C72VG#Q5X+\6?M":FVDA=:/@U;QCH*>[
M44 >!0>(_P!J1D^"QN?@Y\ 8GUUKL?M$K!^TI\1+A/A:B"R^P-\%GD_91M3\
M>VN3)J(NU\<Q_LW"R%K9&%]0-_.NFY]QXG_:Y71/C'/:?!#]G*?Q'HGB"&V_
M9^TJX_:F^)MKHGQ-\*MK$D%QK/QC\01?L=W=_P# OQ!%H BU.'PSX*\-?M$Z
M=/K#R:&_BRVLHU\0R_1M% 'C4&N?M"MXX^'-A=?"_P"#,/PVU/P:U]\6_%D'
MQW\;W/CCP1\01IUW*OACX<_#V3]G*UT'XI>#3JR6-DWCOQ-\3?@_K:Z=<7>J
M#X=-<V<.D7_!'Q;^VI_PK76-5'[/_P"RZ?C#!X[.G^'_  *?VO\ XL#X:ZG\
M,O*M2OB[6/BO_P ,/'Q1H7CLS/>QGX=67P8\1>'UBM[68?%)GNY8++ZBHH \
M@N=:^/B?$C7]+L_AI\()_A#;> IM1\+>.+GXW^,[3XD:S\3UDMQ;^#]?^%<7
M[/E[X8\-> I8FNGF^(^G?&/Q9XA@DAMXT^%=PMS)+:<39>*?VPY/!OPUOM1^
M!/[--K\0M5\;"P^,/A>R_:P^*-_X-\"_#G^T[F)O%7PU\=S_ +&&FZW\5_&P
MT9+._'@#Q1\.?@QH3:G/<Z2?B6MK:1:U>_2M% '@MSXB_:?75OC)#:?!_P"
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M]8^%? _PT?\ 9XM_#GQ"\$BYCT^$>/\ 7OBS\,==,%U>W!^&@DL(+74?8:*
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M+6V^/.DSZN]]8W.M>.-7_9PO+73;>UU6+0;RZO)M'L<"X\4_MAKX1^*5[:?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\&NW_-\G_=L__OP-?)G_  <L?\GU?"C_ +-,\"_^KA^.]?6?_!KM_P WR?\
M=L__ +\#7R9_P<L?\GU?"C_LTSP+_P"KA^.]>MF/_*->1?\ 8UK?^M/G)\!P
M;_RNS\6?^S?Y;_ZY#PT/YYJ_T,O^"&G_ "BT_9>_[K9_ZT3\6Z_SS:_T,O\
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M";'_ $1']N+_ ,-K\!?_ *)>OZ4?@3\7_#7[0?P0^#?Q\\&6.N:9X/\ C?\
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M.K5M*;M%<E&%2>KZJ-EU:/Z-:*_AW_XC,_\ K&__ .;@?_DN5_8O^S%\9O\
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M^'SG[+W_ $(?Q[_\)?X>?_/2H_XF2\"O^CF\-?\ @_$?_,P?ZY\+?]#O!?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY[?\
M@H9\0_VV/B1_P4^_9]_8C^#7[>6F?\$Y?@;XC_8[\??M"0?$VW^&7PG^(_C3
M]HGXQ^'/BI;>!M>^#WAA?BQ:_P!FZ1)\+_!&I>&/B+>1:3JMM?ZMI/BC6'?P
MYXE@TAM=\ ?T)5_(U_P< ^//V+M%_:4B7XD?\$@XO^"F7QT^"_[#LO[2?QC\
M9ZK\?M;_ &?M"^!?['?A?XN>-O#&CZC)JUKIOB*V\:7X^)&J^.]0;PIH6@3>
M*[?2'U37RM[HNFW9TL _=S]@[X$?M$?!/_A:O_"^_P#@HUXI_P""@'_"3?\
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M .TO_P %H/\ AK+X):!_PHS_ (37]G__ (=T_LV_ C_A/O[4_:3^#NB^'/\
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MA/\ PLO_ (UL_!WXC?\ "2_\*Y_X2[_A#?\ DK/QW\=_V/\ V/\ \)WXK_Y
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M+\:/!G[0W[//_!9+_A7WQ@^'W_"1?\(AXO\ ^'>?P]\6?V1_PEGA37?!&O\
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M-)A_L[[3!8Q7EW?7%U\J_M(_\&GW[3W[77QH\9_M#?M#?\%DO^%@_&#X@_\
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M:Z_X:=^#^B?\([_PB'QQ_P"%!_\ !+KX+?\ ";_VEX4T+5]?_P"+9^-]2O\
MQ1X:_P"$:\47^M^$/^)I=R_VS_8']OV7EZ=JMI$G]J-%<&4\<<,9=Q=G'$F,
M\'/#?/LFS/#UZ."\/\VS3Q=H\(\.U*M?!5:>+R?&Y'XJ9+QY7Q&&IX6OAJ$>
M(.-L]PDJ&8XV6)PV(Q-/+\1@+J8:M/#TZ,<PQE*I!IRQ=.& >(K)*2<:D:N!
MJ85*3DI/V6&I2O"/+)1<U+^#W^P/^#WG_H?_ /RU?^"1_P#\>K]4_P!IW]E?
M_@NO^SC^S7^T+^T-_P 1 W_"9?\ "A_@=\6?C-_PB'_#J7]CSP]_PE7_  J_
MP%K_ (W_ .$;_M__ (2+7/[#_MS^P_[+_MC^Q-8_LS[5]M_LO4/(^R3?TWUY
M5\=OA!X:_:#^"'QD^ ?C.^US3/!_QO\ A5\0_A!XKU+PQ<V%EXET_P -?$KP
MCJ_@S7;[P]>:KIFM:7::Y::7K5U<:3<ZEHVK6$%_';RWFF7]NDEK+ZF9\:\
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MMX_\%U_^"J_[2GC?]GG_ (>[?\*'_P"$-^!WB7XS?\)?_P ,"_L>?%'^TO\
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ML#_A6O\ U&O[5_MK_F'?V=_I_P#%C7]Q'_!F9_SD@_[L_P#_ 'Z.OZ/^GI]
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M_ OPQ_Y&S[;XT_LG^R?^$T_MS_D6=2^W?V;_ &;_ *']L_M"U_BQ_P""8O\
MRDG_ .">O_9\7[)O_J^O -?Z-7_!R'_RA=_;,_[MW_\ 6K?@93^F1]$CZ/?A
M3]+KZ'?A?P#X?_V#P-XJ<8<'95QYD?\ K7QOFG]NX#-?$W(N'L?0_M/.N)<Q
MSC*_;Y/C<3@_:Y-F&75J7M/K%&I3Q4*=>!P]GV;8[(.(,;BL7[7%8'#XF>%J
M^PPT/92IX*I6@^2G1A3G:I%2M4A-.UFG&Z/X/?\ B(E_X+K_ /20O_S4W]CS
M_P"<E7[B?\$9?VB_^"Z__!7/_AI#_C<U_P ,^_\ #/O_  I__G';^QY\5_\
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MG]C7]K0C"E'^%C_A=7_!3?\ Z/9^ G_BJW_@GS_\Z:OTN_X)V_LK_P#!3?\
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M #IJ_P!#[]BW_DSK]DW_ +-H^!'_ *JWPK7^>]6M;A#A*$:3CPKPTG*+<O\
MA!RIW=H]\([;O8_?_I+>*'&WA_P]X08[A',\%E.*XIR7.,7GM7_5[AO'_7L1
MA<#PG6H5.3,\HQM/"^SJ9GCI<F#AAX2]O:<91IT53]Z_8]T#_@IO^U?^T9\.
M_@#_ ,/"?@)X!_X3[_A+?^*L_P"'1G_!/GQ3_9/_  BW@7Q/XT_Y /\ P@/A
MS[?]N_X1S^S?^0S9_9?MGVS_ $C[/]EG^X_V_?V$_P#@IO\ L-?!SPU\6?\
MAZC\!/BC_P )#\3-&^'?]@?\.7/^"?/@G['_ &MX6\9>)?[8_M7^RO%WVC[/
M_P (C]B_L_\ LV#S?[0^T_;H_LGD7/(?\$?/^4B_[.__ '5O_P!47\3:_<7_
M (+]?\F=?#7_ +.7\'?^JM^,M$.$.$G0G-\*\-<T963_ +!RK16CT^J6ZOH'
MASXH<;9]]&SQ.X_S;,\%B^+>'LZS7"9/FW^KW#=#ZGA\-E/"^)H4_J&&RBCE
MF(Y*^8XR?/BL%7G+VW+.4H4Z48?QW_\ "ZO^"F__ $>S\!/_ !5;_P $^?\
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M/FC_ (75_P %-_\ H]GX"?\ BJW_ ()\_P#SIJ_4O_@L'_RD7_:(_P"Z2?\
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M9^%;CP5JEB^C>*=1N;7^M7_@D!\._CMX;^"6N>/_ !_^T7_PLKX)?$K^S/\
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MIV5KJ%C<>7+%Y]G>P1W-M-Y4Z131>;#*C^7-''*F[;(B."H_C$_X)<_LP_\
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MCOPU_P#5]?M+U_*S7]4W_!WK_P I)_@C_P!F._#7_P!7U^TO7\K-?H'T!?\
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M_P!IGT!?^4-_H]_]F_P7_J=CS_1#BK_DHLV_["G_ .D0/]B[_@F+_P HV/\
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M^Z2?^J+^&5?FC653^)4_QR_]*9^,^+W_ "=GQ0_[.)QM_P"M+F9_H0_MI?\
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MQ;Q!_P"M)2/O:BBBOZ</[>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P '1W_*"C]N;_NV;_UL/]GV@#]_J*** "BBB@ HHHH **** "BBB@ HHHH
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M?^S'?AK_ .KZ_:7K^5FO^TSZ O\ RAO]'O\ [-_@O_4['G^B'%7_ "46;?\
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M3.OB5_V<OXQ_]5;\&J_D,K^O/_@@+_R9U\2O^SE_&/\ ZJWX-5.&_B_]NO\
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M_P#@F)_R8Y\$/^ZE?^K>\?U_(9^R!_R ?VN/^S:-&_\ 6L/V7*_KS_X)B?\
M)CGP0_[J5_ZM[Q_7\X8;_E+W_O6U_P#KT$?JGT-O^28P/_8MX@_]:2D?>U%%
M%?TX?V\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7\5&A?'5?\ @H/^UG^R]\?-%^"G@3]A'Q5^VKXJ^('PU_9G_;+_ &./
MVP_A]J_[9%FO@[P7X]^)OAZQ_;C_ &3G\-7'P[^-GP^\3:'\&;O1O&_@?XI:
M)XPD^$]_J^G^!)]?T77M1CCU+^U>OCGX9?\ !/3]AKX,?'/Q)^TS\*/V3_@/
M\/OC[XLN=>O=<^+'A;X<^'=)\93WWBLS-XJO[+5+:R1M&O\ Q2;F[/B6^T9-
M/N]?-]?_ -KS7GV^\\\ \P_8:LOVS_AMJ/C?X%_M5_!;]GJTTGPK8VOB'P'^
MU/\ LN1VO@#X<_'=K[4)K&_L_&'[/&H?;/$_P>^*NCV$6E7_ (DDMO$WC'P'
MXKEOKFX\(:MIT.F7.B67V#\==032?@C\8]4E^'</Q>CTWX5?$/4)/A-<Z?;Z
MM;_%!+/PCJ]R_P .Y]*N[+4K34X?&RQGPU+I]UIU_;WJ:FUM-974<C02>J5P
M_P 3?'>G_"[X;?$'XFZMIVKZOI7PZ\#^+/'>IZ3H%I_:&O:II_A'0;_Q!>:=
MHEAOC^VZO>VVGR6VFVGF)]IO)88=Z[]P /X&OA1_P7%_:<^$?P4U3Q-X$_;U
M_8>\4W=O^R/^QA\>OV?/V%?@Q^S1X#\%> /!'Q$\;_'/Q_\ #'XA_P#!-3X;
M> ? =[J_QRN_'GAOP7H/@YKG7I;RY_X0S3M7T;4[+0M)\#WUC\2=7_T#]+NK
MB^TS3KV[LI=,NKRQM+JYTV=UDFT^XN+>.6:RFD55626TD=H)'555GC+!0#@?
MRE_ /XQ_MU_'T_#S_@H!\"_^#<3]@JQ\0?&CP]IWQ9^&?QXUS]I[]F_P[\?]
M6\&>.+5=;\*^)]8\:VGP+3QI8:KXC\.WNGZO<1W6K6NJ1I?K%JEEI]^MS86W
M]6NFRWL^G6$^I6J6&HS65K+?V,<ZW4=G>R01O=6L=R@5+A+><R0I.JA9E02*
M & H NT444 %%%% !7X _P#!T=_R@H_;F_[MF_\ 6P_V?:_?ZOP!_P"#H[_E
M!1^W-_W;-_ZV'^S[0!^O<'[)/[*=JOP62V_9D_9[MT_9NDNYOV=D@^#'PXB7
MX"2ZA+93W\OP66/PVH^%LE[/ING37;^!AH37,MA923%WM8&CK7?['G[)&H:-
M\8?#E_\ LM?LYWOA[]H;7[;Q7\?M!N_@C\,[G1OCEXHL]4?7+3Q)\8=+F\,/
M8_$S7[76I9-8MM8\:0:WJ,&J2/J$5RMV[3'Z,HH \6M/V;?V=;#QQ\.?B;8_
M /X*V?Q)^#O@E?AI\(_B%:?"SP-;^./A9\.4TZ]TA/ 'PY\60Z$FO>"/!*:3
MJ6HZ6OA7PS?Z9H2Z=?WMD+ 6UU/%)PL_[#G[%5S\-]9^#=S^Q_\ LN7'PA\1
M^/I/BMXA^%4_[/\ \)Y?AOKOQ1F@AMIOB3K/@>3PDWAC5/'TMM;6]O)XQOM+
MG\0O!;PQ-J)CBC5?J.B@#Q]_V>O@%+\2M?\ C/)\#O@_)\8?%7@5_A?XH^*[
M_#3P6_Q*\2?#.1K1I/AWK_CIM%/BC6/ LC:?8,_A+4=4N- 9K*T+:>3;0[.(
MM_V+?V.;7P;\-/AS:_LF_LSVWP]^"_C _$+X.^!+?X$?"V'P;\)_'S:G<:TW
MCCX:>%X_"JZ)X$\8-K-W=:L?$WA:QTK6CJ=S<7YO?M4TDK?2]% 'A-Q^RY^S
M+=ZS\8_$5W^SK\";KQ!^T3H</AC]H'7;CX1_#^?6?CIX;MM,DT6W\/?&/4Y?
M#S7OQ-T.#1I9=)ATGQK/K=A%IDDE@ENMJ[1&K!^R=^RQ:S_!BZM?V:?V?[:Z
M_9PM[FT_9XN8/@W\.H9_@-:WB6L=W;?!B:/PXLGPNM[J.QL4N8? [:%'.EG:
MK*K+;PA/H"B@#YOO/V-_V0M0\._%OP?J'[*O[-]]X2^/WBF/QS\=_"]Y\#?A
MC<^'?C7XUAU@>(8?&'Q;T2;PN^F?$?Q3%KZKKD?B#QC:ZSJT>L*-36[%Z!/7
M5VO[.7[/5CX_\#_%BR^!'P9L_BG\,? \?PR^&OQ*M?A?X(M_'_P]^&T-M>6<
M7P]\#^,HM#3Q%X3\#Q6>HZA:Q^$] U'3]!2VOKR!; 174Z/[+10!\MO^PW^Q
M1)\-9O@P_P"Q]^RV_P 'KGQ^WQ7N/A0_[/WPF;X:S_%)[9;)OB5-X%/A(^%Y
M?'[6:K:-XQ?2V\1&V58#J)B 2O09?V=OV?I_B+XN^+\_P+^#DWQ:^('@9_AA
MX\^*,OPQ\%2?$7QM\-9([&*3X>>+O&SZ(?$OB3P-)%IFFQOX2UG4[W0&CT^Q
M1M/*VEN(_8Z* /FRW_8R_8^M/"OPI\"VG[*/[-=KX(^!'BJ7QU\#_!UO\"_A
M?!X5^#7C>;6)?$,WC'X4^'HO"RZ1\._%4NOSS:Y+XA\(6>CZO)K$TNIO>&]D
M><[,_P"RM^S!=7WQGU2Z_9P^ MSJ?[1^FVVC?M#ZC/\ !_X>S7WQYTBSL[K3
MK32OC/=R>'6N/BCIMKI]]?6%M8^.)-=M8+.\NK6*)8+B9']ZHH \#M_V4_V7
M;34?@SJ]K^S=\ [;5OV<M+FT/]GK5+?X/?#R'4?@1HMS:6^GW&D?!F]C\.K<
M_"_2Y["TM;*;3_!$NAVDMI;6]L\+0PQHN->?L8?L>:CX4^*'@/4/V3_V:;_P
M-\;_ !@GQ"^-'@R\^!/PNNO"GQ>\?1ZI%KD?CCXH>'9_"SZ/X_\ &":U!#K"
M>)O%=GJVM+JD,6H+>B[C28?2M% 'CEO^SM^S]:?$7PM\8+7X%_!RV^+7@;P)
M%\+?!/Q1M_ACX*A^(O@[X90+>+!\.O"WC:/1%\3>'_ D*ZA?K%X1TG4[3P_&
MM]>!-/ N9@_GW_##?[%'_"MK3X-?\,??LM_\*?T_Q[_PM2P^%/\ PS]\)O\
MA6UE\3_(DM?^%CVG@7_A$O\ A%[;Q[]EEEMO^$PATM/$/D220_VCY;LI^I**
M /&I_P!G+]GJZ\?>/?BO<_ CX,W'Q2^*O@EOAI\4/B3/\+_!$WC[XD?#E[2Q
ML'\ >/?&,FAMXB\8>"6L=+TRR;PKXAU'4=":TTZQMS8&&TMTCY6W_8X_9$M-
M ^$/A2T_96_9PM?"W[/GB23QE\!/#5O\#OAC#H'P0\7S:POB&;Q5\(=&C\+K
MIWPU\22Z^B:Y)KG@RVT74WUA5U-KHWJB<?1]% '@,_[*/[+=S+\:9[G]FOX
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M?7-A/XX779;.XO;N:W>.2YF9_H2B@#PNV_9?_9HLO$OPD\9V?[._P+M/&'P
M\+_\(1\"/%=M\)/ $'B7X*>"QI,F@CPA\)-=B\/IJGPW\+C0Y9=&_L#P==:-
MI/\ 9,DFG?9/L;M">6NOV)/V,;[P'XX^%=[^R-^S#>?##XF^.G^*'Q)^'%U\
M _A5<> _B%\3))K6XD^(GCCPA-X3?P]XL\=23V5E,_BW7M.O]?::TM9&U O;
MQ,GT[10!Y G[/GP#C^)D/QJ3X(?"!/C';>!%^%MO\64^&G@Q?B9!\,DD:9?A
MU#X\&BCQ3%X$65FE7PBFJKX?$C,XT\,2:X"/]B/]C"'X>^#_ (1P_LB_LP1?
M"GX>^-Q\3/ /PQC^ 7PIC^'O@?XD"6[F'Q \'^"U\)CPWX:\;B;4+^8>*]%T
MVRUX2WMW)]OWW,Q?Z>HH \2N?V9_V<+SQ;\5/'UW^S]\$;KQU\=?":^ OC=X
MTN?A3X$G\6_&/P,FD6_A]/!?Q4\1RZ"VL?$+PFF@VMKHB^'?%UYJ^CKI%M;Z
M:+,6<,<*XL'[(?[)UK9_!C3[7]F#]GBVL/V<-0N=6_9XL8/@K\-H;/X#:K>7
MMKJ=WJ?P8MH_#2P_"[4+K4;&QU"YO? Z:%<SWMG:W<LC3V\,B?0]% 'SO=_L
MA?LFW^G_ !FTF^_9?_9WO=*_:.U6RUW]H;3+OX*?#6YT_P"/&MZ;J%QJ^G:S
M\9K*;PR]M\4-5L-5N[O4[+4/&\>N7=KJ%S<7L$T=S-)*VW:?LS_LX:?XO^%W
MQ!L/V?O@C9>/O@=X//P]^"OC>T^%/@2V\7_"#P"=)NM!/@?X7>)8=!36OA_X
M/.AWU[HI\,^$[W2=%.DWEUIQLOL=Q+"_MM% 'R_<?L0?L6W?P\\4_".[_9"_
M9>NOA1XX\>R?%3QK\,;CX _"B;X>>,/B?,MLLOQ'\4^"Y/";>&_$'CV5;*S6
M3QAJVFW?B%UM+8-J)$$03T$?L^? ,?$R\^-0^"'P@'QCU#P(?A;J'Q9'PT\&
M#XF7WPR,D,Q^'5YX\_L7_A*;GP(9;:WE/A&;57\/F2"%_P"S]T2%?7Z* /F2
M#]B?]C2V\!^ /A9;?LD?LQV_PQ^%'C3_ (61\+?AS!\!?A7%X#^&OQ$-Y>:@
M?'O@#PA'X47P_P"#O&AO]0O[[_A*?#NG:=KGVR^O+G[=YUS,[]3<_LP_LU7G
MB+XN^+[O]GGX&W7BS]H'PRO@KX\^*+GX3> 9_$7QM\&II T!/"7Q=UN70&U+
MXD^&5T(#1%T'QE<ZUI2Z0!IHM!9@0U[E10!\^0?LD_LIVJ_!9+;]F3]GNW3]
MFZ2[F_9V2#X,?#B)?@)+J$ME/?R_!98_#:CX6R7L^FZ=-=OX&&A-<RV%E),7
M>U@:.M=_L>?LD:AHWQA\.7_[+7[.=[X>_:&U^V\5_'[0;OX(_#.YT;XY>*+/
M5'URT\2?&'2YO##V/Q,U^UUJ636+;6/&D&MZC!JDCZA%<K=NTQ^C** /%K3]
MFW]G6P\<?#GXFV/P#^"MG\2?@[X)7X:?"/XA6GPL\#6_CCX6?#E-.O=(3P!\
M.?%D.A)KW@CP2FDZEJ.EKX5\,W^F:$NG7][9"P%M=3Q2<+/^PY^Q5<_#?6?@
MW<_L?_LN7'PA\1^/I/BMXA^%4_[/_P )Y?AOKOQ1F@AMIOB3K/@>3PDWAC5/
M'TMM;6]O)XQOM+G\0O!;PQ-J)CBC5?J.B@#Q]_V>O@%+\2M?^,\GP.^#\GQA
M\5>!7^%_BCXKO\-/!;_$KQ)\,Y&M&D^'>O\ CIM%/BC6/ LC:?8,_A+4=4N-
M 9K*T+:>3;0[.(M_V+?V.;7P;\-/AS:_LF_LSVWP]^"_C _$+X.^!+?X$?"V
M'P;\)_'S:G<:TWCCX:>%X_"JZ)X$\8-K-W=:L?$WA:QTK6CJ=S<7YO?M4TDK
M?2]% 'A-Q^RY^S+=ZS\8_$5W^SK\";KQ!^T3H</AC]H'7;CX1_#^?6?CIX;M
MM,DT6W\/?&/4Y?#S7OQ-T.#1I9=)ATGQK/K=A%IDDE@ENMJ[1&K!^R=^RQ:S
M_!BZM?V:?V?[:Z_9PM[FT_9XN8/@W\.H9_@-:WB6L=W;?!B:/PXLGPNM[J.Q
ML4N8? [:%'.EG:K*K+;PA/H"B@#YNO?V-?V0=2\.?%OP?J/[*G[-U_X1^/WB
MJ'QU\=O"U[\#?AA=>'/C7XWM]97Q';^,?BWHD_A>33/B/XJ@\0HFO0^(?&-K
MK.KQ:RBZHEXM\HG'66O[.7[/5CX_\#_%BR^!'P9L_BG\,? \?PR^&OQ*M?A?
MX(M_'_P]^&T-M>6<7P]\#^,HM#3Q%X3\#Q6>HZA:Q^$] U'3]!2VOKR!; 17
M4Z/[+10!\MO^PW^Q1)\-9O@P_P"Q]^RV_P 'KGQ^WQ7N/A0_[/WPF;X:S_%)
M[9;)OB5-X%/A(^%Y?'[6:K:-XQ?2V\1&V58#J)B 2O09?V=OV?I_B+XN^+\_
MP+^#DWQ:^('@9_AAX\^*,OPQ\%2?$7QM\-9([&*3X>>+O&SZ(?$OB3P-)%IF
MFQOX2UG4[W0&CT^Q1M/*VEN(_8Z* /FRW_8R_8^M/"OPI\"VG[*/[-=KX(^!
M'BJ7QU\#_!UO\"_A?!X5^#7C>;6)?$,WC'X4^'HO"RZ1\._%4NOSS:Y+XA\(
M6>CZO)K$TNIO>&]D><[,_P"RM^S!=7WQGU2Z_9P^ MSJ?[1^FVVC?M#ZC/\
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MRY\%_%'XC&_M]5/C_P"(OA:;PJ^A^-O&QU2TM=2_X2KQ+8ZGKOV^VM[S[?\
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MI8],\/>%_#MEIVB:+IZ2RRR)9:;8VULLDLCK&&=B?@&OTN_X+!_\I%_VB/\
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M;_DF,#_V+>(/_6DI'WM1117].']O!1110 4444 %%%% !1110 4444 %%%%
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ML[N<ZYXFU*X-S^2__!>K_@O5_P $GOVT?^"3W[5G[-'[-'[5G_"ROC;\2O\
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M4_Y->_9N_P"R"?![_P!5YX=KX)_X+.?\FO> _P#LO?A?_P!5Y\4J^]OV5/\
MDU[]F[_L@GP>_P#5>>':_FOAC_E*7Q1_[-KP3_ZF8@^+P/\ R76>?]B7+/\
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M9GE-/@C 8[ 86K@\+A:\\=#'8?)</.IB(UVHTY0CDM*453T;K5$](Q/XYO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[QU/XE3_ !R_]*9_FCXO?\G9\4/^SB<;?^M+F9_H0_MI?\F=?M9?]FT?'?\
M]5;XJK_/>K_0A_;2_P"3.OVLO^S:/CO_ .JM\55_GO5T8O>'I+\T?U5].W_D
MK> _^R=S+_U9Q/L_]D#_ ) /[7'_ &;1HW_K6'[+E?UY_P#!,3_DQSX(?]U*
M_P#5O>/Z_D,_9 _Y /[7'_9M&C?^M8?LN5_7G_P3$_Y,<^"'_=2O_5O>/Z_G
M##?\I>_]ZVO_ ->@C]4^AM_R3&!_[%O$'_K24C[VHHHK^G#^W@HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?D=_P6<_Y->\!_\ 9>_"_P#ZKSXI5][?LJ?\FO?LW?\
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MJGT-O^28P/\ V+>(/_6DI'WM1117].']O!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X
M _\ !T=_R@H_;F_[MF_];#_9]K]_J_ '_@Z._P"4%'[<W_=LW_K8?[/M '[_
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWX9_]WG_ .N_XK/POPU_Y+;)?^ZE_P"JG'GV11117^_!_5QY#^T'X UGXL?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7X _P#!T=_R@H_;F_[MF_\ 6P_V?:_?ZOP!_P"#H[_E
M!1^W-_W;-_ZV'^S[0!^_U%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?D=_P6<_Y->\!_\ 9>_"_P#ZKSXI5][?LJ?\FO?LW?\
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MF,_^7>7Y]V?O7_$L7T=/^C'>%?\ X@_#W_S!Y+[CZW_X>#?\%"_^D@?[;O\
MXDM\2/\ Y:T?\/!O^"A?_20/]MW_ ,26^)'_ ,M:^2**/]<^+O\ HIL]_P##
MIC/_ )=Y?GW8?\2Q?1T_Z,=X5_\ B#\/?_,'DON/K?\ X>#?\%"_^D@?[;O_
M (DM\2/_ ):T?\/!O^"A?_20/]MW_P 26^)'_P M:^2**/\ 7/B[_HIL]_\
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M%I-=A@GCT;P_;PZCXIG2$ZC<Z+::3+:W]QU?[2'QP_X*/^!?V@?!G@O]FO\
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MW_$IUZP^V?8/L%_]JTRZO;*X /Z?:*_ '_AWA_P77_Z6*O\ SD;^QY_\VU?
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M^&?_ /A#?^+H_P#'QX2_X1+_ (2W_A+?^1)_XJ;^P?[/_P"1NUK[7_HWW_\
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M_P Y&_L>?_-M0!^_U%?Q!_\ !%3XF?\ !=?_ (+!_LL>/OVE_P#A]A_PSO\
M\(/^T!XJ^!?_  A7_#M[]CSXM_VI_P (S\.OA5X__P"$I_X2/[!\,OL7VW_A
M9O\ 9/\ 8G]@W?V;^Q/M_P#:]Q_:7V.P_7[_ (=X?\%U_P#I8J_\Y&_L>?\
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MGW__ ,.\/^"Z_P#TL5?^<C?V//\ YMJ /W^HK^0+]OKPO_P77_8<_P"&*_\
MC>S_ ,+0_P"&P/V__P!G']AC_E&'^QYX*_X5W_PT!_PF7_%T?^/CQ;_PEO\
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M1+_A$O\ D2?^*9_M[^T/^1NT7[)_I/W_ /\ #O#_ (+K_P#2Q5_YR-_8\_\
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M\/\ @NO_ -+%7_G(W]CS_P";:@#]_J*_D"_:'\+_ /!=?X"?MV?\$ZOV*?\
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MC_\ ;_\ VCOV&/\ E&'^QYXU_P"%B?\ #/\ _P (;_Q='_CX\)?\(E_PEO\
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M?^<C?V//_FVH_P"'>'_!=?\ Z6*O_.1O['G_ ,VU?TH?:'[_ %%?R!?\(O\
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M (?L_P#"5_\ #??_  US_P 7+_X=A_L>:%_PJ?\ X97^#NB?%G_D3?M&L?\
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M]1\3^,8/&/V2ZUK0K#35M8!!HEMHMUY[3WVC7$UGI3Z?^M?_  YE_P""=O\
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M?_LCB'-\7[5YW'-OK/UK+*%#V?)'*LN]C[/V;ESN=7FOR\JMS/\ 86BBBO\
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M+4N8[2Q\43W+)X;N]*U*Q3^T=$\0K>[HM'U339[._CN9OLMO<AKLPS 'R/\
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M(\!W%CH/PUUZ#QGJUB=?A?1/$&@Q:K8D J_\$</V;OAE^QS_ ,$\?@9^RO\
M"C]I'P=^UAX8^"U[\5-,?XT^"=+TKP_I6OZEX[^+_CSXN7.G7'AG2?''Q%A\
M/7_A^+XAV^BS64_BW4;F]ALK?6VBL(M5BL+;]/J^1/V;M;7Q1X_^//B?Q'X,
M\?\ PU^*6LZCX D\4?#[Q[9> +:;0_!L&A:I'\.K_3+_ .&OBWQSX>\1IJR'
MQ0FIZ_>>))?$ U33KGP]J&EZ18>'=(MW^NZ /@#]OK]AC_AN/_ABO_BZ/_"K
M_P#AC_\ ;_\ V<?VY_\ D2?^$U_X6)_PS_\ \)E_Q:[_ )&[PE_PB7_"6_\
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M_AW)^T!<?'3_ (0K_A5W_">_\+C^T?$7X >/_P#A%O\ A(_^%B^#/^%>[/\
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MMW/B?7-6U/4M0F^IZ /Q^_:6\%?LO?&?]OO_ ()V_M@ZC^VS\%? VI_\$_\
MQK^V+\.)?A)=ZMX/U:]^*7CS]I?X0^'_ (0ZAX2F\4R?$719OA]KOPUFTZ#5
M[[3Y?"/B^?7+G4(="N5\,SB.^G_8&OP=L_!>GW'AOXAZ_=^-?CG\.OA=XD^!
M_P 2?AGX"U[Q+\(OV=]2T?XQ_LW^%QXT\<GPEX#UZSUOQ5XCT#XF#3;KQ-JW
MA75OB[:>%+OQEX7N1KEW\.=;UK0=7U#P]^Y^BS6USHVDW%G'+%9SZ9836L4\
MCRSQ6TMK$\$<TKR3/)*D3*LDCRRN[@LTCDEB 4O%/BSPMX&T#4_%GC;Q+X?\
M'^%M$MS=ZSXE\4ZSIWA_0-(M RH;K4]9U:YM-.L+<.Z(9KJYBC#,J[LL ?S0
M_P""7_P'^"_[/I_;F'PD_:O^%_[4)_:H_;__ &B/VZ-7'PZN?"A/PG'[1'_"
M'>1\+M2_X1GXB?$#^W_^$8_X1$^3XWNO^$4_X2/[>=GA'1_LA^T_5W[6T7PO
M3X9:5K'Q4^* ^#FG^&O'WA77O"OQ ET_0M9M-'\<P27MGH$%]H7BC0?$GAS6
M[75DOK[2FT[5-*:1I;R*YT2^TCQ+;:+JUCXK^SU??!?QM\<(/&>E_M&:?\9?
MB+X?^'GBCPYX9\/Z'\/_  K\/]+T#PMXBUCP=?\ C'4I_P"P?"UAK.N7>H:C
MX7\*(L>L>);K2-.$<LFGZ)'=W)NX #]"Z_+3_@K_ / #X0_MN?L'?M'?L8?$
M3]J#P#^R_%\0]'^#_B'Q#\3?%5KH?BD_#_0_"OQX\ ^.M#U75O!6H^//AX]S
M8^-==\ 2^!M#N+GQ3HT=QJU]/)IIUB\TJ;1[G]2Z_,/]I;3;:]^-U[J/@^]^
M.GA63P<?AGXY^+GQ-\$^$/@_X\^''PXU/P]!XFC\#^(]8\*^.[UOB'J.KQ^%
M=1\06'B6Y\ >&O%VB:/X1U&UUC4M(L]=L;3Q'H !^B_@_P 9^$?B%X:TGQEX
M#\4:!XS\):];&[T7Q-X7U>PUW0M5MA(\+S6&J:9/<V5TD<\4L$OE3,89XI8)
M0DL;HO1NZ1HTDC*B(K.[NP5$1069F9B JJ 2S$@  DG KY\_9MM_#5CX0\6:
M9X=UC7O$\^G?$_QQ'XJ\8^(4\,P7?C/QA?7T&L:YXFL[7P=8:3X:L](U!]3@
M72;;2M*T^-;&"%[B.YO7N=0O/?+V2UBL[N6^,0LH[:>2\,ZAX!:I$[7!F1@R
MM$(0_F*58,F000<4 ?EA^TK\$?@E\:?V_P#_ ()D?M>7O[5?P[\':I^QAJ7[
M86D>'?A.(-"\12_&W4OVG/@/:^ [BS@\90^/-*3P%+X TGPCJ'BO]]X7\6KX
MJ0-HT;:!,D=[<?JQ7X8:9\-_V9]/\<?!_P".7A3]E'XR^ _V;/"?B#4_BNFJ
MZE\&_P!G>^^#>I:1\0/ 7BCP[IGC,6=Q\09_V@_"G@E7\=VGC8>%+GP1J&G:
M%J.DZ1J5CX"\(26>HWX_<^@#)U#7M%TJ^T73-2U6PL-0\1W=W8:#975S%!<Z
MO>6&F7NM7MKI\4C*]U/:Z1IU_J4\<09HK*SN+AP(XG8?F-_P2[^ OP<^ *_M
MY/\ "3]J7X>_M.+^TQ_P4-_:*_;6\1GP'!H-H/A#>?M#'PH+?X4:G_8GCWQU
M_P )"/#O_"$71LO'<W_"+0^*UGN&M/"NEKITIG]T_;?T+0?$/A/X>:7/JWQH
MM/'.I^+_ !-HGPYT+X%Z-\/=<\7>,=1USX4_$'3/&/AS4+3XI6J^"K7PY/\
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M+\+> M%N-:TVRL_%$&BZ+K7BO0]<_8^@ KX _P""7'[#'_#M?]A/X&?L4_\
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M\U]Y^O>TI_\ /R'_ (%'_,K459^Q7G_/I<_]^)?_ (BC[%>?\^ES_P!^)?\
MXBCVD/YX?^!+_/S7WA[2G_S\A_X%'_,K459^Q7G_ #Z7/_?B7_XBC[%>?\^E
MS_WXE_\ B*/:0_GA_P"!+_/S7WA[2G_S\A_X%'_,AC_UD?\ OK_Z$*^K/^"*
M_P#R8PG_ &=;^WS_ .MP_M U\N1V5YYD?^B7/WU_Y82_WA_L5]2_\$6E9/V&
M@CJR.G[5_P"WTKHP*LK+^W#^T""K*0"K @@@@$$8-?Z^_LAI1EX@^,G+)/\
MXPSAS9I_\SS$]C^6OI1RC+(^%N62E;-<;>S3M?"1M>VU[.WHS]7Z***_W>/X
MO"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"^*7Q@U[1+_Q7IFD>!/!?Q#NO@EJ^@W]C:_#WX96]_X^\.W?PM\'Z VA6/\
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MPEXCDL?$.HMX!TRZUBUN/$6^?P;;R:IK'A/PO<V^MWVG:OX@FN+W3/#?B'[
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M+_PMWP3+&MQ\0[:[^'_C&V\+6GAS]9Z /C#]M_5=$LOAQX.TOQ-\/_A]XO\
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M\NG-J&E/XX^'&N^%UCU+6_"GB_4-0.D^'+?^:^&/^4I?%'_LVO!/_J9B#XO
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M1\5? /Q"\$>1<KX27QE<ZAIUKH !]C_LO'3V^ WP[FTKX=6WPHL+O3=2OX?
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M_$/@;0)?BEX\G\,69UWX9V<NG:@^N^$;KPYK%SIP\3^)?#_A<R0^&O P\/\
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M0GA^+/P]CFO;B&Q@M;*&:ZD5IY8K.VM[6.21DMX(8@D:VO\ @F)_R8Y\$/\
MNI7_ *M[Q_7\U_\ .8/_ 'K7_P#!0/B_^;B?]V7_ .]P^]J***_I0^T"BBB@
M HHHH **** "BBB@ K_/H_X.'M$L=/\ ^"MOC2]L-:\8>';CQ!^R#^S1K&L2
M>&_B3\0?"4>I:E#XV_:#T"&>X@\.>*M(MV2#2=#TRV@M$B6R@ECNK^*V34M5
MU:\OO]!>OYE/V]=8L/ /[7__  51^-%KX.^&OB;QY\)?^":_[!VM^ =2^)?P
M]\)?$;3?#VHZC^T%^UCIM]-;:/XPTW4]/'VRTF\N=!&JS/';/*)#;Q ?<^&\
M<IGQEDT<\R#+.)\MG5K4*V1YQA\)BLNQU7%X>K@\%]:HX["X["RAAL;B,-BU
M.IA:SI3P\:M*'M84VOA/$NAFN)X)SNCDN>YAPSF3A@ZM'.\JKXK#8_ T\-F&
M$Q6+>&K8+$87$QGB,'0Q&%<:>(I*I"O*E4E[*<T_XO5L+MP&7QQ\764\AE^.
MGQH((]01X_(/X4O]G7O_ $._Q>_\/G\:?_F_K^E#_AC'PC_P4D\)?\$^OB]:
M^#O!'[-/Q(^/FC_M&2_'RZ^$_A+2/#/AKQGX.^ %Q91V/Q%\%_#Z;4=.\/6'
MB?Q')/::#+=&ZL-">_U@ZAJ$O]FZ9:1-Y=XN_P""2?P#\)_M!_L_^!]>_:5\
M0^ ?AG\</ WQ3UQ="^(&I_ -?C9I/C[X:-I8T_X8)JWA;XD:U\$H]6^)MMK-
MMJ'@K5M2\6VNG(MI>:5J#'4VC1/Z_H8+Z/L:LL!F?A?X>Y=G-"&=/%Y73\/^
M'<RG1ED&(SC#X[V6(P62U*>)IS>09E5PLHQA4J4Z5.&(HX;$XFCAZG\1U\)X
M_P!2C',LG\3..<SR+$2R58+-JW'F?Y4JT,]I9-5PGM\-C\XISPM2B\^RVEC(
MRG4IPE5JUL/6Q6$H8C$4_P  /[.O?^AW^+W_ (?/XT__ #?T?V=>_P#0[_%[
M_P /G\:?_F_K^ACX5_\ !&CP=XU\9_M#W_BCQ#^TEX6^&'PA\=^ /AOX:\)Z
MKX7^!_@OX[:EK_C'PEI/BO6M:\5O\0/B1HGPHB\(>$[;58OLFJ^$_$VM/XZL
M&.I^%HYUA2WO/(]?_P"";7[-'P9\&_M=^//C_P#M%_$J[\+_ +-/Q_\ "OP:
M\.:I\#O!W@WQ6WQ*L_B#X#T[Q=X/OEAU;6ET_1-6@DUJU_X2@MKEUING0Z/K
M&FVJW&I7-G+#O3P'T<:U>>%P_AUP!BL53P^5XCZKA?#3),37FLWJY11P-.G"
MCDD_:5JE7/,K@X1;2EB9I2E]6QGL.>>%^D;1I4\3B./^-<+A:F*S7"?6L7XD
M9SAJ--Y-0SG$X^M5E7S>$J>'I4>'LWJ.<HJ2CA%[2$/K6$^L?B'_ &=>_P#0
M[_%[_P /G\:?_F_H_LZ]_P"AW^+W_A\_C3_\W]?L9_P4J^!G[%GP;^$_[%>K
M?L\Z=\5=$^(/Q:_9W\"?$G5D\2Z?H4?A[QGX3U?^W8+OQWXOFB\2ZOJ&D_%:
M_P!:M;*UN= \-6J>!X]&1Y[::.] CD_(>OJ>'_#OP:XCRU9GA/"+@3"T7B\?
M@U2Q_A]PMAZ[J9?C:V!K34%EM1.G*MAY\DE)O1QFH5(U(1^/XGXU\7N%<SCE
M6,\5^-,96EE^69BJN7<>\38B@J6:8&ACZ%.4Y9A3:JQHUZ?/%QY6G&I3E.E4
MA.67_9U[_P!#O\7O_#Y_&G_YOZ/[.O?^AW^+W_A\_C3_ /-_6I17M_\ $'O"
M/_HU?AM_X@O"_P#\ZO+\^[/G?^(L>*G_ $<WQ#_\37B7_P">?E^?=F7_ &=>
M_P#0[_%[_P /G\:?_F_H_LZ]_P"AW^+W_A\_C3_\W]:E%'_$'O"/_HU?AM_X
M@O"__P ZO+\^[#_B+'BI_P!'-\0__$UXE_\ GGY?GW9E_P!G7O\ T._Q>_\
M#Y_&G_YOZ/[.O?\ H=_B]_X?/XT__-_6I11_Q![PC_Z-7X;?^(+PO_\ .KR_
M/NP_XBQXJ?\ 1S?$/_Q->)?_ )Y^7Y]V9J:;>[E_XK?XO?>'_-<_C4.X[CQ^
M#^1S7]\/_!N,&7_@D?\  %7FN[EU^)'[5X:XO[V\U*^G8?M8_&K=->ZCJ$]U
M?W]U*<O<7M]<W%Y<RLTUQ/+*[NW\&2??7_>7^8K^\[_@W(_Y1(_ /_LI7[6'
M_K67QKK^</I&\$\&<*Y-PS7X7X0X6X:KXO,\=1Q=;A_A_*,FK8JE3PE*=.EB
M:N6X/#3KTZ<VYPA5E.,9MRBE)MG]2?1=XQXOXGSSBVCQ+Q7Q+Q%1PF4Y=5PM
M'/<^S7-Z6&JU,;5A4JX>GF&+Q$*-2<$H3G3492BN63:T/W(HHHK^2S^S0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ***\K\=?'#X1_#'QG\*?AY\0OB
M#X9\'>,_CEX@UGPG\(M \0:@FG7?C_Q/H&B3>(]4\/>'9)U6UN]:@T6WGOX=
M-:>.[ODB>*PBNIQY5 'JE%%<=\0?B+\/OA+X,\0_$?XJ^.O!OPS^'GA*Q.J>
M*_'GQ!\3Z)X,\&>&=,$T5N=1\0^*/$=]INAZ+8BXG@@-WJ5];6XFFBB\S?(B
MD [&BOFOX)?MF_L??M+ZSJ_AS]G']J[]FO\ : \0^']-36=>T'X)?'3X7_%;
M6=$TB2YCLX]5U?2_ GBG7K[3=->[EBM4OKR"&U:YEC@64RNJG@-+_P""DO\
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MBW]J:]J+->7_ -F:\-G9><3]ETZWM+*/$5N@K^>3_ANC_@M7_P!$L_X)=?\
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MOQ8\<?V[_9GF?\+/^(6M^//[+_LS^T-O]A_VP[_V5]M_M!O[3^S8^W?9-/\
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M_JT^O&XT2*Z^S7NEVTME8-I\-S(-0:-;B.*W+3+ZW_PW1_P6K_Z)9_P2Z_\
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MCGXH^-QK$UI.\WQ.\>ZSXZN-/-FD\8CTB;6'=].AN!.6NXH"%N'B@=QF):_
MQ_VZ/^"U&3L^%G_!+W'8OXY_:ER?4X'AS@=QUXZX-,_X;H_X+5_]$M_X)=?^
M%S^U-_\ ,Y7VZ=TI6:4HJ2NK-QDDT[;JZ?6S[H_E?HI+6,KN$[-1G&,Y0<H-
MI<T>>$HJ25FXNUUJ?TCU\@W/[*VJZMX]^(GB36?V@_VBT\.^*]<@\1>%_#OA
MWXR>+O#MMX->^MV3Q!X:L+.QF6P_X1B+4((]5\.1!?M>FKJNHZ*SG2M-T9(O
MP;T/_@J;_P %A_$'QR^)WP"LO@U_P35A\5?"CX?_  J^(NO:O=^-?VFET'4-
M(^+MUXTM/#]CI+1Z*^H'4M.D\"ZH^KK>6EO;K%=Z>;.:Y9[A8/6_^&Z/^"U?
M_1+/^"77_A<_M3?_ #.4P/Z,=!TA- T+1="CO]6U6/1=)T[2$U37M0GU?7=2
M33;.&S6_UK5;DFYU/5KQ81<:CJ%P3/>WDDUS*3)*U8'Q&\'W'C_P+XI\&6GB
MWQ7X#O/$>CW6FV?C/P/J?]C^+?#%Y*H:TUK0M0,<T<5]8W*13K'<03V=W&LE
MI>P3VD\T3_SVG]NG_@M6JNY^%?\ P2\*I')(=OCG]J4G$2%R.?#N<D#  ![D
MD*"1R7@+_@HQ_P %G/B%X(\)^.]*^$7_  3%L=,\8:#I_B&PL]0\<_M0_;K6
MTU&$30P7GD>'Y(#<1J<2&&1XB>49AS0!^ZGPL_9PO/ \_@_Q%XB^,_QU\7>*
MM%TZT.O:?K'Q?\9:YX!UG7'TEK+5IO\ A&-;N;D3:2]Y-<7NF66H37$UDRV;
M//-/;"5OJ"OYN/\ ANC_ (+5_P#1+/\ @EU_X7/[4W_S.5PWBG_@I3_P63\(
M>-/@-X(U/X0?\$S;F_\ VA/CAX9^ OA2\L/&_P"T\UIHOBGQ3X=\6>);'6?$
M"RZ"D_\ 8-M9>#]1ANO[.CNM0-S<6:Q6S1F:2,';1NZTLM7J[]EU\^VG='[Y
M?&/X$:[\4_&O@'Q)IOQC^+7P_P!#T&#6M)\8>%/ /CW7?!VF^)],O[.XN=)U
M:,Z*\<D'BC0M>BLHXKJ5VL+[P[?ZS8WUK->P:%>:9Z/\-/AM;?#+2;_2+;QE
M\1_&B7^HG46O_B7XUU7QQJUJQMK>V^QV&HZNSSVFG 6XF%E&?*%S+<3@;YGS
M^8O]K?\ !>H$9\+?\$CB"<#;XU_; RPP>1GP=CKC'/3WXH_M;_@O2#SX6_X)
M'!2&_P"9U_:_!!V@J.?!PSEC@X'%*\79<\;M\MF[-/31WM:]]+[V=KBZV=[Z
M/1-Z-J-_=3NDW=VV5V[(_8&OC6P_9+U:7Q!XZU'Q'^T7^TE>Z9K?BVZUOP?9
M:+\:?&6A?\(WX?U&PT^6?PQ=6UO<M97<6EZ^-:?1;ZUCM&7P]=Z3I5[;SW^E
M7.KZK_-!^W%_P7G_ ."IG[!7[15]^S)\3_V>OV!?&'CC3OAIX+^*-SKW@/QC
M^T&_AA]%\<:AXCT[3;")?$%KI&K?VG93>&+Y[_?:BV,=Q:FVEE/FA/D;_B*K
M_P""B'_1JO[&?_A5?&S_ .2Z^<S#C#AC*L74P.89U@\+BZ*INI0FZLIP56G"
MK3<O9TYI<T*D))-IVDG:Q^W\(_1M\=N/>'\OXKX.\,N(\_X=S15WE^;8*. 6
M%Q:PN)JX.NZ7M\;1J-4L31JTI-TU:=.:Z']<7_!2VU%C^P=\8[%9[JZ6SM?A
M;:BZOIWNKVY%O\6?A[")[RZD_>7-U,$\RXG?YYIF>1OF8U:_X)B?\F.?!#_N
MI7_JWO']?R,K_P %_?VS/VVL?LQ?%?X _LQ^"_ 'Q-!.O^*/AYXC^*%]XPTO
M_A#,?$#2AI-EXCG?1Y3>ZWX4T[3]0-X#Y>F7=[);@720-7]<W_!,3_DQSX(?
M]U*_]6]X_K^?,JSG*\[^ES/%Y3C:&/PU/Z.,L/.MAY.4(UX>)M.I*D^91:FJ
M=6G-IK:<>Y^*<?>&O'GA;XN8;A_Q#X7S/A/.L9X<4,YPN79I&@J^(RK$\38S
M!4,=2>'KXBG+#U<5E^-H1DJE_:8:JG%))O[VHHHK^IS,**** "BBB@ HHHH
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M,?:\_/R\G)2Y;7YI;'KE%%%?AQ^]!1110 4444 %%%% !1110 4444 %%%%
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M\%.?VJ_^"G7_  4.\(#]LOP3\._V-?\ @GQ^UGI>F7OP@'[-GPX\9_$7XQ>
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M \>V? FNDX],FO?3!+C[AZKZ>H]Z\&\ Q2?\+^_:6&W_ )=/@%W'?P'KN.]
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M1S1)IN[4E;1WO?=G]B>,<>GZ?3_(HZ]:E:&3)^7N>X]?K2>5)_=_5?\ &O\
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MX8XFEE+_ !=YS^WY5^L7_!)')^(7[1[DDM_PA7P;P<XQC6_B@1C&/7OFN/\
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MXE?$KCE><CQ;R!G)'0@\@@FOU'_X)M?L3_LR?&K1?CM>?%/X;7WC.]\,^-/
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M%>?8BA6IU<?A:52E7HXG&U*-2E.G*:E"4&I.R>FK_I0\!?\ !,S]AK5_A_\
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M\.P:K=_$/XIVM\-+TW1?!LMC:W#:9XWL$O#;FZN-U]>13W\[2 3W<D:0I'\
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M\2XYM+VM?V5"E1=63<I4J-**M&$8KR,HX3X;Q..XD>)X?R#$SI9S1HQG7R7
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M19?P[E6#R7 2Q'"?#M;$5,%E>%PM#!8.=>K4J5*KH48.I.<IS<I3DSY#M?\
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MISDX)7I-^SW\'0Q!\(-D$@_\5#XIZ_CKF?K[U[O^RS^S5\#M>_:7^ 'AC6/
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M%L^JW1N(M.LREO=7L]K:^6390VK3W!F^>V^#?P\=BW]F^*3G'/\ PLOXD#.
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M;P/!HESJ_B/3OB=XBO/!VF3:M?V5CX&OK2RUO1OUP^(?[</QW_80_P""S_\
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M'Q @T+Q"M\OAVW /Z.J*_G4T7_@X%L;G]C_4OC%XA_8J^*FC?M?VW[<NL_\
M!-[2OV&]-^(WA/7]8UW]KO2XK:_7P=9_&W^Q-+\,1>"H]*NX9]7\?R^$OLNG
M7L5U;66DZSIZV>L7WS?^U5_P7+_;2L_V._\ @H-X4\-_L+>,?V1/^"C/['?@
MWP=XR^(7@#7_ (Y? SXM>&?A-\#_ (FZ-JFHZ'^U'X'^(-_X/OOAQ\=(/"%U
M8:?IWB+X5V/A&6XFO_$-C:Z=JNKW.G:_;:. ?U=T5^!W[-7_  5H_:+M?%O_
M  3I^$/[>/[&3_LTZI^W3\//'\?A+XPO^T+X(^*ND7OQ*^&WA+0_%GA^UU_2
MOAO\-M)\'>'&^.W@^]G\9^'=/_X2[3-0\,:FTWA"Y\,2BT?4(O%K[_@X+^(.
MM:/^RCJGP9_X)X>+OCC>?MS?&?\ ;9^%7[*?AOPI^T3X3\.:W\2-#_93N='T
MGP5\3-4N?'?PW\-^%?"'A;XOZS=ZW<:XU_XGNX_A;X1\.W'B>WO_ (CSWD.A
M1@']+5%?@I\./^"\?PR_X83_ &R_VOOVG?V>OB#^S-\0/V#?BYKGP!_: _9O
MN/%WAGXEZ['\8[>^\.Z3X4\)_#_XBZ5:^&_#/C.R\7ZUXKTC2(/$!T[1[#3I
M8-8U=TN_"MII_B+5XO\ @EO_ ,%RM)_X*%_'_P 9_LP_$#X#> /@/\7=(^$[
M_'#P5'\(OVU/V>/VX_ /B_X>6'B'1/"^NP:YX^_9_NAIOP]^(6DZIXDT:X/P
M]\06LVKS:++>:K/<60M$MKD _?"O!?@M^T[\"?VB==^-/AWX*_$31OB'J'[/
M?Q.G^#?Q9F\/I?7&D>&_B39^'="\3:EX7@UYK6/1=>O=&LO$%E8ZX_A^_P!4
MM]$\06^J^&M5EM-=T?4M/MOY,/\ @Z-_X+J_%S]C=9?^"??[+>D^.OAO\7?B
M9X#LO$7Q+_:*O]$UCPU%X?\ AQXJCNK6#0O@'K=Y;VL>O^)M:6"^TWQ+\3/#
M\]SI_@&2WO\ PUH%Z?B)!JEWX#_AK_9"_P""M/\ P4%_8-\#^)/AQ^RA^T3K
MWPD\'>+_ !5-XV\2Z3IWAWP7K@UCQ3<6%GI<NL75WXI\.ZY>"X>PT^SMF6&X
MBA98%=HC*SR, ?[;M?Y27_!WE\4?!7Q#_P""NNM:#X1UFVUJ]^$WP'^%?PZ\
M:O92QW%KIOB\/XB\8W6B_:87>*2\TW2O%NDPZI"K>9I^I&ZTVZ6.]L[F&+X@
M\6?\'%/_  6>\8^'M4\-:E^W?\4M-L=7M9+2YO?">E^!O!?B&"*52KOI?B?P
MIX5T?Q#HUUM)$=]I.IV=[ Q$EO<13*DB_E1X/\'?&/\ :8^+NF>$O!^B^./C
M+\:OBUXK\BPTS3;?5_&/CGQOXN\0WIDEE98UOM7U?5-0O)WN+NYD\Z:1WDGG
M<_,U ']W/_!C1I&HPZ1_P4WUV6UF32=2U+]CO2+*]:-Q;W&HZ):_M/WFJ6L4
MI41O-9VVOZ1-/&CL\27UNTBJLT1?^^JOQP_X(6?\$RF_X)8?L$>"_@;XIN+3
M4?C=X\UR_P#C!\?]2L+F.]TRW^(_BC3=)TU/".AW<<UW')HG@3PQH>@^&3+9
MWMSI>K^(K/Q+XKTQ;:V\2?98?V/H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#_,$_X/5O^4IOP#_[, ^%G_K17[55>_\ _!D-_P G3_MP?]F_
M_#S_ -6+-7@'_!ZM_P I3?@'_P!F ?"S_P!:*_:JKW__ (,AO^3I_P!N#_LW
M_P"'G_JQ9J /]'RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H/0XX/8]
M<444 ?Y97[3=UKUW^U%^U)=:=\,_C-K%B_[3W[1@M]5T/X/?$77-&OA'\:?'
M$33:;K&D^';S3=2M=Z.BW5C<W%NSI(GF!T91XA_Q59Z?"/X\X]_@7\5L_C_Q
M2=?U<^"9+F6W\7PK/+&TGQN_:,1!YDJ(I_X:&^**+D*2 N<%@  S$D$$YKY?
M\'?MW_!?QU\'?B[\:]"G\:KX>^"?BK5/"7COP_J&E+:>+[*^T_6$TBVO[32C
MJ4EO>:)K32"]T34EOEBO+2.X60PW-M-"GXCF'@)P9FF88W&XC&YS'$YABJV8
M5H4\3AJ,(SQ%:=6?*\1145'GK2Y8*3GRVW492/\ 4C@S]K9])?@7A#AC@[*.
M'O"Z>5<(\/Y#PSEU;,>'LZJXS$8+*<KP^7X2K6CAN)TY5/JV!I*K6Y(0G4;D
MH1<E%?S._%*[U^QT'0KC4/AC\:=.MU^(7P[C6?4?@U\2-.AEN)/%FFK;V5O-
MJ'ARUAN-1O9 +?3M/BD>\U"Z:.ULX9KB5(V^C9O%>HAF4_";]H@$,X8']GGX
MO94F0G##_A$\@XX(QP00>U?N)^WI<SR_!?X;R+//ME_:K_9)==\KG ;XV>%)
M%P2Q"G:ZL K';Q\[D U[Y^T1\>_#7[-WPO\ %WQD\=P^*M3\+>$[G34U*Q\(
MV+:UXAN3K6N6FB6::9ICW5J+R07=_"\J+.L@@25XTE91&W]/^ G'.:_1RR#.
M.&N"*6"QN SK-:6;8NMG[6)J4L;'#PPD:5.IA*V&A.,Z<8VI0M)S=G.,KI?Y
MM?3>XDQOT_/$?AWQ2\9J-/+>(^'N%:?!F7T>!*%7)<HEEU'&8O-.;%K-IYY5
M^N\V.K.FHSIQK1Y(12^(_FX_X2S4/^B3_M#G_NWCXO\ _P R?Z]/?%??G_!/
M+]K/X9_ 7Q[\;C\4/"'[0VA2>*/!OPM71K:T_9G^-^N7DR:5K7Q#-[<7-EH_
M@N\N[&S#7\$-K>W<,5K>W"74%K++):3JGZB6'[0/@G6/$OP=\-:)JFIZX?CG
MX%\1_$3P#K>EE9="N?#?AO3]%U*\EOKIKI9[:ZFM_$%D+6!+>?\ TB&ZBNA;
M/&55FG3SC]H_QF1<3 _\*'^&PXE=2!_PL;XK#'#9(^0'!)7?E@ QS2^DQQEF
M7TL/!OB;P,\2Z.7X#@[BO%9%B\SQ/#4GE6=J?#F=8'/L#'!8O,<7C\/#FS#+
M\+[?FP5?FI1J4?<]HIK\ \$_!GA'P)\0<K\2>"ZN?8OB+)L+F.&PV'SG&X/&
M8"=+-<#6P&+E4P]#!8+$3<,/7J<KHSGR3E&;CHE+1/\ P4]_9<RQ_LO]IK&<
MC_C$']H_.#_W3O&?;/'X&E7_ (*=?LNL)&&E?M-86&8$_P##(7[1_62)T7K\
M.QU8C_ URFH_M1?#S2OVE]!_92U2]\1V/Q.\4_#Y?B%X?O;FT:+P?JEG)>:G
M;1^'8M?^U_)XKDAT35-3@TF6T5;G3;*YDM[B6:)X5[OX7_%O1?BYH.N>(_"Q
MUR#3M"\;>._A[=KJ\:VMRVN> M6GT'69X$BN;@-8S7T+M8SYC>2'+-$C+7^4
MT/V5WT9Y^]_:?BC!.-=VJ\3Y4YJ.'K0PU6,W2X2E2YY5)J*=.4H7:<9-6O\
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M8>&],L[I%EC\*M'*L=Q#(BR1,\<H4/&[1LK'IC_P6*_8.!9?^$Z^)Y*E0<?
M+XP_Q<C:?^$2PW'7!X.0>AK^:[1W?^Q-((/G2#1M-VCG?*5T^ B-5^0!V8
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MXI\"0QZ-X5\/^#;OQ5KZ7-]J@M]2?P]I]W<:-I[SZM>&VM+9YU_7W7?VPO\
M@D]XFTS]E[2M>_9I_;'U.V_8R\0^'?%/[-$MS^P+^W;]O^%NM>%-#3PYHUQI
M6I)\)TO]1@BT>&VMKNPUVXU2PU)[.RNM0MKJZLK6:+^83_@DAK\/AC_@J/\
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M?#O5_P!I'QC^RNFH>([#XH^#_!>C^.7;4;/[+X<\0Z3JEI;7US;>&]8-V_\
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M(R_B7AO,\NQ&*XUP%;"O%8?'X/,L'*I2CPA2=:C>%&=6G&K!SIMQ4XN7.O\
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MNRP\1> = \9^$QX(\1Z7I^HZ?\);6>^M+_PZJ6R)K#:A]BND74[$VVIAKH_
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M'B!C_$3P\P608_.\?PKB^%\33XBR_$YGEU+*<VQV3YQ6J_5L'FN4UU7C7RC
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M]I<+X?\ @]\0]<GM9CK&N3(;N#2M!NY;2&5& AGN%CCF=9(XF9HI O?MXMU
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MP]5^NU<?2IT5!XBHIQDE:%[G\^S_ /"5AF'_  J/X\GGJ/@5\5B#]"/"9!_
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M?_9W]B?VO>_:_P"U[7W[_@HI_P %$_V=?^"9?[./B7]HK]H;Q!Y-G9QW.F^
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M&AW$C^-M1+^(-2LKVTTFZ9;+1;!1^CM% 'Y]_P#!,O\ 83_X=T?LNVW[-O\
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MI=M:R1W6C^)]&\+^*/#W\A?_  3:_P"#0?P-\3=#_:+\.?\ !2+5OVGOA/\
M%+X/_':]^'G@#6O@)XP^&^B_";XO?#,>$/#'B71OB?X,U/XB?!+Q_J'B72M8
MN->N+0WEG>Z/)HMY8W?A3Q'X>T?QAH/B"PM_]"FB@#^0RR_X,L?^"5EK=0W$
M_P ;OV]=2AB8L]C>_%;X!1VMP"K*$F?3OV8=/O54$AP;>\@?<J@L4+(W[B?L
M&_\ !(+_ ()\_P#!-R*>^_97_9_T'PUX]U#3AIFM?%_Q;?:EX^^+>K6CV\%M
M>VT?C3Q3<ZA=>&-,U9+6TDUKP]X%@\*>&-6NK6WOK_1)[V);BOTOHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _S!/^#U;_ )2F_ /_
M +, ^%G_ *T5^U57O_\ P9#?\G3_ +<'_9O_ ,//_5BS5X!_P>K?\I3?@'_V
M8!\+/_6BOVJJ]_\ ^#(;_DZ?]N#_ +-_^'G_ *L6:@#_ $?**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBHIQ,89A;F,3F*00F8.T(F*'RS*J,KM&'V
M^8$97*Y"L#@@]/Z_,#^1GP$W'BEF( _X7M^T3NST"G]HSXI D@\$!<D9&%X/
MO7\]7B[X3_$CP'^QAX?^+G@?P1XJU&[^(J_$WX$?M >"[;0M8D\27GAN[_:6
M\::[\)/B0N@+:G4+F3P5J4\FGWMX;4E_"?B6*X1S96T<E?UG:Y_P1Q_;63Q+
MXTN_ ?[?OP?\,>$/$/Q$^)'C?0?#6L_L;'Q3J7AZR^(7CWQ)X[.AW?B1OCMI
M,FN/I-SXDN+!-3?3;!KR&WBE>TA8E10_X<]_\%"/,\[_ (>/? [S>1O_ .&&
MB&P4\LCC]H<<;,+CT51_"N"/NU75LI6JX6K&#^&2PZ:G2F]7R58MPDTF^23N
MNAJZEZ<J.KC*=&I[3_EY&I3HSI*<4[KFINI[2E=M<\(.:E%2C+\FOV\@1\$?
MA@K9W+^U)^Q\""#P5^,_A!2#GD$,K C Q^>.A_;YTS4-7_9ZU:PTS3+[6+N3
MXM_ F1M/TVPNM2NI+2U^-/@VYOI39VD,T[VT%FLT]W((S'!:I--<-'"CN/OK
MXI_\$(_VV?C%X<TGPOXR_P""C?PA&F:)X\\ _$:R.C_L3+I]S_PD7PX\367B
MSPZ)YG^/]P)+!M6T^W&HVNQ3=VGF0"6(L''I;?\ !'O_ (*#&:29?^"CGP,1
MY'=R5_89((WYR 1^T/G!5BI&<%20:=HMT^9RDH5:%9S=E4G5H8B-;VLE=KGJ
M<O-+5I3;W5V\Z4O92IRA&,>1QE&FKN$.6S5.&M_9P^"%W?D2;UN?@=\._AUX
MX^#?_!0#P#\%XO#FKW7P.\)^%OVAOB/\#O&%O87T^@^&_"/Q4GT"]UGX2W^J
MHDEE97G@KQO:ZZV@6=Q(AE\+:SIT< D%H43] -/_ .3DO&F?^B#?#3W_ .:D
M_%GO7W</^"//_!08(8Q_P4<^!@0D'8/V&2%RH 7Y1^T/CY0/ER#CDCJ<\['_
M ,$3_P!NV'QAJ/CF/_@HS\%_[>U3POHO@^ZW_L0AK'^QM!U?7-<L?+MO^&@@
M4O#?^(M2,]QYI$D!MXO+7R=S-2;HT*<G>5*%2,OY6YXBO53CL[*-2*]Y.7-S
M7G)<K(C&SF]5SNG)QTLG'#T:4WHEJYTYRT2BU)6C'5'XO?'+X+>*?BQ^U-\<
M+OPE#<Z1X[\&_LU_LZ^/_@EXQN[*[CT>Q^+G@+XH?%S6-/TY-4$0MIH]5LIC
MX?\ $5A!,\RZ+X@D^TQ+'/$Q]3_X)TZOXC\2?LZ:GXJ\6^$->\!>(?%OQM^/
M'BC4_"7B33KO2]3T6ZUKQG?W5S9FUO88)I+:*[-Q'9WB(UO>6:6]Q!)(DNX_
MK@?^"//_  4&*JI_X*.? PHI+*O_  PQP&;;DC_C(;()**>O50:>W_!'O_@H
M-(2TO_!1SX'2,4*!F_8;)(!78>3^T,<Y7(]B<]L4Z=25.E.@OX<Z%6#>[56K
MFE+,)32>B=2%*G0J3UDX8>C!*UVKKVKSI56G&=*I0:47[LJ5#+%E\8S=KOED
MZ^)C!6BJV(JRO>1^57_!.$@?L4?LY$G 'AKQ"2>GRCXC>,R?TSQWZ5^4?CGX
M6?$7P'^QUHGQ@\#^"/%&J7_Q&'Q'^!'Q^\$V.@ZO)XBU#PQ=_M'^*=?^$GQ)
M7P^EJ-2N;CP/JLEUIEY=FU+'PAXM6Y5VMK".:/\ IG^$?_!"3]MKX)_#7PE\
M*/ __!1KX/CPGX*L;S3]$_MK]B8:EJOV>^U?4=;G^VWZ_M 6PN9/MVJ76QQ!
M'L@\J+!\O<?2?^'/G_!0C?YA_P""CWP.+\_-_P ,-'=@XW*2/VA\E2  021@
M<>M9I6DY7>LL/97:7+"=15;M-.[IU&HVW>DFEJ/F]Q0Z*;J/_%%)TKK:24UK
M%V2OS+F:47X%\/05^,O[(*OP4_:?^!"N,Y^9&U0%23_M+AL\CD8)X/RY\;_@
M1\8?A[^Q=^TY^V!\(/AKXPUOQ[;?';_@I)^SC^T!\-=+\+:\_C+XK?LL?&_X
MY>)Y?"/B?0_#HLUU'Q!>_!_X@3:)X_\ "5W865RUYX.UGQH+"::VN$ _2+3?
M^"/?_!0/3?$O@7Q5%_P49^!CZE\//'/AWXA^'U?]AH_9SXA\+R7,FEB_C7]H
M=7N;#==2_:;9)(7E 3;/&02?LD?LS_\ !7E&1H_^"C/[+*M&-J.?^"?=R74#
M@8<_M-97 PH"X 'J228KJK5J59*6M?"UZ%6J]*EZF)P]:5-*TDZ.(HTJF$Q&
ML9>PK344VTRZ514:4*<81FH8C"5N6;]UK"8>O"G?1MRA7G1KTV[*,Z,9_$DE
M^5/Q-_9Y_:Z_;0U[]I#_ (57X&^$$/@_X<_L6_!K]B?X=:I\?M1^)_@CQ'I_
MQ'L_"_A3]H'QWXY^$EEH?@S5;#4IK/XAV_PRT4:[J5[9VCZ[X$BT\3+%8ZB$
M^<_#_P 7]:^//[9'Q%^*_BKP]K_A#QEXM_81_8'E\>>%_$^EWFC:]H/C[2=0
M_:(T'QKIE]8:C#;W4?D^)=*U*2TN9(ECO;"6TO8"\,Z&OWB/[,__  5Z;;O_
M ."C/[*[E5"*9/\ @GQ.Y" YV@M^TR?E)))'<LQ.237QEXV_X([_ /!0+Q_\
M>?B!^T?X@_X*-? __A8_Q*\"?#;X>>)!9_L-F'P\/#_PJN/%]SX6;3M*D_:&
MFDM+\R^-M:.IW!O)DO MDJ0P);;7T=K5X\L'&K.&(5XI<V(YYU:KE9/E52O5
MJU)N/-S4W"@[PIP9Q4Z')3HP;Y_84:=&#ENU3I4\*Y2MH^?#4*+>BY<0ZU:-
MG4:/PY^.7P1\3?%[]J+XY7/A:"YTCQ_X-_9R_9R^(GP+\;7=I=P:+I?QD^'?
MQ.^*&L:59IJOEK;,FK6%Q+X:\2V$,[3OH?B25;J(1/&Q]*_X)Z:QXB\2_LU>
M(/%/BSP?KO@#Q!XJ^,OQV\2:GX0\1Z;>:7JNBWFK^*KN>ZLWM;V&"5[:*Z-P
MEI>*IAN[5([F%G1P:_7MO^"/'_!05D$9_P""CGP,* L0G_##)QEEV,?^3A\Y
M*\$YR>YI9?\ @CQ_P4%N ZS_ /!1SX'2+)&\3Y_89^8H\;Q$;O\ AH8GA7./
MH,]\B2A#EA[W/3JTISG\5IUY5755KWJUE*,:U[)+#TK2E=M==:?MI\[BH<E6
M-2GR]6L&\,XSO]F\F]+W23:OH?/=E^RQJ/[5GB']F?P#;Q:IX;U,_P#!%?P#
MXA^$7Q:_LN_.D_#C]HKX?_M _#[QU\(O$5GKRV_]GVVO:'XCTNSOKS3ENTU&
MZ\+3:U$8)+"ZGW>)_"#5/VM_VF?A39_!J/X%MX&^-7[07_!5#QU\=?CUX-^,
MVD^/O"WPGT[PC^RAH'P[\:^+=-\0>*]$\.:G>_\ "'_$GXO^'?"^G^"KG3HK
MM/%.F&9;&2:ULKZX3]A_AM^Q/_P57^%'PW\"_"GPC_P48_9H_P"$2^'?A70_
M!WAY=6_8$GOM3;2/#UA#INGR:C>1_M*6R7-]]G@0SW$=O ))=T@C4FNU_P"&
M9_\ @KU\P_X>-_LM$-Y>Y6_X)]W+H?*),8VM^TT5 4EL+C'S-Q\QJ(\]-OV:
MA:$:L:#G?F@Y9@\P4W:ZYJTZ6%AB/B<J=*---PI1C(K3=5P<8JFX*G:I%^]:
M."Q&#=+ELKTJ4JD<70CS1C'$SQ$W'FJN1^!7[1D'QP^%!\(_LP?';P3X<\+Z
MIX7_ ."Q7P9_:/\ AE?_  T_X2[5?@[?_#;]IKX7?'_Q3K&@^!O%/BO1=$N[
MRY\'_$?3_% UK1+FWCO=+37(+EHC97$,IYK]M/09?$FA_LXZ5_8ESXATV;]L
M7X"'Q%IT&GSZG;'PR^HZ[;:Y)J\,$4H@T865P\.HW=R([6&&?;-(HDP?V/\
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M?B+X4^)OB7IGB7P1X>N==DA-G+XD\#VK7OA+4+%KG[6]CHVFW0C,<K2'[_\
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M,[74_AY\2-2O[6S2SU3P?X/O=3:*1Y2WTW\ /^#=']J+]F;X[_#;]HWX5_\
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MS?:UKUC$#+"L4?\ 01_PYZ_X*#AQ(/\ @HY\#%<'(9?V&2".,?\ 1P_I0/\
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M..3QS7\?X7CA83+<TRREE'%?L<UC@U6OPCQ+:+PDYU$XK^S+/F<[=+);7/\
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MLO1/BQX]^,UE\,OVHO\ A,?B/X/^'W@CQ$LWP$@DT@:)\-+CQ1<^&SI^G_\
M"GU-I>F7Q=JYU&Y-Q*+P?95$<(@^?TD_"']O8J$/PU_:1V*Q95_X9X@PK$ $
MC_BTG&0![9&<5A/Z4OAW)2MDGB7&7LZL827 &>7A5E']S55Z37-2JJ%1:/X=
M+.S37'N3JG5@L)G+=2-**<LIQ;4?9XK#UY/X;WY:4E&S3YG%-\KD?.G_  3L
MU?Q+XD_9SUWQ5XN\%ZW\/?$/BWXX_'CQ-J?@_P 1:==Z7JFB7FK^,+FXN[1K
M6]CBE>SBO/M,=E=QHUO>0(MS#+(LN1]&_LVX_P"%$?!8G&/^%?\ A?.>!C[&
MF<GTQD\<GH,9S3&^$'[>CA@_PS_:0?=&8R6_9YB)"E2O!_X5-D':<<Y& #C(
MS7-^$/V=OVX/!'A7P[X.T3X9?M,?V/X8TBST33#>?L_07-V+*PB$4!N+C_A4
M4?G3!0"\NQ-S<[16U7Z5'AS6<E_8?B72C.*A:GX?Y[^YCR*"C2YJ;?+2C[M+
MF;?+&/-K<S_UZRB//RX?.I2E4JSBYY3BD[U*DJBYN6*6G-9\J2TT21^+WCOX
M4_$;P%^Q]I_QD\!^!O$>J:G\07^*WP)^/O@K3]!U67Q%J/A+4_VD?%NN?"3X
MCKH M&U"ZN/ FN375C-=+:N__"&^+I9Q)):6L3Q_N+JRF/\ :0_X)>(V5*?M
M^_!%'# J5=/A1\758$ ?*0XPRG&.5.T;J=_PJ/\ ;WW%S\-OVDBY&-__  SS
M"& *[" P^$H(!7@X(S]:YR__ &>OVX=2\:_!KQ[<_#+]I@Z[\"OBUH7QH\#B
M/]GZ**R;QEX=T7Q%H.G#6H$^$8DU'2/L/BC4_/L$GM7EG%M*+E/)*NE]*KP[
M]A*G_8'B1%RFIPA'@#/73H1=*DI8>E>GS.C#$*O5I\UYOVSYG?175X\R>=>M
M66%SIJK4KU$I93BKWGBI5X.5HVYE!VDXI14K*,;)R=3XX_ OXQ_#S]D']J?]
MKWX1_#;QAKGQ TO]HC_@I)^SU\<_AOIOAC6_^$M^+O[*GQT^,_B&3P_XAT3P
M^+4:CXDNOA!\0V\/_$3P9=6-M=177A76/&B:9-/;WR"OH_XC_L]?M:?MH^(/
MV@8?A7X%^$2>"_AA^P]\'/V)/A_J/Q^U'XG>!_$&G?$JX\'^$_CS\0_'/PFM
M-#\&ZM::G/IOCNW^%GA_^W-2NK.Q_MWP0--+B.QU/'MG_#2/_!6C>L@^&/Q<
M$B !)!^RL2Z;0 -CM\.2R[0,+M("\[0#3/\ AH[_ (*SG.[X8_%Q\DGY_P!E
M8-M)QG:6^'!*9QR%P"22022:PG]*/P\G3G!9)XE4YNA"%*K'@'/.:C/ZOB*%
M2$4J,5*BWC,?4YG:I.>,DY65*$7K/Q!RB==UWA,Z4GB<57:_LC$RA..(S"GF
M*A*+6\*E'#4XO6,:6#IQ4;U)R7P'H'Q>U[X\?MB^-_BOXOT#7O"GCGQ1^P'^
MP?;_ ! \,^)]*OM$UW0?B-X>U_\ :,\/>.-,OM.U""VN(0OB/3=2N+"X,7EZ
MAITMO?6Q>WF5J^5OCM\$_$7Q@_:@^-S>&([K1/''A#]FCX ?$'X)>-[FRO(=
M)TGXQ_#[XL_$77M#M8=3$26\HU.VEF\-^)+""=YQX=\1W2742QW,>_[8\<_"
M#]O7XA_'OQU^T?XA^&G[21^(GQ$\ _#?X;^(5L_V>8H/#X\._"R]\7ZAX8:P
MTN3X2SR6NHO/XWUL:I=F]E6\B^QQ)#;K;GS'?\*A_;VVA/\ A6G[2.T,6 _X
M9XAP"P()'_%I>"02"1R<DDDX(ZY_2K\.)8B6(I\/^)5"3GBZU*$> ,]DL/5Q
M%'%TZ?))P4FJ<\7&IS63;PM+2\FXY4./,GHT)8>6#SBM3J8?#X:HJF48J\J5
M'&X;$RBW9N7M(8:<)2E[S^N5XNZC&4_B[]C_ %CQ)XE_8_\ 'WBOQ=X/UOP#
MXA\6?';XK>)-5\(^(].N]*U71+[5OB/8S7=HUI?0P326B7:726%XBF"\M(X[
MF"22-\C^N/\ X)ZZKKNA?\$[?AUKGA;PM<^.?$VC>'/C-JOASP39ZMI.@WGC
M#7=.^)?Q)N](\+6NN:]<6FAZ+<^(-0AM])@U;6KJVTG3I;M;S4;B&SAFD7^>
M'4?@?^W#K5I+IVN_"/\ :+UC3;A8TN+"X^ 5Y:1SK!+'<0*UUI'PSTW4HA#<
M0PSJ+>^AW-'Y<OF0230R?TP?\$Z_"GBCP1^QQ\'O#'C3PWK_ (1\2Z9_PL'^
MTO#WB?1]1T#7-/\ MOQ3\;ZA9_;M)U6VM+^T^UV%W:WUM]HMX_/L[FWN8M\,
MT;M\?P+QK@/$GZ3];BW(<HXEP.18+Z/N'X7J8C/\@S#);YM@.,\JQ5?#T?KE
M.,:D70Q,*E&49*52$:C]G%TYJ/EY-CZ>;<;5<?AJ&-AAX\,XG#SJXO"5L->O
M+/OK2C'VJ2;]A7IMV?Q*HE=1YG_D5?\ !7W]NK]LG]N?]LGXD>)_VR=+\0_#
MGQ=\.?$.N^ ?#G[/>I6^IZ1I/P$TG2-3GMYO!%CH.I)!<1:Q%<0;_$^NWUNN
MK>(=662\O'6%;2UM?S@C\?>.X8XXHO&OBV**)%CBBC\1ZPD<<:*%2.-%O J(
MB@*JJ JJ    !7^K=_P7]_X("> _^"HG@'4/CM\!]/\ #_@3]NOP'X?\O0M;
ME:UT7P_^T!H.CVFVP^''Q'OV$=M9^)K2VACL/A]\0KY@--5;;PGXLN#X2_LC
M5_ _IWPE_P"#:7_@CU!\*OAG!\3OV$/"$OQ*A^'W@R+XA2GXM?'.4R>.(_#F
MFIXLD,NC?%S^QY"^OC4&,FE?\2UR=UC_ **8J_K\_1S_ "9/#GQL^,O@_4EU
MGPE\6OB9X8U=(VA75/#WCOQ3HVH"%WCE>'[9IVJV]QY+R0Q.\1D,;M%&S*2B
MX_J*_P""-?\ P=%_M3_LI_$_PI\(_P!O#XF^-?VE?V4O$FHVFC:IXR\>7E[X
MS^,_P8:_O60^,='\:7BWOC#QYX:T]9X_[:\$^);_ %R>WT>QA7P-+HUU#<:?
MK7]DGCO_ (-@/^")?C7PEKOAJQ_8ZC\ ZCJVF7]EIOC7P/\ &/XY6?BKPM?W
MEE<6EMKVB#7?B/X@\-W>HZ4]Q]ML;/Q/X=\0^'Y;R"W;4]$U"&/R#_D@_%;P
M0WPR^*/Q)^&[WR:H_P /O'WC'P0^IQPM;IJ+>%/$6HZ"U\EN[RM EV; W"PM
M)(T0D",[E2Q /]Z30->T3Q5H6B^*/#6K:?KWASQ)I.FZ]X?UW2+N"_TK6M$U
MBSAU#2M6TR^MGDMKW3]1L+B"\LKNWDD@N;::*:)VC=6.M7X=?\&VOQ$\5?%'
M_@B1^P;XG\9:G/J^LV/@OXH> ;>\N65I$\-?"?X_?%CX6>"M/!1(P(=(\&^#
M= TFV7;N6WLHE9Y&!D;]Q: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HKR;XP_'CX+_L^>';#Q=\<?BCX&
M^$_A?5-9@\/:=K_C[Q'IOAG2;[7;FTO+ZWTFVOM4GMX)K^:RT^^NH[9',KP6
MEQ(%*Q,1\Y_\/-?^">?_ $>E^S9_X=OP?_\ +2@#[EHKX:_X>:_\$\_^CTOV
M;/\ P[?@_P#^6E'_  \U_P"">?\ T>E^S9_X=OP?_P#+2@#[EHKX:_X>:_\
M!//_ */2_9L_\.WX/_\ EI1_P\U_X)Y_]'I?LV?^';\'_P#RTH ^Y:*^&O\
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M_P"';\'_ /RTH ^Y:*^&O^'FO_!//_H]+]FS_P .WX/_ /EI1_P\U_X)Y_\
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M !T\1?M+?!__ ()Z^*[OQI?_ /!/+P_\3/AQ=_M<>!OVMO&?A36_%>J_ ?\
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MK/\ PK_P'_T)/A'_ ,)O1O\ Y"H_X5_X#_Z$GPC_ .$WHW_R%7\NEA_P4O\
MVW/BO^S1^QC\;K#XN^%?#%EXN_9;^(?QC^.FG? B']F._P#CC/XA\"_%;7/
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M33GQ#=26FCZ''; ']%G_  K[P%_T)'A#_P )K1O_ )"H_P"%?> O^A(\(?\
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MX>QN? T/Q+O? =O\)[GQ.NJ1OHD6D6_CF6[N?$"GP];1S:WBP/SEHG_!?O\
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M$\.>#_&6I:IHUU;:-X*\9ZOX?\6:X+K1)]'T:^MO$?AZ;5 #]=**_(GX,_\
M!37P=X9^#7[>_P ?OVR?CC^SGI?PF_8\_;:^)7[.6I>,O@+\/OVGQ:?#;POH
M?B#X>>$O!_A+XSZ5\1/ K^(/$WQELO$GCS3['QUXH^#&E>(_@J8-4TV^\/\
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M-MX#L],O/%LMSXYTFXT'7HM+LM.U6  '[\T5^*7_  3 _;BU3XC_  "^+WQ
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M@\?>*K*UT[Q-XVUKX6^"-4\5^(+&QDMY;*VUGQ!>Z)/JNI1V<EG9O:B[NYC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\?:AXJNOAUJD)N/#,>F$W^I:Q_3A10!Y?\(?@A\%_P!GSP;!\.?@)\(?A?\
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M<^;>7EQ-)WU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&[O8Y]8U[Q!X2T/4?$!\/SSWRI!K&OW>OW"SZK:V%Q;?0%%?:G\PGY/?#O\
MX))?"WX=?#SQYX'TSX]_M(2:OJ_AOX3> ?A%\2;+QIH_AOX@?L\_#+X ^*]8
M\;?!/P#\.M6\,^'=*M-7TCP9XAUW4Y-5F\?6'BNX\>:7/_8?C$ZKI@>!]F\_
MX):>!O$WA_QKK'Q%^/?QR\??M)>,?B)\)?BM;?M57UWX(T7XC^!O&GP%36(O
M@Z/ /A30/"%A\+O#_A/PA!XD\4Q77@YO!M[I'BD^+_%4_B1=0NM6$]K^I%%
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M\0:OHOA@7.L+X=L+$:F_E?H%110 4444 %%%% !1110 4444 %%%% !1110
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M*N'E)2E2ERN44TF[)W2>O4Z:-15J4*J3BIQ4DF[M7Z7-;_AT[_P2R_Z1I_L
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MKI_PZ=_X)9?](T_V /\ Q#?]G7_YW-'_  Z=_P""67_2-/\ 8 _\0W_9U_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBZCJGBOQMINF:QX0C\3'PWI>B:CH.NV.H7^G6_B2[O(K>23PT"BLBR;XB?\
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>T444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img81402019_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img81402019_9.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0IV17AI9@  34T *@    @ $ #^  0
M   !      $   0    !   %"@$!  0    !   "8@$"  ,    $    S@$#
M  ,    !  4   $&  ,    !  (   $1  0   $Q    U@$5  ,    !  0
M  $6  0    !     @$7  0   $Q   %F@$:  4    !   *7@$;  4    !
M   *9@$<  ,    !  $   $H  ,    !  (   $]  ,    !  (   %2  ,
M   !  (         "  (  @ "     @   "S   !7@   @D   *T   #7P
M! H   4    (\P  #6<  !BZ   D3   +'D  #.^   [,P  1<X  $O<  !-
M'@  3F@  $\3  !/O@  4&D  %$<  !1QP  4G(  %,=  !3R   5',  %4>
M  !5R0  5G0  %<?  !7R@  6'4  %D@  !9RP  6G8  %LA  !=X@  8+T
M &92  !N2   =6L  'O-  "##@  BM0  (]]  "0*   D-,  )%^  "2*0
MDQ(  )2G  "6+   F>@  )V1  "@G@  HY\  *<T  "J:@  JXX  *RZ  "M
MPP  KGT  *\W  "O\0  L+,  +%M  "R+P  LT0  +4J  "W*0  N=   +NJ
M  "^80  P6P  ,28  #'V   RQ<  ,Y@  #03P  TF$  -<E  #;U0  X+(
M .6%  #JB   \-0  //X  #VA   ^M$  /_O  $%U  !"OX  1!I  $7%0 !
M&?T  1Q1  $@\P !)E0  2O*  $Q0@ !-LD  3U6  % ?0 !0Q@  4;+  %+
M#@ !3^H  52/  %9M@ !7[L  6*_  %EG@ !:#(  6II  %L<P !;LT  7#M
M  %RH@ !=#$  770  %W_  !>DX  7S>  %_:@ !@AD  83?  &'30 !B1X
M 8LM  &,X@ !CF0  9 R  &1[@ !D^8  97>  &7SP !FD   9S1  &?+@ !
MH:H  :/7  &F,P !J.(  :N0  &N)@ !L+P  ;,@  &U:@ !M]<  ;IM  &]
M)  !OY$  <-$  '&EP !RB0  <WG  '1+  !T[P  =8S  '8J  !VTP  =^#
M  'C5  !YV<  >N7  'O!@ !\7@  ?/F  'V(@ !^)@  ?LM  ']W  " +,
M @/=  (%E0 "!V4  @D(  (*X@ "#(4  @W,  (.S@ "#ZP  A&+  (5'P "
M&?4  A^5  (E&@ "*IL  B^   (R4  "-,<  C5R  (V'0 "-L@  C=S  (X
M'@ ".,D  CET  (Z.0 ".P\  CR^  (^?P "0"<  D'1  )$OP "228  D[C
M  )390 "6',  EN=  )<2  "7/,  EV>  )>20 "7O0  E^?  )@2@ "8/4
M F&@  )B2P "8O8  F.A  )D3  "9/<  F6B  )F30 "9O@  F>C  )H3@ "
M:/D  FFD  )J3P ":U(  FS\  )P?  "=4@  GK&  )_IP "A'(  HF?  *+
MHP "C)$  HT\  *-YP "CI(  H\]  */Z  "D),  I$^  *2R  "E@(  IIT
M  *?F  "IK@  JSZ  *S 0 "N2<  KS$  *]_  "OJ<  K]2  *__0 "P*@
M L%3  +!_@ "PJD  L3Q  +'Z  "RM@  L[L  +2[0 "U?X  MF!  +<V  "
MWH   M\K  +?U@ "X($  N$L  +AUP "XH(  N,M  +CV  "Y;T  NC:  +K
M\  "[V<  O+-  +UA@ "^'0  OL6  +[P0 "_&P  OT7  +]P@ "_FT  O\8
M  +_PP # &X  P$9  ,!Q  # F\  P,:    JP   *L   "K    JP   *L
M  "K    ]@   _,   1T   +4P  "Y(   @M   '10  !W4   J;   &#@
M 4(   %*    JP   *L   "K    LP   *L   "K    JP   *L   "K
MJP   *L   "K    JP   *L   "K    JP   *L   "K    JP   L$   +;
M   %E0  !_8   <C   &8@  !T$   ?&   $J0   *L   "K    JP   *L
M  #I   !E0   84   .\   #J0   PT   ,!   #E0   S8   $D   !+
M 0D   "Z    N@   +H   #"    N@   ,(   $5   !Y@   ?\   *G   !
MV@   K<   ,+   #+    T    ,_   #20   >\   (2   $Q   !+    3=
M   $TP  !0,   9,   #)    HP   1-   %'@  !>4   4J   %:P  !JP
M  +H   "5   !*(   5A   %=@  !7@   6'   &C0   R<   *;   #LP
M!$,   3<   $I0  !2<   8%   #!    M\   *4   "-P   @H   ):   "
M(    ;4   &/   !GP   BP   )2   "D    HP   *O   "Q@   FX   '1
M   "#P   ;4   &"   !S@   ;P   'X   !^    ?$   )Q   "D0   ET
M  )\   "+0   EP   *O   "K@   I8   *6   "9    DH   )M   "E@
M K<   )M   #LP   U,   .-   #PP   T4   *0   "=P   G4   *D   $
M-P   ]$   03   $,    V\   )R   ";@   CP   )V   "E0   J\   +7
M   #*@   ;@   '0   !HP   =H   &C   !1P   0(   #>   !WP   Y0
M  36   %H   !84   6!   $Y0   M    )W    JP   *L   "K    JP
M *L   "K    JP   ,4   #6   !KP   <$   &H   !J@   NX   1G   %
MO0  !((   4.   #*@   *L   "K    JP   *L   "K    JP   *L   "K
M    JP   *L   "K    JP   *L   "K    JP   *L   "K    JP   *L
M  "K    JP   *L   $#   !J@   X    3,   %?@  !.$   3+   %+0
M @0   #N    JP   *L   "K    JP   *L   "K    JP   8H   ,Z   $
M<@  !20   <@   &0@  !@<   8F   #G0   3@   "K    JP   *L   "K
M    JP   *L   "K   "2    O<   +P   $%   ! $   ,1   #@P   U<
M  &H    JP   *L   "K    JP   *L   "K    JP   *L   'E   #'0
M Q8   -W   #9@   KD   +N   "H@   *L   "K    JP   *L   "K
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M+P3\3/AW\4_A/;ZKXRM?![W5EXF\!0ZP;*+Q#97*J!<1*S"%KFW9=R[P20Q
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M9:1I_P!GGDCLK2TB_=QJN$W.=SR,NXD9(KZD_9B_X).?L_\ [&OQ.'C+X;^
M?^$;\2"TDL1>?VYJ5Y^YDV[UV7%Q(G.T<[<C'!%<W_P44^'7B#QO^T+^RW>Z
M+H.LZO9^'_B,+[5)[*RDN(M-M_L<R^=.R*1%'N(&Y\#) S71EE:E0QT/JLVX
MO1N45%];K24M'UU5]FK;XXZG4JX.HJ\5>SLDVT]-.D=;[*SM9/?;T+]NC]JU
M_P!E[X4VZZ'9KKWQ&\972Z'X,T('Y]4U&7A2P[0Q ^9*YP%13DC(KY1_X)Q?
MLYS?LR?\%7?BCHFI:S=^)?%&J?#G2M:\2ZS<.S-JNJ7%Y*UQ,JGB./< J(H
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M6<DD0@+2-]E\X':[QEBDD#A>"0/.?VL/V:/C9HO_  3,^!<FK?M PZUX<O\
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MOC5K#>&+3PR?#BZ39^$=0EBW0217*,\]U!&V2_FL&=5(4*6!7COB9^Q-\1O
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M&+)9+?5[&:\ACCDDM[F)HHYY$=E94WH,@JW/%S]O[Q/>6GQ=U'2?B]^R_?\
MQ^^$=U;6\GA?4_!?AA=:US2+DJPN(;J)Y@Z@D!EFA\M0I"G<2<?'WQU_9\\5
M?LX_\$C_ (X7MOX8\0?#?P)XA\<:)J?@+P5XAO3>7WAZV%W;[WFW/(T1FEPQ
MA9V9=IR222?1RO#T*T,*I1BESTKZ0ESMU(*2O\:DTW>$E*-D[67+?',*E2G4
MK.-V^6=M9+EM2DT[?"XW2]Y6DI-+>Y]4?&SXJ?M4?L3^";?XZ>/O'7@OQ;X(
MAN;1_%GP]LO#B6H\,V4\J1.]EJ"L9KJ6$NI;S0%;#$ #&.X^/_Q[^+7[2'[6
MEY\%/@;XNT'X=V_AGP]:^(?$_C2\T9-:NK4W;'[+:VMK*RQ,SHC.S29&T\%2
M/F\U_:7^*?Q:_P""C'PI'[/J_ ;XB^ M2UZYL;?QMXHUJ..+PWIME%-'-/)I
M]VDA^W%_+VHJJI^<;@,''7?&;0_&O[ W[<FM_&+PW\-?%WQ2^''C_P +Z?H>
MO6/A.W6_U[1KRP+);2QVK.K30O$Y5@IR""Q(  ;FC3A[GMHTU5]_D2Y>5JT.
M3FMH]>?E<KN324KIJ^D9/D;I.35H\U[W3YM;7V?+?F4=$K.*3NS0^#/[2WQ=
M^#'QG\=?!#XN>(M#\8>)]-\$S>,O"7C+3=*737UBVC9HI5N;0%H8YXY=A C^
M0J>AKP_X(?%+]LWXY?\ !//2/C]#\9O!^B2:/H5UK">&9O!5M./%45L9"SWE
MUE# T@B?:MM&BA2N3DEAZE\,_ WC[]KO]IGQM\?/$GPY\3?#GP_IOP[NO!_@
MW0M>B1->U)IV:>:ZGMD+&!N%C6)B6.372?L?_"_Q-X9_X(>Z7X3U+P[KNG^*
MH_AYJ-D^C7-A+#J"SM%<!83 RB02$LH"[<G(XYJ*]:&'H3J\D/;?NN9<L6DW
M[:]HV<5>*AS)+279I6VP])5L72H<TO8OGUO)-JU#>7Q:2<^5MWMLVF[_ #;_
M ,%0/%OCS]KKX!_L<_$G0?&R^![3QUXK\.O%I"Z'!?+IFKW0,D6HK)(VZ18/
MF40-\D@(+$&OH3]KOXE?&SX3GPGX1O/C;\/?@_X9L_#D;ZU\7/$MCI;77B+6
M$(#6]GI4MPD<;,JM(V590'VIRO/DOQI^!/CS3_\ @E1^R3?6O@7QEK.M?"#7
M/"_B'7_#6GZ6\FN);VL9$Z):MM=IE) \LX.3S@ D6OVA/.A_;8TKXW?$+]FK
MXF?&3X?^+O!&FV_AK2(/"<.LZMX'OA(TTT5UILK[;>5MREI<G8R[0WIZ<HTF
MXX>FHN%.K6LK1;V3BM;7OK;F;B[)-2Y8Q.&,IJFJ\[\\J-*^K6O,U+:Z5E9N
MRNDVU9R<CK/^"8W_  4&\2?&?XW?%3X5ZQ\5/#/QNC\$Z-#K6D^.=)T:/2#?
MB0D2PR6\9,+&-FC :/Y>H)8]/._V5?B/^V9^UM^PO8_&"R^-GA/PQ)H\>HW%
MII4W@JTNG\6I:SR@_;)_D6V4F-HE%M$#L4,6+'([#]DOP!\2+[_@J=\2/'GB
MCX4ZK\._#GC#X916V@VJ0?:(;98KE%%O<30 VT=XVUI# KDA77[Q#&O2/^"7
M7PP\3?#_ /X)!Z'X9U[P[KFA^)(=*UN-]*O["6VOD:2[O&C4PNH<%E92!CD,
M".HKAS*K1P]"KBJ$(<[5%V:A))M5E.R2Y-7%725KVZV9TX&G.I7AAZKER<\E
M>\E>/+3:U;YK7D[.]^UE='&_%'_@K'K4_P"Q7\ ?$.DW_@/P+XZ^/*I$=5\4
M70M]!\-)#$7OKMR[C<JE0L4;."S2H"2<@XOP)_;W\0? K]I/P!X-\5_M._"/
M]ICPW\3M2;15O-"ATS3=9\-7S1EK<M!93O'):R,IC+, X>1,$C"GSVT_8-\7
MZY^P!^R7XQN/A6OCGQ#\%89QK_PY\1:?'%-J]A=;DGC\B[7;]HBVI(B2*,D9
M'( /I_[.>E^'_CI^T+X-G^'7[$.A_"'P[H-X;[Q#XH^('PXL-"U&U,:[H8]+
MBB/FM.9"A$Y.Q K?*3BNZ>'R^G[:-.*<5.JI?!HE*2A9R]Y+ELXN/Q2NO>>A
MP1JXN="C*3:DZ<&OBUDU[UTM&[Z-2V6NEVSHYOB;^T!^W_\ &SXE:?\ "#XH
M:#\%?A[\+=>?PNNJGPM!X@U/Q%J4,:FZ#)<L(HK=&D55*#<2#U!P,C5_V^_B
MIHG[$_[36F^)+K0M'^.'[/\ ;R0R:MHUJ'L;^.6 3V5^D$X=5+INW1L&4,AX
M (4,\(^-?'?_  2O^-GQ<T^Z^#/Q0^*?PY^)7BN?QCX?U;P%IB:S>6=S=HGV
MFTN[?>CQJK1@K)R"&QR3@5?#'[$?Q*_: _9Q_:N\6>)_#</@KXA?M%6YM](\
M/7%W%/+IMG:6IALHKB1#L664EBV&(7<N<$$#S90H1H7FH>R4*;B_=YG.]/G3
M:]YZ>TYHOW5962TOZEYO$\L6^?VDE;7E]G[_ "O^5*W)KNWH_M6];_;=_:4\
M:_"'_@DEK'Q.\.ZU_9_CBU\*:;J46I?8X)MMQ*;?S'\J1&B.?,?@I@9X P*\
MD_;:_;E\=:3^U!X'^$MC\8_"/[.NDZUX+C\33^.M?T6VU :G=M*(_L<*W+I;
M1\!F8O@\\8XSY?\ M4?'CXS?M+?\$NO$'P=T?]FOXP:'XNT'0-/TWQ!=:II.
MW3YA;R0JRZ88S)+J#R&+@1QA50EB^ -WOW[:?B'7_"\OAG3?B!^SC)\?/@G/
MX?M\P>'_  ZNK^)M U9=JMNM991OB=",/$J,A#[B1@'>G@Z5"JO:0C)NI4LK
MP^'DCRVO>+5W>,9:2>EM5?GC6J3PL8WDI*"YG9W34H73V=]&I-:Q3;Z'O'[&
M5A\6-)\!ZA:_%3QEX'^(C0W0&A>)O#UJUG)J]IL +W=NH,,4WF!N('9"".A'
M-S]M[]H9?V6?V5_&?C9(UN-1TNP:/2K4GYKV_E(BM85'4EYGC7 YYKYG_P""
M/W[-^J?"/XE?%;Q1X?\ A[XP^#?P;\7&P?PSX*\3W3-J,=RB/]IO7MVDD:TW
M[D7RV<L=O. JBNV_;^^ -U^W'^T1\+_@_KGA_6[OX26:77B[QG="*YM;'4#"
MOD66GK=Q[?WK32M*T:N&"1!N.*\C%8.C+,E2G)<CLY62C9*/-)6BW%2LFK)V
MYM--EVX6O.&%=1+6-[7;DFV[1U=FXMM+797=VE=^.?"CX/7'_!+7]J/]GF:^
MD:32?BQX:_X0'QG? YAD\1!WOK:Y=FYW2SS748)YPP]*]!_;@_: ^.^E?\%%
M?A;\*?A#K.BZ=8>,O"VHWNIG5K"*XM=-,<@7[>WR^=(T2G"0K(J.[*&^7)KB
M_P!J7_@W\^!>C_ 'Q-J?P;\"W7A7XHZ+:'4_#.HV^OZG=21WUN1-$@CFGD0[
MV39RA(W9&" :X'XH?M0?$0_M]?LP_$2U^&?B34O%%[\+M2F\2^#Y;8V&M(@D
M07:P0SA,S)(OF(C;?,5< C<#7MTY8;'5X8BF^>2552YXJ*;<*DX.W-)63NKW
M7*HQVW/.E&OAJ,X27+S>SLXMR=XU*4);Q6KBXZ6?,W*][M'T)\!?C5\8_P!F
M7]L70?@K\;/&VA_%#3_B!HUYJGA3Q?;:''H=XUS:8>YL[FUA)AP(F#HZD'"'
M.2?EX/X:_%7]I[_@HIIGBCXE_"?XG>%?A9X"T76[[3/"FA3^%H-7D\7I:2>6
M9;RYF8-;I+(C*/) 906[@,>H^#%EXP_;Z_;I\(_&37/AEXU^%OP_^%>AZA8Z
M#:^,+?\ L_7-9U&^Q%-(UFKMY,,<*$ O]\N",C[O!?LT?$WXD?\ !*/P?K_P
M;U'X"_%CXF:=#XAU"\\$:]X,TV/4=/O[2ZF,T:7\ID4V;I)(59G4C&2!A<GF
M]FM7&,/K/(KQM#EOSSO:/P<W)[-VMI>3LFG;H4M'9R]ESK6\KVY%?7X^7GNK
MWWTORV(/B]X8^(G[1OQ]\$OXP\*VO@_XO6OP8U368M+CNHKN&QUJQUO3;BV:
M.2)W4QO+!&P <D)(5)SFH_AUJ]S\9?VHO@)\9M2L;K3[[XN:QXFU"RM+I LU
MAI5OHDEO8PG']Y$><CLUT]?<G[+>K?$C7_@5H-_\6M/\.:/X^OHFGU+3M#$G
MV/3]SDQPAGDD+.D>T.P<J7#;>,5Z!7G8C-'3C+#*$=%4C[KO%<[FY<N]U>4+
M.[=H;VD[=%/"J=JO,]7%ZKWGRQC%7V[2=K+66J]T_+/]@;X&>$/C]X]^!>C^
M-O#NE>*M%B^!-S/_ &=J=NMS9R2?VVBJ[Q."C,NXE2P.TG(P0#7IO_!/74;[
MXS^$_P!G_P +W5_J%[;_  ZL?$'B.YGDE\R2%HKZ[TC2D9FSNQ"]X5# _P#'
ML,YQS]_T4L5GDJW,N6R;D[7V;=5]MU[3?36*[V50P/+-U+ZVBMNBC3BUYIJ#
MTV][K;7Y$^$_[%?Q*\*?M[^./&6H?%3XDS>&[_0="M[?5)8?#9D\0/;SWKS6
M4\<>G!HX8UD3#Q1PNWGO^]8J-G1_\%??VA/&'[+7[ GC+QOX#U+^R?%&DS6"
MVER+6&YVB2]AB==DR.AW([+RIQG(P<&OIBOE/_@M9\._$'Q5_P""=/C30_"^
MA:QXDUJZN]+:'3]+LI+RZF":A;NY6.-69@JJ6.!P 2>!6>#Q7UK,,+'$*/*I
MTXO1)<O-%.^EFK;WTM?2QK*BJ5*K*%[N,GNWJHNUOZO^!XM^T-\=?VK/V,?&
M7PV\9^(/'?@7QQI?Q6UZ#PJ/ *>'UTVS\.WUY$WV5H]07=<3I'(H\QI NX;M
MJ#<-G9^%?BM\?_V5/V^_ACX#^*'Q(\/_ !6\*_&R'5%MEL_#$.A/X6N[.#[1
MLA,;N\\+*=N96+=#P0=VY_P5D^&'B7XCZ;^SFOAWP[KFO-H?Q<T#4M1&G6$M
MT=/M8S)YEQ-Y:GRXDR-SMA1GDBM3]LKX<>(?%'_!2#]D_7--T'6M1T3PY>>(
MVU;4+6REFM=+$NFA(C/*JE8@[?*N\C<>!DUZN'K4:M.GSP@N95HOW8K2--RA
MTNFI/XOBE9*3EL<$J,US6E+2$)+5_%S23\K-15X_"KMI)NYPNA_$;]HK_@H?
MX_\ 'VI_"?XJ>'_@G\-_ OB*Z\,:5.?"D'B#4/%%S:X6XEF^T,$A@\P[4,8W
M<'(.,GD?C)_P4B^+&@_\$[/C)?7EUH_A;XW?!?Q79^%]6O=)M8[BQNQ)=6VR
M[ABN%D"I-;S'Y6!((8C;P!K?"CXB_$#_ ()5^,OB-X)U+X(_%3XH>!_%'BR^
M\3^$=<\!Z8FK.JWK"62TOH_,1K<QR9 E;(8'@8&:Y7QK_P $_OBO\;/V!/VC
MM:U/PS:Z'\6?C?XC@\56OAC[7%*]G;64D!M+&28,(S,T<+DG=M#2 '!SC?#Q
MPT9TI5U#V"=%Q=HW;YZ?.I?::Y?:<ZE=)I)):)S4]K*<HP;]HY5$UK90Y:G(
MU]E>][.TMWU;U/I3_@J5^T'XP_9R_91TWQ+X,U?^QM;N/$^AZ=)<_98;C=!<
M7L44R;94=?F1B,@9&<@@\UXW^W/^VCXXC_;MB^"ND_&[P?\ LTZ/;^&[?78/
M%&NZ%:ZG)XAN)97C-M#]KD2W1%"]R'+*0,]*\_\ VX_VA?BS^W7^S1X?\.^'
M_P!G'XQ>%1H?BS0[GQ))X@T<PN3#=QEDL(8_,ENHE;YVN"L<:QQDDY(%>U?\
M%"/%.J:5\4?[/^)G[-,W[0/P5N["*72+CPIX<76O$.A:B"5F2:"24$QN-I66
M$1[1E6WYXY\'@XX=4HUH1E/GJZ7@W;DI<N]XNSYG&,M'=VU:O-2O.KS^SDTO
M9T^DM'[2?-IH[VLI-:I;O0WO&?[3WQ,_86_8#\:>//BYKG@+XB:YX=D$/AS5
MM##6%OXA29HH;5[R,@102&9R9/)=HP@R",&OFGQ#_P %"/B)^S3X:C^*&N?M
M>?L[_&&WM?)GUSX8Z&FEV[Q0.Z"9=,NXKAKF>>,$E!,N&P<CI61\-/\ @EQX
ML^-G[&OQ^\.^%_"/B#X2^!/&6HZ7KGPU\#>+KHW%U97%F!+,]S&\DAMUNG"H
M8I'8IC+< 9W[8Z7\2M'L_!OA/_@G/H?AWXL2>3!?ZCXO^'&E0^"M*;<@GG%_
M'M:[C4$LJ1;7?MT(/I8;#X.$YWY9RYES*U.*4'"#LTVXQ]YS4W3=XM;K2_/6
MJUG".\8)2L[S;<E)]4E)KELX*2?-KI*US]./#VO6OBG0+'5+&59[+4K>.ZMY
M%(*R1NH96!''((-?G3\%OB1^UE^V8OQQ'A7XQ>'?A[I?PV^(&LZ1I-]<>$;3
M4[O4XX-IBL6#*D<-O&I7,VR69FD.3A &_1?0=*CT+0[.QAAM+>&S@2!(K6'R
M8(E50H6-!PJ#& O88%?)G_!,'X:>)/ '@?\ :'AU[P_KFBRZW\5O$6HZ<E_8
MRVS7]K*L/E3PAU'F1/@[77*M@X)KY7!UH4:6)K02;C&\>9*6O/'HTTW:_3Y'
MM5(2FJ%.HW[TTI6;6G).^JU2O;KO;6YX3X7_ &IOVJ/VJ/V!/^&B/"_Q \$_
M#NR\(Z1=7LGA>+PS'JB^+9-/WK=O/<S.&M$DDAE$<<*E@N,R9.5]<^*/[>WQ
M#^,/@7]GOPM\);?0?#OQ&_: T(>(9M1U6)KVT\)Z?':QSW$XC&/.D#2!(U;Y
M21\PP>.3_89^#'C#PC_P02U[P=JWA/Q+I?BZ;P[XI@CT.[TN>'4GDFFO3$@M
MV42%G#J5 7+!AC.163;? KXG?!/X-_LB?&;PQX#UKQ3KWPE\$Q^'_%O@X)]E
MUA[&ZL85E,$4NT_:8)(\F(X9ONX'./I,3#!O%U:7+!1IU9*&R3O"HXJ3ZQ<X
MPNY-I)M746>;%5XT(5(.3G*,K[O2,J:NE_,H2GRV5Y22OS,]$\"_%?XZ?L4_
MM1?#OP'\9?B'H?QC\&_%JYN=,TOQ+%X;A\/ZCHVIQPF:.WD@@8PO#(J.%89?
M<>2 ,''^&OQ2_:3_ &]]5\3?$7X7?$CP?\-OAWX;UZ^T?PWH-]X735_^$Q6T
M<Q//>7+2));QO*CA?(PP7.<D EMMJ_C;_@IM^U?\(?$$WP@^(7PM^%_PAU.X
M\1W5UX\T^/2]4U?4O(,5O!!:"1W$:,YD,I^4[<#! SE?L[^/_B5_P3*/B+X+
MO\"_B5\2M*NO$.HZGX&\1>%;:&XTRZM[R9KA8=1GDD4631R2,K2/D$ D @ M
MRRI^[=QA]9Y=K0Y;<SN^7X.?EM96^'WK7NRN96]UR]ES1N[RO\,KJ_Q<M^6[
M3^)N-TKH\\_8C_;)U#]CW_@D?\0OB'J.EZ5!XMG^).L65MIM[=B*Q@U.[OUC
M"33$@+#$[LSN2OR1MR.HDUS_ (*'>-OV38++X@^(OVO/@#\=M%>^MH_$'@/0
MXM+L[S3K::54D?2YK>X:>X:$N&VSK\R(Q.#R*?PR_8&^)'[1/_!)CQEX4UKP
MJFA_$FQ^)VI>,K#0]:LWBL=4GBO?-\G$ZKOMIU:1$=AL8,I/&:UK"WT/XTSZ
M;X1\#?\ !/'0?!WCR2Z@AUC5_'OPTTRW\)Z+$' N)8[F,J]]A=P18MA8D'IP
M?5IQP<JTY3C&3YTI+W+*'+"UG.[4;\ZYH/F5M7\-^*3K1II1;4;3:?O)\_//
M^75OEY6HR5FV]'JE[5HEW'?_ /!>FZN(762&;X(QR1NIRK*=7!!!]Q7L/_!0
MC]JN_P#V0?V<;KQ'H.EVNN>+M7U&S\/^&]/NG*P7>I7DHAA$A!!V*278 @D(
M1D9R/.-'^%^O6'_!:NX\3)X>U:'PFGP>CTF/5DT^1--%R-4#_9EFV^6) @W>
M6&W!><8KK/\ @J!^S9XF_:6_9A6U\#QV=QXX\':YI_BW0+6[D$=O?7=C,)5@
M=B0 )%WJ"2 "1D@9(^9J>PE6P<:S_=VBI>4?:2O>VJTWMK;8]FG[52Q+BO?T
MY>SE[&%M]+<VFNG<\+^,GC+]JK_@GIX'7XO_ ! ^+/A'XN>";&\MCXM\+0^$
M(M(.AV<TR1O+I]U$QDG,32# G'S*N2,UP'C'X*_%GQ;_ ,%XM.N=(^.4>G_:
MO +^(-/G_P"$+L;C[)H9U1 VC#<WS;\D_:S^] .,8KJ_VF_CK\4O^"FWP8NO
M@;H?[/?Q:^'5WXHNK2S\7>(?&%A#8:/HEFDZ27#V<_F-]N8^453RU&0P;H:]
M6M/A#K6@_P#!9S0=<M/#^M+X-TWX-/HB:N+*3^SX[A=31EMC/M\L2^6-VS.[
M:,XQ7LX>M*A^\K1IQJ\M964:;7)[-.-TDXZRND]Y*Z;:>O%4IPJT90@YN/[M
MN[DGS>UBO)IV;<HKW8VC))25SZC^(O\ R3[7O^P=<?\ HMJ_,?\ X)6_\%/?
M^%'?L!_#GPK_ ,,\_M1>,/['LYX_[8\,^ _[0TF^S=3/N@G\]=ZC=M)VC#*1
MVK]._'MO)>>!M:AAC>6:6PG1$12S.QC8  #J3Z5\]_\ !'+P%KGPP_X)K_"W
M0?$NBZMX=US3[&X2ZT[4[.2TNK9C=SL \4@#J2I!P0."#7AY;6HT\#B/;1YD
MYTK*]NE;73M^IUXZG.6)H>S=G:KK:_6EI\_T/9/"?QST_7?@'!\0]6TO7O!>
MEMI+:Q>6/B2T%AJ&DPHA=UN8BQ$;JJDD;CCUK\V[_2-:^"WP-^&_[:6H6<R:
M_JGQ F\7>*(HPTCP>%M96.R2$C R(;6.Q< \!@3[U]C?\%/O#'BCXR?!C0OA
M3X7T[6IA\5M>M=#UW4K.TDD@T;1@?.OY9I54K#OAC,2%R-S2@ YKS?Q%_P &
M[_[)>J>'+ZUL?AC-IM]<6TD5O>Q^)M7DDM9"I"RA7NF1BI(;#*5..01Q75E.
M)P>%B\36<H\TK<L4I-TUK.+O*-E.ZC?5^Z].\XRC6K*.&C9^ZVVVXI2:<8R5
ME+6/O2M;K%D?_!<_Q_H_@S]E_P"%_BG4KU(= TGXH>'-5NKM$:94MHY7E>0!
M 68! 3A02>P)K#^/O_!;#]ES]H#X*^*?!7AO6-6^*^N^)M+N;"Q\*Z;X/U2:
MYU:5XFVHJS6R)P?FR6^4#(Z5YO?>#/BWX\_X)S_!7P/XE\#^-+CQG\(_C!HF
MA:@RZ)=,+[3M/NRL>IQ'9E[3[.8LS_<RK$FOU$JL13P>&PRH5DZG+4J<KC-1
MNN6G9_#)V:LU9IK7KL4JN)J5H5H6A+V<.9.+E:2G5NM)+9^M]'MOXK_P3F^%
M7B7X'?L*_"OPCXP#)XDT#P[:VE]$SAVMG"\0DC()C4JG!(^3BO:J**^?QF)E
MB*\\1/>;<G;:[=]#LPN'5"C"A'5126N^BL%%%%<YT!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 45Q?Q=T/XB:U_9_\ P@7B
MCP7X;\OS/MW]O^%[G7/M.=GE^5Y.H6?E;</NW>9NW+C9M.[C/^$&_:&_Z*C\
M&/\ PUVI_P#S05T4Z$)1NZB7D^;](M?B8RJ23LHM_=^K/9Z*\8_X0;]H;_HJ
M/P8_\-=J?_S04?\ "#?M#?\ 14?@Q_X:[4__ )H*T^K4_P#G['[I_P#R(O;3
M_D?_ )+_ )GL]%>,?\(-^T-_T5'X,?\ AKM3_P#F@H_X0;]H;_HJ/P8_\-=J
M?_S04?5J?_/V/W3_ /D0]M/^1_\ DO\ F>ST5XQ_P@W[0W_14?@Q_P"&NU/_
M .:"C_A!OVAO^BH_!C_PUVI__-!1]6I_\_8_=/\ ^1#VT_Y'_P"2_P"9[/17
MC'_"#?M#?]%1^#'_ (:[4_\ YH*/^$&_:&_Z*C\&/_#7:G_\T%'U:G_S]C]T
M_P#Y$/;3_D?_ )+_ )GL]%>,?\(-^T-_T5'X,?\ AKM3_P#F@H_X0;]H;_HJ
M/P8_\-=J?_S04?5J?_/V/W3_ /D0]M/^1_\ DO\ F>ST5XQ_P@W[0W_14?@Q
M_P"&NU/_ .:"C_A!OVAO^BH_!C_PUVI__-!1]6I_\_8_=/\ ^1#VT_Y'_P"2
M_P"9[/17C'_"#?M#?]%1^#'_ (:[4_\ YH*/^$&_:&_Z*C\&/_#7:G_\T%'U
M:G_S]C]T_P#Y$/;3_D?_ )+_ )GL]%>,?\(-^T-_T5'X,?\ AKM3_P#F@H_X
M0;]H;_HJ/P8_\-=J?_S04?5J?_/V/W3_ /D0]M/^1_\ DO\ F>ST5XQ_P@W[
M0W_14?@Q_P"&NU/_ .:"C_A!OVAO^BH_!C_PUVI__-!1]6I_\_8_=/\ ^1#V
MT_Y'_P"2_P"9[/17C'_"#?M#?]%1^#'_ (:[4_\ YH*/^$&_:&_Z*C\&/_#7
M:G_\T%'U:G_S]C]T_P#Y$/;3_D?_ )+_ )C/V\?V/O\ AMKX.:;X2_X2+_A&
M?[/\0Z=KWVK[!]M\S[),)?*V>9'C?C&[<=O7!Z5[4.!7C'_"#?M#?]%1^#'_
M (:[4_\ YH*/^$&_:&_Z*C\&/_#7:G_\T%:N*=)476CRIMI6EO)13?P7U45]
MWFR.9^T]K[-WLH[K9-M+XN\G]_H>ST5XQ_P@W[0W_14?@Q_X:[4__F@H_P"$
M&_:&_P"BH_!C_P -=J?_ ,T%9?5J?_/V/W3_ /D2_;3_ )'_ .2_YGL]%>,?
M\(-^T-_T5'X,?^&NU/\ ^:"C_A!OVAO^BH_!C_PUVI__ #04?5J?_/V/W3_^
M1#VT_P"1_P#DO^9[/17C'_"#?M#?]%1^#'_AKM3_ /F@H_X0;]H;_HJ/P8_\
M-=J?_P T%'U:G_S]C]T__D0]M/\ D?\ Y+_F>ST5XQ_P@W[0W_14?@Q_X:[4
M_P#YH*/^$&_:&_Z*C\&/_#7:G_\ -!1]6I_\_8_=/_Y$/;3_ )'_ .2_YGL]
M%>,?\(-^T-_T5'X,?^&NU/\ ^:"C_A!OVAO^BH_!C_PUVI__ #04?5J?_/V/
MW3_^1#VT_P"1_P#DO^9[/17C'_"#?M#?]%1^#'_AKM3_ /F@H_X0;]H;_HJ/
MP8_\-=J?_P T%'U:G_S]C]T__D0]M/\ D?\ Y+_F>ST5XQ_P@W[0W_14?@Q_
MX:[4_P#YH*/^$&_:&_Z*C\&/_#7:G_\ -!1]6I_\_8_=/_Y$/;3_ )'_ .2_
MYGL]>(_ML_LN^,_VK_"=AX;\/_%K5_AGX9O%GM/%%KINC6UY<^(+.554PQW$
MOSVC !QYD8;(D.0<"I_^$&_:&_Z*C\&/_#7:G_\ -!1_P@W[0W_14?@Q_P"&
MNU/_ .:"M*-.-*HJD*L+KNI-?-.#3^:\Q2J2::Y)?)I/Y-2NGYK4]/\ AYX!
MTGX5> M%\,Z%:1V.B^'[&'3K&W3[L$$2!$4?15%;%>,?\(-^T-_T5'X,?^&N
MU/\ ^:"C_A!OVAO^BH_!C_PUVI__ #05,Z,9R<YUHMO5OW]__ 2:<G"*A&FT
MEHOA_P SV>BO&/\ A!OVAO\ HJ/P8_\ #7:G_P#-!1_P@W[0W_14?@Q_X:[4
M_P#YH*GZM3_Y^Q^Z?_R)?MI_R/\ \E_S/9Z*\8_X0;]H;_HJ/P8_\-=J?_S0
M4?\ "#?M#?\ 14?@Q_X:[4__ )H*/JU/_G['[I__ "(>VG_(_P#R7_,]GKQ'
M]A_]C?\ X8TT'X@6/_"1_P#"2?\ "=>-=1\8;_[/^Q_8OM90_9\>9)OV;/O_
M "[L_=%3_P#"#?M#?]%1^#'_ (:[4_\ YH*/^$&_:&_Z*C\&/_#7:G_\T%;4
MXJ$)4XUHVDDGI+5)I_R=TMC.;YW&4J;]UW6JWLU_-V;/9Z*\8_X0;]H;_HJ/
MP8_\-=J?_P T%'_"#?M#?]%1^#'_ (:[4_\ YH*Q^K4_^?L?NG_\B:>VG_(_
M_)?\SV>BO&/^$&_:&_Z*C\&/_#7:G_\ -!1_P@W[0W_14?@Q_P"&NU/_ .:"
MCZM3_P"?L?NG_P#(A[:?\C_\E_S/9Z*\8_X0;]H;_HJ/P8_\-=J?_P T%'_"
M#?M#?]%1^#'_ (:[4_\ YH*/JU/_ )^Q^Z?_ ,B'MI_R/_R7_,]GHKQC_A!O
MVAO^BH_!C_PUVI__ #04?\(-^T-_T5'X,?\ AKM3_P#F@H^K4_\ G['[I_\
MR(>VG_(__)?\SV>BO&/^$&_:&_Z*C\&/_#7:G_\ -!1_P@W[0W_14?@Q_P"&
MNU/_ .:"CZM3_P"?L?NG_P#(A[:?\C_\E_S/9Z*\8_X0;]H;_HJ/P8_\-=J?
M_P T%'_"#?M#?]%1^#'_ (:[4_\ YH*/JU/_ )^Q^Z?_ ,B'MI_R/_R7_,]G
MKQ3_ (*"_L>_\-V?LQ:K\./^$B_X17^T[RSN_P"T?L'V[R_L]Q'-M\KS(\[M
MFW.\8SGGI4G_  @W[0W_ $5'X,?^&NU/_P":"C_A!OVAO^BH_!C_ ,-=J?\
M\T%:X>*H585Z5:*E!J2=I:.+33UA;1KKH14DZD)4YTW:2:>JV:L_M=F>R6T/
MV>WCCSN\M0N<=<"GUXQ_P@W[0W_14?@Q_P"&NU/_ .:"C_A!OVAO^BH_!C_P
MUVI__-!67U>G_P _8_=/_P"1*C4DE90?_DO_ ,D>ST5XQ_P@W[0W_14?@Q_X
M:[4__F@H_P"$&_:&_P"BH_!C_P -=J?_ ,T%'U:G_P _8_=/_P"1'[:?\C_\
ME_S/9Z*\8_X0;]H;_HJ/P8_\-=J?_P T%'_"#?M#?]%1^#'_ (:[4_\ YH*/
MJU/_ )^Q^Z?_ ,B'MI_R/_R7_,]GHKQC_A!OVAO^BH_!C_PUVI__ #04?\(-
M^T-_T5'X,?\ AKM3_P#F@H^K4_\ G['[I_\ R(>VG_(__)?\SV>BO&/^$&_:
M&_Z*C\&/_#7:G_\ -!1_P@W[0W_14?@Q_P"&NU/_ .:"CZM3_P"?L?NG_P#(
MA[:?\C_\E_S/9Z*\8_X0;]H;_HJ/P8_\-=J?_P T%'_"#?M#?]%1^#'_ (:[
M4_\ YH*/JU/_ )^Q^Z?_ ,B'MI_R/_R7_,]GHKQC_A!OVAO^BH_!C_PUVI__
M #04?\(-^T-_T5'X,?\ AKM3_P#F@H^K4_\ G['[I_\ R(>VG_(__)?\SV>B
MO&/^$&_:&_Z*C\&/_#7:G_\ -!1_P@W[0W_14?@Q_P"&NU/_ .:"CZM3_P"?
ML?NG_P#(A[:?\C_\E_S/9Z\5\=?L??\ ":?MU>!?C5_PD7V;_A"_#U_H/]C?
M8-_VS[2P/F^?Y@V;<?=\ML^HI_\ P@W[0W_14?@Q_P"&NU/_ .:"C_A!OVAO
M^BH_!C_PUVI__-!6E&*I2YZ=:*=FMI;23B_L=4VORU(J2=2').F[73W6\9*2
M^UT:3^5GH>ST5XQ_P@W[0W_14?@Q_P"&NU/_ .:"C_A!OVAO^BH_!C_PUVI_
M_-!6?U:G_P _8_=/_P"1+]M/^1_^2_YGL]%>,?\ "#?M#?\ 14?@Q_X:[4__
M )H*/^$&_:&_Z*C\&/\ PUVI_P#S04?5J?\ S]C]T_\ Y$/;3_D?_DO^9[/1
M7C'_  @W[0W_ $5'X,?^&NU/_P":"C_A!OVAO^BH_!C_ ,-=J?\ \T%'U:G_
M ,_8_=/_ .1#VT_Y'_Y+_F>ST5XQ_P (-^T-_P!%1^#'_AKM3_\ F@H_X0;]
MH;_HJ/P8_P##7:G_ /-!1]6I_P#/V/W3_P#D0]M/^1_^2_YGL]%>,?\ "#?M
M#?\ 14?@Q_X:[4__ )H*/^$&_:&_Z*C\&/\ PUVI_P#S04?5J?\ S]C]T_\
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MX0;]H;_HJ/P8_P##7:G_ /-!1]6I_P#/V/W3_P#D0]M/^1_^2_YGL]%>,?\
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M_DO^9[/17C'_  @W[0W_ $5'X,?^&NU/_P":"C_A!OVAO^BH_!C_ ,-=J?\
M\T%'U:G_ ,_8_=/_ .1#VT_Y'_Y+_F>ST5XQ_P (-^T-_P!%1^#'_AKM3_\
MF@H_X0;]H;_HJ/P8_P##7:G_ /-!1]6I_P#/V/W3_P#D0]M/^1_^2_YGL]%>
M,?\ "#?M#?\ 14?@Q_X:[4__ )H*/^$&_:&_Z*C\&/\ PUVI_P#S04?5J?\
MS]C]T_\ Y$/;3_D?_DO^9[/17C'_  @W[0W_ $5'X,?^&NU/_P":"C_A!OVA
MO^BH_!C_ ,-=J?\ \T%'U:G_ ,_8_=/_ .1#VT_Y'_Y+_F>ST5XQ_P (-^T-
M_P!%1^#'_AKM3_\ F@H_X0;]H;_HJ/P8_P##7:G_ /-!1]6I_P#/V/W3_P#D
M0]M/^1_^2_YGL]%>,?\ "#?M#?\ 14?@Q_X:[4__ )H*/^$&_:&_Z*C\&/\
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MJ/P8_P##7:G_ /-!1]6I_P#/V/W3_P#D0]M/^1_^2_YGL]%>,?\ "#?M#?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 45^*7_  5T\2_\%-OV%O"'Q8^-FF_M%_"^T^#N@ZR\
M^CZ)9Z)8W6L6FGW%ZL-I"1/H^UG198PQ:X;[K'<YZ^G_ /!,WQ7^W)X3A\"_
M'K]J3]ISX)R?LWZ[X=BUJ^MKM+#1KFW%[;*;+SI_[+MHXV$LL08"YP3P"^0"
M8?\ >P<_A2M>_1M-I/?5V:7F5B(NE)17O7;2MK>S2;6VBNGZ/8_5ZBN)\4_M
M+?#GP-\'[;XAZU\0/!.C^ +R*"XM_$U]KEK;Z//'/@0NEV[B%EDW+L(;#;AC
M.:3Q'^TS\-_!S>$1J_Q!\$:6?B Z1>%Q>:[:P?\ "2.X0HMEN<?:2PDC($6[
M/F+CJ,URN_+UO;Y]O7R(YE^%_DMWZ+N=O17!>"?VJOA?\2_%^N>'_#?Q(\!>
M(->\,J6UC3=-\06EW>:2!G)N(HY"\0X/WP.AJS\'_P!I+X=_M#1ZDW@#Q]X+
M\<+H\YM;]O#^MVVIBQF'6.7R7;RW']UL&I6NW:_R[^@WIOWM\^WJ=I17!_&S
M]J7X8_LTVMG-\1OB-X#^'\.H/Y=K)XDU^TTI;EL$[4,\B!CA6.!GH?2NBO\
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M:MID9V$//:JYEB4^8F"Z@?.OJ*E:Z+S_  W^[J)Z;^7X[??T.PHKE/A_\>/
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MG[+/B;X1^--0\0:7X;\5?9Q=W.B3PPWT?DW$=PGEO+%*@R\2@Y0\$]#R'O\
ML2> =6_8JL_@#KMA<^)OAW:^&;?PG)!J4H-Q=VD,*0HSR1JF)@$5M\83#@,H
M7 QE*FWA,127Q3G3DO\ MV,KW^;1V4<1&%?#5'M3<[_]O.G:W_@+/RF_X*E7
MD,?_  9__#%6EC5IO"W@I(P6&78-:D@>I 5C@=@?2N"_X+7^$K3Q_P#!'_@E
MSH.H-<+I^N7&E:?=?9YFAE,4UOH\;A74AE)5B,@@BOM:_P#^#8?X%^(/V?\
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M.^$__!0S]GBQ^&OCS1[JUT31)8[C0[K1)A8WWAZ:*,QQRVC[65"J':%9&0C
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M#_@E5XKU+QS_ ,$T/@'K&L7D^H:IJ/@'19[JYF;=)/(;*++,>Y/<]ZQ?%O\
MP2M^'OC/_@F;#^RK=:QXRC^'L.BVVA+J,5W;#6C!!,DR,93 8=Y:, GR<8)P
M >:]C_9O^!.D?LO? #P7\./#]QJ5YH?@71K70["?4)$DNIH+>)8D:5D1$+E5
M!)5%&>@'2O3JUXRGB;;3G&4?1*:?IO'[O(XZ5.V'H1E\<5)2?77DMKUU4G_P
MY^4'[8-UX3_:[_X+G^*O#'@?X%O^TI\2OAWX2CTW6;+XE^(+&T^'O@V%Q#,L
MMO9/93S3W$GF!6<MP\I(4A=R>+_\$ /A';^)_!G_  42^''C[PUX%U+P_H>K
MO)-X7MK'[;X=L+^%M3RUG%< CRHWMXO*+(' AB.05&/TO_::_P""&GPE_:0_
M:PD^-5IXJ^+OPM\>ZE;K9Z]>?#[Q6^@_\)/;KY:^3>%49RI2-4;RGB+ #))5
M2-+]CS_@BK\(?V%/%/Q<OOAWJ'CC3].^,EA%I^KZ/=:G%=V5D(XY(Q+;,\)G
M\T^;*S--++N9R2.F/.C!_4YT?M2I3CY<[FIIKLM--W?5OOV2FO;1FME.G+SY
M8KE:?G;M9-:6U9^:/_!)[]E?X8>+/^#7#XM>,-4^&_@/4O%MQX=\5M+K=WX?
MM)M1D-JLLEL6N&C,A,,B(\>6^1E4K@@&N)\>?9_V8_\ @T-\+^+OAKH&B^%_
M%7Q.:TT3QCX@T;3X+34M5LVU&[0K=7*())00!#EV)"RLH(!(/[)_L:_\$P/A
MO^Q1^Q%=_L_Z'/XD\3> -034(;P>(+N*6\NHKW<)XVDMXH5"D.P&U00#USS7
MGO[,O_!"SX._LV? /Q[\)Y=>^*'Q$^%7CV 6S>#_ !EXC_M#2/#\7G23%=.C
MCCB:U8R2;C(K&0M&C;]PW'IQLE5=50VDJ5O/D;YHORE>U[-::K:^.#_=JDY;
MQE5OZ3Y>62\X<MTM/)H_(S]K+X(_%#X:_ SX"^(? ?[%OPK_ &4_$W@?6M,O
MO#WQ'D^-GA.TN/$^V DVT[2/:O=O<+B0AY7?"L,$,U?2O[3?P \-_M5_\'8/
MP[\/_$#0[#7/#[?">'4]2T*_ACN[#47B%XZ0W$3;HYHUFV2;6W*6B4\XS7V!
M\"_^#>WX*_!CXH>%?$&H^+/C1\2=)^'MT+SP9X3\;>,'U;PYX.E4_NS96GEI
MM\L;0HD:0#:IY89KV35/^":'@35_^"DNF_M22:MXN7X@:7X:/A:+3UNK?^QV
MM3YGSM%Y'G>;^];D3!>!\OKM[://&7]^I+7=<U-Q7E>]F[*RW6MSEG2G[-PC
MNHPCIU2J*3\[<MTFWS:M/2Q[EX%\!:'\+_"&G^'O#.BZ3X=T#2(1;6.F:99Q
MV=G91#I'%%& B*.RJ !7@/QP_::^#_[3?Q9\:?LG0_%[Q%X,^+5[H8NKJ'PS
M//I>N:;;.(W\VTOGA: 3;'4[49I C$[0 2/I2OC?_@IK_P $)_@'_P %6M;T
MW7/B)I_B'1O%VEVZV4/B+PU?1V>H/;A]XAD\V*6&102V"\990S;2,UPU;S?O
MKFB[WUUU3L[^MKKJKV:9VT[17NNS5K=M&OTO;L[=#Y8_X-ZOB-!^SQ^VQ^TO
M^R1H;Z;XN\)?#'4VUVP\;16T0U/5I9Y$6:/4KB+Y;BX1I!&)" W[B0$  *OT
ME_P<1_LNR_M3?\$FOB=9Z?:O<>(O!=M'XPT9HA^^BGL&\YS'CG<T G08Y.^O
M6_\ @GA_P3"^$'_!+[X57'A7X4:#/8KJ;QS:KJM_<?:M3UF5%VJ\\N .,MA$
M5(U+-M49->]:MI5OKNE75C>0I<6MY$T$T3C*R(P*LI'H02*TQO-.C&%.5YQC
M%<VUY1VE;I9I6]+O5DX*7LZ\JLU[DI-\N]HO>-^M];]-;;(_F-_;D_:*\5?\
M%;O%EO\ M$>!=69H/V0?A?X6\37MO&"\0UR6]BGOHPQP<QJLA8@'/V3&>]?>
MW_!-GXFI_P %(O\ @K'^T7^UMH*MJGA?X:^"K/P5X';9\LMR]H+FY"]<LLGF
MKD=1<CK7UU^Q=_P0O^"7["_[/?Q;^&?A.3Q=JGAOXT)-!KQUF]MYKF.WD@D@
M$$#Q01A8T65RN\.P+$EC7H?_  32_P""9?PY_P""5?[/US\.?AO/XAU#2[[5
M)M7N[[7;B"XO[N>143YWABB3:J1HJ@(, =R2:VJ3BU4A#W5RR</*I5TJ?)1;
M4?\ /4RY;<G76,9>=.FHN'S<HW>E]6KL_!+_ ()Y^&/&W[5?[ 7Q@\:>(OV*
M?"/[1.I>/-5UBX\0_%_Q+\3=!T/4="G$*EC&+Z/SK-;8$2;EDC4@]E  ZK]K
MOXN_&FV_X(>_LA_#7QA)9^-K7Q-\1)/#FK6^C>-]-O[+Q=86DX^PZ<^K6<\]
MLJMN,98R?NS; NOR5^J?Q5_X-T?@9\0O'OB;4]#\4?&GX9^'?'ETUYXN\&^"
M_&4NE^&?%;LV9!=VFQ\JX+ K&\8 8[0O6O>OC;_P3"^!W[0/[(&F_ GQ%X$T
M]_AGH44$>DZ9:2R6SZ2T((BE@F1A(D@RV6W$ON8-N#,#GS+V::76E[NG_+MW
M=M.7RC>+NG[YI;][J^M5\W7]XFE?6_5.5I))Q7+IM^0_BOX:_%CX2?\ !3S]
MESQ9X6_9%^%?[&^IV>M#2-2L-/\ B]X4$GCO2IY;>*XB6QCDM9+J2)&<_(LT
MCM(G!8)7@'_!0C6OVC/^'O?[>FA_L^:;=S+JVA0S>--0LODOM/T:WLK2658)
M"PVO+S'A%:1E+!,<D?M=^R5_P1'^%_[+/QQTOXE:EXR^,7QD\<>&[1K#P[JO
MQ+\5-KTGABW9=K1V2^7&D0*DC)5F ) (R<]Y\#?^"9?@+X _MQ?%GX_:1JGB
MR\\8?&2V@M-;L;^YMY-+MTA6-5^SQK LBDB)<[Y7!R>G:913Y8WVC5UU>L^7
MEBTV[QNKR6B]Z2ZW)DWJTOM4M-M(-MM.VZ3]UO72-]K+X=D^%OP;^.?_  ;"
MCP[\"_''@GX&>%?&&AVL<FJ^)M;BT^U_M3SXOMEGJ-XQ \V>2-X&8YR'7"E-
MJU\%_$W2_$G[$P^"NN?M'?L@Z?\ "'1/AWXCLY-/^,?P%N=,TV?4@B*();MD
MBNX[M)@/,82/ TFX[=I#QM^U'P9_X(J_!7X,_"OXQ?#R*+Q)X@^%_P :=3DU
M;5/!FKW<,FD:-/(27.GB*&.:WYV$9E<H8HRI4KFO-?"O_!N#\%M/UG1+?Q1\
M0/V@OB5X"\+W4=YH?P^\7^.Y=0\)Z,\3 PB&T$:-LC7**KR,"C,&#9KHC63Q
MGUC92E"36]K:M+9WCJHM.S6Z6MX5%+"K#MWY5.*MHWS:)]5K:\DU=/9OI]]:
M3JD.MZ1:WMJ_FV]Y"L\+XQO1@&4_B"*_&/\ X(J_LZ> ?^"D_P"V5^V)\1?V
MAO"/AOXF?$/0_'<OAFUTSQ5I\6I0^'M-B>9(HX;>8-&F/+V!PNX>4<'+,3^T
M442P1+&BJB( JJHP% Z 5\9_M/?\$,_A+^T1\<]6^)N@>*OB[\$/B!XD01:]
MKOPO\5OX?N-?C (VW2[)(WSP68(K,5!)/.>715G-*Z<915]U=Q=]NR<7Y-VO
ML]+.5%0;U4HM]G9237WM26^L5?NO@S_@EYX"\/P?%G_@HA^SA!9Z=XW_ &>_
MA_<SZAX>T36+5-2TS1+TFY=H(5F#J/+EB&.X>U#C#9)]M_X-%O@OX.T;_@EE
MH/CBS\)^&;7QMJ^JZKI]]X@ATN"/5+VV2ZRD$MR%\UXU*KA&8J,# XK[>_9=
M_P"";_PG_8T_9TUSX9?#O0I]"T3Q,ER=8O6NFNM4U2:="DEQ/<2[FDEPQP6R
MJ\ *!Q4G_!.[]@'P;_P3._9CT[X4> ]2\3:MX=TR\N;V*XUZX@N+UGGD\QPS
M0PPIM!/&$!QU)K>C+V;DF[OV=.'-UE*-^9OU5EW:2N1B(^U:DE9>TG/EZ)26
MB[;ZNVB;=NY[E11161H%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 $X%?BKXE_8+_8__P""_P!^UI\3_$G@O4OBI\"/C]\,
M]>?3_$2))96=U?WD#&-=0%JLLQ8))#M\V*2%MRY<9*M7[55\#_\ !0O_ (-N
MOV:?^"CWQ5N?'7B?3_%G@[QIJ3H^IZOX2U**SDU4JI4>?%/#/"6QMRZQJYV+
MEB!BLW']XIM7T>SLT[JS3[:.Z]'NC2,O<<4[.ZW5TUK=-=]K/I\SYF_X(W?&
MWXU?LC?\%;_'O[&OCKXT2?M"^$=#\,'6['7[J22:]T.9/*/D2-))*\?RS;6A
M>60)B+:5R5-W_@U8<:=\*/VN%N"(&M_B??F42?*8L1-G=GIC!Z^AK[A_X)O?
M\$=O@9_P2NT74(_A;X>O?[<UJ".WU/Q!K%W]MU2_C3&$9\*D:EAN*1)&A;!*
M\#'GNI_\&_'P3?\ :0\5?$+1/$GQB\%V/CZY:\\5^"_#/C&;2?"_B>5R[.UY
M;PJ)9%9I&)C$RQG)&W#,&UK7DG%N[=*4'*UKMS4D[=K+E[Z)F,-+R2LE4C-1
MO?10<6K]&V^;MN?DW_P38D67_@UG_;4965E;Q1>$$'((\C3*_2W_ ()&_P#!
M,SX.>-_^"-G@:WO? WAF;Q%\7/AL+'Q'XF?38O[;U"&^AW-$]YCSVCCS&$3?
MM40QX VC'I'PC_X(0_!WX)_L,?%C]GO0]:\?Q>!?C!JD^JZK*][9_;M.>40*
M8K1EM1&D:B! H>.0@9Y/&/IG]F']GS1?V3OV>/!?PS\.W6J7N@^!M(M]&L)]
M2D22[FAA0(K2M&B(7(')5%&>PK;$2IU8U4_MPHQ\[1IRC-?>UZFDJDG5C56Z
MG5EY7E*,HO\ !^A_/7+^V'XZT#_@E-J/_!/N34)/^%Y)\5Q\)H+<@K<OH$D_
MG?:?+QN^SL<Q;NGE2+SBOK'_ (+\_ '1?V5_@#^P3\./#L(AT7P5\3-'TBU'
M.7$4:*7)/)9F!8D]2QK[NOO^",WP9U#_ (*<6_[6$D/B ?$FWM1"+-;F%='>
M<6YMA>-%Y/FM<"$[<F7;\H.S(S75?M\_\$U? O\ P46D^&[>-M6\6:6?A=XF
MA\5:5_8=U;P?:+J+&U)_.@EW1''(38W^T*5.L_W52I\;J4YU'W]FXK3UM*?K
M-HPJTHWJ0I:04*D8+LY\S_"\8+RAT/A?_@HY?6?_  2L_P""ZOP=_::FNH=#
M^&?QNTZ;P'\0;R3Y+6WN8XP;:XF<_*N52W.>,+9R'N:Y7_@D'KMCXB^#W[8G
M[?OQ-N]>TFU^)<^JQZ1?Z?&O]J:7X=L$=5-J'!3S?DCC7<"NZT4G@FOTC_X*
M*?\ !/+P!_P4[_9JO?A;\1FUJUT6ZO;?4(;[1YH8=0L)X6RLD+RQ2HI*ET;*
M'*2,.,Y&W\,?V)/AW\+?V-=-^ MMHO\ :7PVT_P\?#,EA?L)&O[1HRDGG,H4
M,\FYF9E"_,Q( XQRQC)8:I3^THRA#RC-\TK^DKQ7]V31U5)1E7IS?PMQE/S=
M.\8V]5RM_P!Z"]3^<[]J7X#1ZY_P0JU7XB>!OV:? _A+X;2:S'?VGQ/\=>(;
M?6OB=XD275 @F$EK90K&)'D"&-Y-HCBEX<LDC?7'_!6?6M0\2?\ !/7_ ()D
M:AJUY)J&I7WB;PK/<W,A)>>1K"W)9B2222<DDG)KZWLO^#8#X Q_"37O %]X
MV^/NM>!-0\YM%\-ZAXY>;2/!TLC.QGT^T\H0B4%SA[A)SD G+$D^N_%[_@BS
M\,_C=^S_ / 7X<ZYXH^(TFD?L[ZA9:CX<NXKZR6]O7M$5(4O&-J4D0*J@^6D
M9..N:[Z=:$7IM[6C->48?$GTOMHDD^FQQUJ<I+6U_9U8W6S<]K7UM?NV^Y]>
MSSK;0/)(VU(U+,?0#DU_.[!X7\._MP_"']L;XF?!S]GGP_\ $[P_?W>M76L?
M%KXW^(+2ZU:QGBM'D>/1;2VL?-MD@BVM#F4'YX0SC857^B-T61&5@&5A@@]Q
M7P+8?\&X'[/^B_$'Q9?:9K7QBT;P/XXN'O-<^'&F>-+BQ\'ZE.YR7EM(@LD@
M[!'E,8'RA-H 'F5*3FYKO!Q3[-M/7K:RZ-:VN['H4:T8*+?2<7;R5[VZ7U6Z
M:M?2]C\NM7\':7\0/^#,?3_$/B#2]*US7O!^MR0>']2O;-)[W0XI/$,<<B6\
MSAGB#IE6\LJ"N%((%>P?\%MOV3_A7\,O^#<GX0^(/#?PT^'_ (?UZ0^&+M]2
MTWP]:6EX\UW9Q?:I#+'&'+S>5'YC9S)Y:;L[1C] M%_X(*_"71?^"96M?LHK
MXM^*%Q\-=8U4:K]KFU"P.KV3"YBNO*BE%F(O+\V+.'B9OG?YNF/6OVC?^"9G
MPS_:J_83L?V>_&2Z]>>"=+TRQTZSNX;U8-4MFLD1+>X654\OSEV G,91B2"A
M!Q7HUJR<ZE2"^*K1G;NH).:?FVK=GNSCP\7"I2YMHQK1?;WY>Z_1*[\C\M/^
M"^'AP?"WXM?L3_ [X<_"?0-9^&'BC5IM;N?AMHUS9^%='\9ZE&]KY=M--L$$
M>XRL27!#&4D@M@@_9[\#?%'X2?\ !=3X+Z]H_P"S1\,_V0[/Q!I,^C>*O!>C
M_%;PO=2>*;!EF*7D>E6TMO*YB=-Q:&"0GR<_PMG]#O$?_!$SX3?$S]D#0_@]
M\0?$'Q2^)UKX6U%]5T/Q7XG\3/<^*M%N3@(UO?1I'L6-0JHFPH J@J<#&G^Q
M7_P1[^&_[&/QAO\ XD-XH^*7Q;^)M[9?V7'XO^)/B1M>U>QLO^?6"39&D<><
MGA-WS$;MIQ2P\U3J\S=[2G*_=2C91Z/3X7=M<J3CKH95*<I4>3O",?1QE=R5
M[K7XE9*7-HW;4_/W_@FA^R)\._VH_P#@OC^W1=?$;PCX=\=6'A?6;=K#2M?T
MZ+4M/BGGDD!N?(F5H_.58BJN5W*)' (R<_M;##':0+'&BQQQJ%5%&%4#@ #L
M!7SY^S!_P33\"_LF_M7_ !D^,7AW5O%M[XF^.%U!=Z[;:E=6\EC:/$7*BU2.
M!)$!\QL^9)(>!R*^AJYZ?NX6A0ZPA%/U2U]3HJVEBJU9;2DVO1V^X^!?VMM5
M^ __  70_9C^)'@;PC^T'XO\,V/PQOKJW\5OX9O9-&02QPRHT&HQW4"BZL-V
MYCM(C=HN)/EK+_X-D/VS=3_;$_X)EZ>NJ>&]#\/R?#?5YO!\#Z+8"QT_4H((
MH9(YXXE^56*S8?;\I=68 ;L!O[9W_!L#^RY^VU^T-<_$S7+'QIX5U[5KPWVM
MV_AG58K2QUV8E2SSQRPRE&;:=Q@:(L79B2QW#[4_9G_9F\#_ +'OP4T/X=_#
MGP_:>&?"/AV$Q6=E 6;&26=W=B6DD=B69V)9B2235X62A2J>TWFHZ=%*.\[]
MFKI1ML]7=(,3[THJ&T6VGUY6OAMM>]FWW6EKL_.W_@O0\/['/[<?[(W[6'EK
M:Z7X/\4OX+\7WV658M+OT8!Y2HSLC4W3#/&YP,'-?GC^RW^TCJG[*O[>>A?\
M% /%VK3'X:_M!^+O&WA^?S4Q]GL((\Z?@YR=TD 0*0"!;8 .:_?S]O']B'P7
M_P %%/V7_$7PE\?-JT/ASQ&8'DN=+FCAOK22&9)HY(7DCD16#(/O(P()&.:\
M/^-?_!"3X*?';_@G-X'_ &8]4O/&MEX$^'UQ!=Z3J-A>VT>L">/S=TKR-;M"
MS2>?+OQ" =_ 7C&%+GIPER?$G)1\H5+>T^::;CYR>_3:HX57&,]FES?XH*7L
M[?\ @2N[[02U1^8.F67Q!_99_P"#7#XQ?&ZTNM0TGXB_M)^*3XEUK4+;]W<0
M6&H:BEO\K 959(C(0000+HX(.*\U_:(^ WQ"\+?L _!?6/!O[&/PO_9QUSPO
M-HVK>&_C//\ &OPIIUYK,PA$@::29K9YVN5W2".69BF. 0I%?T%P_L??#R3]
MDVT^"-_X=M=7^&MKX?A\,G2;P;DGLHHEB56*[3NPH.]=I#?,,'%?*WPI_P"#
M=3X&_#/X@>&=0OO%7QJ\=>$? MZ-1\*^ /%?C*34_"7AJX4YCDMK,HI!3G D
MD<'<=P:NOFA'$R<-(<U-Q?51IJR7>Z236MFV^;N<MYRHQ=1)RM4YET<JFK?:
MU[IZ-I6Y>J/@C]O?Q]\2OVB/^"^_@WPOK/[/^E_M*1^"_AA:ZOI/PUU?Q3IV
MD:.+FYA1[N^WW2R6MR4D9DV?O WE*P)$==O_ ,$GO"GQ*^$'_!1W]J#1YOA?
MX'^!/P]\5>"9M4U#X8Z-\3-!\1R^%=4B@@5)A96,XFMDF225LFV1 )(USC97
MZ-?MV_\ !)CX6?M]^,/#OB[7;KQKX&^)'A",P:'XX\#ZV^B^(-+B+$M&DZJR
M,IRX^=&*B1]I7<2;G[&G_!++X8_L0>"_&5CX:F\6>(/$GQ&#?\)3XQ\3ZL=5
M\1Z^Q1D#3W3J 2H9B J*N225)))Y+?N9QMJXU8VZ-U')K:VBNG[UVI15M+6W
M5E*&MU>G=O=<BC?OJVG\-DU)II:W_F=_8G\3_$"__9/^"L?QE\/ZE+^POX=^
M*GV?Q";";[*NK:A<@,9+PAR\EO 57H$3EU!,A!7]EO\ @O[^RKK'Q]O_ -FF
M#X.:W\"];U3P/<W&H>'_ (/>,M3LK?3?'T @B$(M;.66..Z6)$,83**$G)#K
MCGZB^ __  14^#OP(_X)T>)/V7XYO%?B?X;^*'NY;N77+JWFU*.2X*MYD<D4
M$4:O&Z(\;>62K*"<U#X^_P"")?PC^+7[(_P[^$OBS5_B%X@/PE7'@[QE+K,=
MKXL\/L.(FAO+:&),QJ(PH:)E_<Q%@Q4&NJO.,DHQ^S*$D^K]U*5[Z-P<?=OH
MXNUU9,YL-3<6Y/3FC.+717E)IJVJ4U+W[.Z:OK>Q^=?_  2Q^)6F? W_ (+6
M:'HOQ-_9Q\4?LG_%7XB>%GTJQT/PA=6</@'Q0(HGE>5[%+;*2 Q,5DANI%#*
MJL =S/\ KI_P4%^)OB;X,?L+_%_Q=X+B>;Q9X;\'ZIJ.DA(_,9;F*UD>-@O\
M15@&QWQ7D?[)'_!%OX9?LK_'FW^*FI>+OB]\9_B=IUK)8:7XH^)OBM_$&H:-
M;2##0VQV1QHO+_-L+CS9 & 8BOKB]LH=2LYK>XACN+>X0QRQ2*&212,%2#P0
M1P0:QQB]KA51B[2Y9*ZNDKN35O2^MK*][*VKZ,*U2Q/M6KQO%V=FW9)/Y.VE
M[OOV7XQ_\$AO^"8_[-_[37_!":?Q[\1O"/A7Q9XP^(&G:[K'BCQOJ]JMUK5A
M=I/<JTL=Y)F:!HA&K'RV4,068'><^#^$/%6I_M4?\&?'C37OB;I]IXLUCX<7
M\FG>$-:UFS2ZO;*VCO[2))()I 71E226#>A!V+L)P"*_1+Q-_P &V'P%U#6M
M9M_#_BKXX> ?A[XHN6N]>^'/A?QQ/8>$-<D<DOY]IL9]K#:NV.1%544*% KZ
M)^.G_!-CX8?&W]@K4/V;H;&^\$_#&^TZ#2XK;PT\5O<6,,4T<Z^4TT<J[B\8
M+,Z.6W,22QW4L<_;4Z[@K>T4%&/2+B[W731>[&RVO>VB'@_W6(H.H^94YN4I
M=9*71KS^*72Z5KG%?\$0?@WX0^%/_!+WX)WGA?PKX;\-W?BGP5HVJ:U/I6F0
MV<FKWCV46ZYN&C53-,W>1\L?6OK*N*_9O^!.D?LO? #P7\./#]QJ5YH?@71K
M70["?4)$DNIH+>)8D:5D1$+E5!)5%&>@'2NUKMS"M&MBJE6G\+DVO2^GX'-A
MJ;A2C"6Z2OZ]0HHHKC-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAN[*RN&:_,E_(RQK=,T4-N&6%9HT=T4-@,Q.A\'OVU/VC_V#O^"L?@7]FO\
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MP9IMEXE6PD5AH]K;W<$,82U1C]J>-T9W,VWS I93^GG[!G[,$?['?[*'@_P
MUCX+M-2T6R5=4D\*Z(NCZ;>W9_ULZ6X)PSG!9B<L<G"@A1TRHNESTZVDXNUE
M^7K&SOYM6;1C[6,^65'6+6^VWY\U[KR6J3/8****P- HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG?V-OV;-+_8\_95^'_POT7YM/\$:);:6LF #<.B#S)3CC<\A=S[L:\,\/?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;5HH[C5-.N+2)I20BO)$R*6(!.,D9P"<=J_F;_X@J?VIO^A^_9__ /!YJ_\
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M !)\1?&YUU[09-(\,ZQK7Q4%YJ2:A:2M:VFO-;K83!%D9B9%61MH4E-N'"Y
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M<J.1UJ9MJ+<=65%)R2;LCK_^%$> O^$#;Q5_PLSQ]_PBZVIOCK'_  LK4?L
MMP-QF\_[3Y?E@<[MV,=ZV5_9!T-U#+XN^*[*PR"/'NK<_P#D>OC2RO/V);3]
MCJY^"I_:J^!\WA^YU/[4VJ2_$+2FU@6Q8*\7VO[7YGFFW\RV%P"'6)\ 9&3[
MU\#?^"B'[*?P3^$7A_PK#^T]^SW>?V)9I;R72>.M'MS>R]9)V07) >1RSL<G
M+.Q[UJU'6SZJWFK:_<]//<B[TMYW^_3[UJ>I?\,?Z)_T-WQ8_P#"\U;_ ./T
M?\,?Z)_T-WQ8_P#"\U;_ ./UH?!#]LGX0_M-:O?:?\-_BK\-_B#?:;"+B\MO
M#7B:RU::TB)VAY$MY'**6X!8 9XKTBH&?,'Q:\"7'[/W[1W[.@T#Q;\0)K;Q
MAX^O=#UBTU3Q/>ZE:WUH/"GB&]6-HIY'7(N+*VD# !@8AS@D'Z?KY_\ VR/^
M3BOV3O\ LJM]_P"H1XKKZ H **** "BBB@ HHHH *_$G_@M_X4\<_'[]L_X[
M:3'\8OBMX!O/A+\*+#QIX!\+^&=4FT^T\3Q1R3OJTS[!^\>-4" @A@63JH*G
M]MJ^(?V_/$G[5GP)^.MQ\1/AQ\/_ (-_&7X4V.C>1<>'M8ODT7Q-IY( N?L]
M]*OD>3* I9)"V2N,=!6-2RE&3Z7U=[)\KLW;HG:_E=:;K>C+=6O\.G5I2BVE
MYM)KYWUV?S[_ ,&^MS\.]$_:X^./A_X<_%CQQ\=="3PWX=U:V\6>(?$#ZM)8
M"X%P9-+<[5C66.12Y**I(D*,,QYK]8*^#/\ @B1^W5^SI^U)I_Q \,_!'X4V
M?P;\1>%;R.X\7Z!::38VT'VF0O&LBW%DS0W S$ZAL@@+]T#%?>==V(=^732R
MMYK?2W3HGUW>K9PT8V<M=;ZZ6>B2U\W:]NE[+1(\3_X*3?"/Q%\??^"?OQH\
M$>$M/_M;Q1XL\&ZII6E67GQ0?:KF:VD2./S)66--S,!N=E49Y(%?,_[1G_!.
M+XB_&C_@D5\ _!.C66D:?\9/@>GA3Q)I^FZI?*MG)J>E0Q+-9R3P[U 9?.0.
MI*[MIW;>:_02BL(RE%/D=FW"5^J=-R<6NF\FW=-.R\[]/-M?9*:MW4U%23Z[
M1MHT]7Y6_./]G[]A#XM?MF_M _&[XR_M$> M+^#^H?$SX:?\*KT?PE9>)HO$
M$^FV#M,US<SW$"B L\CHR*F<+D'!Z^8_L[?\$_?VGOB7K/[,'PC^+OP]\(^$
MOA?^R7KEMK:^,M-\7I?MX]ELK>2*P%M9*@FM@I9?,^T8SSMXX/ZU45=.HZ<E
M*&BCRV6MKQE*49=[J4Y2WM=ZII)+.I'G@X2;UOKUM*,8M=K.,8K:^ETTVV_'
M?B9_P3O_ &?_ (U>.+_Q/XR^!?P=\6>)=59&O=6UGP9IM_?7A5%C4R32PL[E
M455&XG"J!T K\XO!/[!WP-OO^#F3Q?\ #N;X,_"B;X?V/P%77+;PP_A'3VT>
MWU!M8L8FO$M#%Y*W!C^0RA0Y7C..*_4']J/X'3?M*? #Q1X%M_%?B3P/-XDM
M/LJZ]X?N3;:GIGSJWF02#E'^7&?<U^5?_!,O]CZZ_8@_X.4O'7@J[^)7Q"^*
MTS? )M0_MOQEJ)O]2 DUK3AY/F'_ )9KLRH[%F]:CF:V*/T2_P"'3O[+/_1M
M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HI ?/_ /PZ=_99
M_P"C:?V?_P#PWFD?_(]'_#IW]EG_ *-I_9__ /#>:1_\CU] 44 ?/_\ PZ=_
M99_Z-I_9_P#_  WFD?\ R/1_PZ=_99_Z-I_9_P#_  WFD?\ R/7T!10!\_\
M_#IW]EG_ *-I_9__ /#>:1_\CT?\.G?V6?\ HVG]G_\ \-YI'_R/7T!10!\_
M_P##IW]EG_HVG]G_ /\ #>:1_P#(]'_#IW]EG_HVG]G_ /\ #>:1_P#(]?0%
M% 'S_P#\.G?V6?\ HVG]G_\ \-YI'_R/7P1_P0&_8<^"GQ1C_:T3Q-\'_A;X
MB7P[^T!XET?2EU/PI87@TRRB\CRK6#S(CY4*9.V-,*N3@"OUWK\VO^#<S_F\
MS_LY'Q5_[;UU8/'8C"5/;86I*$N\6XO[U9DRBI*TD?6G_#L;]FO_ *-Z^!W_
M (0FE_\ QBC_ (=C?LU_]&]? [_PA-+_ /C%>XT5ZW^MF>?]!E7_ ,&3_P#D
MB/84OY5]R/#O^'8W[-?_ $;U\#O_  A-+_\ C%'_  [&_9K_ .C>O@=_X0FE
M_P#QBO<:*/\ 6S//^@RK_P"#)_\ R0>PI?RK[D>'?\.QOV:_^C>O@=_X0FE_
M_&*/^'8W[-?_ $;U\#O_  A-+_\ C%>XT4?ZV9Y_T&5?_!D__D@]A2_E7W(\
M._X=C?LU_P#1O7P._P#"$TO_ .,4?\.QOV:_^C>O@=_X0FE__&*]QHH_ULSS
M_H,J_P#@R?\ \D'L*7\J^Y'S'\=_^":_[.>C_ _QE=VGP!^"EK=6NA7LT,T/
M@?3$DA=;=RK*P@R&! ((Y!%<C^P[_P $Z?V?/%O[+GA?4-5^!/P;U._N/M?F
MW-WX*TV::3;=S*-SM"2<* !D\  5],_M$?\ )O\ XZ_[%Z__ /2:2N+_ ."?
MG_)HGA'_ +?/_2V>OI*7%&=?V!4G];JW]M!7]I.]N2IIN*5"G>/NKKT7]T\L
M\;_\$XOV>;3]H_P38Q? ;X,QV-U;7;3VZ>"=-6*8K$Y!9?)PV" 1D<8KT?\
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M<Y5XV4X*D#<T?_D[_5?^Q<7_ -&Q5\I136'H)_W?R/3QLXRSC-91=T_;6?\
MW$1ZE1117J'P@4444 ?&?_!63_DJ'[*__97]'_\ 1JUPO[;G_*P#^Q-_V!_&
M'_IIN*[K_@K)_P E0_97_P"ROZ/_ .C5KQ7]N;]H+P%8_P#!Q+^Q[HLWC?PA
M#K'A^T\1:9JEB^LVZW.FW=_I3K8V\T9?='+<M-"(4<!I3+&$#;AG]UX,K4Z6
M%P\JLE%/!9FM7;5T*R2UZMM)+J]$>SQ"F\FP%N\O_3J/TVHHHK\*/&"BBB@
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MD%Z+ Q-$5B=6"_8Y VXJ073 8%BM7]GKPK_P5._9K^ 7@?X<Z%X._8YN]$\
M^'[#PWI\]_=ZS)=36]G;1V\3RLEPB-(4C4L51023A0.!^K%% 'YK_P#"P/\
M@K)_T(W[%/\ X$:Y_P#)='_"P/\ @K)_T(W[%/\ X$:Y_P#)=?I110!^:_\
MPL#_ (*R?]"-^Q3_ .!&N?\ R71_PL#_ (*R?]"-^Q3_ .!&N?\ R77Z444
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M]Y'F)BTDT$,V9D)12I'G'BK_ ()[>+O$'PD\0:KX;^'/B#0-:\5?$+P1JO\
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M? W_ )(IX/\ ^P)9?^B$KJ: /G__ ()I_P#)NOB/_LJOQ'_]3?7:^@*^?_\
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MXV<G:R;O9;+\M]WHM6[:!11161H%%%% '"_M+?\ "Q/^%$^)O^%2_P#"+?\
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M?_:ZZXY3DD?AS*W_ '"G_F;?V7E/_0;_ .4Y?YGE'_!2W2;72O\ @M-^P?\
M9;6WMO,O?$N[RHPF[%K;XSBOT@K\7?V]O^">O_"N_P#@J3^R'X2_X7!\9-8_
MX32ZUU/[6U'Q!YVHZ-Y-O"V;278/*+[L-P<@"OMG_AS[_P!7%?M(_P#A7?\
MVNOT;C;*\GGDF1*IC[)8::3]E-\R^MXAWWTUNK/M?J>;@<ORQUZZEB[)25G[
M.3NN2+OOIK=6\K]3[)K\Y?\ @ZC_ &B])^ 7_!(#Q3I^I0ZM)<_$;7M)\,Z<
M]BB,L,ZW U%S,6=2L1M]/N$RH8EW0%=I9E]2_P""%?Q U[XE_L)0:IXDUO5_
M$&I-KU]$;O4KR2[G*+Y>U=\A+8'89XKN/^"H'_!+_P  _P#!67X!:/\ #GXC
M:OXPT71-%\00^)()_#=U;6UT]Q%;7-NJ,T\$R&,I=2$@(#D+\P (/YE4^M<*
M\1J>'DI5L'54HNWNN5.2DG9]+I:=C//,J>#Q=?+JCYN1RBVM+VT=C:_X)E_M
M;^&_VY_V$_AS\3O"5CKFG:#KUA):V]OJ\,4-XC65Q+8REUBDD0 RVTA7#G*E
M2=I)4>[5\$?L9?\ ! GPQ^PQXG\(S>#?CU^T?)X:\%WKW=EX7O/%47]C3!Y'
ME:*6WBMXT9&>1F8*%W%B>I)KW_\ ;E_89;]MO1O#]E_PMCXN?"]-!GEG+^!M
M<&EOJ!=54"<[&+A<':,@#<W7C"EEV4U,704\=:%2/-4E[*?[J33;ARWO.STY
MHV6MSRN:HHNT=MM=_P#(]XHKR_\ 9?\ V9V_9F^ %KX!;QY\0/'7V4W.->\4
M:H+[6&$SL^#/M7A-V$R#M  Z "O$OV5O^"2?_#+OQOTWQK_PT-^TAX[_ +-2
M9?[&\4^+_M^EW7F(4S+%Y0W[<[AR,, >U9T<KRB7UKGQW+[._LOW4W[;>W7]
MW>R^*]K^3'SU/=]W??7;_,^O:*^:/^">O[<6L_MD>.OV@-+U;1=-TB'X1_$K
M4O!.G-:R.[7EO:D()9=W_+1F5V.W  8#'RY/TO7G9UDN*RG&2P&-5JD5%M)I
M_%%26JTVDBJ=2-2/-'8****\HT"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \ _X*??%?XJ? W]BSQ5XN^#.@W7BCQU
MH,ME=Q:7:6/VZZO+1;N'[8D,.#YDOV;SMH )SC )Q7P)\$_^#GSQ-XE^)7Q*
ML=<_96_:*UC3=$UF&VT>S\/>"7DU'2(#:Q.T.J!IR%N3(S.H4*/*:,XR2:_7
MJOR]^(GA']HK_@H]^V_\<O#WP>^/&D_LS^#?@YK=IH5T-'\*P:KK'BO4'LHK
ME[N\9I(F6(+(L<?S$$*W!Q44^95)16NC?317@F_39)+6\GT;M4^5P4GI9I>M
MU*R]=W?:R[I'V-_P3Z_;N_X;Y^&VM>(_^%6_%+X4_P!CZE_9W]G>.M'_ +,O
M;O\ =I)YT<>YMT7S[=V?O*P[5[Y7R'_P2-_:.^)7Q3\+_%+X=_%W6M%\8>//
M@;XN?PC>^*=*MQ;6_B2+[-#<0W#1*-L<X6;9(B\!E]<U]>5T5HQ33ALU%K?5
M.*:>NNJ=[=+V,:?-JI;IM/R:;36G:UK]=PHHHK(T"OR2_P""S7_*?C_@GO\
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ME%VVLOW0K\U_A_\ \K8_CG_LW"+_ -/EC7HG[6'_  ;K_LM_MK?M!>(_B?\
M$#PGX@U+Q?XJDAEU&YM_$-W:QR-%!' F(T<*N(XD' YQGJ:^6/\ @FS^P?\
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M#Q$+0M4D[M^Y&ZU_E=XI=$K&.'<G!<RL]=/F%%%%?.FP4444 %%%% !1110
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M* "BBB@ HHHH **** /S7_;X_P"5D+]@K_L">-__ $S7-?3G@/\ Y29>-O\
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M&I<,9WAZM2,9U(4%"+:3DXUXM\J;O*RU=KV6KT..O&3KTVEHK_D</_P:D?\
M!6BU\>?!OXJ>!_BIXB^&'@72?!=[IM]H$MS?C2[C4GOOMOVH,US<%9%C^RV^
M/+52OF'<6W+C]:/^&\/@=_T6;X4_^%;I_P#\=KB_#7_!(_\ 9C\%^=_8_P "
M?AGI/VG;YWV/0X8/-VYV[MH&<9.,],GUK5_X=C_L^_\ 1(? _P#X+EKR?K>2
MXQO%9K4KRKS;<VE3LVV]=7?;?S/L/K.68EO$9A.K*K)MR:4+-M[ZN_KYF_\
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MDO\ @LU_RGX_X)[_ /83U#_T;!7T'9_\%;OV5?V /^">OP-\70ZAK'ACX/\
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MK/>3;?S.>C2C3@J<=EH?FY_P><?\I8O#?_9-],_]+]2KY-_X(*?\IC/V>?\
ML;K?_P!!>OK+_@\X_P"4L7AO_LF^F?\ I?J5?)O_  04_P"4QG[//_8W6_\
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M %%%% !1110 4444 %%%% !1110 4444 %?R>_\ !W3_ ,IF/$7_ &+&C_\
MH@U_6%7\GO\ P=T_\IF/$7_8L:/_ .B#0!PG_!KC_P IU_@9_P!Q_P#]1_4Z
M_K]K^0+_ (-<?^4Z_P #/^X__P"H_J=?U^T ?/\ _P $T_\ DW7Q'_V57XC_
M /J;Z[7HW[0?_(F6O_7ZG_H$E><_\$T_^3=?$?\ V57XC_\ J;Z[7HW[0?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5^-/[6WQ$^/?[,W_  48^-&K?"S]
MK;]@WX8Z'XOO[.>\\)^.?%\5GJT%Q%9PQBXN[<V[-'<L@520^&C6(D$C-?LM
M7XZ_\%$_VAOV)_"/[:'C[3?B7^Q-\9/B=XYM;V-=7\4:/X$AU&RU:0P1$/%.
MU]&7"H53.Q<%".V:Q;:K*SZ/YZQ_KUL:;TW?NOU/M?\ X)$?&GXH?&_X*^)-
M1^*GQ>_9]^,6L6NM?9[34OA'JPU+2[*#R(V\F=PB;9]Q9MN#\C(>]?6=?G=_
MP;H^&['1_@3\6+[PK\&=?^"_PTUSQW<7_@W3=?LGM-7N[!K>'<]PK.Q;;*)%
M1LM\@5-SB,,?T1KNQ"7-%I6O&+MVO%-IVZKKYW.6B[IZWM*2^Z36GEV\@HHH
MKG-@K\DO^"S7_*?C_@GO_P!A/4/_ $;!7ZVU^27_  6:_P"4_'_!/?\ [">H
M?^C8* /S<_X/./\ E+%X;_[)OIG_ *7ZE7R;_P $%/\ E,9^SS_V-UO_ .@O
M7UE_P><?\I8O#?\ V3?3/_2_4J^3?^""G_*8S]GG_L;K?_T%Z /[0J*** ./
M^.7_ "(,O_7:/^=>)U[9\<O^1!E_Z[1_SKQ.ID? <3?[Y_VZOU/2_B-_R9SX
MJ_[%6_\ _2:6ORLK]4_B-_R9SXJ_[%6__P#2:6ORLK]*X'_@5/5?D?22_@TO
M\*_(_0;_ ()/_P#)NVM?]C'/_P"DUK7A?C/]N'XB:CK)AEU2S:/3;_SX +&(
M;61B%)^7G\:]T_X)/_\ )NVM?]C'/_Z36M?%_B7_ )&/4/\ KYD_]"-?)YY_
MR,:WJ>KA_P"&C[>_8-_:,\5?';5/$T?B2\@NDTV*W: 1VR0[2YD#9V@9^Z.M
M?2%?&_\ P2L_Y#?C3_KA:?\ H4U?9%>++<V,CQK\0-!^&NB_VEXCUO2/#^G^
M8(OM6I7D=K#O.<+OD(7<<' SDX->"?"[]K#X66_[1OQ3GD^)7P_CAN/[)\J1
MO$-H%EVVK [3YF#@\''2ODW_ (.^O^4.>I_]C=I'_H4M?RCU(']^FCZQ:>(=
M(M=0T^ZM[ZQOH4N+:YMY!+#<1. R.CJ2&5E((()!!!JQ7S__ ,$G?^467[-/
M_9*O"_\ Z:+6OH"@ HHHH **** "J7B#Q+IWA+2I+[5=0LM,L8B ]Q=SK#$A
M)P,LQ &20.O6KM% &7X6\<Z+XYMY9M$UC2]8A@;9(]C=QW"QMC."4) ..QK4
MKC_V>_\ D@?@?_L7[#_TGCKL* "BBB@ HHHH **** "BBB@ HHHH **** "O
MY/?^#NG_ )3,>(O^Q8T?_P!$&OZPJ_D]_P"#NG_E,QXB_P"Q8T?_ -$&@#A/
M^#7'_E.O\#/^X_\ ^H_J=?U^U_(%_P &N/\ RG7^!G_<?_\ 4?U.OZ_: /G_
M /X)I_\ )NOB/_LJOQ'_ /4WUVO1OV@_^1,M?^OU/_0)*\Y_X)I_\FZ^(_\
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M,/">E^#?#+?L]_;SI]@&$/GR:WIX>3YB3DA%[]J /UJH/2B@\T/8#\Y?@?\
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M>(O^Q8T?_P!$&@#A/^#7'_E.O\#/^X__ .H_J=?U^U_(%_P:X_\ *=?X&?\
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M;V][<****YR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/D:?9K5'WK_P2Q_Y.6NO^P)<?^C(:VO^"EW_ "</;_\ 8&@_]&35\5_L"_\
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MSACW[K6WE5?G1AAB#QG&.:_3W_B*-_83_P"BY?\ EF>(/_D&@#[_ **^ /\
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M-N!RV3D\Y-5)6 _1ROY/?^#NG_E,QXB_[%C1_P#T0:_</_B*-_83_P"BY?\
MEF>(/_D&OY[?^#B_]LGX;_MW_P#!3+6?B%\*?$?_  E7A"[T+3;.*_\ [/NK
M'?+#$5D7R[F..08/&2N#V)J0-3_@UQ_Y3K_ S_N/_P#J/ZG7]2O[6?[7GPG_
M &?(K/P_\3K[R8?$4#2Q6K:;->1W$:,,[O+1@,-C@U_)7_P05_:C\"?L7?\
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MZ7I]OJ-X,7%U%;(DTXX^^X&YN@ZGM5<K23>SV\R.97<>JW\CY]_X<X_LG?\
M1M_P3_\ ".L/_C5'_#G']D[_ *-O^"?_ (1UA_\ &J^DJ*D9\V_\.<?V3O\
MHV_X)_\ A'6'_P :H_X<X_LG?]&W_!/_ ,(ZP_\ C5?25% 'S;_PYQ_9._Z-
MO^"?_A'6'_QJC_ASC^R=_P!&W_!/_P (ZP_^-5])44 ?-O\ PYQ_9._Z-O\
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M8?\ QJC_ (<X_LG?]&W_  3_ /".L/\ XU7TE10!\V_\.<?V3O\ HV_X)_\
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M%#Q!_P (SX5AO+>P>^^P7-[MFG<1Q)Y=O'))\S$#.W [D"O1H9EN(5D0[ED
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M>U_^6%?ME17G_P!@Y9_T#T__  "/^1]A_P 18XW_ .ASB_\ PHK?_)GXF_\
M$)-\1O\ H\3_ ,Q/:_\ RPH_XA)OB-_T>)_YB>U_^6%?ME11_8.6?] ]/_P"
M/^0?\18XW_Z'.+_\**W_ ,F?B;_Q"3?$;_H\3_S$]K_\L*/^(2;XC?\ 1XG_
M )B>U_\ EA7[944?V#EG_0/3_P# (_Y!_P 18XW_ .ASB_\ PHK?_)GXF_\
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MQ3_X:JP_^3:_2BB@#\U_^'2'[:W_ $D@\4_^&JL/_DVC_ATA^VM_TD@\4_\
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M>?*EJWT3O?1WZ!"*]O-QERIS34M[1TOIO?MU1^96M>)O#?\ P4B_X*G?L_\
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MU33>7(_:IK9*:6VB]K-Q73[+6R26VFQ)1117*= 4444 %%%% !1110 4444
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M?4/ MW=RZ/K.C'S?,>..['G1R0M&J,&8ABV0 ,9^'=;\'? [Q1_P28\ ZO\
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M5NFBB[=+^84445QG0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*%O*>1V17J-.4FDNO^;5_2ZM?;;757)>[%SELK_@F[6[Z/3?1]G;[:HKR?\
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M7Z/T5FFTK+NW][J-_P#IV:\KJUFDR8Q44UT=D_DH)?=[.+]5YGR+\%_^"?\
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M_&'CB]U&UGU>ZL[=]*\17\]PLL,HLY&>Z@C:(F%D2-VWKYR@!SE_#S_@FO\
M&#X4_"/X&^'6F\!>/=-^'_@R7PQK?AC4_%FJZ/HB7KS!O[4A^SVDGVUA'F+R
M;F*,;2=LD99L_H%11>^_?])*W_DTO--W332MIS.S7=M_-OFO]]M-FM&FF[_G
M3^R#_P $E/B1^S+IGPB@O)OAGJD?A&+QKX?UZTTN]NM*LX])U_4H[Q+BPC%I
M)ME@6((+1MD>&P)\*"VA^QY_P2'?]G&Y\$^'+[X+_LDW&G^!2(?^%CP>'!)X
MQUV"-2L,AMULH5L[X@J7NA?7&61F$69/D_0:BKE4<OBU_P"';7W.4G_V\T[J
MR4R]Z[]7]^_WI)>5E:SU?P/I'_!/;XY:!\.O@?\ "BWOOA7)\-?@;XVTG6K3
M6Y-0OAK>N:38RR-#;O9BU\FWN(XV12XN)5F*9Q!NP/HK]K[]FW7/C_X[^".J
M:-=:3:V_PU\?0^*=36]ED1Y[5+"]MBD(5&#2[[F,X8JNT-\V0 ?;J*ESDU[V
MKYN=OJY>[J__  !?TPLN:4EU@X>7*^?1?^!R_P"&2/B_P9_P3I\;>'?V/_@C
M\/YM4\*MK/PU^)5OXRU.9+F<VL]G'JEW>-'"QA#--Y<Z *RJNX,-P&"?L]QN
M4CVI:*EZQE#I*3D_5QC%_A%$*FE)3ZV4?DG*7YR9\T?"+]F?XL? ']BSP/X0
M\)^)O#-IXV\&ZE)?74$N7T?Q';M=W$KZ?+</;O-;I(DR_OXHB\;H"%D7<CTO
MAE^PEJOCKXB_$[QU\4+A_#&M?%*+2+>ZT/X>^--7L(-.731.(YAJEL+"ZGFE
M\\ASY<2[(XXR'"[C]244+KY_\#;[EILGJK-N]6T2733UM=J_W[[O1-M))?''
MQY_X)>WWC[]JOX*^)O#OB+R? '@^U.G^-=-U_4;S6-4\26UK<K?Z6OVNZ,TT
MS0WP+L9YL[&."3Q7FW@/_@B=K3_L/?&/X6^+/%F@ZEK'C;7K2;PU=R6C:CIV
MEZ/I$D']AV%S;RJGG1I';@3Q\JWG2@,V<G]$**<9.,'36VK^;DI7]4UH^B;6
MS95[34UNK?=%.*7I9_@NR/S_ +K_ ()$+\7O@E\1/"FI?!O]E3X$S^+_  TV
MB07WPZ\/C4KZ:Y\Z&=)I[E[*P'V3S(5WV1AEWX4F?C:4B_X)9Z[K7P7^)>@V
M/P1_8_\ A!KGBCP!JWA.SU3P3I#F_P!2O+NW\I9Y+M;"T:RM>I>W6*[8Y7$O
MR8?] :*4O>3B]FFOOO?_ -*>FW9:*U4:CISC4AO&2DO5<MO_ $E>>^NKO\>_
MLM?\$R;C]E^;7O ^C7T>E_!+QEH5C/?:'X?U_4="OO#OB"!8H[B;39[/RI8[
M:[6-7D"S1,)8V.UQ/(%UO$?[%'C#X ?'C0OB1\$Y-/\ $U]:^&)_"6K:+\1?
M&FLW#W]LUY]LAG75YTU"Z5X96F'EO&ZNDH4-'L6OJRBM*E24IJH]U?7R:<;>
MBC)Q796M9JYE3@HTW2^SIIYJSOZWBI-]9:O<_/FZ_P"",.N>,)M-M?$GBG1K
MJQ\1:1\0H_&-S:>=%,E[XHEMY%^PQLK!H8!$RYDD5CL0X.XA>^\&?LM?'[Q5
M^TO\!/$GCZ;X2VWASX*6VJ65S+H>I7]Q?^(WN-/%I%>"*6UCCM<D9:V\R8)N
M)$[X"U]D44HU'%)+9*R71)<UONYY)?*]VDU5;]ZK3U=V[];R:<OO:3?II9-I
M^'^-/V:=>\1_\%#? OQ:AN])7PYX8\"ZWX8NK9Y9!?27-[>:=/$Z($*&,+:2
M!B7# LF%8$D>4^!_^">_C3PU\./V7]'N-3\+M=?!3QK>^)-<:.YG,=U;S6NJ
MPJEL3""\@:^B)$@C&%?YC@!OL:BB-1Q4$OL[?^!RG_Z5)_+04E>4I/[2:?HX
MJ'Y(^#_#O_!-#XE?"SQ-X9\?>'=0\"ZIXZ\#?$OQEXLT_2=1U"ZM=+U?2]?E
MDW6\MVEM)+;7"(8FWK;SH&1EPP;>+7[2/_!.WQ]^T_XU^''Q/^('@O\ 9S^*
M'C;PC9ZII-_X(\16<[>%IK&]E@EB\F]N+6\E6[MC H^T_8U$P>0>5 &X^YJ*
MB.BBE]E67DK<K^];]=7:UV74ESRE*7VFV_-N3E^$G=?*][*WA_[)_P $O$'[
M-WP^T+P]I_P[^!_@_3M0U&[OM<T_P)!)HFGZ,KIF$6\"VQ6_F+*B232?8]RC
M>(Q@1U[A1152ES/^OE]R_P""9QBEM_3;N_ZV"BBBI*"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *Y7XP_ OP1^T-X1'A_Q_P"#?"OCG01.ET--\0:3!J=F)4SLD\J9&3>N3AL9
M&37544#3:V(-,TRVT33K>SL[>"SL[6-8H8(8Q''"BC"JJCA5 & !P*GHHHO?
M5B6FB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML7..OQ2LM?=4Y))6Z^[ITV[W7Z^4445B6%%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJGXB6^;P_?#3
M&A74C;R"T,W^K$NT[-W^SNQGVKY9_8>T[]M*R^+ET?V@K_X%WG@=M.D$(\)K
M>C4EO-Z>7_K$5/+V^9NSSG;CO7MY?DJQ>#KXOZQ2I^R2?).5ISO?2FK/F:MK
MJMT9SJ<LE&S=^VR]3V+Q+^V[\%_!?QEC^'.L?%[X7Z3\0IKNVL(_#%YXJL8-
M9>XN1&;>$6C2B8R2B6(H@3+B1-H.X9]0K\7_ /@IM_P;R?'3X[_\%@X_VI_A
M#XT^'(FCU?0?$EKIOB,7-N;"^TJ"SBCC;RTD$T;M9)(6_=D>84Q\N]OU8^'-
MO\6(OV6K./Q1<^!Y/C'_ &*XN)K**X_L'^TMC>6=I(E,(;9NQ@GYL < 1+)I
MQPE/%SJTTIR45'GBYI._O2C&[C%;/FL]K)K4/:>]RV?W'I%%<1^S?#X_MO@=
MX;3XI3>'[CX@K:_\3R30PXTYI]S?ZG> VS;MZ@'K7;UY^*P_L*\Z',I<K:YH
MN\79VO%Z73W3MJBXRNKGP)^T=_P<!>'?V6_&>M:7XG_9C_;&_L_2-;.@1:];
M_#F+^QM6N#/Y$)M+F2[03+.^T18 ,F]<#)Q7;>!_^"RFA^(/V?\ XK?$CQ)\
M!?VF_A?H/PET<:U?Q^./!,>B7&LQ?O"R6 DN2DTB[/F#.@&].>:I?\%W/^3/
MO!__ &57P9_Z?+6NH_X+B$C_ ()$_M#8&3_PA-_@>O[NN/FY<).K+5IRC]T*
M<KV_[>>AO&*GBHTEHI<K^3G)6^Z._F>3Z9_P<*>%X[./5/$7[,/[:O@GPF(O
MM5YXGUSX4R)I&FVVW=]HFDAGE818P=RHW!!Z<U]"_M)_\%*?A=^S1\&O"/C2
MZO-;\91?$5%;P;H_A#2Y=:UCQ>S0>>JV5M$,R9CPVYBJ*&&YER*^4/"G[6/[
M=/Q@^ =AX)TG]B;PWX.AU[PZFEVOBS7_ (QZ9?:;8H]J$6YFM+6'[2ZE<'RT
M.[+ $C!-=EJ__!.*[^%'@C]FWPO\+?BYX1T/X_?L[^%+BUT*'Q%:K?6?B339
M88;6^-Q8QRQW"VYD6+$\+9C8JI+;L5U5J:CS1[227=JTG+W=U:T>FSD[2Y;'
M+AZG,H2?6+;71/W>7WMM6VM];+6*=SU']D?_ (*Y> _VJ?BE:^ ]2\#_ !D^
M#/C[5()[O2?#OQ.\'S>'KW7+>$*99;1BSPS! V2HDW@*QV[1FO)/CA_P<*^'
M?V>_%]QI/B3]EO\ ;0MXEUT^';'4A\-HDT_6KPRM%"EG+)>+Y_G%<Q!1ND!&
M%[5TGA/]J'XB^#?VE?A-X/\ VK/@G\,;/7?$.H2V/@;Q_P"$=4_MK2X=:^QR
MM+"D-Y!'>6$DL*3!9%+AE)C9N[7/^"VG_(@?L^?]EW\'_P#I8U3[/FJT8K:<
MXP=O[TXQOW32=[/R>B:12=HU+[QC*2O_ '8R=NS3:M==FMTSUK]AW]N__AMZ
MP\17'_"F?CU\(?\ A'I((_+^)?A+_A'Y-3\T.=UJ/-D\T)LPYXVEEZYKW'6-
M9L_#NDW5_J%U;V-C91-/<7%Q((XH(U&6=V; 50 22> !7EG[9O[=7PK_ ."?
M/PJM_&WQ>\4_\(CX8N]0CTN*]_LV\U#?<R([HGEVL4L@RL;G)7:,=>1GE_"'
MBCX$?\%B_P!F'1_$&E7"?$KX67FJ-/''/;7NGVFI36KO&T5Q;S)$\T2OG,<J
M&-RJDA@*B7OW=)?#9/K;;5^>MTM+Z*ZO<I1<+>U^U=KI??1?<U?79Z.UCK/V
M-OVTO O[>/PJOO&WPZN[K4O#%KK=[H<-_+&J1Z@]K)Y;SPX9MT+'E&."PYVC
M(JA^TK^WK\._V5/BW\+? GB>^NI/%WQ@UQ=#\.Z991K+,[?QW$H9EV6\9*AG
MY.74*K'./F;_ ())?%?PO^S'^P%\</&/B*XM]#\(^"?BAXYU"]D2/;':VT&I
MS,0J+Z*N%4>P%?(WQV_:R^#?Q"^*'[.7QD\3?&CX.ZA\1O%?QFT?5]:L[3QK
MIEY_P@/AV"SOQ:V$C1S,(HX?-#SRDA&N;B3G'E@73C&=6C%;2]CS=[5.7\[R
M=[623V=KS4YHTJ\G\4?;*/:]/FM]UDN[;6EKM?IC^VU_P4K\&?L1:SHV@WGA
M?XE_$SQUX@MWOK#P?\/?#DFO:[-:1NJ2730JRK'"K,!OD=<D$+N((KJOA#^V
M]X%^-7[.^N?$K2FURQTGPK%=MKNFZOIDNF:QH<UK'YL]M=6DX1X9E3#;6P"&
M5@2K!C\P_M*^+_&'[#O_  48U?\ :!TWX2_$CXX?#GXF> ],\-2_\*ZL8M9U
MG0KNTNIY8V^R-)&9+6=+H-YD;$*8R6&"#7C_ ,(O#7QA_;?U[_@HEX9T?0+'
MX:>)/B+:Z#IFDZ5XDU'=%H\MSHHAD:\>T68)<FU,3.D7F!6*)N;:6K%1G*C/
ME^/EDUTM)344FNMTU+YI[,WCR>W@IOW+P\[J23;\K.Z^3Z[?07[+7_!;C3OV
ML?B)X1T31_V8_P!L#P_I/C-HS9^*=?\ ATMIX=@AD3S$N);Q;IU6%EP0ZA@=
MRXZU]M9K\\]0U#]I3_@F?KOP_P#$WQ'^-G@GXI_#+Q-XET/P-=>#M/\  ,?A
M\>%A>,MG#-I]VMS+/<".5HRR7&XL@8@H1BOK[]M?7O$?A?\ 8Z^*NI>#XWD\
M5:?X1U2XTA4SN-TEI*T6W /.\#''7%5C*D*6'G7IJZBY>MXI2L^E[23NKK7?
M1F6#IU*M:%&>CDH^FK:OWM=-6=GI>UFK_//Q=_X+I?#'P+\2-7\-^"_AY\>_
MCFWAB_DTOQ%JGPR\"7&O:3X>N8]N^*XNMT<;,H)+"$R%=C X(P?;/A;_ ,%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY\4_BE_PB_C#3H(;FXT__A&]7OO+CE0/&?,MK62,Y4@X#$CO@UZM^QY^WO\
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M_P#R;7T-^P9_P4L\"_\ !0__ (2K_A"M)\6Z7_PA_P!D^V?VW:V\/F_:?/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !17E/\ PWA\#O\ HLWPI_\
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M$?BQJ?AK2]&\$_$F72])M+.*"VE14@>*7809F&$*K@#"CDG>^&WQC^(/P?\
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MC*P^'FG_ !=B_:V^(E]^V!=:U!:7'P D\061TCSGU%8Y-(_X1P1&XC1;;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/Q.IEY^<9Q7Z6T5,)*G-3I:6BHKO[J@E)M6]ZT$N;LY::Z.I>K!QJZWDY/\
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M%%-)?<_E8=5<\U4VUD_G)IO\5\].VOP/_P $M++7=2^$?[8MOX7N([/Q+/\
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MYO\ ^"27ASQYX4_8!\!V?Q$AUJSUP+=R6EEK)8ZEINF/=S-I]M=%F9O.BLS
MC!F+ KAB2":^D***JM4YYN??^OGZ]2:<>6-O^ ODNB[+HM HHHK,H**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>tpst-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-30T08:19:15.3823+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.tempesttx.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:tpst="http://www.tempesttx.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" namespace="http://xbrl.sec.gov/country/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" namespace="http://xbrl.sec.gov/cyd/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/Cover" id="Cover">
        <link:definition>75000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>75010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>75030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical" id="StatementConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>75040 - Statement - Consolidated Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1" id="StatementConsolidatedStatementsOfStockholdersEquity1">
        <link:definition>75050 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>75060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows" id="ConsolidatedStatementsofCashFlows">
        <link:definition>75070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1" id="DisclosureOrganizationAndDescriptionOfBusiness1">
        <link:definition>995467 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPolicies" id="SummaryofSignificantAccountingPolicies">
        <link:definition>995477 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995487 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItems" id="BalanceSheetItems">
        <link:definition>995497 - Disclosure - Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995507 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/LoanPayable" id="LoanPayable">
        <link:definition>995517 - Disclosure - Loan Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995527 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1" id="DisclosureStockbasedCompensation1">
        <link:definition>995537 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>995547 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/RetirementPlan" id="RetirementPlan">
        <link:definition>995557 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShare" id="NetLossPerShare">
        <link:definition>995567 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995577 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995587 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" id="SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>995597 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesTables" id="SummaryofSignificantAccountingPoliciesTables">
        <link:definition>995607 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>995617 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsTables" id="BalanceSheetItemsTables">
        <link:definition>995627 - Disclosure - Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/CommitmentandContingenciesTables" id="CommitmentandContingenciesTables">
        <link:definition>995637 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>995647 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>995657 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareTables" id="NetLossPerShareTables">
        <link:definition>995667 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" id="DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails">
        <link:definition>995677 - Disclosure - Organization and Description of Business - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>995687 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails">
        <link:definition>995697 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>995707 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails" id="DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails">
        <link:definition>995717 - Disclosure - Balance Sheet Items - Schedule of Prepaid Expenses and Other Current Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails" id="DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>995727 - Disclosure - Balance Sheet Items - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsNarrativeDetails" id="BalanceSheetItemsNarrativeDetails">
        <link:definition>995737 - Disclosure - Balance Sheet Items - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails" id="DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails">
        <link:definition>995747 - Disclosure - Balance Sheet Items - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>995757 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails" id="DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails">
        <link:definition>995767 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments under Operating Leases with Noncancelable Terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails2" id="DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails2">
        <link:definition>995777 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments under Operating Leases with Noncancelable Terms (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails3" id="DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails3">
        <link:definition>995787 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments under Operating Leases with Noncancelable Terms (Details) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails" id="DisclosureLoanPayableNarrativeDetails">
        <link:definition>995797 - Disclosure - Loan Payable - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails">
        <link:definition>995807 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" id="DisclosureStockbasedCompensationNarrativeDetails">
        <link:definition>995817 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails" id="DisclosureStockbasedCompensationSummaryOfStockOptionsDetails">
        <link:definition>995827 - Disclosure - Stock-Based Compensation - Summary of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails" id="DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails">
        <link:definition>995837 - Disclosure - Stock-Based Compensation - Summary of Information About Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails" id="DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails">
        <link:definition>995847 - Disclosure - Stock-Based Compensation - Grant Date Fair Value of Option (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails" id="DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>995857 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails">
        <link:definition>995867 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>995877 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>995887 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>995897 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheTotalChangeInTheValuationAllowanceDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfTheTotalChangeInTheValuationAllowanceDetails">
        <link:definition>995907 - Disclosure - Income Taxes - Schedule of Reconciliation of the Total Change in the Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" id="DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>995917 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureRetirementPlanNarrativeDetails" id="DisclosureRetirementPlanNarrativeDetails">
        <link:definition>995927 - Disclosure - Retirement Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails">
        <link:definition>995937 - Disclosure - Net Loss Per Share - Summary of Basis in Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" id="NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>995947 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReportingNarrativeDetails" id="DisclosureSegmentReportingNarrativeDetails">
        <link:definition>995957 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails" id="DisclosureSubsequentEventsNarrativeDetails">
        <link:definition>995967 - Disclosure - Subsequent Events - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/Cover" xlink:href="tpst-20251231.xsd#Cover" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets" xlink:href="tpst-20251231.xsd#ConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="tpst-20251231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="tpst-20251231.xsd#StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical" xlink:href="tpst-20251231.xsd#StatementConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1" xlink:href="tpst-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="tpst-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows" xlink:href="tpst-20251231.xsd#ConsolidatedStatementsofCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="tpst-20251231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1" xlink:href="tpst-20251231.xsd#DisclosureOrganizationAndDescriptionOfBusiness1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPolicies" xlink:href="tpst-20251231.xsd#SummaryofSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurements" xlink:href="tpst-20251231.xsd#FairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItems" xlink:href="tpst-20251231.xsd#BalanceSheetItems" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="tpst-20251231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/LoanPayable" xlink:href="tpst-20251231.xsd#LoanPayable" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="tpst-20251231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:href="tpst-20251231.xsd#DisclosureStockbasedCompensation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxes" xlink:href="tpst-20251231.xsd#IncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/RetirementPlan" xlink:href="tpst-20251231.xsd#RetirementPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShare" xlink:href="tpst-20251231.xsd#NetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReporting" xlink:href="tpst-20251231.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="tpst-20251231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:href="tpst-20251231.xsd#SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesTables" xlink:href="tpst-20251231.xsd#SummaryofSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurementsTables" xlink:href="tpst-20251231.xsd#FairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsTables" xlink:href="tpst-20251231.xsd#BalanceSheetItemsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/CommitmentandContingenciesTables" xlink:href="tpst-20251231.xsd#CommitmentandContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="tpst-20251231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesTables" xlink:href="tpst-20251231.xsd#IncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareTables" xlink:href="tpst-20251231.xsd#NetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:href="tpst-20251231.xsd#DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="tpst-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="tpst-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="tpst-20251231.xsd#DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails" xlink:href="tpst-20251231.xsd#DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="tpst-20251231.xsd#DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsNarrativeDetails" xlink:href="tpst-20251231.xsd#BalanceSheetItemsNarrativeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails" xlink:href="tpst-20251231.xsd#DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:href="tpst-20251231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails" xlink:href="tpst-20251231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails" xlink:href="tpst-20251231.xsd#DisclosureLoanPayableNarrativeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails" xlink:href="tpst-20251231.xsd#DisclosureStockholdersEquityNarrativeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" xlink:href="tpst-20251231.xsd#DisclosureStockbasedCompensationNarrativeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails" xlink:href="tpst-20251231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails" xlink:href="tpst-20251231.xsd#DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails" xlink:href="tpst-20251231.xsd#DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails" xlink:href="tpst-20251231.xsd#DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:href="tpst-20251231.xsd#DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails" xlink:href="tpst-20251231.xsd#DisclosureIncomeTaxesNarrativeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:href="tpst-20251231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:href="tpst-20251231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheTotalChangeInTheValuationAllowanceDetails" xlink:href="tpst-20251231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfTheTotalChangeInTheValuationAllowanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:href="tpst-20251231.xsd#DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureRetirementPlanNarrativeDetails" xlink:href="tpst-20251231.xsd#DisclosureRetirementPlanNarrativeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails" xlink:href="tpst-20251231.xsd#DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:href="tpst-20251231.xsd#NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReportingNarrativeDetails" xlink:href="tpst-20251231.xsd#DisclosureSegmentReportingNarrativeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails" xlink:href="tpst-20251231.xsd#DisclosureSubsequentEventsNarrativeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails2" xlink:href="tpst-20251231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails3" xlink:href="tpst-20251231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfCommonStockWarrants" xlink:label="tpst_IssuanceOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards" xlink:label="tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_Corporatetaxespaid" xlink:label="tpst_Corporatetaxespaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice" xlink:label="tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable" xlink:label="tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" xlink:label="tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxTable" xlink:label="tpst_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionSharePrice" xlink:label="tpst_AssetAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TrancheCTermLoanMember" xlink:label="tpst_TrancheCTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfPre-FundedWarrantShares" xlink:label="tpst_IssuanceOfPre-FundedWarrantShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NoncashInterestAndOtherExpenseNet" xlink:label="tpst_NoncashInterestAndOtherExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PatentCostsPolicyPolicyTextBlock" xlink:label="tpst_PatentCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_EmploymentAgreementMember" xlink:label="tpst_EmploymentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DebtInstrumentNumberOfTranches" xlink:label="tpst_DebtInstrumentNumberOfTranches"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ErigenAssetsMember" xlink:label="tpst_ErigenAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="tpst_PrepaidResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionTransactionCosts" xlink:label="tpst_AssetAcquisitionTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock" xlink:label="tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NetProceedsFromIssuanceOfCommonStock" xlink:label="tpst_NetProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesCompletionDate" xlink:label="us-gaap_RestructuringAndRelatedActivitiesCompletionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees" xlink:label="tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" xlink:label="tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_JefferiesLLCMember" xlink:label="tpst_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationReserveCurrent" xlink:label="us-gaap_LitigationReserveCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NoncashLeaseExpense" xlink:label="tpst_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SeriesAWarrantsMember" xlink:label="tpst_SeriesAWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AtTheMarketProgramMember" xlink:label="tpst_AtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TrancheATermLoanMember" xlink:label="tpst_TrancheATermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_Pre-FundedWarrantMember" xlink:label="tpst_Pre-FundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NotSubjectToExpirationMember" xlink:label="tpst_NotSubjectToExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember" xlink:label="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PurchaseAgreementMember" xlink:label="tpst_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionEffectiveDateOfAcquisition" xlink:label="us-gaap_AssetAcquisitionEffectiveDateOfAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TrancheBTermLoanMember" xlink:label="tpst_TrancheBTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SaleOfStockExercisePriceOfWarrantsOrRights" xlink:label="tpst_SaleOfStockExercisePriceOfWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetPurchaseAgreementMember" xlink:label="tpst_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_O2026Q4DividendsMember" xlink:label="tpst_O2026Q4DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_CommonStockWarrantsMember" xlink:label="tpst_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_A2019And2017EquityIncentivePlanMember" xlink:label="tpst_A2019And2017EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxAssetsCapitalResearchAndDevelopment" xlink:label="tpst_DeferredTaxAssetsCapitalResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued" xlink:label="tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_A2019EquityIncentivePlanMember" xlink:label="tpst_A2019EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_RemainedAvailableForIssuanceOfCommonStock" xlink:label="tpst_RemainedAvailableForIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfPre-FundedWarrantValue" xlink:label="tpst_IssuanceOfPre-FundedWarrantValue"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ThersholdIndexRate" xlink:label="tpst_ThersholdIndexRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionMaximumFundingCommitment" xlink:label="tpst_AssetAcquisitionMaximumFundingCommitment"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_A2019EmployeeStockPurchasePlanMember" xlink:label="tpst_A2019EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AccruedClinicalTrialLiability" xlink:label="tpst_AccruedClinicalTrialLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PercentageOfAnnualBonus" xlink:label="tpst_PercentageOfAnnualBonus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_BrisbaneCaliforniaMember" xlink:label="tpst_BrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PrivateTempestPreferredStockMember" xlink:label="tpst_PrivateTempestPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_StockIssuanceCosts" xlink:label="tpst_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PrivateInvestmentInPublicEntityFinancingMember" xlink:label="tpst_PrivateInvestmentInPublicEntityFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember" xlink:label="tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightsMember" xlink:label="us-gaap_RightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DebtInstrumentExitFee" xlink:label="tpst_DebtInstrumentExitFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_CommonWarrantsMember" xlink:label="tpst_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceSettlementsReceivable" xlink:label="us-gaap_InsuranceSettlementsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PercentageOfCommissionOnSaleOfStock" xlink:label="tpst_PercentageOfCommissionOnSaleOfStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PreFundedWarrantAndCommonWarrantsMember" xlink:label="tpst_PreFundedWarrantAndCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember" xlink:label="tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PublicFloat" xlink:label="tpst_PublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_Pre-FundedWarrantsIssuanceCost" xlink:label="tpst_Pre-FundedWarrantsIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards" xlink:label="tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ProceedsFromIssuanceOfCommonStockWarrants" xlink:label="tpst_ProceedsFromIssuanceOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_OperatingLeaseCommencementMonthAndYear" xlink:label="tpst_OperatingLeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_LegacyMillendoMember" xlink:label="tpst_LegacyMillendoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TwoThousandTwentyThreeInducementPlanMember" xlink:label="tpst_TwoThousandTwentyThreeInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TermLoanMember" xlink:label="tpst_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_WarrantsIssuanceCost" xlink:label="tpst_WarrantsIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxLineItems" xlink:label="tpst_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_O2023Q4DividendsMember" xlink:label="tpst_O2023Q4DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AnnualBaseSalary" xlink:label="tpst_AnnualBaseSalary"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SeriesBWarrantsMember" xlink:label="tpst_SeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_RegisteredDirectOfferingMember" xlink:label="tpst_RegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="tpst_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_EmployeeStockOwnershipPlanMember" xlink:label="tpst_EmployeeStockOwnershipPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_OrphanDrugCreditMember" xlink:label="tpst_OrphanDrugCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SaleOfStockWarrantsIssued" xlink:label="tpst_SaleOfStockWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendsPayableCurrent" xlink:label="us-gaap_InterestAndDividendsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrants (net of issuance cost)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Interest Payable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under equity plan awards (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock Shares under Equity Plan Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock shares under equity plan awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Excluding Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan payable (net of discount and issuance costs of nil and $164, respectively)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Corporatetaxespaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for business taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Corporatetaxespaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CorporateTaxesPaid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Corporatetaxespaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CorporateTaxesPaid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">June Two Thousand Twenty Five Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">June 2025 Pre-Funded Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June 2025 Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assumed in reverse recapitalization (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting rights of preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition, stock issued as consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Shares, Equity Interest Issued and Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition, consideration transferred, shares, equity interest issued and issuable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock, Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross increase - tax position in current period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, purchase price of common stock, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current loan payable (net of discount and issuance costs of nil and $74, respectively)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time cash severance payments, benefits and other related costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change related to continuing operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At statutory rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or nondeductible items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Geographical Axis [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, vesting date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options , Vesting Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options , vesting date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition, share price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition, stock price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net of discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Period of Automatic Increase to Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Period of Automatic Increase to Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, period of automatic increase to outstanding stock maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TrancheCTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche C term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TrancheCTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche C Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TrancheCTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche C Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basis in Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfPre-FundedWarrantShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Pre-Funded Warrant Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfPre-FundedWarrantShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of pre-funded warrant shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfPre-FundedWarrantShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of pre-funded warrants (net of issuance cost) (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share of common stock and pre-funded warrants, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NoncashInterestAndOtherExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash interest and other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NoncashInterestAndOtherExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash interest and other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NoncashInterestAndOtherExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash interest and other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at end (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at beginning (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent Costs, Policy</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_EmploymentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employment Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_EmploymentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employment agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_EmploymentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Angel Employment Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend record date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable, Date of Record</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Cash Flow Elements, Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DebtInstrumentNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of tranches</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DebtInstrumentNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Number of Tranches</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DebtInstrumentNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Instrument, Number of Tranches</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments of debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ErigenAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Erigen Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ErigenAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Erigen assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ErigenAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Erigen Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cancelled and forfeited (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled and forfeited (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research and Development Costs, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Research and Development Costs, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition transaction costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer discretionary contribution amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of estimated useful lives of property, plant and equipment [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful lives of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives of Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total gross deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Non deductible Expense Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Reconciliation Non deductible Expense Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Information About Stock Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of pre-funded warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities, Initiation Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring activities, plan adopted date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sales of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from issuance of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesCompletionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities, Completion Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesCompletionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective date of workforce reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised of stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Cost Number Of Full Time Employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring and related cost number of full time employees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of full time employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid Expenses And Other Current Asset [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Prepaid Expenses And Other Current Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Long-term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2023 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended and Restated Two Thousand Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated two thousand twenty three equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense and Accrued Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, capital shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Geographical Axis [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Non Deductible Expense Transaction Costs Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Reconciliation Non Deductible Expense Transaction Costs Percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationReserveCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationReserveCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Litigation Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, number of additional shares issuable in period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other noncurrent assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan mature date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, share fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SeriesAWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SeriesAWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SeriesAWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series a warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-The-Market Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-The-Market Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TrancheATermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche A term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TrancheATermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche A Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TrancheATermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche A Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Pre-FundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Pre-FundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrant [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Pre-FundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Pre-FundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">June 2025 Pre-Funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NotSubjectToExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Not Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NotSubjectToExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Not Subject to Expiration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NotSubjectToExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Not Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock under equity plan awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A Junior Participating Preferred Purchase Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Junior Participating Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Junior Participating Preferred Purchase Rights [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series a junior participating preferred purchase rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 5)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of operating lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of operating lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, basis spread on variable rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares used in computing basic net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing basic net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares used in computing basic net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionEffectiveDateOfAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Effective Date of Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionEffectiveDateOfAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition, effective date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TrancheBTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche B term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TrancheBTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche B Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TrancheBTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche B Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SaleOfStockExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock, exercise price of warrants or rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SaleOfStockExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Exercise Price Of Warrants Or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SaleOfStockExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrant price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_O2026Q4DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">O 2026 Q4 Dividends [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_O2026Q4DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">O 2026 Q4 dividends.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_O2026Q4DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">O 2026 Q4 Dividends [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument interest term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stockholders' Equity Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_A2019And2017EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">A 2019 and 2017 equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_A2019And2017EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A2019 And2017 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_A2019And2017EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 and 2017 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Participating Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxAssetsCapitalResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Capital Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxAssetsCapitalResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capital Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxAssetsCapitalResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition, stock to be issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Shares Equity Interest Yet To Be Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition shares equity interest yet to be issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accelarated vesting of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Weighted-average unvested restricted shares and shares subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Weighted-average unvested restricted shares and shares subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of real estate property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Area of property (in sqft)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_A2019EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_A2019EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2019 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_A2019EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) before provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of discount and issuance costs, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Current, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Current, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Employee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Employee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_RemainedAvailableForIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remained available for issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_RemainedAvailableForIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remained Available for issuance of Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_RemainedAvailableForIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remained available for issuance of cmmon stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability to be Paid Year Four and Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability to be paid year four and thereafter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 and beyond</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfPre-FundedWarrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Pre-Funded Warrant Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfPre-FundedWarrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of pre-funded warrant value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfPre-FundedWarrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of pre-funded warrants (net of issuance cost)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Available for Grant Per Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Available For Grant Per Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, maximum number of shares available for grant per year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares used in computing diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares used in computing diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock and pre-funded warrants outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Obligation Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, percentage of outstanding stock maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Valuation Allowance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of the Total Change in the Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ThersholdIndexRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thershold index rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ThersholdIndexRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ThersholdIndexRate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ThersholdIndexRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ThersholdIndexRate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Jurisdiction of Domicile [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Risks And Uncertainties, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant Risks And Uncertainties, Policy</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, shares issued in period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionMaximumFundingCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition, maximum funding commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionMaximumFundingCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Maximum Funding Commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AssetAcquisitionMaximumFundingCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition maximum funding commitment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_A2019EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_A2019EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2019 Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_A2019EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AccruedClinicalTrialLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AccruedClinicalTrialLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AccruedClinicalTrialLiability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AccruedClinicalTrialLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AccruedClinicalTrialLiability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Standards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Rental Payments under Operating Leases with Noncancelable Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares purchase from preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, award vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PercentageOfAnnualBonus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual bonus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PercentageOfAnnualBonus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Annual Bonus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PercentageOfAnnualBonus_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of annual bonus.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_BrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brisbane California.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_BrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brisbane California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_BrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brisbane, California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">No Trading Symbol Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, state</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate sales price of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash (net of issuance cost)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PrivateTempestPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private tempest preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PrivateTempestPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Tempest Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PrivateTempestPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Tempest Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Operating Lease, Right-of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liabilities, Operating Lease, Right-of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment and software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issuance Costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assumed dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PrivateInvestmentInPublicEntityFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private investment in public entity financing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PrivateInvestmentInPublicEntityFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Investment In Public Entity Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PrivateInvestmentInPublicEntityFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PIPE Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, fair value of stock options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Nonoperating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Income (Loss) Before Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Date of Acquisition Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition, agreement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Reserve [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Individuals who were not Previously Employees or Directors of Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Individuals Who Were Not Previously Employees or Directors Of Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Individuals who were not previously employees or directors of company.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rights Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rights [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DebtInstrumentExitFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Exit Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DebtInstrumentExitFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument exit fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DebtInstrumentExitFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, exit fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax liability:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cancelled and forfeited (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Issued, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at end (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at beginning (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceSettlementsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance recovery of legal settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceSettlementsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Settlements Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or nondeductible items, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, modified stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PercentageOfCommissionOnSaleOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of commission on sale of stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PercentageOfCommissionOnSaleOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission On Sale Of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PercentageOfCommissionOnSaleOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of commission on sale of stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PreFundedWarrantAndCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrant And Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PreFundedWarrantAndCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre funded&#160;warrant and common warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PreFundedWarrantAndCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Funded Warrant and Common Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credit, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">EcoR1 Capital LLC and Versant Venture Capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">EcoR1 Capital LLC And Versant Venture Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EcoR1 Capital, LLC and Versant Venture Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation expense related to employees stock options grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public float.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_PublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting rights of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Pre-FundedWarrantsIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants Issuance Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Pre-FundedWarrantsIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants issuance cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_Pre-FundedWarrantsIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Cash Flow Elements, Investing Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under equity plan award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Value Under Equity Plan Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock value under equity plan awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercised (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 100,000,000 shares authorized; 4,927,161 and 3,382,432 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ProceedsFromIssuanceOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ProceedsFromIssuanceOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ProceedsFromIssuanceOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assumed in reverse recapitalization (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_OperatingLeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_OperatingLeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_OperatingLeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease commencement month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_LegacyMillendoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legacy Millendo</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_LegacyMillendoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legacy Millendo</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_LegacyMillendoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legacy Millendo [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly principal payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Periodic Payment, Principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income and other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TwoThousandTwentyThreeInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Inducement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TwoThousandTwentyThreeInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TwoThousandTwentyThreeInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three inducement plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, number of shares granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_WarrantsIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issuance Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_WarrantsIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issuance cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_WarrantsIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued in transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock for cash (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash (net of issuance cost) (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share of common stock and pre-funded warrants, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable, Trade</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowing capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_O2023Q4DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">O 2023 Q4 Dividends [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_O2023Q4DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">O 2023 Q4 Dividends.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_O2023Q4DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">O 2023 Q4 Dividends [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AnnualBaseSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Base Salary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AnnualBaseSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual base salary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_AnnualBaseSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anual base salary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series b warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_RegisteredDirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Registered Direct Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_RegisteredDirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Registered Direct Offering [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_RegisteredDirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RDO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual floating interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment&#8212;net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment&#8212;net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deficit Accumulated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Acquisition, Consideration Transferred, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition, aggregate consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of employees eliminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Noncurrent operating lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_EmployeeStockOwnershipPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock ownership plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_EmployeeStockOwnershipPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Ownership Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_EmployeeStockOwnershipPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Ownership Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_OrphanDrugCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_OrphanDrugCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Orphan Drug Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_OrphanDrugCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Orphan Drug Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">November Two Thousand Twenty Five Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">November 2025 Pre-Funded Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November 2025 Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SaleOfStockWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock warrants issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SaleOfStockWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tpst_SaleOfStockWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Dividends Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and Dividends Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_IssuanceOfCommonStockWarrants" xlink:to="tpst_IssuanceOfCommonStockWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards" xlink:to="tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_Corporatetaxespaid" xlink:to="tpst_Corporatetaxespaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember" xlink:to="tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice" xlink:to="tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable" xlink:to="tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockCash" xlink:to="us-gaap_DividendsCommonStockCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" xlink:to="tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_IncomeTaxTable" xlink:to="tpst_IncomeTaxTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate" xlink:to="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_AssetAcquisitionSharePrice" xlink:to="tpst_AssetAcquisitionSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum" xlink:to="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_TrancheCTermLoanMember" xlink:to="tpst_TrancheCTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_IssuanceOfPre-FundedWarrantShares" xlink:to="tpst_IssuanceOfPre-FundedWarrantShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_NoncashInterestAndOtherExpenseNet" xlink:to="tpst_NoncashInterestAndOtherExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_PatentCostsPolicyPolicyTextBlock" xlink:to="tpst_PatentCostsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_EmploymentAgreementMember" xlink:to="tpst_EmploymentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_DebtInstrumentNumberOfTranches" xlink:to="tpst_DebtInstrumentNumberOfTranches_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_ErigenAssetsMember" xlink:to="tpst_ErigenAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="tpst_PrepaidResearchAndDevelopmentCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_AssetAcquisitionTransactionCosts" xlink:to="tpst_AssetAcquisitionTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock" xlink:to="tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts" xlink:to="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:to="us-gaap_RestructuringAndRelatedActivitiesInitiationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_NetProceedsFromIssuanceOfCommonStock" xlink:to="tpst_NetProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesCompletionDate" xlink:to="us-gaap_RestructuringAndRelatedActivitiesCompletionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees" xlink:to="tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" xlink:to="tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent" xlink:to="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_JefferiesLLCMember" xlink:to="tpst_JefferiesLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveCurrent" xlink:to="us-gaap_LitigationReserveCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_NoncashLeaseExpense" xlink:to="tpst_NoncashLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_SeriesAWarrantsMember" xlink:to="tpst_SeriesAWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_AtTheMarketProgramMember" xlink:to="tpst_AtTheMarketProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_TrancheATermLoanMember" xlink:to="tpst_TrancheATermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_Pre-FundedWarrantMember" xlink:to="tpst_Pre-FundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_NotSubjectToExpirationMember" xlink:to="tpst_NotSubjectToExpirationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember" xlink:to="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_PurchaseAgreementMember" xlink:to="tpst_PurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionEffectiveDateOfAcquisition" xlink:to="us-gaap_AssetAcquisitionEffectiveDateOfAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_TrancheBTermLoanMember" xlink:to="tpst_TrancheBTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_SaleOfStockExercisePriceOfWarrantsOrRights" xlink:to="tpst_SaleOfStockExercisePriceOfWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_AssetPurchaseAgreementMember" xlink:to="tpst_AssetPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_O2026Q4DividendsMember" xlink:to="tpst_O2026Q4DividendsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_CommonStockWarrantsMember" xlink:to="tpst_CommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_A2019And2017EquityIncentivePlanMember" xlink:to="tpst_A2019And2017EquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_DeferredTaxAssetsCapitalResearchAndDevelopment" xlink:to="tpst_DeferredTaxAssetsCapitalResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued" xlink:to="tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_A2019EquityIncentivePlanMember" xlink:to="tpst_A2019EquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_RemainedAvailableForIssuanceOfCommonStock" xlink:to="tpst_RemainedAvailableForIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_IssuanceOfPre-FundedWarrantValue" xlink:to="tpst_IssuanceOfPre-FundedWarrantValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear" xlink:to="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_ThersholdIndexRate" xlink:to="tpst_ThersholdIndexRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:to="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_AssetAcquisitionMaximumFundingCommitment" xlink:to="tpst_AssetAcquisitionMaximumFundingCommitment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_A2019EmployeeStockPurchasePlanMember" xlink:to="tpst_A2019EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_AccruedClinicalTrialLiability" xlink:to="tpst_AccruedClinicalTrialLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_PercentageOfAnnualBonus" xlink:to="tpst_PercentageOfAnnualBonus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_BrisbaneCaliforniaMember" xlink:to="tpst_BrisbaneCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsDomain" xlink:to="us-gaap_DividendsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_PrivateTempestPreferredStockMember" xlink:to="tpst_PrivateTempestPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_StockIssuanceCosts" xlink:to="tpst_StockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_PrivateInvestmentInPublicEntityFinancingMember" xlink:to="tpst_PrivateInvestmentInPublicEntityFinancingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:to="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember" xlink:to="tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightsMember" xlink:to="us-gaap_RightsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_DebtInstrumentExitFee" xlink:to="tpst_DebtInstrumentExitFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_CommonWarrantsMember" xlink:to="tpst_CommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceSettlementsReceivable" xlink:to="us-gaap_InsuranceSettlementsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_PercentageOfCommissionOnSaleOfStock" xlink:to="tpst_PercentageOfCommissionOnSaleOfStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_PreFundedWarrantAndCommonWarrantsMember" xlink:to="tpst_PreFundedWarrantAndCommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember" xlink:to="tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_PublicFloat" xlink:to="tpst_PublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_Pre-FundedWarrantsIssuanceCost" xlink:to="tpst_Pre-FundedWarrantsIssuanceCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards" xlink:to="tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_ProceedsFromIssuanceOfCommonStockWarrants" xlink:to="tpst_ProceedsFromIssuanceOfCommonStockWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod" xlink:to="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_OperatingLeaseCommencementMonthAndYear" xlink:to="tpst_OperatingLeaseCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_LegacyMillendoMember" xlink:to="tpst_LegacyMillendoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_TwoThousandTwentyThreeInducementPlanMember" xlink:to="tpst_TwoThousandTwentyThreeInducementPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_TermLoanMember" xlink:to="tpst_TermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_WarrantsIssuanceCost" xlink:to="tpst_WarrantsIssuanceCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_IncomeTaxLineItems" xlink:to="tpst_IncomeTaxLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_O2023Q4DividendsMember" xlink:to="tpst_O2023Q4DividendsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_AnnualBaseSalary" xlink:to="tpst_AnnualBaseSalary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_SeriesBWarrantsMember" xlink:to="tpst_SeriesBWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_RegisteredDirectOfferingMember" xlink:to="tpst_RegisteredDirectOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="tpst_DeferredTaxAssetsOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_EmployeeStockOwnershipPlanMember" xlink:to="tpst_EmployeeStockOwnershipPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_OrphanDrugCreditMember" xlink:to="tpst_OrphanDrugCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember" xlink:to="tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tpst_SaleOfStockWarrantsIssued" xlink:to="tpst_SaleOfStockWarrantsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendsPayableCurrent" xlink:to="us-gaap_InterestAndDividendsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/Cover" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember" xlink:label="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceSettlementsReceivable" xlink:label="us-gaap_InsuranceSettlementsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationReserveCurrent" xlink:label="us-gaap_LitigationReserveCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendsPayableCurrent" xlink:label="us-gaap_InterestAndDividendsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InsuranceSettlementsReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LitigationReserveCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestAndDividendsPayableCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfPre-FundedWarrantShares" xlink:label="tpst_IssuanceOfPre-FundedWarrantShares"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfPre-FundedWarrantValue" xlink:label="tpst_IssuanceOfPre-FundedWarrantValue"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfCommonStockWarrants" xlink:label="tpst_IssuanceOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards" xlink:label="tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards" xlink:label="tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_12"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tpst_IssuanceOfPre-FundedWarrantShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tpst_IssuanceOfPre-FundedWarrantValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tpst_IssuanceOfCommonStockWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_StockIssuanceCosts" xlink:label="tpst_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_Pre-FundedWarrantsIssuanceCost" xlink:label="tpst_Pre-FundedWarrantsIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_WarrantsIssuanceCost" xlink:label="tpst_WarrantsIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="tpst_StockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="tpst_Pre-FundedWarrantsIssuanceCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="tpst_WarrantsIssuanceCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_Corporatetaxespaid" xlink:label="tpst_Corporatetaxespaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NoncashLeaseExpense" xlink:label="tpst_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ProceedsFromIssuanceOfCommonStockWarrants" xlink:label="tpst_ProceedsFromIssuanceOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NoncashInterestAndOtherExpenseNet" xlink:label="tpst_NoncashInterestAndOtherExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="us-gaap_CapitalLeaseObligationsIncurred" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="tpst_Corporatetaxespaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tpst_NoncashLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tpst_ProceedsFromIssuanceOfCommonStockWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tpst_NoncashInterestAndOtherExpenseNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItems" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/LoanPayable" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/RetirementPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PatentCostsPolicyPolicyTextBlock" xlink:label="tpst_PatentCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tpst_PatentCostsPolicyPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock" xlink:label="tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" xlink:label="tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/CommitmentandContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetPurchaseAgreementMember" xlink:label="tpst_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AtTheMarketProgramMember" xlink:label="tpst_AtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_JefferiesLLCMember" xlink:label="tpst_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_RegisteredDirectOfferingMember" xlink:label="tpst_RegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesCompletionDate" xlink:label="us-gaap_RestructuringAndRelatedActivitiesCompletionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees" xlink:label="tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionMaximumFundingCommitment" xlink:label="tpst_AssetAcquisitionMaximumFundingCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SaleOfStockWarrantsIssued" xlink:label="tpst_SaleOfStockWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SaleOfStockExercisePriceOfWarrantsOrRights" xlink:label="tpst_SaleOfStockExercisePriceOfWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PercentageOfCommissionOnSaleOfStock" xlink:label="tpst_PercentageOfCommissionOnSaleOfStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NetProceedsFromIssuanceOfCommonStock" xlink:label="tpst_NetProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_RemainedAvailableForIssuanceOfCommonStock" xlink:label="tpst_RemainedAvailableForIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PublicFloat" xlink:label="tpst_PublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tpst_AssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tpst_AtTheMarketProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tpst_JefferiesLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tpst_RegisteredDirectOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesCompletionDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SeveranceCosts1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_AssetAcquisitionMaximumFundingCommitment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_SaleOfStockWarrantsIssued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_SaleOfStockExercisePriceOfWarrantsOrRights" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_PercentageOfCommissionOnSaleOfStock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_NetProceedsFromIssuanceOfCommonStock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_RemainedAvailableForIssuanceOfCommonStock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_PublicFloat" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="tpst_PrepaidResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tpst_PrepaidResearchAndDevelopmentCostsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsNarrativeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AccruedClinicalTrialLiability" xlink:label="tpst_AccruedClinicalTrialLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tpst_AccruedClinicalTrialLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_BrisbaneCaliforniaMember" xlink:label="tpst_BrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_OperatingLeaseCommencementMonthAndYear" xlink:label="tpst_OperatingLeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tpst_BrisbaneCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tpst_OperatingLeaseCommencementMonthAndYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_BrisbaneCaliforniaMember" xlink:label="tpst_BrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tpst_BrisbaneCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TermLoanMember" xlink:label="tpst_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TrancheATermLoanMember" xlink:label="tpst_TrancheATermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DebtInstrumentNumberOfTranches" xlink:label="tpst_DebtInstrumentNumberOfTranches"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TrancheBTermLoanMember" xlink:label="tpst_TrancheBTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TrancheCTermLoanMember" xlink:label="tpst_TrancheCTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ThersholdIndexRate" xlink:label="tpst_ThersholdIndexRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DebtInstrumentExitFee" xlink:label="tpst_DebtInstrumentExitFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tpst_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tpst_TrancheATermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tpst_DebtInstrumentNumberOfTranches" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tpst_TrancheBTermLoanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tpst_TrancheCTermLoanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tpst_ThersholdIndexRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tpst_DebtInstrumentExitFee" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightsMember" xlink:label="us-gaap_RightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AtTheMarketProgramMember" xlink:label="tpst_AtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_O2023Q4DividendsMember" xlink:label="tpst_O2023Q4DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PrivateTempestPreferredStockMember" xlink:label="tpst_PrivateTempestPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_JefferiesLLCMember" xlink:label="tpst_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember" xlink:label="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PrivateInvestmentInPublicEntityFinancingMember" xlink:label="tpst_PrivateInvestmentInPublicEntityFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember" xlink:label="tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_RightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tpst_AtTheMarketProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsDomain" xlink:to="tpst_O2023Q4DividendsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tpst_PrivateTempestPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tpst_JefferiesLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tpst_PrivateInvestmentInPublicEntityFinancingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DividendsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_A2019EquityIncentivePlanMember" xlink:label="tpst_A2019EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember" xlink:label="tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_A2019And2017EquityIncentivePlanMember" xlink:label="tpst_A2019And2017EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_EmployeeStockOwnershipPlanMember" xlink:label="tpst_EmployeeStockOwnershipPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_A2019EmployeeStockPurchasePlanMember" xlink:label="tpst_A2019EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TwoThousandTwentyThreeInducementPlanMember" xlink:label="tpst_TwoThousandTwentyThreeInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_A2019EquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_A2019And2017EquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_EmployeeStockOwnershipPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_A2019EmployeeStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_TwoThousandTwentyThreeInducementPlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice" xlink:label="tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxTable" xlink:label="tpst_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NotSubjectToExpirationMember" xlink:label="tpst_NotSubjectToExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_LegacyMillendoMember" xlink:label="tpst_LegacyMillendoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxLineItems" xlink:label="tpst_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_OrphanDrugCreditMember" xlink:label="tpst_OrphanDrugCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxTable" xlink:to="us-gaap_TaxPeriodAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="tpst_NotSubjectToExpirationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="tpst_LegacyMillendoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tpst_IncomeTaxTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tpst_OrphanDrugCreditMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxTable" xlink:to="dei_LegalEntityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxTable" xlink:to="tpst_IncomeTaxLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" xlink:label="tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="tpst_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxAssetsCapitalResearchAndDevelopment" xlink:label="tpst_DeferredTaxAssetsCapitalResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tpst_DeferredTaxAssetsOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tpst_DeferredTaxAssetsCapitalResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheTotalChangeInTheValuationAllowanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureRetirementPlanNarrativeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_CommonStockWarrantsMember" xlink:label="tpst_CommonStockWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tpst_CommonStockWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReportingNarrativeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetPurchaseAgreementMember" xlink:label="tpst_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ErigenAssetsMember" xlink:label="tpst_ErigenAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SeriesAWarrantsMember" xlink:label="tpst_SeriesAWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_O2026Q4DividendsMember" xlink:label="tpst_O2026Q4DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_Pre-FundedWarrantMember" xlink:label="tpst_Pre-FundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_EmploymentAgreementMember" xlink:label="tpst_EmploymentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SeriesBWarrantsMember" xlink:label="tpst_SeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued" xlink:label="tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PreFundedWarrantAndCommonWarrantsMember" xlink:label="tpst_PreFundedWarrantAndCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PurchaseAgreementMember" xlink:label="tpst_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionEffectiveDateOfAcquisition" xlink:label="us-gaap_AssetAcquisitionEffectiveDateOfAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_CommonWarrantsMember" xlink:label="tpst_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable" xlink:label="tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionSharePrice" xlink:label="tpst_AssetAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionTransactionCosts" xlink:label="tpst_AssetAcquisitionTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionMaximumFundingCommitment" xlink:label="tpst_AssetAcquisitionMaximumFundingCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AnnualBaseSalary" xlink:label="tpst_AnnualBaseSalary"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PercentageOfAnnualBonus" xlink:label="tpst_PercentageOfAnnualBonus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SaleOfStockWarrantsIssued" xlink:label="tpst_SaleOfStockWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tpst_AssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="tpst_ErigenAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tpst_SeriesAWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsDomain" xlink:to="tpst_O2026Q4DividendsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tpst_Pre-FundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="tpst_EmploymentAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tpst_SeriesBWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tpst_PreFundedWarrantAndCommonWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="tpst_PurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionEffectiveDateOfAcquisition" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tpst_CommonWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AssetAcquisitionSharePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AssetAcquisitionTransactionCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_PlanNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AssetAcquisitionMaximumFundingCommitment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_DividendsAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AnnualBaseSalary" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_PercentageOfAnnualBonus" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_SaleOfStockWarrantsIssued" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_SharePrice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/Cover">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember" xlink:label="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfPre-FundedWarrantShares" xlink:label="tpst_IssuanceOfPre-FundedWarrantShares"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfPre-FundedWarrantValue" xlink:label="tpst_IssuanceOfPre-FundedWarrantValue"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfCommonStockWarrants" xlink:label="tpst_IssuanceOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards" xlink:label="tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards" xlink:label="tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tpst_IssuanceOfPre-FundedWarrantShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tpst_IssuanceOfPre-FundedWarrantValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tpst_IssuanceOfCommonStockWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_Corporatetaxespaid" xlink:label="tpst_Corporatetaxespaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NoncashLeaseExpense" xlink:label="tpst_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ProceedsFromIssuanceOfCommonStockWarrants" xlink:label="tpst_ProceedsFromIssuanceOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NoncashInterestAndOtherExpenseNet" xlink:label="tpst_NoncashInterestAndOtherExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="us-gaap_CapitalLeaseObligationsIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="tpst_Corporatetaxespaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tpst_NoncashLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tpst_ProceedsFromIssuanceOfCommonStockWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tpst_NoncashInterestAndOtherExpenseNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetPurchaseAgreementMember" xlink:label="tpst_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AtTheMarketProgramMember" xlink:label="tpst_AtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_JefferiesLLCMember" xlink:label="tpst_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_RegisteredDirectOfferingMember" xlink:label="tpst_RegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesInitiationDate" xlink:label="us-gaap_RestructuringAndRelatedActivitiesInitiationDate"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesCompletionDate" xlink:label="us-gaap_RestructuringAndRelatedActivitiesCompletionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees" xlink:label="tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionMaximumFundingCommitment" xlink:label="tpst_AssetAcquisitionMaximumFundingCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SaleOfStockWarrantsIssued" xlink:label="tpst_SaleOfStockWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SaleOfStockExercisePriceOfWarrantsOrRights" xlink:label="tpst_SaleOfStockExercisePriceOfWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PercentageOfCommissionOnSaleOfStock" xlink:label="tpst_PercentageOfCommissionOnSaleOfStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NetProceedsFromIssuanceOfCommonStock" xlink:label="tpst_NetProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_RemainedAvailableForIssuanceOfCommonStock" xlink:label="tpst_RemainedAvailableForIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PublicFloat" xlink:label="tpst_PublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tpst_AssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tpst_AtTheMarketProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tpst_JefferiesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tpst_RegisteredDirectOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesInitiationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RestructuringAndRelatedActivitiesCompletionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_AssetAcquisitionMaximumFundingCommitment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_SaleOfStockWarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_SaleOfStockExercisePriceOfWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_PercentageOfCommissionOnSaleOfStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_NetProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_RemainedAvailableForIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tpst_PublicFloat" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_BrisbaneCaliforniaMember" xlink:label="tpst_BrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_OperatingLeaseCommencementMonthAndYear" xlink:label="tpst_OperatingLeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tpst_BrisbaneCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tpst_OperatingLeaseCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_BrisbaneCaliforniaMember" xlink:label="tpst_BrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="tpst_BrisbaneCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TermLoanMember" xlink:label="tpst_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TrancheATermLoanMember" xlink:label="tpst_TrancheATermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DebtInstrumentNumberOfTranches" xlink:label="tpst_DebtInstrumentNumberOfTranches"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TrancheBTermLoanMember" xlink:label="tpst_TrancheBTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TrancheCTermLoanMember" xlink:label="tpst_TrancheCTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ThersholdIndexRate" xlink:label="tpst_ThersholdIndexRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DebtInstrumentExitFee" xlink:label="tpst_DebtInstrumentExitFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tpst_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tpst_TrancheATermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tpst_DebtInstrumentNumberOfTranches" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tpst_TrancheBTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="tpst_TrancheCTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tpst_ThersholdIndexRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tpst_DebtInstrumentExitFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightsMember" xlink:label="us-gaap_RightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AtTheMarketProgramMember" xlink:label="tpst_AtTheMarketProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_O2023Q4DividendsMember" xlink:label="tpst_O2023Q4DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PrivateTempestPreferredStockMember" xlink:label="tpst_PrivateTempestPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_JefferiesLLCMember" xlink:label="tpst_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember" xlink:label="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PrivateInvestmentInPublicEntityFinancingMember" xlink:label="tpst_PrivateInvestmentInPublicEntityFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember" xlink:label="tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_RightsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tpst_AtTheMarketProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsDomain" xlink:to="tpst_O2023Q4DividendsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tpst_PrivateTempestPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tpst_JefferiesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tpst_PrivateInvestmentInPublicEntityFinancingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DividendsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_A2019EquityIncentivePlanMember" xlink:label="tpst_A2019EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember" xlink:label="tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_A2019And2017EquityIncentivePlanMember" xlink:label="tpst_A2019And2017EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_EmployeeStockOwnershipPlanMember" xlink:label="tpst_EmployeeStockOwnershipPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_A2019EmployeeStockPurchasePlanMember" xlink:label="tpst_A2019EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_TwoThousandTwentyThreeInducementPlanMember" xlink:label="tpst_TwoThousandTwentyThreeInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate" xlink:label="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_A2019EquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_A2019And2017EquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_EmployeeStockOwnershipPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_A2019EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_TwoThousandTwentyThreeInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails">
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxLineItems" xlink:label="tpst_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxTable" xlink:label="tpst_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NotSubjectToExpirationMember" xlink:label="tpst_NotSubjectToExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_LegacyMillendoMember" xlink:label="tpst_LegacyMillendoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_OrphanDrugCreditMember" xlink:label="tpst_OrphanDrugCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tpst_IncomeTaxLineItems" xlink:to="tpst_IncomeTaxTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tpst_IncomeTaxTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="tpst_NotSubjectToExpirationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tpst_LegacyMillendoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tpst_IncomeTaxTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tpst_OrphanDrugCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tpst_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tpst_IncomeTaxTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tpst_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_CommonStockWarrantsMember" xlink:label="tpst_CommonStockWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tpst_CommonStockWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetPurchaseAgreementMember" xlink:label="tpst_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ErigenAssetsMember" xlink:label="tpst_ErigenAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SeriesAWarrantsMember" xlink:label="tpst_SeriesAWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_O2026Q4DividendsMember" xlink:label="tpst_O2026Q4DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_Pre-FundedWarrantMember" xlink:label="tpst_Pre-FundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_EmploymentAgreementMember" xlink:label="tpst_EmploymentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SeriesBWarrantsMember" xlink:label="tpst_SeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued" xlink:label="tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PreFundedWarrantAndCommonWarrantsMember" xlink:label="tpst_PreFundedWarrantAndCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PurchaseAgreementMember" xlink:label="tpst_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionEffectiveDateOfAcquisition" xlink:label="us-gaap_AssetAcquisitionEffectiveDateOfAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_CommonWarrantsMember" xlink:label="tpst_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable" xlink:label="tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionSharePrice" xlink:label="tpst_AssetAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionTransactionCosts" xlink:label="tpst_AssetAcquisitionTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AssetAcquisitionMaximumFundingCommitment" xlink:label="tpst_AssetAcquisitionMaximumFundingCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AnnualBaseSalary" xlink:label="tpst_AnnualBaseSalary"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PercentageOfAnnualBonus" xlink:label="tpst_PercentageOfAnnualBonus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_SaleOfStockWarrantsIssued" xlink:label="tpst_SaleOfStockWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tpst_AssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="tpst_ErigenAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tpst_SeriesAWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsDomain" xlink:to="tpst_O2026Q4DividendsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tpst_Pre-FundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="tpst_EmploymentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tpst_SeriesBWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tpst_PreFundedWarrantAndCommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="tpst_PurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionEffectiveDateOfAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tpst_CommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AssetAcquisitionSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AssetAcquisitionTransactionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AssetAcquisitionMaximumFundingCommitment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_DividendsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_AnnualBaseSalary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_PercentageOfAnnualBonus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tpst_SaleOfStockWarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LitigationReserveCurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivable" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapital" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="5" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestAndDividendsPayableCurrent" order="6" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="7" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationReserveCurrent" xlink:label="us-gaap_LitigationReserveCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceSettlementsReceivable" xlink:label="us-gaap_InsuranceSettlementsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendsPayableCurrent" xlink:label="us-gaap_InterestAndDividendsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tpst_NoncashLeaseExpense" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tpst_ProceedsFromIssuanceOfCommonStockWarrants" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tpst_NoncashInterestAndOtherExpenseNet" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="4" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="5" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebt" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="6" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="7" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="8" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="9" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NoncashLeaseExpense" xlink:label="tpst_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_ProceedsFromIssuanceOfCommonStockWarrants" xlink:label="tpst_ProceedsFromIssuanceOfCommonStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_NoncashInterestAndOtherExpenseNet" xlink:label="tpst_NoncashInterestAndOtherExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="tpst_PrepaidResearchAndDevelopmentCostsCurrent" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="tpst_PrepaidResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tpst_AccruedClinicalTrialLiability" order="1" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_AccruedClinicalTrialLiability" xlink:label="tpst_AccruedClinicalTrialLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="5" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts" xlink:label="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tpst_DeferredTaxAssetsCapitalResearchAndDevelopment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tpst_DeferredTaxAssetsOperatingLeaseLiability" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="4" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" order="6" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="7" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxAssetsCapitalResearchAndDevelopment" xlink:label="tpst_DeferredTaxAssetsCapitalResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="tpst_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="tpst-20251231.xsd#tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" xlink:label="tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="1" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tpst_PrivateTempestPreferredStockMember" name="PrivateTempestPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_AssetAcquisitionTransactionCosts" name="AssetAcquisitionTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_AssetAcquisitionSharePrice" name="AssetAcquisitionSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_PublicFloat" name="PublicFloat" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_SeriesAWarrantsMember" name="SeriesAWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" name="AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued" name="AssetAcquisitionSharesEquityInterestYetToBeIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_A2019And2017EquityIncentivePlanMember" name="A2019And2017EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_ErigenAssetsMember" name="ErigenAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_PrepaidResearchAndDevelopmentCostsCurrent" name="PrepaidResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_SeriesBWarrantsMember" name="SeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_Corporatetaxespaid" name="Corporatetaxespaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tpst_IssuanceOfPre-FundedWarrantShares" name="IssuanceOfPre-FundedWarrantShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_PurchaseAgreementMember" name="PurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_O2023Q4DividendsMember" name="O2023Q4DividendsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_OrphanDrugCreditMember" name="OrphanDrugCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_DebtInstrumentExitFee" name="DebtInstrumentExitFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" name="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tpst_Pre-FundedWarrantMember" name="Pre-FundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_O2026Q4DividendsMember" name="O2026Q4DividendsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_AnnualBaseSalary" name="AnnualBaseSalary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees" name="RestructuringAndRelatedCostNumberOfFullTimeEmployees" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_PrivateInvestmentInPublicEntityFinancingMember" name="PrivateInvestmentInPublicEntityFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable" name="AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_WarrantsIssuanceCost" name="WarrantsIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember" name="Ecor1CapitalLlcAndVersantVentureCapitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" name="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_IssuanceOfCommonStockWarrants" name="IssuanceOfCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_CommonWarrantsMember" name="CommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_SaleOfStockWarrantsIssued" name="SaleOfStockWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent" name="IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_EmploymentAgreementMember" name="EmploymentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember" name="JuneTwoThousandTwentyFivePreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_AssetAcquisitionMaximumFundingCommitment" name="AssetAcquisitionMaximumFundingCommitment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tpst_EmployeeStockOwnershipPlanMember" name="EmployeeStockOwnershipPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_DeferredTaxAssetsCapitalResearchAndDevelopment" name="DeferredTaxAssetsCapitalResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_NoncashInterestAndOtherExpenseNet" name="NoncashInterestAndOtherExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_LegacyMillendoMember" name="LegacyMillendoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tpst_A2019EmployeeStockPurchasePlanMember" name="A2019EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts" name="IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_ProceedsFromIssuanceOfCommonStockWarrants" name="ProceedsFromIssuanceOfCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember" name="NovemberTwoThousandTwentyFivePreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember" name="SeriesAJuniorParticipatingPreferredPurchaseRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_RemainedAvailableForIssuanceOfCommonStock" name="RemainedAvailableForIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tpst_StockIssuanceCosts" name="StockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_A2019EquityIncentivePlanMember" name="A2019EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_OperatingLeaseCommencementMonthAndYear" name="OperatingLeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_TwoThousandTwentyThreeInducementPlanMember" name="TwoThousandTwentyThreeInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards" name="IssuanceOfCommonStockValueUnderEquityPlanAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tpst_NotSubjectToExpirationMember" name="NotSubjectToExpirationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_TrancheCTermLoanMember" name="TrancheCTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_Pre-FundedWarrantsIssuanceCost" name="Pre-FundedWarrantsIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_AssetPurchaseAgreementMember" name="AssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_PreFundedWarrantAndCommonWarrantsMember" name="PreFundedWarrantAndCommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards" name="IssuanceOfCommonStockSharesUnderEquityPlanAwards" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_NetProceedsFromIssuanceOfCommonStock" name="NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_PercentageOfAnnualBonus" name="PercentageOfAnnualBonus" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_BrisbaneCaliforniaMember" name="BrisbaneCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_PatentCostsPolicyPolicyTextBlock" name="PatentCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_DebtInstrumentNumberOfTranches" name="DebtInstrumentNumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tpst_PercentageOfCommissionOnSaleOfStock" name="PercentageOfCommissionOnSaleOfStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_ThersholdIndexRate" name="ThersholdIndexRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tpst_SaleOfStockExercisePriceOfWarrantsOrRights" name="SaleOfStockExercisePriceOfWarrantsOrRights" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_IssuanceOfPre-FundedWarrantValue" name="IssuanceOfPre-FundedWarrantValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tpst_TrancheBTermLoanMember" name="TrancheBTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember" name="IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_TrancheATermLoanMember" name="TrancheATermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_AtTheMarketProgramMember" name="AtTheMarketProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tpst_AccruedClinicalTrialLiability" name="AccruedClinicalTrialLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tpst_JefferiesLLCMember" name="JefferiesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 25, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Tempest Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-1472564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2000 Sierra Point Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">798-8589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,344,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001544227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Chicago, Illinois<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Tempest Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, stockholders' equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TPST<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember', window );">Series A Junior Participating Preferred Purchase Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Series A Junior Participating Preferred Purchase Rights<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,707<span></span>
</td>
<td class="nump">$ 30,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">562<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,269<span></span>
</td>
<td class="nump">31,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment&#8212;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">605<span></span>
</td>
<td class="nump">886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,540<span></span>
</td>
<td class="nump">8,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">517<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,931<span></span>
</td>
<td class="nump">41,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,038<span></span>
</td>
<td class="nump">2,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">937<span></span>
</td>
<td class="nump">2,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current loan payable (net of discount and issuance costs of nil and $74, respectively)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendsPayableCurrent', window );">Interest payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,314<span></span>
</td>
<td class="nump">14,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,949<span></span>
</td>
<td class="nump">8,142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,263<span></span>
</td>
<td class="nump">22,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized; 4,927,161 and 3,382,432 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">240,031<span></span>
</td>
<td class="nump">226,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(233,368)<span></span>
</td>
<td class="num">(207,106)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,668<span></span>
</td>
<td class="nump">19,126<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,931<span></span>
</td>
<td class="nump">$ 41,488<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results, including shares issued and outstanding have been adjusted to reflect the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-thirteen</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Net of discount and issuance costs, Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">4,927,161<span></span>
</td>
<td class="nump">3,382,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">4,927,161<span></span>
</td>
<td class="nump">3,382,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,606,000<span></span>
</td>
<td class="nump">$ 28,476,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,969,000<span></span>
</td>
<td class="nump">13,550,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26,575,000)<span></span>
</td>
<td class="num">(42,026,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(207,000)<span></span>
</td>
<td class="num">(1,316,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">520,000<span></span>
</td>
<td class="nump">1,499,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">313,000<span></span>
</td>
<td class="nump">183,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (26,262,000)<span></span>
</td>
<td class="num">$ (41,843,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock and pre-funded warrants, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (6.33)<span></span>
</td>
<td class="num">$ (19.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock and pre-funded warrants, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (6.33)<span></span>
</td>
<td class="num">$ (19.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing basic net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,149,733<span></span>
</td>
<td class="nump">2,146,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock and pre-funded warrants outstanding, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,149,733<span></span>
</td>
<td class="nump">2,146,276<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Results, including shares of common stock, have been adjusted to reflect the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-thirteen</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parenthetical)<br></strong></div></th>
<th class="th"><div>Apr. 08, 2025</div></th>
<th class="th"><div>Apr. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">one-for-thirteen<span></span>
</td>
<td class="text">one-for-thirteen<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Deficit Accumulated</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,695,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 26,768<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 192,029<span></span>
</td>
<td class="num">$ (165,263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (net of issuance cost) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,663,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash (net of issuance cost)</a></td>
<td class="nump">28,591<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">28,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="nump">5,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards', window );">Issuance of common stock under equity plan awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards', window );">Issuance of common stock under equity plan award</a></td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41,843)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,843)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,382,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">19,126<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">226,229<span></span>
</td>
<td class="num">(207,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (net of issuance cost) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,204,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash (net of issuance cost)</a></td>
<td class="nump">6,047<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">6,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="nump">3,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IssuanceOfPre-FundedWarrantShares', window );">Issuance of pre-funded warrants (net of issuance cost) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IssuanceOfPre-FundedWarrantValue', window );">Issuance of pre-funded warrants (net of issuance cost)</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IssuanceOfCommonStockWarrants', window );">Issuance of common stock warrants (net of issuance cost)</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards', window );">Issuance of common stock under equity plan awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards', window );">Issuance of common stock under equity plan award</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,927,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 6,668<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 240,031<span></span>
</td>
<td class="num">$ (233,368)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock shares under equity plan awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock value under equity plan awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_IssuanceOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_IssuanceOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_IssuanceOfPre-FundedWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of pre-funded warrant shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_IssuanceOfPre-FundedWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_IssuanceOfPre-FundedWarrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of pre-funded warrant value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_IssuanceOfPre-FundedWarrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">$ 1,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_Pre-FundedWarrantsIssuanceCost', window );">Pre-funded warrants issuance cost</a></td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_WarrantsIssuanceCost', window );">Common stock warrants issuance cost</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_Pre-FundedWarrantsIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrants issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_Pre-FundedWarrantsIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_WarrantsIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_WarrantsIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (26,262)<span></span>
</td>
<td class="num">$ (41,843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,118<span></span>
</td>
<td class="nump">5,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">1,103<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_NoncashInterestAndOtherExpenseNet', window );">Noncash interest and other expense, net</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">615<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(1,412)<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(3,404)<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(870)<span></span>
</td>
<td class="num">(1,101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(26,820)<span></span>
</td>
<td class="num">(33,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(435)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of issuance costs</a></td>
<td class="nump">6,045<span></span>
</td>
<td class="nump">28,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_ProceedsFromIssuanceOfCommonStockWarrants', window );">Proceeds from the issuance of common stock warrants, net of issuance costs</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of loan</a></td>
<td class="num">(6,426)<span></span>
</td>
<td class="num">(4,398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from the issuance of common stock under equity plan awards</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">4,259<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="num">(22,561)<span></span>
</td>
<td class="num">(8,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">30,711<span></span>
</td>
<td class="nump">39,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">8,150<span></span>
</td>
<td class="nump">30,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_Corporatetaxespaid', window );">Cash paid for business taxes</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Property and equipment in accounts payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_Corporatetaxespaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CorporateTaxesPaid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_Corporatetaxespaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_NoncashInterestAndOtherExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash interest and other expense, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_NoncashInterestAndOtherExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_ProceedsFromIssuanceOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_ProceedsFromIssuanceOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (26,262)<span></span>
</td>
<td class="num">$ (41,843)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1C. CYBERSECURITY</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to our clinical trials and employees (&#8220;Information Systems and Data&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security function is led by our Chief Financial Officer &amp; Head of Corporate Strategy (&#8220;IT Lead&#8221;), who reports to our CEO and is supported by our third-party security provider, and it helps identify, assess and manage the Company&#8217;s cybersecurity threats and risks. The information security function identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example analyzing report of threats and threat actors and conducting periodic vulnerability assessments for certain systems.  Our assessment and management of material risks from cybersecurity threats are considered as part of our risk management processes. For example, our IT Lead and certain management, including our CEO, evaluate identified material risks from cybersecurity threats against our overall business objectives and our IT Lead periodically reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, systems, and data, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: risk assessments for certain systems, systems monitoring for certain systems, access controls, asset management, and employee training. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example our managed security provider and professional services firms, including legal counsel.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including that if our information technology systems or those of third parties upon which we rely, or our data, are or were compromised, we could experience adverse consequences, including disclosure of sensitive information, damage to our reputation, and significant financial and legal exposure.</span></p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including the IT Lead.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The IT Lead has 5 years of experience in roles that include oversight of cybersecurity risk management programs.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Lead is responsible for hiring appropriate personnel, helping to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#8217;s incident response processes include reporting to the audit committee for certain cybersecurity incidents.</span></p></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives periodic reports from our IT Lead concerning cybersecurity issues, including certain threats and risks and the processes the Company has implemented to address them, as applicable.  </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Lead is responsible for hiring appropriate personnel, helping to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including the IT Lead.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The IT Lead has 5 years of experience in roles that include oversight of cybersecurity risk management programs.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Lead is responsible for hiring appropriate personnel, helping to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#8217;s incident response processes include reporting to the audit committee for certain cybersecurity incidents.</span></p></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives periodic reports from our IT Lead concerning cybersecurity issues, including certain threats and risks and the processes the Company has implemented to address them, as applicable.  </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#8217;s incident response processes include reporting to the audit committee for certain cybersecurity incidents.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including the IT Lead.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The IT Lead has 5 years of experience in roles that include oversight of cybersecurity risk management programs.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Lead is responsible for hiring appropriate personnel, helping to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#8217;s incident response processes include reporting to the audit committee for certain cybersecurity incidents.</span></p></div><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives periodic reports from our IT Lead concerning cybersecurity issues, including certain threats and risks and the processes the Company has implemented to address them, as applicable.  </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Lead is responsible for hiring appropriate personnel, helping to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including the IT Lead.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The IT Lead has 5 years of experience in roles that include oversight of cybersecurity risk management programs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives periodic reports from our IT Lead concerning cybersecurity issues, including certain threats and risks and the processes the Company has implemented to address them, as applicable.  </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p id="section28" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. ORGANIZATION AND DESCRIPTION OF BUSINESS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tempest Therapeutics, Inc. (&#8220;Tempest&#8221; or the &#8220;Company&#8221;) is a clinical-stage biotechnology company advancing a diverse portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a wide range of cancers. Tempest&#8217;s portfolio includes both cell therapy and small molecule product candidates spanning discovery through late-stage development. The Company is headquartered in Brisbane, California.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 3, 2024, the Company&#8217;s stockholders approved a proposal to effect an amendment to the Company&#8217;s Restated Certificate of Incorporation to implement a reverse stock split. On April 4, 2025, the Company filed a certificate of amendment to the Company&#8217;s Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the one-for-thirteen (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6e1cc23c-49a3-467c-968a-b436b08a6a1b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:13) reverse stock split of its outstanding common stock (the "Reverse Stock Split").</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 8, 2025, the Company effected the Reverse Stock Split. Pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company&#8217;s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company&#8217;s equity incentive plans have been reduced proportionately. The Reverse Stock Split did not reduce the number of authorized shares of common stock and did not alter the par value.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would have otherwise been entitled to receive a fractional share received a cash payment in lieu thereof. The Reverse Stock Split affected all stockholders proportionately and did not affect any stockholder&#8217;s percentage ownership of the Company&#8217;s common stock (except to the extent that the Reverse Stock Split resulted in any stockholder owning only a fractional share).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred operating losses since inception. As of December 31, 2025, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash and cash equivalents. While the Company implemented cost reductions in 2025, the Company has finite cash resources available to fund its operations. In </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9df2eff9-6afb-4328-8d1e-a0eef5583eb8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2025</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company announced plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. The Company retained MTS Health Partners, L.P., an internationally recognized financial advisor with substantial experience in the biotechnology industry, to support it with the strategic evaluation process. As part of the cost reductions, the Company reduced its workforce by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> full-time employees, which became effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 30, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Further, in support of such efforts, on June 5, 2025, each of Stephen Brady, the Company&#8217;s Chief Executive Officer and President, Samuel Whiting, the Company&#8217;s Executive Vice President and Chief Medical Officer, and Nicholas Maestas, the Company&#8217;s Chief Financial Officer and Head of Corporate Strategy, transitioned to consulting arrangements with the Company, pursuant to which they continued to serve the Company in their respective executive roles. The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of one-time cash severance payments, benefits and other related costs (excluding non-cash charges associated with stock-based compensation), with the majority of such costs incurred in the second quarter of 2025.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 3, 2026, the Company closed the Asset Acquisition (as defined below). See Note 13, Subsequent Events. Pursuant to the Asset Purchase Agreement (as defined below), Factor (as defined below) has made the Funding Commitment (as defined below) to provide the Company with financial support for at least 18 months following the closing of the Asset Acquisition, up to a maximum amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that is inclusive of any amounts raised and received by the Company after the date of the Asset Purchase Agreement, on the terms and subject to the conditions and other provisions of a funding commitment letter contemplated by and entered into concurrently with the Asset Purchase Agreement. However, there is significant uncertainty as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we will be able to satisfy the terms and conditions and other provisions set forth in the funding commitment letter, and, if we are unable to do so, we may be limited in the amount of funding that we are able to access under the Funding Commitment or we may not be able to access any funds under the Funding Commitment. The timing of any additional funding from Factor is uncertain.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects that its existing cash and cash equivalents will fund the Company&#8217;s projected operating expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued. Accordingly, there is substantial doubt about the Company&#8217;s ability to continue to operate as a going concern for a period of 12 months from the date of issuance of these consolidated financial statements. The accompanying financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any separate adjustments relating to the recovery of recorded assets or the classification of liabilities; however, such adjustments may be necessary in the future when the Company is unable to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ATM Program</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 23, 2021, the Company entered into a sales agreement with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which the Company may sell, from time to time at its sole discretion through Jefferies, as its sales agent, shares of its common stock having, up to an aggregate sales price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of its common stock through Jefferies (the &#8220;Prior ATM Program&#8221;). As of June 20, 2024, the Company had sold an aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,017,110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million net of commissions and estimated expenses) under the Prior ATM Program. On June 20, 2024, the Company and Jefferies terminated the Prior ATM Program and entered a new Open Market Sale Agreement (the &#8220;Sales Agreement&#8221;) to sell shares of common stock from time to time through Jefferies acting as sales agent (the &#8220;ATM Program&#8221;). The Company will pay Jefferies a commission up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross sales proceeds of any shares of its common stock sold through Jefferies under the ATM Program and also has provided Jefferies with indemnification and contribution rights.  Pursuant to the prospectus supplement dated June 20, 2024 filed by the Company with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), the Company was able to offer and sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of its shares of common stock pursuant to the Sales Agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> On February 6, 2025, the Company filed a prospectus supplement with the SEC limiting the availability under the ATM Program to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> On June 11, 2025, in connection with the RDO (as defined below), the Company delivered written notice to Jefferies that it was suspending and terminating the prospectus supplement, dated February 6, 2025, related to the ATM Program (the &#8220;ATM Prospectus&#8221;). The Company will not make any sales of its securities pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under current SEC regulations, if at any time the Company's public float is less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and for so long as the Company&#8217;s public float remains less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, the amount the Company can raise through primary public offerings of securities in any 12-month period using shelf registration statements is limited to an aggregate of one-third of the Company's public float, which is referred to as the baby shelf rules. As of the year ended December 31, 2025, the Company has sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">312,830</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock for proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, pursuant to the ATM Program.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Registered Direct Offerings</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 11, 2025, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">405,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">334,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the &#8220;June 2025 Pre-Funded Warrants&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a registered direct offering (&#8220;June RDO&#8221;). The offering price was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.249</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 2025 Pre-Funded Warrant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which is the price of each share of common stock sold in the RDO, minus the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 2025 Pre-Funded Warrant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The net proceeds from the RDO were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting placement agent fees and offering expenses payable by the Company. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, all June 2025 Pre-Funded Warrants had been exercised.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 24, 2025, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">487,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">685,414</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock (the &#8220;November 2025 Pre-Funded Warrants&#8221;) and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,172,414</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the &#8220;Common Warrants&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a registered direct offering (the &#8220;November RDO&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">combined purchase price of each share of common stock and accompanying Common Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.625</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The combined purchase price of each November 2025 Pre-Funded Warrants and accompanying Common Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.624</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (equal to the combined purchase price per share of common stock and accompanying Common Warrant, minus $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) The exercise price of the Common Warrants is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The net proceeds from the RDO were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting placement agent fees and estimated offering expenses payable by the Company. As of December 31, 2025, all November 2025 Pre-Funded Warrants and Common Warrants remained outstanding. All November 2025 Pre-Funded Warrants were subsequently exercised in January and February 2026.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The accompanying Consolidated Financial Statements have been prepared in accordance with US generally accepted accounting principles ("GAAP") and necessarily include amounts based on estimates and assumptions by management.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable and operating segment, which is the business of discovery and development of small molecule drugs to treat cancers. All assets and operations are in the U.S. The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_05603c4a-63ad-49f7-8c55-20c2929846cf;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who is the chief operating decision maker (&#8220;CODM&#8221;), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. For additional segment information, see Note 12, Segment Reporting.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company&#8217;s product candidates are still in development and, to date, none of the Company&#8217;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">instruments, which potentially subject the Company to concentration of risk, consist principally of cash and money market fund. All of the Company&#8217;s cash and money market fund are deposited in accounts with a major financial institution in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents to the extent recorded in the balance sheets. The Company has no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">off-balance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisitions to be cash equivalents. As of  December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s cash and cash equivalents consisted of bank deposits and money market funds.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company determines if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the customer has the right to control the use of the identified asset.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. When readily determinable, the Company uses the implicit rate in determining the present value of lease payments. When leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date, including the lease term.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The right-of-use (&#8220;ROU&#8221;) asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Property and equipment is recorded at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Upon disposal of an asset, the related cost and accumulated depreciation are removed from the asset accounts and any resulting gain or loss is included in the consolidated statements of operations. Repair and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated useful lives of the Company&#8217;s respective assets are as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:40.5%;box-sizing:content-box;"></td>
         <td style="width:59.5%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><span style="-sec-ix-hidden:F_73e1d41b-207d-4eef-a0f5-e1ba66b3ef90;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of the useful life of the asset or the life of the lease</span></span></span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Long-lived assets are reviewed for impairment if events or circumstances indicate the carrying amount of these assets may not be recoverable. If this review indicates that these assets will not be recoverable, based on the forecasted undiscounted future operating cash flows expected to result from the use of long-lived assets and their eventual disposition, the Company&#8217;s carrying value of the long-lived assets is reduced to fair value based on a discounted future cash flow approach or quoted market values.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses and Accrued Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include certain payroll and personnel expenses including stock-based compensation, laboratory supplies, consulting costs, external contract research and development expenses and facility or lease expenses. In-licensing fees and other costs to acquire technologies that are utilized in research and development, and that are not expected to have alternative future use, are expensed when incurred. Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers, the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These patent-related legal costs are reported as a component of general and administrative expenses.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;General and administrative costs are expensed as incurred and include employee-related expenses including salaries, benefits, travel and stock-based compensation for the Company&#8217;s personnel in executive, finance and accounting, and other administrative functions, as well as fees paid for legal, accounting and tax services, consulting fees and facilities costs not otherwise included in research and development expenses. Legal costs include general corporate legal fees and patent costs.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments approximate fair value due to their short-term maturities.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all share-based payments made to employees, directors and non-employees based on estimated grant-date fair values. The Company uses the straight-line method to allocate compensation cost to reporting periods over each optionee&#8217;s requisite service period, which is generally the vesting period.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates the fair value of stock options to employees, directors and non-employees using the Black-Scholes option-valuation model. The Black-Scholes model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, risk-free rate of return, and the fair value of the underlying common stock on the date of grant. Due to the lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The group of representative companies have characteristics similar to the Company, including stage of product development and focus on the life science industry. The Company uses the simplified method to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company accounts for forfeitures as they occur.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company follows the two-class method when computing net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding stock options, convertible preferred stock and warrants to purchase shares of convertible preferred stock are considered potential dilutive common shares.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2025 and 2024, the Company has recorded a full valuation allowance on its deferred tax assets.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; which requires public entities to disclose specific tax rate reconciliation categories, as well as income taxes paid disaggregated by jurisdiction, amongst other disclosure enhancements. The ASU is effective for financial statements issued for annual periods beginning after December 15, 2024, with early adoption permitted. We adopted the ASU retrospectively for the period ending December 31, 2025, and it affects only our disclosures and does not impact our results of operations or financial condition.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="section31" style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. FAIR VALUE MEASUREMENTS</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present the Company&#8217;s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,707</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,707</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,707</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,707</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,268</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,268</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,268</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,268</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Items</a></td>
<td class="text"><p id="section32" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. BALANCE SHEET ITEMS</span></p><p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current asset consist of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.207%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.785%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.325000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">642</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">535</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">562</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,206</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net, consists of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.207%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.785%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.325000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">151</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">263</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,446</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,485</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">201</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,058</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,206</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,453</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,320</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment&#8212;net</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">605</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">886</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense for the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">389</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.207%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.785%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.325000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other liabilities</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">627</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,335</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">310</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,391</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">937</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,726</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="section33" style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities Lease Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In January 2022, the Company entered into an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> office lease agreement for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,116</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet facility in Brisbane, California (&#8220;Brisbane Lease&#8221;). The lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the balance of the operating lease right of use assets were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,540</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,643</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and the related operating lease liability were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,141</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,011</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, as shown in the accompanying consolidated balance sheets.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rent expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,946</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,244</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, future minimum annual lease payments under the Company&#8217;s operating lease liabilities were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Commitment</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,926</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,994</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,064</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total minimum lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,330</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,189</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of operating lease obligations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,141</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: current portion</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,192</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent operating lease obligations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,949</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related to this Brisbane Lease agreement, the Company entered into a letter of credit with a bank to deposit $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">388</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a separate account that is restricted cash to serve as security rent deposit. This amount is included in other noncurrent assets in the accompanying Consolidated Balance Sheets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loan Payable</a></td>
<td class="text"><p id="section34" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. LOAN PAYABLE</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 15, 2021, the Company entered into a loan agreement with Oxford Finance LLC (the &#8220;Lender&#8221;) to borrow a term loan amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be funded in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> tranches (as amended, the &#8220;Loan Agreement&#8221;). Tranche A of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was wired to the Company on January 15, 2021. Tranche B of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expired on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Tranche C of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was available at the Lender&#8217;s option.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 23, 2022, the Company entered into a First Amendment to the Loan Agreement. The amendment modified the Loan Agreement as follows: (i) each of the Company and Millendo Therapeutics US, Inc., a Delaware corporation and wholly owned subsidiary of the Company (&#8220;Millendo&#8221;), were joined as co-borrowers under the Loan Agreement; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the interest-only repayment period was extended through December 31, 2023 (which interest-only period may be further extended through June 30, 2024 under certain circumstances)</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; and (iii) a security interest in all of the assets of the Company, TempestTx and Millendo, including any intellectual property, was granted to the Lender. In addition, the Lender permitted a one-time prepayment in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which the Company paid on December 23, 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the amendment to the Loan Agreement, the term loan had a maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 1, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and an annual floating interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, which is an Index Rate plus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. Index Rate is the greater of (i) 1-Month CME Term SOFR or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. In the fourth quarter of 2023, the Company achieved the circumstances necessary to extend the interest-only repayment period through June 30, 2024. Monthly principal payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">733</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were required to begin on July 1, 2024. Related to this borrowing, the Company recorded loan discounts totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">898</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of debt issuance costs. These amounts would be amortized as additional interest expense over the life of the loan.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 8, 2025, using cash on hand, the Company made a repayment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in full satisfaction of the aggregate outstanding amount, including accrued interest and exit fees as of such date, under the Loan Agreement with the Lender. The payoff amount paid by the Company in connection with the termination of the Loan Agreement was pursuant to a payoff letter with the Lender and included payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as an exit fee. Upon making the repayment, the Loan Agreement was terminated in accordance with its terms and all liens and security interests granted thereunder to secure the obligations were released.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total interest expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,316</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p id="section35" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. STOCKHOLDERS' EQUITY</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorized Stock</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of which have been designated as Series A Participating Preferred Stock (the &#8220;Series A Preferred Stock&#8221;), par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share pursuant to the Company&#8217;s adoption the Rights Plan (as defined below). </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Series A Participating Preferred Stock were outstanding as of December 31, 2025 and 2024. Stockholders are entitled to dividends as declared by the Board of Directors, subject to rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash dividends declared to date. The holders of each share of common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote and the holders of each share of Series A Preferred Stock, if issued, are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1,000</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> votes. Except for effecting or validating certain specific actions intended to protect the preferred stockholders, the holders of common stock vote together with preferred stockholders.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights Plan</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 10, 2023, the Company&#8217;s Board of Directors adopted a limited duration stockholder rights plan (the &#8220;Rights Plan&#8221;), effective immediately, and declared a dividend of one preferred share purchase right (a &#8220;Right&#8221;) for each outstanding share of the Company&#8217;s common stock. The dividend was effective as of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 23, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Record Date&#8221;) with respect to stockholders of record on that date. The Rights will also attach to new common stock issued after the Record Date. Each Right entitles the registered holder to purchase from the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cc2526f0-0ec8-49fd-83a9-ebb177d174dd;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one one-thousandth</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of a share of the Series A Preferred Stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per one one-thousandth of a preferred share, subject to adjustment. The descriptions and terms of the Rights are set forth in a Rights Agreement, dated as of October 10, 2023 (the &#8220;Rights Agreement"), between the Company and Computershare Trust Company, NA.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 9, 2024, the Company entered into Amendment No. 1 (the &#8220;Amendment&#8221;) to the Rights Agreement. The Amendment extends the Final Expiration Date of the Rights Agreement until immediately following the Company&#8217;s 2025 Annual Meeting of Stockholders or, if the Company&#8217;s stockholders approve the Rights Plan at or prior to such meeting, to October 10, 2026, unless the Rights are earlier redeemed or exchanged by the Company. The Company does not have any obligation under the Rights Agreement to seek stockholder approval for the Rights Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 5, 2024, the Company entered into Amendment No. 2 (the &#8220;Second Amendment&#8221;) to the Rights Agreement. The Second Amendment makes certain technical amendments to the rights and obligations of the Company&#8217;s Board of Directors to administer and make determinations with respect to the Rights Agreement and the rights issued thereunder. The Rights Agreement otherwise remains unmodified and in full force and effect in accordance with its terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="section36" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. STOCK-BASED COMPENSATION</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Plans</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2011, Private Tempest adopted the 2011 Equity Incentive Plan (the &#8220;2011 Plan), and in 2017, Private Tempest adopted the 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;), and together with the 2011 Plan, the &#8220;Tempest Prior Plans.&#8221; The Tempest Prior Plans have been terminated and no additional grants may be made under either plan. All stock awards granted under the Tempest Prior Plans will remain subject to the terms of the applicable prior plan. As a result of the merger with Millendo, the Tempest Prior Plans were assumed by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 29, 2019, the Board of Millendo adopted the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;), subject to approval by the Company&#8217;s stockholders, and became effective with such stockholder approval on June 11, 2019. On June 17, 2022, the Company&#8217;s stockholders approved the Amended and Restated 2019 Equity Incentive Plan (the &#8220;A&amp;R 2019 Plan&#8221;), which amended and restated the 2019 Plan and was the successor to, and replacement of, the 2019 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Tempest adopted the Amended and Restated 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;) on April 30, 2023, subject to approval by the Company&#8217;s stockholders. On June 15, 2023, the Company&#8217;s stockholders approved the 2023 Plan, which amended and restated the A&amp;R 2019 Plan and will be a successor to, and replacement of, the A&amp;R 2019 Plan.  The number of shares of the Company's common stock reserved for issuance under the 2023 Plan will automatically increase on January 1st of each year, for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, from January 1, 2024 continuing through January 1, 2033, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of the Company's common stock outstanding on December 31</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the preceding calendar year, or a lesser number of shares as may be determined by the Board of Directors. Accordingly, on January 1, 2026, the common stock reserved for issuance was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">197,086</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,745</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future grant under the 2023 Plan. In addition, on January 27, 2026, the Company's stockholders approved the amendment to increase the number of shares issuable under the 2023 Plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,410,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2023 Plan allows the Company to grant stock awards to employees, directors and consultants of the Company, including incentive stock options (&#8220;ISOs&#8221;), non-qualified stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Tempest adopted the 2023 Inducement Plan (&#8220;2023 Inducement Plan&#8221;) on June 21, 2023, pursuant to which the Company reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,150,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual&#8217;s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2023 Inducement Plan was approved by the Company&#8217;s Board of Directors without stockholder approval in accordance with such rule. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,615</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future grant under the 2023 Inducement Plan.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures employee and non-employee stock-based awards at grant date fair value and records compensation expense on a straight-line basis over the vesting period of the award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Stock Ownership Plan</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Millendo adopted the 2019 Employee Stock Purchase Plan on April 29, 2019, which became effective upon stockholder approval on June 11, 2019. On June 17, 2022, the Company&#8217;s stockholders approved the Amended and Restated 2019 Employee Stock Purchase Plan (the &#8220;2019 ESPP&#8221;). The 2019 ESPP enables employees to purchase shares of the Company's common stock through offerings of rights to purchase the Company's common stock to all eligible employees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 ESPP provides that the number of shares of common stock reserved for issuance under the 2019 ESPP will automatically increase on January 1, 2023 and continuing through (and including) January 1, 2029, by the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of Common Stock outstanding on December 31</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the preceding calendar year, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock, or (iii) such lesser number of shares of Common Stock as determined by the Board of Directors (which may be zero). On January 1, 2026, the common stock reserved for issuance was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,461</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,608</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock remained available for future issuance under the 2019 ESPP. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,955</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock had been issued under the 2019 ESPP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Options</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options to purchase the Company&#8217;s common stock may be granted at a price not less than the fair market value in the case of both NSOs and ISOs, except for an options holder who owns more than 10% of the voting power of all classes of stock of the Company, in which case the exercise price shall be no less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value per share on the grant date. Stock options granted under the Plans generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and expire no later than ten (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) years from the date of grant. Vested options can be exercised at any time.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the merger with Millendo, the grant date fair market value of the shares of common stock underlying stock options was determined by the Company&#8217;s Board of Directors. Up until the merger, there had been no public market for the Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">common stock, and therefore the Board of Directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which included valuations performed by an independent third-party, important developments in the Company&#8217;s operations, sales of convertible preferred stock, actual operating results, financial performance, the conditions in the life sciences industry, the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company&#8217;s common stock.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following shows the stock option activities for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:57.489%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:12.697%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.238%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.778%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Options Outstanding</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,393</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94.64</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,009</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51.48</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,284</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.83</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled and forfeited</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,028</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106.99</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">320,090</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.06</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,014</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.20</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled and forfeited</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450,104</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.44</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes information about stock options outstanding at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:50.11%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.422%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.662%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.182%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.182%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Life (In Years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options outstanding</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450,104</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.71</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.44</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450,104</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.71</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.44</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">441,792</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.70</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.51</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company granted employees and non-employees stock options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,014</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,009</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock with a weighted-average grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51.48</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized compensation costs related to unvested employee stock options were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">389</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,352</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. These costs are expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. The fair market value of stock options vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,576</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,303</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of stock options using the Black-Scholes option pricing valuation model. The fair value of employee stock options is being amortized on the straight-line basis over the requisite service period of the awards. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of employee stock options was estimated using the following assumptions for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.358%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.358%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividends</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">&#160;%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">&#160;%</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected term of options granted represents the period of time that the options are expected to be outstanding. Due to the</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of historical exercise history, the expected term of the Company&#8217;s employee stock options has been determined utilizing the simplified method for awards that qualify as plain-vanilla options.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company did not have any trading history for the Company&#8217;s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the Company&#8217;s common stock becomes available.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#8217;s stock options.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company has not paid any cash dividends on common stock since inception and does not anticipate paying any dividends in the</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreseeable future. Consequently, an expected dividend yield of zero was used.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Company accelerated the vesting of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">266,108</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> time-based vesting stock options grants previously awarded to the Company's employees, pursuant to the separation agreements entered into with such employees. The Company also extended the post-termination exercise period from 90 days to 180 days immediately following the separation date for any options that were vested, including the options that were accelerated in vesting, as described above. Further, in the fourth quarter of 2025, approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">416,005</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of modified stock options were further modified to extend the post-termination exercise period from either (i) 180 days to December 31, 2026 or (ii) to the earlier of (a) the date that is 90 days following termination of continuous service, and (b) the expiration of the term of the options as set forth in the award agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The above modifications to current and former employees stock options grants resulted in modification accounting under ASC 718, Compensation &#8211; Stock Compensation. As a result, the Company recognized approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of stock compensation expense during the year ended December 31, 2025. For vested awards with no future service period required to be provided, the expense was measured on the modification date by calculating the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified with immediate expense recognition. For unvested awards with no future service period required to be provided, the Company reversed any stock compensation expense previously recognized, remeasured the fair value of the modified award and immediately recognized stock compensation expense on the modification date. For stock options that were further modified to extend the post-termination exercise period upon termination of continuous service, the Company measured the expense by calculating the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified. The fair value of those awards included a reduction to the share price for the fair value of the warrant dividend as the holders of the modified stock options were not participants in the warrant dividend. A portion of this modification was recorded as stock compensation expense in the fourth quarter and the remainder to be attributed over the derived service period.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the components of stock-based compensation expense recognized in the </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s consolidated statements of operations for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.403%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.403%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,179</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,222</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,939</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,081</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,118</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,303</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="section37" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. INCOME TAXES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provision for income taxes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, because the Company has incurred losses since inception.  At December 31, 2025 and 2024 the Company concluded it was not more likely than not that it would realize its deferred tax assets, and therefore has recorded a full valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> income taxes for the years ended December 31, 2025 and 2024, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to pre-tax loss as follows (in thousands):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:34.454%;box-sizing:content-box;"></td>
         <td style="width:1.981%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.925%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.866%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.981%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.925%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.866%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">U.S. federal provision (benefit)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_98cdff81-3c83-4c66-ba34-8998155d3a60;"><span style="-sec-ix-hidden:F_14cb7b7c-9f29-479f-8c41-fb9c6a5ca935;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">At statutory rate</span></span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,514</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,786</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,105</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,199</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or Nondeductible Items</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">343</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transaction costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">454</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">State income taxes in California comprise the majority of the state income taxes, net of federal effect category for the years ended December 31, 2025 and 2024, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 are shown below.</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:62.84%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,074</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,896</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,198</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,513</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">489</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">603</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,354</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,583</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,041</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,697</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">179,336</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,799</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,199</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred tax liability:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,199</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 to December 31, 2025 due primarily to the generation of net operating losses and research and development credits.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required under ASU 2023-09, the Company has included only the portion of the valuation allowance related to federal deferred tax assets in the "change in valuation allowance" line of the rate reconciliation. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a reconciliation of the total change in the valuation allowance (in thousands):</span></span></p><div style="font-size:10pt;font-family:Arial;">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:62.84%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning Balance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,799</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,643</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change related to continuing operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,699</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending Balance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,799</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">534.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">501.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">502.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">487.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal and state net operating loss carryforwards begin to expire in 2031 and 2025, respectively, if not utilized. Federal net operating losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">313.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million are not subject to expiration.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal and state research and development carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The Company also had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of Orphan Drug Credit. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal and state research and development carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal and state credits begin to expire in 2031 and 2029, respectively, if not utilized; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the state credits can be carried forward indefinitely.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of some of the federal and state net operating loss and credit carryforwards may be subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization.  The Company has not performed a Section 382 study as of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">455.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand of legacy Millendo federal net operating losses are expected to expire unused due to prior ownership changes.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the following activity relating to unrecognized tax benefits as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:62.84%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,239</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,923</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross increase - tax position in current period</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">316</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,406</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,239</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, none of the unrecognized tax benefits would impact the Company's effective tax rate due to the valuation allowance.  The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest and penalties on the accompanying balance sheet as of December 31, 2025 and 2024, respectively, and has not recognized penalties and/or interest in the accompanying statements of operations for the years ended December 31, 2025 and 2024, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to taxation in the United States, California, Massachusetts, and Michigan. The Company's tax years from inception are subject to examination by the IRS and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p id="section38" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. RETIREMENT PLAN</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company participates in a qualified 401(k) Plan sponsored by its professional service organization. The retirement plan is a defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. During the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the 401(k) Plan. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the 401(k) Plan.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="section39" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. NET LOSS PER SHARE</span></p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the Company&#8217;s basic and  diluted net loss per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands, except share and per share amounts):</span></p><p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.2%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.780000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.780000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,262</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,843</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,149,733</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,146,276</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing basic and diluted net loss per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,149,733</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,146,276</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6.33</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s potentially dilutive securities included unvested stock warrants and stock options, which have been excluded from the computation of diluted net loss per share attributable to common stockholders as the effect would be anti-dilutive. The issuance of pre-funded warrants and vested RSUs have been included in the computation of basic and diluted net loss per share attributable to common stockholders. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the amounts outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.2%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450,104</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">320,090</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,172,878</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">464</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,622,982</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">320,554</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. SEGMENT REPORTING</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable and operating segment, which is the business of discovery and development of small molecule drugs to treat cancers. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_73408227-2688-4970-8a0c-a936196fb1ad;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the Company has not generated revenue, the CODM assesses Company performance through the achievement of research goals towards advancing the Company&#8217;s product candidates through stages of development. As such, the CODM is regularly provided with budgeted and forecasted expense information as well as the Company&#8217;s Consolidated Financial Statements which is used to determine the Company&#8217;s liquidity needs and pipeline resource allocation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM regularly reviews and evaluates research and development expenses and uses consolidated net loss, as reported on the Company&#8217;s Consolidated Statements of Operations, to assess the performance of the segment and to allocate resources.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The consolidated net loss and significant segment expenses reviewed by the CODM are reported on the Company&#8217;s Consolidated Statements of Operations for the years ended December 31, 2025 and 2024. The measure of segment assets is reported on the Consolidated Balance Sheet as total assets. The CODM monitors the Company's cash and cash equivalents as reported on the Consolidated Balance Sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All financial information required for segment reporting that is provided to the chief operating decision maker is contained within the financial statements and notes to financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUBSEQUENT EVENTS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acquisition of Erigen Assets</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 19, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company executed an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Erigen LLC, a Delaware limited liability company (&#8220;Erigen&#8221;), and Factor Bioscience Inc., a Delaware corporation (together with Erigen, &#8220;Sellers&#8221;), pursuant to which Sellers agreed to sell and transfer to the Company all right, title and interest of Sellers in and to all</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the assets primarily related to (a) the autologous BCMA/CD19 dual-targeting CAR T-cell therapy known as ERI-2003, (b) the autologous CD70/CD70 dual-targeting CAR T-cell therapy known as ERI-2206, (c) the allogeneic BCMA/CD19 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as ERI-3003, and (d) the allogeneic CD70/CD70 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as ERI-3206 (collectively referred to herein as the &#8220;Erigen Assets&#8221;), in exchange for an aggregate purchase price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,268,495</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock to be issued to Erigen on behalf of both Sellers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 3, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company completed the acquisition of the Erigen Assets (the &#8220;Erigen Closing&#8221;) under the Asset Purchase Agreement (the &#8220;Asset Acquisition&#8221;) and issued to Erigen </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,268,495</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock. Based on an assumed common stock price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.41</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, the aggregate consideration related to the Asset Acquisition  is approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company incurred approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of transaction costs in connection with the Asset Acquisition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects to account for the Asset Acquisition as an asset acquisition. Transaction costs are expected to be capitalized as part of the total cost of the Asset Acquisition. The Company is in the process of evaluating the assets acquired and any liabilities assumed and has not finalized the allocation of the consideration. Accordingly, the Company cannot reasonably estimate the financial statement impact of the transaction as of the date these consolidated financial statements were issued.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Asset Purchase Agreement, Factor has made a funding commitment (the &#8220;Funding Commitment&#8221;) to provide the Company with financial support for at least 18 months following the Erigen Closing, up to a maximum amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that is inclusive of any amounts raised and received by us after the date of the Asset Purchase Agreement, on the terms and subject to the conditions and other provisions of a funding commitment letter contemplated by and entered into concurrently with the Asset Purchase Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Dividend</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 20, 2026, the Company&#8217;s Board of Directors declared a record date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 30, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Record Date&#8221;), for the distribution of a dividend (the &#8220;Warrant Dividend&#8221;) in the form of a warrant to purchase a share of the Company&#8217;s common stock (collectively, the &#8220;Warrants&#8221;) for each share of common stock outstanding on the Record Date at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.48</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Warrants were issued on the terms and conditions described in the Warrant Agreement, dated February 3, 2026, between the Company, Computershare Inc., and its affiliate, Computershare Trust Company, N.A., as Warrant Agent, on February 3, 2026. In addition, on February 3, 2026, certain warrants that were outstanding on the Record Date also received Warrants on a one-for-one basis, pursuant to the terms of such warrants (together with the Warrant Dividend, the &#8220;Warrant Distribution&#8221;). In the aggregate, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,784,989</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Warrants were issued pursuant to the Warrant Distribution.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Plan Amendment</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 27, 2026, the Company&#8217;s stockholders approved Amendment No. 1 to the 2023 Plan to increase the number of shares of the Company&#8217;s common stock issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,410,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights Plan Approval</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 27, 2026, the Company&#8217;s stockholders approved the Company&#8217;s Rights Agreement. Such stockholder approval extended the final expiration date of the Rights Agreement until October 10, 2026, unless the rights thereunder are earlier redeemed or exchanged by the Company. The Rights Agreement otherwise remains unmodified and in full force and effect in accordance with its terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">connection with his appointment as President and Chief Executive Officer of the Company, effective February 3, 2026, the Company entered into an employment agreement with Matthew Angel (the &#8220;Angel Employment Agreement&#8221;). Pursuant to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Angel </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreement, Dr. Angel is entitled to receive an annual base salary of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">650,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and will be eligible to receive an annual bonus equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of his base salary, as determined by the Board in its sole discretion. In addition, on February 3, 2026, Dr. Angel received an option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269,621</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, with an exercise price per share equal to the fair market value on the grant date (the &#8220;Option&#8221;). The Option vests over a four-year period, with one quarter (1/4) of the shares subject to the Option vesting on the first anniversary of the grant date, and the remaining shares vesting equally over the following 36 months of continuous service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 3, 2026, the Company entered into an employment agreement with Nicholas Maestas (the &#8220;Maestas Employment Agreement&#8221;), pursuant to which Mr. Maestas is entitled to receive compensation consistent with his previously filed employment agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Private Placement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 20, 2026, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with (a) two institutional investors (the &#8220;Institutional Investors&#8221;) and (b) Factor Bioscience Inc. (together with the Institutional Investors, each, an &#8220;Investor&#8221; and, together, the &#8220;Investors&#8221;), pursuant to which the Company agreed to issue and sell in a private placement (the &#8220;Private Placement&#8221;) an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">462,964</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, and, in lieu of common stock, pre-funded warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">462,963</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;2026 Pre-Funded Warrants&#8221;), in each case accompanied by (i) Series A warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">925,927</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;Series A Warrants&#8221;) and (ii) Series B warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">925,927</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;Series B Warrants&#8221; and, together with the Series A Warrants, the &#8220;Common Warrants&#8221;). The Shares and the Common Warrants are immediately separable and were issued separately. The combined purchase price per Share and accompanying Common Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the combined purchase price per Pre-Funded Warrant and accompanying Common Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.159</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The gross proceeds to us from the Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (excluding up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of aggregate gross proceeds that may be received in the future upon the cash exercise of the Common Warrants), before deducting placement agent fees and other offering expenses payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Purchase Agreement, the Company agreed to seek approval from our stockholders for the issuance of the shares issuable upon exercise of the Common Warrants within 90 days following the date of the Purchase Agreement (the &#8220;Stockholder Approval&#8221;). The Series A Warrants will become exercisable on the effective date of the Stockholder Approval (the &#8220;Stockholder Approval Date&#8221;) and have a term of five years from the later of the Stockholder Approval Date and the Effectiveness Date (as defined below). The Series B Warrants will become exercisable on the Stockholder Approval Date and have a term of twenty-four months from the later of the Stockholder Approval Date and the Effectiveness Date. The Common Warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Pre-Funded Warrants are exercisable immediately following the closing date of the Private Placement have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and may be exercised at any time until exercised in full. In addition, pursuant to the Purchase Agreement, the Company agreed not to sell any shares of the Company&#8217;s common stock or any securities convertible into or exercisable or exchangeable into shares of common stock, subject to certain customary exceptions, for a period of thirty (30) days after the Effectiveness Date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Private Placement, the Company entered into a registration rights agreement with the Investors (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company agreed to file registration statements under the Securities Act with the SEC covering the resale of the Shares to be issued in the Private Placement and the shares of the Company&#8217;s common stock underlying the Common Warrants and Pre-Funded Warrants no later than 15 calendar days following the date of the Purchase Agreement, and to use reasonable best efforts to have the registration statement declared effective by 45 calendar days following the date of the Purchase Agreement, and in any event no later than 75 calendar days following the date of the Purchase Agreement in the event of a &#8220;full review&#8221; by the SEC (the &#8220;Effectiveness Date&#8221;).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The accompanying Consolidated Financial Statements have been prepared in accordance with US generally accepted accounting principles ("GAAP") and necessarily include amounts based on estimates and assumptions by management.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable and operating segment, which is the business of discovery and development of small molecule drugs to treat cancers. All assets and operations are in the U.S. The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_05603c4a-63ad-49f7-8c55-20c2929846cf;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who is the chief operating decision maker (&#8220;CODM&#8221;), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. For additional segment information, see Note 12, Segment Reporting.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company&#8217;s product candidates are still in development and, to date, none of the Company&#8217;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">instruments, which potentially subject the Company to concentration of risk, consist principally of cash and money market fund. All of the Company&#8217;s cash and money market fund are deposited in accounts with a major financial institution in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents to the extent recorded in the balance sheets. The Company has no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">off-balance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisitions to be cash equivalents. As of  December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s cash and cash equivalents consisted of bank deposits and money market funds.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company determines if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the customer has the right to control the use of the identified asset.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. When readily determinable, the Company uses the implicit rate in determining the present value of lease payments. When leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date, including the lease term.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The right-of-use (&#8220;ROU&#8221;) asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Property and equipment is recorded at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Upon disposal of an asset, the related cost and accumulated depreciation are removed from the asset accounts and any resulting gain or loss is included in the consolidated statements of operations. Repair and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Long-lived assets are reviewed for impairment if events or circumstances indicate the carrying amount of these assets may not be recoverable. If this review indicates that these assets will not be recoverable, based on the forecasted undiscounted future operating cash flows expected to result from the use of long-lived assets and their eventual disposition, the Company&#8217;s carrying value of the long-lived assets is reduced to fair value based on a discounted future cash flow approach or quoted market values.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense and Accrued Research and Development</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses and Accrued Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include certain payroll and personnel expenses including stock-based compensation, laboratory supplies, consulting costs, external contract research and development expenses and facility or lease expenses. In-licensing fees and other costs to acquire technologies that are utilized in research and development, and that are not expected to have alternative future use, are expensed when incurred. Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers, the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_PatentCostsPolicyPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These patent-related legal costs are reported as a component of general and administrative expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;General and administrative costs are expensed as incurred and include employee-related expenses including salaries, benefits, travel and stock-based compensation for the Company&#8217;s personnel in executive, finance and accounting, and other administrative functions, as well as fees paid for legal, accounting and tax services, consulting fees and facilities costs not otherwise included in research and development expenses. Legal costs include general corporate legal fees and patent costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments approximate fair value due to their short-term maturities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all share-based payments made to employees, directors and non-employees based on estimated grant-date fair values. The Company uses the straight-line method to allocate compensation cost to reporting periods over each optionee&#8217;s requisite service period, which is generally the vesting period.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates the fair value of stock options to employees, directors and non-employees using the Black-Scholes option-valuation model. The Black-Scholes model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, risk-free rate of return, and the fair value of the underlying common stock on the date of grant. Due to the lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The group of representative companies have characteristics similar to the Company, including stage of product development and focus on the life science industry. The Company uses the simplified method to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company accounts for forfeitures as they occur.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company follows the two-class method when computing net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding stock options, convertible preferred stock and warrants to purchase shares of convertible preferred stock are considered potential dilutive common shares.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2025 and 2024, the Company has recorded a full valuation allowance on its deferred tax assets.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; which requires public entities to disclose specific tax rate reconciliation categories, as well as income taxes paid disaggregated by jurisdiction, amongst other disclosure enhancements. The ASU is effective for financial statements issued for annual periods beginning after December 15, 2024, with early adoption permitted. We adopted the ASU retrospectively for the period ending December 31, 2025, and it affects only our disclosures and does not impact our results of operations or financial condition.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_PatentCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_PatentCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Risks And Uncertainties, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock', window );">Schedule of Estimated Useful Lives of Property, Plant and Equipment</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated useful lives of the Company&#8217;s respective assets are as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:40.5%;box-sizing:content-box;"></td>
         <td style="width:59.5%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"><p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"><span><span style="-sec-ix-hidden:F_73e1d41b-207d-4eef-a0f5-e1ba66b3ef90;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of the useful life of the asset or the life of the lease</span></span></span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property, plant and equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present the Company&#8217;s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,707</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,707</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,707</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,707</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,268</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,268</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,268</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,268</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Asset</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current asset consist of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.207%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.785%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.325000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">642</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">355</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">535</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">562</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,206</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net, consists of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.207%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.785%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.325000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment and software</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">151</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">263</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,446</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,485</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">201</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,058</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,206</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,453</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,320</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment&#8212;net</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">605</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">886</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.207%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.785%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.841%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.325000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other liabilities</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">627</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,335</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial liability</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">310</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,391</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">937</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,726</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Rental Payments under Operating Leases with Noncancelable Terms</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, future minimum annual lease payments under the Company&#8217;s operating lease liabilities were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Commitment</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,926</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,994</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,064</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total minimum lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,330</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,189</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of operating lease obligations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,141</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: current portion</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,192</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent operating lease obligations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,949</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following shows the stock option activities for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:57.489%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:12.697%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.238%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.778%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Options Outstanding</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,393</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94.64</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,009</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51.48</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,284</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.83</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled and forfeited</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,028</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106.99</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">320,090</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.06</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,014</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.20</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled and forfeited</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450,104</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.44</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock', window );">Summary of Information About Stock Options Outstanding</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes information about stock options outstanding at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:50.11%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.422%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.662%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.182%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.182%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Life (In Years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options outstanding</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450,104</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.71</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.44</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450,104</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.71</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.44</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">441,792</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.70</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.51</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s consolidated statements of operations for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.403%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.403%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,179</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,222</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,939</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,081</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,118</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,303</span></p></td>
         <td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Grant Date Fair Value</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of employee stock options was estimated using the following assumptions for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.358%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.358%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividends</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">&#160;%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">&#160;%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to pre-tax loss as follows (in thousands):</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:34.454%;box-sizing:content-box;"></td>
         <td style="width:1.981%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.925%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.866%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.981%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.925%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.866%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">U.S. federal provision (benefit)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_98cdff81-3c83-4c66-ba34-8998155d3a60;"><span style="-sec-ix-hidden:F_14cb7b7c-9f29-479f-8c41-fb9c6a5ca935;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">At statutory rate</span></span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,514</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,786</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,105</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,199</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or Nondeductible Items</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">343</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transaction costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">454</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 are shown below.</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:62.84%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,074</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,896</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,198</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,513</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">489</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">603</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,354</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,583</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,041</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,697</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">179,336</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,799</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,199</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred tax liability:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,180</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,199</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Reconciliation of the Total Change in the Valuation Allowance</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a reconciliation of the total change in the valuation allowance (in thousands):</span>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:62.84%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning Balance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,799</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,643</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change related to continuing operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,699</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending Balance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,799</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the following activity relating to unrecognized tax benefits as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:62.84%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.46%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,239</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,923</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross increase - tax position in current period</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">316</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,406</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,239</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basis in Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the Company&#8217;s basic and  diluted net loss per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands, except share and per share amounts):</span></p><p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.2%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.780000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.780000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,262</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,843</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,149,733</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,146,276</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing basic and diluted net loss per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,149,733</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,146,276</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6.33</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the amounts outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</span>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.2%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450,104</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">320,090</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,172,878</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">464</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,622,982</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">320,554</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 03, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 24, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 11, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>Employees</div>
</th>
<th class="th"><div>Apr. 17, 2025</div></th>
<th class="th"><div>Apr. 08, 2025</div></th>
<th class="th"><div>Apr. 04, 2025</div></th>
<th class="th">
<div>Jun. 20, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 20, 2026 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 06, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-thirteen<span></span>
</td>
<td class="text">one-for-thirteen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,707<span></span>
</td>
<td class="nump">$ 30,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesInitiationDate', window );">Restructuring activities, plan adopted date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 17,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesCompletionDate', window );">Effective date of workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees', window );">Number of full time employees | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">One-time cash severance payments, benefits and other related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate sales price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,047<span></span>
</td>
<td class="nump">28,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,045<span></span>
</td>
<td class="nump">28,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tpst_AtTheMarketProgramMember', window );">At-The-Market Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_RemainedAvailableForIssuanceOfCommonStock', window );">Remained available for issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tpst_RegisteredDirectOfferingMember', window );">RDO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_PublicFloat', window );">Public float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tpst_JefferiesLLCMember', window );">Jefferies LLC | At-The-Market Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,017,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tpst_JefferiesLLCMember', window );">Jefferies LLC | Maximum | At-The-Market Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate sales price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_PercentageOfCommissionOnSaleOfStock', window );">Percentage of commission on sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate sales price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,204,774<span></span>
</td>
<td class="nump">1,663,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | RDO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in transaction | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,000<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.625<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | RDO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_SaleOfStockWarrantsIssued', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,172,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember', window );">June 2025 Pre-Funded Warrants | RDO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_SaleOfStockWarrantsIssued', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember', window );">November 2025 Pre-Funded Warrants | RDO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_SaleOfStockWarrantsIssued', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_AssetAcquisitionMaximumFundingCommitment', window );">Asset acquisition, maximum funding commitment</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_AssetAcquisitionMaximumFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition maximum funding commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_AssetAcquisitionMaximumFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_PercentageOfCommissionOnSaleOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on sale of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_PercentageOfCommissionOnSaleOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_PublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public float.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_PublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_RemainedAvailableForIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remained available for issuance of cmmon stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_RemainedAvailableForIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and related cost number of full time employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_SaleOfStockWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_SaleOfStockWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesCompletionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the exit and disposal activities were completed or are expected to be completed, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesCompletionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesInitiationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the restructuring activities were initiated or are expected to be initiated, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesInitiationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tpst_AtTheMarketProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tpst_AtTheMarketProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tpst_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tpst_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tpst_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tpst_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tpst_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tpst_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Leasehold improvements<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,707<span></span>
</td>
<td class="nump">$ 30,268<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,707<span></span>
</td>
<td class="nump">30,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">7,707<span></span>
</td>
<td class="nump">30,268<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,707<span></span>
</td>
<td class="nump">30,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Items - Schedule of Prepaid Expenses and Other Current Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_PrepaidResearchAndDevelopmentCostsCurrent', window );">Prepaid research and development costs</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 1,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_PrepaidResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_PrepaidResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Items - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 2,058<span></span>
</td>
<td class="nump">$ 2,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(1,453)<span></span>
</td>
<td class="num">(1,320)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment&#8212;net</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">1,446<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Items - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Items - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other liabilities</a></td>
<td class="nump">$ 627<span></span>
</td>
<td class="nump">$ 1,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_AccruedClinicalTrialLiability', window );">Accrued clinical trial liability</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">$ 2,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_AccruedClinicalTrialLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>AccruedClinicalTrialLiability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_AccruedClinicalTrialLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,540<span></span>
</td>
<td class="nump">$ 8,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="nump">$ 388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=tpst_BrisbaneCaliforniaMember', window );">Brisbane, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property (in sqft) | ft&#178;</a></td>
<td class="nump">20,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_OperatingLeaseCommencementMonthAndYear', window );">Operating lease commencement month and year</a></td>
<td class="text">2022-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,540<span></span>
</td>
<td class="nump">8,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,141<span></span>
</td>
<td class="nump">9,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,946<span></span>
</td>
<td class="nump">$ 2,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_OperatingLeaseCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_OperatingLeaseCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=tpst_BrisbaneCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=tpst_BrisbaneCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Rental Payments under Operating Leases with Noncancelable Terms (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">$ (1,192)<span></span>
</td>
<td class="num">$ (869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease obligations</a></td>
<td class="nump">6,949<span></span>
</td>
<td class="nump">8,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=tpst_BrisbaneCaliforniaMember', window );">Brisbane, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">1,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">1,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">2,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">2,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">2,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">10,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(2,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease obligations</a></td>
<td class="nump">8,141<span></span>
</td>
<td class="nump">$ 9,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(1,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease obligations</a></td>
<td class="nump">$ 6,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=tpst_BrisbaneCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=tpst_BrisbaneCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 08, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 23, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 15, 2021 </div>
<div>USD ($) </div>
<div>Tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,426<span></span>
</td>
<td class="nump">$ 4,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_DebtInstrumentExitFee', window );">Debt instrument, exit fee</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tpst_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Loan mature date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_DebtInstrumentNumberOfTranches', window );">Number of tranches | Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Debt instrument interest term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the interest-only repayment period was extended through December 31, 2023 (which interest-only period may be further extended through June 30, 2024 under certain circumstances)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Annual floating interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_ThersholdIndexRate', window );">Thershold index rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Monthly principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent', window );">Loan discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
<td class="nump">$ 1,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tpst_TrancheATermLoanMember', window );">Tranche A Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tpst_TrancheBTermLoanMember', window );">Tranche B Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Loan mature date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=tpst_TrancheCTermLoanMember', window );">Tranche C Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument exit fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_ThersholdIndexRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ThersholdIndexRate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_ThersholdIndexRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tpst_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tpst_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tpst_TrancheATermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tpst_TrancheATermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tpst_TrancheBTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tpst_TrancheBTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=tpst_TrancheCTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=tpst_TrancheCTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting rights of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Participating Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Voting rights of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Participating Preferred Stock | Rights Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred stock price per share</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares purchase from preferred stock</a></td>
<td class="nump">0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsAxis=tpst_O2023Q4DividendsMember', window );">O 2023 Q4 Dividends [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear', window );">Dividend record date</a></td>
<td class="text">Oct. 23,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateOfRecordDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_RightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_RightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=tpst_O2023Q4DividendsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=tpst_O2023Q4DividendsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 27, 2026</div></th>
<th class="th"><div>Jan. 01, 2026</div></th>
<th class="th"><div>Jun. 15, 2023</div></th>
<th class="th"><div>Jun. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based compensation arrangement by share-based payment award, purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation arrangement by share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,014<span></span>
</td>
<td class="nump">69,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
<td class="nump">$ 51.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based compensation arrangement by share-based payment award, fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,576<span></span>
</td>
<td class="nump">$ 5,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Accelarated vesting of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Share based compensation, modified stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Stock compensation expense related to employees stock options grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tpst_A2019EmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based compensation arrangement by share-based payment award, percentage of outstanding stock maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-based compensation arrangement by share-based payment award, shares issued in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear', window );">Share-based compensation arrangement by share-based payment award, maximum number of shares available for grant per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,608<span></span>
</td>
<td class="nump">68,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember', window );">Amended and Restated 2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based compensation arrangement by share-based payment award, percentage of outstanding stock maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum', window );">Share-based compensation arrangement by share-based payment award, period of automatic increase to outstanding stock maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,745<span></span>
</td>
<td class="nump">47,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember', window );">Amended and Restated 2023 Equity Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-based compensation arrangement by share-based payment award, shares issued in period</a></td>
<td class="nump">1,410,000<span></span>
</td>
<td class="nump">197,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tpst_TwoThousandTwentyThreeInducementPlanMember', window );">2023 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,615<span></span>
</td>
<td class="nump">67,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember', window );">Individuals who were not Previously Employees or Directors of Company | 2023 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,014<span></span>
</td>
<td class="nump">69,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
<td class="nump">$ 51.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
<td class="nump">$ 12,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Available for Grant Per Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Period of Automatic Increase to Outstanding Stock Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tpst_A2019EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tpst_A2019EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tpst_TwoThousandTwentyThreeInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tpst_TwoThousandTwentyThreeInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning (in shares)</a></td>
<td class="nump">320,090<span></span>
</td>
<td class="nump">273,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">130,014<span></span>
</td>
<td class="nump">69,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled and forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,028)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end (in shares)</a></td>
<td class="nump">450,104<span></span>
</td>
<td class="nump">320,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning (in dollars per share)</a></td>
<td class="nump">$ 86.06<span></span>
</td>
<td class="nump">$ 94.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">51.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled and forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">106.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end (in dollars per share)</a></td>
<td class="nump">$ 64.44<span></span>
</td>
<td class="nump">$ 86.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Information About Stock Options Outstanding (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">450,104<span></span>
</td>
<td class="nump">320,090<span></span>
</td>
<td class="nump">273,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding (in dollars per share)</a></td>
<td class="nump">$ 64.44<span></span>
</td>
<td class="nump">$ 86.06<span></span>
</td>
<td class="nump">$ 94.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">450,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 64.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">441,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 64.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Grant Date Fair Value of Option (Details) - Share-based Payment Arrangement, Employee<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">115.00%<span></span>
</td>
<td class="nump">109.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">116.00%<span></span>
</td>
<td class="nump">124.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,118<span></span>
</td>
<td class="nump">$ 5,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">2,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,939<span></span>
</td>
<td class="nump">$ 3,081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">At statutory rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Operating loss carryforwards, federal</a></td>
<td class="nump">$ 534,500,000<span></span>
</td>
<td class="nump">$ 502,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating loss carryforwards, state</a></td>
<td class="nump">501,900,000<span></span>
</td>
<td class="nump">487,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">6,699,000<span></span>
</td>
<td class="nump">12,156,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tpst_LegacyMillendoMember', window );">Legacy Millendo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Operating loss carryforwards, federal</a></td>
<td class="nump">455,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">14,700,000<span></span>
</td>
<td class="nump">14,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">4,400,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=tpst_OrphanDrugCreditMember', window );">Orphan Drug Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=tpst_NotSubjectToExpirationMember', window );">Not Subject to Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Operating loss carryforwards, federal</a></td>
<td class="nump">313,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=tpst_NotSubjectToExpirationMember', window );">Not Subject to Expiration | Research Tax Credit Carryforward | State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tpst_LegacyMillendoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tpst_LegacyMillendoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=tpst_OrphanDrugCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=tpst_OrphanDrugCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=tpst_NotSubjectToExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=tpst_NotSubjectToExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">At statutory rate</a></td>
<td class="num">$ (5,514,000)<span></span>
</td>
<td class="num">$ (8,786,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">At statutory rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration', window );">Tax Jurisdiction of Domicile [Extensible Enumeration]</a></td>
<td class="text">country:US<span></span>
</td>
<td class="text">country:US<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 5,105,000<span></span>
</td>
<td class="nump">$ 9,199,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, Percent</a></td>
<td class="num">(19.40%)<span></span>
</td>
<td class="num">(22.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">$ 343,000<span></span>
</td>
<td class="nump">$ 709,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation, Percent</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 454,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent', window );">Transaction costs, Percent</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nontaxable or nondeductible items</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nontaxable or nondeductible items, Percent</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="num">$ (478,000)<span></span>
</td>
<td class="num">$ (1,136,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit, percent</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total, Percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Non deductible Expense Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Non Deductible Expense Transaction Costs Percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates tax jurisdiction of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 152,074<span></span>
</td>
<td class="nump">$ 143,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">21,198<span></span>
</td>
<td class="nump">20,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization', window );">Amortization</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">2,354<span></span>
</td>
<td class="nump">2,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">1,583<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_DeferredTaxAssetsCapitalResearchAndDevelopment', window );">Capitalized R&amp;D</a></td>
<td class="nump">7,901<span></span>
</td>
<td class="nump">10,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">185,697<span></span>
</td>
<td class="nump">179,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(183,498)<span></span>
</td>
<td class="num">(176,799)<span></span>
</td>
<td class="num">$ (164,643)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">2,199<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(2,180)<span></span>
</td>
<td class="num">(2,518)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liabilities</a></td>
<td class="num">(2,199)<span></span>
</td>
<td class="num">(2,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_DeferredTaxAssetsCapitalResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capital Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_DeferredTaxAssetsCapitalResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Right-of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of the Total Change in the Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning Balance</a></td>
<td class="nump">$ 176,799<span></span>
</td>
<td class="nump">$ 164,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change related to continuing operations</a></td>
<td class="nump">6,699<span></span>
</td>
<td class="nump">12,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Ending Balance</a></td>
<td class="nump">$ 183,498<span></span>
</td>
<td class="nump">$ 176,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Income Tax Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 5,239<span></span>
</td>
<td class="nump">$ 4,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increase - tax position in current period</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 5,406<span></span>
</td>
<td class="nump">$ 5,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Basis in Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (26,262)<span></span>
</td>
<td class="num">$ (41,843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted-average common shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,149,733<span></span>
</td>
<td class="nump">2,146,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing basic net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,149,733<span></span>
</td>
<td class="nump">2,146,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing diluted net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,149,733<span></span>
</td>
<td class="nump">2,146,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders - basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (6.33)<span></span>
</td>
<td class="num">$ (19.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (6.33)<span></span>
</td>
<td class="num">$ (19.5)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Results, including shares of common stock, have been adjusted to reflect the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-thirteen</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings</a></td>
<td class="nump">1,622,982<span></span>
</td>
<td class="nump">320,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings</a></td>
<td class="nump">450,104<span></span>
</td>
<td class="nump">320,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tpst_CommonStockWarrantsMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings</a></td>
<td class="nump">1,172,878<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tpst_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tpst_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">The CODM regularly reviews and evaluates research and development expenses and uses consolidated net loss, as reported on the Company&#8217;s Consolidated Statements of Operations, to assess the performance of the segment and to allocate resources.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">The CODM regularly reviews and evaluates research and development expenses and uses consolidated net loss, as reported on the Company&#8217;s Consolidated Statements of Operations, to assess the performance of the segment and to allocate resources.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 20, 2026</div></th>
<th class="th"><div>Feb. 03, 2026</div></th>
<th class="th"><div>Jan. 27, 2026</div></th>
<th class="th"><div>Jan. 20, 2026</div></th>
<th class="th"><div>Jan. 01, 2026</div></th>
<th class="th"><div>Nov. 19, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tpst_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Erigen Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionDateOfAcquisitionAgreement', window );">Asset acquisition, agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 19,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tpst_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Erigen Assets | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued', window );">Asset acquisition, stock to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,268,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,784,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | O 2026 Q4 Dividends [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear', window );">Dividend record date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended and Restated 2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-based compensation arrangement by share-based payment award, shares issued in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Angel Employment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_AnnualBaseSalary', window );">Anual base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_PercentageOfAnnualBonus', window );">Percentage of annual bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Angel Employment Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Purchase Agreement | Series A Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_SaleOfStockWarrantsIssued', window );">Sale Of Stock Warrants Issued</a></td>
<td class="nump">925,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Purchase Agreement | Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_SaleOfStockWarrantsIssued', window );">Sale Of Stock Warrants Issued</a></td>
<td class="nump">925,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Purchase Agreement | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">462,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Purchase Agreement | Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_SaleOfStockWarrantsIssued', window );">Sale Of Stock Warrants Issued</a></td>
<td class="nump">462,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Purchase Agreement | Pre-Funded Warrant | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Purchase Agreement | Pre Funded Warrant and Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 2.159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Purchase Agreement | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Purchase Agreement | Common Warrants [Member] | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_AssetAcquisitionMaximumFundingCommitment', window );">Asset acquisition, maximum funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Asset Purchase Agreement | Erigen Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionEffectiveDateOfAcquisition', window );">Asset acquisition, effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  03,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_AssetAcquisitionTransactionCosts', window );">Asset acquisition transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, aggregate consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_AssetAcquisitionMaximumFundingCommitment', window );">Asset acquisition, maximum funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Asset Purchase Agreement | Erigen Assets | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable', window );">Asset acquisition, stock issued as consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,268,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tpst_AssetAcquisitionSharePrice', window );">Asset acquisition, stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_AnnualBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual base salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_AnnualBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition, consideration transferred, shares, equity interest issued and issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_AssetAcquisitionMaximumFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition maximum funding commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_AssetAcquisitionMaximumFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_AssetAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition, share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_AssetAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition shares equity interest yet to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_PercentageOfAnnualBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_PercentageOfAnnualBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpst_SaleOfStockWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpst_SaleOfStockWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionDateOfAcquisitionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when asset acquisition agreement is executed, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionDateOfAcquisitionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionEffectiveDateOfAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when acquirer obtains control of acquired asset, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionEffectiveDateOfAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateOfRecordDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tpst_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tpst_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=tpst_ErigenAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=tpst_ErigenAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=tpst_O2026Q4DividendsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=tpst_O2026Q4DividendsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=tpst_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=tpst_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=tpst_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=tpst_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tpst_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tpst_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tpst_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tpst_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tpst_Pre-FundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tpst_Pre-FundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tpst_PreFundedWarrantAndCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tpst_PreFundedWarrantAndCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tpst_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tpst_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>139</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75040 - Statement - Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>75060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>75070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItems</Role>
      <ShortName>Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Loan Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/LoanPayable</Role>
      <ShortName>Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsTables</Role>
      <ShortName>Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItems</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995657 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Organization and Description of Business - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails</Role>
      <ShortName>Organization and Description of Business - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Balance Sheet Items - Schedule of Prepaid Expenses and Other Current Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails</Role>
      <ShortName>Balance Sheet Items - Schedule of Prepaid Expenses and Other Current Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Balance Sheet Items - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Items - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Balance Sheet Items - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsNarrativeDetails</Role>
      <ShortName>Balance Sheet Items - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Balance Sheet Items - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Items - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995757 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments under Operating Leases with Noncancelable Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Rental Payments under Operating Leases with Noncancelable Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Loan Payable - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails</Role>
      <ShortName>Loan Payable - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Stock-Based Compensation - Summary of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Stock-Based Compensation - Summary of Information About Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Information About Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995847 - Disclosure - Stock-Based Compensation - Grant Date Fair Value of Option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails</Role>
      <ShortName>Stock-Based Compensation - Grant Date Fair Value of Option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995877 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995887 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995897 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Income Taxes - Schedule of Reconciliation of the Total Change in the Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheTotalChangeInTheValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of the Total Change in the Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995917 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995927 - Disclosure - Retirement Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureRetirementPlanNarrativeDetails</Role>
      <ShortName>Retirement Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995937 - Disclosure - Net Loss Per Share - Summary of Basis in Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Basis in Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995947 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995957 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="tpst-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995967 - Disclosure - Subsequent Events - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="tpst-20251231.htm">tpst-20251231.htm</File>
    <File>tpst-20251231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img81402019_0.jpg</File>
    <File>img81402019_1.jpg</File>
    <File>img81402019_2.jpg</File>
    <File>img81402019_3.jpg</File>
    <File>img81402019_4.jpg</File>
    <File>img81402019_5.jpg</File>
    <File>img81402019_6.jpg</File>
    <File>img81402019_7.jpg</File>
    <File>img81402019_8.jpg</File>
    <File>img81402019_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="509">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tpst-20251231.htm": {
   "nsprefix": "tpst",
   "nsuri": "http://www.tempesttx.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "tpst-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "tpst-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 297,
   "keyCustom": 43,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 30,
   "hidden": {
    "total": 14,
    "http://fasb.org/us-gaap/2025": 10,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 139,
   "entityCount": 1,
   "segmentCount": 59,
   "elementCount": 647,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 509,
    "http://xbrl.sec.gov/dei/2025": 43,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/Cover",
     "longName": "75000 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
     "longName": "75010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "75020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:DeferredFinanceCostsCurrentNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:DeferredFinanceCostsCurrentNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "longName": "75030 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical",
     "longName": "75040 - Statement - Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_83ad0427-46c9-40f3-8ea3-599adc8b0338",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
     "longName": "75050 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_06328e98-1580-41cc-a910-5db61b65b8fe",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_06328e98-1580-41cc-a910-5db61b65b8fe",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "75060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "tpst:StockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "tpst:StockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows",
     "longName": "75070 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "tpst:NoncashLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_5674d468-6c98-412c-9336-57931dcfe277",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5674d468-6c98-412c-9336-57931dcfe277",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1",
     "longName": "995467 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPolicies",
     "longName": "995477 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurements",
     "longName": "995487 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItems",
     "longName": "995497 - Disclosure - Balance Sheet Items",
     "shortName": "Balance Sheet Items",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "995507 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/LoanPayable",
     "longName": "995517 - Disclosure - Loan Payable",
     "shortName": "Loan Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquity",
     "longName": "995527 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1",
     "longName": "995537 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxes",
     "longName": "995547 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/RetirementPlan",
     "longName": "995557 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShare",
     "longName": "995567 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995577 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995587 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "995597 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "995607 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "tpst:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "tpst:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurementsTables",
     "longName": "995617 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsTables",
     "longName": "995627 - Disclosure - Balance Sheet Items (Tables)",
     "shortName": "Balance Sheet Items (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "tpst:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "tpst:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/CommitmentandContingenciesTables",
     "longName": "995637 - Disclosure - Commitment and Contingencies (Tables)",
     "shortName": "Commitment and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "995647 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesTables",
     "longName": "995657 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareTables",
     "longName": "995667 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
     "longName": "995677 - Disclosure - Organization and Description of Business - Narrative (Details)",
     "shortName": "Organization and Description of Business - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_83ad0427-46c9-40f3-8ea3-599adc8b0338",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ec632eae-fdb8-4bbe-ae31-e0618a3ad9ad",
      "name": "us-gaap:RestructuringAndRelatedActivitiesCompletionDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "longName": "995687 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails",
     "longName": "995697 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_f01f9f21-5e95-48cc-83bd-51259e351e7a",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f01f9f21-5e95-48cc-83bd-51259e351e7a",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "longName": "995707 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_9b755a49-74f8-491a-8e35-1ea2c98f61f7",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b755a49-74f8-491a-8e35-1ea2c98f61f7",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails",
     "longName": "995717 - Disclosure - Balance Sheet Items - Schedule of Prepaid Expenses and Other Current Asset (Details)",
     "shortName": "Balance Sheet Items - Schedule of Prepaid Expenses and Other Current Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tpst:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tpst:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails",
     "longName": "995727 - Disclosure - Balance Sheet Items - Summary of Property and Equipment, Net (Details)",
     "shortName": "Balance Sheet Items - Summary of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsNarrativeDetails",
     "longName": "995737 - Disclosure - Balance Sheet Items - Narrative (Details)",
     "shortName": "Balance Sheet Items - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails",
     "longName": "995747 - Disclosure - Balance Sheet Items - Schedule of Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Items - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:OtherAccruedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:OtherAccruedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "longName": "995757 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_090576ed-b8aa-4a6c-bd24-ad4fc236805a",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails",
     "longName": "995767 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments under Operating Leases with Noncancelable Terms (Details)",
     "shortName": "Commitments and Contingencies - Future Minimum Rental Payments under Operating Leases with Noncancelable Terms (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d32c69c8-59a9-4557-bfdc-6f0d25e66261",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails",
     "longName": "995797 - Disclosure - Loan Payable - Narrative (Details)",
     "shortName": "Loan Payable - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_83ad0427-46c9-40f3-8ea3-599adc8b0338",
      "name": "us-gaap:RepaymentsOfDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_83ad0427-46c9-40f3-8ea3-599adc8b0338",
      "name": "us-gaap:RepaymentsOfDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
     "longName": "995807 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
     "longName": "995817 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails",
     "longName": "995827 - Disclosure - Stock-Based Compensation - Summary of Stock Options (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails",
     "longName": "995837 - Disclosure - Stock-Based Compensation - Summary of Information About Stock Options Outstanding (Details)",
     "shortName": "Stock-Based Compensation - Summary of Information About Stock Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails",
     "longName": "995847 - Disclosure - Stock-Based Compensation - Grant Date Fair Value of Option (Details)",
     "shortName": "Stock-Based Compensation - Grant Date Fair Value of Option (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_872c6937-1351-451b-abf9-2a2a83e2dc84",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_872c6937-1351-451b-abf9-2a2a83e2dc84",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails",
     "longName": "995857 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Stock Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c3d09bfa-c82c-410e-8c05-013d4096ded0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails",
     "longName": "995877 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:IncomeTaxesPaidNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "995887 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "995897 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheTotalChangeInTheValuationAllowanceDetails",
     "longName": "995907 - Disclosure - Income Taxes - Schedule of Reconciliation of the Total Change in the Valuation Allowance (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of the Total Change in the Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails",
     "longName": "995917 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_518e5fc4-652b-4edf-a054-ee24c0dbc43b",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureRetirementPlanNarrativeDetails",
     "longName": "995927 - Disclosure - Retirement Plan - Narrative (Details)",
     "shortName": "Retirement Plan - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails",
     "longName": "995937 - Disclosure - Net Loss Per Share - Summary of Basis in Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Summary of Basis in Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "longName": "995947 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReportingNarrativeDetails",
     "longName": "995957 - Disclosure - Segment Reporting - Narrative (Details)",
     "shortName": "Segment Reporting - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02b78ddf-da38-4509-a735-32afb066d3b8",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails",
     "longName": "995967 - Disclosure - Subsequent Events - Narrative (Details)",
     "shortName": "Subsequent Events - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_6e35c08f-14cf-428d-a7d8-78364f94ae76",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cbae41ba-0f21-46c1-8226-08889ddc8bc8",
      "name": "us-gaap:AssetAcquisitionDateOfAcquisitionAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tpst-20251231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "tpst_A2019And2017EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "A2019And2017EquityIncentivePlanMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A 2019 and 2017 equity incentive plan.",
        "label": "A2019 And2017 Equity Incentive Plan [Member]",
        "terseLabel": "2019 and 2017 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_A2019EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "A2019EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Employee Stock Purchase Plan",
        "label": "2019 Employee Stock Purchase Plan [Member]",
        "documentation": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_A2019EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "A2019EquityIncentivePlanMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Equity Incentive Plan",
        "label": "2019 Equity Incentive Plan [Member]",
        "documentation": "2019 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r136",
      "r137",
      "r138",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r232",
      "r233",
      "r236",
      "r238",
      "r239",
      "r249",
      "r250",
      "r258",
      "r310",
      "r311",
      "r312",
      "r313",
      "r399",
      "r400",
      "r401",
      "r402",
      "r446",
      "r447",
      "r448",
      "r449",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r486",
      "r487",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r532",
      "r533",
      "r552",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r843"
     ]
    },
    "tpst_AccruedClinicalTrialLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "AccruedClinicalTrialLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical trial liability",
        "label": "AccruedClinicalTrialLiability",
        "documentation": "AccruedClinicalTrialLiability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total",
        "verboseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r116",
      "r628"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalCashFlowElementsInvestingActivitiesAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Investing Activity [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Operating Activity [Abstract]",
        "terseLabel": "Non-cash operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r843",
      "r1153"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1096",
      "r1156"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1048"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r909",
      "r942"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r891",
      "r902",
      "r912",
      "r945"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r937",
      "r946",
      "r950",
      "r958"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r403",
      "r412"
     ]
    },
    "tpst_AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended and Restated 2023 Equity Incentive Plan",
        "label": "Amended and Restated Two Thousand Twenty Three Equity Incentive Plan [Member]",
        "documentation": "Amended and restated two thousand twenty three equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_AnnualBaseSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "AnnualBaseSalary",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Base Salary",
        "documentation": "Annual base salary.",
        "terseLabel": "Anual base salary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of real estate property",
        "label": "Area of Real Estate Property",
        "verboseLabel": "Area of property (in sqft)",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r654",
      "r1088"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "totalLabel": "Asset Acquisition, Consideration Transferred, Total",
        "terseLabel": "Asset acquisition, aggregate consideration",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "tpst_AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, stock issued as consideration",
        "label": "Asset Acquisition, Consideration Transferred, Shares, Equity Interest Issued and Issuable",
        "documentation": "Asset acquisition, consideration transferred, shares, equity interest issued and issuable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionDateOfAcquisitionAgreement": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDateOfAcquisitionAgreement",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Date of Acquisition Agreement",
        "terseLabel": "Asset acquisition, agreement date",
        "documentation": "Date when asset acquisition agreement is executed, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r654",
      "r1088"
     ]
    },
    "us-gaap_AssetAcquisitionEffectiveDateOfAcquisition": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionEffectiveDateOfAcquisition",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Effective Date of Acquisition",
        "terseLabel": "Asset acquisition, effective date",
        "documentation": "Date when acquirer obtains control of acquired asset, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r1088"
     ]
    },
    "tpst_AssetAcquisitionMaximumFundingCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "AssetAcquisitionMaximumFundingCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, maximum funding commitment",
        "label": "Asset Acquisition Maximum Funding Commitment",
        "documentation": "Asset acquisition maximum funding commitment."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_AssetAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "AssetAcquisitionSharePrice",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Share Price",
        "documentation": "Asset acquisition, share price.",
        "terseLabel": "Asset acquisition, stock price per share"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_AssetAcquisitionSharesEquityInterestYetToBeIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "AssetAcquisitionSharesEquityInterestYetToBeIssued",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, stock to be issued",
        "label": "Asset Acquisition Shares Equity Interest Yet To Be Issued",
        "documentation": "Asset acquisition shares equity interest yet to be issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r1088"
     ]
    },
    "tpst_AssetAcquisitionTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "AssetAcquisitionTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition Transaction Costs",
        "documentation": "Asset acquisition transaction costs.",
        "terseLabel": "Asset acquisition transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_AssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "AssetPurchaseAgreementMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Purchase Agreement [Member]",
        "documentation": "Asset purchase agreement.",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r89",
      "r118",
      "r148",
      "r151",
      "r152",
      "r193",
      "r207",
      "r220",
      "r223",
      "r235",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r475",
      "r479",
      "r539",
      "r614",
      "r615",
      "r622",
      "r705",
      "r795",
      "r796",
      "r810",
      "r843",
      "r854",
      "r855",
      "r866",
      "r1037",
      "r1038",
      "r1113"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets [Abstract]",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r127",
      "r148",
      "r151",
      "r152",
      "r235",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r475",
      "r479",
      "r539",
      "r843",
      "r1037",
      "r1038",
      "r1113"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r834"
     ]
    },
    "tpst_AtTheMarketProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "AtTheMarketProgramMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Program",
        "label": "At-The-Market Program [Member]",
        "documentation": "At-The-Market Program"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "tpst_BrisbaneCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "BrisbaneCaliforniaMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brisbane California.",
        "label": "Brisbane California [Member]",
        "terseLabel": "Brisbane, California"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalLeaseObligationsIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Obligation Incurred",
        "terseLabel": "Lease modification",
        "documentation": "Amount of increase in lease obligation from new lease."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r114",
      "r772"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535",
      "r536",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r64",
      "r145"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r64"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r107",
      "r136",
      "r163",
      "r232",
      "r249",
      "r258",
      "r310",
      "r399",
      "r447",
      "r456",
      "r457",
      "r465",
      "r466",
      "r468",
      "r486",
      "r499",
      "r500",
      "r532",
      "r533",
      "r552",
      "r560",
      "r561",
      "r640",
      "r641"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r164",
      "r178",
      "r237"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r122",
      "r123",
      "r124",
      "r148",
      "r152",
      "r182",
      "r183",
      "r185",
      "r187",
      "r195",
      "r196",
      "r235",
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r314",
      "r315",
      "r317",
      "r318",
      "r320",
      "r322",
      "r325",
      "r326",
      "r329",
      "r332",
      "r339",
      "r539",
      "r659",
      "r660",
      "r661",
      "r662",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r693",
      "r713",
      "r731",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r981",
      "r1003",
      "r1005",
      "r1014"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r195",
      "r317",
      "r325",
      "r326",
      "r327",
      "r329",
      "r332",
      "r337",
      "r339",
      "r485",
      "r659",
      "r660",
      "r661",
      "r662",
      "r811",
      "r981",
      "r1001",
      "r1003"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r155",
      "r340"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 5)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r84",
      "r623",
      "r692"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r262",
      "r263",
      "r757",
      "r1025",
      "r1032"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, capital shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r858",
      "r860",
      "r861",
      "r862",
      "r863",
      "r1010",
      "r1011",
      "r1013",
      "r1096",
      "r1152",
      "r1156"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r693"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r693",
      "r711",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized; 4,927,161 and 3,382,432 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r315",
      "r321",
      "r624",
      "r843"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting rights of common stock",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "tpst_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]",
        "documentation": "Common warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538"
     ]
    },
    "tpst_Corporatetaxespaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "Corporatetaxespaid",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for business taxes",
        "label": "CorporateTaxesPaid",
        "documentation": "CorporateTaxesPaid"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r148",
      "r157",
      "r158",
      "r285",
      "r327",
      "r566",
      "r575",
      "r621",
      "r774",
      "r775",
      "r776",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r1092",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r1036"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r1036"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r971"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r971"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r973"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r971"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r964"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r965"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r965"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r963"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r966"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r968"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r968"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r967"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/LoanPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Loan Payable",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r148",
      "r150",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r270",
      "r271",
      "r281",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r297",
      "r304",
      "r305",
      "r307",
      "r485",
      "r550"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_DebtInstrumentExitFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "DebtInstrumentExitFee",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Exit Fee",
        "documentation": "Debt instrument exit fee.",
        "terseLabel": "Debt instrument, exit fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r550",
      "r551",
      "r806",
      "r807",
      "r842"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateTerms",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate Terms",
        "terseLabel": "Debt instrument interest term",
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r485",
      "r618",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r842",
      "r1001",
      "r1002",
      "r1004",
      "r1009",
      "r1107",
      "r1108"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Loan mature date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r805",
      "r1100",
      "r1101"
     ]
    },
    "tpst_DebtInstrumentNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "DebtInstrumentNumberOfTranches",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Debt Instrument, Number of Tranches",
        "documentation": "Debt Instrument, Number of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly principal payments",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r27",
      "r30",
      "r36",
      "r73",
      "r74",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r485",
      "r618",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r842",
      "r1001",
      "r1002",
      "r1004",
      "r1009",
      "r1107",
      "r1108"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan discounts",
        "label": "Debt Instrument, Unamortized Discount, Noncurrent",
        "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1106",
      "r1107",
      "r1108"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation expense related to employees stock options grants",
        "label": "Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense",
        "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of discount and issuance costs, Current",
        "label": "Debt Issuance Costs, Current, Net",
        "totalLabel": "Debt Issuance Costs, Current, Net, Total",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1106",
      "r1107",
      "r1108"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs, net",
        "label": "Debt Issuance Costs, Net",
        "totalLabel": "Debt Issuance Costs, Net, Total",
        "verboseLabel": "Net of discount and issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1106",
      "r1107",
      "r1108"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r82",
      "r436"
     ]
    },
    "tpst_DeferredTaxAssetsCapitalResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "DeferredTaxAssetsCapitalResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Capital Research And Development",
        "label": "Deferred Tax Assets Capital Research And Development",
        "terseLabel": "Capitalized R&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "documentation": "Deferred Tax Assets, Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, federal",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, state",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "tpst_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Amortization",
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheTotalChangeInTheValuationAllowanceDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liability:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities, Operating Lease, Right-of Use Assets",
        "documentation": "Deferred Tax Liabilities, Operating Lease, Right-of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureRetirementPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r22",
      "r135",
      "r777",
      "r778",
      "r780",
      "r782"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends [Axis]",
        "documentation": "Information by event wherein earnings are distributed to shareholder."
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1046"
     ]
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock, Cash",
        "terseLabel": "Dividends",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_DividendsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends [Domain]",
        "documentation": "Event wherein earnings are distributed to shareholder."
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1046"
     ]
    },
    "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPayableDateOfRecordDayMonthAndYear",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend record date",
        "label": "Dividends Payable, Date of Record",
        "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895",
      "r938"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Net loss per share attributable to common stockholders - basic",
        "terseLabel": "Net loss per share of common stock and pre-funded warrants, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r134",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r180",
      "r182",
      "r185",
      "r186",
      "r187",
      "r192",
      "r313",
      "r401",
      "r463",
      "r472",
      "r508",
      "r509",
      "r613",
      "r634",
      "r784"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net loss per share attributable to common stockholders - diluted",
        "terseLabel": "Net loss per share of common stock and pre-funded warrants, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r134",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r182",
      "r185",
      "r186",
      "r187",
      "r192",
      "r313",
      "r401",
      "r463",
      "r472",
      "r508",
      "r509",
      "r613",
      "r634",
      "r784"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r189"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r188",
      "r190",
      "r191"
     ]
    },
    "tpst_Ecor1CapitalLlcAndVersantVentureCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "Ecor1CapitalLlcAndVersantVentureCapitalMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EcoR1 Capital LLC and Versant Venture Capital.",
        "label": "EcoR1 Capital LLC And Versant Venture Capital [Member]",
        "terseLabel": "EcoR1 Capital, LLC and Versant Venture Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r823"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "At statutory rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r154",
      "r421",
      "r450",
      "r823"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r823",
      "r1001",
      "r1008",
      "r1079"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nontaxable or nondeductible items, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r1001",
      "r1008",
      "r1079"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r1001",
      "r1008",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development credit, percent",
        "negatedLabel": "Research and development credit, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r1001",
      "r1008",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Options to purchase common stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "tpst_EmployeeStockOwnershipPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "EmployeeStockOwnershipPlanMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan [Member]",
        "terseLabel": "Employee Stock Ownership Plan"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_EmploymentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "EmploymentAgreementMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreement [Member]",
        "documentation": "Employment agreement.",
        "terseLabel": "Angel Employment Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r99",
      "r106",
      "r107",
      "r131",
      "r132",
      "r133",
      "r160",
      "r161",
      "r162",
      "r165",
      "r173",
      "r175",
      "r177",
      "r194",
      "r236",
      "r240",
      "r250",
      "r312",
      "r341",
      "r401",
      "r445",
      "r446",
      "r459",
      "r460",
      "r461",
      "r464",
      "r471",
      "r472",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r507",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r552",
      "r554",
      "r565",
      "r633",
      "r642",
      "r643",
      "r644",
      "r667",
      "r731"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "tpst_ErigenAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "ErigenAssetsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erigen Assets [Member]",
        "documentation": "Erigen assets.",
        "terseLabel": "Erigen Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r909",
      "r942"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r896",
      "r906",
      "r939"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r526",
      "r770",
      "r835",
      "r841"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535",
      "r536",
      "r770",
      "r841",
      "r1104"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r526",
      "r770",
      "r835",
      "r841"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r536",
      "r770",
      "r841",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r357",
      "r358",
      "r510",
      "r512",
      "r513",
      "r514",
      "r515",
      "r524",
      "r525",
      "r527",
      "r534",
      "r570",
      "r571",
      "r572",
      "r770",
      "r806",
      "r807",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r834",
      "r837",
      "r841"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r515",
      "r834",
      "r1100",
      "r1102"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r520",
      "r522",
      "r523",
      "r524",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r612",
      "r834",
      "r838"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r345",
      "r350",
      "r357",
      "r512",
      "r525",
      "r534",
      "r570",
      "r770",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r834",
      "r841"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r345",
      "r350",
      "r357",
      "r359",
      "r512",
      "r513",
      "r525",
      "r534",
      "r571",
      "r770",
      "r806",
      "r807",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r834",
      "r841"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r357",
      "r358",
      "r512",
      "r513",
      "r514",
      "r515",
      "r525",
      "r534",
      "r572",
      "r770",
      "r806",
      "r807",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r834",
      "r837",
      "r841"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r515",
      "r834",
      "r1100",
      "r1102"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r357",
      "r358",
      "r510",
      "r512",
      "r513",
      "r514",
      "r515",
      "r524",
      "r525",
      "r527",
      "r534",
      "r570",
      "r571",
      "r572",
      "r770",
      "r806",
      "r807",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r834",
      "r837",
      "r841"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r946"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r715"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Axis]",
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Domain]",
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r895"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r69"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r153",
      "r420"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (Loss) before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r86",
      "r88",
      "r614",
      "r616",
      "r630",
      "r779",
      "r781",
      "r783",
      "r788",
      "r795",
      "r1016",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r153",
      "r420"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r257",
      "r260",
      "r481",
      "r482",
      "r483",
      "r484",
      "r517",
      "r521",
      "r526",
      "r540",
      "r541",
      "r542",
      "r637",
      "r639",
      "r716",
      "r769",
      "r770",
      "r824",
      "r825",
      "r832",
      "r833",
      "r836",
      "r841",
      "r1086",
      "r1087",
      "r1124"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r260",
      "r481",
      "r482",
      "r483",
      "r484",
      "r517",
      "r521",
      "r526",
      "r540",
      "r541",
      "r542",
      "r637",
      "r639",
      "r716",
      "r769",
      "r770",
      "r824",
      "r825",
      "r832",
      "r833",
      "r836",
      "r841",
      "r1086",
      "r1087",
      "r1124"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r421",
      "r422",
      "r430",
      "r442",
      "r823",
      "r1084"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r421",
      "r422",
      "r430",
      "r442",
      "r823",
      "r1084"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r154",
      "r415",
      "r421",
      "r427",
      "r428",
      "r429",
      "r433",
      "r440",
      "r451",
      "r453",
      "r454",
      "r455",
      "r620",
      "r653",
      "r664",
      "r823"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Total",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r95",
      "r148",
      "r176",
      "r177",
      "r193",
      "r209",
      "r223",
      "r419",
      "r421",
      "r452",
      "r635",
      "r779",
      "r781",
      "r783",
      "r823"
     ]
    },
    "tpst_IncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "IncomeTaxLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Line Items",
        "terseLabel": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r417",
      "r418",
      "r433",
      "r434",
      "r439",
      "r444",
      "r658"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r823",
      "r1079"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r823"
     ]
    },
    "tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Income Tax Reconciliation Non deductible Expense Transaction Costs",
        "documentation": "Income Tax Reconciliation Non deductible Expense Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Non Deductible Expense Transaction Costs Percent",
        "documentation": "Income Tax Reconciliation Non Deductible Expense Transaction Costs Percent.",
        "terseLabel": "Transaction costs, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount, Total",
        "terseLabel": "Nontaxable or nondeductible items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r1079"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "terseLabel": "Research and development credit",
        "negatedLabel": "Research and development credit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r1079",
      "r1080"
     ]
    },
    "tpst_IncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "IncomeTaxTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Table",
        "terseLabel": "Income Tax [Table]",
        "label": "Income Tax [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid",
        "label": "Income Taxes Paid, Net",
        "totalLabel": "Income Taxes Paid, Net, Total",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r144",
      "r441",
      "r442"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payable",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r999"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r937",
      "r946",
      "r950",
      "r958"
     ]
    },
    "tpst_IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individuals who were not Previously Employees or Directors of Company",
        "label": "Individuals Who Were Not Previously Employees or Directors Of Company [Member]",
        "documentation": "Individuals who were not previously employees or directors of company."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r962"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r962"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r962"
     ]
    },
    "us-gaap_InsuranceSettlementsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InsuranceSettlementsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance recovery of legal settlement",
        "label": "Insurance Settlements Receivable",
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndDividendsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestAndDividendsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payable",
        "label": "Interest and Dividends Payable, Current",
        "totalLabel": "Interest and Dividends Payable, Current, Total",
        "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "totalLabel": "Interest Expense, Debt, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r301",
      "r309",
      "r808",
      "r809",
      "r1155"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "totalLabel": "Interest Expense, Nonoperating, Total",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r779",
      "r783",
      "r997"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r142",
      "r143"
     ]
    },
    "tpst_IssuanceOfCommonStockSharesUnderEquityPlanAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "IssuanceOfCommonStockSharesUnderEquityPlanAwards",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under equity plan awards (in shares)",
        "label": "Issuance of Common Stock Shares under Equity Plan Awards",
        "documentation": "Issuance of common stock shares under equity plan awards."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_IssuanceOfCommonStockValueUnderEquityPlanAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "IssuanceOfCommonStockValueUnderEquityPlanAwards",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under equity plan award",
        "label": "Issuance Of Common Stock Value Under Equity Plan Awards",
        "documentation": "Issuance of common stock value under equity plan awards."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_IssuanceOfCommonStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "IssuanceOfCommonStockWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock warrants (net of issuance cost)",
        "label": "Issuance Of Common Stock Warrants",
        "documentation": "Issuance of common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_IssuanceOfPre-FundedWarrantShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "IssuanceOfPre-FundedWarrantShares",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Pre-Funded Warrant Shares",
        "documentation": "Issuance of pre-funded warrant shares.",
        "terseLabel": "Issuance of pre-funded warrants (net of issuance cost) (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_IssuanceOfPre-FundedWarrantValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "IssuanceOfPre-FundedWarrantValue",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Pre-Funded Warrant Value",
        "documentation": "Issuance of pre-funded warrant value.",
        "terseLabel": "Issuance of pre-funded warrants (net of issuance cost)"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_JefferiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "JefferiesLLCMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies LLC",
        "label": "Jefferies LLC [Member]",
        "documentation": "Jefferies LLC"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_JuneTwoThousandTwentyFivePreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "JuneTwoThousandTwentyFivePreFundedWarrantsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June Two Thousand Twenty Five Pre Funded Warrants [Member]",
        "documentation": "June 2025 Pre-Funded Warrants.",
        "terseLabel": "June 2025 Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r559"
     ]
    },
    "tpst_LegacyMillendoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "LegacyMillendoMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Millendo",
        "terseLabel": "Legacy Millendo",
        "label": "Legacy Millendo [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/CommitmentandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Rental Payments under Operating Leases with Noncancelable Terms",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1002",
      "r1009",
      "r1121"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1002",
      "r1009",
      "r1121"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1002",
      "r1009",
      "r1121"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1002",
      "r1009",
      "r1121"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1002",
      "r1009",
      "r1121"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1002",
      "r1009",
      "r1121"
     ]
    },
    "tpst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability to be Paid Year Four and Thereafter",
        "documentation": "Lessee operating lease liability to be paid year four and thereafter.",
        "terseLabel": "2028 and beyond"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "verboseLabel": "Term of contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r39",
      "r40",
      "r41",
      "r44",
      "r45",
      "r46",
      "r49",
      "r148",
      "r151",
      "r152",
      "r235",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r476",
      "r479",
      "r480",
      "r539",
      "r691",
      "r787",
      "r810",
      "r866",
      "r1037",
      "r1113",
      "r1114"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities [Abstract]",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r85",
      "r626",
      "r843",
      "r854",
      "r855",
      "r1001",
      "r1006",
      "r1023",
      "r1105"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r113",
      "r148",
      "r151",
      "r152",
      "r235",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r476",
      "r479",
      "r480",
      "r539",
      "r843",
      "r1037",
      "r1113",
      "r1114"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r43"
     ]
    },
    "us-gaap_LitigationReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued legal settlement",
        "label": "Estimated Litigation Liability, Current",
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r1033"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Debt, Total",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83",
      "r149",
      "r159",
      "r294",
      "r308",
      "r618",
      "r806",
      "r807",
      "r842",
      "r1122"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Current Maturities",
        "totalLabel": "Long-Term Debt, Current Maturities, Total",
        "terseLabel": "Current loan payable (net of discount and issuance costs of nil and $74, respectively)",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total",
        "terseLabel": "Loan payable (net of discount and issuance costs of nil and $164, respectively)",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Annual floating interest rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r24",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r264",
      "r265",
      "r266",
      "r269",
      "r413",
      "r804",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r264",
      "r265",
      "r266",
      "r269",
      "r413",
      "r804",
      "r1034",
      "r1035"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r265",
      "r266",
      "r267",
      "r268",
      "r363",
      "r392",
      "r393",
      "r394",
      "r413",
      "r515",
      "r576",
      "r636",
      "r638",
      "r652",
      "r683",
      "r684",
      "r736",
      "r738",
      "r740",
      "r741",
      "r743",
      "r752",
      "r753",
      "r755",
      "r756",
      "r767",
      "r768",
      "r803",
      "r811",
      "r819",
      "r824",
      "r826",
      "r827",
      "r837",
      "r838",
      "r839",
      "r840",
      "r852",
      "r1039",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r265",
      "r266",
      "r267",
      "r268",
      "r363",
      "r392",
      "r393",
      "r394",
      "r413",
      "r515",
      "r576",
      "r636",
      "r638",
      "r652",
      "r683",
      "r684",
      "r736",
      "r738",
      "r740",
      "r741",
      "r743",
      "r752",
      "r753",
      "r755",
      "r756",
      "r767",
      "r768",
      "r803",
      "r811",
      "r819",
      "r824",
      "r826",
      "r827",
      "r837",
      "r838",
      "r839",
      "r852",
      "r1039",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "totalLabel": "Net Income (Loss) Attributable to Parent, Total",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r66",
      "r87",
      "r107",
      "r111",
      "r128",
      "r129",
      "r133",
      "r148",
      "r151",
      "r152",
      "r156",
      "r164",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r184",
      "r235",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r313",
      "r316",
      "r319",
      "r323",
      "r401",
      "r463",
      "r472",
      "r509",
      "r539",
      "r632",
      "r712",
      "r729",
      "r730",
      "r779",
      "r781",
      "r783",
      "r864",
      "r1037"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_NetProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "NetProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sales of common stock",
        "label": "Net Proceeds From Issuance Of Common Stock",
        "documentation": "Net proceeds from issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r903",
      "r913",
      "r937",
      "r946"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "tpst_NoncashInterestAndOtherExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "NoncashInterestAndOtherExpenseNet",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash interest and other expense, net",
        "label": "Noncash interest and other expense, net",
        "documentation": "Noncash interest and other expense, net"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash lease expense",
        "label": "Noncash lease expense",
        "documentation": "Noncash lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "terseLabel": "Property and equipment in accounts payable",
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r17"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "tpst_NotSubjectToExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "NotSubjectToExpirationMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not Subject to Expiration",
        "label": "Not Subject to Expiration [Member]",
        "documentation": "Not Subject to Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_NovemberTwoThousandTwentyFivePreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "NovemberTwoThousandTwentyFivePreFundedWarrantsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "November Two Thousand Twenty Five Pre Funded Warrants [Member]",
        "documentation": "November 2025 Pre-Funded Warrants.",
        "terseLabel": "November 2025 Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReportingNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r1017"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReportingNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r801",
      "r1017"
     ]
    },
    "tpst_O2023Q4DividendsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "O2023Q4DividendsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "O 2023 Q4 Dividends [Member]",
        "documentation": "O 2023 Q4 Dividends.",
        "terseLabel": "O 2023 Q4 Dividends [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_O2026Q4DividendsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "O2026Q4DividendsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "O 2026 Q4 Dividends [Member]",
        "documentation": "O 2026 Q4 dividends.",
        "terseLabel": "O 2026 Q4 Dividends [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r779",
      "r783",
      "r788",
      "r1016",
      "r1018",
      "r1019",
      "r1020",
      "r1021"
     ]
    },
    "tpst_OperatingLeaseCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "OperatingLeaseCommencementMonthAndYear",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Commencement Month And Year",
        "documentation": "Operating lease commencement month and year.",
        "terseLabel": "Operating lease commencement month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of operating lease obligations",
        "terseLabel": "Present value of operating lease obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: current portion",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Current operating lease liabilities",
        "negatedLabel": "Less: current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion",
        "verboseLabel": "Noncurrent operating lease obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r108",
      "r109",
      "r110",
      "r655",
      "r656"
     ]
    },
    "tpst_OrphanDrugCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "OrphanDrugCreditMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Orphan Drug Credit",
        "label": "Orphan Drug Credit [Member]",
        "documentation": "Orphan Drug Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r843"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income and other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r831"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net:",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r901",
      "r911",
      "r944"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r904",
      "r914",
      "r947"
     ]
    },
    "tpst_PatentCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "PatentCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Costs, Policy",
        "terseLabel": "Patent Costs",
        "label": "Patent Costs, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Prepayment amount",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/RetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r360",
      "r361",
      "r362",
      "r818"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "tpst_PercentageOfAnnualBonus": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "PercentageOfAnnualBonus",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of annual bonus",
        "label": "Percentage Of Annual Bonus",
        "documentation": "Percentage of annual bonus."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_PercentageOfCommissionOnSaleOfStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "PercentageOfCommissionOnSaleOfStock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commission on sale of stock",
        "label": "Percentage Of Commission On Sale Of Stock",
        "documentation": "Percentage of commission on sale of stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "tpst_Pre-FundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "Pre-FundedWarrantMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrant [Member]",
        "documentation": "Pre-Funded Warrant [Member].",
        "terseLabel": "Pre-Funded Warrant",
        "verboseLabel": "June 2025 Pre-Funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_Pre-FundedWarrantsIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "Pre-FundedWarrantsIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants Issuance Cost",
        "documentation": "Pre-funded warrants issuance cost.",
        "terseLabel": "Pre-funded warrants issuance cost"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_PreFundedWarrantAndCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "PreFundedWarrantAndCommonWarrantsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrant And Common Warrants [Member]",
        "documentation": "Pre funded\u00a0warrant and common warrants.",
        "terseLabel": "Pre Funded Warrant and Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par or stated value per share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r325"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r693"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r693",
      "r711",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_PreferredStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockVotingRights",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Voting Rights",
        "terseLabel": "Voting rights of preferred stock",
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r50"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "totalLabel": "Prepaid Expense, Current, Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r241",
      "r242",
      "r773"
     ]
    },
    "tpst_PrepaidResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "PrepaidResearchAndDevelopmentCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsScheduleOfPrepaidExpensesAndOtherCurrentAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development costs",
        "label": "Prepaid Research and Development Costs, Current",
        "documentation": "Prepaid Research and Development Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_PrivateInvestmentInPublicEntityFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "PrivateInvestmentInPublicEntityFinancingMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private investment in public entity financing.",
        "label": "Private Investment In Public Entity Financing [Member]",
        "terseLabel": "PIPE Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_PrivateTempestPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "PrivateTempestPreferredStockMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private tempest preferred stock.",
        "label": "Private Tempest Preferred Stock [Member]",
        "terseLabel": "Private Tempest Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Gross proceeds from issuance of common stock",
        "terseLabel": "Proceeds from the issuance of common stock, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "tpst_ProceedsFromIssuanceOfCommonStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock warrants, net of issuance costs",
        "label": "Proceeds From Issuance Of Common Stock Warrants",
        "documentation": "Proceeds from issuance of common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from the issuance of pre-funded warrants, net of issuance costs",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock under equity plan awards",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r111",
      "r128",
      "r129",
      "r140",
      "r148",
      "r151",
      "r152",
      "r156",
      "r164",
      "r173",
      "r176",
      "r177",
      "r235",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r313",
      "r401",
      "r463",
      "r472",
      "r474",
      "r477",
      "r478",
      "r509",
      "r539",
      "r614",
      "r616",
      "r631",
      "r666",
      "r712",
      "r729",
      "r730",
      "r829",
      "r830",
      "r865",
      "r996",
      "r1037"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r559"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r115",
      "r629"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment\u2014net",
        "terseLabel": "Property and equipment\u2014net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r559",
      "r619",
      "r629",
      "r843"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r93",
      "r94",
      "r627"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r559"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "tpst_PublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "PublicFloat",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "Public float.",
        "terseLabel": "Public float"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement.",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r265",
      "r266",
      "r267",
      "r268",
      "r343",
      "r363",
      "r392",
      "r393",
      "r394",
      "r398",
      "r413",
      "r515",
      "r573",
      "r574",
      "r576",
      "r636",
      "r638",
      "r652",
      "r683",
      "r684",
      "r736",
      "r738",
      "r740",
      "r741",
      "r743",
      "r752",
      "r753",
      "r755",
      "r756",
      "r767",
      "r768",
      "r803",
      "r811",
      "r819",
      "r824",
      "r826",
      "r827",
      "r837",
      "r838",
      "r839",
      "r840",
      "r852",
      "r858",
      "r1029",
      "r1039",
      "r1100",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r265",
      "r266",
      "r267",
      "r268",
      "r343",
      "r363",
      "r392",
      "r393",
      "r394",
      "r398",
      "r413",
      "r515",
      "r573",
      "r574",
      "r576",
      "r636",
      "r638",
      "r652",
      "r683",
      "r684",
      "r736",
      "r738",
      "r740",
      "r741",
      "r743",
      "r752",
      "r753",
      "r755",
      "r756",
      "r767",
      "r768",
      "r803",
      "r811",
      "r819",
      "r824",
      "r826",
      "r827",
      "r837",
      "r838",
      "r839",
      "r840",
      "r852",
      "r858",
      "r1029",
      "r1039",
      "r1100",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Reserve [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r896",
      "r906",
      "r939"
     ]
    },
    "tpst_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Direct Offering [Member]",
        "documentation": "Registered Direct Offering [Member].",
        "terseLabel": "RDO"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_RemainedAvailableForIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "RemainedAvailableForIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remained available for issuance of common stock",
        "label": "Remained Available for issuance of Common stock",
        "documentation": "Remained available for issuance of cmmon stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "terseLabel": "Repayment of debt",
        "negatedLabel": "Repayment of loan",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r148",
      "r157",
      "r158",
      "r285",
      "r327",
      "r566",
      "r575",
      "r621",
      "r774",
      "r775",
      "r776",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r1092",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense and Accrued Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1084"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r897",
      "r907",
      "r940"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r898",
      "r908",
      "r941"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r894",
      "r905",
      "r915",
      "r948"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesCompletionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesCompletionDate",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities, Completion Date",
        "terseLabel": "Effective date of workforce reduction",
        "documentation": "Date the exit and disposal activities were completed or are expected to be completed, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r261"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesInitiationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesInitiationDate",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities, Initiation Date",
        "terseLabel": "Restructuring activities, plan adopted date",
        "documentation": "Date the restructuring activities were initiated or are expected to be initiated, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031"
     ]
    },
    "tpst_RestructuringAndRelatedCostNumberOfFullTimeEmployees": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "RestructuringAndRelatedCostNumberOfFullTimeEmployees",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring And Related Cost Number Of Full Time Employees",
        "documentation": "Restructuring and related cost number of full time employees.",
        "terseLabel": "Number of full time employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of employees eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r75",
      "r625",
      "r646",
      "r651",
      "r663",
      "r694",
      "r843"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deficit Accumulated",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r106",
      "r107",
      "r160",
      "r161",
      "r162",
      "r165",
      "r173",
      "r175",
      "r177",
      "r236",
      "r240",
      "r250",
      "r312",
      "r401",
      "r445",
      "r446",
      "r459",
      "r460",
      "r461",
      "r464",
      "r471",
      "r472",
      "r488",
      "r490",
      "r491",
      "r493",
      "r507",
      "r552",
      "r554",
      "r642",
      "r644",
      "r667",
      "r1156"
     ]
    },
    "us-gaap_RightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rights Plan",
        "label": "Rights [Member]",
        "documentation": "A security giving shareholders entitlement to acquire new shares issued by the entity at an established price in proportion to the number of shares already owned. Generally, rights expire within in a short time after issuance."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_SaleOfStockExercisePriceOfWarrantsOrRights": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "SaleOfStockExercisePriceOfWarrantsOrRights",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, exercise price of warrants or rights.",
        "label": "Sale Of Stock Exercise Price Of Warrants Or Rights",
        "terseLabel": "Pre-funded warrant price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]",
        "verboseLabel": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issued in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock price (in dollars per share)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_SaleOfStockWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "SaleOfStockWarrantsIssued",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock warrants issued.",
        "label": "Sale Of Stock Warrants Issued",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Basis in Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r823",
      "r1079"
     ]
    },
    "tpst_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of estimated useful lives of property, plant and equipment [Policy Text Block]",
        "documentation": "Schedule of estimated useful lives of property, plant and equipment",
        "terseLabel": "Schedule of Estimated Useful Lives of Property, Plant and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income (Loss) Before Provision for Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1007"
     ]
    },
    "tpst_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Prepaid Expenses And Other Current Asset [Table Text Block]",
        "documentation": "Schedule Of Prepaid Expenses And Other Current Asset",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureBalanceSheetItemsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r559"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Information About Stock Options Outstanding",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r398"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Options",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r77"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Grant Date Fair Value",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r73",
      "r74",
      "r75",
      "r122",
      "r123",
      "r124",
      "r195",
      "r325",
      "r326",
      "r327",
      "r329",
      "r332",
      "r337",
      "r339",
      "r485",
      "r659",
      "r660",
      "r661",
      "r662",
      "r811",
      "r981",
      "r1001",
      "r1003"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r822"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement Geographical Axis [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r229",
      "r230",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r614",
      "r615",
      "r616",
      "r617",
      "r680",
      "r681",
      "r682",
      "r737",
      "r739",
      "r742",
      "r744",
      "r752",
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r771",
      "r785",
      "r812",
      "r813",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r853",
      "r858",
      "r1123",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReportingNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r794",
      "r802"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r791",
      "r799"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r193",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r210",
      "r211",
      "r212",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r231",
      "r789",
      "r792",
      "r793",
      "r795",
      "r797",
      "r800",
      "r801"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r212",
      "r223"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r226",
      "r229",
      "r790",
      "r791",
      "r798"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "tpst_SeriesAJuniorParticipatingPreferredPurchaseRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "SeriesAJuniorParticipatingPreferredPurchaseRightsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series A Junior Participating Preferred Purchase Rights",
        "terseLabel": "Series A Junior Participating Preferred Stock",
        "label": "Series A Junior Participating Preferred Purchase Rights [Member]",
        "documentation": "Series a junior participating preferred purchase rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Participating Preferred Stock",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r985",
      "r1041",
      "r1044"
     ]
    },
    "tpst_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Warrants",
        "label": "Series A Warrants [Member]",
        "documentation": "Series a warrants."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B warrants [Member]",
        "documentation": "Series b warrants.",
        "terseLabel": "Series B warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "One-time cash severance payments, benefits and other related costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, award vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, share fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingDate",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, vesting date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options , Vesting Date",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options , vesting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Assumed dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r398"
     ]
    },
    "tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Available for Grant Per Year",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Available For Grant Per Year",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, maximum number of shares available for grant per year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of additional shares issuable in period",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod",
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod",
        "verboseLabel": "Assumed in reverse recapitalization (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "verboseLabel": "Cancelled and forfeited (in shares)",
        "negatedLabel": "Cancelled and forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end (in shares)",
        "periodStartLabel": "Outstanding at beginning (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Total",
        "terseLabel": "Share based compensation, modified stock options",
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning (in dollars per share)",
        "verboseLabel": "Outstanding (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, percentage of outstanding stock maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "tpst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Period of Automatic Increase to Outstanding Stock Maximum",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Period of Automatic Increase to Outstanding Stock Maximum",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, period of automatic increase to outstanding stock maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, shares issued in period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cancelled and forfeited (in dollars per share)",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "tpst_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice",
        "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice",
        "documentation": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice",
        "verboseLabel": "Assumed in reverse recapitalization (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r370",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Employee",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number",
        "terseLabel": "Accelarated vesting of stock options",
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationGrantDateFairValueOfOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfInformationAboutStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, fair value of stock options vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, purchase price of common stock, percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r1042",
      "r1047"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147"
     ]
    },
    "tpst_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "SignificantRisksAndUncertaintiesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Significant Risks And Uncertainties, Policy [Policy Text Block]",
        "documentation": "Significant Risks And Uncertainties, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r122",
      "r123",
      "r124",
      "r148",
      "r152",
      "r182",
      "r183",
      "r185",
      "r187",
      "r195",
      "r196",
      "r235",
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r314",
      "r315",
      "r317",
      "r318",
      "r320",
      "r322",
      "r325",
      "r326",
      "r329",
      "r332",
      "r339",
      "r539",
      "r659",
      "r660",
      "r661",
      "r662",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r693",
      "r713",
      "r731",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r981",
      "r1003",
      "r1005",
      "r1014"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r54",
      "r55",
      "r99",
      "r106",
      "r107",
      "r131",
      "r132",
      "r133",
      "r160",
      "r161",
      "r162",
      "r165",
      "r173",
      "r175",
      "r177",
      "r194",
      "r236",
      "r240",
      "r250",
      "r312",
      "r341",
      "r401",
      "r445",
      "r446",
      "r459",
      "r460",
      "r461",
      "r464",
      "r471",
      "r472",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r507",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r552",
      "r554",
      "r565",
      "r633",
      "r642",
      "r643",
      "r644",
      "r667",
      "r731"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsUnderOperatingLeasesWithNoncancelableTermsDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement Geographical Axis [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r229",
      "r230",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r614",
      "r615",
      "r616",
      "r617",
      "r680",
      "r681",
      "r682",
      "r737",
      "r739",
      "r742",
      "r744",
      "r752",
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r771",
      "r785",
      "r812",
      "r813",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r853",
      "r858",
      "r1123",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r194",
      "r314",
      "r315",
      "r317",
      "r320",
      "r554",
      "r577",
      "r657",
      "r668",
      "r679",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r693",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r714",
      "r715",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r731",
      "r781",
      "r783",
      "r859",
      "r1154"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r194",
      "r234",
      "r314",
      "r315",
      "r317",
      "r320",
      "r554",
      "r577",
      "r657",
      "r668",
      "r679",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r693",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r714",
      "r715",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r731",
      "r781",
      "r783",
      "r859",
      "r1154"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r900",
      "r910",
      "r943"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "tpst_StockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "StockIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs.",
        "label": "Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares purchase from preferred stock",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r27",
      "r51",
      "r54",
      "r75",
      "r298"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Purchase of shares of common stock",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r75"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock for cash (in shares)",
        "terseLabel": "Issuance of common stock for cash (net of issuance cost) (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r75",
      "r659",
      "r731",
      "r746"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised of stock options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercised (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r75",
      "r376"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate sales price of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for cash (net of issuance cost)",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r51",
      "r75",
      "r667",
      "r731",
      "r746",
      "r865"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Stockholders' Equity Attributable to Parent, Total",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r54",
      "r55",
      "r67",
      "r695",
      "r711",
      "r732",
      "r733",
      "r843",
      "r866",
      "r1001",
      "r1005",
      "r1006",
      "r1023",
      "r1105",
      "r1156"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodStartLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance",
        "periodEndLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r99",
      "r100",
      "r106",
      "r107",
      "r132",
      "r160",
      "r161",
      "r162",
      "r165",
      "r173",
      "r175",
      "r236",
      "r240",
      "r250",
      "r312",
      "r341",
      "r401",
      "r445",
      "r446",
      "r459",
      "r460",
      "r461",
      "r464",
      "r471",
      "r472",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r507",
      "r543",
      "r544",
      "r548",
      "r553",
      "r565",
      "r643",
      "r644",
      "r665",
      "r695",
      "r711",
      "r732",
      "r733",
      "r750",
      "r854",
      "r855",
      "r865",
      "r1001",
      "r1005",
      "r1006",
      "r1023",
      "r1105",
      "r1156"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r324",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r341",
      "r485",
      "r498",
      "r734",
      "r735",
      "r751"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r568"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r568"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r568"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r569"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "verboseLabel": "Sale of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Total Change in the Valuation Allowance",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/BalanceSheetItems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Items",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxJurisdictionOfDomicileExtensibleEnumeration",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Jurisdiction of Domicile [Extensible Enumeration]",
        "documentation": "Indicates tax jurisdiction of domicile."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r823"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_ThersholdIndexRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "ThersholdIndexRate",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thershold index rate",
        "label": "ThersholdIndexRate",
        "documentation": "ThersholdIndexRate"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1112"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "tpst_TrancheATermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "TrancheATermLoanMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche A term loan.",
        "label": "Tranche A Term Loan [Member]",
        "terseLabel": "Tranche A Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_TrancheBTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "TrancheBTermLoanMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche B term loan.",
        "label": "Tranche B Term Loan [Member]",
        "terseLabel": "Tranche B Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "tpst_TrancheCTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "TrancheCTermLoanMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureLoanPayableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche C term loan.",
        "label": "Tranche C Term Loan [Member]",
        "terseLabel": "Tranche C Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "tpst_TwoThousandTwentyThreeInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "TwoThousandTwentyThreeInducementPlanMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureStockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Inducement Plan",
        "label": "Two Thousand Twenty Three Inducement Plan [Member]",
        "documentation": "Two thousand twenty three inducement plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r431",
      "r822"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross increase - tax position in current period",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r822"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r197",
      "r199",
      "r200",
      "r201",
      "r614",
      "r616",
      "r786"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheTotalChangeInTheValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "verboseLabel": "Change related to continuing operations",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r860",
      "r861",
      "r862",
      "r863"
     ]
    },
    "tpst_WarrantsIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tempesttx.com/20251231",
     "localname": "WarrantsIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issuance Cost",
        "documentation": "Warrants issuance cost.",
        "terseLabel": "Common stock warrants issuance cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares used in computing diluted net loss per share",
        "verboseLabel": "Weighted-average shares used in computing diluted net loss per share",
        "terseLabel": "Weighted-average shares of common stock and pre-funded warrants outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r187"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Weighted-average unvested restricted shares and shares subject to repurchase",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "negatedLabel": "Less: Weighted-average unvested restricted shares and shares subject to repurchase",
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tempesttx.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasisInDilutedNetLossPerShareDetails",
      "http://www.tempesttx.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted-average shares used in computing basic net loss per share",
        "terseLabel": "Weighted-average shares used in computing basic net loss per share",
        "verboseLabel": "Weighted-average shares used in computing basic net loss per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r187"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-15"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001193125-26-130490-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-130490-xbrl.zip
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MFV^>7,FA)@'>D*<#<-OZI/W@4L&^7>XS>X/8>W*O&F 755[7)YX-XKBES+?
M4U)I6?K:PN_A1"NX=<(4 1XDH.E=H"S?O>0^P@KAX69)KYF'K6:"H;U-3!>K
MNVM,TSO^V%58N'MQS>5QC7-23WAMK!^I7N ZI;RDD>7W#:=*5%-D(]:\(P$]
MCA;.5R\(C;C+/RHL^^'8H\8RQ_-<3XT9^*_>(#08AFW!Z\#]1WD@=M(O[MW
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MDL"0M$C NQ E-4;J., ._Z (@0'3^ZR4KR5"!+W)RE-/ B2.VDOT49]])$G
M^VW0$]$1)*#%(3(%R9!5W3^XV'IU197[B^F#RJ E?,Y7Z(K<04?XD;?>;B >
M],0O1MY4^(X-_O_%U>R.9!JAAQ#I[B,<!O_P%ZT-?ML'6PD<.9&).<!CUIS8
M=:5@76"!!)C6 ))S"'>%7X42_%\4RMY@:#KV$E7K:*_UBRJMT)Q]_L;GBMW,
MOE;0GUL9-:P-FOE>>BT=F/&8SGW"O8396+YNV)*@!LG=8E'X,Q_[G*6LPV!#
M>Q,8T9JW5>'X#W*<41.'.06LELJ[B,?9_2L'7/$L2\C-]R6H0P:/EV P])&
MB!XPWW#>( 'O]E]!-T6AN GQ=5JH^S[#BGY-E'QZ[6DB\Q4PT)0W3B&F3!#8
M*G7<B<RJ>+AWTWG-^F.[]Z)WJ:D/7R9!2RX1,..0.X5SCW@X-R?VF\P-'&E.
M6'_N64=V]+L91;)?6G4A^YE()OU>,>Q7>5.%E#A"Z/&2 U(35P;EY3GA2IK3
M_F<#U4XB"-:[@K&FAV)A#Z8G+@[I],$??"XN4^:Z=/U23@9^+O:K0M(WW L2
M<$ZIE@18W &]4Z#&3/VB44A1M"E??X:*U(,%ETC_A-=/F4N_N 7^#7Y#1"<1
M7Q-428 E-6)GIW2-#8+%BO_\2B0-9X)IV(=^4M&8E>\(8Z!W>5OD[/3-WV[8
M0<SJ\L']NHU+ L?\72.%DQPW@M4B-U[!6/=M4\9 K(T/LUC@=KUK+YB9]K4.
M,^<9_S3&W51THCJM55-?^_A%&OI@KE!L=QE>E@2D!V)=B'B'GS0:8WY<B!X5
M')C#_*011+6BJ(<D( &&H[F\L WS4@Q0/N4[(]2X^&SJI=QN=^$Y96;;"[2:
MKLAX8'$HNQ+?Z4$"?F.0L8ZFARZ]]S$%?> ,F)3/]:QAMCI( )GEMVI4+4\C
MU^4&()(_G*R$XG8%3\JSO>RA"$+Y="N!63P,L3\+MC=S)DICF[/$4+9F]!$6
MS)1;HCR=)."GFW)U5!WUK'HEXE^*(U8G=0G 8.+:$0G@ATQW$\*2$,18#0N(
MXF*C@;^>8)-XF(6>"N22 VXL$C$_U%L7@7,['@+?) &-EW /[T*#^?I$$W7B
M/C/M-9QGO&(:&S?JN3A8@75,B G3]<LM"KX%,9Y<=8Y<A&#11%4H"$?77,)(
M@*:+8UZ1X2P"'^3'0@*&,6S$UY-#^F8Q1"Y%R$)7(+;C< GL8*R-?OD*^@36
M<98^?M-1/<I@\"GBE,-5YQ'^M,7K?3JC)N< X\6SSR,\IY"JYA./H) :F5Q<
MQY1[E!3WF0%4*5Q;HZ*TI,Q 7Z*M(]"L&+ =?V'Z_;:;59[39"WMBIR0#'?7
M91+@B*3CK[H)V0S"*SNN&UQP=BI@:W1V%O2_%/C!:'^N-82-5G;5$#V=CS_A
M^@[GK=<[.U2C[%I4VC"R-*H4?;XE(]FU;$H+J-<5>4VOZR=IUAJA1..1T0)C
M)#*.FZYX80)%I'1/F@T[7.T*=*5U9QVB+3NZWQ'49A41D^>WH6<$8R(!MM0^
MPN\]5-4V%Y\[U[A/K\NA!"NK2P8CHEY-U;Y]F?SF1UCZI\JVIXH-T;VU1KWU
MVM%7?FP,(+SS/RU5$8-/IYTUW]G96=]69&B"E;J\])&?,I=L@8W4"0[X2'MS
MQ2@2DS,40JP>O+Z^[%:!BCGJ&I<Q67'RD[!SV9R]AVU!V13@=%7Z6+7$-%Z5
M[)54W+M&CV75NCCVW,Q-P3!R!4:K='X54NP>4@,I;'4M\.@Z\B@NKJS3#LM9
MKQO@;*08HJ+A#SF34N;[V>+M;"U52Y7N'C)$"GYKM?FUZH=7A7[<';9V98DR
M2D9JHH^FE,CQ<ZRM%/0# <N61/9:SR3,TT+GA,&C6BDQR?QJ$^.GJRBD-KSN
M@SYJW7%*.(K!832E9_70MRM9L; DZ?Q>-+])7"^86%L_!HUO$9WIQWE:97-=
M$ [H8R8>4$TLA6,A)O7.RD(['4_'C1AS+8%RBO',!,+==G+QV!8-LZ'090RM
MW[F5T9L\POT*5 7:6,@M[)6W,W!U'=CMS_J#!HSG..4O<X5_Y =;F'.5'%U:
M_/V'&@VZ(18TH->%&!#IB$-#8M*(4Y,6N%O<ZA1)O=QJC);G#,Y=L;Y,AX,V
M/4Y:]3 [3Q3'OW6!UW*N;GF].7(@H*DP"-.GBF%-B-*HQF[:T:7RF F'Q$/G
M[.S&/!)@MSSJ]'G,>/0&T<S5K&+FO/C6U)R_',L:;Q#@SZ'9QO>>IQ0;'.I'
M[7/G,^[L%";HDL>M[B9&H^6/NK;YPRO^XTN';6\G)N?-R[J=_77C*)WB%9[R
MK56KI<G+/ZV*?UAE%/TPGLVAYH7Z OE'04&>W?K0+/44J^4;AW6Y2V5>\&T2
MX/^T)U6KO*NP7+<F(50();MZ4BC]^=]O+,,H#5&5C]B$8D0L/6-9WYV!E+#A
M@S0((1;GP!JX)MS;@9Y</DPQZM[W/(2 <<MR5'S JV<@M7JEWXU36^I^E*O$
MM8()LH<G3^!7AZ70(R3@EB[3B/&*A9C_S$CI]O1!^J?/\>>] \DR[SVDO 80
MMEO4Y8INX/*,7&:@BLECWY>R@G-A4[!0C; >F,XPL<./YU5LSDI5T-?2J(O#
M]>>.C;KRE=SE>G^0_,"U[V7S8]AIO^-&/O(X]RL?]\M/.Y(;'4D]2H )C50F
MMKU^+EF9(#K2);=L)K7M<]XX[Y'S>F;)#[=NL::[+U,2PKYADX32:V._*;T@
MI"'FPO$@!D()07<X'(=MHO%#!\FY&Q:*1PI@S\N. S.QQ6W$$M,0JH-82OR
MOO(-BED]1!$$!,>FH1,7O*"$"\%O2,"D2U<4F%QJ,*E70F>O:GA&$1;P2]N0
MH\Z#/KMW5/^O/B[3?#YV@I_1GX$W](80N<N7-'D70#/)[]T\7JR5L;U54$>P
M>!<$$FHDH'K?5Z,Y\I,9SK+GI;##*U7RUQJQHA[1@#\U!0^U(IW1=P4=:*#X
M4TZ:; D/!]$;,A'#\R5;[=@\^O73DCGD>:<)F.K9F4V?C=$^3-X&":#:WL7T
M-5K!CRK7OQ\*@ Z7HOCNYW\_%R%FJ/"O_O[F<$D8^1L:R(,RG1[&<%.*\BY=
M<%#_^SE7I6?KFC'5WT^SQG4$1\\?C&WP$'=GRY%;-J_!"J,"(2B*>E.VXGVT
MB5BBVWHOD8U0*]XN^/;N[(%XOTNJX/[8=D97[-'Z09]CFX+]D;H]\3@N&AJ
MVGEKR&3$?S4DD5%G<:Z]XN0C+"^F'/?%Z0%+[=4[>>N4SVPNM)S<LOUXT(OP
M15]56(;685(]N<O7Q:??II=)+%<-I S=46,IK6TNL=(:M8[4OE]MS2>I(;#+
MT<6X3\G'DEI [$]2"QR8J,T.+C5M_9RT(/S677E>/=KDZQ,! V/VJU=;AL?:
MZMNZJ=0"\W;F^<;N_O#^1VF'HI=(0$EV\&[4:1.[L/35[UJN'F5ZDQUPR$@8
MAW7 E>FS\""C5+*QE.UP5XM2XUMQN=4Z1A5=DCAC^BQA$O#0 K]. GBVW$G
M_0$2,+)/U(0V(H_8I$@ 02#RLYOXP7$+L#NJ01Z2%8K_-EKY&%I_@/J:RHP(
M =LL/LF_5'.-=;9"8P\[']F!7?D7MA^,/8HXG)U3C3*%G'[T2][GHON6H51P
M,0HO!6MD..3>07?I$L\5W\N[%<=U;O)(_(K#(GO7C5N8S=;T'@LW$D#'MME(
M#/85WXXE :\RB&?$IX,)](>P14$2P'AWUPO31ER .NJ"*-I+E&41MMF#H(4N
MN?>2 #DH+A0ZG4YD1WS?R"(^06"9?2W*MZ"5P:79(*Q79 W=1N'LT$&0'?EE
M1 H2KP;YE50)97H &6\<[0,;L[0PL^PHMXX(SJ.3_'7F/"V'1VO[2?D44!O=
M"Q./S)CO_,A+?G-*QBO:"/TK#W5"NA];5;P+I_W-@DOZ-0T@J*^[.*N2Y_YT
M[ "Z=;[_PV ,S/,;JBE5"U4TVM=\(><KG.?M'HUXL1K#'CI5(;J]0:+.]N*[
M(!7F!\^NI-RKNX1[,>-[3/=T2*F\4>&:]&<XS:@RD^SS9:*/7FY*_#.)64]^
MIA/4DB_,R0CI2JR)ADK2O30Y7YR4KNU0V5SX*<O'>FQ93"/OU(9")++>_*3D
M+6(S83(--O -Q8DXC07+P:,T05SI3+7CJZ*,%/OBK]G:;MRO69??OO?VF#.[
M*=,N4S*E'B#W!5@HQ8/5T_#S=P553Y<9V36\VJE^JY?7'"D2U])9+6D+6W8/
M5.3L3VAL'WLN6Q2!MD,$%MTKCY *NO@DZV4,0\Z!;!8)" K!F5<F$T_#!5T!
M&I\#WJ=4<WDE)83&O@XB@.)&>.)(0+UL!S+<3V# Q<U4F'JT?65F<$BW+UV;
M7*'8@<<G>E+WX_8Y=;[7@4O78>N&8*_#*.:&I/&@WX/?Q-U;\7HY[+#57LPW
MUL%\^J 8*7?C_;8EM_KC%Y,H1*,:_I(@=#-YV7B7L B2Z2!&.:>=\O3Q]IE7
MTVY\? +=.9G((6\2!A,<G:CSR[@E[!4&YB[_^R-X#^3-/I%8P](7*'Y-XX=6
M6,X<8[&4<1%E;<HQIX! *H++=TX8@Y+X2IW"H)N;-O4#4[JKZPF]QR?+V2YK
M\;08SCWOX#6O5!@L)J37L270^L S$\C)(O$OEO<OL.V]PIFSD_DX9N9P =4M
M4&P[%^>M?FX,ZN!83.\NVS315A':%''=PTIV!WV:V['IL+DPO1X._R#2JE/Y
M!GFY[!T'X[OHFK<2LU_Y8^BLLIM) +-#K.@<PJX/7GCW9GG=MM4+>(%8VHR1
M<T3OI[?/G,,XPB.JXU)HHR>B1@6GGR3PM51IBF@SR82GS>%3[1'3H( @/& I
MB^^&H;N)<O?B$O$5"'<\F0P;"1"'0G#GNT\Y),5WA^$%N2.(N9E&F(GQL?&1
M;ELF5J-WGBS!;SDOT;8?5Z[GON19M+3E*]R%^#,2_7Y&XF]Q,A]_II,_MU8!
M><!Y,6Z L L&G)KGT"_Y(>J76-486$7P';VU&$1NB]?LF AWH7\)]#]V&&S"
M,=KX.1(P(W18ZS*'<&7X[V2)OQR=N?U&O(UZ1;SRO4X(Y^_A<S8G.T2@?/-A
M3<R'5.889GN>-O5,^,J8*?#D6=+.)>8\U=,G;HGR'WYX8K5XXG92F,[P 7TH
MF,6G33W0Q$!%,!53?D9@I1 -95@$X:37!I$&;"1G'/=0+MH'0Y-1'8H1NO.(
MQX&V;N<CQMDNO1;P5XL_P=%X@0+RS? >F@5_/;%X4F23YLVNS. =79$8<2[+
M#ZOAKZFX99>_YL$V"VM@)$ EK1ITY!$T+@GZZZ+2'2;L-U5O9<:6[R?AD^3M
M#)HM8^_-HCVR#SXX-6+1S7O+)UMSA(RL0MD;+\!SV5^KUR"GF2KVQUV'PCL1
M,P:U,_#S)1,J\P(E2AH=)7.>0G?$7/$7F[SG8F-ODX!?];$C 8'P&1)PR+R+
MP;."?6G3D,*EBI.N=R.*T#4DX-M2FCSW'7JF&]U'T; XYSH-.;6GB'\G_;*W
M%ZRK;L?3HB5["UVQNS&R2-1L;8$=;H$HYEI"K1]L%[4KO0"AJ)'+]W"=0K><
MSK<W'#6*:1'0+1M3D/^BY<Y803O+)ULTJ<MNIZ[>4FSM"=V:0+2@%5I*%=S<
MN?6'B+&GUS9S6T]H:>M B'&=#L(0XFDZ&J+_'FR?@&B)PMV4$C^D&4%@=DG
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MHQS%?KX0B#J@.O>#N$^T9?@M1C)^MX%Y,[.W\3,8CA;1)L?FOH_>ED7\)?E
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MR0(<)RF\GZ-T*8K%;R:-WNH\RX?);9>LO=0W#E>R)6P^0-(!$[QAV_UKV0O
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M[_N$^R1DLJ=_U/5?'J/7<3#VDPGSDE!Z!G70A>YD$;P^>BO?P%_\X4%7+?[
M%%M24M3W*'D7SKE_U<^#NZ^]M2MF V]%DPD7(@3;R[9&B*DPY S;[_#)]M5
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M$"KF)JEIQ'E'>NDD.J$)FQGL.:::M,4BFM-^H/<A3*3@6-X?(9JX+M*K&GW
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M[5B8OR;AM,X+(_M^:?[@K$HCS$ODMP-C&?'4!W1$#!FD2P$U 34^B0@!+\
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M^AM,I:>R#FEJB#?)8AN\4570RB?>'DGSXX5]!G&/ X$;5Z* #FC-7,@GM/\
ME S3:$"M9O["%RB2+KQ>(R#KX'D"HBM^%[,)5B,/'G*R[$INJ*$HH"#\8:S,
MG4/P 25?0!)<>!'D5^+R%- QP4.$-$=[A689LG/"E )2,SZD\0&7XB<VMP\Z
M2$A 4V-K#J.-6$HF2/1Q%%!H.IF[]3#:2.<PVJ@-3$C>>W'^F?O__MN!8>#/
M5[KV-NIVR?</T%&'WZ &NM>_&"LYS'Z;4(PKGQ+:7@MU?# LGN?"<_O[MPNC
M/-A0*[5)7D:S9?.IEHH\".G\L# U_P;3KWB8^7\/[7 _OYW@2I#(%[G>HVMJ
M20&)P0+F!^X7>LP'92GJ&*7NK'U/)+,- #CF>D'HX5>_?\59F)O-']!6"9/I
M,PXC)^9$"ERR =P2A_^32X8@N:&$^..AX3\?<MB"'B/,=;40X;$W@KINEYV3
M%!.Z9T6MJD@64C5LI?(]?15_\Z&;Y>)P9%UVYBB=KM'/,SQY--JG4]YD'EL_
MM[7$*$!EQ/J9)8O;P @A;6;2'I-8MX;,6$[YU]5EF8ECWG-]+</N;5S<NM='
M7]9\CGGNS1.E2!;\LPBO1O3>F2T7XB0X"9WR6HBNY68GW^C#3'O(X?*MZ/F&
M_QLPW&8]6:&&X+XO8NY(],BLW=YBUJ8_;5DM>.N0ST3B+G.)3Y("YU0IJ@G%
M;NUI8#-Y].[T@<<N!<15</Z_.D.8+!5</.>JNPGN(W7)'?*9>/8$9%T$] :X
MN6L/CZ,^(-?]P8D#Q;N3X? CA\'L&$+_TRVCLBQ22'C77M*WW^_QX^)(0 -1
M_"#$Q/(Z6=92E<4,M7&VA@)*2FDE 7./'3S?^H5_E[C_!\?/7XLR[.O1R ;&
MG0[(NMV"4#XU6UO2Y__B"[U )(K/?U<!4()=D@[;C$'D2W& #5>1FE+,'^BU
MA-TJP_@]=>I@UF&JO*UWY<CC1Y6\.N1KB9CM=6'R,T>='7\**)81-T]N[@13
M0-KI!8]OW5^I?'W'ZX"SE$8GK7-"_>^,V.B_?PUMEJ3@"^Y\BXZ"#5X]%*N6
MZCQKB?879VVB3D"O7:^JO)?'D5T/FJ?N)G+-UYU=D+<ZC^L8'CJOX\7:GS^C
MK[7/IL[0Y+8R]B+BY5GF+X*/*K3A=-.FLF,0X^(J)^'51)=/$BBV]R]-;^WD
MAEXG%2'2&R^K&DM&006\#2+Z1_-L+BK4LG99:+/=-=8TUN2DSSJ+M-9#L_(=
M([SE2RG+GF+3.E]2'O?8"U&7,%GBZ'[2^>B[*+F'CY')GOL5)S)J<,)-;#UH
M+E47 ]0=?AOS&TYWSZ^:3'QC>BFBZ)9DX]1JI_CX]+#?2417$[0D<:-XB+-?
MJC+>[8D\S\,=?C-(FLAW/I/N&7KIYVT*^H2TM-+I%_7@TQY0[F:?'.V3/=:8
MLNK]RS^X3.K#9BU4')JBX?F-''I/+KM6M$[S!XV?Q:^]1]M;V91&EN^D5$5C
MJD-GF"Z718I1W3=%_,"\V6NCQ=._J'JER:[=2?,COB1T95G&>27\O#1ZW/">
M%C&JOY,$Q8F!F<F\WL@&>?E8^QWB6-R0MA<MM?<+ZSE:;^&HH)JZ02P&>6ZP
M5-Q9ZWV@I<;+Q++D1]D[/H\$%2_%@>2.G(.L1F?X<;DMPI@E25>)=Y4*,H9?
MU9:@G'[$VI\K?H/X\#A*Z-ZGHM,25V.@0J&"B%.?WZ4+B=PU-B,B8(/F.I^&
M2SYL*^]W!?JJ94U30'3>Z;=C9/E7&&AU:565UGH5[R=9M,#GQE(N;Q! B#-S
MZ81@7,)\<]K9GFTT V'P+HZM]N.P]D-T9C,]3M=AA49;W.:$=!"_J+5 YGW,
M\P#!DX()?4U>^K"3Z4%C:)>7H4P<$C=>3=_63]':^>GRAI345C\ZXG(<?O7E
ML$KY[JZGUEMG,9212<$,[#)*7(*%5+%G+M1VEK7KK*&P8-].KBXX8VOYAYFL
M,P2]O<04\(W(3Q+AA6#]ZZK]>..W&ZVL'*^(N4&%ZBM,9Z,_-4B8NI;<$R$:
M7P/:]4H-1'AN_VG<JOFC_?! H</C:;P>2O#VTLW++#[R G."]^B/:BH(G,CM
MQ.J:6W23;.U9-(]784H2Z,PK3^HD!"DPM!>O<FJ;R5TG-,([(_CLEL9/]+N4
MQGT2#I1Y59(PHE_.]6"T04YFV9G)7IO[RBTH2E20H59;YE*<6W5V_LABM399
M3J<LT#4R[_WL'@4$DPX;!-MX>ZQ2-U59O<<?KKNQU;H[RM7F0H^C4SV<'#E-
MG*Q U_/4SZ' "'YYJH&6\GUE"P<B8_":1,#%\2%'(HO7Y2'OA Z]PM*[?6MG
M!/Q<SET-[V@H&.0X&Q/5W^V HI6E^RJ<8))72K>O*JW[N3CFJX'7K#9/8IKU
MF>A'&S%7AK":WA=R[5'TI1W:6ZN:ZWHEU3IT PFJ)RV$$W=LY25G S4[>VH;
M6*EGU: <>XXN>;JY^QI9K_W,U\H21K*NJ[YV<88V[Y)1[J_QU"O/L<K+_F#-
M'A6;3]Y6WZ>OEN/6,K.&96O0^28WFKOE\)46L\6"_NI<NQW<!Q>^MRC[.>X+
ME19'BG]AU[IQ\]UY41Z<][&TCS799"['1.:)%A7EC,6/9%[%>U7%%7>2M0.G
M3#DN0-YH&5L\;D@0_M"/.0.7J*VN^+%M4N(D?[NVNC\K?FO';BK*'%S4X?*8
M1K1<Y.&5:+_JM(J\')T1,]E+5N-I,-SPSHH%^X7"X#G?S.;M_(S"5E>/XS6Q
MJ849O3G2* VJ&50FM+<FMQG,6.I7VG?>4J*O29?_E4UW1F55ZFD-MQ8QW<W
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MFX 4J0+2$GI-: ;2;OR<<]NYYS[G^_L]SYUD_MDSLV>M66N]ZUU[;](OTA+
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M@U7LG%VAZ5WLLJH(\U;[AB\2[-IY374G[<-EAU2)0@"4+6?1G3X8,'>22RC
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M]^;).ZV6E"W>L+!4JFQQS1EE-8:SC!.#_\A[^OYOO.>TA(P+=KTD +VFA?+
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M>-F^73).Z7J3@+1I Q* ^D!QN)K:#HD1ND1&+X, @_8S2&2-*X1K9M'(_TN
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M=FZC$8K(+2OPS;%9?3QF34_W:RGUF;6 X2>.!Z^WR<$V JK>)PB.$.T>2Y.
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MP?7N+#)GF--)! L*)_XCSJ[?.*W/Q!U\M>S-L?SEW)AW87^/\/F+W?8RCPZ
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M]/5(OQ7B_583\=7G3:N.C,R@7C#G[JXM#[+\E,_7)@$Z*4&,L&JC[\/;F+#
MIK<L=N5OJC$47'.):OM.D+8[M4KE6/,J96I\"*E:-RC8':H9&37AZ&6-E/><
M5K@/Q[^<5D2[P?%7X<Q!L?(]ONF=]'*J1\3CZG 2("C?%\)A)]W9 J#V.G57
MC* W:B(0L%$BF1&+_&AS' '-;MJ*8 HCCAGKEPZ.+=VO_8BOYK9+,45H/8;T
M+,8J\-ND.T04VN;/9A)^.-VYSM(]K"\*?8@A!\8\$D-L[N]B[+_1?K26@[:K
MPB[J7#.0:8Q[9VRR4#X.FTR_&=93O#D(M8;Y-^!Q&BH]^0=$[:$A>\FCUC;9
MHP0.Z @[)58'=O6;TKF<VA=S/<0-XD-UJ,W(AA/^,AE'M?_WR,;;-S1+%U.+
MRD14O-(G*.._#+_N37921G)M?SH2:B;Z0GJVRI=#36WL#9D3-<$Y%Z$U=EV;
M57>K18@!V;L;ZE>.*(UC+N=3_).<GE!D)?_ WGBVW0TZ)LY'U340D\=&(HU#
M@Z?EE[Z&YD%ZE=H\>]5;P*5*^&M9A88DH(>X&S*(-(OWP\/&S<AA5TB4_N.Z
M!N9$8!'DDG^:? G->AXV_W(1"4LZ:9;%NV0ABA99XUR#8 1_R#K$Z.9>1-27
MI#.+'ZU"ZU;C)&"[$:9RYJFQ<?8 :T3<CR$!'/@T;"%V] CV<1T$","ZK#T)
M@R419\^T;)U1\GW1-:"S#=<Q* 5S*W5]W$N1"?=4T,GH= 9VD*CCID5LY-_%
M^-:%YQ 53_E>EF,*B9S"E!_SSF+.@@U5?;9M24 39!5R8PY6!M^2G&Z5#=%J
MQ3Y$N]['Z*0ZTN3 [)F$!8)3) 5D&[-_ZRJ=EG2BWZ-Z8'-M.,^Y'M#!_OJ9
M4'J9LI+<T@Q?.0*OB&GKU0!A/B?GX.^,^TA:AUH;9]RK;1EU%_UP6_C>GIC%
M"I,0'4K>Q 2[C@%;C+F%V!<$G!O M=?)7D[X>3T#9V7@-7=G*VT&CIR;YB9<
M#.$[@J3)C(/OWKHLOTRD)>2N8,!]Y3QXM0FYY/'2ZC3S8*D[;?@0YNSO7U6Y
MOW]I8P$[_\+;%^"-IZ2/-HY:!#HM6%(.H\3*D/3URH)U0M1 ,+)V!V=6\KW-
MT21><9$OY))_X-=-QF42P&9IDR8M]ZVGN0 LY_9^F(]._J<+6 #/7A P($T_
M'Y RP,H^T'&^(UJZ_H K42%2I$(YFV5%42Y24V6:D40FDQTWL0,0NAZDFSK>
M^'7T^!V$QM)-"W5%.ZQW^B$H$L%%O!%B7!-N53G6+."6;>1_[6J5S<A)#K^R
M63OO? \0RKY6IOEUD5,C!%P4!SIFW2:,;PX%LD:!G?(;L-)("-^VWY7/+E#!
M]*UAG+'.=Q[VA@?:(Q*!<_!2_UGS\N)ML@3+$[ZQ=[Y-[!TM5INXTE\3=C#<
MW7$N[1Y:9.+P$51[IW]#6J+<).BG=]2YJF99,K0*@N.@JTI'J"W7VX:!L5.Y
MUOAN;S KMF:RX3YT\;K?[O%^PO&H[:>9$>(F4>>;&E7WG$OV.\]0Z?LFL)>2
MT$.B6B$)\"&#A#4X.NCCX%)JSFG-7[ Z-CD[2R6C<BDD G1@&J($WCR5E.R!
M',AN(8Z/I<D@AF PUA#&DE>.;UD<J4-.>4;PT@?@V+^/WJ; QQBHXT8\TF-\
MCV?J/ B[6<:Y)+F/-<LC 96BD/XA_['XJ4KXB<"I158()1CCNF.!JQRF)>!=
MB'XXZ4G0[&.>'(QTMQ8)X-YK!F\>F*S?P_+5!8S?(0'E120@4Q_#B! BG]7Q
M'XG#HF;:D7@YR!D.3A:V?,/%9<9W\0"V6XCQ&2-.^),+6@3.\\S O:L_+N@R
M\:%2(GN6ZU"K#-Z@$>NQG*E</2@Z43-O>R"E:%3S,:9W'.PODEM$E8Y:QECT
ML@(DX 7HO+53UL5QB[L-K>$/QW*=S@\[C5;V7)51_9#4Q4 ,"$;,5F!-]S6>
M9-]EM3NU&$C7[8'':9Q'LT:UB@2D[W?-[D=X-$>UCN]<6V",??3Y2:[VLVZ%
M,9U;NX^)+9BNQ[78[65IFE]8=Z=FY2_7/H=Z;5/8>_+Z/M+QTF&]YLP5[)BF
MZN7<OM9J54_(:?8^F7?LE='*TT8?ZD^#OZV,%S"?G'I>C/_,^ND<+SHK>0^J
MCBTF1T"DD&"4^719?N3"\I2J4T[TY_3E7\^%A0_Z+HS2.AHM:-2L!HWLRBY)
M,78$0:+WCE7?5$RL.)6Z30V8^8J4+YP3;"+:XCUM:+LA"?PG32@P@_,B:[/U
M\A"/]N11M"]D][&[X.9EBUGV6_8=QUP41XG)^KW!R&0;1>/D)17:[A'^ .L^
M*,THWOJ+4^O%L683YFY/5WXU#9O;FQKVM_JIN G:OJV46'AQP#JR/.YH\$XX
MD=V#5<V/\26/M/R:XEW9<<9$C89LEL5>)L[.V>)K7(',[_H J!)XH'2#F0R?
M&3=8-".4\5<+8W\51LK?9*1<J558!T>2T\34J_JQ4E;E&Y^#SH(/3\<W:)*Y
M3/7._5-LTUB !AK::%)PQJV\6=(9?!*%0GFGGH^OS=,>E;EVS.#,6U]J*H[$
MA8^8W'?N6WY^K&+Q[[!/]F4_$D!L JU#C,$86!-$!IM!U)J-(OB"A]LH,(Z$
M:6:BQ"G(M0O<6[QY%H_^@X^L)@%G>XCAUDSX'I'[D#6J;46>'&#3G>0\$'0]
M?--T61%7*XDW.+!#QKO>"@3_.(2\P@>8/!",+/4!'UPJ5\"DXN/(&_C(;X(I
MAM6DOL#/8N=A&UVV'BC0*9\\Z]F6:U7/R!\5$ J6E,I  OAARS>EVJ9UC[DW
M(.2M(VM8>8C#0I?&?%H4W&P/D M,C^9@7S_>>6MID30\&CR=-4<"_F:'S5V9
M6^.[)H2;D%5;T!N8D"21S,#F$A8NDX!4"'@4V]2^2.>&UT4-\6)5E]??AE ^
M]QG,!-M.^*X).$;JU7[U+/87"S],2I!L0M?%$R]C)3L:';OFI*-22Y%S@K4W
M7,OL5$P22U^_',I<],8JK,L?LQEU46%BU%Z/?HHAPAO0CCU98*PUYIQ4<*^0
MV.B18^.T3O.W#F&V,.08DCHFD&?BRJ#=;*HM5A!9W+8LAA;Z6#@_XP2]-%F-
M"\ZTI6%<G>DZ]U'0I/@E=6C!"@FHUAU[32,;#C=DN$X[!&:!,F.CEF!]W8T5
M$\?E/ &.W6>PY&*(R[NO<$=/&JH[2ZP?RD$1GD+*:)-X.1.X2D+.4AN+JY_%
M64HQ=??8X,K\1NK/EZ+I1JB0F]2T%,$Q./F<^0X)KMQK3 YI(+$0=?1T=,@E
MI#TZOJ_+M,CV<XOOET$D+C'>XR10D5W4G84$*&8VZ>U:DX JR,[/[ !7K7&\
M02G6#]G7:[KXV$9VT%N".M^M\(E;O0AM0>BU9R@^PF7V1-H?T&J*@_)NUG -
MD4FBAOC[PE^<Z/WNU$37L\GO3\ZK9GC")07QG=SPL=9DS+6G:HK%7U[1SM@
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MEEE\O*-R!]X(L:!_WJ+4\(:T'A74)]@M$\T7'U+[(>H,?C$=[ACY/AJ1'P@
MPFF^:M& W5-S:-N^$7VG6#)=5IOH=N3SF.J+TB=E$OJ*U-8*.X[S^/;-O!+,
MQY=3(W;D>Z>DCE0O^RHHX^[>IJ3<4M>H&0^43/@49'8REO4AH_&WOEC%<, 6
MM0?MMFKDCI5>X$KH^&RS[HG(#P2C=+1R;X'B8;DWII\$Q*A:D>FO/NR(TU8
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M^AG#-.T=_@:#17T/-[#)67#S:.L/,YZLO4\(8 N/8V$P?..MWQER;H^"J6>
MEW]]>>@,@"/I-E9? 6((\7],]$B?/&KCH,)L4NXF@NP<'1"$CK\<?NT,@"^
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MR)<L]%^.?9H1<E%0EIP+F,<$C'V("I-6S<Z_*L.# 9/L#!+>):^>(" 7)D<
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M;!:YWP.G><$R630PY6I/=?]H&["&WR,X_=9CUBTR7]YI\\^8*5PO?@XC'!G
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M+J*$X#!01U4DO\@;AW^L'J#9AHXRA[1L,7-L&=C7)*\_<;9_8@_^[.8CL9J
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MJ5 2%T1,E"SO7GORYQQW7E+TQE?=*H^W_AX5'3%?M#YH'Z$N2WU*<1:^JMV
MT&$&U"ZVB-E8=(Z'? ?MO:W:G$8\L._/,QT)(Z^."U]/K["_'4KI=S_!<)I;
M5S7/+O0;!_F_+.(I>7VC^H)V'=KNA.=#4^I :%19\$)D.FYG.3CFDR4E6]-F
M5[8UIQHFKM60EG8[7YWF6LBW6JV]'AX?P;Z;9'V2X[R[ZOX7RF2M'F>T7G=!
M1"\^HL=)J$_:U9%@^JCKY?J7J[TVRXV9R5+J$>A^Q-'OQTCWA>:0D9"C.E<_
M<=9?4P1[WJ:[2[;W=-AWF/R(OZO'*?>)]3A_WA5@ZL,%/>X/>_*_'YB>767P
MVW\W^C^8]H6\5==$/LJP0GM09UWN&3PGQK /2 ",QWH21ES@%8G)*2.>7?43
M:?A R',@]%;'D8:@I2D+G]]/J+*<_BN"^D+[4_A!@U[@7U[JTY2L0-.CNZG'
M':&:PHPV/8Z?W#9EQ#('N;G(%M0&?/5\-+%H*-$]3KI_;,"G;FPC_=BQM!7#
M+D5Q24QQZ?9%XA5VH\;XT0#UE-:1_6ID&;Q,2<X3U>//LY<R.9IKMV2$"RF4
M[)HI51-\V_V?F:PS0P?!-PV/G^7'^LWDLKQ/9/ZCOG ]M/[OU3^==WK^KU'*
MZ]KBM/5?3RM,$#4:3]Z^Q^[U<9T,?<1* OVRU/M5?HZ^6^\B%B5OO[#B*M]_
MC(\HR+DVVS_GR DGE]>>:900&>/6_KBXM9GK/V;./CSOFX[:+"!\]H';4?0]
M ;E;^M^^Y%'O_>LI]X\?#$D^MOW0VC^E:QX^>.FQ_H4ISOG:%MQ1:(N3_[_>
MQUUF7"MI"52><TS%,&;F^D/4+"]RO1YW'$Z7I/ SG]U+F/OJ@ZIE\LUXT['6
MOKPW#4+^L[KBZG<_[TAB^"X,"2L._8<JJT--S;5V;$ECS/PGNFIR/"]+-/>D
MT%FL,N/-%8\6O=2&0EZBC*-=*LBZ*?Y)SU1Z^777;,^C31M^:6@H/6G%CHPW
MK@=:[J:C6=3%>IQ\V$"/N^'Y[P>\OHCT.#RLQUW<"'1O8^, A3SZZSEE%R,K
MX3IP=+110C5"#L/^*IUKNWR!<'E\2(D+2+E2O]JE( !R2F<O'AQ/814L&GK5
MWY-!SPP[\N/!S!TKK.?D_"_#Q/^>:0/YK#3='=2,_9)JRMH#M6LNP;E*>0;!
MA&4_NY;M"LDO5Y3(_;ON0[;/R^%8_Z#?Z=4?*LPK)V;;;I=%5/WX7>KS-XL4
MZW^8XXJL64Q^GP1Q=+K7Y"_^ ?_MRTC"?/8ZQ N> 3O%W"6DA7#[+O@"*%$Y
MY1IG"VQ&]\P++.M"=MR+$EP5/QB;.F4N4!M>\U^#WSC_UPW?'C4,+7UM_/._
MKO#$YWW_*Z=-@ZYJ+(-&01AF4M!6E-0EM&7WDOD%+=1TN472\(:AB"<@(WLZ
M<:B:+0]HOJJJ[4MZ9&Y&Z2L#1XK977^<T<H7Y:V3H9N.W^H.O)<9N@5?\:^I
M]3-E 7Q]&U20Y4O&)(-9PJW"=YFL0_=H,<[@A\:*W]^%)=K;/CO,J!RS+[OQ
MU(E>?K=B.')X*/""<,G5QQZ7$3%$0.P(J,E*A1ZWA)FEU.,NBQB4\T(GB',)
M":J"R=(FE]H:#,BSA!R67^5PO&SD9B7E]/V 8_2-Q96#T>%_!:[\K=&RI?7X
MT35_SID9^ ^+&I.LW8@.<9_8J;/H-='LE]QZCEC.,9#,(\*[U&Q[>,(?6E=Q
MIWWSE[,S]FV<8V=E#46TTRZQ?,'S)YG=;[=TB3WSJXS_E%N+%/5D,(AX$;!B
MQ8(,5;OZ.4AY0;42$ICY4RTD+Q#(3J)'] 2#\NQ)YS#>F>;];3]K?MQ#6W'I
MZ<_17H*U2P,W3*;=(9S4X_YE34?E=0!B;:99KGOL18^3Z'%U>/5^</,H)UO@
MET"<YIHC?G#ZG<02YY[/*I5'98?R_<F!<)^(/WY?4/CK6>+AI9U+-T2M?;+<
MFX;)LP%R'64R5F&&OTSE$]LP[K  YU6J@@C&8R4N$!]I..O#R>&[^?GO>])U
M(I;?^%S0U%PHV=W+V[V5OER2>.S4J<T!UB<^S^G_3X3-!SFJ=Q(*AVS.<H!R
M%>_R/(G9W 6D9?$-Z'*0FB?P2M8,XZ417B\#EX;VVQG%GMVZUF/KV@/MUIJ9
M11V,4];!K<Z)4)QZ#@;F4QB83[#_T.-L?/U!?TVF[K'0@N4*URF#TFPGI#%&
M4$CIHZTU-%MT>5<5R_]>8+)-S?6DN7E!VWNKO-Q^K*MSB'P:W5(P]SSIV7]&
M6?X-I!/ 4"KLXJTV&W4T4[X3=PX5:1@0+Q_9_^,MMCV8UB@MMMH-N69[F1S]
M^$/W9[H#M2A0U#N=>IL4&>WRRH3O=O=3I.P/P<#[9MPYX_\8C:(=_W]-H:YA
MS=4]!8YVRJZW [;H8K23ZRC 0Y'M\CG3C$GB%2=;D-_Q>;;B?!*@+CXMD1\>
MB&VJY5_^3M0@\*X9DTQ^_&O9TYYU6^AWE[SP\_@/&_0CJ@.ZB;525R2T98I&
MD]LICN^!!:@U<]XKK(1MI.\@YSK)/2:[<W]?O<ZT+77,_<ZSX@,3H7UGU"0+
M:TN/J.B6HA^EG XJ#+0C%HWH-2L0 ]2\V:FOY3+X_!^+@YI43:+N(1#'&<(K
MG\'-VO5(&,AK8V3FJLQ#6[+:2 M+QD=W.2WO6E%7%-+]?<&MAM-FCQ;S'9:X
M4%V/OWQPVS']N.#Y"P*XG_H&4''5RU3 ( 8 M0<H:A75-Z8S6(?*X0*%YFK5
M'G+NF>: %U_TN$LB"K.D>[-#KGPA_49"_ZWD1BN90Z+8.78RE+W+^-E_AK._
MU&K] ?%AD>(7T1.NU R#))4 T,D7V7/AJ_=W-\R^NYC_/%4%6#!_&KNQJ0[:
M6*08]I8&PPDSL6LS.V.B?<9BSYS-7K'Z&\+1?WVU8M! 4Z#C @FB.4,(!:O1
M!N0[>$CAEB-[#7.5[9?KN59CFN3WWH'EXZ5[GQ:.[NP[$N4K"ZDVNE5JN4%P
MZX^:^]J,?PFV6.T!]E]Z'.8")BEWQV*^T3T"XGD9W+F326]OLLCT49Y51'CB
MR'+;2=LQ9+,RD<J'N=3,KMLA'],(NYHS.TK6GW;>N7WX'?!D"K$Q0$VFM31F
MYCNLYV 654T'$U4S5]0GY/L P_<Q*^T9>64]JG GU6RG&%W1V,4*>A N<]X[
MTQCB$_VG[7YU:F.&\Y7'QMW4_X2#M9[S]W\W^K]E&OL4/*K)[!?,@3JI\#%Z
MI9PJBT]Y.%C=,>&OR;')OLKJK&LW='ZX8?5J4[=%?]H$_"'B)2'C"*#'7>^$
ML_2XV.W^H-9/1-B-TTW IVN">,RS;6AP0:'U6==KR:N^(W-C C;9R <XB+4>
M=]7M>SV.%P9\MH@1;S&RWO__>!Z()8EN$WY[/;<K\,+4%RY4:B#_1![=8K;#
MQ5CT%FB[@@?^U./R<.XVR*0>)SY#5I1S[<A'TSQ>B.9A:GI/!!VO8C?_S7RN
M"LA7UQM"IDP#\<? 4S1EFD7)1]FGG3U)O*4)9P>ZA_)VKOA)%L(AONG1>>XB
M'P$PSVC'.@YAZ*D K=KD]>NXL67(,2A4PL GEFRN[ZF.I#2B/;UT81<]:=VO
MB\N+ :"L.0.MK&AM,'/?_?:#;'A%IG,>J7V#XLKH:N52SI7:.O&!ET^S''+$
M_[P)B*'*3N?;+ORIC6(ZMJK=Y$!_QHZ0X/KW!V]NZI&^_A4-6C?J6^&EJIJX
M]../;0?;_][T/<F-D'O03G/F6';AQ1:)Y4/OM8<VZF9/_GJDV >\\H^/32R^
M(O[^BQFD$^[ZMS3Q\DGU$:N_]=/C/%#/>MQ^ZB\ &$X8.HF'70<0*X[F%UWI
MY/2JSU-.M!(3[@L]SGC@S]6G3T.I*C>@9:4BO*IO=_T3)K"OE]IFEUU5Y<E=
MF+#A(JN*\+84-9?HZD4GR9>H#?)<D8(K!P\PKI!M4&?F<TVQ[K;0FMU/KLN8
M:6-DHZYP3A7MU/C((LK2/<IHNT,0NRPM]0BZ'$ZKH5(GFFQN9 X%0-X2]\2]
M'_,4S;?.DY_YN$$2S6.LTTZR7XAJ&6H/E7QPQ6CY<RAR#]RI!+)\[*1![E8M
M<C,^=XEX-%UU%9/C\]LO('-]_4Z=>PAGM<_.#-T8C)</;CQKT4X'3@%5X;)!
MB@_K^5U W"4'@[@6+/<!UJGR&':7-]F2Y:<:IHAGL",]S'NAH^[3E85,[.Q9
M-TV/C"(9]WA%#L\=:HG849:A2B2M[&4=/E;QOK%?79Y0'5<92*=M,OX<NX,=
MQ^Z4@Z'<-]Z:?-UEWS@M &\>M28YZGX5+BY.&%#5U(UVN'R28,;^6'6\BT0=
M8P_%92C0'J'3-\)HJC^ ?Q-/K\9; 2??0\P4^F[5[*;$O^6#H>C"#5@.SJ#]
M9 >4@,P#$;D3VY)9-.KUB2:?@P1![Q1H*?CI!6$IX\KKR' 9ZSLHK"^I*/)E
M=<B'4\?N^U>WWBWVW_>Q_K<E_*"79FYW\",^;E]F=&5DQ3]4V)4Q60%Q55,O
M.B^/+-4]C(7BQ&2["9(9U,!33ITO:&I,#SWXNB:D>W9J-^0L7%[;*.R2G3W4
MT#OBP#QYZ-HN<?ZN0=VH6 1&RV%77B[P \\&$.\B^M)'109H1XD=S*ED.>=/
MM),,GW<+DE2B[)2TAIM)=ID"*X6:I U]!GF]O5_XQ&S)VIK6^J"*Q(*(^[/T
M_)S*X2$<^[?]U'3N$S*RE*(U0@<(]=[G1<>TA 5HMQXWA[06B<P,1!?1]+CZ
M+'$CG'2?M8\SZ1UQ,QLLKSNL(EM%KN^OFJSA;KL>&KUF(.QISID)L]O3;D5!
MFSF7]#C%KT"#7>M+ KPV"[%3M8_&M?&ND+QA RTQ_B,\VD(UYXN6,(M:1VSA
MTTJ1V;A/?QTO 'PGMB^O7I=S-^KW4MKU2''<O4A:RV15R"OXAS_FZ.*ZJ!U[
M*[!C$XF1SAJZP%PQE9UBA?8X;00_-)TDM'UBDA6'--68:_3YDWG](/BJ( FZ
M-HULI9<R?V)81M$\$DH<NSWIH=*4#W?O1M%F;Q0>>]R[]B[W<ZXF'RN]D"T&
MZO"3%\ )C1(::-LD\ ?=1C>,6;!LF^#4^S%P1:O<EK_GI$SU<<@?I&;@:D4%
M(7477\$3KR?H]\3*VY,U)Y =I\M&[@UM,AXKLX&IVI58G"W4QUPU'0J6ZG%S
MZ[GF[&Z1$6DC#"C;KY#<:%Q3E(PL;@)=<Y'3F <RC/<6KNY_"_J5%_&8MX9"
M^HHD$4D?GI6]+RB(.%[Z:*R_,9CV\[##YM9&Y#D6\+> &$#"M0SL*KM$B92+
M9/LI=!65&:D"I!E@^V20HMI.,:5Q36?;(=^!"ZAVOH&505#R 7[AN_T@IFDI
MRF@W27NX  JI>)0KMPH/O#<6]WU#?K\4!QRYL9_ZTOL%QXD5@5VG%A ?!!0/
M&H5X> SR5G1.SF@MD850W*0QZ' 0/JUZI$VDNVHRX4K\94]R#KG^A+U+427M
MK$\GQ]?HG%+WTY#8._038?+Y=K!Y^.9P?BG]U&H<6A[/^U2*+9[#_DT$[J.^
M2=5,8Z\2V6U-1,1V #4E0,:!.@&Z,@S&QT#]E5"HZFSZ Y9W@P"^JB#,-:?L
MZJ*3OAT/&5E1?!BZV7:/SB#6W__D"?]@]>2OYQ*MN_9'S.'QDQ'+4G3^7<Q)
M$"#,'%^\C0X ]0.MT3'D=*>5, "EJPAYK,-W$'_8S[&BE8.#&6'=+ /54?B"
M*B]U5SWDE5_[4^'O/4GT]:Z7FI^+EW=Z/#6>SML!E*SD3A9I@?=Z'!B@Q^$!
M<<AG"DPL4%_ EJK7<=U%\:=!JHK<.F6_1S$QO.V50]$STM*P"9^LUN$]_#U
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M[C_:0R)7TUBJ$%\HHROJ[:VVC<1/"$FB,G[LS[2#>40X&S/FHP'U6M\P-\;
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M3,<']7RY9?T@@_=XLBKZLL,_4#G'=>%D,<$ B@1::"1EJC\YEB5'65]).-H
M/!,I$4R'Z7(J0:7*7]5@.D-PIL"_%I_J\:)^\->AX. JI&5EN/C.@,J%DL?Z
MP>L$6T4Y2*2(V:5HP&YQI$NX49+O)>RFUAM2.7^FZX2 !U/YUDT"W3QLNVK:
M1 /_A"A;MD>@5*"0<KS'MX S 1K;TWO/UB72LINR3>\;L&<(N[6*\,,N?1A/
MRH3$:O$:+$!$+R,$6[J$DON :4] HKUZW2RY@;Q@ E[$#)#\$:-^;"$9Q-)]
M:M'T( Q7*X.+EH"FNE^O\'++/M&X2/EOPAU#1%U_$^4[:I"906'@0,#*66:O
M^M2#/V,1:#NI['2AVNH]TCE2#*O.9X$.%/&\5I^T&1(TH$00W8G2 )T@I"U4
M5@ %(E0@YFD0=8^@4R6P!612JP.R7W3@JXE9S7:W=0A;.W9_&'HL["7806@@
M=](UUK!MF^ "Y,N&IY#AB_G#F%YQP@F E"CPXQQY="64IW,96$ZJ7[6RB;RR
M;#+B>[#-MVWJA_O^:^N$1'3=&HR!D\+7"66"_]P@GTW],R5SB,HN-BVNIB.V
M058,<OV-Q5B*"IN4V#BQ/YN3W65P'!WO(\E\_:(Z/MQ'YMM5K(MI:F\Q:S:I
M31.T$V8M]\\Z>AZE_A$1XFA_5BQU_9]QP50 @QP9X#(94D@QP975 A$;82E8
MBT U1<56GJP06.;2-<Q6"REGJE'IX,S/3Y&CKHE(@U_)Z261EP;<?&C&F5[Z
M/1ES7<=6LZF7R5)(>@?0._\+L*#3.5O)0D7'/I0B7MD&ET .S NNRKB9WW7\
MEF G,^)4DXG=$^-8S\]P5.BNIZ\>"GL0=;D$;T2]%$$<,B(>J9 *IJKTTI'K
MR2D7%.HR'<YJH(0=:["XIXH#7[,=X*ME%+<C[L'\?3]*Q<;*?XOP%^NZT(#8
MA$\42JD#](X^"D+.3$7D,GGP?MO>E+DK$3^L228I1@^KM)K>GM\\6I)H_*H@
M3^K8H<?UAF\3<'-$JC)*FD1#$PV([TF 6^\HDL> S!%QAB1?]%@NNRIF#5:/
M3*@*?Q1&58(0O/M04%0-Y-?IK=8G73$\L5VD6=+JK1L2F)N\1KW=H6Q&U(>B
M_>85UVO>K8.F158(?7T@0P>!6M.K!Z3)G4;KWHIEKQ:B) IE'%Q)#ZQ DW?[
M\=5#B]!AKP<D=A*KZ?SE3?"X-J4]^D?5<B>GVXN=WWY_?[QTUNWF_E.*?!4N
M-0XA28GDDC;BF5V(S2@-?'>G#[Q:V1%03B4XLZDR^$3&A.2@W.SH;R1E=]7L
M:-!$&:>;T5973\'D:<Q^\&UN:'PIHQ6C[;6H FG2R+*4 \\A)%<YCG)@DBJ!
MK;&0:>*@MWXS]4FF&%=8!(6O_T7Q>)98Z3$QDPW2HK%!$:).OJOQPM"NWO)-
M,3D-Y_H()1W78!O>D&B'UV"!(O5]A&>^6M)F F7P<D!O*GB1@TX0D+B+B3RJ
M<L42.J$6:U+G+95J;O)O/T$3QS4X8.M@4'CJBL!!<1Z[:PQWS^HSM8@,N+-&
M(SA,@5P71V(^ !#S$44!@: ._5E]Y2&855<D4($6@D@<45S(?2)(?PP+LK6Q
MVZDN11-ZKCCW)N$()J%5^.SVYHF6Z\9!V [O;4,[36OG5NZ;QJ[!;/*5@))X
M@31G0;,=M0F8B.7 -^&)[\Q-C@&]\4MIZ*. ,+F$3M:B6_?5ET?;';&O2PV-
MO#Y\_6/[HR.G+_7CJ]N]%4%68@-N(\2BHQ!@=MRO.9<:IMD^;J6:/0A/;,C5
M\KU>/Q3FY3&Z:#=HX-ZWC1819'2RS^W9V2WKA**> (YI2*&D.@>=AJYA,9"0
M2007WH&#< A%0C0PV(R\B=KL2?!Y"00_*)Y5"LW=*.XCN_0I?$&940L]]O<X
MFZ_4UV!N1<\6*K2",5"=7<J["64R/_+/@,6VLC68C-5J\YB/$HA-XZ-G?,9T
M@M\%9;J2E/#Z/L4M.KH?4P=TC]7?>5L7<%AQ90>0RD.NWD'!\ F+'2PQM&_U
MR#1[,65Q]&NUF0/0S6;166)0PN1"TH46.:RW&L#+*U-HOOWPNZ;R#BV+QI.^
MW%9F1]L6@)Q!.5R./]+EO1583C/;73VZFNH%4%.6O$P8WNK#%8(W4WRM\L)9
M'C,GN"AH^J1"V\GQ^K[(NYW\B)UWUD'AHDOJ O2F"W B%*T*W^7+0,Z3SE H
M>*"#5)O-0/Q93C7N'+8!,$DWSL-Q-1YQ,I0::G>EA:S!-DZTA/B6&TFIU2>\
M[Y1]N* O\H$?D48%7'$C);S8(>%VXC@".%-.&I-B#TW3T5OP?O:0LW+"+W.#
M>4)X*39_:UL?X2)O;%RW ]9O5'G 9^!?/3VS:8S,F2TQZ!"!)ELDXPEH8.(N
MF_4/WH?>M@E(3%P@T@OPF/8HPUP.2\:_T?M2YHU,ZSZC5*RYB7WCS^(LGYW]
MHULI(Y<R@Y<O1)G"A&@TUGT+B<:F O9?#&_USNN4PXIO7K"C+D2]7O_!>J>)
MIMB==*M-(;\0 O7ZHR+[#07>XC<=.I$WMU_ZA09J]&4DREYKB[W0?E+]C;@&
MXR#;6UVY,G=!W%DH@"UMRZU.7&KZN(1(SA;*  O3#&GYDYD+PLMWG^([)^TS
M&1[7L]9@HSGY<U+FEFHNPC[J>ZN%" U?%D)@ D6 /O0(#6FHB(W>(#@%Q'_M
M*?[*BB=$<]*4.X3;FEL&IC&Y4N5I\@PECX1<XXX'[_1YF=97^C'OR_7UT\5.
M2W!)"\ZBY&8*P 5RF<*-3+XIL1^EV6\@\)UL]>'A5\E$!$$:"C<>\\! <]QG
M+0#.DMJW$(XI50^N).@4!#1[EW!QBA,>LF%A0;I!:(>[QEZV]N,"$4VER:[!
M@A&0MG8RZ8H!@B=*KS$IQ$]MVR&^J#W,:BDAH)A@ IUAOVJ3(YS)Y$S/CR,8
MTN<@-3IJ(T L5D[8#=QH:RCSP"H)$;6M ]7;@>I;9OO*[ IG< >+25SS*#Y_
M"NQZG1&#D*>8<Q8W"JRAPT U%QYOIOF%U*[#R5 3H !RBL"<0ZYS2]L_)I1=
M5?;JQRV-;QV;>=X<)F'?V+CWTZT C3'2.#/_&ZO&;SZ<,^YC"THD_M=PA9'R
MX\QZ\^.]KGWAK0BV#UWZ@$N_L9<I]T@K^DS_+S6D%"WR?*G;^$G%GKRO%7V>
M&(=MH18[3Z6\%H.:5N]3 TDQ/H#E&@S2BQ H_YFCT[B<_%TH.T;\F*VA"?$!
M96>FF3E7+Q69JNK=P%U,IFX)\Q)K5S:U?Q M4U V-TR6KS3JV9:IF#H["D\R
M:DF%</4M258O14Z5$2K.4>N6!6JB#+1>$F*"&18M0%LB_QCT9SF8<<XJVBUF
MJM.V-U&";4R]N61N<ZAJ,MW=@&!1 ?EXYIY\Y=88..K;^2C:WZ^)TA0AI J1
MPO?DNL0%"71B59L9X1^1HBV<:W?5B^1@JU/(FRDJDWRRS.>G"><-DT.XE<K.
MN;87]_UT<Z?H_H!]KW@M"U#_2/RSJP6D*\A/6,QJ&LFWB$V6T.Y";!7LA["@
M;4>4L+1-?8"H2OPPG+^C9JAM1V"^4K^^$?\9TSB^/TP/+A/@+5\O2GX_[0<7
M"TQ</K;7O%GW4T*@)LWQD<.?$6XLX&O0N<Y9A\,_H?3QY9;IP>H$$R[\MK=I
M:]]6I'-*]$',P_T;(.UTQ_OAVLL3E!9V(DV4BH2]U U"18$4A"LQS&0C1/4"
M3M$$F+11O&QB$[ 8:Z2G+F;+M["\6\&\-^IF9;SPX?6RZSV'$*U+#Y)_J?ZW
MMX/\9OT91GY7610FU>ZD)??J-PZ?DD^MUH1YIF?]U]H^K@QGOB]XIKT?JJ9G
M-X=YUG^LO6EZQU6<2. =TLA#P2!S/FK.9V/;/@_!*3N=!F1M527B[G3K"]_!
ML$I;>^WWMI@N<;6OA(UNLBHJ:DU[)&;CK_K($A4%>R'JDPX.+A4M0Y $+>A;
M @^N4%#;H$0. @X-'$]TJ4^8FF">23T%:I'+W*Q*,<<B(\25RX(-SR?,3NWY
M>C;?.3A4J.3]:@UV_ R)S9U;@SV:17-\Y\A+NTV$,H;4W_E/X/8#]4&:I_KU
M">BG,Q[!CY[,Y(0W9CS[EG,CK2'K;LG,P>MO_0**1P(:^ZS\L"4>(UWJE:WW
MMW0%K:_=)7NB1K>4(]Q&4!'1Y&LLMSKH)%#"H;9W.VR9.%DZQZ/*$."<#/&Q
MN:BXC:#%C7(:IQ+Y;ZH3)4'G4KI>;D>.?[_5B:M5K[^()%,W$_W-!B?8YD7Z
M:6XET&\-%<8]$R&]@[D&.S"X[CT!NWJ7ZNLS:G/#=)$7OYJ+$B>$4/H5-?NK
M408$+0#)T!L_N&?\RZDKP0+G@L"F@R^>IO_0WVMS5^+ZC=R'F;-H.$J5<!BR
MXGBA7[,V4<38O0GYF_J;\@ZTH]8!;<FBXK!Y9LJK#>O^C8BH'5CJCKC__%&^
MGF^DN\6I]W3C=W^UKPFT$)VC'9<F5'H)H#MQ"6BX4!_:__V806^<<!=TA#YA
M GP9$,</1_11;$MF/2+S+MX[8=W6.U78$G]UZW0:I,TW^$.<O:H*?/EFPE[R
M>N(&C]G9Y/*30 8G,4:H(>VH&;(K9%9;5*SN,_NZMO_43)\I/O6EN[!<SI[Z
MG^:0_INU1U5%! X)1' O-W!P<@0KR!%@<B62*-)A.()B-7[L]<16T*6!(]79
M4DO%4J5F<[YGDVX\\<Q=,+&G')@Y,VH37*'_72IR^(5IE!=^#?:7QC1HWKZ^
MP!GV1"ZH=AJBEQ!V0W[G09Q+8[3Y&6Y:]BTS)!94=JJ_]V',(=K+HO-C@".4
M]6-\7K]B/E\MS?[4:'__Z*>RA(UW#_QWE!;])XAAHU F$,W1[O3:3S\)M0)-
M'&:''<*FS30_^ZG "G!(H.">S33?C;$]4_K)#<K]=W#ARF):?>U8;@N^Z.5>
MVUTHOZSY9^34M@T"!>@6B;W@VD66$"KCQ\Y"U\&WHC+E!.)NFNEPCZS!Q*PW
MK]QX[\#FMUZTIKP$!DZ&% =$R#:F[;YK73\F>3:QKLG_VU\! @6(,O6353*5
M7>.M"ST"FKB+ ODF!EJ2>$0@.5!OH&P-S? W$B*!)MIJ!$W#=-C,A)NZ< VM
M,-,+'J%'(PTH9PJ\.SBD+2.?\)-T#V'JZMV ,NB"]??P(TT#5*1 7I3N_BP7
M4?GGB;9(#3ZAOJ!V4<>*>"ZKCTGG$",./!BX/O&V&1S(8$]1.2W#X(:Z8JCK
M!)1L^(C3*P/9,C2T4B9P\J+LY:V0ZDJEHE0^AJ5)6%-NH)C.P],Y1UCSR+_D
M$6D,622N)*I1FJ.$BRTBE(W.<;_&Y\P,HQ6^$Z0YR<*=(P%S 2$EE6DE:<7]
M8XS&8>SYB/ +!@6#_;(!H2%7Y-_FG/##DC:T;<%G=^4CH!*N2 3+&*_!DB?D
M8X[X2!$LAREP3MZ9+J)J8_+W+RFLHV X[Q&*6D239[',0@)6XBG^RTU7GDN_
M[_CQ-_"\A5A\0V$/J;XCX4&QL,]'I-%I&>FCU^./?/Z615)N4\&;</55S7Z0
M*K)M'93\1U\,3/C\#@PRJS81>S]^*_TGITM4SA.H$@3M$KP41YO.$A<@ =1=
M*A])8\$)>@602?M*R)T]#RJ6$#*?9D:]*)E7+(SN>I2_>Z=J>5FERN]O*5D?
MI,[+\V7^K(DK,$ F46M8\]1):K+6W$(_?EFDGM<)M^)3.W[Z$%Y17H(RE9S4
M5J>I;_/_?O;TLM;9^.35IGU+K=,)9L:ET+5)VFAB8OV1Q8WC,W .OUK*.^"@
MLO>V5Q\OU?/%<W9W)IJWS&0&P"_89<[4>C1D>B#JZK40]RB+?S%PLXC:U/;.
M]_&-2I(F5_.H?JP8UC^9G<HNRQ/Z/G$^FPDJP)Q0#M/B<&0^6W4&R$][FN>"
M\:GWO/&H^O8:S(]_8DH](< D#"V/$A,1RP&M-)-.9"QZ$U'?CC/8ED'_(;"!
M(CD(=>L"J^=JEH.3?:P.553IZ(5 @_,7F&\OG<<TUM:;_&.!D[1A ;6_>E?D
M<D7 4_81](K4JQ32<PU6H$,%0D1JY/TO6"15L+=IWGH-9AG!%XD*+DJ@M0:;
MLFD>(?GZC,1$$A3-UF!U&:^3GT'8H/5D^B,MR(HMZ?-:*:N9,K&]L1$X@T[\
M!+EL-)[+30O>6H]\L2NJOG]6MQ <O=CT/QI#_'=K3J_O3:;^TR9)P&:<2IW4
MIK'BJ4H7/DK/^>\3V$(D#EI=*VDT9^Q9X>AQJ,AZ:$-.^/KZ>LR [Y?< NP5
M[9_BLE>$(2@=$DV/%(A3$@'TC<^?.?M/KB,V$Z1+B1T:"M!VH@I4XMP&1L2V
M?2P5=6,-QJA.=/+WX^0-+E8$>F#FB+OZC;(:5<_FA 8,O WSF>?]L$07BABI
M>]3TJJ3=G[4SJX5^HB/CLZM('^^SH$/-(M]$W3R DA&^1]?AYD&3I"K4.@%,
M5#^<)CN8N!O<\HQX4?O*P,HD(P)WP--HY8M0H2^L+-SJY\B43R/EW;V6-[?<
M'^87_?NGY)R$$LL%7GUM"@3C?J(>%--O*QW-O?Z([;/9C7!\>/Y9>J?*E5\D
ME=&9$'R&4T.6 =(NY1326*<0O\17N*07 ,O0^PL.9:A=(I4L6 >*5!SUIG /
M'M&.EJ7(5M-X7J$TH2DPE<'MW8Q5^OTF\<S'AK$CJX8\XRO[#7HJ;FV3\-PK
M'IE-@X]8\<ZM/N(.G5_-(_GYQ"#^.>/I;(<5*L+;>\4%1VYXR9U\H#FT&\A/
M+K8F*5Q[WKW-U4$_8/M/6>??E8M_<^->U$'A.T3M\H)NSC5B'Z*NY/5B>NPI
M"XU[+&64(J3)W95SR=+!N'!@"KR<_+S;5\J6STP9F4Q[2J_-@C$+" <A5Z"+
MS8S7IT@!J1SFK38E2-L^<O<+((/>N\G?>S/0\[@NZ.>SQH^"(^=+ E[T'.PX
M8)/5;FU3=O?A3>SC_[0FXS^L%>NF1/(W$.EK, 6!"+Q2%ER?^6C^7L%1Z$XP
M<51H!I)?9R2@=H,$YF-2\6=\HAO0,54>>NUZJ8FRLI/-\5+#XS?-%QDBXB3<
MAA^C71.8@&31N<2A)LYGWFC0_0DQT"0^S"":=F_DV\#H>(#2/;S/V1?-?1IC
M-LTUM:\&SF'E%6_SKM=Y5#AA&&__SK F(!QM0@[ )83UKL=;M O5@>K8,"^S
M %-TG.!PX4RS=D)]I;Z$HZCF*ST*"BK^]&G]W==UC0TIGR5"OG+2"5(T:HWR
MO!^PR-W-[%B$"=]2ZR)BVG0GO--LID5U!K51</"C68A6H<H8WT(HEX:D7V_N
M]U&Z9VD2,K&;KK+MD0RO]PGI+R;6@9KLQ7;T[1SBHZ<"+P@#B*3R@\)9"9>^
MI=ZD"4F F;:TJG=VKW5@N,'!;L;HY9*@B\2@XJS/$Q@K15J,]<[]D<'OKA".
M00XB=L!,/ <D=C@D3*R#LCE',&->-F-T#31 2J1<Y,S=.-ZI4CE?S>ZC6)0$
MFH:99-WQ]#P6%*Y>VRM^H$?!/EFO//3O>3'J65Y)P J*?/[IS,&#4=X/BO_,
M1+_\J,2#YELR,WKCMF20[\6+?E?N8CS<1S$GU5LK*RDA-''9IXX[+5.*>MJ0
MA$TBTGH4\J+(@F,<.!U]>T(F@/B18  ZO)Y0 ;_?;$(@5TY$.:08]3AUZMW>
MF8$ZY.*Y1PW8Y_RWVMPG<H MF_D:M[DZ1KB1H WA@.AV*=W>/TOBT^'B>.SK
M*#'/7=;_?+9^"OG8]<]?>NFFF2YK=L=HPFE7-$_WEE8N@&%_3P/A+E!+D4 ;
MPA837)F5EVJ8*.V MO5 :P;#X/([_WE.SH SF%>5K9ST2RW@_$ ]]#1FT2E'
M.Z7SPT&GK(]Q[_X:/Y_TWIO)BBSMHIM',R9TH! 15<\6A8 \?CC2D'*1BQ2'
MX.T3BDR">ZCQ0F>Q05=R>)"4S0LJTR_;D=)"O>?EQ)VU:FU^V7SY0(]F8\3?
M>?7Y)P0YZ #'01V*Y6;'"^4(^P$6@Z5DT"^B2H:Q;+14@(8IN)-EAPN):EY.
M#5O59?D,#?_@]@]'%P\:2]T*,6Z@U$G@+_I^^&O7VD!<G)GVY*),X(0,V)M@
MAIY$2V)YU M, O+_NS$:7H[<?S@MO[)P=I@9%5P4Z)MR6'7BQZB_^Z3E'IN8
M/7AY#DODBOBV;0U !!TIAD=SF'%7+C>_J@6:;A$.%$)6]*QLY8'6H5\=C<E/
MW -6KLA/>+Y95K[6<>6>I_VB_OL?^RZ^^5N\%8$'V-DT<MK!9N?L3F0<>7.;
MOONW ^->_M?)<A0)#DX=X\\TZ>N07NA\()%B5.ED8(I]<RY&KRQ(2?EE^E:G
MR^')_S0.L"-H&'C2/H%'+60!M/=RGYI>,37SD5L@B''<4-NMGF("'/U=5CSP
M[PQT"">:":J[MO@#(X9/#2;[.:D.IX;[C>)._]6=-2"3SH()3@/CT[%$+;QF
M.T+6;$>I+=9<="0AE%.IUM&VK36G,ZRY-F?Q!'.^07K_%.9(:=&KAGM8U^CH
MI'Y_]UTGS[_K N395WPV(X62%@"6XXG>$&X;S3>WY>C[P 4ZRG3;.2^G[W86
M3HW-P/X /4XRFTK-LIU[\W1 Q1!Y*?J5\W>5IWO_YM$.R(1W8/6.4%U@RB1N
MP<-YF-5\@CI0U&$RG$-.%JI".#:3WHIXG:\Y6&&X?CRAH!JR[Z*_^!;5L1#?
M7]F3-EQT,=3\\6SMF)D3C/[-3O-4?[VTWK\?ZPT../2%V2D[U/:'W4!8US4-
MU+=JVPQ4%M4-+(V;.-2GJ]FJ2:F=.M]05]>0HA>-Q1<E;.TW<M;P^2O!VB#2
MVB-8GO]JD1:PT+NPCH\B*$#CH1RU6Q$<##D5+250!#=-TK/_<43G%CIP6Y6=
MLVT-]E=\T)]0C'2^%.[GK!G<S2-"TL^@%KHW>J!-4K!K0!#!;E4=H[?!P<H,
M>H;$*+ZN/1]15T<9J#1"2D,I+,L,UX]+6"_T:6I-4_]2=S=FJ_YB\$+1K7.O
M'JF3_YIVL9 >N[<=GM \G2*P ^8XKG02#,KLBDAT!*E)9LILTF8(@P'3G^"0
MX6(WN)6N%OWS.,HQ/.Z7@27T>79@_#T.N1AL^YMYIJ4Z02@MV %$I)DY@IKM
MZ$W";1"&BT@3<";1&OA0FH9JGYDOEQ,2JC@_R9C0'@CK#L)YRT\<6_^9?K:M
M^:=A00IGV5;U4-=?T9L+]LYG\O4)]M #SAKL-DL.?7GQ%@H%M7 .&V@!O2(*
MH$+0 K23*:0GW26%S\B&F=P%O^,49L6E@3[9*QH3JZIO=MYXV-$0\DU#5A1C
MY-<:.\"(5(HD0.=,QU!<)_F]"PAUB-SN+06P$LTL)KTL%EPCJ,'@Y8:BF<:H
M[*1%U%BIS_AJB=LK2NZ"25/HXL]@K0CZ7\UN 1-C! @03O>HCC4C<1RD\9.T
ME?E](DZL !+CBZ%L>A1CBR<]4ERU*K%B=&(F)V[O! 8SWJ$^7O%6O8=RH##Y
M@J4+_L!KH104PFDUH9'AA!V<C'_P%I;617T"/?:XF W0E;!4^CWX,N6EG8E%
MGX%^6+="_G=N=%G6\/ . \9/>T[QW9&7I+^Q1,-9DAA*<LY'-FPQ=:6+)OK_
M2E-'GKK!Q7Z4]BQQ'5 L8O4&ND?V:#?49=B!Q1.9R*1YN?[1V5FI2PV#A6X[
M7[U,WYYJ5M!J3R']A2U+><,@6<""8UE3C8_EX&B]\63IAD5%F)EC)5Z"LQPG
M0)3C;QL,,M\9+UC01^WS(LH76E^];/%9D*PZ^/FS@RG7_>GEGZ3;Y!KD/(Y_
M GM=N!M:YNL0/Y!5S:RQ7U-)6P2.(M:_V.4Q?V$/8]^>(8$M9]SVM(Z"30TC
M[:K3+C5'9WP5_V^,GOY:Y&DQH(EN2HII4X%$R)81J#\ML$.VYTN(^+SH0LZ\
MHUE(J<L?KWLQ$!2QX#6E=LGPJ+ZU2E7[7QT@C4QAB8NBYCHP+=BQ!E,C*A!,
M("KGV-Y7/M($.\ A01!>L/O-6.K#I6KYF>:\^ZYB%R[@.>Y7G^!>=UPEK5^#
M74**],+5G&CRR#+/'Y("+&=G+F%R>^,1DF82;*FQN/N'L@XOFAD\F8EPZMI^
M[RA(J;BM3G/:.OW\KW!]"9;<$BB#FG35KACB#E%]1!T!<$E!'EW> /EVF#J2
M,:$Z7#'RH*>JO&#.I:GY<D&PEZP@MR7@HDP*)T+W[B1+G'0)/>+ \R>?:18)
M\LO46XA_OO\JC5/MF&Y'QTVLAR(CGQ^MVJ6T$L^*-S+0G?KQ^53Y]ABN^TZY
M/5=S;QH/_I6 5U$WM&TI83Q"[2]IIR9*@E'8=<4]H"-!EO, RC!\J'^QOY.L
MG=;YT,R&I_EOBL$AC\9GYY1DK?R^KN8I[0U$;R#"9]=@LD;DU-&F=G+"2DE'
MVH:>L%4X]WJ1*.=Y"X[W52BIS?G6]E,"0HN[N>:F?4&_S"W7-]4/%L2?'T1>
MV*C9G'?IS5_=*#5)FB_A[Q4.R/H#?^[K4&F(]#XH<M0.1O"&,&QR4F7A@6SD
M:J9VJI&=A]WA2P'J3VTMXW==UI_MB3'7>XV0(2((>X"J;+9/_,0&()&>(?[M
M[M8PW$:\/#T*'4<Y4'SBDWX.,?[)R*> K/-O/@M/5ERV_/VX3@Y[[Z^FO3-S
MY*\3M@L/@C-0V23BTQ@/ [HR&EN%_20$/I6MW;[@U_%C=L<DJ:F7*VW1OJSZ
M=+F8F]8SR$0>#K/<+_>$.7QP>)AW'?#P."9=65RQ#^,Q.G;B#F8,\SI58>^Q
MS38U],W[GG<I.#Y_ZO\\J>"HV%O27X@V;Y,PO T=NP:3)H-PT8>FF16P%_-S
M177U[7]VI@T&9L\S*Z"?DRZO0..EZ8'.AK+=DYA''NP=SHZ,RO7E+T>?;/E8
ML%5S*^T)G"K<1'KSX!F)68%>V5A]KDJ9(XS53ER2,D<YM&[>5S#S04%F8K+D
M(S/\/UZ)YG@4D2 \&,M+'VK3%+@U0#V<14A'@_J\A-&K0&-[R?/.@B:WS.#
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MDJD%MO()#,=[>;I+>L>-=9Q+C)\6.,G=+AR>B5=P].PZ^E\O#72NJKXR?_&
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M^UTW%K6!C"7?U#Y?D5GAD'KGS8VQU #JBL6;ZXX2TL:ST\6?5DQG-,=#U9?
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MZ\A#-L^*7,65%$L?Y>18:EOE3ILYA5>8/]'2=E2SYY)Z8/N [+[OSVD_7]J
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M5AYX0+^SZ?*M1\'YQZ;.]I_[58,K&I[V8Z4P<'04^R+F-/=UYS^OT+,]\T)
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MGB>[&(1'FA@IJ80Q&X/FB5YC[2>]_E*1,\'/GU!69ZR;O[4GY :@0B]^/3J
M4D6,P@"EI20B"/O9>#\1F&8D84^B)UD7J UCF("_/08A1[#RP&7:IZWF8]*+
MU .5BVF"5UN M)N*HYN:NK7'T>Z>7Z;=*U8>NCD]XZ>V? ;/(H=)C+S@V*>W
M.IZ)&3C;^Q[^1.U3X-%@X]&&V-2 ZXD:J@,9,%\SU=I5J"C'<@%51-I[\\Z7
M:QW"-B60@PQWI>X_0656$FJ!@;I("[4G/=]_KUUP_!AZ[7*YVU%7QRA/Z)G:
M][!"F.\N:/HEYW0\)FA1\BSGTOBZY[RFP:$OTVB$=8?CN1OOO$,D>-5W"O;_
MKE%L:5+3I)L8=)&YT?\G]SKENGY],?\/ZD+>I5N)'QY_+' X)XD/9DA@;RG]
MN_=IGU.,S-R@U)>-SNGK%K((O^R/3XRXOZUS\V SUYWG2=5G98NTWIW=.1[L
M<7"4/))H>/=)INO$K2*ZML2/]26G6K6[F<\<'+P.]KP\>7 7E-X9->!N08.)
M+@*UR2$D]R'M7W$. 7VC/3?O/'O-J\[V!; !&GH"@L<M=<I#;4)?5GAK2ZA[
M5T[5.JONX$NW=.T0- ZL.&IJ )8&.[P+ND5*F%<!R$Q*_XX^&9R0+YS<UVE.
M&Q8S8K'TS@6V?E[),7UH(G3.TS,PYU-I>%!)@+1O7M-V>QKWH][DYPZ2>"T6
MBKX[2R,D&!\A)?!4W],@4H T_)$K(JF:)XY>7:0Z9B5"<NQMF)"^YTVW&)"$
M3J^PQR_6,5)5:T[Y"EVM.:,Q,0+)&W.$N5+/U%NO5L?LN_3??WQ9;>?>-&LQ
M9W8W]9G;J(VF2I&QM,./T2=Q+X.@T</97RWMG6>8J87?6BTMND:6\=MX*B?>
M,1L@@5=<[5SG-'#^2&1\J_>>3Y_?G?0V!UDZG%01*(JH&/*-4DM('OUAFF'5
M/]*M7O4H3N _M;BS!=07=\495VLM1?'JF)'6<\[MS:,3GNR:?M'I'=B[06SL
M&E?X^BW?F0]]+C?.-CRIJCIKHK[GX(G4AP=/_!3VOWIPX>'!VT?,#BJ<> @^
M$3ON%/H;@EA&M@5W.?\(A5-QT"'(-0P$Z W[$4LV5B881/5&Z(]" (8BHT$4
MMTB6;7_ BPO5\%DWN]+(WN_BX3B2.3)^UN#QAP]DM0]O'W]X^_"@XI&[(NH_
MPY.<G>P<L_>[6#C9'3I1?NQ$[#O^@J>(+P!]9BY;IYN*%W?'];[)D$LO4/!C
M&[W,>R(V_ 4N\QDWD'6M'E__)RG@#_XXP[G5L1&3G[V9N>ISQF&1X]A92:61
MOF^DC9=D;V)/8W^NEGZYLWDT1NO: 2_[;5<3\*-<GM35T4J579 6ZWHN3SXC
M>V-]A9MMJON_+7TKX7OSJN_-2_M$#YZ(30['7FA96K[T]V$[9L<N:%_7$SB0
MG,@3---O@5!-'Y[Y>N==#N&M9C+9J.*VQRN&7HW!X6THH 7N(TD!]JQB $E%
M)9$8KH8$0*5V?7X7)")25,(;IC00XHU/H FL62!OT:VR+4C*,V?JK;1-<Q4I
M'K4A..T_:A52LLSZ[-\:@"I$&C3/S9<7<XO8)W#=:L9G>)\H#!?(+(5W&$;#
M/2*)Z ['4YKQL2<9E-A.X8+2)(%TCF&DW"89B8?U!MTK=O,_->?#<-R!K,]9
MLLQC!LT$I:O>8F;9+KN@;@78PJL<.$>BTHW/G_G:I/NBL2'VHRLNF:>&41\U
M%N=+\&Y2\T"<$8(V9$CEEA!> 3'D2 ,*.8+1DEONT3Z$I$+ JRT16='9<:BJ
M9@LC$]]07,6R*Y?^ ,2)YC[<!2V44EHA*:2%' C#<TBPE]0,[4<DY9_B/L)<
M]*K$?L0U@7NK#RR]W04U*:<5HW/8-.470KS3+1,WG_8:V%1,YA\8:7[>A!/]
MNAI-2="]Z.8^.GL]:SKH5-/.4]ZA/-HFH(K-9A\.(##<:V?X#@$SH8LJ9$(B
MI,&9+D$C"/+ZS";7K!G0U#%J2QH-OA]CS(3VTI'P\:(FID#2%DD4\'%F1G15
M6E!?8"X)3;6+9\V?M$*Z=<E='%C(YAP19 T#/HQ&GN YQM0 I1G:34J3WN:(
M[X+>SES+<>ZKAI.)Z@PL"<GT#<=+K1$5ICB15 ]]ZXFF/!GR3C,?W;8:47[4
M>W"WK*';5?LB:*J>@K@I^#2"I3$*\]D$%++P;''L^+833!RCR6AE^0#="X2T
M4([&Z-:<BY'CPIPK%(+DJ<2^W;&>S 4_:I8+A NMA;HNLT96?.S;I@H?W7#3
M&0X^MO?/"P ,Y4C"%L$<4;=%9X[D"&FADB(15IM$/,$0&.!G<!Z$^\(\'@,+
M9^P9I*(>Z%*DT2J>HTUY\E:/-(T$%P>U"]")"""&!A8*T-N6WL_*IB*#G'XY
MQ^29_:1D W];O95RZXW_'KF(X18>LR(030EM5/@,E,5E(OH]%&@4>BQMZ!1"
M'KU$G>JI32#)Z:(. OC>&<]L9,G\7* !-_\%K5:(C(HJ#9AR_2T-3D!IA)U/
MZ"AS675"@%9<\;&=?^MGON'6$@__3S^4/QA%I@I';/CR"/'T*@6\"_+U"*56
MP81(M_D7(Z\V*;KMP9CJ-F-L]LI!X<RLW 7X<73[+_/<_IUM\E@U8-]K9T'S
M:ZEG\ AE@>\%Z+7K?RNC13.SZ6S^-S]^#Z_I)QB?'&;K\J8(#<T#?);ICYAN
MI>D_TCFDFR<&1QWG^#+-\4V5$$E_HCU"/['3I8B\@#@6T!Y?W+4^&>D:_%0G
MYU9UB0?EB_M]#)<MR'>,!?8T6H9WV)2!9ZD ^GR/_<M]!5LH(C4,T_&,J3XB
M:)P'Q?@#YHMP8<YU;C;,7Y  1K=A5&AX863^Q<^_9^?<; SRLC)Q!S*XY<J)
M+$T73=2)1-O/U;H73>)V0;$1N%N$&6<3ONU)N&ZW3B05-L.F12:'0Z;-%[-(
M11ASP*?,W]4WX0$[C+]KG9NX91S=!=(1#&)\ME=TD*H^)-:_X\=1UELI+FGX
M;[QY<#9*5QV)SD<2ELU9:MPTW$+])ML] -%4RA&'LWX MN&,M;?Y8"(#GT#R
MK9V6(N<,)/+$,5?&7^/M$@8'(&+X%"/=HJ_D\FZ]<JU6#==KD>UY/RJ]"F^8
M5ZT82X^^'FF&Y\-\(8#"$OT/6Y[O'RL</W9ID$.[H !2;#MB79<=QKG"3.R%
MI6)E6T8[+Z'8%@'5U0&[(/$-#,1G02X0=YCB[RG&A)$W)3'PS@F=38E9='*,
MIO>43>-3V\_[5EML0;@S\W\[+F;Q1N?5F)#TWY19/C+S[Z3]?U\5OH/K-@FK
M37%][?2W[/0]AB</]262+*TAK]!T%!WC"(0NO$%Q+I56=^4$2O;<0[V=DI=N
M=;/Z)SR4IF[(GKN">PU=I]#H)@,DD+$0>LP9>,%@+QI7TW )6*')<'@*XK!F
M?#89E620N1'KJ\N_M$ZQF[IR[@$\6:;2K%7%2GLD*V^3A9&R\F,E_CR'^( 8
M@ *GACF2@XO@GLTD7/U4+VH6QE+G5I#\H(\,?M3-P.@*[!L<=28^'7<;G\"3
MG CWWQ(?ZY2K'"I8TY.V*?8^12GMRDXYO+PM-F].[>#N^12#UH"50KX@6;8,
M$M^?"IR]W"<<.9J<6U^[P-OAQ)W(6"^F39OLG4"LXK@D;<UQ*GQZG1KE-58T
MT4RWLB<VC1;DH,,J+]!_?ZE129^X=0>\&,EW'U.0E0,X[X($C'E]\X;<=)[@
M,J$)0A<KX+VOP$(XIYB01Z<8?#0EE_E#FK O:*9=4WX383>J[*\R\GZTU9B-
M!CJMZ<S<COAF]>//6=P52!V,GL$/R37FU".L#A+&L"=\":7BUMT8)E1"CX<Y
M3223J4!&B%5AO&?2*PL0IN&U*SO5U;6I1E8L.>@U1JH!L2L$PV*E'!T;A1D@
M8-XA,%G<PC/<<>QI_ET51O+% VH1&4P%:@N!@5N =5>;4$F/B'*KVNAG'+-)
M72O28<RMSY+;9D]FKV63<5YL>&^>\D+ND,U\6*SUN//[)Q9!E70XH$9:GV)?
MX7TAU)4.0*=C6-[,I?N\XY@K +7H"UK0D=G:JXHQE4Q[S3&<T#7T V(#_#'G
M2@)G4@*)"HRO4OF2L7H$O^0Q-V);E.B-DT+_\$+D+S"WU_]6AU<&^+EU?SFW
MC10P/'..ZDPFS6S3*+TX$22NKI8,D4,VN@!K5@SS[MGQJ4(&+P.IU/6AWRB&
M\6F6C#BH(Z[OM*S;)<VC?5.\:VZ(7>--01AV8!G>%Q+#G[[4MPD&DKG$TR[#
M#"3+F5N"JM*2:[Z*PB@Q%7J,I9D7-VH-C)X.!/&UJ2T:=F-"*+T\TG=QMDOK
M5H9O'F0[DF7R]]P3MI!#VD.Z!7^(.&1\EO<.U@@?P*5@!0!<80!,#'L&74K%
M9E0C(4>,T(S<80G@_JKT]ZKVQI56Z;F)=5>)KK5#56'GP]:@6B>#%1#/8-Y@
M0'_1A9L;#%LH)35L]D%D.$;,;8Z8%8O9-KX%^P=S@O%U7FF,J((Y.>'%%/Y.
MB:VMVF@6%L9<+%WU/,[8XL:_-*@AX,H_[$S=QPB6ZS9EN'I<?@LI)C%,"7&0
M_<8RN.[3.&^$$$:!L0M*$'C8Z<?6YZ]0FO1CK&E03" -X\44Z,DR6.K51/52
M.G#T:GMGYH&B"M= ?+GN8-41\]<T0QGUF*NX[%I <7L %0MCV$ !=0)'5DI#
M?YLHRDTD[E\Q5@5R:7E[NZ4]6!V%:+@M ]\_I&XRLHXQI Y=^ $.>46 H&?)
M!A$$[Z-3\":]=Y)3UE>I.\/41,Y1,D_D$#>1(US)^X"HB^1(@!?N<#-*Q\.7
M.8*1S,CN;18?WW@2_L8G2%W$]L0>6RO&&.U*M,3FC-9W4A:%3(0VC234A\=4
MKKAB\>%1!I I&* 8R3EJO\!WH?D"K@\AB%[KU2,U;0_ 9GP<FYE@^@6FV\"\
M?.NXSC!DSLVJS',:<!K[ERG4_JT1@-M,A%>'.N<CCO!3,"FIF>ZY"W*?]#P[
M$_&B&(0-YWV!,<+ ZQTT"J"R1(]EIO .3=!PXD#18FMWM10U(>VU.^<*X%4%
M^)@S\HN8A %;M)@%\XDK\&0TR+ W% A4G-1%!DG3])O>C--UOC0?*ZW+H4EQ
M;/C8V\Q[][<URV8"@G$%N@<[#FDRYXA7T@ATJU>\$=?$]5^+I/1=$(BH&B"-
M;:1"]B,X)E;PXQS#<6,1=,4/EV:2" 5M>)U@Q8]QLD[7V5ESQF;2S?$MF=D8
MP1M-LZ=5>&.XH&% ";?>S/;FO8/([8+^6X,FXL!$@1F._^<PM )SJF<ST5B<
M,5G_"MW8/4,GI!@)T-0[4.!I?_->O6B!I"8V,K=:9(=U6E=.[YX5W"I%CZBO
MO0LR($CS.6LLA.&Z"YII9)W\3/+"S:C_/3/7"<0)8$&ML71CT+*Q+$,JA3:.
M/=6]$'6["7)PF#G03Z=VR 6.63.<'ZA,5G&T"P,,_)+\VB;'KK1-A5N5C/F0
M3LCS:<+^/7SOE&+L@$@:'E "<\1B>BC-E.1=T$WP_9G-=0GV!8PWMV07% A-
M( I-&2&9GA<-W0#+$32BFRC4RNA_40'D7K40B,6^0^D<K/;+=F9ZI/'JH]M5
M$C<TFL%_._L@<-T.V N!!$G<0A&E_@JLQ;RW=I:P,'R?Y,-W)JD)NA[/OH7Y
M%PBGX1+Y'+':KWM^3P.AUQ/,E*,DAUU4MY]$A5UT[IVL]2I''HI2"^0=(8[K
ME'_*K!$^9\&5Y%;!%I(0339=?V^:37HL6YR# WP9.-8?[B.<'RJ1U-C?7(:Y
MRB!6TA /*-)&$"HD<=M3G#C6G!OC)C.$NY;@LH47#V#],DZ)4MI,Q)C^DA-S
M&6F:NQ3#-YW2 ..($ZCZ;TG Z>R!3>#T$OT%E9(F#P7*V><X-\<Z%=B&'-'1
M6AW<-'EAKCJ;+!>@I0L7-*<)BYE/O9[4JFZ:=3MXHJ5Q;+W@X3T_^\D:(XN:
M->5=D V((\9]T&GXMP(\?QD\KEO5*))]QX+_=Q@PP:CLA37V$J0WB(* %-GI
MC-)4'Y(/+9+.GCI,3<I +<0UT!5;6F->81&I\A!SO(BRDM/_@#JG;M8P#M6I
M)+5\?=%,\@<#YSM8=4Q]SM$!WB'F(D2$S\&N A"V#6\*)H-5P0[CI'$!FH8]
M]6LP1BP:L6!62]6$#,#$.U47YF 6[<FSO5C%$:("((4@)EX>W5 >O972)XD5
M;6@AOADI'C,ZQSN8QS["SW?N1!BN6S$<+X+MH;0,=./C<8VM]$N+FZGR_P C
MC*5%@8>Z,7@)CN[/>=A^-+F7G\6-@EXMSRNUH8 ;\J+2][)(A7-N_J(KVTY!
M]XH",SPI5C$"F^;]<$"/TFU X(CYL6#<#)(?7[HX0T1@ > OD33-X0%8+*'I
M5BMUDCBFNYF:KS1)[X0S#_SJ,Y9,7[,E6#.FDG39PH=_F;>.+4UH=9[)/\KH
M%#6I=75;=<IY+/ #QQ'C*S/<XO!#$L-A>#J%Y0+\S8LJP!K_TY:;@0OL4OO5
MC3N",65N4\W3.0J+^ <0:2'71332]G.GQ>*]/;/V;9]UARQGKU&*R>56Q6[+
M[=7TZG7(C*M>=L4\@IN@"P746CD2YUC5_.BV\3[-\(%W[R)L?8QAPO+GEAF%
M^U ]<-WM6@0:./E0>2#/$*BG$A)A(AAM6GEM&')S/T>9D8]?F,TS[\U!)6Y4
MZW8%KR]+UJ\>3 H)#V+#V<=Y_3"&2PQA9HV,:\)QQ&&L-0"N0H8FRHN/&T%?
M\3XB&J02FG%@C Y063XH6;0_.Y6H#I9$(\UCW( :7;&:KWV%?5%E'H'1P?@2
ME]4<E42-X*8A^[_67L-U:_YM7](-(_F3 -72?G@2XJBQ''KJ,K<5YJ_-C'DK
MC7CHPSP52!0;P5&U@'H:9)TBF1=J7==D\+R)R<L.V@6))M56IPW%<_+1R5;A
MK\!+OUA7^#,O8V<)0KB%A[A6U$!M\KPA?A%*UV=K84>=$ V[H!Y(RCRTH7E\
MRZH<>Q(6%Q3&E\(?+FAD4?JRB7N"?'IG2O"A-6Y6QF]:VN5S:1=03PQ?:!D[
M_^UO@'V/XS.01!+#!'6 -T%HXF_96CZPFQ1@1WYB/\W# ";;F&,[JD-'=N>+
MX)+$5K#G %091IYIVMNPYBD]@9$I_[H<#4WZ/:<\9<:@))T8;W9[=%N3-J;A
MW<;]R'T,6YC3C'G+SQXV?!30YR.B/><& _:(?YVW46F_,%X,>#I1W!6=L(I(
M:._/1%+7-O<CG;/DE1L^0ZZ/A\'%@;N?MJ^/GB"L&]2D;N?8!X;<JR])_ Y+
M13 NX0!-/[H)6V1Y%U2'HO.5R'XA;DXS]"'N'X$X36.0/_8OK"].$$_- I(Q
MFE+=18N):0AR1/10>LH"?M]PY0R -!G5,+(-":F>719#1A=_&3LU#A+@IXW]
M%_FN*<3X<+-@M_@T'[]NQ8A<W-I<CRWFC5$:*.N_: 0\J?E6/-5J4P:8HOIU
MTZ%O(2*8\Q0^&,18C(5K!FVY)<&H)R>@-1B8K/&)%V%I^I9CT*9WX7*7F=$H
M0%& (SY+T\ODKV0_AKM)$N'-[8*D< LED'K* #C.@)*,E>/<!;XSQOJQ1P "
MHV@1'*<CC.R3;HT-AQ]!=Y!W/*MK _3;P?'A"'VZO7L 7KF5.C#F9D.JF[PY
M ;,D!5& 4R@^7,P(+&QRQ'P&("#^+H$OU-(W^8)YA 'I(0ECS@&EE4 TNY=T
MN#- Y2%'>R%-W_,SQZK(&AE:5O- KXLJ-=$)"]=+*=?_$F[M8S89ADRY%_!C
M[%XI[]#6_S1POM&IR[Z&'F3E_P5A[ P);.16X@'H&LDLX*<-69XCND$R+.Q8
M\ 0&#]B$%]'H I:3(FWBX"@CO?9['1[S@=&),UN((U]O!+C>2KT/&:)PQ @>
M?W<\KOLZR1<UNPL:D,[F2. 6"6]K#_+>X\2-SX 340MS:I^V:?IX3&@Q8-N)
M"'J%IM"NZ+?K/VI"Q,M+CC8%29+-&,/QW\WY5O5Y*HS79OF._68;$EZ2 C=G
M3%A5_ 7X5*6[1EZ66X(UQ([(J^;V4AJ7Z.?N,0BTX#2_P@#$?]S2L!)F+=D-
ME9C3VCLXZ!(VWC!E+ L^HD0O*2A=:57IE4[/;YUI,K%M)]C6KD)YAV3X7DT$
MIOB?+"X_J,'#]_G;F*>,T6;6/N(G_]IDB+A1.%78KUL;* A#B'P!EJA?/87'
MZ)U7VG]DE'IR*R9WH,US)7G"WZS\(_I"="BG_PA0G3DR@\Q&,HEQ&9K&WS^6
M*&G.'< 5"T7_6O1=ZL?OYU@PY@C)F\;R7Q NZ%CJ)U*1?_[)1-O1L,TC?PSN
M,SR+2P*=6Z1]R0&5E:Z(6;= :U_-O+<":WSZ"5]([(,\(#!L\-/#5D I^RIZ
MC95)9&Z3H?$D"2.E:O2F6?U(,%$*$.Q'"!!E!ZFDA_GRR0.VX[PY*AQD[A<J
MB2_WL!:>FV*E];,-;XR>SOX!!R[@J8GIQJ=PW2=A =7VW;N@XYWV# (<\"V<
MX5QF]B=2A\X.7V\"!JDRQTGUI8 C[45P#=UW#&-8MCHS_Y1V87.=.'8WFR==
M%S<SA-)9N)?+]V8Q(,6^@QTB-)C'&1_BS9'$>((<.^8NB.S?!-W+T1OG'?)O
MK\DL\(<=X!Q?(!Q&6W7/2T_5Z@8)DIWE3S$O/FM7+HV\5YLF_7G>C>)JJIU#
MFW'YQ@(#IYW7*V'T;K88=I32$$1(#N*(E6-" ;<:0-V,&41/G<E,3-Q:22,6
MO ITS2*@-*3T<]RE)^(?C"\T9QF6:PCWS)XA#+X"TT;9O906.$=LDR<<! 2P
MKW+4N6W&.NY_Z]0](MVZYT,U+<YKQB<H<E]V[BU?->!EU&)4&7K5J'L57P.)
M,I.WTJ"UP<'5OZ>/T])U&DW/-A%*(0P$=-:*5<K-ART\H3#@X#3</\;&F,N
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M;S7</%BERWQR&%P%*+*# %EF#UU6@ EDB8\P\3"<&->75W*4^:&G1T*%'*C
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M(!@D#L4U!!B":IRWG5*=7TS@&QE61>+<$12;P?6=2Y!#H_(E;2R))*1V:/G
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MHY/YI_T)#; N0AI4I/UTX)P>KQ@IS6RU'&V$/>)KC/U;RESOL*L$'.S&(1H
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MB7&ILG_EEOTAVUO>2K?W1D%+5MKM=9LN#?A!CJRL:7>9L[CE6-D2Q^WM0EA
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MFPN([ G D7/Y!UH)[8=+(2CES4]PM075#Y.":"U!FV1C^8>1UUE^)'A2^S$
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M_.,5Y1$4%M0[]95:+<1+F*N-LTSYP.XL;A*9=%XUQW><7JQZ\&!6[=?E #?
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M0IZ5_LZMG!GPC@WP3,UV>/JO*5$Z==(8%9#2F2.R'"=,5P#"*,%=DT4< (S
MX.N,$VNX<V+0J,&AK.,EOWS[I 8;'EF]>MDC'+=?.#0QV'II&Q1@_\9^&-]0
MWK_!08L&PB)(@U,;NZJ\JP\ZGA&RN ;E;]2L#?,\_]:\M:WDI/F<YR"R[L&;
MP$0/3,;DTM91MQ/1*<3UM$S%].U*!S&U@:W5\55O@9"&2@\*<"I74H?P86)"
MQ_UG'3S+\Y0#)^1UW8OFD5*+7-/M<B%\.MEE5I+(.2O=%VKAGT=1Z.U/4VO+
MCN[03.8<_W:Y3=KT3OU<MWQ&1+Z[&N=IKHF2Y'Z[[CN](R4Z(\56\I],N6>.
MTEX 40>07Q1SDF/I),2^<G90*QG"_6Y B-9768=2W6CZ^.66KDJR6(^19LU#
MS=83:7T<@XD^^=1@$F[C)760U#XQ9R^AT$*!)7EY"3)Y*5>&^C+NY_T)K%O5
M_69X)<;I105C)U\HQ*GUR.+4S<HTK#I\K-]-FKJ7NHLZ"W3;?YJDFZ#G-98J
M*EQX.3.^I$W.G''2NZ+Y%>*\LH\X$KBA_,SCJO.W*'+!&K9<'%D!_H*CH"6
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M/0RQ+:.[YOJKFICI,(_W#H/'Y]^M/&_TCRYY]B"D6P:+L@1D9)] "74MV/5
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M+MCGAO6%>[_R>#L/$5.<*5BLL+[48YL(D9%<L?P[%O=VX=%^**\&D@.^;=)
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M3.<C=T<Z-7U6G6GM1'&'%W)8 %EO@;2U?A&OYR2SS:.K(H+Y;^=G!@Y!)R\
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M+J]O0>Z]GP&6B1%["0AOHEZLJBE5(X,2*WN-6ONXQF%^L&3./W)D12NJK.O
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M\OAIU)XPQ;&FVPFB+G8=WM*4FO*7MX;Q\26>9<U7(_:]\SY3<^%Y]7P63.2
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MXP;*%4OWEF!^[=9N99/E8HQK.5NN0VN:?N&67#&&+1E8>T+L/[?1D6GTF$O
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M&?B?01#G?_4%T3J]OT@&U5I=>1B">GM$XB,GG(E<]?":68-P3C&[$UO$..;
MU'@G/$D?UA8'^";-5 )KB4VP#\L7IMR*"27&H>.'E_1E#<M(1):/:OA^#^7_
MZN1>N#$35HUI:_O1ET$:P&*T;J]N;GVBQHIR;HR2U((LK>*'._3=LTI"&R2S
M]PR^^D"2+Z]9C4QAY68F_MMH_@>[.7\QZB!M*PUKYQA;^G%@.5U0/S)M[SA9
M9S3*2Z6O;U4>_L.B\ V[<"L):[8FK H^Y5C'F^PML(I&78<AV <+(DKK!YXL
MSD[W9>AU$+EKQ.T/(3I?WL2E^:ND&KU"[S6$0*(ANZ!/)5CI*SUL-0^T1<9
M-P9.^E@%Q@B5:;\JOJ(PO=Z5\5_W+D2?>EV"PTAY/V4UVZ;=S>5\Y]P/V"QA
MI83MAU9AFG7#)IPLN(587S)%@*;3&DP9=^++!Y(5!0XPK(Y8)LRL=:0G55D%
M!@;/6!D[U#6FVUEI!WF&%+D&C+%6?<L]<QW/F10B(J."-L>3L#,ST']0=K;<
M(MH0'U&#*6N=9&'XS;543V50AVW*<07DR8](B 2H(!$N!.8;'"\&:;^RW!#$
MR4"GPP%26;R#L:X!LH>>>06'?PC(&EQR?(.A/OAHMBO1_L+7XQEI!\_'5D:%
MT8QNN[_PLM5BW@UINILD;(\W+Z.?R%L*I66D*?Z97%3=R"9DG(E,F):YV5P<
MTV<GT&%@%U<BXIN!^>U\_X^/I5MN5G'X@,Q@I]=BO?'IYRQ=)X/!W@H7]OK>
MHO*X=Y+:VF,L1^UK)H&^OH%BEP+] __Y<-=MLE7:F1Y_:M16=_!RZ0/(^__3
M^),3#*[SI3T?4&G'4@1I BLT ,YR YGLF^ D*XZ;VZ3(MN*(?00EL+0P$I/\
MN,DCJLQ2/K.SN"4QDD8:Y,#>+&%.C89S[2+R]\<+"ZXLO_\1]>P>678',E-;
ML!<T8U!3%.0&L5YD"H$!>TCV3D;L(:P6\C/'G73:%)*VM4*FPR2_3U"7"D3'
M[\S6VS#RD9_,0T*"&7I$N7[]KM[EJR,M/5I3Y34>3ANV7\]3-&S"&=)#F?I&
M*\J?B[1071KG9@,TQR]:TO#^FL]X7I8":>7*>G;Y%IGU919V>1[F];HE([DO
M_M3C;8@_N(O]1((:CCBPA:!Q.NVP35B1GVJ_)^DXCH1Q&PLN240^)%=W\^&'
ML39I23<J9!N@O%CX$2(Y@2J*D42?KJX&M1C)EC%FK3H\^4:0\,$_$GN8XT7W
M,/HUQ!K^5" \#-O\>+VQUOP>ZC?%&-Z9#IX62, <]<-5GWSFS=9$AXV0_<B3
M'@9VL#;81#!=?OY!RR[.OX/7 ?DD)#B&39Q6!PL)WT&I3XM%[>K5"X#'4J03
M3R6#U:.Y?*K YTJS]-SW_6S394]->WN\M/6U%T6GAE-4K<^%E-F,E!S$?.4/
M\V=A8$U:L<@1#?N2B9'&%/?%+HO31W_=2\[(U#UUV6[^?:&"<[TG!5><$<'!
M%MG>25C 9F*T>&-DX-K $1#).T!F$E@XYGAK^J09ZQ03V;8#29P6 L,)H,_0
MP PKEYE#M6D!$VAKPI9_2]N1Z9R+3"A-*JT%&B@68-J%E1(1<I\,:/!E)7 4
M^X-5*\?DWG%?8V<^>,J"YYB.T D&?WVULZ_P*$B9)BC@U Z7,]):@.\FKNY#
M@/8*_XQK"E]TJAHQ"/DP_79QJP VL@(+(AG3RF7;)DY:?K=ZQ^PQB! -[[[X
MR6:.15*V,DT]6&*1QWW'J]$?C%4TRZ:P359.ZYEE+)W+C;B669FV6T(MM-6\
M?O2QQ=W9]"I[]]G3>=,]QEL;0]F&N1E.C4Y<K_^S HP\=R"_<,O(IU0)[ P)
M6^/[D.]>"!-'6#F 2/M:,E+>",K[CA4C86-;A+ZU*"QNWT**&5Q@3!T:M+L&
M9%7-3%F$4@A)-YD'%*2MI*Q&Z$G1/<?(=2-SPQ5!1;F3.Y ;.Q#PU%]+%(04
MXWW#"L,P^SDNW-P67<P7S,EO33I,WQEJE\302:9"*C1)/;BB"5[:6N)GQ3K
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M?SJ+100"C$XT50Z^EKI/S-)V7:)Z=(I/*WP<O6ZCE*$4E/AF>]4$JUW#1X5
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M2=\(%Y!]#X*U$W?Z:87G2*ZQA/G[;RZ7[X?,1CC!=$,I%FJDP..@\+ZM?\U
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MG!,^2/81@;B V6:@#7XIXG[X9FIQ<\E4P('(\-(8G.-PZHJDOGV6=K94[78
M7W6(D928]*@9**A!7=%AP$$5<D<P>&JN"MX)3R ?:#F\W/Z)*MH"!:F?JOV1
M4F'!B<_=_27O^[:O7N 3'NP=*L&)N7>NN:C[38!^\!.YRQERB<5C6NJBQ/)0
M^5.[6:%)O$C,P;]5P'"AID!F]@RTC9".JZQ;'68?\\.23.92\;P!I"1/!WWJ
M$33!$][ /)H3 -XW&]'TN/QK_>IPN-]FL_"X8QUQ=$5S=(RXW._C<=$TR\H3
M%LQ7$W[2:KU']H5]5V1$\L7).TB.!NL>H"RSJIA&B8'T8BZ.[ /?BVT+HN]
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M$<N1P6_ >U>J3JP[U=>04#]'PP_DJ%WT+W*[DN628>HYP)#BB.^F=<=I.I!
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M%1<YM*]Z%DK79N'9A]D]N(:\OG8M>C, 9[BB+7KV^SY7I]@R]3G6WK4=GRL
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MIHN.4]A^F5M^/.BMO:GG!3=H(S+>[0M<E.J-OZ2=I'4)...BE0XY!9;9<=3
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M.(2%UA%T;.^"+/4/Y3OS7#.>VC;F:Q!0_L&5(WP7  E[JD-YR:KXGE3'6Z1
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M-O[C%0O-D?=&$<7@O(O6[F$%-6\?76K+,((I%V)K;LPFU<X7OPR$2%U5_O"
MC3IIPJ ZQ]B^H=QK"8?($WZ'/(/\^/ X)L^KW F.<"G.:<PO\7L4:H M+%T@
MR [E_$G>T/(/]0E%J;;9SKK-]I_1)JC6/^S>2BEVBJ1FT%%,4172^N$2)/X8
MAP?#N&?%H)ZTJQ5Y=8N]38VW3-*/M1<0*/"HA=,=IJ..7_'?VDZ(;4Y4@IL<
MSK-7_9UPG?^R1=&/=F8-605MTC1;^BV:Z(Z)7R6-T#E]"2I07>T!.]-7P/2B
MMG6< 5QQAUZ:_; (HT0HK_G>"8^IB3G% YVZV9*W]=O/J2+EX9ZWS/*S_*@
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MN.N9\+/WFN='CAU1ZXNM<M4N)+9?[A6)\K,EV"5/WLL_%^YVTY50?L7*3.X
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MELAIDNE=Q//J!3[ALI#9%]GO>\-*E-IV=.*>#VP+UPW$2]?=B'NPK1"M)";
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M%K]C1$M01K7[:W!<0Y@^EGICPELIC-NJ/AMK.B&'L]Z5\Y:]7EQCP![.:R6
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M7:- 1@G%GG>WXGX%68N(/&8ME'XL+,!'R2#_$Q8F1N'LI]*S.,L<[30I8ZZ
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M(22"OW,$C6[4?%V;H0D7_7[G;[[+,*>A##(.:WK2NNXP6*!X>TOE>[LT)B(
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MS/2$R"#D>B?O&6 96="85!]4.FLO%D.3HI2C$YW7/#$YH)Z1J-=^6-=+TX>
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M]9"CR+"<IE:"3A]0+Y4BNAW:'IY<IXT7D"S!S'!>Q.R]@_ISU5).F^UD4K^
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M9*S="6L[VQ(Y$'(E;?SX242N-@O49RV_KB5VUC6C '?D[@6[8WPB+[T,Y^_
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M!!LJ3XA\^R,V5MYJUUH ].;+P::/=?'H*?RMZ4,Y6^115P8W7208O!C[@5+
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MVBR\WF'WZ#+=/4-<=2.BB<@45$LSCY44I>[C?[]7S@&8(O6?)\$&H1[^!.@
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MAJ8A(RN3TBM_9[AV.!0D ==1]^/PXFS4DAD[@N/%3Q(@?.EQE%TZ[O;;\-=
M5BGO-- I0/ .M2J[)\LME]95#Q%4\?8CM;A5_PH9CE^S.@"I@V8MZ5\*-9*J
MX:@I=5Z8_0,&D![<L")$(VQXPC%B&YHRG4>O0?'VDY0)JH1>].YF=!5NCJH/
M[>LWD?:+RLK*5P8S#]>\]IOIDG][P,T-%]/EW.234CAE]?K;?+6XA?O%W*]U
M]HN3'9P&/4.)1)^H8Y&^1?[U#=ZX;%D]SOF.DW\V[3]GG?;GOAE_^JQ!990J
M@CRSS(&1?/\?PG>4N,EV8ELGC.&(#I+H)3 9$E5@HA+7XY>JL<)4\C:Z._AU
MDKI&4BH9H'N]KQTNCF_SPGL9  .9>.L;UQKNE&=F(MYF]G%$S!%$S8UMXZW\
MZGB>@B(=L-TRC99 3BSQ3@4CD5N([42&-@@7;[5IK#,F*MN)C%/RCX%27B)E
M?LJ7DST.C<,9:OD42WH:56O/DQ0@.$M@+->8V-9$0N(U 7I[]I0*+#$.+&5,
ME7$=7;_Q; "G#&7Q&N!7)6"][/CDG^;&$9G)KC@%HA N,1V]X].K3QI9]6QJ
ME?;^**@3!LT<"A+=.$UGB?^:XJ\-:F!XN["<#Z#-=(N8![B;JQ;0%\XNIV9#
M>D!7_&M<U#;VN]%>?TA^)%PL,)2JPCT9^;I),V]1I_33%850KQ. &202SKT&
MJD"B&_^@F^:_P)M.:XM/\([RFP@(WC^ [!*CPI(-1QB7? VV?@(>?2CNB6^%
M'V?B85/I@\K9QLM/IL"XT?:IR>43AC[=J\:P_D30;Y%+QP0(827H P6PLY>#
MVM&P$_L2QXE,RWBBWUCK83?;2BQ:OEG=9X8^[K7,O!$!(=G/LU/T$S6:Y6:^
MR+H#7RK3'AKIAS*X])T87 1F=%4]VO)LZQV_,"[)C5^!GJ:C)PH[,(#%\I@V
M1X2?L\1386?/Z+>1)NIIG%APM<(#UV<*H..*AO$VA;A9C(P'SIG;N?Q2K[0(
M1UCSZF\^5MBI<0SKEI]=(G[5?<_U+)L]Q+H>."@XP<:I(K2C (>-TQ0Q_#C*
M="GFC7";?1RZUJX8D)T>;01*J10)PCZ\-;#6T:NI[3)28:*"BPIT=R9YL85C
M9UL!?G<\I.KQS<T#C'!H'='4S9.JG,H8=3Q#VX.&,;$;=OH4KB(<'^SP&Y/:
MKG"/?KQCH#[7U(,P0A*M18M (\2W)"I:>;Y5N'$0?R6X$'=&$^,(!">'L[Q-
M!X/#$G7IPC_7^5F%6*;TJ,:J.2WL;Y@2YI_1_>E#ZQ_A8)_1-S8)B:"YX6 #
MD\:3@GW!GDN<Y!T?H 0&3RIPL.!C+AJOS">URN'N]UX$(MHQ8E@,<AK(2BE>
M@$Y _<,KKMI5@7CUZ6#Q^=^NV*B6EN+8UO=D7(Q[\W#X:/U@:Q\L\V9".Z9V
M>6DW#$5*,L<'Y);\I(BTGFJ@HA]"!]XV#M01Q? VU0 <6 X'!QBI,*TP9L-D
M(W2E[96#DEZV+WM?;<W3&/S*8EHE8J:L83*@RZ^"LW6V  &XD">".RCRD"@T
M2 1L*/^Y-\*;W=<-<XZ$RV HK#-S0)NJ'4>L(2;R- L#(GK"*+O P@]>4LH[
MV6G)X<:;U>0Y@QU40]UO#_]8^5:X@0+$TEM/.M&#"-@BQVTZB6_6EE#<XX0>
M+T/V(.\L.[Z-&%?OM8>MDGSYSB>=R1:W0+/SHV2=[YOJI&W^,$@2GUZC)'"^
MK!#W;\3+\VZ1Z8.?26_-UHS_STVO_S\]-LU.&0,I713.G?+M:]_W[RERXI[T
M_3W6+-[*O!/N)':H_:3+H>^5#5H?&[2?"A#M=6Q]'M@K0!!KR9 ;;7#%I3KV
M*_NI]=$".QV5[9C,D0<_#N92-&<<1(I?N[C8V/RLG*7UO!E+>ENIYO2PU/>0
MB*G%_*$[UL_SOM?17,B.LVF@<^MA 8(D1USF9 H0O6YHAAN8"VW,>%$F7 0(
M3>Q\E'HIWP?.5GT5*I!8.?P9 :*<HN[-3WP ?^]I&D^")$ <,8'M %AVR5=6
MQI46_US3CXHMBAOTVQ=H\&_6UQM-K?N&KS]N[3O.,8O-^"VURP@#2?EVHM:E
MPDU_73U'G'E[C'>//.*F/MF&B\F]#  =%5J;*_P;;_6$4-54>SR^M?[:IW[X
M1Z#6$YMKC_]EOM/7ZG3.C$CH',H8CLSP,2]AIL^.IK(.$76C)]'J:(8Y_H(
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MSQP.-^VM;"3O-X:W;83XUQUS_@+FE&,B>^2(71'#ZFO1#X-3QCXJGP4(&4B
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M[)+\Z&;7EGB&4_\MZM6 'FO<ZYXCKPN_X"[<3WN_W>*(R4#7UPJ:4:6TG90
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M<-$9$X;+J,3[KH[[2Z"@5G>"<RFQ 2>-S?VL"/P4]KMWX?OZVLL57RYV==+
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M/<[92/G<U?X=4G<AH57\B/=:<@,B0K63+ 9N#?/V^+B,.QO<>-ZSC6E!&P#
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M0<MZOFV^]DV=OKJDEQ'AZM[:L)8EFN2YO*#N5521MD6F[JSY2VEIKKSYIN\
MU?()2=]@=$'5S_@8"&>5D*)'RF+WM084$6TO/!U=RLR/LOO]=]Z8]WC/S>LF
M&ZLZM!JW*1'N3:Q9R25D\D$\9BT4A"!;"4=0G+=:4M_%BO.Q9M!INR@UTA0H
MO>BH),=O*"*%GE[;O8S:]NIJKJ IBPOO'%C[:%O-A],-*E..ONF/5/'&W1CP
MNL5<CY"%+$\7KR8',$=$3BQ?:5:Y1G/$7DEF1]6'DFQ2\@>I>[6YS#O/?::Q
M#E N+J5)%D/"K?&E[LU;4NW=R'Y[JR&:4N/,>=CR[N)M]&-$97\@+M2'F02
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M.ZD\36*,=SFK:&Y4TO&A"\J9GLB#DL ZK?X(&>T.@(<I9TR?5UMCTD1:9D4
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M*I1 _S3MUU(DMQU#=![RM7EW_3=5/$_Y-O)/H? 2T18&-&'8W#DBI^%>K2G
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M#='R^X[4U I4^7*YMTEA14OSN;.9;F3^ NZV! SDKM'74X5Q;E@3[(&8PG6
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MXPHA<R;->G_]B!M[M;CE3OVSR*GK+J%'[[A.SV,#DP+\P!YC*_IX_Y0*FYK
M/= >3-O)\)FD.F:%%&^&K(28Q0DE_J6(]X#7%C!8;IHGM_/UO<4/:FJY;K(5
M1=^,))2)1@\/OO'ZY=W)&,+/9-";(Q:BRRVU.P'>9B8.V08V(A:V"I8JHWAZ
M/K13%Z$Y##>"@5U%BTFFM)TMOO+8G(IW8*C*,+7JXWQ,-?AHKIV\4BY4I,4'
MD(X)9LF+QS_\'8>>FD_^JY,C$MY&W QO(P0YU_#M>$ T5<XUH;3:O&AI//3N
M16UZY."GNI<7']P).GNY0M$4=]9O44ZAY2E+A]9C6%Q=9G856?_SBJ$.IEJB
ML;F#Q9TD,X8;R!1TA>3'WF:</(,) TUET1:(>].+MKNU9F!XYP=F5[+<;T:;
M@-NDHI[Y*>;RA._7A%[?[CYXPP).E2&EP>L,NVA7?Z.[$W)(C2D8 L70=VBZ
M=0^PX7H_YVL3PE'05C,H8&FV5]@#./7X4/T>.X<Y?] Q(RD"4#F)4R<;7@WG
M1=P]F+N .TK=_9=.OW'L/=HG64.*X\(;::I($"\E7:TGWR2M]DK&9L;*WAS<
MFDTLI#V;3LEW[%K 9;:N&WY07W"R13#SUT\]/@/U_G/6UK^5\V/7'^QU6N^A
M7()!6"[ \R9%J]GS*2I]=2!?5X[EJHZH;['ONLU\3:[M4SZ, ^_*?94%TG=@
M7C;C)%BN>"[R,O>%HO WB-\.4[U<H>W[-@S6I810?G'^Y.6QMBFCZ\=:<$;H
MQ6$S5Z(3W#J,5X2B1K[:()B &MU/UGZ-=G)J\OA]UG$A$E-'DE$=Z4[#):YU
M\Y;81W2%@MS)R>3BZ_T8;IB;A@>T7I.-VQ[J5\WF1'0G],25?TP)#V,%"\ZR
M,*+RZ.KRS=B%8 GI^N,%W.O#\,D%W-F.!=S49&B5V!/!_KK^,/S4*<8A^'NP
M^TVY+/?XR>^EA=$ATU<3>+VXM(#_MD[:1JC^SKQ#JCVVWI)XZO)B>^(Q(4)1
MS_]?.]+F?W=MJ7SXX\\S7[^_M=E @;]#,O5RDD?4S-=G'^TL\L:FWC2U>WRZ
M$'3KKI?23,9@6GO1NJ$ZJND;_S*7I _4I"WR:Y\J-[YXL7DNW^U/./?RQGOI
MA]OV5 <MZL+P*'(!9]3(!CXD#V,X1Y:QT=@/"[@;8CYWQA,33K KB'G^CIEC
M^PP1AXF]"[B'PE ,O8%,TA=.,6I!L\<&9QIC]E)N!P'I&_#!$< "^AS*BB3K
M&^RN7L"]9[+A@.;4!9QWI;ZF: &W OA,\EF% ]JI"LF\73* 6,-85-V?)\G<
M(;7.M(F+&B/;%G!_ZE8%+?J/:?\Q[3^F_<>T_YCV_XUIS1RY82:5N.%C?J0Z
MYY/:RSOQ#*ZQ-O>]R]:WO.4]7H_<(DS<!Y9M#W0R__AGRNF?+/=M?H!_1C2!
M*7X@>L^D]?ZBS*_3KWO;;Q,N+Y[I3:WX/VNR;+@P]C\ 4$L#!!0    ( '%$
M?ERH 7P4;@<# -E- P 1    :6UG.#$T,#(P,3E?,RYJ<&?LNPE0$^W7)]H(
MR$Y$5@$)*H((R*NR*%M49!,1<0$%(>YL0E1 @L:T@.P"B@JOH$1%0&2)R*:
MA!V75\.^!"$+*K($.@JA)4GGMC-3W]2M^=^9J9FY-7-O?:%.*G1WGCSG/.><
MW^\\?5H\+&8!J_8YNSD#$BLD@)/H'R >!1P!B?_)UY]!_F?'D! W RJRDH"T
ME*3$>F"%BH2DBH2X'< "@(3T?[P ^$\OB1624M(K963EY!70"VI6 2LD)"57
M2$E*2TM)H6>OH^<!*17IU>NV[EZIZG5*9OTEM6VQ=Y[(;MA3V:)^J <RV'[Z
M<IR<O(:FUAKMC89&FXPW6UA:6>_8:>.XU\G9Q=5MW^$C1[U]CAWW/7/VW/G
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MDS&V6-T8OM-[_0WS'ORDBT :&:75)MW"L68QNLAG\A91A1@(%@-J"#V;@AI
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M2!$)_"+1;1RK#GP5W2(&%,G= 9+P&%IB8. &_BW1+5-<$$Z=<=R?Z-*FIS6
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MB7 #!,8+C9XJ'9""BE,69>T\GL[X7L;O.\^3E?F^)%1WZ:! >["Q9!51+N(
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MIR(1U^X#,>F@Y5A%(X_1@B(>?YU ;TH,**,1/5+,5A!N$N5J\NT@Y2KV65Y
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M"N,,OW5#1HP,/U8_\^!NF2=2!V5^%X$M1CC6/5JUD5 ]FG^OF[Q*:-(3%:;
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M([&H3N6]KF;TU@VRD_?Q0R0S-E8.QCK70)-QC5O9\S+PU7:5<X]A/Z<^$J[
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M<U4*#K:[FSO$<"Y%>S4.D90FK8:TM\<?ZUOUF*<+VF5%;6E$2?\:M@?0%#"
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M^I"4SB'M)*Q+$2R+>N8DD+(;F&3)8$/GAB-X-8WA'->ECB5]>G?JN$$E\^L
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MF6:QXN @+>F^?WWB->R"9:?0YO]"^(DQ57Q/RU2".CY[B?;J[ #M,QQ'RZ)
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MHEWNBHMYBM(.G4ZCBKIV3;>VPCPGK>03!X^=&DL^><QIX_+@[-]K?>GR Z_
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M.#>Y4W+@UJU+C?(_>;?#!S)=E:8[/W:>\?2PW-/S+:)V_-J\"?\L[HN..B5
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ME^XZ/%?P.Z3N0[SMQ!^&[Q?5/,5GFURKE$42<*";Q>C$@_L:!(H<%J7#6#Q
M:S\8 [1WT;U+VI&;9NE8]QR+^W.T1\O!%K'MO%L/&K'N2M7'I,L>G]@2?Y=!
MF*:UHVHLYCI9AK>=N'KQN,V"P_W6QPJ_9.?X55YYZ65[]TJ$7,_GD(./NW<>
M.'PQ9I 0)3S!NP^F+3WG$KK)V[JY:"U@Q+M=PZQ=8T<NONP2(ONGRJ6M!],4
M )Y'A]D;=Q>BQX6\0YSI01^!>YUSQIF/E,^WB!+6KMUA4[)A=9CVA)N6YG8^
M^XD9@ZT_78B))4X'VG]NX_T.*X%77GCXNG"AZX5GRH^>YTN:=<7'5;-#U2^?
M^C%DK)YZ:,=;"9U#TYZN/J9'Q^@'[:<&K9^F,G.J45\";[VWR\W-K#0B[ PT
MT[01Y?[">_<[NB0_>U$\/&7!RZ,W>AN1A-O.VRJ>*EB_Y=]'G6^/%0<6Y\T
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MJQQ-5Z"*MH_4'7$_/;K$4 2=9\^"]MSNLZ-*X"E3H?.7/2+Y=N6$Q9 ;I.#
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MG>TS'5>_Z*Q^L7)I]E!E+%4C2-&Z7?WP/9C!IYOVG_&.8<86\?G_7-=0=[Q
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M_X@@'BX[C6F;"9C4_$K)E;N)7"1POZ*&M\63/;U1HCU)6,9:@_*[L])G!+\
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M9)@W2,G*=CK1\V.>#S\T>6];P+@U\+=!U7HC=VPJM.NT9W_GGXSZ[/J['_G
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M^.*42Y9YU164.D$[*>)R:0'@OWL&VERU>*S&CX**F+(=D EVV)RXS$[4)C!
MD7@E9%/K8"$T6L#(:\+K\P6<E= MFK59]U-?\DOE#>Z 7W'B\P2.M=\ G3@+
M+%:@15O6@#2Q00?2\HJG$GOX6!D0KUT9Z]%LBY$R:.J?H02!17*1"<ZSK,=,
M$:_8L"59F6IWLA\V*_K63=LCRFR]Q7W>?ZU&:F)S<=SMUK5V((4#;4]#"  W
MCSTW)5D-?)L9*6 S%S!)!/0[A@#Q0VE1K9S$'_E 6FJ:?(>DC6C2S,'%4PV1
M;6DAZ9QP:Z-LR+EU;+L(N?MR%+9./0"RF/R'M/V" '??N635H:ESK49AIA/F
MU<&?RBI=,;C&05C5%5$028(1#@ &,AK"B/S85D82"<M2@MU%;"%F$"@9RQ"E
M\)/AS91EOEXJT@>L;?@HFOX-\+7$XS5X,:< NOJS,5VCJFART O;NW' =KV;
M%_1I-M/(K7KE*!T&&KH8H#LAD0,>Z8K%+67)T]OGLQ[P*".*XJB$%J]U_;8;
M)JN7I?!OL'1H>/#OR(-DII*?=N]'/T4!8164YG3(--';H]M,:F3?4VO)7U%]
MMG^FK,CA,!) X#X6V6%AO;V"H;.)ZV/PH^@:BUYU_,^$-8%VN%L .?B0X(#,
M\95[3AR0.;D'@\$P9XN@--""F]>:H)AI)-!LF(EF:YC6=&Z9V5?;2]\(VX)I
M2=,F939[-\4O8 Y6E8J.WBT8[<KQ:@L*U!W+W$KQNYKR+F7?E%$,9@&S"SN2
MO5BI(0W@W@&4$55D#-!E<Y]8Q383Y>!@*(UG@W>"O/G8.WK6T*]L*+0E71S)
M)\6Y,+ P&6SCY]TRG9&!%.T'RAPU6]R]GOJ!^SW**TL2CEK148ST/@+."1F_
M=!>+=1%9FK0;J)6=H'HC"HG\,$O8D+O+%D.=XJ,HRU&9R':N0TE'+'>>FF$'
M,7G*?W@Z./:6*U_RR]H%NL;56O!J.-.S>FM/E4DZUEEK?G P^.&X@)%30899
MFQ>A&^D#EA"XJ&@"C^*PIVC7"2JV6_\I8K?(<9;V_XHRIAOZ6ATLX1XPXM>L
M2CO4C:R&=3Y87^!_A9(%+I'./4RSS',=#A^^I__<[^$(B)T1A2:)M=MB-4D4
M78>PB9Q2BP:IN^(A!$M3@73!RI,B]:R[.7M86^J@!,D!F@&(+NKD%9VY[6?$
MQSQA^UH1.RG8YN"7@-:<I9PXDV MO/> JLV!/82,F6C<&C97P(1,CC#*TH1U
MDBWT?NVV>GP4I]0@+MAC1@Y>!86):EIP2V"+8O\!;1MVDC&B EDT92EVY_8B
MVZ@)#J T.8;CQ)9FS^D2&F_6M<6?>^T8O-6,LF+"BC*+:LIE[]!VGZ,;H/\2
M 1]&/$Z%[1=FYSB HL7,<+(+V!D;3[N0-V&>CH.WSL1FF5;VVT7"?@43Z8Z9
MR;%"F@>YD$II'I&+7P?.Y>1FK'?S=>\:NI0W>#Z<AKKQ92?=1Q;+[M1+LZU'
M?3=*7(6C(HV!\7<Q%I(#!4@74.HRZO?+\.<34MGI<ZLM#EK_?L6N"^/$XL +
M;0GP 50 +S65YL!+_?*U:!OYE*'QUC&C0=-;Y/,384S(0!#;X&G0.'^K]M[P
MG&)0CA]B+;I0/>KNV>!WS>SZO?FQ2;*-K<,>[.S LWAD'X&;SP"#8^'=1/$W
M:%"B 30M0Z=\<@$3;8-ML@=X%X"F8^@?WBQ@HA(0#8-&TA_P\=$%S/(0>&=E
M,N$UH60!PS-#&KO@C>X,<:S81YRUE3XL9?C*2$02E<43]PN8LP3(4+VMQ8@T
M5"-@P"9^B +ZPL4PJ!T$E"UJL5!OVFB&@NQ/J)@@3^.H(SBJNAE#Z /:Q0TB
MAN)^>H/T429Q^MPOH@4 #/Y>3(*/OIE;Q0&_>NX7Y[ 6,#&>Z/47>CU8;+>$
M"7FR%S4$3Q']+Y'0XH8^ F\AQ)/ N_]L039VCOXRQ4TSIX^@RZ9#XJ"!FYA"
M)Z-46@/POK!?L1M(HPZ(N@]L2().J\$.L8@Z$S; @8M=1=L:'2+R:2,H5@*-
MJ'=:'AN^@"E'71:!IXA\;(/75_N( 7&:^"*%U29]>DUF7I'4PH9UN] 96PT)
M044':3+@S1B6X_]JZ8I>P.!LC:A-SE -/W._^":4*2!A:!X4A0F1)\T<NL"]
M7PD%A.51:SP_((;4FN:L;:FCARQ$P_YZ:R%R3@[K09'_2H^.;,!/':'8RE<#
MT%8 ULT)Y2NF!/,)MSBOB<T!1(\>X67FN0B.(Q0FT:YCQ?$"[/[,V/_S8/83
MJ$W\5\I^4<2HOP5[HMHND?FD;_49_8-/L'D =Y0PFB8>@4ZBK3ZVF+>,FXX#
MCP/)B^D&C."#_?#V8C\]E01Q!#0E,N!?2L>VD% U[=Y/F7-4XYU,:[%Q.%;#
M.(3"ZW@S?;/H]T#MKA$*O,%6'0I]0K[G-U+Q0.RY_P RB6RFN:"\87]]]4P+
M-A&G2I,%8WF,Z+2C%#7:G]!3 4X%DJUGZ7J27%Y],$T=I'GRZ^SL/YA&]YM]
M<CW2?4WPPE^#_\NE[Z7IE+?QER^U.X L=)K7D'+( '@$!YDL8*874Q#M =6C
MY])BD4V533.WQ[9Y:I^BE!/5%^\PK[%C2&NL-Y[-(\>GVV9EF4#8%RA$?!$R
M+W5PJ!G.?0,"^[[A8!<DA<W]@E?S'4.--$(6&1K;#@IGM1FQL"N/.)S<?%,O
M.V"]0P#P?(I4KEFOZW"TMC+5_-H]G0R'AQ?CNA^YZ;J=BE#&T%M'D0'VZQQ.
MPRAN1&]0G"YEF- Q_@DO68]$[SD"0E,<2V72D->YWZF'MD],4/,6Z5.W"*\9
M.Q_LG_UTH6BN:EG:"S_W!YFB"'[KY*XZ+(_1PH@&M&D&>= O[CA*L1<P&C3E
MPN84/Z^=D(\ KT+]V7CS\8Z#K]M,&'R\HK][<7+HJKM6A^YY>!UFZA3F;ZEG
M_$054J0OP$TAO1Z$U8W$.T65S5VC8TU\7%O7,J2+H%'K)K% WI/D35A;:0=
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MSF]2$K=+L$C?X+>4EP%:K!Z6/'7T1,^7/TZ>_WFF;WIZ//Q6G4^2^>V7M[0
M?1)X =N2P5P.JRTV:13>UW^-M!16@CP+X=50Z0V1;(MK;%.6&B@=>,K#QY?
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M9\D?@;$[&Q J](G=M:%EE(BRC!)NF4.2$8'YD=:+9Q?.0* $/PALSV.G#B'
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MAI[8^>C.@33VI;T'XIR?:FGD6;I/CL^8@M8L3D@-&[E-KE9%(GLRLOUAF4<
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MYE@V%[<!^69M6TE$K5,=9Q:P>U??6Y6L=;(B2Z]8PPY;^[:RMB9MQVUWVXW
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M)69AXE6OY_-2;[.V7.N6"U"53>!AMXP2'3SAP]QA;XNCB5TAX9=Z2^M-9Y0
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MGYZN0>! 3I[MW@$?UZ( [;(Y R:U>0[6I='1"D#S.6!%&6P] G@?TR07 JF
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MOW+I30[)&F:<+>D+UW!(*E]Z-!!\[+Q<XF#]+I7C 5R8V5 >NC>RW0CKAYS
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MRB-]1O$ZT9N9K]()_H-$#(ZWQY@(,92Y.:2,?_QK\0;E9R[B)X0A]PS..+M
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MA/!\ZEP4^A3(Q+VLS*:0IB!_0CPU\[+&Q?.GOA[A3NC5Z$W[4_U\^N;>5J'
M: \P3M+J7$^8C&ZHHDKTQ@A1#F6&/]2XMPV3!M 7*0WHD A/GTOY]?/-T1[^
MQH-)\J:!8BBU-"F:OZW9K9+#!PRY]Q]<NFR@C,U" &<1-">@E&Z!;#>*TL$P
MC$Q$$LT!'JIYE .0%$W"B;F&W3FK=;";F.9JBB^-KIP;K3<,D;,=4JT;Y35+
M*\D\-9@ @OQ:9^B%KC3PDNF64?NF,G38( $4<?;TOQYL'6:IZ>0J"&64#:H9
MY$9-VA$.<E5PQ+27LLYE?!I)5/PZ@(S//2=BEE1\]6I3X*;,MSO/,C/,\88W
MZ3%79/5E[>^IW7OZG0+J!P7W."<I!:<^/F<H^;40O',3:*??8 W N$T$EV!U
M?%VH-#1X"Q9OY%_Z9P.8'.]V.5E1XKM<9IB^-G[NRS#F9-'X^K',*Z>=%ZU#
MC,SYC=YRHS;_<#2_A0.&QF"2R+O] TA:]+_."]V8*&7 +3KH9!R2>DOU-\.2
MNFFE72= ="J\G'UIJ/YN@!!VXGBC_^5'VD]:4^$(G,3*6[HQLMT422@]S-!G
MHEC<IF0.78((17%5+ND 2-,F++81<*-L+'0YH@/']-)<EJPG[^1M_%@W\-F8
M4W42%J]%_+5G@[C3.6K@@?5:_^WV$)&"K'OH@EB5HU_JI+GV^^A%&I0 T00!
M] G#@8;,PAOU7499%1YA^U)<,Q\'\[\F94C< "%/XBD6*.",)^TM9QF/_2;-
M5GGH7@B@F(#[ZG9GS3B& J2L+E,#2:D2CC)KP]:HJ^#PPC<76@;*?2D5(6S0
M]2.F]2UVM#+.PPU]]%/(3K-_MS6@7/3#K&X7W J1@B4EHOXOYMX[J(GH?QN-
MBB(@(+T;%1#I(AT"49$N(+V#2 =IT@+$!.D=Z:A 5(1($Y$N)70$!!202"<!
M1)HDU(6$<./W_=VYOSOSSBTS=^:^?VQF)[.[Y^S9<Y[/\^R>\WG4^3RS8%FX
MDLFR)?NGJYVO]BFQ[V$;/>I"R19Q^AA>[0.E;;>65%9NOY0?0FX*><.G(*M@
MJZT?QC3^G?1" 3U)&26M'AS.2>QWDE>VSBK]O ,"%:=8=L\+40O]Y\^HUAJ(
MMP_L1=PZ28&ZHRX#U3W3)7_;\(P1-H ]KE##;%+>1\^MN6UB7WQM\XIM\LS
MW$I3KH6G4$:R+&O@'3!>(/1#=T2YO1?R\:?/UOMTU5D&C5%WG5GU1;.M>J]8
M9XY<A7]8DK#2DFG:K][,HC#V4(L=@)M^AWI53WE3Z+8)IZ #V,E+=1ZR)-",
M3]77!#*6C.A@&@_'$"*PD4-#0FY+9??']?:K*N]KUFT&LG0;8C0D/S7H.T$R
MM/E;7AG]7: (:%"?Y/@IJ)CG)/\41!B#42E[SL]?\'])&B(H71A:B-];\GW
MG"1$I@.02POT=@:A;V#=74@FB.H[[VG^0\Z=:8/@4B\+"V.[NT*YN_HTJ>Q)
M?2+!(C1)()+ I9HA=LW/;Y3<_:V7EU:4!?A2<GVI^M=KRR*%-OC94<=1"*J]
M"3>[O,S/?^[[GKQ;))0=N=A,K8<^5.#?&S6,:_4%RBB2F2(.T\==J,$Y)O-J
M]X2U:BQ),IAC]X9F)%7O3]:]E/M35>>>ML/W$FRJF^N:\5!"(OW%BM&.+W3Q
M:_HT?!&]-4"X%*5"'=L-0&1'T?+C7>ZM-/^(8V1Q/?L9BO\JY5+<R0<0E%B
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MIILR@O=IGEB*<T*?TX<?!262@AP*RP</CA_R1S[S4@X_$]7OKWJW\VIP?YE
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M[<ZJ$-LVX5;G#T+'(;5+XMS)&D^#FNWN%>NTF- ;^<[[)ZR\OH')/P7-/%;
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MM44::%3BEC]\XRIT]FV<.E%$;$YY?Q7#K52]$GV@<-**7'S'2/A]V)]!EIM
M>B#CKC!G&8UIE3%F6GFK7]UULN8S_5'MG/-7ON5F-F<KZI&5T-G;RL.(4C('
M%9QJ**-0EF"/UFM+1\'0:(H*2['7%VA*9>EXW98Z3FOJ*F_)R/6,F,@W1W=$
MVI7!:<B>!P/J&&VZ@N^]A*HG@[$2%ER,+U?J=RHAGH\S@[+%?I;H,\0O&^7@
MJ'Q$]*,9CHV4'@T)(Y 2;C5=DM3+G^?M4?$/\G0'^-TX8_7H[FJ9!4(TE19_
MSWQIW2A/K=BY@2CSOS WD[]T=4\HL',4 ;VK?\E+&11=L-,/2FO[XHX%#S9#
M&8'Q+H3"IW@+0D-;Z<:QW8S#PL.QC[B6^GR6K[K.SDW'*4$?"SAG1^.[SX(@
MCX*$*/S1XRF'/"0/B[3K<AM.Q*!5K?=JVTXW+5/=7<I&Y-?T_(VSS6>PDQM&
M,_[YY"L*J;Q'KN&P5O5K#>7?J^CS@]EG@J^9<,4L/2MP&6]/W32<.5J\#.N_
MIZWQ!WKB\"YKQ7#U[>'J'R@S08VL>0KR0,5DD!V-GNOC6Y35A06$Z\OJA(.E
M?3SX;Z;A#A%_UXU)7Q^)V>CL''%W'O0++?JX\G0^:@81SJC=H2TUHOF-9DCI
MG @N<ZK)%A]B5C;I43%W,A[KT<[=*[\G91*KR17*>=3@(YX1]>V3=4S-K:&:
M/1EIAH1</O8ULUC8]YZ[(BKR@G2*>N\YB:]-+&?J_JQ;"JH?4?6 E"KBV?&8
MK^4(W='3\!"A1Q$GL,,/IN([A<!CK9"H,^ \ 9D^E:*G7G>XSS[ENYH6+4B@
M0;1&8#564IY5:<TD?3GPLNF=V=P0D;3/RUN8"N5\UT8Z!0W]].B5]YY7/:0.
M^S-6C-'*G;[,&J-/ M,*UR]]_M)7KO-UX/@X:_S<*:C:U#U%U5]'603C&U_]
MY%P1[=B[$-?9?FZ'2&+! 6V1H=+ATG1!J&%ACM[@[<-QA^6P9QORP<7U+2TM
M\@$.#\L+UD@68['*FM[#XH&*H2ZH9ZQ_(2^^&>I.':.&U./)$5^;21TNR./T
MR7+-P$M1]XK_%E87#<^"[]$ZIP_QU/*%1?KPF;'>5FM#2IU [^A!DF10&$MS
M+K?7,:^R,['Z]O:-GQM?"&\6O#6!Y+@<E0A@Q3ZGS5N,HW,&;ND.='!_I8F2
M34$ZZFF@6B\*%3R#JJ,2*,T\%+N<KZM778IDQL$VB7:Y'H,OS$./E]F>1_>+
M?-K>[G46'S!\&*_V0*W9<TA'T>5X351H^L=:<%"CG(UUV^L3BW3"][!9F3[=
MU6KC_5/0/E),-L4%%#"N/IN&*9))]P*J>U$$XX5?BAWM@MA6@27P],(B-*[5
M$F>OMZ1#!,?O(Q-LA(NJWJU;5%JL&DX\<6UBFYF_-V4MN7SWJE^>IPC'$930
M36&R/(E#7$=@*9(GA=+[YH3X;K4;@26 [1(% \MUN$QDJO<:Y5@?<3$6B'LQ
M_D9?4G?%X^]UIUO<%S!6."@-W'')CM,OGX"-(]N^6OS\X.UJ<^Z--(/45"77
M ?%11K$ZI_T!N4(]*SAO#U[\GKR(7G8QG7RWXZV.[WFU12(,AM70ZZ9E'%+/
MI%[];G5$>%L?M(W^&6X^?W=)^7")?(PP6Z&_*T2Y'[*Q@:+4PX<($0>#)SE0
M#_#E]796 $RZ0Y8 :O&%X >4J0DR=-&(TQ-Q]:=$W5M(2+]QT62?IXO^-4A-
M]T$4I.HO5X@15/=]24/FP\SF8!-U<\$/5P,IRNN:B."TP5V)I%8"3[MCV@ Q
MNTKT4:"=FMT%,;%WIB7"&AR&J1[W_+T>/HTR,3%056TO-PU^4T*?7<)WHT"H
MI+Q^/SE4;]*O-&DYYN8 O[,0:[C+TPCF-3N1]/8;<'7 L5@3#TU$*!#2(X/H
MI/#C>&RK*YY1M3M<?W[6_6N-@8994V.#=UE7<QK+C2,%A9]*O2'#UUF^"KWH
M=8:H;I%^&1]&;B)SO1<QP,W&S6C2#<04JC:W;-%Q1L]>WP@06$SU&L7[5E5.
MP;X@STDE!N-:O#$B#]NPC[YE3/6>GR ,/SFS.VW^@#7 7IF)X7S*R,ZW&YZ.
MM]/.<247:[!<:J&[U"V75*$T?@J*(0N5/TP3OSR;+>HTIT.R'M#4?UGQ;=W2
M;%51*\>J2W(^F/WZEE^2T>N,X*<K.56UM>[5TELY)*'(><<M10*[0$DR.&F>
M:2='Z:BQT.S:5?>F?H2LB?362Y+0!Y.%NE-0!^B6?2)0OQC=?&? [[7U0_8S
MN<XYH$#'Y2D2HI]$8T1<L"2LDME(N.U4N"3!M.OVG$=T+_0RQ+D,R'L(I'ZP
M'ET9QO,IR0OTZXZ_ARWK\\&F8@@<S4?G4DY$J"2V!(B@_I8!M43>U<5#,CNT
M<U[N1U9O&EL7D@.B1F2S)*0EOYM==ANUBOO>ZF_+(1B\(;Y%C:)WSYU8CV)<
M1URS ?96CV)4P,?K)0]*XX(3%^GM!"+AGG%=%IZ]EIUCHP(B"26ZW2R.=/?:
MX*XJ!IU.*XDQ?Z3CT7T992^1[EJY3#'FVH;RJTE/NP=ZWT^X#W&XC1TVF_FU
MY5:?.-;Y!.H0+[QVK_RC4EA4_VX]]\<ZKT-%J8/&!\]7)3E=$KE8"][8B@&?
M0,_;MV E<=JIV$N5'5%!D%%1%IYD5=?$)Y] C7-" 1V+@2EGQC!GR/^69_YS
M;#,X!76JMW/":!?3H]HEO: L9"AAM5M%I'LAGL(/6'L'$J\?>-OS=LJ=B!BT
M_)3DE864L;/T!L)QO[XR^+@YH5*#TP%)+)D]^>!-$9(1T84B&(*O>!Z\>NL1
M!$YQ9)?TDR KLC]-F9ZS]SQ\*/GNSKIYOJ[J(!,RY/(%:*<U\X_Q7O6KQ[_5
M\YC4!0;\ V+6W5K]\EUG!30?;00.,=N/CP98V1E>-T%?\<KV-Y,)OB8RF%WG
M/H$=N7W,)+>.-1<?S%XQ++QHV!J&HQD_F;49L] =#+!5.$;]+"W[</?M&F]I
M6\!O :C.N/2^=]US7NOW#>-;KBU-5H\=BW1M;MII1;)^NY>2*4[^BEQL1!%L
MJ#5N[.\Q8H/3$*PF*=R(X2MGL?6,\A!1\5G/+Z,]:D:&K_1#?K8^8BG.-%!V
M21X>KRO3NB;ADA?PJ/Z$P1K9*8?YMUJ@H9+HA6P(W1IU(BEY6.JY(!G(9[MT
M#K*87_4%C_WUN??52=U4(C/A^=<,.WC5;M[6UBGH0CV@W[U0ZY> $$&,+'#
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M04C+SD#O@+BR^,=#4G4-^5^FMH$%$(6/\@-)I<Y<@'8O%V<#DK4N]3&8!<Y
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M6.>.P9J+,O)-A0J\CI1=6*]Y[$?@6%ZB]RYP0Z_3/UB,9C! P\1Y>VD??*G
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MT=PK^6;64M\8FM"Z,6%?]S*8X:78WSXCTZQLC:GG.X<MC9YU=<UQ!O\]Y;C
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M<L-G@)QWF7EZAW\WHMY:/T9+;RGOT^?9' S%'"QUS-Z,M0I(G+F<E/<2Y?A
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MTTD/Z=,4/WJ33KA&J=RLE\O%'3JHW5I- _@02=R# 8Q6;S,';SW+HT.>^O6
MLX0F#RHO*:/>8!]6Q74]%K4ONJII$>TN.9J^Q&^4LYHQ^VFE;Z:^=$JF[ SP
MIMFBG31;%:?<W"36OT\>DN_?9W9F4_A)"--12G(,X62QMUQ_@HJ-EI)^6,%W
MZBYV'";!6_@-4G0TAF7)[ZSI_<9X+>SZVWINT:3[J4;+E*XXKJ;J!>EJU;U.
M#%IAZY4KJ%X=48MLK_;WE:T_DH3Y%G7CA[ROQKB[FDE)R2J)ZFWX6:6_IOM1
ME;M#H_W5&+Q1[HS7C ?"QS>BRO>EEW;17YBA7]^(XSU\7Y[M^>/"4.>>556R
M&G5>A(^2M87Q9!/Q/ -\F^P"QB*XJ9RDZ0T$S]_)UO.-WGI8+)IW[.8?CQ?I
M-0YM(\XJNW+M"8\?5@KZ@6PZ2='=OZ!@^62WZ$)3Q:(O>JJ/F2T]M!S[Y#D]
M%7-3 U833"9A>:657@CCEZSP!$W(J&FG4"B=OQO[VA_@ZFB?/W^!85RRO@-G
M]  /RSROGI6B2%\^TWBI5O#Z[4"MMT3J7KJ-^@D;<@9+U+A;A_ PC70\. /$
M[QJMSU#M15KVQY-E K&(>M.M.APEH ?[AYMTC"_KA%_[Y98\:3Q<B^!=SYI&
M'?:G<EQR<"]2,MH3VK9RI&4K<AOB6]!X$@;G])1 .=H7-9@(?&V:V6YHM0&E
M+^4#_>O41^9@ZX)\17:P)2C"C"A%.MHP,9*#0E2V*H1VDV]6T#C?&+)X< G)
M!J&DVIEK2X46%\7W%=^A]]D^[F&$+KXGZ/C']$WHZL5.B.]:9RH9L1=5#%B;
MI3\I_Y!7/F\<IK U5&2ZA5X$TC4K#C7K=D.K\M<R A(5ZMM7+*$!>5]6;1LT
M++"/I1JYI2T3RNP?1N5$K@0>%56%4HZZ9WY[RW-QY/('P"8T>^'M81#\[O/(
MB*9O;6XZV+SP5\DM^W\PBC1A\KKO7TE?LJ:GU73FVT\ZT7%N0M6]TMV=K@'A
M/(""AA($=N5?JZ7S: 0V"'9>0YBW<PQ8:5!-2T5)B+NR/IPF,&?NUF15*;VA
M>^A<GR']JGOEB!12LA!.$^QF>G70]0)NE/JSNQN6F;#Z8!A3G+DYL;L-B9L7
MAK.1!02":%15E*2^2+8?3[W["9,8?*K-(6?O934?RI,G/Z<S(M>X[6$-RF"^
MN/"L.0GL,S]%[V=Q:D06X) "(0770:)[]%)9@.VE8/AE1#L$\6]G:L]VSZG*
MW-\_K)2O5#I2"FX-NYE%D, VN3??5IE,N\]57XJRE:RFJU)U-Y-;2/RV&W#A
M5B^P9U8K)"OPW. $^XTFI[YB5;M\K:U'##MM;8*OYE)*J[IA=PCF)1>>I=^X
M)'M"!'+JSUAT8Q6C)><]WP8M\<N[&\J<#AGJ.]2G'/3\]3_5^8Y8?]!VW(I(
M(#!H+LSN7AN0R'+9$YC5EOIN0?0KB^P>K8H/RC>R?6]DK+LS46+-.I+H< 8P
MX4?XFOY>AP?2I+V ^]%Y-XB0QU7CD'8.NG=CK8'= 3+S.L)D*U(8P4T/P0Y3
M(2!C0?X?NP*(*650-POTKX/E1EUFXE#@<WO5[[I7:I^NW!9B3CP#9)I&U4+H
MAG#>XLV^+PO_B@@8]_N7SSM^ML5%:=@6\&4PIFV-A@4Z"C>XN[SE,*S:N404
MI$$B D&CK*Z^$2+<I"!D_=K6+L.;Y;I8"T+1-/P[4>W(^5J!N-T*SSM;::RL
MWYL/[R57#>8WG>#"T#2;)%2\%5Y&MC J$3(AXV+E_BO-4S'>(I&CT<3:A)B<
M4[A"S3X#W*X4/)%9:;YI*K4$.THBE;S9M+0,: :SG4H'W4B_RH]3M*KF<[.V
M/-8LU;OLT3#H;VVHJ3!_IZUR]7P,JY[ZHZ %_Q]K]*B /U<)>I$+ VR6!(EX
M52\6AKNCWD7CP2]#S7-NRBG<'ULXG;2/'D\41;_FOOHT]*IE@4'5D-D9X'P.
MS4";)7=*0^LYPCK.8Y"A539 *UBBH1+8@\%;(4EBL9W("]":-K@,I1[L1G'#
MPA6'=P_D? V1G:F]W-L96W*</6*(QT_8.2HZV+MN:W;!*T!P$<6<CW'MX;4E
M*FO.N:MYLHL7EFZV:Z]<SQF!6&93$0L:7EK!^*_=RW9G@*]ESAD@XX\9+A)6
MYAD&7^JDNBTM/2VCY-<[".8Y9B$/Z@Y+*4T8%VC$U*D1C$\4L L1]A 4%+U2
M:L<'_"RQF?@4C/;=\L,BR"K(]@_8M^!%K=&(]<BW3P=UFM?J$+F('O!_,!$\
MHAO\QEF I+R$O BS)?D7DU)/$$S032RK3^W+NP;CKJD[EPSL<&\X2XK*/&]\
MN,Q^,IFN7[1.9^!P*>1BR\J^BY6$Z!< *V**@5Z#GIL\D$VYJBR$5NQR/82&
MT.1:V3AV_ S@G=[*K^&D>DG\>D:.M[UA!1MQ__49P&6-T3^6$3_/YUJ@MEHF
MAW,LH\]9E*X41)W?JG[O:1MK4J&5(6J>M[YOE%=HK9CNQLLOMNM[0,&O;6>?
MRI+0]M_P1S%4,/GZ9/"V?5#]:)"V>K>6ZQ_49R<C?R&>S)$?3S,-<^DNWW[R
MPF;,WR"![U$Y'2CVOPR7?OD7L)*(<.:0JOW#?ZMYI 0B'\F.D&!*BCN]3PXF
M/< /0V_(?YMP5LK="A4H+F?(7IP*,OY5FV,@,;+,/)U^F9O9@)E/R.;P"P9O
MAR&)AXQ@B!LDIN/!0)SA^%O#;ILML/Q-C@LO)K>;+W59::1=1^4LE8ZV26_O
M/5Y+B/8P4O0(W#?.-+,9E>^]J>HEAG@/--PM)/*VS7/4*+"2+)0'2:W\5@+*
MW6X<O3+#'X6LO'H?7V4&25ND?WR@A]+_.:M=SE.Y#L]7M-B/,$K,6WZM,;24
MJF4S= :XC/"HBD!>#*Y>Q,2!>:DB4+;.U.G*4M97. 3G;_?IHNG :MM#MF].
M!N+A'B%OA>2QR0W_V?3^:XM "[77UHFO3@/)_ST> ^+3!I(+)OAZJD31US %
M0)*\6S<;20*Y'5P(55Y2WSHZ?0CC),42<CNJ1%Y50$.QTV/SI-A...\CGKXQ
MT[B*RP;5^7\<(IZ:BVKV@%XX6G3._^:7OZG11K&Y 662K[O/V7E'J<)(;<TO
MS_5ZOL;IMN0FU_87FV-DX6YD.MF2 (DD@W&-#;L,"] :D6\Y82O,*9P)A<8W
M.@.PYTTOZQ5=?6#>:>V94I^>@])*WW7OK:,835/GYJMGI/XG(9IWUCOTO##H
MU8E&K6AY]]"O#]R?1\=N!>=7G1J2^>BO^)P!HG8-9_9?X.YH?S\:0+Q?(^KE
ML"O93?=<?L3TWJS(YFX,(^-I!#ZLY_[)9!UUJ)&M?9*4NX@@.<!5\&BL+ZOQ
M%P=&V%V<,;1D]'FQW:^BYE^+T*+;Q6] /^:R;643BUB5(9&N"(/[SSS>+^"#
M- )R"I1JW<5E@[)J\I93;=(Y7D"L1QW"D)L0?FJ/#N="J\ 0":E,R%5*MDA=
M(95W-\:R/LQ;$=*6,.NZDV^G_G/47N]!A3<JY? "OB1!!<COWNCVIEFFW -^
M!;]:S3!]T.*KEW-S3MGZF_>/&KNYCOOF>K:75Z]>69C4^R;9<8^KUO=K]""[
M6\;S0]?-5/]CFV6%#B!)VHW,8;S(@/6]0-:D15,#_I+I"%G\T_1Z"/$M*=G]
M2;)K',O8;2 1RMXCWINI>\_I,Q#PRODM8N$;C08>MIG.E"QPL-\6@V;>,='T
M7MNRG<56[H3]#3\#&#[L,EM)R'\.5B[.^U2MLERH]FG:-->*%UJ\'0X9. /$
M'J.95P_\W\=KAICF]U\TYK3/9ZI32G35RO ;+I,<*9/VB;=<,T]WT=23-U+R
MEA&#Q]-4JI9$=&V%L?/DH: <YYV1K1W?PP<VYOER0?GRW>?G@S][\BIQQ_,]
M?FBW_#8B,BVY;C\*C$9LA<PBL,8P'E% ^3O2ON%TVX'TO2)ND,C%DQ-8%H&-
MRM1T!OCO+2EK(847RM %KA]JTS;&%J@.J[*Q;MJ'0W,"LD*T,IK:9?6]7UU1
M^MK;QI"LYT42),TL#$51N4@]A$O8^8O-D$73. R;-^AVF/_"$"_)+/I/)*+0
M:4",^';&$626K=/^?&2Z/QVHQ4ZW,+FF<Y7TRN85WE;6AY<^=D!JR<LDVDWH
MZ2/\7J)E:?W'P5G/RJ>YWYKM6V.)L<-#?X,S7TI!8^.A#MHXV%*$\O,LV8YG
M=@YE;ZVJ3-51YNCJ[B[+SCN)5T&"07D?BG8%AC/1(33O:YX!?.9_KX2= 6+>
MDM3EU0X($ZF (0MJ32+<B1+XFT1/+*04Z,AY^9-"%X>Z36,+U F"^K+O2.$=
M5)FOO^IXZR(N%"S;.S09W)/:;W(!L)K>0O17G0+OOUSG1GT*2RQ+XSB67D@:
M]9U!BNL<E "E7_N_HS%P\N6$)7TR)Y+X.,N.A"14$?-(BO@S0/?;6T%#;'\+
MKC8)/&M">=I<6B&]/I9_4I-J/ <T>R-M'U9YSCO@PY-6EU>P9]W^/GY[V<LD
M6)T>*^J^ZWV74K[;8G,+2^<'%&*D#$NNU]G/G%Q:OWNJJF'Z=WX1?C-%BI15
M0)#W%SCPR_8QCEI$;2L+67F$:W29LIFCC%2NG '"[*M$5U#\&FKC3\X =9(=
MT7T\-],!#E_IA2*WW[YX06%78U5W'1+VXYU]4=  G, HZY-Y JD7G6A5LH%Z
MCH--@Z!"TMS0^+H$.J+6<<WC[1 D\>=1+O^H;WDYF\CU[RX]#%=LW<AK*/BF
MT+/+)<"*Q88<TWRKXL-OL(FUEBHO\6^[-(Q)H+"S^GP*C[''32;V72N__WBH
M32I9:4<Z]GHAQ#\>[G:"ITT7)-KGO(,4XF@Z0 =(8G-HJG,RF;]+@,3)JB29
MX ;U%2O(/$?FLE6>6TSE\2CU<\KO(CO. -A0> _@(GBQB,JRLW&;,)'.>,"W
MKW&T$+P.Z4\A\XHN^?Z;DC9\252K/)F!4MIZ$7H&6+*)6$LQ;L03X\J'PG%
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MY13$*J<1O ],@+S-H01@]RS.#O.&?T!VGE?V@:,3(Y9%GT5(NLI-2\5)LCL
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M<0A#@VH*YV].M]/%#)FB.D<&]VWD%>(Z'=A+'F0>?8@U262M*,CT*>5_^O$
MLKU&%C*C\QJ4QW!D,ZP'&B&@#% 6 5PF6GIB2.&-G.M-GOI943D2+A62-P+T
M9,]*,S4L!E<D[ES_7DIVS!D8</-1:!="YSP6$L!(UI.;C"T^D0\R[X#O@1 G
MBGN9I!]H>R:&/TB>?W?^.,T;,KF:-6MD'W=41Y\.I9OY5#P!+SIW*;_,#U01
M3W3,#%K,'EY2S3JLKDA+4FDWR;K)?P$R.<']K:[X@5#"#%6+#WJG=!CXVX<7
MFH.-V<J^%XF,193UE_2K.?_ZDI899]Y:-;R.YD%^LKL#C\1*<1 $*&-P$3\V
MUQ4_O.!6GE%E,(\8P%B.=VK*E!ODFY1K:!9J\;QJ3DV)BV<W7"&'@([_R )J
MYOF3P'5T33CKG>HU[']=Y&$31'L-ZZ_];^MZ]3Z$W*<\9WH?)> 5@3 S#S12
MMQ54,-:R0::=[V0E:MGEJT$KI7]T9H#^*AT(?1NV0=T*K/8ZU\&L<3?90VYE
M-J>]+M/7'79:G#-?-CO=1-I+%4HE7,W6E8H3>P5],U!DDMY4>B/S.)NN*">V
M/)]XT*:.ZJ"'>B;-,F$@,6URB$<$KW8(.Z#2R0).,-$"S)VK7><*"XPAF21M
M?W=W:ZG_NBY DIU.]]__. F%YN1>)EV&SQ^5$7[GXLTQB>5%%O#CGE%-ORN'
M%B\%Z!I??2[P\HA\'K=\ ^MZPU$SUN*::/CY-JK#2UXEFX9$JW?VTMU(I<NG
MD"@XN>?Q.S;4R:^Y1O'RJY#XTCY%T2RVI#4:$L,#PGJDNC)I&L*Z)^4WXR_I
M\&\GLJ.DDLJ>"=T7(_7Y5?<+M6]9=MQTCO9+$-]/%]='ZO38,3ZKL;%^_UO)
MCL>H?:!2)"G>64Q,T>ZEP:8!:_JTN4W_C4K?<QX\S=$['QKZ<X%6(TR.\C"J
MOFF/(J3;=(6W*D%<NCRJ9R0_$JY9TOSD_9UZ=X/:>$>>,T9W'0.NI$B@F$0_
M>8YN=:U:AK\U/B^&.CFV3#HJR#R:RE&09"3>B3Y^#>ZE1_G$,ZRE,(ZUK^Y'
MD^B+_O?6**1OWVPKDHGTP5L-3J;PT^X*OL@9BX8AB1<Q?>(6 <*KSB%O]LVY
MLTJ$WBF'Q[,LH&ZC"U'W1_*NRMW$>!.,H@3>BY5L?\ECSP>[I=2GC<&0R[AT
MQT_/]X>&(1]Q9<,L;_NPY;@:^$#*^QPAEMA/Y6;YON^K@W2V L9&6X11F?\:
M"3'42]PP4>YX>P2ZL]QW 1J_?QW=<@$"1-#;J3BF&>LCNO,LM*,4!(CN:I,@
M1'<,T]@ P38$FDB'MK?W)ZK6I_UM3?6+;^>S<[49Q9$45UTQ":L?^8] G6UD
MJM_YH<1>7^99,%<;7"T;ZE'?]FFC.B?3?>WS$PWVWO\W.]5J@&Y,MG-S\ROR
MF4OCH)?A*EBIJ'H8-7#<><H4CQ"MLJXOJL$,L[H&O.Y-*+6^&_@PJ'A90[Z.
MD)6;KCULLNE>\B5$W1W0/P,C^R] %(>S"$.\]9$O((]O[/:]YUDXK4J'/^ZR
M T\*4&^Q?!^7.PM.B!Y1K"YHN":<=CF+U5O&^X[L =\;Q>+_>Q >;?TK,*7W
M#QJ^D-?Q9R,@2A!(C4I2KH'QCB'/CU[9/S):ZLOG") R6A"Z4I.+U[M)5KT*
M=.UZM#J5#B%J;V4 'MS+ F1MC0#/I5C/Z[I6DVIT'"5W0BUF'D'A&5>Z<W""
MI-:/[U[PA2@^?RVF:E^3Y;^3DU^IL1_5\>I)TP+M-0M_S6$-I7;[8>1-2L(6
MZ<J_;[VS#0'AXO9E'B)/$N[6,D]J3XXDBIW!"4;_$.-3O&?Y?K;/E?_H\U\)
M'KV,%$S,LP<8;YKMR(>LR2U*DCF5??PA N$UFVYNH)M%>U2!()]&Z+E7Z4%)
M]Y^ J"&/]G?5'2#ZE&!&IO7D>ZS_+52@EXRATG$D: 5J91+N1X;938[BG3%T
M@R0Q@Q/-LPJ0D7=%@BA=N_YF8AHZXUZ>X/LLYM:23I.RK[:YS_SO.XXD=$29
MYC9_DZBP3VAN7Y9/#X5!X,O-5UI&][A!SI\O0&H:( UW<,]5S?7 ##Z?Z WT
M"[=/1W[Z\[YU?L+[\4\SJ8-QZA-&%$]^6$@-/#C]!O5[C4,7W93I952XY-M(
M.9VCIN*@)FM4T*^<PM*H:;!JGQ!/@?G6\>,DVDYZ9(1F593("271/L_%FZ%"
MU#D!-H5>B=QP%KAU+QUV<OHSOEM=U%8C\^;S,[[T6KL9]J1CP?1$#"3+;\.0
M=&6>/-7Y_VZ$#R%) D(TO2JY\8/88:Y%X+-[*MQ.BJZOB"Y"XLCT:^+9$YD0
MBQ8]D4%.C\BGC\5)W6*KXLGU45@MU=3ARZ#R'.H[KX--(AZUZ+ZJ,G=[UYWP
M;;<X'L>C.&P%TK9)>5K[[9Z1X>#O9Z\Z7GG+GCZ->V9\-<6WWAO.(SJMUA8>
M]P;$'H&K@1IN_5';2! 771)FZ-#9IE6T.5[%*Q8$<3DH"(L)9JW0O](1#*_S
M5QP>"X&^8YH=)#&8U@%4_U8)\5H[ZY"=R""L6"OD[)$[E+\O!(Q)^QZ#3C4C
M<-94H:-A-@+7/CQB.WM::7?B1VSN?:']_'8+]+][OIOJW]T^.LW%\&2_%?LU
MPO$N?EWH\O5U<!33>'U-"$@@Y]MY\,BE48T;FMJ[-R^UB#DCI.,YC72@<(I1
MG;/OM4G=#AQ ,7D$51>@L/MDVZ$* Q[BO3 :P[VS;5>E.J&QO&BR>]8_PU?8
M22AON>7P9=PG_0JVE)>\,Q=T"597L24;]>Q)OBK+F;DX#Y@A5XK'83QO./V-
M;,>"TF6'L135;^UO!MK[TVP8"CS^=N5^6@Z0S3FP5)L^1/]./:$XL247[]^B
MMBM9(2\7G*>(G'^P!\JAO?)>L3F20)BJ*8DOJ4N?#?Z%X3;U6.IC<@TE^?/&
M'Q<%-@>D[?)Y:CQ]<EISI?M9X#K4.&@X[VCG*6DHH%=!6GJO8T&3(P0,ARH4
MX7[TRS\7?G&O8CYF&).S!!SN3467U4ZZYO^=W^5(VW/T_Q(P*=K<])=B4_8>
MR.]2^J>6F;^R\]7'K\_WW,QTK :6<J=?J$CN5/M";,>M3<?J;664D,/GI87+
M&[VKHA^F>O_.:7/:<Q'K9V#>-B$!.$%>DC;:$0W(OYX^>OEON1YN?H2#S=,8
M$?0 7RSI&\&22'T!8O"4PY7<K:V N?4]RK#D7<4JYKF/<\T]KTE\N'9M3@:#
MKCKRQKW*;>EBO&^RP*S";*C6G%B4QF$:,F3[(9HO!T3)YQ-I=(]G:YK?=?%X
MWBM]V5LN>[?:W_G-R_3^Y2_;AO$HY9M%LCLKE_KB(WD$!=;G0OA#9-O7*[FY
M>Q4/"F[E@[)892BV]"V??LQX9[[WPCN_P= C4>/2U^T6S_$:0(L,@QKRV&^)
M_OOZG@R**W4\ZFJ&>'UUCLW7Z<5M4C1=V ^'M276@R^%/J@7%O5[".XK%/5;
M<#[YIBT$,2-G,/%_1]]VD6@SSFX OD>P)*SG=$_!*.)^V98GMO_@2JOZ?H*V
MQENY\2_-K1;7&Z6UOFHVI6N!HI\/Z9Q+]7L'U!@K"H%6UI6&FPX4>^2$J!<4
M;X-2?RL:JY3@2K>T-)M5[C;?;?#T;S3HLO(L:AQ'HXP?E!EH\QP6.\0';&C<
M^5'607OR@1/$&)!8>4!#6"^D6)]V/PE@+UN)]Z?9.LE)^P%T/4CM)K$01"/'
M<-LR\-3[4ZWJC1NL"]EJ_NZTVVTC]L\Y[9FR?U]VB!)G?R?C7LXJE/)Y71#'
MWZLD-)ZC7L_98\2]QA*P0Q6C$KLN[!P !Z4NA5H&P'R(2<@>%-[=OW$[_,P?
M"#X:OP!%M:$)=<TT":H/L<=X1<#3M1"\7P730?B=R+^8VGV@1:G-AE!^K7+Y
ML2<X'&6CY$1QM.[[8@^L6L>#0;?ZS$^CW5)=)=+ %CDZ[8+TIW[JK9=\?U+S
MO1L*5"Y]ZI#%K V5\5--K O<7QZ>;K)T_3*Z&"1?:_?BL]0SZ6T:W3MJ-&NZ
MBI<^[#*_"%\N;O2R>Q/Z9;!A/H@J?<ILQWY&(#PQRWQ_F%SN>G*YV37(+R((
M"AU>S'IGCVR([(815IRU7\#<1"ZF./LIL@K4<[4I1&E.RLU*+BTH15YGE?,<
M5!CB@HRDVFA6<,1>7F$)[VI<-,@-^M;W4JF'7G/EP7\.'SK40$(! 0>J*UE'
MIWBJ#,?F8']KZ-,1P)I$6WO&T4/F_=EY$HD=.9 ,WR )]^$']3X9"$BG:NLS
M'"8I_[9.4MSP65BLK.H0C#6U&0KXDIX\DPH+W+$)#TT>^Q+[]N7EK+R;FB >
MOE6'!D52O;Q*V]XI><YAWHK%S0;SM@PSK7BEK2>Z>2;7TN\PW=*\U[^W,8SL
M_EU<]-\/4,B X="57UHO[_B&AX^E3K_Q+&MK<'?BU%\L#+8B6;D"4@^C"=-1
M3/&M;#@IZK?CQ:A.6PR$%6ZZ%)..V69$%]BYHKRT+4.:.)==V:Y81*)N%=US
M(YFC5K)A>/<AZ'_0G0Y,TOQUJ;G?^UBY)=Y6@B,.?AL6=30G>A1*4'PG9^*V
M465;H??RA9/7C5]J/28"5HZ&AX6\93\PNO;W%E,"RQOM#,4+'+BQA3?U\E%^
MBEOCWGPLH\W^JCFDWV>GB!:J%#,=D;DY!J,E^X57W-3S=?8&U'NY0*B:FG1<
M3B8%#\WG=E@[_3JAV.A.^T$1]$HWXSUA^T"^T]"%"U#J_7>7NMQ9FW[1."SX
MCF5N%S(IT0CRO9/=U5(<-J:9B .1X&0&-Z#Q#UZ0@=$%U*YXQ;Y$N;0DA;$@
M^/#3L7)2VTU$%B]LW?3J]*&VU+B1:Z[96-'7NZ5L\S%I:W'WQ9QL!PJ0'U =
M"M#G/\COE)M;T]@)F16'\NL1Q-0Y71N/:'%*!W6CPE-4I/+ 4A[--/Z>N=D"
MNE<-&\S?LM+B571WNZ<7JGJL/=QZ%A_4)GUX=&^E#17.WT?3M&%"D?S[&OW:
M@U4\(_@WKE%H/-[HDU6Q\Z++C50#25&N5JOF@+F-/]NJXE4@.^Y5W&=!?Z(6
MSZGQ]I/<][Y3(=P"VO/U]_CW?P7[;1@4.LZB8/C!W<LI9M96RR+C(R\G<93<
M%R#%8_ZVM':$.?XZT0" $=@P'1-@;0$UO'DL4=#?-/(E1%_]^FBU7!ZR87N@
MMCZOY>Q>Y$>S!Y]T*&*K"&NFV]W45[OI(X8?++;O9 FX]H13/PEK]Q/E.5#U
M#?/Y450WK^?Y,M1Q%M*/)K)6DQCBWI)H/YTYP:V/&J*/ZEN!(A+?2*M]'C3\
M!>!)'2;/3G ,M_@4ZZ\Q[4])9T4MRY$X0<OG\+K(#%T1R?<LA!JKR?A*A>_L
M]+5#XD3[5XXNYD!016XGM;9G9?]9<?Q$V:60_,_<[('[DR=MVP'6\W8K'%KW
MJ&[T')P; F.I(8;%XZ<K)JI_CCT69!B7 >;5Z@G&-TI\HU/G=GOEK+IBPA7I
M4^/#^],3L=/KR;&]S)XBLG59J^'$1P>]BNL3<20?Z$H]%']/$;I2#6,GL1-U
MOIT7["*O%G<9TKGE\+S52&J?(MU,,O4T_CMWL 2.GCSX9I\I^U+H$<-UCN2_
MA2$2YP)W%J^W(8T*))PC;UVY3'$<*X1^?$E<\0M%7"D#KY*P]&VKA\>?)+,+
M#;RI0</LE^+,O^J>MDC8S<-VU57.0U$O<&=,R'X(#=1Q&7A<#,3GTM918@C8
MC8,_=1_K7>9V@_-\;F>SIVC142I1<&I2NOQN&] PX_&L,%VYLWH!.OP.I0_X
MW,USK&#4=)GUF]*PH ^P3]Q\:O2MG3\8!#U'F3P8]Y2L#^V5%!YSE1O[^M7=
M=.Q/3\&<C &U(6R?%'PZED.QMZT\KA"?')X\'Y];K(K[SEF_,XV"PKY1I6=*
MWAWW,NB+0$Y J))VN/ T6'3[(8$^APW*AN O@QO!TR44#VE&?^4+=+V^Y0C'
M??O[GO5ZX--7FMJ]6OO_ M%;<A_Y<N??GCVY=4=Y9YKSI$DN&)<5V9(S2)#4
MSC&B:CU^[MOWH!=G3R;,K28L6B5O!W1==EF^BTG(0Y40A=?X.+M?:@MBK,.8
M)B@G!*#J+-J#WD_2FF@N[ZBUBX($@.U@GWN6:F-GZ*K!71'IO-42N3QV/U @
M-EN#PC%XUE9"U--S[KPU0JBZE-\G9RF;E+WYT2@D[*$CST"C)2/MU3+MJQ1\
MC!_+T;HEVR4_KA+':M>\]:3G4]<:[]&(\EQ.#(_3N=G2(WPPZ7(P_[)]++C@
MW)_40#;)452'(VIE21NU4HD&(\"$HO6C#\V #(D#GPDX(I3;*!L)<ER.]"(O
MYW;JW\BX%)R/VGY(UOVFHM,!:834>&U/0K8CSZ2)HN?94(QX1A\E!A4EJ:J.
M,)0,<TW=7'8"@9/^>_17!/TQ_L.4)LCO%]4;O4MY,06/0BK[;[T =YQD2 T/
MP(7]MMW,(I0\^Z)M[BJ^7.1^1</?]GXJ<4NSP1W5&F"++FQ<T 6UM_?Q]S+A
M]K;T0C?(C=!K>F-9JE[X99Q:Z!^9-W\HM&E*:+9@-Y +L%J;W :I[8^$LR.[
MI)Z_"/4+4.3D"IA<0JD$A[&\R=PNIU/L&&J'?5PT_8K7$=WSG,>IF@7]QU$2
M6]3)I@FSH'=YS6$_LRCB3Y%OWFR5LNZ=Z";?>% C& 7;"_,)G]2\XWL/\M.+
MR.)+8MCXY]0:B%= ,N$+TYP9#J<#A*^ 491MD5*A7_!95L^BS6P?N^F_RIPJ
MFS:X=T>D[<=31.\KFTBZ<XD"MV\J]SQ[0OCOJ7']\3D7NW22\[SVI7%[B/1?
M'(^QEDG?FF%W[MTK--Y]9R'[.<HKF<K6Q2_#?-ZZUGU*_%GY]##@C=1$P*2B
MB%;U^,F3^B!<-76VMO;E2Z\/CLDZRM28OF27'>[R0Y&'G^GD]"KI"9K<8N,]
MLM%$]OVCWBF4.\UY>16)[6XU!G(%;@-_ (TV@B=[@CO_&V9=TBA5;WDFK% )
M_3#:[X%H,%+0_G#_W/)[YXV15Y;S'F[4>CDR]PXHL[)\?MYDM$@3O'8MG#[=
M88$93EDE#8S_F=;*M^7='K$,(-5=@$2.A8;::!&J7A&H*T@NXBU/TZT^3%\(
M0FS%MTKMZTQ;F:KT%\L_6R5@.2<]WX!;W;]%G"R&XLNZKQ[RO^VC3'P?TW2K
M&S$4U"',+,-5;:!B\H?KEJ>[A*V*I=665].#SX<"$_WL'H(^TPV[2Q$'9*>0
M*]*@^*1TU7N&Q.<_//8!-J1YLS#$]H=OO<TAM_I'R.IH0_N8V\\;.1N;N3^
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MWP/QM3CYRBSSX^4KB#?!]IY8L>LRW-EUUJMBQ>[7BK3HJ.)3;(*L+9\TTE^
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M_!@NO+;8>HW^TM=F]>V]7KUK:M_OO(Y_XT()O/[W7#$9"OVH.JUM&O($(IH
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M( /WS9D@7/8H!-\-G2'=^1H%N4HTP^>]TU65Q\V#X?-&#3JF.^ET?^+<.,=
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MUCRF>LT57BE9874!FE& V;H%XBEN<2H'!:7(OQOXU&%Q ?HLQ8AX#IACE_F
M8DQ&E/HU0*L;PHR@X2AHD\4CDZLM-I6/HW!M])(&]<7S0_LS_6(VV]DL(\2*
MSYD7(.GJZ.4ZKG]S_0&-]X;UP>(A>&-T5'-?/$(M" >-27%1;JO,^XD50Z@5
M /D6"CDTA.GH[=N?L_VU_3SY[>L2P2XS"7]CAKR^ZH)(Z:B5)'+GYFN6=A9
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M50W>INLDHP0;V?8!JUTE8G7KQ[6"&!$L 0BNA33(X_'.)9@.]#6+1,DWI7<
M _4W#B]FD&;J..)+D) _TQ(22F=K+2'EH<,<Q7;0K<H/TAUO5!!UY<W1$0&'
M'8SE],@>N(@?CK[NVK.>K\8KK Y/)CE\U3R)X+YXKNIXT^WVB3TFZ@I7)4;:
M?D3LF5](\?HSH' [E#?WI_)-O2SC:T5W?_RX$VY6>.N&E^,)+VI:9,A-(GG@
MQQ8B+.V+P"J,0;Z;<!^.(_F20%6UU'#*/;):7!,I$],84E\QLRA,10J@L2I*
M,DWM)\C18(+]+^<W[4E[#[QJ1 60!2.^/=/X@9H2AG8/<7-1_A@E/Q0_?$B$
M5+C_=2@'FJ3X?<'%]43)KN+DYYU;"SZ\'IOW]AT/]W>?OI%C?ZX\8)ET9(.S
M$RQC"L,:%ST,'F_HI8B30F /76P"!M-7Q#U2W:U[G2POCW"V'SR5-!A@ID:?
MN8X3A1T4D.I6+2[](.YS\$?3+<0)"N!" 8T;6+#,BTW@R"$;^Y>//\$9OR<V
MFI,2<WN_[WL#!)#]":+@6/ELC^'AF@BQ^AW^LFVW%!+&UKTUF@J6_^[/2\KB
MV6P;:=+2OS+VLBE8[/S8>K#<A::45?OQQL'G=4%UP97G58R-6O+_VO'UMM=G
MC0Q*IZ7M(MO4P,R&6@&-XB"A%68J=;YO@43-Q33W]J?<F&!$O$-WP9)BI=UK
M4LT-\$T.?Y;WA[.C:A O>67-)Y8<F'[0UN6>WH$,J^1.XLIO_9U64=?27RB$
M!8=D3$%*H<?V=/ZZJU:WFUM.\D,EH%Z3.G622I $W<")[XK@;6"XNP ZQ!1=
M^WMP2$76C]<H4K=! QU].Q28.2E]_;_VTJ2I6NO&QK2,P4'9]VF\03P9H=/[
MG5<CX'C.@SSTS'28-1^@)'4Z]@VH%&)BVT^6X\KH!D<?JN1C^$\PL.$VJ?D)
M&F^I>B$*.QFS8[P\3'4BE8&<:9C3Z1]2MN+"FN(:P[2WA _O//?.M*M#LN3*
M%[.PYV"=<^S&^90/>\W./*T'WCUC=ZN1952M;*3KR*?W&Z':*0F;E.1V6QA8
M2Y ^\*U#C.E33YO5<&3*Q?\J-$T.%[VQ.*J.77NKEM08VE34;2L8KJ+XMFZ5
MP\U#4=]N(82)WK#B$^O42:"\WHAK%T QZLIQ.<-4IX>T&+NS8W7K_,S:9\>R
M+=3=_>8'VR="#'<9[EI^66O6*WSGX 6:G/!J21\ZC0B$1W&DEBP!"F.$2>G[
MKC\!R05$M3I4/@<MV#VR'49 <:8_7KD]8:S7@W\LSAV,_$R7TSVW$?KAU4[(
M?V;O?AZN[N&Z 2*H/,R1T7B/ BZCIMULP('2*Y6)%LHX'SNL",<3N&&CI".*
MJ[^6U\YVT3LYMIY$#63+#/C1LI216<Z+<V<=UJV[JR3N4FG)"ANJQ EOAQV*
MAW=:B2R_ORL3=G].3^*SVS[&VKIYC,:_K.W%D<3.?J0(D5K<89'+\@4%@+_S
MK#1N%6&8EUR0N%:1O]'U?;?_H(E_\?Y$V]4(NUE7OX^OIQ9**YN%ON-Q09D+
M"9!IWZN.A,[[KH\66@)]-<M":\9.#?K]^==YJ<0?>Y),^MP&[>H$T/W.). 6
MAF%9@\>#,G2*XJ*K3@I!=U&+R=-CHOAU,KY];S4FP%CRMTGOU[[2 -:%H6J7
M?[:E-K7?+YS /WGFC$"6HX"S*Z!)UQPKGUNZAIP.8WT'=9YQ!)F3F>N_V\VI
MF=(X(ONB/< J>ODM3U8>F1).D93Y&J2M\]]_M+?A";,NE]U?+U:R3\:/VF3/
M'1EI34C_&E=6^M/+ZH*E<NU>FV-'3LI D4@ )[<,L\ P%<O081^$1C&">*U*
MG (=D^ZQ.==G0DJLF1OC?U?M)[_^DFQ5$YE?+6YR?Z>RL$.IRUR45DX_<I;8
M.9Q&V#N&\D;%E>PAJ($E9P"!Q#\6,CB!\TS5M_1W3F.VHW!0:^9Z/(>^/XO1
ME&4QPF+V2[2_WOD]M-8N K&9G_)Q-,).RZ>KVVE49WD]1OE2<\H&^JO!TANL
M9LARK;+DS%7R[(EAT4_Z?1\7#!S.C_]TV.U0\_\FJ_S_Y2WC@>MYF_[50S9]
MPJ;<\4;V56GO7#,]Z1M[]\A<NZW4?&1O FTU>(I_.<?ZD]B^W4_OHNZ*@<>P
MT"Y[)IJ&[/VWG;.!"#@$"[N,U2T;/C?#,JW?;R'$VG\;;B%VX2H&AGHZ+("(
MC.+D_:\>7L8XCP4_.&(5XIXW:I41LH5@[83'F?HMA"])#OH$'0#EX*''!BA)
M_@G&/P.M+P+YU70Q4=!QR035&W/4O\'ENPN8>$[?K4C M=V2=3QOU'%#H60P
M2B%S(P!PNZHR<M5:ID?NU0#V5J#FC>C )"\K6^5B04MKE= >U^,2W1K5TM<N
MIY3TZV00@1,ZH,H6@B'&M+L DIAJK(O T'!:T^!#'?PI,G]U+<[MW(1O!%FU
M=21<84G+7!$SK^6K6!I4HG^'BA#[.0.):H"><V)[H%E2,XJA"U2?G. HL%4]
M[.A%QMVM]IR+TU<\,B66R'F4^^&#?E=V:?_!FU;\.S^[)[6F]*#YS#T>KH!,
MQ_E%KQWZ?:L9EA'44-/);+P$* 8DLD+ VT\XZN A*E*48PS&T*IM#+@:W9#\
MJX1179&SYY7^>J,;/;Z)$Z(?O?5]$\3Y6QPW%?F#^H+W@EG^!3O^#8'2)_SM
M>C+7:B^U\6L]?M#)^R+SSV.)F3IS#2KZ?W)IGCK/D2YC>3!;EAG,,+M&MZ&S
MGY?.PW)E/46_&E3NRW]5,-(T9#)_O?AP_,>NPO3&D*JH(/GC/#+G"+&7W<KV
M"_Z\>],615$\KA@;QN[NG!DS/\S#2;.0<2%,48 @"D>Z[028S RDF0;>\4ZS
M. #<O],P\QD2!Y\!W3URLL#BI(?L)"_&U_[2M&NG\8.<F*=]"RX[O'=>W(0'
M:;YQF-*6H$\HP!DUW4VE+->QU3C[P40Z,4WI )C\)&#26$D#R)D.4$*._VC,
M&6I$"MKQ;H0M!M^."KW^INU2K&ISVCEF5[(R<NT R&8;XOFYE1Q%G;M;"#^Q
M>&@W^(CV*!Y[9*RG]4S->N^#')[VA:@5Y$R02,K9#\&5]VUT?X4<^0]<8EV'
MHX#E0Z<1R3-3'IE$;%A9;J&B=N%&3RP$UGWOCZ%KM*FKA&ES#=M/1E1II?WN
M>7G!31,=<E=%3/[%W1VP,^]41?EFRA,^D@ 'G6DIJD#/AWP=).<X:/MTH5@S
M]C@9QS!,3:Y=5[MW"/\?-(R]+8)&6ERM/A)Q(?!?Y?]T%[49U3S/D7*&A-0!
MJ6[,+A^ "LH]P5G;,'U(-(T97,@O,*=U[BFNS.9KX;F.(I;;%4Z-/.NH5P*-
M\\-[US0T71:9YZ(R]6E/<HJD1/3RQ6Y=GN*PS.=U-!Y(6) MA,=P22@J36=Z
MA3K<,QP/J1*G"WHHPHU^C20Y-_(WZZ<!KLZ)FEAMSNT([$LW[VOCX5^T/L[,
MFATHRCJ%U)3FV23!5RB*V'F:Y MK\/GEE7*.+ZA5,[5XWF/*S9\D09!?K G4
M23(3H ONUUV\H_2NPM3@M<O@X0=7W <E8J%QS1<GP^2Y,[0Z45Q4EXEY0:*9
MVE-_"X4OC9UZTWYDI9+@"O]\?[/1JV?S69')^\1OMT@.F-T3QV;/?KZ2B_DE
MS+;D\'#?$*F3Q)FNL;G*]VZSV#[,ZY)TSJDE3\,/K8^Z//2 H,E8_W;!N?^N
MSP9?IRMH.!FQY$M/OZ$(&5R4M#3>%(#;"'9*U#(B@D1]5M) 2228<G9-:I47
MU3!J" =P_']P_2EF.^AQ0H^&E"\W./O^O=_VO0N ?BU.>NY4^9:R R*26OH9
M+K25*7UH]U4PEWT>[PI,5-,I(G@#ID-=K3]!Z56D78W++P J#7[2 U--_E';
MJL$]1<#@ONN/8_DU)K80-TKBD(!C)GAL Q*2JH1FB'O,,/25.&2#6F>FG,LB
M06ZB4:-Z2,T>^%7T-"#P5B5.@/;2[T;L%N)J>XIR,#U3W)+]8]7]9Z3FD-R?
M>8[,14CT':PVM>!NI S:L\]6IC',Y #+2Z,&,Q@RTJ'A"*3V]4^X0E4(G2CV
M<NBG9K%R/*G!4%V0?T)Y?L8@9 =FH86:"#-W/*;!N*N.CR,#'J*)*K\GB7)$
MRSO+_)20(S4WXH*<7KT0K/3*T(]^[IZWBM6IC;(W2PP[ZICR!&D$7],SD#;>
MCOL UB.4QJC>E=B#<#7IR,ZZV-:*>II"B>00J\?81/2^[,BB21PZFXC+YKFE
M5GCR[1O3Z=>!_[ P] E$ZD^WDLS"]8+E;+@B"&9D@2?3V'5<FT2[C/=LSZ#8
MC'+L#-=GOJG=QUNJKL=^9NDK]U:XMS&*+IB&W17(Y8H2.V\&=6@%H@ [-'D+
M<1(\0"VRZ[<P8B9VS;IUKSSUKQ\(>U'Q*/)YRT:DT7-B3!A6^MIMFZ.= XKZ
MF!YD/(DZ@TRB["51LRG;R8_$[LD6'P!(C-ME_G<FT_!G@.;?[E<"+#2^K-D[
M+1[S'OV4H#%DW ?7_$9T=>"MGZ>O)Y_S_GEME\"F'N$+Z35I>97M@K-"\1&^
MP-Y2AHGN/IGSJPLEZ3=Q)_WK_=)1KS>CANH2?S33[IV(:K[98/5)8?\OTN>Z
M7I0,7G +P:NQ/8W2M)),E(+X^VDKT[]_%Q8DXG6\:8R=1G%G >.TFFLM8QQO
M6OA4EOMBZ[[S(6]M]IQS@6+2SB^M:T"BL.6.NQ^A%79^!&X.$N!8Y+,$FPY9
MO"Z*<Q ITJ&&&R0\"JNZZI^B20,PZ>4=NN;-;W<D7WO5_EBL*4=FJHP'N7Z<
M'43L-$)Y9H*'B?%KZ-W0.%&P$9MT%"1<CZ&1)"W-"C')!O/Y1W<U3X:O*O[(
MSU'G=3,;#OIP\X7,HYL"V\\'$=A.P&Y/\D2#1Z+N$[TITQ26QFB33GJ)DB%R
MGPMEH5A]#&^&:C8H,KZ27G.Q4_:77"%U%N-Q3F<E^/)]1^';AVZF*GP@MI!
MM<S.3''"0,DKY#(-R*0[/#\T:2&)5QPKZ"MHT7M8S!_[/2;,T2U9I9-2,?,9
M^'@E/3U@8(R_XQ8W$45-1 (.=5,\O?-T;*=.7*0<41KQKJ6>N9*FK6UF^6+!
MJ4#OH>R,=3,I)UI+ST9JPY\8N//[S\OW%T_(;$8S,=W&'L?!ZTR%SLA,5O3P
M7IQ GX5LH_^>O@L;[L Z5.!_./Q WH7 !X<:NI[OGS^&@,2V$$$44&N2(ST'
M"=FR+W'.<?-(U$R"+*D1] 82[#TH/1;' :A(D=5$_VTP^#;X(J9UHE@=15,:
MJZUE5#:.:3(&#9?K5UN4O I05-B5N&\A9C)IPPS24V*G*8E:R0R ?-,C+E*'
M!;_C2KJ3R\"5KF*+\3_M19+]%UL/A1C:*[B_794E__(7N;EO0.*@@T4_C(3K
M*.I#5(O.,@\SE=7S%;( U4X Q&ZTY-(25=$HV*5\"W&_K&<#DOU:&\+@H&F3
MJ:&#M+:EP*3(U/S^QZ/&.BF<;W IZ6;'2W%ND' ;6Q:<ZQ87U>AS_5,&%,:$
M;B'0EV)=?HY$%*F:'YS7C8]LMW%U'"TI*FIXDUN(X,INWSDE2%'(A&',ZQ6&
M]1/_#6.3_DY*ZJ9/ C9H]*+%0V^<=E/;[<IB:=^FAIR_G==S?J8\/<M4WT*X
M8!)*! EB! H)B-!A'"_'U=$-UX<[2Z8MJ8D)FNT:_G0[#?60=BWJG&]%?Y !
M1:PW--L-;.ESK7CZVB/ 63(H9V+4)_F'@I<W-$^$N;Y9;%L#H997:,@$"N!8
M@^F^DWB78.'?:GQ?QTRN9F9F46Z#M9D>W^:QI$_&RFT&/WM4;5!8SK_W^JW]
M&5<39%B892* 96%!)-L<;P0X+^?2ZD3 ,.K9WY&M=;$U'#WQZ0!YPG.+6=G*
M6\]%O@5$Z:NT>?SZ8UOYS\DH[.==!.H!"=Q?QY$,A(1BX$[^A=L.&>*D>CW,
MFUJXR>$S"I4=MVU(8Q::PV8%8C3WBUV;0>\K$]>?"R5.5C1EEPSFW8A\CX!(
MQ,Y;\/#U6DEQ^S8D1Q[X1! '9BM[D&3T'-^G0DP7<8>[G8H3<T9#&&81:<Q+
MW2$5IG]4E&PR?_%!;,LWFWK=F3?(;U_Z\Z:Z-+/ZG%&ZU^_]"&O+L>E'[.XV
MY&PG,KE-I&:6-#ESI/59@]P4"RWH\^9$LG<97L]M":L0 &GN"L_D.^-?^WNS
MIJFW\8#[BMO%A,]+GULBCK\5?ZUT] 1JQ_9"Q0X*<%-LF<C4H%GWDF:L:4.L
M D"?'M+VS$,MGN,"9)X#:M/I:!'*AX9WF0F&J9?]&ZO7QU3=JIWXO-^>L533
M,U5;;X"' 7VXEI%XV!O$_B*\[Q!D\M_#BL5;J%- JV&Z\WN=?8O-(S,!=U1K
MJJ;*7X-1'B$^)5;C(UYCE1G^+EJ*O73-(*^Z1#B:GW53*ZP9[DN8A^"3F]Q'
M!'E_C/2!9K" IH!1Q"6BTQ-(M&')!1.1.][-S4M'95D>8IZMJXYOD@DC[V2-
MK4^?1GZ68Y" :D@8%GF\YS.ISHQ#<UL(,@$C"SJ,+T"2HXEW#0.'?#L[9!+M
M6UK>8 3!AM-MHT$&H-;*?N0T(TI:K_SG#]D-!X=-1!]<&]@ =5Y$!6%!XVY6
M(A.Y?)M]BX-B3E0"$DV3S1-FZK=92X_JA$_N^^O6DM8A.^O.U_(U//7#9=^4
MSU_G,KR.&/5=.7()+F82FJ T(#FRT2R0FWX0_B(49]=+[N]-]]% "N/F>UT3
M[WL#'?4O%UM,?N4:)]C3.[7&<[807?H5)W':.CYY3N.,N]0.-S:*^YB#9.^!
M@WJ/ =!UL1@%4H#./25I9FU5S4+R=;IMOMI81(U O\D^<<L:ZS(PT2$PQLF4
M]TV>6G-+?E2L_H&3_%_"UB>7827/FP&'$4/HA YT,$N6!]C'0;?W!+WQ&L:R
M-N=B%?HY+A-SI<9FVC"=U1;QW+9BZ  ?V=UXV:W0NNMY:.,.5DOL2(<\1PZ(
MQ7UF[B<B\#K FH?F>,6MGSW0'J#F^<2?Y%"9E*:\\?O%A !(C!2PA0"/H2&A
M.K8_-(*2M9 G=B(M)!8WX/&'(/0MP&BS/]7,F.J&400S>UI#'D:.=--C3BTY
M9ASC& ?'F(6ZS2RP0@</C5LA#>[^&>).0E^(8G46VG@QL D81(_KA*=N(13P
M**;%O>LQWO=N!Q.?^Q<<=4U*S?JO^$96QZ^]&<Z_2$48T!@-"3JS/8B=!AT*
MT&@44:'_7O!Z20HY_><6XBY'(\ KYNS8^3&O/(,!#OJY55ON.5*>9^XR\-'C
MNZ#[ ]F=5@@:B3H+UT1SHY\('NZK9#:P+G+?< S+AYG#M.#VL8XJN83@=G,L
M75'65D<S@B*&J^X:$&]H& ]/:):P[S!F^_P32:H,K:/*<?:=WT+P_\.?XA9:
M' *'6=/<#+Q,%!T]/=RS\1<F4(%8O"GOY":I*U/BJH..H?U94;WOZBHE77(%
M/FXK1F:JA4,_&!$H-3>@#=JUO3][!&Q@6Q*^HQJ176AQ$,.Z])6PG^,$WI-M
MWC!YL,F#=TANBIX]J=6!_.:RT#+I^'OCX%QPT[<&_]]_V#X%VFU0.@R&7<1.
M9U00)8'2W/<6QL<S^*MDNQK.R;&FMX8E KC0?CI?7C/L]H5Q#>B'!S*MWN3\
MD74/[.I0OE?9JG:!;1GL%<'G_7><IXJ; '=E6-Q,KW25U(N#ANSK'#UF.4F^
MG0_XA4DLAAGQOO$)>\\NHF1-<+A;NH9]08^85F\KB#VJX*;Q^\R[+MM]%_0.
M%NCMA8L9T9F>H4>E=*"@*61+WDKLBH4B1PHLX $#:;]*).U\*Y8*7Q:KC$<$
M,BPF9D<D8S3.O"8U'[W:)V_4JEFOOW\6,V;<@P4/8#B2C^@M/0\[='"#K!-@
M3!7NVZSF7P\7HO_OS8C>K^^FB]S7[+7_CMF$R?0QA[(5A)^+I)WDG@:,[W%D
M@/XN,OH> 8ES/@4XQQMHV&BNU?!T%WI7%)1/64JJ',YVG>Z6MM=0L5$IRAK2
MQ_]M,W*]>PQ+5MWH=T6_1Z<59G8+?QV%#BQL(40YF.<X?<?\'5$RF<E/1K!J
MH[4B8O$/][=F&!_-3N@[7K<J"5]T![A[=Y4T)BX+L-TX9X M!,-[#BF+#P3W
M,HWI/G7^3%?%0,?V\74L#RY%*V2Q;Z67()KRQS8^[]F#:IT2&MM3M+1)8-!^
M,0QZ<=&M^Y8(*^IPB^R&XP#OB,V3\JP/Z=(C'\2^.UMY7_]\TJ()\L*\1G,D
MYZF3# R,(X7MW3;$SN,6>N1,8=SGZ)(DDKR%,-ZRQ0;V"9V%JX$Y'E<:RI]H
MMI[MKR,_FO'Y:%B:E40).<S#5>P0 TE4;/^P&(AFY8&VMZ@D^07(#(@O)RB
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M-RK%%=E9)#QW"3H$/O.G)46T%2GWDJ2#R]^-&RH\2M_Y?>9<:TNTK78.+NA
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MY<R0[$-B-3I8\6/-H,:>]J7X"U79T(/TW<NRLP\&NII[LDI6GB_]6U-\PZ,
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MZIT[#A]IL=#M!.ONO&YK& .^-N%!12Q/52Y6+V&,&*$)-Y,>1JB>[WK3DT*
MQ92^>0U2Z@CI:YC+N&MWHG5%B^PD9A1Q.JJ??N%8V/PMRML[BOJ&LO&/=JPK
M3[TDW61?J&E5[J?=P4+_@,8.WSK\W?3*0XG'2XLPQ'$>FDQ]#V$<Q27!&!?Z
M$ZWR31GH3>=8;" ^R>O".B#>/43I8B%V(Q<SO[1(,<]G+=9=0OY5A-GG?4DH
MJF_DXWJ4FH$[N6!2T$S^7-RWD/[IOW\W;^?>-V:!S$!G>K*LU.;MHZ@OOT?_
M'HN%]:JRMN\F\&W:QH=VZOWQ6>DMT'7R;M[7_/W,GOLO/$=*AM"&-+P8JNX2
M8RR)IGM=;I$G-5YOA R^7C>2>?#:NSKOV.(=5=6%]^LV%'DBK]AJ/,IVUBG
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M51WQ:^;'-[4ZH&=3N*'*>,W-\(7[P_=[0%1_>=S<&C@ (SMH099$^3D/UT/
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MT-VWIBA3QRK4(AD.*F]O.ZL%E*:FRI_>6QYK"K7B+X ':$F@A.W,Z\;70]K
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MHD0Q;^56X3^WV9'\)\S-@C%@M/M8BP*OBUSW'5)_AI%%*@OPW<-,>F@9X^?
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M?[N/Z.VD0)ZZ 0HF7'E'BDB^*5*K?<M%&S0@_"\:TT%FG$:H\KHAI*IG[%N
M^9Q&$KU?"4F93R<^ARH'>KSORDK1:3$A-:6NR]PK]OI:7E 31,I5]+[:-:"\
M6R)W"\07VH"N_DH3'0(8^"]?8?QFO>)30#?P@Q9MYAL>R3^*^L%V_D)3_?#P
M\5REPBRC]!OB]_[M[,EYIWQ5,&#G'2,.'4M->._[I(SO36TS,D,1]MJ.HQ85
MN&2(:O"/(<*?-%6N+I77-W8KK<1GJC<@3A?4VBMBZE+.>':YF#S*/C[X)V_'
MH,6*XO%ABV K*SU5=;WNJ5-UZ7AEHR#D;E-M&W:7]L[J1KO3P@QG_BINN"V\
M'-)1[D ;:NE9P4TQY%D(CNP]GN3O[127F&$8 PZ?O$LOZ09/SI]FFG02DEL$
MDCR9B>_Q,G;^?AJO*JQ>8<7[6>J'+M37U3[LV&V@F:J=Z#/5QS'IQC+N(2'^
MW SG2E*:R]+P2B8V^2]A89@G GU+9KAB)^I-LM[.BN^YC$T@TX*PO.H($Y(=
M 610 /XIS!,OV0+MZL9\Y9N/?(.@A!G!5K])K*-Z$QZPC"I0_7,AA6\#?;6K
MQ_Z86!TH12R\3ZRP[_JCZ!4N4*4 ,7.,F&W,.U_[E\RX@5AY0<<KH$SH2<O^
M-*XG$2X&""[G6P/!ZC^FOOD@98)D^R*^FLW8%%VUV'BLG6MP=8>!V/+ILE9>
M%1^:<L?2"[!M]MB@D\Z>3?7UM;!==GZA:G_O"1WPO;2@*.-M:'+_PX_K&:;?
MDBX?>.G!L.9W.?#7YH=QSFY!FF]=,/+0K\W0]N [QL>9*@Y"YWR-=(O.[<7O
MJWNGIT6W,28]/@P9PW,4K'E2HH D?YS%HW\0#QKRP61@D'T$]>3P$T0UPST[
M/&L3G%0I&T$BI75M/I6-J8,WC5CKL*QN'1GZ%'AB4LP4AN]/(C.BY[LNVOF_
M/LKL82DQ2A):-*:G7P?F$A[87:$M$60=KUU2UAM>;CYZQ:_DVY?JU;WY89+
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MT_%@%_;LK#*6^E)#%\<309;RW0K&VS&;)]X=":FKRG[U*\Q+R\MG\?UTT6V
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ML@5J('/D(*SMSL3]TG?D@ZKX+]\#Y(M7B"1FULN* H#UN4_B7V0D9G]U<N
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M!/>& P/N5LR@;@+18/F2A+.'8LY=C-M=3XRST8EYR!)233OZ[+ED*VDS$"#
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MOD/GCC)_5I8M9ML2.M6]3V3,KYSQ!JOY.%%&ZV]]4\@1.KM3HBOG8GDPB%/
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M$:;E9:<1["2IO2[S(RO-<G-\Q)192DT]$> W7/_#O,=?HXV5EFE7$7#7!;A
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M]T<N7*)^YS(-/0T-/3L3 Q/[_^=VW@%@O7*1DT;IT@5!P$76"Y=8+YSW (
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M".%78K53O?CD['NKKYFS?T+$GYWLP.,?H U@]<7BF:1V=1M"$(^JH.]<_A5
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M.KD1]C8ZM*A!G17'?W(\\1=BSZO=#OIQ86 A4;>#8S.O5N&-PQC<"Q=O:R=
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M:7[4D@E[D6J&#72QDHXW--Y8>FGJ.M;BW6PXYQ[*@FO!;V/SNH W%,+OU=E
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MG>9B9F)S9: /SW"(Q'B*KP-G^_'VX^UJ@59+&%3OA-<J/Z*'ILIMST/$"^9
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MMM.5S7=ADE:!1)W6*8D_E5*\9TS@$=K+'U)TMG.:1./^4-@H@^UL!"4<0Z_
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MO1Z_2U=.>Y=BIBF@J>MGHU;O>T:F32)TLV2NUC)Z!U[:$M]2=^Y?-ZH&%2J
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MT46BF,!]WJM,P' :FPB=BH6N./JH07_)>+-&H?P<]']Y#&3%L4)Q]R4<NN8
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MF?SSB#1TCA,VSI_+?\P4:4.;#%O3F 06) _W5-UR<_<B)KF:)JN_MH@^O/K
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MWT9SL 9GW:\5^%($,:/6.]WY6S]=+NN8O;F<*#AS:Y%FU7\F=2R10+] $.S
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M]\')S NEF#B!]!5T<52LRXN"8X9JQZ#O&5AU2_&WL6K2&RY.M!^Z#ZY0[5>
MLF/(1.DG&%G7]&KI'[RSW 6:5MJ9SBGYKN"^,,A&?4[]\5W=O*.:U(<#<P4
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M$K4A8S=J&QT)W1#YA=SNV8O:@/X3;L'?K%9#J>V3!\3>-B[MF84$+ Q,L=%
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MIGP84R;Z="N#HM*ZCD.><DV/<DXW??6)X]275J6'ASU65-+W#C3N)[ (0UP
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MGOK2RS,GM"J]+#E1V3^LK9Q]C;!7)6!VX8+PNW/"X=?LF1I/:#C]=2DGZW]
MVD6_IRK2NS G@1[T/9%GI8@F-M)Q7\C=*0U;$I_3D-6MCVWRXCD_%AA%K!B
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MJS(%S<W2$6J4"E6E61A/\XR:;DO6!;QOC7]NSX<EO"M1\!;6LJ,NLZ/IA;9
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M@ Z?KW49]IOU*^?%(]3> @[8-N6L4L=<IS%F]O8@?[$HH7G;GMV,IYGQ7Y]
M5.J#2(+8\3X"=>$:$!3PJ;/ :1"X.I&T\>'5^,_59VLG;KBKLO?Z[ZP&P01C
M<:AQ#E>J( T4AC;'E _E#&Q_\Q%FNA9KR'AUT4JF<H7\X<3*V)(;9I4'7[F\
M\@X<J<[_<M*:3\S$1^QYXOW'=U@FO:P,VN-9J%_+$)HA-!".I2JD,U8H7#+%
MVAIGB9(X8?B-_;- 53 '0S=U*.OH&/5,<+-?L"">F.15M)QJP1ERXX%[38KF
M@7--C#] !C-0500G(#O+C(R;8A\E2T_#P(L!&KFA?K8XYKY(Q6AO?E5A8=/
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M.]XWW!ZGQMVISC6H"@DL[ I^@;3K<N%T2,AVMS8_8.86N+/JB!=O [-!' 3
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M)Q$Z;0KO1/OF>Z9)@3SYND.1D[;'._#BMD;ZVH];SZ\SB29Q1Q..(?(AH>[
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M JK:D5,-$5%<4^X8T%ALS9.)UH.Q; O$I1$^AL_*]#*=^.,_2EN+V;51 />
M#>?2E\#3M,6H/*[,U/K%<E*?@P-R>;'(Z-'QFW7WMM<3,*7K1C*'8F1^%;9!
M_$E _I])C*?*8GDY ;%@,EC,.@P&W*"44.;WZ"*$1U*-O;X6LV^G$:^V+7()
M]QDRS>?6]5EA&_E<><P/X 11N_^\?7ZOL_>G1'>QY)F ;Y#/HF'/X][M'&A.
M[IAG,E,8O-A$M&OA ISMQ!U5_=X_*\K[JJ^DW$;MHDWP6CA_X5H\!,/K=/5?
M_R( M;\1@"?VWW&B]6AN)5Z_/L2DH":P?+U7[_G^^6[HZ^N/PN:.*T@D.HNQ
M/3#=ZXMS;-JB\'2:2)=T@Y(Q$_-^XVV&?0<W!_EK=.YXNW VOS+!6 C"A.WD
M&!3Q6"D'1?H!5,, '+9>"_:*A$ 6!:<YPH-^C5093'?8L[%_H\*K_VC1SG"V
M&?H$6 $L4:VC8XVE:?GP:TS;F--!!=?.#PG[%+[^*D:->T8N/P&U7\"ZX^.E
M8"6"=9L0*&KI0NF+)D5[Q6[[EI,>KE</3)V=C;K<\>D /T]J1/K^2Q7)E!)!
M<M6?:P_QG-U2SM+1; FV+K>'%6J"::MZ0,(*E_-TI%T7ODQ_'J8VUPJ\\6+)
MN;,&G@0(MY34J#8FB%N]U7XT. G9<L_PG9"Q YT0QQ.Q9"^ZB#;9WIO2^#7O
MUM?*[NOAC\]N/_;9_]O(.T@(\X12[K^34]:_\W$;R94TO \V[$(=P\6)I@V;
M?RC^YI)]3=MGEV/3B7M9.9>?F0=/2O9P.V$RAS%;.#"F5@)A/GE!<=](FX.M
M]R?/'<)R[F77PI,A?UC3&IAH,S8#M-B"]9W!6"!1;9A47++2]".+,D@*(CBK
M+^P'O6GBGQ&1)8X,;OC?J F^A:N"M@7?LG6_T>?]R:_E@A)TMZM5=BUWU]UR
MO9ER?PVN>5*V8R6O8["#E3Q@:CJMI-I5[9G.PY4^#X$[G(5%G+NUV3DR$65G
M9!E&%RQZMD:<4)K^)VWPU[H).#@U!R:Z#/*:<A46M.!HW-$BE1]>VDC)(KPM
MU\!_K6@,S<V??:TDU^VK:WUI1EW$L%TUC3YQ>_BY><;A'P\AZG1$#!*PU1(<
M4C1OID5'!N"?!I4]-W[A/#RB$RCFO?6UN[*?C4&+S&HZ--<8RF.#-FK-UC::
M-ZR=O56^?)KIT_&ZHJ.UO_P_X+_D.W>:\>>!=;D/E6 B4Y1A601<K;B5=;+K
M0:>^&9O\%D8Z=/1;QQ="[H*F>/?X]<P;S\]DCN%N"%BF0Y.Q/KY1ZW+<;U@)
MT41:J/$=Y%#&-[V0D."A)1=VE9U!4\C5I#D_@'+"=RB(1F#A(Q]0RC<AM^HF
M-P@(7!NE/'4DR6"]7WHNB7T>U<QZPVS&Z:H"OXBO ++U5T,,#O5CY^KEC.=[
M?8+E[Z%D% ]ED?'#L<U2\%)G N!+1T;E/WB>O8-0?31G\.M!D\^)I; T!X\9
MHT?;TZ$9I+\MT_M_+S/_TW1@B,EG^\'ADVYWWXY(5M_2<?Q]+_V&[?K_[1'7
M_^V'D(91Y'9R]X+OV1=0K74A:M&WE+8"Z-NM5P9N)XD3/P:^BM%=2/?IH'I-
MW0&;&_$BF"/<#JR\L3L#&E$F)QV_#)=OJ4S+HCG9K\Z5ZZV>VU("E#.5W9^/
MQ$"LYKVLNK ^J?(GF*3Z?.CYK[V<6?PV5(^UD*:J!WWCMZ-W\X^3/M5Q.'NV
M*=$(= =(=%(3#C>N *8RHRBG@8^F(E&N7=4',YQ"/U])?C"\A%#S?7G/)#+T
MZ0DE>;8CVB>)ZEO_JO=NM8ET3&FJETW$J9Z2V!=;]:4E?O*I6HS6EUF$@)\&
M&((1&!$P\5HGQXRMY[$+TW6U_%Y!8@;H,^3CO6C\4TNQUN]9.&*\.;O)*#2
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M9Z!0L(9XI.ICQU[J7(LU\5T,>XO':X\T?:>6VERH3<A O2GL"SC"/H#TXLJ
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MI6T#Z/UT-C+64/ 1P8SU-&.F_<MH8Y-QJ>"6$R=DA(:6)6<HP*5X+]M^M#6
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M@X%Y5&.KU+;HL4NUKFR^\4KX,('606ZS8UGWZE3-WYLV5(M:+GSX8>;J<-1
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MR'GL%[-12(!B&^-(0$CD8RS-[7P;/4%+=1GM,E ^N3SGV*!:?U3ZMVC2[_W
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MAOK5H!3*@ZO!*/*MRUCKD*+M8Z+9CY)OKJ\7L.86T06=O=0ST,RTY'9\+:<
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MSWKM/V8?!>DV7QGDUNVM4M[XZ;-$YC& P++U'KQ7+4HI+F1M&LW[K/KS4O\
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M9!LI/YK7"ZI8"X4RPJ%DQRO:NQ_9L+#XB2@@J/L4F1_P):PJ?"QQ^)'T[?\
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M)S*GW#V!]:S:+3/T/_9^\<;-)MO"&HW?^G6RYTVXF;_7(!G8">I%>F^*-/\
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M'0=,_2@,V\.HPHQFE=3M&X9/4-VJ-_W:-U 89^7Z4KA<D:-MV<%U'3OBE+8
M=AV['VI%#HV&<[<<8J*:98HG1& ;K\W/Y4NN@T.AD634&=3C@?.>M7A(Q<X
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M*VDF2?M(>3KGQ,>WTR$?:!'B38!R?<BO%-1LY=/N9+:1=A7[W/WJ[;_A*I=
M\>7>HW"-=,S<H_7&*YWQ=K47B#43<K;^1&?X5ZUS5)*3;-X1<4D8S1(MG&Z2
M>9,Q(EC*\(.W-.TZ&6:X"(FX=<+W%31JACCB'+,>?Z4\B+3X\2.R7$;X&T\$
M'WK(LTVMX(=TBL24 \M<9Y[UZ=X;^"4]QX3A\3FYBGM/]9((^64#MCUKAO#+
MV^N1FSMU\N95+;D&XFM;0?'&O^%])NM %TPTV9LR1,,'KVK2-MWL8ROLMSV?
MX0M]MU])R&6%,!1_",=*^H-)N_*E7]YE&_*O(/V=?#<-YX3M[UTPLKEP<<J
M>E>WOI<<B[K=<,O\/MZUK#4Y:CUL7A]W&X\G[PYR*1LJPRN!CG/2JT=U]DC9
M9D 9>=Q%,75(9=V)0PQUJK&1<,B-D8).?X>!32RQ#))4=.15&35HXFPA#MZ
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ML[=OG5=KC@;:N29D9C@D$]1489ECY&1UY'3I2,#--YMW1R;EVGC/6GK/'Y;
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M&*\1GF2Z>O  0*U&9?,TQ9@956Y-"HPM;TJ]267(7XQ;U18XMGB_[UU:L&=
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M14$R!N7$&I>I0+T%%EB)%"KT=:[*L'H=+1 +P<XIMW&?M$K8AEQXFO$F%W\
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M:_-EC"H>GP[XRJ*^WV4C]:-;^U'J[>0Q+&XT,T=RFM!\Q!@51OW>CCH8>DO
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M.?)AFEAK93N?_,5RDW)58TUYM K%$&U>M\UDT(6^WV]_>U3%I-Q [KG4>!*
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M48P2[>,GX.>#K,MY'1YLX^W1JAVZ$%USHNA#Z7CNT50!SHCKLTX4?*2C+I_
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M=$$CHL?+Q]$F3%AF2M<>-B$GZBVAT.]<B)@-A\_-/'1=B.0WL?99I[L$V&P
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M;?$W9/U%<J&+ZSN7@"@MMJ$N-N)RW,"TE!NX= &]!_H,/WZR#<1*UET"5GX
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M %+A53 2P0(TZA(&5R6SM_IJWND#U.Y!&.CC08B<2&C?A+^<\UNA==G^P$O
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M&G/75+!S([VO^>+_CQ_@Y=3_ U!+ P04    " !Q1'Y<5@]+ DPO 0!,?@$
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M; F.'K]4L!?W#JFPD2.^++ "(PT3=[VHP6P[,[&!EO1O3>49/08;>A;-!?N
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MA'4L2AZ\/H!ZU63F%A;MNPCPK)AX4*>_#[5'T(-3XM_!7@/*.-'L?BHA92C
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MQTPZC(&UEP0@8&W&O,M:&HPKF^4A^7F=>WGNX'&Z=Z<Z5H]?9:W%D[,^S*_
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M2FCX8*I-]GUA/EJ:R->3R;@?N"*H62'J-B"KX1F4YH5>=:A .HM[&-=S/:
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M-'@MD/3SWN#GA7S0LV<L1G]7X(-Y%6N=P._6\+>-.\TG&J8"O^\)V";_J'8
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MT94"%:997-]SY^CBB5<!UIUN-G>.O(F[_,%A5[F?87#AA6NS4A;OQ1WD\AQ
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MG\3'\ZYQW7&BKJ]9I"-H4!^Y0@ 66/@N\LT293[9!#^UU@,7[[3@N72V@D[
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MJRD8@M?'BQQ263>ZT2R+CISY<8I?B5,2=?-T,)%NE++,&DR^OG;G+R"EQ\L
M$<AP5"-O7[+6'&FWK<0,N ,5MXEOOR]-'^C<=>_KTMQTU&[T(KP #WCG3"<P
MUE9%+EU,'!P0I4SS!3S=&K:8CY,"X^AX^=XP@R<:^T<16Q@&>O\:BQLP+=Y7
MPG(:X]F+/X\OFQO8:7"M;"#P\E/]2P_7G[F9,_7CE5G:K) B_3WUSTE^SNCL
MKC?)4,-2I\MCS\(K-,JH)Y&^_6=Z0XQ[NX]6OR\/=Q^WA=V^$]1??.[(([/C
M)RHTCL)2LR[NU#Y?_R')H]/PB4C4\J-5ZSGON#M-?8[N&,HM%9.*>4*?[G%
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MIEOR+-=&GIHA$BVL<8>RCP1=D+8M;:$W/\BX9/SP-Z?B;WEPG@@Z62UZQU9
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MA8\W*W8+K,#&1\#8:_634%KUY +\KM8]"P07KXHS:3KO-K1 -W./"_.>BKA
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MSU3309H$)%K"@?6S0Z2]\XU-\(XI&TY4-PN_$^IF31\#SZ8%@B%S8IA],^A
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MH8GM0)8G7.F-#*Q<(*DU#ZV>I2B.?+RM$2A15F5,SC_&B%WS8AC0CVJ0:S.
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MI*C@YZK\UIWXE+;VOUKM\:]F":V(TQSI>G.I(VLU?CLH7?G,&)#?)4BV<A%
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M6-*-9+ .PW]VR]KJCT>-T.%B/2A.M%=\%O("UW:@U9#ZXC#)8^1V')S'Z'*
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M<RTMV&G"9!NBCK&)&(X>RQ-@TZV(&\3:DC+D.GP F)HZ5VOED-!)VD0P$Z/
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M1W2Z&);U]S4MV%:P1DK_<*TH7IZ(2$ GYGUD?+0F'K-*YV/5<=@.@C[+/E"
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MG$(*%K@L+)I5_K'%. %W.?_X#H]MCWWX(5U89?+<O.@ L2-:7OI0&\)7A:6
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M(OPSO]!MK"TZ(GRN=K"^[6,0ZZ(+->9K<Z#)9-&R\U3PUI]A"+%&2/>-246
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M_F( 9W/8T@$WR$@4B[\FD1<UD;&>O^,PTF@*7:^5+-W?W(UBKW4$OM95SGR
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MO_T@*R!%P)2J%?H;WUJ]YV1P7-&JVCTFNH ]]X#2;[HUM_U!KHM9['0D1[C
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M^G[FYJ-(V)!V<(A11YA2&<_(HZR_S_037^%UX!&,DRH1>PX%;<FF96*%!5C
MLY<&FT$BA:O2";H-*,38Z5K%^BFL <4X<MQT 'M&C4@*6M:R$N)X@*Z)TT29
MU9QJ@6?=G?#T\I-M\L][;95Q3][Z[;-VJG+BNW2+/'Z_57>667.E.<8-_+5
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M\LG)_W#^=W]"?FA,A7AL/'>47>B#=/U$;6$,?,%4JZHXD>A4:C5Q>@JTEQ=
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M_=-8P\:!"C@)(B@.45YQUC!EJR!_H1K1U7M-8*#$"54"S1J*%C$ZL M(4T%
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M0+A?N WT!Z;;HO\"[6-#B]VPG3S7!)/TNU)WVU%.F0PT&Z[SA@DBWH14@M?
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M+)&!V-/W Z*F<;O^^;QI?9-+A<])B+T_(="2]APBJ-MLQ<O<B-7IU%88Q,/
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MUEQ1"B,B>^!%7V!OD$MTR.O\<\0S R)+^%MOKP+WL4N9+OL._^RL\V^TW+5
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M82O(MZUK4(M@81[23A2#)8[U3=LO>;;Z5XVB/,[=V9FC9*WQCW*.W/USCB]
MS5;SK4G2C5J\2+\8-*HR-!8"&=G<=1T'@'$M2'8?:M0TSC]0_G&P859@UM((
M:]=M%S?5&R'[-P[F !A5/_FH0]"4XPUW@LT;!W&F<E\'=4C.21B]<.RW)Y\^
MEIJ6*LU=@]^T'$XRE(LC9U8Y0AT2;<B7R=:CCP$S]1O5I:?C>,^*=\O95A,>
MM''\'@V2%%R2(O4Z%7:4:>4Y=PZVKEMMS/CDO:_03);8^PG=S[C,&,QS/CI
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MW=HV81M'>YH[OI#G/_X2_IWD).1?/_@5: =_"W+&+ZO_(':HP;_+<NAXXK^
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M4T+LRVSN]-7Q^,.X^RR.V65>3XF_:FCQ;*%,=X2C/%9??D;^>BR!F_M)L^=
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MA@,=@71G_J4%GL#UH*0 3DU(,GU)E31F8C>U5.["#B#H+O@4$O(90LQ\6 Y
M>[R:6LGT)1]Z\Q3F2Q5R?><U6V5Y+U4@?\D?D@2O):Y[<3C2Q*%H+%(?"*=F
MT:+P3 Q*%'F.DE!8!%SHC5KL@O'[]]#GX"FWMJ^Q#,>V^+CIDC>BU;@!SWZ[
M^J&YVL'M_H/N\"]++0\G$,D_G+-_6 VR0:;M JP)M&3K'@.?,[%X3[>[G%S_
M%'D4L*-K(="<ZFA-I=4P.(A\I?5ZZ12K7]#-*IHLH/%EVKF.84[52^NYTFEZ
MIDZR?WR@J<+I04VDBOO)SCDL8:?]@NH_H<H^:KQQG\_?[?I3Y)Q>@D,"(GN
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MK*F//Z[2A$-W 1[Q>UZ61Q((PWW?/YKH=CH?E3GY]G.C./GL5XNAZ<8Q\^)
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MZH19ZO%<;;! *C9KL-N3A3MJ*C=QMM ZUW[%O<HE(*08.JUD8=DDGDVZ^_$
M%=$"(.R=%4>7;:L>%2=F*A9+*!86F^71AW-SO?PNW58-^>DVA'Y7[S0GMR;
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MRVU2U LXX6F3U=W';.Z&_71KH^IR"T/XS>AE7V\ZUY/;WJF''&&AN3F=4$X
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MW1.X!9W4I1=L2C/::$U%3,]NL/"-3Y%9E\DQ=;PRW&2.L#<RX^IPNQ7>1J=
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M%%=WGBH5BUCOK:UL0,:,J3GCG)UQ4#^?)/@ES<F1$F/O0? !?M:[[ G<!CT
MO]K:#.)G&A=H9A\&,': $=L!8+,>?HYXAA9#G2&UC6SGR"!#%MP^;>]T(O:Y
M^]@$T6:EW3I'86]C*O/*X851R1Q8.9#@,O*-L%XY@HCBWIQ@80Z3J(L*]D[
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M[]A-MG'DX_V,H0>\4U^ QNMI33Y37P"[2#WE;OO ^7*>!+_,I5!'24 2#:R
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MMAU[L2"'"\E%==-WIL8(BL9,7=YA:;;V&AK*-.J>GR31ES?!;"F@H&<]<D]
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MH_2V=8]6OEAUP/,IEHO51P)- 0/=$T!P_=P &#^^Z7Q@->9]@H*51CC*U(Z
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MU?D_T"<XJ-8"6MZ,&?@1V'YXITYQWOK&E"TA[(6+ ]*/)WK!TM;)T;?:,T\
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M?)-8\$^!X(#V2+92'M0%E"[,A;.<<!<^2F1(5#Q"B4 =U(,J>%MPPKBR//(
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MQ\_DU/^.>5JS>=N+-,2#/\>LIK?'4G805*$N9%%!8P&RNK&Y0<IS]1HS$?W
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M4:K@]X!H32R?4R\;(Q!QL[-*SKV F?5UL-F\A'@Q62_>-BDPX1%=DCC4/F0
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MM)XGS8D0!K,2)#@819=%6X-9,1N/O02W-(8"Z[CL4Z!>Z<I:>GJ-WH2.8IQ
M9D7=\Y#:[: H%=/<. FLNMUY^:L<39]I=/DD]8C.1\?>P4*=G LV*>7Z%;Z+
MD/]([VGMS1XGND<KLZHYAQ\9N>)6VBM+Y#??#;G?T%!I8N2MPF^@>@P]^ESW
M8"7:Z:1A=9Y2!>%UC@I5XQ")XH$K(C?!A6HEL\A."2Q[QA12XV!3R,VQ*UZ@
M.:>TCG(5O'U$=,MA<Q1E1XQ8CA7%QS]9B".ZCFOY 3,W'Y7T;[DU]_<P+8%*
M134&!4:=\ _NY#/&I>GTQBTQLQ79\$T":SV8WVNS*B6$^=U7/:B!D<7=4%VL
MNEE-ATX^9S18]GE3*X@0&JSK[+YEJC[-^#+5$W&+8'FFS4&KP++%BW-.-U5A
MB[Z_6>ARG-VS@!VRSHJ>V.V!V@BO#2X6W I/R_W?1JC7<X\>XNVM]%6H'G$_
MFI=PYW6=?D[<3H.FKN[FXRX)?Q48$?![N>'_L)+S-&..*/,,30XZ/0B\%?.[
MH"Y+."$J)<]64#:3HW)#N=CNYPY:/^NK-6)[Z7)"JW;H#D5.*ITQJ>FS]%ZR
M*M'TGEG\'%0*#&!+@B=J$FKE1DXZC82,IE7$Q.&I)@=<3[>0%[SG, J86/84
M?1:^K"'0$WH_ Y$K$6")*S3U:(H0,1N1CK[\D,Y$3KORPEOF_$;#FB8LZ)O>
MSTP12GH+BY-2/XQ3JYG5@?/CXQX+X[>B=$^\K&]J8Q'U*%[W@;$#[Z/>Z&9W
MA1C.EJ<7./LN31X_9U7@YU-IZ%F ";E.]7 Q._EAKT_UXF&;*X49<_?.\#3K
M>SDS:H,]/H6[QCQ._&@F6NG$?W0_YH9EG<9W]598VGK=2$[X@]3J@;N+;*0+
MU:)G!U8V@$=ZZ!LMX=<QS>O+(#C@",51B;Z !-9%9T7,NC&[); ,C'*[RH/O
MX&( A5%JA%0F9(T$%!H_T^EF,4^,6D2_=%\YMZ5 [9OFN5H'RO<%@2FYRTGH
M+#@D?D4'O$KC^!D >V4=^%E96)[H+W EM*&RK\A<(]H#V4R,DH,*GAX^3,0
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MWCZH7>_X[TOA4)LE\"PAK2(M3[E4X<"/=MVMWH]'[TM@%+JB>(2B(/4<CW&
M!V7R-A>[?"%,&@S:1(3H3PLZ"]Y+WT'&:]'3.E  @E%51S(0VB5WDI"0[5]1
ME&U$>\Z'Q #PX#C-M.5%W3SC6,L-1:-A1:_C28XUM-5X+(N>1]Y(4A</D^6(
MH< 1GF^JU#]:0#B>0"O(NG=FAW@:1*1CFFMJUHQ-@UG(%9KLX@]$QEGT2V?W
MQF=?+=X&O([X0KRW)W)/H<%:L?&<^5G^CAHG#W0Y/.L5\%U)N0QA^.F-#NK
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M5X]=W3;&8.YQ-R.UB@J]C=!C8(R^O%G@B._8!&V&KX!2:?@%XH O>J],7+?
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MJDM[3T>^5KW=Y>"RTS X5ZZI+,(ECA9H7HIO5TQ$_FPX051=&/&.LQN[,S\
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M4Q2%!X%&!EGY&RZ;O)F$Q <XIZ$/5D;:I;VHFV]+O]'\-Q'!68%W?5W<Y_#
MI-BG!''S EYQO#6LEK0L'L!M1,L(#A#E(4<!6HAJ?%8/704".7.I#EJ$PS-?
M0N)(\5C92'[;P=+Q\HM5RN\7$_NC8IN-4[+VE/W@<D^F[4G(3<J2KNPOHD;,
MQS^0D*ZSJ&1=J(J2P$Y@-OM^8 ,^!WU/#F%F2\G-/K4/HZ[DY59/"AV:BON]
MAF/KFCXXO0OATI5H]Z*3PDP0/I\][FD\+)!W6M52SGM-VOY?0DY+8(!O['>G
MN16\!';FTX0$YLE6G!@ HZ-3"?<>CYS"E%J,-+J%3998C%?5Y8CRYY?<U4A_
M!F_VI&X]6>'5AU' CU9Z&IVOD@5;G#6ZS]^Z<$=/G;?WE>4>%OXQ>8,N#]'W
MRQ:2&=%K00)S1/3AA"\>=.P3_M'%[!W(2H+C,CH.8"KY'RX/_^R>\>0_-?7(
MOU2O?:8G^29(8"B##Y<I_.IGB>F?Z1QY_0_D-XV;/TI@[NBB]^3R1*$*TG,T
M(7]R(]]]S#+)20+S&5WM4(+.<=<]QU!F"8J'OW /G0^^^F+Z5?CSY_?H6<<J
M$G_=<!]F_+D-0HIE8R2PO5]$-S'+V5#H]U.^;#61!,8P[=#B\#],OSI0./VA
M]1JCA5TE@:ETV'>K"L^#A:4V3J5V)&-"IEP\1VWKX6W<9>[^%%W5\AU]AGM[
M]]PZMN>6W-Z'+QN__/DPZS_]#?Z[QL:/2%8CGR>Z@SEMNI'AL$=41;(DX#BF
M^;F6QBL&7?PK-9KCK5R46O#")3)+LQNZVAVL.MR\JKJDSM(O\Q&<HM</S=4/
MQ>@8YWI^&C9\&,&GI- 1#AK$RU#LK 26@]S2'L>A9^(4T.3R+AIDS=11'OUK
MK!W#5=1/O*775O_R6D&H6H\Y*VC:1;>MH:/U></+&S-?6 1=89[HA8,R:40"
M4Z3/_O7S++HT"&=]EX>>D%@ZJE"2=-=<%-T5X@%SAHX]E#@;FQ$L/R;> S5V
MS5@#[-[\C6]!7^]!-+(J<#&6DTV!01]U)\XFO+5G)((S_GY+A9\6>S$H3 QR
MLD0L=Q!,[Y3.,-Y,)?6I5V)O\RV@C[.QBN)7$EA]Z\K^"O$[I (]-'9Z@BO3
MTR^!J1(-1.7-4SR0SG"S9OYP3B-JQ3V:)K1)8+]1>@?G279/06]Q-N=M''9B
MUTLZ3-P1S?U.GGU :7A#UDF@3!60+/%%.$VA/8^]E6@Z0=Q520AE!E2TY(-(
MYA6OI3($X%#.?6O?O1ZLT A:/2AW2K!MJA(>T7YW+WSH;77%K;_OB0D26"0&
MTD\7JKHR=?9 W\$XGVQN1 ^%A>5,=%,@73?:\@3HW(W1^0B0TX3.((V#RH\7
M8*;9S&*#%"07GFZQX_,CP*WC@5EY(KB1<<F@)R"82H:GUM+6W)P^CR;JJ/PL
M"48:_EG\ZBPJ@Z(AUA+N!+%I%A1M":SK4H>F>%AS-2.>G:.>C>=B)B>.0_)U
M%!5"J_>@&6F7J_9X+K*/K+*4;9U:]^TVS[CP>6N6HA).$=]V.@!&]KGC"WX%
M[,5;/PI^F_[)S<?)FX@!4"SX<+4W8+4/RT(PI4G&\T60,_\1Z/BNPC*;N N:
MYK"O_SA'K5G [= XA]Y;_&&.$;0;KD!$M3^K-[1(U-%KB)SP;<_/A.!2AI'*
MK!M/A"@1A4CF_.SGB'#828R#/DA_$S/NH"ET <FY$A@>WQZDM[XR72$><C-(
MMWBR%DC/$!OBY*!GXK?=JUW!&N!ZRNF1=EW.6ZM5M^MK2P?=7_N?V"A TTK:
MK07!XK=E4GPA3N %Q7(GTA-P4X).'XKR:GL(Z+ U@?!->\O([&<J+9*L8O R
MB^>6?G**H^C+T%PKK/AGX4NCZV/WF,UOP@UN?[>%+DLO2YKM;N3,DQL-&"_M
M^Z3?D_'PG43Y84PL9BO1%RH5;&*)!\MDH6@0U</>:L&^9JVSE=X.2"D2R[+N
M^>&4SE&%5O0+0+@?%$<E#6)1&>>:2MC:@?Z1$W9%_%.8<MQ3S+*YP%-H+8$E
M7R79B7N#S2'7! Z;A>M#RDA@YV(5"*$<IRH>18[P],N<#T3GTK*+BQA)B!/@
M&BWC7+LU]=229F)FTY[VB693DLH%RS>MQ:/\1%2\+DSD+RK"S%;@Z@=6*KBU
MH9WL1M0*8G8@R\%RL!T5S4LZTFU5&&P L#.QR:ASG/I6\%SI0\+ (>!310T4
MMGHNIE8K:*AV]=NS.K/:TX4+.I\V&+PO$'J*WTA#P)T&&0752F ],>0N"AR#
M7[U!WWY6 IN]19<:MS-D>>%)42L='SLE@7$'LHC&X&L^2IXM1 /,Y6RJ4&["
M<B5BELW0FXB/B1 $G@#Q;PONE&D\'^ 7YF]*ENG"2,,.,MPO7?A$8C040X5T
M^8^!O@=<),N [P?.I7=LF!:>@@X^66P($)I#B4D/B)? O0"I%93 ^D@[H4Q@
MFHO*,1A:PZH+3<?ID<@-BSB59C(<E;\<"A1\?N"0;B/#3R2#6$Y?$:C+H,LT
MP[6@\!'INJ)1-(C-(,/#QY8G>G\,)+>;)E7@RW:#CH4I>M9?(NV<*NKPFDF?
MJT,"]ZXVRT=C;09^S2'6"DY(]YTK)@0W2>_304)D@1MIV&$3Y,LC*\^G]ZKK
MJ(W>#AY?Z\?(RD^,8'/:G2L)ODX3Y]!ZLUU/'$V+A'H=AFY(1M\G^8RT1P&L
M64<H1*!.ZD(V,Z]CSE*@/:TKYH*CXM>L5R""@9S,YTE@RR 8T4/:#G%0F34=
M,$(723_ZQVJ7=@1S7,<:&N*RMT%9S #H4,V2CO88VI[C=I5;5\2A:$$-%E!=
M77SLUGE67<FW]!4XD,@?%-V7!O+T #\5LA4HPZ=?<%971 (;X0XHC),X1-(G
MZ@-6E8!K'WNK4(T;FS[1 8/NA8(1P8.:Y!O!!Z5R_ 9R9Q2+>4,"X^QZF>P1
MY/YNG>%;I(@_<(U\B*0%&J2WAW%6Y'MGE"<LI"DHL%?3H80+5X3R#XV:)@2I
M! \V9]LD*!KX#5NZ:D0TCL:_=>GCRO=K31^K:&UK*39\<).7$-J,^UM?RMV;
MI$[F1HK0#/*0OEX6W7=0([J.Q:(W@@A^+(03:)*[CJ\-R J=7PS6=&@2S:7[
ML=(%^M%A#QV/)1[Y:S%19T\)PRZ]AS;U=" (Z"C\\58"2UW+A[\B5[(6!A^Q
MSF 4I<Z##'A)8-(LU>5$CXK-*MN;S>4 YU[4BM^ODQ#0S8="7Z !"@)=9PUZ
MV*F^'3M$=TA;M'6](<95[A-+>'I D5#W4K%^N@0FE]]92%>0RA[%&<)?1"?0
MQ&ZM_Q2,_(?EE\0L\KG\*5079MO::JJ.$<3FN"&XR#0'$R$"4J-! 8O:Y]D+
M%'4IA>2J>('(+MS&=P#^ $L[D*N461YU)2T'?'\L=*?5146GSZ\/9[!?DU>0
MTO6H$K7%8R$#Z^6#@,QL[/)W$-N+4UNC76-O)\8)? BI=/S;Z![R]G9M02RA
M:';BN@59,:J(RHMEA791%$,':X6^#W'^@=#7P[&9/M*+WCU8>[NS3"DOYER0
MY_I[.F>&TLK.(J'FV<I"?P#7@VAET5;*I=.:2J/M0UP0N,ZX^B%J]9#HC@06
MCE4A(/D4,(UV@/".>U6PNHFPZI$UX.D8G8OK3;3.KX+"V<$MYA]^E?F&$GC^
M7&G,:?8DM6<&#D2L' 2G#T/>7 HR,H"9*=1]@(.N,G5VC290X 32HKQIM'\6
M7(80VN/$QHZ8G0O)^_+IV[2S.K!,K'_G\"=T"$SFD)FK:65PB G@F,$[H0+@
M!?/'[P&KR<18SL'#![&')KX]/U,(;YH*<KZAJ777H.E%2^GN%PTO6Y\];;\A
M3[W\ -N#A RQRQL$.-(8'3B!N_:?(\T1R&RZE'+#M0TZR?6K*[: F,DO@L*X
M\,T!KAQRCM@4++IF24X/E@'3TRU[QM!N=01$K_PC=C"4 X4>R5K<:G&W;+JG
MV.%18?0%: (L%\L^D, VVTZ0(W"0 9-!3D4V1O3BDH/5(:3 AHB#K+GL&Q@Y
M$H:@GN3**5K)K";ZY>,:1;0:=/1E<+7S2HPX$]3O84,#1\!_UB6P;4(/X!W/
M=SQ>:R!E7?][RBSR_9B:L-IZ&2N=10V@"]5I'.:*;B6DRT7UPE,1'?NA4PY[
MI-25"4;_ELSI2 ;8QT2460#5<S""4R3\E:TF1/!BE4Z]A_ID/^<OS_$PU]G;
MT1NX6)5%Z2U%J2]4-WR8$B>2N_2D:T*7>@[I'Z#EP7Y^[+#87 @?M61/D<5R
M(;-P;?&X5')+R=Q6F !\Y>=!N;R!'=!(-ZZAF&#.T9O()7IPD;\$B]^)T<,5
MHPEN6 _ -W7EVW22^I<8NU6<7<_I;QL%[0_I&31%<I<59O9Q0/KRA, 50G(D
ML,Y5%HH?-TR, P+YZM %+BU59Y^H,7XUL^P@-"'P%5J)'@JMN;$L,K\!PH-*
MF.RV62B"D[]-:.3F])I#Y^@#::V\2ZU?=P&IM:.7?B31F\7#%. X=MJ)P8\7
M59*V$+4 F96-<0#UYP./1S/$LZ(R!QTHFH=+)29MJ1)8+5(:*2GQ>-\ (+&7
MGM.A19>RSM_"<$JO[P12H3DV6VIK<>50!CWOVTW2X"'^G_!EHRRQ'B9R%3(@
M"]7MN4VX>KV/S%2'W=#%U4YZ0WHW.[7^/X4H(OTL?7YNI"B4@C B/7!";+@T
MLQ>J .>.C2;(EV(Y0;3T!Z/$<T_%0XG@XYMUP@/ISJ/?2I9BXCS$DS7ES]/>
M#1OWI[:U9XUO_?RY<+_<^_>/CC:^-W']TM/HHG-($[C>DK<9YO_?;6L >;Y4
M1!1<(\_F(OFQ;. $7?2;4 T7*\T'0?2/6I3F2M'M$IS(E6B-VT::HGRIAPNW
MEXO?"L1R" GL"?(&=44"@XQ;A>5Q_"8)[&E<M 16%9NV-/?LA?B8NX'T)U?M
M)+"Q<WM$)?-2OC24G\6(RF+E);"UUK\'OO8$)\]C"A1_=J][\)\V5O]IVD:_
M%MJVAKLG@<5<^'"%)KTZ)R2D)YVAGR^-@*<H3O['"SBBK]2) *ZQWYV+EC.E
M,@?'0+[F=D"T;_ TS#_%G%7!]H^8']?3,5PM)NV[ \F"/#4)2B\X4&%V[\.L
M=?BK[I^=-_^[1SN"26^V7IX"&GM:'12A G".8W"MW3\B)N)R(H>.( @8 5M:
M8_!/#IN9G(L8L3SHQ/J\%_7K[FB\SJ^WG1+[_"_3KM!>#["H8EE=0(7?"O77
M$F/ ]3R2X3Q);_Q;/GQ^PBXQ-0&I.!TY% @ENKM9#1\]/=IN6Q64^3A5[;/\
MAS:- Z&_>V7=L]7[K&>05-)2NAKQ#Q&GS7NVA'J%]P76][QJ%*[QYKVHUP?,
M93_>M?DX7)Y)R/G]@BKK-LV]Z?Q@JNG)!YZ/:@G4)&F"4QP32!=X:(PT( V(
M!*'T=7_6R! F!CZ%[&D;O\D9@).&);"-S2_)N-&:IA@5IV&Q/N0D\!IKCG'B
MF%J(K-V?MHZ=>?;BY<OGA?97 R-U+T<4_YYG$?X'_.. \,BZ8*\4_ 2T))7F
M^5LDL*]:0:T,++2+MMP/O.!BKI'TYRG;Q>8S2S@X.HQ#U\);72FC<C0LEEZZ
M,C2;ZQK"8DB%8I769U=M/YOJYGW\XUE:>,I3ILG9(PHCM0F$0Z9FW\M*<&MB
M:93)]-"/57&!^CXHFK.R<R=HH9M=ZYQ]0<W8L_MUC?KNBKVVEG9W%FS?;;OB
M<LRL<L6-1"!-T(&3E$D!7ZIW.?14,E+HS1/9]\T80'$UPJ"F8:(,D,C-[_4=
M(6E B0'BSHGV&.X6*(Z#4Y; 0@ADY]'7C">+FK>Z%*O;/5U>W^K#?7.@RY-C
MR)"^=0]E&B66"P0&>%NH())GT,6>*CDFND$R$OX"KN?2(R@YA1AY!WWH=I^.
M.<3@T+=5,K1#MMRL64JD*Z$=.5LM747GDJRT,%#Q0IN+667$A4VGD_+G&_DH
MSD2O5'5)8.K"[< <UYE!UB;$]LYLA9YS8E!]= 7AH8JH$\VT7*)IS<(EU@RE
M)G*_^Q_M[:U%KB]:VPOWGVU5Q^OW3\9\=':<<S 0#]%_$2O -U*RD*I"[5D>
M:,"-2"8I0NH'L=ZY<U(SMIIAESI^;W959H'//[T85[64V(( NT><%4N;?! 3
MOA-6+2V)YH["+M(X'3B*83'$6A'\4V/T,ZO7D4H6L5/9?-=QS"Q%';>Q/8FS
MFBG6 J1FAZ9$-!'=%UZ9H.P0:O%JCW WOZOEB9R]7PZBS"@,/DZ)UJ['H6G@
M1Z(2<=MI: _NF9&S>E6UY"XETJ]X>F,B XL@,PR%QE"MP'>>#OC:Y[-6N>+L
M6B%V:!G582A^TX9E#N2PUM/1R%A>[;E%"8RAZ9J?1K("1AD,_9GQ'5.66E>I
MEQ-*09<-(D>BL>@OAQW"$.!Q%0\K%[7.M]MR$T3VT>7,ZM!A#Z-FMCPKZNO8
M +J7SWZXBFUX"@8]+DAX$M!?AT^\$%E<>M_+CW!CU#&I?. RWL*S&9-&;TKO
M1F53U!PP0@1@D/%IK&.7^$VP+H!-=3@P/XS7K$@)UIAPV$4P8G 1J:9_C*)B
M_J@?]ST!U%5$/$'_<.M];T7;U?R<4"=E];]I/Q]!;B+\K+%(#!"56M"2V^!=
MM%2'_;>6>#)"U3EFX96R"M"WBPR4$6W'R9$#N>;0!/\JN.4FC3"[Y* ZW*XS
M@U"/(V1AMT1&@]F,'R]SZXK*"=G=;4ECWY8$/WN7OQ'=(4=2I@0\\@H3M.>]
M2W^\<((T."3N*4Y/6345ACTFT'W'$F)3D WKC-44J9(KP=WJ^GAKYC.#JY]:
MX]]U-<$D&7=]2V/4:LS%O$YM5/< 9(H3JLQQUWLILL*= +.'O7-A9H_44_::
MDF?SKQ&/<*4?!X<0[@+Z^R0P!-&Z*HKE5 &L=DM@:@GL+?Y"AS'T259A*M5O
M$G^!D!D^2C,):VSX^IG_&[NJ?K$MJ*<XQ>I'0<J7!>6MS7X/VEL+W0[XI)[S
M.7A(V2G:4/&%"<?L]^,A87<44_:+'7^>]-5%K)0"\!YR0Q%3^^@2$F$F1H@_
MD)MPO<@<3,-Z/B;2OQE[G?0+0._%9F&4UY I]&;Z\AJG*O8OZ.I?PCCH((>M
M.@V5+3$T2U_."?4269^>-%BE<G<EQ*'RQ?ULX'<XM!?.^%GLYH.."M1PAE64
MZ6 L[D?N%,NZ\<C2Q#FC ^06K22",EP99@]4PB%G%'=0.?3T*_0>N$(T*R)U
M>:Z^&:3T)8)*+Q[G*T>QE=[=QC"6!.5_;!"5]7)CE;"5@4O;H.3?2XZVYW$#
MW3Q-?;K=[!:-'0OJ'K5VN";'H"_U;UHY#[KTRS$,_WR2"T;Q?(=C8F)BZYK=
M[%BO?[@>/4LS0\4\:&XO%CYIR!KG'O,QSD3)/VDZ6LJ:?9IQI%!#O$WJ;S:)
M)S"_=,B3.G&-[+[5*4PG!>'5BP.\8[4@7C>N,:PU#ZT]FPB5 W])7?0CS<<%
MX#H3)QM3 :EPDLBG0)ETVKL2Z_1O,=;=;6_4 SRA#N;*C[YR!;(C84*\=41
M1"U7"K0(&W\^^R'ID":L<(H.OXBG)#"%.DP82D4\&M!Z76@H,!4>%STDZ<]
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M/AND-T"JD>GDKL-2:;X1\$ZB2RWK)0GLSCG2.(7O'D->,P4^$ \)PLFO.S&
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M7E2W9SK=[C0TC'@S9711?Y*W4%@X0Q9E[81H N"%P8UB,V',P(?R*YHLFV@
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M>U@_[QNZ2_%/*'%YH$5ZHIB7"FRD-]=B,8OJWY\,R>_FK8-I7G^5F(98SDW
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M0,ADWH-JH\ZQ&TMF.A.19S4+B9K9G.$_T2_F#]!<*2D9MBQ&,,0DWN MA6D
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M,QOT3. P4-YPTFULKC<:#&Y$]W11O;IK]$TSL@MHCW=O=:ZFJH[&C7U<HCB
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MH7L4U7&289+X6B_/@'&DDV'_#^#G!7,E#:@IIY&D\3I-@&ZNJ"XM?R8W_TG
MA"YI/P!>;)MH#)83/=&V)9*O#7?[3(&!I\R/>FMA=H@(N"F;TXQ"#<QCML#
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MM@UPX!2B'*'5@Y@\'JOVKLSO#UY?4Y[7./77X\&FAOM&^AM=/SO\OU"+E77
M=U>0K[BSP18M:"</L/.^(O\T=QJB[_D)A+EWYUDS?\DIS+:!DC3Y09CKD29+
M5.2:T7EKF:W AI]>UM8]B)?H[4]R<MLU4-YP684F/59>*1BTYZL&7\T.N-WY
M5>#*PY?;;4U^Z[=CM0XR832/DX[@YZ2:Z(UR-)-:7HED\"<-%DPC$:(/K\\
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M V^ZSU=U/]V]/4YB5UY8W%IMN^V<(?WSNHMW<RG/>/M0#$^QSO+/,CG:RSS
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M I\/2.S6HZ%E/E=E]]X&"QG< ^8[E*L?XTY&M\H,URY,?<@K+UZ*BQ5(Z=$
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M@2.KF,U'+$]E< TQV>O'_N5<;5>L(<ZUB5V[VE*="CR(':WWDKM'QS;;2*>
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MX042G4%UI>2?+745.+$B0LJ$/HBQIGA:W2S',.((<I\&_25/]\;R#XRV6&(
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M[4'^<UKR;D5">!&%HVBT^71\Z_LF#P:7@A=K'R3.4A7#*C@GUOVL6XJ,7-)
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M^"WXVC?(L.C'LX_?V@AC>D6HBQJD'NB"ZVAJV=_=9>(HH!PHVX AGJ3RA&*
M2D5$@I\Y?Q0"R <-5#YNP*I^_5*"DE/Z7<"$=W,[>@.6\HD]R*OR"T8@+B<T
MK3^Q8Z.%;[I/DV7>(EHBW1FAA*XPLL*))TS.=O#F]\Z#IMB<;NVG1#"_@)9P
MI%]R]7^[[4, 4C2B@J?FWSG[]Y <@:=P=57O;WYL^=,C=/7F",C%=T3,H'\)
M?2.OL[HS.':%/*$ 8  F3XA'B]+=5/<7]LR(9AW@4]WZ6W,'7Z[ H<?0!1%
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M7P9K)^2%-LML0"PP+!ZPH0NV!H](WX<V>O;>P^Q[(VIW@MO?!"\/I7D\:3"
M[5#M(P01)CE=.M6@'! Y??)"2-TP56];K'CCT(5[59L;O#6X1V]/P+Y/!1=;
MC)9=3@G<:ME<>T8. 46R3.ZG^I;;9'GP0.G6A:^'DV]F>.UE\E8RI+3+]@PP
M(0>G;!&W#71*0 @ZA_2<#W&GDQ*E;9/LG/=H94L:)ACN\Y]Q[-WG#KOM]](*
MALU>71YF'PIUVU^UB&KXW:7 /;A?W./GTFPRDK^M_J;'X-TO]K8_Y71&3KRY
M>?J#_H#OP"V/>06>')SE^ H%O$$TD&TL(0 Z0V^VO@958-U&?6'?KVGPS1/
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MUE#^YYL6&#G$8?Y1KA_2R]<C@;II, 19M#I#ZBZQ;/1L=W&(6E6N:F^#A["
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ML6(DS*$ZX>L+?P1A>>0C@"PTT%; NP)J-E L('+/'#Z>"SE;'ADBQ@7<Q8X
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MSPE>&<KWATT*[RV*(<VY<?QWPS] 4$?$V!'(6X3:6,I  VPGT@D';//<ZT<
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MXQ ;5]6#K9%%>''CEHH#YICS?.!!A$_\8S 3H5JPJ\D*ZR(L1YA0CG2X->K
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M<=P4<PS^+X!:LWYDU=AAHXH$EVN16B[QW2Y"M7G1L_\%\<ZX-0)EBK58L/L
M$OZO5Z*3]R_^YD"ED188*#/%KCDM6'[PM"]3O3-C"P;?3<!YK[*N\EV!.NT[
MW.V^Y"?>35$IBA,0QM: T4WW[,<)B0[^__D$JO>_%.I1+L\[YC LXVC=,VU+
MJ! ^("R[UDOOZF"C9[W1-RW%\_PHWZY&T4V_6&]QY& TH!D*TM>J4SGBUW,G
M/B6SOU,44YOQSZ%CGF&,;@9[3Z_1G*F]A''UO0M;4"O=&;ZG--VZ;[C;KLEX
M<$<Q8,O-C6,W-VJ7N<&?>]L<_OM6PR?5Q%4?^!U1,LPQX8O9*[?)D>MO >NW
MX,0LU5\ 30FY(WVTHC</8ZZ:02]-UTFI)#?'VGOOYN<'!FRHKJ(E !A#RT"P
MQ*L/%]01X]T(RX,*6>(MF'6TQJY-P?-D;VZOIY]W&W<#1KZQU/X%&7?78G(&
M@6=-N8$3O1JG8NZ-;BP/B'SQ.1P*V('0E"/E.#KJ_W6/E3ZW Y9TUK@D0$%N
M&L[/G&DMK4/W\_.-R)+C:R^]7'LGS?[]CS2\Z=(ZPD9<R (454BZ3!A6ZB'<
M-J/*JS>OT)JI4"!^39L6#?R>T=;T$SP+W9X\0/XHAH:<GKY+]]2=OR+8X25H
M%Z%N,B [3LU]MA6VQ7H7Q$0GPRI0 B<W4_DZ+*_'S!%C]I(MZZI =.* :T,Z
M1^IN7G@Y]"8D1;-7TM>IZ:,^K@;[L"?[J+W 8U)U?T<C3N9DT?:'>)O"G?;3
MPL+K7GY3O(5N<FK:.&-9IY+!WX TRF(3],\E6/J"")56*$*MXXI0E1M6"[NH
MTY;Q>!.<B1O[Z>#KU,51%LB7LSS[XFM?Z,THCCVGNOA:LQQ.]1 5IEV'6@W"
M_(YNY6L^J>'MM[,&!BD]_',Y7P&32*1TJ)5X^,3AW\C0SO]*A<LC(GZ%8]JH
MPFN-P%3]!LIKH%&2\=.0]6I"F.&(V!>WB11]H9LE\L1M=G<8,VY<-)R%U1?D
MBU!CR5Y7&24B5*,SPW\$VT37(8A#V<[<B<32*K1B34H@1Q?\518!=K7)>DX;
M/IV2:_0OE;)FI_V8'(A@KO^&WVXOZ_E*A'+LDB4C1&_0H O.^_KS\FOZRQHD
MV%@U= JO!#1OK#L#04M>8>.3-*(5_:T!5:(U4VNK/CNO1/A&ZJ_*]U^,#W/#
MQUF"XWKQFSYW--Z1KCO%NKNO?S(TQH!VI;9GA6J3!GPHV#<PR[&8A!L/=\R_
MA8%[P$M\'GR^\$6>"'62>EC0Z4#@L&&QMH#?#&V^##+AB!5L3R<EP!T3S6BA
MG0!-N(L!29F"]*YO6+B-FLI:N2LPHO7BH&V,6-B E,H["5)HH @UKH&3$NQD
M$X8B.-9Y7//&'L'^+^3S(I1BE?@7NJ8*V0)]>S',%NE-[_&;&DD)GMUAU9+%
MZW_[KZVN"EB]F60&)R[P &MO 0'JC$1 A0,5%T+IX^:SDB4"RYYM4.13DHS
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M>-I4^#D;8"/'I$Y2NUFP<Q12SH0WB$1X67I,T@3RB[35"\G2+T)K5K>&9"?
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M4ATV -$0,IJCA[$K@4:R4%V36%9C3(PRO:!A7^/^^>;YF8B=MC/,3K9O27E
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MV<Z("BZV:C*:X%4TFJ-^*S) X)0;G&?P-C?W6_^"8^_.=<U08K;8Z,XU$1*
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M]=P!>XO-J:%P-*_D$N"+YVR<89/549X'D@AV_#<NKOY$M0O38TW, *W ;.X
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MUC*XX][9C3S5=;MN/^QAJHNNA:UY>)*L:,('H.5]AFDB3=T&30 1Y[I%QN&
M=:N693MZ@"KX+?;29S.:.DDUTAIGBCI 4JUU  MF_@PZC,_X5/P211M/LEJ5
M;.2&.A &TS86P5)_V[;#_\#9MWJ['B?G[GJ\O-%MD16& [B*:PL;*D6P)K"3
MV'^I)UWXC885OU1CUX<GT-B7O0R20FR<Y5G/;?;+LXU1(*OC&AY,0,<4EWKI
M/]?/P>=HF@6^1><DNCXI#<[P?YXQJO$7;^L__LZ[W\*VEMO 8%/WG7LOZ75L
M/?3.T/O<3J?<3],)BU8O7%/3S-W[7EWU256_I+'[RK[U>2_@R>B;3? .WX,
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MM7#"D!2FD#C^?>3G2 ,2* 8;PJW+_U[\NX<*&7:(U 8<5-;LAM?/U?T#V8$
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M"L0N8;ZXOM&9G^4U&[Y*$68_+),,8'>:ZQSX=5IB:6ERD;^PP3 N8$T_]WI
ME(RM3;X/:KKD8K]DR.QVV3J6WQ_>\BT[;&[H-JMI/N))=K0*@&>OS0]"?YL8
MP)]>#10<_/*W;6!KZ58[A3=9!WJ#6M7W7WF4<[3="4?)&!CQ=%DL&65H_37C
M5)KA/]U3?/Y6T?G2 \_J*PLN9YT]=C+O6$O1R5LAAQ,O)^+RMSO91>&^_6_'
M+?YW7^H?B$-MJPC6PB9B0\?HOKJT+I;O9J"]22"%J?BP".9?N?6(F*KB)KQK
M74+/R&^U]6F*BH;Q_C7W=7$CIYWTK/>AL[7D1>K6?$Q"E8Y:FZZV^+D4QGL1
M,1%KXY [E;T+D# *R&S*SC(SL?]I;LG5WJJLRZUAP/Q R;*B8F9D ^ZX[N]'
M]*X&;%_'7',ATEM&MT)\WI4>DDP+D&PASCAM'78JPV6B!1Y]4.38;4/A+6P)
M2J]G<*.+<:L3CTA.+X9GFI7KN 1&L?O23[,1"H9C/I19QUUQ>)9(B!"G+F4I
M=[:0#;AFD,3<>T9R &0(:\8)JB02\$JB!*XDB,YD6,2^ZGB=M7FR69<S9Z9M
MJWBA>\E8V5C[3 7G6F6/77W\?$Y]7>;W-1JT;X&E/92IV-DU )<HR(>'YV&,
MN>EAM]>VB(*S)QSKL@?QQ\J,#-)9CL9_+WH,8W!&U7,[GWIAS)0_;B][/.(F
M48@'.D[U+-L2/,3/*+P7J[[47-Q*?75IT:B$C=W)K^14?;08]!HY*9F_ <SO
MJ:ZL>H"/_[IK-L'BYDZ_>VB'&4N/FLJ&[F6\SYGWC@Z8.@ZA=&%I\N7=;\S*
M#*[[?$GN@\,5CGM[MP*_G6WYBEN_7^X^_6TQ!CI&EVSQ*/3T'/L"-0@?-I8W
MU\3,?YH?$UZ%.HV;^DI;C=YXG]@#!=Q\XJAM]*26GWI?)ZA#=%K&.!NK9665
M+HR7PMC>4)<4]N'C7:K5NY?#US._.?WE]?CEXDZM6T_OW,)QZW&3G#Y;3>$5
MT3%0M62W:SKL5I.GRS6MOZ:=^2:[LJS^^IZ[[Z):LN_XK[/"<O?5:-KE9WIF
MUP%KWM!M4.\X,/; #*TI&2-;BVE+72I3S2H,Z'84H'R49!EHHR)P-WLFDA<L
M[!P2F7-$MQ$Q)+UBW$%<1%]R0>D@_J [SG139?%PVT0G>DZ'@G)% W\21*HI
M%Q#^CGUDVRF!9'7"N5D#74%M6SL16>2KCF\ZN? /4$+!-==?=ZUKR(QB?[O2
MJ;?M4"_17Z)L\VN'(334YHL$+!^94G!45:BK+=VRFKP#:*:N'1 %-G 9:Z66
M%V1_%*-,WI$.ZTY[&>]I7;E<YZ+76<G(<&[EC1@-':!?-@N\<3<LHO).](&C
ML\:>E7>:<BYF>5R\.#BX?ZJL V5]_^B$8:O;AR,H!<%LP[J8!T7Q'?Y0@'7+
M56!I.%?.YHRAVOV\DX]W3FS>?Z5H1]WY0TV#]@O&)(.UZ\3TM[X*_2A%*-$#
M1';0UI/.]"[35(D(?GJB9!-Q&_''O'"1G181DE<,*;(S7'/X].W0G]_[V9W\
M)O3EGJ4YU_<]DI5+P&2PLL0Z,S(N (!#I)K9;BGL-%XX+AOG0Y ,ZC_T7?ZU
MU[65_'[UI5='D4A!S&#LF#,--C=T7V#Z$9+<<,&%4XMY'Z/%]=Y$7[L8X?OO
M9K55]8^-A)R7#EOC]\3HWO]1P*54I"9GAD6"R+:52DFWU@HUK!W(SQ10=I _
M,^%P5M2IRSUF@6'O2,=RH",G*H&)Z*5](ML<Q]?X=#?#_"F.CWY>Z4>3 LJ?
M_1I%\"^,G_MEC),FSD!/)I&'*5 ,>B?S9T;9[5.RZQPG=XSJ]XJNO80B^6-S
MF:4R%0P/6Z,H$&<N<)C^74G]EMDJH/EH;!Z4W7^BGX]1FG_39V)SK'1R]:MK
M!6DA/RC-\M37K'T;A%9,C1)&5ZS5,HTJ42>JM2-K9FF;0C$:4,=;74O(CH^Y
MYS0=<2;ZEOELNJXA="M L$:/J4%9]9 .1087O_OJ95)GODB\[5&3<KI_SYOL
M=N(:_=^3*RNK!RV2]UPWJ^AOM+?T(<^>1==LPU+7Z2&A/M0G]ZD@3*[$XJ#W
MM%H;/S1-2+Q96CHKR/CV]:FU%S&X.VU?KAU,C.LI+9FM:K+HPE3C#14=%*WQ
MVA;V2:5&O)ID0_R-Y,N_)[V(5MWS5'7R4O'3MQE,;#+*]']FJAD&C!:-(W>2
MK,25C?OYCBHWQ]Q!Y;HU'1&AHJ>JM]=<VW9/&]V$QK*[AHC(S_$O>'OVYWP9
M+^Y/0?T9V3>\)W\\V^;%ZYC[I^15C//:#M$MN;/3FZ6P1X0'\(T1G^4YM.KL
M)F"B950%NCN.T<&C=Y!TB@.Q*E5#R-A1-&3,MP<)\233<;@&;C7VT=S-9<,M
M2TC5R8<GP;#J<G3TO!ZHD:+__&YDX1=/N]NXUPX%%VN9%<NE:97@AK9L<U!]
M8@XM8,9U\L1H5J)@3"8P%-3X-Q(+H'.,>'-Y&8Y4C1BT9JM_SJMMZ'N9>*5?
MZ^RRK2>V\DM=_8-/O]T3C1116JY*8=>#;[P/MG2#U-:"INO#NE*%B4H.OS(?
M=1V=8A:^[2>WQA>1MH54)$@@UK2/>G=W[.%WN_M*8;&=Y(_(I3.4$+3H%#(9
M*_IX27[&1QV:,! AU(3'8]NXV;!T?L<<#9FT(+*,&M<V5:B9#0,;\>&^VSGF
MUH[:3N!V"RR01(C2[W1MKN"4F=P?3 ^_U/; V^W4OTSN%YL;/<;ABCBD)LH2
M@O/=V*9#B2WI=W0/IGA#Y3S,(RELO1$)E^-!3&_G,@?__,6<NT $BZH2-.@8
MFZP7,WZENG<I2S9HIQMZ_7H->BY_FM:NU1,?@$[D$ -82$4R$HILJ;=HX"\H
M3$I4NXW,9.2MD<[5W<L)_6)TS2&2L,UC^FJ0QFI/X<AKNXCB/VM*T1FO?VY8
M-$?+[')%E6=2.QWY:_+:NL[W<%L7G#%?:..7@Q"N%I>'/UX/N!71C$ <&1QT
MC+QK7-I886;QPV>X<5_2K?VD,?5?I]*A?T>OA[!L7PNP@$490K>.PH&8Q$(H
MI<U7GRN%^3.3N%:6L8WHW"';^>+2H/X*(J&SBE,U<_1574,=Y>D._[O:WYR/
M(\M=%L/G@N\"*V<AQ7&,BNA2BD N]I'-GE7$8Y-&.Z#A+),KNLO[:-\Z*,PJ
MG1RU!,3)605!BS]'5?MNEIH/%<<OE=I?9+RIJ*_M*YG@Z#6<^N%8(%+/Y&6)
M2TN7TV?!M<B1 :R7UZC'B)>DC:+]]<'WGNG?L@<%F@C6%V)!S.DT"QVG^X*T
M<8E" > Z/QKI11\H%@KK&'4Q7I&9>.H7ZOA-[HK&HIZ]F1K+(%;KV+4TB\!O
M"7:_/]%\TENT2_*GZ!J08-SN:T@,T+2K$D KT6J.UF:<CV49$6;+%V8]R%>%
M;_VQXO?]/Z2P G+@)#-@*!.C(W(%T DV/@+"T :!:]&+P-%=O:B=>#2B6<&=
M9 'YOS"IRVE*78G;5,"G;H1D+$@Z44+\<WK\7 \]S.?D/-?+\3P8.H(RS,S+
M0I\S_#'*D2CD .=;N8/M'<) <9-124DIOZJRLDH<UVSAY3GH.73FS="0EQ>+
MSXY1).X^G;##[W3ROFXG=9?C.V\4_%I\$J>:836'1,?Z)-LE0UH$:EFCL66R
ML0@9OK:3%$+%9K9P5QLC-HX:.*SCMU-F QEU+WNR9__S4G@Z%GG0?.KKJ!X4
MSG9?]7"#WY))CH"!/*)+D;W1NZ.5NSY6*GS.N>A2_"E-<=TSOT/FN\\\ONY:
MDG/>J>#BX2++'?J]5UH$DRV]I8_8/0\8$VYPU[_5YW[_=G1?_M Y_>603N?E
M>:8I^1BQH[590_S*YCJ?MHXX(ZP%Y-O0JI!#J^00.'\?(/#R:.RN+<2.DY55
ML:VKZ*2J:M#@/@F#URC*/X''\6W]G8&YU2'/C_X%'GBKP$:ON_/'"/\.ZQ3(
MR&"6;I)#*#X'& JY*2Y5C+IR1N^8T #B#D8S4K^F+?IZ#(W61'_\8%'C[.GI
M<)NP,W'KC\&A=P>.M*A@*X]1/V,'.DX!WQ\"*<<90%LL.U';>DAFV&8R'C,1
M59DC<(%KI<"1PLXH*Q=05* &1QF(7*_I(]G1?;$S6W=S2HP\M?_QPE145QP\
MF3V!?=HI&YV_Q!E9J6J_ /O3!_4KY';DSO@;_M&7T'SMKT^/ZRY_)#I+%!/7
MD,2%TU1VMB(4MA9 S&4M8F>LKGA^2OS%"HV<K[TBVV+?0*OE!&^#F >967J>
MG(6J8@A\9AIL\.CII0R8V$C\8K81(;-J@F FV]&TS:KK@?RC, >:JCN$=.PS
MI^[(LGA_*'+O1$SHB(9VEN>"%^>W&JHS)Y<S5Q9B]_%O@@ZC!;M7H@CM%B@I
M"E8>D^'00V]P;*X(3&EU'<RC)C5KC)).0MIYD"7_S^G#DV[CK&9ST#*Q<3^P
MQC+PP!M;7JI+.=O0:^X0_-LTXH^NV_E=H;M4KE-8WY@WJ*MZV!JD9#>UPU1R
MXW5:IBPE#\6I57CMX"-G(?4U/,XS^&^R2S9-9E&D,*V2F\%^PQ^_>7EZ$7WW
M[:+>/G(SP<R[_.@[LW6KH!T9-8T&O @#1^Q[&Y&Y0<RMZ&!':U?HX;C2$?[*
M_:JUKB\3XZ$(7R/P$P-7.!8H4>M6Q2C=OUL6Y.IYIC@LX(9"U9NIE8L[-B=%
M(D0VK+?VDF",1&&W%!9G_<N*/Q^$,=:N$"M;9*/ YX7UB'S6+I#04/<X#1:D
MY?LD'+#F>R-5JS!(HGVK5MX\_=9+O-:=.IX4MGW2,F+BX7S8R"GWZEA,^@50
M+CFSS'L$(_QHXN)%B90YH%)53HNO ?>F'M1WFTXL;E]9[4\BV8.+K2G$(QT2
M0W!GA$7TJXYBG8V3H[\<D**CHF-WE?$6LV"M3L<$SMFUPR7]EWR\'1:#^T7;
MP_E)<Y]H=^^N_>K+=WQ^?BDS/J2JN)CV!3-^<\7J>J^PTL/Q=D&7:4RVU['O
M%76U56DR.7+..$2_YDY@WA.MA5^14Y:"*( 37'1B+)DFZKHD/R5WE5C6Z=#;
M:"SPL?;FA)AG(2Y]-L\T]K>OK,F87W#IF:^:>6:N9,'E?DE,S$R<.:?/>#"Z
M7C_#P_5HW!UG;+H%&G"7P@;^!UUO \]4__^/K[I*"$7([;JBR&V*2%@W%Y*T
M4@BQRN4^+96LS,Y50FY7"E?$*@FY2^[*W;#A*K'<9V*V581Q)N:P[>QW?+[_
M[_?[^W^_G]_C88^'!V?OG?-^O9YWYYR==_U9?F:JG=9/ZGK@BO.<MFBOW3;<
M_5R%:G&*W?[.<FAW0UB>Y7WB=AO["S:V/X(GZ%F*=J4OXXT%23OWBN*_EV7"
MVK7@=3BE0R!"0*T/L1%0+Q)/AG("XY;E+][_>)VQ&5+:V77URM/P6[[X-M'!
MC  K3[=\[);C5D_E+<V>)SZ;^ESJT&CA_ECKN$6P6RS;53':'#SW\8W;[HMF
M;L$?194%\:56QQGI\Q_WA-_,2&4X9-U^=<NQ=6XS81TG-W-<0?YG[@%Q8Y.N
M:$,U'Q-_HTNJI6ZN^9R1S8Z="-^'E9J7*T 3'3<Q<C> ;9CX!E6.L?R@7 C+
M;=#(0N/ZLP;?'4WUQ\K=@>';HK<5B%-[*9+M[>78[A-<%-<O3,[.75DT+)P!
M+K)2]B=<+YQ2JNX2BUM'H!"++('@^QAG=NI0W]=NGE&O3?*Y;Q -EE43'B#:
M@>7W&ZYSR^_B:BWO$=786MK(Q-CMYCO4"]6(5RIZ;LC).M^9K=;R/M, R*?7
MOGU;DS+Q[G',]_9D^F;#U/BD7"5.Z&G:Q8;3('?+?;I;P5&%^.<=YXV]&F\/
M%*C?*.S)PUJD'Z\.Z7]Z\62.U<<(/?WV+=?23N:N0V_];B2_=[=A#5C=ZZ0[
M$M;WUNE@C<"K\<E*!^XWTA?2+E#O+C$4Q'LW\BUY:\;1B;G;M8U!4QI5F;@)
MNDW=K.$3XQKOS)>O'5=0"KY-B16=88]4%$I0K1;^'"T-E\::BH$)RJ'Z;/O&
M$?D\O&G,8804<L1_ESV[.\4:7^*U6%3W;Q[UQJ)G_/EM>8C:ZV:-$;X00G^D
M!OGL3*$FJ&%OET;_!X]4FP59F-[!U)0],S(MK3ZX)5JH1 RI5_%*SU:M[#=>
MWQ'[36BQ6+S/HOKK09/M ;MV;TX+7=!YL/)+<+JO*A-[?\SP(35(SJ_#=^<
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MX$UT^8Q:R>IM93?(<G"/[VY0]9[=_B!J92T=?[<.$039+R0DO6V"]X0B42T
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MTL_4'2]*4 I[(*F6 !W8::B=_Y5R!M+T6+3$=2IT4)9-,. )"4KH%-]L*O8
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M/6R MS_L>6OE/-R[@[;;YLQS" @CW*TU[F$&RX[[3SO[7_K^XUF[D+&$$Z3
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M$!].GE;,G?-;6:N^V&:5G>KI0A/G0;GTX^>]3J/$O?VK0-11E.JK@8*_J?V
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MS)3:^ZIZ\O$C?W)?8[9>K_U2V:_4CFQ[R'M8M[U_8-2Y;RH"*J%J- XS?IG
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M8F[1*6O;MBW.^O[)L9DS-B&..2DY;EG!'3FQJ9L\DBZ4->UGUSZ)SO$:H^N
M]4YL=3[AD^]KH.K;0Q%#X$0["16<X$="))%= UK;D40-=B"+G#\]%D:QS#6?
M%YV].U[EL_5A"71W@2:Z:6'DP+GCGVWCN>")SCX;BN&3$D$U!>:/J02J4O?)
M'EA7C&O :<(7^?YN:QU=I[ 0\W=(MV3,#C#87?0F\+J*L[Z@P[G.MG'CDC[\
M.J2!(3J,704=0%9\X:FC<@]+;96 I=63?9<%_I%-SR$BGRG<J%\N(\#.U=WV
MV&)(IZU!6GT[S+HK#S:$2.&"LT+\AA@9ON0I)'_\,8!WG'L(.Z+ "$M$6I(;
M\OMU*V&,_&&=W?@K,-G>3G1/P!4>U7J-34P_S8J% 6P3X6;=KC1>7-->T][1
MU_HX#AO GD?TR$5-B!E$"N._Z=VC*9J/K5#)4O/-VG&\'U@SK!-Q;%_3]J0G
MM=F&60=U+V\:-M?7W=4X,I.?N<7#)O18D7'@M@^>S-TO*4&W;QDYAW/>4!^>
MSY%:7>Q.9P_A;AK07"R<3Y;ZA39\^OM#UX61O#BF9FR)CGLAGU9B:G-ZA<=%
M8@"U%86],$ 9)=Z^%J*TC!),=/9ZSRE%2R6#T,"1SHG3T$+2\>I$3;)QP$XT
M/2?$B<@'UFV&]%.0D<QD]M!B P"I+=A_2X0BLC\:U*74S6!]4-W\Y)Y%_A:T
M(T_IZE["VG][=Y8SB5+;?:G4#.SO?8O6WY(=N_!IP#0MP HUCTK9X+@Y_6T(
MJBUF,<!(L=FHY5+P[SDQ%WG+YDBC(<,Z&BN3C0*]05\K*#-%ZW4<RTM78/!@
M,  _,,]!/MBB0JJ0:@!\L9R]"HS\48&6^9O%I?X%]ENOA6FX$_DF"LSE5AKU
M(V/:D8W*NP =$L*H2)?XB%D#ZLCO?2AB3#2B9]@EN1?0%E!)6EA]FBNQ_<"9
MPVX +-\"7V<7>X:>:6VPE(>PPY2-G[#OS2V15".J*#S?9U*\%)@*D(P6HH\5
MKQD\-H1=;% -6XJ=A(/B(,F*.A$SB6TQ/!6'UQ/55?+;]2<NC+6)9()L5A%D
MY S%"(B_D&V1H6G7'C']IKV!0%6]2><9K6# ]Q#XY'.(SK/4\^:SU^?I"\XH
M3ET 1TRX:"2$N*%M*-LE0=N)'UE-P"<C07M3>R*GFMD4NJN"$S>TJP^Q0M[A
M*BPG'<1^XU>N/>S FU-60JJ/H:W?1IM\'!E[0M+!6^P#A0.AW)74C6?3DU F
M:7 7333K3/L<N% ^T(:;Q\:X;>>YK<_R DZX6K3V9 :W9N<YVX]'K,G3G#I2
MY$BC..[(UE?;T=2F,NG'7_'AH@+S%VY@BY9E?AK]8_2MD/9X\B7K$0^_YTEI
M&%')[X5WJ<+=EX/<UH54YC(G3;RRSG9EN5Q(E.K/(\I&O+.<$W/RR@A6+!40
M:^97/AL?4H&B1+Y.4<JD>.X:_,96<?@Q:#N?]#-T8C.'[ICF*Z8G5#0S"&N&
MBFUW'VU*JQ;J>/O_(J7SO5IP*Y"/1(S]>G'YZ_9=HD6_';>V;EOG!O;JK8^9
M3D7?A7L_T I;5]YM7E;^." C2]>[REG/9SS5[HKL0=,AZGK*>GD,P'L<8+BX
MFO&7!<C]&9F.(EC9TOG)09*X3T*#4@09A[3X:<(MN49" _$2 4"OX,9Q56<)
MRT/J-E:5=L]RET)+!,1DRFFEY*_<L!/% >23JGL' Y[7V.(HU-<X#'"6T^_U
M&JA@O";2J!N[J%L@+2>H8!@;3_R9NF/L&B'&7ETI$=XNSF\!;U/QHDR&,MOJ
M*9?9R(&\&&MM"-K>8[V_/KM3\'WW$/WBD[K!ZX.^0,=]$]8S1P^7BT4>Y& 3
MQR,C!U0"LM6.\/_^.N*K&?#,0'-%K^1"JI*28Y7^FMB-W06P_^W[FCZ@ET>*
MT2Z3_/2[R1N]FMPS7PI_G!#-BB+R= (Z0S63FSJ;73)%YS/!#[Z\>?B>I1+X
MR8(S6S5>:\KN^_^]P6E7V[C8!!*MK<!S*-1X3. D,AX)?DA0XDSV0E$*3''V
M84TA8QG0"S&0E]^)TK65 48!_:) .0F501/9J+M^''KT"UI0TX?_ !L34'ON
M,KH (G\9P85&8^$([B=08D19"["GH,UQ< YWL57[*]2#%-4(#EUS$A)DD? F
M^1VJ*8(>?#E^,Q0NP%<+B(/$X9/P,L@KBA=ET*B3&O>(7"LT9RW+$_\\&B".
MBV7-LE07O#I,V*)O#P6UGN^\,1UO8X)FP/]Z".I%L)X$?ET >-PIF?-*G#10
M- =&_,^=JN 7_^6Z".@4X;7PGMJ%*U-JL%Q\'C"']XTS<%V@.=4D]!(0)VFR
M<Z%#5O*,<[-3B< J>QL><(N[FF43M7Z.DZ"#^]/>BA6LOZX;V4B.<XD^*!IB
M"@"-XZ%=^QY]OV:N8^YS2'B; ]9Q@G!_ZNO(:1Q>$2#:C[U-7&$?+JXY!J&#
M6KI>GE1G!V5(!L3,9H"FP*C7F4R@8&67:&W9G^,,9>62,UK#H;:F5RF50X_S
MH1ROY"C\V][.OE^[NAP[MIZS]@WSZ0QS&^T$#@-5K\Q@-G8R121M1Y9/\,'!
M*2=Q=2NHAO12%_'NV01#";^:<ES4WDJ,SU[_"E(1<9LXVC89N%50)"\MMH*^
MRH<,O/:8\/F"6H/DR]A5_=^U]$TR6M+ZKOW5V]EPU;I<MD+0WD]LQ)6B]LL3
M41Z4J2%O3,1[\>J4R^@!?J%<@L0"RUC$$&*(L8*4J63.V;8VN2=_FK+O58VX
M[_9<F]"S!3&L9M=I78OI+O]0/;2Q1V@=GG=VOBBWZ2=Y<P=Q]#V?,3 L.045
MR7:"]4^YY?.-A&1 S?ZJN)S/$ ;*]OK!KJ@V(*SNG\C> 9%PMSJ[&G2:P%41
M_GN9KT0._X.]-XUJ8EO71N.R042(B(#2Q:5(*V #TIHL145!0$!!08F*2!,Q
ML 0)&E(JG;01$5 $(@(BTD2E%9$(H5$1D4X$E'0JTDE%,!:D4KG%.GN?>\Y9
M[OOM[]YQ?]PQ[H^, 97*K#F?^;[/\[R5RIQ#I+F<G.ID'WY,-Y/JZ-\SAJC5
M]%5>-!P24X%$W$,IIM%Y<"N;")YKF\0)/0Y 92606&0C*6JPH#I+LF:>K>>/
MT&T,N=@8HHHI489#*2<F#!(NP6:EHS3-/OQ:$HG7(<.V:GW&]W(\PY#[.A>6
M<8M\CSC06'Q'9FXUVGM#=$)70G3AB*A!R( 5A[AMDS+"<R*''MK"^4?SK]A3
M5TGR_(B0OGD;?9#.-9^8WY8LX5WH:J6V!CUA6PMN8(0O<X7JPJ0&=E4^#5*9
M;DH6$%8/CKZ3+1L;/6<Z5Y-R)HBZ0X*:WL::W%5"*8;->E_#9Z'DIX3T,BJ<
M)QVYS%A6Y4@*; 2F'9*D-6C#)Z!&T(V'O<)HPO_6/\2-NXP>\P=;$_DX)<BM
M,:NZYF(D[\E,IR)U;U=IY<>(T!_";T7W!\=4U XO1*R!QC;<X\[GA"16):LI
MB"S:-;_J O335G+-YJ+,)8(_G4Z4)?@19"AB421T(N+/D]OFIA*ID47PJ2MB
M-DVK-F'?62,=(2[.-))X(*%[-%2B]8WR;@V^#.R'E<_Q.IO)0TS1/LGUAA60
M%9OO@0YC\*?(2HB=C.,2!AT<A1WO;OG)Q,R4B(>"=-FC(.I*GD>Y/,T\4E7E
M<+M$XM RK-4[(U>LTUUELEQ]W/(ML(V#9?DQ(7W<I-_\PX^-;$Z%^420@/6>
MPV,\)Z=P*AM2P:>B.\+.MLGU@B7/A"5L1%,8=\7&.7]?"(BS _<K4?&L)[5@
M87]\:=5A*NW=]<@'7QIG(AWL<YP*25\)JP%N.E#Q#.T\&Y%%7=BB/BBQ%+87
M%DV(028BNT,HUX@85[RE1O"9,77TUMLX64IGR_>Q.0^Z&6'!N"<Y?BU(3JK?
M%TZ(-V,N]??>T,-;V7AOU-;M]O['U^4>8B?OH9RZC:5&]9+DX9<!C4KS7P4-
MM/%D6G K*&Y<OR8.9.+<#+Q/=!$24NK)PE,4,H\U ?CZG8@\P36YFFL# <6$
M9H8LO+*W_O <+5,H6Z]PAOG#497X+M3(:MC1N>6ZYUBN)I.ZO!_P,QFP0Y:E
M\HBQQ*H:>&5%,V$1-4(L[X\8"OTF<M"AM:.U&XD\Z--X'F\&=DYN!E7M0"FF
M58I9043>FA-7578NI52K.YX6-UDEUS/40CO(;MUF#MB)S@7> >_,Z\JS%B!W
M*CV$.+!&=!JL@94$R#+4R2XZ*G2>>,FDGNREK:,-<QZQ)DW*:>\\1YH[DX"5
M--UQ7"4]!586FPY1[<#,J_BU1?%4!Z-DI$0UR>3,YYJ>F79'0_8[/_NND>[*
M8^9N54%[R"VR5>3WXRT :,]1HG&\#22%<&0QT-CR)ZW7]0A$\Y=B_(&K*L0J
M\SADG?FDC!_O*0Y#\>%NJ$ELY<0*J>MS$5+0GDX>ZG%#)P.1\<9M6K]777F#
M7=:\ $E])\54]4],AXL] G&/%K.:<5M%>=V(G*W8ECC_V'^T<YOL)ZI6K="1
M=25/", Z=%XA%&&,)N.Q'?> X[;\ES8'GB+O!]>-COTDS20#"KG&DFN$X\GK
M$85 T"E/[ <1GZ."$^:<0'RDV\@99+'=8#NH4T"(S7).)G#O5L 7P>'4>V.Y
M"KTX_IZ80BBQ)3-3"]=G6J;.4XB_>)^B>J2N^YO1!(P%+I03OV 'OPGX-1,E
MPD01RM]1-$1]M$Z45@@T.K."6)=PJ@3?8[1W7I,[^]D<S/P";RO8@-AI:(>A
MW9\96IJ@>S$(4C:75LE]-2ZO?$$]\<#LV0?7]LA-,G/*+L3G##0 <(CL.5U8
MA80L6RC>/+^_%6TSLQ$8R&\D/%2=>$H"+_+>,(5#+<!"O#JEI(6Q%*](\=@)
M>A>>G[^WO+T0W@&E@C7L?@]5W#(;Q;*/X[JN]?TVNT(YBRC5SE5> U03H;J
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M\8#6A,+HP@UK7+-G/V\;LZAM)=P"?M69?$2K7;P)>'M9' 3PG[&"&$B(V5S
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M1OJ95O>[.BQ/B1NZ?P?+L D7:R.O@%4-:A1K+JN9,Y IHD*)8#COX[VT(I@
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MDJ6UX>9+R7Y-^SH6]2IJ:(SXM6@F?2#;*=$%N.TY7OT]*R:T5-)..4%I,@Z
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MZ5/RA5\GHAJEN41%L-\;<@$H02 ^AQ&%2 YK'EIKCTH9)/6[[FBX^7Y /K%
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MZ8YD@_3)59(K84GTSX SDO][)%$-L!"<06YQ=A)&5^H5DC."K8:<D=CGA/&
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M]M226'TIX_-EP=X0T2[6I6TDP/Y^%&8'(4RV&:'=T;^)N(G&0R[N%W)3Y7%
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M#/_9\C2GNJ(RZ8Y/M?SP_?@U=VOII'A?BVW/A%'A&S\WTP^O:=]I\BF8[,%
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M7U'+!I#PN/>%7_*8-O4X8\NU;<_^WSD6_?_)L__+L?_;+PKDP*X=O.3M$H'
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M44IB8FO-.H?,\Q-)D3[!K .N)XS$+!S>^EL'- 4/L"M:9*,0_?WCV5Q^(T"
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MO)$^7'2>&LJY.##1%QW@2ON\%N5L,G2#K+'*T>^]4M< C"36(Z5F&QHF,K"
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M[J]MB=F0/P%_"I2\&PP;&62$TR!I^<.AK)$#H#9[I7_J882BK[UD8ZDO&WX
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M"'M<+"Q4;0Z 6>P3[6P$@\_.9JJ(='S0TU[ ^_*RK]@C!%J@%==X!JTQ>P[
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M!:KY!G25[U/0F82!F_Z^QKGN_N=(TD%OTUXO(3OR?WF'P>Z.XOIL&L6TJJ@
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M"W*0QX1KV3]!3>Z1P3?577,LU?.ARGXK:,;#F@RB8_8AX&.6/SS3!VN-"UI
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MT<TDO>]#[F/Q^DY^0LMOC&]SQ]T66G)AK&\0(O6_6P'I=.Y>50B!T]JSKGE
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M=6^Y=NWF>QFJ^3COA;+_+NZ2NV<F]<J3=Y+(*VL1#<'Z9_7]"E4+G*"9/W$
M O&Q3B1CS8WED-:BQ7 _(VRQL<"^)4!-D!F^S!0;XY5M"7F3$2T0[EC OD\)
MF][L#?$"$]D(T .GL/&2H+"<H(BHGULBZXQCC!M6IC3><;^.-,RLQ'[:9#9-
MKQGQ[V"'X8#K'MQ\ :&C<P F(YI@A&=C%9:A2F153/!8W$#6 %:[?=Q$&.G9
MVL1-VCAM&<I\4.L-AM#^6?8,/(FG:7QNK!6I=XWU^,64+S^8]1=&<9FB/:T
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MU,0W^($;)K'^U/2F_W(CGP3_,&"GAA8LC _-[?71)Q6.O3/Z\:[99J[!  .
M\4BI%.*]+ZE'*R^P:]_>JZH>PACN/8(V..KA)7NO_T/_7WHL(^^N8(_X)XD&
M2DU=5^>_\LT1LAKM 9:;Q/2VFG-[LP]?'BJ%&XC#CI)_JX,".$3/1"2B78_'
M:Q)R.PO>/_OVHAO!,&9/E3YR>'AS)30$=7W/J^]K'+771P3B!-KU:<) ))X@
M%'R^@2)-/L0TQ=.BLRRG[Y./"8RS?')63V#.S\M&(6B!.J7R.T?^S')+<_Z
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M%&F?QQ_T%"8.\4?]#=_G\1C6TZ>T#83$RU\!4!3\8?6KQ*B[NO:8J6(21PS
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MP'S I+%VHC'F<EB@5AG&.ZCX5P.YF?&&G%TZ,Y&%*8;4A:R'T088X@#(BR9
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M)H/.:O@WM76CPQ9'"0Z(ZT#,_#Y/$N=O.HH(>:HKCDEL%UD8$EJ=%:,[Q")
MZ^0R-'[*TK/<I:&'/A1RYMHEK8Z9JMI99S<UQX=A71%';;#==Q2R;E'!@=(3
M88@,G6SI'9]RZ$&8U)/L@(@Z.R^3" 5=<5DY%Y'@FIYLX[-YS6-=7JO>(G&X
ML?=+8#[=6\F5LI9J!J=L"W4O19PYTE<EEJ726-P0ZM^X"<@QM1"_NP6D(^=
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M0[49I;\V?,$5JC_)K'V>MCG;GPD6T^"X.5JH1@D.8?PNV7QLG\<//*72_P\
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MOH/J,M\&2\"]7"<A\]4@<3WCU]]G3X]$N,.(N]*.:3F"D19C.ZJ!'48FA:7
M2ST+(:S_49*-YC/+$V9?VFW.G7O .6091%O@"/&RZS4QLFZ*F K$?7;![X:=
MYSHG[#?*Z":8$B!R_IM+SO/B2^5I-.?T0_#7Q^LN!:/?MSX67");'M_GN=9$
MF]QXSLWG'("7>:^+HLH=#*,^#R$@F?:##C:01W@!ME0Q&KIGG^=P_2RQ7+\L
M%S^$7=V+Z8V;?&9Z7WU'__2>I>[\0'2QF[]TUBA,9@!8>I2@=)X8JEF[?5ZG
MVBCMO]*4#S]OUO Z\M"=J@ARIE)Z&NY&8*?5<+JSC[PXSJJF<:_)?+9KZV>W
M;1+EG:>_9\"B2*6MR)-/M*DL/Z\M66_XG9A462OITB.D7KM>/4VLJ:2#W?*)
M*]%^8\MNS8%E[!I"$#AVGZ<.&H<0I@XE2\QJD#!42(^<*J4YMEV5ML]S<U1K
M\\2:"Z?2-P;>+)&G6%D#1PV-JDD,JL98[0G@7$B[=B-5K$2E\=^&.-^IA1PA
MO(W<".7"B"- "?,OSD>8E)X^4P4N.F_Z;V.-.,(.: N;_PSN!QUK-PK#?8'K
M_EP:(^IJO&509:+5C?JE+V<&Y%GNHIUS+4@1E1BISX$XORBYR7'(WZCY3!2?
M@2P"1JOIKTF!R/SN9TO>HF*(+=\PE(0&I@7"HHW^XR7MA^?]78FH='3XRXWG
M<\X-SS.6!/"VM\8UIRUM9H?<1L-CP,[UC9VQD8S?TD/N""5V<:>V_USC9"Q'
MF>7'SH/XN5IJ3!M/&)Q#'*;;R9\8;W?$.DV98OU7J,G^5<'2>]0QJ[?UHV??
M-;2/I6%?34W[M8X&.#A$/?BRD4$%1!7[^O)J](CB[.<OQA)0+[X-R&1[-E0
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MO$%+L#V-4><IA"U;)4T*XDXR%2;BZ&XE_XGD:+.I):KGF*:,*/83 S&6 +L
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ME\"\,7J;UM2<J+[3AT*3S^<L;?4V,XXVN[RPO'"4E'IW:,J5<0F ,4$U?2&
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MN+!/H9,, F.8(+)YFA497)<W,&*>S'-=O=73,#OQ\(TKO72=X.R]*C@8>5O
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MT+OA5?/C/U,E:O _;O,%4(]V(X:-[A&F65UB2-9R],WT",*8[@/FC XCQVU
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MRRMDPN*S= J3#];H)L*@P&"QX;S]UTJD"4B3NQ<M+SUNS@.7K<\, ?=ZX]A
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M7:&1C=%7/4*[E/YEU>&O:U_0[0V16\(E1$W[&<:D)J=9*M?G$K/ZHJWCYU4
M:R!ULL[\"W5V]N744DQ[1!&=JNYEV6S:-A^Q/-$_6"XF9*&_#LGX9AK250@A
M2D69)"-V?.3^">0-6-L:I62G\&_IF63A^FRQ*L(3!Q)J'4&I]6_%S0AU2(MO
MIU]F5F!-@9G"7A5T;.AU+9"62U?7K"C7$;63]*<R;S>^?Z\_/.[Q%?;G#X9"
M&':*#(1Q#],8BFF,_%K5*7,Q9 %L9*$RSINB'/UX>B<F<=%:=ZREND=C*1M!
MP(?:!VR8ZM+W#_&::3WTGD?IS\3?-8J)<=]-EP0XYZNSQ5;-^9N3RTQNB'II
MQ*7Z24)^C0:E6='P 6VB?[S(P:?&<++>)2C(FQAPL([KU*I]@K#-+>P0&ELC
MXWQ<Z5JJE=SLK$NJG@W+3[^^E)[YR>CY"-T*0?#U3B!:/$N]7>D@-G)4XDE)
M";_%T8,)W2HM0$9DYGUD%YP&R^?7&H'IK$?2L0G!3I#_P.X5>I90Y[5[#XRW
MKZEA[%[QD 7"/:R2;<*M (E:]*=XR5H42!7OZ;YWJF4\9H%3'Q[Q])\?#*$*
MM,_I3U!/BI/&X!CO%;_[=S<VY@-8*W'UE^ H1@\TQ>_ PK%TL14O,$L(630#
M4^J6:S5Y< JT8 ,&%6L)G7DZ],ZN/RU4T7]^^'$S:4<P(\\\^L4!ALLA"63E
MS_Q-(_3=4S$JO++OP4N(H=:YR['Y]26#X>G%Q$+:)_"_4S&3=E$*V64M0=6=
MU4"'E2/1MO\ENC!:V]-"2:XL #88NL=O^1EUR/+1>TOT^0#%PHO/&:O#AUI^
MM/KOZZT+M&L^8^JL'<H)US"]_&>.M;&JX3N"W60:3DUZ$B6U?X!*"B2N'F^
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MN[NLUA?92:9]D2T:O7HL.?_8X"*-)JL*@\PE>KFC1QR+:!IF&'.IT,:GE@.
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M$=^,/WID[M?W0S3#JCUG<G);S,UBOY(_;KX,(5]5U9=+655[D <_XHF]:8(
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M>_$6RE4H0<@<#!?])LVC:E'?>:V#5 4A9E:MX]:-HW3&!MA(<EZ^VSTR\0\
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MEUZ[UJ?#ZM9^H9]3S<Q?'\G9&=)T/FIS-> V*Y>5"FLAAOB$Y#I)^==R%MX
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MD:6E.IQ-%YB+MFRJ%4\]Y;CT%-_2X5XY_D-3.V+?4NQVAJV'%:=7(]/KI&4
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M!L!,F*'#O3E(_#=MG F@<2-QMOC+9W0M5A+7*M:1E4OP<;3Q2, ,2]D_P1O
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M^_P8[.>KK$_0']@E%G_JFN2./SQK[^Z??.?<6V?M08@V4JAQ@@=^!2V2:H)
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M/55-R'L@I7H- Q4%37BIZ5[M/7(H/H&/=Z1EG+.DI8G,D -00<8XN3<;-=/
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MB5;NQ&.X'H0L).3WX%Y7%RBDKHWSQJ_:LPZ8I\,QA=VWV.%R'<Z:'=,]E[?
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MK?@W^)D_+, &Q97M<Y<U\F:RE,\]1)OKZJ&82.WO/@+MSOGJ;R>Z=^^B:]Q
M( SS31RU#JV*@OIYJ'$?:S[#L[Y_:Q4L4[E04BQ;&R>N?:#"9!KL9S'R(T;!
M,V3-]\\:_ SS"M@A4&CR[]>L6!V*H/H/+^T+3(\K^7U&E+F(HZB3,QMMV2(V
M%M*L#/"7W2R>:(O<ULA@IUJQ$5#^]2AS$=L1^J##E29E%R-^T..V:V\1UJPF
MHA%G09CWP];(^_P4.CW<7!@S7FPV0U[I]I.VH.<0_-*P )MI%\N^7""D+=7A
MRC[G1FH\D5^$72(;./F]U\IJ6K.W.:DW\%NK?&]JUM]);[?'U#E/CEK$VB=<
M&_)6/#VUW'O=&?Q"3L<HN>YX%4P&S6T9Y[HQ, B[_;LV%UU^F )63-@7Y33+
MY,(:_A-A.4 8/<5<V?G[LQJHI6?DH_T-8?&-#UN<OLE:C^=KNC!QB6I-)=,_
M@3U-SPHIE\1E9]'U;34^U@6UZ?,'U(4P'\//%(*!<WN=@QAB-IWF-%=F%=21
MS6RX7D-78?<ZT0)8A[O_NGC=%T,5ZZ0_?-5%/TK,&X5FU4XQ) VD^%*V;:>K
M"0E=";\B9G <^4J]!'3%>8LBMJT<2.)I7*F8+EC$>;RYP%XAF9ILXB<Y#\8-
MJ>7(9A/_'?0'&DS]OBE9E>HN\H+/7<>T?!WN>"/\0N1J>98PB](W2]G(7_ /
M'/+/KY*F[^Q YOLS9+,Z5=V9$PGL;92X2@)QO>>B.CC_R1[UXPN+^BLAK=MR
MEMB[%#X.GE,I/#(O?NYDSU%YB;%^/8$3E;245Q7\4)";ABYNT+C28&8=8=:-
M'-@;LMH)5T%ZC<;VPER;^M?Q,1O?QTRK\HWI9Y;1,T%!?<QK61RQ+%V</L$S
M-R!G< A"[4/1ZH^PGZ+GDKC"YB*<IB!?/J[-&!$"Z00[M)8:M(=%:B;,@>?E
MWCD:/DZ&*1XWRCG+J\7D:07PJ('?WA3KN>%:"KX<VM+.:;7P1=OY"^T%;FN&
MO.=T!$G9H:4\M4]UO-SQLL7:$,.*N_)83S7O:76<<D@9M/&MUU8&\_E4*@Z\
MY8HIU)9<\*BM( &8>:0]ZN/JSTPI08V7VBKGO,T%GP4%;>FF>KO(FV_;C%31
M&=# ;KY?S+#5';K$4CRB.$_/[Y,.E88Y9?I=#U-OM2"LU3[&",U,P'##$F,3
M:W(7=": ;09^E(P>@79B1XQ=YT8E+[O>R#>K81!'CD07(43HS!?#R(<%<6P;
M##I4&9>G&O>%,:"9+K8IKNZ,Z<3X9^$PC8AO9!J$7T,<X9_Y^E^1!=7<]!HF
ML5F'6_(:LFK0X4QX?4ZP5[W,@*IF<QO<UH,;1SK4B'N7:#UL16,*@T,5<;%)
M^%&B:WR3N"*7O;FTZQ00JL/UGB-=WL]2;W?9#ZXD8GS<E,9+NLE?L,"H@U4O
MP6;.XXG*U"@\07)F12J9:T&<,]Z*]YJUO8%](.E7:KC;M+)$?#^LO>LKX6SO
M&'&S0)94P<<+6.;>[@INFL#-!>Z72#CKX5OVQ032/-:DHI-<=O/N-!JA<V(D
MXCA*<@X!SH-\::E2:?LHQZ+%?J0[$'!B*)G2-H0,QGW^+N>/C.JE"@4F5C1>
MM6/EJ >T;@P[6T/7Y=JB=R558'QC._K"/) GP9M8ZSO<8]NJ*//0U@M'AYK*
M?52KRWP$Y+;-^_1:.^#KZH=^<+N]: ':^B0_H8*K/H=9@G!><O<8M/M#O_8Y
M9_-]X$G0.UB_HG[[5JG3I?O:^]Z#U<]-5^?8+6/\IA6)-;]55()G#,0)LEF_
M@Y\K%3]*@##K0S)U$C3170F^;O+*E6P7I8.1#=_0-UMN$JU=R0ZBXQVK(:=T
MMI?&)6)]V"#A:8YIU?.K-=LMJGQ^)FZB* 5]J]AXR!+MD3N-O'9JO+.IV2L$
MO%X?B7:+S49K\"J *_$I3ZFA0%9*,Z#T8/=SL++9?7?,<!=HD\19POZ]S<JG
MLKR]M?%@14VVW^.QN4)H #4_Q,LC)LGTN76#B+XCWICUA<V KL(W\MG>WT_%
MLSP]I_>[%B"NI!+8^)>;^_')E>(EB(MR[DWED"DHW-^^=BQVV@YP^C OGX8X
MO7/T:KU(?H(0+4K8,49WE/Q9?=-.Y2M&7+(%EB[QIU6&LY3WQ:6&F2F(E^I]
M'O4 5]&<"T;6<P@YVTI6 JDW1QE+_6+OO'VN\2Q(=[-YWXNLA5>0&UILZHIC
MP9 F)W(Y/F/4-5PUEKSBM[+;KAL@<JT/Y\UD-;&>/+?BZ5327_TN8$$CD%XM
M'3Q4<>$%?'8RL^.+<W3%_T]5_T6J:ON9L'.J57()VFB]CIRDP^G+Y'VL!4.;
M8 C=PGI%3KF*[/W^R4>ASS$1U,YSM2=?;'F<% (M01VI\$7*R@J5(L1S?A!E
MH#O'3EO&5XPE.-J.703*#,5-,3*">P%KLNX<7]C:1)5Q19;PT99H-<\"=E>>
ME96NFKZ"3?7BAMT>LE$4/P' UY!=#G\L1'PKS?=APM.!!8X;1-?ARN^Q"I5-
M=S+KF9<J"?IMR&JFVUQ6TC"69Z,%J:*?X $-89Z$R[%C.9-Z4R=WP20%>51=
MW8%/=R6J!+P+M6V*^,,Z7()^_X>7BN'#L.MNS0$AOXY;#6_2D-T?T"M[-J#O
MU(\Y'<2%)2=1B_#"[8^D0<ABT76UEY"O:AE7M\8ZON6KTEW4?U0*<_J[^^WW
M?G-Y65+$N73OHMLY?J-,> _CLB6?A+"-QL6[,"Q06$XN:_H3@SB+QD(&69F1
M(+W1Z7>!UQR[E]P[<VA OJ5X[I6;3MW3[U+@2=W>#N]_6MV>UU,T>E+13:HV
MB(U6IS(MV/9/GL$!X"'BC AT88PLG;.R$OZARA98L,F0O&T@AVR(V(-[^&6,
M_'0HOMY>4%QQ"]T"A3;B+TE?A7UK+2$U_" Q5.!$Z_1B ^FELK5O%WL;M+?
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M*JX33& SI<BQZK5JRHQ<XMPAGIPV"9OW:PN^3!HU3^4?A*7<BLPN4 8EYW>
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MO!C=N?1B:IOQP*>+^"(_]P[IP,>S-[)[7&5WY1Z1S;%'[T#-L\NA\YI]GMW
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M1VZ[KE_QT<O5(Q&;\L[QAPH:^=@B3;9)M6I%:9 !+$6AGS1Z?2HBY6>0"V'
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MU#T=-LX9P]9!<E41@:8)C(Q:W^7HPEJ-[M8RK=I1N_X0-:E^;";VG1"MS\4
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M-4<']YP9R'2RJ]MURP*(V)MPIJ-H .HV=^GD."I7<U]DF2*&*0\^FGW["@B
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M:(YRS%BYD-,""E%,I9"7R!Q)F\6IEAA:%J 1KZ]EXA[(RI-R^GB,!THR+[
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M_/QS!W-0LT#/ Q+65O),=0K^<!7Z'>#$DUELUI\&SE^H27\:.4?@_\8!%"X
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MT6:B_!/VM[83#>CB1S&WNTR/WWL;,I@:L*;@H>FN,^<<MQHI?CG,N42 Z$8
ME3LLN5=9X1<@G8N-4'H3;_CZ)12V>:J"B_7=Y%11= 98%F).-0"L&45&V>V"
M)%-! AX@?>O@[OYL0X=G?NZ#QX_</2S>=*99PLB7% 6/EMFHV<L4V4)M84F#
MRJ@M!G+68>=%:*9"@!KW= 2R[G">T\=HYAG58WER-:F\6B^3:\<SPI)%-5&^
MHLBVR3336IQ\M>OQIJ:4TZ)"Q[UYLN>]-PK@VO8P:_\82]2XG=MC@S@HQ@&K
ME  O'HSH:S4N%SN4O3)6Y*D Q0U2D\PX+X<SDZ_Q7V#95_&%JC2FS"J%H.#T
MM,[Z[D/5R06\A$_[ H.D'K2!3M-NL=^KX2U;70)B]FW_3.V&YU/N:0&J*&WB
M ZW_P.\X?0RA\XE^WZOG C*X%>.C%E/V,\?A4[$CZ&EAFPW:(6Q [^9FM213
M1X9R'!'H^/XK,RILUK:[O_F0_P2='QEM5ST!2Q ?UKRW>@_J:4+<"6TSQ(C,
M@T:UH_')VS,QH4A-FD#,P)=@9Z]:Q='FL<TQ@30KS* <B%+""O-QZEE+)6-5
MRY,WU$7H7!H788W-K/MR939AEGKBRR9H$?SW4_Z:#D.E6G94,W:PYG51::YD
M"C$"^] ETSNB#(9*/>@L.$&26]DSGGYXH-K8)_@BY?@&B5!"IBW]".L6;5 X
M4H\/L,9BS_T_.5O*I^S)OP)M1N(%LK M.3FG>MZH;H%+)L+(9DJKJY1Q MK%
M$S,)G7;06&MIJDB K81D]H@7[EBM"$,B%4WX]+8%R"!/4_,,*8=IUE%>Y8\C
M%9');.NKG1)T;M,=6HN"?(^IRE[SN/C^0Q+!WRUX2L$BN;@QDS@W3TUZO9*H
MY..M7D\I^70 ^-+':M((^MYJS,JKVQ/4@18UZ9B ,.LC3#L(6R;N1%8XU\ R
M\!NA-6Y>2P/4]-DE14H 80!C0"<\H-^COPM%6+@E91?1H"8E<5\3KQ)&#:LT
M4R=E;13$#QKV!MQJJ9G2 NH/<\6=A(0.D#GNAE"')110383=&C4XG$3\"&]C
M HY5&@$X#QT+8V!MU3AH*Q:@)K6J28H3JGCZ>Q,HMR,%DNV A* VEYFI2<:N
M!,UYEIHT+A6?!2/G0,M. YLX*,@*"$\1:X9;:D$\@XH7!6DN_&F' '_'Z@8T
MXU7!UUXFYDOCG@#EPJ^_# 2J+D!Q3I4!ZM8T*K:6+KOR-?"/\\WI,FUPC8V<
MRC3-!!DA86@E%.B#ND#HLS!0X KQY: ):A(^DX( AK03U$\U:5L7U,(,54**
ME1D**/<EY[DDSPHX0'%5=8Z^BP_\.V,DN!:%,+540)@#6D],%& 1KMT'Y2S-
M:V2R,-P1Z0 7DQE]W7L:TO1^__;M-5$M!4,A4>@EJK(5C$)PNV!XMW+J-$I]
MS]=.-CT$)'$7*./ES*%GDN9^H+U"L%$*+@*#NTNM>H!W1W>JDB"9DHX /!3&
M@&/KMPWEN-N)RHO&^#P("X1B'UN5\X<,.+5WH#)06,=+%)4*+3R% ZCPL8!N
MB1A&UPU)6G))$#/?2TK^"Z?^ Z,_,^[6D4&8+=Q3J2;I IEM!AH5QP0I"RDA
MHA: )YX.@@X5X/,9FG$G; 4D_Z@F558>@[\N4E!(3)(,38+D-XE2S0(I)Y_X
M*)G##A)@H3XRN*IJ_B8UZ7**BD<?>G"5+.FT'@*6/IJ.,;\V<723ZABQE!!+
M$!7_;QOJ;8'*\[\]/E\/DH%XBDM&DV6#9:RAJ26U[7 WU UI0AT8^]W&!BB?
M?A^^#]=PWJHR@@"[^$Y :WI&_L(";/#Q.(TK" N (WH UKG=X//#D!"PC;+.
M/UHQL(^)7(5E7E#90Z6KZA4?N025@=/74;&?H0^+?J0T?=_7]+_/.4V'C!<*
M2M[HC=@%4 *;-'O[$%46-$VLRQ04Y#4P72Q18S$/,];,*,:=HA7.6*$*>&9<
MM5 0YP^B[E@F,8E^C[U0:=P*:38@!$&^ ]KV5G5):="C)HD'*6)FP#T5YQ]Z
M'3>DE($[^4'8;+C;"JU6-'Y[^C+@W#BJFJ1=1=AD?L4;#!AC/!6?SSS.))<8
M0,_>*WCF:E+ U[]ED9I]OV?<S%9=4YU5G25B%7T]UG3PT7<>_*^B,UM*QER^
M(1\R(,$.\'!Z$+%G%&'&UVQXKFD!((E)H%5C0*N>$(:58GKO'F"$5L*@>O@(
M5 :HYX*+) +^:V!=_]>>(:F(Z_!O5&Q6Y1^@BVS@-3.D03TYWT!78P*==,*(
MA?LRL .4[H.H&:$OP+R8)B73\-D@SJMZ+$83S40S:(@!2!07#VLE7>FEM%8Y
M==/%7GP(9'(177/A@5POXE<'S4-\$&OVZQ"\TU$,?P4 Q50U*=Y:34K1F+T&
M_/Q48\P@2G, L9ZKM(BR)@PEN)T6/IN)[H?:V\N_@FK9-X1-I*-K-.O)[X:>
MO;VN.JVRZ@.I^7</OTZK[\MW@Q,_ J!N$7 &RB)T9BF] =[/_!:" .J$5**:
MF(I] I@ DD2O3<6S9VI@>%H-O.M*J 9K-]&WU4.R*4HKW,ZU!7X SMR)Q?90
M$"Z HHF@G<O?[SY,:7W_+^?&9^#FT0^_&HC07J\<CT]0%< :@-3DQWZH#'"
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MQ\+]*!B&I.(SF%_+,<" &0Q\HZ29#EC#9X=0)G#=2I+J.+#Y:^BY((I,5$D
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M5O*PP"8D]XR,G-W^"Y85OM*B_T.*L2&K8&9;*HW[WZ<5O*SL1A%W0L<&[5.
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M]>GM+C%%@D1+]H=YE<,FN)8 ,ZAXS$V,ST+IF]]\6?R$*Q)7%(]:GN7]W*C
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M,AEE'=6D>8O.43$$L_?C@M7 U'W.<-1\.'-F^A?(R<-?[0>NU>\1/BM(P1H
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MJZC1KW4)L6;:A6P;T@/KT="4))VAG I66\J*@H-J2SVN=54NEFD-]WYO"*7
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M%Q=[&W-R<OAS!75U>1)R9'@DV=0W.C8V>O>F/1H-4-*&_5+O97:HZ]";K$.
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M/;T]<%Z;C#SSK&_%;/'-?\W;+ [7/=K_J/7<_.Y]J&@0J=9O9J5FWO,!":J
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M54H;=LZ*LLS!(TF(9Y!G,.F9HS"P'%Q"!*2$U('ZDG9[Q47F H%:H(S/Q#G
MIPK$N.T JXDX@&X)1*?!R7@QQ7201JD"\FM IJ3X^S3WC$L\><9.J&KX$.RM
MP&34QIF(G-(4 [$$Y*CL8&;$LOD%ZYOMUG](?O8Q>USEM?T2U_IF??IAVUB[
M8)M#86%V9P[]].?^"I8QE"<:1G;$,LR@ZN!.>*>2C1R=<ZMM4*'71ODG[F$^
M&(T[X=Q?F%O^=&QWT+M1S9YG)3Y7XN.QQSVM"F[V[G=I@O6S7^V UT"[D<WE
M@T,^RACB*IR-!)"?Z+G +SHN!%;3UW9V-_77?8W:N?^Q3U*L4EE&B+6;V3&,
M_7*H_X3WWACKN4EGVC;A<OB/X9TID@*W0,D]&]S@*W))64XE]G>LWWTVLX/J
M!1]>0I@U4_.)J"5$LRLJ8WB;#AV?B-U<B],!^<R5/1'+5<@!IH+11$AE 'Y(
M:"NF-<=44P[%@OHJ]F1[^()ME%7!A+Q,<B]2X +M#E]P@$U[M%:\.==GT%Q0
M+WQ)L.<Y:%>6;8]4</7PJ8Y&C7^-<ST3+)X*G_9"TPMNR57([.$UW=I-(PR>
M-D_Y*[0 !@4"/\ ' >2$6LE>'KF$X'W.PKJ"&\1RTTNQ-C[*]$85/K/^7GUV
M"%22=!]ZH*S0FI!DBT.++&9LLJ<7&AGS G]^R_(/E,$D$<-(NU/;QN9]GI"H
M63>T1A#&50<J!TB:JQ#CRG>F&!PQYT>U;](Z0XPG\%X0+=E*<WQ"935_(17;
M .:M.;SRR6#BV8Z9T<N7G2<WCQ.[-O>2*T_)GX6G:6UTZ.Z&\"(RA6$HV 'Y
MJ>6I@F6P/G08T).K6E/01WTWM!0P]' HB*+\^*G>N=U!C-I6"TQ^*M]\U<6=
M:X3/J"G*,> &$(K\A#NR7\/9FK?/H.575,E64MTE\LXN(9;1-U*S1?1UQ<WF
MG7P/%17K\Y#F!!4\HAT&CM4/VX#V:;,C3A0!BN;]O+8O9H!\F3/S\F%/>#<M
MO(1:=+"Q^AGS/3XL$[<A*E"?A3VA(&2[$C>X2"VI,H]PE;?8L!'CW4$\"8:5
MI?)W*@?=#SECUD#Q(JO-!>%E5+\#P&QIQ1Y9LN1#9\OE&G+0;SWAQ:-7<0^Y
M[=/9.@*+3V.0,(/$[_KT!*J[^E%&H>N$0?)"6"2SR4H_?1(;%@H&G5Q\2#>/
M)*Z(#<81; :HTJ/9KRSEJVN02,(3H@R?QC]WI7((6V@-0E$^<3V;%C=RVSPP
M+?)G=>D3MAUD?$2W4IA!-^S![E<FQ[<*C>#]*NZ/U'SU;\_Z9L]%/Z!V$SH4
M?* _^R/0*/GXMBBLE#IW!/2MS=R.L4LKO?%E#\(C2+LJ_OM09U"H'>5J.=.(
M$]]GG2XA\JRAC4N(6(<EA/\<:]Q5N\K+I;%UP@"\J.K2DOW[DEV5V#Y9:6O^
M91>'!/HVFCN5\GGG?I+EW80-CF)!< T_Z0/YSP,O<F*$__?1TBY+B+>_+R&&
M=60'.([#:"_;+PXP%M[_]\"-XPO[_A_-")4;M(8-H+MZ.E6HT/$>I'8#; AZ
M3]H\U(7BA\5B[0^1.!VQGBC'7R4+=D+]QX#KVG>"S5UDFKN]N.$,;)MC,N5P
MU^^XU<,_#SI?>>J,"U/4#"R^[_]"T15,J\4; CUM/QLXQ<A9K@Y(IQ$K"$"=
MQG<Q9U:^;&S84)?H<K76XVYZ)2KB!NU (JX&:]5_M89C>/)VK*&A"R_B4SWU
MMNW=$]YW=N#?RH]HMRGIJP!]L=,F]?:7%__RN-;TT7GGZ;T77CC]S.K?K7/6
M;6]VG3W[Y6SKKM? R]1=[[^B\S_YE6[O7A9HW.SV[JCO]K!M)KAIT5GACO87
M;5O;JO@'FM7@SM;M'@GGGRK^?<I::)XAWJ]ZW,4]R:QM[N1Z%CM'/1K[XYA)
MV=82%2L+7Q<@P;]340;8"N\L[7IJG2H@EQ$A3].:=-&702GJ C'24%>:=(:7
MV9\"^]-H[BI*NIPGA7\N/ \1FC1:RR[LE=!RJ5J^HK+\X1CFWA@*Q>.]Z WC
MO7SY!$S2\*%1L%]1-@ECEP,Z(*5#1*DA*Q8YVA_'V"A+U7@DWO0^U AD*^,:
M%X65(_C5RD[;%W4 $;:[B$>.N(ZJBA@6MBYU&<-O''XM7(<3]^$51<*JUDP:
M/DDI-*?M!2G9'">M.=5'(:DL4PDSA"98+Q4+244VH793,HI1=0 [VX6X]BS$
M;-;^Q&S]85!<-^S4.;N!:#)6F'ZW-,?3K[C?M[HN358&FT9KCG\_0V.K"I,W
M2]=ZJZ39Q=8@DXG[>0];K4O8;N%,OJZRKL7:1BL(5E#E>%,?:E-*\Q5X'^B:
M1L$XM_NU'H_HA'+#&^I[_&==]G[@X[\V704-1Y1I9RZ'^Z7NO@/&&9KF_+/S
MCNKO<<;%3WO9FJD3=SY"_R"12OZ)MF=WS$^'\9XG)&]Y^RCV]L>!-.MCX<1-
M4N".!KE%B9\J3/!&^7$/_!7]E]D?&0&OSP-XF5E99MDUT>_EQ]MW?&GI_7M;
MF]GS==)RU>]_;0G@,&\\ZVCYV'6R/$B%3&<#QPFFL,/B'<%6F0^@D;98,I[K
MV%>29N_B_?-]+FS+L?+'L&^?+B*=2 V3:/'NU^<2< 4VJ?-FEV0]?F,%\W_-
M=;V.MOZCR@)@05L8DURP325]A9>5- E7X9!!(PP#G"%)E[I:4^G;X-@:J,TU
M#68HI9EHXUA=_)F\92N$/T;..\?+YE)F!FT8QX!\[F-AQ@S9[P3[Y(MZ7E5]
M-P=#+IKYK*+ )H.:'5 S;0?])YI%KPL%^E6+C, OXWVL N5BS@\VGDI6ZDSU
M0\C3"_2J35$%N_5+YHK7UFYFK!X/V<S\K6?F[J_>3YJN: :3SMS+4X7#)N.:
M75"C:M*O%><!.3Z)HMOUS2#U(JR&^MAJ=B8*W3W+A0+BZN/8"I8QR6U-FLH7
MO[\7CE0V8HY4=<7(UT4%DOL:+0I99(U(2)U'K0?]1H2WP&+OUG6Y1JKZ;P+3
MO:_ S=O,JZBA.UY8JYW^P6+%QTYO]T";[2K<^^^O>S_0$HI.2$(CE543>3M4
M[]>LX1J!:X)O=Y;ZM/Y##1=?"D"J7C"0Q6%F__KZYO-MO[^NO,_CIHO#UOVS
MZ?[)Z+^OF.\H-\KFIIV=^1A2BS%(+3?WTP\R7M_UC25& Z<:%BBRS\&0H9)R
MS1+E!$4JV#)#$;HZ( >F/"+AG/G0;;+:,=%W<YL_^#9;D6.O%)0I:G5O:PP(
MJJ[IGW*9SI"Y9EZ^Q)F>)1EM"?(FFTNEP[\L/J.[:KN$&_ *MG9W-\Y4!N]>
MO./"A;;49=*6 >,JISM@\BQR/>TH,9V^ :I3L-:."M<*UK\;D<4D[LGF1LGV
MW.=$Z(K!95)<QV D\6(?V;9X^EA#_6)@K_!W]H#P-#3!B/@FL('R1:I_:S=U
M8B/+I<KOC7U-L2X*'2_O%T6244PUVA+>TX$EE%$-)2&;N_M:7E665U+I&E+9
ML^>WX.#7I UKO+UT./:BME5K#35%@H/[(-?'HV@39VEF%WR^$W,))H'F-'>E
M-,,U\W%.^!E ?NT#:%UL!, X._9O]4(0=_?A2%R^V]0]Q\L49<&$_Q/+VWG4
MVS/G_XXX!][!(\ ]AAF1U/CMMQ[A-QRIC#W"-?^$W7KW0\+PKKM;J2GYRG]]
ME5P<R-??*0KOW05?1B+SE5>HJ\Z:^IC>$*F>V224(:&T_XC0:4_$>\\"ZVX,
MEU[R6!F0;A'SY45ON9_!P5C;/-6V7[I*9A/-@:?EY2%\E-W%WQ+LK0,&>TZQ
MGX<PI*721>B[U+MD(H#]=31Z"4'7\325P[?E,L]OWSDPYNM78L+\'*]L"8'7
MU=MKWO";_\]/;M'\J:4R%#XPW#^,ZF+#,%.[ OW5X80_79*PA, 5X.=41.W/
MK/_+%_R??HJ:=(3Q]0L:,F/\DXZ?O;F$$ CGUW++\8JL)<274(,E1'C0 FT)
M,?XO;8?+EP]Q <47&",%^&3&QU3A,'HBH$<(>)5>6$R_[E;E1N]=0M1UU>_8
M]J9M0??VG\JW(LI_6/G3U?WK7+0"[=^1!T-^@EZW;5I"J%<KVPL97[%B#3Y?
M\.\_;E3A+#[>NEU]ECS170/<K)FLF9@<D?;.;WD@'%)#_/^_,J[_BZ0+(&A-
M*$P! ;;' R6,, QT&*_<]-]=J)9KC?$WT$ ]0QG&^#M>:XR&O.E-WQM+P(Z8
M26Z!UH0!^:.!%!VF\--^7_2QU'C#_BX+ \1;@JV0J0XJK&2IB,T>/XQK:J!.
M%5</F5WXB,N!CP&X:PL[J.Z^P&?1B!8%>Z6W#+;(D6PEKNC)N-48-?LD\"@S
MLNPU1D)A%BYX/Z8.G@26$%=AWU+(:= 7L1C%O2,D42P/*S$IA:P[2K*E.!&?
M67/7MAEG)P2/XAS9S3@#0,O[FCUM0RVE&3P:"W'*]NDHK:WU(4V:+FPC8X(:
MNUQ\A";4(-_J1M#BSDP[M;^5I4\+ J6BP79+!4OR36! V^?K<[0G9@FQWCZ5
M9J\^Y+2]H@SSA'IYX0B8F\T=S<^7399[/!VOG0_[J$V+JZW_R]^MIK&Q+_L)
M@JH_L818.$15JUPEIL#7WWH%2/AXA_1ZS;19"+P/VA@&H@8]@9#2AU'%)L]T
M_$U5SC(/&@^Q;A"":=R,6-*BS25^.(G;C-WZ="L@N'^^/IU3LOB:B-"^%B(9
M41Q#%:.%:$)C0!PPZ2RP<)9*\@;8J31R+.!Z!LA]Z1QBT1EP!F2D<07K(61S
M@"RD**Q"-N86ET>QR 94OG]T306'MH3\B-MT)<%2WK/L6_!"8!1]#1^:Q!6I
M&*OH;P5Z/3P&LQAE192P<P.])>MB"1EN!\N259DU: ,H7DS_ 676-15#T7M_
MX +[0 _V2N48,!:RF<_6&COJM?EUSQ),%T,74&.)(:4 YD"PH5*:AK.*<+LH
M5'O8>G7!^B4DF?YUFG?9.VKYJ4.Z.IF\6X)" ](,=3<VWL%7%=#0.S/PJ6?6
M<&'R6'\(&%*4$*;BA+<M(:*XZ4N(FBGNDS&!(V0,?FZU"DAA-P7FWHD'2*_J
MD:\X]A*1^,1I8A'>F.K=BC:CHR#6PLGQ4R]OO6F9$Q6RLP4VE7>LVBI'BO=<
MUPS;F$S+EQ 7IU?IZ""E"9T^;REA6T-<%5*\!6NO_,;WXT!]>$/66AG)=*0/
M^7C$LH!NTA5S%^]O93XGBX%FRWM[9AM_^Y42>S?ZC+ P^,"_D%$OX[)D*J^Z
MI-I<@V!RZ!>X+?_00!J?'MUJ\2W#N*QP%/5IPU# )OK648;59(TPE6X*49(4
MQ($B?R!L4LKD<!BA-OC]T.02PC"[N6X^_SGIR7N:1V<N]T%0,#5)C--[T8,A
MS[S^#,4KD2NAF$B?1]Z8Z[#]^?YYPF3,R!>1\Y6CFJ[#9IDV8I+IZ^7UYH=+
M#JOS+:G_87H5;OWYXO%-.1VW\7G5\%I=X4B1T2(AVP=0GN8))%$CEPW0#H*5
MU2IV%LJ@0V<4B@'5O^T52-L%=D'Q1\$Z$1'RM_)OB%79>$L"AFV ^LA;NI ?
M HX^Y[2*W4E"IG9G+5!3QD3@SXQ_0 \2_3JW"TQ&W1B9 ANJ;6OQ!A"9.Y/L
M<*978#<B^*E?@(8=L_H/@I89,=.9@JU50''!$ZC0G>QZMH/'-8H,D#F,?'T'
ML22)CNW3&3RCS1[>O]7.S_/QFFM 0 O!AKHB1G@-OVX*9P!I6L]VUV3PO=%I
M_ VJAF#&X>JL+QX^38G_#G$!ZFY4.#MX)%P^1X5/E5&3?NNE>3Q^]X[XJ*!R
M]/43:GP XIN^9F\O%J,O64)8CFBM -8KMEEPE/;'HE.@:ROZ6B!%K,_KMNMP
M81N=H28I"VY@?=3?L ?F2]\VDE2.H>)BJ^>ZG)1S6?&,V5S\LW8 F"IP+@S6
MELT'$W_XOKN$%$;AD;IH_ZIBR Q5!2U&2;\*P9 [#ZFF38RU4P*#J'FCQ1RN
M2)[N/Z?% 9/R9KG^B-']TSJ[$AY"#8<Z9CQV(9='!M;>3++/@L.!8:D*5UX^
MYC#7BZ!'T4Y#@X]A=V@<O"@]7*1 -OGD=\,.X4^H+#7]#HB;^JRFL\(5BQM^
M2Y'0=0R +]-/I53 [E>X8\0UUH8Z" _)OGQM+LAWU<CB4LXI7W!Q[,6\7-T]
M7<;?N(<)]!,@G]*A*/E:+IF_OF1P?$\ABD*WHPJFU))A5)4N7SX8[\-M@/*B
MG>7&\-YSY2.R8R6A]Z&JYJYIW^>%EK79G]"#&"5Q4OAT  X&T:_0+*%Q&=":
M25\_[N:=2E]-PW8+5E!W2^BF8!-P]VU.>'()S1/D7ML,.G'OC<L&!TEN[>U,
ML9PYC /L8=\:-((4\E-/&#!U[4%R+U M$FP%RD33AB,H%[ U0V +/1(1*)/L
M]=3*UN;"^ R7H*+R\NR>[.,UP+$4)=?((=)B;L=([=?1>1=>75QA;.-PJ8NV
MW$-3$K>L;SS>Y,R(K/%]X(7Z][7U88OB1)<7&=+RURL>5FV^LY(]IQ>D.1&Y
M[C_?O#Z>L']=+[2!7<%A7V(S6Y^_T96)O\@U@^)$+>S5EYTQ T21%::U%[JC
MN!N"-!WY$A29+B)VQ'DG >ECVF1Z%]*:M@<H2(U)DJ\*#!YVO4J..>3"1FK_
MCEI[=NATB&Q [O,H^+WL;!/I29"(? 7'CG;&6%MV# Z+KH1C:V]5O?<V&N)K
MNOA1>:+M1T?D^87$)L+@5*N:U33IWL*NL9=,6U)-O4'DC5FB&>T D,]<<(&B
MFZP*F!N!]J8.9XHY[)ZBO)RM<G>,/MO[@>65=RQ/:Y&;5C:PJ7AK!QRFQ)NV
MA9%+K]++ W2N6R//);Z*0QO$Q@"?KPU':&T;=7=C.M,B9 \?H#3;G&QK#K&]
MU2IVRZ;J'ZWO<[R,]1(P] 9?/R6A3('&=D%=<EF4]J="U=Q10)Y!?\4M_BZ:
M74Z+!X6IO+]U8&DZQY1F ])SRBO+$AE*:P!7':9.MB-_R**L"B&A]@#VX@R:
M1?>;SO<RJ-P7B,_X_*S0L<!-KYRR-6L'TGPQ7VO;!IJJI!+.L04?B*"VN4PP
M@) +H6INTS@Z8Z<NM"U<M5NKNNGKAD*HG_KF")&TG93/4'XW 0B_X9*][@)X
M\,D370EBQAJ%M)T  X9Z0>0$24&4[1;Y@-%!B_=P=K00<'M]OYCS!T:?ZJVZ
M";DDQLB-9*<C=LJH)8=Z<&81<7'Y_H63LJ@K@51Z]_%N&!\>2EDQ$V((?&IX
M3'*XHIE%T"/@$XOW9J5Z, VZHTGVT21#F"=0B$A4O(9Y%NI^!)]ABX7FL#'Y
M023=Y5D_;R\-5[P>>%2J7+04"W:#X4QG]^!M2XA6M_RBIP-027M#)Z;&D22J
ME5^&S<&^!A"CI*1@8U7$U3Z*28HX,2B$&+'KT7.S?_'B"_S_C+(X0<T^"$QG
MG.N*'0RBNDQ:(==&N#DUZ.4]&?"JB(QSRSH[Z U0)DN!$LWT=XAS(W#Z%9[%
M-IFE&$+EK_H3&=<$:^$]59"Y K..:MMB]/#1G0TRZ*M$NXHIELVEQ2;UDTE^
M?<ZL+,$R*$W!^ODC;9-@U\L>Y_'@Y3.4ID!4G9)K.#*/SH C.33/OIF13=G'
MP;(,GMQPU&JXT>%]^Z[@**OXZS/HU=20OM/W;[E[^:+W=Y-E#M0/MRQ>)#SZ
M\X<Z,<$D2F $,=1LRY$0RQ[^E4JJ7]/P9G!SCH*S_CH)A>F-\;"8^ZV;CRG=
MF_5[84&&T^2YKDNG15N"RE]D9NW;@WY+3!7R6C-Y-@1EW36:W6.M%.6NLP@V
MM 2ZB$YEZ_.$.7O8:VE&#ZA%+1:U](W]=CA,#;^ZD^\*U'>?%H)ZSTNI)2)=
M'I^P!03,^$=0G*.%:M +^&<)4:JU[XXEAXM"-G8YHXU#J)YG=1<3Y-M)"RI[
M%QG(^7Z<F31NF!WL+O9W"VD,?QR1>/M39L)VM[LUZ=7GDDM#?"_ES^?<;?\K
M[\ 2XH[.@JX+"=^7HIG-^T%/31[T4L5E"M8"9:Q9I!74NK];%S+!:&6\V%"M
MHJ1U0:3F> :2QT@/U,^*\9DV&W4CW&#4'>.444M. 7ILNT9NLZXL&29PJ4V?
M$8O'N#<8)%9FP+!^ ^3[:/-MA>.VUN/]-43S05HP5*Z?\PE BKB65"?&FOU*
MSF85<9F$\N0,E=6ZA[X%-',+Z^.HT$;01<8:**G%#5<3_]3[J4@Y1)P8^\;6
MW 3T)XW4/D@#(ETJM)[6&H^AK(4]92"12::Y O(3V:IC-QE&?\7U&:C8&?@U
MN"W('Z/F?]1TR2/=TEAI-;YX_Z#!17105<;94<%/P(@>8:(=E$J$ZYQ@1BET
M#8M4!;LW92O3N[0.M.TU8$Z!B&4I'^^&'CF&-\\?Q>VN<=U-$NBQ]G5=KAD?
MLCP+HJ[%AJN-$(-C%O594?6GF+V](&7BL((ETV^F_P@^*EGPI!V GJO8QA!;
M%2Y.]MP'L"5WZ&915L+KM&VX39!J7!2]OQS>WLVH+B::0<03P.SL$H(YR3_,
M@78WXW^O[J!;CQ:; [WUH_:3VQ!P+70-;%8WL2UPV)$][0LN-!2O)W;<""]Q
MP[3<U5?UE7#@\.Z?@3AFI&7NQNZ9(C*R*9&3__+<8X)RHWWZ.;!W^'X9E=XG
M$LON],P\@1V4T[7"BZV\ H5K<WDVFBD'GDY2L#:E\E9@EE'W8X@%>;^5ANPV
M@"641H389;U^].+66 O2.,)M30,E_,J/5@)FR9CQ^\A:H:6V3VC N-PV2K>-
MDNLQ(BB9]64I_ !*F;="]^\PUCA+KQ8;@'@1YS#7N8'T'Z*8[@#\2+<# ])0
M&QD5P^/U1 EF-;7[UT,M>>>4<BM)XG3XO+O2$1V@0SOI/+(E$;S(47/"?9_G
M]I\ Z8WGE$.8TZ#1&POYDR@W1BJ/@J1>[AK[?=\MFPV_=F\/B-@9Z)WWYQI#
MS=7>@%\A6S#@-P:SEF&QD0?89\@^*VM+'PV3W )N3'SL#K_^=7^?<X[[/C"D
M[.E(?W[5/_4M1:50D+B>HRETXL1(D>,!7P9'Z_!WV,MBT<Q"[Q9YRO>>#HNW
M!9NCXF6"TI+(732;#OK.]U2YXBTS7LDV?OV8VC*L;@F5:&V XCMD:T-ESN_$
MU\"PZI-(O'MT/JXD_C%Q "($+UX -9DJA@D5(Y8AK_-U1$HMJ:]D)80KY38#
M$8'VF5.TK>4^ZRT2>^@VH%UC'Y-CN+>67WBYU*"N/IMV\%!P?L02 B=81=NR
M6.<LE'EZ"2 I^%75GP&O4#+2Z__3AU%D:Y(IJ4L(8]C;-=OY0S<O&X.DABH9
M*=@S]\ZVW_>^PAFKL]2NKP*1S,OY>*,(M"E\ZIZ@S.GALOEP(I+>RS#^#,6"
ME@I!:5@)C &&*^I=Q76=6C<X^!DX*4W#6KK\(UC1C1'8E$JO5=Q+WR#,Z(L7
M#OX12*W6(;;.*;PR>#!JCQ4Q,];7V F[>\Z(]G+A,(Q??(@-*4;V"L.EN?4%
MS=W*\8:O:H+^:8BD3)L0&CL7]=:>/EB@1F;(U^ VBY3(M5#R_>*O1UA:XS:.
MI?A10HSCQ<^BMFB*JG'M\OS%F_"_:/'Q8%Y LOXKU[IXE%/'="SQ!GXU&4O1
M3Z%O&^M'H;/>?AI^PT ',B+?!T,F1GNZO5[X(D- UU2R(R9F(=GA^+.>_I .
MGK#:0<UXQVABHV![@*Y2:YB@7((WA>1BU!XH[^E^)2M[-VUG#^RI(/] S K!
MLD46X<%0>+C3W<>X!N4&[AJ2I=N_0'PF#:^,WH2S G;H/#>5U^Z^OVKAYZMX
M1ZSGPE%J43/1E.XTYN_&F@"!I !FBR7=NA<V KU]H.Y8$*-:P;Q6DQ/47&P$
M<O@XBYH4;R%Z+<T]LFPLQ*J'MEY)L1[;03WRM7F>7I=</CSR)Q1]<-$*2E#Y
M!K00D;"1:C&^>;[@VJS4''(7X3;UT<PKGB6'-EM5OGPP$%7(2IL-,#Z /@DL
M#O7(?+^N/&\4&[G5^.":IF^-"X=H5HL"I]BA2*VUMDMNX;*$^)$J4BTA1+X^
M(BMO4:.#A@HXE0',)A;HUYQ8E^W,-2%PX%]X8/@-V%%)7"DC=47*WMY6+Q+.
M@(%W,4W$M3@KB-O<C\/TS;*[N<A(6?K->Q&)QSC<,91#;TPC^FAW#=XLJJ_>
M([=<Y7O@S1M#TA##KPK0%)5$6"2F/X\V*\R9K&0^C ST:&S_Y\_10G+.K?VD
MM?KY],Z0[0T H8F]8;ROV* 62A=>[(KQ\&F>3ZLL8Y3XWJ-6BZT(:5@?#C5?
MY-4)[Z^00S[-(:B^&KP%5"\ZU#%+]I\3N:$XI++39X=]5OM^D;XBRCQ;K*0L
MNC7-H:Y?:P ' RW/'YT=G7-C-?V"VW;71WDQY1[5/:@WAF5"7? #&Z59S@OM
MNT_U.#MBFM#AO32OA]17$$M<Z/7YW6Q#=(7TT6(!2!&A/, "$=M,Y]0,<1LW
M18#OF3A',(0/\P!N.DRQ3YMU((W[-%UQ3<,&D1+NC<>Y D'M#\?\"ZYXX37)
MBSVRL*F[3[W"'@?"G@MN,&:Q:H8K(XB'-T(?P3*5IAI8T$&$U32CTL'1PE+Y
M*P\_)4LLM&Q[2O/7#I'UVE[)=:]Q(RQ0UM6]\/KRG,N$E;1?P.'JRGU:&]"I
M5(W_(0*USA^QN(F;MH2(0F?.,=;@MM*V-73/Z$ $:DTO,HWVAXS8H@-H_OBU
M]L#;6W.)S+2*:>V&@2'JSUW28UG3XOSA@(Q*#O^<VLA"=D[98-BN[PF:#]]]
M0J2&3F5]\]/<A!@+1ZA//S<73K_"Y-9+1=F.*X,E:@PB$K4!\O68SKTT%9:F
M[G$FK(=](1*X2R[2;NP\=W@)43V3=!=EM%S<Y6/!?C)>;'9R^*<ZA'B1!8>B
M<RKHF'%/$4HOZ]-75: \2F@FL#Y#5?4WX]>[9$\;4/_PD1N?\07U?6O[INV!
M-]X413[9]0Q(2;NT/<;&_5!'S7AX-Q?>J90^+__ ?E?7)-P HP&_HT36L =T
M6XU$C5L),UW<<^Q5>31W/HB^/F$''JR/:33Q#5<._?F\5]#]L/;NDV.7^?M5
M2<F[2/E=,48'ND6:Q+@[D;,U"/IN:IE:-*HUA21* ^S.A5T1.!LAR!"_=N$.
MA+;04=!T,N@JD;T&+;@?!P-/CX:@[I!GIS-="\FL+-Z"G"DTXA/N>W&IU_%K
MJ9>_MEA:_@GEG5Y,!![N"*(217$:&78855O7X4PESQ@6?+WL_,O/W9R2;.]B
MPB[B+O(NEZ"MQ/:\I%?MGW#QZ'\8V?@5>$H+.,V<X!%D!:KI#-J*2MHE(/U)
M>"7-HT-X4:HO%#&8TDK?I,I1K2LPQ07JI<&@'3.=5Y/>?510!1)9$]@KVQ\,
MMK"-G,<-SUR>1?<,KK.O>5Y=6]]8=/)E74W==?6)EUE]ACD'J.<.?6I\D=YB
M&+3E8OW-P(3SU;5U-;F'USLJTG^Z^5A?BJ\I?DZ^#QN"+HO35WG"C'S/LQ##
MJ.]FY2"4_]FS(Y2MLDSKQ/T\;J!HMQ2CG-);E1<^H3/:&<IVEUC?;11#T5/O
M<BC*82_?MP3^"%#4N/L@1G,-V-?W"3($V?X$?6J+3-[*6!$SG0F>I:&[G'[O
MGMUKW\_*&A3C3)[5@363:77,A\8D.@K\J__YJ*8CLOY3IE[M/'J O9[O -JV
M"(W@PTII*L/L,X0!U\P;7@3ZQ:=IMDJNS69F BEA17>I/(T?%)E0$I5O=9M_
M<K3@Z:CY4&/C^P)_RQTAGH:L'$:8#J/(:RUN+NRC'0,M6Z79;,L:XH^1(2N@
M@)*11$R&"_+J_&<1(P.W-10\#(<^IAZFH^%?@#UU]T9#=*QQ[2UY0$$3>Q66
MJ&H;SZ\&']U5)1N*ALW=J/HC0W0BO5]6EW99X#H:Z)H);UW 0VY?O: K)<0(
M]'J!6R3#]'R1)']>4Z=>%RME#IN#]E<#1!;&@]1]$;5N+>4/HP0>0F$D3")O
M#T%VD[F.LSGQLWH"V\4R@8VV+[&E$7F#_B,<#Q9?4S00#(B1Q3]!.Q7L-30#
M'AA77ODKYO(E_@F%T$8'VY-4;1MR B<.DQ\,4=V)_32C$BS]6&.H>DAO_!C;
MI_^5._)=_V]=L>CKP'[E-',8">@S>11SJ.1P)UKYB:4R,GQ5[%[E\U%0H,*G
M5= "2B**[4@8,[E\N'%6R[4H<RJO'!B3W69GP"=*ATY34T[.5PDHNO*^$0QM
M0E>7-7N8JIFYV#"U,,M'@5P13'T[W7H+.C\G#D&!JP7&'7G!0-K;.F6RVVOL
ML6)4G[*'S%!NZ>?2#JONQEUD'^^GG>(.M6N^X?Z\AY00S6AQ4A$F8W@5'PB8
MZ,+N?!Q%_Z7 ;S&'MO\>'-, -5:,YXW)\A\7&SRK[9YQD$[(+:@%?NF#Q[LP
ML#G0[P<(BE1&1XQ\FN.M)#>?@T9S$U-%9O^*[%LKBM+L] PCF?GOVL7/O]+Z
M8T1^E=OA7=6#C]=6;Z\JWV52]<M&UL=XED#_>SO^ )7]->?_,**F;^ V SJG
MOF440K2"EHN$U:XI'+X1 +RC%OL]@N1-]<SFP>#PD!==5FK/KDN5&_NTFZ#0
M%E<TJ0_KI<"O/'LZ8F#QS#74EG.Y9XH_'5+E;'IQ\_QA^YA]7.?,'Z\<8#G\
M,/5,8GWDGU^O/$#<6_Y)*!N4=%%]%)]*/E&#O$ 42T4./P2P,BFP'S(['&!=
MI^$Y6-5":\A6X@^1]079#[IFMI(YMV0+OVK?%/GT3<?DG)P6%UMT7YJF>3U*
M*/N?WW)86$+\SVV*T-H7-L,>BT]YF$S=AVF'P26$JDXR&2V:O*+DH)OIQF!-
M_ZNA\&:W#YTZ:P2'2[06 BA<@==%0B(YOYKT>%3FRP_$B#)=VGQ>QK+64]="
M-R4?]J$9 9^)K9@;B4P146899+6;MAKR*J\3$5<%L3/E5KPE1.87;]#S2-$I
MT'&F4"_'/E7=@44G"A -M:B343C[?FSPN6A5$G2_ ^M1,J:)']ZZ:,9-^9_?
M:YA8WLVX8+B("8!P\V]OZE"#$.D82[2A:D8&J7M:Q?,!*=C3()3[Y37])\CS
ML,Z6RLDD'V#ZQCU>BG_W1&G7^>X'9VQX1I[$#O11T((S,REF&?&_>O]8L,MK
M=94=;_-.1U'+C;8?#P;D;MQ4\6/$A9NVJU\U//W(S**W#YM#.0KY=;S1#"8;
MMQ<DBM$9QZD$T5=J61!80;=$;>3UV7=6H$]T8)Q@NX>C;O0*9X=IWB@X'E#^
M9#SQ<<;PN-NG:H9S?:IVP W[K-W:SX-WR^MG[RM6XB_[IM).1G11/Z8-;][8
M>3'KT)U_&]C&V!W25TRGT7P D-@TO),'[5ZP>ZU:#P<HA28R^IMZ^U3!+UY@
MN(C^B[ G9GR<\T.KR*TRC:QLW-U:C!04)[V8Y1 4<^E8]S)2O9M\.!@ZV=)%
M7!O)YL]^VXEO0D);/,I:V-?=,)GX*/:-D!V 38&88C6.VPK=5]Q%:BX"!6F7
M^$A+$<8&PXR1;J!]'QURKI14%[*QAW8J62DW?'0' SO*?VRS>D_SK&V &.H-
M%,- :O1L\57<CL6ZV6"3-F5K"D]H2L-#R3K@C:2FJ!QS<N^K6%GUKMDNW&4T
MN\+69JU#O[,0/6X,V7OW\/>7G7W]-#*N>'57[.E9O/[I02*U]A<,EGBQWU^&
M:_B$?I[^1/EOB 6:>@&MJ=J5)$Z\DKS!'[1L$5ZKIXC1$P/3$S6'*WA"9L@V
MT)+5'Y0<HG%P&!<:1^P)M,RMB8CY&U]GU\MWOX>[_X@(I8QA9 Y-:&M:M"(I
M"/.]R[HS>P4<6SJ>G]@P1E"R]*A9(DF]!R_ 6 YACM>#[!1:$D6Y99:QQ[X6
MS+VC)*R51UCF=P0+F32O"TZ\(+GAX@V^_L)1*"D(FE:A9:8J0HM-W. IZ'Y\
MJ *C!Q->0%N?RES3*V!]H&6(%G^?2-L"S*9:V:4_4?F@+2/K ])F!N"=]^[N
M,58%$Y5]3#4G7AS??P^-9S2%XS_T\W4I-FRZ>0DQS\5M#7 '/JOC.,"@"&_@
M.$-B7Y7KU2Q?<*"W=[2I63F%%/'H%,XITE]N%+-X.!P8ATY#C.8"?\'JQI[+
M?%RHVY10C:QS^6"9&))3@F=^Z$O$0-L_PX5S5Y<0$XT0<0EQZK-DVVL!%+H0
M'B6OMF]FF--60-_4@XR548PJR^9%>U_(46%DJB RL<2'4!/.>+2V=GZ:2?^)
MY@5LYC J!L8#OHRV/XXDJ%E,J^FT/@^?(* L>]9HWRC.NDY+4K*^'2&:,29D
M $'[Z#PR^]42XG5L,>-=P?8E1'<>[NOBS1H'QP %/JTR1HX89:R)F>FC)9'"
M'T;\"WI@8TE,[V[5;D[16NS)IU%*(G"[&GA0Z<]X\8DG$)N0%]#[$72N?S@O
MS2SA,\7SK750E\;7M6EX>\\YX/WPKD*1*'!R(F1M;>[ZR]A3=I4%L5CZAKHL
MU5[.AZ*S$2T%9M&B[1B[KHKG]19^+3 2Z,_AVP)E359(,<4:*E+9YS@Z.UB"
M^IGP.9(RB+C6]_'95P6FD?VBIGJG:P_.+B%"G9E'TA<O7>AQ64DV^>K?X^)[
MA,0Y\+DSMMQ]TMN[E[>X.^!EAXO#Y"ZME-!?,7D)<WG&9[SHS.^\WLE+-4&D
M=J>IS[XOJ-,_U?143$TXV:6=Y]<6#WW09?I2) __,]\%?.L;UZT@I$PY3P]4
MJ_Q3'M*\H)-8%T"_R8K86@OE*8P.]HOK#^;H55]!9O+:>G;#:YFG^& *H[D%
M\$Z-2<:IFXU)NX>@#<<[+\62334HH0-L!X1JYKH%.-I//%WN)>CJ%.,:S96B
M]B6TH+" ('/A%VJ24IK].P$ZR-X/3%4#8ZW*_)LJCJD?:!I$L@CHB\\$5^%7
MCPZ'E"BD68''7CZ).AY$?WQ<_W]X!R0!/4!1887&N.UP8,\T3YBJW=GW 6#K
MG+86YP:CGD,IELS8*Z$,59&CJS*G]W,NF1*C*1!9:!F99.<EA!Y5=/IY.L$L
MJC"_\1XU_GCO1 W:/"E@<KV"DJMC#/EWT!.+X -*B@#361/;,TV ;8OU^R[Q
M*0\Y_)N^2I_VT);A'Z&;R.NRA$#W(J)YI& -:*TQ]:KZO*^7_'&G]P?A<^XU
M1H34""-IIVBN0K?!)''5.-&DYF^^C1*=Y:WH'>VFN4:>N]<:J<JQ/0Z=N#\@
M.Q-(JHM\(HE4+OAZ$H#%NSE\RTXJ1E0X=;^"\TI_L/=;"KA!39:*IG/D-KSV
M/80!J8(]. T[DE5!W)Q O(34Z*?.+PK554$R23V$Z_^5)2I>U<.9G*PI$J9S
M<)G1ZN#HX[6 5VV>RO% S\B>$(L./*'\RU=-%W1B(7[L?^'MO:.::K]UT?A9
M$!$14#I$04"E64"4ED_YI H15$HH41$I$1!I 4*B]"(@(* @O8F4(!":D @)
MH")20I%0DXA*7Y'B$I)PPM[WGG/WOK]]QQWCE#_6R!]98XVU9GGF\[SS'>_4
MP76I!<U N_OB0AJCV+=F4&VP]]/[L=+VF . ^%,]8>:^P1O7$I<PP3SXWFO(
M\ KM:&E;:""4+T@9=R(A["N <<HCH@A2TG%>*J#Z\:X-V&*K_P8H""Q[J="'
M&SL2!-JTK4DQ[S.$41FT^ZFT:%(%$AY:1$-GF_5CKKH6@$D,!E+4/5#J>U2A
MYXB.Y5M7#US17-#U'A>^ HS5\#(&!O0QE-K<9GKR8G^'*#_!.%70V'IU\9++
M[&"_4A!WO36B/:/&L3W 1ZLO7C'*_Z)\+HTAJ4B\F<'_K-ZK9*9*R $8C5H+
M$Z)@-4>(QQ="_$6NOD93*0B?J+5$'^?TY?LOU0F"NNTA0M%Z&BC5ZQ]E"TN3
M\^<:EHZV/C(5<-2CFOI1-KVK*D$41<<H@J'2MQ^551U3X=&BD>"_):ARBP00
MJ\+N^*+*T/'=YJ.5ZX)"UJT#&HHQ-QIJ1AYHU%=\K$J=MJIKKDMU=]S-*ML9
M[$*VX&,8MX_C#Z!W;YBQ.+_0"X:#>FK "ETYVN"\,7,;$IDQI<#:FQS3:LC4
M%[=D51$+Z-/['##G![4L#)U8!UOPD5BI7EB,?Q5"5BI,Y69&]]]$3BV^!PIA
M2W-:>1R-9D@_!A9LF;(=6;;DZ?WH&]V;,8D8E_RY;4A==3+PCK&7Q=+NF,-H
MT75),30866UWIX[B[WC_'.4NV'B9#;75Z@VX&YXZ-4K'=46UCK;>7N66\?(8
M1BA+YAG<#\#=BC $CB9^0N.=6JA<=3:\GD7H"\>*>SY#AZ!4',(NL_GN!^SW
MP?CN*P\N&A,,<@1&(V?#/_W1$C1:M9.##@08X#:LP<AMR&'B"<R#X>HU9+3<
MB1&W0:R4114["#1V98(8%:9Y@@O30JZ;/M#,FLSY+.@+S)/-$QP<H'SH1N3
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MI[9<K^]NWTOX1@TX:=$VY, X=V6QSFC7G]\ ;".9I5@63Q3&* $C=5L&;%/
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MM[P*OKEK_KF58Q %&DL2(HJ YRDP8>YI<*&==) KAS:CS.>JL'B47?1G[D'
M+=J_7=/FAQ5+*%[/.*ST9XA:;%/N?L&IDC O;Z6LDZV]O^2?'>J*_X.?R5S*
MWH)B!S>_X.E]8]T;U9RL;8B[T&$09V'AYMR/Y<?X@TB6@_V 9IRZ2UWRK>$U
MTE_H,F<BU7_T78;*36)KN+1-<\9%L1LJ;W)WF_/ *I57U'76^Z0N \RK'"+L
M;B^2(?NE62-:K75O"7=H>G> D)0C.D/@I6H9L"8G5L\:HGUK^:;]K,=#/4TV
M =GM=^29?E.Z)(2/YF_E[#M#>HK;3SR!3F.(1V!EV3=!7^:T.%MA5 USGH7L
MR!5@=4?KW6# HPU.$,-#LS6$,%?ZZ_6MMVX"SLW!7EY^OJAB,'74@M04/A5\
MIQ'-2'F^>^ G_A2+U(U[L@TYR$;.",601 S.\1P3QER)WZQUAPE@A)BXV-S#
M0%D"5Q&5:G(\V0C@BR8LW24C6$E5)SZ_5<JACZL9L;[=3N"_NS?D[;&_3"&[
M4N&074-I7P] 3N)SN)+<45*M3U>>'#J-[M;>1XO8" +K6+#V"BQ7 _0%^IA(
M,E(.O=I17C*U#;GOZ<6 [T<[4&CX6'\M*D%><VMC:&W!RB,$^_&A2][O@+6K
MD"-6.Y?5M<'B\WIG^;^;%+L7G-L?.?A&5,;(NE)!Y.+^>Z?;=TW<?!(/R2"J
M 'V+3\KM2IMW3B_RT*#%.*[JF5<YHP-_49GX1/^%;)S O/A?VQ#3@76[NR\0
MO6'YTMF)AZ2W7&^4>^@$OGR-7!E>#I"$KE;W;/"$0S@%<S6;0E0!S8%I+C_!
M#:#AH.QK_:V"*)9H%ZZ^!5S2.\\3CL13@-%+[811LH%,,P",+E>Q+VIH"1<Z
MFI:JCNY!-&;\534-.I, QZF=8Q'#K5VXW3#:T#9$0^ NZ?GJ-J0,.J 25?>9
M&0W&=#L?^E0W!?W,:KX0D''7XP=>..-[<Z!2J:CL8XK.)7V$N7 49;#<Z$V4
M::>EB)EE]SMXM-_\T-Q(2<;=TS<J]M\L.U'@<:70\IS%1Q5-:@/7>'D2O=*-
MBR8>!_$ 3VWD11+E01+=)UZP,ZDJ']W8WC+)C0H6*RFQ5+\S2$A(U"IJ:P:Z
MF@HM5"@7,E+;,?Y;Y>KU%>]DG4<Z-J8!'^;HTAB/+!9Q<O6.T_LD03+=ARTJ
M8$]MA;-LZ<8=NM)((31UHT0\</-WYXK,3^ZN_@"5HG(T=@2ZF'/^ULB2CY;/
M*=JB!\M1J_C\EPK1T(B=H<GAWYXN LILD5<I3].8,!IUM_)39D?WGF1ZWQZF
M4J[*7.>::?N]EW!A1FO@#$U2*32^]Z&]D8MU+N:URUM[^?>M@XE0T,CO43O/
MW;=OV9XTTON:Y:D.STXWCEX=&RHWNW1?<:CD@%_Y(;NILV]H$21ME4>S:;5>
M)6*3E=BW[(O@45> Z8P[?)EER,Q\JIAFT43--@'C6$@*]@*P*?#2JQ355)]C
MWUL[?UCZCBP!N)HE<;\Y\6_["=OF4;HR6P,)J@=Q]N, ,SA;=6?2+=>UHDOO
MQI8?#P0\V&HLJ1_TJM$.$JC(Z:I S5@(=*^\OLK$T5+\?U"U5H3!3++-R'XH
MN<)O _31TPCSO>0>11HK:Q3^,!AGA<TD^Y3$#/1UR9TL:'>60->17WETVKV2
M.W^F(.7;T/ER%\_;M9N^54\I)7&?:M;25?4O&=V2?I-E;=GGX)KPP0\CR'_7
M]\6!KR%G?1->#2%:TP=_NZKG++W=,F6I;*!'#>0Q-Z@8]SQIGF8S;%^BJTR*
M.@+*3WA0D]F^&<S:2]C(\:6OB/XD&S4ET:9NW Z8U*8T:#^T;"FRR)\><_2H
M\T!$ZDS78V# /U AS"6AZ"6V!=-'K%-P>+A_Q. 8NN@Z*R;VF_8C_H.B*$2V
MUD1#C7##R#Y%-::BZ"R#E+L">B>#:DB.2!^H.,H5AQ&TMR'GT^6Q$], HG0"
MWC$-*DY_>@HB9;!#E)SXWB=YA_9*OK]N]UC@+Q-("D>PS%A2/37!.L&)J5@$
M]Q])]$P^QDV>?6IQI*;.)$'51Q)=C"ZY/G^SWKK+QJ3X^J-4!94BR"=#"(H)
MVXO]T%*=N/<]RVU)8<L"G;4Q3MF<W$@)@W:M2-H;:T>7C7AK"0G.A4QEU66K
M)!J:#'YO["?H5KC&4QW$H+1$E*MZ@58ZB0Y_#P5/X]AB*ANQH/:,1B)1%#S+
M8\#4 3UMEI#%4("%@AE+* GF\;;*WF&.>'Q$[Y*\ISS9L+E.U#2@<,+Q6&/N
M3;'5*Y*M[^?U<5SI(JX CS__4\?E#]B&1/4M66Q#/L]"<";K3*@<5@(=P>A[
MG$W&'@43F; HKOS;44T?80^L/& ;NPX3=)PBICSL"Z)7!:Z:^).RR7(GJ-];
M!PEV52^]%VFA7B@+_V'_"G'DC^XN&&"%!U6GP_.!WJXB(('+GQB8>XHU&LG>
M=:_!X!+GM?GX?*Y&:\:GCHT?7X!-H1K$1P']K[%M[5?V")O\\ KXL3.,(GPX
M',<8Y@6W!N0C5#L)Y^D]%8GVCYC+O33S&)TO-)D7/;U[$2N%:@Q9:J1,)Q+/
MIZZ8YIGH("EY\<[R+&*4=]J4G;/TEH6*;<I2U;I[5KO7S-#A8);])'+\U*_E
MV;Z&T55?GMH?X*%,Q3:DT)YGTY9M2,>/C=)MR/='K9ED''"S#U0UCB->P-B
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M#FD9?H:9%F^(Q6$DF9XO;]\UPNZ81^Y]^^ 95\5"I^HR_KU?N'__\\"M?-L
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MK08J#D2<KL8[C8;T!;@.:]2_&UPKT'&H:V@9#MDS3J_Y4!/MEY3@E6@2Q-7
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M\E1#X9SU"->NR \O;[A\VO5=]L^)G@ ]EXB@TE[%B8Z9OB"U/3_5;'5 JZ4
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MZJNZD3]Z6R;9BA^S*(AXE&$0->KO&M;-.>,2DT,L51MX+.84C-R.YL53X@]
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MB1M_1AWV>KW2UAYY[4,03\:E[IW;"OD6_YFOX610SL,Q*@"\1^8,G;#ZY#N
M[BF^3.>CKM2QLBE-^".^FMZ1HP0A1T%$@Q]1W2-P0+"?:W!B9?94WU8'0ZGC
M?(L'4]96>-G^N6T_@Q$8NFK,6XBGN-AOI_0TD@@UE:N]N"09H7M!0G_J9CW?
MV55>EV=5Y35=<"S?3C4G?:]BN_;,#>[BDC:#Z+L$F(@:Z@CY8QIXZN-.[?C[
M *AV6;_7.V]\_48OR\5L3+7\@V/LKN6X"DI4.[?D7I DM^J&OT+N'/(3\J?'
MF>+/*$5&N@BG:UU9M4-?3-"49[C+=W]Q'>4GNS]=S<QAU7+"8#.B*RO>V90I
MZ+6CRA@LI_%!J)AUT7U%I&$/B:^)\@8!A&M/)+RZXN5'X?,CDA#I2S@5AK)/
M_CNDA75^SWI35,;E1B @L33,RP<VGD=JAG1'*U.\UAT9:;8MC**\>+0[20S8
M[\0(.[B<GW$8;S>C;]P8T79AZ79^T/!5FV;NK;6QGY8A/2^4U;6,AWU\J[4=
M>_RE&"UI[P[P-*GK6ZF4*+>2WIW+!D%O?Z]U-1D?DT!*9/Q>>!;\/.C2ZYET
MR8:8^7R3%]B2 U "T.Y_Q_(A7,Q4,+/G5K6\U(QZNCW*WOE%V9B;F9IS<(55
M6ZK_JD?X^55V $E:"YV<?WFCL]J"B#X,\X%SWYYFAM,)U\-HX*E1&CB!,JX.
MHT@RT#FOO:W? R;#87A^5^Q+[=RX"O%MPX]^+JO)JG.2^C\,L8"%-GA/[@#4
M"&/+#O5LL!^L[FUS^BHWYML<'^OM >C! 0B0;UX_0A]<)$+H\:A;G'_&HDXP
M=-(\J%'Z6A@A;TX\.$F@S>>6O (*3#5G=3*H"+#O?Y-M5LUO7O[,[K-IS!=4
M7G=$9."]#T#3+G_?#2 1^JU3#D"":(IR"[UI,AVJ36X%)S3N3FPK6Y $K:&!
M*^$B$+^F)TM[KAWE/]A8*%C[JXC.[XZ.ZJ\?W=_[L)29IIW43=[[_8#CJG[U
M0U7SK?+'7]^4&(2Z)Y:<#W$/9+XK.Y.GB/M#_44)+>] OS9- -9$G.(J,ZCS
M25^\:3XV\P.7@ &[JM1BG8^5%QX,%;T;7PEN$@L>-=-:_WH *@IC!+P*A%'L
M8H8A%^TAC"R(:%W.P\T#D!!&*O( I.:W5?IWYT!WI@+ =X\Q<QTHHB"F(=?'
M45<X&'G8=R\L(6OM,V/(K44B&A\G\6D(+9-&+I@8A?X9'BB,C)WY''6X:>!=
M_^&&K)$J>#I.;,Q(T0?&O;7ZP\)F8GLH88@19SZA\B!SD>"(XV5/U0^KOFD>
M&UD-S0O/$Z6[NA!KH<%.@F>>"( ^T:^/=P'C^_^H%RD]YNJZZ20]GBS#.W%C
MKBOQZK/?<=WIC^&/HR\@DT2WVNAH/3J,N*=5*P4I\FPU"L_HH7= '>SSAP0)
MXAE2_\D4BTIGE.13?$8S#4_EA$&U$7[&^:<K16@V,1AR>/RL,EE4AM)N0HYL
M75 TZII_T5YR<Y!Q2Y,7)X9:R!%:L2?<NS2K<"ZD6/K*:(Y!Y=6 WVD)_7WL
MDU'[JN1%"]:;1V<.0 .OV,.+6YPB#V-'.4HS>-@GG?8O^:+YC,XM?VCS6E=0
MP[)ED!N6CV;9G^&-EN7ULRLR0A/5_M/47XN4-8>=#]UFWV9=9]MU)H:Y%?*O
MI>J&-;UFCT' VD/3L!Y.17W5Q9VK TK)!Z 3WFRMYZ1I%H:0SW[Y;MIE[K,7
MI>.VVXWIW(;2:;=I-S]GE^EI2W]_:,@_ >ZG/NW#TIS5>]%3'WOA DR%Z7G<
M8RHLD21"JTVZ;>-363(<BA!9TJV"\M^9E3/$-O;GQ;__-?+/MX\GRCRO'X N
M_L9.A6\%=+H',_MX"I!YV^DBRCPOAN.!/-7"Z#<2]95F8_"5YP@NVP+;)*T[
MKZO#6EDEJ7NF0>N1R/3+=V1NT!P$"8WU[8/J^:'EXGY?U_?;?@W]R8^J@O2K
M=\,RW$X.LP69ZB,(?RAB9T"STTVHJ6U?]Q'*/OSAZ(QW[A.+'9>/T?KKV+-@
M?HU9EWXY31.'VT7#">&F--(CL+(?;>1BAY$4DBC8N?]J^2[F$V12*KQ[XCE*
M!0BN^)HSVFDD>%<7M7X.B"3P/X)[O?AU^+#5-ZLCA]*M*X #D,FX/THQQ$OD
M]6]D]^]=ZX9Z[YLDGV?+@:Z6[]XT@?)8X'V-:K>)]9PR[B"YH-B>3LC2.F3:
MB>9PI^KG'Z\D)G]:]X,P6-WR?:E-*P^+0XD[H1Z.K+9!:^[<P;*R]P4)9H;*
M\JP04Y8TYG5Q5&X@7C@(-F+7 TW38_ H?@'P^Y!]T82?)?"4.I3^R>__\LY;
M6O!;<V."8EQR-C\.M!.X%3JFS-%.[$^P)E@W]G#,&.E8NRMV"G4K&G)]#.HG
M_]L;S64D"SQSF(FB[Q/S41"/8:W+A_?M<><6%F0#5=85=":H+JT?9KJ4L1LS
M?Q_QXSU&[/'U!R"?8GY39K[HNE3,JDY(5E*2^)K^$"J<J<Q*D1[=:02T[(LL
M+&D)5\7C+L# [3=XJBIY7]68'O72TU_ ^Z*](=-IE(VU 1_ZS$V@))SJ%ZU,
M11!YP$D&;E6OOW^H]'KE&S[1X":-Z%%<OVGTDI(FZ>VT+6UYKM!)?4-&74'7
M@VW$&.I"@-'>IN(>Q5!DOT4R,CPUUS07B$KH##0*,>9^/G3H&6W3'.!NUX')
M#=3Q8[<+?P?W..9>&HFSR5#R?6;+-.VQ/NK#'@A0[XN68*I054PYR5.0*Y8&
M+,ZZQW53&BYX2EG&[@VZ/RH,GKH:EP@W5JQP2*TXY?M\X7D!!Z,=#T#@RZR\
MXS"JX[YEL.8!2"%AWQ0S!#G58M27SX[">X,S<#) Y;X7>P)_FGF,C,B2.4OO
M2X::T0.=+1#[,*9+FGU]W@U D;RN](OD^LV+_CX2G_2KK+4AWX_'WVUDQ-_8
MREO;XEIN+U5\9D]^-$;%>P_; Q=E0AJ?W>: ,CR.>8$6[3P?[V6,,644+52[
MERD4Q>1E: ]\#?:>M/U1ZEQFAI 3(&BMGIG9Q*RM!UUDO8612Q(4G^L#S?2S
M*>KG/F( SZ'#=V],2::<.7V[J.+(6;]U7#+)!,R'2XRY@";>IV<W"WE*V612
MTE?C8K ]+VLDM?K=G IHP7LMK:;@A,_U*:/8[?<8OL_)N>?*[AUS4'JV: 7K
M-S((TH$M<W>^P(*1E+OT5M&=#_9%5KCK^A[ /%RY(]+,_FNI;2%%T?E7X84O
MMI:N/7H-].IVE[<:$(8/WOMQIQ1[""+:)56,9YBQT92!>\"S'H-TG!2#UX]>
MM1-K.2U2^\8E:^H 1!UO:O]G>?+,Y\L#?0GNL2=NHGX/*)<%F4B8B=O<SEHZ
M )FRWAI!?#EVG90.\\AI9PAG]4"X $,3!A$SK>,)Y@/B3,?7UK?%55&:[\M_
MXJ<-!K/N1;E'O?<90O#6.O^(?CUKS6NGI;.%2'/6[<V:VB#^3_;&\4GMIF1T
M2F4%H=KD0WZVSF-P"E,W,L#_=6M;BHC%NL*O&R>'6JN+1<YHUL*W>M$66 &&
MD->Q/'IV:7*I[;8(%\3^]ZV8+U7IRYXBA:\7UFAF54V_&M%2%':2D9#=5WKS
M5[W>'*_,[G+NA9?N@=6V'?I76MXW/"W_6OZ%(>)G[=-V!_SX $3&HFL_%)$Q
MQ[_? 1:I]W_<1JIWZ^B>P!R*4?N4%G:/TG%I<%GD-E-I^$O=K/$YE:>:?>=O
M,CZ:?.E[ Z/?QG[7$X$#5CC%[/(K?9WJZ;">3]-HB@ A:)(K[DFD!-NO,1R]
M9GDF;O&&EK^N]R*J/!0XD>'X\]#4(Y"'D("^S>B+6B"A9"40L'41'E-\UK,[
MG5A4X7PB6W+5;"LHN&UFY?3G2W_X?02F+8YM5CYU<,QP=YB+/P!]Q<&60L@!
MB*RO&D.RC%/5YM^9KJ@[2XR:X[D2.;XC1/>58!/LB;'""_W@A%[+"X.H=WR5
M. O,SEG3)5E"JY4CP6: _22G'F45GCTOMB8BTGS$8WS10"^_5<WT!,6_V"Y7
M"3YSYPIA"O%1W'I5/_?D*9[5FWY[NB,P\AM271[1>B9I1VA\JQ^?8:1/;X[;
MADWG@B%+,B*LPAA](*Y'UPW"V%V;H6(.&\MD4.!@0&>CQWGO#LDWEF2+!OOL
MADOH%&^N3"9.CTPMPB=_A/_O( AK9,&_K+S&ZJ@='U;=MB'B>S_12)IAO3:L
M.K3&L_\?"T\):*)8\D'U2^_X.&>C%"U8)B<:D?[5-6O:,QFV!-LH0^7JJ],K
M*U\FO/$OK &Y1#PX$4;FH&0](@4K0PDEG?*&-(&3M05]W^\:6P^CO8;$?//\
M_"2A_G(#"/^+F8+GE+]<>_A%K GM#N.&D=]!&BIZAZ8<*0>@]2BR2U:*+5.?
ML=L+.8DZ>0"*][OU[9D%D$'>2"[69&3DQ856Z_;BQ%O&VSMD3OS2OJP.SZ9>
MOKJQ;B0ZKL5RM\K<4_[$"6[6N#04A-#.0Y[D#<PZ.?SUXA\UQ_2!>_'E^>[+
M"[?G';6I4E_>TUQ$K;D?)SC=ZIWX6=&?6%8BW@VMKT<P;^Z% / #T&F_9>&>
M63!TI_FT[9?Z&DFLRJI@;I\2,O]%L42W9TZE3=<(\?Z]\Q1O<Y\!!Q3]S>)_
M<\6R?S>K_ =/?MEF2H"EP4]4XPZSIP68AL!R#<J2 >OI.&+#>G0 "G"U59=<
MQ8AYMJ&3(S,;HM\RS[:.\;+/Z&9?/=8QRUWA8NKC7R[_7.2_NAYF(9N$$8,>
MH6W,&--Z6^GN%,2Z/HR@K W *#!N0@U[  \)_8'^=[1=D"Y*0<>7CC0-Z/;,
MG4[JR0W_8&S*PX-,%!IKDK[\OLE3\\K;*U#\++H7.U-!X>J$3QON!+'RH!%O
MD?UL$=BZ811VF7VB8[AQ<@PE2YEJ#/.+.@XD5!=\STJH;O>IJNY+;!>&?LCS
MJ4'&3BQ\BC!RX?\CRYA86&1+D'9PQZGH/RHR0HJ7;G C *\#4-S19YL/()0N
MPZ?_N%T$L=OHJT05$J&0+>5(&+NH]_Y:K5.B$[>G$MSNN;**MCF&=[F_Z+=Q
MWIQ#8^G[#^R3#%'";!81!ZGL1IFZ7"R)V_L%?_E%_\&81ON68G+%]0H#[?O+
MF^:O\UK^Y*F4RN4C_IPU4AZ#+3V/^?NH=Y'#Z-OT%U@-8(8:M9\5AQ:J+J D
M]:7)8SIE+J1@F^"/(4);14H#</,6NY#*E6:V6&S?OW5)>:VXCGQ)%^^<\OQ;
MZ2*0T<RG^[8HPW$.,D#$V%^6WR(S"=2L.*9H*3 _8].PKYX$-2Y;R<V=G-29
MDYS@XT"&C^^>=,YVSD[=FZ:.=OK4;$IUS]? 'Y:B63'?X"):\/0#$-W:>MJ4
M:AH_XYQ&8)\!CC!PDN?#WO;4O)+[UD@20$;NKHLP[LP24W>G7?L['3PW5:<O
MB-N\?!(SFK;G#.2]F >^RO^+CR\UOMA-#;0+[%S@QZXQ;BF:5-0&#RB"'U8.
M6LF,",2&^YM/P$[WLY.+1>9?%O.(FXKW8(7SJ/3OL] @\0^N:UYP'N><R*!*
MR-H[P>?Z%-'SH\\*2T-+_5KV#D"/8.1R4H-, 7V7LIXQF+=O+OX>RD5>U_FO
MF94-\ZYZ*['21XCT:#\ >;4V U%RHA=%TU\$W'U*:4E_7_N1N+0^ 0$N+*ZU
M!,+^DM;3; /VW^>8!IDM0)CU"-//GVS]:$\Q4[LR3#P4?HPI\@WE5'7][K][
M\=,<H#SF_HY$\#AB>7)V3KOZ?96/H'FL67NC%R@;VM^%_P#K)LF@E  -!IJ0
M9Z322N_K@\@LH?F@NEXA]Z2QR=#+-.D 2W/P&E;")WCEI):/5DIC*VW\J.:/
MSV*YTW[(BN86,T<FK&I?!9>!G'53Y&=54--7K9H,ML^:IEPJUU8)N&"3H*2!
M.6F HE<KGHP9J5!IM:O4*BQ#EVWALE$1QN"K,,=/[I97F\Z/1;CYG%=\3&#=
M;_\Y^M'MB^I'G_!?KLX'H%.<SC=!/U1/@,B@*1@M3**1,*NDJ=J"@%,$GKWS
M=>"05X-ZG^KQQ371XM.C6\ OE;,3*$$OA;=G6Y$]*\O]P1/\9E*[L6(>*:3-
M<+; #V-\-WH:0F<5QZA#QI#_QFUS<=5AES9[&V:SLB -4SX+*EK66?C?XY]
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M,?12]S#I8A1\$8, KOO,M[%Y](%S(?:9F&EO"8>$! Q!JN(@S-9M5&#B7%V
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M0TRG%NVR3(P$+@Z8RQS 3:#_!XZD_ZU@\Q@"6I7?!/&WLC]JG+M?04]6WA:
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MR4HH_^-37=.?5,:!?8A ]-\'"GF.<,".&%_F\'#DKQHRU95^<IYQ&>!>.V*
M=2NK1G=+PD-J(ZTF=N(<V#RZ@(V5:ICE>'C0=@@#>O2>=7&5CW;B<(XAZON#
ME&7WV-1K0L?1:I=J'/,>OEBUN5&_+C!78:.U>L:U+M"A1%K[K(&EM3K]LYZ1
M4:CJ9YW[R#?N767VVJ&Y#2+1MX;2'*4LW@X45B>_:4Y[$&Q3?J$Y9S2<&GGV
MS#[D^!]U9OQ.AC=\^H^7YG?TR]DP, *G ;0E!N\,IW493^2IRT[/^D\57FWI
MR1]KGMTZ=G$LJM#Z9-J9Q-]2F<:C[B1>9)/F(^Z\%'9C+7QQ@H.[^?FMDZD<
M5.8!<E.#@@_7A"ANU,P2#/VSQ=.IX.3Q=^;?WY^Y[JX'"77 @-I8RL5!YEW%
M'FDA4[2/GY[*@U!L9A'WBHR&K70AV[!D$9?B8E;DT#M\.CSLA59]B\.7P/XW
M:(^*]/2@M6I7I1"H?&%@_JFFY8 'MNPG8;:$N!U#,H^LR,37@*C"A@4I7_%K
M:X\\H(]P/.":D7HF:97D:.$WE)VA["OX-6!RJ;(D\W/CG_HRR9W5V_>QF0C@
MVG]WVO^B*_)PVR/]BG?/29'4'/YF49K1]IR'!VH(>TS.1?5EYK4<6Y6,I[.]
M0LW9YB.#DH9Y#G_*8AEPIA<(!>38W,\HZLEP?J. :J8&JX$*7RR2E6:5,V4J
MHKP16%?0D6'*/#S!/!N]N)4I*P>LN=1R<&:'*(G4;!EGRR+-QW'4NZ/#-P!T
MPE:$3II9;ML8&@)?G(<1TNF^X!8P2\\$.3SN\#$P3*P/G>C=W]M[L(_8L#?5
M86";V:$91U+U:9$YBS*8MGHX5+HFS'I<NZ% ^&D&W]+)#9G(9Q7^76?+Y]D4
M1SHQ5)*?2IP. 2._+!4A3CYI8VI]",X0?U3ZR^"W-HN7A.9?-I+IU;_G6/@Y
M[]H]88U7654JJ@$V6#4QG7[?\XD&C8_O%,O-CA19/.BR! ,#!LH,V]AZ+'UF
M\.)PJ>TH;P;3;%$RNE3/(:716';HW,CPN6-#84<GAMXZ\S_U#G3J=NBCR!VG
M':O:R.[[.MXS6QB^9OF=6<LJ9_.P"<06:#J<4\^;"[JQR?L0KI51+75IIB[
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M\+U1)U<ULBPBLK&P(+),]N)AJR0][C>(GB[A]^$N@3&S*U\=N+>^A)!$N;=
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MERG^_DKKG08K2R,L9?8XKPZYFS^)%ZE[.(5'1+-\?/P+<$=X)2W[7YU1R?@
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M.KZQRBEW:R-UG*+U_C'1<_&&FE-7[OWD\]-ZM8T/Y2[!@A]+(* X9.XI2FJ
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M=A1-@B,H8(/2.Y397.#M<LQ?2I3QB[BQ2Z%+3?M*>NI  \8KAC4DRJRK=*9
MDFPP"H_8A*=QO67341U#?MVHIXQE@ W6 SSKC1>&6@S%%7UD/Q^8M0<]^+R>
MN4JK$XTO^N9"=BIGR+S&XMZ_(RB?33467U0KP)Y_:7ZC(+F45> _.9S@G7]$
MG?OFZ5[_-*?C47K'=L<T<.*I1*&L7?$P]1>K'3^S7&+VUE6>*Z#XSKMJ+%PQ
M3L3P\5&DYA4!25_$U7(6<:Z%@*R/#WD1%XZPII9A9$]5N2SBOKSD=#&1+0EM
MY#3*BD5<#&%$T$I9Q=M )R%'I2.<85"C,R,O8NG0=T'A&6XK945,PRB6\5*_
M//%QMGS[+&'U>)/_[3W-3\9#+;L=.Z=#O8[T[YQ5XSUK7[RX-?)=31Z>R]C-
M$#<-3<VI]FNZ+5<A[,=(",.89JLT'P+.DU.;JC+./G/.J_\"485F,QF+N BR
M3O3EDY/S)Y"TV<M#FM44Y #=M22B<072Y],[IQ-O?O/,A7OKGQFTR7?(/EAO
M/UE@^XOOT6:;N.*6XX5.QE$GGN5GW_O^5NPTI>PU%8F;00TZ-3?9*APH-]>\
MX:.?(C A.HY=#SO^N!GX7$NSB3\UN8A[\S?OIW^WF]%3/R!M0TW567%\,[H+
MA+_.CY[)!>I%N>#9&;&S["]+"[BA5$K),"743C/;R1L8W5<Q7'Y8T.Z_,,IB
M1P%XS893(?3=@W,S:Z,78AHJ86+K[J@&WI:Z6]&1R,QUS&;E4ML7<:93O,WT
M[Y"B2#;C3Q=GU'!$F:5^[';1D+ZIEV<F>!P-K 2B<ZFRD)F<O[HW(=?AH0[_
M_(^:9=!HZ:/[6T5R)?\1K2K><FLCU)A1'^(_(KAJLHH]S(+&)8AU@=J*K,1A
M$NVLO@_^\VYIX]?[6,($@KV.B[@?\.@A<'AH$7?_->-'QB  !1#%+)GGC2JZ
MAQ3_ME-9"#GEY:C6H;[(7ZR5)#<:14G)M@\[2;Y!J16EN^G .:=@YQ0PLK/Y
M@*QK303/#AY*=PN$V(>0W\O0<]#?E9R/+NQ<AF[P>&%&FM,_X'$G -G&%A!7
M1?+KCB*M$%N1T$I<S_B35<M*!B)G,@$]MX2S$"L8+JZ$OHBZ8!MR#S9(W&ET
M&_(2MFVU=(3/,[8CP7+""DID$.4&KY600^7N8P='S5\6?ZB$<.!_D[&G384S
MR [/:R33:&"]H_J0\D?U<S>O$LWKJX1D.D5U AEJXV.7CRPC#D^V6NY!XF74
M[.URCNF[:/[Z6;UP46E;L3&L7QZO8*U$E_>0=M')4!/-5AB4.W/]^/5R.C!(
MIP[00[&IOD5W0 +DS*P%1CY$5<QTD#. VD^W9?:7E,4(#.5\AW@^I6]7WW-D
MFD28\/8Z,]P;8$X'\!7Z/7Q/8XR< 1^C_G!#+F0N8W;8@P++KP;J<E3J;5'B
MAOLE[ZY%+N+^X]EY_L>I<)IO*7M?J:ZLG[LM=+Z<T "]%X<$_U;3>BGZDMEK
MZL453XX=7=/C<G1C]K&FW36WM)W0/\#6 ;-S156,=DK-Y8S*\4&7CJQRAB34
M,.7[GCDOKZ1#7OT/ZM6WP/,QQ\46A\C->=%>OU7.V>I:'-3^M.GF)EY-7?,-
M^W;N;IN[]\]=^/WG\R/[RH_%CY_==PYP>'KDWB]1_NQK;0/MQW^Q)EYV>&IV
M?-?/\]\74KU8%V4%*W[D>L,V@AD]:.\4*2 7ULK;2T[^YLJ=G?>/O3W=;-I^
M5[E\DT!1[1A1'U1%T DFK/&(BBM\ZA+W87WB:T+5?Q?[X*]#Z'9J"FOV*&_#
M(DZF):-J_ *4"@RIRL<+8S-4QHQ!%\LL]JF/"UOS54FT&CVB9^^T_:R:Z)T\
MJ3RJSHMW_35.3>K=&V,G?]'/F:G7432F.Q8N*#]]VC]D:OCM(J[P@E;.,)4P
MMO=>D5:^XN>%%^=K&L)WO"V<W='WRS;Y\U,!1X_<.NG[2W7UK?R>(P9D_TIU
MRVR3^O[IR-DCT,@6V"H3/2)C$%O#Z=0[D(==XY8_:D_K[T@G[OZ-ED]*=RD[
M3[^_X<RXCZSBB&6<O*7BF3SB]\3J^_R0_ZSPI?]308 7<3J:48)Q&#9'#^@^
M:J9F,PV4I=]5D;RBV31;:4)>W6_<0X]1SY?(3!E='P%5^Q'FJV+GY@&Z5Y(L
MB3&$*9D>2E;P#6@&1#U:HD!<G!\&);9W5EI$4NUCI_=RAIG_7FV3?75L>AZV
MD9-340>MJ=<J5W0'-#:-A[X",S26 U9(F8)SW1##R+JJ#.=L[@$,,3,#BO7@
MN$6<H1T0?A%VD%G_G18.8<$-+L=X9^!QK?V'5T6GJ4/,+X\6 O[+>F>BYF'U
MZW&!I&:FM:<2-4<(\'+Y3#O'F/%:/#9-E%8Z!M$=F:VD]9!IAEL 5-[6U%$&
M.R(<!:LMR=^_K@5IE#U)SY':'Q(&M0A:^I6=3BTW'E-BD!$5[9VF2Z)?-Y--
M60>&\<430VU!GM=+D7RX=Q%WK(\?;G]R1/D3%!R5T& :Q&^W""6*#P+ZM 7%
MD>I>IRY#6L%^=4$\7VPEY!E!';<M*^4AYD<IZY#=!(-KGO]3)!/^4]P/6<!%
MFM77H2'I$%.SA^:B4":IG])!&6NX9$S6+ZGS[*#@$%=9"FJ%')(!63PSB)T3
M!UA,B(=R>=_0;(0\IQ['2MUV@XE0(C;G;10=^F$D7V;A(&CB-5<A!ET",3.E
M'C2.6_KWUWG@!F# C^T2,Y7!V(C.43))&Y 0R%? UW&BKJ9'%)U$-BY8="**
MX_#<NX6"+$4O$"$Q1#ZK/)!KH^MKBV3?NQ#:=/7"/>O[T(-\XRG4^F+\ ^ON
M5<S_1MI]P5;_JIV8)Y$64*"3P<U'_ZYOJE=?YY_WRHDNNA*JFY.8"80S,VL$
M;H:'.[<X'-I<<=/+W+9CHNK&^J\V_0] < W_7] #U[R-4-,XU:K:";;Z@.>\
MR,-%R@N(KLI%C&#F:*G)5=IIVJ<1:<#2XUQ\[6DT^J(,+R9H=!)-4]GP>1(.
MFLE0P%M&39GMC.U,0<VD[=6%S;0"BO>NRH+ ?H^N1K#U*#^")28KJ0@1FJ>H
M\]W602*Y<X<D$[ D$;!TDB0S[#B95E!7UD/8\K[\_H]?!,JKK S,H10Q\4B1
MT$IP,<)R([RS]-+3CT&KRIYY/(L.TJ\^$V-?B@O^'TZ*^1\F(+IURU*_1=0Q
MABIC"6UUH^\'*!.0FZJ-H2BMU_&^85L0KUFU/PHPG\%(CI@&XMRL5*1(AEE?
M_#R6!+(SH^A^).4B5.L/N8^R+/XN@(^_MXNG&G\L)!64_\G_2=/%K[]3!(M$
M! .2 :U4RNG@#S<K*&WO35M#OX$);<2\!LGJ6*['%6A,[LC;\AP"A$P]6J,4
M:&?F =KH45E2 @4BY]%W63^^#6\%36F)(1"#K97C1GP0.$':T#)TS4WT7\I%
M=CUK)$RYT,O8J!'SZZMN U-WY8NXX7FE_=(^  1M6JGR,J!%LJ<Y*Z@W>-J,
MUXWS!K1.(8F@+JL"(BG&=* >*>89-/2['7WXT:Q@ZG>M-)1<$7D".3@9#,7S
MFC$-9J3-APL)(_PV+,NY8= (N5^SG-%36-"&SR)]@[A#GR3*XN>01!#B+&6F
M<Z_ ?ROV5R,4V?LH0;O$F+L+[@RL&ZIGKJ?9"!HM]R)7H& 1H.=(-D*J1MH6
M)+F8BJZE)8A<J&FXW?]E@?A"'68K$:0'#M>8[U#("5,A\!?!!<8;"8%[ &+)
M!N_*$L%KH9N'-%9N9@&"B[*9#,J/$'/Z$*QGK[%Y74[KC])LAB79P3+.U)R,
MM2)*O.<EQD669BD"GGMS-Z-6?9<?>=]06="MV?SN$#0B!UM9YNC72-%3=#/R
M%"I0& 'X !%O)5S%DG%6(^+>H1,\A SCY7Q!4K3W$&JH8&HCC0<&W3;!6L+"
M^-&;G* M\R:%]YP7XA^LD*P PIC#>.79@?C7"<I8]6W^.>RR?0F&22SJ(Z0@
M$-D$N<J8;;D!0A>_^[]SZ_J<7A]ZQ3#MWCD70QJ<*BI/M/VGRO[!RZVTTL#C
M$PND_^4[U/\_>"W_,J99G06QY8T=E+=CPE \LAV:]T<XL*$7,J[:0/?IXUE&
MF,U?=W/@T$H/(!:J"$:7Q R-#WLX"1C20Z3$9<&3/C1=V7P6Q_&)F[>"H/\V
MREDYN!#1__ E]YKSAS%EP#0FC]^VJ#D@] EL=0(7?C#R"4W'.[3_$+;WS#NC
M<.OMEUJ]OJ\LI7KKGSZBG[?5Y[;?5GGAZ9J&W/<:ST$"Y$U-9=4E8!XRDBE6
M*,@=,\.U<N*40L;,!+]:Q(4QTT97]#%LD"'E%3@\D^[#H5MB!#1=*>^RD 2-
M,+I8YCSG\:NA.8_'%W$;N<NIT4#F7!+FW4_R7O:75O>=:^P[UT0M6\3%4MXZ
M'%77Q8/#BJ "^5=TEV9D%[P]GF 6"[DS<TN19DA76%!LV<_XAO%&?(T[%&<H
MRS65MX]=1U>(.3GV18$O>RM1A[]:'XRV(,5_EKRT'2S>7'ELP"Q^AU>AMZWM
ML+VI=^YX7^Z.BVS=SZT_=WSZ-'H^1S8_M>XQ8JK\!VE1Q?"%ZD.!O:3-R,F_
M1]KXR\L@[IX@O("9Q;"'NEJ[5M #$?89><2<ZGI%E&0MUT)%0K?UA#TGF?3&
MNI$&0W<UNXS68JI3-L!C?3%-!J2YH^MZZ3H<=#<\T_&:W!&Z!DZ8.JHZPF@O
MMLXXC"2%R>QC0ZR4:>H'=%_XCQFY?LZ3B6);N*'H<;3E6J90)+@:FO7DH\MT
MWD.0'8S<^O39]LH6J'M;1<Y6) M3%<'2YA^1FGT\=2D8PU]-$W4LS$^EP+;*
MHQ"C%.I3^M0CP5*FMA@9:F=IH0EEZ*D!MTWE* VY*Z>8T/ZBE<I..@LMMC.L
M:(FO>+8].^/T'%Z13!'WQ!*$>0H>=)Y.4]G0PQ&9Z@382K1'_3@3EM8#L\1U
M](,OU#6:371K!)#CE]&UD>N0I\R_%)I4S*2[Z<I;'(3%.Y%6XK4BH:1N2$"^
MMHB#TA'7DPB[ LD1DBR9\K\NN[R>3\]O%Q_^8+0,0Z;JH6E;U7Y-#PORI:P<
MYZ]G20NF1E3'HL!5&C.Z3P]Z1N7BK2B79!-TG0C#^;*Q%,;F*'YM>/MVMRN0
MO/,5PX7?&TL_ TF$EKM@_Q35881PL+\RSK;21M:0(J?HT[+0X&JX0*,]# DZ
M0 M,YHM>C:[X][XLA?CL6XC6"?AQKNH"V+HOCC#BV^YBPL;8[%6H*1+,'L;D
MLH PO1PR%Y*^@D*66FH:RECU-"OA'O[:V4Z\:6L%C7WP16^ ,*B*N<L#Q^@5
M![6&1<><C5[94EE?QMW3,#CX+^OZ2JX)7'&B-2:&\&EZ6I9KLO<'YE_93J>&
M/OA0TBC0!>>IFRHOS5N@9FSJBPP_'"TS*87+.["2!4;/Z*.^,)#JR-R [H1(
M;*WK/V <&DG-<"Y\__@IG"!BZ7.WTP9#MR$W9;:1=;^AAYTB8SAL;FUU4W+'
M=,FV*KLNHN#<<.R9VV%&'U+_A$YQ^<9FE^(FW/;L3OO.*5ZG_(5W[U/K#66T
M9J?JN8WKVO_IRG@7V;8Q49 OZ)5;:LMOI.1\WO%KT[KV,Y%C;DY%9QPJJFCW
M[.Z%90D$%LD/=_1;;^NH=]H14[:UZT.B9J-L$;<2JXF/KM*_PXCY^M*#(0OV
MT0L/%W$I#/ GIIBB)*D+@ BJ-J.?KUU/2.8Y([DJ"BU'SDK' A/IDB7D.>U#
M=8&I294CNM3<8HZ<&NJ&Y,B\]K3 G@+09.30XZ-RJW*/F+"5'S[D5I@.YF[W
MH)-U:)0VKO'=@-<_N^R=H'&/K'I,.7GJWD^PT:A9)7W/YLB#/MF^RA?'[(_/
M>]T-ZNU; ,=U9R?A^7'7UBOARVA/?[W (V;4Y&UKO<C0+SXJ.'6^R'3CV+)?
MQ@)W6I9]YV<V8.VK_WR?)FQ#]T6?VT=[GXCC2I@/^9&+.&2KJZ;'+&':\U()
MRA@DK4,/(^-PCC2@@Y_&-^(Z0"KO03<_E1NM63HFP.NAA/Y/Z#YUN?RG.MA]
MC.FV+%Q!74,9Y3+,S&+38"W_WM&A@.S1HT[X'WKX/^#3F^PQ_30O>1OM;.;9
M1F#R:SQ;@;>?NV2-&7%EO1R2!=T5V2?CYY+PR9.'X;.C[/+'90E/D4ORA>'(
M[A D=CAN.[I+;^#U&YY30/JK$OXA( _/I'MCHO%$_8!A3Z,*7:@BU@C8-OK-
MTBJ'+/22RI3NWH0DJ;8%TQVAKE3'F;6T?*DDIXZ0<U5Y_1F:B.1P:%TB<(2E
M/<V7A46NHXVT:5;!L0472P)IRP44K9UUS+43).<Q?@P9L6+E8EI>Q%D;S3)C
MN#)>,ZSA!"8_7,]*&I#MYJ$ WQX'LMDRTZPX^T/RK8](]@RA/V4=QBMTS1_%
M6^ ZGG.OO<96=X1_X^HB[H8]NEPZDHOO(*T>K',W/]5[;-OR*3(F?\\)J!WX
M%=BZ'S5<Q.F&J<PUYN4"AA$TKV2A7[/$ %0.RM8C!!F80CFO,D6W^@-0D;I9
MLXZ#'"5U*?G:2473_+>:)-$PO]YFCJS#>"U92]=3_8CZJ$NY[G!X&Q/J5 1@
MW)BJT44R(# ((3^5(+^[!4+GB);#"+E]5 <1G(&#/7OI[B64<8W+'8(A#: @
M!Q2NS:K[.T8GOX4O)Q<8COAXX+RPM-!" A6</-9SSVF,$F6,;-X6Y"Z<HSRH
M+F.8T%VAR8FKQ[,+%W%YO*_1#3 [E6M=TE#-H406FMQJ>LPO'U?:/YT,NL-Z
M]%;G]6!I4F2XT="Z?V;0/9[3QEA9OZ_F8Q*K #&;L7#V%Y_]&_'7G A,K-+R
MJ6 R:$ZGJ,SH#/5=W@;4<JF7')!6*,KDN=!&E(<&)<)B%V0&+E+B86IR'67U
M1XQ/$Z:/J@Y&5SV/(-1V";VF$WWAK46RRJU"48E8+(DR+60/3VL:U0\T6.%O
M4^9+P[ O 8LX;0ZZG2HFR(9$%> 9,!9LP\Y:>V5C9@P67D9=R@ZF.E==J6[A
MJQ+,.&])G8TJR_FN]SJ88D:@/IBL?H-0.BAUE&E#>.85B^#$23<!UL\2=)$1
MV9@@AYI>; $#&;R5C*%B8V08P]?/FEY+\P*?H?.5]$,/:)URSU>2C&)KY#9$
M\>FIL',+EMLR,QE;&N&.C KTT,"G2LTG-6N)4K-X.AA6$93IZH<\(N*L((K(
MF99:D$U;=.(B+HVE[<2Z3EA--X?*96]J%42CCX6$=(T%PE:8BA9QQHU9<WP3
M^@'X2+6":C()&->?<GKQ-51<\(B6(/#G;?QEHMUHV>>5\ZAAL&*POF1I9Z6O
MYBCBF5>%X-1U53 :@PS OO*N:]P-JMVT%(&D[A[/ !E_NN>A@IE::#IM4:[I
M"[5%DA[1P-#:]S+[1.&=?S^I@EKGTYQ]AZ:YQ*<TU_:"0N<;7/=6] PV9[L_
M2HR!R"\P3+*BKVOHG<)\(7.X0)D*Y<[D C^%:,G)T_N@&OQPLR_B?NFL"J!O
M5#^98^6XT"6Z_'-,PR#4EL\EIVL,$9^PBH^6]DB*PH)&ZSO54U^9T'95YH&[
MRFDG(UM%0F:FQEQ=S=OHH?*D;>Z2V4R[J_;3EKP%5U<.#(_YPQ0E(1?==P5*
M'NO@ZVKVOFN%YP4,@KJ$?XZ<K:3H>*:C5"C>;1/$"AIPLY%CR@*>1/*?!7(#
ME2!BPYFR9FM:-0;(!UF+ZVG$.Y$@PN<9T"^\A$2OF,-C^]6_DO3I[OU$DB%J
MBT0^H7G*NMHH^DBGR+^0F!XT(ZO@6=7>4@F#'O-FY#H/8)-:>4SLJ*K=91B+
MK>2>_X\M8Q>'_P]02P,$%     @ <41^7-UPO2:8$P( D%D" !$   !I;6<X
M,30P,C Q.5\Y+FIP9ZRY!UQ33]<N.@F]"PH(B*B (%6EJD!L@(" ((+28J,+
M46J0$!3I5:D*"M*D!I0J+9$N(%(%"4)(* I2$M$0)82[?=__^;[S._>[YYQ[
M[MWP9$^FK%FS9LVSUL#.YYU9L,O4R,0(P& P@(9^P Z9-] 0[>$*@+DY4 (
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MP-4: )\+  1X 1 R , C00#BQ@!(#@7@L2*$40">8 %(.0) J@@ :<4 9*@
M\.P; "^> / R!X""7 "*-0$H\P2@/ F "F@MN X *B$953H0: "\AFSPQAN
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MIQP =S:!\!/ D;D ?MT4 J3#C9<0/9A!H /XK3P OWT1PB: N^0#N*LY! :
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M0^V)T'@%J!VR,QMD3_9S$*!XP5X$M4/UG%" 88/B&YP$(0T"Q,5P*.[ [2%
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MMRRV5/KG[2\NR*8.*![R_E#H;:=R[#V\64F>Q^A+W\2GX$I*0JJW0CW+*>Q
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MR++43.L1M3KTROP6OXX(LON\@ %)U>5(!K<%A?->' TUZ3:GT&7)D%]ONV;
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M&.<QXHT_:4JCS(?9[>YC"[SD<9_*?U=+5QL>X$\,%^3FRJ+A9,A<\3>W7^X
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MC35_>&QZ'-RZ%Z;NJ526^]R'C4LZJ-M;J)OP6F>U%\>\225U(,4QUHQ[<SN
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M9<1N&3%#J6:,CO9ZO!"CU8MZRV;\YLA<4]R:E+1GC\.HCVK6B4-!EZ7ZV>\
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M,<#,1 !-AW:BY ?9'K/8?8"-$R.4,+&A+N_CTO#^TUC9]^0YEQ[UBNNLDI2
M%*V^\NYK ^A4- P="Q%"6E;[XHX#!?2M2V.&.F6:V,I;_N[':^L_#=U[D>W(
MLXBRT,$3!:",SW9NIA$2Z9;;'%G\)_C$>#87Y![8QQ@>V5!3CQ]#^Q'B<$<
M SA#[ 802XY4C-_*4*8C\F;=ZI/-"O7/F;DV! FJ*^P2BB'B=N_PM#+YC8(1
M+UF3FR$UI'8N*!Y]2+?5F(SILA&R>K?H2 QHP)2[P*[O_6U>W+(V<P/_,5G!
M_K4U*20OY7:%:?2,]4QZCMUX0\8=^/<!_+6>_%$W#0/VM1V]HH^0%'R]68?(
MY,"L33Q5JA.]"Q .<&ZX59;0<MFOM'[I0>>5"+$(YNWQRU1"XHP<7>21)MNY
M&H@W'D1JE$U%-2PYX_%)4S8-,3+K[N%W9'NBA:F?0\:*EG+S7S6M;>J?PFJ-
M<$$!Z3$73G!!L32XD292J[:)T:+U'0B3:;GI<22/;;=7J]?WS>WOZOQV50KD
M\(.A$K\^_W X5X_/^UTUWE?^*8<$R9HX5:TS:T.3HV\Q [Y5;=HD%!K2?1X]
MZ'N+3  ;FE5-^=VW.JGSP3W<Q/OSP*[^$-(A+N@>-HZS;^=Y?7JR%F+]\SA*
M8'C9?9%T6W8'R[2:FCUDVNC*+O)\6G1**,?GAO8UB6R+C"<G;&GR7% UQ_1I
MF:K59;A&NGT17NK/JW0TW1E^!&D#B,P2B+!9 LV$3K01!M VHYHB;4(ZEH-U
M.U?ZOGBZ.J7-F^>L/ZBN.F)K^?':4-F ^0'(93PY1Y%NQ\M#Z+;K:"^:2H]L
M8!G% '*X7SS7A12[L1,LQR(=++YMG?,K[%UX-^&(:\W/Q[B[^]1?#V8Z+6?!
M&O5HJ *]6C_??!MC$3_)#2)-A90SOKY8]0 []'/;/VF=%(>O;VS'I'#T1]@Z
MY#^?+(H@G:E6$B_TY-5-&1(%FYLQJFKMM^YF%&H?>'_L4=N>L+=(7O%&@@$?
MZK1E!T<9R""#19:(1IG$34[^6T3TT-!*C_7->JQ7DCE?3Z#(/L==NV;U,)9L
MCBN)[IT3/K?42-CVB32YBSP/Y%+P*48'WC-4GB O%R'*.IK>R9RN=SN^K;ZD
MWK7GK>]\XHLC^_9XF?\X]*?E>INMD3KJ.T:4"X+)\Y,7EJN*?Z) WS1U)<="
MP8DSRL-68R\U#SOLZU6&13XO#B@U<GH\8Z/%I!W2L?^R:"$9'LX6"^0D0H#@
MHF=%"Z&>6*"DBN2(IZ1_VU9?7^#L5^55-76@F!7HBY'"*2+O#6_8,HS)9@GQ
M\:%1KF8I)CZ5R&$S_%^_]T1;1@3?4'OO>4PL QJ(M >6R.F/PYIN<\XR<F.1
M\L*?D'G>^2<_5;C^6BIWPUFXMGN''K:8.&?2=^3( 6*ID6-F^+SYFZ:WRJ.M
M@2G%!NLG\X("=+>L-<K0EO(.$CT BQE'YV]/ET6$=Z!4&3TQ;'TJ6.I+P(8\
MV&$LH'(U]!.?VK/Z.#.G@I@+!TVEYYZ%2VA6,$B?MT6Z"O0_Z\]HTTLQ:?45
MCKAA]GFC*KA"551@<Z.51,6YG&O=/7UJ3\_J&\KVPQI=.7([TY8/X4.$'QM0
MM'%%4<L6E9\60"^CZ'=J&+0;J0'Y]*T.(_6Q \E"4@X\)RA\_? 6!5FNG.&)
MS 01R\Y7+]F-5CT(T(9-]55$6AH@OM80=*//%5W2=GY.!\D3Q*'3\[](P_=9
MMUO17S^8W$?O1?M#XR!U+YV&>+N>2H8HFKW!YR)FCHS3]&S]OR-KI)6CXC/:
M>EP +%-LIPFGBO3@U8XYSBB)O\6*BJ6)Q'%!!S>6!-.%_52L:N-9>G.6'L?6
M9Q.]LTZ:<4&N2KL*M1Z;Z/4[V"[.JD:XJ*VNXIZ,Y959C4:JFAJ%9]6P"A=^
MQDITLM5W2HV.L$-C7'+;%"!TFY1B^H_Y*<<HD=OU(U*6SWRT!NZ$K3T/@*B3
MZ5'J8$HZK8 >.>N3AC4$DPG)BD)(-VJ  :)Y2!<J-@DEN2P'8''[2_VD8+N%
M+[61O]6'N6'79CBQ^E[AO]:7'SJ(_[>J]"L]GPB3B-4>,-&#1SEVXWVJ8%13
M+!5^\!;@<WV8N"9OS7*(GK+Y=%?K@&#<'06OI^\T1;X.@'J/.BU V7)3K%"V
M%\]@6?X/<SM7$S!UN8]"3VF:K"E&Y^G';_P-UY7.N34;]WM%HG^[JZ#-\<;B
MS%W,F9>[[.\NVF?KM3B0<KUF5J;KIB?]U3)OE,FF^QF (49C[DW+U1L0A_*B
MI(S8_Q9)=)JUZ<0#IT1H5;R0TMK!<738QW:>L?WH&')W/%W?0=9M>CSI6%K
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M^PW%:LV(#N_6^'Y!(G?E3&C;>0FP%1=448'M@%I9UK;BH*GXL[D5%_V3YJE
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MBTIVJQFJCXSL2Y6</6V87SX;YJO\Y=S4T9MKC4=D_Z9#:'!Z&36\,Y\+V@?
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M]B53T!)(:YB56+?1T<$Z0$-/P[&_7JY./30X0?F9Z)[S8<JG*U\]N@:I07_
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M.INB-I2Z>"7GZ8VWTIH#2 *=Q[Q>?P.@G /GHWQX%.A/IYE%MOS.FS=-\<:
M#Z/9.O\S6A2N_%LC8,4C10Z6^))=D6T94GBF(5AA_A,44%9H]J""8T@-*C06
MX^RJ^U  Z@3A74\)]!<#RWR32YG:$WK3_XCX.NK:K-OGZB43E6C81CKG@"IO
MJC4Z/UM\E>G?"K@R9.HKW"07F:0;<2RS/.E000'*O<JG+1\LDBQR3;\<*4DY
M-V!*ZE"<R**0VDD3XU: 8 !OC_R09X?9ADB=$[$L 5G.8+&JRLLOXCJ]GUZ\
MN,+^>HTO);A;^Y;_,\Y0RFN14_WK%IS,%J<MS\%1.]OLAR%HP:!G[&F#[K.;
MMZNXH(>"(YP0O#_TT> 2AGZERHFJ\IB7)?@ 2TI=WM=P)B_9A%+EHF#4\,3#
M;C>./C>'>1WH5H[8+3UC572NE-*GG+K9PY; N(P8\FC,GDV>"3W]9>M_Y,65
M1E'A!P@A(<=.+&14:O1Z*V>:JRAG!L.6(L' 63[R0;2 WBH(BIB:7:DG6QD/
M!$AU/(Q/<P]0:AOZ>Z [RFCXBVCBY9#XC^8#EU1.FQLU,R(Y^VOIA-GP92Z(
M+D49^$1-3QCR4ZS%O?8J!X)7U)=.M+9&7K6/!4L3GV7L?A<S5^(Y6PW#%?B:
M_&JL+]:;DT::;^"(REF_/O2XO"RIK]\IN#5][SNS?K.>U<#"N!,N3%U:NS9E
MIW>ZYYNP%=K@/0+:@6\4:5><DJ/ZM!$F%SJX(+$6"#J\R@VF*(G3!Z*'EAP_
M%*J;9<P.!FA4(J<\HS6JA+WX%Y[HI,8Z;2L]<#Z4_<CK3K1($'3W!+KMHV(M
M)YG!WY5+]*YG))O2(6F:"NNW@: WB"%J3]OVLY5@=]=KT;U'EP_-:3U>>T($
M*7A96 ?"6H[<7)ZR<6^H^3G6T/SAIVV5]*G&H:"P-:?6)JA#D__X$!.B68_F
M]T.+0LA?HR"=1D>'-JI"W.FH1F4%Q1'LO:'(:6%50^,CP2=:!F2HPB\<U[Y$
M?[3;+[&L2'>%3T(HT XPH*]"$4DPU*</_VFYN_E+)$Z39#>,O.CGAUAWF^QB
MOCWXH?M(RXP]RL-'.\*OV< 4<JD."AS%MKM)<02RJU!?U*FD)"E%H=!4>W\\
M+/_&^PNM68+/JUO*2R7O@L']R><0+W#AOYL\QO"^)."D3P>$6,$4^[!3R/9L
MVER(?M"JW6-=VQRW^=>H1E[O(8T520<;\(#;HY?=MHE'7_-+_!RK?+EH'PV\
M&RQH+E>>Q^3[3Q<NSW9TM9=J!A3+#D:U_H[$#JKCE=:&.8(42AN]D3J^;$,W
MH!#:H_B<@3O45)> P 5*0VJ(#\5-L?OA,SAL;LKJ;-N>R)1*\_O&,N9'&_9#
M?/!\2-O_DX2/ &"L+Q=4:]8!F10F=,I>W]9/:I$J9CO26T<*5=][/2_]\="A
MKF'M4^)PD.]?3S$JD/;)'6&&(ON0#D6_DS#)9PQ<9/!W*HKC5%P 5]LH)V,&
M-)%]?<M(;3#0>K=>ZX:?0E?JE7<GVQ^I19?QR:(_0-F'5BGX90]&'!=$-484
M4W.[\(F-#=#)( !/M4F4<Q]=OH=?&!,X:YK1\[)0+/RK*:U,_/VZ_>*Z?J1%
M,#[TU*19\3 E/""X9+8ZSD'UBWV$0;O61E#V]^R5>B [,_=LZM3-]2V.P&O6
M<:3!3CF/+>(@C2;CG?#]0'B/HX+46 "QPV)\XV>]AI'J0N:E0&1B=O%Z]EVU
M:J?@Q".[M4-8K@>UB)<^="<?"2IW,)%VX'L$6MZ+_,TZ@V[390NR3G)&N2 9
M(RU$N",C8#41=\[M<GCUE+^3X]HMHJ')EV3[M#T9N];EC#PS%?B/X^*J'Z)6
M)&.%WS^YN6D)O5E459I4Y1R@>K95'C=+AA*G'( _-.7;SG..,D*N'5*GF,S6
M\:!W;R^2NN"4_$E=S\,]!\N_^6M-7RI:[ B;-[B62M14_@T#<X2>[M2&0J;$
M>.JDK/HMI56D8PVI/SI/1XH430C*0^RB][_./#^;B'*X6WN'R2X=?;ZK>1>^
M(9PMQ\?21$U!Z_0(G?W!/=V%$N/UL(ZHJBG QR%IJ,?M>?;I]9[3VL^\B>'2
MLL>[)A-/AXO40[S1D_F?N: /JVU6(A12!T:$B/!I-Y)_TN7CM<N[V]PG/.Q$
M2<9$CL]=YT3E+*?8S%BUPN&(\E^#%@8#.WE-M@T$IP<Q8JL6:G(F#1AW1YQ<
M0.1DX[0?K':]D2/XC<[I@30J+J>R;D7 8*4 I M,QDN1O++O#JT./HJP2%E.
MM1H^R/CTN:T?A>#TH>O2WK+4.#,/I=CB?%W$NAX*EL9/795#H-!Z6LS(_4H#
MF)B7!4.71%5!CP,>"<.VUIF,G02D%,_*XCNY;!-Z;D]_A3&%<.BY@F6!IB\%
M5Y<ID^G[(_9'VE7'@S&K2KL%I.=;(+-0MF@6N:P'#JCH/^:"O"_:K7<WN.\!
MHH+VSF253[A/F54*S*Z'6ZSI-5_I5\%HLJ_L(GUVUXK5?'@_5Z7SY3/D:[N9
MX?F\0*/@R UB<:R3-,$[5Q]X5;I,XX(>JS?3]M2;S0N_\&+P,YUY#/6VD18R
ML*YI1!>3@*_#)-DDAE9=F=H*%[WE+YODRJ[<Y^"9\/?E/:*::?O/8?5VBHSX
MD%?HC<M\=.@M.GS9@XYG!HT;@L^F5B#@LX8\"<=6+7.'Z>R_^OA-IG=#!'$N
M_)I2CK=JVJX#)NC+]SD])!'EG:P H_TD(&S<"8#!* !2^T%^VR>5FJ03B0Y)
M-(/WKU;=2O2_G@F"JB-Y=3LFU&@?6P=X3"FXPNJ"RK:$4A1WSZ2:M>- #&A*
MR0C[!*4B]GR:)4P[Z;+U?>6,MN_A^ZIQOF9B*D+'^JVZ-FW?5.9&EF2Y3#;\
M;G[9^+*\:\3\R^CY7#.UO$;B>-/#L]F?'A:3TZ=(/:3#>-]T (R/08(K.81M
M*$U5,9HC[;*X;=/A!NVZ$)91G)S_W'9EM7'Z=$[C"65O*TR+T)SZ[JNA4SR&
MI-*BRE"G\/A%.//5X#P ):,?0T20#N07]5;&E+14ALYEQA&<Q.CQZ+WFL=DI
M5)CG"^7LFH ,4*;>P%FGG^,TWAA[G@/.K"B@HP.G.1[8 B/#$Q5$4]I> [.?
MMZ=^XHX.4?\/YMXSJJDN:A>-KP4!$6F"M*A4I42E*2"Q 2(O1$1$:A10"!&B
M="0D*DI'! 1>0<DK"(@0(Q"(U- 1$) .H80$1%H@H80M*=SXG3_W&]\W[AWG
MW''&N3]6?FR2N=;:<\YG/@][K;6UK2W2/I6=>?OU=U]\'!CAUI*-*RWD2G;1
MDI<O3I./W 9\48?#HEIP$E'8)OL9L-1BNP-+N;[UR&Y8T.*NDT=B1>*K5--5
M4\-U.&_:*%^'DJJ-[#KP^-QJS";EM0.Q@G3K1C3)L3!DRS7>:+48P36TL2K(
M(/&]L1Y8*>X%,B^-+]+.RFS>?DW^0H[!G(S$M:@WH<H^XS^Z/FFS;E*LS6#*
MN#^5RKS^]W,97H: DO#YG=7M[8*)C16(1V51&^I0-YGGN]O>"TI>U-29P67\
M!A5\X6CL)9T'/S/.KF2H7I;[._?YVU=++S&Y?T!ISTW A*G"%^ZCP\8PYVH=
MZ=AHOF9$E?_/$5W\W&!>ZG1Q>$J'M(0%02'7U.]G:LF_;P?-S 3=JG%5@ J.
M"M<$L*9WP^FRL>)-#NU1M?=TRY4(":9FS;%9"ET^'G^WY9YZGWN/]]T\2F9?
M=7'/F6NG.6>>IRWR!O,CYB<4(\?GZ8Q@KYX'!D:'9S?F$NDCYN%6!?A/]C>V
MEE>RZDFEOT<$(RP%T@O^' ?Y;-CG,:2%.M;>"B[#ML)C<PY'GFR_S'PQ]-9L
M%^M"O$;ZSPCIRLZK!_Z^==7_P_7.3PU*WW= GW',Z_"X>G7@-$>4"V>%/J.'
MUSK1R$*+62]3):&G,^:TG)0-1;GFM_>UHQU3^!U@ICDY&EY&;L_&QF=E)M1#
MT-[ NT+GCKOY0!X=%4]MD8].\CO:?/E!B*4\!++^0-=T#'1'+GZ;SNY4NM:#
MC!"H>M+7RXJE5]^GFJOLO6IZR'*/?+M<W6<9NP1BE=?GSZDU:;<VZBO+ZI;Q
MQ?--%=92#.=:E*SW_<E4V"PC?X7#AB=BF5=1@#ITF<JQP38*%[)6_]0TQ]:<
M4\#30F1U>[PIJIB"'ZZX&Y(V46RM-/LF:U^L10FZ\GK+X3NA;P'H<U.'(OX0
MF.G=GF2P&E<=69A@D!PCNX:8.C1<D:U?75=6^9+?KYHJ_&%O7[IJAMC\Q=$:
MX8;CY"NU EFY;Q2]=]  ?Y_:S#\)T*;!,?6:5<BZ"%KO"^ZC\S'/#3H44_F1
M!6V1)8:?1V?-'<Q%I$6V-68*N5*>M)@VZJC6=5[V^])Z)JQ9@6$LIJN%$C.]
MM77X5*M^(.'U@.7)%8B<=L]+ET!):Z7!TMYQ^\_3>(:TM&>_KNZ6F[[[\H/*
M.D:NLOC6[?B#>7,WYWZ>"$[-M*CEGPBJOE75BFT\A!$#+M-@7,FMZ7>_7G"U
M:&2Q2:"PT=FP" _+1[P:ZRB>.O_:Y;._O(&]?O>491?8>;OS*V&,/&V;PH&@
M00(!F2P^X>N8!7X:A'0[V!1YZ4KJHH\._79*OM>52S]O2CI(>_^KI%7Q>:*)
MB/3XY%#(K#*L@Q1.!]XM^GHC4:WZ&K_N4KSF9[T[N?&:H/\_M<_(UAV0'%=K
M6EPN#-5,&8G5?V?DSGK11?')"MH2(3E_*)+J7#J #6>W*Y0?.O4^_'BU,]=$
MD$T$KBC01:<"Y[38X>7,]G8L<"48==B'DL@7&\321$K).Z#GDON7?\D>"K]Q
MUF4'="[U/M7P  :S[Y)(4!W7W!C:C6W2A1=.Y*QT#"1]'"SF?MH!Q3O_UMH8
M68<78K0%/;P)$V^D,F^ Q3!=)&=8P@>6X NUQGQUXN#Q"I*Q:4BGKK"5JE[<
M<]S\:L-S@M9ZP*,-&XP:9GP;VC(L0*_\>N$%Y5TCW/.HF:[DY\7W^<>&-PJJ
MRRL4@D\_"GM 3SV_2CQ]]7E\S=A%DXN$<-X+J!^6(C6=S)79:@.7Q;0GQV:)
MM^F80?>#Y>;K=:.:;_'!M4G8T'_<IT9_7SIU@!P1^//BU$6*DL&12[*/*^RH
M>;.O5_VG9E&?',LKJX_<#$BR6LAE/PYV947SS,XY=U2F$RO>;(>;8Y0$JEH4
MRG)A;PUAU,,XC=2*$8%NXT  >$/6Y#".)KX+^#Q^]>L@^I'T_I=E4UWAQMTH
MQ?99\0>UJ. CFHH;.R BB2M;3D>U$ "C+H'V(F*;LY>@N[@V":W#.?(C+_*3
MZAB?OK]L"H[3S4N_$E"8,7/LS>[ITRKJC@T%&X#^8KK%:_?,?H:;5H>;F]L'
M/\VS0VP8-C+<7;@*XJ+A75Y>7@;U]B'$\Z5[.0[<$[S,^J-H5Y9WDCX\(0?"
MTHC^=QBMP>RGF@_4ZGT KBW,K(N5+P9TEKE:U R@R[^]O3)[X,ON=?&9$:ZL
MR<S6\M]D,5-4),<5?018(H25VT=#9;@JS-7HH/$$L,CEXR6I[8?Q=U63]<Q3
M]GN>Z"I5Z19I0<C;C-SV_D"0F9^E6%M/=?O.A.$A.G:O[W5;CC>Z^8YD69G\
M]MFP[5[R6L9>DG;\">-*:_%%=G.NA=GS1>.8@=/@1IPT@+5F[H!:<'LBZY%*
MH>;1*YV=M"QN!U9%&QG4+6U(RY#)T@\U%WORW3:F<77<GIW,BR)/EV#V\K)V
M0#Z0V"Q(.T24BQC0J&.2$_U,3R-IDY>MJY-<_U&M)*FK'#HMT;.E[N4'[-W3
M'X73(<[-V9$=A53[U[=<;,;.$R+R'<@A'Z8^G90,63CR86##L=P%ST :;2>Y
M8SG6_'[^$5XZ1B(LK4U9-<N*QIQ*B"0HG>FY:IO_<7RLZ?Y;%W/56-5[KMA#
MNQ]V@.;JP8)$$&1/HP4ZLH"+Y15CQ/C]RF>)P[5V3!6'3/<O0RO:)1M4:+.-
M[#^I,J1XN6])>VQ['*$+1R4OR/W^Q8;QWF+4L8V"%"]E%\WL@)*,?\6X-,FO
MML3M@&B2R79,_[>4@A>TJQ_N!J(*W"U%K ^L?[WJC/A[PGG6#WW>4GO1W-CM
M[A%JKCT"DN4WB0V(K.@S#IKC5?:E)64P6L^9A.NGX[;R"@J7Q9O("<:0-HBP
MLR_%8#! -,%'(Z>O(.DS<2Y+^LW=KU?N2W1*FJL%/)Z5W*^13\CZCXUZ,#<H
M7[B48V#T1,>^R<A18M%1$HOTV99'9#KG_QM0F83IA%%TAT&?UF@7SS5MWM^^
M58GOZ.'E4(=Q.B\?FW(SBJH'AB<Q$2_^9_]O_+_2%">P I T:HUFJF*.]GNQ
M7C]&#*OVI=*<UQ1.'V__5>OY^M*R].&VF;?>0LHF'&.!QZ[5BG+^YH_!9>N%
MYHUA"3JF3DS7\23_%?[PU'GCI1X.^7[0N]D'H51%;!+F-K]=(*ZWVL4N\P^&
M\?XM*<'ZP)9Y\(M?!@RP$KYPYK/;UCL@88N7O7>/^_#M(BMK[OK0.#?#7_UV
M^3;1XD 8LV^$RM>K"SK%0OV3Q;D*K-7H^L,3\,BD3:B,K[NB (J?_8(Y7#F4
MC\_KDM91T3L-.7W/#CSA,2$'GXHX OT=;ON!,726F%8_7#&\Y7=>>R90AD-&
M2O.%!Y*XA=+4[JFE,M_M=35.NCG&0="+$7FZ%"=9:\*<83?T07T2NB%M]<=Y
MKWZ]*QPA)IGI&,(EQ]O97XPN/;^4JN?,^J+YU_7]G:D81#)?U)'%N<Y+\^(5
MRK(K>6\8P5>H11K+RVR*777$KH>>:TE]5?P^SMV$K6>G\DR#>BBJ]*S0K7!/
MK0WB$)VSY%T64EFIE8KX:H (O&9:[<ZJV!RWQKM833K_6G60^6T@4&]_WCG2
M@G9@QBQO<8Z@KP%[(P^^-C-%5N:N7R&7D:J2;UC-/,$GEEE)U?JJIJ3D2"8G
MOFJ.W]H!O30F,%S^+!N$<B/I)S#' 7OV4P#_Z*-:VSLL?J$:^K06.KTD*Z*&
M^#OS](<OC3%^_;US9K-"3UJ&KG:*^/M.E#W<3/U9[6;6'^JGFN:'A^A3/DZ_
M)YC>S,R;&]H!34/,0U9*<BHY6?%<+2:$>SB9_FM9P$WW*@ *S*D9]A< R7$/
M0]+;BE%Y0"KU$C,R(RM'(@/YG 0O=[N=2@+KOXC2,[RA^-IML7T,[<#QY0_#
ME:#3M3@%Z'UX-%R2:T(#[UM0EJ\8?+"IX](T7%W(/;[?[X&[2W;8D&=$<4S6
MC&_^]S:U@^T(2K&#2 !.*[IV@KT#^HHXIX/.0A073D!SM@,^&BT8YM9N39H8
M4-B62Y$RO[$<*<PXE6CQ@O.8Z\)+X.N'S5QE>2<3!9'810?O0?_=OZ'E9HCH
MOZ(@3^]PP#<?>W/M8^+3V;.H4Z=\"0+BO2CP15=8+A10"VW'RJ+#1K0W(8GP
M<O>\XGF^QGU291F2\\\8OSGV_56ZLA=Y?JE"-M#\1UJ/WFO/:PYIM3?/\3R_
M3R^_>S>C(Q\2ZCMB;B'Y>@96G!63]V@N 86\9ER0O5ZZE<QPXW@"ENR+S /;
MOV+WLO$&=</9#[8M7@ZO^T:@"+FET5AU)T_>MZSK1SKF\4DM?F9IM%5I1+WN
M%R1>XWKID(YGEG5(5G]PED&JH>:\DY5"^M,;QL_VFX[,)#=B =6M%G% %[P,
M8:+H$(8.G7%PIJ5>P#^"W2P=DANS_#+C;C69W\VCC$\V'KBK8Y=,R3&R"-7S
M6_\KPWX[G+,/\UV"WXXMBXGB@H;-1(F#1!<UMQLPD?F$O 42R9OW8,%?N/E<
MXWT-[8"'_[Y0.I.[$#B _T!GW/O]N*V'[^=$]&1XFCG9#>N@*JDX@Y7:C"*]
M4<W<^(;_(SL#_E>:UKHG7V2( T:'5PM"X36_ATHD-T)CC%&M;8#]O8^(QX4O
MJ"W#U7N_=SU2_%2FO76Y4S@.I^I_YQ+WN63S1DZ\2MC@B]LU9VL(68^PZMGF
M@1&I!4.#Z;C\ 6X_U(CKR9% >[#:N8HFS#3V\^Q&46_FC"7@13&K^/BY_-[1
M@6"-EYS@CPG=4ET5A4GHEMCW/8$C\GK\)JC4*G1Z)B'Y97F88VB30G*T1G/2
M9RS"&3U26 +U7L?T#0"U=62&XWRDC*/[7);E.[7^H7.K6-M0E'G$$KI*=VX\
M-%--P'MUMM:TMFM<K#%' #!_?S,KAB^\%<G2:\!(\E+^/+BE)#1C#(=U"=PC
M,[U2L+S6HC E=8<KUO/!"N&J52\AZ2W7)86M#@8>O;@()>&X$N4SA_&"I#G>
M;R8<!KW(A"750]S"<MM;G+EFTGU$J! BH%,TO$"3]K)S[+F/2N+53K571S7*
M"$N3,B?JS67Q;PV6?/W.?A[/#_5'.+G-HQC@"C:9'K(07I"].C3FWKFM(JC^
MP,G59<A,\G@>7]B*#HFJ/SB$1T-GQ*S_'LB 5-AZDJHB$,?2&5XI>B_2NDY\
M_:M*Y=P1PG<<988O',.YPQ_&,FW@T631(.P8G);9Y A BQ!;L((%C-Z ^F M
M(O" S6ZW@NZ,2A;.+-P5%K!6GI:8EL%CYQ)?6%F4?")4:/9,GOMW!8=-9PR/
M#+:=MBL402ZWMD)/:!F,N[/)[XA0@4B?SJ^.:4%B@7/M;)<J .N=.Q[&,U,L
M^;&0Q1@P]S8YZ=M[_NW !=6QNCTIPM>O2KQQ.;A/O(\J1/9(IDBQYP511@2,
MV*]X__*5Y^%[:R%,Q[]Q-LS,Y\M<&(JN57=C\0*-H%I%<KAX^)[V[I-FGA?L
MCWAN&K7" 36"@$DG[("8=@009H"243JC:1K)_&45";;Y4EE3Z:8<YN3_FMA'
M%-,STYW]>=]NK5!1D7?"P3;W^8DNAOD@DNCZT\1@A):1Z:<^?FT[,S[16T..
MJRM-Y]1?_3"P@/P<9T@<O\R$\P]6 <?HL&AJ!:$9+,^%#,Y\87DSQ/Z=1*N/
MZ,_'QU7X*/N8DC./'./2%(S\4N)Y[WA)Y/O=$+:I@#."N9 ^C!^T45ZM,J/L
MSNZ'\U'?7\\D]1X+-5M&-IN>%P2/$W!7EO&-3!1*,'5@>=)1B<1Q3I)E<X;R
M*=;I02)6J+:GQ]Z6M#;2D62-CEU>S+[Y1"0*#K\5%KK,_)3IJ$Y-K7F4Q'U;
ML#$PM798A=H2B,\MP87F!I!@(:?<>.-U3?&:1?_?->=7'$6/%E+**I[.C*W5
MH>V CB#!XA7O[H]>1M)U3L@0@@JF\'-7Y)ZX@%Z&_4YV3_]=+IC9[Q]FVOQN
M@7\>>B?R#P(#@F!N%4^<4J@$CD^I/H-*PLLHS<'JA+N'@HD6:WOB<SSB+JVV
ME.A%Q8-XKO\O(]J]KG#S3\;ZX,:0?%':#"39?3?@DL^] 7BR"BT&T-!B-T*"
MCGY$LK VW..E2]'QM^&9"H<G)\Q%2A\^JML/VJ0R;7M'4?3,!AR@7<@(9[FT
MNLORNYCBK?N^F,D-08EX#?[ VA,JYY^?B-QVGL&5W@<C\VXR-]667TMC6KSW
M8G]FVQ#2ZG*V:ZC6,CN@B-YN]EM5QI2P*A^ARM.O)''S_XQN.@4L$4RFR/)%
MCA5R;9G<>ADFF*$5K$:(#HZM4# AU3RS,A"GQKY/GTTLQ$DQWEQ_.Z.HB.9-
MBP.JEHQCS')VV(  E#CB8^)L^T%3:\\ '0':^+A=&FC>SE7+I)CVKR]D5MZ8
M='4-#T\(S!-_$_:-"J\)NFFN^;']@^=^E^IG1/^A=UMU677+0T1]O-U@T4D"
M_74^Q%++O6/2(+??BC("A6"G/Y*9UK XZ"&T 4<ZS)L&CP[: 4DCR'M,_3P_
M AES;><UFBO9E:4&-=9!&3Y^T]>_IT+3_,!'&MS?;"0#9Q/XPB,L#;[(.8[\
MO+%0$[M_4RRTD:\>U9(*A-ZHX>@0XNCQ)ZY3])]_TI(ZJO+]9*&0=NTISF)\
MH+]=.1^+B( D3"P@72:<7<B=)RB'*SL5WV' $;^PX4N8=KH $#E[^,/0"@V&
M.$<=_7<RVQ/ ,M.:L;NYCCX#@$)S_:D!78*?SF'ZV*_:E/8QQAX/DZL99^^$
M>^WZ\OA.8"5&'2B=%B"HB2S[^9#9(1\S)1:FKA!0ID10Q9:,RQ&GEX:?]5J)
M[7'T.'=8N"5)H;A#X=AH9\C*!#18:XX<@V-:PV-V0&+0Z0_U^KPB[>#D(S:L
MW>W.)^<=M]%;(=UYS7_E?]H7K_;D;_#AE+6!4UU0Q42_2^5)/M2K^4X+Q7-%
M>ZJI%OU49'V&5:OYC8\Y^$^/K//?&^AFC,&'N_#COWOYPG4<(;0OB\J5+J;+
M,IYR+@/>E@"*GH0UAXL"\(9A^>_&S?,9UE_T,V6O8Q8M[QYJ:^[-FGU^5)/+
M$\#F!*9EFUTC8*1M_7PQ0-SEL)DLK_1ES*>P+NL*K;DK#W2]I&P=P2=C:>&-
MT'!N)S]6(Z'WZ<Q$5]VU%?OH(ROB>'02!XQME*V7PPCPYV4^ZQE<&GT+(+ N
M;0\1.5A)[A76B1'(1LVMZ4;_*=>[]D= 7^Z+?-\-NGJN[]'M^#.^/_(CC:J'
M73]O$W\AK"K9JQ[WJ5]*TFH77=Q*-JY=HT24WK+2K2_9+F[D2Y<R-9X3Z\2M
M22]'_NYC'"\E/MUW6,[C0NR_C_=>AXKTY<:K::C_U!D[%?_\ID=)QE-SZ9NO
M_[>]U^+_#\T1S&*WMVS'-)(E+*=KXAC<6Y7^VW9Q[^&&-(Q74M8]S8^S#^[3
MGI7+G&R06,_)8VJQ7T&_&&9.C\-C9:%,$MX_S2;;/?5J?8<.T68VH> .9M!A
M)LF[_:WWF4Z'R;2CLGVD?JI)#;3&^O?C@^,N>/XM1^[C<)R[G>L.J.F?BH\8
M^7DX,]4J4"-6OE-C$+T#4OEN'7W=Z_+L+@E*RT?-4Y=>PNQ_.%PS+7MT_,Q<
M_"L[<QFU_WQ&6AO_QY:R<06@0"\RDVND<7"Q5@7?T></?W5%E+DS>#^^CE[^
M[5):@Q!2TEK?XDM2 2U'GL@.J)3 XPFD%<"#&=5U.NIF0FTT"1D"G'Q'Z64\
M+5IRUX13HJX!6@6C)8? XKA==>,F'57<'1 Q,M=R&I))\C\WF3.TJ8;07!NW
M/]NY):(U309T=T#M4$%QPBV/TY'0I]7^N'_G*S$'AM$7Z03PA%MMJ!DX>E@Q
M'Q]_[ !*XW=EI_#:L\,-)C8/H15"C&26+"V&*Y',=A>(;61K5AN.)3M3DG.
MZ1+VZ1;'/^_^=GJM7^!C9;?Q%1'M?T)55R/'ON6^OG?CX'7G]4O"P?X!KQUS
MYQ(<,47.W0N::QWF.R#M6>YK:2\>7)MP;Z$^8:,SGEL&6',N @(VAN X\'_
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M3@@XZV.@OW.=K4;DO?R,$<%1BJ?14^"J0?X@Y0/Y$+%@>&_I'8(LA3\R%UY
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M*X[< 7VTC%^:%_G/C[M8&GQ1048K<C&\<KX)XC37 \!/*_0^)XMHFR*FP:*
M]\UL&)%E:M=ALCA@ULAI3[I^]&CTWK1/SPK9E/IC/+*I%><66AA8>L22HK4W
M"T@-]@A&>G1^RKP]IB)AM@]M4Y@*JN*<WRB>#3_S)#_UTIA68I!,DO4)"UC^
M9F@9^G/W>&X(.7TX&S_?%8SD&@<CKNGDS_4C?T6&8,T$XJ*>!#VX :/,S"3'
M\!6YMUGM[6["ID:T2>?QUIQCK-V+_;=%GS[TZI]@W!Z^/7MC-K?H^*5$/67D
MYK/Z/Z> J6(FX>6%#*M"[@5F;R/XA2%V']><YO)MQ13^KS/"T/!'9,$E5DG"
M(Z]NL8;OMN_+]HMN76B-_.4V&H-QTR\C95&M@^9Q;E/XM_J>WCK!]=5.\ZDC
MW13V0H2.I"F,+V+#3&Z!@['3.+*\J01-!\IQ:5769OH7Y2-NN:.O1WZ:0R(D
MSW([G#QMOC?XAS@<F7T*U^/WX9BVD%BR/'0Z!0[B2N4Y(>2Q;;"G"S28)&+;
MOPA=[*U>F']9LMM;E;EZ_0AZ]N"'SXS"D"GDAF1\TYG7]K,A?DV.B^^,- Y7
MH]0G!VR[>GBFXW"O ORDC;F568T%17\3<XL[P\.1[XHGP"M1C-VLFAD(0V):
M!S+-?\_2HQ5R3]:!FVZYJR>T2"U4'APPZ/Z^=4CS2?FW^6]%;W4O-B[-0<M)
M7*DM=@Z06<+_#M[/U^6>9R8_KY?E=SS^65E9?V8 [9[)F!E[@)^-;W!Q.BF,
M?Y8!UV/(]9J$3?,K[!QM\PK5-'WRNN[A"4>NV65&%-G>F!IY7)!J;9SR*^IY
M]O#V)C%/KH+2<SJ>LNVF/XYJ_[/:QV0'Y+T#2G(_2V9!$^OW<I58WG'!MRSJ
MABIP^Q"DK9$7=I[VJOU-/3_M'"SH#S\)7=!:3VB$?@EM&%\%SJ6U[H .S@%Z
MS%Q4#!NZR]&UDMD,6,+\E*G7_3S:U&NM+\NFDO9!7W5*GW/7>ZFU*<3. Y2,
M&">8NUN5]Y)8\#A3<:,X';/.ZJV8%9O*P@+TXI27Y$$[OJOWQ,A/.%<*PC:K
MYL5"IW]"E,).KM(=6R#Q T8-ZH/02NZ]C]F\J\(&^+/A9@(-D($L/VER&.7\
M\GZE)D]2P)UM^5W0#3]H^0Z(K]"ML@-*F?_O+@JR\L2N]1T0USCTS[+Y/,1_
M<,TI!)B;;/G?7(-?L+L ANZ F@NQ]W#;AKBQ'= .2&PN12 V!:CS7R]N;NR5
M_C]C'KX'V[B+?+?W&4[:DX>7:J$*\0\#<6@3SH6P3,O^3'MF_HOI >W<-=/B
MVZ;?DM-%O!A)IXK3GFAM3I$-R=,3O;]K>SGGP#)81EWP'=9HHAK,[T61IG6M
M2P)GZ,V9^%1BRF8AUT2!C13T^AA0$BAC=0$3;],4W&-/3#=V P7?368^[Q?P
MZM:())DE+/[-+]Z^/XN!T@3U(I8M34Z/_,9<!4*,_BQLL=AD"H)POPUD!Y1H
M)XBGMC_KZN:GZH6P-.'\'1 K?DM>8-A%KW?[@$ $1&GL@#J$ON1SBU<L8[#-
MI>3[Y&TCPE,J< F!Y7HD_S<V';_V66Z/Y6!_W(-SCT#Y5\^_@/R$!YB:\)62
M. 8[H+XZ]!_-*64MJ!32_\5@75L\=/C[.C_JI("R=0@TR,7E$]B3G)1U<#L6
M4"<O_\KCBK/2)PL;P,\R2+>J999_=(L_W6A)E74)/=G9="!ZSU_[9R5<DY<%
MH]FSP,.9NG!TP^#7AS![N J#JRMF(W,3DX"631;"</)[7B!1]:TFR(L)DMGH
M94CL@-0%(R)P9 D[H(VL:W1!_SC<FD^.X ^D7IY.3GUJIK0W?%1&8[.:Q/[A
MR$ZKJSJ)^)I_Z=W,RN<ZV2V8-HO,E4I@AQ-Y>5PI3]D&5-3IT4D7-R)[8?J=
M@<<_);87[ZT]'#TJD=*FU;<#HHU2R^$\A9&&5>XQ?3+_M M?$(AI>4Q9WN,I
M[/P;K<'BV2]<EYQ &*_RSU&]4(TQ;-B67J*.7%^3P5Z\3A!\?>T]C<I<1HT1
M^$E+TZ'\0UGP'9!<WG]SDV56]!UA_W>'L/Z'1Z#:F*.83NR>(!AP5KR!>D %
M4&)F\B7.>]*DJULH <"-Q@=)H^0ZN].D-71EVH-CH2DU<D>:IGEVG&O81D,!
MC+F)LH-8O,WD!NBSRM!*C,*@-^EK5*.\5T#C<<JWSOFF0PY/0<_.[7$4FNDV
M,L_D'Y1CV@QV(7A5X,8W&1/EXB9=_/Z:GKZ<MSF1O761UIR;@D#[@KZZ RIU
ML=\!]5LA-SX?I2=V+84;OX\M5OB1U\WIX/2STVKK=?Q+ZBWOWXM*/]L\?K:3
M:>,$"=%E)Y0Y?ZZIJQ"$V7Z_'9!F!B"[ _(0.'%^ ;FX^-ORO[L*H"2@L\7?
M=T#+QTG\MRF-S_E[SLO.2MN9HQ_][WO;^O]C@[\ADX2XA[OH&HUQ4!]1\%^
M;/.6)"#4*B_;#-OK[NNHHX*<TAB447MK)5+V)5KNGH6#W(1=V>A9$497ZDG&
MQN^/A/H;B8[9Y@&<SZ@KY [2ENHL-\U[(5UF#<N53&-_!=YSK@ "C1W%-T34
M2Y4"!&9HJU"S\S)?+MS%:O#RN(!L,N/,@K\'[KT3\?EA%<7L"U[CH LRJ!_Q
M^9.5/A^1=[8KBV]3N)@-8UE^DT=QI00H= O+=)FT9J?[63=K-)!PH@.-)SQT
M-?C#LKF;WF?DN#BM#LK^R;F57N9,UAJ9 F;OXI71@"(6T@:P9BTU&E&%^4;6
M)^JCZ(>&#'2\:1N![3^[E>,E*/L28UZ5!(3[X([N/EK%D\HM?WWSO7S \.D;
M2=4&)\X1.5.PD?QN&2OUG[+W*:'+]-?V<+6%B;7>T4RV[0_L7=R8=<,.2)AK
M8- ZE3;][K2VY.+#/:14K]KR+XK[4BU"CSXTNA-$Z($#VB/<PAF^\.H.Z.[Y
MRP(@:X3C*WX+5-]> 2B^YF(;!;IL6>,C=GY4R[E"[8;_ARW_U:%_!@KE']ZD
ME?6!BY6-A^:8 @(6G,")S*6WM47$)AQ(ZE X]6T[GHL1P/,,.F 'E#,EN$^-
M,$'*P+]@#/KR6>"H8#^S?4GWR659%,-7K]Z_.W+Q[)X9C2\&OXT$@"P,"#+^
MLD8SC"LGD"9K:I@1FIB[] MMQ^VNY=6P@ CS2!U=I _W\\.9H8CV46I/FQ 7
MJC"3R64S<7P1+,=X>YPO;,2)#-L!L=M9I$1MTWOJ+X>WU1)E#S=U]GXSR;&P
M_[IR;EKD=QY?48J5P(^&1>. 4W6"2G%MNY O_.?DTD46:=E\!G+85UEKR%3K
MXV6"TT4__VJ;[VME9TQ.0^8NR^W>X[EGA,)BJS3_]I)[D?8)>KOLY\^D?(S/
M%"6$_.U74XECA7L_VZR'$(OU@0BA79DP1A$SM&$;SCC'BA^Y"+Q7)QMPL:/U
MXN'Z+&_?M&:E\LKHJVX]-W_7>\KLGNNYS:MS%^)<X,JPC))V0/YP01%N,W;/
M9A,.AAU#7S$H)A.OX#PX#J\?75S3$XI<^8".'VVS%3+@5J BH? .?N7Y(J/.
M_K-0Q7FX9*TEYUX8G'8^N9T05Z_4'T2-"42.5'_&Y8?=MX&YUKI9G-U#VC=C
ME;&7-YY2.27G>%3146L&1EFGARYO3D,HNZW*AE#UVAW,%QNGD?0$_''A"M&@
M^J/4A!HW8TV/JHPF\8W<#&9+3ZI%]/F&FFWQ=M0HM!E._,78R@,*Z49-?XZ!
MO<A43IL^LE$3;FJ=?WOQ"\47]M%24WAO0\BM4]$\>L'IMN6WCI^ *)I C3:@
MGH5L0QJH^[G0'P(@7+F3.MY,]9!WSS3XF&[3<BKA3C%*SYS<]2KO:&3-Z\\/
M[3-7CO^J"2#SQ=()2/TJOP_!/RNR?F1CB==&'KE6#E/75F2M:@K#W1D,+6K1
M#+8,WNJ2G.2N-K"9_&('5+'O!8O3:-1KBE&)YT=*5(B+%STG0CQYF??VC3@Y
M'V525=(4HJ=$&&DO6$9/^:<$A(YYO7<_5SV!70 ,HL\1 "D'EGEKLP_F@%%1
M(#+2$R4OH'AWEB6DJU]]T;S]ZNN=74(?P.7X$<8QCB/7"'@';L#;3Z/B37<7
M=X66A&7>S+QDG!FGK=P_ISZ0LM%54Y CE.654C_H.5X>\'D]?0-^F"O!LB@4
M9.(%IF7+57VR7F,UM#D)>:%FT&S@T!K!WT#,V,=C+2&\,.CAM?%GZ0JGKJKN
MKC,0<L[.B!^HKL^RSTX@O\4C/_PNJ>A?S!\ZI[G(&R'!$3)JA"W_#3\G:D3.
M JU;-U*T>=C0T3F=71[H[?^J"QOV!=^Z=/+)O5>74EJ48B>N^,2E/OQT2J@'
M+H9%@&-SM 2I_M)FVNUQVT@S1@(5 Z.;V,ADG"#TSW#LE[L,6N:_UR1:ITA[
M^Z),WHPKG'>'/:M7Q29UT4M9$?3C\\>BL$URVAN0Y3.F^&QT<\$.R,<S=!4Z
MLVX"]/2F?K4RVP_DP($3+=1#T3E]@!DL>G=SE+U+;*B.()/?XSHE#I_QLESW
M/U%>&=CJ>02*LH5Y]P8/ ($5VVC7RH6(X"^+;8,:<BM5VML[($G9=0"%U=JH
MFA,X&LJHF]$19T\!D&GH7P8E9@>J69UAR#9*7K-BV]J<VTGVVGE#L0;&Z0^G
MN_0^'T&/2L#.[,V^ 0RQI.BVI:R9MDK,V:%:\??<_4,$(MZD.67A,3I#^=CA
M:K>ZF=Z/'8_\MTR4YH[MQ;?6JSBHEIJ&K[;B #6C%G%A8&1:T4P8Z&;%M+B#
MF=@6A*FY@%'ZM-/4(I7//=C<?1YX]*%5IZ4?]E %=:JGQ;7&;V)/W"A_D%H.
M23 [B;8%7@CX:!.A9@C<'G)F85LC(0@F\0[:S$[I\'@EQ%+^9SO1\_K7: =/
MZ;A[ ::EDLF:Q08G3D0<+N*&9#GRD?:(F@54G"IOW'!EMF(A4Z/R!5_4@H_,
MR47:V"-3;?*[<ZT"ZLZ!I?D3)##1L5WGS'D->F8;+-I,7,"OQ9NGCJZAA:8C
M4)*V* -LA:W9Q-H\)7/L;OR4'#ELZN\+WZQ/MX,#T::UI'KFOH1'?@0K>H)3
MR;%4'5^+I]D.E^6.S_XC<4S]XOJ<J@#4'.R>F%K;9-.-EJL*$?6[?V#DIM"7
MF >S\Q#5&M&KIN<C"L?<$,<5L,?MB_";LT=;1"P6V7%:C/OVPB=%V>!2[#+C
M$4>7_RUG+X"*+,(BW</@YLFPJAI71H:K).>,WA>]0U5'*/N0Z,LO/D7LS<4P
MMA!59M4+N5/#B*"S'T^^/)4>NAI0G%\QZ)$]8./LMUD3LABX _K+#!I63.]M
M@DIRK_1O5'%AGGCD@%.8Y95G+D@'E_VZF!;2#5<C-;6PG]7WU=[<];J9]/8N
M%]Y )24G$U<!C=!6;&S]T;H?JZ8(V@Y("5DOV:_Z\MOEPO%O6>.(D',)#[V3
MCN3=W]OU5>AMBGN%  >;!EP:<&6&R=.BY,S;@%-$.$W,PK#AX7#YU^@;N\Y*
MN1C4+O&_+R([T&#.@; 95T&F1:#O !%%"[<>H^)K+[)VMYAI,7EU/V=AJ. :
MMTAK6X1JPG>)#S7')]LV#@:\CS[I'.^'4G;PGG27)Q@IU.#=)HG&N,;"5@94
M]&;UR')1 #Z(PLAVUP,V9U"C1O01-B21&_D9?8LY5?QG.Y+[:1=&(*Q_&47D
M=!]U-AEO>:"#]^#HI[B>^^LF0B;MS>U#>\S^ O)9]M,]Y1PH$-6*D]@$*R^0
ME0SV$^M05C7]0>/6X(.NK@@C1V9EUO PRS7\TNT]YOX_JSP2"P->65O35Y_P
MC7AU9MJ&Y3.HF.VM)NS!!:@X]^+T;.GPII@N?_U&[5#K)ZM'LJ/^_IZ'69;^
M#4><W"BV'M>K#/C*: B 9^%N [MH5#FTP2 &O"!PX*K'4/ []U^W!U!$0<:[
MCB^$&AXJR-)94:U:R[+BTD>NCW^Y*5H:9W+-&((9V<*L/*Z=<IUXF['$W*PR
M.!<>.<X0J*2$5.6>2;_N[H@($MDPPW #"VAM/=M$B8>A6G28ZW0>*0KM^+F+
MYF;4 LMUL?8V_$*R=\Y/3I/IFIRS>G_/BIM<?B\SJ#- R(^V"FABGZ]PE69$
MN['-]6>8J-A:T4]./I3"%\'6$2Y)WHS0*?BHRG.G"=>+1I2_/ZJ<_MZL%O5:
MDX:&T627 UDJ@EI9ZMT(%X:'!7YC"3W'Z(A+^0[C4!6H,@1U/)3DCME\E<>?
M\QGWT(-V)]4\_2N9(<PY%99MR\LSTT)?JN.W]C'\T8^F88?"3!>K&14OR/&Z
M04"BWNU]NM=LCJ7,Q%[[5[_@S)DS5RRH!\CO+'CAV.!5M2'.NI43-5TUVQ;H
M_/#Y]ZV^.;>W!#M-4IF-A5B=SO>I% 3D7S,QS%0UI!66Y+S5C'=LQ)@!V!FH
M*!  D5[,PL;IE%12QKKT4RRNL#,=#UW[[A'"&WSY:=^1].:C@JB*QI)68TU%
M.1?AW2R-E@'(LSG J1 8'KGF9BQ>$5EN-PR1'![>&W]:?V0?=;FR8_]]W<6S
MWA[M;^I'^,?Y@SB2=ZN?$5]F"C^=40LXY (!UB8,3UCVS8$[Y&'=&W/(:.+7
M+,HYR5&8_J-VT\0%^9PC30>3V66"U$$L08DHQGA1& =6$?D72H1K-,! [Z('
MU;<\AL3B@[6RGW=_NE8RK^+3UU4P'(_P/&#TM5!,Z62ZODT/>[CCY*<%9,B(
M2LQ6>L5][J>A.]41)G#+D/FZ+6NG(A.$4G"Y@!6WXBI?"S3?AI+R (W4@CL4
M5G.S_^Y(,/0@XLM"]\<P]S8++RFX?F:<_\&-E"O7;?3+Y&;7^FU*+,TY:IC!
M'$5>>?U?/E2)6@T4WAG NJ<NFMS>=(&53>Z \B:Z_%OI$ZUG^DZ+M)S:XR\R
M9K=.CC9UFD%%DRL.YK$DX: =D!\P0!=JYHF,M/*%!VI=/F 18<?I_<AUI8E<
M^N)9JDW*9W6XL7KX+I*:QZL,X6%LXQ&O(0)V^EV]Z*!!ETF$F+4+>;@"<;SR
MGVY4Y2_'VG?R)_8K>_U=IJ4R[7\)_S1KJ-$95L[S*JDIU@&[N2WWW[YVXT:\
MBQ-VX40-.]3/Q4:G?O4G=A^V\:(?RM2 Y>+**F2T(Z?A2H!E6[WZ0! !- F;
M'GS>Z/G1];+G _8-Q Z($E"2TB[_+E-4*[KSJZK\=BJ$<IFNPA_9 9437FR&
M^P69H)31QB,&J](^&45B+;OM26Z:_UIUOC%L&='[.$J[?4HC1#K9A/=F8P<4
MCP-AY-#60" >TXTYS_)R/\GJC0\VL;$*)H@*ZB4TXEZ1KZ/4A?7?U1]K;B<&
M%*5@OO5K3NSQMQBH8&JP%5F]#=1$<EEMJ*AR71Y7#;B+!US<ASUK8+HF8VT9
MQZY8@7O"QI?7]]XI]&TSDE'=G:X588#]"<>6%F'U?_\.K?O9A=1?'8JUVVZU
ME"TTL-;-8*?\]*6X9+ KB*C@2M2RT7OT0UX^V>N\*#T-TS<EP)CGY<XVER(B
MY7= S?7R:<T>MS]_/A9]PB/F[^C-]RV(5YEQQV97&>X)?U8@3-2R?C7#GY"E
M59&1>DTX*0W8062U?9GQ0M:[!J]G5^?&JRJG+@Q_U=XMFOY@GRO8F!<=C'L)
M+O=>CGN/UD*-C;1+ .46-I?V&]19MI@IP,3"4R==;:3+.O85&C"?QTF9:(^M
MM_4-(KF6O,Q,&G:9RCG+W37@3R8:F&!E?:K3&<N''MRR.3GM.[+UP@@=I\HL
M\4RK6)E16KH6$GP<U_1K[Z_.<?O(C01R77FY<T'@S;G9-,XU/:P^ :PS'(?Z
MM)A<[I,;W_+E/Z]BMW!;M#1-?/CH@F), S3&""Z,D4*8@6MSIA9_P=9)'0?1
ME53]U ->N_L:MN.7M=9)TR-MV&>X<D(R7_\R'4OA3/.&?B7J^N^M?Q/,\A>U
MQAV<+/!#OP'W.F69DRI*;^6XC0@?=P6%?)'Y'F9"QS7@Q=GR+,LF-TLV!5#Y
MB'3>_!XG&RM+S\")CS$^7S4ZZB)<B\OLK1$5MGAY_=B9GV4.UK3:T+*0<<=:
M^Y6:^>IEATRH%H4![_J 'V-3NP(WYN)98$#CSX;=_< O=F!_T Y(%'V3&=.Z
ME"RF.; 9&=C,5TMP>[%2^G4E18F;V]G9I+S'M_&F'VB$Y-"MIIZ[4O.FM9*@
M=C_<K&H'I-%-PW(D#))Y9Q'!2S*SV[^X.".!%EF^,@S=H.6/E-Q\_>>QOA>V
MHQ73064[H,B;^UEND;O@4/X8>.T1O"R4E^ZRRKMDZ@B_\)_6PPB=8 T( &('
M='\UJEZ5M948O*^?JT53,G.S=ZAU"=<5JZBUKJ)V)3F-@[Q%/N0TD36ATP)M
MH0B]0XTC5T0GXS']5$6^IN]C70(M2<.E#Z-D>;@*'"WVX=O]9^RK?D?5"C+/
M':T^!#I0)<,1*EH(J1[&&>3_K)4-(8F6W;Z?:*68,-\9IC(ZT@PF38")[0W8
MQ!%W8P#%+)_V;H-%L1__+1Q(2_*X381+W#:]?'!X*[5PC)O[]9B7ML5^T &1
M3IL3;3?FMRH3K-S(3;T%=0/.YE8%>>-^V<.&I)G@$=MNLW*^\'G. TP'F!@:
M4T$5XG<67JSHYRH<D%J\)0][X1]T]HZ47NQD[?SQ=:=X,UNGKQVFZVR9/R\?
MW),MJ 8%W#];E>/=PP:LF>!GJZ9[9V!__7.799CVR!M1N2\DQ;&KNL([/FA2
M,>KH,\.U/!6HMZ,;<M(H\D9HW>H<SC/G747\/ /I/&43*J*96ZHO^'AR%D[Q
M;.6?8XHW)$LAP6)H%;\9JA*"G>.?1.,D6>@8G[_EUVF:]TCKI.5:ALD_3ULQ
MCMA&0\P)[EW@SS));6#)$: Q*]MIXDEDV@7B[HO$$?SFQ^Y/2X\?O<2:[?/J
M2IWQ#S ,'";?(ON DZ<D>!GU!X HNFRR 6H9LC_LU@@C2Z -QNY7<[1=GJVL
MT2Q3JNZ<BH>=UUKKX@NO<_RXIWAD[/1<LE+8.DTCCDS39F;Q>W_9&%''1D+
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MX^FA%J D5-_*9.[@=GQ[<<[DV^]IR=1(E40#"98T,%;N_"M89&HU ,'?]?J
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M4]^^,+H-EO(*UK'?L7;L$IR"9 >G=B?BO&+G/S_TL-%YC;;S^<\JRF<T(D?
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M'0]RU&"KBA2\6I*;J3J_B'U*6#8R@/(@M\PU.'N2-\#W$(@)"&L.TF6+2<L
M(JVH3>/BJ6+EON8=0@>]I3V^JGQ^T3[MV&:)-[JS_4F6N@O&6TS\ 6:8CRM2
MQ$E!05F'V>J]Z ,!*TV) >OFM/@DCTG;F*]X(QGK^"[%:N4[L2:84Z9Q3]3U
M=M]Y KN&/@&T':+;<9XN\B"KYD0LT "#_>PQ4.!!O+";CF?0<-"V@(DY(-10
MBQ/&!MYSNX&]VBQ83'6L3LJF(MYP7U+[3F+5Y *T\OP/]B#@<;-444R'4I4P
M #1486DV<EY;@<^6YK/UIQ"DEIRB<Y,LIH_0TRPCI,RLLU&A<,3.*=/]SMJ_
MU2_(-:3Z[5'F''&B>@?Z+->JG;Z2G2_%*N NN!PEG/E9[?B]Q39VX^=J):80
M]E^O:A_D0?C+.'C#(Z@=((Q,H+^A=6C3Q.</T*(7WKEOYG!6#67-/_$7+^8]
M%BFI1YRG_M))N[W[*?ZBG)2?Y@X]0'"KZ+UT_7&@H7'/'%KF$[V9O!!><)9Q
M?JUV3]DL53H@^/M=W>('A^',=*7 IVK/6'FN:&"7=U9TL5G19.Y,=T?(-:M8
M)Z*)[\9]=/,KV^:IY0<[%$2?%<U>:S10R?^V<=CV1O1:8FR21XG]2/:OV%2U
M9#+55SQA I"Y@;I ^ZE7DM9[YLU">WB?B^N-_*DY%>>Z#VVFC]4P;?-6&<>J
M;<3?9Z0%YU;S[[>Z?@_E]O=KY70L6SR):Q:Y@.-!7 $3'J2G$'[/;L@-6%;H
M"%$&1ZTEY @(KX?>2.98<E2[Z  [.BB/$V3.@[R59OISA;-XD)>G4"=X$%P=
M^(0K>-_5)2IY$BH18,Z09W84,$7T9VL?YP;(.-;0YNSMA492^UU*,Z@7KXI[
M:T7<2G<YVM EZ=$E.DEFRX HRS_$O,V2V@)!]7IYM@_]RF>78G>N:GWJN<K(
MQH_M59O7?XQ<WL%TD8FJ"1[L2&STTZPX*D_>12G?38PL>W/F)45Y4J6_^'P!
MX^%C,ZVLY[&?BPN0 QCU.*T<OR(<?6UZEZ^+[?M$4^W"1>(&E'#=#K2Y<@Q;
M<HIQGU-HJ,,$*$NA;"L<G)G=+"F,S&O0"?/UDHW_T"M;\\%FPPJC5!F2!3_<
M)*N1_M-W*J+KX<#QE<1?5OF2.Z;\2EXF^E7?Y_3IYCADV'1:Y-:&UIIP=^FS
M[BIM5;!@J-%;FUM_I#>U?CWA\&JUX3'#J]+4.Y#_'=^105+6C*WBL5/63],8
M<RM8$G%"Z2G,@SQ,;)878+[>K1D@Z8"_4+"!C^ATN>1JVGOAN,KT0J)BR# $
M.1,;W1VI?.M@^FVWM(;^QH(7O@K0Z.O]J08N]S)&/9/3!A;Q<I[^5\RD]?6#
M5O6]! .>HNPI%AHV\3KAVOJ72@9U3A]5//ME'_6-;;AM3T5-B.BERK+R6",W
MMUWG_OCCQB'E<*NDMB]\Q?:X(X4QZ0])FT$^6H[W]UL9W?O_H_JLP'<8S5YT
M1+,91K,D,Y7<,/6J3'7BA5HZ-+PS<OC.X(%$A,X^\CE/5N]I!9=GR<\;8_?H
MQ8N>W*H@  P];FF3+\:A;G!2<;XQS$3'MI+*,6G3S//9^J]'RQ3R%#-5@KE"
M1BQH )ZQ"L[ZAZBS3+L)8 ''-*V]_,"PC9/S$$DM$^;4+M5]+8,J6L2+7.&_
M]H,P$0'Z>9OZ*#<YXL(2+6<Q^ZG$/6[C\\6'V=Y=9QX;Z2^;MI,E,J@=T*_K
M&Z,DG%)Y7@>A#F"G$-G(E3-XACMSA98WA7^:BZ6(QA@(378+_U[A1)O0<CB5
M8\DO:RYLF"S\?*<S*(P/BQ"H"](.)"^068HH30Z&K1'RCJU!@T6B!-_/^<.1
MU>4]5 F2U QIWW=79R&DC=3J'W5B)7DJ:.JFUSB)JQ\H2Z^KY-9 A3U@9>0F
MA!?SE.-UYK12I!];[3/3,%,"X\@*P77F"ZV]:F  FE3H7(/^]V!]SV[Q";@<
M<-N2%,EXQ$Q@605H3/@W8G<RURDS5*_'WA]XD*\FP9.OM/R8@8'^GC^<ZSK+
ML\W]XGY)GMMQJ56AC'/G7^NG*)^,@7=*=7:9@ORHV]?M;N4XR[@H6^E4C7Z+
M>;L51AG1J;+D6]B'3^*V$C[6OV:I<-N@PER)<D>0[PB<K>CA$K7X)$\:B14E
MAI\>J6O4T;]'. 5,E#F<R4P  8*Q=2ZP.*>XKJ M?X[_V8GM8ZPAO0F[^4JT
M*=!PCS -@](L 9;@''139]=@I8=-OG+YN 5^;NWTK'7<*67O8<74;QPD2!$T
MS_Z#<,$_L,\-3N<Q\9?2+0<>J*[I"\75(RM'A;1.(F\U/CI^@/)$02%T6^%+
MJ[/\N[/Z0T^*;I=?M3HK*]JH,6Q)\6^PE+H_?HCFU>@%89HTR1^XLYF;]XX9
MU/MUY=J=YJ@T]VR[%RGW3C\*5%POV8P^.NO94.-5>-SP"/L8C=""$W *\&]Q
MEOEAX$AA3?!WO2[VH)&'1[?UH4X6*J /]+(UF384('1<N)*V%(;2?<NT;&1
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M$3B[BM)MNM8N<<PX50]G?!VM\FBE72.=@AJ<'C$'94 ;Z"9!S_P.Q.$5T2'
MAI[*/DBF/0-'1GMRI%N8@V$YLLRI^FK%ZFPJ][+C8T9GN@YV+7!LY59(&UR3
M^QU.NP0\A9;AGN ,-&CDKT2NS(^E2H$!I2KN<$TM^1&]=9\A*TK1^V7$B2?G
MV9];3)7,P;F_,$W!1&*%EBJ==&0J:D,O)0N-2M[4BL[#9.$R,\Q>WMJX]?E.
MS2I<:2.=\C# H%M<'+Y/ VGKP*4ZIED2#'QJN#:_0X2-['H)/R7!J7PS=6-7
MF5/K=U/[K;/H@EN9BF!RP$0YM K#5NYFG@ICR-),V J )VLWHSP$S[K03N;4
MY1LF833:'X1@%^J]QCDSK\O7@_VQ0P4;%Q@+6TH>W0VC62W%;.IB#)69EM<'
MV#9O9Q-^#^*KTJ;'7DB4=:O26USBSTF-**[H4&OBV6)GKQJ"!"O,F_LG*&*V
MHP^CA\:%:*LG'=WE]S#+_-]YO&A3,:,[.IH_WFW6-5JV,UK0X,U=XNR?J/I<
MWT;QLJ$WCO6.?QIG:-PK7I@;].=,OG0:,$M,?N/F0_V>:.K=?C_#51P:O^X_
ME^IE]#-8E"TSSX,<7<.#Q"9BZVRQ!W%DC2[P=W>GF7$\R&%C&+>^>\6P+X[P
M$X@%I7X2>\C*2)SNUA$.>GAY)]:I6>C.59P8R@PFU/<UJN!F0,&DEXRP5,][
M[LC=V&[&B[SI-Z$YD= 3=]!W!N:TEWD0]KYTAB(=NA ,?DN2@C6Q4DWI:A6S
MC Z[1L]-5'W=T>#A6V5D&G9TY%"YWHN<ISM%T ]$/ZC\_E20*9WI=HIR0G2O
MT/D!Q47R9YEB('G\F(]9RRE_)?[O16M]O[9*K<^6_A-8]?_Z KENU3I[#Y%"
MIB;0NV8F[Z5/=<< .]C^A8Y&KL5S!%'V>9]<^O83ZD/-O?M]_8PV+NR6A8@L
M[ XIAB=R#3C9/,@#^% >=Q>"OF)+@R\0Z>93K5]Q4DX>2^]: Z>\RF_,]C8^
MV-X[I'#AT(7=L2,.,-6JWX]_[7FH,.J[WW6X8FW6U2L->(KJC=.9&CM2BR>T
M$T'#<5F%,N0X$2@^T'J83"G1)VAYTOV]LP1$JA6AOK\D;CR[R+DC3&W@>Y/H
M2;LO;9"__N%N;X4C3F1B*V'-&J0:2FYE$<J6N:\(Q3=8,6:^X)=FF%U<4K3Y
M3/X:C&1K%+HG^_%)9 /LR.,NE=^[?A=W=P8NN:[;.WJVMX_I] X>SVM/K9E9
M)\/KUN:W NT2WMK];6HJW"#I[QC]_FV;C24!H8V-THCQ^W:#02%O[@ID_G*-
MT%:<<'WUY.059:@PL_42/5;,/'NNVK-05NVC2?EGTP'1FV+O)SCWD8_/EM(-
MTQA!R7&966X'^2<^A]^+>WY:RG:[[-ZTOV(]]U(Z8>>V?!*ZZ]&-(?OAMA :
MH7'?:,4>5:3WP5ZDJ;_RCE^GYQZY\_UN_^_(=/:?=0)N?A<AB<S4S^-:GYC4
M8$EH 9P][GP@4(;=!*;U>! ^V"*,!_G S8,3J< !. V!8>?!)]PXK3S(&K1_
M?I/SUZ&4B31@V;->8>O\"1U4%=8A?O\24_IW]Q],Q=>5GY7%A-7+=%*PT?4G
MZ;M3K3I$H[C-TU\++IS[>=[E]!D1TV_-O@-)[\;G)/5R^G6%[[E4WHKLB$M^
M]7*WJ&H(PB'T6/^,G8D<0&M'=)/X3.DOJJ.0JTNBSK^+D:5+_IF_>F]-K'Z1
M:'+A9,TZQ3UZQ';_,4G/8RO\@NT![@<^U=&(7"*I2@X3.O=LH)VG,)I^#40_
ME:+"C--?1V<+UY5G%T#A),:#_'S,# ;EYG;"YOU^E=(2V"2<'0^( @NW4GD0
M"X=P/W&^?SNXIP@D'5:KM-<7K,1-E#:FL1QU-M+B=:UAVHK>+#(0OWY^(LMV
MKV<+];VL#RX:<%_:@QZOMFPJUKS.A%'(PVH3];3Q-VEK2\\5:QTW?(UB=*VR
M&T^F5)D*[MW1QF= '(#2KL:("LUART2;50"9 *\F[G%:+%>VQ@)^@38I.5#I
MZ")%YO^P^_WWJ?!M3]OF5.@JC%0.^!UO$8:SF]/DD[Q9![A#SFK(QXT,^0..
M6!$3WV O=[QW8"C)5A=1-7FB*2JL8ET[F0-."4\.(S,SSFEC&(E$F*LS4L<"
M$',9B53_NE4.2(U#O9GE##Q='C^9P\E]@!8@W6CF__S#\LF1ZD3C%^4;9/>5
MG^@3T]21>'^WRA"[K=R67B9A@!MA5T#'I#?S($V&\81YPE<[^<G >V8"0O7$
MW =YKV-(?+>ZO>"CH5:1NF!TEIUKP$AJCP]^CLN#?&E)KTG%_0Z-/EHDO+6D
M+0KCY*]BHJ37%S8FTV'/]/(B?>!1UO93C>O5RYH>5>LR_;\>EGUKUHF059 W
M&20H@T;X*E.&N4&!,T_#6FT)%9'/#?@FX<^QM+?#S3-A4REG]!=,'/IJWS>5
M?AV_=>@R^U6#;":Y$%[1VIH.&XZ<,(FJ#0'>,K.;)=!_5K!NIME%JAHQ"E&Z
MR@OX\(SMF!19"5F^SK]*_@$/J+J,17#FI*!\IS)4&J!BAE 2[HM$'^$CVRN[
M)+E (L:Q+RJUS?ZNO*/7-D?_PXY/HR&<F/^559X5.(/)@R2_(-S"L?X((/,@
MEXG:JS-/>)#I(\XZH(>TA<VXPK>BU2UX$'?L#K;Z5F]@M_7E_&^PA =*4HM'
MS+!W,YT^(HX[>02YMQ\4Z*JUECC7%#!VI&FC<*Y89LHR @7.5G[G@8HS%ZZQ
M#/,G8\1IOUX+#$\#%>02K,2''XLVRI_**S.=%LZCTOV]E/-^?P(HS3P(\37:
M6U K&Y?Z"U.LT@D@,!L'@_(XOF%;"32#; )Q5'!&*6I<YT%*2H'? [B7+< ?
M:,SRF1(9'B2A2H9;?X$',3/)\H O"U6!;<S9X3<*-NW8H53"/ C*!VU5WNG+
MG[&, AW[Y1=_!:.W_56GLZ7.CH&@^;/%529UPKWRQN;1V^C=,6S3O 9 I@VA
MW9QVWVZO8D%L?$]JW 5^7\5]$0()FV-P#(SF%4GUH+DQJC@? "2,;V@N#8B9
M8.9,G7%KD:@VXL8\'*R>B3Q2DRAX.%G]X-X-3XU;QJ$W]06?GYC0@1E3;OI)
MI^YV"PBJ5)#J#^??6964%!> ;T^O+:KTJTO!78BOO3O?Y^&.VY"%L:6W=HK=
M*^DS#83H3 %F_J1&A#Q_+THR.)?L+C9*CE.?NA:\!/9"\^:H>((+2ZW>H/):
M_>U1QT=3:]E<F<8)?XZ$5SB,:3L+DA._3P1AH '\.O=@_!OD(1[D#[34+,QC
M9"8$<R%"5-?3;Y&TPSLI=K5MK1C.](,ML'B0BY%?>!"FNL,R&I\X)=-\KU*E
MO7;DL8=U.;+.UW\$T%PP+$^YX]AT;U^A\D=D6XZ0SOAFS>9&.DB:QZ%\A-_E
MJ&,@8<9;\B!3%4!C $J$!WG72<OC079M;;K$#PJP]:&,$/#FA0F +:D&I2T
MP^O<*-&GX!^X6?&(AENY8S@'L%\X1K(&65G<>^!+Z$9^6=I4)>\":,5]8->H
MT/_TI$KPMT5:.5C@]PLFZ#+X.TS^_5-D:U780YAJT+DH2E"X:_6_@=>_R#0S
M[$A-$[1J*09PSQE8@XK,!<$:R5$D3*2!IN&+PNF.]\WA^!?5Y8+^SS1^\46H
M#VWX/5U;0X'6M]T23ZM_.K5$*F_D2E:5E570R,V=EI8Z*:4;'O<3RDVD1?24
M<WN(,MZD^N42K-CQ3S=A>XC9H=D+^3E7>BJ+@Z[Z?YP_LE'O;W#SGDBF1,6'
M:P4%1LC#@YNK2"?G;J<?(..@M1[]W\K[* ![OSGC5642=Y?-5-R%23QUVQ0T
MHAK;0(Z2WQW3 !=-M>-^^Z&-$>WTOT6L?C-G)XE5&=/<\Z6E##5L%0T*^788
M\V@>5732:T27441W:R2$$TIQ(*9X+#&OK9_P")J)JD7XY]HWN 1J'7N(5!,>
M[_VBD(7$M<V]:M3J^S [F3\071-?17S_;J-B=9IH;I%3:)QR)79*;5]?+M["
ML8LUC%@DW^U9Q-(N6&(V6UNQ JB'[K6^1>RK3*^W[$OUY32-Z+530^8?A@RL
M+%0O+0BD[]85,Y?UZKO_Q/ JA/6NW@;T.>9H(H-0L?2E\W'C"NKPUJG,2=RS
MZL\TW'.#O6*-# L)RAW3%XY:RF45&K+1[39G9SXUZ@[8]#@H&Y3%MQ\W_;WX
MV2;'-Z^V;NEU]Y4K-WN#/YO-V[A]7Y(#4KU>6!FA=P(-)K![:L 4C+U_B1'-
MK*%[,33HZZW=S^IW5O2NUBFO!A1X[;R0ZY&24H^DKGVP5TBUUG_=_MXQ=2FT
MW5@EN:O/RL^LLVK55,5W#1&L-N)G<M%CQ:BRKM?4<R18(YG<WF&+&=_\VR7C
M53DL6[R&8<-YLK7OP(=R$LDJ"G"9X$%BM3ZL\B [&OCCQO.TBZY>U$0>^YXH
M$/M'K-.K16,9C/7&+,L,1/IK]>"T; !Y70VL=#&/%NG0OU9HN7/>7Z<ZR=GC
M\="K3+>X;(C9VZJ+R&^ST;/%EL/]R6=\D(CLONH:-CF_V_A=/K_V@!('N0&M
MKUP!9ZB8/]?*E04J_&%E&H&;IH:@I7-%ECFY]8HH.;#[[P( <QJF"2H;8&>>
M2EG,>,0(,J[Q=?%<KEQ\FWL^02__COBY!W?#^4IQ+X&)9_!*I:8Q2^ZN#)8^
M\\K,I&[\HH%JO6)%J;16-6=D=G),P?42*DPI=?J#S3:="?X_96V-(QFB6R>O
M;FRB2,\R#WT*-2_T"QVS8L2$%#7@Z1EC5?'>G3?HL*AB]N$<[>D?+[X6[=]
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M4"AS!%7=0F7U""8$0L)5Z[X5K3)BL%Z.3L,C@UU=Y(RB53O&HVERGVO &'N
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M,-(R+W.IG;7/2S]0)0%+5&9W<G"^7K'0<H MKM\BK\=Y_0"DKZYT( 8EE^O
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MC V%+0F 076A+H+@WPI;>:(/\K\2'2Y$H8!Q>O/(J758,QB;@LT/8 3!!SF
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MYT[BFU5V].^%'#OR; #] [-R"A2!I 7,G+"U[QUE*FC;$\XX-CJ/\^RD_(/
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M@#I*8>$5Q>.]CYGXJJ3#OKP1$_O+3<R'A>^$-7Q[FKV@#"!CG\'7;-%@^)F
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MT_G!JC[C#U\& SXGG:R6[LB@)C;FV_"=/X%:I73OG4<KT[>5D2BL37E(QVR
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M&JP([=\XE_C^3"&_F=KWW!L+6X4KMHNY2]2Q[W.@(1=TSV[O=IB& 4J\(;(
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M?;\FHB<RAZW$<D32IG]D,XE3/KLR",,@M&($,1Y&06X QI>::;4:8GWWK;W
M)T6\J=:AF23W]W>K]UC:3,4RM"BL?<#Y4O3 7[@DU7]%@Q-^C**LIX7>B =D
MBG%87X)^KP[R]O^"=GQ1'F.S8BMV.^0-QYH;RA-%2ADPS9$E+$3J67M:WLW(
M")P?P)&XE?I.T6HD,%W5]!KLWJ7]BK^8H0K/;Q7*5Y=/N&MB EXD%RGQZ#DK
M_6,A)=HODS[ 3+MMXC"-_'8?,'2Z9=-P:4W=1D(4E.%@&F=W@!#7=-T=<Y1W
M>A+=A17DO$ )E#HX+@3&3$O,QJ]JWM@P\K=4SYF4?N<L=U!78/.?&]"A,LV'
MD5:#4W6$Q&>$NCC7:!V(0LF14.V/HU-";:9O5%!:?^LQ.<^YH?D_48\HU9 X
M;3FR<J2J#F-F*=&#=(N,/S#@L>A3L05Y=EPA-<";@'BP5V\E+4Q5G4$,6\_<
MA3/KP5(JWFW?GNYSYK<WVR]=U)*6([:ZD=>G9C8-B+H3Z-[4X6J<?-F*ZJB.
MB*8%AK6.&'WTKFF8G'+2[+^]Y7VU2QKO0A#T?7_?(#.JC(8W!/>U-5UA:L2H
M"2V9"B!][U;"8WH1#Z]JE8BB?^N?4'=+_':XN#.Y':G\%0(H0*(;O'>YR9DA
MHL?*27>>6"73'QNQD6FKVG.]T/CRQ+BCPSBIS3(?9EBE=^RY/O_E7PIO^<;!
MQZMCC"B'%\0L[,9[_=V>^+*"LJX,W*F3%:QXT_W[A?>0]0R"(^PS^'47]!EP
M;!@5R&#T=5#$M [^A&I74;'\;0,+:6\+&E_PGKJGB2[W2%SZ1I46Q$M$G#[H
M@(AL@S^KO<R:,9\S76TD9W@^(_=7%MTU=O35+!NO-*'D&)5MUAE-$*=2H361
M=$6VQ:)4&T98RY8MOD 1HONY!);,4P3QCN8K;3QP S+I/J$QWO9IQ,';-H:O
M4X]<X<<I 9A=B&T#^DO' >'I" )CDYJ9L)3&5.GHF8J37! T7P):3:XY=L&.
M%OF=$K#P6KT_%L7W[\?5SM/:QNPKOSBGN96[TPHBJ&7!/@'H]K7L@(YHW9@R
M#KP/9);^X1W_PEA.]ME4IUY>DK&.D,EBRCQ]^_;4VWU>CQN"P*T8R3XF'X^?
MRM!D'2+\Y%CRT06G*%$!1C1/<:@@N?-H3)[MHHJC>NFFH'C+2"\XU;(U:;S.
M1S#P[M44#Z^1V1>&RJ6.MKIYV. [%^4&KLV.=.L=T+O^\!,!9E +A5URZ(^K
MTU 47W[GY^,-^6@H?^:P0NS\?_TJ<DN/M<4MP+@G\*-<&-#=VQX;I0:$X9 Q
M[58:-_-W0'%:GD<_9@DR)AY^WLL_4VV\XJWQ7?3*0NN,9RE_Y_#P5N(N'Q7$
M-+O^YKY2I?!Q+C 2HDJUA*=7HHWJ5MHW1WR=[ $I@VM!YM"@8WE)/3?.MWE4
MU&@1GC^5OSZ4DB\R7"\3[#@VILXR"F#+_1SY8&\>DC*.7ZJN)UCW*]'MS?LB
MB5/U6?(#.R!GK 3<28HA%/D,F)_"1GESSHHKI13?8/ (-/ZG^M/I I$'[^.W
MWH]!E7*NU78=;!1@6>W.PPR4/B.P/2$&>G@'Y*$H1B5&\LYS+C)\4'="[GTE
M!/K\V?X1BZ)<G8Y?"NKO$M#]U/QOA.);4 ?Z[ CG+$.S'<PP2  M[( JB6\:
M#)BY1ERLMHH[6IO)*][EVV)VH\M6=S='?>YY[_=Y0+N1PGO8[!)S('[ ]!-2
MS1,R54FI*:0K,EVH)^L*LAE$&^" <DNO$+2QO[SZCUJCU8+MK#<?Z?CI5.'7
MOH2()TNFQL$=(F?0TODAZC/9I^_"_"R*27'KL-5Q8Q&(ZT6+^IG7'UY.+CIV
MF"&>40U[22STVO)+ZZ7IW4$;!<P7<>[_W?$P!BO$$T,BIMSH=XJ5DJ<,JCWM
MEJ''W56,CB21E JDP6[O)I[O0<75:Z#&M,"#AAQE0()9/LZB, *71-@:@+4>
MTQ/7MC(VWEZG7<74-!E"J00_:SH:HU^5<M7W<F+IG<)SAUA57A,J8<W<G^4?
MC&^:F8YYO/N]JT_3^?52K1<#?I<3"-^G\V_4DH)7V[OL)JJ\K*WF<V((1EOA
M)\T<W&[_C_3P__]4./2U]\6A!;E8CIARE%80C7($D&O]K/^VIQB^G2?N^<YK
M[E ![/U#%4F0G/1ZN>G4'+V+8<&*9JK\(0HU74$I,D>JSN@&?F9L1B^I&>7'
M^ON>.5%U0/)+^_'-S%RN/R?4::'^EN%_Q^+U?UZL8L?=VL''M4ZS59"YYH %
M[&CV=$_PBSKCO%1!I)>KSW'+VX\K:FPT,LXE76])=9^\([*6UMEW#!6( &35
M*Y@8<R![VC0<<J+A])2CD6W#3S_'?3JBURCV]RZ_(< ^_9KL_BY^I71DM?5,
MV*S.PV[XC4>&US)(ZAR+EX%X/-U_@A1W^E'1X8=DDYZ1>3AI<["?I3V=TW2O
M@IOKK_SK[U8)F<&=64I /W/. >@**?A3I_0NW3I2*FO4+*L;GGT&\HPPZ&*3
MMSIF-*%//7375NS[RS\->KOS#_*3HWFT_AKG"H OL@-$1Q2PDL9/7 M^-.UQ
MJS'*/4"+F1P5UML?(YTXWX,TT^\C.TZ*7+QN:(:@!H0D6S6._RDO9UE;ORQ9
M&TS3<I$O7)$>#<B V2KZP_(( 0%V*O/%"G,[H%@*XZ$CA&J5$%0&PQQ!7T;^
M_53,)%FTL0A(:R7Y)\$"U*_=E[/M7_&B9S$.^2Q=-J>^O7ADW['"]O^XQ=?)
M7RG5&NT*F49?>?)#VOR  -4DA2D^ZC#X9)!$6Y7 X;\]&Y-9_=YUZ6YB^^GP
MLT^C7<X]NEK_P'G<FQZ\9:N!@Z_6!U;5_!C.C4X:8>'QC1-6F4MS$JRZIEUT
M].N'RO?]W=I^<+!CDRP2,Y70"4\0'?]SK]W*[AJ,9-A7XE[?K9Y],N%3Z?&<
MFCVALS9>48_W[_]]-'L'-)77),34B- &3P("K5GJ0'8IZ@%CA2-3)QE.7;2W
M41XW/'ANU$*-VUZ&KRMY$%-CFS)6>=PA=$^/@A,9NFT]TZ/ FDFA]RB(04=[
MUF9C'(=RAI=QZVHBJQN=')' YIL%N5.*RBU-0D#B=,)QU/T$>T=-G0$_MC[B
M\G)UE',$[\<2V:%9I*&_Z[Q#U[G8?\<W/Q3P)*"[F:-\ 7T#*&/?)*&T  RM
MU^@VD$DK@[>BY0D-D2:$H6J%LINDWZ9/%Q57+_7N9[R7=N?\(LO;=P>=373*
M-3&'*1%GA[E*92$UHY8^3DL.,Y7$J0Q\_9]UBM[8.+U8H6L'!,/$BP<VKXAQ
MY#XW#6O9%AI,)YQJI[+UU^'PB]F-[TN7YXZ1,U*>&3E_5A$E**AOQ.ZK_J)M
MS\CE'1Z;HD2/.O'70_=PS'^BSC,%G#):2!K1&W"!4]5%>/>9+'!%96? IKXC
M/8__8M@W%_S]^GC2FT)%*3+EUN6F0 /%\0#[CT7+"CUP7Q1.$>U0B<@Q:(JG
M6)I!#P 6O,/!M+.^K#! A0KE!WQIRK&<L].]T(X NQ^$DO$_5MOAU>G&ZZFE
MB9>MKYPCU+BZ=87/).TY>*0JJ,2I@A')8D"%_[HY'.$8497W<GR!=HVX]7LE
MXPTO31+AGT(R;10,@E^LC<','AB!SD<_7+YFKGZX370SJ F*-:8O$T)*,\8T
MK17J'8E4 FES8)QBY+#M$PTD-&,95G!B' 0_U]PG!*@T:TMCJ<0$K1LT13W;
M(<23S_BZ_A6_GO'@&]/O#%Z6Q\#.OW?C/Q/^_>V_#XJE%>:Q0I"I IX0$%:.
MO&M!A;P1EWO%DW)2PE*%)!:LK**RD:G4Q-]1%XY/-/[>:QGW'>'ON=>H^ODS
M<D;)6'=7$X$C/0U\:8+.UJ3!WL[ *06XY7IV6CN'Z-$Y<-*Z!0N&3!5KD*6&
M>$<Q+?6,'5""*E0 R::E)E,S3$^18>FH=.68R^DPJV4%#,7(]\3GN)H>M0:)
M%F'AS^>P>?_OQH'*R9FCF!4?U%^_3@).DV)<3D[VV_[DNV5/(4Y^X]2,!K]L
M%UG%M20 "FYA: 5'I"P=Q<<TNL-(:%-\B1!P)RL,EUYV&2@8SDU%HCMZSHY/
MG@^L>2M=('0^?OC$LB;\CVE,^FBT*N2@@5R8G_U97Z=TFZE0S<6^2M(XWW5X
ME/V!]U+@J_</4"1T51*O>5V9J\E K0_VZ&;5]!=6?8'U=F]29HHY@W;^QEZE
M?D/679 J7!LF#EP=R1$._)J^08S34LL!UAR^_#6S[G4]<['@5WO(34<'6_MJ
M\]MN-BX")R8NQIY1#6>]W28R'N!(4!MNSOI*5+]&7)FV E*YF2<O#@E'!1^Q
M>D.^6"/ZUDCE1I4^W=7=2SI56*W!K(-]4.Q<<MZ3(!.%I<75!LO1E-]EP4Y]
M%5H]J2H\Q*H7N>Z6",41KYV=TQ0",'=A2Y;!MS0CUB%%,X((ZRDW.TJ8C/KK
M/\:'SPS35SCM->S#[^^DI+MGG8&D:C7')O9JMA,9YL0(-'_]2/JVHR];N95W
M=% +'EC4[,J*051Y6#2(BO:_=KE,\&WPK)2.>S4]VP5J\]J #@_"5PS&&\MJ
MC>TQBS:X'V;L_O4#(FM)?XN7&\Y23S+O8TYH79W&A6VGA7,@<M$44Z8Q_L/@
M@MTCKXK&WJ+!9:_I=Z6X,\_.TOQA4@?/-QI0B; ^X*(Q)9+HAH@1'6D296ZV
M*$>EN[4V^K;SCDE>K!C,XPU'_Z#(+E.6-L4>SEZ4_@??^*/KMO_D415#Z]B@
MLGZBO1-KS:&R;M*GFU554^U>AW<Q0,CFK@7@.8U_%KDSGL.\CIP&(Y8I%[=.
M(5V^ESMO12(WJD?FC!F4 UD2[A;W'0WU$_,K#.Z%R73_KHXYXGG&]O#WA-<E
M.R#P#NCY6<VIR#9!L>9TQ&L4C"G1:;<1NUU&B$0IBV!)21U\]U,7;!%>GF4Y
ML5IO<E'-F1F'RN]TI%S\8IJX4E8V,CH<9*N!F=FL&9K--7L4J84BS >[<S8,
M)]<I]T8_X6+]<<!%72P-2D)0CV;G .F>8*I3(35! @K4#9H/#I"#)1I%EG+]
MOI C;)[6!-1:/7I<-CHG86R9P#NL25..AM3T+=&IMZ1:,,>:P( U3>OE<NXE
M(/G!X A$!,;:?I%.HHE%P&8(>W7U5O/96L"3)BUOPRM>7?[U[ ]ITUVR]7D4
M/7@Q]T-0/M<34UN-?3;PLCJD0@<92!=F^\&((&UU()#:B_N'=WXW4W>@+_U<
M:;A3"".?)E0@KI%^P)&%0HHSPPUFG]F&5\A4&P70>+>4-W8_9JHTBP]8Q'%N
M&($/<HS[.3>8=K/3#QBC4?XA2J1QX\:A,EJZP3KKSHM1[^X8Q NM3H+H\I/'
MR9#3%]M[Y22)LZ-SHHV6A#.-XY3"+;DMS6W'I?<;,KM($$&<RD,+_T1=<:F*
MI&':3$\NDB&C#>!LI)_-O-FB>-Q(IE;.@J8/SM,]]:'T<RMXK1GG<Y9+=>R>
M!34((!^0Z)F'-!_IH_:UA]SK)%\U&KN,VN\7$P)IXS_[+NKL1&7&^)O+ X?2
M];]BZ=H/Z@>[@@*57!WS1NTAC= YUQ*XSE"13H?)B4EU;%<U5\U88<5M#'O'
MS$%H:9JM^P=<O=FZA:<?/&O>7LV].Z<WK-IK/KZT'1&'\>(YL C'0[NE=9=C
MOWTMD;I66;%2U*V(X :@$W(7[@9RFN"ZV&=9<5Y9KW1.FI_Z3R#N>[:J=N6N
M(TGO$Z;YO'])4!I*!:BZ&S<J[66!_!B;X/%WIZ##DSN@_3+<+,SCE5]R3L &
M0^[VL+8PYR%@.*(M-8 /-CVQ8&VD%>-]^-],I<(4].,YK]["@)\&YH^XP[M@
M])4;BO+</4IS0_U-(\!"_J9'_I#EZD;\Z(;D16B6^_-$S\(3ZG:GGH7\.B/X
M6GA4A%FY"R#B.R $9-QISH@!I7NR39'"4$ !$>R)*7;7%AITB5^T/Z9?7K,\
M7S#F>?<1ZOOJXW_NGM@C'!E;)F^!2F9%&X:D*=X*KK_>,SE&'QK(RRGD'W)@
M/(1U!A,NPMP*BDA<973DW\61B[NT* IE^-.+=^0/3P38 5'!K\JF5_CMD?^,
M_<G:7PN$3?=ZK=JTA9Y2?;7OCLC;.^=5&K+?)_X#OM@7Q?E[<C>O/^OR[M$9
M")QFE>$$+ %E9KB6%%-IK.&J)\R;AA5:J8DV6%8<._-KLF-4H-%S<F_F9(3"
MHA IAL>?S>RYMWMNTCRD6FYI;EHHW.[L2/[4MX8#.%C6]4&$TL?!4I=W-QU^
ME169K\D+O,F<?E!X^=XQK=&I-(XPKY/'C_]K(<W-UY;@#8%%FB0TPM$*\.V1
M;!@MM?XF'(K?2 ^G(*X5=R*?OLK7/Q=42S7RG"5?.)EM?=P3IR8VW%'M\)@P
M\&@YJQ\VGO*E1N>,5L'\PV2>30VA*E_FXLNBA?(,8[E@U01G)H*.94I-\W%$
MQ?NHV%;%X,!62#CTZ&\F)FZI[#E="4*5(C;NA]5(HA*KWYZMESTH>_?K6Y^K
MT .\=BC##A>'K0[L"-%>M.66H(\#8IV#0.PO#\I>%&;JHI9F_GQ-3\!Y=\6-
MF;C9),9'":EDN>\!1[XX6 ^ &7#EI59:PA%,\RVUE6@GI:$-"&""5I_(2]UN
M8Y:0=?)M[044;T3^FW?%4L_O:)[(TV]2Y7+TOY]$.' _81#^50R^CK[3Z._:
MB@SC%([%KKKX06 \8&&%I0D&N2G9.K&**;7^=X1/91PX;G#$1Z%PK/C4)[/4
M(COZ^FSRN_H"6GJ8N76U>9C)[-4B^B=#A.YD"AYPSO6O24KR-5'&-?H_0U=?
M[([/U!2WP^7.)_Y)URE[)_-=_47>(<>8JY9[= U^?SB*=Z[-A_]Q0'37$@[+
MYR3>^;^H7?E/#2=7-HQS:ACB3AGCHT6V<H].F^)'4)Y43Z-[%>E;9$V;PB\U
M2=(P6Y%?Y]SVIUB=<P.MXXQS"O(>T6BLE^+]99<LI:PDV@L:K0I_8$Y#GIJ>
M0-T;V $]^W(95WT]8VHNVH_K:Z?2>RGFD^)Z2;V&/4HW\$:2WSGMYNJKTF?V
MT2!BF*GD$Q.\0:QP@VL!YSPWC:=DQ[$:>KR+$M5-<O.2Z,(I=CX^@J039=4Q
M11F_$NYZ3"+F;KD#_Q5VVDJQ@NTCGXP,LC%AKK?'?U(Y0--VOC;6^K+4@6KS
MZ/689"<<)75;E06![( \A !9:+MR3"#X! ?R1*@%<P)IVNDDAO_I)SJZ<<OP
M1R=U+OFQ)R=#<:^\;%6Z\/6UE'1DWMTIC0_G8\] HX@,0T1,^F8S41CIIE</
M^"IV)C3MF8<>QL-6U.I_6>@/K?]9;JB=$G">G259U5UJYZ3%GGL<;]*_K:9S
MT]_U(&D1OC5FK-R"<!RO"@RL7Q2MGK&"HL!S)I!HJP>,&NZ_&]-L\ZYI3 T,
M/*;(Z.,=:Q;+D"-IC[&(FM_'JQ#)A+AQ@AO@W8LJ>K([E)^-H#2FE/^Q)A%"
MT7LY;DRQEI5(V-39P%9)S2CLO89+S.ZT&NLDV*;YG<M>E<KJV$8#?9G#8=#<
M=2M8=6D]8;,N;@<T/X93*+'-ZXI]9.%X-GE+7F8S^#K1<A85PX#^74G'H51W
M(=VT_:T[D0\ED<NYU<\Q@Q6[.QT<D.ZO!@J&9:J0!TKW'.ZJ\/S72.7?V+C(
MX_*>4=V )H^_ERE%Q49QA&B.ZHO-XC6XJ5U1CU9@CMM,+*19I8[:6=4H.Y-D
M[0U.>V7'ST-[5K\__V;Q_>']L&5#!1TK0T.C'/COF>^CE,)@_X5'C0M.W?9.
M.R!M6]WM((,M!R:8Q&9YCFI#@)6I^*)<1YAZS0Y($!4B%.VOUIAZ/XANWL+Z
ME7?>+,RH:58EXE+]/=08"'R6@> (YW:0SW(3>(<XD(Q'C!(X1! M8P_T6+Q7
M<E.O&NLL=B2KOJAXK6(\\^.?@Y:.S1%+C['5\I_"9JH<94[O@,;[O>$SRSEP
M'4LK[.IUS'CE++&/DMH4V0+AATQE0(6U#R^ ^3=*)!+V+MH17G&>3,=,ZHZ$
M."W\F%S''8?VO:ALE:]*S%HX1+KPY*G^) 'WX2/?#<RN5DO? 9W2/LF1 B2H
M(QE?G6X-HL' ->@1./K4$,>V^,_V!:>&9B+^//M6'M;SB:3SJI=SK*?<\\34
MY[Q79CHK1,R (65+M6$PT%BUK%"ERG$<H[Z%VQPW3N\OR"#.F2[]M5-X!R2R
MK\UC#WULR*!F%8%?.S-QD1N+QDJL1<.J!(/1#?F5$[26JS#9L<<VH0*Z8Y(2
M>U'RBMELR=V\3V%YUS),(Y6;!'A=&N*85_J1/%$MR3,GD)V.H6H*1R(FGV?;
M:](.I]6)C9Y^^NSX,]/D=?'HVD<^?[WP(SU#?IAC6&LF"UT/&A>)UILKFWEI
M*2FE&YA]\V"&*2+>CJ\5]VH'=%AQI4FDBS$ZA8BKSO08M$]^V"1.KLW[U2-U
MSXOE/-I%^!*OKJ.D)&,;[7;,Z^NV JN)F^'?E\#3!*2*W4?MC,N(K5#P/5JF
M,<(U43+XT>?&FHN''CT>6*F-I4:7_Z2HW^8;_U3DF^S$PF5D-I4[+>-V0"#H
MH( 2S, _+#)-8:X?,^6S XK0!XB[RML$*X$,9$$ *0;/TZ*EK)2C!J0@IA5-
MGM9^(/6Y218%(OM;.H[U:J3=!)46UX<)?GV,K9KP,K]5Y%[TLN/A_,4;$.M3
M[;SC]R_!#$S+WJ$-NJ$?WJ_IM2B/86F=7\&_JK[RCC&P40TJL&G$P05SJ.,=
M):@>\VR]XX3A-HH@Y+5FGQ=UC<>3C^GX<\A6S.>6<@3T<VK)-.X-4;C!GWF7
MRKE:AC*/T2?4_>1) H/6G\-,'%5-I/[U2&UI60C*7_OF.]-6+Q5_[8S2](;,
M2:4F#$.=G9HA5USEM>%YPE%U T\B4II6[H\;R# [.[& #'TS@>A!#&V29:R\
M:<""D-I#\SRU07^N[IK-L):!)]R'L&W'+?_3J]HKR%#J"*JJB.?7LLY "O$.
M999!EFXQ$ZB(&"W;CPMVG7'X18,&M4"97(^; 6FY\R?N<".?^"(N%6:*ZWGM
M9ZZ6S1GN4_?!W)<O/'V]>=#>@^=E:+UA[+XM.]*;$FQL[%6VJ7,]?]X-4/K&
MV0'5[5*?^\KM*Z'0XUH7BU 2W!3M_7VTW4FN'G5@LQ4G%&>X#<?>/#T 6W;J
M_AJ2_#T\<.R4*R5<%JW^;I<[N94O[A(,F3_JD/T8EQW0:_&Y:*T])4B3OD<,
MD[>S.R#SAGK":FJ0TDA+?VG9RS2"3?FO&6_EKDCNGIQWC;]I+!BN:7,'-)"5
M$6"G8"D>_V':7*+#T&C89WP'9. 4O%A"["16CG*$9:=9T PGAG9<B&0:PZC#
M3B1VDP2.W.#JW6W:;<QS-KE?,HRS^KI3->'X.*?;5?=;;'[1O;5>^3?HL4\B
M6Z?X.N,$:'K--U1W0,)0.\ 9P^]!4FZ#BL,UA##/1['/(_R'YXSOSCN=MGLR
MT^!5GA0N*-F.*Y$ON_3H74'QK>&-55@'.?J:MV-*V;-R5Y/#JI/*5059'C]X
MA.CD$->2"<[6WT:\LIAU)<,8SY2+]H.7@(_#P,=RF7&]A9DGNX)I49Z_H9\[
MNINS_[G?\U[:2O/8U/+YX)6#Z!XHN,&2;<39SY1+* ",/*E]H:FD_)3O=9+Y
M&&\,3>/+8'N>=>A%3Y?X46G7LH:N4"]I$T  ^M3,4.V,N='3TK3[:6I-RT$R
MJXTD8TL$N<34.F!E9!76LP+3F,]/A@&8.,BSS. V#.,A92_'+F+% 'H4Z?*U
MCA*A5)9E>V ]38.0[L>\>>YNQ)6:I(,RK7N[PA\;2%I,80"YOTLIC-U6[U]6
M@PC@1YM-Q<E LH/[LMO52?M>>'%+T?,'YQI>X7*D]:5.66_%@Q 5GW+4SCPZ
MP=;<G>!87HK<ZD]SZW=YO '8]O5/:'T TDID& M%006TC*E8,#+P(4.I:!JW
M#V7$3(M1Y<J9#2F5^35"C49GDOT;"#!/Z9K10Q&RY)JUCT]=6P^2%=$#$(8)
M!8P>Y*D!WDP(C2]T!^0&B9949\1E%>51 *DV*U]">$%%8RJ_\RK"2Q$A8U_O
MLC>AFAMWO_FWY*,]7]CIT6_^Y*2-63D93N!6[#>&2:.N0VE:^1=#"L;7O$R@
MKS-'NS<K"9%_?<#W-]QA:Z"T?S;<*N1H N IKN;#(:\5?"_DZUN#'-CVM;IG
MQQ%[QT6(_U;F&*AB729RD;&/]9RH.B+F:2J\)N@NOH6ZG<HGK(_7\_YC2[S_
M!(/>_RW*K:>%OA+WHW^2CTN"F3N@,)3"=.9^D[1[QLR#R0<+G\D\6$KN?G]:
MH]Q$XO1IM6&SVX-P9T&5!S7]JHO!FIK(RTMT%YOLT%-MWBW15XJ+KUN"'N_Y
M6O0G)X9B)5/PYC^S.NM_Q?^*_Q7_G2B'L,(![V*."W!@.N'0'R>Y(2WA,J"D
M=7-;&TM3 ,TNWOZRJQ]/X9S'I!&S=Y<KE<:.S1P\;2JUVLD[W\8M(L[+@:OY
MN%N[<F\KZ#98C_-B%RC"FP3^P^X]S1;=O=T9H2WOP+G;Q#P81?VR(7#K9OOZ
M$^_B_-SQVA2<*$)1Y[?]M]=O+5DEC]V6MSE7F<J<TWW3*^(HUP2:>@7;$]EJ
M!80+3N(Y:+D&1OCW[6X'^T/M#2UTO.^5I/,G[YS1?JB;H4^ZN@!F'I6C&^_F
M^>O<CY"5'[M$L:<;Q$7G-&!8A[D?M"S9TN@N\DD@>!H113X'=-$00MPJ>M:5
MD;:6'9#U&D[N2\)W85,M;%W\H]=>*4TVUA*Z)X,/@)!B2V[LA\B,:7 ;)4Y[
M'W,X-;(0J*>:Q@B^EC*,MLDF]I=_-,I47RHMIS?2 N+O'AV4/N$)>G$V!SV(
MEF?V<4ZZ. #6V;_^E$U!]P#:%"NF;KZJBMJ?883;$U>W?9''+\4@GZ7>_M8;
M=;[YH4D0A"3HB?EK=KS2#!&337R.4F'NNUO+4(Z>N[3_8=_SRH6;KM_C?H'2
M&$\W-*XF&&ZE3:MG3O>%$QEW^TA2T[+1A'1$VTJ<&13)8EG"GM0-7E8BRY=-
M=\<Q\35O$R\*A);&W^%+=^K73<-3DM3A[!W0WEGZ=YS5XK/4B/[\/NM?A0B8
MC->"XII!_K NM'[-A(W-ECS(+6P2YY@"X25(O5;(,8X@35GDC];"2Z7W.+O)
M!?% ;D"HQC6]W4N9.1UG:_\M=5$-L>^DG+W<=!F92^ULY8*IE#8"0R/2:T-0
M1S6Q2.Z7I]?QI\'O63TOG )/);B?4Q(^E[S5134%Y-(ZE?<#B"E*_"XCXO$G
M,&+N#^ GQ7= =YG$L-D1/T=?,XO+C^T*LE6]",:!$JJ*9YJ>I/5*K1S3&X!4
M8):.,Q"L(FX!Q#,.3H.V8@X!:^8)M#AR"ER)6-#^"?.LQ:]$S.6YC-4Q_>];
MUW1%?@S-S3C Y=D0F!SNLIQ_347F6>MG0Q//6?4O_\0C'UG$VI',P['O<BU,
M53]8U.%9@[[+B"B(B#\=S'H#6.>X\Z0!:S@5*Z)79%#T"R[^.A&(L3ENG_=6
M/4&\IBOTJN*-QP$=CV*?$?!$D@N5&-&D.,\##36=0\J9,LFE6:X)D4K^XS;X
MX/9FS1R\VXDO+<DI%C^WK7]C.<)S;>+QY43&@]4!M>&1E%S4[<'+G(Z)!U:?
M;S4<,KB5&R=&,!G.9HORONV JB#TX[L$XQ4SK1U*.G%6PA (5R>4>V"/\<Z7
MFF'%D!96A*&"ZS7U5XV\][]]0[7)UGG1ZLXONR1>9'(EN7[3I3>P"I[9KC;H
M&ACX=,N%55ZLU9=B3TY)22UF):/K8<,+VS9<,6XJT:,1/@WIQ) D6E^NBY^-
MV.V:]@"2['MOKR0=Z9H!F%5:@DR/5FQ^V(]IG]</LWVN\6O',!)8[P!?]FWC
M8KTI"!@IUS'@[IOA:> GZ#-J[JEMUAS_1("0VLHN"X/&4FH*8S@Z&E^AI&C(
M 8^7GK,Q-$J\)/^@6J9>^X#CK_E-.^,?4?E[2=FO7+(T81^^$O;<]ZRT/7@P
M8+2(]V,']-FTTW2,S9H#Q&CTP+_^^4C4J2IC0_@]OI:J8B3&GMG^N@8W9Y-G
MH3,#I=XU.1G7_-&*_/',NZ*UZ[IV"G<U>&OY)L9$:T4K=E.JMQVJPC>>>+(4
MO_GH=Y+5XO+\H-<F%/?.3,?9YK^WWFZ-Y?AQ2]&BZ)X=T!B&4:4MPX$ @=S:
MV?\HUFPQI4D82['O=8_-;D'<$[5ZLYX'U\PA_GW?0<7*[8#"L>R'F/X;# 1O
M?^=?OXJMN1W0@=TS0\UX(V"&#02PA(SQ3@&8[-TKU?-&U[3[2V*@$#KQ28=Z
ME_92R-N-\;C6%;>$O#9&KYWJI"E"UVI>_#/B=[F+>%>]+?<[-R^GR>W__"_S
MV"I"M+8\,IGMPA/5BU1%"&UIF[("?\E8KZW-!M57:!$#CT\O<Z=':Y#+9XO"
MLR^MX@P-[/6'8O.6!_KE IN:K%WBGDZ6\J8'%6:@XUC>X78JY9?+M%X$&MS+
MP$X7MF-$D"7Z7T852]%GD,Z* >Z*3U(N),[$3NA=^&<Y[+PAIU7ZQ($02V@Z
MA&$&!9PHC&W,:R*C#\HHPE!O[-ZN:=D6A5$!J894HMNY^6ZSGFRA%12=YS3!
M^4+)\H9J2G3C;X: U>A<DF_:G A&(9-?V>U&4Y3]W/7.52^R6R.Z"\NP4@;@
M0K$C68([H @8MTQ;G%M.AB?0^R116KR._B>K@P&=7]CWZ(%_<A%R\0K?T=*8
MYJ_;T)8W_CUE<)8NM];3#W-T:R6X!-(RE& :?RH0\64MB_[H'MX(\5RPX8-U
M!;J=R""!&54X(C4'0TW; 5&/\'Y@*G;[J98WR1MB(]Y+]JG0*76K***&)MIS
M_&H'/'6W7R,T><-0O$8+="Q%^R=*@[8_HS,+PI]X=B2JT$B\]?%<G:-3PZ4%
M7?'K3Z&T,IF#<R;'/%:WZ &["O:(14KJ?.#3NP:Z/IGTLQCII!W0R72#QHPE
M3X[Y7^=O% 0P9JMPK@)105/$F)<%A<R(82_.Q2EC<"N4)*D\]+-#YKEM^WF=
M,0F%BFOT/:-)^B(4=!N8L!F*04#Y%].:Q#XS,1'X/GYR008-<@19I9.L-XJZ
MY<.,LE+("/PQ\.UKA*ZK%K7RJ%9:1Y$4IAF)%B=-W#ORTBF#8>^0; CVNTPO
M@<U?OY/57RI5"!I]AW+CEJ'4V ?^E@M"/)3?I$_4?)Y7QPIPP-*,'N^S'P*W
MJ]/J4O ?%"^_<KDG:_:@\OJCVT9G/P4,3]&*QTB%FM$+M6[7\[F+G[1[NPT4
M\5D&>53,RS-I(>";X924VM$NS97"4:=KW$;T64"9-<S +.V U#:&Y]JPIV$:
M+W^K!R26)L)&7EQ$7)N)V0=^CV][<D]4ONV?&^4"+.)N<U4#0BQ=X+U<Z#0#
MVB$43588_!C!=AC4/@/H(HX94&-NA)U:1HP9ZAV^HGL^\/2AW^?/C+9@!+75
M46(,#$?$FN7 W(\]BSX*+'9J7ZIB^F_&<^[E(0FF=34ASBQRAX*]C-^[+6]Y
MG1I\U)MG-KK[;C@'0\>JOD*J.^F*[-VY;<0@3/.%\_CFM\7:YP?6'M4R')QD
MA[7N,VULVP4S\ML2.Q%N9^ON11BOJNC/&.Z)2#$QUO&?^9!A5]*1$]YXZ_<R
M'N:>=@WOJT=.,VI72B#'I% R9@),)LI**"F4]5S62^Y'E S[$4J4L=(&WKO0
MOYAUDFF<0X9MOHD[[2<=6AJ[3ZKDH)7NGI1WH7M$QD:__[4Q2(@5W0&=PCRU
M3.8=3^ '3.T8?5%JN*/(T,%6<9_Y;9T?)6X85>O  ,8_ZF5M_WP/="48CD?=
MD)ML4@:2%ILI_ UF);\*WP?GSVM8!RS&+B===QQ"/S:+]@[SB6R%EQ.,'>&N
MP>4U3F_D=2T\A(+'M@O=0EC!"US;+@#':@."IP;%)SU(<6W)< MDP*EU^M$=
MD%G2+$^>T_4X2I$:\#8G8N+;X=#2O&7S W0!5CJCJ1%>[!""[;#S+(]S4<H/
M]"Y!:M@,4.,/13A$*7FZ6#^^\2NO%O2VD \L:TS-H*M,X9;<$-1&(V/\,&[C
M_M ![D8&Y?:FAKACVYJ1M-%EX_,PZ;<?] L5/[ @NASS?E1( 6H_$$M69"J_
M5JM79W1\/!^CSQCN2)-&L *WWL\0:X]\^482,0GJ<^F/R3U\/)-<X>-4?A%.
ML!Y@P] %U^WB\?HRC)Z4K7Q9SK9T4V# '[L!HI=IY,W\^(R7HV39P>K&)SGV
MQA:/&/&X@OGDH"^K":1E17,0^-Q%I7VB(+<+]:8Q4'&4,D.A-76;$*.&] L6
MJ/_E!TC[!8D'1V4\]RZ^4'55[N>+/7*@$]H>C(26OBA*-7%)>:IOCR,LZP"#
M$JZV<A1FM6G7=G-C)/M32)1S^(\>W8IHM93AV[,!AVS>0O=IW]E--GN8;X%8
M4E,%S5BL\Z4G\15')W]>\D3E%T9!L:*M]4,"VREO%.*V*FD0^B_5[+S+J>L'
M\MO]M40@I<7\];YC"QDS#9:L_DD.WM,6WG/F$:]T$8]3' 5*)QM&L#F!'I3<
M=];\S%::/S&,Z*8LC,3[&^&.CH_]\85V8M13I*M^H?]4?O.47IVH2Q)ZQSZ*
MMAK_H7TWLH.L!=@SPZB7/2'QZ\%02??T;\-B;=J*R19?AI]&F@:_KA5U-GA2
M\9AZYM#9NUL9ZE1XJ*K#NXS!%$BSH=5N@L.(Y..\YF20^64[((4R#-A4+9\'
ME"8<0J[I,=<U5MU)X4WYDFDA2AE^C,P>D3:]$WI9X>\^G'';?WQ(' BCFI30
M$'RH4]PTCN<.B'\T0<T33CM8Y9*[.&TQ6NY5YB]@7Q(4!3V/[=8S50SHCI;Y
M8:1YPM@*>#D]M0-:VJ+5A_ Y,-O+RVBX& )9DH#_/"1';!I.47:%N(;:EZ3$
M_S X#OW>,$D$58F]R//OV0?K%AO6=FP:>&>QAL_+BEZI25_M%$'J!O3G*[/]
M.Q #O.G)<7BC8],.*(>HQ;%F$FABS;@W.R!A+1%X$3+YSJ!7 :--E.+)E"9?
M:&"0/,0B2#2_VEKR@NW5UTH+L=U?0_7/\M%/TX@GT)V0,YS'*+EI9;&%$3M,
MBSW7:]!@9*.GS$E38J@A]+P?NE^JZLR)KU?/!WQQN#AN6ZHX %L)?MFAU1M@
M!VOBQJ7 NSI(Y?;;AH87>;>(]Y:[%7YCCPE"6;[,M&:%1HD.LA)3&'6O-D39
M*<QZI'#HR5#KKQYOUC>7E&Y[5:]_:!.Z&= #^OLDH8R,-K0"@[B$8T,XACN@
MUVN=+[%1#<;3"H(2EKS^42^O4MSS<J795]1@-U_^\X^.*U$TI&3Z3GV:R@@P
M9QM"6.L91C,%W*S1.I7M@9E9HZ7:7<U4!%V9]^)Z%FWB(E!FGK1);:,2FXU3
M+O%!BM\:!^<JWU9>M3HO>]\Y+R'E*ZGU@,%^\4@'YG("%7?"O>X6*QOA68R,
M-G >]/P7>XV>$]LC^U/STEX#K:.:;X7:*$=R 1S3FKJ<4M;L/PV60%H;,*VC
MRO!E8"/F4Y(VWK=F:[K:O;SAU_N<\'M[^+#BT^#@/1XC*3N@0RL=B'A(5=Q,
M5BU3P<P38LX\F!S()99,V'G4^)+LJS*"PPE^L=]B U3B.A[M>1ID75P8;HZG
M&#7-VQ+[@VS+$'[%_J2F3#O'#%-.\MH@W"/D_93IFW1(6Z\DG'YBC9[*&O7]
M9?IOUNES6:>/^'3\H3K:VIH>.:A[Z-NYS&(&Y%4@XB-O@B*A*F%>DC]I^R>=
M?;_DE<A$O_'^LODT(_=_MQ.S-E92>LTOJ1,>8:FX:5_W;GIA_VZ^AH99KQV6
MSZF2_Y^^.O$_*&@8=^C88#,&[]829_1U!W1,]3I*A^IIFQ-<<EHV5>AJ;N+3
MNY*R!B<C'OJ4WKIY0J$$>Z>B[B?%*/T'R5-=7["$U'7*W>E"_0-7TP.&S+".
MZR5^9BR'E[=&J5ON9RT6:K2M@?.[NDR?FP)Q$TK ,JH:1!C6+77@.%'3FV2F
M$\U==>OZ%KWL:4H9_8-+1(2JE-S^IZ-?.)>Y'QHD&-8.S)I\:B:8K;Y)4ZKD
MG6,>P<*S$'2!V8CK=@[Z2U+?O77K70X3E;R3#.A_<E;2TO++$+*#\/[JS)HZ
MTX_^LXO!G.$!=(TGM#=+@=''XY]F!$ZM$P6?,N;"=A5C!A4T%/G:E%6V1!F#
MD&ZPW;:[,GZL:8 WQEES,^,.T#8$("6T5,_T964D3(M%:1\!K*V T"K%[VFK
M[]L;AUJOIP>KO;7K4[ZQ)A.5<=[$)Q=L:F;Y?>C==LG8AC6YK^_3+6<:*[B<
MU]BG!JZ@M&H0@$2$]Q17Q:P*:/0AH*]4#QU)JZF;B/$\^XERY'M_\=:5CGHS
M2[3#M+?T%FXI;K?50KCI.Z GD#?;D3$\$93<3Y0BS5/_9E>11$S)8HP_:D5?
M?-96^T?<AY.1SHFO8D$*\X:7G">@JGX!A"X%F3^IJ:1FY2 [NQ+*'&7T^_^3
ML: P31SOY/$W,RU8\=QBK;-,7ZH0G7\'=%BY75*$,4F)D$[F'3,R%>;6D69I
M-R@Q14G7>>[).:+3$6?"6#(G:T-FU.H:Z[P^0,D9IETIWY>F^U=68;AV6=0K
MMC*Z XN/;,'%D=0;F0JLG[O2IF*J1UF#SA/;_:F3^P=*LL_Q3^ JD753;R6)
M8-ZAQM6S^'&6C, ES"YZ4.CT:42\M=-YWD]LN^2)02T9ESQN6 ^O*W0D..HW
M!O)=VRU#>HJ^.HA(O?&<27]DN59?2&+U^QM#'"7LUG_VI=@65N%YQ@;HBY#$
MM4CZ'/O@(A3_#+^;I4ZAM('\,HX(4#$EA-?)09:8#I1MN/-Z_*3$U GJ@:?B
M:6*KN8_ST^ =A5EW6KCOB5,I3A(,<!CJ!5%"K01*LNB "..>KZ"L2X'.UAK=
MOH?JL)J14WYT' *Q7[H^S^/H2&*\;VR(K<Z#D*&!Q;7%$&4\J1Y?ON%J1,9O
M8^PV"4;D2:%XSJY:WW\?$/%F0SF7@6QJ7R28'R55R+D1:<8VC:RF@.89K>4.
M$Y<ASVJ#I X5R92T.:E?K3_H\RC[=Q?[WBY.J6@%E7,P3+XVTU>8:HUH[3T+
MV&,RU1CQ7^, W)0IBL5)(!O>9<GC^+9E^M]<./WV[7W8.^EG35]SXJ/\K#F.
MI)#!X$+_G*72%6(F4;!1?!E/J==:9)ESWS= V.<XA_M1?-1:Q,IEORK5-0KT
MFW3#L-+<^[G:^LQ_0#VJ P92CT$"CT&@?3^]RG(;:Y).)SZ-<)7_TWK^7>PQ
M-%Y&Q%)Z=CS-W+G6+VJWP84PSHY*D/!MY=>H)W,> 9)[AI>5M, A!7!KDO]&
M2F[$L<BD29I_TO7?2+2UZU,=+_Y+FHY@EA.C/.YHMAA)R_/3^$*J!6S3:AL7
MIY9I0K9Q=2S7JH\I.G;5X9^I@Z>O7V@\&ETT\@'W?9/25X]N#(Y6G19-M_><
M*1NNMR]TT6R1%![D'*#>4KDWX,GKR?_#JK"U;6[,6WT2=_?"LK,-]?9I9X-E
M8S>4&6!&W0'%29[DM3+5L=S\?&Z!0)]<7Q*8W'RI1]@K+J7)6N?ZCZ-7[IP6
MZ3>SZ)-3"MAH7!EAD[DK9:U)E[2B8'#[_!I"?G4%EH83@#5=9PSS$DIM[1?L
MG(KVD29)/S*FOT0U6UF=;3[80-3CAC6)N=>1$XK*PXH<%YS >I'&=43FP?P0
MM5A3@=L_.]8<;MB@:I[,[/OL=OX.:/2SV7U7^4FY718TVLN=]C;%+&Y7--NC
MOSOQ53,PH>N'UF_5F;;6?U%N@/"-*PFQ4#]+I#WKT?/J)9_;PE_UG6/:BF.7
M+!FC5H[>SQC<%MP;M4>C2O=O-BY=D%AWIBU/2+<N58E*IQ%6QZK6A)V*=*QK
MBM!>;B&;B[E$<O*64AO[NGUJ]S@J9:G)&A.\C#2-@SQ9$?A#%F4^X DP*)'E
M*#-:C'RIVFDMRZ!/'E;;0_S*[VMF2,_>=HUZ-E,N'"N</2SZ&>+6]PMM>@CE
M,Z+E2S-6T:E@8R)-(ZP-8MIN1D8U#>_3QTE-.$%S]*</593>O57\SZKOJ_4R
M$;.V1P8E*_ZK'KTO[=CT@.%_\W65"]TV54=IJ:0_R8/W>ILD>=\H0CPQ.&N[
M("%[0G$FKFK,1J+1?'G[UB4^-M-.3ZL\M2*QV6;O$=#5?PZ8NK$O(?E, 4\J
MYM"]CTN,E3#_4VJ.DH-T M]2X)5O YVR:[*;I*5.>-7%'X>DHM<O70K!&U'>
MKP=O6,.7/?&D)?0/A:=UN&0KS$L#B%1W!DL.>)Y:DTCZ$[CM,*(1F%:SF?ZL
M%E-(N2<S$6'_5NEQIBR_5&;'+;9*K/S7]B+(4Z%(MWL,,A8<21H 'R(;?(*9
M[S)6J]$K#H:'TG6S;HC:/JA/>#^K$O1><],ZO_]NF9F"[/J:1*%8B3VOGCN7
MP3D(J(0P-MLDU9FR];<R1Z.TO$LRQI,]Z-+J(Q7G(@8F3Z<8\!\.->E?^P9,
M[]_6.?FHVYC$/0&5+B7N/QYM3;"BD)=;HN6+_O]%;8K1%^QG&5S&H+C(4%Q#
MZ,]>7JE1]=(D[\>2&ZG)EAM9O3)NV$.;Z>=^Q/$.D)%GJ^?W2[7 7ZK)-)"S
MH-MMCU996QE5/P*F&X.#T(85R)L L=2\<"D)E9Q2J$DQ].A[7P(OGCS]H_#R
MN^>3[.>-ILY,97H] ]J,.>T"^):BG !H'N=N^C*I!7+$"5G<(>BZK'3_&?FX
M^T!4;%*4L_RK:[3[I*-4[$-<^PX(N$C@2'0Q!Z>)'-&C$!*6*A2G?28J=W@=
M?,)NOFDW <VVL U#?\A/(Q2EA77I3Y-$N6.23QZ@ZL<W7*B]Q/8W1->2ZQPS
MWZD@[:L[(.<O7]*[%1*6P'3%N)G,O*@'YVN\.OBW/O.![E?".OE-Q6Y6#WQX
M]RB(-IM,;)3O6+YJKPV_59H^=*NPL<=M4S)1QQM<A=*&U !GJ=5 OD;DLO:Y
M,AS'5/IG:]R-P@G*0N _X^KTA3V+CHU!0"GD,^[FF6Z'LG+W^O8Q$O.EXZW!
MFD]?NA?FOF*K SEG#E I8XB.ER-I-,Q8 JN#US>@5O51!V?/N1'#EK#ZHK)U
M+,/HO=+/!U5-_:*@:PB'(Q^L/:<PP.6"2)K0V Z(1FA+.($ZP"W@B?V!\/MY
MET$[IQ/V=^8XP*^B&94V_$J&QA>6ML)N[FF\,5N$:0Z$_.YK .^ 7*V;L=LH
M?'DN3^"-_M_/;W@_?YV&,%Y3IE[REK]LU;Y(+E&T\TF8/.S32*3/93<X%T;'
MR>2D*6S=Z+)?CN>Y)<]C&2\*PZ>K$AXQQ99:V1Z 7(NS,MX)B74 +"[ Q#UK
M)BGNZ?IN*:]MFB<^31Q[Z0N]RQO ,,RQX90JO6;<(6!@8<V>^0YZW,R^N0[R
M6K76O\RE?>EGT$*-5?^1KG\9X_\6RS^I3;O0])!12'=A^W$> WQ/IC+E6+(,
M2ECV:,/-=$=<C-H.*/:E*RO#.<'CN->S:GPD72G_!:I:L_+KB2O& 79$CG#T
M"E4O%/*,(L!1!&JI9X6F-Y=6J$8QCH?!Q^W*-K!1JF-/(D: "9O.RX$"7D]M
M*K04__U5G#1>X6A9]&E-KSK)D53]H7%RN$PRX\9_X>Z]HIK:WG_O6%$0$>DB
M1*6I-*6JE&P+ B*P00&IV8B4$"$" @$"41"0+B"@(&0CO49JI"72142D2T)+
M0I&>4,*"%$[\G3'>B_=]Q[GYCW'^9YR+>9&+E34SYU,^WZPUGT?')+U;1;I(
M[17F4?W8'?84-,3+'A[ZM"XV4,^08<A=PP:D *,$*(#/Z/U1!Q)<"F8^# ]I
M46@G"#6#M:.Q_KW(6^]=:Q_WGV@]]*0X%<G;[3V0N6&>"*8]PT:CW0EB$S!]
M67;Z/LB+#YGAJ"]5-1S=[I%J/HH]42%\R5TI(VYAM]/OE$7C7W?%ZI[G"+&+
MPRX VHPTP)2+"L2:&4R[I%Y@QXU7]?I'Z7^Z,IBO5JA(P5=\:S_E:[\Q#'*6
M_93?^L22_/;=>%-=/Z!<Q'H-KEE@9Z!Y]D&++@^9^IZUC^L_4'D0ZV97"<\'
M VLV@N63C8F:JLTNEQ3W00%J 2M#GF..F9/JHP3G:1*!(QG<WF$#IA6&Z:'^
M%/,,-I+9X,@!)AS!74V(QO5)3]UQW9]95Q82"C(JX1/^"6[][8VF(YQ<?X2+
MBZN0N8^/S[G$BS(6Z8%N7ZQ IXUG#CC9,MTXDW\.L\]@(+P5+"]Z2">$]AIX
MO/YWDDGL#E-K\^]IOPLZ'X,"JDS.?>M:D N(]Y]USZ!%Q^H?1K<^W@>Y28$[
MSEBUH>X!MD&E&O1NO;HU#*S$U'-=TL 'H79G\P[V0_=E\8G2%''>F)"=YQGM
M3_9(7M <G(G)[TJL[UL'Y=6P$>)BZ!;4SV;,/:\NL8:AQ:YMYF,B69?Q=%Q[
M65.%2;MHX^1:-#^KJM2P6*\\Q[[_I 3N5O=;E_#V[+P+Q6&#!!RVG3#^@#+=
M-GT0F;.W9"Z&^F=,[#9M[;WKF5YU''WBGD2&:_.38O?9N>'+53_TW;AF8XRR
MH1%6NID'4,_H2:\KE;<@QP %2G2B/]_X:;TJ(NEFR?>.RZH?*T4,/XEL:'<C
MB+TSTQVJL>":C"YS(90'H%.,NDN'=GF!;4;+5W7AA4[HMD/D7TKKG16O$LY^
MOY (UM#=2!&L])9=D'XD9G8UV^ZJO<FOS< Z,^B/C<"Z%'-W>)^9QR!6@6Y(
MNLAHT8>'CIHT><'@=7LN3"]TZSV6!%,0?D,K(HB,CD$+Z?I3^ +QGVCH]NF3
MQEAXC=W=I11'C<O?JMK*OR"2QV1/-;V^T(A]!:G?>1FF&?9C;Z&CXE)=KY1"
M6Y5C?5/ATMZ31K>JW#XX.$NO;B2?+"V1=H5D#XJR/EQV%'*%,XA7I4>OZ.R#
MCHB/[(,\I+3)JAU)B>"38?)(@?NT80*MLOSQJ'\V[]K@4I +HEHC^;VRN\F_
M4T^>WGK7XQS._^?8L"H_RIF-VUX'+F9$/0\]V$TNBM&_0/Q]PRVU )EJ,2F:
MI/PC]GPR5GK [;BOU_W[BV+O1&+EYXEV518?BOLSJ'.ICLIRFL*9R\^'\;"5
M/FK/ZDPAN[?]QY*Q%JM\#6]>.7TSK!=*LT_0850!,60I(4/VNWW04P&!17UU
MCSY,K/\^*-H$1OYU/EFWXW,ZW3O;6M3AU)*X5&]B'6,4OMG_]S $9@[(A_TY
M2MDQ+<C10BI0,.VJ0LB,VS3-L8C:?1"HFTPG.R-[W4\00XD3O7I?$JWCJQV\
ME5Z^OGA7<7F=!'6B@R/W02[8V,:,"&J0KE418/CP\Z"(^N=)N?P*T8E#/VA7
MNQVL7"[?2I?V7RPK;@B>NG2OOV!5=JVR;OJN:T21986'14[B/?W,>NS4F*GM
M^&*(;1EKDQ[(X2N@=7\AG-9$\P.JY(5N0J(7.6Y7@R#HB3G1?-P'"].7;DCR
M!BI5<(:2:N$FQ^Y'!ERY)L-#^D\7U+_TQ5E^[+2Z]7@GOM%9NO:K9DW7(/\2
M R]OYV&EV=J8_)Q!^Z!F7-3<+6IOAG//V9F(1_L@F@E7X@"&7/' $DJ:*9<6
MXO3C:"M3@H-K%S(5)%4*<[BD9TN(-98/4#+__J-;-W,72H%&DVD9J[G,("+@
MIA."X%_"''VJB3AU\^E5 <96>N/'H'*>;S5ZY3YB'/F#:GZM!>^Z'CT:+0KY
M)IB-V?D76\JQ<?<N^5PXN68-O4AQO%QBI_9L"*LTRXVYWQO2]FQU9+V1VIR3
MBC1,7+-.(1#SGR;2]O=I3GG>&>V=VA"^$XVZHMZYG233(]\C__UU&Y$ 5?QZ
M%#\/J-.SVO9!M=IM?7Q=4WRCY2@#,O0T46XMJYBH_[ORL?>KP,-GP_./6AX[
M=\H@2)5U^HT[YW@"$X+FALA]T%;4F4TP<&'%\!XM>O5 /HQC!T#N &.4$"A_
MI[#]>5R]NJ'L0/=&Y,;HDLD;K=E#R<0F'V$9<R%[7GRWNGEC//4H)FO>-*"F
M9:VB]VY^4711#!K6J;EP\9MQT=RW(;NIQ45W=$WQQUCJC?]9J6!W@2/9SRF
MLDKV08Q2%F4?%/$2Y<>T"AL!TTH@Y/<(_7-('28/TX5SVARXJQO*CF00=%;
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M]P4%\;1#^5E^M.YH#M@V/^'LC1GM3E7_!K&\_ 3Q*-*YI,O7Y22$XD-Q3"^
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M6KYY2/BFR[#@BP.Z(X[Y4;SBCW'Z?)Q?3E?8N2@A+XKY"8#G=@-MK0KN+Y=
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M9ZP G]2'UXE4IL=.L@*9*JPMA?ZOT\2X@);RP80,+>+D&KYW-Y1K'NA6&Z[
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M+X/<;,4(;&4M)U7;.P&I]O6#%6OR1/MOQ@K/K4-+NSUDR<9=1WS!IYO/SQ"
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M(;2XR6G04]7Q@,8@W+UB3S4PRV9HTLR.-&GSB^D6"TPS/+E3_!>YWK$/DM:
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M4#<"/'=&ZE'*9,*O!48ANUC_'/"XF_&!'O@%GA0U+< R=*=XW>@E<Y)+NDN
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M?-V?W/6W'==20@#L,MC/Q$[,'N_<XR=?4%.]JUB+MT3MC&S*U=I<VA5C!K!
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MEJDV.P'[Y@L]T>"U\./?U=FL%M9H7WY8H@44,TUSW >1>+JG!2"N^Z#7^!.
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M(L3YN'_PQ?FB+YT=6:<7^F-:R:RH1J5VWIU\_L$YR+,TU\[__'+\R?E8R-%
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M>Q/-X7E\[3XEZD^[YZDV>U=:CE!2'AJ32EU^U@.AR[GV)@ZTIZ@G8#-BV!M
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M:B"'^L3VCN]Z; 9V1Z [G .%X^!ODY293X,$6',L02D%8S\DB9=0$L*_G+%
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M(%;OEISEIMZBN&E")8N$(2Z3Z->B>(0[!2O=C8,X\@SWHM[240\""TM2M1,
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MD3H*XICXH? (]6)#>!0+@JEYC(J(^7$O]<<^>(/ZH"TPZAD%MIDO(U#_@R
M9FS0DQ2[,I12NW'O6/!="EV:SZ'0S4VJO4L3[$%&@&%*RM #R]#%[O3&38C@
M2J/L=H4TAOG];6/;^_K_%8%4A#*)07P;%ZTY[.N0>)03HUTOHCK60=#?2L6G
M>&<^:2#8\R)3!X-A65PT\;JW$J8#6 0A8P%QN7;Q   PZ#PN26QHE&!&J<][
M:]#U\/B^D[=^YK/KBSA18#4ICBVD0Y=AT59( I\;X4:1"L32=?"WH=RX@?2I
M*WWB<=:VX$^\1,%VA8(%(F9"]C;:LZILY+[;M;<K?N=#JQM#7X164> GFB7$
M"S$ [DE).#8/#Y6(/!&%(C&]%9L]Z^&^P% 3<#YA8E>1F%/LD<UBM&0X,$BI
M$R9<&KF].Y:QEX:H/S]1W<AA>!%1Q;[Q-0](!-9$XPOD)G!)%/(PD"SFQN^=
M'Z'/-3)'I9YI]PW<^TV4S;R,GRPPL])E;AA'6A&1<. B/))$*"QB4-1(/X@2
M-^QMZ+K1N?>Y3+-;^N\G7=>Z/#2OT 1R@2E.+@/#5.F$&.-ATIG'B.!10L)
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MJ ?NJ>5X#4#$T5#3A)C8@\5KGI!$17B@$?,-529D86]UQQ5&6%?>A_$FW?A
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MX9;>P[;<EAO$M^TY&#N',=?>.Y]O(-B*PZ>QF:UPEL],H_C=DL&/8\ -88C
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MQY:P&-0 X?EH'.+8OXUR[03NIN.[?NB\PULSK.D5;80>*WL?$%:#HK*B"%8
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M%:&S5-^^00/C&=PQ'!@,=GRY_7/QKSMF/BR0<P BW-XH;(HZTM.XUZTA/RL
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MQH,SFYH"*)46RE&C$G\9*_.8J>G\>P2@--<-WE<#V"VPGDN;?F:M:TP>!+/
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M^<0YN<Y5B=&^[CWVYRD4=$K;],[:IZ"06K=N$X2T*A@7.8;I,M0>0?&T9C\
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M_R&7ZS/P1;Q :UT@AXZ+31Z+4V;SL=YA=%&ND_V\(HV5SK/D""5>Y_GR''T
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MB P1AF %,/[P.-F*T+FLZ?1F->N7J2MT@+();#DLIVZXG#2_(+WU]-\/9A)
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MSAY?5V=+T"CP,ZXBA[Z"<=GJFC^#<%F".5JG;&3*C@HB ,NO^'5;H&]AJN8
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M[)#\7J=D@1SL'0;+86G"="ZKFEWPD%P'PS<G+QK?&N<W5_5TU>I,W)N.$GZ
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MA 8W&'.KMSVW^GC,K8ZYU3&W.KBB'!QU*2&H\O, HQC(6T]0Q%[1+,N-55H
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M^AU6%V8EE+1%[[VN>[";R7Z)ZP&I$&]GS"P4Z.JN@@ZVU>&\$?6N:%F\Q=L
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M.?Y6$$_5WB"8!Y]7-!J>PX2$F) 0'Q$)\?V$A)B0$!,28O2)8JI^T\L<ZBJ
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M1N1(/]GN#M-2,H+]%!W^V0SD=V8MO](/Y[HI1ZZ!+J6<,38<)3.;F](2DG7
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M+O(VE1)53R)(L7[-D<T+1HP]=@UM0"37$J=5U0G#*&*QB.O((D\Q A8[/GK
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MC#]&$.HB)R48/-$Q%3#@.0^4^K'[8@,20M,1-*)N!/L83X(33JA,5*,2J$T
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MV^G-9JJQ)A>8XOI7+GL7+$^3^!,$ZZ.9<:XYZQA31^1\?<(F,E*FN:Z-Y[_
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MO!)..$% 1OX;7F2O--*\G'AH6PG0>4WU.V;$+&$NH/AD)JR^5@Z-T]ES5:[
M$9DTB]T1'935YE<ROY$-[.V$,E6BIM/9+:UQ?V"+SN"4H%T-SHS-[ J;^_G!
M(.W! 'N&<)930B9C XKV:\[=!AGW%8K;[@+<K'20XK)IV4OAN=A#S"^(/L[3
M*2.&;]RTZ?*8B\RX S5[6@F7V ;\O,SWLKN@$/7\(K5OA(2LJDZ4\[<:&37F
M-7F,.:V5W-#0VSH<K4.899MPUWV7\:7 '+H0WAUW]/)]/Y)35(%Y9&WZ >_R
MU04%I[.O[%JMP=_UBTW9=<HN4*3I[+,T?)TT!WZ.!#!XYC^5F+RCD.2OVBD8
M^\Y/?TW? :FM,A;(>XZV2Z^$.7M5)."R;/I.N[Y81L)(LBTO&VB%'+QDT?93
M[F.W9\M*V!98.G.YU=W.4,"&K<\='V7M]!NUZ;%+TJ,(@S,]$'X0?ST;<B+K
M+KOPU)Q9<!!1_"9#^![5L. I'SR&>6AKB0<Y+P @KKDJ]F*+52A6[([2=?H7
MSDPOEGP-2/>BZ1K#J'I!>C@/>$]XIMXD&]O0-^+=QV%!*!O: -Q7B3J4+O4X
MV8[ZUHNQOUT3 PJG4U4LD)">XR4J'ZQYMCJ<-[NR,(4?%:YZ+H8R1N64ZD31
M:4LB$P2R#/Z3 (<#<R57QFSU721JEV4D@RJ]GK%06(<,QA0K\"VP/V?B2--I
M4F8K!37%N?6N$(+^3DFZ+5:Z7U'KQ[;0%[ F41TKTU#/HFS<I#0]*;KH5IGE
MH:S"ZE<^P^G"#O.@<>L?W_E5)D-(WWF\=#CD1%_G $"_GU'*Z1:D9.>S"PK?
MHWP7KR*9VSBP>MXT@I:/Q)@'US70S%B5?(?@>@MDQ"O>M3BK[KI^HXF^.L/$
M2'(5(D$]6N,8FNU$;&W9P]YT83=M6M?T5S)*SO%A\OLR4$Z7S@Z^=["K+XL8
M(YW.GB7R?*Q5D.?CC?&2 M"4 @48/4*I@P'&XSRMXDO(T?/.)[DO']+%6UY2
MI['M,&T(B6KN9H]P.GOE(LZ,;$)NA!;&0F;+6K)_%5Y)3P9]X=/9V7+9M'BO
MV$!O[XTD58_']G=[<!)YD+WPS;"TFPV.>OD SI'F1N2?4J6Q! E9N:A']*N]
MG'4%U1,\9.@]T N7#1ZNRNL.Y^%F&+,GW9./OV?5.NY@5VLI1UFB>*MGQX^Y
MUL3R2'AY;/.11[7(*B.5YI<B9@(1IZ9]AZM$/R.9E@]90+ U-_6(5L(M"YCX
M6RK?EWU%"L3Q,N.E8%>YP*)K1'ICU197]3W:#3X9AWQ40>3U @_'2TNHR-BS
M*XS8: 4.8O#LEQG9=%(TCN_)C"23E%"1#L3&G!\-B-PG4-%]!!5]-8&*)E#1
M1-A\3,!@(&&5.5]4+W1DPU%"COM?D?28719TH-U>:G>LZB-U(.UT7$\E63)]
M )DZ0QR2^FW;[!IZ1)'WE15=04UC(L1<+U%12 _?YXMF4888:-8]Z^G)(*%L
M*%<7$ & W5BV(J$4;4=E93);/$+8U'(W[FGX WE:6LZI_Z24M)_<BJ>>L2Y@
M4;O3)4KOIE3C7T*>GA955/8S93Q=2G\NH,UDCY^3/7;<:U[/O&TF"I?4\! -
MJ*+:4X9JG^>-( H$;MMRD]7R)K.=S/;.W&C;O$>Y99]MZ:A+<3# E*63_4WV
M=U?VMPHH8V6.<#*WR=SNPMP&:5(;EFU?[H:PCC+2I@.O%AMT7/2DG1E58YV)
M%H65J)'#F>1DNY/M_@&VJSUESUH>@TXT/[")_X@_3^8XF>,=[=Q)'SN&C5(@
M2AS(PTJ7*&:VT(WL=]F>'Y%70H6Y[@T9=:0!!RP"N^M46ON]D.Q)Z_K^57!_
MCD!P!2Y(U5:E2$:JMSRPA2^77*7<*PY@QL7/)6JVP!4V'?/U"!VL0YM#>F%4
MZ!Y@<98.BOKV T<==5*/FK$<KPVL5FOR@!GT%;-E7;D MO YNM3O"YB\=.KI
MCX7@#,>F%'#\;')BIQKU:=0'@Q-83&EN8A2L')>X8$MC>Q)O +\11!1#0Z*X
M[DA=VQ?C(A0R84%1+0?F?@05<*3YF:ZPUVLSAX"+&W%!,FIPCUK3'WULPR-T
MCCKIC/:GR24K7>=C#!IA',K65 !<3$B"0D]6B+^1W17=T4$)L8NR2R U9GMC
M%4WZL.P1VM#@S^ZWH<O*%XF)B)9@C[UE6?00 0.&.6N ;-#=D]7<;'>"1];^
MB>YA#B]=UMTN%"M\,O]<H9O1(LB@*(-_=1RTCL.H=CN45YS.WI1U?B?TH7_V
M9#'KTB.<\VR$GHFB;>=R+\T8)%)U9O .Z,H;O:I>YU.S[Z4K\J,*AX]YV#?B
M8\>';#,5(XTMMH:1RWO "_ %A3D 6LZC61[9'-JPA=00?%O-&,Q:<70J$@&W
MVB9_2QM7PSL<9A/B2A ?6]*6TL@$EJ*CT9OC%@FOD$"["A!R,NF@?%YMH8U&
M>F9JZS>@4>[XK?+'/]($YR= _&C;F?9YC]1DI@6@U_!.HTPH_UK^]>31M^,P
MQ$H6]&_-);V5#5[)TXNR+BB7^.'K'_GUT#L+HGBXEPW?@]@1J,C@BJ+9XO&'
MES:/8QN&]<\@I#6C-/NV$(]6[ ;R5GQS3"8^N P[JJ"V!9;$T+T5XV*]YFZ4
MJ6.(;7O-,/V'VN"'A,1# _S,/,NKONWZ0F"E>')F&7%,!+P$XBH /7N_1<QJ
M'Z+OK/M:7BWF%P;F]D7W9:9C.S!0,[[3V=\OP+\@X$&W=PXAZ+EYR#;!0YVT
M#&3^4J'Y/A06U.:YC'GH/";OW3H<) !V'V0BG%A!$I2_:E+%;CS'9:!^I(>U
M/2UJ=8;FX9 ,BE 4-?;9#U\'HZ'7;1;$AZR'V5GB$4/.;G/000#=*QF2YEQG
MCA <FT!)]Z&US0P:T[01U[N4G"O"?_$UW"*=#ZAR\2$28;(D*^?J@[=D[X'=
MB9RY6<^C2'E?)U"X&Y20S.<WT[5\H12I48O[+'OA:8CJQ:LT$:7OM>,EH,O%
M3Y-%I]IY)1M:,E XZ-EE%L/'BLN.<X6"\MTHC%AB*T1-1BNO^!H\CXC(E_%#
M?K;I2Y(##3&:9N1\ ]=-M5+.*#DEYK'G;'J*T*:%U")+U7>-:%[S9D5$FQ&T
MC&:WDHW>4;; KPQ?N@C[1O>6>'/[L#MV$[Q'A6V_*R*!^:K88& A6SD#T?K;
MW?:+=*&Z5/)AC#2KP2_\*I;U9\5Y@4B?CYY"<K">-G4=*O$XYPB[D+&78*8I
M]2IM,DS%O/P(!)?+E)Y&IQYF55-C>))R'5ZU40E&QT0X\F)/QZYF+V[&>U,>
MLE^5_%@I+<$@ 5B"K2^Q"#N>2KXHZB@M1D:(O DS/\+U1+F(I@3R3NG3T$.C
M* 4C$S%@Y%.A-EQPXD\+ (,C)_R =GO;=#^';7 VH9?O.WKYZPF]/*&7/R%Z
M^3,/]/-R&^T1NH/QSH3V(#8=XRU!U)%FH2/?""*8G2A?BG (-Q&]3T];GD1<
MK<WCZSPU:JE*HB+C\N0WEQS;"7N@5+Z/C-9ZAI5A>GGZV>XF=YQ/WK^"!EHN
M3'2'>;,(74]"'9@QTUAZKN8GUC!23#Z66QY58O($4)Q]ID@:.1*;J@XIWW*P
M6A(OEZKY<D6JZV(XM['4)$;T:TT?_]%3Z,1L'LT'S\#]B:L19UU'F0#]=LF,
M&*X807[D:=5T.B_/P\'TD)_1WA7JB(IU9*/-HD)%G)]^SWVS4(C&S+55C]G6
M79$X+I?F\1]'Y4IOKGK@@*8<-I;PI]HYIYWMBQ=\H-=/G\XM"66UA<'\M')9
M+"\:9)UN]8PW9&ZU3C3'.$.&069#2^9I41<K^O^S'KRN<__U_Z%OK*"6:=4&
M6T;>Q'74Q<FE^#K%VCV&X05G"TH>I-(RC-W@\?NS%*7K%__0?%ZS<#Y%J>NT
MS?BWK,2B#4$\^66!GND5%W5N<]7'+TCZ7THL S!M:-$O[J0CAJKLH@#^>\T7
M90RC<4Y77]+@)=HSY=U2!6(J]5M"TF!(M4@&TR@-0:%@<WM_?'<BK=37%;;@
M+\HOT_Q[T0;/6JH+^&^G;TX]I!TFS+\SD9HMH@E:=5J!_J+48UJ5 ,^58@I4
M^*2:=:3-Q5-4R^:\)H^T2F@["3[HJ/Y2]=6[*AD]P'+%*PT5"VYBA8B[IR=R
M@OX3>GE;U4W+RFH\$FW_M*-VVBZO_==VZ*PEIICT?E /U,?&UV*#YEKI5(*C
MT4N)"\W##3>AP"++>O]D(<_#HNTQ)_#DT9,GZ>R" ZA0JEST[X0NIZF74O2P
M8*S;TIW)E'I&SY,;8S0C=EM&9)3[-Q@SG8Q7BBQAV793#90V$+I>%&HQ*I:Z
M3F:S\883!824@S4-6.E !.U&<H:3)-*878NO=#HF@[B##-Q)/MF>/*2;FK.9
MCA%)7KE-1RRQ;<B^F?5A0[Z5*R9AIV6HD>ACT3 YF#"!:) R.J<_V!/8$.UX
MP_*;<X#.$\ 6$:Y C.TJSIR,NG)U?F[1PA5$CV<5;Z65&"]X:WF:B]PW1U][
M<6<'@==19ZN7?U,@J&0U[A%D81ERH]]SL9%B0B^87X?TR,C$KQ3+8]"BW/FD
M>G'.#AA?'_!'RE"%58-8BD(AX\T2&$RAI4_MX,<4"H'X7*7(4A_?+N1(ASGQ
M66;;#\J$52CDO7+1T!%JBD?0FSOV>.\)+.U3T#Z@"%=N5#\\(..MX<23Y3-I
MH=2U10F&ML3_<YSS3@/$HJZ;GIL&K;C_[D(7$1@,X0SP?PDEB_J< Q$NYYI?
MXY,O BC^/'B&B]1MYE8*6F12,* \G\E'V!RLDQ2B[\X7@O&KZ@5$?B14S]5Y
M_['0@<\L5WH^?%LQ^+?W6:K=".+MP\U&V2BQF\B!C@>X9EJ'1V,3,HZ\@67D
MD.!#$N!T&B63E+#=,>\FXQP!<%K=2HG-CEAO,MZ'G'@[^VC::#D:\W=QZO_#
MEW6^J>0+6&%F[GVFWI>JKH5#T[T*GN-1C1V!1M9$+J]SFMV%[9^79;@**\47
M%"QQHFP&@TLMG9=#U"C],]_97H3=50AU=K:#9\DTX?&@XO-R4J8#,NG4O)SV
MR.OJBDK3B&B(4VE+#SE.V81_%=6VV*5JS..O?_A&%((W"WHC WW@Q&$8P6T:
M*@7%=8J!". DG6R4%_(69Q$@P-A))383&$%W!$?P;U6_/\';^M "^9]KY_Z[
M;(3)7@>VJBR<ONWB#6RP3QZ)TT=MSG\SMS_Z]9CY\2X-V()"1QT)XE$&6NOB
M<.U&AB:9^72D:(4YB9!S[TOB WCI\55S"#R="X$=O*E_;(?YK<!NAHFG0T3=
M4/6_+J6,(>QE\RYD;+V<'/.U[@54/7IO[D5R*EH8K&8>:089'M2#+4<XQKD6
M0PE51-XH:@:C',K;:I"69A2QFU4QZ"Y!_=FE+T1*5_=2<)VQ4'G(YNGO%D\,
MW)S\Q<^V0S?A/>XCWN.;">\QX3TFO,=1O,=UV\N ?AAJ#G1%J]AMVA6@!E\Q
M\QP^8#S>CK>; 1S295Q;!^Y8,#+_?7NMI(XB<]QWOIGIXM^##>CM 2@V@Y]*
M # L-G$EY*J.^QVW="P<FFN>2CFPL)I;:BH1C40Q^ !WQ9RX1@ILT*?]>TA@
MS-2?#10BL&H%@R"4:7Y\[#-U.8]3T-\4]MD$4 KP$&9$\00 ;Q=(8C,*]Q2Y
MY7#R6[_*I.,QD#+2)\B-D5!5MWP(UX:=8T^@J'UTFSV#O=(Q^N\D,Y?.7K$[
M#(Y=71] =]0P0!PM) LCH6XH)>"N]&W<$ $.6CC'KAYOD*)!8Z7>F'VO0K=L
MRX55-AQJ_8@;\,E(3@E<'P1Y/F;D"DV<(>/>8&A1FC'DMLXY ]?,S0A)G,N1
M*5L,D13+=UBJ#,7QK-V_RW_HM(=K='=A*%7 0]X<K\M5N:B=&T*0HSF(P17L
M=F,PGL+PN8'OY:S)=WH/<%-2,&;NX^HEQO7A4I"XC'6,Q)U(#7JJ+MVH):*(
M?ZYE2Z/.-%^.J3@=JGNQ#U:A&O2^T#^MU=8DC86?U#<XPO2NDE5.K:X8L1 #
MM<5OJ8V(LZN+MD7OV7LZFQR @-'#[JR\(@?6#A^S3H)%6-<\51'G@_+B]2(Q
MUNJ/#MWMJ1YMEDD6C<)[5&DR?<7:T:.(C,Y.],NKYS_-9\]>Y&C'&^H=!R>7
M0$M%H=C!1&VZP]V/[!Y\&,?OHEBT34&!UH%F&_3:.B?8Y@(S8("Z)*AG@I"F
M]':)9=GU"P2S.^DN+)BRH]\"B.3YEP_9AZ6&L0>V31;\^U*%@6IZ9]4NC@F-
MAF"7376)AH3)Q"6//!(8R(H<\?%P R-,%=$BX_8[_&HNT:7EMU7F0&+<=9UB
MA;)TC-J%3@CG (ETVH&RUW$YKP'ZK',N%0#)\6<FI?BYF=.AX$=VH>SA0M;]
MENN)TA3Q[..[*<41'6 KM.^7RW<C>F",4NK 1W(Z>Q.6$@V,O&I-9C3)RM3<
MR!FJU6^O56<9/#Z9?2T,7';D&<#$&.ZZ<YP:WO73^^H@@86N\:A)14#4B$36
M]?>LW<.C-^[OH%@8_,XN( ^PS-OL&EGF'@6W'GR6?@*C#FY_H<"N8[G)RQNU
M/:,(X#SJ>-90HVU6#"J#)%R4"53,J,:<C:P(0([)0-BBN-0>"ZCL76.,O&O>
MDU79W*Q"6@?#=;&MRI;2RX"T]/.O<<&9C&BK>CEN0K+OR&^\'K<?U9Z*KI2G
M-MHP0/5DPN"QB]&&=2]QKL*? "$L&2FRSW&GK5(=+&6_47U&:[[2NTX@._:9
MT<)X%$7*!*XPX-;1W $)[*DZ<(/+L[!IR+K2$64#[*\3'#/N.(+3/K9<=T%*
M[=?+%(V]J/78?G!?HO./'8R=^1S&50>XDWX\R))5ZK1KQ ZMGE'O371ADAR8
M& _OD/'P=Q4](3^/"91$86"4QRW8V\0("]OW1DAU)DK9R:+OPJ)'H^.DC3>_
MA<C=K5?"?/8[-9I3N;_DKP(XL_*MBVEU3*OCKOR]'_>0$%/ 'L>EU#.A22Z#
M2+BB1&[<P5154P0[47"2,T%E75')&G=N+(0X:,V:Y!9?3M8_6?]=6;^QP(TH
MEIG%FT[HK$(# Y_T$U$)"KMT)*^_L^N8I8F3V4]F_PE"HNN"&"VJY:15RCL5
MZD#GX?H[][LTG%&'STW>48N>L&SW$<OV[81EF[!LM\:R3;O6M&M]#!DMF4"J
M*M;O'I_K.]X<',U@N DMW:F15H]TM.?<SQXC(W6?IHQF?-A<&O/7H"-&6\SH
M?U5=X$GU*1"<EM1=+2G7=.0*5$G/@:Q[MW?-R6 288D'C8[!I&JBCK!$FF]D
M-&"!*65,NRVNXJAD-\^(:5:4*7&PF99?,>B;'"[A2>QI6@QWN1A22[BIRJ6V
MM-5E^Z;J[VJ1Y#.S.@;.LAH;"/JTJHYS(.FB1,9'>LF_5P_J3R0U85#'8]N^
MEF^XM(XK"DOA.AX!AB0UXI$2Z'60C.C;/-BR9*1N2;>D$ -%(8D$T-[>N^$.
MY.O"Q33&G!YK57GT<MX6H)=#]31D+C9#UL['0H^,-5V%H/ST.P= ,/:SU679
MX9M/FPU@42&D<&B400;,5AOROBO@S>L3#^F@@]/M6'!4>]3T""V<0V4EI:HV
M_"/H 3Q +MW+.0@ZZXT#62%$XWA1._!5."^[*N(X/'T^<'S+Q**?N#Q&[Y1=
MQ7ZV$@P/%[4!)^=)%+-&ATZ?CZ+(Q;"\J=QK=M _D7,Y@B^*8S$&U1_#0ZYM
MA,4$1?PP$H.742^FY2!XCQW(SWE2?\,$_&[#D"/H-VV0GR4DUHJ,]L>>0^\,
MM];--5+S)Z8SO0:#R3,!\1O'W8MRIW23E(*P  7NTV0%7C][\<9D!1A'VUWK
M"?GQL&-*>^I@K%DI\@J=>%)6*+KQW4E"&!W.ZGH7<1/-J:,+K(I%J.2(1;EQ
M^ET)O G5AXAXL_&QT=$HHX<Z&J>27TVT_ @-SAN>5EX&>EEE8\-<CD6$*328
M/^;#%  $BCRF.&!<''-'WA]Y(N>^[]%L0^OHWGXW=\<G7/6?8,#BY0#9=0.$
M'A-T+(/E<97T]_]B;"5LI,,0F\=6*M< O1V%0VM32340"]#"(H89U1%,>#V=
M$DI2"( *-H=UDW8L0C#\W] TX_R4;.@ZD^@]5AW.92]EI5YR<V"<N4<F]=%1
M@2QLQ\^Q,*:#+98]G;KG5F*7Z$Z99X]U\-YA61OY0QL[-YF=.!\@R'((#W;-
MLF3VR&M&::V=HTC:Y!%&9.XB4T1 VX<IU(T"1CAQN1X6P*RD034,L*ALI'5H
MV7TMTDR8#\SAPDR+I$4&IL70\,DRHR->L(0D2$9-G%<$,Z#MX;SOP1"@/$C;
M -^</>ML YQGBSB'0Z/JO>WXCBG/A>+J]3<K02ZMJ_/ #D)$#!D]L:"KDUFW
M;M2G1$RTK' _ HEY"00>&AOTJI)*6[!'7)2U>@Y8)6Y0+G7\UHZCNPL.IYGU
M25XX!;DR5PQK2(.\SDY$((J;@B?:.&0>_FU"I,>+B[E9:7Q^;2-,@!PU0=GI
M=S"A_8D\RZ_KI+4UL%Z>*A\70%TF.E5Z[ SL;U@A%SQ@3OTN:5')%!9^$A)M
MNG-.![G^K7]X<79M8EA&OA?NO-F,/"^3,55@'6E=A7H_F',],O]C8#J,+=.M
MTCL,@\ [T0&9GL.P]8UOZDY^Q"EPX-C$>>\3;G6Q7"G>01KEC^0V$I89E1\E
MQVU?[DRRF2M/*J:,N1J3%X]\ZC+7EV8X^0V>SI+$IMQ,0%N$GY<P) @4A1&.
MN%CSCW-#]NN+SUZ[#V.&Q.21EN ZRH31^!7N'T_F..P=&Z':W$!;.C+.VY<Y
MK.EMV"MC2K@5K%ZI[ICH]\Q_V[\W?"W2VHTI7?N9[ -=7TZ![B8HS\N(?OYO
M<*4I<ZFD]NCT*K3H4:EV0&': 5KFQV17R_MDT>YJIM!ZR?<;55B]-JLF4Q3#
M\&@OKG17G%=X)/7LV1.Z?/IG@^(*F^;LU:NSU__[__CAZV]^'/PISH(&U%S*
MCK-;1>3J.N*TT@S":2H>5X]+ S7.'65DOQ)@;S-L^FWC^@>\Z^0LY.4-SL%F
M.KN1\:'$M6(QIB=0*580HBYFJ$"('C6#2B,?6L(=Y>.M$8;$\GM 'WGQ9Q6'
MG,N@H?'-%RJSR+;PEUX4#'>5#*@E+K9F_=D6YR8PU7T$4WTW@:DF,-4G) ;[
MG/<9[]/AK%?HTI2+WL; ,Q'X(E?4C<)=%Z&HF"Z9=W'$%/AS (%"3%<4+M"Y
MR04>U^F[,-A;'O"NG\GL2MIA#[";5:P52[MFC4L^7DG@0BB7,X]E$EPY\'7&
M:G]S<3&C2)N&9">DR!VM@>LP'BFE1B:U @ J4H <3X,G@-]DJ7^PI8[03UC3
M. [GJ9E:[W2RTLE*[\)*TSQ2')]#Q5, <C#$*Y331O 5$+A0W YKXG%9YR:Z
MU<F*)RN^(RMV+16M95\$^D551D@)EY0U_'6YRX1KGNSRKNR2RY]AVRO[BD2I
MK)P^(8=OU_[YV$V;>U0^^#2R2-F@5L3?*>=Y6),CE2I->+^UAN&VW+*3\JC;
M 3[$6G?2@&"7;.S&]^B-?.PE\%,06-J5$F$:5#69NC0TZ^(\& B='OA2!6S6
MS;)G%#?P:T4KR>UY6VSB"AB^"B.UC&4B9N 64/XR;]2_]))BJ[!E.'DC9N ,
MXX#[>PRHR2!0O;>ZWRQ"*U2.UND\O-"KH'UTN3&ER^:'5-89B9Z[@ Q=(-J!
MWH 5TL3MI(;NK:QR\\WY7$5#>1=5Y<^6%!YWZG9RF,2 U?PVSYW96BT-]%2)
MHMRD2,'12#K#LXMMV'6D?NN09C GNT0-]E)9DXX,16[ 4K\=B*ZB8NLX(_TA
ME<E\66RU#3Z7)\RG\PW?ICTOZLB/+)3"J;:8&I3F:A8!^$P\O-A[%CH^!B(8
MJ:)J3A<5\+]9G?0Z[$/T<^4N1HGCSSE91I%4 Q-M%+8K6%D.1S.3CR"JZSDZ
M<^I9!J3#B/O:@(@L4!5)X<6FQ(Z.*F9Q79[63XA_-B08;;5,E9\(QLU'&Q9H
MK#9\W93+$"3"4[G:O.>IC($<\0T@C;B!CV[]2N,YLOL_X/WDK((BO;;=XZZL
M[?8NK6G;)N;F*)/\.>\I2.?K4>YR,2BC+\\D#@5J+XBQBF5E6RPL>3F8,>UK
MJ8 Y9;9Q8.4ZKI/!S,9.NQPY6>XY@#&A'85(RSYFVR;098UVIT <V_&!'3R<
M(YMU40IK?K'E  H"[?7L4A+)'&(512'HY[4Z$5-Y\?<LE\'E:=[*ZC%>TKB+
MNX")/?M-N_JQ33PNU7V)5!ANTTO,V"W%0(PO$HVCEA5]C'X[I%D5>I>+DHS[
M7&HZC/#KXKP&:'Z!B=L?W $F962\:LP-VP./NR.YQZH*//E%*4'3UU)B$F9P
M:3GMKB&^]A&!>#B3]D"6H03,IJ)Q';A>;M#>J#*O4R9:+GM@I0YN)_I'2+K6
MB!<N9GP>/&9NCXM"(BSYL*)F,4<&%9LK4$PC( 5W-OL"I/)%VZ).)YU31#B%
M3CF*FXUR\;Q,6*='L, 81X!R']"5HM0G;. R0MY4X19AG=S./7*VGR"=.AL5
M'\JX]HX3_?/6GBM2.M;W?%3+!7$:5&YB6]X5QN*!#K[NIT)3^PQR [EX5>;Q
M!\<,%*8*ASZON>A&@9[=F[#0^'6*<@Y@M&GBM*\1$B_++0.BZ:'0(MITUTU4
MS%D;1>81O(S7AO<X$]"X1R;[L>.#(\SU4?PEI@4'(RR'4PZ\%T5G.2)]DHEC
ME*T1G ]4D.8\K=RN4!/D?UK#BR)WLA-R4G.'5>20<5=V_'?ZY::1<R'PETW'
M 53F0_UX6&(;+G0)N=ED1QB8.-7^=OKF5&=;.$\U >4CJ@ VENFL6@.O":\X
MX14_(E[Q^PFO..$5)[SBZ!--E& "^$DD(YIOYG%/)B;#]03D;%(44SX*_4NE
M0MC>O\]S;R]/78J+@RTN;866]OVE:5:S%UD%[15#(Y=N[G_YEQ>OTMBCJ@@*
MJ4!3I5\P7I)'^27<:R'?V$C^!N.A9V.#_K+7:DF>,GV]CW1]4JCA--*T<KKQ
M[?$(O,6IJ]AC.2_:J)&5 4CY#0'\S^D']GBPK]@Q7%0PH![(R;$P[-GVYRD=
MUW"&0@['KW40"G MF/=S9O[@<$9OGO4S:QMS_+U/8JTD157)3Y_#*+S1!QQ_
MOM5G%UDJE&PC,QAY;F.$%":4V(RK@=(JN R4-/'CYB'<NMP9E81X@J9UQ=BU
M:0J)KI[ABV=VE<NJX>JDOM_0:9V?KLG)),:\36HS$I&:478C0S-2U94O2E$C
MDE Q 5&'AY6D/'A91(^6B++"*H;*Z9+E>8)*'BY%QAUSPI]L[41&88_;]DLV
MP:_+UM6)I*@B=QN.#1WY&R,',[@UNMJ3@QN)%8XK"*'*W.3!&L)].EJP^7@V
M&N#:E7*A4+VY_[=LAEQBSW]^>I9Y;GWDZ36"5W_9EC*B)N\49ZM"P2@2Z=<H
M>0NH:<!M1(>ZS,ZU#BN&5+.9@F-20?&BEMT6_4IE#?' J^(*HXQH@E45_B_?
MP!,DA\W/>J<R9OAH)LO(ORCK0<Z2]7 >L/_)=A$I):>:I;SK2XP<5\#/OZNA
M\#V<Z6Y3Y?H6]8C!3M6."]0%F818)_G'6]1,A-%1*KO0ID0M3_LA$_Q^ C3=
M&:@YWTZ.=%=O;_D3(G0RU#_"4#,>LL9K'GO]Q,D:)VO\(ZPQ<E-FZ3 :<=,X
MTF2"=V2"+L>6"@B;X*US[,DP)\.\"\/4R3>A/]N5.[ O56%'R=ED<I/)W8W)
M)7S#D2K@$/<P6>)DB7>S*Z_[KF"<C#$F&TC0B=TK?^1VZUDRS&*SSQG0G!MA
MD]5.5GM'5KL$3^/HN,]D<Y/-W87-K3$6P -_%"/&A)FN];QITP2,X+"54%NH
M*B>#G SR;K FP/-W:HAY2'D(YYW,<#+#NXX@MR 2%F).  %:)G8-[^6GH[)N
MDUU.=GD'=AEG,D/YK[X-/Y(M3I8V6=H=6%I9_Z.OG=ZKNC\!P_)8='E9\CS7
MLF7V\2K-JDP\' S*2_0;5A 3^1I,-O*CVD.>B1[? @6'17,9E,CYHER4NR'[
MN1\&.0H/ VHI3G3;Q'":5\IYJ#$6-)@4AXR?#0$+)X*HQ 'ZVODCQ9-$WDK1
M\*&+C< Y!<)U-Z(Z#3$7-2IY>)39LN8J!7.]#EXDQ:?'RI(DCD-=18-,]B=.
MTHZ-Z%\C?_5KXC^HFBNIJ]ND=K$JMKO$\,7/++P? 3=';00P@.LZP@CG\#/V
M(.9IALL$&NR<C$$>Z"\G4!^K[3"BKNEDM']D%L[*6CS(*"-S$%=PLV@RWBF#
M[EPLZVPDG>=RV39/I^&7^S[\\L,T_#(-OTS#+Z-/]+<&CRH'2S\MZF)%_V97
M&96#C@QH*$A><?/:DU69M.:R/"\K<=CL=@6:.IQ_$6H]GO3(Q__C=(:1!6P#
M71= ,;.DBC5G32">#!C7M4M$(",1W&</9_Y$0HD.5ZS3YD<X?ZX!C2N1@,D:
M]BH Y%!TXU%>T^^8$P=O_&\UL^&\V3UP\9:W3:3B04S+(/\DWV(38@"$'U6T
M!!T;1ZD#=B8$0ST$?>0]=P$2Z;LQ9B#C!D@X\QK#!:RW53.B?'\-L8 $SDFQ
M'6C>%:X52'0$]^1#SF?,W-':5!B6=EE?-M5E1GRL8^%RQ!C4L[R09Z35.W*#
M-Y22E*!2]/19(+"1QGVQ&_LZ#VY%R>NW T7Q[':Z:XPW:44F<AUMB"6AF@,5
MR,B<E5]%-I3 5!#,TV*/[NA%I+?=A:6WDS:4FT7?=CK\$E^X,FD=&5=CN@FO
MVNMU'WB^GIFI)5FA:Z/DZ?F!8\$)H'8U\E0Y6ZA'MJB1[V3[BA<6&.X'HDH^
M9TL *4L<0<0 6>0V2;G@F#XKW)[<ZK6RPCR*%%J^S?AV'K 7^_4HR<<N7U8#
M2H3!+B.>*<Y\,H^9(AH2F5+FN$1_,*?F,:X46NW]<ES*CF)\+D>P*G1?V9D]
MX<_15V^''PCE17I$^_N0T0PJ=XY2\U:+!%-S<(-TD$71E9W(>[$PHA T'6[G
MOBAPO1#88G]L^>,PM9+3R?H6MEK/G4K+C F_+ZX5&SS";G3PT-*7;&T"<'J?
MM$3_G7CN5FOL-6\DKU-@_?2 AHG5X_UHS<-X?+\S''Z;VZWR@]ZT\H7]=-9O
M98Z$B7"@VI@ZO8Y4$6LLCK+/(\MX_ E.HN$!Y'.*MK:LW%FVJQ/PBM$WBWW3
M)D8>C3-F&U;&JVQ0=W>?:(P_]J(PCE?99H24-3@/&I&;8]JY+VXQN)]M4)6,
M:Z>:X^[?,"&.[_"BYS:2Y.Q&DN2AW:@I#"V$YX/5*N@2ZX"+H)A]SI'/B5"0
M\EZ*%(/R^D&<:9R-]+H\VQ[G#.&=SD)39$Z;,/P]%^LA9LT,J[;/W"95$9E7
M^[W5<?,.@>V/Y[R9_=$K"?7R3,&V2W2!4D]&36)%EH9MK$)90[11[3HS5M38
M;?!AZI 8U61JA4:5+B4X LEI:6,>[X!-66OO8-]=%Y>-*)M%,@<S\]U>GF1U
MP!-M@RT95:1,MLQ'O/A T)07L;+>BJJOC(=C8H'2IC5KK^T@BE(5?;V\N%<T
M<Y]H(]ZVY5+I<8S AD?QBW-K[/D\%B0(?:=MJ.H0L=_AX8.QA5.TL>24ISZU
M%177\S5G9!K:(X/],%*]@+G&K]JTR[,.-2S:7+Q_$7K49<O2Z[>4W+Y']O2Q
MW<*;1.,>]Y];O1@-W&ROO223<%KOV:N/!C&P 0DF#K:5Q)B4NKSD3QRK1^)8
MYAEYVJY%WKB5\\D_RI51N*]$'].SH\<274RS;.OGZIKH/I[.WKB-)MH_72FW
M=5&&LHK\K197,499VHUREH[DKX,H8Z'Z!D=EJ4&N$EA24J7Z:,L-\8*CXCF_
M+=8[GSN^<L_F2_:Z,3;?M'=D)/%'VN4/=UG]7>A6+2R[QCR8]NI@#5C5 SP.
M\KQA)1N*/U/T*ISU$7T 3O^51EM)SYYBQ"78ONB*(6=^PQK/<K*L]DL&1XN"
MHK<-[$$BXP,"3WQ,'0+3Z3(:0DQ;%DFWN_'DH.&GM8OGHN*VCF<M7]%S:Z#M
M32P]X^MQ#L-+.7@O,!=XL16X]+WPR1W"Q'P#;:J7B5\HO53>8Y5<;2(DG3 9
M'^\-?O-HPF1,F(P)DS$N ,>%IL/-,TD5)0_=6;5#JTRQ_!*&^S$%@'V]\THL
M%V0ZLU"+9E'#.A=7AIV,51R? &GRQ7)T /#)/FA-DL+_O@V[OJU-^RD)%#W@
MT(G2UY;?6'<D^!Z 86Z5X1Y/;3FL'FD C]4%'9>KA@)<O/-9BGW4$A,<>30Y
M<4D,]E@4PF2P!+?;-E)D684=YDYJHW@=1E6([84WT8(8?@;:1TL!C?3CXW7H
MJ>7#76R]0MZ$UDC/" 8$6=]^PZ1\U0K) 04#B#57 @$%.@!7Q>$_;2_8>\X1
M0Z'Q2!]%^NW/FF[8A(H4SL '8!9&,N03_F%^[85!U 4VQHWUB^:8NMLF%'4W
MN._1YX^WBFH!1\BB"H40$#7@9A4JR<\NFJOXSEWU4US00:@8Y9ZDHW&-74:L
M,T[";_)T]K+6<T3DM)F!M*42GV\ZLNBG>*[>.:Z9+@-OKJ$3<%;7);94I5IT
MZ09CPT:/S)@S=^PH S9GT9;\4D7ZYY97F:ZMY"8W7YJO">>/BXLWL2,\B4ZX
MB@#7MY(A"F6N-U@6=5@'9O >:,5UF;LZV]#2!J+HA=;SSQ1M$U&$9;VN>IYH
M2$I/Q:+IKTUT\?*=4!$WS+U_8UVD @S:S%),"_&0FGH_7(1,V%TLE?C6U7,H
M EBQ99.'8!A8UZQW5X59OYGF>4__18BL] [%;A<V@N*7FF._*YW:XMQZ'JWA
M?09W.(\^*S4\0MBH*K*>U)R5):T >!0*IHH# Y1B2F)]B4;/&[R?_)4QA"#L
M#FY!KGNP_;6#&[E-C2_%4:DI<'.="]KE.VGH296WYJ$!%D>ZMOC% +THSX1W
M9YB5D6+8?%:A,SAR8=&C'EYA&U6Q%CS&))-PPA,MT!4TVAZP.WEY' ^7(XN\
M'G ;'&1O5% I#Y#(MP0CVO>[J);S,_II'4(!M610Z%S:K6>T4B\ XV'--[1F
M-6%2A4]R&[)\\'X%GST7T';A3IO0@!=%I_#KJC(2>RZM;7M61)/-4^M;%N/C
M"WT'PY.N%KV;T+/NI+G4HZ-$0SCBW.F?57NMF$6HHO3,GOUM'D\OO[6F:VJ
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MZ48O#_:)%6UP&"TP.Q3RQ$L15WP?[Q2X!>F49B:-PQ\67,<CXQH^ T<(BK$
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M54&,SS&D2':.W,*=?EGM=U%VW!%UD.A9-,G=8\=Z)>ZL-*J9^_@%-J,E%(C
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M0L]E1<%YN\V)+$UOB];&_!@H_/D3,'H=0R5=7?BSO:!F7+U-%+7BGKRJ=[
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MQ^:3&1+UGD8=G:+>#54V*.8FI=-H5E?UCAP+\3T+E);[(Y0O4(E3DH7H[$R
MF2X!W]P+<)7^ V&\'&'#K]@YR[WVS=C@AB<+XKGTM),EEW?U17WZ28U)(? +
M*APG,")6[*1BC)NQM9HI+PUC"_:V?*<!.^;=_/9?[%-.\YAU&9]VDLB 4R+9
M3 L?0@RZC& >]@P;(VCWGOKU U5MR#NNU2.+8 N//9'_XK]OPZ5RL&CM:\D!
M??I[_N,H;Z@=[F/J6[&Z3A!\T<U5MZ7J/Y#P)5.5:(22:FMHFZL>$HY9 >L!
M,-.4-T.1ES:17H\-D//4 J3&-8VM7<1%U,_8) B9<E7V%7K?TB]/N]%]QQJL
MI)]*@J=H"JP/@C2,FP=%^%)TWY\HX=#IQWZZTKOKR9)E:GN3F$#1"S_8L.[6
M3DDAPGR =G@/?3"9D"JTD435FH[0IA;::A.E$-YIH7PLM*<:"FYT<_>5!9YV
M/.95B%P,/@N('HF>X K;6L1?ARNRWR=^4JM0S(O<@TW<$(U"?QET<!L' =>
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M(,P9"',&PBRNJ!((FVYO1FU+?%5RRH1*I/LR;RZ$1 ,SBX>)7^<)$R&.XA\
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M;/#G31_/O"4F%E]!N\)8@,VGV]+@HO1KERD1%PDTHS7D$';A"68@Q/GN5C"
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M$7=#@H4C:)V?4O6PC3=(&GOR]I/1#AU"G4"UI"!U'5F9)W/L?!7"+J[_NU1
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M0CU@?N98P=SFR(VSS$) @N]UN776?!H,Z1C:- #R'K8T:CY+\/)@G8[M.3-
M-+4]\T=2_DPE03KQAUKP-6FJ#7URFAY6'Y-9@<8"%,F5HAQS(\@&@S+(*V%3
MBOF&=70.GC MH!_ (8\)]S"GT[NVNVD9=1S=:CRM*L%9DEY&QSIJ/5!64J^G
M;TFBG>G5Y"&YX_I*=,-DG&.,R@F8L0527 :NC]3I]\FD<T2SJ$8>%!(I;ZE/
M.COD :0GI1KGPJ='2^)R.T 7-G%7"OB:AC X+<!+I<@#J5,WA-1_@"DP2BU'
ML0OFNYU0&TS(-;<6 %(@.=/,LJ4S WQ I_?'"-9,^<+W"#FSF^<LQP-F2G3:
MD/&)K:HN\$:F:I&B=:W:E]M14N!X_]^=<YT^H'?^X?GP_@TO=(([=&]5@9 B
M(XLBG?2=EWX?NNJ'A5>((X:HY,V_@4FW863+:6M9NG7KY9>I2A"$NZGU 6%V
M)840JY5-RP>HW@OG,$5_E[VD+W;HNX4NY\LLLJ#]5$U-96P$1J<S\!/Q((CV
MT@DOXFI<I"K;D;1TQOY4_)$P3),[XL._0P/7!)Q>9NL!N33B^3@LD0C:I)*&
M';/LJG2*?OCWZSK:.94!B2V!F0XYN.MDHDA%6J.QM7J>+ 7$61L_5:ON6,XA
M:>7IQY+BT#&CDBB!@$U*'WO\12ZY*HJMM[0)\F54+<N%AUPP)!C#)UO^/K?\
M'V++_R_GEO^YY7]N^2^NZ$5(BJ8;Y%?U]H+2952;+P*=V#1))DW\[+,0]:DE
M(/9.'T?!0.11Z]+TU*BLD,(L+H((UVQ_F81(;9:W%GE>5UC1(.011\6B[:HK
ML\60GPO2$J6RG=(N_GES]$!?/K,EN,J+=8@^Y\(4+D!<B,*E[TG%EAL^Y#7)
M9S%GS#GK<UCH-@DP4DJ@@>1"K.N4=5W-?.$+"]B_4RVP(HU1ZD0?M[1$$"25
MASBZ1XE-2S(P>%Z5>;^&50M-63+)C2;*WN-UW]F30#[+ZQ7RNEI34\79W;CX
M/,P?N%\E6'*!)VAJU =JV576PG4C@FGNA]I739.0#3(;?2)1T\MS&^P![?&/
MU)I*#?.$CZ7_NJIWLM\4DY,@OU+][W4BU<_)'8AR+Q4UO-=50R&%E&=:F"YF
M!7_7HDY5\F799U]WS0:_K7OO4B C0[1:6"%:;J[7[X4H#  VZZT+L0,2-](P
MCPNRJ26?D^4*)5[ 8ZZ]?)]>W]TLAC(<+T?8-9;8]B"'B8=]@DG1I'U\IP82
MH:1QP2&08[4C0^HP<U?%8\KR[K*.#6OQZ/T72S</IZW;@Q]%+9_-$4VIYN W
MP:^V^I6I*5*K,!JKK)!70W+TP?Y1YAM<.?72F8J56>9P_&T+_'CWP1N/^F$!
M3F<(:(UN0@6]3Z!?0%YZFQ5H@Q=G9$?JOG0??I%=+A.?=/NLB6_R6> 1&#SM
MSJ4S/E/[XOF?7OSG'_*2P_3-+-86D/1^B7?PC'YR^"\B(*:T=_:VTEK%7_OC
M7_[P2;V^+Y[_Y4\O/O_+?_[YB[^^^.-?OOC+BS_]X<N;F#ESNOY?[XB LFP:
M6R%)[;%0)Q:&,L__?/'BSY9ZNAP_O]2G8KDP+C'-EW1J_TU.;43Q(X:>T[E*
M%!"J)X*F,!7G4!(UT;+VTMB')PJY:-]1!Y&IGM!EBXZ4Y9L'Z!EQ"[D3Z9="
M8E!IMJ61H1C"CJT-8'(EC=O[-,+$_U4@6"Z'*^E(OJM;!@U0-WX=N$<(#H10
MR[W3&43":5*]]O*RY (+16KNQCXFHS1EQ1KQ'"S[PPM*NM&7$A^N(YLJG"<5
M5B5E5-@2.SA[#GT=5]GARFUQ'9_Z,<1L1V?"^3_JBN8LDVJOS$]9"T,E][@I
MP/$/O8TF5)>6P9TT!3R)SM(Q[(0N> UY763_:(  2"2_@W;_'@U6^1S2?G-B
M5)61_ST[L[,S^X#.C./^;V.*&E:O>+;C)0$ET$^/UY_K/:>, A%L'W@N4S*$
M.4LQ?^N&F-.;^-GNAEU!3+%C/KQ-(X\*+?#2X;H_:XFNDEL4=JE:]-8(0H(?
MQ42&_&-@3^8?-Z$K"AUEV8!SB[T,PV-!2DD+T@DO]-C()/:V?,<3%_SO)B.'
MO.ZZJZ%+K2#=GA7P$,PXB#*RLI*HF4G?_.C]93,?7/)S,&X4K8"JD'OFIW'+
M7ZLHB Z"2C7&(43,TUAARD=@R[X-H3; ((,M0[Y,?"-8U;%G(Y+++]O:EV<O
M=_9R]^SE7FED9D=T*W;X<U*"?(.$D)T(9^RK5^0+?B3RAGX <>2P L*/(CW
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M'_8M+S:V3.XXN[;$D'ZE%+F%(V+UPYN7]D+C;;WX[,4+1; -1Q:P] NVHN@
ME<C/__0'K8B7%>WEX"TMT1_(DE%50\ "#6B:50%4*' 2%JU<??X']T8@+:Q8
MA"N,1HX'R%D!A<;BO/YBMFD8_5[1!41J.'TH;@ ^'ZU':L'3#_P^F]4;JL?$
MZ.MG!NWXEF:\K;QS!3&]0<OZB.B3N7.G1GULD6'=2WQI, U(_S7S&7W8Q3B
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MVG-5M^/<K40DSOR,+&4Z<)DH_HU+&RAF[E4<[3^0(^I?Z(*S0ELTC*0-G:"
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MO'JDZ\N^ZAHNRK?/=)UTIM90',6J+>/I=T-_8D.^1OF?OX=D(+7(W0,\)S3
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M>F%_'Y^KI_S_, FNIV;[)F"DJ%I]BP+G$?/E]W1GT_VW6.L?,P/[8VY@_["
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M:I.'VPU^ZV)[EB#+<F#OAT9'_QP2Z,@%91G%N$9<D3 /#9\UQ3Y*EOI#F#X
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MJ4ZT5J81L1+4_XNOI&,JT?OC+".$=GXL24K,5T&CQ';BYGL8#"IC@6,$2GY
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M/F?6J\IA5</UM4)7>HN-WQ#138MZ6M0/XTA0BSNM.FDT<!4MTKDJJZO$51_
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M3:F+4,@52/V1:#CZU/5/:/-\@X[\W^VB198^9;3%I=2^(RQ4?"&-(6E->2M
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MD3<-7Q#LMJ>Q <4<[O<+SFLL;R9KUR/E%/F YZ*%:F=IU@ [12(!CV$ 7"F
M7TU]96,*^R$$)RTP!1&"M+'1CUG:OU\F=89E#CP^JL6:ZL422+K[@12?YLJ
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MO(S_C1OW"8="T"L-S>;_EK;T+IC&Q D[@!=W8:)Y7BE"Q538*;,KL#*H],R
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M['J<*50$JL=%5P+5(8*J8XT,BW*H"%0)5 ^1K@2J0P15TQTYKDGL2J!*H'J
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MVK__6V!9QFO\P[1:+668YO;[V00U4Y#:@ XEQP-?[6C%C]3T@);F:VDF"C1
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M+%KE6W]I]WSTC:-=8A:34E/!++N %[T06#NKT<(09U,N287YY"=Q7,YX+QZ
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MKL<<F;ZU<+<[O6!OY!?_4#=N/7Q/4;9:6BTI7/#82+BEVL4^YM2*-+48:XG
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MXJ15O_RR'<^*SSKJ #,"!\ I[.^>R-0'47X!O[U WL!=Q[C)=\$J<.* D<-
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M!W[K!QY+L/Y(\^)FJ()<C(1YCPND4[>34V?2J=OZJ9O@()D_ZN*/?N>0?1Y
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M[_T&7UN1:]UY$WK%8\0T/ 85G[SXSTF6WPEF6R.K/.JXIR_WM(51$MK,C'W
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MMML3G[+ <@W'3'0_,C%\Z1AZ:&.EONG;;I3&IA<LI=UM!(FVRJ>Q$SJ!GSK
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M6P@_$D38"]D($W:""0YAPN#5NJ;XA-2ZY^?FK'=0E*MZ<J'Q[U,^J7AU=LR
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MF#*%CH^XS\U]=V1J(BLEI\9H@B-WB&"FP$D\CI2T4,H)GP?%+DO>*N?4E2;
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MP80.RK JWZIDODUD^,G4^>0ZZGEF2VJ(\A0-46) D!C=>&S9=#[QHT;CZ3@
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M8(.\R[[JZ53#6>][HPBA"^5S98DMK2<B9X(8(P,)EBD!LC&G>JOWS:T;17R
MU;Z)=/E[1Y;UKA%[$EF"7MT!YY%X(36-2(D5!XL__6+3YZ2":E$PII0AQF.S
M'F85T2!0"<A4Q9G+"[L]Y_ VI;Q1!B\D[ONP)8T_=9TA[CM'B(L!T"AIC>G4
M)A='XM3$J<F+G!CWB!@WB=C$J4F%O\*-4E'!I1>$VQ+4<99[8DSN2!EL'JQ0
M4A3T/EDEUZGPL;)J;[Y?GO=PWDPZN+TXN EB$J<F3DU:?&+<PV3<)&(3IR8M
M?K<6+R4OF2P$*:VE1-A*$&5Q^J/5"K1[5H!B?.]@:-+BC_7@/O.V",>0P;$Q
M[.-0<CB8KBI!G2-48 106DV,#I0P YLIK,R-O%=7ERBV'C!S@Q9IW$=_16-2
M&/N.._UBTV23)\9-C)ML\L2I1\BI2<0FQCU(QDTB-G%J<GM>,4K(R)RQW)#*
MQQD/W!%5F)+0/#>JP&HXOI5_?(_DA9?1QQ*KVA9.A7TY$@9,\>3S3*<VX4OB
MU,2I285/C'M$C)M$;.+4I,)?$0(L2VM+4.$+IBLB;*&(*IDD1CI/BRI7E==[
MS%Q(*OP1G=IGWGCB8*8Y7)FG@"E$TPP[P\PNLLD0;J^_ZJEK#D!&IYCV\1$W
MJ1('K4KDA6+6<TI*7Q@B-+/$B!!(04MLAN6I]5M)D/?H1K"F2K1]"'Y':?8Z
M"K,/(,M.HRB[=W,".:ADFOF:CG"R6Q.G)DY-KL'$N,?$N$G$)DY-^OP5W<6,
M8:IPCAB7%T3DCA%=6D>D5J6C1>$YW]+G]Q/=C^5,UZOS]VCYF.:^ID.<X"9Q
M:N+4I-$GQCTFQDTB-G%JTNAW:_1!<2\Y5Z32TA/ABIQH[!QLO&>.E;0JV#[;
M%"2-_G@/\3-O67 PL?]W?I8-QTT*Z1]Y2-_ *?+3Y3LG<C++FO&P=MF"D7I*
M_@-4*>Y/ZV37/1;SMZB3\\3^_="HD^V71'F/>#F)\B3*GS'[]Y>YDRA/O)Q$
M>1+EB?V3*$^B_)GQ\@.+\H>-ZCQ@L]$?>]$UUC%62)4'HD4EB,AU22IN*R*<
MR6DH&#>ZN!Q%JD).JT(*HD+P1$ACX-=>$LISR?*"AY)6EP>?O_.SMR,[/O>_
MCIM;A(D:V!EX=4V\B!4#5K#^Q8P.&#0W6>_F7'8(+703>CZU1$_HF=#S&-!3
MB-Q3I1S13@%ZVKPD"C"3.$.IJW+JM=_JF7:;'(R$G@D]4VN&0TG/^.7TU]-W
M+U]GG<\F>^6M/S=^FG$ZR%C.9 _PI*?[<(R*$3MA*++<>&Z&/JE&#ZP:W8W:
MSREAE&O#N-2&F)*CLF(<J9BBQ,#?KF2^ OWCLK*B'>@CBN;$4U16RB"(04>!
M5*4)N<F=IOJRLM(V<'@_GS4S/4+JW[MM@QA4K!S0@O9=2;G$A'U74P[PT"?;
M/D'8GI7N/_6 K1.6W0[+"NJTKU0@JC(Y$1Y13;*<5*+,"RN$587<"Y9AO</9
M> B;T[3%#GLJ<>AA%Z($90G*$I3U@IL3E#T?*%-EGDOE.=%62")R4Q*CJ"&4
MV\+F/@0>MGS(NA)&E=H147E*A,XIT;F7I-*6,ZY=%0KS:%#&1#[(>;+-$J E
M0$N E@"M9X!V]$'8G)E"TQ+LNB)H(FCA $HK3E2N0^ZH<IRKK=96U%OF,(4I
M1_NQ%):80EHB5*%E(4L."+M/ +UA));S 2]40M)>R)Z4RI0@-4%J@M0>V(@E
M,U(JL/),Z001 !@ 5T&0@A>!*:[*<MM&+#R7-E>!4&$#$0RSE$JG2*EX(4(E
MM"^+1[,1BT&1<*V/%N(RMPA>:'CL!SA-W=\M]?@)Y_S/^TK+6:WN>PNZA4)+
M?\H^^F8^G#6#K![9X1PW/FMCUI<GK@RR,_W%9\;[4:;='_-FYETV&V=3'X;>
MSK+9F<^^KR!?N_*E/'@W/_?3VG;BP/+"""XTR1EW1-BR(IIK16@9BEQ56M!\
M2QPHKETN6$E$@>G]>0 %V6M.9%5I9Y7)HY9\G3CXZ.%L-;X=U# 9UK.>;!Q\
M1D  D=E9/9W!ABQY?8-\_[EK.YYJR2T390U2,?,A ,L _]2C['0RK8<Q7^PD
M^^1]]FX\\QD=9.^GG_6H_K>.N*!'+GOE&SNM)_%OX$WDMU_F33WR#7 O4 ,$
M]$S7P^9D_>0_)%C>+K.KO3?;&T&WI=Q#/NM*_>@#,R&?: O2"=9R@2(+F:9!
M:?1R/(I)LQJYZTT]TB-;ZV'V:09OG,./-YM)N?H+HL%?X=_%(_V;U"/GO[U@
M/X-8^T9</?41O5_ L\[/1S^[&EA87[S 3[<P]D0"5.*BNW15>*."=U!8UN%B
M\0#QM\2/W,^3<5/'BT_]$!C]BP>(_H;40@HLT?K;#;6^XAKZ7K^]W3=:S6(3
MR?*^[#VE^<X]/%OF"G?KKD=#$ ZDF>GI[(6>S\8_;WX &]"^/=&??9LW3'0
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MG"@**Z@)0NRCK>^'Z1B6\YQZ^AZ;-#B$&M&$7\=(W81?";^NPJ]0YDQ*5I*
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MDL?I&1_,(S5 $J,>&Z,>.8)XB__GB/?6$.$ ""I?%L2#?,YMZ87BY3ZB%P^
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M6N^([:1TTZ1T):4K*5U/KG1=,?R269O+2A,E*DH$UZ#>6"E(Q8K**VZ41H?
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MRY4O]ZH4[2TU<U#2'HYB>?8AG(1N"=V>GOX'R,H)W:Y!-TV-#T5!G,T+0"I
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M^E]UDYUKYQ<R8 (RL(G&J/_FI[9&?03,L-92'<VCC(3=C5]I (GAAAA-FX]
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M1 -O#^%B>+-H"0*UHK,Z[*;8()M/HGG=FLOS\TS'S$S\P0&(6%7ZHA(Z)P*
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M#-8RO%C7%]="FMA=9 :L.)[/=CZ7-O40'2"MHAJE+KYN']*W>6Z?Q^VIBRE
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M;BP8+M&QA2MX_<V>Q2J/%;\L[=A/KU^N+-B-*Z+OI_,'C?$AVR@[2HOV/!X
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M*G!*\ZT2F=MXIAZ5Z6XG&F7/ P5+F7><<?!@I:F<Q(';Z!-5QA%MC":A<L"
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MCL[EUNQ0=7MYW=?A=]MYT\N3:QAV[TMID/308:8@A;(B(AYJBICD FG- W(
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M,TV\Q#\?,?YY]R2 YT#JH]1)Z"E-,LE/%ZF>N&@ECZ.5W('JQZV7"%++$$5
M1"53F>B M(X&,>^M8DJ$'?V5[Q+O;-M!/'<]Y K[/1--I.!7P:^"7P6_'@*_
M"!9<2,\1H%!$3%"!5!TYTA9K0@4 E=KJTG67*.>>\>L0W<$%O IX%? JX%7
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MX9<JZY7!5Z/)?%K!DN_9:.B:SC*4>$IK31%7RB:/1HTT-PYQH6FM@HM&X*M
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MB]9B^)#P(20X_=QJ#HO9RE:XM\.*B!-,AQ@HOEMWB $(H.+5*H!: +4 Z@
M]9KAQ\'*6GB!-*,> <3)E,^K$%'<&:R"])0,PC.V ^^>VC=&L#C50\P'/EBX
M?&H'6NFB-*PN2FP(^#'(31B&&E2H6ZA[J-0M(:B#8-+C5K\C%R$*;Y&57"!&
M<(U4% )%BR,+PD1:QRWUF[E ZN"0UIB!R@Z:MW)*HP!J/'7<)ZU]^"V4:HI/
ML+Y^+FXYU\=]K@OX'!]M2PNEPT0AIPRGP2JD&*>(40G8XBP!4!)62V, A-3
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M=N&WZ?R_ JRDWZ=WB>R=)+F;$V-+!-1JX&K4@2"0]LK72EH4;8R 0$X B^"
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MEYF;[#]V93'O\3B/ *=<"LFQLDA*(P%.G4-*YQ(9(ZA@%'M&W2:<YL0(Z5Q
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M/8S+VSVI#.YKK>7YU+WW5<)IK\8)EJD+ZIU61"!OO$/,!8.4E X1S[DSW(1
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M0"')@.%^Z^($,++1QQ:.ESZW79W)JZ'<$E%7UW[BBOC):2!E>4$%T^ S&-!
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M(#9RC3E>GAP#0:ZEKR63-F/NY]!3\FFA'Y5R!-?MAX90]Q GFJ"_U"]?.V^
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ML^X%X0(8YO6ZMT7U+P%5O,#$/8S'4R>;..%CWXMGB!/D$:*$G?3W!,M*)'3
M)DFMI%:6F<CU=:1)O:II"UITFF%/AO\N1WW4PF+;MV&YRZPYJ E4=4]&X_0!
MNX!&E.F4 R.)376OT*7,X5E_C3Z%@<VB*QA*%Y<VXR2B?E<+R(=8I* Q,>>N
MI-;OSZ/1.2A]X?)4IEAYU.(6"Q1C SR @ E7X&_[C<"C8#R4Q9(+=!H1414@
M,$=S+\[G6V<C/PX)7O];!B1BW2.P:'B*IA=/R636H@;9Z"JLU#N)O/B;A/R9
MLI<'U)2@!'/6[#7.ERX907?X56UI"!W30'0&(_"\11WT+F#S,D+2'H4^X!H\
M*XM,LX(OIBI('MDM"W]?(?RE9L'H0F[&DMO+UT;P=AK *[])[>+%ZIT2?1M3
M2?4T7 "AP)58$X+ZPP(;Y^FX(/F)9/5+U-HA'2F'T14/O+]X)JSXXZ^@Z28W
MP.3T5!Q36OOQE\LOU"QMS522^]M\3U]<1;*A4\3GXB:,OK&C5J/9?E. H3PI
M+*3H &_ ?AO0Y_8DQFM"ZTBP"GQEZZ"_-K Y D&,$Y5A0AR:]2"@Y 7*93E/
M 4JYU"P<DZV A3]YT?S);,UK8I:*&9H_! $@T.)S;!X6&5K,U375%8J,Y+4-
MJ0HG8B'(CU4Y,,1&"\E&/&>C*;!1UKI>Y0QQ]8ZU1'=MS[96M!8,59)']Z[3
MCG.LO080PMWXTI95#E*=?44U)4-Q06CZ9-N#MTF:Y3_J$IFRJ<\:+)3PDI(!
M\<(E8&$L9,E)G>%Q3R@[]&2N_!)<XF]XU %NYMH#]\285O4]669-JZIJ4.8Y
M?*BS+U]_.;E@IV>?OEQ\'GT]_7+V>@.''W/I3688;5%7P#:(<)5\,P=5ELS[
M!,T11OHP:25Y>D^-[[L3/FFT!IU:K]=OUSJ#(<>R(^/:>"!$AW?%N#.>KMZ9
MZ?;ZG4FG-ZCUW.&@UFFVW-JPW>[5NOUANSEQIZ+5S^[S"W?R#H.JS<:XVQQ%
MT6@2+D!+?O+Y5?$RR]3[+B8P>3\6&Z;*>\UF:]SKUJ8#@64$N*@-^V.LT#[D
M_6&CU7=[:Z6O[CO5LS!XP&RKP$9<3C53 04*EOQ='0% GM\/<[N3X4#@=K=;
MPPGL_K!5&_2'PYIHM)L]/FUU)]VU8A6/8>ZOT3Q('L3;[K#5YFZ#U_I=CKWJ
M>XT:G_!IK8G%,!O-WF0R6+NZ]DC>WFZR56 0V0N 'RAW9W<JD/@,J5]KLB3B
M=*##\RZT.AD*I$$] ./6[GC(3*&BZH=T'=HKG&F=)F+..HT!EMX%FW(AKC!5
M" -#E[7_K6_,AK87% [E@L+07E"P%Q1V>4%AQQGC[6I[4L?U(OS J>>)/__*
M3M__A7%06.(/C[(O>U]4?DV"79S\/+KXB#<IP$4\.?WYC/WZ^\7IY<?38_06
M+]G77T9?V?G%R3].SKZ"'WEY?B*_J/3Z*GT\<9?@5#7^43%W_BQ,,&G8]UQ,
MA=GGCM..K1M^J< PZ?1?GN>M4(5^GF#=,,3-[]+%0D18=7KK&A?[;\,QN@"!
M/CU]0L)E'$24@Y7/_]5<O9Q6?<(15FXVZNRC"LC$SGKBJ<P!S7-*?\9H+89J
MGY13-X@L#7C-(X\#L*;3O9K+%W%U2"P[N=$5(T7B.W-F55[KD]+Q&8\RS#O\
ME H8"YFHE\Q6;K'HO$!R_>8RQJDR@\::S#JT6"Q!0;M@%L_7-T+@-UZ$!?ET
M4K9L$R,#ISVJ1!3)P^,@9'*U3,++,(AGW@(>FX>4@[C,\[_5#"J;$P, F_U-
MT5K.2KDC.!$<"8PE?EL#3S=,E?<D!QT.ZXV?WJN?NUC"9Q&+=[KV-;P'QX;!
M,V_LVHL]F;[Y3O]<_PI^-LF0!HW>'M8'K<%/IJ.D@3]Y2F\W/=BK]WK-!SS7
M:=:;#WIALU5O#UIW/OBWMTFT1A+E)@Y@;TOW_P:H*QW2=](MQ0]*H-K:U K^
M*7J@ZF_I]M4; _B,*O>XW%=#P4_7PAC&D\I%E(^6>U.#QV"RS V6NFJ18+-+
M;U(&47:$S[<#9'PN"FYI,K'4WANU1U>6V$]&[',5)+$4?RJ*:^#'+@%VE'/Z
M;6:",,"8N]^NHC -)C4U67<Z;4S=EV! *I&ANM5.?N8)X,4;V5GY;G"'BZEU
MZKW!T/R_[B:SGU.D5^_#C];#F=O/]*CYIIH"OK/-?IPD;T7$3O>%TW#O K/A
M*JN#)>ZP.KTJH:<UY LG]Q.P+#JM#[,PUI \H5Q<)F(Q$P'[$/')LMJ&I&4-
MR:.WNULNDR^'AD]@2+B7I0A2,.^%4_1I;$73>B.'+!.1%R=>(-BY\'WOK[]X
MY%FI>+2N'KQP&NZ=+RV:?WX-;17Q4X:%/'?&A<\N.!];,/_2A;)7+I(OAX;6
M0!P,+UH(?]B2<!$&7L(N/9A'$EY;>;"Z^;DYTNKFI]/-\ _,LOJ[>=D!,TEK
M/OCU->'3E2=Z[<*X[U"X@;1R_:?TIA'=@'E/ZZ[A\/&[,8\%WH%9H1".D*]F
MO;KF8Y@O.]U_:#:;FHYAB;X)L8"9^=F=+'6QAPAS"R4*IZ/&[9[B,,^VT!5Y
MC.KRN)G*;0$GA%@\88+)BF6MIK8\<-,IBH[1NVES+\5CU4M1A5]',=9"&[E_
MIIYT1?(T8.IQ)/]W)SS=>"1'-UX)/[<.AI\_ S^CG^RP]9 ^BS%!!A-OFYBB
MRWPT"/@++-0GFV0OHG JJ'P>50_!"GRRKJ?J&^::7<]U0JZ;1E2J,Y;%D#V7
MA50($[@^=F39R3G='I6%\Q-V$Z8^-O-=K>1.N?S$\K* 9BC;QI6LA)KFQ:F+
ME4]#%&&J*0K4\9<.TS3 U2S"6+\8/Z8#0?D@?#SSYH[1"D\.+1M'8^65G<@N
M*Q/>JMTS.J Z*SO.M]_[_832G*;JTV779/B/ AVHF%LLHFMI:6^IRKYJ6=%(
MKUQ-,'7;)S&.4NQL*F\7Y-;=T_:\]BF4E9=EN7?0++"0HG(Q+Y/@'Y\XI1=^
M\,+8]02^YC1PZ^Q(W7V07Q<:HV/582],8W]IK#+_'4&)XKHV%:6GIN.M1K.)
M*F]E=9_PNU]YH#]JXV^RXC3X@6-0()_(=F_.J)T7DX&?18'XSNG6!E\(>,"-
M%3&F;[^]Y>R$"D^M?_]&S?8SIYFV5F?:*I\IU67SYOF,G1U-]S3 MS;,M[HA
M=GNG C\GW[D+# ,;GJPO5#>JI-\4=CV?-[$:3?12<4S&SI?"C03@"K!36+06
M[P1OFKR<A>* 5D-U,*9^J*JAJOH)&&9%V+;)\]R/0W-9]Y]C^<3.P#SZ?@JV
M'2GB9#S:*9FA_BW.\=?4ITDVS4G"L,*C*;'S6?UC78Z&0WP&<,O=60H6-4'B
M@SY+4ME_]*MP9P%HLJLEC@NO;LF9L@_URSI^=!* :A2R!RT->(YM-D0"R.+W
M %X7Q5COG)YM ,T^Z^GD?7%"JIE^NVI"W#1.0?-@R4GQ?8'N>"R[W>!7"ZRV
MS7S!0=W@728:E"@Q!L[*ER!+9&+1;E6W/49DDM?T_C,%E3[%_CM4\IBV\9OG
M^[%L.1U=BXUJL0(W""MCB4N3PNPEP57*K-CFVZSMKVD@E$ ;X'H;LRZ%,GM>
M*8Z"?=.Z!T?)+18]=RD626[D2BQC/AO2@;>;OB\+\F= 4WS)2Z7A6WUQQ5TM
MGLOU5S>':MX&'<XSR^^4/-!6#XQ -?@T@K-..= />.$6!C%UASZ7!*T[#^.$
M]&:08.''V"#O/V#^IK7,^M/@<F4]4^$P<(9.L:67 !N,32.T(N>HF!8S#I#(
M)9LGG4!:O>Q=A@SAYHU_/HO(_:::XQR'=:=H(NG;S$)*13T$1;OV]IP$OBH+
M?R4"V!1?\L $^%8UR(8E9KW F&J(D%48SF^=*D\4/G.S:]43 98H7,@*[K(6
MIE!NK6RJ+I&;+#Z<74'%'44M#CRV,FEX\TR &RN5.A4<=M&@>]1Q3+49D7TU
M8.GSU$^\!78!WT!A3\3F"H#0Q;TL]AWZF"\&R7 >@3T)?>\[NK-XH18GQZGG
MVARE8F4^TS R*9<9O<R63<SAT066G:+(\J!A!VI\"9;?P6*;*XG+U8"I0?"M
M)5>)X8]1 G]PQ4%*.RBX@*]3^*8CZTAO5E&%%Q"D+YC:TR (KV7PXHO11X =
M?3C]\L9A)W.!:OM*Q?UPS9>RZHRZE8_?D09T\F!*RURV 6<^U$<:BV"'F1S8
M& @$)ODE$E=A@,+W:P'^%']%'=<Y]O%SI5 $[+??ZI_5[U'I_Q-[%Q@/7;JS
M$$N_3MEO_,:88K;;$IY8H//B@,Y=B8NO'N^4$>A>L"?S8SZC@=@T1NYA_09(
MPC?AQ;$/S@EB!%)W<M@"JNEJ^$."G_4(Q$='Y]JL8[.%R;47AZ#B+^&U,'JL
M!M/Z<G6*52V98(L%'F2QP';#%@NTQ0)W62SP!9F9TBCPJE% -?]+BC'H"Q&#
MI4$5;A@*'9MK]]DO !C@G;'VLO*OWMP"F.^P449DC]H?9D:/@Q^2Z/;/"Q'$
M$BB[NBL7@?93\(C"0$\(2PFA56/'PJ<.7-I?@7^_60T9J(#=AK<CE;::P9E(
MHS"&+T4QROM;,M%VU8PSKYOLG!0;3/5I$,_Q-#!W3,"-'2")LV4LM(NH.H71
M]']6+NQQF,+L_)4B7WF(50_9ED,V!X;+^>]0=J+4<UC=2O0_\U@!3CP+$]SN
MD<(T1^(*VP$&JTZ<#@;<(\I0MM1L@<9R]"O7%I)OPJ4(\,?W>H/LMA9,L)6<
M;N62T!&VVK65MR%5J8R_>B1SN7Q^(WL-P8!_>#Z\^2]X-8@=BJ>,<EPNO.0O
M8 SI9L<8Z<;VZJ!__I*AFYG@/K@S+I:THO-L[N;>#.E"@?^EHLF(V^8<>#F"
M"5[*#IOK&@-GY?H"O#O56/*7,  FPNI2V'P+E@FT2###$0@[BC$Z08[[K^GD
M2F2^_F5*K2HC)*'LWH4J[5=XM5BN42CS8C$G@/S8#6YI(48/;Y_# [$46GST
M-H_V&+4RGX0.8.O4!_N[.HO,427.=HS^)3A\B3NJ6EL7?4ZP1V 5HD)X"*=&
MCTD%JIYS.>PMC XVYIM0*0_%=TH1R]MN.MIC14=61-9+O=?!>,FM#NN=KA#F
M(<%X9^6@SSSDSA_:/@"?O;3LQ+P\F+<I>FZ88C"A:\'S+'&GN.H1H'-_^9UT
M^3V/S[4SC#4'6XW&L"R'8,,R='RO,<#FQ-2T3DW$R#"B@#C#PJX!$BBA#3]!
M$P28(*9\H-#%Q*$XBXJ?G8SR0HE9M'8:NJG1];ZHPPAC%(/&L2J!N(X58'QC
M@F"=@$3-+EL*'JF^PG- :9E."[/3C[+XG3&7LEDHY;H2N\:=4S'L#>:\ -5P
M7&W?/U-7U6Q;+@3FH7WTL,@A4 ;H"S_\:SD7)K2D%EGJ<W6&L19S7!K,)8^$
MB"[)3:@((SM1RT$R'IMX_"H &.2Y&+"<I*ZR"K&.M4S4S#(.R::1LS)BM/+
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M9G%6RY;B;5KZ'6QQ+4[':+'IBVR@^(W6LJ7TE+5#Y&["^]6)LU;9KGI$D-B
MG09"RDX:(DCG&#Z08/T4E"OK-'H A?#G%QGR8)>U_Z5E'GEJX<7UTO9'A:!(
MP#RLA.%B1P_U+8%37N20C2L"DW05<8U$@?/5KV-55 7@']U+!@PR23G>IEFA
M ST2L7F8805-EGBG='$4/>8T5)P"N%$,AW<&S&70-40D109EB'W49.17$B%/
M4T38H&LV"1%BS&L./(S03)6ZU:5J8[K_;TB@9EH,:MW<U&$Q"_AA\KT.L%2^
M+Q)3D&@$64H@LT<FDXBNIH= 5+S[@#U>5*EUV&SC+N)X:8RBEF2>I.J#$;I0
MB(*935\'4(WW2KN^#%,6SZ@=C'XUMI?!)C$P3>P00\45Y-N (B,M+!4('E7&
MCIXJHGV-. GF>0A"6>D*YZUV<]IZ#M-9!@7O\4)8C?<=WW2&N@.@IC?YGQ\^
M_6O0ZG7:W;%;&W<'_5IGW)S6AOV^6YN(07_:&'8&;G_\ XD'$.A"3/_GA^-_
M-5KC_F RF=8FO#VH=;J-88WWV]U:N\6GXT:O-VF/!S^0SOF?'X0[>:<V^6LT
MH>T%RWH.\'HDH< GGU_]P*0D_L\/WO<$EO]=3&I)E(J*[( "+1E7%NCX]UL@
M^I//% U;E>;C*?%.E'@O2+S955:0&O4P>'\N7L=VJ*0(*=>W&>3 C!&S+EQ9
MN T,2AI)+W"\-*^UY; Q XHR*RD/(J+:3GT$-'%FV2<Z7J6P5I@(HW*6="Y7
M5^;S&WA-E-U:-^(B='/^!L\J>"P=RPF D^)KIFFDD!A=_A=7(9%+^L6 ;D<P
M@45VHVX#66_R0]LJ;+ZMD7OXV4(MFRUDLX4.HT;ND^NWJ8?51*JD<3G%]L5W
MJCVBG:51$*14W@5CFQ@I^ 18BS4;X#-CO@3^9.K%F%Z!U468H'Y;V;%\6][\
M[F"E,H\J=F+6+JT\RR[%<X PT*7J^O1 ]RF]')E)1H@6$\__U6RNL C]EDJ:
M(M!\EV*BNPN0HSJGY>3$-YMU=O+_G1S__O7T'R?L^,OG\Y.SR]'7TR]G5?:(
MGMPL7<ZH_D JCS&SG&==GJ=84T$50PW#!+QTL?ISSZP-;&:U$,C,"C?KD 4Y
M8E1\CD^0*'BFJ7*.FC7X5ZW9!N1'T7X@4NA^8X!@0!3-H^D+]?TE?7^)WV?'
MT[HK;3B?XUOQ%PZ*EFRZ-'!4DI@\"55G7S:<8'!&.J<#I<+F?44J60%Z6.D1
M9&\Z$E6^%\ $67LRKY=D6(_8*%52J'S.;^!3%2S% :- 'L@CMW^BVNNW=L>D
MI#YXJ?0)J;SW#%C)7^9OP:/;]<(HIN!A'8;)^@OR1I@J\T'6^#+6A'%<%]_P
M;D=U2X9[K5O2K+<Z#ZA TJ^W'U3NI'UWV9+UQYJ->N<A95*:G7KW0>_K/JPL
M"UCDSMU58"I?ED6JI8H7L'B.:B&H$TC#Y'V*;JUJ8?=A/_OP3U"TEN!/2/!+
M[AOWAN\H^-&N][NM6VM\E".[;KW=VUW5CZ<CSM_&T=N__VCY\0E)_H5NH!+A
M1X@58_KGT8];[/ZSLVCKS5%[+[5I++=L,MMA4#OY,P5 3&QR&N D$-.?^UPR
MD>D!KK*2W:*GJ,/F^^P+NFMW;D>%);MC>>8I>>9KF'#_5FE]2%4Y5XCI]#X^
MV-.74"JY%7W0Y6LN$[&8B4!V;:YV5;GNLU>5>^+-?X+Z3QBEKA!5\Q7ODZ[T
M]KV2==CH.9U&PU)VYY3M=GO.<- \%,H^RO8_*6$I1ZOU_E (>T L.VCWG,:P
M8RF[>^OEM(9#I],O-V$6@3XW J6?O\.F*YY[CVW=XI@QJZU2(:EZ.9#0ZJK=
MD[77:#@-"PGW ;;[?0><4$O9W:N"0</I6I[= V6;;6=@";L/PCJ#/L'"O9=S
MM\COT;%'/D^%S_Z 4>"WU0X^]FSPT08?#T,%MEHMI]\86,KNG+)MP/"MYV^9
M8(./EF6WI6RGVW8Z7>L<[</M[#F=9MOBS$./,*XT2:^0J+P<G&<CBGM0[8.F
MT^]8U;X'G#=L.BT;GME'>*;?=09MZYO8B.+A$-9I]%I.=]"WA\R5A( 'V3GR
M18(\&\S;!\CK.X.NU>M[T.M#3,MJ'0IE;3#/LFRGU7/:O8-AV0.B;--I-AM.
MNU$>I[ @[[E!W@/C?!O:O55(@%X.^K,AOCT$HGI=I]LI]SPM91^E\+L]IS.P
MN'H/E,5$U][!A/@LKK8LVVNUP!6\XQ8)_ .KA.VG<M^F:]Z%FK2]7KW7Z_^T
M1;FZYRQ6:]2HQ1*?->R75E,=,V@B"Z-,;:%P=(& I>6AJ6SQ>UIZ#0>/WXUY
M++!P\0I1V[@?V915Q< =E_D;/(*(:D:&)_!-B 5,SL]J::N"S$296XA1*+QC
M5&4N#O-L"UT[=U>%,:F_"9]CIQTL13C%AKW4#2>F<D=LP;V)KHN[J1R@(]O(
MJ,+P'I97YTO9F,6HF3@3V+,BD+F?[(BK_BQ8U5# ;ZB4YX_=/EW8==B/S;8S
M[#;HDM&/K6[' 7-&I16QWRU=DI<-$U72JFS?F+?"=70O,YBGOW1TKYOU=>E*
MC=FPJR.M+.%"S+SHCI74V:7(:BBN6(O];OX#W;,S'JG&11]E?Z14MH.B4L5W
M%@BM #\? I%55>D/H"@K1+G;JG$_/\VVK;GVI(R&[3U)T/,ZPE@77OVO-;O6
M[&Y4 25V%G4LO[K"*L")D+W%9!NQ*?<B=LW]-&N_%2[RRL#%;FJW&&>S1F\$
M?'B-+R@4ZY5==7$,007"L."W*@X&) SB8J,X^%)VC87GL]FI*7'7A3?(-FN+
M-(I3?)>R(]A*-NM'HRKWTFI@Z:J+&WDQ5&<<GJ%:^68=Y8T+]*@96: *CF<U
M]@T3;31H=E2O&5_5/X:=P=9UCGP5CZD\<IJ4-[O. YBCO#GA9=9_6'92+?WJ
M.)QX4RR)3-8S7'@NZS<'[$@WW[X\QK]U7679Q UT2#I?R#X^:2QG!+OF4I<<
MM:-;\ ML2T3%JK-:U;+!7:C[ZL'&4_=5U=L'_1TNJU27-A7.B\%OT2MAI3+T
MAEX)75IP+#(@.@FI0YR6$Y(1-\$7"9AB. ?RR952 Z(Y7V+W.- C/L@K5<F^
MC6&LVJZ$VFX=C-I^(6A^,Y)7JY+U(6N(4"<LKQ"IJHM6%(21FN'8&LR-O(5N
MDTE]UT%I1:B^"J9G$86@-.<%^P0S=V>RMT6A!O\-MHV0=?BMTJB$TF@?C-(@
M"Y[A/;2. G$'O#,6@0JQ8%\30A=C$0AXG)CTQP&@E$&CY; ?.YV.T^NU9!"D
MT^HXPTXOBUP\+!!BLGTY"L.>T!N!V,-!F)/#2!!,=^91PXL@B;QQ*F'*G$\$
MVNXTUIAQP]NR-H:=1O/HVQM"J;I=-,$V178D9K/AM(9(RX'3'_8E)9M.I]E_
M<#"ICA#'B!=1!"W?RBSTI9 2^U%5'''RW<=W-%ML#LN?T311M%5DRI$=E26(
M1FS$QF&0JL5T6DZ_/9"D//[RX6+$TL4T@F'RUQ('M9U&KR,G:J[KSJFV>TVG
MW6RM3!6876R<;#"Y9<(PD7:WD5-,Q]3NGD@3]JN[2K-;)[)Q$OVVTVVW[B0:
M_*0'1+-ZO@IZOG,P>OX+N#QB'*6(K-KDS?0<YLU!<7G C-CZK1 _/@8\!O]V
M# 42Z:ZFU$\=04C>OY7'I?U;L[);DJG+"W352?9'P97P)9)9+$)/APQB$6'_
MKIB<N*V&H[,"5P@\B31F#_J6I-GEV,4'6\I:$:J$"'4/281^34&S=W6W-M-F
M)1F"D(S+S7.F#+9(Q)'&3@FNGPD"&EZ0FJQOB!5UAS/Z&I<R\!:GS<-[M;@]
MM$YQCSLD>MFM]AY_),2*1QU[(%=CUYINA[SU'VLJ0#L<MX:V"[KA"!N]Y8Z.
MT<8N=T*RQG5)6*I&XMOT"(R(QMH5\(8)F\',S&YZ,'J=G99[0:,8PZ\C]\_4
MT\X0?'T67LLH:'.H5WV#44P\8)YL<3"-;AN;IKY?2X#PB(:]&&Q^'NZGC\&N
M>N$$E@ >W794O<%?8OA5M8"?E+[)6:%'(7!B$L^D,V@0@"-$Z;T<DN]56H^-
MA<!6G!!UR/B,C'4]T1KN%2BC$-ED0JP'^L;H5KG/5JC;*)SG3)!Z5?KU-H'/
M9)B;+K647=TK%*5]3HR$\ F>P\?PX%!B*G"U836^N%UGR$" F7@D#6#^5G ?
MI/[)HR8_JOH*.@K6Q8^WB-Y421!9(:71["*O)J;;Q+?>$XB?4$]EK)$',T[G
MP?N"1[2:(5KO>@&]6EV%@0^&\$FI>P![5E* S^C6F65 ?M\RG[1W+]1;=B%"
M_4+FQ193+1M5D:!FNUVZA[/L'I*:MW+0R V3+6R+7\ &R(\7_$I(+Z_&IT"&
M=]R_X<M8M4@UF:.02$R;G;/+^K;O=G<?=\OH/CO[G*:@()(J3#'G\+CN78O_
MA;^-&(7>@FX)P?=,VHH9EPU1<CH 6=7OF'BYI!;0.O=R@U6BB!5&JP+5!'L1
MA=?>1*!1\;XKO FS O0%>+8 /E76@$;!68_K+'H6?_-\'S,BP,WXCOA8!*Z
MZ8>^4-DA,0RM&DB; :TJ4)M9Q/8:A.H_SN#;.UTU/+!.(P!BB8^2%26$VF#V
M(G=.\A@90";9#K[PD>&4R70:)6FQ=!O 5*&KX.)/8W<F)JE/)X,N6*Y8T,&?
M(=Y65%ZFJ!Q^K&VKY)8"Y6BY:.0!.ZO(?"6)N6MF^L6+DS#"6VD81S/R0BD5
M)DN@N5%G4XO(H]COM9AY+EA0U!KA="HH#.6'B%M%-,^32K.DP\PP@U_X!^9
M^)ZX5BE]YAMCK9$F*X_) !L'>D4AOLL+ONFQ\_>"?:=H!YEX5%IX  9$#F\
MS<4S;P$:U$\PEHVF?R;\A3IGP*U1&:^8#1'+8^*5&> S^!%0S/TV W;&_$*"
M/FDLU;?.P?1C<*?AO1K')/R[?%IJY GFY8)'$#.-(FDI]"7.GUZNJ%*(.5K6
M-5@7V&AF<"^;<3SDE!E<FGJ4,ANS<13RB;_,F%'&+03 6)F$@-R+7\#[:MF&
MYS^KLZ*8J%'76-L<[K:D5,=@ANPE,A1">3%<9L%.O!AXV,QRDTG'^##]^$H
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MF$+ %E9;ANV#4K:!:HNJK2S\\/?AVV;O[>%$10Z*LL.'$-:":@NJ#XC'FUW
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M;)%&<<J!)C J+!2>369B"9OO\CF]U$M\>"M\.TU]GW'7!5VA7@UO 8E@89K
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M=('DVS7-K#HH^-%;9!<2GR]HXS!#L$2BTLP/O@TQD08![?UOS)]7@J&X$=-
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MZTJC?JO"V!O\NF?SO^=R7B(QQ:MNL0I12"I3%'J,A^L>'11LP#VRV+KT/U0
M2N(N=:ID?BDM41Y[G1H_+]P[RU @N562"\T">:K M2I.TFK(-.!W>_1$'M'U
MU:I^J_JKK_JK"Q!;&A>N($6I[)NM>T!$FR=ZD'FB?9LG:O-$M\X3M=;06L-7
MY AE89."1R2-8Z\RGE#% ]'@#\6FZT.'+0N^U/<V>012("^?3"DSAPH!J%01
M?TE'Y2 =\D!'N4&@@C!+9IGE=NBL%UG/A9)-,/<#;S9G+>'4QHY<-\(W?(3O
M\Z3'[(8B9>'14;7,-,:S:AQ.7\?'%C'DN^EJ*K+$F+QWA ?N>7T7Y9[1@37W
M8\RB\^;C-(I%H>O+VKD2"$42<> H)KZC% BJ:RY+JI37O8,G."8L3"C3$1:0
M^XFY3Z@27S;<H:XD+S[#J9+*S[/G2IN._%-*Z9)GFYL"%Y2)!F@@] (C%U(R
M)<G_ABK[.KU+I93@Q;PT C,!$M-TAJVVOEVN) =Y.PQ4+HF9VWRJQJ'L2RWD
M=9;=EW](>IC8?*!&.J.D:R>>.Q4?T<8NR ]YU:5$@PJEJV^U&]NN?B17LK+X
MDSM"/+*R4H%RZRT59+U%8R*%25#-0QC$G$#Q>7 INQN?/X!;W:]5ZC&HN5[9
M@41BA6/0/&*Z.D-HAIT@L4Q1C5(DP#GPPHDJ= QOJR4S3V:#Y:EA^"B)GYG3
M"J()?!O%JNPG?B%3>[-$61E=1>=F(K';^HAXQYB@A:X65@ 6E#Q''JNS6G.E
M5.:SY-UC*?:8Q:%O'96DUX. M>E^V1LD2)A>J<9O!"WT#+/5Y$14=2UTQ\#U
M>AZWODLF$*[OVYJ,KK_P+OIKU4G[\#Z#3TZ.G]9?H)(KZ9+W>*7/XHI&5@F(
M&94#D(Q"PJ]4RUI;/]6>K6V7N?*IMBZWD& GF_H'RH]R/.0ELG*S=#,+28/+
M3=0E]Q"NEEMFFHW< 950RHN[8J2&&FU8-V\*+1!-5<9&*Q86OS.MK'%P0J2^
M?1OEJ/\.\]146H>S_;/K&R21?2W2=SC4^8U.?$7&36ZPLMD6[R"*>_(&@"(Y
MN1 %K:5I2^-M2R=;YV;+5*<Y^(C"5W("3X 62Y1[N+I;Z^E$>0+_-GF<\AZ8
M:LJ,U],BC^1-0J,4K&26=7UQ^7N>=$U&ZHCFI!FFS&V5/'JB?I'#NM/I1OE'
M?E676M' >;'Q BK!5%#RXS3&B[(Q^=7%DB)Y\A0K=:,+_>O9ABGK*W*JA(4J
MA(@&05^=X*[N%VWHI$C=1R2!+#_@O$W@\ULD=+M%R[B^M<.+5@@V1FU(OO>9
MYI7U2&4UQ2#50:L-4#@K9WC$WZ@BYU>1N"+)SP(+ZRR7WT?0$1)T)C:O3NW@
MXW<%ALQJ@!Z-Y90Q\9Y4,?<%E9ATJ<*)7++>@<*JU73NY)>C4!8MRP(U>!J-
MZ?R\P(;.+1R: [8W#@/K3.FWD_ FR"" P(U)Z+JD D%U$&1)]$S7XPF\40)S
M&DDF1(M&&VLU;3&?/4'!S?II)V;G:T=>/"F$<Z40ZYNM9NTPXA.J75D0@(+"
MED/+VC_H2QB%BXESBLF?JU< D96O9&(JL!8RKWJM@C"O) ZVJXL*7U&>K31L
MS/1)2-_%(HFSUNWY?2M]8^"VJP)XU1*D1<M5\58#&B4I.%@/6EX,!_[>G#5M
M-C%6RE7>1,A]"CECNA-'.=+PD:P/EE\TE4T]U(%)$)H')FN9UP@PC.L2/)M+
MG8WBS<4EG?759F^$%196$<]0P4NU<6!=,?)UEURKO$SG<W2N-PM<%?A]M4$&
M*('_9(S]37&^G)PZB\?YX("-]_1MS>=+@'LR1T"./6S6&S^]5S_'E@)\$8MW
MJGPM'EGBV#!XEHJ %>5D);EW^N?Z5_"S27;B3J-W^_7^3V:.@#[SIB2!MYL>
M:W;JG<Y3/M>N=UIW/O>WMTFT1@Z5'S& [2UE >.$6>9CX <E9^)K,RLD9F#J
MA?I;YCO4&P/X#/THA-1J**FOUU)XC(=5>H1\NCQ)8_"8'(TL!40:CD6"'7F\
MLO7NQ@!O9U5!XQ42,I+)ZR&W2H-Z4H)_P@/^$UTVY6_CZ.W?SQ7"Q]MB],'1
MCV_LGCSAGGRATRPBO2QZLKH+FZ>"-*BUZ_UN:Y.2NP4==^MM3.);SV/:?NI'
MS3='+<LM3\DM7T, 5K?*Z6W&D,#./:SA;JP?_'3KG2RQ1T^=3K_M!FZU7S^+
M<#IELD7LE@+=J?<&0_/_NK=*-Q&D5^\_5I;;>Q'D!^Y]+EK[W'UZ^UZWO]O%
M\WQ+V)T3=L6GM91]"I:UIJ5*IN5X%E$=2<'.A>][?_W%(\_*PS[DH6%5N%7A
M!T396UC6JO JJ?#/X!=PX;,+SL=6#G9.WF;#PF^KNP^+LK?QK%7>55+>%R'F
MK%UZ,(\DO+:BL',"=P86>5OM?5"4O85E,^4-_\ C_YTOM0V/;CJU*%S"[ZG;
MYG=G#CWG[?S2]*E:N][I#'XJ<N).<ZK:NT^I&NR,2D?-+4X%GV[3_N/1D]D=
M:<J2S;*F*F:J63&++$\[SE.6A;SBJDJ8ZU1H57=[PY5.2N&DJYMAFF3YG_(F
MX5HF6Z%:E"T,<Y"%80:V,(PM#+-M89CU-$"3%,I^;9\9V-MG9F!_6!\\(%.O
MU:C;1#V;J'=HY*Y$\A<S$K^^F/ AN>,*QDO,</HG7@$X,8KH;1L!NZ<"J6H
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MNC:@> 5.ZM-GWI1S::+UKLAZL_?=%!/F-NI=+&"ZX]0V<Y,*UPJ!B/IJNY[
M^QWMXH./BA]Z#='6?7GB',]UTX+/W[^9A9D%A>8/\>_/L >)[AK8_>G=H22'
M[K?ZQOZ$YL61\@YC42'R[E_]WZ93[F$.GBEUR-J# [$'VW4NTN%)XP2'0HV_
MA4D:LV.^0/O!/OSCE/WFS>%5DRU=H6<J!+^?C@[5TZ=/7'(+I;GM=-I-I]/J
MO@X*/\1B[?:Z2+M>?EO$6J\G59$_63/V$MR:CX6SWDU)6]:SL9Z-]6Q>LFVP
MGLW!FX3M;O3S))G!3$;!E;#=JRJA*I^ZYD!OX'2[K==!VV=W5]K=>GG)'VN2
MK+MB;=/*$8M8S$0@>Y]7VS9UK&W:_?XW^QVG.^R_#LH^NV5JUN^/ :QALK[2
M*[)'?)X*G_T!H\!OJVV0NM8@[9X!^DVGU^N]#L(^NSWZO]8:66MDK='FU%JJ
M*\1C]IF+..%QM>U1S]JC/023>LYP0P7I%T=8:X^L/;+VJ,+VZ+8ZZ=6T27UK
MD_9@DYQ![_X)60=)5VN2K$FR)JG")JFL74$U3=' FJ+=;W_/:?7+^RF\.+I:
M4V1-D35%%39%Y5U#JFF,AM886;_(&B-KC)[(&'7K36N.*G<3:.3[NAC9?2I
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M>Y,U@MY)ICK[HX1,,*Y^XH,7QJY'5-(@669 _]AI(-U\W%B<+9V<I N,E;H
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MU7__I66:*P5+'C!/NA(>L)I65Y_UA#F8#67Q- N9G#F0;"EL5VXA7A/NQ-?
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MBX4]NI%O_;$C^/W)BOP>#Q1-%?C7(/Q+^+?8P('P+P6#2V#&FEK7M/J<2R8
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M?:=8VG9S;'.*83Y*117/&%YY75:2%:S *]2>*-=4>^X8M>?25\7BAENR.S:
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MH[7J5_T#EA2%LW"1P"1<L W$(V)P+]AW55I"?5O#ZYMOV,<+IO!%'&D0L$L
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M/4X4C 3#E><33U2N[EQXK_O#$] G^[D7-#]"NW?2:#]3B) 4UQW?(\I]WCU
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M77I/*5[Z['2A=+<**;@UQ?UW$$(JNTLO.%VTT B/OFT:%(=DD@B22*=IRT@
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M4Y#FF"V)I4\2T$XR=".QK/#R@H8;N'4E"@RSY-4>G-BH,X"B# ,*2Q;0BO'
MJTTD&2(FEFR\RM$A%0.C@6.=YP;F-#\P56!$=E)C<Q5(LPIO</VY#$Z]K<^.
MD6J;@QX1=(N%@L-&FSX)T&2V]X$5<QWX?< 7ZO(^;98OF>C0J'5V<WDZJS:?
M9#<:94299<<0*$Q@+$8:"Q91'FX\RI1-P,-=\D ?$_#:$OPA$GCA6X^B)QY#
MY"9#<@1A24Y.A8O.Y 3-F).745/64-*YXHZ7$>REJNA:ZACH7<Y-$A5;9%K+
M+?,/C%^BSJA8>7AT7;;X$6?%]W@Z!CY:)0$<#\^RLQDO4<U^LUND3P=J,XS)
MY@9MSAQPGCW^^2O\T&[D?Z@Q\FLV\4(>^BT&]92#)@5<EL0C]YAN/DZE9HS&
M>@4D0,H^TOA'(,#;E(Q1=F:JL\'OW0GKCP*>'1@->*YEAFQW"8J-R/WL#Q6<
MZT7>]T5.9]81:%:J*QZS?^"BZ^]U07Y-9D@:1-XRW/(<?0M2]W9[ID'J6FZ
M<B+^$K*AX[ -8'SY[+WXFV0SR.*NO)-/*>49V@BZ7^\(F=N7M/P C=E9YA7.
M^)7PW)_''7P>,72-XVJ]4;L)#$5EWN;4Q\@C(D5UH=U\#DY&DHF7:L<7.<U_
MOLKA31^<A(4 K_)$ZG< ?2Y'JS+2^12!-U0 %8Q^@&9=3>, '29Z[CQ(:PW
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MBT=]\$)#2>(/II(?A'M;= &.;]4)+WQ\J,+JRXU+[&L2/W")HU3B)R4QM5&
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M.'H1%%X,AA5N$ QNP[0N(&:^*?-'!@>(2])LW1\BNG Q.6BBK@;#GY8H#^M
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M=,5 Q,\1!*?MM5(,C@[4;@DT)O)F5M_#U6N8QEBI6GW'E^@  6[H+G!3&HL
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M<:R@%HK:MH!WJGK*8X$M"M,$;$<$V]EN(V*97ZS%#XY_+2$^89V02&S\-I(
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MEPM_-/ID>ZQE!>%+'58JN4(YV+AFQ*M^0&&TLC(D_F8%SF6R:K= G6^TI7U
MXM+@X5R%\"<A:Z2;Y#S-;JPX#*'OZZ/CN>KFN:515FP>2'JY$4Y(=7.E ZT
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M/ &%R8LA"C]9@5UI"XF&X&9IME2GA:Q 0:-#SCY?'*O!BURY/5!2XK7=3"N
M9 5IEZ2Z#/L/P;]]Z[TCEQ4V@[_BYUE*F!V6,:[+\4Q,:JY3=&^3#C+.^X@[
M<KG)_9,R25LZR JBRZ)B6'D\HMMG?_P/#TO T?JU1D-MM8!Q0KM;;R)6L^0B
M24B_,D4?5O5(\ZHJ[9(-ED''\\$H [E)6KV"M6=:09Q]O3^"FZ?!ZSSD1^Q
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M3\#ER^)7X0<KR+)W##,/(S,71=UJ!U8@G1768@I0C?]*.M *$,J7L$D.L*:
M7M;)0Z4:%098L>5J06VL0%/;RB.TM\:W)4DB[R5-2$V5$*O::[ ^A;Y/*XR2
MH ZE[-Y[9?./"S$L(9?TS9(^%%R"D0@YFC/- ]DW@(%X+L$,]X2@ZQ^X!ZB!
MW/N-K"3KOCSIAZVX;!J5JVVJ6-U!(>FISQQ%@>[;D-2GC&-@4YB;)][F ()Q
MX)+!4/#D-4).$O>JW]W^*U;02N8)%,]5]1PJ!UL!RMT.RT<1Z4,377OQ/HP=
M?[FY#R$*^0U+@(26-8HG=5G'_(M0='K#HX4"EA,-A4XP'4*]T H_UYMFQ?F2
MR'*EZZ!.3=:;:=S<37/6%*9CZ0 KSF64NN??0A\O V$;DY9;+W[6"O06V\I0
M4_I%FKR&$233*#3%FAE6 )7[G!R?Y&R](I1\CL)TCV\G"U-T_"SBX<JAQW1?
MU_V[[YJ6W/\GM/6 (07)@[.K).7*QEAQHE Z13,-7#'4_!L*F</KPQ?/]['.
M'RHBC62#K#F!O'@-5:.\->-\CY&'R7^OZE:H,].2^X%9=!HD3G2X]7PLE<LO
M2&F0%>=3+X6TEUNL $J1"UGOK"@,M0*,4H9,K=-%-=9J93BDA7GC943K1"8(
M0>SG'LKBO?BH;5=@C>6L.-<L!I;=&99X+%7[Y$.M $,(T9%EH&I$]JBF60%>
MH^%5+N4V3#(O3ZR^AZO7,(V=P%U]QY@_@ D(W05N2E5L<%$JI S]J5:<8&=E
MK%:B[[^J)3*+0)54'1,2".4"3-T,*T[\"H9 6#.IS8E?!VH9A'_)_7_*X5:
MPW-^5B$+45:6HY'R(NW95@#;^5YQOR!7%6(BH:Y>G8"Y=S[3V*"F2+@)OFT!
M]T?1[CY4<_C"SU;0A;HAF$4-OO+N(NJ*4:H:0;IS[0"T9[Z*)6DSQYH?4RJ.
MTERHJ3+4"C#D_):>#:;[._(L>V\T$)MZM?39=NTRYCFP5FBK=0&MK(0_TT:E
M K)BB!T$EQ>+D-7 O&M1M+]QOAT UR4]/*#OY*?VZ1+93"N O'$BX-30)89L
M[]KSTT3N?E(,M0(,:1$SL64?5)92E!?4F6D\U)C4Y(;&:SR'$#(*2<D3>(M?
MO?TJI IF-:VMPW0KSK3<C4QE#9.-LP( I2SZ-4:;U+_W-ICJXG7D[6E#)Y"1
M;MX31&VM-P%6AZA>K3"3#;.X<5/*%13TQ7?O*G0K;E'Q-^,;O4A=+PDCF?M6
M^,D*TBMZ_FZ=-5(7UU"-M0(0D(&6&VI4PELC(1PL\><RC*+P.ZV5C'])I/)M
MF_GFI</EIQ\__?1??\S"TQ4F!ODPXV_4$]JS[,^L3^05*<L2[1W,J>!RR%\G
M[8E6D*2BP8)>%1?MR>:)D69>@VZ(17<G.E3(L#S _):?L9R-XLN&$DK24>8W
M3X-_$"8#VKUMN=D@>4DOC>%6W)1[E"2@YU'25@?;R\99 0!D7T*!+?P_(%^]
M814VT(HUUIIH!8@0_PRR(4@!>9W(2\R#,"U]P_\?=""Q:*ST -LN8@7H2A'Z
M 2DR]=3CK0"H;Q)/<R4D:KD9U/_3\MM6('I9#-R"_!D93B3#K-C^$X*.P,CE
M%IVZ!MJRD58 45;[K\1.H,262(.E=4P&JKE6 (HE0JR;K1-B2<071&B8R0VI
M6=S6C>_MO,!16/"ZK61>,JK)7"M4@JS(2+H3K3AGQ=X@'U>=/=XXR0K0LH"U
MNV"?)O$]%)+[J%&JMCK<"G!()2WFR[BO"W22#K0"!/U*TC*X]&=; >S5*P@A
MF64?'#(T^-U'^9^>(0H+DE^_[EW,]B[<<*]@HSV6L\6&R5N"*.R8_&<K3B\/
M[KC F'7!Z^2](=:O%),8+4*)7 @8!=DS3:@/>U-V6-5J;,-_Q0KD9?8FEB@F
M<Q UC35.M-0U1?1'AY1 OG821U)2I6FL>4FF4"MO^3U $3C?:N*%FR981&25
M?D--E*:88 5(BA<N$[=Z]6NH6<4*X&]3S-*@NC;6$6Z]=]*\MD9:4XZV IBR
MKE<KL"D'6\(#,7-F12@\>F6J!IG&P5:<RC!5B6K3N0;]@AU( _FBOLB:^0)H
MU$,9[;&0?!VE6Y7MOV:8%;@&DW;"3-IU/;ADXZP 8!EMG8!57P+[5NA[KL/"
M.A\Q:8.-GDJPU1SZ6#/C>^AO&.>R((GXCZ]A(+%TRWXW?],>PC=R:2J)9;<0
MM5MJ%J/RB'99Q HBS\1C%+UY4!I"YH3 G/V->A=(<:M5F#B^^#NQ?X;)WU#R
ME#6SI?(V=4W(*'^2#UN!XE)P?S%V5\A>JWN+VZYAG \P.\AR[P7@$9#QP)IA
MYKF"$&PMQL$C2>$_U4@KB$\PL8'OO*ELLG*T%<!D,F7@9J%;+,BXICYL\RPK
M@,.J;N[E;-")JP.M $&W>1Q43KL-4T4H2[LUK !<=%.HC3;5459L?K27F"9M
MW(81^Q.,DV;23;L#*Y"^W&PPI!IU5*4#K0 A-_@3BKX\$/K62#&M##<NK5!S
MS\T.15"/]',4?D]>@;:<X%"66&J&6G$JTE*D\LAAS2EEL/Z_/^10W>-_";^0
M'_:"W@J_LR]60,1:[!Y?Z.3]]_@QPW!^^M/'3S]]_$/BO(=!N#O\@4!\A16K
M_%Y $LZ__Z[\@=\5$(L@1P,K6[^3'$18/ /21"S,EG^-T(;N,,9;)"<0H_7O
MM^';'_#)DQW"/WZ ?_S^/7;_26RS=!=@Q.T<J8&4H*K8E4DZ7$8[(VX9K"TU
M6R0_3[PE 2T%1E*/03ITD*UNG/B%W#MV.>A^D9_$_"_YQG-#*:^<*#SPHKF+
M[;YYO#$0U ),:>^2@>8VG9>"*;Z?Y3U7QDU,U50,N<'ZAQ#^*R'IXKBNFP2M
M] ?.3LE>A*#]B[^F6-..'ITH\:!X(0V^8%%>O/<8;44EQ6FOI29&NZP[G@3K
MA6$3;9$IGK=>O'9\4&74Q*$<.O5K 5&=1()NQ&AEZ$1;I;(95+8L&I^%+5:&
M3+HU>0G;RO9*PR;=(I@6(GQHY&$E+Q7))(L.8G9I9<?ULR8%H,'#6]FZ:ORD
MF[YPW0CZKM/_ 8GPHW+#LK&&-_NIQ68_&=DLY$$OHU7XO2S8U(TTL5%R>981
MB7@)UNH;IQAN8LN/89PX_O_S]K4L0CIXJN=6DB$O/K'BSQ-M2>4H%;95&3+1
MUEC,YN'CIQ=2]D*RM<J0B;8&M40@-OBP>PE]R;Z*OT^TJ8>P\%FQ9+"P-=FH
M26_K+\CW_S/ ?.T9.3$F*I>XJ=0/HVK\I)M6%#6O;+8\;M)-,A&="KLT=#U)
MU7M5#)]8S*N+!9;(=]+A$ZL@MQZ6+7?)312%T5480=(VEM<4]TUCTN1J272%
M7^MMF)<"D&HF^:A)-_B\<WS_,HVQC!:KB;<X:M(-UMKG*QN5CYX6HZ^8A3;M
MLS!HTNU)&BI5=B>.F9:G:E2&KG+6NDD3,ZLXUXDA</T)#&/00JP2"R/A6<US
M)Q8%;][7)&=+8;:0#IN67!!42O7O A>]_R=2W[;RN(DV>8%/U26OD?RQ*OX^
M^;/*38NW^"]U7JOR2",;Y4Y]G:V*8R?:[-UZ$[&PMHLD03'U4RK.O6;P5)1)
MOW[K1;L[5T:9A=^GW92"VXB_3KNA<M9G=5/9B&DWIHJSK&ZP,G(J$PPX\LMA
M;:(-IO"[9%.BUW^08(J] SK,#^M7S\\(/P\)T?'K\YB0HD,]C%P4_?OO?OS=
M8H^9#SR+__Z[3[];I#'>5+BGC9[@-^8INZ<X4&Z7[#6!AD-DI)VH44?]J'WC
M8^#)MP!%+8,"JT[L.1)0X]TJ^= 9CC[."4>52]:,RS'0=#QWK%_<PQBXPV_<
M2V@UD35>Q&)4!4/2IY.\A]H!7O51WCF6?G]RCUU;*E('OC <_722E-19HJP$
MW3 T_?&,)FG #T//G\[H408=,13]^8PBW: GAK&_G#'6'&7%</6O9US5!W<Q
M//U\QE-]7!F7PL_:< 518DP;1].L%&(]-%4BZCBN3E-IZ86K4B@?Q]19*'<K
M480<-V=)W)6&,W+\G$5QT4.>QU1R_)SE<+<:V,F1<Q:Y756 *4?1H)+V,9J4
M&J);.9[.DG:.K$I4+3=0GJ7LYJA>CJNSJ-T<3LQQ=1:U=>.8.<8&%;F/EZV7
MHJ8Y=LY"MS)NFZ/H+'<W1HYS5)U%<%7,.L?060Y7A,US!)WMW;JA^QQC9WF\
M9;8 =Y"?971U9@+'T5DVKTF-X$@Z"^62U R.G+/)NS9%A*/I+(@W)*AP1)W%
M\:;D&(ZI0:7Q8]1\2RDY'"^#RN!'C)?B2S][\W<E-8EC9E !^X@Q4\V-XC&4
MIRM)2[.M:E(&6&H!1\S/(P<JLQ*RY4*N(U>2Y>U5L(+E^$X A:812G*RF;RZ
M;)>BE[P6.N0T!&ZU1Y,BQ:[U=&-5/<4=ZL-BT[:9]T-_]^4)QH"@/9[U]B\?
M:ZX8K!._8HJ&_P%*?G-\L*I<T)K67K E[9 5H.C--7<JM"N'HM5%^5CD@\T7
M1Q9:6/$>Z0T4IC75\%W1NB3F-SM.M\#*>0WZ$1OJ2M=RC?(PHQOV$F)&!C86
MD@X^*%@+S<<E>U?-,/>$AL%VQ3H! FW4\CG%8&.;OPOB-")")4JP'$E0^X36
M"+\FU3KVFI,,"C.)MW5HVEF,HK>&-T<YW!@ CU&X1U%R@#[/T/@IZY_R@%1
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M'IEJN[AF43E>#V<=0R)G43>^+P9U//T3E(@W4=/OVHO7?ABG$;HZO,"NUBF
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MLXE*N<IC9!&G6[2R4;3 6]@[GLLM(3R[] H3--X H?M:QM%[.?NB#3O'&5H
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M=54"+AK0.0LLJ=6,0MB>5*X? T&^M;BI"P60*0_S()\NZD<!=XI;.@OLM7L
MU?K/&&9YBYX]?8Y>Q]5.O3&/'C&U4EEG$?^E3U5U&)XGJFKY58/Y8+H8N2/%
M6-7O^L<SKAK,'!Q3?SICJIOYA"/PSZ<>U58CN=ZFD+#PQ0L 14_P;?_1.9"A
M7P.,G2+IQ;]XR>M#&*PA2,Z'MP.L$A8%PIV]V(.@\>S%%IXD?A^N4_2 J7;U
M'?EOB B/2A"[+G?V>,_%XST?5Z;N90 U;/4]['FE^"K' 2[^II)B6Z]S%"#?
MAJDZV*#E,L<!L/<VQ!&39086/&J_OPHOT:/CN1S;F,6L7E&$G$TB%TUZK&;]
M0?8\0$L!Q (^?B>@_SIR;][7>.C%#OZK"[3*M2R)(SCR,(AL0PW)*/63; ,&
M-,DN\ CS+'!2GT,@I@J!T%/)3AJ9-H=%6.TALB$BPB8$'94WVR;$C</&,NUW
M%FEG@_HA9^[E[F%X.#MR>V&1VC+.OMU^2"3VD;/3MZ@J]#'-G-W"G0ER))>P
M;36S!D2>VH;$,/F7$4H''B\NFZ)>_O5,=[K&+(ZRG\\$UHPTT=+&Q>9),D?,
M!K[<ATZ V3LH%Q:67&AA0+U&+\E=@)7Q5*?5B6JTP=IJXH9NG36J]30HAQL%
M0-LQKQAL"?;KPB1D(PT&> 1;+'?N8%,-C9BD0ZW9>&UM ,7@@5V]$*8'S% =
M658:80FQ?G&2%!ZH:_PJ:]%L8<+02(R<8/V*+C20*1\Y\'Z*D#^D\(WEAGV[
M?%5T9HR#KTMM?)5'6D*$=UBYP>)!\H1IBL2[:E%B==8XZ+W21F]YI+D&/$SC
M7FX 93?O(*^F7OR:M0=5(+AYGE&>OV)LO(;39T.LV.@CBM8@]&[1)7(BC,QO
M^/_#HR_2K@8T>NM8<ILOG=B+G[&\[[C+@&\4-OA1ZUK73!_Z?K^B*"95M['J
M\2XY"M4H2Q"-J<(+76_-;NTC)HRUMP?54@/-RLF6 /<U<&@'#>1>,P-88S1+
MFQ4LX<UW<9Q"KH<^5R[., ;&$]H7MJ78>V78J"+:S;N7W%8B?FL&&D,?9]PL
MUZP&@[*1=AC.&FPFQ6+G*OO$20<3Z5DWU(B:4_V"&B-*,5Y!9K28!8;JS1Z9
M:[.LKLP2-ZKB,RH<S@))G1EVT4HTBP@J37:D1.DLD*3+D11VO5G@2./2:1D;
M9Q)+UH:@*H;/6>"H,Q>7F%EG$EO7AJ@JYMY9X*@%46D8EV<1;=@"947C]2SB
M!SMB1]-B/EUAF>- H;X%?M"HP2/&G-(#,$J@X!$BJ*W/8=!HP9/#6X,[8Y20
MP6/&7JV7A&-K]HJCVAG#431[5:C.2\21=!;MZ[Q2'$L32/-F@YF?DW#]#Y &
M\-Z@<7=R..Z89@I#0RQM:9 QAVC>!Y@<P^7ARG?BVI)C=3.,@7'K>-$WQT]I
M8=KX"W* LK 8_H3@L<<*#1'.OP;A2XRB-ZK9[-,$_XS% <^G_: O#V0Z :@V
MN'6TSYF+*X#2OG%MTZS"D$DK^EV1/*P(\US@#3M9Q+1RV*0;Q0)!&JU?G1A=
M;".$J&FFN"EE74[]N>:8A9-=>]@.-9/'F']A8JZ]+QH3AVXHG6 E\XL3_0-A
M90EJ8.S48:3*L>9BLKPWS\6O6#T7*H\:NBD:_M-/__7'["MJ!"I&FJ/3]"7V
M7,^)#@+AU:19J,>; X%7<*&"PE6XVX<!:!IU8-3.,09*:3>U)"T?.S!A/T;>
M&_'%$#'UD0O0Y-351*XQR[SX(XH4-92B'F^>Y=5LNSAF8*KX*]K@$X4\U/LK
M-15(1IDKM@NGQKA51;\LH4X^UFB=X# @NWE^Q:IT?)$FKUC'_0VY*@!J9EAQ
M O6=<JL#!R;?9T*5%W]- R^,'K'$Z(&!&)R$&:MZ9/)EC:S?:ZEQV/1=\(;Y
M+76D/Z8OOK>^"1+\2-QZ@8-UJ6#;R+)U5[#A-M1J8-5Q Z/\9AU&'Z^<O0<%
M%OSU1>!^0U'L!,DWC#QHN$!_4F.\W0+FD@$*K[<F!VJ89$Y4I-=50X[1F6%>
MXA5YI8ZT6QEOPSW&;',9D2VZ1-!Z1!&AF.:;K9QIR6UI"9GF9$N H[=ZF29Q
MX@0N?AI:\ )QEGDQ6J"H*R=^;9*HR\-MN$/?0I YJ(C1?&\*HRTA)PT(:B:8
M)R)68P;BSZ%K)7[<W6OG4&PP6$]7&BN8>W'(M04G-Q9H(V_=Q,K4XPT^FIAH
MZ(ZN4_ [T$ 1NM.K$ N^4>R% >FOC?^=>/@LGL%'X25>I93"0(O:X7Z5>^%$
MKVNMZVL6B2EC>\T*L1(%I?.DT=ODLN)5NEMXBTX:7^W=2UF$B=K-,PN,*?Q$
M>9-@A0MG%LAI] (5'@,-VIL'UG0<3R+F%.Z=62"KUK65W4(=?],LT-7HIA+I
M:CSAY-0[.4A=:848Z?*S<:H8Z123D]U;F4=P%O>TUK$H$E*M&V]VJ%*046?/
MW!@(5-4S-BEQ-(>@%B2U>@%E%E3705-JZTV=19& 1OFMQD-[T@CJ]W"V=".?
M-"9;OZE-ONG984M]*VL]W[/ 4]NW4VT2F0>ZFF(,"CQ?0H.\TLGO3TY5ZB/[
MJT,"9E$91O,2JMT"L\!2QP>PD;8&S2(]?O6H9/P9 TE'R:X:XWQF43RGJZY=
M?2_'0-=1$I8ZXFH6!8=:4E2-"V ,=!TE12E#X&91?JDE02FP.@M4=7S\I$1U
MVI6IVG-SG=#'6=2LTD9=33CE+(I4Z2.J9]#FA%6K+*@,\^+$R 43/0IB\H'C
MK@[SZ#N!HH:%=(BY2':VB]J\QM(@8YO]'#E!@A#H*VE]T0392+,1Z)= X*SP
MV@4F[6!+W9N[O1\>$*K/Y-)?P(ZSJ2'[ZCBC!230_Z2 Q#?\_ZK5BR4%).3C
M;0&AGHJD8VVH2961M_@ "#0>7QZJ5^"[$[F:%:QZKC]TT9I//W[\F?JD[P*H
MQXL?.>"P-:5KZF=,6OQH!>_O<G,7N"!#IXZO*-,D'V=VJ[]XR>L3\LGQQZ_>
M?A72L AEM::V*QC,Y>+2%,B3.9&3O0+=QTE,2/Q%(/&XJ1-TOT5M88KECC7-
M7-WPL]3$KE3<JJ*.*,6(S@N;14I%2:CN_:6\=QYT1W150L>9/Y-60Z]#UC@?
M'/@]R;E3_,MK^ N*T$,(\>=O7IC&_H$+B/$RNO8BM,;+QO0^.\%!_>8,L.H8
M[^9%X.+_^4O[Y[-QXO'==_+_OF%-.S,NJ)K #OH)8XBB(ED]-R^.L?=,E2)G
M#D#@:BGGHWQJZ(HSC%L0-KC\'D!C &]??VL;YQS?6W3SOO<B,IC>I:&?GLKZ
M!AO88B'06R?,%_$U\)+XZ?EK?>79VCFC*&$BB67OMH8JUC#/7K:C8@5+8D^.
MB7$FOF/D\SD*X\%ER9HO#7W$.V(#QLP-* LTEM7W</6*Q1<GP/_$&SJL\ *H
MG2S1>U%[B4/Y4$C/[!<$KD6,BC<4.5MT\XZE6X^)O8,_5>UW,'0[>^DI8R$Y
M79.=UU--B]GF"KARIH:B-XQ ^5D]A"2S!%'9(5Z%B>.+OX-- .L)?T,D07,;
M0# [?<#I 2H(8YIO'Y_ P';^C8#-R3X+KJF5]L?XW.G1)@,QC-B?8)P*K1-O
MPMYW0L6D\_9RRXT0=$GS-9QW;Y?NAI8F=#XY= G6'GO%Q[S<7*0)5K(2;XVE
M@PCA4:M0#UN3?_[X2%",3KG3T+(&^X8M1,:.CG<X9HEE;X[G@RL+\Q@B0N%-
M2\JZ3?EE&RH/L@1%NE,LSF.^CH -WZ:0OLC;HBG(I_TZQR=^7*S7R,>R-61E
M4!L@/=VAY0[E=XZ/ 3$12N"HE$%P9GN-Z/^.I%8W?_?X4,HYRH7K>C3J3;.4
M\YA?/#XT<HL$[U47+Y-7%*U>G4"J7 ^-T[:?/WD$EZP7Y$>(0\[T+<,GT+P_
M6V2>1L#8HW)-6A /*/*T^K"YV! 6(*P #D):A"@=GVP"N7*DL-Z5JH"1$;YD
M1]2W+)ZWD'I1\M3-HCY-33AN)6- ,_QU?GA34904N;- 3V-8;KG6A20 =AZ(
M&CJ"5DE_,RJZ)8^YR$L1-P3OGC2.&N-_>0&,UI&WIUJ:<MCX7$5=^[Z7_Z1I
M5C,HN.9-$1^@4Z?3X6*/*Q+@2,&[)TV\/;(8LA=KB/#@DT;RJ.)4S9,Y1BTV
MFWB)CB35',X]CXIUX['=P0++9W$0TA#S5CCM%-A]^@4'1]552Z<V1J$]FW#9
MP%B;@^UG48G0,E&V&OM_/H6>B3"%QF/U"0>\0.*P#-8^;(_)98L^D#%*3EJ'
M3RUC8%,2R2PP99D$6Y?/,K^*LL/S J4U[=0+AC9QA/XY1_.H4&N&70R9X33&
M.<V.C0Q !K.HO]O =MIDI\T"7^/PEXE2Y,XG-+UZWIAI-XM2PT=V;139>[.H
M=6R9PJ65^S>+2LK#'LST*8>SJ.)LV>V1IRU.6 'Z9(YBTNQ)?D"G[1,=YZYT
MR,/DZ)ZYQV1:P5B= \J/XVS8GMZPK9%?RH_G;$B<\'AT<E7YP9SU^PD/IG7V
M*S^EL\)O[REII-#R8SP; Z:2H=MEX_+S.=L$VE^S41)[^8%,H/_;V';H.=WM
MG.C &CPQBCW*%D3GE@#CU'-I+H$SZ'=L*;+ -GB!M?$=&*F>$#0P0T]H3;5W
M[S>RDJ)\R+3?/EHR.\[ZN_W15M<J3V3$/ 1#69VF_4)'2RNW8;1!'EC(1JO9
M4_.EHT6;,4[^ZY]. FECE'T>Z.M3/Y5-T62.YGO5 J46;<Q>8C[7,;<"S1P.
MHYANMXGC1;;DC3:![K;;L!?AI_ B_OI16D;\-.J?#"\'CE'E8$\5D,2)$IL,
MDL.=Q\16A3&RT"V,NK?OOM2E4@T:D#&/T^A@\1@T;^UGBNP ;0&"$T?V&):6
M0=-_SJ?1S[ R2LH$?;IO@O-Y#",)CY%!<1:O)K1$C9%7,8_7?DJ+U1A)%N=3
M&L'@-4:BQ?F@1C&6C9*)<3ZK82U=XZ1CJ*5 J\.7[H)-&.THLE_"-!%U2@&G
MY\BF<V33L44V#8.R+KDPC3SI"4%Y!OSWJS @=)$Z_@I%NT]U2)UX)Z= J?:Z
M7$X"O7>89+P@]M:C]*%J_-[1HI!6C[@(H-@C@EJ$JQ#^Q @$4DA'9;':GS]:
MSML,H28;'+=U]B ;/.%;8(!]]]S4"1_&Q78;$;_#)%R_^WZ.]@BF8O\GQ.?M
M8>BSXMQF6?1Q\.)A:*G(VR8@WO('S_9&HV%AUF6HCG024UM99M&DQ.I;H^5(
M.0>,&3RALIP_B_KT]IV(OK%H%A7![7N AC0VS:*D[S'>L>E#UL['-J;1:A:U
M?^T[,?6K==J%?>Q[M?H\3Z==\]?J6V,@_FPN!S22Q6["XK\V1II5B^TM-Q1K
M1QE31L"!)FY.DL;%+BLEHZQLI 46?TZ].6WSM@N\\4N#T;YQ 6- %C N-N:M
M.QDRSMRY#-TUJ7QL@ZUO#$7G*,XA/'?WY0*10SGE\H6/S]^6/4DDKYP_Y4R5
M',-9W/S!89$81XF 0/Q?.?+P?_SZ!/N5,,KB;\='['5H_A;B&^[Y6 I[PC?]
M"U9T2#>382]%^PU,?^[2Y[[\ZTF?/>]D8^SLV09.&<GFL'LB:'WRXG_<DB:-
M6.?#VMA42)5^]W11.N%#4/?Y29\!]E'E0U#\_83/?KJ'H.[STYX]_:CZ[ N_
MG\;9\W?B&DK=H\"=^GTJ?-<.4VJ-.4MNP&XV'\TB#$YI:A*Q)D7N+- S:C-P
M">YG@=01W![#'=,L3F XZ]L@SB<-\]4\CF4,;E.RC\TB8'A$^I[(C#>/8QKS
M=1V"!L:(WK;F%*2&\P+'*$G"GWY_XNSW:+E&J97Y:=+KT1_33#(/CN!\Y+;H
M6:0='.GIE 6CTTPL4/@T^:-<LG/S8/WSLVPEQ98>Y=/,J6BBV*)UGB<KG"G6
M-,7*70C3)9/8&.%+_EI!,&L4?)1!ON>HS$84W0688H@-GFSS'CX".U='W=;-
M. >7VA!<JCBAVBCW^CG'YS>N/"4G%">KV]I="KCF9&/ />$7!8L:KQ>!>XW>
MD!_NB7.:;JLVM4%GIKF<!A2@R/'QWB[<'=9C@$<DWAO2 4QOKB6RWY@V[=K'
M:A8NLK/OV/0): A,&B0[KRB24?1!W5=P%BC6$OE$[&D]L[- W;%X84_;%]Z:
M@#4%JNF09]:D0_&W<MY1G!,T_>-]&,>7:!-&Z#$*W[P8?_@VC(0)1VG;R?:?
MXZ!!G:^;85A7AR.ZQ?<!*G5X0>H%V^4>103U[.C$X\+_B!-O70MFMQ6/"0V8
MAI&WK;=G=%KPF)!P\X[I%_,X+W"B WDO'D+\:Y!@]N#3VG_$(S,<EK2_:-.[
M4LLFJN)ZQ^LX"W%I?(3^_^U]:Y/KMI'H7]G*]V/'3C:)4S>W2O/RCG?.:#*C
M8Y?O%Q>'A"3&%*F Y)Q1?OT%P(?XP(L42#2D^;";XU$#1#<:C7ZC/M@7I/A,
M24]]&3%)_E22>1%<9>G1PX7>:$,)HH^]?JI6RZX"]OQKO3Q>[(D'8>W&(BLH
MGE.4Q(O:,)8O5[*819YM&6\K8UP]8$"+UPCF<,#M,XITW5VHL<L5G*O')'O)
M7_^%_&R5$#,Q+ 0FU_6NAC="RA3YWVR2MV\#%!94)/\X$H_\QV^W1, +=KOW
MLV%R/:"-YQ\^AU%$A%PB)A,7SOY1<=LN),NY)E=LF%V3"^I ;G3J%))+60$\
M+!0>O1U2R0#I*,-,7F]^S]?,O6\?[$=_Z[64GJXK%*-UJ&3N#K2]3(W27+I.
M<J*!'J2!3SZL]="T5A3:]F(;.NZ3%P:/2,DA1T![Z1[4_[N( ^K^C7[*<9@&
MH2^\I'5'&1892[S?>O$-SC>%H!+?C +(F50'>B]'A8+ N3AX$-;V_7:])EH6
ML<)J9J0)F<^(6*E^&(6%/9[=H8"Z_%G!.%G#H04LX T3,]N3E:6A337Y-$59
M6EKY\88Z )H7I,HI/&8F%]!N'?W3<6]/9XT -%NYX,PH2KYZL8^Z.%QO:0#Q
M/E[LZ-4H0'SP-+!412ENLA%V'7L2%T[3D==QG5R6[YCK@^F[.7D.CRD(%0&B
MD<!30HFCX<0X:S82^4-JVO ]%F=-$ZDGEBMO+BKU3#.ZPI79%T$@I9^IPT-R
MC\Y9DTSA+^)>7UT?S5D32#=:T:24P!UT ;>\CF^4E[%Y$=>:OA(MDEYGG3PP
M1A0U_(!G39LQ4DCI=YR"8H[*(ZD/]*PY2U,HB:S<*;)K(/"0Q-=,R=*WVLZ\
MG]8 X6S$[WW67:\49X[+>V?=9FH =XT*'UP0\7K<)*3M6;?&FH:C.I&9#PJ.
M#>V<=<>O 923QHCF:S)E(W.94]R5K'5TAX_*+@ )..TM$;@&QV4WF/W&1_H'
M++*0!31]$<LUT=)"LFQT2X]H&A+MY3;.=V7AASA0/F02:,>EN@U[FD?_(AUV
M1H9,#/I@G$XATU^!QD./";W/<H(B9?9")/(+\VG_E&%L-'!NT)QDA$X3?&BJ
ME._>HFZZBUIACRS$KU8BSPT?,1T<S)X0]E$OV\K4K"Y(A-//O7NGV_ 9!K?/
MM<V85M'38;O,&0]ZC[7Q'3F9_?UUL^B%3VY>]?:@_>). ".@.*JLW9BQ?-:Y
M$2-);#+6=)[QW9&$'6JFGVL<V.S1'V36GG70:L+S/H;(YQG",<N\0RWILX[Q
M3,B_(^E\GF^1G)3S/L87,M]S&>=/S=K_4A+U;Q]$'>>#J0CXPP<!#3AT:H7_
MPY12\R//^U+1SXS%]$-!OQAM:.-KARDXUIE5D=.,\70VY%35&WUGUC+BMO1S
MAUI#O'$5 <U:/6!Z(G(SBWK6H!<'#Z'W2E]R#1UM%]W#Z1%EJN>?9$-<:(ZA
MBY=D!@AH-EAOT*8)QAF.N?(_>"0I(I;H<[C99LOUEQ05!.=%64?-8S\>XW:.
M7N\H<)-,5<&TH;- 0+?!8T\X(5R6'9XB+\X6<7#[[SQDKX$,.F+B6:8[<#6U
MJ[^5Z@^E-'Y#*7T<PO=Q[D7I8I?@+/P/+U/.U*S6M[611UUOBV(/N4.L(U)O
M0EN$ZQZ_SJBI^:\MHZN/'[2X3#06SA;TST'3K4K.0FEKI(,SQ2;Y%!S"+;.M
MN+$E'WAJ3KWV]B&Q//AO/VGQJWP&.,3_$1-55I?X!3"<Q6LG[H).QN693P,L
M+2"N!1V[<62%W#1I*F\(OR:PO*O:MEP=2!EG5!DE9]LWN'+<8RUGX\OCPW%G
M664=7D1VU*#3/-KR-$K*L_'S:]!^"AYT^"P;<QF<=9<-(V>;[WXP2K?.I>QX
M'$KI[ICO/2X8/#?B) N=+U.DA#HL!Z?U[UQ$:NCIIF#A$;J(9,_33K7"4741
M:9PGLUOI YLD2]/52V20S\UH*B9<&^1DVC5U%;-IEV#R9!0/K;<3UY;KU18Q
MY;2JKR#_S6O\Y& >S;D&_L_#YWYQ#\=,NH^_?0]$0I]J5THN-Z,^WSU[8.(E
M\W &Z8(;2+[1+?K.W>=FG@W)"9O$R5$PXFW<U[, *@]?8DS4ATT<_H?1JK*W
MGY,HNBM"#$YJ"EV=2(#F[;L?Y4$8;XK#1 NA"+(Q^0-]W\C;A3$#?T99CN,F
M401R??+/6KOK!)@(Z"""_D@9G607R%HQ]4#2:& >48?D'9&=USFF0K5X>(E
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M3R,_8I5ZW&P@0DB<[HKW385#(YBDG,*TT7[\=B63Q.:P&!B"G_K)PTO,3+*
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MN1%IT'8@#S%I!2=0K'9#II"&=VN4-<4E$D^)/T/B"-0HY5GK:<[G0AN#5]X
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M6F5FL-B)U(+Z[S/!N+IG".=V,RN[*/_E3% FUR4-:XC0_.M0-&>*&6C>*MW
M@6J8U0[90A<R%Q?9" C[TN$Y\4Y4@!87+7)I"Y8N +?[1HV"X&T8:TM5N=8%
M46'I( C<KF9SB\L4N/GY*^8#VWVXPICAR'O'XO3)[1U\492"+P($T);EEE1@
MV5N<(DK"7;-\C#TZBT,@?-(+X2&\(%)Z^81*40O,VH+E?GKNXJ5#@)R#OGM9
MXR#T!MEC(ST/,I^WM,9"VR?EA:\>9PTE'=<N%R>-@2"T,86AP8&T*,\T7'L"
ML:8>:>_4\#UY_)/"A;6V= WW'!<-]3B+UJ':_R:P$)4#;6I?7 ^;2/7B ?>3
M.#MIFO-G<=Z$*4V4S3&2>*+N\HP ? YCVJC@F59"1F5I;/J%+ &W+Y^49NK3
MHT5M_8B97$3\I3=4FD?I]Q#20P6WY6GAVS\"C_N<CK0L+0F,4UF!II[>!&[Y
M+BN $]L>%RM*_P1!E#X@HDHAP6Y5J-WDW)8OTK&$'(2@]!HE%L"[3T 7._I?
MSLC;4R@C%&*0)>]0A'OU0)K#82(HYM?AV KG@B;#Q]^J4*3VL1=JHYZI_F.Z
M7)>XD%\AB-LGG*S#["%)N1DMY*I(*M(719BEO>Y0/<"RC8 (U1]13. B<K\N
M@AVY3M.,CGJ3(?P)*,;R/:V+:4O,K@CBZY"KA$-%4,*6/'P+)T )TAS+QQDB
MQII,3%,/R+34(7V#WE"4L$!!B3D1_$40D_63P*SM%$[H94 [BKJT_W(&Y]+*
MF<S80;S-?(]J(3T8Z]F"89UM[(>^*@!KBU3N1V?-8GC[NE9?>(CTK :DM64K
M;V0N"JI1%KW8@GM7X+KF0UMWPG.O4:GWG3?"8O#PA!M2$%4</Z/= -=0T:88
M!- 8X]M@R9I&Z^^BY"L($^P1970]A"]HB"JX.GQ)*9_4LGA!'U<1EH/=H#U&
M?L@^XI!51C'NY$S0EZYQZ).M*G,JVG]H0!:-(@GW8>H.N$'%_]9GC?QC2]NO
M/I,-+QZGX=JV?++?A;$7^QVR.T-6 5+W\1NAI9*7*J?8*BG%E3#WR"5S>,A&
M<VA"Q34*TCLR)WN>):9-HAL99>YSAZ:D643L+BJ?L.GU/.X:'?"KS<'*(.YQ
M=8:L4YRWJL7KV( %%"(HCAKK;,OB<^GVH>"G$RWYCT,E);TS9!UWJ,IW+!4W
M6.]P?7_VAZN1&<:LFLI&;71+@5^O>]IUWCUEU#)E*9DWJ'@_B)N:V7Q#[7(4
MOZ*]=M%]OH__&9T1,7-T4A!7V N00Y7>I_'",SD8AS)^2_.N>8C##!Q-P :=
M(J!*/AQC])P^'?#KXDT3JKIARO/2O%D&5\\[1HQF7.?X4M99H]S??U7&U0\P
M8W+#R="-?^E/8 W)ML^4BT8+Q&IAVOS&%*?";<9%0&-]B8J@Q_J\": A*7$0
MZR')F\!>8L$ /S8_\4!_ IO9$RK'M"BI0C'.7DV4IH>9BY?F8&#[=?2]#-BL
M>M!89*@KY%,5,V6K%'L>6^L2@AE>R0"?57]]^H.GH9_,N22DIF20S92542XB
M44;+F,E G->F_T=Y3AO @':.[[_1W"GN8(LY/%UO#!>-'ABLW1CD1M'?IR'3
M B((SUVBB31GZ$=*ZS#J#ZO&T1\/,"7L6%5YYX68=6?Y3!9-_IN)BA=_BX*<
MOA17_UQ<1.0@-8Y..218TL<5<TQ?KR4:9UA54D)(*RN676-QQ)OGO^)WL>$.
M'IOM,F?S, G6W'YB/'A@W8CT4=(?#_IX-M\ 8T^>'H]FNW=,?<>5M=QL2P$=
MQ $]<@3=I-U[3&L@SJ79QL;P\ZEINK2#S]B,W/OVL)-[I'_T@C+3"TK18<+<
MHH5>$>T3PO.*Z X&PD%#>,:)-A[]&XU*$'R@%UKA7NZT=P1UB:D;5VH]2/4C
M;L:%7;C)AB'>:BIXC"&2?T>(K3H.%CO:1?@_[._J#/OA];@?K4S-(%*RZC!4
MBD$VV\H98C^^N61J>L<$=6UZ]#UL@(2TLJ-SW[Y0/H,)7T)K8<U4H!+RFOPU
M),M<X="+Y+V0 ,G;,VC7K6(YB5IM'!F!BJU@D;Y:+1\ 6LS-U%8.@F2<K*M<
M8^ROQ*ZZ2W+L3(W2;$0)W_@53)=,E-77Q)E:@MEH0D0SOZC@4JGR2&3^ZBN*
MWM!G(IZW_(1J,"K*93=LY%X%)R%:3^,&PDS,GXXPG<8)A)D(/QE?.HL;Z!;2
M^72$V3S@4>Z+WI,P[TT'VC2HVT^AAN_CV!3L"JT3EA3]%J9D.7<);@P I/8?
M5TP3\PH+)R>[=.S!6F#26/WM>X8]<LF&L8</S/FC_^CXB,_=D'^D6>@[TX4:
M/DD)-Q("QF/-L#F[P4U*1FY'N6F^Z!(9CR?.%)GJ&5TB0WU*3%&AFA#@O<:Y
MS9)U46Y&E,WZ5UJ$]HP(?_OD\B[C&F"N,OYR>3O#$Z,ZR"ZR.Q30WIFT4UY.
MF/30 G;LAA(VVN3VPFY30C##N1!H>E:Z9D6=]W%5VD& BL08FH%88!I%R5?J
M+G;&6WHZ6YTC5:;G):)RD L@)V"O455NQB_Q:[4QA^YG/IV=SI0PXSB*Q>+$
MA+KI$FJ%/4(<OZ(.K5/W13F6$*FDP3ZGDL096MB10<Y$;Z:1-,Z@/SUWD#]>
MD^L\9'TQ6'*M._VA3F<.@]C/]$+N8(;H/I6K/P$P) <:? .P'S;SQR,,)R[?
MC+TJ1]K(-T ?@$$&V>C#,.0KT#CK= H9F!@T#PVUPD:ST< /0>,D(W0R,[?A
ME%$35F<+6U.SPL'3,(+N203#Y]Z)TWWZ&8:]SSS#9_0N<R:#ML?:^.J/=R56
MV--2O!AH"5!OI8(RQ1Z<:W69%0+U?G'Z)=5>T :V#;!VTM8S17>Y_I*B3J=[
M=VC1W4R-;6?5-2ZCVMA/!:OS.<6==ZQ&'VV]\")TM%4'G8-^ W)0G35(3^T)
MG-_F&&>:IZC%6E>XE]TWO'V8>1&_TX4S<="QV*L:S\-_U^:4ZZQ&GHRX]C ^
MK!/\U<,!_^&6L\.?_*/33K7I_2 GH73;IAJ) O ?=1E[1/I4HK("O[%68JR@
MUXO29A\#A]XQ.8UY"@.M=7!Z4;W!SY?,]:B#6#WJ/>[  86S<%G?$0&P]<7+
MM#,!"MPAAGV6XPR_OK-RU#S6-Z5KY>EQ5 $,9_%\/5>%16<4''2T(V>@0V.#
MK2P5BEJS3"<=M"P'J5S0F6'J]>OU<1XV%@*+J95[3=$FG@$.FD9T>#UZF/C4
MU#P]0EG7X/;ALX)B$*F>KKWWLED AF:.Y<GD1J<G^ EAQIAU'TW6@_T^O@FC
M/$-!!PI0E.879C^A8/%&Y-$&/>:[5X27:[;,=)EG:>;%0=E3WN?9;M()&B_=
MO.2O_T)^MDJ>T3XGVTI.\!)?LS9-4=NRA5ZT-"W)Z#-!*"C'PNX#-XH0'6$P
M; Z8J [C\N%D&#0_3!*UN'HX!9K#M:^#\E?Z_UX)G8H__Y]OR9K_[NWW8;Q.
MZ)_*/\1QDK$9V-_HGU#$WN'XKS"HVU:';UZ&5L4%\83+:XSMRV=$E_N'_XJ]
M'2&P#F2Q%4&&/]%_I7\/DIT7QK2T?47^^P__E>:O:19F.5W3CSC)]__X ]V:
M\.^E8&+_WK,W+5?%5#DN.2P.(];ZCJP;TQ9''ID)>WY6_O>W8A39?<P>&DQ#
MEBC1RYXJ$%3#%>@5JR3,2RZ\HFY_0N361$]"U>#7HG$J&8E>JSQI/9P9QY$=
MI-8P']LF1'<;]^45/PNN$JR>\M<H].^BQ,MJKFS^R9W]>2&?(;IP]5)>^Z0)
M?H1YN'9,\RS?J*6-BU=?D]4VR6D.S^HK@3VPAD34R9#1Y'7RE_ -4=]#&VD#
M$\$D$.^<I14618./7Q&Y_*Y0<2%(#ZA\8)/_T^*.L7QB%]__\;L?R)Z2__FK
MF@7T@$%N\RT.-R@N3+\V5KQ?0*(PX/F+2B/0'F!8,H<Q5:&S"00SYQG3]G9*
M $#N:G&97,ENFMZ/(!&Y3O ^(=,0WGE'*66\XY;T?P&C"OC,"21#[/B&+CE0
MG^YR>@V6.U+(_ I/#4!X-\!3:=$M-N3RIC]UK K1SR!Y<$G]*O_\\TU('V>/
M@\YI$OT*$Q6\WWKQ#<XWA9NR@XK@5Y"HT-=G[\F-@'/Z]]OW,+M#M9TC^!&,
M?%#>2-(.F%3[>R("KVIE2^[@U9:HAMXZ.V[F*3- N;C58K0G$[ON"\'/(%F:
MBI*_2 4-[U>0J"SB./<B&MQZ(9N)#[6VW_N[.V>2FJ@X][.<ODS+3%;V9@_5
M>2L?WUT>1:MPAVYW^R@YH.,M/FYLDS8AL?XV"%N_V0N'X'W\1C"B/]W'A3?F
MEIALV>$NC DU"8Y<-Z+V*)@\W;'-KY,X#8.R+07S&Y;.48[-7ACK9..9.D<^
M+S+X3YP4GBIH(O9<7>JGSP3E9E,*F\HZJ]3_(@.A( 3_-W<$Z:V?X._*I)Z'
MR">;]3/"*<'H9P)&W] I?NIX5(8- BE!7L)-'*Y#GZSZ.4Q_IVSZA9 ,9V1I
M+$DK(2+Q4/S_%7K/KJ+$_[TVV\<-[A(BJWZR+1C8VT;IEBFF=75S@2KW)W?X
MFS[4])!T'9W=OX+DT*.W@>/RZKLDN$#N;%2Q?)G+SPDG&5&ER5ZT=J$=59
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MBO*30564=R;P4FU:4)%>@ AHER,TY*85$NOY=W1L=:8K8ZOEG*M$\E*#V7%
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M*(:93V1GR0P;Z@QK30QL@7^RGV%89YY/NFG:YIA%IV$=#FM:C7;2H.RDQP_
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MCU"0]ATID^B/#@G9JLK@V6"7P&URX$B_?4$$__9C6=(Q"?BF>W-R/*3>C%G
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MK/;ATJP6""0V,",6DO; "JKQ2$*7C#Z>*K3#2/''NZN,T'!,#2Z$KAA'\.Y
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M;.]^11O?M@=M2.O811J9GJ#34UD#SL1?:EU+#:6R3-%DKA=2C8 7!PRO+^2
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MV("$"R[ 86;9<BK,.)56NQ%%]1$JG+02(9FKB+0RUBA$@@@R:&60XFWL6R*
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M%?]BAFLTW ^="O*NY_;Y"_KMNA1J32%?4!515D[S8O&J7BY5,8E*];HWA^&
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MMX:Z5J"7+,9]5\Y2?44,$M(W=P\3C(_]2T?E.I\'1)%E,(&O*BPF5AU?)CG
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M[=)Z\#MUEMMOYG_B9)DJDEQ[F1G[PKE84&^3HJS8.A3OD[7#9G*)M884+0(
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MNG+"F!VEIMX0:9_EP20I)O4" YY8R'*D1X;'5'F(^X-XIB0GN2O.DH]9]3+
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M=EWNR\-% Z@//'A=EBZM1UJ$.[,#^IU7-IV8IM$X-W1BW$^ASB0/TA%J\N*
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M20X;OH\;?GLJSUH;GO,>4!62IVER2AU[O8)T 7_DD&YC26IUT$%9A<%A_54
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M^<R1;;A2S+U 1B.:B; 'H3N%J:FXEF(G@ZNLL_&!S49$!3MSA2K)5[;-0#
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MT;G*5-L[;)6((D&"2$V^0FK3Y#^8%K4N9=MB-T\B&BZ?/ZX$4,4EW;(TB'H
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M>8?(\VD8)-GX2LAL<2"' M^O7,K[ ^ _96KKVP+PE>J3^MJWH[HU %^KHP&
MOU7JX\76 ?"E<]8 P!].R$.=D.T!X#<QP1L1P V^OGXB@'6ON@'DNP7G8WLP
M\\V < =]8RE,1$/V8]CL&S;[]B#:MQRX*J?SVX&KK :;#.H#5K7WQVQ[\.%V
MMT[K@@.^X%[)UGQCV%#T=^U5%+).T2':C?F]O*Y*,-68+KF)2EF!F,\W-:C
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M1S_0H?C*,=\^MKE^!)YP</,C?/.HD43:&=<5FYGLMW.QF:E8V^TH4YAJ'UW
M^6&P#DYCOZ>\R3P3JY?-VK%2F91+T26(=XLYQ=Z4-0BEFA;Q07WO&[QL_F6A
M+A4:LT:33XV,A=QH)]H5RT]#_G6"V70;$ -8T@<.^)^O%7FX-S[,LVF"S80
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M(G#30:_G=?$UX".#^VVGL75P*_&?*HN+D NIC7HA/7W]AL%F*?UY2)@2#&2
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M+SE/XO-H(&J;@^+ FNG*&C N!L")E2.HX'+ M#Q5M$^NEHE!! L0X-+2]8A
MO^"LZ4UPC2)WX"L1Q2Y$!K!^;&:78@Z[C?I-,'%D[F*V\;=@O#T48TEL0_ML
MPSH#*J&F:I]1.-7"94;68;AJ0Q .P>S))'%ED7>@+(*4LN"^T&K5N&187XZU
ME(B8!@F>*?6D(;"[TR"DB/5+;O!Z^E/00(3_\W_(9$Y4/Y6$D@AR^P1YG1%[
M3I$YMV5-OK#[9$I?'TM72]]0RUMZ6[)T7HZ-X-8DTWS-H +Z2MB.A5U>=!=F
M=D#.'BRL)GB@9.;VY(#*2WE-\# <_9C3#6.EY1T14?LJB0'LUDL"-.0 ]"@
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MQIF!$N]VY\6C<%HPTIQ["GVA5.]=,FT'<Z.J#68^;E]"H)(*$S^>IF4;N'"
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MG8%%JVWB-$PC*!^Z -S:N[WIG=?=O7>O:^[T<LE<GBY?MS"J4700O.[N.-Z
M-IB+%;G^JY713^I*)=D$$Y3?X@2ZAU/5JI:_ ^SXZ3>.,R@4%G65HZ"G?[[F
MVBW (YU1JS=77G%^MA_\R+/^%"H@:V=V@V/H^Z.^9G>'N1L <G<TBA4WGMOV
M(B@9#,ZQ6),QXFKX<!/J6[;-2813AT"U&96S-3YB\".D?H':0'Q236W)@C]+
MK$1MV)*@Y\&. *P73+@VW7#X2^UV9U,^A.;^W79W^P]S> 29[$FA#@J _@U+
M19X*W,WZ0-#=3/AB!^9P<Y0^K&_-/:'A[W9W_O =%&-PV4-Y5?9O.G7W7??]
M[B^<^^Y>Y^J_\KE'--X6O-.-[[U7\DW>'7S1L'F;&Q[/,[MYDY(W^Q7W3_MX
M?!A[4MZ!_ ,Y7 T7X!^VWX(+>:5R1*;G,>F+S^VVW+W<_FONHF88=-4;G)^=
M)PEY+>H/5EX=_1KK:Z?__?ON[\M:I_59CU_SK^;#[HLY (U6RZK*%W^=?]IJ
M7-]'%F^1XQ4E:Y;XUMRL!QZZB.NS6.T0\N.SDY=[V]M[QF>3E6KU2NUNO[EU
MI43W/D?=NQCIJHCG,L13YO[9SKTH.U%V(G R]QLQ]Z+L1-F)P,G<;\3<B[(3
M92<")W._$7,ORDZ4G0B<S/U&S+TH.U%V(G R]QLQ]Z+LGJ.R6S _?_']XO"K
MB&#+1%#FO@7J3_\!E= ;VK?MUXDOMZ=D=W]9/25/VAYQE(W'*L=^G79V1W0!
M/I8XB^H]#O66 4*Y&\1Y45*? YX5-3SAHET/"S0]--[^AIX'>M8H"8&:I4.,
M#O=[\-ON4CC WQKZ_5V=%3MON_NO]VVWQ%,W5^SM=]^_6;!#8F^W^_H7SMV7
M[HHULL'27]&V%7GL@MXFLR?M%2U^;=K07M'TTLC&IZTB+MT5SVJEI+NBK2^)
M)"^>IWC*W#_;N1=E)\I.!$[F?B/F7I2=*#L1.)G[C9A[47:B[$3@9.XW8NY%
MV8FR$X&3N=^(N1=E)\I.!$[F?B/F7I2=*#L1.)G[C9A[47:B[$3@9.XW8NY%
MV3U'9;>L4DQII&VC3,K<MT ?;G8C[28]J]#3W4U/UT5ZNMU%*>%6LJ3GT]X_
M*BJA(?<YD52?$ULP3NA>F^8SR ;8T'PXS)6"SKC.(XUNP=>R54R_V"R60K]T
M,)WHU86)_(RMZ5X;V7F8*)CE<+[%V^]"C],@3&=!E$W3,I_!QPKEWX7*\[C,
M]"]A"MVG:1FG4[RQ_BO!8]7/24SOM%G4LVP6)N4,63JQT[R8-G6:ZWOA#WSO
M3J"O$%(?>= +B[BXLR4^M+?2IYZJ$A^ZJ%\X4/^9Z@G1)]*U]2C=L?I#X^B*
M#VT1] 7?V$F>7<5]U>\$H^Q:73FJ\3:\P0"G$);T]N*B="HOSJVK:1$'%EE6
M?!WA5KD"TF*],DTO;;=-<Q5LN"/1*OW\JU[-?IO>K-_N4J]:'X]!ZIRH@:1,
MM(71%PB':%\<@DGP6>F!Y"I2<1/6B;8R^O"X+(+#P2!.XK DX0XCK2K[81JI
MX#HN1W@+A@VI(:F$A?Z8Z+^*@\I^RF<DYREUE.^#1/U\V8]S\H0 "F0Z3C_T
MXV*2A+,#^+7."L^OMIDH/ 9XZ!^%O7P-B.%'-K;'@XU3,']:=L*<(5VJ/^BY
MI:\G^IVB4-_+<*#WY0=A<AW."@KN^<M;B51T(4[@%KRVFO.+YH&MV&C$SQ4L
M95UEXIH]O^6$:8^2L"A@/?7I!J &_M6?5?Y[7>A>-TK*/!Y02[!_WFQW=^^'
MP=. W_.^^_9^S,IW!K][870YS+6Z[;]D@]!_#_]K&;#/?6)_X[C?3]3#PG]W
M!>$7"0ONW2$?57G=JXIK.P ,JN8U.+[27]\9R&WK&F_X6OXQ[R\]/$^V*WFR
M^7=E=XGOBA0&/.7LMR,A(X(G@B>")X(G@B>"MQF"-U^"X$>8WW3?O'G[R*'D
MUN7K91)D$F029!+:/@G;CQ45EES++<OPKK8*AWD<)I)@>3;K][R2*ZO.72WL
MI#XI \GQSU'<B\O@XPKK3I<V4P^=@06#T)\APX1K$2;!CQ"^+58X/<NIMG[2
MMVA^]_2K1K"^,44%N[AE%'TKIE-J$\1\KLI\'HGYM'/B"DI7;CK7XR42ZRF[
M33&98C+;HNU6:RH_K= >U&E!VVXJ3\;0@X+=7<_)6C[2[/SO109-+%KS:6>B
M/\VAJ0I*WZ'_1.REV,N:O?SS52_KS_[U7W^^&I7CY%__#U!+ P04    " !Q
M1'Y<C.M!MP\\  !+" ( $    '1P<W0M97@Q,%\R-RYH=&WM?7ESV\J5[]_)
MI^C)S$U)>9 L>;?DN56T!-F<:'LD9<>5E[H% DT2UR# 8)',^?3O+-V-!@C*
MR[4LF$8JE5@DV.@^W7WV\SLO_V-G1QR?],]%S\_#:WD<9GZ49$4JQ=;P;%N\
M&9V=BN/$+^8RSL6.F.7YXN#!@YN;F]U@$L99$A5YF,39KI_,'XB=G5]?XH!'
MJ?3P8W'LY5(</-Q[^'1G[]'.H[W1WO.#_1<'^_N[3_=>[/V?O;V#O;WR5\EB
MF8;362ZV_&V!/X(WQ[&,(KD4)V'LQ7[H16*HW^F(?NSOBEX4B0'^+!,#F<GT
M6@:[..:?7\[R>?3KG\7+F?0"^'_Q,@_S2/[J_F-G?V_WX;.7#_AO>.*!>N3E
M. F6(LN7D?SOORR\( CCZ<'SQ<?#N9=.P_C *_+D/\+Y(DES+\X/_W<GC /Y
M\6#O<.=&CC^$^4XN/^8[6?B_<L<+?B^R_&!_;^^7PT62A3CE@U1&'I+Y\"\T
MGR"\KKUL)T\6!WN[3\+8#/[P<![&.S.)2SS8AR]61QLG'_&E.-EQD@8RW8%/
MX!TO%WKX21+SO&!"BUPMAU]V2-]-O'D8+0]&X5QFXES>B$$R]V+]X#C)\V0.
MS]+ZO"B<PMMQ0OJ!2$YR^%K]15_!GS #'%Q/PD^B)#WXSSWZS^'-+,SE3K;P
M?'FP2.7.3>HM>"XWO-9Q$@6'UL3W8>*WS96^^R#3&.D0)[$DPMV$03X[F,#>
M^/ ]G&*8E?MQ%H[#7*AC@#_\]>6#1=OHM9Y"WYH@?_W/_:=[A]^+$CZ\5*8_
MYM$Y<@>C'K#+HXOSD_ZQ>S[J]TY%__SD8G#6&_4OZ M\P#V&3\7H37\HCB^.
MKL[@24><]09_AR]>O1>:U%^SQF^]I'_^[6]_^]<?F="=$]T1;WI#\<IUS\7%
M67\T0AJZ1[VKH2OZ(P$D?G4Q>B.V^MOB_&($5!ZY ]R6WODQ? B?PA.C-ZX8
MO;^$_WG3&XF1>W;I#D?XZ:!WZ5Z-^D=#$"?G1[MB-'![HZ& ]UT.^F]A*!K&
MWF[[FCP %FY8N1]Y6?;??YE[L PU>?I_^%NF?]%4U7S]2:-8N-.+AU?M2YG,
MWH_#9!X^AM^N\IG:@NF!//7B;)*D\X-BL9"I[V7RL#7'O0?<XAC..!Z\ 1S3
M'A[XL]X0CK48NH.W_2,7#NCK@>LB6VDD*"T2SUF<'SS=??KTV2_U/?U*&N\_
MK-(8E9QPLOQ:?OVM24<,]S/H5Y)/;.6S,!-__<^/#_?V_<.OY(-$D4#Z24J*
M[T$!I$\CN/<"5.3PR\\)O?D@S('(_I><G&DJ):KJ;9(O3-K@<%L G>E*RD"$
M<9X(+Q/)1!#]]U]\Y92O99J'OA>I\Y@5<)VM=3S;??3LFZTDG[6)KB+PEDB_
M\^1:SL<R==!F>H+G6?[1X_R=CJO[4?J%,13;1-ORS'IQ(,"X740REQ'8AGB^
M,AG N$CG,R^#\RR&8':&/GQF+B!L3@['G$_XT^YL?^79[A53$##?[F"WA$^[
MDXDD?TM[#[XCQDLZ_&.9WT@9BY/>T>AB(%[U+X9'??<<9"CJRX[PX'JD"T50
MD:13+X8Y!?1;^3$$]2">"J(SW9C(NU%<7XIACOXA^.,8%. ;#YU.F[&_)YZ?
M)VE+]Q4W!@RDUV!-G9X>X09&X3Q$;A6%WCB,PGQ)',^+E]UV\G5-PZF,6[F=
MNX+/&N\JS5/,@7=*SY_!U16IG,@4%2Y0M\*8=:U22(&%$%Z'0>%%(-I 5GD;
MPE\OO31?MG&_E#H11<S^F>JV7,.9AS+;U3_HK#N+BN_>N .W-W3T04=B\O%G
M<KTXS$!!&V=A$'KITM%7XU689'XH8U^*4^9T++6^D,7UT4T3XV^!LRUXG_!:
MY3,O%SZH:AY<L![<JT"--9!93EK@*>B&<2;IPR/8?&^LQ:6YBDY%8<375I5C
MGIQ1&_@QI1T]U9K_#$RK,/8F.1H#FZ,M*?*U\3Z#.%T4:59X,"4X"C !8+MK
MCQT(6%I)8([+J?Y@)/U9#(N9+G$<=;Z)84MQ$LHH$%L>'FX8'G9WGM$A#.0$
M-B/0SZG!MHG+=(RCB7$ I<"*PO@=WA\F<\D[DC%,GHXZD%KF8@+/S6K4Q>T)
M)+#N9%'NWF6:!(6?9]5-0G_'FBTR+ P,R3!E/B+CJ3>5^O3 !V#MH8O2')9,
M69DL1<R:M * K"2S?T<3T3_"&7@^7.7 PQ-Y$\+*JMK ;G=DK"-S?O'.H?B
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MO3!"SIBK3Y0!;XU0IY+R=P';PL0IJJ.+3.M2G)^_;2K<42S$:UQ.E9IY/;'
M"'@"NJY(/! Y^.,X4<.68H5L]QK&=&,"?<5?@.7^ 6\MZJT(\PD_)_A+ZD6@
MXAMI%16[F<.S[*640VR)H!(U^#T$F(/;$\M)N%;XECN^[E3_L8-3R5MS5OUY
M!)AJM)3;I:3:4'+5RD C::G2"=('@@0QP,?+&KX7I;XI-R"#XS@*<A<E$?MW
MV!6&T"J2 ;H*("ZL9>DHX!]"R"DBF>F,N$SZ1<J=%D&!F7GQE-RO[ ^R'ECJ
M%CPKE2<9>\.#7>&R!G2#UTJ$<PL.3%5Z-CO,IJ'"0UU1W2Q7DQ=<D^=.I61J
M9<0Z\XJ$IKL/#^YAXF2PQF-JOR!98-)I$8>L,N*?"(I#^T00LDB'FF9$OEMZ
MX81 9BF!4FUD.3.DO:.IPKWT;-K@VX@$Z%VKK/*/4TU1RV1Z,K-;-]$:])P^
M(6N7U72=52L+?1>2.%)^="NE]U:G)IUL2DHM;P0V?-2.ZTY'NQ\=;9.;7 PD
M6#AT-'^$#(,*")"%Z.R4N972 RJR,4DHD+@T5,5JX9(F@??O BPV1^/YK-3#
MK53HK>$ 6^$V#$9D71?#)<0>[HF.2DKV2=9@H+OIYY^(RJ&>J?NCJ?9LM7 P
M#FQ'4;GV<J$;Q]>>EO-Q$H2J=D(7!% L,H2E!FCF)I4UK5V&LK'7*A^69DQR
M#%1#TWPI_FLV6QXJ+'6>%\9PTR0&1=4LD<H.G'6%'6M?C(JA0?,GBSPD-"@=
MQZ%%%B8VI8-,ZQ;:<>K[X=2;W$1DI"J/:\FFXJ)TD[6+58\XI,LHG64-L\E0
M7E?#C'>.6S!813SUPND&CFRWMZZ;<;>Z3]&_F8=YP9@JU0P7JP<<^R"KEHFC
M ]=?M4H87/<[NMURTG7QE!Q@IBMKD^VR[^^; ^E=?]IEWW\_QMC8>[!5K+#3
M!N[A+C[=Z!S\]O:AO;U*^A:(9&X$:G5J+1VJE$G(P2Z4L"L9DM6>)I42.Q:S
ME0)E&P*\G$ FMM ES< TT9(E^V;D1+?UL)0)T3J#SF3>4>)@$LEJ?NYM]K'*
MJRUCT5:W!AV[68I_@Y! =#TX$_TYZFV2[=HMK8-1S4BXMO.O;L[A-#:]Q#FB
M;=B;3,((R]\S1SMC8RY-&2\YR@2,'SBNE0],2B(J-W#PL J;+6Q33A[&NK^=
M01&P=_630$>5%L@\I;+@E5)M U-5[Z-K'0-.[))E[=KJM.Q4>BBK_$DJ E6I
MX^;B.LH-C_^B'^ _J%>'R5G7F=8V\+X.BC5@11%H@QUU^0PLB-T?^_9VH,Z;
MD#OZN,L=[7)'N]S1+G=TPXRL3<X=54I?FU3F73'D.I^J@ENV,2/MRG1T+3*)
M?=:XI,@IE:U*"10H@E$2<AZ*K2<Z7ZSK*@UWJKIQE,HM-7PU%5V.2).E%^7+
MG4DJX2_.CEIX8;!3+!ST:<;91*8IYT_ '5U(=.XX(DQ3>9TH[RMOCE-&=TRC
M>GH_ C.I9V!FRGEKP;4TV)&K2S)E7%P-"0/ETI_%L/E3*GBSLFPPNVAGANE5
MOJY@S)R*?S9SRCA5<PUBK4Y)839MC8M<Z>A:LU<G,Q C,YW/-F%HF;;QLZW<
M[62 E55DG ?&:<(8\5-MI-094OCCJ\=(3[%BGG2>Z99XII]UGNGO&[)3 :M6
MR9#.'WT/-_#91ONC1]78K G+MNK<UT'*,7=U+&\#%]<%%ZQ2<981"\MJB8R&
MRUR!UG!,L@YV8KR1U^CI-IUM+:@WE6-:8GK20S-/E0*54T3L-@3N9K>X<G^5
M..*?"),KWU]6I-<ZB_(3877/@BW_'"1R5.:0;CZE=:[!)3?9E3:^:L>6[H4M
M;;(%5V-+Y6EK%U_2=A(R)'/5ZQS"+GR@^Z0@>[&$P/>P7&"BBBQ@Z&L9APRU
M6S9@L+A7R:\TL&TES;_" V^=% _W239(K5CQOB>5@;F#>:2KUBB;LPE4HQ(F
M5'@A'H%W( -7+79U\0Y;DY2RC@^J@CA=RU%+_,O@;&03KX3U*.&8KQ:JK$\?
M(*\R#X69L3:@:<57E BP@J+."I*HBGU,,*5UHO(H&X(:'2[O/7+*32[6&Y)&
MT#94O]4<0F7(9N*)V*JE0FX[XJG8:DP'@J] T(DMO4KX^SD^&LAYC.VAB?3P
MX0NQ]8Z;R88(N$2)VQ[,/ST4IZ''/?#@7QIK"GZQOR>VSHGM9=O,B/;WQ=89
M_!!FX<4R*;+M+U6Z.G?)?=]U[2YYWKE+OF<B7^4Z=D+N'@[^\XWV4IP1K)E8
M<]#:<(LK%4X;!,NI2;YL.3(GZ>.AGBRF,DUDS'T 9B"KQ,Q+YT;OK_AYJH$C
M[38)4^WV0,G/*3E4[Y[ H[[$?QE$#L?N+>NH !<\K+H0</RI<5RP;##^1P/3
MPY1=ML$9C>8&@TG4WM.$8)=>&",<3!150 FR(J3-9%W6$:1E9@XW#*9F.70
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M>Z_=L1S4<D1,3!_CZ-O[LW_E-[W0__C[Z8.3BT^[VMZ<^AE\7[R9EW#O@36
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M.&]17%%NO<N#;Y7(),DF-_'&"A@_!S).7/["%EWJQ\H<.S/HN*<:0G3*H>"
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M[9Z@XK^'KT)4"G)8Y9)^ N7>VPZPWE/$O6@Z[WC-T2+T87:X#Z'?XTV5T*W
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MUHS/%X\F6;SZY4\O'LW+1?++_P=02P,$%     @ <41^7#V !E'9!0  HC(
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M2Y!QB[!A(^Y>L<<Q^';:V*6K[@NPS3P7S@%\S:^9:(P&B" 5R*%O91>!"6W
MDIN"ORD'4.,I_%D*'("'SE+YDY%VK\T#MGG Q^8E/:$\()V:IY!>(*10>IT2
M]8D !( JIECFX^8H% H20DCMPP2?#/#G'NJ-Q5O!2I4Z"YL;6_P0GF)%"TLW
MY'H(JG((6,?0$5>$0!^J6(Q3;)FC4J+4_&@J%W#K'NRW790MIN/UF<Z*HQ)$
MI%!O7HSJ0_Q-NA:(6B!J,YI? R*,RC*#OD,'80&\RX/ XH\Q50C4"1&-4#,M
M9T!AC>+GU6DL4WE)D!=2+P#?SJ<Z^$5\#=\0C^XF[.L^M-_QR(ZU/V-TD<JG
M=[?8,]V0&E67D(@]:A]'0^01ZIXN*Y+0U:#?[_9?U/2H@9(7%F(;4KY+8PX7
MBGP]?W&*&#!U[Y2!#LM 7#=04R%9NI28[_#U_HOF;:GZ'E!U7:KGTNLJOOK.
M>L.;5<2_S,;(ZCM?-)E;)[R!%?YG1 5;5&>#M[7;9G2EK+EP4<&,@HZ$RZH=
MI%O2U"K:J%9=^,*2A[AS]IVX=;/<$6I=S#YQ@^[)L-_QEQ#7;I1MF^E6FM=(
MD[6BNUO1M3#QF&>G%5TKNA83VMEI%?N6HOMM$3^4\);?1P@EW8/"51>A_WYB
M[=G>^JW<%C\>\6RU^-&*[N%%U^+#4YFI5LE;T3V\Z#Y,!63L^!*2D@X+LM_#
M$03VDN?%B/UAP K: ON1GWBYT_'N_A$. 7.Y.>B]K^,C_D%I[I]J,V#]$UL5
M/ZLOE_E-J7#$@[X]A#-5YFI]L^^J%?EOGUWYXMG6O2Y0:?LIM-O/TW2YAE<L
M5IN*?NLP[+&LOT YA^*"GT-8TB.>.3 QEW.^L'X1'_?HRWF'S\8]_\V]_P%0
M2P,$%     @ <41^7 PTX:#)"0  \E0   \   !T<'-T+65X,S%?,BYH=&WM
M7-MRVS@2?<]78)S*E%TKZF+9SH127.7)I<:UF\R6XX=]A<BFA#4(< !0LN;K
MMQL@=;'DC)VU'6O"5,4V25P:C3X'W0V"PY^BB+W_>/Z9G25.3.&]L(G4MC3
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M9NQ"YUS5!4?:.9UC63\^+L58Q1*R14/T-SZMKOP<XB4*0&W7,LPFPD%D"YY
M7!B(9H87@Q7!#E&P55G.#,YVN',%1M'HE%;@U3$3J9O$&6H\P>=HFMC9SR][
M)]W!L$,U3H>= O^C@A>*3B2W]NU>SK%Z5<G_QFLP>[60M=:/MT[:HRK4JVVP
MQT3Z=L]"0GWW;J@PT5*;^&77_QO<KM!9L):1ENG@AJ1?$^[NNOYP/1$CX5C
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M%_+WG (?19(K7).0(1+A./)7),P^:3 B1</V4%J-XE[,7?<F_X%>IU%+M,>
M)SE#"6 Z9R@8N@W9V>8<*;33-24I<5PN#%.:.K/+4LTDI!<0/;!+/V0$KZ0%
M*$3A26&L!]+YM1.D6LD,4F$JR>=1)N%ZW2"M9ATKU\/#*=4V=JI[1-Q$4VY
M"A)PPTA+@8?^<#A\]:B H!5IAGFE-\6T_C*Z!*A0.AEW%A$EJ>4YP_R%+7:.
M0K^S_DKFNT[EL2#>9!EB3=R^B0U"0EGC!N0<: / $'S>*UVP,/#^30CH0BW#
M_1-VF0/7S $:.X4$BBF&W##LT:;FP(4E:H)A:RDB3YJ@39H=$[Y  ,*8QJ&<
M\'*9:*VCRIHP*]B2U5(B$J#LDH!@)FR^B=F&P& )H+M\CV!A\>)@-UU ]RH
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M@;^))2@@IU![LV<.I#7^M0I=.&G['I+-621!JQ']6-E?*=AE0M(6O Z3H/F
MP4%7WB8\3JT! B.R5OK2K!#/YEH$0&N'%XM@D@PFP#2 L,LU[EU+_L<*@RG@
MH,U#@<C'@0*T?9*>K%E().3-A;.$=H5^4S2>D&L5SQ-S'U(#UK[UV]!=D%'7
MAJ%0M"5I$MV3Y0TP%>0NET6:V+B+D -A<#(.&6R.6% ?)6_J!V,C^_JQ)'/
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M6_]$W'R9I<N]5_E=XK_[T:MIA[]RB\,M)HW8B\(3K9JU4*[+U/:V8"0LQN"
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M*SD&UP[,%H?:UM<*OFHO"QC)VZLIEEY'L19%Q->OGX45C@@+S,%[!8Y^-ZG
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MNA7TS!#[W,[(0ZP"(.6=^)CB*:%P-HL]+ &RIS,2+^E\EIX>ZJO8@DV!M2S
MI4ZS&)EL3@EE]G"^Z@2+_J'1IHU?A)OV=&6V+U^XHP?;CO;OWW]T/#H>W7\P
M.GAX=/SHI],57#5L:SKYH/42EIE9Z(A=BH"T!2YH+@"IXO#0&@P\$U4XUETA
MM+'&"Y5Q-*&&,HAV'=TWK1W9:Z9&>:" NQ(,06]V452QH?XQ90#J@QCCW+8M
M(BD6+'STD(FSRJ!%1OY_H(>!'OX*/9#"(^XDSY=YRZC+5-9SOW I1^M\?/R@
MK8/;!I%M@O0U?*GHQYUP6CL8@UH%6B%<*2+@MXLEFL D$[ 53NQFB8'>:ZO^
M^-.';_C%*?LA4G@5NND-=#F/UW[-2)(*'%.BVI+8G:Z83M.)EF_(G8J!9,5:
MR\E$@&IYY10W^RM&;*63=$G*JSB%-XT)-E +-:PI]K\1ZYAQ3LJR29'UA!8<
M!&=VK=C)L\AHH[K\C.3T/(6O!N8V,+?;9FY\%7L1"=Z-WW5O8Z\S<\<+]79(
M!D2$#9!O2:7@N%F6RO-&<6C!4E.!UX76ICA=BV%*%3PJL@LD5:(W/C<%&&,S
M,]:4+1?D-)'6VE.OY.C#PWM'G8[S@!$1ZY9FDS=@2OM=1'C;NN[!5REH=[.
MH3R:L;(:!_H71]M5GGFW"WUL1P-@A&+I"G6:09$9>-NMX>JV@+0TORRR2QM]
MWNH'W4__@X8Q(.IG050.XG.!>J!M)+/^(+T1NN'$!VJR&JP%OHW2(;(/B#T@
M]A=";+^?J"[1(^<9+=D+U:-&VU:CKLQ<::G#B&BMUO5$1GV*L*A> _(/R/\%
MN7H8D=,G<A#>SZ4;F#B; 86E,8-YPT7;H!^!@UE\S<E&*B'.DIIEH[+;$_;W
M">FACQ[KPQ",^VT%XSX:@G&'8-PA&/<C@W$_ER! 8!AD@1]!%B#7 88<<4>#
M;:X>OJWYAJZ-6)L5B@3FY!)E8?AKUBB,0]+X-ZN*E=,5IVD.CZ&%58:I<%)R
MN99%,YNWY8'M1LV/"CCYKH+2KS5VYM;:V7V:KH,K/>S"ZB2@;C4OXHZ&:OQK
M5^\TMJQ753&15FIM2:ZB(&H<B?0G%X9B8P6M"]!SZED5J@<IL?9U4T5)FG!Z
MY.C!AO6AW].W(7Y^0UG47R-.K%:S&3D$GZ)C98@!\V#SMBFC]YHJL2?1,PW*
M$*5W<,7QIVML^P5(>IDFFH+1.SQ3E'#!=$%7NJZ8["H+=4<TW$B2*I:@^,IQ
MT\4-ED!AJ(G$>KFY)0RUU MRGQ6Y]&F:J*;B]^FK+<ZM5I;HHP<VDM^+WN?4
M ^/DAF^U%$&QV0'H0"^+*TY']:-B<9[]B#MIWF"C;,&Y5!.X;=8111MT 3WH
MC&,?9SL/A1I@'!ZQQPR049M*+7V#"1B!)6;:@<SZ_^#W/XI24EIQ#'< ',B>
M2VC ?O2R*9'Q(AO;<K!RFM**EX[&N39=T/S&.9N,'O]08=.@!?NY1ET[;(4+
MF&Y$+ IXY[^TS<1MDU^N6&/'XH8!8294_\S6]]$*JZ<]<_M!BV]^1A'%4R-2
M^YMP6=+7P0MGQ=,4U$";!??U7*@/&A,=Z)Y)4CPU0!F)MH0;#I:/P1IKR@;@
M7!>Z_K %)RP2>UR&SQ&F55I_,%5US$O(8LHBX_#UX7[:&OWM#A,C?7[/I:GT
M;74)_XZNJXL0]Q%<3>YZ<'>E6R$MM,D:#7WJ4J49Y=\@]D^;NBD]V[A)CO%E
M-M/&)6 G[9R9=($!7M;Z9[H%DB0'W,$R'1>,%*05\AYP??BF3HC=X%TFUZ5K
M8RX\L:DDQ1'O@3+5S%",;*A%<]&M\A%$IJR8,[>PL5I&3:)8+F9V^@J7(EE4
M?=#'09H<[\82K^)KC\#C1RUFU&(WV/,6*Y81M(LQN3P"YH*@7FB,/*/+BN]A
M0IFJ#BM?^+F"MB+:P)NVRLX26/2;"RSRNM14I]$9*]#1&^X\_%X3_^>N/HB6
M?D^;=VAOKU3&*/=<KBMXU2A,,%[0 X?0=6" 'RFO!\(RR4I]8A&ID7.%4K&-
MPI7G6%R=S%,]Q23 24-BLX2 $O.98$):*_",:' SZBP(?C.<2,+8NF+7 EF(
M,]_&(D.Q6+U G@"_L5&110_2\SF^-O)#;058XOV4#ME8*Y'GVX\0I@(ZVU76
M&(;,\P#3B4Z:TF@W+FG2OR&6%L';"\L+WR@P0;4^(?,#THCM (Y%UEPR0!GE
M@"$.;E2L<4SVICJ2G (?[FTITMP=WMH#U'"@Z-[# E"?XFD!6P&)9MAVBJ)[
M,8N2M\8)RN:NJ;#5>:W*=6@;,0<+4_)-1Q+LQ$0_\KYJN GR?9.WA7GI\CU-
M'IO%FC5)MB&A$"X")LPQPCC;0%8.1*3L3DJW/CZ@QNGPK9A;Z-O1H7P=K!ST
MQ0HC+7/,K:QP8T(D2YR?U"]4:SV[$D=D=J$6H?G4*"T>EU0$ BQ&2;0BM&[J
M1OD':IN],S#L 0?#(6GB\B@4,.PSA[+Z&-NLI=0LF4E($*D=+GI=B"GO[>-8
M45O+P:527#M* 2@4F=#YC0!51#M3XU39)0PW]]8^[E@B]C>CNO]W<3L-Q;^C
MN_1"TAN=/6)FN(]GF>B*B XL(D0Y+).W+3]1P2F03&O([(14.=U^@0W&E6_(
M=9QDXA$41R[XH3EH<6)[D22N_\51)%(""TJ(8A&;I<+0IEP%(!2ZYD$L9^KG
MMXTF0MO1"9>!66J5L1;D <O K\=6(AEL-S#3V9#T1T'>CK$H>:7U G[#Q2-:
M>>L3'$=25>U%[*^K9:Z\BTOLQBQ[$!'?:"HIEEQSP67U$TKD%2EX-8LV)J[,
M7G7V65EP%]/?[W48#T$L=SZ(Y?$0Q#($L0Q!+-];1;F_(G3>L+D#:!D57H(O
MB[(9JK"W#35=2I#(:ROMJS:>1DW2I'_)HQ(F%7P0TE.$-$LAS^ R)CWQV1Q-
M%4X[/:]%WK-%.LB&$ENUMLE@$36HRG3KN^*\**XMEZ!GD%T<WHU)!<<E8?\%
M,A3;,Z>5D/UBYXQ*$4? @]-+7J9H<ES :Z)95S:V"XJ7A15-6S5R3Z.=I[N^
M(HCNY))M!TBS*;73QHL%S>4HAT_3I &M%+:>-"B-KV03N!@1CF)KM++1/-;8
MW2JB+> Q'XO2_^B$ZBHP@.X\NV;):J:PWT5[:'^-M+2;KE*5*44P^U42 Z$N
M+-W2ZX45$Q\CZ2E5"GS^A;<RPWI'[5AI]'& @*W2$I/%)W4)3/E'+@[U"ICG
M(K?.YNZ:4#\RF[U!C,%*<W6 5& )>I1RA32QYL%*D0**V=CBVN;H/M1\\[!5
MCO)\Y,@U[$,Q#"B5Q$NO7+HI$%@U:1URQ%CH@TR0^%]K_^)*_*X^ GFZ*$T;
M$Q@<C4\5NB$IVT%S14YT8E+$FN+(-<R"H,*<L@=8%Q6-["#86"# ;V.VPR4O
MLCT*.?EB8WM%S1.O$WQDD^W&!*T<_W!L #./ )&((\2R6845]]),8?@.8 X:
M#% ?C6VI/L]V80>MYNDRCOXH@'-$EX 234DY?V@E=MP'N<JRI)9"9%)U-531
M_(GG99V3>*9!&*)0'RS5*Z/)$3_N)'RF"5?KC =R52K)N$T+DHLVS4T%3]YI
M;%DK+E!?+;'C0!CF ]0(K'+MC,!3"E7]HTEF9/B-(Q-"F4AM39 \5,ISZ;KF
MZ&I<9L/]!^ YW@%<]EB'BVIETN- 7KD((!S*A4OMQV*>,B?9 :T-"'2-QN88
MRVK2RPZ*$7M^8)99422 OUP(3(IU /'#H7JX[*UPK+-47UI2Q$*ZZ"+!*@-+
M]KG7!5]W8TWV$@Z\9!=4;-PV:,:V5^:D3!?4Z:9+7(F]96!AT+QPJ]$28D9+
MH65%<R8<1M0<Q)*:B CD/;4"@>MS&JLWM;*[JG@-QJ [;PPZ_H+&H"?WQD6R
M_OEO(,S4B^SG_P]02P$"% ,4    " !Q1'Y<;3A2A$N@   =QP  $0
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M,#(P,3E?-"YJ<&=02P$"% ,4    " !Q1'Y<SOU$9O<  0!.!@$ $0
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M,#(P,3E?.2YJ<&=02P$"% ,4    " !Q1'Y<5M/JLC9#! #2"2X $0
M        @ $R@Q0 ='!S="TR,#(U,3(S,2YH=&U02P$"% ,4    " !Q1'Y<
M+)9&S*=' 0 D.1, $0              @ &7QA@ ='!S="TR,#(U,3(S,2YX
M<V102P$"% ,4    " !Q1'Y<OI $[QH)  #<*P  $               @ %M
M#AH ='!S="UE>#$P7S$R+FAT;5!+ 0(4 Q0    ( '%$?ES\-\J@@H,  '8P
M!0 0              "  ;47&@!T<'-T+65X,3!?,C4N:'1M4$L! A0#%
M  @ <41^7+=9[,6GBP  Z(,% !               ( !99L: '1P<W0M97@Q
M,%\R-BYH=&U02P$"% ,4    " !Q1'Y<C.M!MP\\  !+" ( $
M    @ $Z)QL ='!S="UE>#$P7S(W+FAT;5!+ 0(4 Q0    ( '%$?EPF&"7)
MT2T   !> 0 0              "  7=C&P!T<'-T+65X,3!?,C@N:'1M4$L!
M A0#%     @ <41^7-,%4X B*   5DT! !               ( !=I$; '1P
M<W0M97@Q,%\R.2YH=&U02P$"% ,4    " !Q1'Y</8 &4=D%  "B,@  #P
M            @ '&N1L ='!S="UE>#(S7S$N:'1M4$L! A0#%     @ <41^
M7/)=H)6W"0  5E    \              ( !S+\; '1P<W0M97@S,5\Q+FAT
M;5!+ 0(4 Q0    ( '%$?EP,-.&@R0D  /)4   /              "  ;#)
M&P!T<'-T+65X,S%?,BYH=&U02P$"% ,4    " !Q1'Y<C*I[]W0'  !W*P
M#P              @ &FTQL ='!S="UE>#,R7S$N:'1M4$L! A0#%     @
M<41^7-UG[<9%+@  ,$@!  X              ( !1]L; '1P<W0M97@T7S$N
9:'1M4$L%!@     7 !< F 4  +@)'     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>tpst-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:tpst="http://www.tempesttx.com/20251231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tpst-20251231.xsd" xlink:type="simple"/>
    <context id="C_83ad0427-46c9-40f3-8ea3-599adc8b0338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <startDate>2025-04-08</startDate>
            <endDate>2025-04-08</endDate>
        </period>
    </context>
    <context id="C_83e9d5ae-1ac2-4dfe-901d-1fb708223a37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_872c6937-1351-451b-abf9-2a2a83e2dc84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8748646b-ce49-4cf2-b51c-cd12c0ce32e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8889779c-cd1a-4a88-8d46-c213f770f4d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:A2019EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_89243837-7c70-4e55-8184-5818a993b299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpst:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-20</instant>
        </period>
    </context>
    <context id="C_8a8915cd-0e0b-49eb-b2b3-419b16f12b37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpst:NovemberTwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-24</instant>
        </period>
    </context>
    <context id="C_8bd98920-97ac-43e9-83d8-1afbd38624a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:Pre-FundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-20</instant>
        </period>
    </context>
    <context id="C_8c81e754-6ec2-4618-b538-4c6094074920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-24</startDate>
            <endDate>2025-11-24</endDate>
        </period>
    </context>
    <context id="C_8e605970-763d-474d-b0cb-5de22ba59e68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-15</endDate>
        </period>
    </context>
    <context id="C_8ef892e0-d716-4056-9b12-9c9a7aa12c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-23</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="C_8ff57b73-22de-44f4-b372-68161891a853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9031d7bf-fa77-4e96-815d-3e2cf8c46a92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_916c82b9-f557-4ed2-9797-e0d652612305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">tpst:NotSubjectToExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_92c5db01-9c2d-4afd-bde1-9f72beed84e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <startDate>2025-04-17</startDate>
            <endDate>2025-04-17</endDate>
        </period>
    </context>
    <context id="C_98b385cd-564a-43ce-b857-c685a4784e21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-15</startDate>
            <endDate>2021-01-15</endDate>
        </period>
    </context>
    <context id="C_9ac57279-acec-4da3-9e70-2e34cfbd934d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:SeriesAJuniorParticipatingPreferredPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_9b1b80e6-f451-436f-91eb-8955ad7e6679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9b1ec7d9-4f7f-4128-b459-36816f64018b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-24</startDate>
            <endDate>2025-11-24</endDate>
        </period>
    </context>
    <context id="C_9b27f837-5200-4262-b142-35394e148530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9b755a49-74f8-491a-8e35-1ea2c98f61f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9d204fd8-22c5-49c0-9f16-eaa7fe7bc752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9f019654-8ffe-45bb-a4e5-13052063f719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_9f9f175a-2500-4de7-add4-0941b73b5ed4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">tpst:NotSubjectToExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a3400db3-e1b2-4661-adf2-7b1ef948c2b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a379ad4f-c5be-41b5-b49e-a2850e59bc53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a46cd5e9-4d74-498e-9bdd-3fe5cb08caf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:EmploymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-03</startDate>
            <endDate>2026-02-03</endDate>
        </period>
    </context>
    <context id="C_a5315be7-426f-4a35-bc3e-9d8bdffaf36b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-11</instant>
        </period>
    </context>
    <context id="C_a6cb3954-c17c-46fe-8f17-edc83f6fb2e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-24</instant>
        </period>
    </context>
    <context id="C_a94b87ad-49e1-4a01-a0e5-9ac323ad9f6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a962bb72-7e5c-4f7e-9290-db4536a5d91c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ab6430cb-a886-405c-91eb-7aff47df90b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ad6d3810-e138-47f4-b494-587bf0b0da1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_adde1910-6137-46eb-9b4b-8af558580c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_b06ce1d5-43af-4875-915d-0b69099c48e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b0987cd9-5a24-4759-9d16-ae81baf465af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:Pre-FundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-20</instant>
        </period>
    </context>
    <context id="C_b166bd00-a5b2-46eb-bcf0-8a5010ef48da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:ErigenAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tpst:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-03</startDate>
            <endDate>2026-02-03</endDate>
        </period>
    </context>
    <context id="C_b2e0866a-1fa4-4872-b525-bcf7fc4bf8cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-10</startDate>
            <endDate>2023-10-10</endDate>
        </period>
    </context>
    <context id="C_b3405bb2-c492-46ef-ba86-83755523024a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b5528348-f1b5-4a4d-8927-ae662ee9eccf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tpst:LegacyMillendoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b90d1f82-feeb-4b7e-b350-61e27474eff0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bf3af50f-3aed-4972-822b-f4464ec34192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tpst:OrphanDrugCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c0d8ea89-cc8c-45be-bc99-628196dc6c0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-15</instant>
        </period>
    </context>
    <context id="C_c3d09bfa-c82c-410e-8c05-013d4096ded0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_c6e78168-a2c5-460b-b80d-8a8b0415a3a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_c7a9e8d9-54e8-4bd7-bfcf-2da3a970b22f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c7f4e70e-297e-4e0f-9e4c-cf579d45fbdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_cbae41ba-0f21-46c1-8226-08889ddc8bc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:ErigenAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tpst:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-19</startDate>
            <endDate>2025-11-19</endDate>
        </period>
    </context>
    <context id="C_cc23a656-ad79-4d18-bc37-248f3df07c4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:A2019EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-17</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="C_d07960dd-fe9c-4566-abd3-ddc3571ebd35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">tpst:O2026Q4DividendsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-20</startDate>
            <endDate>2026-01-20</endDate>
        </period>
    </context>
    <context id="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d48d584b-746c-47de-a737-fa3d182f9772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d6236c64-7c86-4bbd-a146-18c57a7267cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dbd9479a-dda8-49f7-909e-f327ddced2a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TrancheBTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-15</instant>
        </period>
    </context>
    <context id="C_dcb60290-a2fa-4e02-8588-a3425a10e251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e001f4eb-5e39-4fc6-86f8-e7d36c542298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TrancheATermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-15</instant>
        </period>
    </context>
    <context id="C_e1a70b55-a6e2-4450-8567-d8933403aa20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-20</instant>
        </period>
    </context>
    <context id="C_e36e743c-bf65-4bdb-bbe8-1719a8f75e7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tpst:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e4e85a24-a7ee-432a-b926-c4bcdd8d3d4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e7009405-d7f0-4b5c-971c-06a829c4d118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-20</instant>
        </period>
    </context>
    <context id="C_e84c96bf-09c7-4644-ac47-8073761fa16a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:A2019EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e8e8425e-8552-48b9-b19d-732d38689041">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpst:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-20</instant>
        </period>
    </context>
    <context id="C_e9697112-510d-4538-addd-de1c50b2db0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_eae918eb-3de4-4147-a020-481aebcd8e1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tpst:IndividualsWhoWereNotPreviouslyEmployeesOrDirectorsOfCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="C_ec6026bd-9c80-4233-9bc5-2e05dc22c3d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_ec632eae-fdb8-4bbe-ae31-e0618a3ad9ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="C_ee3c2c67-1de7-4901-bc90-59a0afc42477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ee9ba139-9295-4f17-8cd1-d43d46ee649d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f01f9f21-5e95-48cc-83bd-51259e351e7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f1d00723-6493-47bb-9c20-796c424cdfab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tpst:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-20</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="C_f4bab170-e7d7-4e1f-9859-dfd7e52308cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f546958e-8be6-48f3-adf2-b8d67c893d64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-20</startDate>
            <endDate>2026-03-20</endDate>
        </period>
    </context>
    <context id="C_f721aedf-b106-461a-903b-46e34a9f1d0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f8276a73-58b9-40f0-8e8c-d2c73f397848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-24</instant>
        </period>
    </context>
    <context id="C_f8ce6377-25b1-417f-a67b-27dd94b6927b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f941fd95-2c63-4333-b1fe-fd70c5cce07d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f9dcc510-706f-4f08-bade-b100bcff92b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fb5c878c-f0d7-482c-814a-fe0164e7e33e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_01635993-0ae0-46f3-a1ac-7f468a6e22a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_02b78ddf-da38-4509-a735-32afb066d3b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_03c240c2-1a9c-4f7e-818d-a75b93b79bc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="C_06328e98-1580-41cc-a910-5db61b65b8fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_066bf70d-7a44-4797-b1fa-45ce89b04609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_072f2ea3-60bc-461a-af30-65a53c97af2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpst:PreFundedWarrantAndCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-20</instant>
        </period>
    </context>
    <context id="C_090576ed-b8aa-4a6c-bd24-ad4fc236805a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_0914ade8-ff10-4219-ba68-53e47ff2c071">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0b479aa9-6c7e-49ea-a261-63a2a337465f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0c195dac-9159-4433-aab9-8a61697eeb1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-10</instant>
        </period>
    </context>
    <context id="C_0d904433-7564-4710-8699-0c23e7ee67c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0ec6ba97-3919-4714-a934-2525e2f12f8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tpst:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-20</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="C_112906e9-cd45-450d-8e9f-7f8daac97dbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_151f94be-33aa-4e72-91ab-8bdd1b7a21c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:AmendedAndRestatedTwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-27</startDate>
            <endDate>2026-01-27</endDate>
        </period>
    </context>
    <context id="C_15eeec6d-ae98-4bbc-b091-1fe5a22f07be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TrancheBTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-15</startDate>
            <endDate>2021-01-15</endDate>
        </period>
    </context>
    <context id="C_1637137e-aed7-4f2d-9427-075a1f55122b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_172aae3a-09ec-40f0-8e3c-93da515273fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_1da28e56-a036-4c1c-9957-b3069151a0bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1eb9e2a4-c74a-4bb4-9c41-89af539af6a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_217bd4e1-fa9f-48ab-92f5-c15124d00b07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <instant>2026-03-25</instant>
        </period>
    </context>
    <context id="C_23067402-fab4-4583-a8ba-7a645e0e1ef8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="C_27158267-e15b-4d03-925a-581587ce58e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2996b18a-b543-4592-ab8d-b832965d6add">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2f5116a4-019d-49e2-b693-5a9344db56a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3665f268-732d-4aa6-b123-f1529af2e05d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">tpst:O2023Q4DividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-10</startDate>
            <endDate>2023-10-10</endDate>
        </period>
    </context>
    <context id="C_3ac82a9a-bb9c-42a2-a8f7-52fd9198caf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3baddcb5-d5e9-4033-a4a1-870013c37ef9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-11</startDate>
            <endDate>2025-06-11</endDate>
        </period>
    </context>
    <context id="C_3dd1d89e-976b-47de-b4a0-39ee50aa0671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_40c12f7b-2097-4b34-b237-498396a49865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-06</instant>
        </period>
    </context>
    <context id="C_472dac54-6d43-4ba3-b05b-f300ae5059c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tpst:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-23</startDate>
            <endDate>2021-07-23</endDate>
        </period>
    </context>
    <context id="C_49c54967-da26-4ce8-b371-c1af8c5252ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4b4a9e1c-7ea2-4fd6-9990-5b75e3c05009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">tpst:BrisbaneCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4bcca309-5038-498e-a62b-782042e16268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4ecf269e-0f88-4788-aa4d-c460ebc3cf9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:ErigenAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tpst:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-19</startDate>
            <endDate>2025-11-19</endDate>
        </period>
    </context>
    <context id="C_4fefbbfc-8096-46ef-bd2f-5065850f98d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <startDate>2025-04-04</startDate>
            <endDate>2025-04-04</endDate>
        </period>
    </context>
    <context id="C_5044accb-f46c-4dbe-954f-4ba8e4e9b034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5380a6a2-f90a-47a7-8a71-4bbe6510990f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_5637d434-2834-4e0a-be2f-fed606708f35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5674d468-6c98-412c-9336-57931dcfe277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_593fb7f1-b481-4017-9df8-af3cd7cf78c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5ac6b064-5ae9-4c1e-a875-a49f5a60bd9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpst:JuneTwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-11</instant>
        </period>
    </context>
    <context id="C_5cc9aad1-44ab-4aae-ac30-ebf9766e2451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tpst:A2019EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="C_5fd11135-0c20-48b6-804e-5fe44ae3180d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tpst:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_62d04cb4-5a63-46ed-a664-419caec2a7a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_65c167d4-fb8b-486d-a124-daec790a028c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_69c4f05e-7e57-48e6-b6d6-083e708f8908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">tpst:TrancheCTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-15</instant>
        </period>
    </context>
    <context id="C_6c5a716f-97f5-415f-b72f-9c157e671bc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_6cdf488d-d731-4f05-b3e5-69a6c55aa717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-20</startDate>
            <endDate>2026-03-20</endDate>
        </period>
    </context>
    <context id="C_6e35c08f-14cf-428d-a7d8-78364f94ae76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_70845e48-f71f-4ea8-8d6e-8b92f4df5950">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tpst:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-03</startDate>
            <endDate>2026-02-03</endDate>
        </period>
    </context>
    <context id="C_717feb2e-7a7f-45b4-b13f-aa87773d18bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:ErigenAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tpst:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-03</startDate>
            <endDate>2026-02-03</endDate>
        </period>
    </context>
    <context id="C_71ec2d54-80b0-474c-b65c-486a56573a94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_73aeb815-2afa-4516-9756-8b7f3643ad5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_79115bce-54bc-47dc-8643-ab28b5ab2326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tpst:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="C_7b1d730e-ab40-4eba-8cbf-0692f0eabf49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-03</instant>
        </period>
    </context>
    <context id="C_7bc99182-65b5-47d2-9586-940c0ab19557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_7c4289a6-f95b-49ac-b1e3-b9d55e86a9a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tpst:EmploymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-03</startDate>
            <endDate>2026-02-03</endDate>
        </period>
    </context>
    <context id="C_7ca8d315-3fdd-4df9-a57f-592e58b29648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001544227</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tpst:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-11</startDate>
            <endDate>2025-06-11</endDate>
        </period>
    </context>
    <unit id="U_Employees">
        <measure>tpst:Employees</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Tranche">
        <measure>tpst:Tranche</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Segment">
        <measure>tpst:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_52dc9e07-b38c-418d-9941-12a551955bee">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_8edeec8e-b1c2-40e4-aca9-6d622747d550">0001544227</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_0743b076-071e-4274-9c3a-052099742eaa">FY</dei:DocumentFiscalPeriodFocus>
    <dei:NoTradingSymbolFlag
      contextRef="C_9ac57279-acec-4da3-9e70-2e34cfbd934d"
      id="F_e4806dbc-e3c2-42da-9512-4b39ded09472">true</dei:NoTradingSymbolFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      id="F_a61cf309-8cf1-44dd-9cf6-1e067a7c3d48"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      id="F_eafdf1b5-430a-4ed1-b977-b8a69e22fd10"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_4fefbbfc-8096-46ef-bd2f-5065850f98d4"
      id="F_6e1cc23c-49a3-467c-968a-b436b08a6a1b">one-for-thirteen</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:RestructuringAndRelatedActivitiesInitiationDate
      contextRef="C_92c5db01-9c2d-4afd-bde1-9f72beed84e5"
      id="F_9df2eff9-6afb-4328-8d1e-a0eef5583eb8">2025-04-17</us-gaap:RestructuringAndRelatedActivitiesInitiationDate>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_05603c4a-63ad-49f7-8c55-20c2929846cf">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      id="F_73e1d41b-207d-4eef-a0f5-e1ba66b3ef90">http://fasb.org/us-gaap/2025#LeaseholdImprovementsMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_b2e0866a-1fa4-4872-b525-bcf7fc4bf8cf"
      decimals="INF"
      id="F_cc2526f0-0ec8-49fd-83a9-ebb177d174dd"
      unitRef="U_shares">0.000001</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_98cdff81-3c83-4c66-ba34-8998155d3a60">http://xbrl.sec.gov/country/2025#US</us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration>
    <us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      id="F_14cb7b7c-9f29-479f-8c41-fb9c6a5ca935">http://xbrl.sec.gov/country/2025#US</us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_73408227-2688-4970-8a0c-a936196fb1ad">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_754e9ab2-330d-46e4-8daf-f757175550ad">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_277100bf-b0bf-4472-b9bb-3deec85320cd">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_eec4eee0-19bb-4d41-9277-c35a8d5a2a27">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_db98e06d-7497-47c7-9bf9-64772e245ed8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_62aa3888-4a51-4818-9451-b4335c2777fb">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_494bc836-c6d8-44d4-8008-acbe690aafac">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_4888d952-8ac9-4f3c-931d-4064d422f820">001-35890</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_89a6fbbe-7aeb-44eb-8c6d-16ad937cb9c6">Tempest Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_9811e36d-6304-47ba-9828-8453af4aa67e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_ca96e718-c123-4dea-9052-13104d971854">45-1472564</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_38249a19-ff61-4461-9cd8-dc60b452cd75">2000 Sierra Point Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_cbc150ae-1c59-438c-bdd7-37c0aff35633">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_49238708-cae9-43c8-b998-db6aeb584a38">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_80a5d3c8-c2f8-4322-9fee-caf0bb3f76be">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_0b206e27-a1de-45eb-87b7-d9ca4bcbb45c">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_0bb2bd59-9d0a-437d-a532-6c7bb4957dd0">(415)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_223309eb-34d7-4e68-a585-f8619492ef95">798-8589</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_2f5116a4-019d-49e2-b693-5a9344db56a5"
      id="F_e2397b0c-9023-4212-88b9-9821140202e3">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_2f5116a4-019d-49e2-b693-5a9344db56a5"
      id="F_1a70b696-7aa1-42ab-b082-2b38c3ff7c2a">TPST</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_2f5116a4-019d-49e2-b693-5a9344db56a5"
      id="F_59a5461f-a7af-40d2-996d-ba1899996dde">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="C_9ac57279-acec-4da3-9e70-2e34cfbd934d"
      id="F_83a716b5-2e47-4b43-bb23-07ad21dc2d56">Series A Junior Participating Preferred Purchase Rights</dei:Security12bTitle>
    <dei:SecurityExchangeName
      contextRef="C_9ac57279-acec-4da3-9e70-2e34cfbd934d"
      id="F_27b55552-1ac3-4515-8bbf-937c6b50d5e4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_55c9e220-aa03-4561-bb26-1e4774bed59b">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_e2cefa73-3c96-4f5e-b466-5b45fc0c1b34">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_360ed4c8-ce85-4ecc-b136-f90e87ec7eb8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_4f284b4d-8159-4e4b-838f-4fccff68e911">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_2822a9ed-d3f0-4a35-ae97-af0997eac297">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_50495445-e512-4d7f-bc1d-609a1a7ff2de">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_25b248ce-84e4-44c2-96d1-4b9dcaf9f140">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_8f70e38f-3c5f-453f-9020-d825910aa836">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_14810ef1-2dc0-44b0-91e0-4e1ca6682872">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_a2859d60-a46d-48e6-9969-9ddbd53b3ca6">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_adde1910-6137-46eb-9b4b-8af558580c47"
      decimals="-5"
      id="F_410133f8-45b7-41eb-83e0-5988a049c569"
      unitRef="U_USD">30100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_217bd4e1-fa9f-48ab-92f5-c15124d00b07"
      decimals="INF"
      id="F_58fcc11b-9f22-4267-81f6-e734e19522a3"
      unitRef="U_shares">14344034</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_d9726c0c-f483-401e-a1c1-6bfc8925b40d">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;None.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_642cee8b-6acc-4f69-942c-a39dac411cf0">&lt;p id="cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ITEM 1C. CYBERSECURITY&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk management and strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to our clinical trials and employees (&#x201c;Information Systems and Data&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our information security function is led by our Chief Financial Officer &amp;amp; Head of Corporate Strategy (&#x201c;IT Lead&#x201d;), who reports to our CEO and is supported by our third-party security provider, and it helps identify, assess and manage the Company&#x2019;s cybersecurity threats and risks. The information security function identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example analyzing report of threats and threat actors and conducting periodic vulnerability assessments for certain systems.  Our assessment and management of material risks from cybersecurity threats are considered as part of our risk management processes. For example, our IT Lead and certain management, including our CEO, evaluate identified material risks from cybersecurity threats against our overall business objectives and our IT Lead periodically reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depending on the environment, systems, and data, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: risk assessments for certain systems, systems monitoring for certain systems, access controls, asset management, and employee training. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use third-party service providers&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example our managed security provider and professional services firms, including legal counsel.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, including that if our information technology systems or those of third parties upon which we rely, or our data, are or were compromised, we could experience adverse consequences, including disclosure of sensitive information, damage to our reputation, and significant financial and legal exposure.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee is responsible for overseeing Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including the IT Lead.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The IT Lead has 5 years of experience in roles that include oversight of cybersecurity risk management programs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our IT Lead is responsible for hiring appropriate personnel, helping to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#x2019;s incident response processes include reporting to the audit committee for certain cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives periodic reports from our IT Lead concerning cybersecurity issues, including certain threats and risks and the processes the Company has implemented to address them, as applicable.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_2d5b82f0-34d9-4fe2-8f5a-8ee2adc339f8">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_b9bfb13a-7700-4a5c-b6a5-7ac945ea40b4">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_594c2328-5673-4f32-b133-3cf55612d3ec">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_8deab51d-f14b-4ef3-b7d1-6ae2a49c18f8">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee is responsible for overseeing Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including the IT Lead.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The IT Lead has 5 years of experience in roles that include oversight of cybersecurity risk management programs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our IT Lead is responsible for hiring appropriate personnel, helping to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#x2019;s incident response processes include reporting to the audit committee for certain cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives periodic reports from our IT Lead concerning cybersecurity issues, including certain threats and risks and the processes the Company has implemented to address them, as applicable.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_664ef5bc-9198-4fc3-9272-1adde526897b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee is responsible for overseeing Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_093a338f-9494-4915-a53b-e811738a2705">&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including the IT Lead.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The IT Lead has 5 years of experience in roles that include oversight of cybersecurity risk management programs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our IT Lead is responsible for hiring appropriate personnel, helping to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#x2019;s incident response processes include reporting to the audit committee for certain cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives periodic reports from our IT Lead concerning cybersecurity issues, including certain threats and risks and the processes the Company has implemented to address them, as applicable.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_dca79e32-2f40-47db-a66d-19b4c00e508c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including the IT Lead.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The IT Lead has 5 years of experience in roles that include oversight of cybersecurity risk management programs.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_c679215f-02e2-4bb2-9404-8dadb91cb34a">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_e6c6c55c-8835-4621-b9fe-9ef09b90f93b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our IT Lead is responsible for hiring appropriate personnel, helping to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_8d470aeb-3e09-4d5e-9c37-1c2c3731f426">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our IT Lead is responsible for hiring appropriate personnel, helping to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_853d8e72-3c82-47de-8be2-b0f479dfa2d2">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_470e733c-5a43-4155-8d21-e5139e1c7754">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified.  In addition, the Company&#x2019;s incident response processes include reporting to the audit committee for certain cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_c75b0bed-b782-4ce5-b1ce-e53b4277c88a">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives periodic reports from our IT Lead concerning cybersecurity issues, including certain threats and risks and the processes the Company has implemented to address them, as applicable.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_b7ebaf81-7639-418c-acde-c718aa2846bc">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorFirmId
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_ec5d9cf2-decc-48ef-a4da-b3ab4cd517fe">42</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_d0242edf-327b-4fd2-992f-0ab3f2a7f0ae">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Tempest Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, stockholders' equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_5621ff4b-9b6e-4497-8c48-6d906501b3fc">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_ab496330-6ceb-4a13-9af3-30364b9d1048">Chicago, Illinois</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_c069e2e8-a13b-45ca-9f81-3dd0472ec6f2"
      unitRef="U_USD">7707000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_c67d744b-8a31-4477-a031-d47c5854bf52"
      unitRef="U_USD">30268000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_30cd859f-ad28-400c-8114-4cfabf05ec8b"
      unitRef="U_USD">562000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_c4fc84fe-226b-4d09-aa1c-36bbcea58694"
      unitRef="U_USD">1206000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_ffd73efd-673c-4d74-90a5-136afd288661"
      unitRef="U_USD">8269000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_1fc8f61b-5bc7-4bf8-a65d-cc2e03e245af"
      unitRef="U_USD">31474000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_0b520529-d2e3-4fe7-a14c-01baf3d6c428"
      unitRef="U_USD">605000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_d74ce3d8-f55f-4b54-b00f-6ac321dc7f4b"
      unitRef="U_USD">886000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_b4c2695f-6618-4a5b-8d28-30c503945e0e"
      unitRef="U_USD">7540000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_34ff7f4c-7e80-4731-b194-871e3d1bafdb"
      unitRef="U_USD">8643000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_b8fb8fb8-5f58-4050-937f-2a3c56d7332d"
      unitRef="U_USD">517000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_5f3a7b5f-7de0-4564-b8af-7899af798aa6"
      unitRef="U_USD">485000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_0e6cc10e-4125-4398-9ac3-f5d38a617b3e"
      unitRef="U_USD">16931000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_2293a8f5-1213-43ac-92b1-cafd434067a6"
      unitRef="U_USD">41488000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_fb01508e-c8f1-479f-9829-95d4592b3049"
      unitRef="U_USD">1038000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_ab2e428c-e25a-4a55-b356-4a5e7dbc189f"
      unitRef="U_USD">2450000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_5c2bbbcd-354a-4b94-834b-40bb7d5a9d74"
      unitRef="U_USD">937000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_d004455a-3db3-4899-8e03-160aba7500c5"
      unitRef="U_USD">2726000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_aea821b9-9dde-421f-be68-c3b2a946e800"
      unitRef="U_USD">0</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_bd93a1c7-de31-426f-8731-c88a660e9e41"
      unitRef="U_USD">74000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_ba10a5ec-dcdd-426e-88d9-a04929e8b675"
      unitRef="U_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_2f0056a5-0123-422d-99dc-c065e6aa95ca"
      unitRef="U_USD">6354000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_34f5f3b6-d3e8-441f-95be-91bcd3dc8654"
      unitRef="U_USD">1192000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_c8348152-a5d1-4c9f-ba99-ea127b7af8bf"
      unitRef="U_USD">869000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_a7d49d84-e295-4e7c-b350-b11a470d02e8"
      unitRef="U_USD">147000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_0a936472-33e7-4070-8ae7-2e340ad2ed9e"
      unitRef="U_USD">1762000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestAndDividendsPayableCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_7847be7b-6dc5-4283-9a3e-fa462a0bfb70"
      unitRef="U_USD">0</us-gaap:InterestAndDividendsPayableCurrent>
    <us-gaap:InterestAndDividendsPayableCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_cd3e7e6d-18ca-4cf7-b872-3e39582b0a2f"
      unitRef="U_USD">59000</us-gaap:InterestAndDividendsPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_32dc3532-5f95-47a0-9f5a-a2cb430840b9"
      unitRef="U_USD">3314000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_7dc13bd4-a545-4e5a-91a7-7ff6a589115b"
      unitRef="U_USD">14220000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_99776cdf-ad61-4b58-8201-9e938ac4bc70"
      unitRef="U_USD">6949000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_fadae0cf-d08a-466d-b736-a873510fa9bd"
      unitRef="U_USD">8142000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_c167e0cf-897e-4860-a0b2-5d0e9ef45513"
      unitRef="U_USD">10263000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_05b71ed8-3171-451a-8851-95c0083bb5da"
      unitRef="U_USD">22362000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_4013ee34-8236-408b-82f9-a727a80e1cc7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="INF"
      id="F_bc06d075-b296-4568-9617-96e61a67bbba"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_6de793cc-8edd-4b6e-a6c2-583538e4e388"
      unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="INF"
      id="F_d1e2e04b-6071-4c33-b913-e4fcdc85257c"
      unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_ef02e0d9-4617-46db-8a78-ab8ec21df597"
      unitRef="U_shares">4927161</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_7ad5425e-c6af-420c-a289-ade0ad3f78d4"
      unitRef="U_shares">4927161</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="INF"
      id="F_a825041d-7b1a-4e40-93a7-71735bfc1683"
      unitRef="U_shares">3382432</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="INF"
      id="F_c49487f4-c674-42b2-8689-808d4378f62d"
      unitRef="U_shares">3382432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_9cee43fb-5ccc-4e36-909b-199a1d954e50"
      unitRef="U_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_9095b77b-8616-4328-bf62-7772ddb0da59"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_7a823370-0688-4ec5-a3c3-9cc56cb1fa4d"
      unitRef="U_USD">240031000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_d279497e-f43f-4de1-9102-97489a93c8f2"
      unitRef="U_USD">226229000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_07f4055f-0878-44ce-8210-0f1a31ec7665"
      unitRef="U_USD">-233368000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_bd61f735-4de0-45ca-ba9e-78292d2d7859"
      unitRef="U_USD">-207106000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_84885503-d27a-47ef-9f5c-5fa0c61f0fd8"
      unitRef="U_USD">6668000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_7b5dde92-d256-44bd-9581-1ac29b0d66b2"
      unitRef="U_USD">19126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_e300e6ea-5f36-4366-97d1-1a385c11e18d"
      unitRef="U_USD">16931000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_a56b0e22-87f7-4cce-b86c-d6ad631f5c85"
      unitRef="U_USD">41488000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_83ad0427-46c9-40f3-8ea3-599adc8b0338"
      id="F_6adafa2d-ee1b-4d9d-9637-e18cd2281e36">one-for-thirteen</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_dfa800ab-ff4e-47fb-9626-44e375380d21"
      unitRef="U_USD">12606000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_3d5559be-483b-45de-970a-6e3024c9dfd9"
      unitRef="U_USD">28476000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_02c49138-adae-4482-b5f8-854c31c08ce5"
      unitRef="U_USD">13969000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_8df0ec52-8d4b-4261-9c91-9a9374d7f555"
      unitRef="U_USD">13550000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_a0a6c4d8-601d-4314-8add-530629bd10f0"
      unitRef="U_USD">-26575000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_44520852-5123-43f1-82d6-76c75a507385"
      unitRef="U_USD">-42026000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_45f94701-b18c-4f79-9876-028ece12f11d"
      unitRef="U_USD">207000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_458530c6-814d-45ea-97ae-0a4a7f3e1233"
      unitRef="U_USD">1316000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_795a930c-43ac-4f3c-8977-23ccfe2fb346"
      unitRef="U_USD">520000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_c413fba0-5cc0-4ecc-ae75-d084956d6a83"
      unitRef="U_USD">1499000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_9b6f9539-98eb-4f6d-aec9-7a1d6f805516"
      unitRef="U_USD">313000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_151f2354-08b7-410f-a4ac-905f33fa4685"
      unitRef="U_USD">183000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_04a3c696-619c-42f5-b4c1-e65bd1598a70"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_c63df706-1748-4ce1-8031-7115476c52fb"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_4e518c21-3dd8-45cf-9d2d-1a75dcb0b632"
      unitRef="U_USD">-26262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_dfc3ea47-86ce-4d47-b630-44e0e8076fbf"
      unitRef="U_USD">-41843000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="2"
      id="F_c6e60cb1-7625-45d8-890d-f502ccb2045a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-6.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="2"
      id="F_06d8a560-9214-464d-ad7f-d5ceb179abd3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-6.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="2"
      id="F_6448a7f3-d0ae-4461-bf4e-c13a95ec4ec0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-19.5</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="2"
      id="F_b454cb84-8963-4090-ad49-9160d559a804"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-19.5</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="0"
      id="F_97f8f9d8-ccc1-41b2-99d2-edaf2bb90a5a"
      unitRef="U_shares">4149733</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="0"
      id="F_a4deed85-14a1-438a-b3cd-6a644a58efa7"
      unitRef="U_shares">4149733</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="0"
      id="F_5b799a36-beb6-4e4c-98b2-34a6c04e7709"
      unitRef="U_shares">2146276</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="0"
      id="F_a0c20a1c-3071-4a19-adb9-c780da554e35"
      unitRef="U_shares">2146276</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_83ad0427-46c9-40f3-8ea3-599adc8b0338"
      id="F_746f33fe-fb05-4adc-b8a4-cd6a7ebf54fa">one-for-thirteen</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SharesOutstanding
      contextRef="C_06328e98-1580-41cc-a910-5db61b65b8fe"
      decimals="INF"
      id="F_deb034ee-1ce5-4660-b1ff-6565a703b6c0"
      unitRef="U_shares">1695788</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_06328e98-1580-41cc-a910-5db61b65b8fe"
      decimals="-3"
      id="F_b42365a0-32ef-4d2a-afb4-37ca6f666a0f"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_62d04cb4-5a63-46ed-a664-419caec2a7a0"
      decimals="-3"
      id="F_752287a4-7e99-4e43-aea7-2cf109f6388f"
      unitRef="U_USD">192029000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ee9ba139-9295-4f17-8cd1-d43d46ee649d"
      decimals="-3"
      id="F_b21e6b15-3d12-4408-a953-a3ef68d63943"
      unitRef="U_USD">-165263000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b"
      decimals="-3"
      id="F_122135c1-c10f-49b7-b270-7e4ac2dd08b1"
      unitRef="U_USD">26768000</us-gaap:StockholdersEquity>
    <tpst:StockIssuanceCosts
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_12c14a01-5590-4e1a-a6d0-0a6b97deb82b"
      unitRef="U_USD">1105000</tpst:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9031d7bf-fa77-4e96-815d-3e2cf8c46a92"
      decimals="INF"
      id="F_27531bba-54fa-42b6-b8ad-71688d4e0f82"
      unitRef="U_shares">1663554</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9031d7bf-fa77-4e96-815d-3e2cf8c46a92"
      decimals="-3"
      id="F_9b5e468a-7a63-4681-8e1c-57b1a4eb3585"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_27158267-e15b-4d03-925a-581587ce58e0"
      decimals="-3"
      id="F_8fbea954-085e-4929-9b7e-60ac1ebb49b3"
      unitRef="U_USD">28590000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_34efdc33-3757-478d-bf1a-4224af8b2900"
      unitRef="U_USD">28591000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_27158267-e15b-4d03-925a-581587ce58e0"
      decimals="-3"
      id="F_d913b6c3-f5ce-41af-8deb-9a945e46952e"
      unitRef="U_USD">5303000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_b6b0afdd-a781-44f5-bb4a-f95a9be6bef0"
      unitRef="U_USD">5303000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <tpst:IssuanceOfCommonStockSharesUnderEquityPlanAwards
      contextRef="C_9031d7bf-fa77-4e96-815d-3e2cf8c46a92"
      decimals="INF"
      id="F_3788bf6c-3a4f-44f2-9bf9-3b4dcdb41289"
      unitRef="U_shares">23090</tpst:IssuanceOfCommonStockSharesUnderEquityPlanAwards>
    <tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards
      contextRef="C_27158267-e15b-4d03-925a-581587ce58e0"
      decimals="-3"
      id="F_487a9565-f187-4f49-8711-72c292e1b871"
      unitRef="U_USD">307000</tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards>
    <tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_4520479d-bfae-43d9-bdbc-f1ef04e92f46"
      unitRef="U_USD">307000</tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards>
    <us-gaap:NetIncomeLoss
      contextRef="C_8ff57b73-22de-44f4-b372-68161891a853"
      decimals="-3"
      id="F_0855fa8e-edb1-4b1c-923e-7a2ef09e7bff"
      unitRef="U_USD">-41843000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_b5dc921b-f6c9-406a-8ba8-75c7a1cda353"
      unitRef="U_USD">-41843000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_5637d434-2834-4e0a-be2f-fed606708f35"
      decimals="INF"
      id="F_4b4f5945-1a0f-4c72-8a16-e7bfba68263d"
      unitRef="U_shares">3382432</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5637d434-2834-4e0a-be2f-fed606708f35"
      decimals="-3"
      id="F_185932d9-88b6-4e9c-b712-af4da160f375"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3ac82a9a-bb9c-42a2-a8f7-52fd9198caf3"
      decimals="-3"
      id="F_8d0697dd-a1d0-44c6-9ca8-8c80df509bc3"
      unitRef="U_USD">226229000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_65c167d4-fb8b-486d-a124-daec790a028c"
      decimals="-3"
      id="F_017e31eb-d163-4eb2-ad37-b42aa72aff16"
      unitRef="U_USD">-207106000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_4689e5e5-9c8a-4547-8713-cf6f78c8a0b5"
      unitRef="U_USD">19126000</us-gaap:StockholdersEquity>
    <tpst:StockIssuanceCosts
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_a8197f69-05d1-4da8-9e7b-627dabdbf922"
      unitRef="U_USD">535000</tpst:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_5380a6a2-f90a-47a7-8a71-4bbe6510990f"
      decimals="INF"
      id="F_dfb43dd2-f338-4fc0-8213-45aa0d6716d4"
      unitRef="U_shares">1204774</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5380a6a2-f90a-47a7-8a71-4bbe6510990f"
      decimals="-3"
      id="F_95c135e1-af53-434e-ba3d-7cf382b0b536"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7bc99182-65b5-47d2-9586-940c0ab19557"
      decimals="-3"
      id="F_7a5d85ac-912f-4efb-948b-07e2d13ec4ec"
      unitRef="U_USD">6045000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_e7b366de-50c3-4f01-b2f3-7a24e5abfb77"
      unitRef="U_USD">6047000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_7bc99182-65b5-47d2-9586-940c0ab19557"
      decimals="-3"
      id="F_778e11f4-be7e-4cab-a85d-b7901716a2be"
      unitRef="U_USD">3118000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_38d7a618-9c61-4697-a06f-eb03db3aabf2"
      unitRef="U_USD">3118000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <tpst:Pre-FundedWarrantsIssuanceCost
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_4a68e08c-c7ce-4024-bb5f-fc28438d01a5"
      unitRef="U_USD">416000</tpst:Pre-FundedWarrantsIssuanceCost>
    <tpst:IssuanceOfPre-FundedWarrantShares
      contextRef="C_5380a6a2-f90a-47a7-8a71-4bbe6510990f"
      decimals="INF"
      id="F_a462288b-bed1-42c8-aa73-735832d06c53"
      unitRef="U_shares">334000</tpst:IssuanceOfPre-FundedWarrantShares>
    <tpst:IssuanceOfPre-FundedWarrantValue
      contextRef="C_7bc99182-65b5-47d2-9586-940c0ab19557"
      decimals="-3"
      id="F_491435e4-3c7a-420e-bb0d-7fc0fc485461"
      unitRef="U_USD">3309000</tpst:IssuanceOfPre-FundedWarrantValue>
    <tpst:IssuanceOfPre-FundedWarrantValue
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_55372564-7cc1-4c94-8ca2-aca835e26309"
      unitRef="U_USD">3309000</tpst:IssuanceOfPre-FundedWarrantValue>
    <tpst:WarrantsIssuanceCost
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_2a9941dd-1471-45ca-baf1-2badd4c50b57"
      unitRef="U_USD">165000</tpst:WarrantsIssuanceCost>
    <tpst:IssuanceOfCommonStockWarrants
      contextRef="C_7bc99182-65b5-47d2-9586-940c0ab19557"
      decimals="-3"
      id="F_9b50220b-9e2f-4e3d-86b7-100b86a06f33"
      unitRef="U_USD">1283000</tpst:IssuanceOfCommonStockWarrants>
    <tpst:IssuanceOfCommonStockWarrants
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_277cc70b-62a9-4c68-8725-b5de169089ea"
      unitRef="U_USD">1283000</tpst:IssuanceOfCommonStockWarrants>
    <tpst:IssuanceOfCommonStockSharesUnderEquityPlanAwards
      contextRef="C_5380a6a2-f90a-47a7-8a71-4bbe6510990f"
      decimals="INF"
      id="F_0682ce31-7e6b-4a2c-b4ff-617aabfe1ce9"
      unitRef="U_shares">5955</tpst:IssuanceOfCommonStockSharesUnderEquityPlanAwards>
    <tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards
      contextRef="C_7bc99182-65b5-47d2-9586-940c0ab19557"
      decimals="-3"
      id="F_abb286dd-bd06-40d2-a7cd-5a87d166e339"
      unitRef="U_USD">47000</tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards>
    <tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_f83e5338-9a5e-4d60-aed1-bee2d2719629"
      unitRef="U_USD">47000</tpst:IssuanceOfCommonStockValueUnderEquityPlanAwards>
    <us-gaap:NetIncomeLoss
      contextRef="C_9f019654-8ffe-45bb-a4e5-13052063f719"
      decimals="-3"
      id="F_d226580f-a494-40a7-93c9-4db01f623ba6"
      unitRef="U_USD">-26262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_440e188d-ad84-4c07-8623-db11d901eae3"
      unitRef="U_USD">-26262000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_ad6d3810-e138-47f4-b494-587bf0b0da1a"
      decimals="INF"
      id="F_3ab235ab-b734-4cbd-9281-bb73d72e9afb"
      unitRef="U_shares">4927161</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ad6d3810-e138-47f4-b494-587bf0b0da1a"
      decimals="-3"
      id="F_61dae98f-89b0-4eab-b520-94706c44c865"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a94b87ad-49e1-4a01-a0e5-9ac323ad9f6b"
      decimals="-3"
      id="F_870058e3-ac45-40b7-b81b-13c6c0eff3f3"
      unitRef="U_USD">240031000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_71ec2d54-80b0-474c-b65c-486a56573a94"
      decimals="-3"
      id="F_02b6a170-e6fa-416d-ac93-80af0d18d338"
      unitRef="U_USD">-233368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_72b55801-b7d4-4dec-b6f4-636f283877f3"
      unitRef="U_USD">6668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_83ad0427-46c9-40f3-8ea3-599adc8b0338"
      id="F_c36b434a-023d-4c79-a3a8-17f6089a4103">one-for-thirteen</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ProfitLoss
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_1a129d77-bfc3-495c-8c7f-fd466c41bf44"
      unitRef="U_USD">-26262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_f7025527-f95c-40dd-ab03-fb28483d46d6"
      unitRef="U_USD">-41843000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_fb60e182-eaa3-48b0-8c9a-46bfbf4a0155"
      unitRef="U_USD">266000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_fecfecfd-eecb-4d35-9e76-e2660c7e4837"
      unitRef="U_USD">389000</us-gaap:Depreciation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_376febd6-7c30-4bf7-8e75-6440df9aa9d6"
      unitRef="U_USD">3118000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_aa5c2fb0-d937-4ad8-9c1c-21b752ab8263"
      unitRef="U_USD">5303000</us-gaap:AllocatedShareBasedCompensationExpense>
    <tpst:NoncashLeaseExpense
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_299bd61c-d6de-4ccd-ab0b-1f36820582cf"
      unitRef="U_USD">1103000</tpst:NoncashLeaseExpense>
    <tpst:NoncashLeaseExpense
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_dcca4ded-52f0-4184-b93e-26ed4f8bde6c"
      unitRef="U_USD">1309000</tpst:NoncashLeaseExpense>
    <tpst:NoncashInterestAndOtherExpenseNet
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_79b7db5e-6939-4939-ab7a-6e9375161b8e"
      unitRef="U_USD">85000</tpst:NoncashInterestAndOtherExpenseNet>
    <tpst:NoncashInterestAndOtherExpenseNet
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_8a81f6dc-c5c8-4998-88e4-673b79d9c3d7"
      unitRef="U_USD">202000</tpst:NoncashInterestAndOtherExpenseNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_e97cc797-8f85-475d-9564-8578d97adc17"
      unitRef="U_USD">-615000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_a843a280-da38-44d2-9025-f4112f415645"
      unitRef="U_USD">110000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_ed7bb6d1-a7f7-4de5-958b-70aedb16f62d"
      unitRef="U_USD">-1412000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_18ce6673-4e67-482b-822d-5be12a8eadf1"
      unitRef="U_USD">1605000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_b9da7c75-e439-4d79-af89-1f5160a4692f"
      unitRef="U_USD">-3404000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_858a1327-fb14-49d6-965a-ab52aaaf3eb3"
      unitRef="U_USD">1273000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_f033ea76-e6c8-4f8f-adb8-7371de04629b"
      unitRef="U_USD">-59000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_2f1027d4-4efa-410f-86d3-462ce400f3b2"
      unitRef="U_USD">-54000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_242d3544-25c3-489f-8354-ee05bd67473f"
      unitRef="U_USD">-870000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_9ac93702-059e-4f1a-961a-d0ad2dfc92b0"
      unitRef="U_USD">-1101000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_d167881d-990b-4201-b75c-0879b06bdab0"
      unitRef="U_USD">-26820000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_4e6e10ed-541a-4b75-b3b5-9e5f087f165e"
      unitRef="U_USD">-33027000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_385d1c77-2f93-4f4c-b18d-57855dcc99c4"
      unitRef="U_USD">-0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_83593086-0c9b-4a52-9f65-8b86a2b28ecf"
      unitRef="U_USD">435000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_a2cc059a-8491-43ab-ac54-9269e83b8ab8"
      unitRef="U_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_73aaf04d-9152-43c6-87ac-63b95bea72b3"
      unitRef="U_USD">-435000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_0de3ced2-5a67-498d-8111-3040ba924319"
      unitRef="U_USD">6045000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_3769e5fe-6dc0-495b-b092-01c0659ffb87"
      unitRef="U_USD">28591000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_fb114eb9-a7e0-4086-aa0a-fca55f2102ed"
      unitRef="U_USD">3309000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_9050282d-5f01-4920-b112-4ff3d3559fbd"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <tpst:ProceedsFromIssuanceOfCommonStockWarrants
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_27567631-3598-429d-9a5d-85868c37c003"
      unitRef="U_USD">1284000</tpst:ProceedsFromIssuanceOfCommonStockWarrants>
    <tpst:ProceedsFromIssuanceOfCommonStockWarrants
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_8de2c2c7-6e34-4c00-977c-a430ca431c8f"
      unitRef="U_USD">0</tpst:ProceedsFromIssuanceOfCommonStockWarrants>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_e8443224-3061-4418-9c48-6fbc985d4057"
      unitRef="U_USD">6426000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_f19fe438-4430-479e-9ffc-782c087e608b"
      unitRef="U_USD">4398000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_fbf369fa-d18d-4a05-8e57-915c51a1b388"
      unitRef="U_USD">47000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_ff30d48b-ce2f-4340-9e92-d3769c215d81"
      unitRef="U_USD">307000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_493342a6-b70e-4f54-a46b-b739629293a8"
      unitRef="U_USD">4259000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_31e98d6c-b425-48c9-a671-8a33a8f9d499"
      unitRef="U_USD">24500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_a5a3ae2e-7c03-4f96-8163-626e70f798bd"
      unitRef="U_USD">-22561000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_1e23d547-278f-4ccf-b7cc-6b326279a42c"
      unitRef="U_USD">-8962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_870b727f-9100-40a9-b33b-b573c9075b5a"
      unitRef="U_USD">30711000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b"
      decimals="-3"
      id="F_8a1bef66-dc06-4fa9-910a-2b6ca561431c"
      unitRef="U_USD">39673000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_2fc2ed94-cf31-47a5-b968-4933cd44c777"
      unitRef="U_USD">8150000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_bb3c75d4-8c8e-4215-a9ed-f14b081a6285"
      unitRef="U_USD">30711000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_77dc302a-529c-4452-b150-598877e77240"
      unitRef="U_USD">192000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_b132dd22-96ba-4123-8149-aba9f52cb6f5"
      unitRef="U_USD">1177000</us-gaap:InterestPaidNet>
    <tpst:Corporatetaxespaid
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_2595f321-e6eb-403c-bfb5-219fc8e866af"
      unitRef="U_USD">43000</tpst:Corporatetaxespaid>
    <tpst:Corporatetaxespaid
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_b95920b3-2d74-486b-a274-85b3dd6af6a7"
      unitRef="U_USD">54000</tpst:Corporatetaxespaid>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_72e695b3-abb4-4fea-8974-13a0607d889d"
      unitRef="U_USD">0</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_1af23daa-0e42-4f6c-a6bd-da935d37ddb3"
      unitRef="U_USD">0</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_40ddd2dc-7ef3-4b75-9e81-f305adbec75d">&lt;p id="section28" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Tempest Therapeutics, Inc. (&#x201c;Tempest&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biotechnology company advancing a diverse portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a wide range of cancers. Tempest&#x2019;s portfolio includes both cell therapy and small molecule product candidates spanning discovery through late-stage development. The Company is headquartered in Brisbane, California.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 3, 2024, the Company&#x2019;s stockholders approved a proposal to effect an amendment to the Company&#x2019;s Restated Certificate of Incorporation to implement a reverse stock split. On April 4, 2025, the Company filed a certificate of amendment to the Company&#x2019;s Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the one-for-thirteen (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6e1cc23c-49a3-467c-968a-b436b08a6a1b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:13) reverse stock split of its outstanding common stock (the "Reverse Stock Split").&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 8, 2025, the Company effected the Reverse Stock Split. Pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company&#x2019;s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company&#x2019;s equity incentive plans have been reduced proportionately. The Reverse Stock Split did not reduce the number of authorized shares of common stock and did not alter the par value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would have otherwise been entitled to receive a fractional share received a cash payment in lieu thereof. The Reverse Stock Split affected all stockholders proportionately and did not affect any stockholder&#x2019;s percentage ownership of the Company&#x2019;s common stock (except to the extent that the Reverse Stock Split resulted in any stockholder owning only a fractional share).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has incurred operating losses since inception. As of December 31, 2025, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of cash and cash equivalents. While the Company implemented cost reductions in 2025, the Company has finite cash resources available to fund its operations. In &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_9df2eff9-6afb-4328-8d1e-a0eef5583eb8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company announced plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. The Company retained MTS Health Partners, L.P., an internationally recognized financial advisor with substantial experience in the biotechnology industry, to support it with the strategic evaluation process. As part of the cost reductions, the Company reduced its workforce by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; full-time employees, which became effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Further, in support of such efforts, on June 5, 2025, each of Stephen Brady, the Company&#x2019;s Chief Executive Officer and President, Samuel Whiting, the Company&#x2019;s Executive Vice President and Chief Medical Officer, and Nicholas Maestas, the Company&#x2019;s Chief Financial Officer and Head of Corporate Strategy, transitioned to consulting arrangements with the Company, pursuant to which they continued to serve the Company in their respective executive roles. The Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of one-time cash severance payments, benefits and other related costs (excluding non-cash charges associated with stock-based compensation), with the majority of such costs incurred in the second quarter of 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 3, 2026, the Company closed the Asset Acquisition (as defined below). See Note 13, Subsequent Events. Pursuant to the Asset Purchase Agreement (as defined below), Factor (as defined below) has made the Funding Commitment (as defined below) to provide the Company with financial support for at least 18 months following the closing of the Asset Acquisition, up to a maximum amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;that is inclusive of any amounts raised and received by the Company after the date of the Asset Purchase Agreement, on the terms and subject to the conditions and other provisions of a funding commitment letter contemplated by and entered into concurrently with the Asset Purchase Agreement. However, there is significant uncertainty as&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;whether we will be able to satisfy the terms and conditions and other provisions set forth in the funding commitment letter, and, if we are unable to do so, we may be limited in the amount of funding that we are able to access under the Funding Commitment or we may not be able to access any funds under the Funding Commitment. The timing of any additional funding from Factor is uncertain.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expects that its existing cash and cash equivalents will fund the Company&#x2019;s projected operating expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued. Accordingly, there is substantial doubt about the Company&#x2019;s ability to continue to operate as a going concern for a period of 12 months from the date of issuance of these consolidated financial statements. The accompanying financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any separate adjustments relating to the recovery of recorded assets or the classification of liabilities; however, such adjustments may be necessary in the future when the Company is unable to continue as a going concern.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ATM Program&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 23, 2021, the Company entered into a sales agreement with Jefferies LLC (&#x201c;Jefferies&#x201d;), pursuant to which the Company may sell, from time to time at its sole discretion through Jefferies, as its sales agent, shares of its common stock having, up to an aggregate sales price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of its common stock through Jefferies (the &#x201c;Prior ATM Program&#x201d;). As of June 20, 2024, the Company had sold an aggregate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,017,110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million net of commissions and estimated expenses) under the Prior ATM Program. On June 20, 2024, the Company and Jefferies terminated the Prior ATM Program and entered a new Open Market Sale Agreement (the &#x201c;Sales Agreement&#x201d;) to sell shares of common stock from time to time through Jefferies acting as sales agent (the &#x201c;ATM Program&#x201d;). The Company will pay Jefferies a commission up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the gross sales proceeds of any shares of its common stock sold through Jefferies under the ATM Program and also has provided Jefferies with indemnification and contribution rights.  Pursuant to the prospectus supplement dated June 20, 2024 filed by the Company with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;), the Company was able to offer and sell up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;205.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of its shares of common stock pursuant to the Sales Agreement. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; On February 6, 2025, the Company filed a prospectus supplement with the SEC limiting the availability under the ATM Program to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; On June 11, 2025, in connection with the RDO (as defined below), the Company delivered written notice to Jefferies that it was suspending and terminating the prospectus supplement, dated February 6, 2025, related to the ATM Program (the &#x201c;ATM Prospectus&#x201d;). The Company will not make any sales of its securities pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under current SEC regulations, if at any time the Company's public float is less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and for so long as the Company&#x2019;s public float remains less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, the amount the Company can raise through primary public offerings of securities in any 12-month period using shelf registration statements is limited to an aggregate of one-third of the Company's public float, which is referred to as the baby shelf rules. As of the year ended December 31, 2025, the Company has sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;312,830&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock for proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, pursuant to the ATM Program.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Registered Direct Offerings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 11, 2025, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;405,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;334,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(the &#x201c;June 2025 Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in a registered direct offering (&#x201c;June RDO&#x201d;). The offering price was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share of common stock and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.249&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 2025 Pre-Funded Warrant&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which is the price of each share of common stock sold in the RDO, minus the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; exercise price per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 2025 Pre-Funded Warrant&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The net proceeds from the RDO were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting placement agent fees and offering expenses payable by the Company. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, all June 2025 Pre-Funded Warrants had been exercised.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 24, 2025, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;487,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock, pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;685,414&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock (the &#x201c;November 2025 Pre-Funded Warrants&#x201d;) and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,172,414&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(the &#x201c;Common Warrants&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a registered direct offering (the &#x201c;November RDO&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;combined purchase price of each share of common stock and accompanying Common Warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.625&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The combined purchase price of each November 2025 Pre-Funded Warrants and accompanying Common Warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.624&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (equal to the combined purchase price per share of common stock and accompanying Common Warrant, minus $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) The exercise price of the Common Warrants is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The net proceeds from the RDO were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting placement agent fees and estimated offering expenses payable by the Company. As of December 31, 2025, all November 2025 Pre-Funded Warrants and Common Warrants remained outstanding. All November 2025 Pre-Funded Warrants were subsequently exercised in January and February 2026.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-5"
      id="F_682f356d-a0e1-4558-90c5-1552b6a069aa"
      unitRef="U_USD">7700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="C_ec632eae-fdb8-4bbe-ae31-e0618a3ad9ad"
      decimals="INF"
      id="F_8d478ddc-9c9c-4b27-9b21-ee5bad88c4eb"
      unitRef="U_Employees">21</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <tpst:RestructuringAndRelatedCostNumberOfFullTimeEmployees
      contextRef="C_ec632eae-fdb8-4bbe-ae31-e0618a3ad9ad"
      decimals="INF"
      id="F_b41a7aa3-6663-4d32-9512-e5345f3fbb19"
      unitRef="U_Employees">26</tpst:RestructuringAndRelatedCostNumberOfFullTimeEmployees>
    <us-gaap:RestructuringAndRelatedActivitiesCompletionDate
      contextRef="C_ec632eae-fdb8-4bbe-ae31-e0618a3ad9ad"
      id="F_40e40a43-850d-4237-8628-4e4a465d4dd0">2025-04-30</us-gaap:RestructuringAndRelatedActivitiesCompletionDate>
    <us-gaap:SeveranceCosts1
      contextRef="C_a379ad4f-c5be-41b5-b49e-a2850e59bc53"
      decimals="-5"
      id="F_c75da55c-28d3-4952-b39f-06321d3812a8"
      unitRef="U_USD">3200000</us-gaap:SeveranceCosts1>
    <tpst:AssetAcquisitionMaximumFundingCommitment
      contextRef="C_70845e48-f71f-4ea8-8d6e-8b92f4df5950"
      decimals="-5"
      id="F_87e694a0-4821-4f55-816e-4d4d0bb75bc4"
      unitRef="U_USD">20000000</tpst:AssetAcquisitionMaximumFundingCommitment>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_472dac54-6d43-4ba3-b05b-f300ae5059c5"
      decimals="-5"
      id="F_3cd8a4ce-7ff9-4dd6-8a71-ec0c447881c4"
      unitRef="U_USD">100000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssued
      contextRef="C_79115bce-54bc-47dc-8643-ab28b5ab2326"
      decimals="INF"
      id="F_b7b9f1f3-34e3-4a07-9930-14d1ccce4137"
      unitRef="U_shares">9017110</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f1d00723-6493-47bb-9c20-796c424cdfab"
      decimals="-5"
      id="F_8067a6ad-1034-4b66-a1c3-5c3b951ddaf4"
      unitRef="U_USD">42700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <tpst:NetProceedsFromIssuanceOfCommonStock
      contextRef="C_f1d00723-6493-47bb-9c20-796c424cdfab"
      decimals="-5"
      id="F_ba5126a8-2289-4a9e-ae31-755eff75c533"
      unitRef="U_USD">41500000</tpst:NetProceedsFromIssuanceOfCommonStock>
    <tpst:PercentageOfCommissionOnSaleOfStock
      contextRef="C_472dac54-6d43-4ba3-b05b-f300ae5059c5"
      decimals="3"
      id="F_393c9d9b-5917-47da-888f-103a0fdc4a75"
      unitRef="U_pure">0.03</tpst:PercentageOfCommissionOnSaleOfStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0ec6ba97-3919-4714-a934-2525e2f12f8c"
      decimals="-5"
      id="F_88f5c195-79f6-41c4-8ecd-caebf2d421e9"
      unitRef="U_USD">205000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <tpst:RemainedAvailableForIssuanceOfCommonStock
      contextRef="C_40c12f7b-2097-4b34-b237-498396a49865"
      decimals="-5"
      id="F_da3dc099-7d6b-4e33-8014-5354899c5630"
      unitRef="U_USD">14500000</tpst:RemainedAvailableForIssuanceOfCommonStock>
    <tpst:PublicFloat
      contextRef="C_f4bab170-e7d7-4e1f-9859-dfd7e52308cc"
      decimals="-5"
      id="F_6b0b1abe-f28f-4e2b-a84e-552881514dee"
      unitRef="U_USD">75000000</tpst:PublicFloat>
    <tpst:PublicFloat
      contextRef="C_f4bab170-e7d7-4e1f-9859-dfd7e52308cc"
      decimals="-5"
      id="F_3b279fe4-5b17-4753-86b2-2754c37fe555"
      unitRef="U_USD">75000000</tpst:PublicFloat>
    <us-gaap:SharesIssued
      contextRef="C_73aeb815-2afa-4516-9756-8b7f3643ad5d"
      decimals="INF"
      id="F_afb163ed-aed7-4e5d-b149-b89d8df4d8fa"
      unitRef="U_shares">312830</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_6c5a716f-97f5-415f-b72f-9c157e671bc9"
      decimals="-5"
      id="F_98e5db4e-c04e-4314-9632-41ecac17a658"
      unitRef="U_USD">2800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_3baddcb5-d5e9-4033-a4a1-870013c37ef9"
      decimals="INF"
      id="F_20ffc007-b3ea-49b8-beb2-4371743b9620"
      unitRef="U_shares">405000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <tpst:SaleOfStockWarrantsIssued
      contextRef="C_5ac6b064-5ae9-4c1e-a875-a49f5a60bd9e"
      decimals="INF"
      id="F_26b5aed3-40e2-45e0-a7ae-63b1e871766e"
      unitRef="U_shares">334000</tpst:SaleOfStockWarrantsIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_a5315be7-426f-4a35-bc3e-9d8bdffaf36b"
      decimals="INF"
      id="F_64b1da2c-320b-4747-86b4-14a4c9ced044"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_5ac6b064-5ae9-4c1e-a875-a49f5a60bd9e"
      decimals="INF"
      id="F_95669863-450b-47e9-9384-3e31d84b3931"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.249</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5ac6b064-5ae9-4c1e-a875-a49f5a60bd9e"
      decimals="3"
      id="F_6d918bd2-cb01-4584-a2b8-403ec447c37e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_7ca8d315-3fdd-4df9-a57f-592e58b29648"
      decimals="-5"
      id="F_8d369927-eda2-48e9-befa-7d4e86152375"
      unitRef="U_USD">4100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_8c81e754-6ec2-4618-b538-4c6094074920"
      decimals="INF"
      id="F_ada7b591-eed8-4fb7-bb0a-9e3ff7ca7901"
      unitRef="U_shares">487000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <tpst:SaleOfStockWarrantsIssued
      contextRef="C_8a8915cd-0e0b-49eb-b2b3-419b16f12b37"
      decimals="INF"
      id="F_90380e16-6861-4bce-b1af-2f85f393662b"
      unitRef="U_shares">685414</tpst:SaleOfStockWarrantsIssued>
    <tpst:SaleOfStockWarrantsIssued
      contextRef="C_f8276a73-58b9-40f0-8e8c-d2c73f397848"
      decimals="INF"
      id="F_f937c59f-7e2c-4b6f-9018-676511a35b79"
      unitRef="U_shares">1172414</tpst:SaleOfStockWarrantsIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_a6cb3954-c17c-46fe-8f17-edc83f6fb2e0"
      decimals="INF"
      id="F_375e6e7b-2cfa-4a71-836b-829d31432854"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.625</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_8a8915cd-0e0b-49eb-b2b3-419b16f12b37"
      decimals="INF"
      id="F_41f57811-d729-45f6-88ac-2022296585af"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.624</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_8a8915cd-0e0b-49eb-b2b3-419b16f12b37"
      decimals="3"
      id="F_0105305d-c54b-41d9-bb1b-cecce089cef3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f8276a73-58b9-40f0-8e8c-d2c73f397848"
      decimals="INF"
      id="F_721f765c-20c1-4fa6-8d0e-9bd549f3110a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_9b1ec7d9-4f7f-4128-b459-36816f64018b"
      decimals="-5"
      id="F_fc5b9d5f-422c-48bd-abba-f9dd0e4b2f16"
      unitRef="U_USD">3800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_0d7e37a0-bab5-4d6c-931f-b040800c466f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The accompanying Consolidated Financial Statements have been prepared in accordance with US generally accepted accounting principles ("GAAP") and necessarily include amounts based on estimates and assumptions by management.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company operates and manages its business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable and operating segment, which is the business of discovery and development of small molecule drugs to treat cancers. All assets and operations are in the U.S. The Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_05603c4a-63ad-49f7-8c55-20c2929846cf;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, who is the chief operating decision maker (&#x201c;CODM&#x201d;), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. For additional segment information, see Note 12, Segment Reporting.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors, availability of raw materials, patentability of the Company&#x2019;s products and processes and clinical efficacy and safety of the Company&#x2019;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company&#x2019;s product candidates are still in development and, to date, none of the Company&#x2019;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Financial &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;instruments, which potentially subject the Company to concentration of risk, consist principally of cash and money market fund. All of the Company&#x2019;s cash and money market fund are deposited in accounts with a major financial institution in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents to the extent recorded in the balance sheets. The Company has no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;off-balance &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisitions to be cash equivalents. As of  December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company&#x2019;s cash and cash equivalents consisted of bank deposits and money market funds.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company determines if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the customer has the right to control the use of the identified asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. When readily determinable, the Company uses the implicit rate in determining the present value of lease payments. When leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date, including the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The right-of-use (&#x201c;ROU&#x201d;) asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Property and equipment is recorded at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Upon disposal of an asset, the related cost and accumulated depreciation are removed from the asset accounts and any resulting gain or loss is included in the consolidated statements of operations. Repair and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated useful lives of the Company&#x2019;s respective assets are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:40.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:59.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_73e1d41b-207d-4eef-a0f5-e1ba66b3ef90;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of the useful life of the asset or the life of the lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Long-lived assets are reviewed for impairment if events or circumstances indicate the carrying amount of these assets may not be recoverable. If this review indicates that these assets will not be recoverable, based on the forecasted undiscounted future operating cash flows expected to result from the use of long-lived assets and their eventual disposition, the Company&#x2019;s carrying value of the long-lived assets is reduced to fair value based on a discounted future cash flow approach or quoted market values.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses and Accrued Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Research and development expenses are charged to expense as incurred. Research and development expenses include certain payroll and personnel expenses including stock-based compensation, laboratory supplies, consulting costs, external contract research and development expenses and facility or lease expenses. In-licensing fees and other costs to acquire technologies that are utilized in research and development, and that are not expected to have alternative future use, are expensed when incurred. Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers, the Company&#x2019;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These patent-related legal costs are reported as a component of general and administrative expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;General and administrative costs are expensed as incurred and include employee-related expenses including salaries, benefits, travel and stock-based compensation for the Company&#x2019;s personnel in executive, finance and accounting, and other administrative functions, as well as fees paid for legal, accounting and tax services, consulting fees and facilities costs not otherwise included in research and development expenses. Legal costs include general corporate legal fees and patent costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#x2019;s financial instruments approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all share-based payments made to employees, directors and non-employees based on estimated grant-date fair values. The Company uses the straight-line method to allocate compensation cost to reporting periods over each optionee&#x2019;s requisite service period, which is generally the vesting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimates the fair value of stock options to employees, directors and non-employees using the Black-Scholes option-valuation model. The Black-Scholes model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, risk-free rate of return, and the fair value of the underlying common stock on the date of grant. Due to the lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The group of representative companies have characteristics similar to the Company, including stage of product development and focus on the life science industry. The Company uses the simplified method to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company follows the two-class method when computing net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding stock options, convertible preferred stock and warrants to purchase shares of convertible preferred stock are considered potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2025 and 2024, the Company has recorded a full valuation allowance on its deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; which requires public entities to disclose specific tax rate reconciliation categories, as well as income taxes paid disaggregated by jurisdiction, amongst other disclosure enhancements. The ASU is effective for financial statements issued for annual periods beginning after December 15, 2024, with early adoption permitted. We adopted the ASU retrospectively for the period ending December 31, 2025, and it affects only our disclosures and does not impact our results of operations or financial condition.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_38e3599a-7792-4061-98ba-fb1e07f0f4a1">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The accompanying Consolidated Financial Statements have been prepared in accordance with US generally accepted accounting principles ("GAAP") and necessarily include amounts based on estimates and assumptions by management.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_06f0f3de-c69b-4b5e-a053-ee5443e7ac5d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_e44fd417-881e-4fb6-ba12-96bdd91d4583">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company operates and manages its business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable and operating segment, which is the business of discovery and development of small molecule drugs to treat cancers. All assets and operations are in the U.S. The Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_05603c4a-63ad-49f7-8c55-20c2929846cf;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, who is the chief operating decision maker (&#x201c;CODM&#x201d;), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. For additional segment information, see Note 12, Segment Reporting.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="INF"
      id="F_d914ab86-53d5-42af-be73-0174df85a58e"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="INF"
      id="F_ae69006e-93a3-4b03-aa3b-f1a5e9530ccf"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <tpst:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_e98e3528-a3ec-4782-a301-e81e4c88e592">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors, availability of raw materials, patentability of the Company&#x2019;s products and processes and clinical efficacy and safety of the Company&#x2019;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company&#x2019;s product candidates are still in development and, to date, none of the Company&#x2019;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.&lt;/span&gt;&lt;/p&gt;</tpst:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_3a03beaf-f080-4c1c-b68f-a1803de939e8">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Financial &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;instruments, which potentially subject the Company to concentration of risk, consist principally of cash and money market fund. All of the Company&#x2019;s cash and money market fund are deposited in accounts with a major financial institution in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents to the extent recorded in the balance sheets. The Company has no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;off-balance &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_0e2d67d8-ddb2-4d4c-aa0d-658dc3c0decd">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisitions to be cash equivalents. As of  December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company&#x2019;s cash and cash equivalents consisted of bank deposits and money market funds.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_ec5de951-8f9e-4e68-892c-d894b75a7ca8">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company determines if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the customer has the right to control the use of the identified asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. When readily determinable, the Company uses the implicit rate in determining the present value of lease payments. When leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date, including the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The right-of-use (&#x201c;ROU&#x201d;) asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_8edf8a65-0cb4-496f-a588-d8aead18a11f">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Property and equipment is recorded at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Upon disposal of an asset, the related cost and accumulated depreciation are removed from the asset accounts and any resulting gain or loss is included in the consolidated statements of operations. Repair and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <tpst:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_103b4d4e-fc30-48f6-ac51-8ec8160bbd7a">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated useful lives of the Company&#x2019;s respective assets are as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:40.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:59.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0.037in;vertical-align:bottom;padding-bottom:0in;padding-right:0.037in;"&gt;&lt;p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:1.5pt;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_73e1d41b-207d-4eef-a0f5-e1ba66b3ef90;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of the useful life of the asset or the life of the lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</tpst:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f01f9f21-5e95-48cc-83bd-51259e351e7a"
      id="F_ad5d93d1-03e5-452c-8b94-3bde40e2c28c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0914ade8-ff10-4219-ba68-53e47ff2c071"
      id="F_37f4e70b-6f83-4b85-9e5b-4a449454b48f">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_172aae3a-09ec-40f0-8e3c-93da515273fc"
      id="F_40b22d30-45d7-4668-bdb9-e3a7f01f21ad">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_8c6425c9-d8e7-4d14-8d02-2a3bdf0abe73">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Long-lived assets are reviewed for impairment if events or circumstances indicate the carrying amount of these assets may not be recoverable. If this review indicates that these assets will not be recoverable, based on the forecasted undiscounted future operating cash flows expected to result from the use of long-lived assets and their eventual disposition, the Company&#x2019;s carrying value of the long-lived assets is reduced to fair value based on a discounted future cash flow approach or quoted market values.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_35463e5a-bbb7-4b1b-bab5-3d38dd9847a3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses and Accrued Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Research and development expenses are charged to expense as incurred. Research and development expenses include certain payroll and personnel expenses including stock-based compensation, laboratory supplies, consulting costs, external contract research and development expenses and facility or lease expenses. In-licensing fees and other costs to acquire technologies that are utilized in research and development, and that are not expected to have alternative future use, are expensed when incurred. Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers, the Company&#x2019;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <tpst:PatentCostsPolicyPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_8e768b6f-5e32-4756-995e-c4d6ba4d2def">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These patent-related legal costs are reported as a component of general and administrative expenses.&lt;/span&gt;&lt;/p&gt;</tpst:PatentCostsPolicyPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_de4e138d-ec44-407f-a6e0-570a652a01b1">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;General and administrative costs are expensed as incurred and include employee-related expenses including salaries, benefits, travel and stock-based compensation for the Company&#x2019;s personnel in executive, finance and accounting, and other administrative functions, as well as fees paid for legal, accounting and tax services, consulting fees and facilities costs not otherwise included in research and development expenses. Legal costs include general corporate legal fees and patent costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_c28da51f-7e3f-43c2-af01-5cf0e9a3e991">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#x2019;s financial instruments approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_aa1b8769-54e6-47c5-bfc2-7f9c6b4d0ac9">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all share-based payments made to employees, directors and non-employees based on estimated grant-date fair values. The Company uses the straight-line method to allocate compensation cost to reporting periods over each optionee&#x2019;s requisite service period, which is generally the vesting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimates the fair value of stock options to employees, directors and non-employees using the Black-Scholes option-valuation model. The Black-Scholes model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, risk-free rate of return, and the fair value of the underlying common stock on the date of grant. Due to the lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The group of representative companies have characteristics similar to the Company, including stage of product development and focus on the life science industry. The Company uses the simplified method to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_454d2a26-b480-4c06-b5b9-88cbc6faf9c9">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company follows the two-class method when computing net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding stock options, convertible preferred stock and warrants to purchase shares of convertible preferred stock are considered potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_3c35e2e2-7c59-4399-bfb7-677cd9c7b653">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2025 and 2024, the Company has recorded a full valuation allowance on its deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_7cc6342e-9846-4ec9-8855-58093638d797">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; which requires public entities to disclose specific tax rate reconciliation categories, as well as income taxes paid disaggregated by jurisdiction, amongst other disclosure enhancements. The ASU is effective for financial statements issued for annual periods beginning after December 15, 2024, with early adoption permitted. We adopted the ASU retrospectively for the period ending December 31, 2025, and it affects only our disclosures and does not impact our results of operations or financial condition.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_8370cd4b-0603-4872-92e2-412b1d2f81bf">&lt;p id="section31" style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present the Company&#x2019;s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_6803e81e-6f03-4f2a-843b-d7b426e18c7e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present the Company&#x2019;s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_593fb7f1-b481-4017-9df8-af3cd7cf78c1"
      decimals="-3"
      id="F_7f8e0a1b-3917-48e2-818c-d0d372f62557"
      unitRef="U_USD">7707000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_83e9d5ae-1ac2-4dfe-901d-1fb708223a37"
      decimals="-3"
      id="F_d6993a35-6ef9-49a2-b9b0-d83832bc67e6"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4bcca309-5038-498e-a62b-782042e16268"
      decimals="-3"
      id="F_a85b7df1-30b5-4274-942e-2338e44009f1"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_9b755a49-74f8-491a-8e35-1ea2c98f61f7"
      decimals="-3"
      id="F_abc80f9f-115b-435c-a4fb-30ec2c7c5066"
      unitRef="U_USD">7707000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_593fb7f1-b481-4017-9df8-af3cd7cf78c1"
      decimals="-3"
      id="F_6137ef6e-1838-419e-99fa-4ddb8486e653"
      unitRef="U_USD">7707000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_83e9d5ae-1ac2-4dfe-901d-1fb708223a37"
      decimals="-3"
      id="F_106567d5-017f-4626-83f5-9b091263fb8f"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4bcca309-5038-498e-a62b-782042e16268"
      decimals="-3"
      id="F_718888f1-5852-4172-af73-4e9e408dd1f1"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9b755a49-74f8-491a-8e35-1ea2c98f61f7"
      decimals="-3"
      id="F_b6bcaec7-120b-4510-8578-db305952010e"
      unitRef="U_USD">7707000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e9697112-510d-4538-addd-de1c50b2db0d"
      decimals="-3"
      id="F_fea32db1-b4a8-478f-b84a-a56caebeacfc"
      unitRef="U_USD">30268000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1da28e56-a036-4c1c-9957-b3069151a0bc"
      decimals="-3"
      id="F_d2db810b-f970-4f21-b5e3-1dfeab9ebc74"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b90d1f82-feeb-4b7e-b350-61e27474eff0"
      decimals="-3"
      id="F_b32e8cff-3aa2-4a9c-b000-87fc89ed101e"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0b479aa9-6c7e-49ea-a261-63a2a337465f"
      decimals="-3"
      id="F_65be45a7-c715-4d29-9aa8-6028ae64336c"
      unitRef="U_USD">30268000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e9697112-510d-4538-addd-de1c50b2db0d"
      decimals="-3"
      id="F_0d0b19fa-54f9-4226-88e3-c7a07675cbbd"
      unitRef="U_USD">30268000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1da28e56-a036-4c1c-9957-b3069151a0bc"
      decimals="-3"
      id="F_5ef8d228-03ea-4011-b5f0-891fa111ac66"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b90d1f82-feeb-4b7e-b350-61e27474eff0"
      decimals="-3"
      id="F_f4f71df9-1e3d-4d67-92a4-055492395466"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0b479aa9-6c7e-49ea-a261-63a2a337465f"
      decimals="-3"
      id="F_a8a4aa85-fbe4-4b32-9b31-b9654fe3badb"
      unitRef="U_USD">30268000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_aa67e4d2-5d57-4d99-bea3-405fd57cf23c">&lt;p id="section32" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. BALANCE SHEET ITEMS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current asset consist of the following as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.207%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.785%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.325000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net, consists of the following as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.207%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.785%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.325000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&#x2014;net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense for the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.207%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.785%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.325000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trial liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <tpst:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_0c065dcb-0c1f-4e5a-91e2-7eaacb449b5d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current asset consist of the following as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.207%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.785%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.325000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</tpst:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_4f70deb4-4ef9-4298-a8b4-460c02154125"
      unitRef="U_USD">196000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_ed70d322-a2fe-44ce-8942-bc5a413d28db"
      unitRef="U_USD">642000</us-gaap:PrepaidExpenseCurrent>
    <tpst:PrepaidResearchAndDevelopmentCostsCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_f1b4b775-c0e1-4551-85d0-f9f0834b47e2"
      unitRef="U_USD">11000</tpst:PrepaidResearchAndDevelopmentCostsCurrent>
    <tpst:PrepaidResearchAndDevelopmentCostsCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_22a4f1e4-45f2-42d8-91b6-81a2bb068c12"
      unitRef="U_USD">29000</tpst:PrepaidResearchAndDevelopmentCostsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_f0e176af-ce50-4ed2-ae3b-11a4f67d08dc"
      unitRef="U_USD">355000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_9de7024f-1c58-44c1-a132-e9ed682e22d3"
      unitRef="U_USD">535000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_67c1de5c-b5d5-497b-91ca-1ef59b1372be"
      unitRef="U_USD">562000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_877ffc44-a886-4bb6-9b48-833a766f56de"
      unitRef="U_USD">1206000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_fec32ed9-fc80-4bc1-9d6e-d2550ea6abe4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net, consists of the following as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.207%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.785%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.325000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&#x2014;net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f01f9f21-5e95-48cc-83bd-51259e351e7a"
      decimals="-3"
      id="F_47777dfa-af42-40ce-a6f7-8c197455ab6a"
      unitRef="U_USD">151000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a3400db3-e1b2-4661-adf2-7b1ef948c2b3"
      decimals="-3"
      id="F_0580909f-72dd-489b-a2e3-7220bbf3d26e"
      unitRef="U_USD">192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0914ade8-ff10-4219-ba68-53e47ff2c071"
      decimals="-3"
      id="F_d94c7ccc-0157-43b4-8dae-465a91f3c2e0"
      unitRef="U_USD">263000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1637137e-aed7-4f2d-9427-075a1f55122b"
      decimals="-3"
      id="F_acf3c103-2dae-4622-9b2b-7d6507eab66d"
      unitRef="U_USD">328000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9d204fd8-22c5-49c0-9f16-eaa7fe7bc752"
      decimals="-3"
      id="F_ccf0f35a-eb8b-440d-bac4-6249bce3682d"
      unitRef="U_USD">1446000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5044accb-f46c-4dbe-954f-4ba8e4e9b034"
      decimals="-3"
      id="F_ae2988fe-05d4-4e47-84e0-8abde093d9de"
      unitRef="U_USD">1485000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0d904433-7564-4710-8699-0c23e7ee67c2"
      decimals="-3"
      id="F_d3a7d79b-483d-452f-b477-fb48c6555e7f"
      unitRef="U_USD">198000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fb5c878c-f0d7-482c-814a-fe0164e7e33e"
      decimals="-3"
      id="F_ecf2ee0f-5e37-475e-82a1-ca05f3b48775"
      unitRef="U_USD">201000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_bf21c18f-0e83-429b-9d99-82444d5a6c6e"
      unitRef="U_USD">2058000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_68e86532-a552-48d1-b421-532372fa3221"
      unitRef="U_USD">2206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_47346723-22e0-48b3-80cf-0e5e950b889a"
      unitRef="U_USD">1453000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_6957b62b-4d01-4c57-be64-d75f27b6895c"
      unitRef="U_USD">1320000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_9a86fc56-7cb6-48cd-a60f-34505b762e62"
      unitRef="U_USD">605000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_ba3defbc-f6f3-44fd-a811-b5903800bb94"
      unitRef="U_USD">886000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_a4f92c0e-6f60-4466-89a6-ee127ed39667"
      unitRef="U_USD">266000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_2b7a64bd-b25f-40c9-b456-362326c0fd6d"
      unitRef="U_USD">389000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_16224a33-98a7-4327-a48f-f6864d23a488">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.207%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.785%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.841%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.325000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trial liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_06972d93-d370-4634-8c84-9aaacbba3dfb"
      unitRef="U_USD">627000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_aa7d52d6-2524-4e82-97aa-806a1878ffbf"
      unitRef="U_USD">1335000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <tpst:AccruedClinicalTrialLiability
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_a567d05e-965e-41b6-aa2e-6aa6eb9a42de"
      unitRef="U_USD">310000</tpst:AccruedClinicalTrialLiability>
    <tpst:AccruedClinicalTrialLiability
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_f8233e25-51c0-4353-a5b6-87a4be6116ba"
      unitRef="U_USD">1391000</tpst:AccruedClinicalTrialLiability>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_824b70a9-47fc-4d6e-8461-6887ce026106"
      unitRef="U_USD">937000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_e01bf9ad-6ea4-414f-a97e-929ab87318f4"
      unitRef="U_USD">2726000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_2071214c-81bd-4ba5-a4f0-4c1a2419b43f">&lt;p id="section33" style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Facilities Lease Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;In January 2022, the Company entered into an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; office lease agreement for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,116&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet facility in Brisbane, California (&#x201c;Brisbane Lease&#x201d;). The lease commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the balance of the operating lease right of use assets were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,540&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,643&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, and the related operating lease liability were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,141&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,011&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, as shown in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rent expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,946&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,244&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, future minimum annual lease payments under the Company&#x2019;s operating lease liabilities were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total Commitment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Noncurrent operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Related to this Brisbane Lease agreement, the Company entered into a letter of credit with a bank to deposit $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in a separate account that is restricted cash to serve as security rent deposit. This amount is included in other noncurrent assets in the accompanying Consolidated Balance Sheets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_ec6026bd-9c80-4233-9bc5-2e05dc22c3d2"
      id="F_21d22392-588b-4283-95ac-569238ecfa60">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_ec6026bd-9c80-4233-9bc5-2e05dc22c3d2"
      decimals="0"
      id="F_a2044bf8-05e3-46aa-bbd9-52bfac80f518"
      unitRef="U_sqft">20116</us-gaap:AreaOfRealEstateProperty>
    <tpst:OperatingLeaseCommencementMonthAndYear
      contextRef="C_066bf70d-7a44-4797-b1fa-45ce89b04609"
      id="F_d48222fe-a5e9-4cc3-af08-2e8e55d8aa49">2022-12</tpst:OperatingLeaseCommencementMonthAndYear>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_c45ee610-3419-4257-a9de-bbd067437045"
      unitRef="U_USD">7540000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4b4a9e1c-7ea2-4fd6-9990-5b75e3c05009"
      decimals="-3"
      id="F_b525723d-0705-4b09-aba3-b99623c00d77"
      unitRef="U_USD">8643000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_e55478cc-925f-4e93-80a8-cb871e4edca4"
      unitRef="U_USD">8141000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4b4a9e1c-7ea2-4fd6-9990-5b75e3c05009"
      decimals="-3"
      id="F_435e75a5-fc71-4cc6-a7f4-4fc7852078b2"
      unitRef="U_USD">9011000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_f8ce6377-25b1-417f-a67b-27dd94b6927b"
      decimals="-3"
      id="F_ff6b5770-b7f4-437a-84fa-108c67259d95"
      unitRef="U_USD">1946000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_3dd1d89e-976b-47de-b4a0-39ee50aa0671"
      decimals="-3"
      id="F_a79a8df8-637d-4d87-96e9-dd0a92e9a831"
      unitRef="U_USD">2244000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_82b05689-940b-45e8-a76e-df9f778727c4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, future minimum annual lease payments under the Company&#x2019;s operating lease liabilities were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total Commitment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Noncurrent operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_a4a25d73-29a3-4cc1-a398-f759ec0baec9"
      unitRef="U_USD">1926000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_d82e79ae-66fc-4c56-a22e-d10902452227"
      unitRef="U_USD">1994000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_31ba7be7-d069-4493-941d-1d6fd216e6ec"
      unitRef="U_USD">2064000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_72b50670-1430-45e9-a6e5-878cb258089c"
      unitRef="U_USD">2136000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_fccf8b29-f900-408e-9667-8bcf67ea74fd"
      unitRef="U_USD">2210000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_83283d63-032d-4aa3-96c3-43c2238aca34"
      unitRef="U_USD">10330000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_1d3e526e-b4a8-4816-b487-a9c0329365bd"
      unitRef="U_USD">2189000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_925fc019-54e4-45e0-a4a7-3f5942529bbb"
      unitRef="U_USD">8141000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_b5b6bff4-b8f9-45fe-b8cd-63e966d5d53c"
      unitRef="U_USD">1192000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_d32c69c8-59a9-4557-bfdc-6f0d25e66261"
      decimals="-3"
      id="F_d443ffa7-566e-41e9-ac4c-a9af2758e3a4"
      unitRef="U_USD">6949000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_090576ed-b8aa-4a6c-bd24-ad4fc236805a"
      decimals="-3"
      id="F_422c78ea-89c7-4bf8-ae6c-85acbb374b7c"
      unitRef="U_USD">388000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_387058d6-0554-4084-b6c8-ed2ccfa73a56">&lt;p id="section34" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. LOAN PAYABLE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 15, 2021, the Company entered into a loan agreement with Oxford Finance LLC (the &#x201c;Lender&#x201d;) to borrow a term loan amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to be funded in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; tranches (as amended, the &#x201c;Loan Agreement&#x201d;). Tranche A of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was wired to the Company on January 15, 2021. Tranche B of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; expired on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Tranche C of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was available at the Lender&#x2019;s option.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 23, 2022, the Company entered into a First Amendment to the Loan Agreement. The amendment modified the Loan Agreement as follows: (i) each of the Company and Millendo Therapeutics US, Inc., a Delaware corporation and wholly owned subsidiary of the Company (&#x201c;Millendo&#x201d;), were joined as co-borrowers under the Loan Agreement; (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the interest-only repayment period was extended through December 31, 2023 (which interest-only period may be further extended through June 30, 2024 under certain circumstances)&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;; and (iii) a security interest in all of the assets of the Company, TempestTx and Millendo, including any intellectual property, was granted to the Lender. In addition, the Lender permitted a one-time prepayment in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which the Company paid on December 23, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the amendment to the Loan Agreement, the term loan had a maturity date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;August 1, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and an annual floating interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, which is an Index Rate plus &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. Index Rate is the greater of (i) 1-Month CME Term SOFR or (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. In the fourth quarter of 2023, the Company achieved the circumstances necessary to extend the interest-only repayment period through June 30, 2024. Monthly principal payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;733&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; were required to begin on July 1, 2024. Related to this borrowing, the Company recorded loan discounts totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;898&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of debt issuance costs. These amounts would be amortized as additional interest expense over the life of the loan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 8, 2025, using cash on hand, the Company made a repayment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in full satisfaction of the aggregate outstanding amount, including accrued interest and exit fees as of such date, under the Loan Agreement with the Lender. The payoff amount paid by the Company in connection with the termination of the Loan Agreement was pursuant to a payoff letter with the Lender and included payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as an exit fee. Upon making the repayment, the Loan Agreement was terminated in accordance with its terms and all liens and security interests granted thereunder to secure the obligations were released.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, total interest expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,316&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_c0d8ea89-cc8c-45be-bc99-628196dc6c0b"
      decimals="-3"
      id="F_980d885a-32f1-4a2f-987c-7b9666d3b61a"
      unitRef="U_USD">35000000</us-gaap:DebtInstrumentFaceAmount>
    <tpst:DebtInstrumentNumberOfTranches
      contextRef="C_c0d8ea89-cc8c-45be-bc99-628196dc6c0b"
      decimals="INF"
      id="F_662fed36-d0cc-42fb-a5ad-bc523aa5bce3"
      unitRef="U_Tranche">3</tpst:DebtInstrumentNumberOfTranches>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_e001f4eb-5e39-4fc6-86f8-e7d36c542298"
      decimals="-3"
      id="F_fdf4b670-5a8e-4340-adf5-46579bb5653b"
      unitRef="U_USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_dbd9479a-dda8-49f7-909e-f327ddced2a0"
      decimals="-3"
      id="F_058bba6b-d763-4136-98f7-64b04d201e6c"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_15eeec6d-ae98-4bbc-b091-1fe5a22f07be"
      id="F_8acdf799-3258-4fef-9ed5-720e062e2d0a">2022-03-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_69c4f05e-7e57-48e6-b6d6-083e708f8908"
      decimals="-3"
      id="F_3b728de1-608c-48c5-94f8-8cf46288eca1"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="C_c6e78168-a2c5-460b-b80d-8a8b0415a3a5"
      id="F_b73a5389-2bf1-41c8-a0c8-4aa4acf21b17">the interest-only repayment period was extended through December 31, 2023 (which interest-only period may be further extended through June 30, 2024 under certain circumstances)</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="C_8ef892e0-d716-4056-9b12-9c9a7aa12c94"
      decimals="-5"
      id="F_4a1521c1-2662-4cb3-81da-38df38486b93"
      unitRef="U_USD">5000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_8ef892e0-d716-4056-9b12-9c9a7aa12c94"
      id="F_cabdc669-5523-4c44-85c7-ad6518a4b4ed">2025-08-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="C_23067402-fab4-4583-a8ba-7a645e0e1ef8"
      decimals="4"
      id="F_da3661c8-e2dc-46c4-bf58-f9e8089e0b2e"
      unitRef="U_pure">0.0715</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_8ef892e0-d716-4056-9b12-9c9a7aa12c94"
      decimals="4"
      id="F_2b6d157f-fffb-4449-b028-14a7e4761c21"
      unitRef="U_pure">0.071</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <tpst:ThersholdIndexRate
      contextRef="C_23067402-fab4-4583-a8ba-7a645e0e1ef8"
      decimals="4"
      id="F_79e40e68-02cc-42f5-84d7-b5659e5ec26b"
      unitRef="U_pure">0.0005</tpst:ThersholdIndexRate>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="C_8ef892e0-d716-4056-9b12-9c9a7aa12c94"
      decimals="-3"
      id="F_38d34cef-7bbe-49b2-9396-6d33e28ea12d"
      unitRef="U_USD">733000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent
      contextRef="C_c0d8ea89-cc8c-45be-bc99-628196dc6c0b"
      decimals="-3"
      id="F_a82f6427-d26a-4f21-91d7-d68f0c4dd816"
      unitRef="U_USD">898000</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_98b385cd-564a-43ce-b857-c685a4784e21"
      decimals="-3"
      id="F_69f16f0e-a6e9-4b26-b594-8add6792e986"
      unitRef="U_USD">95000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_83ad0427-46c9-40f3-8ea3-599adc8b0338"
      decimals="-5"
      id="F_cc7a16ce-5f41-4086-aadf-0e41d86bbdf4"
      unitRef="U_USD">3500000</us-gaap:RepaymentsOfDebt>
    <tpst:DebtInstrumentExitFee
      contextRef="C_83ad0427-46c9-40f3-8ea3-599adc8b0338"
      decimals="-5"
      id="F_bfc320c1-f83b-45e4-b86a-3b5cc0d53c2c"
      unitRef="U_USD">600000</tpst:DebtInstrumentExitFee>
    <us-gaap:InterestExpenseDebt
      contextRef="C_c6e78168-a2c5-460b-b80d-8a8b0415a3a5"
      decimals="-3"
      id="F_d2002640-f89a-4e4c-b8ae-050875c4ece0"
      unitRef="U_USD">207000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_e4e85a24-a7ee-432a-b926-c4bcdd8d3d4a"
      decimals="-3"
      id="F_209b4a74-163f-4134-98f7-b6f5e6af1e9f"
      unitRef="U_USD">1316000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_64ef9e28-b259-4a79-9981-74c3bb6d6dd4">&lt;p id="section35" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. STOCKHOLDERS' EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Authorized Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is authorized to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of preferred stock, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of which have been designated as Series A Participating Preferred Stock (the &#x201c;Series A Preferred Stock&#x201d;), par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share pursuant to the Company&#x2019;s adoption the Rights Plan (as defined below). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s Series A Participating Preferred Stock were outstanding as of December 31, 2025 and 2024. Stockholders are entitled to dividends as declared by the Board of Directors, subject to rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cash dividends declared to date. The holders of each share of common stock are entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vote and the holders of each share of Series A Preferred Stock, if issued, are entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; votes. Except for effecting or validating certain specific actions intended to protect the preferred stockholders, the holders of common stock vote together with preferred stockholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rights Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 10, 2023, the Company&#x2019;s Board of Directors adopted a limited duration stockholder rights plan (the &#x201c;Rights Plan&#x201d;), effective immediately, and declared a dividend of one preferred share purchase right (a &#x201c;Right&#x201d;) for each outstanding share of the Company&#x2019;s common stock. The dividend was effective as of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 23, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (the &#x201c;Record Date&#x201d;) with respect to stockholders of record on that date. The Rights will also attach to new common stock issued after the Record Date. Each Right entitles the registered holder to purchase from the Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_cc2526f0-0ec8-49fd-83a9-ebb177d174dd;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one one-thousandth&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of a share of the Series A Preferred Stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per one one-thousandth of a preferred share, subject to adjustment. The descriptions and terms of the Rights are set forth in a Rights Agreement, dated as of October 10, 2023 (the &#x201c;Rights Agreement"), between the Company and Computershare Trust Company, NA.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 9, 2024, the Company entered into Amendment No. 1 (the &#x201c;Amendment&#x201d;) to the Rights Agreement. The Amendment extends the Final Expiration Date of the Rights Agreement until immediately following the Company&#x2019;s 2025 Annual Meeting of Stockholders or, if the Company&#x2019;s stockholders approve the Rights Plan at or prior to such meeting, to October 10, 2026, unless the Rights are earlier redeemed or exchanged by the Company. The Company does not have any obligation under the Rights Agreement to seek stockholder approval for the Rights Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 5, 2024, the Company entered into Amendment No. 2 (the &#x201c;Second Amendment&#x201d;) to the Rights Agreement. The Second Amendment makes certain technical amendments to the rights and obligations of the Company&#x2019;s Board of Directors to administer and make determinations with respect to the Rights Agreement and the rights issued thereunder. The Rights Agreement otherwise remains unmodified and in full force and effect in accordance with its terms.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_dcc634ef-69ca-4973-b380-52c1af8bd4fb"
      unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_fceefa88-7474-4b97-8fff-dfef1e9c6f75"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_774c2427-e78a-4364-b45d-4d850acefee5"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9b1b80e6-f451-436f-91eb-8955ad7e6679"
      decimals="INF"
      id="F_5a337341-e519-470f-a76e-99e3feb1e0d1"
      unitRef="U_shares">100000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_4d0695ac-47ed-4a29-8127-2bb51e7519e7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9b1b80e6-f451-436f-91eb-8955ad7e6679"
      decimals="INF"
      id="F_8a277550-673f-4d60-b7c3-71c80890cdef"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_d6236c64-7c86-4bbd-a146-18c57a7267cc"
      decimals="INF"
      id="F_b7189df3-0b76-4b63-8479-dd6624e31ee7"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DividendsCommonStockCash
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="INF"
      id="F_a9db4e6f-b969-4ede-95a1-841b18a9bcc2"
      unitRef="U_USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockVotingRights
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_c0aa33c5-0c6b-48ff-93ad-5d0d4667fa73">one</us-gaap:CommonStockVotingRights>
    <us-gaap:PreferredStockVotingRights
      contextRef="C_b3405bb2-c492-46ef-ba86-83755523024a"
      id="F_daf961b4-c868-410a-9470-2d01eb86c4a9">1,000</us-gaap:PreferredStockVotingRights>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear
      contextRef="C_3665f268-732d-4aa6-b123-f1529af2e05d"
      id="F_2acb0d63-6a05-4c5b-9997-30d2be8215c7">2023-10-23</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0c195dac-9159-4433-aab9-8a61697eeb1c"
      decimals="INF"
      id="F_661d1adf-56a1-4523-a60f-cf69f7fd3f16"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_1495140c-8fe8-40ce-8465-55edac490660">&lt;p id="section36" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2011, Private Tempest adopted the 2011 Equity Incentive Plan (the &#x201c;2011 Plan), and in 2017, Private Tempest adopted the 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;), and together with the 2011 Plan, the &#x201c;Tempest Prior Plans.&#x201d; The Tempest Prior Plans have been terminated and no additional grants may be made under either plan. All stock awards granted under the Tempest Prior Plans will remain subject to the terms of the applicable prior plan. As a result of the merger with Millendo, the Tempest Prior Plans were assumed by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 29, 2019, the Board of Millendo adopted the 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;), subject to approval by the Company&#x2019;s stockholders, and became effective with such stockholder approval on June 11, 2019. On June 17, 2022, the Company&#x2019;s stockholders approved the Amended and Restated 2019 Equity Incentive Plan (the &#x201c;A&amp;amp;R 2019 Plan&#x201d;), which amended and restated the 2019 Plan and was the successor to, and replacement of, the 2019 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Board of Tempest adopted the Amended and Restated 2023 Equity Incentive Plan (the &#x201c;2023 Plan&#x201d;) on April 30, 2023, subject to approval by the Company&#x2019;s stockholders. On June 15, 2023, the Company&#x2019;s stockholders approved the 2023 Plan, which amended and restated the A&amp;amp;R 2019 Plan and will be a successor to, and replacement of, the A&amp;amp;R 2019 Plan.  The number of shares of the Company's common stock reserved for issuance under the 2023 Plan will automatically increase on January 1st of each year, for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, from January 1, 2024 continuing through January 1, 2033, by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of the Company's common stock outstanding on December 31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;st&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the preceding calendar year, or a lesser number of shares as may be determined by the Board of Directors. Accordingly, on January 1, 2026, the common stock reserved for issuance was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;197,086&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,745&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for future grant under the 2023 Plan. In addition, on January 27, 2026, the Company's stockholders approved the amendment to increase the number of shares issuable under the 2023 Plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,410,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2023 Plan allows the Company to grant stock awards to employees, directors and consultants of the Company, including incentive stock options (&#x201c;ISOs&#x201d;), non-qualified stock options (&#x201c;NSOs&#x201d;), stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Board of Tempest adopted the 2023 Inducement Plan (&#x201c;2023 Inducement Plan&#x201d;) on June 21, 2023, pursuant to which the Company reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,150,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual&#x2019;s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2023 Inducement Plan was approved by the Company&#x2019;s Board of Directors without stockholder approval in accordance with such rule. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,615&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for future grant under the 2023 Inducement Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures employee and non-employee stock-based awards at grant date fair value and records compensation expense on a straight-line basis over the vesting period of the award.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Employee Stock Ownership Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Board of Millendo adopted the 2019 Employee Stock Purchase Plan on April 29, 2019, which became effective upon stockholder approval on June 11, 2019. On June 17, 2022, the Company&#x2019;s stockholders approved the Amended and Restated 2019 Employee Stock Purchase Plan (the &#x201c;2019 ESPP&#x201d;). The 2019 ESPP enables employees to purchase shares of the Company's common stock through offerings of rights to purchase the Company's common stock to all eligible employees.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2019 ESPP provides that the number of shares of common stock reserved for issuance under the 2019 ESPP will automatically increase on January 1, 2023 and continuing through (and including) January 1, 2029, by the lesser of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of Common Stock outstanding on December 31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;st&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the preceding calendar year, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Common Stock, or (iii) such lesser number of shares of Common Stock as determined by the Board of Directors (which may be zero). On January 1, 2026, the common stock reserved for issuance was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,461&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,608&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock remained available for future issuance under the 2019 ESPP. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,955&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock had been issued under the 2019 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Options to purchase the Company&#x2019;s common stock may be granted at a price not less than the fair market value in the case of both NSOs and ISOs, except for an options holder who owns more than 10% of the voting power of all classes of stock of the Company, in which case the exercise price shall be no less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the fair market value per share on the grant date. Stock options granted under the Plans generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and expire no later than ten (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) years from the date of grant. Vested options can be exercised at any time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to the merger with Millendo, the grant date fair market value of the shares of common stock underlying stock options was determined by the Company&#x2019;s Board of Directors. Up until the merger, there had been no public market for the Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;common stock, and therefore the Board of Directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which included valuations performed by an independent third-party, important developments in the Company&#x2019;s operations, sales of convertible preferred stock, actual operating results, financial performance, the conditions in the life sciences industry, the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following shows the stock option activities for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.489%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.697%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.238%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.778%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance&#x2014;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance&#x2014;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;320,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance&#x2014;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes information about stock options outstanding at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.11%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.422%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Remaining Contractual Life (In Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;441,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.70&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company granted employees and non-employees stock options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,014&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,009&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock with a weighted-average grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, total unrecognized compensation costs related to unvested employee stock options were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,352&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. These costs are expected to be recognized over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively. The fair market value of stock options vested was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,576&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,303&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimated the fair value of stock options using the Black-Scholes option pricing valuation model. The fair value of employee stock options is being amortized on the straight-line basis over the requisite service period of the awards. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of employee stock options was estimated using the following assumptions for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.358%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.358%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;&#160;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;&#160;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The expected term of options granted represents the period of time that the options are expected to be outstanding. Due to the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lack of historical exercise history, the expected term of the Company&#x2019;s employee stock options has been determined utilizing the simplified method for awards that qualify as plain-vanilla options.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company did not have any trading history for the Company&#x2019;s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the Company&#x2019;s common stock becomes available.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company has not paid any cash dividends on common stock since inception and does not anticipate paying any dividends in the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;foreseeable future. Consequently, an expected dividend yield of zero was used.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2025, the Company accelerated the vesting of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;266,108&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; time-based vesting stock options grants previously awarded to the Company's employees, pursuant to the separation agreements entered into with such employees. The Company also extended the post-termination exercise period from 90 days to 180 days immediately following the separation date for any options that were vested, including the options that were accelerated in vesting, as described above. Further, in the fourth quarter of 2025, approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;416,005&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of modified stock options were further modified to extend the post-termination exercise period from either (i) 180 days to December 31, 2026 or (ii) to the earlier of (a) the date that is 90 days following termination of continuous service, and (b) the expiration of the term of the options as set forth in the award agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The above modifications to current and former employees stock options grants resulted in modification accounting under ASC 718, Compensation &#x2013; Stock Compensation. As a result, the Company recognized approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of stock compensation expense during the year ended December 31, 2025. For vested awards with no future service period required to be provided, the expense was measured on the modification date by calculating the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified with immediate expense recognition. For unvested awards with no future service period required to be provided, the Company reversed any stock compensation expense previously recognized, remeasured the fair value of the modified award and immediately recognized stock compensation expense on the modification date. For stock options that were further modified to extend the post-termination exercise period upon termination of continuous service, the Company measured the expense by calculating the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified. The fair value of those awards included a reduction to the share price for the fair value of the warrant dividend as the holders of the modified stock options were not participants in the warrant dividend. A portion of this modification was recorded as stock compensation expense in the fourth quarter and the remainder to be attributed over the derived service period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the components of stock-based compensation expense recognized in the &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company&#x2019;s consolidated statements of operations for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.403%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.403%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <tpst:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum
      contextRef="C_8e605970-763d-474d-b0cb-5de22ba59e68"
      id="F_f2680257-81e8-4b0c-84c2-b7871888fc75">P10Y</tpst:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfAutomaticIncreaseToOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_8e605970-763d-474d-b0cb-5de22ba59e68"
      decimals="INF"
      id="F_7620b672-3bd5-4bc4-a801-642482727c07"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_03c240c2-1a9c-4f7e-818d-a75b93b79bc7"
      decimals="INF"
      id="F_3a9e7d5e-837c-4b78-948f-8ca779fa904f"
      unitRef="U_shares">197086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f721aedf-b106-461a-903b-46e34a9f1d0d"
      decimals="INF"
      id="F_2a255b65-656f-4ccf-9bc6-0d9837506e18"
      unitRef="U_shares">47745</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_151f94be-33aa-4e72-91ab-8bdd1b7a21c2"
      decimals="INF"
      id="F_1dec7cc4-b1b5-4c72-a872-a1c807dc9781"
      unitRef="U_shares">1410000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_eae918eb-3de4-4147-a020-481aebcd8e1d"
      decimals="INF"
      id="F_4d107dff-28a7-4fed-812e-6d2d7d9b8a63"
      unitRef="U_shares">1150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c7f4e70e-297e-4e0f-9e4c-cf579d45fbdc"
      decimals="INF"
      id="F_efb29447-5eb6-4ffb-94f0-5fee3e236cd1"
      unitRef="U_shares">67615</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_cc23a656-ad79-4d18-bc37-248f3df07c4e"
      decimals="INF"
      id="F_af7b8001-f90b-4cd1-86b8-701dccfb87fd"
      unitRef="U_pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <tpst:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear
      contextRef="C_cc23a656-ad79-4d18-bc37-248f3df07c4e"
      decimals="INF"
      id="F_83376484-8a3d-43d0-aac2-d828d5381590"
      unitRef="U_shares">500000</tpst:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesAvailableForGrantPerYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_5cc9aad1-44ab-4aae-ac30-ebf9766e2451"
      decimals="INF"
      id="F_6a25ff35-32c1-4184-82ae-ba0f8dbf27cd"
      unitRef="U_shares">38461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e84c96bf-09c7-4644-ac47-8073761fa16a"
      decimals="INF"
      id="F_7c14cfc2-ac6f-4f19-ade1-4ab3793227b9"
      unitRef="U_shares">68608</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_8889779c-cd1a-4a88-8d46-c213f770f4d8"
      decimals="INF"
      id="F_b04075db-0afe-4ab3-b9ef-5f954040fb04"
      unitRef="U_shares">5955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="2"
      id="F_f7aa1cba-87da-4e2d-b326-e4d22219b5a9"
      unitRef="U_pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_f5b77a05-871f-4dc4-88bf-93885c428fb4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_04d2a762-47a8-4e76-b2d1-350bb8078de7">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_7f648362-ebae-4ee6-aea1-dbbecdcc65ba">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following shows the stock option activities for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.489%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.697%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.238%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.778%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance&#x2014;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance&#x2014;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;320,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance&#x2014;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b"
      decimals="INF"
      id="F_170c9803-68a6-49f7-bcbd-87857e3a4b97"
      unitRef="U_shares">273393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b"
      decimals="2"
      id="F_46787330-aaa0-421b-87a8-0f5fd9ab61d9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">94.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="INF"
      id="F_ab84e1a1-cd95-4e3e-b93d-07d8f5d32a04"
      unitRef="U_shares">69009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="2"
      id="F_becd5a6c-e322-4d87-baca-bbc41abc8c09"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">51.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="INF"
      id="F_c9158b34-a389-4595-8c23-fdab4cd2c19a"
      unitRef="U_shares">6284</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="2"
      id="F_28a64d87-60cd-4adb-9b1a-8d5fbd0b95c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="INF"
      id="F_d1377f10-c5f0-4aab-85fb-804fbb05f015"
      unitRef="U_shares">16028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="2"
      id="F_6eb736d6-942d-4fb7-b938-185ca08e7d21"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">106.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="INF"
      id="F_f56ef6db-b756-4103-8f66-fb0f4e6af23f"
      unitRef="U_shares">320090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="2"
      id="F_c8a52eb8-8452-427c-9cb1-b76b97aa23f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">86.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="INF"
      id="F_93084b63-d474-4777-ba56-5ee0a76ee00a"
      unitRef="U_shares">130014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="2"
      id="F_a703ea2a-9bb8-470f-a862-61c3e85c946d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="INF"
      id="F_5a18f243-fc36-4704-92a2-4fcaadba0c22"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="0"
      id="F_0779ca61-2631-46a9-8e4b-1f7a12273732"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="INF"
      id="F_fd66a802-a56f-4ea0-9c80-787d379942bb"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="0"
      id="F_ecec0db6-7b19-4883-8785-1e2bf69864c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_0a0bf6c8-9d98-448b-b0f6-c32ffcab9e5e"
      unitRef="U_shares">450104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="2"
      id="F_80a74f16-3a71-4fa3-9e2a-b5bfef1f4a58"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">64.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_09f23c56-296a-4328-887c-43234652bce7">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes information about stock options outstanding at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.11%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.422%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Remaining Contractual Life (In Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;441,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.70&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_83281dc7-6c10-4e3c-a64e-b491bb298ce9"
      unitRef="U_shares">450104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_0ccb1725-ff4e-46ed-bc08-46dfefbe46c9">P7Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="2"
      id="F_305962c4-af2b-411c-b28f-453753033026"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">64.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_f39fd556-cf0e-4913-9cf6-2b730bc0865a"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_2bae21b5-81b3-4d7e-bc78-371dde1133ef"
      unitRef="U_shares">450104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_699000cb-3d32-41f7-ace6-3cdcf218993f">P7Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="2"
      id="F_cfee0614-8e03-4464-9013-458e59837752"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">64.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_14a5a242-f00f-4d0f-a288-171d17397681"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="INF"
      id="F_861857b5-ce27-48ed-9b8e-80b7c1a3109a"
      unitRef="U_shares">441792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_8e4fb0c4-391b-4c79-8643-306696f90222">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="2"
      id="F_248f7790-d1f6-40b7-9910-42915195158f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">64.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_70618d25-0066-4af8-b4ba-aca7f8e5454e"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84"
      decimals="INF"
      id="F_29a76ca1-bd88-4cc3-a006-8150c464c037"
      unitRef="U_shares">130014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add"
      decimals="INF"
      id="F_8da764e1-8a27-418e-896e-90e8baaec9b5"
      unitRef="U_shares">69009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84"
      decimals="2"
      id="F_984f988e-7771-41f3-9a87-59d256619e52"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add"
      decimals="2"
      id="F_ad1bf0ed-2875-4399-97ba-b2c158ac8a37"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">51.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_dcb60290-a2fa-4e02-8588-a3425a10e251"
      decimals="-3"
      id="F_2ac44bf9-fc1d-44eb-a46f-5154cb9c08cf"
      unitRef="U_USD">389000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_b06ce1d5-43af-4875-915d-0b69099c48e3"
      decimals="-3"
      id="F_9d8d387b-fbff-43c6-a30e-d41b3038fd9f"
      unitRef="U_USD">12352000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84"
      id="F_05bb933d-604a-4aee-97dc-896c93aa3e54">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add"
      id="F_828b461f-be53-4bf2-a992-a6de9f3d45e9">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_59b13f20-cc85-45eb-be6b-bcedc279ea93"
      unitRef="U_USD">2576000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_9f006e19-a93d-4bef-b341-10b175d458ae"
      unitRef="U_USD">5303000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84"
      id="F_8d393c9e-76ac-40da-ac87-38152e383cbc">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of employee stock options was estimated using the following assumptions for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.358%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.358%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;&#160;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;&#160;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84"
      id="F_6a3073e7-1145-4513-af3f-67bd755124a9">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f941fd95-2c63-4333-b1fe-fd70c5cce07d"
      id="F_fa2a42bc-9157-4981-a828-301908cd8bb5">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_1eb9e2a4-c74a-4bb4-9c41-89af539af6a5"
      id="F_56c3a4a8-d110-4f99-9ba7-7fe72e849226">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84"
      decimals="2"
      id="F_55c99471-a4b1-4906-adba-298d7a34fe42"
      unitRef="U_pure">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84"
      decimals="2"
      id="F_fcd942d2-6ad5-40dc-b2c8-72e7424c3f6b"
      unitRef="U_pure">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add"
      decimals="2"
      id="F_87d8f4b1-55e2-442b-95cf-63e453b16670"
      unitRef="U_pure">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add"
      decimals="2"
      id="F_40baa22e-a591-427e-a545-3e44836ca27b"
      unitRef="U_pure">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84"
      decimals="3"
      id="F_22fe92de-4fff-478f-95b3-dbf7dcdb0701"
      unitRef="U_pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add"
      decimals="3"
      id="F_a49b3639-d8f0-4e44-af95-78e813417363"
      unitRef="U_pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add"
      decimals="3"
      id="F_4f91b725-392d-437c-b818-c5c2bba8081c"
      unitRef="U_pure">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_872c6937-1351-451b-abf9-2a2a83e2dc84"
      decimals="INF"
      id="F_4e60d739-ae95-450b-ac7f-5ea75456e252"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_2996b18a-b543-4592-ab8d-b832965d6add"
      decimals="INF"
      id="F_3dcad65d-7813-46cb-bbc3-899d2b579e60"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="INF"
      id="F_f393956e-a0a4-4533-bcd7-c0164bba7be4"
      unitRef="U_shares">266108</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="C_5674d468-6c98-412c-9336-57931dcfe277"
      decimals="INF"
      id="F_617b818b-9739-4ef8-816d-ff10a7f265c5"
      unitRef="U_shares">416005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-5"
      id="F_319ea4a1-bac8-4873-a43e-73f100c5687b"
      unitRef="U_USD">800000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_7d3784da-6642-4101-b9bf-b46a57b94f9c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company&#x2019;s consolidated statements of operations for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.403%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.403%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cceeff;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c3d09bfa-c82c-410e-8c05-013d4096ded0"
      decimals="-3"
      id="F_cd2f3691-df46-4712-89c7-d0e4000e1956"
      unitRef="U_USD">1179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f9dcc510-706f-4f08-bade-b100bcff92b0"
      decimals="-3"
      id="F_ae012e03-8645-40b2-a056-e71971359d4d"
      unitRef="U_USD">2222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ee3c2c67-1de7-4901-bc90-59a0afc42477"
      decimals="-3"
      id="F_d170b7bd-7de3-4580-b2fd-f08d046af9d1"
      unitRef="U_USD">1939000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c7a9e8d9-54e8-4bd7-bfcf-2da3a970b22f"
      decimals="-3"
      id="F_190475a7-e72c-4f0d-ac15-beb8c73f3ff5"
      unitRef="U_USD">3081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_c52b02f4-71cd-430c-a9db-4c79e5849074"
      unitRef="U_USD">3118000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_1132e4c8-4a83-481a-b12d-d26e4b671c04"
      unitRef="U_USD">5303000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_0dedbd16-ba36-46d0-9446-cfd6ee76fccd">&lt;p id="section37" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. INCOME TAXES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; provision for income taxes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, because the Company has incurred losses since inception.  At December 31, 2025 and 2024 the Company concluded it was not more likely than not that it would realize its deferred tax assets, and therefore has recorded a full valuation allowance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; income taxes for the years ended December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to pre-tax loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:34.454%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.981%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.925%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.866%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.981%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.925%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.866%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;U.S. federal provision (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_98cdff81-3c83-4c66-ba34-8998155d3a60;"&gt;&lt;span style="-sec-ix-hidden:F_14cb7b7c-9f29-479f-8c41-fb9c6a5ca935;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;At statutory rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or Nondeductible Items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;State income taxes in California comprise the majority of the state income taxes, net of federal effect category for the years ended December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 are shown below.&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;179,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 to December 31, 2025 due primarily to the generation of net operating losses and research and development credits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As required under ASU 2023-09, the Company has included only the portion of the valuation allowance related to federal deferred tax assets in the "change in valuation allowance" line of the rate reconciliation. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents a reconciliation of the total change in the valuation allowance (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning Balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change related to continuing operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending Balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;534.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;501.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;502.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;487.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The federal and state net operating loss carryforwards begin to expire in 2031 and 2025, respectively, if not utilized. Federal net operating losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;313.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million are not subject to expiration.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had federal and state research and development carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The Company also had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of Orphan Drug Credit. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had federal and state research and development carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The federal and state credits begin to expire in 2031 and 2029, respectively, if not utilized; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the state credits can be carried forward indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Utilization of some of the federal and state net operating loss and credit carryforwards may be subject to annual limitations due to the &#x201c;change in ownership&#x201d; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization.  The Company has not performed a Section 382 study as of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. At least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;455.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thousand of legacy Millendo federal net operating losses are expected to expire unused due to prior ownership changes.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has the following activity relating to unrecognized tax benefits as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross increase - tax position in current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, none of the unrecognized tax benefits would impact the Company's effective tax rate due to the valuation allowance.  The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest and penalties on the accompanying balance sheet as of December 31, 2025 and 2024, respectively, and has not recognized penalties and/or interest in the accompanying statements of operations for the years ended December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to taxation in the United States, California, Massachusetts, and Michigan. The Company's tax years from inception are subject to examination by the IRS and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="INF"
      id="F_3e1fff73-116b-4995-b0a9-d78b2ba53a99"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="INF"
      id="F_34f21e69-6a09-4d68-8500-c9a484c7684a"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="INF"
      id="F_27e0667e-6a43-4e0d-a303-8553c843124b"
      unitRef="U_USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="INF"
      id="F_9d7a8860-dc7a-4a28-9d06-2470405ccba6"
      unitRef="U_USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_8d54386c-2bfa-475e-8701-518958abb586">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to pre-tax loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:34.454%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.981%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.925%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.866%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.981%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.925%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.866%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;U.S. federal provision (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_98cdff81-3c83-4c66-ba34-8998155d3a60;"&gt;&lt;span style="-sec-ix-hidden:F_14cb7b7c-9f29-479f-8c41-fb9c6a5ca935;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;At statutory rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or Nondeductible Items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="2"
      id="F_1ec13452-d978-4f42-b369-0df16946bcf1"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="2"
      id="F_61d520ad-638d-43fb-8370-9f36964f3933"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_cb9a7f0f-fe0b-4f6b-8f95-8529941b766c"
      unitRef="U_USD">-5514000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="3"
      id="F_ecfce884-69db-4948-b1fb-e57f840b6775"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_3b468568-1d3d-41ec-971d-f1e3642d1be7"
      unitRef="U_USD">-8786000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="3"
      id="F_b3baa14b-9e18-4ffc-8c5b-481b5d8c2d39"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_bb94cf8f-39d2-4c32-99cb-83621440eb21"
      unitRef="U_USD">5105000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="3"
      id="F_78c195f2-b1eb-4a6a-a352-3695413b064f"
      unitRef="U_pure">-0.194</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_51ffac50-803f-4855-ad2d-7e8a1e0f7cdc"
      unitRef="U_USD">9199000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="3"
      id="F_0eceb92b-57d9-465b-84f0-18b91b4f896b"
      unitRef="U_pure">-0.22</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_4f9ea619-107b-4b64-a755-1db38a905919"
      unitRef="U_USD">343000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="3"
      id="F_1ba26399-6a6e-4d90-8443-ffac57a2addd"
      unitRef="U_pure">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_3d2920d3-ea30-4d28-84b6-7a49d6acb540"
      unitRef="U_USD">709000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="3"
      id="F_93d80805-9905-4c97-a8d4-eecc20060c65"
      unitRef="U_pure">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_89e90af0-9219-4035-a1d6-a5077843f50b"
      unitRef="U_USD">454000</tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts>
    <tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="3"
      id="F_9ca12b9c-901c-4cbc-bb18-7cd68195afcc"
      unitRef="U_pure">-0.017</tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent>
    <tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_1fcba0e5-5f22-4262-8aef-04998526b5ad"
      unitRef="U_USD">0</tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCosts>
    <tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="3"
      id="F_4cdffa17-7256-4e9f-9880-34912539362e"
      unitRef="U_pure">-0</tpst:IncomeTaxReconciliationNonDeductibleExpenseTransactionCostsPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_8aacb2a2-0533-410b-9373-507c6bf094e4"
      unitRef="U_USD">90000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="3"
      id="F_541ed3e8-0f71-4842-a65d-e15971ec6a77"
      unitRef="U_pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_cdad1c71-c712-45df-a71b-4fb1b40d636b"
      unitRef="U_USD">14000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="3"
      id="F_987d8135-a002-49b1-ab18-3783946d0379"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_8683d97e-91b4-4cf4-b24c-dbea3f1da3f6"
      unitRef="U_USD">478000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="3"
      id="F_253ba773-db45-4692-9369-db4712f70aae"
      unitRef="U_pure">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_65126cce-8bc9-43d2-8553-0ea3b7a3209b"
      unitRef="U_USD">1136000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="3"
      id="F_6628d36f-b2d9-47f9-8436-6ab5eeec6463"
      unitRef="U_pure">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_b8ffd299-52da-4dad-8823-fd294574118a"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="3"
      id="F_e1a9d2f7-a9d3-43ac-962c-3875a5e74565"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_0938c358-8b0c-4792-b19a-22c47550c722"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="3"
      id="F_8c80573e-a795-4778-98b0-90536189b5d5"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_24e9e969-d6d8-4f76-8f29-ddd4ff4fca54">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 are shown below.&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;152,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;179,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_610de1f1-9ec8-4bb5-a901-8406cee14ce9"
      unitRef="U_USD">152074000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_6c7ba049-3bde-4b81-bc99-de84e55cade6"
      unitRef="U_USD">143896000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_ab73a5da-8352-4e99-89ad-6c2042b29c92"
      unitRef="U_USD">21198000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_a5f41589-63f6-4e61-97f5-aae08eea799b"
      unitRef="U_USD">20513000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <tpst:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_efcd9b0c-cbfe-4cbe-a367-2d1c90521b3d"
      unitRef="U_USD">489000</tpst:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization>
    <tpst:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_dce36c93-24b3-4e7e-8374-357a5afd28a5"
      unitRef="U_USD">603000</tpst:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization>
    <tpst:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_f3eef81d-f78f-41e3-8ce4-5c11625176e8"
      unitRef="U_USD">2354000</tpst:DeferredTaxAssetsOperatingLeaseLiability>
    <tpst:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_61383256-3457-4b0d-be29-d2a6e342fe9d"
      unitRef="U_USD">2625000</tpst:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_86218abd-6660-43bc-991b-174478d551ff"
      unitRef="U_USD">1583000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_a5201d6a-4c85-490a-9921-a36a6ca9e4d6"
      unitRef="U_USD">1167000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_f7e21ef5-adde-49d6-9fdc-a66f43ae5338"
      unitRef="U_USD">98000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_9726f43b-8042-46d2-a6ec-c5517639f74d"
      unitRef="U_USD">491000</us-gaap:DeferredTaxAssetsOther>
    <tpst:DeferredTaxAssetsCapitalResearchAndDevelopment
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_069d4749-dd26-4d17-abc9-b905b67485a7"
      unitRef="U_USD">7901000</tpst:DeferredTaxAssetsCapitalResearchAndDevelopment>
    <tpst:DeferredTaxAssetsCapitalResearchAndDevelopment
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_716e450f-7965-4bc6-9fda-569ad5d78e6c"
      unitRef="U_USD">10041000</tpst:DeferredTaxAssetsCapitalResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_ad71cc4b-2c7d-48b3-90af-a3f42b1fb560"
      unitRef="U_USD">185697000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_2bf8a5c5-5056-4275-a6b5-9ba953d47680"
      unitRef="U_USD">179336000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_e37e53bd-21f7-4ef5-98f7-dc2540adc5d8"
      unitRef="U_USD">183498000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_c3f78759-97ca-4e9f-8e4b-02736124b320"
      unitRef="U_USD">176799000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_15f1f5bf-186f-4b83-ad67-28eca0a81c16"
      unitRef="U_USD">2199000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_92163a29-0d58-4832-87b4-792b565ac747"
      unitRef="U_USD">2537000</us-gaap:DeferredTaxAssetsNet>
    <tpst:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_c6aa6a17-c063-4043-8754-64a3cf4a163b"
      unitRef="U_USD">2180000</tpst:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <tpst:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_0663100a-7616-4c2e-b9b1-6fd6612057a6"
      unitRef="U_USD">2518000</tpst:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_018f6f89-9d2e-4c0f-a534-fb9ca88ae32b"
      unitRef="U_USD">19000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_208f49b3-6ad4-4243-ab0e-b2f182f27d21"
      unitRef="U_USD">19000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_05db6c44-0dc6-4309-bb18-bcf7ca587f0c"
      unitRef="U_USD">2199000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_933fa6f5-b13f-4e58-ba20-1b975b416bb2"
      unitRef="U_USD">2537000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_bf8e4783-4ac6-4e70-9603-16a2c6fc580b"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_400b99f6-37a6-4054-a4bb-b489d547b884"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-5"
      id="F_6878619c-88b8-40dd-9a08-bb737431e43d"
      unitRef="U_USD">6700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_6a9a11bb-781c-43e6-9847-22201329f3d0">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents a reconciliation of the total change in the valuation allowance (in thousands):&lt;/span&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning Balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change related to continuing operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending Balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_73eda927-ebed-4dfb-988d-2e66db6bff30"
      unitRef="U_USD">176799000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b"
      decimals="-3"
      id="F_2e7f85fe-7bd0-42ff-b4d3-dd333c85dc62"
      unitRef="U_USD">164643000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_521bc147-2656-4226-a592-a8288ceabe5a"
      unitRef="U_USD">6699000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_9d4ce301-dbb5-4318-a7a0-ac3a03286caf"
      unitRef="U_USD">12156000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_59e97c9a-b316-4e6e-ac2c-8aaab6d13eb0"
      unitRef="U_USD">183498000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_af9ab513-cdcd-438e-954d-e52137deb96d"
      unitRef="U_USD">176799000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-5"
      id="F_f2dacf9d-2737-451f-b44d-6972e29012cc"
      unitRef="U_USD">534500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-5"
      id="F_92f62300-f770-46e6-b7d9-7f48b7257b6a"
      unitRef="U_USD">501900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-5"
      id="F_29f02096-8fb4-48d7-8869-4ef491d37e8e"
      unitRef="U_USD">502200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-5"
      id="F_a9438165-91b7-49ce-a594-66294ae7142d"
      unitRef="U_USD">487800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_9f9f175a-2500-4de7-add4-0941b73b5ed4"
      decimals="-5"
      id="F_94cb502a-9a98-4050-b84d-446ef026461a"
      unitRef="U_USD">313300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_9b27f837-5200-4262-b142-35394e148530"
      decimals="-5"
      id="F_0bde609b-aace-41ea-b091-54ecad4ef1bd"
      unitRef="U_USD">14700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_01635993-0ae0-46f3-a1ac-7f468a6e22a4"
      decimals="-5"
      id="F_716fd5d2-82bf-4807-9bf2-3f78dc547e4c"
      unitRef="U_USD">4400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_bf3af50f-3aed-4972-822b-f4464ec34192"
      decimals="-5"
      id="F_e0569662-5aac-46c8-95c0-7f5b713a7c80"
      unitRef="U_USD">7400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_49c54967-da26-4ce8-b371-c1af8c5252ca"
      decimals="-5"
      id="F_c126ff20-602c-4378-9466-36cb840395e3"
      unitRef="U_USD">14100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_112906e9-cd45-450d-8e9f-7f8daac97dbd"
      decimals="-5"
      id="F_b02debce-6439-475a-8f3d-d8e491cf9761"
      unitRef="U_USD">4100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_916c82b9-f557-4ed2-9797-e0d652612305"
      decimals="-5"
      id="F_6a9b6f0f-b512-4380-9a21-958833ea6293"
      unitRef="U_USD">3300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_b5528348-f1b5-4a4d-8927-ae662ee9eccf"
      decimals="-2"
      id="F_3fe1d538-8ad4-4bea-af3c-8a885a5830e6"
      unitRef="U_USD">455800</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_2483af98-53c2-4914-b578-046de1f3cf8f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has the following activity relating to unrecognized tax benefits as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross increase - tax position in current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_bf24ad9b-664c-4e70-9b98-a63010fd4dff"
      unitRef="U_USD">5239000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_518e5fc4-652b-4edf-a054-ee24c0dbc43b"
      decimals="-3"
      id="F_9aa4fe87-6898-46b0-afe0-523e0be8289e"
      unitRef="U_USD">4923000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_aa629fd0-035d-4e9e-a702-480a8632e20a"
      unitRef="U_USD">167000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_f8232c55-d9b4-4452-a5fc-c3baa9744141"
      unitRef="U_USD">316000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_6e35c08f-14cf-428d-a7d8-78364f94ae76"
      decimals="-3"
      id="F_f96c1937-784c-41ea-8f2d-7ae27590368e"
      unitRef="U_USD">5406000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_d4ce13ec-9904-4f97-8c89-e6d62c5d08e7"
      decimals="-3"
      id="F_e2b016b4-e878-4765-8386-f61e11727d7f"
      unitRef="U_USD">5239000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_784a21ed-0bc5-4e6c-9b79-ef189bcff86f">&lt;p id="section38" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. RETIREMENT PLAN&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company participates in a qualified 401(k) Plan sponsored by its professional service organization. The retirement plan is a defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. During the year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company contributed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to the 401(k) Plan. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company contributed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to the 401(k) Plan.&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_433b9df6-529b-46ed-a992-bed531dbd105"
      unitRef="U_USD">124000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_5e6cfaae-45ba-4afd-b0d8-afc230df4a35"
      unitRef="U_USD">161000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_ce2fe71c-2c16-45f3-910b-33c7a2d0c54e">&lt;p id="section39" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. NET LOSS PER SHARE&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of the Company&#x2019;s basic and  diluted net loss per share for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.780000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.780000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,149,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,146,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,149,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,146,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;19.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company&#x2019;s potentially dilutive securities included unvested stock warrants and stock options, which have been excluded from the computation of diluted net loss per share attributable to common stockholders as the effect would be anti-dilutive. The issuance of pre-funded warrants and vested RSUs have been included in the computation of basic and diluted net loss per share attributable to common stockholders. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Based on the amounts outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;320,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,172,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,622,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;320,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_89202f75-acda-41ff-9c8a-8c22c6bf0d2c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of the Company&#x2019;s basic and  diluted net loss per share for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.780000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.780000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,149,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,146,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,149,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,146,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;19.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="-3"
      id="F_334f28fb-6633-4cbe-9a5e-aa0ef609f0c8"
      unitRef="U_USD">-26262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="-3"
      id="F_03c4086e-e1c2-4e11-82bc-3fed697cc084"
      unitRef="U_USD">-41843000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="0"
      id="F_5ee9d0cc-a7ad-439a-806e-404cb8fd6a13"
      unitRef="U_shares">4149733</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="0"
      id="F_4cfdbe2f-9c5d-4a33-b1a0-20d6cd2d2291"
      unitRef="U_shares">2146276</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="0"
      id="F_26965830-e5d8-436d-a5d7-9db86d0a97fc"
      unitRef="U_shares">4149733</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="0"
      id="F_65ef2f88-a8b4-46b2-81b9-daa5550d0294"
      unitRef="U_shares">4149733</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="0"
      id="F_aa760a87-cfc4-4cb4-87d6-ccb110f3dbc8"
      unitRef="U_shares">2146276</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="0"
      id="F_9cc12566-b4ee-44bd-9340-48efdcb4d27d"
      unitRef="U_shares">2146276</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="2"
      id="F_4264d6a5-a711-4a0c-8db3-a69900da9261"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-6.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="2"
      id="F_5a9f4e5e-888b-49e3-9188-964cb272e48e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-6.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="2"
      id="F_ecbd2e47-769c-4b97-a1f1-5629d9f41ce8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-19.5</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="2"
      id="F_fa9fbfea-65d8-47cd-803e-5cb5478b6fcb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-19.5</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_be79b2c7-e08d-40f6-9d0f-fd9c42765614">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Based on the amounts outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:&lt;/span&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #cceeff;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;320,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,172,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,622,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;320,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a962bb72-7e5c-4f7e-9290-db4536a5d91c"
      decimals="0"
      id="F_ab1ebd36-91f9-49ea-a988-dd9a45f83d6a"
      unitRef="U_shares">450104</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8748646b-ce49-4cf2-b51c-cd12c0ce32e9"
      decimals="0"
      id="F_2bd6c827-6a63-43bc-b45d-8878b3eee981"
      unitRef="U_shares">320090</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ab6430cb-a886-405c-91eb-7aff47df90b0"
      decimals="0"
      id="F_5110a425-10fc-4a95-8dbe-138b6c6d581b"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d48d584b-746c-47de-a737-fa3d182f9772"
      decimals="0"
      id="F_7d777908-552e-470e-a6b3-52403d83b99b"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5fd11135-0c20-48b6-804e-5fe44ae3180d"
      decimals="0"
      id="F_96838ba6-6db3-4f80-bc3c-6b36b47f6b5b"
      unitRef="U_shares">1172878</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e36e743c-bf65-4bdb-bbe8-1719a8f75e7c"
      decimals="0"
      id="F_af33111b-757d-4f48-ac45-46edc191567f"
      unitRef="U_shares">464</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="0"
      id="F_aeda049f-d86f-429d-aab6-79826d1626af"
      unitRef="U_shares">1622982</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d3c8ebfe-b4e7-460b-a197-7f578ca46622"
      decimals="0"
      id="F_fbb605fa-eafd-47c4-9a0e-77bce7ba138e"
      unitRef="U_shares">320554</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_f232d177-ca5d-457c-bfa8-e367fc326cae">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. SEGMENT REPORTING&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable and operating segment, which is the business of discovery and development of small molecule drugs to treat cancers. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_73408227-2688-4970-8a0c-a936196fb1ad;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As the Company has not generated revenue, the CODM assesses Company performance through the achievement of research goals towards advancing the Company&#x2019;s product candidates through stages of development. As such, the CODM is regularly provided with budgeted and forecasted expense information as well as the Company&#x2019;s Consolidated Financial Statements which is used to determine the Company&#x2019;s liquidity needs and pipeline resource allocation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM regularly reviews and evaluates research and development expenses and uses consolidated net loss, as reported on the Company&#x2019;s Consolidated Statements of Operations, to assess the performance of the segment and to allocate resources.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  The consolidated net loss and significant segment expenses reviewed by the CODM are reported on the Company&#x2019;s Consolidated Statements of Operations for the years ended December 31, 2025 and 2024. The measure of segment assets is reported on the Consolidated Balance Sheet as total assets. The CODM monitors the Company's cash and cash equivalents as reported on the Consolidated Balance Sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All financial information required for segment reporting that is provided to the chief operating decision maker is contained within the financial statements and notes to financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="INF"
      id="F_064ed277-98fa-4a05-a76c-cd428eee68dc"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      decimals="INF"
      id="F_130b0e9a-432a-46e5-97d3-0a449d9b2337"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_5642c8b6-ed1c-426c-a206-b84dba0473ff">The CODM regularly reviews and evaluates research and development expenses and uses consolidated net loss, as reported on the Company&#x2019;s Consolidated Statements of Operations, to assess the performance of the segment and to allocate resources.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_1aaee9f0-beaa-40b9-aab8-3b4c4b99fce8">The CODM regularly reviews and evaluates research and development expenses and uses consolidated net loss, as reported on the Company&#x2019;s Consolidated Statements of Operations, to assess the performance of the segment and to allocate resources.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_96f0508e-a2ed-44b9-bf46-4dac5132fbee">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Acquisition of Erigen Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 19, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company executed an Asset Purchase Agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with Erigen LLC, a Delaware limited liability company (&#x201c;Erigen&#x201d;), and Factor Bioscience Inc., a Delaware corporation (together with Erigen, &#x201c;Sellers&#x201d;), pursuant to which Sellers agreed to sell and transfer to the Company all right, title and interest of Sellers in and to all&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the assets primarily related to (a) the autologous BCMA/CD19 dual-targeting CAR T-cell therapy known as ERI-2003, (b) the autologous CD70/CD70 dual-targeting CAR T-cell therapy known as ERI-2206, (c) the allogeneic BCMA/CD19 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as ERI-3003, and (d) the allogeneic CD70/CD70 dual-targeting CAR T-cell therapy with a gene edit in the TRAC locus that inactivates the T cell receptor known as ERI-3206 (collectively referred to herein as the &#x201c;Erigen Assets&#x201d;), in exchange for an aggregate purchase price of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,268,495&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock to be issued to Erigen on behalf of both Sellers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;February 3, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company completed the acquisition of the Erigen Assets (the &#x201c;Erigen Closing&#x201d;) under the Asset Purchase Agreement (the &#x201c;Asset Acquisition&#x201d;) and issued to Erigen &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,268,495&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock. Based on an assumed common stock price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, the aggregate consideration related to the Asset Acquisition  is approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company incurred approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of transaction costs in connection with the Asset Acquisition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expects to account for the Asset Acquisition as an asset acquisition. Transaction costs are expected to be capitalized as part of the total cost of the Asset Acquisition. The Company is in the process of evaluating the assets acquired and any liabilities assumed and has not finalized the allocation of the consideration. Accordingly, the Company cannot reasonably estimate the financial statement impact of the transaction as of the date these consolidated financial statements were issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Asset Purchase Agreement, Factor has made a funding commitment (the &#x201c;Funding Commitment&#x201d;) to provide the Company with financial support for at least 18 months following the Erigen Closing, up to a maximum amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million that is inclusive of any amounts raised and received by us after the date of the Asset Purchase Agreement, on the terms and subject to the conditions and other provisions of a funding commitment letter contemplated by and entered into concurrently with the Asset Purchase Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrant Dividend&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 20, 2026, the Company&#x2019;s Board of Directors declared a record date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 30, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (the &#x201c;Record Date&#x201d;), for the distribution of a dividend (the &#x201c;Warrant Dividend&#x201d;) in the form of a warrant to purchase a share of the Company&#x2019;s common stock (collectively, the &#x201c;Warrants&#x201d;) for each share of common stock outstanding on the Record Date at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The Warrants were issued on the terms and conditions described in the Warrant Agreement, dated February 3, 2026, between the Company, Computershare Inc., and its affiliate, Computershare Trust Company, N.A., as Warrant Agent, on February 3, 2026. In addition, on February 3, 2026, certain warrants that were outstanding on the Record Date also received Warrants on a one-for-one basis, pursuant to the terms of such warrants (together with the Warrant Dividend, the &#x201c;Warrant Distribution&#x201d;). In the aggregate, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,784,989&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Warrants were issued pursuant to the Warrant Distribution.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity Plan Amendment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 27, 2026, the Company&#x2019;s stockholders approved Amendment No. 1 to the 2023 Plan to increase the number of shares of the Company&#x2019;s common stock issuable under such plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,410,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rights Plan Approval&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 27, 2026, the Company&#x2019;s stockholders approved the Company&#x2019;s Rights Agreement. Such stockholder approval extended the final expiration date of the Rights Agreement until October 10, 2026, unless the rights thereunder are earlier redeemed or exchanged by the Company. The Rights Agreement otherwise remains unmodified and in full force and effect in accordance with its terms.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Employment Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;connection with his appointment as President and Chief Executive Officer of the Company, effective February 3, 2026, the Company entered into an employment agreement with Matthew Angel (the &#x201c;Angel Employment Agreement&#x201d;). Pursuant to the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Angel &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Employment Agreement, Dr. Angel is entitled to receive an annual base salary of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;650,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and will be eligible to receive an annual bonus equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of his base salary, as determined by the Board in its sole discretion. In addition, on February 3, 2026, Dr. Angel received an option to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;269,621&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, with an exercise price per share equal to the fair market value on the grant date (the &#x201c;Option&#x201d;). The Option vests over a four-year period, with one quarter (1/4) of the shares subject to the Option vesting on the first anniversary of the grant date, and the remaining shares vesting equally over the following 36 months of continuous service.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 3, 2026, the Company entered into an employment agreement with Nicholas Maestas (the &#x201c;Maestas Employment Agreement&#x201d;), pursuant to which Mr. Maestas is entitled to receive compensation consistent with his previously filed employment agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Private Placement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 20, 2026, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with (a) two institutional investors (the &#x201c;Institutional Investors&#x201d;) and (b) Factor Bioscience Inc. (together with the Institutional Investors, each, an &#x201c;Investor&#x201d; and, together, the &#x201c;Investors&#x201d;), pursuant to which the Company agreed to issue and sell in a private placement (the &#x201c;Private Placement&#x201d;) an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;462,964&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares (the &#x201c;Shares&#x201d;) of the Company&#x2019;s common stock, and, in lieu of common stock, pre-funded warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;462,963&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (the &#x201c;2026 Pre-Funded Warrants&#x201d;), in each case accompanied by (i) Series A warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;925,927&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (the &#x201c;Series A Warrants&#x201d;) and (ii) Series B warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;925,927&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (the &#x201c;Series B Warrants&#x201d; and, together with the Series A Warrants, the &#x201c;Common Warrants&#x201d;). The Shares and the Common Warrants are immediately separable and were issued separately. The combined purchase price per Share and accompanying Common Warrants was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the combined purchase price per Pre-Funded Warrant and accompanying Common Warrants was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.159&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The gross proceeds to us from the Private Placement were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (excluding up to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of aggregate gross proceeds that may be received in the future upon the cash exercise of the Common Warrants), before deducting placement agent fees and other offering expenses payable by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Purchase Agreement, the Company agreed to seek approval from our stockholders for the issuance of the shares issuable upon exercise of the Common Warrants within 90 days following the date of the Purchase Agreement (the &#x201c;Stockholder Approval&#x201d;). The Series A Warrants will become exercisable on the effective date of the Stockholder Approval (the &#x201c;Stockholder Approval Date&#x201d;) and have a term of five years from the later of the Stockholder Approval Date and the Effectiveness Date (as defined below). The Series B Warrants will become exercisable on the Stockholder Approval Date and have a term of twenty-four months from the later of the Stockholder Approval Date and the Effectiveness Date. The Common Warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The Pre-Funded Warrants are exercisable immediately following the closing date of the Private Placement have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and may be exercised at any time until exercised in full. In addition, pursuant to the Purchase Agreement, the Company agreed not to sell any shares of the Company&#x2019;s common stock or any securities convertible into or exercisable or exchangeable into shares of common stock, subject to certain customary exceptions, for a period of thirty (30) days after the Effectiveness Date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Private Placement, the Company entered into a registration rights agreement with the Investors (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which the Company agreed to file registration statements under the Securities Act with the SEC covering the resale of the Shares to be issued in the Private Placement and the shares of the Company&#x2019;s common stock underlying the Common Warrants and Pre-Funded Warrants no later than 15 calendar days following the date of the Purchase Agreement, and to use reasonable best efforts to have the registration statement declared effective by 45 calendar days following the date of the Purchase Agreement, and in any event no later than 75 calendar days following the date of the Purchase Agreement in the event of a &#x201c;full review&#x201d; by the SEC (the &#x201c;Effectiveness Date&#x201d;).&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AssetAcquisitionDateOfAcquisitionAgreement
      contextRef="C_cbae41ba-0f21-46c1-8226-08889ddc8bc8"
      id="F_7d37a15e-0a5a-4869-a2c9-bd35f16145b9">2025-11-19</us-gaap:AssetAcquisitionDateOfAcquisitionAgreement>
    <tpst:AssetAcquisitionSharesEquityInterestYetToBeIssued
      contextRef="C_4ecf269e-0f88-4788-aa4d-c460ebc3cf9b"
      decimals="INF"
      id="F_14926b0a-7392-434e-9229-07e929bd81f8"
      unitRef="U_shares">8268495</tpst:AssetAcquisitionSharesEquityInterestYetToBeIssued>
    <us-gaap:AssetAcquisitionEffectiveDateOfAcquisition
      contextRef="C_b166bd00-a5b2-46eb-bcf0-8a5010ef48da"
      id="F_920acc23-f21b-4018-af99-21487ac998e7">2026-02-03</us-gaap:AssetAcquisitionEffectiveDateOfAcquisition>
    <tpst:AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable
      contextRef="C_717feb2e-7a7f-45b4-b13f-aa87773d18bb"
      decimals="INF"
      id="F_2c07d6cf-f853-4fc2-b704-72600f6cc185"
      unitRef="U_shares">8268495</tpst:AssetAcquisitionConsiderationTransferredSharesEquityInterestIssuedAndIssuable>
    <tpst:AssetAcquisitionSharePrice
      contextRef="C_717feb2e-7a7f-45b4-b13f-aa87773d18bb"
      decimals="2"
      id="F_906b1af6-c6dd-48fa-94ac-0c36cdd77813"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.41</tpst:AssetAcquisitionSharePrice>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_b166bd00-a5b2-46eb-bcf0-8a5010ef48da"
      decimals="-5"
      id="F_3405374a-8abd-4e1b-b7e7-d2ad6ee34524"
      unitRef="U_USD">19900000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <tpst:AssetAcquisitionTransactionCosts
      contextRef="C_b166bd00-a5b2-46eb-bcf0-8a5010ef48da"
      decimals="-5"
      id="F_a6d973be-73f4-4f56-8813-617b62dbdb1d"
      unitRef="U_USD">6700000</tpst:AssetAcquisitionTransactionCosts>
    <tpst:AssetAcquisitionMaximumFundingCommitment
      contextRef="C_b166bd00-a5b2-46eb-bcf0-8a5010ef48da"
      decimals="-5"
      id="F_372fd4a9-34a6-4fd1-b147-d2d07d264e28"
      unitRef="U_USD">20000000</tpst:AssetAcquisitionMaximumFundingCommitment>
    <us-gaap:DividendsPayableDateOfRecordDayMonthAndYear
      contextRef="C_d07960dd-fe9c-4566-abd3-ddc3571ebd35"
      id="F_9ee73a95-eb61-4f03-8936-3c888363a8e2">2026-01-30</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e7009405-d7f0-4b5c-971c-06a829c4d118"
      decimals="2"
      id="F_22a1c669-6186-4533-a174-72b2041ee67c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_7b1d730e-ab40-4eba-8cbf-0692f0eabf49"
      decimals="INF"
      id="F_74bfd87d-de30-4536-9531-1d9be8db74c0"
      unitRef="U_shares">6784989</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_151f94be-33aa-4e72-91ab-8bdd1b7a21c2"
      decimals="INF"
      id="F_bcf9b1c7-bc72-49d2-95a7-cc7e8c5721d0"
      unitRef="U_shares">1410000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <tpst:AnnualBaseSalary
      contextRef="C_a46cd5e9-4d74-498e-9bdd-3fe5cb08caf8"
      decimals="0"
      id="F_62a97c94-ace0-49ed-bd74-14377a3a686b"
      unitRef="U_USD">650000</tpst:AnnualBaseSalary>
    <tpst:PercentageOfAnnualBonus
      contextRef="C_a46cd5e9-4d74-498e-9bdd-3fe5cb08caf8"
      decimals="INF"
      id="F_d1bbff44-c48b-470f-9ffa-4392e1ae56cc"
      unitRef="U_pure">0.50</tpst:PercentageOfAnnualBonus>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_7c4289a6-f95b-49ac-b1e3-b9d55e86a9a6"
      decimals="INF"
      id="F_fbe36441-8c5f-4e1c-a988-e629acbcb240"
      unitRef="U_shares">269621</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_6cdf488d-d731-4f05-b3e5-69a6c55aa717"
      decimals="INF"
      id="F_830e3121-0c8c-4541-9f69-e8534ea935c2"
      unitRef="U_shares">462964</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <tpst:SaleOfStockWarrantsIssued
      contextRef="C_8bd98920-97ac-43e9-83d8-1afbd38624a3"
      decimals="INF"
      id="F_846358f0-2ec3-445c-9a7f-98ec1a83d6d9"
      unitRef="U_shares">462963</tpst:SaleOfStockWarrantsIssued>
    <tpst:SaleOfStockWarrantsIssued
      contextRef="C_89243837-7c70-4e55-8184-5818a993b299"
      decimals="INF"
      id="F_3979989c-6e05-42f7-a531-1615a740f981"
      unitRef="U_shares">925927</tpst:SaleOfStockWarrantsIssued>
    <tpst:SaleOfStockWarrantsIssued
      contextRef="C_e8e8425e-8552-48b9-b19d-732d38689041"
      decimals="INF"
      id="F_93167e24-0525-47f1-9a6b-03f6ede7554b"
      unitRef="U_shares">925927</tpst:SaleOfStockWarrantsIssued>
    <us-gaap:SharePrice
      contextRef="C_8bd98920-97ac-43e9-83d8-1afbd38624a3"
      decimals="2"
      id="F_f25fa92d-1736-4bc1-a922-8b5ad0e8c38b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.16</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_072f2ea3-60bc-461a-af30-65a53c97af2b"
      decimals="3"
      id="F_9a8d04a5-7253-4e54-aac1-a80336432f68"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.159</us-gaap:SharePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_6cdf488d-d731-4f05-b3e5-69a6c55aa717"
      decimals="-5"
      id="F_e8a680c6-95c7-4ff4-b306-85588b6f9dd3"
      unitRef="U_USD">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_f546958e-8be6-48f3-adf2-b8d67c893d64"
      decimals="-5"
      id="F_b89750e0-5ee5-4967-b7a5-a8e708a791aa"
      unitRef="U_USD">4000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e1a70b55-a6e2-4450-8567-d8933403aa20"
      decimals="2"
      id="F_8620451a-6392-4b52-825a-c46ac608cf0d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_b0987cd9-5a24-4759-9d16-ae81baf465af"
      decimals="3"
      id="F_3131b590-3c26-4d8a-9249-121cd39a8a67"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_5674d468-6c98-412c-9336-57931dcfe277"
      id="F_5dad0284-6673-489a-83db-b8ee4a5eb4bf">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_5674d468-6c98-412c-9336-57931dcfe277"
      id="F_a6112b65-f8e1-4fae-97b4-c49a79027c61">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_5674d468-6c98-412c-9336-57931dcfe277"
      id="F_cd98e336-329d-4192-8799-e0316af25d53">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_5674d468-6c98-412c-9336-57931dcfe277"
      id="F_c923ac0a-75a6-4560-adaf-18534016dd87">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_02b78ddf-da38-4509-a735-32afb066d3b8"
      id="F_826435bc-b587-4b1f-977c-de87f0948c7b">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_9095b77b-8616-4328-bf62-7772ddb0da59"
          xlink:label="F_9095b77b-8616-4328-bf62-7772ddb0da59"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d279497e-f43f-4de1-9102-97489a93c8f2"
          xlink:label="F_d279497e-f43f-4de1-9102-97489a93c8f2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9cee43fb-5ccc-4e36-909b-199a1d954e50"
          xlink:label="F_9cee43fb-5ccc-4e36-909b-199a1d954e50"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7a823370-0688-4ec5-a3c3-9cc56cb1fa4d"
          xlink:label="F_7a823370-0688-4ec5-a3c3-9cc56cb1fa4d"
          xlink:type="locator"/>
        <link:footnote id="FNT_74241657-edda-4a4a-85ad-6d4a0c4dfaad" xlink:label="FNT_74241657-edda-4a4a-85ad-6d4a0c4dfaad" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results, including shares issued and outstanding have been adjusted to reflect the </xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-thirteen</xhtml:span></xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9095b77b-8616-4328-bf62-7772ddb0da59"
          xlink:to="FNT_74241657-edda-4a4a-85ad-6d4a0c4dfaad"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d279497e-f43f-4de1-9102-97489a93c8f2"
          xlink:to="FNT_74241657-edda-4a4a-85ad-6d4a0c4dfaad"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9cee43fb-5ccc-4e36-909b-199a1d954e50"
          xlink:to="FNT_74241657-edda-4a4a-85ad-6d4a0c4dfaad"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7a823370-0688-4ec5-a3c3-9cc56cb1fa4d"
          xlink:to="FNT_74241657-edda-4a4a-85ad-6d4a0c4dfaad"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_a4deed85-14a1-438a-b3cd-6a644a58efa7"
          xlink:label="F_a4deed85-14a1-438a-b3cd-6a644a58efa7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_a0c20a1c-3071-4a19-adb9-c780da554e35"
          xlink:label="F_a0c20a1c-3071-4a19-adb9-c780da554e35"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_06d8a560-9214-464d-ad7f-d5ceb179abd3"
          xlink:label="F_06d8a560-9214-464d-ad7f-d5ceb179abd3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5b799a36-beb6-4e4c-98b2-34a6c04e7709"
          xlink:label="F_5b799a36-beb6-4e4c-98b2-34a6c04e7709"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c6e60cb1-7625-45d8-890d-f502ccb2045a"
          xlink:label="F_c6e60cb1-7625-45d8-890d-f502ccb2045a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_97f8f9d8-ccc1-41b2-99d2-edaf2bb90a5a"
          xlink:label="F_97f8f9d8-ccc1-41b2-99d2-edaf2bb90a5a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b454cb84-8963-4090-ad49-9160d559a804"
          xlink:label="F_b454cb84-8963-4090-ad49-9160d559a804"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6448a7f3-d0ae-4461-bf4e-c13a95ec4ec0"
          xlink:label="F_6448a7f3-d0ae-4461-bf4e-c13a95ec4ec0"
          xlink:type="locator"/>
        <link:footnote id="FNT_b817ca04-9246-4cb1-a879-d662ded3e863" xlink:label="FNT_b817ca04-9246-4cb1-a879-d662ded3e863" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Results, including shares of common stock, have been adjusted to reflect the </xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-thirteen</xhtml:span></xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a4deed85-14a1-438a-b3cd-6a644a58efa7"
          xlink:to="FNT_b817ca04-9246-4cb1-a879-d662ded3e863"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a0c20a1c-3071-4a19-adb9-c780da554e35"
          xlink:to="FNT_b817ca04-9246-4cb1-a879-d662ded3e863"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_06d8a560-9214-464d-ad7f-d5ceb179abd3"
          xlink:to="FNT_b817ca04-9246-4cb1-a879-d662ded3e863"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5b799a36-beb6-4e4c-98b2-34a6c04e7709"
          xlink:to="FNT_b817ca04-9246-4cb1-a879-d662ded3e863"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c6e60cb1-7625-45d8-890d-f502ccb2045a"
          xlink:to="FNT_b817ca04-9246-4cb1-a879-d662ded3e863"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_97f8f9d8-ccc1-41b2-99d2-edaf2bb90a5a"
          xlink:to="FNT_b817ca04-9246-4cb1-a879-d662ded3e863"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b454cb84-8963-4090-ad49-9160d559a804"
          xlink:to="FNT_b817ca04-9246-4cb1-a879-d662ded3e863"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6448a7f3-d0ae-4461-bf4e-c13a95ec4ec0"
          xlink:to="FNT_b817ca04-9246-4cb1-a879-d662ded3e863"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
